Interation Record ID Interaction Category MASI-Microbe-ID Microbe-Tax-ID Microbe-Name MASI-Substance-chemicalD Substance-Name Substance-Category Substance-subCategory Substance Exposure Details Microbiota Site Microbe Change Microbe Change Statistics Metabolites Metabolism Type Metabolism Enzymes Metabolism Effect on Drug Experiment System Experiment Model Species Model Condition/Disease Metabolism Mechanism Outcome Reference ID Type Reference ID PMDBI20000001 Microbes metabolize substances PMDBM2008040 2749267 Absiella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000002 Microbes metabolize substances PMDBM2008040 2749267 Absiella PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000003 Microbes metabolize substances PMDBM2008040 2749267 Absiella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000004 Microbes metabolize substances PMDBM2008040 2749267 Absiella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000005 Microbes metabolize substances PMDBM2008040 2749267 Absiella PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000007 Microbes metabolize substances PMDBM2008040 2749267 Absiella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000009 Microbes metabolize substances PMDBM2008040 2749267 Absiella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000010 Microbes metabolize substances PMDBM2008040 2749267 Absiella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000011 Microbes metabolize substances PMDBM2008040 2749267 Absiella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000012 Microbes metabolize substances PMDBM2008040 2749267 Absiella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000015 Microbes metabolize substances PMDBM2008040 2749267 Absiella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000016 Microbes metabolize substances PMDBM2008040 2749267 Absiella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000017 Microbes metabolize substances PMDBM2008040 2749267 Absiella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000018 Microbes metabolize substances PMDBM2008040 2749267 Absiella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000020 Microbes metabolize substances PMDBM2008040 2749267 Absiella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000021 Microbes metabolize substances PMDBM2008040 2749267 Absiella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000022 Microbes metabolize substances PMDBM2008040 2749267 Absiella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000023 Microbes metabolize substances PMDBM2021281 31971 Absiella dolichum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000024 Microbes metabolize substances PMDBM2021281 31971 Absiella dolichum PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000025 Microbes metabolize substances PMDBM2021281 31971 Absiella dolichum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000026 Microbes metabolize substances PMDBM2021281 31971 Absiella dolichum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000027 Microbes metabolize substances PMDBM2021281 31971 Absiella dolichum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000028 Microbes metabolize substances PMDBM2021281 31971 Absiella dolichum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000029 Microbes metabolize substances PMDBM2021281 31971 Absiella dolichum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000030 Microbes metabolize substances PMDBM2021281 31971 Absiella dolichum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000033 Microbes metabolize substances PMDBM2021281 31971 Absiella dolichum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000034 Microbes metabolize substances PMDBM2021281 31971 Absiella dolichum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000035 Microbes metabolize substances PMDBM2021281 31971 Absiella dolichum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000036 Microbes metabolize substances PMDBM2021281 31971 Absiella dolichum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000037 Microbes metabolize substances PMDBM2021281 31971 Absiella dolichum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000038 Microbes metabolize substances PMDBM2021281 31971 Absiella dolichum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000039 Microbes metabolize substances PMDBM2021281 31971 Absiella dolichum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000040 Microbes metabolize substances PMDBM2008042 n.a. Absiella innocuum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000041 Microbes metabolize substances PMDBM2008042 n.a. Absiella innocuum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000042 Microbes metabolize substances PMDBM2008042 n.a. Absiella innocuum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000043 Microbes metabolize substances PMDBM2008042 n.a. Absiella innocuum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000044 Microbes metabolize substances PMDBM2008042 n.a. Absiella innocuum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000045 Microbes metabolize substances PMDBM2008042 n.a. Absiella innocuum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000046 Microbes metabolize substances PMDBM2008042 n.a. Absiella innocuum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000049 Microbes metabolize substances PMDBM2008042 n.a. Absiella innocuum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000050 Microbes metabolize substances PMDBM2008042 n.a. Absiella innocuum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000051 Microbes metabolize substances PMDBM2008042 n.a. Absiella innocuum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000052 Microbes metabolize substances PMDBM2008042 n.a. Absiella innocuum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000053 Microbes metabolize substances PMDBM2008042 n.a. Absiella innocuum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000054 Microbes metabolize substances PMDBM2008042 n.a. Absiella innocuum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000055 Microbes metabolize substances PMDBM2008042 n.a. Absiella innocuum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000056 Microbes metabolize substances PMDBM2008042 n.a. Absiella innocuum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000057 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000163515 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000058 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000163515 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000059 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000163515 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000060 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000163515 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000061 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000163515 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000062 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000163515 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000063 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000163515 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000066 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000163515 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000067 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000163515 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000068 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000163515 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000069 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000163515 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000070 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000163515 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000071 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000163515 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000072 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000163515 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000073 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000163515 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000074 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000165065 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000075 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000165065 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000076 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000165065 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000077 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000165065 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000078 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000165065 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000079 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000165065 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000080 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000165065 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000083 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000165065 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000084 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000165065 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000085 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000165065 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000086 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000165065 PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000087 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000165065 PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000088 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000165065 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000089 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000165065 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000090 Microbes metabolize substances PMDBM2021395 3088138 Absiella sp000165065 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000091 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000092 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000093 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000094 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000095 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000097 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000099 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000100 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000101 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000102 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000103 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000104 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000106 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20000109 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20000110 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20000111 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000112 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000115 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20000118 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000119 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000122 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000123 Microbes metabolize substances PMDBM2008045 1427378 Acetatifactor PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000124 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000125 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000126 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000127 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000128 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000129 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000130 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000131 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000132 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000134 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20000137 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20000138 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20000139 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000140 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000143 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20000146 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000147 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000148 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000150 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000151 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp003447295 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000152 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066365 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000153 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066365 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000154 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066365 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000155 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066365 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000156 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066365 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000157 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066365 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000158 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066365 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000161 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066365 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000162 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066365 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000163 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066365 PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000164 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066365 PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000165 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066365 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000166 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066365 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000167 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066565 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000168 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066565 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000169 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066565 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000170 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066565 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000171 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066565 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000172 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066565 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000173 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066565 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000174 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066565 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000175 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066565 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000177 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066565 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20000180 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066565 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20000181 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066565 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20000184 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066565 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20000187 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066565 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000188 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066565 PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000189 Microbes metabolize substances PMDBM2021396 1872090 Acetatifactor sp900066565 PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000191 Microbes metabolize substances PMDBM2020278 290052 Acetivibri A ethanolgignens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000192 Microbes metabolize substances PMDBM2020278 290052 Acetivibri A ethanolgignens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000193 Microbes metabolize substances PMDBM2020278 290052 Acetivibri A ethanolgignens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000194 Microbes metabolize substances PMDBM2020278 290052 Acetivibri A ethanolgignens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000195 Microbes metabolize substances PMDBM2020278 290052 Acetivibri A ethanolgignens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000196 Microbes metabolize substances PMDBM2020278 290052 Acetivibri A ethanolgignens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000197 Microbes metabolize substances PMDBM2020278 290052 Acetivibri A ethanolgignens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000200 Microbes metabolize substances PMDBM2020278 290052 Acetivibri A ethanolgignens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000201 Microbes metabolize substances PMDBM2020278 290052 Acetivibri A ethanolgignens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000202 Microbes metabolize substances PMDBM2020278 290052 Acetivibri A ethanolgignens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000203 Microbes metabolize substances PMDBM2020278 290052 Acetivibri A ethanolgignens PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000204 Microbes metabolize substances PMDBM2020278 290052 Acetivibri A ethanolgignens PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000205 Microbes metabolize substances PMDBM2020278 290052 Acetivibri A ethanolgignens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000206 Microbes metabolize substances PMDBM2020278 290052 Acetivibri A ethanolgignens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000207 Microbes metabolize substances PMDBM2021397 649746 Acetomicrobium hydrogeniformans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000208 Microbes metabolize substances PMDBM2021397 649746 Acetomicrobium hydrogeniformans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000209 Microbes metabolize substances PMDBM2021397 649746 Acetomicrobium hydrogeniformans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000210 Microbes metabolize substances PMDBM2021397 649746 Acetomicrobium hydrogeniformans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000211 Microbes metabolize substances PMDBM2020282 85698 Achromobacter xylosoxidans PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000212 Microbes metabolize substances PMDBM2020282 85698 Achromobacter xylosoxidans PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000213 Microbes metabolize substances PMDBM2020282 85698 Achromobacter xylosoxidans PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000214 Microbes metabolize substances PMDBM2020282 85698 Achromobacter xylosoxidans PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000215 Microbes metabolize substances PMDBM2020282 85698 Achromobacter xylosoxidans PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000216 Microbes metabolize substances PMDBM2020282 85698 Achromobacter xylosoxidans PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000217 Microbes metabolize substances PMDBM2020282 85698 Achromobacter xylosoxidans PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000218 Microbes metabolize substances PMDBM2020282 85698 Achromobacter xylosoxidans PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000221 Microbes metabolize substances PMDBM2020282 85698 Achromobacter xylosoxidans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000222 Microbes metabolize substances PMDBM2020282 85698 Achromobacter xylosoxidans PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000223 Microbes metabolize substances PMDBM2020282 85698 Achromobacter xylosoxidans PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000224 Microbes metabolize substances PMDBM2020282 85698 Achromobacter xylosoxidans PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000225 Microbes metabolize substances PMDBM2008052 909930 Acidaminococcaceae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000226 Microbes metabolize substances PMDBM2008052 909930 Acidaminococcaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000227 Microbes metabolize substances PMDBM2008052 909930 Acidaminococcaceae PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20000228 Microbes metabolize substances PMDBM2008052 909930 Acidaminococcaceae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000229 Microbes metabolize substances PMDBM2008053 904 Acidaminococcus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000230 Microbes metabolize substances PMDBM2008053 904 Acidaminococcus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000231 Microbes metabolize substances PMDBM2008053 904 Acidaminococcus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000232 Microbes metabolize substances PMDBM2008053 904 Acidaminococcus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000233 Microbes metabolize substances PMDBM2020284 905 Acidaminococcus fermentans PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000234 Microbes metabolize substances PMDBM2020284 905 Acidaminococcus fermentans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000235 Microbes metabolize substances PMDBM2020284 905 Acidaminococcus fermentans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000236 Microbes metabolize substances PMDBM2020284 905 Acidaminococcus fermentans PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000237 Microbes metabolize substances PMDBM2020285 187327 Acidaminococcus intestini PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000238 Microbes metabolize substances PMDBM2020285 187327 Acidaminococcus intestini PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20000239 Microbes metabolize substances PMDBM2020285 187327 Acidaminococcus intestini PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000240 Microbes metabolize substances PMDBM2020285 187327 Acidaminococcus intestini PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000241 Microbes metabolize substances PMDBM2020286 1852375 Acidaminococcus massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000242 Microbes metabolize substances PMDBM2020286 1852375 Acidaminococcus massiliensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20000243 Microbes metabolize substances PMDBM2020286 1852375 Acidaminococcus massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000244 Microbes metabolize substances PMDBM2020286 1852375 Acidaminococcus massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000245 Microbes metabolize substances PMDBM2020288 1872103 Acidaminococcus sp000437815 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000246 Microbes metabolize substances PMDBM2020288 1872103 Acidaminococcus sp000437815 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000247 Microbes metabolize substances PMDBM2020288 1872103 Acidaminococcus sp000437815 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000248 Microbes metabolize substances PMDBM2020288 1872103 Acidaminococcus sp000437815 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000249 Microbes metabolize substances PMDBM2020288 1872103 Acidaminococcus sp900291475 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000250 Microbes metabolize substances PMDBM2020288 1872103 Acidaminococcus sp900291475 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20000251 Microbes metabolize substances PMDBM2020288 1872103 Acidaminococcus sp900291475 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000252 Microbes metabolize substances PMDBM2020288 1872103 Acidaminococcus sp900291475 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000253 Microbes metabolize substances PMDBM2021398 1871002 Acidaminococcus timonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000254 Microbes metabolize substances PMDBM2021398 1871002 Acidaminococcus timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000255 Microbes metabolize substances PMDBM2021398 1871002 Acidaminococcus timonensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000256 Microbes metabolize substances PMDBM2021399 1872122 Acidovorax D sp000302535 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000257 Microbes metabolize substances PMDBM2021399 1872122 Acidovorax D sp000302535 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000258 Microbes metabolize substances PMDBM2021399 1872122 Acidovorax D sp000302535 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000259 Microbes metabolize substances PMDBM2021399 1872122 Acidovorax D sp000302535 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000260 Microbes metabolize substances PMDBM2021399 1872122 Acidovorax D sp000302535 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000261 Microbes metabolize substances PMDBM2021399 1872122 Acidovorax D sp000302535 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000262 Microbes metabolize substances PMDBM2021399 1872122 Acidovorax D sp000302535 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000265 Microbes metabolize substances PMDBM2021399 1872122 Acidovorax D sp000302535 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000266 Microbes metabolize substances PMDBM2021399 1872122 Acidovorax D sp000302535 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000267 Microbes metabolize substances PMDBM2021399 1872122 Acidovorax D sp000302535 PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000268 Microbes metabolize substances PMDBM2021399 1872122 Acidovorax D sp000302535 PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000269 Microbes metabolize substances PMDBM2021399 1872122 Acidovorax D sp000302535 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000270 Microbes metabolize substances PMDBM2021399 1872122 Acidovorax D sp000302535 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000271 Microbes metabolize substances PMDBM2021400 80878 Acidovorax D temperans PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000272 Microbes metabolize substances PMDBM2021400 80878 Acidovorax D temperans PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000273 Microbes metabolize substances PMDBM2021400 80878 Acidovorax D temperans PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000274 Microbes metabolize substances PMDBM2021400 80878 Acidovorax D temperans PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000275 Microbes metabolize substances PMDBM2021400 80878 Acidovorax D temperans PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000276 Microbes metabolize substances PMDBM2021400 80878 Acidovorax D temperans PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000277 Microbes metabolize substances PMDBM2021400 80878 Acidovorax D temperans PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000280 Microbes metabolize substances PMDBM2021400 80878 Acidovorax D temperans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000281 Microbes metabolize substances PMDBM2021400 80878 Acidovorax D temperans PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000282 Microbes metabolize substances PMDBM2021400 80878 Acidovorax D temperans PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000283 Microbes metabolize substances PMDBM2021400 80878 Acidovorax D temperans PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000284 Microbes metabolize substances PMDBM2021400 80878 Acidovorax D temperans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000285 Microbes metabolize substances PMDBM2021400 80878 Acidovorax D temperans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000286 Microbes metabolize substances PMDBM2 469 Acinetobacter PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000287 Microbes metabolize substances PMDBM2 469 Acinetobacter PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000288 Microbes metabolize substances PMDBM2 469 Acinetobacter PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000289 Microbes metabolize substances PMDBM2 469 Acinetobacter PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20000290 Microbes metabolize substances PMDBM2 469 Acinetobacter PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000291 Microbes metabolize substances PMDBM2 469 Acinetobacter PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000292 Microbes metabolize substances PMDBM2 469 Acinetobacter PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000293 Microbes metabolize substances PMDBM2 469 Acinetobacter PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000296 Microbes metabolize substances PMDBM2 469 Acinetobacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000297 Microbes metabolize substances PMDBM2 469 Acinetobacter PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000298 Microbes metabolize substances PMDBM2 469 Acinetobacter PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000299 Microbes metabolize substances PMDBM2 469 Acinetobacter PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000300 Microbes metabolize substances PMDBM2 469 Acinetobacter PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000301 Microbes metabolize substances PMDBM2 469 Acinetobacter PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000302 Microbes metabolize substances PMDBM2020075 470 Acinetobacter baumannii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000303 Microbes metabolize substances PMDBM2020075 470 Acinetobacter baumannii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000304 Microbes metabolize substances PMDBM2020075 470 Acinetobacter baumannii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000305 Microbes metabolize substances PMDBM2020075 470 Acinetobacter baumannii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000306 Microbes metabolize substances PMDBM2020075 470 Acinetobacter baumannii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000307 Microbes metabolize substances PMDBM2020075 470 Acinetobacter baumannii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000308 Microbes metabolize substances PMDBM2020075 470 Acinetobacter baumannii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000311 Microbes metabolize substances PMDBM2020075 470 Acinetobacter baumannii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000312 Microbes metabolize substances PMDBM2020075 470 Acinetobacter baumannii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000313 Microbes metabolize substances PMDBM2020075 470 Acinetobacter baumannii PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000314 Microbes metabolize substances PMDBM2020075 470 Acinetobacter baumannii PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000315 Microbes metabolize substances PMDBM2020075 470 Acinetobacter baumannii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000316 Microbes metabolize substances PMDBM2020075 470 Acinetobacter baumannii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000317 Microbes metabolize substances PMDBM2008061 n.a. Acinetobacter fasciculus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000318 Microbes metabolize substances PMDBM2008061 n.a. Acinetobacter fasciculus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000319 Microbes metabolize substances PMDBM2008061 n.a. Acinetobacter fasciculus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000320 Microbes metabolize substances PMDBM2008061 n.a. Acinetobacter fasciculus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000321 Microbes metabolize substances PMDBM2008061 n.a. Acinetobacter fasciculus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000322 Microbes metabolize substances PMDBM2008061 n.a. Acinetobacter fasciculus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000323 Microbes metabolize substances PMDBM2008061 n.a. Acinetobacter fasciculus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000326 Microbes metabolize substances PMDBM2008061 n.a. Acinetobacter fasciculus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000327 Microbes metabolize substances PMDBM2008061 n.a. Acinetobacter fasciculus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000328 Microbes metabolize substances PMDBM2008061 n.a. Acinetobacter fasciculus PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000329 Microbes metabolize substances PMDBM2008061 n.a. Acinetobacter fasciculus PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000330 Microbes metabolize substances PMDBM2008061 n.a. Acinetobacter fasciculus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000331 Microbes metabolize substances PMDBM2008061 n.a. Acinetobacter fasciculus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000332 Microbes metabolize substances PMDBM2020294 40214 Acinetobacter johnsonii PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20000333 Microbes metabolize substances PMDBM2020294 40214 Acinetobacter johnsonii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000334 Microbes metabolize substances PMDBM2020294 40214 Acinetobacter johnsonii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000335 Microbes metabolize substances PMDBM2020294 40214 Acinetobacter johnsonii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000336 Microbes metabolize substances PMDBM2020295 40215 Acinetobacter junii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000337 Microbes metabolize substances PMDBM2020295 40215 Acinetobacter junii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000338 Microbes metabolize substances PMDBM2020295 40215 Acinetobacter junii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000339 Microbes metabolize substances PMDBM2020295 40215 Acinetobacter junii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000340 Microbes metabolize substances PMDBM2020295 40215 Acinetobacter junii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000341 Microbes metabolize substances PMDBM2020295 40215 Acinetobacter junii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000342 Microbes metabolize substances PMDBM2020295 40215 Acinetobacter junii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000345 Microbes metabolize substances PMDBM2020295 40215 Acinetobacter junii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000346 Microbes metabolize substances PMDBM2020295 40215 Acinetobacter junii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000347 Microbes metabolize substances PMDBM2020295 40215 Acinetobacter junii PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000348 Microbes metabolize substances PMDBM2020295 40215 Acinetobacter junii PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000349 Microbes metabolize substances PMDBM2020295 40215 Acinetobacter junii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000350 Microbes metabolize substances PMDBM2020295 40215 Acinetobacter junii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000351 Microbes metabolize substances PMDBM2020297 106654 Acinetobacter nosocomialis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000352 Microbes metabolize substances PMDBM2020297 106654 Acinetobacter nosocomialis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000353 Microbes metabolize substances PMDBM2020297 106654 Acinetobacter nosocomialis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000354 Microbes metabolize substances PMDBM2020297 106654 Acinetobacter nosocomialis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000355 Microbes metabolize substances PMDBM2020297 106654 Acinetobacter nosocomialis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000356 Microbes metabolize substances PMDBM2020297 106654 Acinetobacter nosocomialis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000357 Microbes metabolize substances PMDBM2020297 106654 Acinetobacter nosocomialis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000358 Microbes metabolize substances PMDBM2020297 106654 Acinetobacter nosocomialis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000361 Microbes metabolize substances PMDBM2020297 106654 Acinetobacter nosocomialis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000362 Microbes metabolize substances PMDBM2020297 106654 Acinetobacter nosocomialis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000363 Microbes metabolize substances PMDBM2020297 106654 Acinetobacter nosocomialis PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000364 Microbes metabolize substances PMDBM2020297 106654 Acinetobacter nosocomialis PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000365 Microbes metabolize substances PMDBM2020297 106654 Acinetobacter nosocomialis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000366 Microbes metabolize substances PMDBM2020297 106654 Acinetobacter nosocomialis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000367 Microbes metabolize substances PMDBM2020298 48296 Acinetobacter pittii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000368 Microbes metabolize substances PMDBM2020298 48296 Acinetobacter pittii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000369 Microbes metabolize substances PMDBM2020298 48296 Acinetobacter pittii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000370 Microbes metabolize substances PMDBM2020298 48296 Acinetobacter pittii PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20000371 Microbes metabolize substances PMDBM2020298 48296 Acinetobacter pittii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000372 Microbes metabolize substances PMDBM2020298 48296 Acinetobacter pittii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000373 Microbes metabolize substances PMDBM2020298 48296 Acinetobacter pittii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000374 Microbes metabolize substances PMDBM2020298 48296 Acinetobacter pittii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000377 Microbes metabolize substances PMDBM2020298 48296 Acinetobacter pittii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000378 Microbes metabolize substances PMDBM2020298 48296 Acinetobacter pittii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000379 Microbes metabolize substances PMDBM2020298 48296 Acinetobacter pittii PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000380 Microbes metabolize substances PMDBM2020298 48296 Acinetobacter pittii PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000381 Microbes metabolize substances PMDBM2020298 48296 Acinetobacter pittii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000382 Microbes metabolize substances PMDBM2020298 48296 Acinetobacter pittii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000383 Microbes metabolize substances PMDBM2020299 40216 Acinetobacter radioresistens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000384 Microbes metabolize substances PMDBM2020299 40216 Acinetobacter radioresistens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000385 Microbes metabolize substances PMDBM2020299 40216 Acinetobacter radioresistens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000386 Microbes metabolize substances PMDBM2020299 40216 Acinetobacter radioresistens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000387 Microbes metabolize substances PMDBM2020299 40216 Acinetobacter radioresistens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000388 Microbes metabolize substances PMDBM2020299 40216 Acinetobacter radioresistens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000389 Microbes metabolize substances PMDBM2020299 40216 Acinetobacter radioresistens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000392 Microbes metabolize substances PMDBM2020299 40216 Acinetobacter radioresistens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000393 Microbes metabolize substances PMDBM2020299 40216 Acinetobacter radioresistens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000394 Microbes metabolize substances PMDBM2020299 40216 Acinetobacter radioresistens PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000395 Microbes metabolize substances PMDBM2020299 40216 Acinetobacter radioresistens PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000396 Microbes metabolize substances PMDBM2020299 40216 Acinetobacter radioresistens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000397 Microbes metabolize substances PMDBM2020299 40216 Acinetobacter radioresistens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000398 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp000369785 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000399 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp000369785 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000400 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp000369785 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000401 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp000369785 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000402 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp000369785 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000403 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp000369785 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000404 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp000369785 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000407 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp000369785 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000408 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp000369785 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20000409 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp000369785 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000410 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp000369785 PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000411 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp000369785 PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000412 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp000369785 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000413 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp000369785 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000414 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp002934695 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000415 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp002934695 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000416 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp002934695 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000417 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp002934695 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000418 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp002934695 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000419 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp002934695 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000420 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp002934695 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000423 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp002934695 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000424 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp002934695 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000425 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp002934695 PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000426 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp002934695 PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000427 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp002934695 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000428 Microbes metabolize substances PMDBM2020302 472 Acinetobacter sp002934695 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000429 Microbes metabolize substances PMDBM2021401 108980 Acinetobacter ursingii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000430 Microbes metabolize substances PMDBM2021401 108980 Acinetobacter ursingii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000431 Microbes metabolize substances PMDBM2021401 108980 Acinetobacter ursingii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000432 Microbes metabolize substances PMDBM2021401 108980 Acinetobacter ursingii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000433 Microbes metabolize substances PMDBM2021401 108980 Acinetobacter ursingii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000434 Microbes metabolize substances PMDBM2021401 108980 Acinetobacter ursingii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000435 Microbes metabolize substances PMDBM2021401 108980 Acinetobacter ursingii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000438 Microbes metabolize substances PMDBM2021401 108980 Acinetobacter ursingii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000439 Microbes metabolize substances PMDBM2021401 108980 Acinetobacter ursingii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000440 Microbes metabolize substances PMDBM2021401 108980 Acinetobacter ursingii PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000441 Microbes metabolize substances PMDBM2021401 108980 Acinetobacter ursingii PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000442 Microbes metabolize substances PMDBM2021401 108980 Acinetobacter ursingii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000443 Microbes metabolize substances PMDBM2021401 108980 Acinetobacter ursingii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000444 Microbes metabolize substances PMDBM3 1760 Actinobacteria PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite NAPQI n.a. PMID PMID: 36467581 PMDBI20000445 Microbes metabolize substances PMDBM2021402 202789 Actinobaculum massiliense PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000446 Microbes metabolize substances PMDBM2021402 202789 Actinobaculum massiliense PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000447 Microbes metabolize substances PMDBM2021402 202789 Actinobaculum massiliense PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20000449 Microbes metabolize substances PMDBM2021402 202789 Actinobaculum massiliense PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20000450 Microbes metabolize substances PMDBM2021402 202789 Actinobaculum massiliense PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20000451 Microbes metabolize substances PMDBM2021402 202789 Actinobaculum massiliense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000452 Microbes metabolize substances PMDBM2021402 202789 Actinobaculum massiliense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000455 Microbes metabolize substances PMDBM2021402 202789 Actinobaculum massiliense PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20000459 Microbes metabolize substances PMDBM2020343 55565 Actinomyces graevenitzii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000460 Microbes metabolize substances PMDBM2020343 55565 Actinomyces graevenitzii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000461 Microbes metabolize substances PMDBM2021403 29317 Actinomyces sp900323545 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000462 Microbes metabolize substances PMDBM2021403 29317 Actinomyces sp900323545 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000463 Microbes metabolize substances PMDBM2021403 29317 Actinomyces sp900323545 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000464 Microbes metabolize substances PMDBM2021403 29317 Actinomyces sp900323545 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000465 Microbes metabolize substances PMDBM2021403 29317 Actinomyces sp900323545 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000466 Microbes metabolize substances PMDBM2021403 29317 Actinomyces sp900323545 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000467 Microbes metabolize substances PMDBM2021403 29317 Actinomyces sp900323545 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000470 Microbes metabolize substances PMDBM2021403 29317 Actinomyces sp900323545 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000471 Microbes metabolize substances PMDBM2021403 29317 Actinomyces sp900323545 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000472 Microbes metabolize substances PMDBM2021403 29317 Actinomyces sp900323545 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000473 Microbes metabolize substances PMDBM2021403 29317 Actinomyces sp900323545 PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000474 Microbes metabolize substances PMDBM2021403 29317 Actinomyces sp900323545 PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000475 Microbes metabolize substances PMDBM2021403 29317 Actinomyces sp900323545 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000476 Microbes metabolize substances PMDBM2021403 29317 Actinomyces sp900323545 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000477 Microbes metabolize substances PMDBM2020321 103621 Actinomyces urogenitalis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000478 Microbes metabolize substances PMDBM2020321 103621 Actinomyces urogenitalis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000479 Microbes metabolize substances PMDBM2020321 103621 Actinomyces urogenitalis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000480 Microbes metabolize substances PMDBM2020321 103621 Actinomyces urogenitalis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000482 Microbes metabolize substances PMDBM2020321 103621 Actinomyces urogenitalis PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000484 Microbes metabolize substances PMDBM2020321 103621 Actinomyces urogenitalis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000485 Microbes metabolize substances PMDBM2020321 103621 Actinomyces urogenitalis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000486 Microbes metabolize substances PMDBM2020321 103621 Actinomyces urogenitalis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000487 Microbes metabolize substances PMDBM2020321 103621 Actinomyces urogenitalis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000490 Microbes metabolize substances PMDBM2020321 103621 Actinomyces urogenitalis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000491 Microbes metabolize substances PMDBM2020321 103621 Actinomyces urogenitalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000492 Microbes metabolize substances PMDBM2020321 103621 Actinomyces urogenitalis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000493 Microbes metabolize substances PMDBM2020321 103621 Actinomyces urogenitalis PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000495 Microbes metabolize substances PMDBM2020321 103621 Actinomyces urogenitalis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000496 Microbes metabolize substances PMDBM2020321 103621 Actinomyces urogenitalis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000497 Microbes metabolize substances PMDBM2020362 1656 Actinomyces viscosus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000498 Microbes metabolize substances PMDBM2020362 1656 Actinomyces viscosus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000499 Microbes metabolize substances PMDBM2020362 1656 Actinomyces viscosus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000500 Microbes metabolize substances PMDBM2020362 1656 Actinomyces viscosus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000501 Microbes metabolize substances PMDBM2020362 1656 Actinomyces viscosus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000502 Microbes metabolize substances PMDBM2020362 1656 Actinomyces viscosus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000503 Microbes metabolize substances PMDBM2020362 1656 Actinomyces viscosus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000506 Microbes metabolize substances PMDBM2020362 1656 Actinomyces viscosus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000507 Microbes metabolize substances PMDBM2020362 1656 Actinomyces viscosus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000508 Microbes metabolize substances PMDBM2020362 1656 Actinomyces viscosus PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000509 Microbes metabolize substances PMDBM2020362 1656 Actinomyces viscosus PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000510 Microbes metabolize substances PMDBM2020362 1656 Actinomyces viscosus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000511 Microbes metabolize substances PMDBM2020362 1656 Actinomyces viscosus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000512 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000513 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000514 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000515 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000517 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000519 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000520 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000521 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000522 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000523 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000524 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000526 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20000529 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20000530 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20000531 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000532 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000535 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20000538 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000539 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000542 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000543 Microbes metabolize substances PMDBM610 2049 Actinomycetaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000544 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000545 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000546 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000547 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000548 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000550 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000552 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20000553 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000554 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000555 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000556 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000557 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000558 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000560 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20000563 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20000564 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20000565 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000566 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000569 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20000572 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20000573 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000574 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000577 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000578 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000579 Microbes metabolize substances PMDBM2008075 1918385 Acutalibacter PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000580 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000581 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000582 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000583 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000585 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000587 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000588 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000589 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000590 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000591 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000592 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000594 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20000597 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20000598 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20000599 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20000600 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000601 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000604 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20000607 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000608 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000611 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000612 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000613 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000432995 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000614 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000615 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000616 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000617 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000619 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000621 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20000622 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000623 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000624 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000625 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000626 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000627 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000629 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20000632 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20000633 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20000634 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000635 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000638 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20000641 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000642 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000643 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000645 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000646 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000647 Microbes metabolize substances PMDBM2021404 1918636 Acutalibacter sp000435395 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000648 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000649 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000650 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000651 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000653 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000655 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000656 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000657 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000658 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000659 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000660 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000662 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20000665 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20000666 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20000667 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000668 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000671 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20000674 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD2000006 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000675 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000676 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000678 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000679 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000680 Microbes metabolize substances PMDBM2008078 n.a. Acutalibacter timonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000681 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000682 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000683 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000684 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000685 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000687 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000689 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20000690 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000691 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000692 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000693 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000694 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000695 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000697 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20000700 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20000701 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20000702 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20000703 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20000704 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000705 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000708 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20000711 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20000712 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000713 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000716 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000717 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000718 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000719 Microbes metabolize substances PMDBM2008079 3082771 Acutalibacteraceae PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20000720 Microbes metabolize substances PMDBM611 447020 Adlercreutzia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000721 Microbes metabolize substances PMDBM611 447020 Adlercreutzia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000722 Microbes metabolize substances PMDBM611 447020 Adlercreutzia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000723 Microbes metabolize substances PMDBM2020002 446660 Adlercreutzia equolifaciens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000724 Microbes metabolize substances PMDBM2020326 1464554 Aeromicrobium A massiliense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000725 Microbes metabolize substances PMDBM2020326 1464554 Aeromicrobium A massiliense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000726 Microbes metabolize substances PMDBM2020326 1464554 Aeromicrobium A massiliense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000727 Microbes metabolize substances PMDBM2020326 1464554 Aeromicrobium A massiliense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000728 Microbes metabolize substances PMDBM2020326 1464554 Aeromicrobium A massiliense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000729 Microbes metabolize substances PMDBM2020326 1464554 Aeromicrobium A massiliense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000730 Microbes metabolize substances PMDBM2020326 1464554 Aeromicrobium A massiliense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000733 Microbes metabolize substances PMDBM2020326 1464554 Aeromicrobium A massiliense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000734 Microbes metabolize substances PMDBM2020326 1464554 Aeromicrobium A massiliense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000735 Microbes metabolize substances PMDBM2020326 1464554 Aeromicrobium A massiliense PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000736 Microbes metabolize substances PMDBM2020326 1464554 Aeromicrobium A massiliense PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000737 Microbes metabolize substances PMDBM2020326 1464554 Aeromicrobium A massiliense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000738 Microbes metabolize substances PMDBM2020326 1464554 Aeromicrobium A massiliense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000739 Microbes metabolize substances PMDBM2020003 648 Aeromonas caviae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000740 Microbes metabolize substances PMDBM2020003 648 Aeromonas caviae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000741 Microbes metabolize substances PMDBM2020003 648 Aeromonas caviae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000742 Microbes metabolize substances PMDBM2020003 648 Aeromonas caviae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000743 Microbes metabolize substances PMDBM2020003 648 Aeromonas caviae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000744 Microbes metabolize substances PMDBM2020003 648 Aeromonas caviae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000745 Microbes metabolize substances PMDBM2020003 648 Aeromonas caviae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000748 Microbes metabolize substances PMDBM2020003 648 Aeromonas caviae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20000749 Microbes metabolize substances PMDBM2020003 648 Aeromonas caviae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000750 Microbes metabolize substances PMDBM2020003 648 Aeromonas caviae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000751 Microbes metabolize substances PMDBM2020003 648 Aeromonas caviae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000752 Microbes metabolize substances PMDBM2020003 648 Aeromonas caviae PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000753 Microbes metabolize substances PMDBM2020003 648 Aeromonas caviae PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000754 Microbes metabolize substances PMDBM2020003 648 Aeromonas caviae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000755 Microbes metabolize substances PMDBM2020003 648 Aeromonas caviae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000756 Microbes metabolize substances PMDBM2020003 648 Aeromonas caviae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000757 Microbes metabolize substances PMDBM2020327 196024 Aeromonas dhakensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000758 Microbes metabolize substances PMDBM2020327 196024 Aeromonas dhakensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000759 Microbes metabolize substances PMDBM2020327 196024 Aeromonas dhakensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000760 Microbes metabolize substances PMDBM2020327 196024 Aeromonas dhakensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000761 Microbes metabolize substances PMDBM2020327 196024 Aeromonas dhakensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000762 Microbes metabolize substances PMDBM2020327 196024 Aeromonas dhakensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000763 Microbes metabolize substances PMDBM2020327 196024 Aeromonas dhakensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000764 Microbes metabolize substances PMDBM2020327 196024 Aeromonas dhakensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000767 Microbes metabolize substances PMDBM2020327 196024 Aeromonas dhakensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20000768 Microbes metabolize substances PMDBM2020327 196024 Aeromonas dhakensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000769 Microbes metabolize substances PMDBM2020327 196024 Aeromonas dhakensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000770 Microbes metabolize substances PMDBM2020327 196024 Aeromonas dhakensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000771 Microbes metabolize substances PMDBM2020327 196024 Aeromonas dhakensis PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000772 Microbes metabolize substances PMDBM2020327 196024 Aeromonas dhakensis PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000773 Microbes metabolize substances PMDBM2020327 196024 Aeromonas dhakensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000774 Microbes metabolize substances PMDBM2020327 196024 Aeromonas dhakensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000775 Microbes metabolize substances PMDBM2020327 196024 Aeromonas dhakensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000776 Microbes metabolize substances PMDBM2020261 644 Aeromonas hydrophila PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000777 Microbes metabolize substances PMDBM2020261 644 Aeromonas hydrophila PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000778 Microbes metabolize substances PMDBM2020261 644 Aeromonas hydrophila PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000779 Microbes metabolize substances PMDBM2020261 644 Aeromonas hydrophila PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000780 Microbes metabolize substances PMDBM2020261 644 Aeromonas hydrophila PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000781 Microbes metabolize substances PMDBM2020261 644 Aeromonas hydrophila PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000782 Microbes metabolize substances PMDBM2020261 644 Aeromonas hydrophila PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000783 Microbes metabolize substances PMDBM2020261 644 Aeromonas hydrophila PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000786 Microbes metabolize substances PMDBM2020261 644 Aeromonas hydrophila PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20000787 Microbes metabolize substances PMDBM2020261 644 Aeromonas hydrophila PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000788 Microbes metabolize substances PMDBM2020261 644 Aeromonas hydrophila PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000789 Microbes metabolize substances PMDBM2020261 644 Aeromonas hydrophila PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000790 Microbes metabolize substances PMDBM2020261 644 Aeromonas hydrophila PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000791 Microbes metabolize substances PMDBM2020261 644 Aeromonas hydrophila PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000792 Microbes metabolize substances PMDBM2020261 644 Aeromonas hydrophila PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000793 Microbes metabolize substances PMDBM2020261 644 Aeromonas hydrophila PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000794 Microbes metabolize substances PMDBM2020261 644 Aeromonas hydrophila PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000795 Microbes metabolize substances PMDBM2021405 948519 Aeromonas rivipollensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000796 Microbes metabolize substances PMDBM2021405 948519 Aeromonas rivipollensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000797 Microbes metabolize substances PMDBM2021405 948519 Aeromonas rivipollensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000798 Microbes metabolize substances PMDBM2021405 948519 Aeromonas rivipollensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000799 Microbes metabolize substances PMDBM2021405 948519 Aeromonas rivipollensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000800 Microbes metabolize substances PMDBM2021405 948519 Aeromonas rivipollensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000801 Microbes metabolize substances PMDBM2021405 948519 Aeromonas rivipollensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000804 Microbes metabolize substances PMDBM2021405 948519 Aeromonas rivipollensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20000805 Microbes metabolize substances PMDBM2021405 948519 Aeromonas rivipollensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000806 Microbes metabolize substances PMDBM2021405 948519 Aeromonas rivipollensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000807 Microbes metabolize substances PMDBM2021405 948519 Aeromonas rivipollensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000808 Microbes metabolize substances PMDBM2021405 948519 Aeromonas rivipollensis PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000809 Microbes metabolize substances PMDBM2021405 948519 Aeromonas rivipollensis PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000810 Microbes metabolize substances PMDBM2021405 948519 Aeromonas rivipollensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000811 Microbes metabolize substances PMDBM2021405 948519 Aeromonas rivipollensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000812 Microbes metabolize substances PMDBM2021405 948519 Aeromonas rivipollensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000813 Microbes metabolize substances PMDBM2020330 654 Aeromonas veronii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000814 Microbes metabolize substances PMDBM2020330 654 Aeromonas veronii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000816 Microbes metabolize substances PMDBM2020330 654 Aeromonas veronii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000817 Microbes metabolize substances PMDBM2020330 654 Aeromonas veronii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000818 Microbes metabolize substances PMDBM2020330 654 Aeromonas veronii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000819 Microbes metabolize substances PMDBM2020330 654 Aeromonas veronii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000820 Microbes metabolize substances PMDBM2020330 654 Aeromonas veronii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000821 Microbes metabolize substances PMDBM2020330 654 Aeromonas veronii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000824 Microbes metabolize substances PMDBM2020330 654 Aeromonas veronii PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20000826 Microbes metabolize substances PMDBM2020330 654 Aeromonas veronii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000828 Microbes metabolize substances PMDBM2020330 654 Aeromonas veronii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000830 Microbes metabolize substances PMDBM2020330 654 Aeromonas veronii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000831 Microbes metabolize substances PMDBM2020330 654 Aeromonas veronii PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000832 Microbes metabolize substances PMDBM2020330 654 Aeromonas veronii PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000833 Microbes metabolize substances PMDBM2020330 654 Aeromonas veronii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000835 Microbes metabolize substances PMDBM2020330 654 Aeromonas veronii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000837 Microbes metabolize substances PMDBM2020330 654 Aeromonas veronii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000839 Microbes metabolize substances PMDBM2021406 56946 Afipia broomeae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000840 Microbes metabolize substances PMDBM2021406 56946 Afipia broomeae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000841 Microbes metabolize substances PMDBM2021406 56946 Afipia broomeae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000842 Microbes metabolize substances PMDBM2021406 56946 Afipia broomeae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000843 Microbes metabolize substances PMDBM2021406 56946 Afipia broomeae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000844 Microbes metabolize substances PMDBM2021406 56946 Afipia broomeae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000845 Microbes metabolize substances PMDBM2021406 56946 Afipia broomeae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000848 Microbes metabolize substances PMDBM2021406 56946 Afipia broomeae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000849 Microbes metabolize substances PMDBM2021406 56946 Afipia broomeae PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000850 Microbes metabolize substances PMDBM2021406 56946 Afipia broomeae PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000851 Microbes metabolize substances PMDBM2021406 56946 Afipia broomeae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000852 Microbes metabolize substances PMDBM2008084 1766253 Agathobacter PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000853 Microbes metabolize substances PMDBM2008084 1766253 Agathobacter PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000854 Microbes metabolize substances PMDBM2008084 1766253 Agathobacter PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000855 Microbes metabolize substances PMDBM2008084 1766253 Agathobacter PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000857 Microbes metabolize substances PMDBM2008084 1766253 Agathobacter PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20000859 Microbes metabolize substances PMDBM2008084 1766253 Agathobacter PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20000860 Microbes metabolize substances PMDBM2008084 1766253 Agathobacter PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000861 Microbes metabolize substances PMDBM2008084 1766253 Agathobacter PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000862 Microbes metabolize substances PMDBM2008084 1766253 Agathobacter PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000863 Microbes metabolize substances PMDBM2008084 1766253 Agathobacter PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000866 Microbes metabolize substances PMDBM2008084 1766253 Agathobacter PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000867 Microbes metabolize substances PMDBM2008084 1766253 Agathobacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000868 Microbes metabolize substances PMDBM2008084 1766253 Agathobacter PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000869 Microbes metabolize substances PMDBM2008084 1766253 Agathobacter PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000871 Microbes metabolize substances PMDBM2008084 1766253 Agathobacter PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000872 Microbes metabolize substances PMDBM2008084 1766253 Agathobacter PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000873 Microbes metabolize substances PMDBM2008084 1766253 Agathobacter PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000874 Microbes metabolize substances PMDBM2020162 301302 Agathobacter faecis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000875 Microbes metabolize substances PMDBM2020162 301302 Agathobacter faecis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000876 Microbes metabolize substances PMDBM2020162 301302 Agathobacter faecis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000877 Microbes metabolize substances PMDBM2020162 301302 Agathobacter faecis PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20000878 Microbes metabolize substances PMDBM2020162 301302 Agathobacter faecis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000879 Microbes metabolize substances PMDBM2020162 301302 Agathobacter faecis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000880 Microbes metabolize substances PMDBM2020162 301302 Agathobacter faecis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000881 Microbes metabolize substances PMDBM2020162 301302 Agathobacter faecis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000884 Microbes metabolize substances PMDBM2020162 301302 Agathobacter faecis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000885 Microbes metabolize substances PMDBM2020162 301302 Agathobacter faecis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000886 Microbes metabolize substances PMDBM2020162 301302 Agathobacter faecis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000887 Microbes metabolize substances PMDBM2020162 301302 Agathobacter faecis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000888 Microbes metabolize substances PMDBM2020162 301302 Agathobacter faecis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000889 Microbes metabolize substances PMDBM2020223 39491 Agathobacter rectalis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000890 Microbes metabolize substances PMDBM2020223 39491 Agathobacter rectalis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000891 Microbes metabolize substances PMDBM2020223 39491 Agathobacter rectalis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000892 Microbes metabolize substances PMDBM2020223 39491 Agathobacter rectalis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000893 Microbes metabolize substances PMDBM2020223 39491 Agathobacter rectalis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000894 Microbes metabolize substances PMDBM2020223 39491 Agathobacter rectalis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000895 Microbes metabolize substances PMDBM2020223 39491 Agathobacter rectalis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000898 Microbes metabolize substances PMDBM2020223 39491 Agathobacter rectalis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000899 Microbes metabolize substances PMDBM2020223 39491 Agathobacter rectalis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000900 Microbes metabolize substances PMDBM2020223 39491 Agathobacter rectalis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000901 Microbes metabolize substances PMDBM2020223 39491 Agathobacter rectalis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000902 Microbes metabolize substances PMDBM2020223 39491 Agathobacter rectalis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000903 Microbes metabolize substances PMDBM2021407 2021311 Agathobacter sp000434275 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000904 Microbes metabolize substances PMDBM2021407 2021311 Agathobacter sp000434275 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000905 Microbes metabolize substances PMDBM2021407 2021311 Agathobacter sp000434275 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000906 Microbes metabolize substances PMDBM2021407 2021311 Agathobacter sp000434275 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000907 Microbes metabolize substances PMDBM2021407 2021311 Agathobacter sp000434275 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000908 Microbes metabolize substances PMDBM2021407 2021311 Agathobacter sp000434275 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000909 Microbes metabolize substances PMDBM2021407 2021311 Agathobacter sp000434275 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000912 Microbes metabolize substances PMDBM2021407 2021311 Agathobacter sp000434275 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000913 Microbes metabolize substances PMDBM2021407 2021311 Agathobacter sp000434275 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000914 Microbes metabolize substances PMDBM2021407 2021311 Agathobacter sp000434275 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000915 Microbes metabolize substances PMDBM2021407 2021311 Agathobacter sp000434275 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000916 Microbes metabolize substances PMDBM2021407 2021311 Agathobacter sp000434275 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000917 Microbes metabolize substances PMDBM2021407 2021311 Agathobacter sp000434275 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000918 Microbes metabolize substances PMDBM2021407 2021311 Agathobacter sp000434275 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000919 Microbes metabolize substances PMDBM2021407 2021311 Agathobacter sp000434275 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000920 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000921 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000922 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000923 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000924 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000925 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000926 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000927 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000930 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20000931 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20000932 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000933 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000934 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000935 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000936 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000937 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000938 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000939 Microbes metabolize substances PMDBM2008088 2048137 Agathobaculum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000940 Microbes metabolize substances PMDBM2021284 1628085 Agathobaculum butyriciproducens PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000941 Microbes metabolize substances PMDBM2021284 1628085 Agathobaculum butyriciproducens PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000942 Microbes metabolize substances PMDBM2021284 1628085 Agathobaculum butyriciproducens PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20000944 Microbes metabolize substances PMDBM2021284 1628085 Agathobaculum butyriciproducens PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20000945 Microbes metabolize substances PMDBM2021284 1628085 Agathobaculum butyriciproducens PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20000946 Microbes metabolize substances PMDBM2021284 1628085 Agathobaculum butyriciproducens PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20000947 Microbes metabolize substances PMDBM2021284 1628085 Agathobaculum butyriciproducens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000950 Microbes metabolize substances PMDBM2021284 1628085 Agathobaculum butyriciproducens PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20000954 Microbes metabolize substances PMDBM2021284 1628085 Agathobaculum butyriciproducens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000955 Microbes metabolize substances PMDBM2021284 1628085 Agathobaculum butyriciproducens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000956 Microbes metabolize substances PMDBM2021408 39484 Agathobaculum desmolans PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20000957 Microbes metabolize substances PMDBM2021408 39484 Agathobaculum desmolans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000958 Microbes metabolize substances PMDBM2021408 39484 Agathobaculum desmolans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000959 Microbes metabolize substances PMDBM2021408 39484 Agathobaculum desmolans PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000960 Microbes metabolize substances PMDBM2021409 2048138 Agathobaculum sp900291975 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20000961 Microbes metabolize substances PMDBM2021409 2048138 Agathobaculum sp900291975 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000962 Microbes metabolize substances PMDBM2021409 2048138 Agathobaculum sp900291975 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000963 Microbes metabolize substances PMDBM2021409 2048138 Agathobaculum sp900291975 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000964 Microbes metabolize substances PMDBM2021409 2048138 Agathobaculum sp900291975 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000965 Microbes metabolize substances PMDBM2021409 2048138 Agathobaculum sp900291975 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000966 Microbes metabolize substances PMDBM2020333 739 Aggregatibacter segnis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000967 Microbes metabolize substances PMDBM2020333 739 Aggregatibacter segnis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000968 Microbes metabolize substances PMDBM2020333 739 Aggregatibacter segnis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000969 Microbes metabolize substances PMDBM2020333 739 Aggregatibacter segnis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000970 Microbes metabolize substances PMDBM2020333 739 Aggregatibacter segnis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000971 Microbes metabolize substances PMDBM2020333 739 Aggregatibacter segnis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000972 Microbes metabolize substances PMDBM2020333 739 Aggregatibacter segnis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000975 Microbes metabolize substances PMDBM2020333 739 Aggregatibacter segnis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20000976 Microbes metabolize substances PMDBM2020333 739 Aggregatibacter segnis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20000977 Microbes metabolize substances PMDBM2020333 739 Aggregatibacter segnis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000978 Microbes metabolize substances PMDBM2020333 739 Aggregatibacter segnis PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000979 Microbes metabolize substances PMDBM2020333 739 Aggregatibacter segnis PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20000980 Microbes metabolize substances PMDBM2020333 739 Aggregatibacter segnis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20000981 Microbes metabolize substances PMDBM2020333 739 Aggregatibacter segnis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000982 Microbes metabolize substances PMDBM2020333 739 Aggregatibacter segnis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20000983 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20000984 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20000985 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20000986 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20000987 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000988 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000989 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20000990 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000991 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20000992 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20000994 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20000997 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20000998 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20000999 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001000 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001001 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001004 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20001007 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001008 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001009 Microbes metabolize substances PMDBM6 239934 Akkermansia PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001011 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20001012 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila PMDBD2000013 Abiraterone Therapeutic Substance prostate cancer n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Promote the body to respond better to drugs n.a. PMID PMID: 36467581 PMDBI20001013 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001014 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001015 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila A PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20001016 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001017 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001018 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001019 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001020 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001021 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001024 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila A PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001025 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001026 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001027 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001028 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001029 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001030 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001031 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila B PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20001032 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001033 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001034 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001035 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001036 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001037 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001040 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila B PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001041 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001042 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001043 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001044 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001045 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila C PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001046 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila C PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20001047 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila C PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001048 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila C PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001049 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila C PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001050 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila C PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001051 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila C PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001052 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila C PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001055 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila C PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001056 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila C PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001057 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila C PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001058 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila C PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001059 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila C PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001060 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila C PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001061 Microbes metabolize substances PMDBM2021410 1872421 Akkermansia sp001580195 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001062 Microbes metabolize substances PMDBM2021410 1872421 Akkermansia sp001580195 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20001063 Microbes metabolize substances PMDBM2021410 1872421 Akkermansia sp001580195 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001064 Microbes metabolize substances PMDBM2021410 1872421 Akkermansia sp001580195 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001065 Microbes metabolize substances PMDBM2021410 1872421 Akkermansia sp001580195 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001066 Microbes metabolize substances PMDBM2021410 1872421 Akkermansia sp001580195 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001067 Microbes metabolize substances PMDBM2021410 1872421 Akkermansia sp001580195 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001068 Microbes metabolize substances PMDBM2021410 1872421 Akkermansia sp001580195 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001071 Microbes metabolize substances PMDBM2021410 1872421 Akkermansia sp001580195 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001072 Microbes metabolize substances PMDBM2021410 1872421 Akkermansia sp001580195 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001073 Microbes metabolize substances PMDBM2021410 1872421 Akkermansia sp001580195 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001074 Microbes metabolize substances PMDBM2021410 1872421 Akkermansia sp001580195 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001075 Microbes metabolize substances PMDBM2021410 1872421 Akkermansia sp001580195 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001076 Microbes metabolize substances PMDBM2021410 1872421 Akkermansia sp001580195 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001077 Microbes metabolize substances PMDBM2021286 28197 Aliarcobacter butzleri PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001078 Microbes metabolize substances PMDBM2021286 28197 Aliarcobacter butzleri PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001079 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001080 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001081 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001082 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001084 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001086 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001087 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001088 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001089 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001090 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001091 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001093 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20001096 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20001097 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20001098 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001099 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001102 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20001105 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001106 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001107 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001109 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001110 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001111 Microbes metabolize substances PMDBM2008097 n.a. Alistipes A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001112 Microbes metabolize substances PMDBM2020341 1470347 Alistipes A ihumii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001113 Microbes metabolize substances PMDBM2020341 1470347 Alistipes A ihumii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001114 Microbes metabolize substances PMDBM2020341 1470347 Alistipes A ihumii PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001115 Microbes metabolize substances PMDBM2020341 1470347 Alistipes A ihumii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001116 Microbes metabolize substances PMDBM2020341 1470347 Alistipes A ihumii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001117 Microbes metabolize substances PMDBM2020341 1470347 Alistipes A ihumii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001118 Microbes metabolize substances PMDBM2020341 1470347 Alistipes A ihumii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001119 Microbes metabolize substances PMDBM2020341 1470347 Alistipes A ihumii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001120 Microbes metabolize substances PMDBM2020341 1470347 Alistipes A ihumii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001121 Microbes metabolize substances PMDBM2020076 626932 Alistipes A indistinctus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001122 Microbes metabolize substances PMDBM2020076 626932 Alistipes A indistinctus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001123 Microbes metabolize substances PMDBM2020076 626932 Alistipes A indistinctus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001124 Microbes metabolize substances PMDBM2020076 626932 Alistipes A indistinctus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001126 Microbes metabolize substances PMDBM2020076 626932 Alistipes A indistinctus PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001128 Microbes metabolize substances PMDBM2020076 626932 Alistipes A indistinctus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001129 Microbes metabolize substances PMDBM2020076 626932 Alistipes A indistinctus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001130 Microbes metabolize substances PMDBM2020076 626932 Alistipes A indistinctus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001131 Microbes metabolize substances PMDBM2020076 626932 Alistipes A indistinctus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001134 Microbes metabolize substances PMDBM2020076 626932 Alistipes A indistinctus PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001135 Microbes metabolize substances PMDBM2020076 626932 Alistipes A indistinctus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001136 Microbes metabolize substances PMDBM2020076 626932 Alistipes A indistinctus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001137 Microbes metabolize substances PMDBM2020076 626932 Alistipes A indistinctus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001138 Microbes metabolize substances PMDBM2020076 626932 Alistipes A indistinctus PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001140 Microbes metabolize substances PMDBM2020076 626932 Alistipes A indistinctus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001141 Microbes metabolize substances PMDBM2020076 626932 Alistipes A indistinctus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001142 Microbes metabolize substances PMDBM2020076 626932 Alistipes A indistinctus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001143 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001144 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001145 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001146 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001148 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001150 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001151 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001152 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001153 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001156 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001157 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001158 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001159 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001160 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001162 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001163 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001164 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001165 Microbes metabolize substances PMDBM2008100 n.a. Alistipes A sp900240235 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20001166 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001167 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001168 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001169 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001171 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001173 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001174 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001175 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001176 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001177 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001178 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001180 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20001183 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20001184 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20001185 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001186 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001187 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001190 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20001193 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001194 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001197 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001198 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001199 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001200 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD812 Sulfasalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. "sulfapyridine; 5-aminosalicylate" n.a. Azo reductases activation n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes n.a. PMID PMID: 36467581 PMDBI20001201 Microbes metabolize substances PMDBM2020340 214856 Alistipes finegoldii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001202 Microbes metabolize substances PMDBM2020340 214856 Alistipes finegoldii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001203 Microbes metabolize substances PMDBM2020340 214856 Alistipes finegoldii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001204 Microbes metabolize substances PMDBM2020340 214856 Alistipes finegoldii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001206 Microbes metabolize substances PMDBM2020340 214856 Alistipes finegoldii PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001208 Microbes metabolize substances PMDBM2020340 214856 Alistipes finegoldii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001209 Microbes metabolize substances PMDBM2020340 214856 Alistipes finegoldii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001210 Microbes metabolize substances PMDBM2020340 214856 Alistipes finegoldii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001211 Microbes metabolize substances PMDBM2020340 214856 Alistipes finegoldii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001214 Microbes metabolize substances PMDBM2020340 214856 Alistipes finegoldii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001215 Microbes metabolize substances PMDBM2020340 214856 Alistipes finegoldii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001216 Microbes metabolize substances PMDBM2020340 214856 Alistipes finegoldii PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001218 Microbes metabolize substances PMDBM2020340 214856 Alistipes finegoldii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001219 Microbes metabolize substances PMDBM2020340 214856 Alistipes finegoldii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001220 Microbes metabolize substances PMDBM2020340 214856 Alistipes finegoldii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001221 Microbes metabolize substances PMDBM2021411 2585118 Alistipes obesi PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001222 Microbes metabolize substances PMDBM2021411 2585118 Alistipes obesi PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001223 Microbes metabolize substances PMDBM2021411 2585118 Alistipes obesi PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001224 Microbes metabolize substances PMDBM2021411 2585118 Alistipes obesi PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001226 Microbes metabolize substances PMDBM2021411 2585118 Alistipes obesi PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001228 Microbes metabolize substances PMDBM2021411 2585118 Alistipes obesi PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001229 Microbes metabolize substances PMDBM2021411 2585118 Alistipes obesi PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001230 Microbes metabolize substances PMDBM2021411 2585118 Alistipes obesi PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001231 Microbes metabolize substances PMDBM2021411 2585118 Alistipes obesi PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001234 Microbes metabolize substances PMDBM2021411 2585118 Alistipes obesi PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001235 Microbes metabolize substances PMDBM2021411 2585118 Alistipes obesi PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001236 Microbes metabolize substances PMDBM2021411 2585118 Alistipes obesi PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001238 Microbes metabolize substances PMDBM2021411 2585118 Alistipes obesi PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001239 Microbes metabolize substances PMDBM2021411 2585118 Alistipes obesi PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001240 Microbes metabolize substances PMDBM2021411 2585118 Alistipes obesi PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001241 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001242 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001243 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001244 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001246 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001248 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001249 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001250 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001251 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001254 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001255 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001256 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001257 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001259 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. unknown toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001262 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD1166 Dolasetron Therapeutic substance antinauseant and antiemetic n.a. n.a. n.a. n.a. duloxetine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001263 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001264 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD1227 Hydrocortisone Therapeutic substance immune, inflammatory, and neoplastic conditions n.a. n.a. n.a. n.a. 20beta-dihydrocortisone n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001265 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" fungal infections n.a. n.a. n.a. n.a. ketoprofen n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001266 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. ketoprofen n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001267 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" lower the risk of cardiovascular disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001268 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD563 Mycophenolate mofetil Therapeutic Substance inosine monophosphate dehydrogenase inhibitor n.a. n.a. n.a. n.a. mycophenolic-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001269 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD1376 Praziquantel Therapeutic substance Anti-infection n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001270 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD1406 Ropinirole Therapeutic substance Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001271 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD1467 Torsemide Therapeutic substance loop diuretic n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001272 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001273 Microbes metabolize substances PMDBM2020342 328813 Alistipes onderdonkii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001274 Microbes metabolize substances PMDBM2020194 28117 Alistipes putredinis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001275 Microbes metabolize substances PMDBM2020194 28117 Alistipes putredinis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001276 Microbes metabolize substances PMDBM2020194 28117 Alistipes putredinis PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" cardiac glycoside n.a. n.a. n.a. n.a. dihydrodigoxin n.a. unknown involved in substrate metabolism n.a. n.a. n.a. inactivation n.a. PMID PMID: 36467581 PMDBI20001277 Microbes metabolize substances PMDBM2020194 28117 Alistipes putredinis PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" antimicrobial n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001278 Microbes metabolize substances PMDBM2020194 28117 Alistipes putredinis PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001279 Microbes metabolize substances PMDBM2020194 28117 Alistipes putredinis PMDBD1227 Hydrocortisone Therapeutic substance immune, inflammatory, and neoplastic conditions n.a. n.a. n.a. n.a. 20beta-dihydrocortisone n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001280 Microbes metabolize substances PMDBM2020194 28117 Alistipes putredinis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. ketoprofen n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001281 Microbes metabolize substances PMDBM2020194 28117 Alistipes putredinis PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" lower the risk of cardiovascular disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001282 Microbes metabolize substances PMDBM2020194 28117 Alistipes putredinis PMDBD1298 Misoprostol Therapeutic substance reduce the risk of NSAID induced gastric ulcers n.a. n.a. n.a. n.a. misoprostol-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001283 Microbes metabolize substances PMDBM2020194 28117 Alistipes putredinis PMDBD563 Mycophenolate mofetil Therapeutic Substance inosine monophosphate dehydrogenase inhibitor n.a. n.a. n.a. n.a. mycophenolic-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001284 Microbes metabolize substances PMDBM2020194 28117 Alistipes putredinis PMDBD1376 Praziquantel Therapeutic substance Anti-infection n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001285 Microbes metabolize substances PMDBM2020194 28117 Alistipes putredinis PMDBD750 Risperidone Therapeutic Substance second-generation antipsychotic (SGA) n.a. n.a. n.a. n.a. risperidone-M1 n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001286 Microbes metabolize substances PMDBM2020194 28117 Alistipes putredinis PMDBD1421 Spironolactone Therapeutic substance diuretic and also antihypertensive effects n.a. n.a. n.a. n.a. 7�thiospironolactone n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001287 Microbes metabolize substances PMDBM2020194 28117 Alistipes putredinis PMDBD812 Sulfasalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. sulfapyridine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001288 Microbes metabolize substances PMDBM2020194 28117 Alistipes putredinis PMDBD1467 Torsemide Therapeutic substance loop diuretic n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20001289 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001290 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001291 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001292 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001294 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001296 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001297 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001298 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001299 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001300 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001301 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001303 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20001306 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20001307 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20001308 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001309 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001312 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20001315 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20001316 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001317 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001320 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001321 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001322 Microbes metabolize substances PMDBM2020344 1288121 Alistipes senegalensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001323 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001324 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001325 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001326 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001327 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001328 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001329 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001330 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001331 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001333 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20001336 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20001337 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20001338 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001341 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20001344 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001345 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001346 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001348 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001349 Microbes metabolize substances PMDBM2020345 328814 Alistipes shahii PMDBD229 CpG oligodeoxynucleotides Therapeutic Substance oligodeoxynucleotides n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Alistipes shaii as a bacterial species positively associated with TNF production by tumor-associated myeloid cells. Oral administration of this microorganism to antibiotic-treated mice restored TNF production, enhanced CpG oligodeoxynucleotides efficacy n.a. PMID PMID: 36467581 PMDBI20001350 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp000434235 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001351 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp000434235 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001352 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp000434235 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001353 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp000434235 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001354 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp000434235 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001355 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp000434235 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001356 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp000434235 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001359 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp000434235 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001360 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp000434235 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001361 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp000434235 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001362 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp000434235 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001363 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp000434235 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001364 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp000434235 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001365 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp000434235 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001366 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp000434235 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001367 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp000434235 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001368 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001369 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001370 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001371 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001373 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001375 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001376 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001377 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001378 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001379 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001380 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001382 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20001385 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20001386 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20001387 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001388 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001389 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001392 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20001395 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001396 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001399 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001400 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001401 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp001941065 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001402 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001403 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001404 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001405 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001407 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001409 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001410 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001411 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001412 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001413 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001414 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001416 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20001419 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20001420 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20001421 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001422 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001423 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001426 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20001429 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001430 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001433 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001434 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002161445 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001435 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002358415 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001436 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002358415 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001437 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002358415 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20001439 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002358415 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20001440 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002358415 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20001441 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002358415 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001442 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002358415 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001443 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002358415 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001446 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002358415 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20001450 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002358415 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001451 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002358415 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001452 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp002358415 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001453 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900021155 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001454 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900021155 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001455 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900021155 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001456 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900021155 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001457 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900021155 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001458 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900021155 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001459 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900021155 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001462 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900021155 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001463 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900021155 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001464 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900021155 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001465 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900021155 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001466 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900021155 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001467 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900021155 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001468 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900021155 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001469 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900021155 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001470 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900021155 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001471 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001472 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001473 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001474 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001476 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001478 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001479 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001480 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001481 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001482 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001483 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001485 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20001488 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20001489 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20001490 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001491 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001492 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001495 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20001498 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001499 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001500 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001502 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001503 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001504 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900083545 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001505 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900290115 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001506 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900290115 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001507 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900290115 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001508 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900290115 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001509 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900290115 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001510 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900290115 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001511 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900290115 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001514 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900290115 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001515 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900290115 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001516 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900290115 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001517 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900290115 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001518 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900290115 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001519 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900290115 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001520 Microbes metabolize substances PMDBM2021412 1872444 Alistipes sp900290115 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001521 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001522 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001523 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001524 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001526 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001528 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001529 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001530 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001531 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001532 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001533 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001535 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20001538 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20001539 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20001540 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001541 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001542 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001545 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20001548 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001549 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001552 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001553 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001554 Microbes metabolize substances PMDBM2021413 1465754 Alistipes timonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001555 Microbes metabolize substances PMDBM2021414 209880 Allisonella histaminiformans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001556 Microbes metabolize substances PMDBM2020390 76122 Alloprevotella tannerae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001557 Microbes metabolize substances PMDBM2020390 76122 Alloprevotella tannerae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001558 Microbes metabolize substances PMDBM2020390 76122 Alloprevotella tannerae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001559 Microbes metabolize substances PMDBM2020390 76122 Alloprevotella tannerae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001560 Microbes metabolize substances PMDBM2020390 76122 Alloprevotella tannerae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001561 Microbes metabolize substances PMDBM2020352 419015 Alloscardovia omnicolens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001562 Microbes metabolize substances PMDBM2020352 419015 Alloscardovia omnicolens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001563 Microbes metabolize substances PMDBM2020352 419015 Alloscardovia omnicolens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001564 Microbes metabolize substances PMDBM2020352 419015 Alloscardovia omnicolens PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001566 Microbes metabolize substances PMDBM2020352 419015 Alloscardovia omnicolens PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001568 Microbes metabolize substances PMDBM2020352 419015 Alloscardovia omnicolens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001569 Microbes metabolize substances PMDBM2020352 419015 Alloscardovia omnicolens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001570 Microbes metabolize substances PMDBM2020352 419015 Alloscardovia omnicolens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001571 Microbes metabolize substances PMDBM2020352 419015 Alloscardovia omnicolens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001574 Microbes metabolize substances PMDBM2020352 419015 Alloscardovia omnicolens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001575 Microbes metabolize substances PMDBM2020352 419015 Alloscardovia omnicolens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001576 Microbes metabolize substances PMDBM2020352 419015 Alloscardovia omnicolens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001577 Microbes metabolize substances PMDBM2020352 419015 Alloscardovia omnicolens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001578 Microbes metabolize substances PMDBM2020352 419015 Alloscardovia omnicolens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001579 Microbes metabolize substances PMDBM2008116 n.a. Anaerobic PMDBD2000014 Sulphinpyrazone Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. Sulphide formation n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Sulphide formation n.a. PMID PMID: 36467581 PMDBI20001580 Microbes metabolize substances PMDBM2008116 n.a. Anaerobic PMDBD816 Sulindac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. Sulphide formation n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Sulphide formation n.a. PMID PMID: 36467581 PMDBI20001581 Microbes metabolize substances PMDBM2008116 n.a. Anaerobic PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Sorivudine hydrolysis by intestinal anaerobic bacteria results in high blood concentration of 5-(E)-(2-bromovinyl)uracil increasing the level and toxicity of 5-fluorouracil during chemotherapy. n.a. PMID PMID: 36467581 PMDBI20001582 Microbes metabolize substances PMDBM2008117 n.a. Anaerobic Bacterium(Mt1B8) PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" a weakly estrogenic compound with potential health n.a. n.a. n.a. n.a. Dihydrodaidzein, equol n.a. unknown activity increased n.a. n.a. n.a. Increased activity by conversion into Dihydrodaidzein, equol, or O-desmethylanolensin (ODMA) n.a. PMID PMID: 36467581 PMDBI20001583 Microbes metabolize substances PMDBM2008118 n.a. anaerobic cecal florn PMDBD553 Misonidazole Therapeutic Substance Tumor Hypoxia n.a. n.a. n.a. n.a. n.a. n.a. Nitroreductase toxicity n.a. n.a. n.a. induced neurotoxicity n.a. PMID PMID: 36467581 PMDBI20001584 Microbes metabolize substances PMDBM2008119 13334 Anaerobiospirillum PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001585 Microbes metabolize substances PMDBM2008119 13334 Anaerobiospirillum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001586 Microbes metabolize substances PMDBM2008119 13334 Anaerobiospirillum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001587 Microbes metabolize substances PMDBM2008119 13334 Anaerobiospirillum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001588 Microbes metabolize substances PMDBM2008119 13334 Anaerobiospirillum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001589 Microbes metabolize substances PMDBM2020354 13335 Anaerobiospirillum succiniciproducens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001590 Microbes metabolize substances PMDBM630 165779 Anaerococcus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001591 Microbes metabolize substances PMDBM630 165779 Anaerococcus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001592 Microbes metabolize substances PMDBM630 165779 Anaerococcus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001593 Microbes metabolize substances PMDBM630 165779 Anaerococcus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001594 Microbes metabolize substances PMDBM630 165779 Anaerococcus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001595 Microbes metabolize substances PMDBM630 165779 Anaerococcus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001596 Microbes metabolize substances PMDBM630 165779 Anaerococcus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001599 Microbes metabolize substances PMDBM630 165779 Anaerococcus PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001600 Microbes metabolize substances PMDBM630 165779 Anaerococcus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001601 Microbes metabolize substances PMDBM630 165779 Anaerococcus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001602 Microbes metabolize substances PMDBM630 165779 Anaerococcus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001603 Microbes metabolize substances PMDBM630 165779 Anaerococcus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001604 Microbes metabolize substances PMDBM630 165779 Anaerococcus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001605 Microbes metabolize substances PMDBM630 165779 Anaerococcus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001606 Microbes metabolize substances PMDBM630 165779 Anaerococcus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001607 Microbes metabolize substances PMDBM630 165779 Anaerococcus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001608 Microbes metabolize substances PMDBM2020407 33037 Anaerococcus vaginalis B PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20001609 Microbes metabolize substances PMDBM2020407 33037 Anaerococcus vaginalis B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001610 Microbes metabolize substances PMDBM2020407 33037 Anaerococcus vaginalis B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001611 Microbes metabolize substances PMDBM2020407 33037 Anaerococcus vaginalis B PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001612 Microbes metabolize substances PMDBM2020407 33037 Anaerococcus vaginalis B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001613 Microbes metabolize substances PMDBM2020407 33037 Anaerococcus vaginalis B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001614 Microbes metabolize substances PMDBM2020203 33029 Anaerococcus hydrogenalis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001615 Microbes metabolize substances PMDBM2020203 33029 Anaerococcus hydrogenalis PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20001616 Microbes metabolize substances PMDBM2020203 33029 Anaerococcus hydrogenalis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001617 Microbes metabolize substances PMDBM2020203 33029 Anaerococcus hydrogenalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001618 Microbes metabolize substances PMDBM2020203 33029 Anaerococcus hydrogenalis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001619 Microbes metabolize substances PMDBM2020203 33029 Anaerococcus hydrogenalis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001620 Microbes metabolize substances PMDBM2020356 33032 Anaerococcus lactolyticus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001621 Microbes metabolize substances PMDBM2020356 33032 Anaerococcus lactolyticus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001622 Microbes metabolize substances PMDBM2020357 1287640 Anaerococcus obesiensis PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20001623 Microbes metabolize substances PMDBM2020357 1287640 Anaerococcus obesiensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001624 Microbes metabolize substances PMDBM2020357 1287640 Anaerococcus obesiensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001625 Microbes metabolize substances PMDBM2020357 1287640 Anaerococcus obesiensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001626 Microbes metabolize substances PMDBM2020357 1287640 Anaerococcus obesiensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001627 Microbes metabolize substances PMDBM2021415 54007 Anaerococcus octavius PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001628 Microbes metabolize substances PMDBM2021415 54007 Anaerococcus octavius PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001629 Microbes metabolize substances PMDBM2021415 54007 Anaerococcus octavius PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001630 Microbes metabolize substances PMDBM2021415 54007 Anaerococcus octavius PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001631 Microbes metabolize substances PMDBM2021415 54007 Anaerococcus octavius PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001632 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001633 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001634 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001635 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001636 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001637 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001638 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001641 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001642 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001643 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001644 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001645 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001646 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001647 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001648 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001649 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001650 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001651 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001652 Microbes metabolize substances PMDBM2020358 33034 Anaerococcus prevotii A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001653 Microbes metabolize substances PMDBM2020359 1720199 Anaerococcus rubeinfantis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001654 Microbes metabolize substances PMDBM2020359 1720199 Anaerococcus rubeinfantis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001655 Microbes metabolize substances PMDBM2020359 1720199 Anaerococcus rubeinfantis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001656 Microbes metabolize substances PMDBM2020359 1720199 Anaerococcus rubeinfantis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001657 Microbes metabolize substances PMDBM2020359 1720199 Anaerococcus rubeinfantis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001658 Microbes metabolize substances PMDBM2020359 1720199 Anaerococcus rubeinfantis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001659 Microbes metabolize substances PMDBM2020360 1288120 Anaerococcus senegalensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001660 Microbes metabolize substances PMDBM2020360 1288120 Anaerococcus senegalensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001661 Microbes metabolize substances PMDBM2020360 1288120 Anaerococcus senegalensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001662 Microbes metabolize substances PMDBM2020360 1288120 Anaerococcus senegalensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001663 Microbes metabolize substances PMDBM2020360 1288120 Anaerococcus senegalensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001664 Microbes metabolize substances PMDBM2020360 1288120 Anaerococcus senegalensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001665 Microbes metabolize substances PMDBM2020360 1288120 Anaerococcus senegalensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001668 Microbes metabolize substances PMDBM2020360 1288120 Anaerococcus senegalensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001669 Microbes metabolize substances PMDBM2020360 1288120 Anaerococcus senegalensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001670 Microbes metabolize substances PMDBM2020360 1288120 Anaerococcus senegalensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001671 Microbes metabolize substances PMDBM2020360 1288120 Anaerococcus senegalensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001672 Microbes metabolize substances PMDBM2020360 1288120 Anaerococcus senegalensis PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001673 Microbes metabolize substances PMDBM2020360 1288120 Anaerococcus senegalensis PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001674 Microbes metabolize substances PMDBM2020360 1288120 Anaerococcus senegalensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001675 Microbes metabolize substances PMDBM2020360 1288120 Anaerococcus senegalensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001676 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp001182725 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001677 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp001182725 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20001678 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp001182725 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001679 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp001182725 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001680 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp001182725 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001681 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp001182725 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001682 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp002359915 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001683 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp002359915 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001684 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp002359915 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001685 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp002359915 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001686 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp002359915 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001687 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp002359915 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001688 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp900258475 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001689 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp900258475 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001690 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp900258475 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001691 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp900258475 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001692 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp900258475 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001693 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp900258475 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001694 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp900258475 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001697 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp900258475 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001698 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp900258475 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001699 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp900258475 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001700 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp900258475 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001701 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp900258475 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001702 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp900258475 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001703 Microbes metabolize substances PMDBM2021416 1872515 Anaerococcus sp900258475 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001704 Microbes metabolize substances PMDBM2021417 1527 Anaerocolumna aminovalerica PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001705 Microbes metabolize substances PMDBM2021417 1527 Anaerocolumna aminovalerica PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001706 Microbes metabolize substances PMDBM2021417 1527 Anaerocolumna aminovalerica PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001707 Microbes metabolize substances PMDBM2021417 1527 Anaerocolumna aminovalerica PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001709 Microbes metabolize substances PMDBM2021417 1527 Anaerocolumna aminovalerica PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001711 Microbes metabolize substances PMDBM2021417 1527 Anaerocolumna aminovalerica PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001712 Microbes metabolize substances PMDBM2021417 1527 Anaerocolumna aminovalerica PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001713 Microbes metabolize substances PMDBM2021417 1527 Anaerocolumna aminovalerica PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001714 Microbes metabolize substances PMDBM2021417 1527 Anaerocolumna aminovalerica PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001717 Microbes metabolize substances PMDBM2021417 1527 Anaerocolumna aminovalerica PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001718 Microbes metabolize substances PMDBM2021417 1527 Anaerocolumna aminovalerica PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001719 Microbes metabolize substances PMDBM2021417 1527 Anaerocolumna aminovalerica PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001720 Microbes metabolize substances PMDBM2021417 1527 Anaerocolumna aminovalerica PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001722 Microbes metabolize substances PMDBM2021417 1527 Anaerocolumna aminovalerica PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001723 Microbes metabolize substances PMDBM2021417 1527 Anaerocolumna aminovalerica PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001724 Microbes metabolize substances PMDBM2021417 1527 Anaerocolumna aminovalerica PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001725 Microbes metabolize substances PMDBM2008134 264995 Anaerofustis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001726 Microbes metabolize substances PMDBM2008134 264995 Anaerofustis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001727 Microbes metabolize substances PMDBM2008134 264995 Anaerofustis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001728 Microbes metabolize substances PMDBM2008134 264995 Anaerofustis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001729 Microbes metabolize substances PMDBM2020410 214853 Anaerofustis stercorihominis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001730 Microbes metabolize substances PMDBM2020410 214853 Anaerofustis stercorihominis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001731 Microbes metabolize substances PMDBM2020410 214853 Anaerofustis stercorihominis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001732 Microbes metabolize substances PMDBM2020410 214853 Anaerofustis stercorihominis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001733 Microbes metabolize substances PMDBM2020363 156456 Anaeroglobus geminatus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001734 Microbes metabolize substances PMDBM2020363 156456 Anaeroglobus geminatus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001735 Microbes metabolize substances PMDBM2020363 156456 Anaeroglobus geminatus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001736 Microbes metabolize substances PMDBM2020363 156456 Anaeroglobus geminatus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001737 Microbes metabolize substances PMDBM2020363 156456 Anaeroglobus geminatus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001738 Microbes metabolize substances PMDBM2020363 156456 Anaeroglobus geminatus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001739 Microbes metabolize substances PMDBM2020363 156456 Anaeroglobus geminatus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001742 Microbes metabolize substances PMDBM2020363 156456 Anaeroglobus geminatus PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20001743 Microbes metabolize substances PMDBM2020363 156456 Anaeroglobus geminatus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001744 Microbes metabolize substances PMDBM2020363 156456 Anaeroglobus geminatus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001745 Microbes metabolize substances PMDBM2020363 156456 Anaeroglobus geminatus PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001746 Microbes metabolize substances PMDBM2020363 156456 Anaeroglobus geminatus PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001747 Microbes metabolize substances PMDBM2020363 156456 Anaeroglobus geminatus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001748 Microbes metabolize substances PMDBM2020363 156456 Anaeroglobus geminatus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001749 Microbes metabolize substances PMDBM2021418 1872518 Anaeroglobus massiliensis PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20001750 Microbes metabolize substances PMDBM2021418 1872518 Anaeroglobus massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001751 Microbes metabolize substances PMDBM2021418 1872518 Anaeroglobus micronuciformis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001752 Microbes metabolize substances PMDBM2021418 1872518 Anaeroglobus micronuciformis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001753 Microbes metabolize substances PMDBM2021418 1872518 Anaeroglobus micronuciformis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001754 Microbes metabolize substances PMDBM2021418 1872518 Anaeroglobus micronuciformis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001755 Microbes metabolize substances PMDBM2021418 1872518 Anaeroglobus sp900240295 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20001756 Microbes metabolize substances PMDBM2021418 1872518 Anaeroglobus sp900240295 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001757 Microbes metabolize substances PMDBM2021418 1872518 Anaeroglobus sp900240295 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001758 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp001305115 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001759 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp001305115 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20001760 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp001305115 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001761 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp001305115 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001762 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp001305115 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001763 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp001305115 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001764 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp001305115 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001765 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp001305115 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001768 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp001305115 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001769 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp001305115 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001770 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp001305115 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001771 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp001305115 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001772 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp001305115 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001773 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp001305115 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001774 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp001305115 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001775 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp002159845 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20001776 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp002159845 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001777 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp002159845 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001778 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp002159845 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001779 Microbes metabolize substances PMDBM2021419 1924094 Anaeromassilibacillus sp002159845 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001780 Microbes metabolize substances PMDBM2020366 1347392 Anaerosalibacter A massiliensis PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20001781 Microbes metabolize substances PMDBM2020366 1347392 Anaerosalibacter A massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001782 Microbes metabolize substances PMDBM2020366 1347392 Anaerosalibacter A massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001783 Microbes metabolize substances PMDBM2020366 1347392 Anaerosalibacter A massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001784 Microbes metabolize substances PMDBM2020366 1347392 Anaerosalibacter A massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001785 Microbes metabolize substances PMDBM2020366 1347392 Anaerosalibacter A massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001786 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001787 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001788 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001789 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001791 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20001793 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001794 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001795 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001796 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001797 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001798 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001800 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20001803 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20001804 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20001805 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001806 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001809 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20001812 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001813 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001816 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001817 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001818 Microbes metabolize substances PMDBM2020367 264463 Anaerosporobacter mobilis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001819 Microbes metabolize substances PMDBM2008144 1794910 Anaerosporomusa PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20001820 Microbes metabolize substances PMDBM2008144 1794910 Anaerosporomusa PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20001821 Microbes metabolize substances PMDBM2008144 1794910 Anaerosporomusa PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001822 Microbes metabolize substances PMDBM2008144 1794910 Anaerosporomusa PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001823 Microbes metabolize substances PMDBM632 207244 Anaerostipes PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001824 Microbes metabolize substances PMDBM632 207244 Anaerostipes PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001825 Microbes metabolize substances PMDBM632 207244 Anaerostipes PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001826 Microbes metabolize substances PMDBM632 207244 Anaerostipes PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001827 Microbes metabolize substances PMDBM632 207244 Anaerostipes PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001828 Microbes metabolize substances PMDBM632 207244 Anaerostipes PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001829 Microbes metabolize substances PMDBM632 207244 Anaerostipes PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001832 Microbes metabolize substances PMDBM632 207244 Anaerostipes PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20001833 Microbes metabolize substances PMDBM632 207244 Anaerostipes PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001834 Microbes metabolize substances PMDBM632 207244 Anaerostipes PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001835 Microbes metabolize substances PMDBM632 207244 Anaerostipes PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001836 Microbes metabolize substances PMDBM632 207244 Anaerostipes PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001837 Microbes metabolize substances PMDBM632 207244 Anaerostipes PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001838 Microbes metabolize substances PMDBM632 207244 Anaerostipes PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001839 Microbes metabolize substances PMDBM632 207244 Anaerostipes PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001840 Microbes metabolize substances PMDBM632 207244 Anaerostipes PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001841 Microbes metabolize substances PMDBM2020368 105841 Anaerostipes caccae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001842 Microbes metabolize substances PMDBM2020368 105841 Anaerostipes caccae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001843 Microbes metabolize substances PMDBM2020368 105841 Anaerostipes caccae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001844 Microbes metabolize substances PMDBM2020368 105841 Anaerostipes caccae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001845 Microbes metabolize substances PMDBM2020368 105841 Anaerostipes caccae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001846 Microbes metabolize substances PMDBM2020368 105841 Anaerostipes caccae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001847 Microbes metabolize substances PMDBM2020368 105841 Anaerostipes caccae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001850 Microbes metabolize substances PMDBM2020368 105841 Anaerostipes caccae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001851 Microbes metabolize substances PMDBM2020368 105841 Anaerostipes caccae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001852 Microbes metabolize substances PMDBM2020368 105841 Anaerostipes caccae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001853 Microbes metabolize substances PMDBM2020368 105841 Anaerostipes caccae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001854 Microbes metabolize substances PMDBM2020368 105841 Anaerostipes caccae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001855 Microbes metabolize substances PMDBM2020368 105841 Anaerostipes caccae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001856 Microbes metabolize substances PMDBM2020368 105841 Anaerostipes caccae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001857 Microbes metabolize substances PMDBM2020368 105841 Anaerostipes caccae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001858 Microbes metabolize substances PMDBM2020369 649756 Anaerostipes hadrus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001859 Microbes metabolize substances PMDBM2020369 649756 Anaerostipes hadrus A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001860 Microbes metabolize substances PMDBM2020369 649756 Anaerostipes hadrus A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001861 Microbes metabolize substances PMDBM2020369 649756 Anaerostipes hadrus A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001862 Microbes metabolize substances PMDBM2020369 649756 Anaerostipes hadrus A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001863 Microbes metabolize substances PMDBM2020369 649756 Anaerostipes hadrus A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001864 Microbes metabolize substances PMDBM2020369 649756 Anaerostipes hadrus A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001865 Microbes metabolize substances PMDBM2020369 649756 Anaerostipes hadrus A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001868 Microbes metabolize substances PMDBM2020369 649756 Anaerostipes hadrus A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001869 Microbes metabolize substances PMDBM2020369 649756 Anaerostipes hadrus A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001870 Microbes metabolize substances PMDBM2020369 649756 Anaerostipes hadrus A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001871 Microbes metabolize substances PMDBM2020369 649756 Anaerostipes hadrus A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001872 Microbes metabolize substances PMDBM2020369 649756 Anaerostipes hadrus A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001873 Microbes metabolize substances PMDBM2020369 649756 Anaerostipes hadrus A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001874 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp000508985 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001875 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp000508985 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001876 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp000508985 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001877 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp000508985 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001878 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp000508985 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001879 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp000508985 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001880 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp000508985 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001883 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp000508985 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001884 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp000508985 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001885 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp000508985 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001886 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp000508985 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001887 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp000508985 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001888 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp000508985 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001889 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp000508985 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001890 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp000508985 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001891 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp000508985 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001892 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp900066705 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001893 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp900066705 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001894 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp900066705 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001895 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp900066705 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001896 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp900066705 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001897 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp900066705 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001898 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp900066705 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001901 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp900066705 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20001902 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp900066705 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001903 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp900066705 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001904 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp900066705 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001905 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp900066705 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001906 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp900066705 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001907 Microbes metabolize substances PMDBM2020052 1872530 Anaerostipes sp900066705 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001908 Microbes metabolize substances PMDBM2008150 3118652 Anaerotignaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001909 Microbes metabolize substances PMDBM2008150 3118652 Anaerotignaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001910 Microbes metabolize substances PMDBM2008150 3118652 Anaerotignaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001911 Microbes metabolize substances PMDBM2008150 3118652 Anaerotignaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001912 Microbes metabolize substances PMDBM2008151 2039240 Anaerotignum PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20001913 Microbes metabolize substances PMDBM2008151 2039240 Anaerotignum PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20001914 Microbes metabolize substances PMDBM2008151 2039240 Anaerotignum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001915 Microbes metabolize substances PMDBM2008151 2039240 Anaerotignum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001916 Microbes metabolize substances PMDBM2008151 2039240 Anaerotignum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001917 Microbes metabolize substances PMDBM2008151 2039240 Anaerotignum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001918 Microbes metabolize substances PMDBM2008151 2039240 Anaerotignum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001919 Microbes metabolize substances PMDBM2020370 160404 Anaerotignum lactatifermentans PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20001920 Microbes metabolize substances PMDBM2020370 160404 Anaerotignum lactatifermentans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001921 Microbes metabolize substances PMDBM2020370 160404 Anaerotignum lactatifermentans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001922 Microbes metabolize substances PMDBM2020370 160404 Anaerotignum lactatifermentans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001923 Microbes metabolize substances PMDBM2020370 160404 Anaerotignum lactatifermentans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001924 Microbes metabolize substances PMDBM2021420 2039241 Anaerotignum sp000436415 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001925 Microbes metabolize substances PMDBM2021420 2039241 Anaerotignum sp000436415 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001926 Microbes metabolize substances PMDBM2021420 2039241 Anaerotignum sp000436415 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001927 Microbes metabolize substances PMDBM2021420 2039241 Anaerotignum sp000436415 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001928 Microbes metabolize substances PMDBM2021420 2039241 Anaerotignum sp001304995 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20001929 Microbes metabolize substances PMDBM2021420 2039241 Anaerotignum sp001304995 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001930 Microbes metabolize substances PMDBM2021420 2039241 Anaerotignum sp001304995 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001931 Microbes metabolize substances PMDBM2021420 2039241 Anaerotignum sp001304995 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001932 Microbes metabolize substances PMDBM2021420 2039241 Anaerotignum sp001304995 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001933 Microbes metabolize substances PMDBM2021420 2039241 Anaerotignum sp001304995 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001934 Microbes metabolize substances PMDBM19 244127 Anaerotruncus PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001935 Microbes metabolize substances PMDBM19 244127 Anaerotruncus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001936 Microbes metabolize substances PMDBM19 244127 Anaerotruncus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001937 Microbes metabolize substances PMDBM19 244127 Anaerotruncus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001938 Microbes metabolize substances PMDBM19 244127 Anaerotruncus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001939 Microbes metabolize substances PMDBM19 244127 Anaerotruncus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001940 Microbes metabolize substances PMDBM2020215 169435 Anaerotruncus colihominis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001941 Microbes metabolize substances PMDBM2020215 169435 Anaerotruncus colihominis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001942 Microbes metabolize substances PMDBM2020215 169435 Anaerotruncus colihominis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001943 Microbes metabolize substances PMDBM2020215 169435 Anaerotruncus colihominis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001944 Microbes metabolize substances PMDBM2020215 169435 Anaerotruncus colihominis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001945 Microbes metabolize substances PMDBM2020215 169435 Anaerotruncus colihominis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001946 Microbes metabolize substances PMDBM2020215 169435 Anaerotruncus colihominis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001949 Microbes metabolize substances PMDBM2020215 169435 Anaerotruncus colihominis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20001950 Microbes metabolize substances PMDBM2020215 169435 Anaerotruncus colihominis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001951 Microbes metabolize substances PMDBM2020215 169435 Anaerotruncus colihominis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001952 Microbes metabolize substances PMDBM2020215 169435 Anaerotruncus colihominis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001953 Microbes metabolize substances PMDBM2020215 169435 Anaerotruncus colihominis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001954 Microbes metabolize substances PMDBM2020215 169435 Anaerotruncus colihominis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001955 Microbes metabolize substances PMDBM2020215 169435 Anaerotruncus colihominis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001956 Microbes metabolize substances PMDBM2020215 169435 Anaerotruncus colihominis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001957 Microbes metabolize substances PMDBM2020215 169435 Anaerotruncus colihominis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001958 Microbes metabolize substances PMDBM2021421 1720200 Anaerotruncus rubiinfantis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001959 Microbes metabolize substances PMDBM2021421 1720200 Anaerotruncus rubiinfantis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20001960 Microbes metabolize substances PMDBM2021421 1720200 Anaerotruncus rubiinfantis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20001962 Microbes metabolize substances PMDBM2021421 1720200 Anaerotruncus rubiinfantis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20001963 Microbes metabolize substances PMDBM2021421 1720200 Anaerotruncus rubiinfantis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20001964 Microbes metabolize substances PMDBM2021421 1720200 Anaerotruncus rubiinfantis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001965 Microbes metabolize substances PMDBM2021421 1720200 Anaerotruncus rubiinfantis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001968 Microbes metabolize substances PMDBM2021421 1720200 Anaerotruncus rubiinfantis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20001972 Microbes metabolize substances PMDBM2021421 1720200 Anaerotruncus rubiinfantis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001973 Microbes metabolize substances PMDBM2021421 1720200 Anaerotruncus rubiinfantis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001974 Microbes metabolize substances PMDBM2021422 1872531 Anaerotruncus sp900199635 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001975 Microbes metabolize substances PMDBM2021422 1872531 Anaerotruncus sp900199635 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001976 Microbes metabolize substances PMDBM2021422 1872531 Anaerotruncus sp900199635 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001977 Microbes metabolize substances PMDBM2021422 1872531 Anaerotruncus sp900199635 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001978 Microbes metabolize substances PMDBM2021422 1872531 Anaerotruncus sp900199635 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20001979 Microbes metabolize substances PMDBM2008157 82373 Anaerovibrio PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20001980 Microbes metabolize substances PMDBM2008157 82373 Anaerovibrio PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001981 Microbes metabolize substances PMDBM2008157 82373 Anaerovibrio PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001982 Microbes metabolize substances PMDBM2008157 82373 Anaerovibrio PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20001983 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20001984 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20001985 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20001986 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20001987 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20001988 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001989 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001990 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20001991 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20001994 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20001995 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20001996 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20001997 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20001998 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20001999 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002000 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002001 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002002 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002003 Microbes metabolize substances PMDBM2008158 3030910 Anaerovoracaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002004 Microbes metabolize substances PMDBM2020416 1391 Aneurinibacillus aneurinilyticus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002005 Microbes metabolize substances PMDBM2020416 1391 Aneurinibacillus aneurinilyticus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002006 Microbes metabolize substances PMDBM2020416 1391 Aneurinibacillus aneurinilyticus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002007 Microbes metabolize substances PMDBM2020416 1391 Aneurinibacillus aneurinilyticus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002008 Microbes metabolize substances PMDBM2008160 1935176 Angelakisella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002009 Microbes metabolize substances PMDBM2008160 1935176 Angelakisella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002010 Microbes metabolize substances PMDBM2008160 1935176 Angelakisella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002011 Microbes metabolize substances PMDBM2008160 1935176 Angelakisella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002012 Microbes metabolize substances PMDBM2008160 1935176 Angelakisella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002013 Microbes metabolize substances PMDBM2008160 1935176 Angelakisella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002014 Microbes metabolize substances PMDBM2008160 1935176 Angelakisella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002017 Microbes metabolize substances PMDBM2008160 1935176 Angelakisella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002018 Microbes metabolize substances PMDBM2008160 1935176 Angelakisella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002019 Microbes metabolize substances PMDBM2008160 1935176 Angelakisella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002020 Microbes metabolize substances PMDBM2008160 1935176 Angelakisella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002021 Microbes metabolize substances PMDBM2008160 1935176 Angelakisella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002022 Microbes metabolize substances PMDBM2008160 1935176 Angelakisella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002023 Microbes metabolize substances PMDBM2008160 1935176 Angelakisella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002024 Microbes metabolize substances PMDBM2008160 1935176 Angelakisella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002025 Microbes metabolize substances PMDBM2021423 1935177 Angelakisella sp003453215 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002026 Microbes metabolize substances PMDBM2021423 1935177 Angelakisella sp003453215 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002027 Microbes metabolize substances PMDBM2021423 1935177 Angelakisella sp003453215 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002028 Microbes metabolize substances PMDBM2021423 1935177 Angelakisella sp003453215 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002029 Microbes metabolize substances PMDBM2021423 1935177 Angelakisella sp003453215 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002030 Microbes metabolize substances PMDBM2021423 1935177 Angelakisella sp003453215 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002031 Microbes metabolize substances PMDBM2021423 1935177 Angelakisella sp003453215 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002034 Microbes metabolize substances PMDBM2021423 1935177 Angelakisella sp003453215 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002035 Microbes metabolize substances PMDBM2021423 1935177 Angelakisella sp003453215 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002036 Microbes metabolize substances PMDBM2021423 1935177 Angelakisella sp003453215 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002037 Microbes metabolize substances PMDBM2021423 1935177 Angelakisella sp003453215 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002038 Microbes metabolize substances PMDBM2021423 1935177 Angelakisella sp003453215 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002039 Microbes metabolize substances PMDBM2021423 1935177 Angelakisella sp003453215 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002040 Microbes metabolize substances PMDBM2021423 1935177 Angelakisella sp003453215 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002041 Microbes metabolize substances PMDBM2021423 1935177 Angelakisella sp003453215 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002042 Microbes metabolize substances PMDBM2021424 1870985 Arabia massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002043 Microbes metabolize substances PMDBM2021424 1870985 Arabia massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002044 Microbes metabolize substances PMDBM2021424 1870985 Arabia massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002045 Microbes metabolize substances PMDBM2021424 1870985 Arabia massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002046 Microbes metabolize substances PMDBM2021424 1870985 Arabia massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002047 Microbes metabolize substances PMDBM2021424 1870985 Arabia massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002048 Microbes metabolize substances PMDBM2021424 1870985 Arabia massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002051 Microbes metabolize substances PMDBM2021424 1870985 Arabia massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002052 Microbes metabolize substances PMDBM2021424 1870985 Arabia massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002053 Microbes metabolize substances PMDBM2021424 1870985 Arabia massiliensis PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002054 Microbes metabolize substances PMDBM2021424 1870985 Arabia massiliensis PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002055 Microbes metabolize substances PMDBM2021424 1870985 Arabia massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002056 Microbes metabolize substances PMDBM2021424 1870985 Arabia massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002057 Microbes metabolize substances PMDBM2021425 1871014 Arcanobacterium A urinimassiliense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002058 Microbes metabolize substances PMDBM2021425 1871014 Arcanobacterium A urinimassiliense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002059 Microbes metabolize substances PMDBM2021425 1871014 Arcanobacterium A urinimassiliense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002060 Microbes metabolize substances PMDBM2021425 1871014 Arcanobacterium A urinimassiliense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002061 Microbes metabolize substances PMDBM2021425 1871014 Arcanobacterium A urinimassiliense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002062 Microbes metabolize substances PMDBM2021425 1871014 Arcanobacterium A urinimassiliense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002063 Microbes metabolize substances PMDBM2021425 1871014 Arcanobacterium A urinimassiliense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002066 Microbes metabolize substances PMDBM2021425 1871014 Arcanobacterium A urinimassiliense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002067 Microbes metabolize substances PMDBM2021425 1871014 Arcanobacterium A urinimassiliense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002068 Microbes metabolize substances PMDBM2021425 1871014 Arcanobacterium A urinimassiliense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002069 Microbes metabolize substances PMDBM2021425 1871014 Arcanobacterium A urinimassiliense PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002070 Microbes metabolize substances PMDBM2021425 1871014 Arcanobacterium A urinimassiliense PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002071 Microbes metabolize substances PMDBM2021287 565 Atlantibacter hermannii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002072 Microbes metabolize substances PMDBM2021287 565 Atlantibacter hermannii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002073 Microbes metabolize substances PMDBM2021287 565 Atlantibacter hermannii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002074 Microbes metabolize substances PMDBM2021287 565 Atlantibacter hermannii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002075 Microbes metabolize substances PMDBM2021287 565 Atlantibacter hermannii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002076 Microbes metabolize substances PMDBM2021287 565 Atlantibacter hermannii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002077 Microbes metabolize substances PMDBM2021287 565 Atlantibacter hermannii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002080 Microbes metabolize substances PMDBM2021287 565 Atlantibacter hermannii PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20002081 Microbes metabolize substances PMDBM2021287 565 Atlantibacter hermannii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002082 Microbes metabolize substances PMDBM2021287 565 Atlantibacter hermannii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002083 Microbes metabolize substances PMDBM2021287 565 Atlantibacter hermannii PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20002084 Microbes metabolize substances PMDBM2021287 565 Atlantibacter hermannii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002085 Microbes metabolize substances PMDBM2021287 565 Atlantibacter hermannii PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002086 Microbes metabolize substances PMDBM2021287 565 Atlantibacter hermannii PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002087 Microbes metabolize substances PMDBM2021287 565 Atlantibacter hermannii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002088 Microbes metabolize substances PMDBM2021287 565 Atlantibacter hermannii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002089 Microbes metabolize substances PMDBM2021287 565 Atlantibacter hermannii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002090 Microbes metabolize substances PMDBM2008165 1643824 Atopobiaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002091 Microbes metabolize substances PMDBM2008165 1643824 Atopobiaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002092 Microbes metabolize substances PMDBM2008165 1643824 Atopobiaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002093 Microbes metabolize substances PMDBM2008165 1643824 Atopobiaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002094 Microbes metabolize substances PMDBM2008165 1643824 Atopobiaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002095 Microbes metabolize substances PMDBM2008165 1643824 Atopobiaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002096 Microbes metabolize substances PMDBM2008165 1643824 Atopobiaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002099 Microbes metabolize substances PMDBM2008165 1643824 Atopobiaceae PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20002100 Microbes metabolize substances PMDBM2008165 1643824 Atopobiaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002101 Microbes metabolize substances PMDBM2008165 1643824 Atopobiaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002102 Microbes metabolize substances PMDBM2008165 1643824 Atopobiaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002103 Microbes metabolize substances PMDBM2008165 1643824 Atopobiaceae PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002104 Microbes metabolize substances PMDBM2008165 1643824 Atopobiaceae PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002105 Microbes metabolize substances PMDBM2008165 1643824 Atopobiaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002106 Microbes metabolize substances PMDBM2008165 1643824 Atopobiaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002107 Microbes metabolize substances PMDBM2020427 1381 Atopobium minutum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002108 Microbes metabolize substances PMDBM2020427 1381 Atopobium minutum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002109 Microbes metabolize substances PMDBM2020427 1381 Atopobium minutum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002110 Microbes metabolize substances PMDBM2020427 1381 Atopobium minutum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002111 Microbes metabolize substances PMDBM2020427 1381 Atopobium minutum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002112 Microbes metabolize substances PMDBM2020427 1381 Atopobium minutum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002113 Microbes metabolize substances PMDBM2020427 1381 Atopobium minutum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002116 Microbes metabolize substances PMDBM2020427 1381 Atopobium minutum PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20002117 Microbes metabolize substances PMDBM2020427 1381 Atopobium minutum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002118 Microbes metabolize substances PMDBM2020427 1381 Atopobium minutum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002119 Microbes metabolize substances PMDBM2020427 1381 Atopobium minutum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002120 Microbes metabolize substances PMDBM2020427 1381 Atopobium minutum PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002121 Microbes metabolize substances PMDBM2020427 1381 Atopobium minutum PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002122 Microbes metabolize substances PMDBM2020427 1381 Atopobium minutum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002123 Microbes metabolize substances PMDBM2020427 1381 Atopobium minutum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002124 Microbes metabolize substances PMDBM2020005 1396 Bacillus A cereus AD PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002125 Microbes metabolize substances PMDBM2020005 1396 Bacillus A cereus AD PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002126 Microbes metabolize substances PMDBM2020005 1396 Bacillus A cereus AD PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002127 Microbes metabolize substances PMDBM2020005 1396 Bacillus A cereus AD PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002128 Microbes metabolize substances PMDBM2020005 1396 Bacillus A cereus AD PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002130 Microbes metabolize substances PMDBM2020005 1396 Bacillus A cereus AD PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002132 Microbes metabolize substances PMDBM2020005 1396 Bacillus A cereus AD PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002133 Microbes metabolize substances PMDBM2020005 1396 Bacillus A cereus AD PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002134 Microbes metabolize substances PMDBM2020005 1396 Bacillus A cereus AD PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002135 Microbes metabolize substances PMDBM2020005 1396 Bacillus A cereus AD PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002138 Microbes metabolize substances PMDBM2020005 1396 Bacillus A cereus AD PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002139 Microbes metabolize substances PMDBM2020005 1396 Bacillus A cereus AD PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002140 Microbes metabolize substances PMDBM2020005 1396 Bacillus A cereus AD PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002141 Microbes metabolize substances PMDBM2020005 1396 Bacillus A cereus AD PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002143 Microbes metabolize substances PMDBM2020005 1396 Bacillus A cereus AD PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002144 Microbes metabolize substances PMDBM2020005 1396 Bacillus A cereus AD PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002145 Microbes metabolize substances PMDBM2021426 518682 Bacillus A sp001884105 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002146 Microbes metabolize substances PMDBM2021426 518682 Bacillus A sp001884105 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002147 Microbes metabolize substances PMDBM2021426 518682 Bacillus A sp001884105 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002148 Microbes metabolize substances PMDBM2021426 518682 Bacillus A sp001884105 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002149 Microbes metabolize substances PMDBM2021426 518682 Bacillus A sp001884105 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20002150 Microbes metabolize substances PMDBM2021426 518682 Bacillus A sp001884105 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002151 Microbes metabolize substances PMDBM2021426 518682 Bacillus A sp001884105 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002152 Microbes metabolize substances PMDBM2021426 518682 Bacillus A sp001884105 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002153 Microbes metabolize substances PMDBM2021426 518682 Bacillus A sp001884105 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002156 Microbes metabolize substances PMDBM2021426 518682 Bacillus A sp001884105 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002157 Microbes metabolize substances PMDBM2021426 518682 Bacillus A sp001884105 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002158 Microbes metabolize substances PMDBM2021426 518682 Bacillus A sp001884105 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002159 Microbes metabolize substances PMDBM2021426 518682 Bacillus A sp001884105 PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002160 Microbes metabolize substances PMDBM2021426 518682 Bacillus A sp001884105 PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002161 Microbes metabolize substances PMDBM2021426 518682 Bacillus A sp001884105 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002162 Microbes metabolize substances PMDBM2021426 518682 Bacillus A sp001884105 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002163 Microbes metabolize substances PMDBM2020400 1428 Bacillus A thuringiensis S PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002164 Microbes metabolize substances PMDBM2020400 1428 Bacillus A thuringiensis S PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002165 Microbes metabolize substances PMDBM2020400 1428 Bacillus A thuringiensis S PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002166 Microbes metabolize substances PMDBM2020400 1428 Bacillus A thuringiensis S PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002167 Microbes metabolize substances PMDBM2020400 1428 Bacillus A thuringiensis S PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002168 Microbes metabolize substances PMDBM2020405 1890302 Bacillus A wiedmannii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002169 Microbes metabolize substances PMDBM2020405 1890302 Bacillus A wiedmannii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002170 Microbes metabolize substances PMDBM2020405 1890302 Bacillus A wiedmannii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002171 Microbes metabolize substances PMDBM2020405 1890302 Bacillus A wiedmannii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002172 Microbes metabolize substances PMDBM2020405 1890302 Bacillus A wiedmannii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002174 Microbes metabolize substances PMDBM2020405 1890302 Bacillus A wiedmannii PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002176 Microbes metabolize substances PMDBM2020405 1890302 Bacillus A wiedmannii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002177 Microbes metabolize substances PMDBM2020405 1890302 Bacillus A wiedmannii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002178 Microbes metabolize substances PMDBM2020405 1890302 Bacillus A wiedmannii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002179 Microbes metabolize substances PMDBM2020405 1890302 Bacillus A wiedmannii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002182 Microbes metabolize substances PMDBM2020405 1890302 Bacillus A wiedmannii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002183 Microbes metabolize substances PMDBM2020405 1890302 Bacillus A wiedmannii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002184 Microbes metabolize substances PMDBM2020405 1890302 Bacillus A wiedmannii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002185 Microbes metabolize substances PMDBM2020405 1890302 Bacillus A wiedmannii PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002187 Microbes metabolize substances PMDBM2020405 1890302 Bacillus A wiedmannii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002188 Microbes metabolize substances PMDBM2020405 1890302 Bacillus A wiedmannii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002189 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002190 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002191 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002192 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002193 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002194 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002195 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002196 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002197 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002198 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002200 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20002203 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20002204 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20002205 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002206 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002209 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20002212 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002213 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002214 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002216 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002217 Microbes metabolize substances PMDBM2021427 329472 Bacillus AC sp900199695 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002218 Microbes metabolize substances PMDBM2020386 1468413 Bacillus AD massilioanorexius PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002219 Microbes metabolize substances PMDBM2020386 1468413 Bacillus AD massilioanorexius PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002220 Microbes metabolize substances PMDBM2020386 1468413 Bacillus AD massilioanorexius PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002221 Microbes metabolize substances PMDBM2020386 1468413 Bacillus AD massilioanorexius PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002222 Microbes metabolize substances PMDBM2020399 1622072 Bacillus AD testis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002223 Microbes metabolize substances PMDBM2020399 1622072 Bacillus AD testis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002224 Microbes metabolize substances PMDBM2020399 1622072 Bacillus AD testis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002225 Microbes metabolize substances PMDBM2020399 1622072 Bacillus AD testis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002226 Microbes metabolize substances PMDBM2021428 1816695 Bacillus BD tuaregi PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002227 Microbes metabolize substances PMDBM2021428 1816695 Bacillus BD tuaregi PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20002228 Microbes metabolize substances PMDBM2021428 1816695 Bacillus BD tuaregi PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002229 Microbes metabolize substances PMDBM2021428 1816695 Bacillus BD tuaregi PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002230 Microbes metabolize substances PMDBM2021428 1816695 Bacillus BD tuaregi PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002231 Microbes metabolize substances PMDBM2021428 1816695 Bacillus BD tuaregi PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002232 Microbes metabolize substances PMDBM2021429 1805475 Bacillus BE massilionigeriensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002233 Microbes metabolize substances PMDBM2021429 1805475 Bacillus BE massilionigeriensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002234 Microbes metabolize substances PMDBM2021429 1805475 Bacillus BE massilionigeriensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002235 Microbes metabolize substances PMDBM2021429 1805475 Bacillus BE massilionigeriensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002236 Microbes metabolize substances PMDBM2021430 382695 Bacillus D sp000821085 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002237 Microbes metabolize substances PMDBM2021430 382695 Bacillus D sp000821085 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002238 Microbes metabolize substances PMDBM2021430 382695 Bacillus D sp000821085 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002239 Microbes metabolize substances PMDBM2021430 382695 Bacillus D sp000821085 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002240 Microbes metabolize substances PMDBM2021430 382695 Bacillus D sp000821085 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002241 Microbes metabolize substances PMDBM2021430 382695 Bacillus D sp000821085 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002242 Microbes metabolize substances PMDBM2021430 382695 Bacillus D sp000821085 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002243 Microbes metabolize substances PMDBM2021430 382695 Bacillus D sp000821085 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002246 Microbes metabolize substances PMDBM2021430 382695 Bacillus D sp000821085 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002247 Microbes metabolize substances PMDBM2021430 382695 Bacillus D sp000821085 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002248 Microbes metabolize substances PMDBM2021430 382695 Bacillus D sp000821085 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002249 Microbes metabolize substances PMDBM2021430 382695 Bacillus D sp000821085 PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002250 Microbes metabolize substances PMDBM2021430 382695 Bacillus D sp000821085 PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002251 Microbes metabolize substances PMDBM2021430 382695 Bacillus D sp000821085 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002252 Microbes metabolize substances PMDBM2021430 382695 Bacillus D sp000821085 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002253 Microbes metabolize substances PMDBM2021431 170488 Bacillus E coagulans PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002254 Microbes metabolize substances PMDBM2021431 170488 Bacillus E coagulans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002255 Microbes metabolize substances PMDBM2021431 170488 Bacillus E coagulans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002256 Microbes metabolize substances PMDBM2021431 170488 Bacillus E coagulans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002257 Microbes metabolize substances PMDBM2021431 170488 Bacillus E coagulans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002258 Microbes metabolize substances PMDBM2020380 1499685 Bacillus J andreraoultii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002259 Microbes metabolize substances PMDBM2020380 1499685 Bacillus J andreraoultii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002260 Microbes metabolize substances PMDBM2020380 1499685 Bacillus J andreraoultii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002261 Microbes metabolize substances PMDBM2020380 1499685 Bacillus J andreraoultii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002262 Microbes metabolize substances PMDBM2020380 1499685 Bacillus J andreraoultii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002263 Microbes metabolize substances PMDBM2020380 1499685 Bacillus J andreraoultii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002264 Microbes metabolize substances PMDBM2020380 1499685 Bacillus J andreraoultii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002265 Microbes metabolize substances PMDBM2020380 1499685 Bacillus J andreraoultii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002268 Microbes metabolize substances PMDBM2020380 1499685 Bacillus J andreraoultii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002269 Microbes metabolize substances PMDBM2020380 1499685 Bacillus J andreraoultii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002270 Microbes metabolize substances PMDBM2020380 1499685 Bacillus J andreraoultii PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002271 Microbes metabolize substances PMDBM2020380 1499685 Bacillus J andreraoultii PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002272 Microbes metabolize substances PMDBM2020380 1499685 Bacillus J andreraoultii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002273 Microbes metabolize substances PMDBM2020380 1499685 Bacillus J andreraoultii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002274 Microbes metabolize substances PMDBM2020380 1499685 Bacillus J andreraoultii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002275 Microbes metabolize substances PMDBM2021432 1196802 Bacillus K alcalophilus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002276 Microbes metabolize substances PMDBM2021432 1196802 Bacillus K alcalophilus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002277 Microbes metabolize substances PMDBM2021432 1196802 Bacillus K alcalophilus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002278 Microbes metabolize substances PMDBM2021432 1196802 Bacillus K alcalophilus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002279 Microbes metabolize substances PMDBM2021432 1196802 Bacillus K alcalophilus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002280 Microbes metabolize substances PMDBM2021432 1196802 Bacillus K alcalophilus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002281 Microbes metabolize substances PMDBM2021432 1196802 Bacillus K alcalophilus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002282 Microbes metabolize substances PMDBM2021432 1196802 Bacillus K alcalophilus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002285 Microbes metabolize substances PMDBM2021432 1196802 Bacillus K alcalophilus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002286 Microbes metabolize substances PMDBM2021432 1196802 Bacillus K alcalophilus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002287 Microbes metabolize substances PMDBM2021432 1196802 Bacillus K alcalophilus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002288 Microbes metabolize substances PMDBM2021432 1196802 Bacillus K alcalophilus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002289 Microbes metabolize substances PMDBM2021432 1196802 Bacillus K alcalophilus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002290 Microbes metabolize substances PMDBM2021432 1196802 Bacillus K alcalophilus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002291 Microbes metabolize substances PMDBM2021432 1196802 Bacillus K alcalophilus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002292 Microbes metabolize substances PMDBM2020385 1402 Bacillus licheniformis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002293 Microbes metabolize substances PMDBM2020385 1402 Bacillus licheniformis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002294 Microbes metabolize substances PMDBM2020385 1402 Bacillus licheniformis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002295 Microbes metabolize substances PMDBM2020385 1402 Bacillus licheniformis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002296 Microbes metabolize substances PMDBM2020385 1402 Bacillus licheniformis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002297 Microbes metabolize substances PMDBM2020385 1402 Bacillus licheniformis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002298 Microbes metabolize substances PMDBM2020385 1402 Bacillus licheniformis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002299 Microbes metabolize substances PMDBM2020385 1402 Bacillus licheniformis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002302 Microbes metabolize substances PMDBM2020385 1402 Bacillus licheniformis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002303 Microbes metabolize substances PMDBM2020385 1402 Bacillus licheniformis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002304 Microbes metabolize substances PMDBM2020385 1402 Bacillus licheniformis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002305 Microbes metabolize substances PMDBM2020385 1402 Bacillus licheniformis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002306 Microbes metabolize substances PMDBM2020385 1402 Bacillus licheniformis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002307 Microbes metabolize substances PMDBM2020385 1402 Bacillus licheniformis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002308 Microbes metabolize substances PMDBM2020385 1402 Bacillus licheniformis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002309 Microbes metabolize substances PMDBM2020395 1479 Bacillus O smithii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002310 Microbes metabolize substances PMDBM2020395 1479 Bacillus O smithii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002311 Microbes metabolize substances PMDBM2020395 1479 Bacillus O smithii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002312 Microbes metabolize substances PMDBM2020395 1479 Bacillus O smithii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002313 Microbes metabolize substances PMDBM2020395 1479 Bacillus O smithii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002314 Microbes metabolize substances PMDBM2020391 1648923 Bacillus paralicheniformis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002315 Microbes metabolize substances PMDBM2020391 1648923 Bacillus paralicheniformis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002316 Microbes metabolize substances PMDBM2020391 1648923 Bacillus paralicheniformis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002317 Microbes metabolize substances PMDBM2020391 1648923 Bacillus paralicheniformis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002318 Microbes metabolize substances PMDBM2020391 1648923 Bacillus paralicheniformis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002319 Microbes metabolize substances PMDBM2020391 1648923 Bacillus paralicheniformis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002320 Microbes metabolize substances PMDBM2020391 1648923 Bacillus paralicheniformis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002321 Microbes metabolize substances PMDBM2020391 1648923 Bacillus paralicheniformis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002324 Microbes metabolize substances PMDBM2020391 1648923 Bacillus paralicheniformis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002325 Microbes metabolize substances PMDBM2020391 1648923 Bacillus paralicheniformis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002326 Microbes metabolize substances PMDBM2020391 1648923 Bacillus paralicheniformis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002327 Microbes metabolize substances PMDBM2020391 1648923 Bacillus paralicheniformis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002328 Microbes metabolize substances PMDBM2020391 1648923 Bacillus paralicheniformis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002329 Microbes metabolize substances PMDBM2020391 1648923 Bacillus paralicheniformis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002330 Microbes metabolize substances PMDBM2020401 1033734 Bacillus Q timonensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002331 Microbes metabolize substances PMDBM2020401 1033734 Bacillus Q timonensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002332 Microbes metabolize substances PMDBM2020401 1033734 Bacillus Q timonensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002333 Microbes metabolize substances PMDBM2020401 1033734 Bacillus Q timonensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002334 Microbes metabolize substances PMDBM2020401 1033734 Bacillus Q timonensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002335 Microbes metabolize substances PMDBM2020401 1033734 Bacillus Q timonensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002336 Microbes metabolize substances PMDBM2020401 1033734 Bacillus Q timonensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002337 Microbes metabolize substances PMDBM2020401 1033734 Bacillus Q timonensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002340 Microbes metabolize substances PMDBM2020401 1033734 Bacillus Q timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002341 Microbes metabolize substances PMDBM2020401 1033734 Bacillus Q timonensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002342 Microbes metabolize substances PMDBM2020401 1033734 Bacillus Q timonensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002343 Microbes metabolize substances PMDBM2020401 1033734 Bacillus Q timonensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002344 Microbes metabolize substances PMDBM2020401 1033734 Bacillus Q timonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002345 Microbes metabolize substances PMDBM2020401 1033734 Bacillus Q timonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002346 Microbes metabolize substances PMDBM2020447 119858 Bacillus sonorensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002347 Microbes metabolize substances PMDBM2020447 119858 Bacillus sonorensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002348 Microbes metabolize substances PMDBM2020447 119858 Bacillus sonorensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002349 Microbes metabolize substances PMDBM2020447 119858 Bacillus sonorensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002350 Microbes metabolize substances PMDBM2020447 119858 Bacillus sonorensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002351 Microbes metabolize substances PMDBM2020447 119858 Bacillus sonorensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002352 Microbes metabolize substances PMDBM2020447 119858 Bacillus sonorensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002353 Microbes metabolize substances PMDBM2020447 119858 Bacillus sonorensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002356 Microbes metabolize substances PMDBM2020447 119858 Bacillus sonorensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002357 Microbes metabolize substances PMDBM2020447 119858 Bacillus sonorensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002358 Microbes metabolize substances PMDBM2020447 119858 Bacillus sonorensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002359 Microbes metabolize substances PMDBM2020447 119858 Bacillus sonorensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002360 Microbes metabolize substances PMDBM2020447 119858 Bacillus sonorensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002361 Microbes metabolize substances PMDBM2020447 119858 Bacillus sonorensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002362 Microbes metabolize substances PMDBM2021433 215720 Bacillus sp. 5-2 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002363 Microbes metabolize substances PMDBM2020080 1423 Bacillus subtilis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002364 Microbes metabolize substances PMDBM2020080 1423 Bacillus subtilis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002365 Microbes metabolize substances PMDBM2020080 1423 Bacillus subtilis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002366 Microbes metabolize substances PMDBM2020080 1423 Bacillus subtilis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002367 Microbes metabolize substances PMDBM2020080 1423 Bacillus subtilis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002368 Microbes metabolize substances PMDBM2020080 1423 Bacillus subtilis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002369 Microbes metabolize substances PMDBM2020080 1423 Bacillus subtilis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002370 Microbes metabolize substances PMDBM2020080 1423 Bacillus subtilis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002373 Microbes metabolize substances PMDBM2020080 1423 Bacillus subtilis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002374 Microbes metabolize substances PMDBM2020080 1423 Bacillus subtilis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002375 Microbes metabolize substances PMDBM2020080 1423 Bacillus subtilis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002376 Microbes metabolize substances PMDBM2020080 1423 Bacillus subtilis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002377 Microbes metabolize substances PMDBM2020080 1423 Bacillus subtilis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002378 Microbes metabolize substances PMDBM2020080 1423 Bacillus subtilis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002379 Microbes metabolize substances PMDBM2020080 1423 Bacillus subtilis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002380 Microbes metabolize substances PMDBM2021434 1196805 Bacillus V massiliosenegalensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002381 Microbes metabolize substances PMDBM2021434 1196805 Bacillus V massiliosenegalensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002382 Microbes metabolize substances PMDBM2021434 1196805 Bacillus V massiliosenegalensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002383 Microbes metabolize substances PMDBM2021434 1196805 Bacillus V massiliosenegalensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002384 Microbes metabolize substances PMDBM2021434 1196805 Bacillus V massiliosenegalensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002385 Microbes metabolize substances PMDBM2008187 n.a. Bacillus W jeddahensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002386 Microbes metabolize substances PMDBM2008187 n.a. Bacillus W jeddahensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002387 Microbes metabolize substances PMDBM2008187 n.a. Bacillus W jeddahensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002388 Microbes metabolize substances PMDBM2008187 n.a. Bacillus W jeddahensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002389 Microbes metabolize substances PMDBM2008187 n.a. Bacillus W jeddahensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002391 Microbes metabolize substances PMDBM2008187 n.a. Bacillus W jeddahensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002393 Microbes metabolize substances PMDBM2008187 n.a. Bacillus W jeddahensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002394 Microbes metabolize substances PMDBM2008187 n.a. Bacillus W jeddahensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002395 Microbes metabolize substances PMDBM2008187 n.a. Bacillus W jeddahensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002396 Microbes metabolize substances PMDBM2008187 n.a. Bacillus W jeddahensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002399 Microbes metabolize substances PMDBM2008187 n.a. Bacillus W jeddahensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002400 Microbes metabolize substances PMDBM2008187 n.a. Bacillus W jeddahensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002401 Microbes metabolize substances PMDBM2008187 n.a. Bacillus W jeddahensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002402 Microbes metabolize substances PMDBM2008187 n.a. Bacillus W jeddahensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002404 Microbes metabolize substances PMDBM2008187 n.a. Bacillus W jeddahensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002405 Microbes metabolize substances PMDBM2008187 n.a. Bacillus W jeddahensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002406 Microbes metabolize substances PMDBM2008187 n.a. Bacillus W jeddahensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002407 Microbes metabolize substances PMDBM2020394 1499680 Bacillus W rubiinfantis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002408 Microbes metabolize substances PMDBM2020394 1499680 Bacillus W rubiinfantis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002409 Microbes metabolize substances PMDBM2020394 1499680 Bacillus W rubiinfantis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002410 Microbes metabolize substances PMDBM2020394 1499680 Bacillus W rubiinfantis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002411 Microbes metabolize substances PMDBM2021435 1196806 Bacillus X simplex PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002412 Microbes metabolize substances PMDBM2021435 1196806 Bacillus X simplex PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002413 Microbes metabolize substances PMDBM2021435 1196806 Bacillus X simplex PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002414 Microbes metabolize substances PMDBM2021435 1196806 Bacillus X simplex PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002415 Microbes metabolize substances PMDBM2020267 820 Bacteriodes uniformans PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. quercetin-aglycone and polyphenols n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Microbiome-inducedhydrolysis leading toindirect mutageniceffect n.a. PMID PMID: 36467581 PMDBI20002416 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002417 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002418 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002419 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002421 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002423 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002424 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002425 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002426 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002427 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002428 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002430 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20002433 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20002434 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20002435 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20002436 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002437 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002440 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20002443 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002444 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002445 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002447 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002448 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD2000015 Anti-cytotoxic T-lymphocyte-associated antigen 4(CTLA-4) Therapeutic substance negative regulators of T cell proliferation and functions n.a. n.a. n.a. n.a. n.a. n.a. unknown side effect n.a. n.a. n.a. resistance to anti-CTLA-4-induced colitis n.a. PMID PMID: 36467581 PMDBI20002449 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002450 Microbes metabolize substances PMDBM28 815 Bacteroidaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002451 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002452 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002453 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002454 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002456 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002458 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002459 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002460 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002461 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002462 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002463 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002465 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20002468 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20002469 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20002470 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002471 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002474 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20002477 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002478 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002479 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002481 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002482 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002483 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002484 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002485 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002486 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002487 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD595 Nitrazepam Therapeutic Substance anticonvulsant and hypnotic n.a. n.a. n.a. n.a. n.a. n.a. Nitroreductase activity decreased n.a. n.a. n.a. Involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to nitroreduction n.a. PMID PMID: 36467581 PMDBI20002488 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002489 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. not absorbed intact but undergo hydrolysis by the intestinal microflora to steviol n.a. PMID PMID: 36467581 PMDBI20002490 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. not absorbed intact but undergo hydrolysis by the intestinal microflora to steviol n.a. PMID PMID: 36467581 PMDBI20002491 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. not absorbed intact but undergo hydrolysis by the intestinal microflora to steviol n.a. PMID PMID: 36467581 PMDBI20002492 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002494 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002502 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002503 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002504 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. Formation of three thiazole ring-opened metabolites, namely, levametabol-I, II and III n.a. unknown activity increased n.a. n.a. n.a. Through thiazole ring opening閿涘evamisole formation of three thiazole ring-opened metabolites, namely, levametabol-I, II and III n.a. PMID PMID: 36467581 PMDBI20002505 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD619 Omeprazole Therapeutic Substance gastric acid-related disorders n.a. n.a. n.a. n.a. Production of corresponding sulfide metabolites n.a. unknown activity decreased n.a. n.a. n.a. Through reduction閿涘meprazole production of corresponding sulfide metabolites n.a. PMID PMID: 36467581 PMDBI20002506 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. Compound K n.a. unknown activity increased n.a. n.a. n.a. Through hydrolysis閿涘瓘insenoside Rb1 formation Compound K n.a. PMID PMID: 36467581 PMDBI20002507 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002513 Microbes metabolize substances PMDBM31 816 bacteroides PMDBD471 Lactulose Therapeutic Substance laxative n.a. n.a. n.a. n.a. lactic and acetic acids n.a. unknown side effect n.a. n.a. n.a. The drug is hydrolyzed by several kinds of intestinal bacteria (lactobacillus, bacteroides and E. coli) to form lactic and acetic acids, which lower the pH of the intestinal contents . At the lower pH, ammonia and the other amines present in the gastroin-testinal tract become protonated and tend to be excreted in faeces, the accentuated elimination of these amines is responsible for the laxative effect of lactulose n.a. PMID PMID: 36467581 PMDBI20002514 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl)uracil n.a. unknown toxicity n.a. n.a. n.a. Increase toxicity by producing (E)-5-(2-bromovinyl)uracil (BVU) metabolite n.a. PMID PMID: 36467581 PMDBI20002517 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20002521 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20002522 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20002523 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20002525 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002531 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20002539 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002540 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002544 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002545 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD1460 Tolcapone Therapeutic substance Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity n.a. n.a. n.a. a potential link betweenthe gut microbiome and tolcapone toxicity n.a. PMID PMID: 36467581 PMDBI20002550 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002551 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002552 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD403 Glucuronides Environmental Chemicals Environmental Substance n.a. n.a. n.a. n.a. diclofenac,ketoprofen,indomethacin n.a. unknown toxicity increased n.a. n.a. n.a. Increase toxicity n.a. PMID PMID: 36467581 PMDBI20002554 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20002555 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002556 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002557 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002558 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002560 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002562 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002563 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002564 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002565 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002566 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002567 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002569 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20002572 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20002573 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20002574 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20002575 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002576 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002579 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20002582 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002583 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002586 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002587 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002588 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002589 Microbes metabolize substances PMDBM2020009 n.a. Bacteroides thetaiotaomicron E50,VPI 5482,DSM 2079,ATCC 29148,NCTC 10582 PMDBD1407 Rosiglitazone Therapeutic substance Anti-diabetics n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20002590 Microbes metabolize substances PMDBM2020009 n.a. Bacteroides thetaiotaomicron E50,VPI 5482,DSM 2079,ATCC 29148,NCTC 10582 PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Biotransformation n.a. PMID PMID: 36467581 PMDBI20002591 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20002592 Microbes metabolize substances PMDBM2020267 n.a. Bacteroides uniformis CL03T00C23,HM-715 PMDBD558 Montelukast Therapeutic Substance Drugs for obstructive airway disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20002593 Microbes metabolize substances PMDBM2020267 n.a. Bacteroides uniformis CL03T00C23,HM-715 PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20002594 Microbes metabolize substances PMDBM2020267 n.a. Bacteroides uniformis CL03T12C37,HM-716 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Biotransformation n.a. PMID PMID: 36467581 PMDBI20002595 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002596 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20002597 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002598 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002599 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002601 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002603 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002604 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002605 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002606 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002607 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002608 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002610 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20002613 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20002614 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20002615 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002616 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002619 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20002622 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002623 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002624 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002626 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002627 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002628 Microbes metabolize substances PMDBM2008195 n.a. Bacteroides A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002629 Microbes metabolize substances PMDBM2008196 n.a. Bacteroides A barnesiae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002630 Microbes metabolize substances PMDBM2008196 n.a. Bacteroides A barnesiae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002631 Microbes metabolize substances PMDBM2008196 n.a. Bacteroides A barnesiae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002632 Microbes metabolize substances PMDBM2008196 n.a. Bacteroides A barnesiae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002633 Microbes metabolize substances PMDBM2008196 n.a. Bacteroides A barnesiae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002634 Microbes metabolize substances PMDBM2008196 n.a. Bacteroides A barnesiae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002635 Microbes metabolize substances PMDBM2008196 n.a. Bacteroides A barnesiae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002638 Microbes metabolize substances PMDBM2008196 n.a. Bacteroides A barnesiae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002639 Microbes metabolize substances PMDBM2008196 n.a. Bacteroides A barnesiae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002640 Microbes metabolize substances PMDBM2008196 n.a. Bacteroides A barnesiae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002641 Microbes metabolize substances PMDBM2008196 n.a. Bacteroides A barnesiae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002642 Microbes metabolize substances PMDBM2008196 n.a. Bacteroides A barnesiae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002643 Microbes metabolize substances PMDBM2008196 n.a. Bacteroides A barnesiae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002644 Microbes metabolize substances PMDBM2008196 n.a. Bacteroides A barnesiae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002645 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002646 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002647 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002648 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002650 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002652 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002653 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002654 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002655 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002656 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002657 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002659 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20002662 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20002663 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20002664 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002665 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002668 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20002671 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002672 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002675 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002676 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002677 Microbes metabolize substances PMDBM2021436 1263040 Bacteroides A coprocola PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002678 Microbes metabolize substances PMDBM2021437 1263041 Bacteroides A coprophilus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002679 Microbes metabolize substances PMDBM2021437 1263041 Bacteroides A coprophilus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002680 Microbes metabolize substances PMDBM2021437 1263041 Bacteroides A coprophilus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002681 Microbes metabolize substances PMDBM2021437 1263041 Bacteroides A coprophilus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002682 Microbes metabolize substances PMDBM2021437 1263041 Bacteroides A coprophilus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002683 Microbes metabolize substances PMDBM2021437 1263041 Bacteroides A coprophilus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002684 Microbes metabolize substances PMDBM2021437 1263041 Bacteroides A coprophilus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002687 Microbes metabolize substances PMDBM2021437 1263041 Bacteroides A coprophilus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002688 Microbes metabolize substances PMDBM2021437 1263041 Bacteroides A coprophilus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002689 Microbes metabolize substances PMDBM2021437 1263041 Bacteroides A coprophilus PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002690 Microbes metabolize substances PMDBM2021437 1263041 Bacteroides A coprophilus PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002691 Microbes metabolize substances PMDBM2021437 1263041 Bacteroides A coprophilus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002692 Microbes metabolize substances PMDBM2021437 1263041 Bacteroides A coprophilus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002693 Microbes metabolize substances PMDBM2021437 1263041 Bacteroides A coprophilus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002694 Microbes metabolize substances PMDBM2021438 1907658 Bacteroides A ilei PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002695 Microbes metabolize substances PMDBM2021438 1907658 Bacteroides A ilei PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002696 Microbes metabolize substances PMDBM2021438 1907658 Bacteroides A ilei PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002697 Microbes metabolize substances PMDBM2021438 1907658 Bacteroides A ilei PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002699 Microbes metabolize substances PMDBM2021438 1907658 Bacteroides A ilei PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002701 Microbes metabolize substances PMDBM2021438 1907658 Bacteroides A ilei PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002702 Microbes metabolize substances PMDBM2021438 1907658 Bacteroides A ilei PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002703 Microbes metabolize substances PMDBM2021438 1907658 Bacteroides A ilei PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002704 Microbes metabolize substances PMDBM2021438 1907658 Bacteroides A ilei PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002707 Microbes metabolize substances PMDBM2021438 1907658 Bacteroides A ilei PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002708 Microbes metabolize substances PMDBM2021438 1907658 Bacteroides A ilei PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002709 Microbes metabolize substances PMDBM2021438 1907658 Bacteroides A ilei PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002710 Microbes metabolize substances PMDBM2021438 1907658 Bacteroides A ilei PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002712 Microbes metabolize substances PMDBM2021438 1907658 Bacteroides A ilei PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002713 Microbes metabolize substances PMDBM2021438 1907658 Bacteroides A ilei PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002714 Microbes metabolize substances PMDBM2021438 1907658 Bacteroides A ilei PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002715 Microbes metabolize substances PMDBM2021439 1841856 Bacteroides A mediterraneensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002716 Microbes metabolize substances PMDBM2021439 1841856 Bacteroides A mediterraneensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002717 Microbes metabolize substances PMDBM2021439 1841856 Bacteroides A mediterraneensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002718 Microbes metabolize substances PMDBM2021439 1841856 Bacteroides A mediterraneensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002720 Microbes metabolize substances PMDBM2021439 1841856 Bacteroides A mediterraneensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002722 Microbes metabolize substances PMDBM2021439 1841856 Bacteroides A mediterraneensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002723 Microbes metabolize substances PMDBM2021439 1841856 Bacteroides A mediterraneensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002724 Microbes metabolize substances PMDBM2021439 1841856 Bacteroides A mediterraneensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002725 Microbes metabolize substances PMDBM2021439 1841856 Bacteroides A mediterraneensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002728 Microbes metabolize substances PMDBM2021439 1841856 Bacteroides A mediterraneensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002729 Microbes metabolize substances PMDBM2021439 1841856 Bacteroides A mediterraneensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002730 Microbes metabolize substances PMDBM2021439 1841856 Bacteroides A mediterraneensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002731 Microbes metabolize substances PMDBM2021439 1841856 Bacteroides A mediterraneensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002733 Microbes metabolize substances PMDBM2021439 1841856 Bacteroides A mediterraneensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002734 Microbes metabolize substances PMDBM2021439 1841856 Bacteroides A mediterraneensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002735 Microbes metabolize substances PMDBM2021439 1841856 Bacteroides A mediterraneensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002736 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002737 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002738 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002739 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002740 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002741 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002742 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002743 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002744 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002746 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20002749 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20002750 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20002751 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002752 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002755 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20002758 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002759 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002760 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002762 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002763 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002764 Microbes metabolize substances PMDBM2021440 1263052 Bacteroides A plebeius A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002782 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A salanitronis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002783 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A salanitronis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002784 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A salanitronis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002785 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A salanitronis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002787 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A salanitronis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002789 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A salanitronis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002790 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A salanitronis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002791 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A salanitronis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002792 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A salanitronis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002795 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A salanitronis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002796 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A salanitronis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002797 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A salanitronis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002798 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A salanitronis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002800 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A salanitronis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002801 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A salanitronis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002802 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A salanitronis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002803 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002804 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002805 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002806 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002808 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002810 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002811 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002812 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002813 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002814 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002815 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002817 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20002820 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20002821 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20002822 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002823 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002826 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20002829 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002830 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002833 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002834 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002835 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000432735 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002836 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002837 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002838 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002839 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002841 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002843 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002844 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002845 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002846 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002847 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002848 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002850 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20002853 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20002854 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20002855 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002856 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002859 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20002862 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002863 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002864 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002866 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002867 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002868 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000434735 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002869 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000436795 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002870 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000436795 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002871 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000436795 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002872 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000436795 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002874 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000436795 PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002876 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000436795 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002877 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000436795 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002878 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000436795 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002879 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000436795 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002882 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000436795 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002883 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000436795 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002884 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000436795 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002885 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000436795 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002886 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000436795 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002887 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000436795 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002888 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000436795 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002889 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp000436795 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002890 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161565 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002891 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161565 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002892 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161565 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002893 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161565 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002894 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161565 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002895 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161565 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002896 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161565 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002899 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161565 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002900 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161565 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002901 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161565 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002902 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161565 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002903 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161565 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002904 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161565 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002905 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161565 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002906 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161565 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002907 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161765 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002908 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161765 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002909 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161765 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002910 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161765 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002912 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161765 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002914 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161765 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002915 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161765 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002916 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161765 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002917 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161765 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002920 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161765 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002921 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161765 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002922 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161765 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002923 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161765 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002925 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161765 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002926 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161765 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002927 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp002161765 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002949 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp900066455 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002950 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp900066455 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002951 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp900066455 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002952 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp900066455 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002954 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp900066455 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002956 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp900066455 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002957 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp900066455 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002958 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp900066455 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002959 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp900066455 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002962 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp900066455 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002963 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp900066455 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002964 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp900066455 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002965 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp900066455 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002967 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp900066455 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20002968 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp900066455 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002969 Microbes metabolize substances PMDBM2020420 29523 Bacteroides A sp900066455 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20002970 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20002971 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20002972 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20002973 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002975 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20002977 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002978 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002979 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20002980 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002981 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20002982 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20002984 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20002987 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20002988 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20002989 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20002990 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20002991 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20002994 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20002997 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20002998 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003001 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003002 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003003 Microbes metabolize substances PMDBM2020068 85831 Bacteroides acidifaciens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003004 Microbes metabolize substances PMDBM2008209 n.a. Bacteroides B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003005 Microbes metabolize substances PMDBM2008209 n.a. Bacteroides B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003006 Microbes metabolize substances PMDBM2008209 n.a. Bacteroides B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003007 Microbes metabolize substances PMDBM2008209 n.a. Bacteroides B PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003009 Microbes metabolize substances PMDBM2008209 n.a. Bacteroides B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003011 Microbes metabolize substances PMDBM2008209 n.a. Bacteroides B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003012 Microbes metabolize substances PMDBM2008209 n.a. Bacteroides B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003013 Microbes metabolize substances PMDBM2008209 n.a. Bacteroides B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003014 Microbes metabolize substances PMDBM2008209 n.a. Bacteroides B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003017 Microbes metabolize substances PMDBM2008209 n.a. Bacteroides B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003018 Microbes metabolize substances PMDBM2008209 n.a. Bacteroides B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003019 Microbes metabolize substances PMDBM2008209 n.a. Bacteroides B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003020 Microbes metabolize substances PMDBM2008209 n.a. Bacteroides B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003022 Microbes metabolize substances PMDBM2008209 n.a. Bacteroides B PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003023 Microbes metabolize substances PMDBM2008209 n.a. Bacteroides B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003024 Microbes metabolize substances PMDBM2008209 n.a. Bacteroides B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003025 Microbes metabolize substances PMDBM2021441 357276 Bacteroides B dorei PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003026 Microbes metabolize substances PMDBM2021441 357276 Bacteroides B dorei PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20003027 Microbes metabolize substances PMDBM2021441 357276 Bacteroides B dorei PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003028 Microbes metabolize substances PMDBM2021441 357276 Bacteroides B dorei PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003029 Microbes metabolize substances PMDBM2021441 357276 Bacteroides B dorei PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003031 Microbes metabolize substances PMDBM2021441 357276 Bacteroides B dorei PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003033 Microbes metabolize substances PMDBM2021441 357276 Bacteroides B dorei PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003034 Microbes metabolize substances PMDBM2021441 357276 Bacteroides B dorei PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003035 Microbes metabolize substances PMDBM2021441 357276 Bacteroides B dorei PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003036 Microbes metabolize substances PMDBM2021441 357276 Bacteroides B dorei PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003039 Microbes metabolize substances PMDBM2021441 357276 Bacteroides B dorei PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003040 Microbes metabolize substances PMDBM2021441 357276 Bacteroides B dorei PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003041 Microbes metabolize substances PMDBM2021441 357276 Bacteroides B dorei PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003043 Microbes metabolize substances PMDBM2021441 357276 Bacteroides B dorei PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003044 Microbes metabolize substances PMDBM2021441 357276 Bacteroides B dorei PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003045 Microbes metabolize substances PMDBM2021441 357276 Bacteroides B dorei PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003046 Microbes metabolize substances PMDBM2021302 204516 Bacteroides B massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003047 Microbes metabolize substances PMDBM2021302 204516 Bacteroides B massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20003048 Microbes metabolize substances PMDBM2021302 204516 Bacteroides B massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003049 Microbes metabolize substances PMDBM2021302 204516 Bacteroides B massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003050 Microbes metabolize substances PMDBM2021302 204516 Bacteroides B massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003051 Microbes metabolize substances PMDBM2021302 204516 Bacteroides B massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003052 Microbes metabolize substances PMDBM2021302 204516 Bacteroides B massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003053 Microbes metabolize substances PMDBM2021302 204516 Bacteroides B massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003056 Microbes metabolize substances PMDBM2021302 204516 Bacteroides B massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003057 Microbes metabolize substances PMDBM2021302 204516 Bacteroides B massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003058 Microbes metabolize substances PMDBM2021302 204516 Bacteroides B massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003059 Microbes metabolize substances PMDBM2021302 204516 Bacteroides B massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003060 Microbes metabolize substances PMDBM2021302 204516 Bacteroides B massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003061 Microbes metabolize substances PMDBM2021302 204516 Bacteroides B massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003062 Microbes metabolize substances PMDBM2021302 204516 Bacteroides B massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003063 Microbes metabolize substances PMDBM2021302 204516 Bacteroides B massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003064 Microbes metabolize substances PMDBM2021442 671267 Bacteroides B sartorii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003065 Microbes metabolize substances PMDBM2021442 671267 Bacteroides B sartorii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20003066 Microbes metabolize substances PMDBM2021442 671267 Bacteroides B sartorii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003067 Microbes metabolize substances PMDBM2021442 671267 Bacteroides B sartorii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003068 Microbes metabolize substances PMDBM2021442 671267 Bacteroides B sartorii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003070 Microbes metabolize substances PMDBM2021442 671267 Bacteroides B sartorii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003072 Microbes metabolize substances PMDBM2021442 671267 Bacteroides B sartorii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003073 Microbes metabolize substances PMDBM2021442 671267 Bacteroides B sartorii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003074 Microbes metabolize substances PMDBM2021442 671267 Bacteroides B sartorii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003075 Microbes metabolize substances PMDBM2021442 671267 Bacteroides B sartorii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003078 Microbes metabolize substances PMDBM2021442 671267 Bacteroides B sartorii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003079 Microbes metabolize substances PMDBM2021442 671267 Bacteroides B sartorii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003080 Microbes metabolize substances PMDBM2021442 671267 Bacteroides B sartorii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003081 Microbes metabolize substances PMDBM2021442 671267 Bacteroides B sartorii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003083 Microbes metabolize substances PMDBM2021442 671267 Bacteroides B sartorii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003084 Microbes metabolize substances PMDBM2021442 671267 Bacteroides B sartorii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003085 Microbes metabolize substances PMDBM2021442 671267 Bacteroides B sartorii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003086 Microbes metabolize substances PMDBM2020420 29523 Bacteroides B sp002493165 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003087 Microbes metabolize substances PMDBM2020420 29523 Bacteroides B sp002493165 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20003088 Microbes metabolize substances PMDBM2020420 29523 Bacteroides B sp002493165 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003089 Microbes metabolize substances PMDBM2020420 29523 Bacteroides B sp002493165 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003090 Microbes metabolize substances PMDBM2020420 29523 Bacteroides B sp002493165 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003091 Microbes metabolize substances PMDBM2020420 29523 Bacteroides B sp002493165 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003092 Microbes metabolize substances PMDBM2020420 29523 Bacteroides B sp002493165 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003093 Microbes metabolize substances PMDBM2020420 29523 Bacteroides B sp002493165 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003096 Microbes metabolize substances PMDBM2020420 29523 Bacteroides B sp002493165 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003097 Microbes metabolize substances PMDBM2020420 29523 Bacteroides B sp002493165 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003098 Microbes metabolize substances PMDBM2020420 29523 Bacteroides B sp002493165 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003099 Microbes metabolize substances PMDBM2020420 29523 Bacteroides B sp002493165 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003100 Microbes metabolize substances PMDBM2020420 29523 Bacteroides B sp002493165 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003101 Microbes metabolize substances PMDBM2020420 29523 Bacteroides B sp002493165 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003102 Microbes metabolize substances PMDBM2020420 29523 Bacteroides B sp002493165 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003103 Microbes metabolize substances PMDBM2020420 29523 Bacteroides B sp002493165 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003104 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003105 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003106 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003107 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003109 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003111 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003112 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003113 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003114 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003115 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003116 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003118 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20003121 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20003122 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20003123 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003124 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003127 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20003130 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003131 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003134 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003135 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003136 Microbes metabolize substances PMDBM2021443 1841855 Bacteroides bouchesdurhonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003137 Microbes metabolize substances PMDBM2008215 n.a. Bacteroides C PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003138 Microbes metabolize substances PMDBM2008215 n.a. Bacteroides C PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003139 Microbes metabolize substances PMDBM2008215 n.a. Bacteroides C PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003140 Microbes metabolize substances PMDBM2008215 n.a. Bacteroides C PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003142 Microbes metabolize substances PMDBM2008215 n.a. Bacteroides C PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003144 Microbes metabolize substances PMDBM2008215 n.a. Bacteroides C PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003145 Microbes metabolize substances PMDBM2008215 n.a. Bacteroides C PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003146 Microbes metabolize substances PMDBM2008215 n.a. Bacteroides C PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003147 Microbes metabolize substances PMDBM2008215 n.a. Bacteroides C PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003150 Microbes metabolize substances PMDBM2008215 n.a. Bacteroides C PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003151 Microbes metabolize substances PMDBM2008215 n.a. Bacteroides C PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003152 Microbes metabolize substances PMDBM2008215 n.a. Bacteroides C PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003154 Microbes metabolize substances PMDBM2008215 n.a. Bacteroides C PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003155 Microbes metabolize substances PMDBM2008215 n.a. Bacteroides C PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003156 Microbes metabolize substances PMDBM2008215 n.a. Bacteroides C PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003157 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003158 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003159 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003160 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003161 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003162 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003163 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003164 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003165 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003167 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20003170 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20003171 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20003172 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003173 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003176 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20003179 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003180 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003181 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003183 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003185 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" cardiac glycoside n.a. n.a. n.a. n.a. dihydrodigoxin n.a. unknown involved in substrate metabolism n.a. n.a. n.a. inactivation n.a. PMID PMID: 36467581 PMDBI20003187 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" antimicrobial n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003188 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003189 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD1227 Hydrocortisone Therapeutic substance immune, inflammatory, and neoplastic conditions n.a. n.a. n.a. n.a. 20beta-dihydrocortisone n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003190 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD477 Levonorgestrel Therapeutic Substance contraception and hormone n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003191 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" lower the risk of cardiovascular disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003192 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD1298 Misoprostol Therapeutic substance reduce the risk of NSAID induced gastric ulcers n.a. n.a. n.a. n.a. misoprostol-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003193 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD563 Mycophenolate mofetil Therapeutic Substance inosine monophosphate dehydrogenase inhibitor n.a. n.a. n.a. n.a. mycophenolic-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003194 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD750 Risperidone Therapeutic Substance second-generation antipsychotic (SGA) n.a. n.a. n.a. n.a. risperidone-M1 n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003195 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD1406 Ropinirole Therapeutic substance Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003196 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD1421 Spironolactone Therapeutic substance diuretic and also antihypertensive effects n.a. n.a. n.a. n.a. 7æµ?thiospironolactone n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003197 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD812 Sulfasalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. sulfapyridine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003198 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD816 Sulindac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. sulindac-M2 n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003199 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD1460 Tolcapone Therapeutic substance Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. a potential link betweenthe gut microbiome and tolcapone toxicity n.a. PMID PMID: 36467581 PMDBI20003200 Microbes metabolize substances PMDBM2020238 47678 Bacteroides caccae PMDBD1467 Torsemide Therapeutic substance loop diuretic n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003201 Microbes metabolize substances PMDBM2021444 1263038 Bacteroides cellulosilyticus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003202 Microbes metabolize substances PMDBM2021444 1263038 Bacteroides cellulosilyticus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20003203 Microbes metabolize substances PMDBM2021444 1263038 Bacteroides cellulosilyticus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003204 Microbes metabolize substances PMDBM2021444 1263038 Bacteroides cellulosilyticus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003205 Microbes metabolize substances PMDBM2021444 1263038 Bacteroides cellulosilyticus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003207 Microbes metabolize substances PMDBM2021444 1263038 Bacteroides cellulosilyticus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003209 Microbes metabolize substances PMDBM2021444 1263038 Bacteroides cellulosilyticus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003210 Microbes metabolize substances PMDBM2021444 1263038 Bacteroides cellulosilyticus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003211 Microbes metabolize substances PMDBM2021444 1263038 Bacteroides cellulosilyticus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003212 Microbes metabolize substances PMDBM2021444 1263038 Bacteroides cellulosilyticus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003215 Microbes metabolize substances PMDBM2021444 1263038 Bacteroides cellulosilyticus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003216 Microbes metabolize substances PMDBM2021444 1263038 Bacteroides cellulosilyticus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003217 Microbes metabolize substances PMDBM2021444 1263038 Bacteroides cellulosilyticus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003218 Microbes metabolize substances PMDBM2021444 1263038 Bacteroides cellulosilyticus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003220 Microbes metabolize substances PMDBM2021444 1263038 Bacteroides cellulosilyticus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003221 Microbes metabolize substances PMDBM2021444 1263038 Bacteroides cellulosilyticus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003222 Microbes metabolize substances PMDBM2021444 1263038 Bacteroides cellulosilyticus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003223 Microbes metabolize substances PMDBM2020006 626929 Bacteroides clarus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003224 Microbes metabolize substances PMDBM2020006 626929 Bacteroides clarus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20003225 Microbes metabolize substances PMDBM2020006 626929 Bacteroides clarus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003226 Microbes metabolize substances PMDBM2020006 626929 Bacteroides clarus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003227 Microbes metabolize substances PMDBM2020006 626929 Bacteroides clarus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003228 Microbes metabolize substances PMDBM2020006 626929 Bacteroides clarus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003229 Microbes metabolize substances PMDBM2020006 626929 Bacteroides clarus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003230 Microbes metabolize substances PMDBM2020006 626929 Bacteroides clarus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003233 Microbes metabolize substances PMDBM2020006 626929 Bacteroides clarus PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003234 Microbes metabolize substances PMDBM2020006 626929 Bacteroides clarus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003235 Microbes metabolize substances PMDBM2020006 626929 Bacteroides clarus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003236 Microbes metabolize substances PMDBM2020006 626929 Bacteroides clarus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003237 Microbes metabolize substances PMDBM2020006 626929 Bacteroides clarus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003238 Microbes metabolize substances PMDBM2020006 626929 Bacteroides clarus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003239 Microbes metabolize substances PMDBM2020006 626929 Bacteroides clarus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003240 Microbes metabolize substances PMDBM2020006 626929 Bacteroides clarus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003241 Microbes metabolize substances PMDBM2020006 626929 Bacteroides clarus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003242 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003243 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20003244 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003245 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003246 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003248 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003250 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003251 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003252 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003253 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003254 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003255 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003257 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20003260 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20003261 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20003262 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003263 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003266 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20003269 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003270 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003273 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003274 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003275 Microbes metabolize substances PMDBM2021445 1871006 Bacteroides congonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003276 Microbes metabolize substances PMDBM2021446 2024197 Bacteroides cutis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003277 Microbes metabolize substances PMDBM2021446 2024197 Bacteroides cutis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003278 Microbes metabolize substances PMDBM2021446 2024197 Bacteroides cutis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003279 Microbes metabolize substances PMDBM2021446 2024197 Bacteroides cutis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003280 Microbes metabolize substances PMDBM2021446 2024197 Bacteroides cutis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003281 Microbes metabolize substances PMDBM2021446 2024197 Bacteroides cutis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003282 Microbes metabolize substances PMDBM2021446 2024197 Bacteroides cutis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003285 Microbes metabolize substances PMDBM2021446 2024197 Bacteroides cutis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003286 Microbes metabolize substances PMDBM2021446 2024197 Bacteroides cutis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003287 Microbes metabolize substances PMDBM2021446 2024197 Bacteroides cutis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003288 Microbes metabolize substances PMDBM2021446 2024197 Bacteroides cutis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003289 Microbes metabolize substances PMDBM2021446 2024197 Bacteroides cutis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003290 Microbes metabolize substances PMDBM2021446 2024197 Bacteroides cutis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003291 Microbes metabolize substances PMDBM2021446 2024197 Bacteroides cutis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003292 Microbes metabolize substances PMDBM2021446 2024197 Bacteroides cutis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003293 Microbes metabolize substances PMDBM2021446 2024197 Bacteroides cutis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003294 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003295 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003296 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003297 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003299 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003301 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003302 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003303 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003304 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil n.a. PMID PMID: 36467581 PMDBI20003305 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003309 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003311 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003313 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003314 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD2000008 Genistin Therapeutic substance Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003315 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003316 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003318 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003319 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003320 Microbes metabolize substances PMDBM2020264 384638 Bacteroides F pectinophilus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003321 Microbes metabolize substances PMDBM2020264 384638 Bacteroides F pectinophilus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003322 Microbes metabolize substances PMDBM2020264 384638 Bacteroides F pectinophilus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003323 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003324 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003325 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003326 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003328 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD2000009 Naringin Therapeutic Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003330 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003331 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003332 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003333 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003334 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003335 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003337 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20003340 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20003341 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20003342 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003343 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003344 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003347 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20003350 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003351 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003352 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003354 Microbes metabolize substances PMDBM2020409 674529 Bacteroides faecis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003355 Microbes metabolize substances PMDBM2021447 1263045 Bacteroides finegoldii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003356 Microbes metabolize substances PMDBM2021447 1263045 Bacteroides finegoldii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003357 Microbes metabolize substances PMDBM2021447 1263045 Bacteroides finegoldii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003358 Microbes metabolize substances PMDBM2021447 1263045 Bacteroides finegoldii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003360 Microbes metabolize substances PMDBM2021447 1263045 Bacteroides finegoldii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003362 Microbes metabolize substances PMDBM2021447 1263045 Bacteroides finegoldii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003363 Microbes metabolize substances PMDBM2021447 1263045 Bacteroides finegoldii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003364 Microbes metabolize substances PMDBM2021447 1263045 Bacteroides finegoldii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003365 Microbes metabolize substances PMDBM2021447 1263045 Bacteroides finegoldii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003368 Microbes metabolize substances PMDBM2021447 1263045 Bacteroides finegoldii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003369 Microbes metabolize substances PMDBM2021447 1263045 Bacteroides finegoldii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003370 Microbes metabolize substances PMDBM2021447 1263045 Bacteroides finegoldii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003371 Microbes metabolize substances PMDBM2021447 1263045 Bacteroides finegoldii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003373 Microbes metabolize substances PMDBM2021447 1263045 Bacteroides finegoldii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003374 Microbes metabolize substances PMDBM2020534 626930 Bacteroides fluxus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003375 Microbes metabolize substances PMDBM2020534 626930 Bacteroides fluxus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003376 Microbes metabolize substances PMDBM2020534 626930 Bacteroides fluxus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003377 Microbes metabolize substances PMDBM2020534 626930 Bacteroides fluxus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003379 Microbes metabolize substances PMDBM2020534 626930 Bacteroides fluxus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003381 Microbes metabolize substances PMDBM2020534 626930 Bacteroides fluxus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003382 Microbes metabolize substances PMDBM2020534 626930 Bacteroides fluxus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003383 Microbes metabolize substances PMDBM2020534 626930 Bacteroides fluxus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003384 Microbes metabolize substances PMDBM2020534 626930 Bacteroides fluxus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003387 Microbes metabolize substances PMDBM2020534 626930 Bacteroides fluxus PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003388 Microbes metabolize substances PMDBM2020534 626930 Bacteroides fluxus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003389 Microbes metabolize substances PMDBM2020534 626930 Bacteroides fluxus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003390 Microbes metabolize substances PMDBM2020534 626930 Bacteroides fluxus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003391 Microbes metabolize substances PMDBM2020534 626930 Bacteroides fluxus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003393 Microbes metabolize substances PMDBM2020534 626930 Bacteroides fluxus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003394 Microbes metabolize substances PMDBM2020534 626930 Bacteroides fluxus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003395 Microbes metabolize substances PMDBM2020534 626930 Bacteroides fluxus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003396 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003397 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20003398 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003399 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003400 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003402 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003404 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003405 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003406 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003407 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003408 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003409 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003411 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20003414 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20003415 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20003416 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003417 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003421 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20003424 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003425 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003427 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Provide resistance to theantimcrobial/antifungaleffect n.a. PMID PMID: 36467581 PMDBI20003429 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003430 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD452 Ipilimumab Therapeutic Substance a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. stimulate CTLA-4-induced antitumour immune response, thereby increasing therapeutic efficacy91 n.a. PMID PMID: 36467581 PMDBI20003431 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD2000015 Anti-cytotoxic T-lymphocyte-associated antigen 4(CTLA-4) Therapeutic substance negative regulators of T cell proliferation and functions n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Bacteroides thetaiotaomicron and Bacteroides fragilis were identified as responsible of CTLA-4 blockade and ipilimumab efficacy through the induction of a Th1 immune response,enhanced anti-cytotoxic T-lymphocyte-associated antigen 4 efficacy n.a. PMID PMID: 36467581 PMDBI20003433 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003434 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20003435 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003436 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003437 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003438 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003439 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003440 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003441 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003442 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003444 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20003447 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20003448 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20003449 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003450 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003453 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20003456 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003457 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003458 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003460 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003461 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003462 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003463 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003464 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20003465 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003466 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003467 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003469 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003471 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003472 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003473 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003474 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003475 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003476 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003478 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20003481 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20003482 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20003483 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003484 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003485 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003488 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20003491 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003492 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003495 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003496 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003497 Microbes metabolize substances PMDBM2020411 376806 Bacteroides gallinarum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003498 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003499 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003500 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003501 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003503 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003505 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003506 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003507 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003508 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003509 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003510 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003512 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20003515 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20003516 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20003517 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003518 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003521 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20003524 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003525 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003528 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003529 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003530 Microbes metabolize substances PMDBM2020412 477666 Bacteroides graminisolvens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003531 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003532 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003533 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003534 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003536 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003538 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003539 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003540 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003541 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003542 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003543 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003545 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20003548 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20003549 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20003550 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003551 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003552 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003555 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20003558 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003559 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003562 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003563 Microbes metabolize substances PMDBM2020262 329854 Bacteroides intestinalis PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20003564 Microbes metabolize substances PMDBM2021302 204516 Bacteroides massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003565 Microbes metabolize substances PMDBM2021302 204516 Bacteroides massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003566 Microbes metabolize substances PMDBM2021302 204516 Bacteroides massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003567 Microbes metabolize substances PMDBM2021302 204516 Bacteroides massiliensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003569 Microbes metabolize substances PMDBM2021302 204516 Bacteroides massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003571 Microbes metabolize substances PMDBM2021302 204516 Bacteroides massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003572 Microbes metabolize substances PMDBM2021302 204516 Bacteroides massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003573 Microbes metabolize substances PMDBM2021302 204516 Bacteroides massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003574 Microbes metabolize substances PMDBM2021302 204516 Bacteroides massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003577 Microbes metabolize substances PMDBM2021302 204516 Bacteroides massiliensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003578 Microbes metabolize substances PMDBM2021302 204516 Bacteroides massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003579 Microbes metabolize substances PMDBM2021302 204516 Bacteroides massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003580 Microbes metabolize substances PMDBM2021302 204516 Bacteroides massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003581 Microbes metabolize substances PMDBM2021302 204516 Bacteroides massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003583 Microbes metabolize substances PMDBM2021302 204516 Bacteroides massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003584 Microbes metabolize substances PMDBM2021302 204516 Bacteroides massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003585 Microbes metabolize substances PMDBM2021302 204516 Bacteroides massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003586 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003587 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003588 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003589 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003591 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003593 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003594 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003595 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003596 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003597 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003598 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003600 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20003603 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20003604 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20003605 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003606 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003607 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003610 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20003613 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003614 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003617 Microbes metabolize substances PMDBM2021448 1903262 Bacteroides ndongoniae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003618 Microbes metabolize substances PMDBM2020414 1347393 Bacteroides neonati PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003619 Microbes metabolize substances PMDBM2020414 1347393 Bacteroides neonati PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003620 Microbes metabolize substances PMDBM2020414 1347393 Bacteroides neonati PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003621 Microbes metabolize substances PMDBM2020414 1347393 Bacteroides neonati PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003622 Microbes metabolize substances PMDBM2020414 1347393 Bacteroides neonati PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003623 Microbes metabolize substances PMDBM2020414 1347393 Bacteroides neonati PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003624 Microbes metabolize substances PMDBM2020414 1347393 Bacteroides neonati PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003627 Microbes metabolize substances PMDBM2020414 1347393 Bacteroides neonati PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003628 Microbes metabolize substances PMDBM2020414 1347393 Bacteroides neonati PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003629 Microbes metabolize substances PMDBM2020414 1347393 Bacteroides neonati PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003630 Microbes metabolize substances PMDBM2020414 1347393 Bacteroides neonati PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003631 Microbes metabolize substances PMDBM2020414 1347393 Bacteroides neonati PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003632 Microbes metabolize substances PMDBM2020414 1347393 Bacteroides neonati PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003633 Microbes metabolize substances PMDBM2020414 1347393 Bacteroides neonati PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003634 Microbes metabolize substances PMDBM2020414 1347393 Bacteroides neonati PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003635 Microbes metabolize substances PMDBM2020414 1347393 Bacteroides neonati PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003636 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003637 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003638 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003639 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003641 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003643 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003644 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003645 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003646 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003647 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003648 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003650 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20003653 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20003654 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20003655 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003656 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003657 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003660 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20003663 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003664 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003667 Microbes metabolize substances PMDBM2020415 291645 Bacteroides nordii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003668 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003669 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003670 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003671 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003673 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003675 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003676 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003677 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003678 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003679 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003680 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003682 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20003685 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20003686 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20003687 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003688 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003689 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003692 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20003695 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003696 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003699 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003700 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003701 Microbes metabolize substances PMDBM2020543 626931 Bacteroides oleiciplenus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003702 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003703 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003704 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003705 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003707 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003709 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003710 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003711 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003712 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003713 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003714 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003716 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20003719 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20003720 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20003721 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003722 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003723 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003726 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20003729 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003730 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003734 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. unknown toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003736 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" cardiac glycoside n.a. n.a. n.a. n.a. dihydrodigoxin n.a. unknown involved in substrate metabolism n.a. n.a. n.a. inactivation n.a. PMID PMID: 36467581 PMDBI20003738 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" antimicrobial n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003739 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD1166 Dolasetron Therapeutic substance antinauseant and antiemetic n.a. n.a. n.a. n.a. duloxetine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003740 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003741 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD1227 Hydrocortisone Therapeutic substance immune, inflammatory, and neoplastic conditions n.a. n.a. n.a. n.a. 20beta-dihydrocortisone n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003743 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" lower the risk of cardiovascular disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003744 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD1298 Misoprostol Therapeutic substance reduce the risk of NSAID induced gastric ulcers n.a. n.a. n.a. n.a. misoprostol-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003745 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD563 Mycophenolate mofetil Therapeutic Substance inosine monophosphate dehydrogenase inhibitor n.a. n.a. n.a. n.a. mycophenolic-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003746 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD1406 Ropinirole Therapeutic substance Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003747 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD816 Sulindac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. sulindac-M2 n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003748 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD1460 Tolcapone Therapeutic substance Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity n.a. n.a. n.a. a potential link betweenthe gut microbiome and tolcapone toxicity n.a. PMID PMID: 36467581 PMDBI20003749 Microbes metabolize substances PMDBM2020263 28116 Bacteroides ovatus PMDBD123 Brivudine Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. bromovinyluracil (BVU) n.a. unknown toxicity increased n.a. n.a. n.a. "Conversion to hepatotoxic BVU;(GF)reduce systemic BVU exposure" n.a. PMID PMID: 36467581 PMDBI20003751 Microbes metabolize substances PMDBM2021297 310297 Bacteroides plebeius PMDBD1227 Hydrocortisone Therapeutic substance immune, inflammatory, and neoplastic conditions n.a. n.a. n.a. n.a. 20beta-dihydrocortisone n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003752 Microbes metabolize substances PMDBM2021297 310297 Bacteroides plebeius PMDBD1376 Praziquantel Therapeutic substance Anti-infection n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003753 Microbes metabolize substances PMDBM2021297 310297 Bacteroides plebeius PMDBD1406 Ropinirole Therapeutic substance Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003754 Microbes metabolize substances PMDBM2021297 310297 Bacteroides plebeius PMDBD1421 Spironolactone Therapeutic substance diuretic and also antihypertensive effects n.a. n.a. n.a. n.a. 7æµ?thiospironolactone n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003755 Microbes metabolize substances PMDBM2020418 310300 Bacteroides pyogenes PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003756 Microbes metabolize substances PMDBM2020418 310300 Bacteroides pyogenes PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20003757 Microbes metabolize substances PMDBM2020418 310300 Bacteroides pyogenes PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003758 Microbes metabolize substances PMDBM2020418 310300 Bacteroides pyogenes PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003759 Microbes metabolize substances PMDBM2020418 310300 Bacteroides pyogenes PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003760 Microbes metabolize substances PMDBM2020418 310300 Bacteroides pyogenes PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003761 Microbes metabolize substances PMDBM2020418 310300 Bacteroides pyogenes PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003762 Microbes metabolize substances PMDBM2020418 310300 Bacteroides pyogenes PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003765 Microbes metabolize substances PMDBM2020418 310300 Bacteroides pyogenes PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003766 Microbes metabolize substances PMDBM2020418 310300 Bacteroides pyogenes PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003767 Microbes metabolize substances PMDBM2020418 310300 Bacteroides pyogenes PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003768 Microbes metabolize substances PMDBM2020418 310300 Bacteroides pyogenes PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003769 Microbes metabolize substances PMDBM2020418 310300 Bacteroides pyogenes PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003770 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003771 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20003772 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003773 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003774 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003776 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003778 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003779 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003780 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003781 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003782 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003783 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003785 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20003788 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20003789 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20003790 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003791 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003792 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003795 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20003798 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003799 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003802 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003803 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003804 Microbes metabolize substances PMDBM2020419 291644 Bacteroides salyersiae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003805 Microbes metabolize substances PMDBM2008234 n.a. Bacteroides sp PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003806 Microbes metabolize substances PMDBM2008235 n.a. Bacteroides sp.22 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003807 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp002491635 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003808 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp002491635 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003809 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp002491635 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003810 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp002491635 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003812 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp002491635 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003814 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp002491635 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003815 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp002491635 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003816 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp002491635 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003817 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp002491635 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003820 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp002491635 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003821 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp002491635 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003822 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp002491635 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003823 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp002491635 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003825 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp002491635 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003826 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp002491635 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003827 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp002491635 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003828 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp003545565 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003829 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp003545565 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003830 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp003545565 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003831 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp003545565 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003832 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp003545565 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003833 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp003545565 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003834 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp003545565 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003837 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp003545565 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003838 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp003545565 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003839 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp003545565 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003840 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp003545565 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003841 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp003545565 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003842 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp003545565 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003843 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp003545565 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003844 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp003545565 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003845 Microbes metabolize substances PMDBM2020420 29523 Bacteroides sp003545565 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003846 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003847 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003848 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003849 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003851 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003853 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003854 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003855 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003856 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003857 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003858 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003860 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20003863 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20003864 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20003865 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003866 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003867 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003870 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20003873 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003874 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003877 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003878 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003879 Microbes metabolize substances PMDBM2021449 871324 Bacteroides stercorirosoris PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003880 Microbes metabolize substances PMDBM2020083 46506 Bacteroides stercoris PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003881 Microbes metabolize substances PMDBM2020083 46506 Bacteroides stercoris PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003882 Microbes metabolize substances PMDBM2020083 46506 Bacteroides stercoris PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003883 Microbes metabolize substances PMDBM2020083 46506 Bacteroides stercoris PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003884 Microbes metabolize substances PMDBM2020083 46506 Bacteroides stercoris PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003885 Microbes metabolize substances PMDBM2020083 46506 Bacteroides stercoris PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003886 Microbes metabolize substances PMDBM2020083 46506 Bacteroides stercoris PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003889 Microbes metabolize substances PMDBM2020083 46506 Bacteroides stercoris PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003890 Microbes metabolize substances PMDBM2020083 46506 Bacteroides stercoris PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003891 Microbes metabolize substances PMDBM2020083 46506 Bacteroides stercoris PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003892 Microbes metabolize substances PMDBM2020083 46506 Bacteroides stercoris PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003893 Microbes metabolize substances PMDBM2020083 46506 Bacteroides stercoris PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003894 Microbes metabolize substances PMDBM2020083 46506 Bacteroides stercoris PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003895 Microbes metabolize substances PMDBM2020083 46506 Bacteroides stercoris PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003896 Microbes metabolize substances PMDBM2020083 46506 Bacteroides stercoris PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003897 Microbes metabolize substances PMDBM2020083 46506 Bacteroides stercoris PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003898 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003899 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003900 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003901 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003903 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003905 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003906 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003907 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003908 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003909 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003910 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003912 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20003915 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20003916 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20003917 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20003918 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003919 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003923 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20003926 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003927 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003930 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003931 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD452 Ipilimumab Therapeutic Substance a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. stimulate CTLA-4-induced antitumour immune response, thereby increasing therapeutic efficacy91 n.a. PMID PMID: 36467581 PMDBI20003932 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD2000015 Anti-cytotoxic T-lymphocyte-associated antigen 4(CTLA-4) Therapeutic substance negative regulators of T cell proliferation and functions n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Bacteroides thetaiotaomicron and Bacteroides fragilis were identified as responsible of CTLA-4 blockade and ipilimumab efficacy through the induction of a Th1 immune response,enhanced anti-cytotoxic T-lymphocyte-associated antigen 4 efficacy n.a. PMID PMID: 36467581 PMDBI20003934 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD123 Brivudine Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. bromovinyluracil (BVU) n.a. unknown toxicity increased n.a. n.a. n.a. "Conversion to hepatotoxic BVU;(GF)reduce systemic BVU exposure" n.a. PMID PMID: 36467581 PMDBI20003936 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20003937 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD1451 Thiopurines Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. unknown activation n.a. n.a. n.a. Microbiota as IBD therapy response biomarker n.a. PMID PMID: 36467581 PMDBI20003938 Microbes metabolize substances PMDBM2021450 1917883 Bacteroides togonis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003939 Microbes metabolize substances PMDBM2021450 1917883 Bacteroides togonis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003940 Microbes metabolize substances PMDBM2021450 1917883 Bacteroides togonis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003941 Microbes metabolize substances PMDBM2021450 1917883 Bacteroides togonis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003943 Microbes metabolize substances PMDBM2021450 1917883 Bacteroides togonis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003945 Microbes metabolize substances PMDBM2021450 1917883 Bacteroides togonis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003946 Microbes metabolize substances PMDBM2021450 1917883 Bacteroides togonis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003947 Microbes metabolize substances PMDBM2021450 1917883 Bacteroides togonis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003948 Microbes metabolize substances PMDBM2021450 1917883 Bacteroides togonis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003951 Microbes metabolize substances PMDBM2021450 1917883 Bacteroides togonis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20003952 Microbes metabolize substances PMDBM2021450 1917883 Bacteroides togonis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003953 Microbes metabolize substances PMDBM2021450 1917883 Bacteroides togonis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003954 Microbes metabolize substances PMDBM2021450 1917883 Bacteroides togonis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003956 Microbes metabolize substances PMDBM2021450 1917883 Bacteroides togonis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003957 Microbes metabolize substances PMDBM2021450 1917883 Bacteroides togonis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003958 Microbes metabolize substances PMDBM2021450 1917883 Bacteroides togonis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20003959 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20003960 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20003961 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20003962 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003964 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20003966 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD386 Genistein "Therapeutic Substance; Herbal Substance" antineoplastic and antitumor n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bacteroides uniformis is a candidate bacterial species associated with the degradation of the isoflavone genistein, based on fecal isoflavone degradation in the presence of these species n.a. PMID PMID: 36467581 PMDBI20003967 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003968 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003969 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20003970 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003971 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20003973 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20003976 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20003980 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20003981 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20003982 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20003984 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl)uracil n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Sorivudine is an antiviral drug used totreat infections of varicella-zoster virus and herpes sim-plex virus type I. The drug (1-beta-Darabinofuranosyl-5-(E)-(2-bromovinyl) uracil) is metabolized by gut bacterialphosphorolytic enzymes to 閿涘æ¹?-(2-bromovinyl) uracil(BVU), with high hydrolysis activity in the contents oflarge intestine and cecum in rats. It was found that theBacteroides species B. vulgatus, B. thetaiotaomicron, B.fragilis, B. uniformis, and B. eggerthii have high activitiesto convert the drug to BVU. n.a. PMID PMID: 36467581 PMDBI20003986 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20003989 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003990 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20003993 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. unknown toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20003995 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" cardiac glycoside n.a. n.a. n.a. n.a. dihydrodigoxin n.a. unknown involved in substrate metabolism n.a. n.a. n.a. inactivation n.a. PMID PMID: 36467581 PMDBI20003997 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" antimicrobial n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003998 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD1166 Dolasetron Therapeutic substance antinauseant and antiemetic n.a. n.a. n.a. n.a. duloxetine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20003999 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD1227 Hydrocortisone Therapeutic substance immune, inflammatory, and neoplastic conditions n.a. n.a. n.a. n.a. 20beta-dihydrocortisone n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004001 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD477 Levonorgestrel Therapeutic Substance contraception and hormone n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004002 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" lower the risk of cardiovascular disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004003 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD1298 Misoprostol Therapeutic substance reduce the risk of NSAID induced gastric ulcers n.a. n.a. n.a. n.a. misoprostol-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004004 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD563 Mycophenolate mofetil Therapeutic Substance inosine monophosphate dehydrogenase inhibitor n.a. n.a. n.a. n.a. mycophenolic-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004005 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD1318 Nicardipine Therapeutic substance effective in the treatment of angina and coronary spasms without showing cardiodepressant effects n.a. n.a. n.a. n.a. aminonicardipine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004006 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD1376 Praziquantel Therapeutic substance Anti-infection n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004007 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD750 Risperidone Therapeutic Substance second-generation antipsychotic (SGA) n.a. n.a. n.a. n.a. risperidone-M1 n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004008 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD1406 Ropinirole Therapeutic substance Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004009 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD1421 Spironolactone Therapeutic substance diuretic and also antihypertensive effects n.a. n.a. n.a. n.a. 7æµ?thiospironolactone n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004010 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD816 Sulindac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. sulindac-M2 n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004011 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD1467 Torsemide Therapeutic substance loop diuretic n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004012 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD1493 Vorinostat Therapeutic substance Anti-cancer n.a. n.a. n.a. n.a. vorinostat-M1 n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004013 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD1460 Tolcapone Therapeutic substance Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity n.a. n.a. n.a. a potential link betweenthe gut microbiome and tolcapone toxicity n.a. PMID PMID: 36467581 PMDBI20004015 Microbes metabolize substances PMDBM2020268 821 Bacteroides vulgatus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil n.a. PMID PMID: 36467581 PMDBI20004018 Microbes metabolize substances PMDBM2020268 821 Bacteroides vulgatus PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon,Regenerate the active SN-38 in intestinal lumen n.a. PMID PMID: 36467581 PMDBI20004021 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004022 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004023 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004024 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004026 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004028 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004029 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004030 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004031 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004032 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004033 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004035 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20004038 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20004039 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20004040 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20004041 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004042 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004045 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20004048 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004049 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004052 Microbes metabolize substances PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004053 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004054 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite NAPQI n.a. PMID PMID: 36467581 PMDBI20004055 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD452 Ipilimumab Therapeutic Substance a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Bacterially mediated B vitamin production and polyamine transport deficiencies associated with increased risk of閼辩春TLA blockadeé—炽儲éšæ”duced colitis n.a. PMID PMID: 36467581 PMDBI20004056 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD176 Checkpoint inhibitor therapy Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity decreased n.a. n.a. n.a. Decrease occrrence of side effect n.a. PMID PMID: 36467581 PMDBI20004057 Microbes metabolize substances PMDBM2021451 1745713 Bariatricus massiliensis PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20004058 Microbes metabolize substances PMDBM2021451 1745713 Bariatricus massiliensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20004059 Microbes metabolize substances PMDBM2021451 1745713 Bariatricus massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004060 Microbes metabolize substances PMDBM2021451 1745713 Bariatricus massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004061 Microbes metabolize substances PMDBM2021451 1745713 Bariatricus massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004062 Microbes metabolize substances PMDBM2021451 1745713 Bariatricus massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004063 Microbes metabolize substances PMDBM2021451 1745713 Bariatricus massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004064 Microbes metabolize substances PMDBM82 397864 Barnesiella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004065 Microbes metabolize substances PMDBM82 397864 Barnesiella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004066 Microbes metabolize substances PMDBM82 397864 Barnesiella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004067 Microbes metabolize substances PMDBM82 397864 Barnesiella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004068 Microbes metabolize substances PMDBM82 397864 Barnesiella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004069 Microbes metabolize substances PMDBM82 397864 Barnesiella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004070 Microbes metabolize substances PMDBM82 397864 Barnesiella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004073 Microbes metabolize substances PMDBM82 397864 Barnesiella PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20004074 Microbes metabolize substances PMDBM82 397864 Barnesiella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004075 Microbes metabolize substances PMDBM82 397864 Barnesiella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004076 Microbes metabolize substances PMDBM82 397864 Barnesiella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004077 Microbes metabolize substances PMDBM82 397864 Barnesiella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004078 Microbes metabolize substances PMDBM82 397864 Barnesiella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004079 Microbes metabolize substances PMDBM82 397864 Barnesiella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004080 Microbes metabolize substances PMDBM82 397864 Barnesiella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004081 Microbes metabolize substances PMDBM82 397864 Barnesiella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004082 Microbes metabolize substances PMDBM2020270 487174 Barnesiella intestinihominis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004083 Microbes metabolize substances PMDBM2020270 487174 Barnesiella intestinihominis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004084 Microbes metabolize substances PMDBM2020270 487174 Barnesiella intestinihominis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004085 Microbes metabolize substances PMDBM2020270 487174 Barnesiella intestinihominis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004087 Microbes metabolize substances PMDBM2020270 487174 Barnesiella intestinihominis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004089 Microbes metabolize substances PMDBM2020270 487174 Barnesiella intestinihominis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004090 Microbes metabolize substances PMDBM2020270 487174 Barnesiella intestinihominis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004091 Microbes metabolize substances PMDBM2020270 487174 Barnesiella intestinihominis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004092 Microbes metabolize substances PMDBM2020270 487174 Barnesiella intestinihominis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004095 Microbes metabolize substances PMDBM2020270 487174 Barnesiella intestinihominis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004096 Microbes metabolize substances PMDBM2020270 487174 Barnesiella intestinihominis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004097 Microbes metabolize substances PMDBM2020270 487174 Barnesiella intestinihominis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004098 Microbes metabolize substances PMDBM2020270 487174 Barnesiella intestinihominis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004100 Microbes metabolize substances PMDBM2020270 487174 Barnesiella intestinihominis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004101 Microbes metabolize substances PMDBM2020270 487174 Barnesiella intestinihominis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004102 Microbes metabolize substances PMDBM2020270 487174 Barnesiella intestinihominis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004103 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp002159975 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004104 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp002159975 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004105 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp002159975 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004106 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp002159975 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004107 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp002159975 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004108 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp002159975 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004109 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp002159975 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004112 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp002159975 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004113 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp002159975 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004114 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp002159975 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004115 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp002159975 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004116 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp002159975 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004117 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp002159975 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004118 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp002159975 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004119 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp002159975 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004120 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp003150885 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004121 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp003150885 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004122 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp003150885 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004123 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp003150885 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004125 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp003150885 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004127 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp003150885 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004128 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp003150885 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004129 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp003150885 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004130 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp003150885 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004133 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp003150885 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004134 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp003150885 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004135 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp003150885 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004136 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp003150885 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004138 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp003150885 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004139 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp003150885 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004140 Microbes metabolize substances PMDBM2021452 2033407 Barnesiella sp003150885 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004141 Microbes metabolize substances PMDBM652 n.a. Barnesiellaceae PMDBD2000015 Anti-cytotoxic T-lymphocyte-associated antigen 4(CTLA-4) Therapeutic substance negative regulators of T cell proliferation and functions n.a. n.a. n.a. n.a. n.a. n.a. unknown side effect n.a. n.a. n.a. resistance to anti-CTLA-4-induced colitis n.a. PMID PMID: 36467581 PMDBI20004142 Microbes metabolize substances PMDBM2008243 1922299 Beduini PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004143 Microbes metabolize substances PMDBM2008243 1922299 Beduini PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004144 Microbes metabolize substances PMDBM2008243 1922299 Beduini PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004145 Microbes metabolize substances PMDBM2008243 1922299 Beduini PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004146 Microbes metabolize substances PMDBM2008243 1922299 Beduini PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004147 Microbes metabolize substances PMDBM2008243 1922299 Beduini PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004148 Microbes metabolize substances PMDBM2008243 1922299 Beduini PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004151 Microbes metabolize substances PMDBM2008243 1922299 Beduini PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004152 Microbes metabolize substances PMDBM2008243 1922299 Beduini PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004153 Microbes metabolize substances PMDBM2008243 1922299 Beduini PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004154 Microbes metabolize substances PMDBM2008243 1922299 Beduini PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004155 Microbes metabolize substances PMDBM2008243 1922299 Beduini PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004156 Microbes metabolize substances PMDBM2008243 1922299 Beduini PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004157 Microbes metabolize substances PMDBM2008243 1922299 Beduini PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004158 Microbes metabolize substances PMDBM2008243 1922299 Beduini PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004159 Microbes metabolize substances PMDBM2021453 1585974 Beduini massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004160 Microbes metabolize substances PMDBM2021453 1585974 Beduini massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004161 Microbes metabolize substances PMDBM2021453 1585974 Beduini massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004162 Microbes metabolize substances PMDBM2021453 1585974 Beduini massiliensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004164 Microbes metabolize substances PMDBM2021453 1585974 Beduini massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004166 Microbes metabolize substances PMDBM2021453 1585974 Beduini massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004167 Microbes metabolize substances PMDBM2021453 1585974 Beduini massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004168 Microbes metabolize substances PMDBM2021453 1585974 Beduini massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004169 Microbes metabolize substances PMDBM2021453 1585974 Beduini massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004172 Microbes metabolize substances PMDBM2021453 1585974 Beduini massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004173 Microbes metabolize substances PMDBM2021453 1585974 Beduini massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004174 Microbes metabolize substances PMDBM2021453 1585974 Beduini massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004175 Microbes metabolize substances PMDBM2021453 1585974 Beduini massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004177 Microbes metabolize substances PMDBM2021453 1585974 Beduini massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004178 Microbes metabolize substances PMDBM2021453 1585974 Beduini massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004179 Microbes metabolize substances PMDBM2021453 1585974 Beduini massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004180 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004181 Microbes metabolize substances PMDBM87 1678 bifidobacterium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004183 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004185 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. æµ?L-rhamnosidase-producing bacteria (Bifidobacterium dentium), it was found that æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside. n.a. PMID PMID: 36467581 PMDBI20004187 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. æµ?L-rhamnosidase-producing bacteria (Bifidobacterium dentium), it was found that æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside. n.a. PMID PMID: 36467581 PMDBI20004188 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004189 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004190 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004191 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. Compound K n.a. unknown activity increased n.a. n.a. n.a. Through hydrolysis閿涘瓘insenoside Rb1 formation Compound K n.a. PMID PMID: 36467581 PMDBI20004192 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004196 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004197 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004198 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Released of diclofenac from glucuronides n.a. PMID PMID: 36467581 PMDBI20004199 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20004200 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon,Release of indomethacin from glucuronides n.a. PMID PMID: 36467581 PMDBI20004202 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD2000016 PD-1 inhibitors Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Gut microbes enhance the activity ofPD-1 inhibitors. n.a. PMID PMID: 36467581 PMDBI20004203 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004204 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004206 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD2000017 Anti-axis programmed cell death protein 1 (PD-1) and its ligand (PD-L1) Therapeutic substance immune checkpoint repressing T cell response n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Bifidobacterium emerged as strongly associated with T cell response, and consistently, oral administration of a cocktail of Bifidobacterium species combined with an anti-PD-L1 antibody nearly abolished the melanoma growth n.a. PMID PMID: 36467581 PMDBI20004208 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD471 Lactulose Therapeutic Substance laxative n.a. n.a. n.a. n.a. lactic acid,acetic acid n.a. unknown activity increased n.a. n.a. n.a. Produce its therapeutic metabolites n.a. PMID PMID: 36467581 PMDBI20004209 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD403 Glucuronides Environmental Chemicals Environmental Substance n.a. n.a. n.a. n.a. diclofenac,ketoprofen,indomethacin n.a. unknown toxicity increased n.a. n.a. n.a. Increase toxicity n.a. PMID PMID: 36467581 PMDBI20004210 Microbes metabolize substances PMDBM2020434 28025 Bifidobacterium animalis subsp.lactis BI-07 PMDBD558 Montelukast Therapeutic Substance Drugs for obstructive airway disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20004211 Microbes metabolize substances PMDBM2020434 28025 Bifidobacterium animalis subsp.lactis BI-07 PMDBD1407 Rosiglitazone Therapeutic substance Anti-diabetics n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20004212 Microbes metabolize substances PMDBM2020434 28025 Bifidobacterium animalis subsp.lactis BI-07 PMDBD329 Ezetimibe Therapeutic Substance Lipid modifying agents n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Biotransformation n.a. PMID PMID: 36467581 PMDBI20004213 Microbes metabolize substances PMDBM2020434 28025 Bifidobacterium animalis subsp.lactis BI-07 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Biotransformation n.a. PMID PMID: 36467581 PMDBI20004214 Microbes metabolize substances PMDBM2020193 n.a. Bifidobacterium longum subsp. infantis S12,DSM 20088,ATCC 15697,NCTC 11817 PMDBD558 Montelukast Therapeutic Substance Drugs for obstructive airway disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20004215 Microbes metabolize substances PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004216 Microbes metabolize substances PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004217 Microbes metabolize substances PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" cardiac glycoside n.a. n.a. n.a. n.a. dihydrodigoxin n.a. unknown involved in substrate metabolism n.a. n.a. n.a. inactivation n.a. PMID PMID: 36467581 PMDBI20004218 Microbes metabolize substances PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. ketoprofen n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004219 Microbes metabolize substances PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD477 Levonorgestrel Therapeutic Substance contraception and hormone n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004220 Microbes metabolize substances PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" lower the risk of cardiovascular disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004221 Microbes metabolize substances PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD1298 Misoprostol Therapeutic substance reduce the risk of NSAID induced gastric ulcers n.a. n.a. n.a. n.a. misoprostol-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004222 Microbes metabolize substances PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD1318 Nicardipine Therapeutic substance effective in the treatment of angina and coronary spasms without showing cardiodepressant effects n.a. n.a. n.a. n.a. aminonicardipine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004223 Microbes metabolize substances PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD750 Risperidone Therapeutic Substance second-generation antipsychotic (SGA) n.a. n.a. n.a. n.a. risperidone-M1 n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004224 Microbes metabolize substances PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD1406 Ropinirole Therapeutic substance Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004225 Microbes metabolize substances PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD1421 Spironolactone Therapeutic substance diuretic and also antihypertensive effects n.a. n.a. n.a. n.a. 7æµ?thiospironolactone n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004226 Microbes metabolize substances PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD816 Sulindac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. sulindac-M2 n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004227 Microbes metabolize substances PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD1467 Torsemide Therapeutic substance loop diuretic n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004228 Microbes metabolize substances PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD1493 Vorinostat Therapeutic substance Anti-cancer n.a. n.a. n.a. n.a. vorinostat-M1 n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20004229 Microbes metabolize substances PMDBM2020433 1683 Bifidobacterium angulatum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004230 Microbes metabolize substances PMDBM2020433 1683 Bifidobacterium angulatum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004231 Microbes metabolize substances PMDBM2020433 1683 Bifidobacterium angulatum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004232 Microbes metabolize substances PMDBM2020433 1683 Bifidobacterium angulatum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004233 Microbes metabolize substances PMDBM2020433 1683 Bifidobacterium angulatum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004234 Microbes metabolize substances PMDBM2020433 1683 Bifidobacterium angulatum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004235 Microbes metabolize substances PMDBM2020433 1683 Bifidobacterium angulatum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004238 Microbes metabolize substances PMDBM2020433 1683 Bifidobacterium angulatum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004239 Microbes metabolize substances PMDBM2020433 1683 Bifidobacterium angulatum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004240 Microbes metabolize substances PMDBM2020433 1683 Bifidobacterium angulatum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004241 Microbes metabolize substances PMDBM2020433 1683 Bifidobacterium angulatum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004242 Microbes metabolize substances PMDBM2020433 1683 Bifidobacterium angulatum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004243 Microbes metabolize substances PMDBM2020434 28025 Bifidobacterium animalis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004244 Microbes metabolize substances PMDBM2020434 28025 Bifidobacterium animalis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004245 Microbes metabolize substances PMDBM2020434 28025 Bifidobacterium animalis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004246 Microbes metabolize substances PMDBM2020434 28025 Bifidobacterium animalis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004247 Microbes metabolize substances PMDBM2020434 28025 Bifidobacterium animalis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004248 Microbes metabolize substances PMDBM2020434 28025 Bifidobacterium animalis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004249 Microbes metabolize substances PMDBM2020434 28025 Bifidobacterium animalis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004252 Microbes metabolize substances PMDBM2020434 28025 Bifidobacterium animalis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004253 Microbes metabolize substances PMDBM2020434 28025 Bifidobacterium animalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004254 Microbes metabolize substances PMDBM2020434 28025 Bifidobacterium animalis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004255 Microbes metabolize substances PMDBM2020434 28025 Bifidobacterium animalis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004256 Microbes metabolize substances PMDBM2020434 28025 Bifidobacterium animalis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004257 Microbes metabolize substances PMDBM2020012 1681 Bifidobacterium bifidum PMDBD2000018 Gliadin Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. unknown Induced disease n.a. n.a. n.a. affects the permeability of the intestinal mucosa and, consequently, could be involved in the early stages of Celiac disease pathogenesis. n.a. PMID PMID: 36467581 PMDBI20004258 Microbes metabolize substances PMDBM2020012 1681 Bifidobacterium bifidum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004259 Microbes metabolize substances PMDBM2020012 1681 Bifidobacterium bifidum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004260 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004261 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004262 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004263 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004264 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004265 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004266 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004267 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004268 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004270 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20004273 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20004274 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20004275 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004276 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004279 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20004282 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004283 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004284 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004286 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004287 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004288 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004289 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004290 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004291 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004292 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004293 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004294 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004296 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20004299 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20004300 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20004301 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004302 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004305 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20004308 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004309 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004310 Microbes metabolize substances PMDBM2020272 1686 Bifidobacterium catenulatum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004312 Microbes metabolize substances PMDBM2020014 1689 Bifidobacterium dentium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004313 Microbes metabolize substances PMDBM2020014 1689 Bifidobacterium dentium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004314 Microbes metabolize substances PMDBM2020014 1689 Bifidobacterium dentium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004315 Microbes metabolize substances PMDBM2020014 1689 Bifidobacterium dentium PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004319 Microbes metabolize substances PMDBM2020014 1689 Bifidobacterium dentium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004323 Microbes metabolize substances PMDBM2020014 1689 Bifidobacterium dentium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004324 Microbes metabolize substances PMDBM2020014 1689 Bifidobacterium dentium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004325 Microbes metabolize substances PMDBM2020014 1689 Bifidobacterium dentium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004326 Microbes metabolize substances PMDBM2020014 1689 Bifidobacterium dentium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004329 Microbes metabolize substances PMDBM2020014 1689 Bifidobacterium dentium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004330 Microbes metabolize substances PMDBM2020014 1689 Bifidobacterium dentium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004334 Microbes metabolize substances PMDBM2020014 1689 Bifidobacterium dentium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004335 Microbes metabolize substances PMDBM2020014 1689 Bifidobacterium dentium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004337 Microbes metabolize substances PMDBM2020440 78342 Bifidobacterium gallicum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004338 Microbes metabolize substances PMDBM2020440 78342 Bifidobacterium gallicum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004339 Microbes metabolize substances PMDBM2020440 78342 Bifidobacterium gallicum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004340 Microbes metabolize substances PMDBM2020440 78342 Bifidobacterium gallicum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004341 Microbes metabolize substances PMDBM2020440 78342 Bifidobacterium gallicum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004342 Microbes metabolize substances PMDBM2020440 78342 Bifidobacterium gallicum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004343 Microbes metabolize substances PMDBM2020440 78342 Bifidobacterium gallicum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004346 Microbes metabolize substances PMDBM2020440 78342 Bifidobacterium gallicum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004347 Microbes metabolize substances PMDBM2020440 78342 Bifidobacterium gallicum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004348 Microbes metabolize substances PMDBM2020440 78342 Bifidobacterium gallicum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004349 Microbes metabolize substances PMDBM2020440 78342 Bifidobacterium gallicum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004350 Microbes metabolize substances PMDBM2020440 78342 Bifidobacterium gallicum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004351 Microbes metabolize substances PMDBM2020440 78342 Bifidobacterium gallicum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004352 Microbes metabolize substances PMDBM2020440 78342 Bifidobacterium gallicum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004353 Microbes metabolize substances PMDBM2021454 78344 Bifidobacterium gallinarum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004354 Microbes metabolize substances PMDBM2021454 78344 Bifidobacterium gallinarum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004355 Microbes metabolize substances PMDBM2021454 78344 Bifidobacterium gallinarum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004356 Microbes metabolize substances PMDBM2021454 78344 Bifidobacterium gallinarum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004357 Microbes metabolize substances PMDBM2021454 78344 Bifidobacterium gallinarum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004358 Microbes metabolize substances PMDBM2021454 78344 Bifidobacterium gallinarum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004359 Microbes metabolize substances PMDBM2021454 78344 Bifidobacterium gallinarum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004362 Microbes metabolize substances PMDBM2021454 78344 Bifidobacterium gallinarum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004363 Microbes metabolize substances PMDBM2021454 78344 Bifidobacterium gallinarum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004364 Microbes metabolize substances PMDBM2021454 78344 Bifidobacterium gallinarum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004365 Microbes metabolize substances PMDBM2021454 78344 Bifidobacterium gallinarum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004366 Microbes metabolize substances PMDBM2021454 78344 Bifidobacterium gallinarum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004367 Microbes metabolize substances PMDBM2021455 1682 Bifidobacterium infantis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004368 Microbes metabolize substances PMDBM2021455 1682 Bifidobacterium infantis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004369 Microbes metabolize substances PMDBM2021455 1682 Bifidobacterium infantis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004370 Microbes metabolize substances PMDBM2021455 1682 Bifidobacterium infantis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004371 Microbes metabolize substances PMDBM2021455 1682 Bifidobacterium infantis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004372 Microbes metabolize substances PMDBM2021455 1682 Bifidobacterium infantis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004373 Microbes metabolize substances PMDBM2021455 1682 Bifidobacterium infantis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004374 Microbes metabolize substances PMDBM2021455 1682 Bifidobacterium infantis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004375 Microbes metabolize substances PMDBM2021455 1682 Bifidobacterium infantis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004377 Microbes metabolize substances PMDBM2021455 1682 Bifidobacterium infantis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20004380 Microbes metabolize substances PMDBM2021455 1682 Bifidobacterium infantis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20004381 Microbes metabolize substances PMDBM2021455 1682 Bifidobacterium infantis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20004382 Microbes metabolize substances PMDBM2021455 1682 Bifidobacterium infantis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004385 Microbes metabolize substances PMDBM2021455 1682 Bifidobacterium infantis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20004388 Microbes metabolize substances PMDBM2021455 1682 Bifidobacterium infantis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004389 Microbes metabolize substances PMDBM2021455 1682 Bifidobacterium infantis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004390 Microbes metabolize substances PMDBM2021455 1682 Bifidobacterium infantis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004392 Microbes metabolize substances PMDBM2008252 n.a. Bifidobacterium lacrimalis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004393 Microbes metabolize substances PMDBM2008252 n.a. Bifidobacterium lacrimalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004394 Microbes metabolize substances PMDBM2008252 n.a. Bifidobacterium lacrimalis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004395 Microbes metabolize substances PMDBM2020085 28026 Bifidobacterium pseudocatenulatum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004396 Microbes metabolize substances PMDBM2020085 28026 Bifidobacterium pseudocatenulatum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004397 Microbes metabolize substances PMDBM2020085 28026 Bifidobacterium pseudocatenulatum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004398 Microbes metabolize substances PMDBM2020085 28026 Bifidobacterium pseudocatenulatum PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004400 Microbes metabolize substances PMDBM2020085 28026 Bifidobacterium pseudocatenulatum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004402 Microbes metabolize substances PMDBM2020085 28026 Bifidobacterium pseudocatenulatum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004403 Microbes metabolize substances PMDBM2020085 28026 Bifidobacterium pseudocatenulatum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004404 Microbes metabolize substances PMDBM2020085 28026 Bifidobacterium pseudocatenulatum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004405 Microbes metabolize substances PMDBM2020085 28026 Bifidobacterium pseudocatenulatum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004408 Microbes metabolize substances PMDBM2020085 28026 Bifidobacterium pseudocatenulatum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004409 Microbes metabolize substances PMDBM2020085 28026 Bifidobacterium pseudocatenulatum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004410 Microbes metabolize substances PMDBM2020085 28026 Bifidobacterium pseudocatenulatum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004412 Microbes metabolize substances PMDBM2020442 1694 Bifidobacterium pseudolongum A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004413 Microbes metabolize substances PMDBM2020442 1694 Bifidobacterium pseudolongum A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004414 Microbes metabolize substances PMDBM2020442 1694 Bifidobacterium pseudolongum A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004415 Microbes metabolize substances PMDBM2020442 1694 Bifidobacterium pseudolongum A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004416 Microbes metabolize substances PMDBM2020442 1694 Bifidobacterium pseudolongum A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004417 Microbes metabolize substances PMDBM2020442 1694 Bifidobacterium pseudolongum A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004418 Microbes metabolize substances PMDBM2020442 1694 Bifidobacterium pseudolongum A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004421 Microbes metabolize substances PMDBM2020442 1694 Bifidobacterium pseudolongum A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004422 Microbes metabolize substances PMDBM2020442 1694 Bifidobacterium pseudolongum A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004423 Microbes metabolize substances PMDBM2020442 1694 Bifidobacterium pseudolongum A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004424 Microbes metabolize substances PMDBM2020442 1694 Bifidobacterium pseudolongum A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004425 Microbes metabolize substances PMDBM2020442 1694 Bifidobacterium pseudolongum A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004426 Microbes metabolize substances PMDBM2020443 78448 Bifidobacterium pullorum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004427 Microbes metabolize substances PMDBM2020443 78448 Bifidobacterium pullorum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004428 Microbes metabolize substances PMDBM2020443 78448 Bifidobacterium pullorum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004429 Microbes metabolize substances PMDBM2020443 78448 Bifidobacterium pullorum PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004431 Microbes metabolize substances PMDBM2020443 78448 Bifidobacterium pullorum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004433 Microbes metabolize substances PMDBM2020443 78448 Bifidobacterium pullorum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004434 Microbes metabolize substances PMDBM2020443 78448 Bifidobacterium pullorum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004435 Microbes metabolize substances PMDBM2020443 78448 Bifidobacterium pullorum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004436 Microbes metabolize substances PMDBM2020443 78448 Bifidobacterium pullorum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004439 Microbes metabolize substances PMDBM2020443 78448 Bifidobacterium pullorum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004440 Microbes metabolize substances PMDBM2020443 78448 Bifidobacterium pullorum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004441 Microbes metabolize substances PMDBM2020443 78448 Bifidobacterium pullorum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004442 Microbes metabolize substances PMDBM2020443 78448 Bifidobacterium pullorum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004444 Microbes metabolize substances PMDBM2020036 78346 Bifidobacterium ruminantium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004445 Microbes metabolize substances PMDBM2020036 78346 Bifidobacterium ruminantium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004446 Microbes metabolize substances PMDBM2020036 78346 Bifidobacterium ruminantium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004447 Microbes metabolize substances PMDBM2020036 78346 Bifidobacterium ruminantium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004448 Microbes metabolize substances PMDBM2020036 78346 Bifidobacterium ruminantium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004449 Microbes metabolize substances PMDBM2020036 78346 Bifidobacterium ruminantium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004450 Microbes metabolize substances PMDBM2020036 78346 Bifidobacterium ruminantium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004453 Microbes metabolize substances PMDBM2020036 78346 Bifidobacterium ruminantium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004454 Microbes metabolize substances PMDBM2020036 78346 Bifidobacterium ruminantium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004455 Microbes metabolize substances PMDBM2020036 78346 Bifidobacterium ruminantium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004456 Microbes metabolize substances PMDBM2020036 78346 Bifidobacterium ruminantium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004457 Microbes metabolize substances PMDBM2020036 78346 Bifidobacterium ruminantium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004458 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004459 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004460 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004461 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004463 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004465 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004466 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004467 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004468 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004469 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004470 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004472 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20004475 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20004476 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20004477 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004478 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004481 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20004484 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004485 Microbes metabolize substances PMDBM2020444 158787 Bifidobacterium scardovii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004488 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp002742445 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004489 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp002742445 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004490 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp002742445 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004491 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp002742445 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004492 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp002742445 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004493 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp002742445 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004494 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp002742445 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004497 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp002742445 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004498 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp002742445 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004499 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp002742445 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004500 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp002742445 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004501 Microbes metabolize substances PMDBM2020446 246618 Bifidobacterium thermacidophilum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004502 Microbes metabolize substances PMDBM2020446 246618 Bifidobacterium thermacidophilum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004503 Microbes metabolize substances PMDBM2020446 246618 Bifidobacterium thermacidophilum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004504 Microbes metabolize substances PMDBM2020446 246618 Bifidobacterium thermacidophilum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004505 Microbes metabolize substances PMDBM2020446 246618 Bifidobacterium thermacidophilum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004506 Microbes metabolize substances PMDBM2020446 246618 Bifidobacterium thermacidophilum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004507 Microbes metabolize substances PMDBM2020446 246618 Bifidobacterium thermacidophilum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004510 Microbes metabolize substances PMDBM2020446 246618 Bifidobacterium thermacidophilum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004511 Microbes metabolize substances PMDBM2020446 246618 Bifidobacterium thermacidophilum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004512 Microbes metabolize substances PMDBM2020446 246618 Bifidobacterium thermacidophilum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004513 Microbes metabolize substances PMDBM2020446 246618 Bifidobacterium thermacidophilum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004514 Microbes metabolize substances PMDBM2020446 246618 Bifidobacterium thermacidophilum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004515 Microbes metabolize substances PMDBM2008258 n.a. Bifidobacterium vaginale PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004516 Microbes metabolize substances PMDBM2008259 n.a. Bifidobacterium vaginale E PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004517 Microbes metabolize substances PMDBM2008259 n.a. Bifidobacterium vaginale E PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004518 Microbes metabolize substances PMDBM2008260 n.a. Bifidobacterium vaginale F PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004519 Microbes metabolize substances PMDBM2008260 n.a. Bifidobacterium vaginale F PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004520 Microbes metabolize substances PMDBM2008261 n.a. Bifidobacterium vaginale G PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004521 Microbes metabolize substances PMDBM2008261 n.a. Bifidobacterium vaginale G PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004522 Microbes metabolize substances PMDBM2008261 n.a. Bifidobacterium vaginale G PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004523 Microbes metabolize substances PMDBM110 35832 Bilophila PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20004524 Microbes metabolize substances PMDBM110 35832 Bilophila PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004525 Microbes metabolize substances PMDBM110 35832 Bilophila PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004526 Microbes metabolize substances PMDBM110 35832 Bilophila PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20004527 Microbes metabolize substances PMDBM2020195 35833 Bilophila wadsworthia PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004528 Microbes metabolize substances PMDBM2021456 1720313 Bittarella massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004529 Microbes metabolize substances PMDBM2021456 1720313 Bittarella massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004530 Microbes metabolize substances PMDBM2021456 1720313 Bittarella massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004531 Microbes metabolize substances PMDBM2021456 1720313 Bittarella massiliensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004533 Microbes metabolize substances PMDBM2021456 1720313 Bittarella massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004535 Microbes metabolize substances PMDBM2021456 1720313 Bittarella massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004536 Microbes metabolize substances PMDBM2021456 1720313 Bittarella massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004537 Microbes metabolize substances PMDBM2021456 1720313 Bittarella massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004538 Microbes metabolize substances PMDBM2021456 1720313 Bittarella massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004541 Microbes metabolize substances PMDBM2021456 1720313 Bittarella massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004542 Microbes metabolize substances PMDBM2021456 1720313 Bittarella massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004543 Microbes metabolize substances PMDBM2021456 1720313 Bittarella massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004544 Microbes metabolize substances PMDBM2021456 1720313 Bittarella massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004546 Microbes metabolize substances PMDBM2021456 1720313 Bittarella massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004547 Microbes metabolize substances PMDBM2021456 1720313 Bittarella massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004548 Microbes metabolize substances PMDBM2021456 1720313 Bittarella massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004549 Microbes metabolize substances PMDBM2021457 1470358 Blastococcus massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004550 Microbes metabolize substances PMDBM2021457 1470358 Blastococcus massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20004551 Microbes metabolize substances PMDBM2021457 1470358 Blastococcus massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004552 Microbes metabolize substances PMDBM2021457 1470358 Blastococcus massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004553 Microbes metabolize substances PMDBM2021457 1470358 Blastococcus massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004554 Microbes metabolize substances PMDBM2021457 1470358 Blastococcus massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004555 Microbes metabolize substances PMDBM2021457 1470358 Blastococcus massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004556 Microbes metabolize substances PMDBM2021457 1470358 Blastococcus massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004559 Microbes metabolize substances PMDBM2021457 1470358 Blastococcus massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004560 Microbes metabolize substances PMDBM2021457 1470358 Blastococcus massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004561 Microbes metabolize substances PMDBM2021457 1470358 Blastococcus massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004562 Microbes metabolize substances PMDBM2021457 1470358 Blastococcus massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004563 Microbes metabolize substances PMDBM2021457 1470358 Blastococcus massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004564 Microbes metabolize substances PMDBM2021457 1470358 Blastococcus massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004565 Microbes metabolize substances PMDBM2021457 1470358 Blastococcus massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004566 Microbes metabolize substances PMDBM2021457 1470358 Blastococcus massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004567 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004568 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20004569 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004570 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004571 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004573 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004575 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20004576 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004577 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004578 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004579 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004580 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004581 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004583 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20004586 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20004587 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20004588 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20004589 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004590 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004593 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20004596 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20004597 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004598 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004601 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004602 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD1460 Tolcapone Therapeutic substance Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity n.a. n.a. n.a. a potential link betweenthe gut microbiome and tolcapone toxicity n.a. PMID PMID: 36467581 PMDBI20004603 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004604 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004605 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004606 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004607 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004608 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004610 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004612 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004613 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004614 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004615 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004616 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004617 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004619 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20004622 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20004623 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20004624 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004625 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004628 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20004631 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20004632 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004633 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004636 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004637 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004638 Microbes metabolize substances PMDBM2008264 n.a. Blautia A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004639 Microbes metabolize substances PMDBM2021458 1737424 Blautia A massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004640 Microbes metabolize substances PMDBM2021458 1737424 Blautia A massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004641 Microbes metabolize substances PMDBM2021458 1737424 Blautia A massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004642 Microbes metabolize substances PMDBM2021458 1737424 Blautia A massiliensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004644 Microbes metabolize substances PMDBM2021458 1737424 Blautia A massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004646 Microbes metabolize substances PMDBM2021458 1737424 Blautia A massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004647 Microbes metabolize substances PMDBM2021458 1737424 Blautia A massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004648 Microbes metabolize substances PMDBM2021458 1737424 Blautia A massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004649 Microbes metabolize substances PMDBM2021458 1737424 Blautia A massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004652 Microbes metabolize substances PMDBM2021458 1737424 Blautia A massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004653 Microbes metabolize substances PMDBM2021458 1737424 Blautia A massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004654 Microbes metabolize substances PMDBM2021458 1737424 Blautia A massiliensis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20004655 Microbes metabolize substances PMDBM2021458 1737424 Blautia A massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004656 Microbes metabolize substances PMDBM2021458 1737424 Blautia A massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004658 Microbes metabolize substances PMDBM2021458 1737424 Blautia A massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004659 Microbes metabolize substances PMDBM2021458 1737424 Blautia A massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004660 Microbes metabolize substances PMDBM2021458 1737424 Blautia A massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004661 Microbes metabolize substances PMDBM2020196 1322 Blautia hansenii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004662 Microbes metabolize substances PMDBM2020196 1322 Blautia hansenii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004663 Microbes metabolize substances PMDBM2020196 1322 Blautia hansenii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004664 Microbes metabolize substances PMDBM2020196 1322 Blautia hansenii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004666 Microbes metabolize substances PMDBM2020196 1322 Blautia hansenii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004668 Microbes metabolize substances PMDBM2020196 1322 Blautia hansenii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004669 Microbes metabolize substances PMDBM2020196 1322 Blautia hansenii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004670 Microbes metabolize substances PMDBM2020196 1322 Blautia hansenii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004671 Microbes metabolize substances PMDBM2020196 1322 Blautia hansenii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004674 Microbes metabolize substances PMDBM2020196 1322 Blautia hansenii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004675 Microbes metabolize substances PMDBM2020196 1322 Blautia hansenii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004676 Microbes metabolize substances PMDBM2020196 1322 Blautia hansenii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004677 Microbes metabolize substances PMDBM2020196 1322 Blautia hansenii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004679 Microbes metabolize substances PMDBM2020196 1322 Blautia hansenii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004680 Microbes metabolize substances PMDBM2020196 1322 Blautia hansenii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004681 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004682 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20004683 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004684 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004685 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004687 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004689 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004690 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004691 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004692 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004693 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004694 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004696 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20004699 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20004700 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20004701 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004702 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004705 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20004708 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20004709 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004710 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004713 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004714 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004715 Microbes metabolize substances PMDBM2021459 2025493 Blautia hominis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004716 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004717 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004718 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004719 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004721 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004723 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004724 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004725 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004726 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004727 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004728 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004730 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20004733 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20004734 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20004735 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004738 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20004741 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20004742 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004743 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004746 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004747 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD772 Secoisolariciresinol Therapeutic Substance anticancer n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. unknown activity increased n.a. n.a. n.a. Protective effects against breast cancer n.a. PMID PMID: 36467581 PMDBI20004748 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004749 Microbes metabolize substances PMDBM2020197 33035 Blautia producta PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004750 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004751 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20004752 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004753 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004754 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004756 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004758 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20004759 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004760 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004761 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004762 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004765 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004766 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004767 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004768 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004770 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004771 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004772 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000432195 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004773 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000436935 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004774 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000436935 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004775 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000436935 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004776 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000436935 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004777 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000436935 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004778 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000436935 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004779 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000436935 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004782 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000436935 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004783 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000436935 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004784 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000436935 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004785 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000436935 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004786 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000436935 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004787 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000436935 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004788 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000436935 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004789 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp000436935 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004790 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004791 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004792 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004793 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004795 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004797 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004798 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004799 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004800 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004801 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004802 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004804 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20004807 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20004808 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20004809 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004810 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004813 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20004816 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20004817 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004818 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004821 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004822 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004823 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp001304935 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004824 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004825 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004826 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004827 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004829 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004831 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004832 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004833 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004834 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004835 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004836 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004838 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20004841 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20004842 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20004843 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004844 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004847 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20004850 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004851 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004854 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004855 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004856 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp002161285 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004857 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004858 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004859 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004860 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004862 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004864 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004865 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004866 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004867 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004868 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20004869 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004871 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20004874 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20004875 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20004876 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004877 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004880 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20004883 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004884 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004887 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004888 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004889 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp003287895 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004890 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp900120295 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004891 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp900120295 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004892 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp900120295 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004893 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp900120295 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20004894 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp900120295 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004895 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp900120295 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004896 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp900120295 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004897 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp900120295 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004900 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp900120295 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004901 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp900120295 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004902 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp900120295 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004903 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp900120295 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004904 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp900120295 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004905 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp900120295 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004906 Microbes metabolize substances PMDBM2020453 1955243 Blautia sp900120295 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004907 Microbes metabolize substances PMDBM2020451 53443 Blautia A hydrogenotrophica PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004908 Microbes metabolize substances PMDBM2020451 53443 Blautia A hydrogenotrophica PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004909 Microbes metabolize substances PMDBM2020451 53443 Blautia A hydrogenotrophica PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004910 Microbes metabolize substances PMDBM2020451 53443 Blautia A hydrogenotrophica PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004911 Microbes metabolize substances PMDBM2020451 53443 BlautiaA hydrogenotrophica PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004912 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004913 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004914 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004915 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004917 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004919 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004920 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004921 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004922 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004925 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004926 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004927 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004928 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004930 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004931 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004932 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004933 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004934 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004935 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004936 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum B PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004938 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004940 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004941 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004942 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004943 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004946 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004947 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004948 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004949 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004951 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum B PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004952 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004953 Microbes metabolize substances PMDBM2020040 40520 Blautia A obeum B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004954 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004955 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20004956 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20004957 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004959 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004961 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004962 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004963 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004964 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20004967 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004968 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004969 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20004970 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004971 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20004973 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20004974 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004975 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004976 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000285855 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20004977 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000433815 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004978 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000433815 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004979 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000433815 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004980 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000433815 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20004981 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000433815 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20004982 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000433815 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20004983 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000433815 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20004984 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000433815 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004985 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000433815 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20004986 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000433815 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20004993 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000433815 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004994 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000433815 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004995 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000433815 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20004996 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000433815 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005001 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000433815 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005002 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000433815 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005004 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp000433815 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005007 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066145 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005008 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066145 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005009 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066145 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005010 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066145 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005012 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066145 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005014 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066145 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005015 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066145 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005016 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066145 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005017 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066145 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005020 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066145 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005021 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066145 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005022 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066145 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005023 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066145 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005025 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066145 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005026 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066145 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005027 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066145 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005028 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005029 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005030 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005031 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005033 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005035 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005036 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005037 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005038 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20005039 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20005040 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005042 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20005045 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20005046 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20005047 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005048 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005051 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20005054 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005055 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005058 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005059 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005060 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066165 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005061 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066205 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005062 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066205 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005063 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066205 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005064 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066205 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005066 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066205 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005068 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066205 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005069 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066205 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005070 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066205 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005071 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066205 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005074 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066205 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005075 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066205 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005076 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066205 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005077 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066205 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005079 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066205 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005080 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066205 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005081 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066335 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005082 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066335 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005083 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066335 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005084 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066335 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005086 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066335 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005088 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066335 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005089 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066335 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005090 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066335 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005091 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066335 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005094 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066335 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005095 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066335 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005096 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066335 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005098 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066335 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005099 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066335 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005100 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066335 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005101 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005102 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005103 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005104 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005106 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005108 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20005109 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005110 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005111 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005112 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005115 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20005116 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005117 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005118 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005119 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005121 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005122 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005123 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900066505 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005124 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900120195 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005125 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900120195 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005126 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900120195 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005127 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900120195 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005129 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900120195 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005131 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900120195 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005132 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900120195 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005133 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900120195 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005134 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900120195 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005137 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900120195 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005138 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900120195 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005139 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900120195 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005140 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900120195 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005142 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900120195 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005143 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900120195 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005144 Microbes metabolize substances PMDBM2020453 1955243 Blautia A sp900120195 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005145 Microbes metabolize substances PMDBM2020454 418240 Blautia A wexlerae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005146 Microbes metabolize substances PMDBM2020454 418240 Blautia A wexlerae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005147 Microbes metabolize substances PMDBM2020454 418240 Blautia A wexlerae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005148 Microbes metabolize substances PMDBM2020454 418240 Blautia A wexlerae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005149 Microbes metabolize substances PMDBM2020454 418240 Blautia A wexlerae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005150 Microbes metabolize substances PMDBM2020454 418240 Blautia A wexlerae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005151 Microbes metabolize substances PMDBM2020454 418240 Blautia A wexlerae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005154 Microbes metabolize substances PMDBM2020454 418240 Blautia A wexlerae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005155 Microbes metabolize substances PMDBM2020454 418240 Blautia A wexlerae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005156 Microbes metabolize substances PMDBM2020454 418240 Blautia A wexlerae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005157 Microbes metabolize substances PMDBM2020454 418240 Blautia A wexlerae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005158 Microbes metabolize substances PMDBM2020454 418240 Blautia A wexlerae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005159 Microbes metabolize substances PMDBM2020454 418240 Blautia A wexlerae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005160 Microbes metabolize substances PMDBM2020454 418240 Blautia A wexlerae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005161 Microbes metabolize substances PMDBM2020454 418240 Blautia A wexlerae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005162 Microbes metabolize substances PMDBM2008287 n.a. f Caulobacteraceae g BOG-935 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005163 Microbes metabolize substances PMDBM2008287 n.a. f Caulobacteraceae g BOG-935 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005164 Microbes metabolize substances PMDBM2008287 n.a. f Caulobacteraceae g BOG-935 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005165 Microbes metabolize substances PMDBM2008287 n.a. f Caulobacteraceae g BOG-935 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005166 Microbes metabolize substances PMDBM2008287 n.a. f Caulobacteraceae g BOG-935 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005168 Microbes metabolize substances PMDBM2008287 n.a. f Caulobacteraceae g BOG-935 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005170 Microbes metabolize substances PMDBM2008287 n.a. f Caulobacteraceae g BOG-935 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005171 Microbes metabolize substances PMDBM2008287 n.a. f Caulobacteraceae g BOG-935 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005172 Microbes metabolize substances PMDBM2008287 n.a. f Caulobacteraceae g BOG-935 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005173 Microbes metabolize substances PMDBM2008287 n.a. f Caulobacteraceae g BOG-935 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005176 Microbes metabolize substances PMDBM2008287 n.a. f Caulobacteraceae g BOG-935 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20005177 Microbes metabolize substances PMDBM2008287 n.a. f Caulobacteraceae g BOG-935 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005178 Microbes metabolize substances PMDBM2008287 n.a. f Caulobacteraceae g BOG-935 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005180 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005181 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005182 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005183 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005184 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005185 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005186 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20005187 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20005188 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005190 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20005193 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20005194 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20005195 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20005196 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005197 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005200 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20005203 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005204 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005205 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005207 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005208 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005209 Microbes metabolize substances PMDBM2020086 52584 Brachyspira pilosicoli PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005210 Microbes metabolize substances PMDBM2021460 1977261 Brachyspira sp000431595 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20005211 Microbes metabolize substances PMDBM2021460 1977261 Brachyspira sp000431595 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20005212 Microbes metabolize substances PMDBM2021460 1977261 Brachyspira sp000431595 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20005214 Microbes metabolize substances PMDBM2021460 1977261 Brachyspira sp000431595 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20005215 Microbes metabolize substances PMDBM2021460 1977261 Brachyspira sp000431595 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20005216 Microbes metabolize substances PMDBM2021460 1977261 Brachyspira sp000431595 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005217 Microbes metabolize substances PMDBM2021460 1977261 Brachyspira sp000431595 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005220 Microbes metabolize substances PMDBM2021460 1977261 Brachyspira sp000431595 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20005224 Microbes metabolize substances PMDBM2021460 1977261 Brachyspira sp000431595 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005225 Microbes metabolize substances PMDBM2021460 1977261 Brachyspira sp000431595 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005226 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp000015165 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005227 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp000015165 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005228 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp000015165 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005229 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp000015165 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005230 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp000015165 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005231 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp000015165 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005232 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp000015165 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005233 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp000015165 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005236 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp000015165 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005237 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp000015165 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005238 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp000015165 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20005239 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp000015165 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005240 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp000015165 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005241 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp000015165 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005242 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp003020075 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005243 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp003020075 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005244 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp003020075 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005245 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp003020075 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005246 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp003020075 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005247 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp003020075 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005248 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp003020075 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005251 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp003020075 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005252 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp003020075 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005253 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp003020075 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005254 Microbes metabolize substances PMDBM2021461 376 Bradyrhizobium sp003020075 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005255 Microbes metabolize substances PMDBM2021462 1118054 BrevibacilluC massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005256 Microbes metabolize substances PMDBM2021462 1118054 BrevibacilluC massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005257 Microbes metabolize substances PMDBM2021462 1118054 BrevibacilluC massiliensis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20005258 Microbes metabolize substances PMDBM2021462 1118054 BrevibacilluC massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005259 Microbes metabolize substances PMDBM2021462 1118054 BrevibacilluC massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005260 Microbes metabolize substances PMDBM2021462 1118054 BrevibacilluC massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005261 Microbes metabolize substances PMDBM2008293 1696 Brevibacterium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005262 Microbes metabolize substances PMDBM2008293 1696 Brevibacterium PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005263 Microbes metabolize substances PMDBM2008293 1696 Brevibacterium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005264 Microbes metabolize substances PMDBM2008293 1696 Brevibacterium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005265 Microbes metabolize substances PMDBM2008293 1696 Brevibacterium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005266 Microbes metabolize substances PMDBM2008293 1696 Brevibacterium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005267 Microbes metabolize substances PMDBM2008293 1696 Brevibacterium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005268 Microbes metabolize substances PMDBM2008293 1696 Brevibacterium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005271 Microbes metabolize substances PMDBM2008293 1696 Brevibacterium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005272 Microbes metabolize substances PMDBM2008293 1696 Brevibacterium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005273 Microbes metabolize substances PMDBM2008293 1696 Brevibacterium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005274 Microbes metabolize substances PMDBM2008293 1696 Brevibacterium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005275 Microbes metabolize substances PMDBM2008293 1696 Brevibacterium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005276 Microbes metabolize substances PMDBM2008293 1696 Brevibacterium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005277 Microbes metabolize substances PMDBM2008293 1696 Brevibacterium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005278 Microbes metabolize substances PMDBM2020465 1033736 Brevibacterium senegalense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005279 Microbes metabolize substances PMDBM2020465 1033736 Brevibacterium senegalense PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005280 Microbes metabolize substances PMDBM2020465 1033736 Brevibacterium senegalense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005281 Microbes metabolize substances PMDBM2020465 1033736 Brevibacterium senegalense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005282 Microbes metabolize substances PMDBM2020465 1033736 Brevibacterium senegalense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005283 Microbes metabolize substances PMDBM2020465 1033736 Brevibacterium senegalense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005284 Microbes metabolize substances PMDBM2020465 1033736 Brevibacterium senegalense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005285 Microbes metabolize substances PMDBM2020465 1033736 Brevibacterium senegalense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005288 Microbes metabolize substances PMDBM2020465 1033736 Brevibacterium senegalense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005289 Microbes metabolize substances PMDBM2020465 1033736 Brevibacterium senegalense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005290 Microbes metabolize substances PMDBM2020465 1033736 Brevibacterium senegalense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005291 Microbes metabolize substances PMDBM2020465 1033736 Brevibacterium senegalense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005292 Microbes metabolize substances PMDBM2020465 1033736 Brevibacterium senegalense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005293 Microbes metabolize substances PMDBM2020465 1033736 Brevibacterium senegalense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005294 Microbes metabolize substances PMDBM2020465 1033736 Brevibacterium senegalense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005295 Microbes metabolize substances PMDBM2020472 292 Burkholderia cepacia PMDBD452 Ipilimumab Therapeutic Substance a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. stimulate CTLA-4-induced antitumour immune response, thereby increasing therapeutic efficacy91 n.a. PMID PMID: 36467581 PMDBI20005296 Microbes metabolize substances PMDBM2020043 28121 Butrivibrio sp. PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. quercetin-aglycone and polyphenols n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Microbiome-inducedhydrolysis leading toindirect mutageniceffect n.a. PMID PMID: 36467581 PMDBI20005297 Microbes metabolize substances PMDBM2008297 3085642 Butyricicoccaceae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005298 Microbes metabolize substances PMDBM2008297 3085642 Butyricicoccaceae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20005299 Microbes metabolize substances PMDBM2008297 3085642 Butyricicoccaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005300 Microbes metabolize substances PMDBM2008297 3085642 Butyricicoccaceae PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20005301 Microbes metabolize substances PMDBM2008297 3085642 Butyricicoccaceae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005302 Microbes metabolize substances PMDBM2008297 3085642 Butyricicoccaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005303 Microbes metabolize substances PMDBM2008297 3085642 Butyricicoccaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005304 Microbes metabolize substances PMDBM2021463 2049021 Butyricicoccus A sp002395695 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005305 Microbes metabolize substances PMDBM2021463 2049021 Butyricicoccus A sp002395695 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20005306 Microbes metabolize substances PMDBM2021463 2049021 Butyricicoccus A sp002395695 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005307 Microbes metabolize substances PMDBM2021463 2049021 Butyricicoccus A sp002395695 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005308 Microbes metabolize substances PMDBM2021463 2049021 Butyricicoccus A sp002395695 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005309 Microbes metabolize substances PMDBM2021463 2049021 Butyricicoccus A sp002395695 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005310 Microbes metabolize substances PMDBM2021463 2049021 Butyricicoccus A sp002395695 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005311 Microbes metabolize substances PMDBM121 580596 Butyricicoccus PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20005312 Microbes metabolize substances PMDBM121 580596 Butyricicoccus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005313 Microbes metabolize substances PMDBM121 580596 Butyricicoccus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005314 Microbes metabolize substances PMDBM121 580596 Butyricicoccus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005315 Microbes metabolize substances PMDBM121 580596 Butyricicoccus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005316 Microbes metabolize substances PMDBM121 580596 Butyricicoccus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005317 Microbes metabolize substances PMDBM2020198 501571 Butyricicoccus pullicaecorum PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005318 Microbes metabolize substances PMDBM2020198 501571 Butyricicoccus pullicaecorum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005319 Microbes metabolize substances PMDBM2020198 501571 Butyricicoccus pullicaecorum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005320 Microbes metabolize substances PMDBM2020198 501571 Butyricicoccus pullicaecorum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005321 Microbes metabolize substances PMDBM2020198 501571 Butyricicoccus pullicaecorum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005322 Microbes metabolize substances PMDBM2020198 501571 Butyricicoccus pullicaecorum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005323 Microbes metabolize substances PMDBM123 574697 Butyricimonas PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20005324 Microbes metabolize substances PMDBM123 574697 Butyricimonas PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005325 Microbes metabolize substances PMDBM123 574697 Butyricimonas PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005326 Microbes metabolize substances PMDBM123 574697 Butyricimonas PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005327 Microbes metabolize substances PMDBM123 574697 Butyricimonas PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005328 Microbes metabolize substances PMDBM123 574697 Butyricimonas PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005329 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp002161485 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005330 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp002161485 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005331 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp002161485 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005332 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp002161485 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005333 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp002161485 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005334 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp002161485 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005335 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp002161485 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005338 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp002161485 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20005339 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp002161485 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005340 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp002161485 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005341 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp002161485 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005342 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp002161485 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005343 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp002161485 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005344 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp002161485 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005345 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp002161485 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005346 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp002161485 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005347 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900184685 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005348 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900184685 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005349 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900184685 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005350 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900184685 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005351 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900258545 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005352 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900258545 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005353 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900258545 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005354 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900258545 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005355 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900258545 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005356 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900258545 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005357 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900258545 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005360 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900258545 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005361 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900258545 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005362 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900258545 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005363 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900258545 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005364 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900258545 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005365 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900258545 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005366 Microbes metabolize substances PMDBM2021464 1969738 Butyricimonas sp900258545 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005367 Microbes metabolize substances PMDBM2020474 544644 Butyricimonas synergistica PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20005368 Microbes metabolize substances PMDBM2020474 544644 Butyricimonas synergistica PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005369 Microbes metabolize substances PMDBM2020474 544644 Butyricimonas synergistica PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005370 Microbes metabolize substances PMDBM2020474 544644 Butyricimonas synergistica PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005371 Microbes metabolize substances PMDBM2020474 544644 Butyricimonas synergistica PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005372 Microbes metabolize substances PMDBM2020474 544644 Butyricimonas synergistica PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005373 Microbes metabolize substances PMDBM2020475 544645 Butyricimonas virosa PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20005374 Microbes metabolize substances PMDBM2020475 544645 Butyricimonas virosa PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005375 Microbes metabolize substances PMDBM2020475 544645 Butyricimonas virosa PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005376 Microbes metabolize substances PMDBM2020475 544645 Butyricimonas virosa PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005377 Microbes metabolize substances PMDBM2020475 544645 Butyricimonas virosa PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005378 Microbes metabolize substances PMDBM2020475 544645 Butyricimonas virosa PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005379 Microbes metabolize substances PMDBM2020784 45851 Butyrivibrio A crossotus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005380 Microbes metabolize substances PMDBM2020784 45851 Butyrivibrio A crossotus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005381 Microbes metabolize substances PMDBM2020784 45851 Butyrivibrio A crossotus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005382 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005383 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005384 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005385 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005386 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005387 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005388 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20005389 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20005390 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005392 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20005395 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20005396 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20005397 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005398 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005401 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20005404 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005405 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005406 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005408 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005409 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005410 Microbes metabolize substances PMDBM2021465 557553 Butyrivibrio A sp000431815 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005411 Microbes metabolize substances PMDBM2008304 n.a. Butyrivibrio A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005412 Microbes metabolize substances PMDBM2008304 n.a. Butyrivibrio A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005413 Microbes metabolize substances PMDBM2008304 n.a. Butyrivibrio A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005414 Microbes metabolize substances PMDBM2008304 n.a. Butyrivibrio A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005415 Microbes metabolize substances PMDBM2008304 n.a. Butyrivibrio A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005416 Microbes metabolize substances PMDBM2008304 n.a. Butyrivibrio A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005417 Microbes metabolize substances PMDBM2008304 n.a. Butyrivibrio A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005420 Microbes metabolize substances PMDBM2008304 n.a. Butyrivibrio A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005421 Microbes metabolize substances PMDBM2008304 n.a. Butyrivibrio A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005422 Microbes metabolize substances PMDBM2008304 n.a. Butyrivibrio A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005423 Microbes metabolize substances PMDBM2008304 n.a. Butyrivibrio A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005424 Microbes metabolize substances PMDBM2008304 n.a. Butyrivibrio A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005425 Microbes metabolize substances PMDBM2008304 n.a. Butyrivibrio A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005426 Microbes metabolize substances PMDBM2008304 n.a. Butyrivibrio A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005427 Microbes metabolize substances PMDBM2008304 n.a. Butyrivibrio A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005428 Microbes metabolize substances PMDBM2008305 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005429 Microbes metabolize substances PMDBM2008305 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005430 Microbes metabolize substances PMDBM2008305 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005431 Microbes metabolize substances PMDBM2008305 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005432 Microbes metabolize substances PMDBM2008305 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005433 Microbes metabolize substances PMDBM2008305 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005434 Microbes metabolize substances PMDBM2008305 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005437 Microbes metabolize substances PMDBM2008305 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005438 Microbes metabolize substances PMDBM2008305 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005439 Microbes metabolize substances PMDBM2008305 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005440 Microbes metabolize substances PMDBM2008305 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005441 Microbes metabolize substances PMDBM2008305 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005442 Microbes metabolize substances PMDBM2008305 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005443 Microbes metabolize substances PMDBM2008306 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005444 Microbes metabolize substances PMDBM2008306 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005445 Microbes metabolize substances PMDBM2008306 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005446 Microbes metabolize substances PMDBM2008306 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005447 Microbes metabolize substances PMDBM2008306 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005448 Microbes metabolize substances PMDBM2008306 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005449 Microbes metabolize substances PMDBM2008306 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005452 Microbes metabolize substances PMDBM2008306 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005453 Microbes metabolize substances PMDBM2008306 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005454 Microbes metabolize substances PMDBM2008306 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005455 Microbes metabolize substances PMDBM2008306 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005456 Microbes metabolize substances PMDBM2008306 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005457 Microbes metabolize substances PMDBM2008306 n.a. c Alphaproteobacteria o RF32 f CAG-239 g 51-20 s 51-20 sp001917175 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005458 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005459 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005460 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005461 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005463 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005465 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005466 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005467 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005468 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20005469 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20005470 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005472 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20005475 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20005476 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20005477 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005478 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005481 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20005484 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005485 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005488 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005489 Microbes metabolize substances PMDBM2008307 n.a. c Clostridia o 4C28d-15 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005490 Microbes metabolize substances PMDBM2008308 n.a. f Muribaculaceae g C941 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005491 Microbes metabolize substances PMDBM2008308 n.a. f Muribaculaceae g C941 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005492 Microbes metabolize substances PMDBM2008308 n.a. f Muribaculaceae g C941 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005493 Microbes metabolize substances PMDBM2008308 n.a. f Muribaculaceae g C941 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005495 Microbes metabolize substances PMDBM2008308 n.a. f Muribaculaceae g C941 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005497 Microbes metabolize substances PMDBM2008308 n.a. f Muribaculaceae g C941 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005498 Microbes metabolize substances PMDBM2008308 n.a. f Muribaculaceae g C941 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005499 Microbes metabolize substances PMDBM2008308 n.a. f Muribaculaceae g C941 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005500 Microbes metabolize substances PMDBM2008308 n.a. f Muribaculaceae g C941 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005503 Microbes metabolize substances PMDBM2008308 n.a. f Muribaculaceae g C941 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20005504 Microbes metabolize substances PMDBM2008308 n.a. f Muribaculaceae g C941 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005505 Microbes metabolize substances PMDBM2008308 n.a. f Muribaculaceae g C941 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005506 Microbes metabolize substances PMDBM2008308 n.a. f Muribaculaceae g C941 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005507 Microbes metabolize substances PMDBM2008308 n.a. f Muribaculaceae g C941 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005509 Microbes metabolize substances PMDBM2008308 n.a. f Muribaculaceae g C941 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005510 Microbes metabolize substances PMDBM2008308 n.a. f Muribaculaceae g C941 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005511 Microbes metabolize substances PMDBM2008308 n.a. f Muribaculaceae g C941 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005512 Microbes metabolize substances PMDBM2008309 n.a. f Muribaculaceae g C941 s C941 sp900321725 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005513 Microbes metabolize substances PMDBM2008309 n.a. f Muribaculaceae g C941 s C941 sp900321725 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005514 Microbes metabolize substances PMDBM2008309 n.a. f Muribaculaceae g C941 s C941 sp900321725 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005515 Microbes metabolize substances PMDBM2008309 n.a. f Muribaculaceae g C941 s C941 sp900321725 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005516 Microbes metabolize substances PMDBM2008309 n.a. f Muribaculaceae g C941 s C941 sp900321725 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005517 Microbes metabolize substances PMDBM2008309 n.a. f Muribaculaceae g C941 s C941 sp900321725 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005518 Microbes metabolize substances PMDBM2008309 n.a. f Muribaculaceae g C941 s C941 sp900321725 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005521 Microbes metabolize substances PMDBM2008309 n.a. f Muribaculaceae g C941 s C941 sp900321725 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20005522 Microbes metabolize substances PMDBM2008309 n.a. f Muribaculaceae g C941 s C941 sp900321725 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005523 Microbes metabolize substances PMDBM2008309 n.a. f Muribaculaceae g C941 s C941 sp900321725 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005524 Microbes metabolize substances PMDBM2008309 n.a. f Muribaculaceae g C941 s C941 sp900321725 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005525 Microbes metabolize substances PMDBM2008309 n.a. f Muribaculaceae g C941 s C941 sp900321725 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005526 Microbes metabolize substances PMDBM2008309 n.a. f Muribaculaceae g C941 s C941 sp900321725 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005527 Microbes metabolize substances PMDBM2008309 n.a. f Muribaculaceae g C941 s C941 sp900321725 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005528 Microbes metabolize substances PMDBM2008309 n.a. f Muribaculaceae g C941 s C941 sp900321725 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005529 Microbes metabolize substances PMDBM2008309 n.a. f Muribaculaceae g C941 s C941 sp900321725 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005530 Microbes metabolize substances PMDBM2008310 1980685 Caecibacter PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20005531 Microbes metabolize substances PMDBM2008310 1980685 Caecibacter PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005532 Microbes metabolize substances PMDBM2008310 1980685 Caecibacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005533 Microbes metabolize substances PMDBM2008310 1980685 Caecibacter PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005534 Microbes metabolize substances PMDBM2008310 1980685 Caecibacter PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005535 Microbes metabolize substances PMDBM2008310 1980685 Caecibacter PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005536 Microbes metabolize substances PMDBM2020476 1852378 Caecibacter massiliensis PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20005537 Microbes metabolize substances PMDBM2020476 1852378 Caecibacter massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005538 Microbes metabolize substances PMDBM2020476 1852378 Caecibacter massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005539 Microbes metabolize substances PMDBM2020476 1852378 Caecibacter massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005540 Microbes metabolize substances PMDBM2020476 1852378 Caecibacter massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005541 Microbes metabolize substances PMDBM2020476 1852378 Caecibacter massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005542 Microbes metabolize substances PMDBM2008312 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005543 Microbes metabolize substances PMDBM2008312 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005544 Microbes metabolize substances PMDBM2008312 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005545 Microbes metabolize substances PMDBM2008312 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005546 Microbes metabolize substances PMDBM2008312 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005547 Microbes metabolize substances PMDBM2008312 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005548 Microbes metabolize substances PMDBM2008312 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005551 Microbes metabolize substances PMDBM2008312 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005552 Microbes metabolize substances PMDBM2008312 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005553 Microbes metabolize substances PMDBM2008312 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005554 Microbes metabolize substances PMDBM2008312 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005555 Microbes metabolize substances PMDBM2008312 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005556 Microbes metabolize substances PMDBM2008312 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005558 Microbes metabolize substances PMDBM2008312 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005560 Microbes metabolize substances PMDBM2008313 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 s CAG-1000 sp000434555 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005561 Microbes metabolize substances PMDBM2008313 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 s CAG-1000 sp000434555 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005562 Microbes metabolize substances PMDBM2008313 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 s CAG-1000 sp000434555 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005563 Microbes metabolize substances PMDBM2008313 n.a. c Bacilli o RF39 f CAG-1000 g CAG-1000 s CAG-1000 sp000434555 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005567 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005568 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005569 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005570 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005571 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005573 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005575 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005576 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005577 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005578 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20005579 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20005580 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005582 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20005585 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20005586 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20005587 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005588 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005591 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20005594 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005595 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005598 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005599 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005600 Microbes metabolize substances PMDBM2008314 n.a. o Christensenellales f CAG-138 g CAG-1024 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005601 Microbes metabolize substances PMDBM2008315 n.a. o Christensenellales f CAG-138 g CAG-1024 s CAG-1024 sp000432015 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005602 Microbes metabolize substances PMDBM2008315 n.a. o Christensenellales f CAG-138 g CAG-1024 s CAG-1024 sp000432015 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005603 Microbes metabolize substances PMDBM2008315 n.a. o Christensenellales f CAG-138 g CAG-1024 s CAG-1024 sp000432015 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005604 Microbes metabolize substances PMDBM2008315 n.a. o Christensenellales f CAG-138 g CAG-1024 s CAG-1024 sp000432015 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005605 Microbes metabolize substances PMDBM2008315 n.a. o Christensenellales f CAG-138 g CAG-1024 s CAG-1024 sp000432015 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005606 Microbes metabolize substances PMDBM2008316 n.a. f Oscillospiraceae g CAG-103 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005607 Microbes metabolize substances PMDBM2008316 n.a. f Oscillospiraceae g CAG-103 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005608 Microbes metabolize substances PMDBM2008316 n.a. f Oscillospiraceae g CAG-103 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005609 Microbes metabolize substances PMDBM2008316 n.a. f Oscillospiraceae g CAG-103 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005610 Microbes metabolize substances PMDBM2008317 n.a. f Oscillospiraceae g CAG-103 s CAG-103 sp000432375 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005611 Microbes metabolize substances PMDBM2008317 n.a. f Oscillospiraceae g CAG-103 s CAG-103 sp000432375 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005612 Microbes metabolize substances PMDBM2008317 n.a. f Oscillospiraceae g CAG-103 s CAG-103 sp000432375 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005613 Microbes metabolize substances PMDBM2008317 n.a. f Oscillospiraceae g CAG-103 s CAG-103 sp000432375 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005614 Microbes metabolize substances PMDBM2008317 n.a. f Oscillospiraceae g CAG-103 s CAG-103 sp000432375 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005619 Microbes metabolize substances PMDBM2008318 n.a. f Muribaculaceae g CAG-1031 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005620 Microbes metabolize substances PMDBM2008318 n.a. f Muribaculaceae g CAG-1031 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005621 Microbes metabolize substances PMDBM2008318 n.a. f Muribaculaceae g CAG-1031 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005622 Microbes metabolize substances PMDBM2008318 n.a. f Muribaculaceae g CAG-1031 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005623 Microbes metabolize substances PMDBM2008318 n.a. f Muribaculaceae g CAG-1031 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005624 Microbes metabolize substances PMDBM2008318 n.a. f Muribaculaceae g CAG-1031 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005625 Microbes metabolize substances PMDBM2008318 n.a. f Muribaculaceae g CAG-1031 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005628 Microbes metabolize substances PMDBM2008318 n.a. f Muribaculaceae g CAG-1031 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20005629 Microbes metabolize substances PMDBM2008318 n.a. f Muribaculaceae g CAG-1031 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005630 Microbes metabolize substances PMDBM2008318 n.a. f Muribaculaceae g CAG-1031 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005631 Microbes metabolize substances PMDBM2008318 n.a. f Muribaculaceae g CAG-1031 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005632 Microbes metabolize substances PMDBM2008318 n.a. f Muribaculaceae g CAG-1031 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005633 Microbes metabolize substances PMDBM2008318 n.a. f Muribaculaceae g CAG-1031 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005634 Microbes metabolize substances PMDBM2008318 n.a. f Muribaculaceae g CAG-1031 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005635 Microbes metabolize substances PMDBM2008319 n.a. f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005636 Microbes metabolize substances PMDBM2008319 n.a. f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005637 Microbes metabolize substances PMDBM2008319 n.a. f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005638 Microbes metabolize substances PMDBM2008319 n.a. f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005639 Microbes metabolize substances PMDBM2008319 n.a. f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005640 Microbes metabolize substances PMDBM2008319 n.a. f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005641 Microbes metabolize substances PMDBM2008319 n.a. f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005644 Microbes metabolize substances PMDBM2008319 n.a. f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20005645 Microbes metabolize substances PMDBM2008319 n.a. f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005646 Microbes metabolize substances PMDBM2008319 n.a. f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005647 Microbes metabolize substances PMDBM2008319 n.a. f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005648 Microbes metabolize substances PMDBM2008319 n.a. f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005649 Microbes metabolize substances PMDBM2008319 n.a. f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005650 Microbes metabolize substances PMDBM2008319 n.a. f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005651 Microbes metabolize substances PMDBM2008319 n.a. f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005652 Microbes metabolize substances PMDBM2008319 n.a. f Muribaculaceae g CAG-1031 s CAG-1031 sp000431215 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005653 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005654 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005655 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005656 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005657 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005659 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005661 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20005662 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005663 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005664 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005665 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20005666 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20005667 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005669 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20005672 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20005673 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20005674 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20005675 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005676 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005679 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20005682 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20005683 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005684 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005687 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005688 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005689 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005690 Microbes metabolize substances PMDBM2008320 n.a. f Oscillospiraceae g CAG-110 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20005691 Microbes metabolize substances PMDBM2008321 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005692 Microbes metabolize substances PMDBM2008321 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005693 Microbes metabolize substances PMDBM2008321 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005694 Microbes metabolize substances PMDBM2008321 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005695 Microbes metabolize substances PMDBM2008321 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005696 Microbes metabolize substances PMDBM2008321 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005697 Microbes metabolize substances PMDBM2008321 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005700 Microbes metabolize substances PMDBM2008321 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005701 Microbes metabolize substances PMDBM2008321 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005702 Microbes metabolize substances PMDBM2008321 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20005703 Microbes metabolize substances PMDBM2008321 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005704 Microbes metabolize substances PMDBM2008321 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005705 Microbes metabolize substances PMDBM2008321 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005706 Microbes metabolize substances PMDBM2008321 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005707 Microbes metabolize substances PMDBM2008321 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005708 Microbes metabolize substances PMDBM2008321 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000434635 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005709 Microbes metabolize substances PMDBM2008322 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005710 Microbes metabolize substances PMDBM2008322 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005711 Microbes metabolize substances PMDBM2008322 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005712 Microbes metabolize substances PMDBM2008322 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005713 Microbes metabolize substances PMDBM2008322 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005714 Microbes metabolize substances PMDBM2008322 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005715 Microbes metabolize substances PMDBM2008322 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005718 Microbes metabolize substances PMDBM2008322 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005719 Microbes metabolize substances PMDBM2008322 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005720 Microbes metabolize substances PMDBM2008322 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005721 Microbes metabolize substances PMDBM2008322 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005722 Microbes metabolize substances PMDBM2008322 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005723 Microbes metabolize substances PMDBM2008322 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005724 Microbes metabolize substances PMDBM2008322 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp000435995 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005725 Microbes metabolize substances PMDBM2008323 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp003525905 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005726 Microbes metabolize substances PMDBM2008323 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp003525905 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005727 Microbes metabolize substances PMDBM2008323 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp003525905 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005728 Microbes metabolize substances PMDBM2008323 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp003525905 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005729 Microbes metabolize substances PMDBM2008323 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp003525905 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005730 Microbes metabolize substances PMDBM2008323 n.a. f Oscillospiraceae g CAG-110 s CAG-110 sp003525905 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005731 Microbes metabolize substances PMDBM2008324 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005732 Microbes metabolize substances PMDBM2008324 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005733 Microbes metabolize substances PMDBM2008324 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005734 Microbes metabolize substances PMDBM2008324 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005735 Microbes metabolize substances PMDBM2008324 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005736 Microbes metabolize substances PMDBM2008324 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005737 Microbes metabolize substances PMDBM2008324 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005740 Microbes metabolize substances PMDBM2008324 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005741 Microbes metabolize substances PMDBM2008324 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005742 Microbes metabolize substances PMDBM2008324 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005743 Microbes metabolize substances PMDBM2008324 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005744 Microbes metabolize substances PMDBM2008324 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005745 Microbes metabolize substances PMDBM2008324 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005746 Microbes metabolize substances PMDBM2008324 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-1138 s CAG-1138 sp000434675 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005747 Microbes metabolize substances PMDBM2008325 n.a. f Ruminococcaceae g CAG-115 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005748 Microbes metabolize substances PMDBM2008325 n.a. f Ruminococcaceae g CAG-115 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005749 Microbes metabolize substances PMDBM2008325 n.a. f Ruminococcaceae g CAG-115 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005750 Microbes metabolize substances PMDBM2008325 n.a. f Ruminococcaceae g CAG-115 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005751 Microbes metabolize substances PMDBM2008325 n.a. f Ruminococcaceae g CAG-115 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005753 Microbes metabolize substances PMDBM2008325 n.a. f Ruminococcaceae g CAG-115 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005755 Microbes metabolize substances PMDBM2008325 n.a. f Ruminococcaceae g CAG-115 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005756 Microbes metabolize substances PMDBM2008325 n.a. f Ruminococcaceae g CAG-115 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005757 Microbes metabolize substances PMDBM2008325 n.a. f Ruminococcaceae g CAG-115 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005758 Microbes metabolize substances PMDBM2008325 n.a. f Ruminococcaceae g CAG-115 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005761 Microbes metabolize substances PMDBM2008325 n.a. f Ruminococcaceae g CAG-115 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005762 Microbes metabolize substances PMDBM2008325 n.a. f Ruminococcaceae g CAG-115 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005763 Microbes metabolize substances PMDBM2008325 n.a. f Ruminococcaceae g CAG-115 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005764 Microbes metabolize substances PMDBM2008325 n.a. f Ruminococcaceae g CAG-115 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005766 Microbes metabolize substances PMDBM2008325 n.a. f Ruminococcaceae g CAG-115 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005767 Microbes metabolize substances PMDBM2008325 n.a. f Ruminococcaceae g CAG-115 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005768 Microbes metabolize substances PMDBM2008325 n.a. f Ruminococcaceae g CAG-115 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005769 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005770 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005771 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005772 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005773 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005774 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005775 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005776 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20005777 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20005778 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005780 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20005783 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20005784 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20005785 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005786 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005789 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20005792 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005793 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005794 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005796 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005797 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005798 Microbes metabolize substances PMDBM2008326 n.a. Ruminococcaceae g CAG-115 s CAG-115 sp000432175 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005799 Microbes metabolize substances PMDBM2008327 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005800 Microbes metabolize substances PMDBM2008327 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005801 Microbes metabolize substances PMDBM2008327 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005802 Microbes metabolize substances PMDBM2008327 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005803 Microbes metabolize substances PMDBM2008327 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005804 Microbes metabolize substances PMDBM2008327 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005805 Microbes metabolize substances PMDBM2008327 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005806 Microbes metabolize substances PMDBM2008327 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005809 Microbes metabolize substances PMDBM2008327 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005810 Microbes metabolize substances PMDBM2008327 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005811 Microbes metabolize substances PMDBM2008327 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005812 Microbes metabolize substances PMDBM2008327 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005813 Microbes metabolize substances PMDBM2008327 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005814 Microbes metabolize substances PMDBM2008327 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005815 Microbes metabolize substances PMDBM2008327 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005816 Microbes metabolize substances PMDBM2008327 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp002492075 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005817 Microbes metabolize substances PMDBM2008328 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005818 Microbes metabolize substances PMDBM2008328 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005819 Microbes metabolize substances PMDBM2008328 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005820 Microbes metabolize substances PMDBM2008328 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005821 Microbes metabolize substances PMDBM2008328 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005822 Microbes metabolize substances PMDBM2008328 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005823 Microbes metabolize substances PMDBM2008328 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005824 Microbes metabolize substances PMDBM2008328 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005827 Microbes metabolize substances PMDBM2008328 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005828 Microbes metabolize substances PMDBM2008328 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005829 Microbes metabolize substances PMDBM2008328 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005830 Microbes metabolize substances PMDBM2008328 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005831 Microbes metabolize substances PMDBM2008328 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005832 Microbes metabolize substances PMDBM2008328 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005833 Microbes metabolize substances PMDBM2008328 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005834 Microbes metabolize substances PMDBM2008328 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003507295 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005835 Microbes metabolize substances PMDBM2008329 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005836 Microbes metabolize substances PMDBM2008329 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005837 Microbes metabolize substances PMDBM2008329 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005838 Microbes metabolize substances PMDBM2008329 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005839 Microbes metabolize substances PMDBM2008329 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005840 Microbes metabolize substances PMDBM2008329 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005841 Microbes metabolize substances PMDBM2008329 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005844 Microbes metabolize substances PMDBM2008329 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005845 Microbes metabolize substances PMDBM2008329 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005846 Microbes metabolize substances PMDBM2008329 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005847 Microbes metabolize substances PMDBM2008329 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005848 Microbes metabolize substances PMDBM2008329 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005849 Microbes metabolize substances PMDBM2008329 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005850 Microbes metabolize substances PMDBM2008329 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005851 Microbes metabolize substances PMDBM2008329 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003516865 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005852 Microbes metabolize substances PMDBM2008330 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005853 Microbes metabolize substances PMDBM2008330 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005854 Microbes metabolize substances PMDBM2008330 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005855 Microbes metabolize substances PMDBM2008330 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005856 Microbes metabolize substances PMDBM2008330 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005857 Microbes metabolize substances PMDBM2008330 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005858 Microbes metabolize substances PMDBM2008330 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005859 Microbes metabolize substances PMDBM2008330 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005862 Microbes metabolize substances PMDBM2008330 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005863 Microbes metabolize substances PMDBM2008330 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005864 Microbes metabolize substances PMDBM2008330 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005865 Microbes metabolize substances PMDBM2008330 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005866 Microbes metabolize substances PMDBM2008330 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005867 Microbes metabolize substances PMDBM2008330 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005868 Microbes metabolize substances PMDBM2008330 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005869 Microbes metabolize substances PMDBM2008330 n.a. f Ruminococcaceae g CAG-115 s CAG-115 sp003531585 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005870 Microbes metabolize substances PMDBM2008331 n.a. c Bacilli o RF39 f UBA5348 g CAG-1193 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005871 Microbes metabolize substances PMDBM2008331 n.a. c Bacilli o RF39 f UBA5348 g CAG-1193 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005872 Microbes metabolize substances PMDBM2008331 n.a. c Bacilli o RF39 f UBA5348 g CAG-1193 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005873 Microbes metabolize substances PMDBM2008332 n.a. c Bacilli o RF39 f UBA5348 g CAG-1193 s CAG-1193 sp000436255 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20005874 Microbes metabolize substances PMDBM2008332 n.a. c Bacilli o RF39 f UBA5348 g CAG-1193 s CAG-1193 sp000436255 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005875 Microbes metabolize substances PMDBM2008332 n.a. c Bacilli o RF39 f UBA5348 g CAG-1193 s CAG-1193 sp000436255 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005876 Microbes metabolize substances PMDBM2008333 n.a. f Lachnospiraceae g CAG-127 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005877 Microbes metabolize substances PMDBM2008333 n.a. f Lachnospiraceae g CAG-127 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005878 Microbes metabolize substances PMDBM2008333 n.a. f Lachnospiraceae g CAG-127 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005879 Microbes metabolize substances PMDBM2008333 n.a. f Lachnospiraceae g CAG-127 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005880 Microbes metabolize substances PMDBM2008333 n.a. f Lachnospiraceae g CAG-127 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005881 Microbes metabolize substances PMDBM2008333 n.a. f Lachnospiraceae g CAG-127 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005882 Microbes metabolize substances PMDBM2008333 n.a. f Lachnospiraceae g CAG-127 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005885 Microbes metabolize substances PMDBM2008333 n.a. f Lachnospiraceae g CAG-127 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005886 Microbes metabolize substances PMDBM2008333 n.a. f Lachnospiraceae g CAG-127 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005887 Microbes metabolize substances PMDBM2008333 n.a. f Lachnospiraceae g CAG-127 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005888 Microbes metabolize substances PMDBM2008333 n.a. f Lachnospiraceae g CAG-127 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005889 Microbes metabolize substances PMDBM2008333 n.a. f Lachnospiraceae g CAG-127 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005890 Microbes metabolize substances PMDBM2008333 n.a. f Lachnospiraceae g CAG-127 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005891 Microbes metabolize substances PMDBM2008333 n.a. f Lachnospiraceae g CAG-127 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005892 Microbes metabolize substances PMDBM2008334 n.a. f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005893 Microbes metabolize substances PMDBM2008334 n.a. f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005894 Microbes metabolize substances PMDBM2008334 n.a. f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005895 Microbes metabolize substances PMDBM2008334 n.a. f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005896 Microbes metabolize substances PMDBM2008334 n.a. f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005897 Microbes metabolize substances PMDBM2008334 n.a. f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005898 Microbes metabolize substances PMDBM2008334 n.a. f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005901 Microbes metabolize substances PMDBM2008334 n.a. f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005902 Microbes metabolize substances PMDBM2008334 n.a. f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005903 Microbes metabolize substances PMDBM2008334 n.a. f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005904 Microbes metabolize substances PMDBM2008334 n.a. f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005905 Microbes metabolize substances PMDBM2008334 n.a. f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005906 Microbes metabolize substances PMDBM2008334 n.a. f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005907 Microbes metabolize substances PMDBM2008334 n.a. f Lachnospiraceae g CAG-127 s CAG-127 sp900319515 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005908 Microbes metabolize substances PMDBM2008335 n.a. o Christensenellales f CAG-138 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005909 Microbes metabolize substances PMDBM2008335 n.a. o Christensenellales f CAG-138 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20005910 Microbes metabolize substances PMDBM2008335 n.a. o Christensenellales f CAG-138 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005911 Microbes metabolize substances PMDBM2008335 n.a. o Christensenellales f CAG-138 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005912 Microbes metabolize substances PMDBM2008335 n.a. o Christensenellales f CAG-138 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005913 Microbes metabolize substances PMDBM2008335 n.a. o Christensenellales f CAG-138 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005914 Microbes metabolize substances PMDBM2008335 n.a. o Christensenellales f CAG-138 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005915 Microbes metabolize substances PMDBM2008335 n.a. o Christensenellales f CAG-138 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005918 Microbes metabolize substances PMDBM2008335 n.a. o Christensenellales f CAG-138 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20005919 Microbes metabolize substances PMDBM2008335 n.a. o Christensenellales f CAG-138 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005920 Microbes metabolize substances PMDBM2008335 n.a. o Christensenellales f CAG-138 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005921 Microbes metabolize substances PMDBM2008335 n.a. o Christensenellales f CAG-138 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005922 Microbes metabolize substances PMDBM2008335 n.a. o Christensenellales f CAG-138 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005923 Microbes metabolize substances PMDBM2008335 n.a. o Christensenellales f CAG-138 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005924 Microbes metabolize substances PMDBM2008335 n.a. o Christensenellales f CAG-138 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005925 Microbes metabolize substances PMDBM2008335 n.a. o Christensenellales f CAG-138 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005926 Microbes metabolize substances PMDBM2008336 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005927 Microbes metabolize substances PMDBM2008336 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005928 Microbes metabolize substances PMDBM2008336 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005929 Microbes metabolize substances PMDBM2008336 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20005930 Microbes metabolize substances PMDBM2008336 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005931 Microbes metabolize substances PMDBM2008336 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005932 Microbes metabolize substances PMDBM2008336 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005933 Microbes metabolize substances PMDBM2008336 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005936 Microbes metabolize substances PMDBM2008336 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005937 Microbes metabolize substances PMDBM2008336 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005938 Microbes metabolize substances PMDBM2008336 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005939 Microbes metabolize substances PMDBM2008336 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005940 Microbes metabolize substances PMDBM2008336 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005941 Microbes metabolize substances PMDBM2008336 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005942 Microbes metabolize substances PMDBM2008337 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 sp000431675 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20005943 Microbes metabolize substances PMDBM2008337 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 sp000431675 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005944 Microbes metabolize substances PMDBM2008337 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 sp000431675 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005945 Microbes metabolize substances PMDBM2008337 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 sp000431675 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005946 Microbes metabolize substances PMDBM2008338 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 sp000434775 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005947 Microbes metabolize substances PMDBM2008338 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 sp000434775 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005948 Microbes metabolize substances PMDBM2008338 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 sp000434775 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005949 Microbes metabolize substances PMDBM2008339 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 sp000435475 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20005950 Microbes metabolize substances PMDBM2008339 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 sp000435475 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005951 Microbes metabolize substances PMDBM2008339 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 sp000435475 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005952 Microbes metabolize substances PMDBM2008339 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 sp000435475 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005953 Microbes metabolize substances PMDBM2008340 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 sp000435675 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005954 Microbes metabolize substances PMDBM2008340 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 sp000435675 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005955 Microbes metabolize substances PMDBM2008340 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 sp000435675 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005956 Microbes metabolize substances PMDBM2008341 n.a. f Eggerthellaceae g CAG-1427 s CAG-1427 sp000436075 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005957 Microbes metabolize substances PMDBM2008342 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005958 Microbes metabolize substances PMDBM2008342 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005959 Microbes metabolize substances PMDBM2008342 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005960 Microbes metabolize substances PMDBM2008342 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005962 Microbes metabolize substances PMDBM2008342 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005964 Microbes metabolize substances PMDBM2008342 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005965 Microbes metabolize substances PMDBM2008342 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005966 Microbes metabolize substances PMDBM2008342 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005967 Microbes metabolize substances PMDBM2008342 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005970 Microbes metabolize substances PMDBM2008342 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20005971 Microbes metabolize substances PMDBM2008342 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005972 Microbes metabolize substances PMDBM2008342 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005973 Microbes metabolize substances PMDBM2008342 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005975 Microbes metabolize substances PMDBM2008342 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005976 Microbes metabolize substances PMDBM2008342 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005977 Microbes metabolize substances PMDBM2008343 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005978 Microbes metabolize substances PMDBM2008343 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005979 Microbes metabolize substances PMDBM2008343 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005980 Microbes metabolize substances PMDBM2008343 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005981 Microbes metabolize substances PMDBM2008343 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005982 Microbes metabolize substances PMDBM2008343 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20005983 Microbes metabolize substances PMDBM2008343 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20005986 Microbes metabolize substances PMDBM2008343 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20005987 Microbes metabolize substances PMDBM2008343 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005988 Microbes metabolize substances PMDBM2008343 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005989 Microbes metabolize substances PMDBM2008343 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20005990 Microbes metabolize substances PMDBM2008343 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005991 Microbes metabolize substances PMDBM2008343 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp000433775 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20005992 Microbes metabolize substances PMDBM2008344 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20005993 Microbes metabolize substances PMDBM2008344 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20005994 Microbes metabolize substances PMDBM2008344 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20005995 Microbes metabolize substances PMDBM2008344 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005997 Microbes metabolize substances PMDBM2008344 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20005999 Microbes metabolize substances PMDBM2008344 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006000 Microbes metabolize substances PMDBM2008344 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006001 Microbes metabolize substances PMDBM2008344 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006002 Microbes metabolize substances PMDBM2008344 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006005 Microbes metabolize substances PMDBM2008344 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006006 Microbes metabolize substances PMDBM2008344 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006007 Microbes metabolize substances PMDBM2008344 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006008 Microbes metabolize substances PMDBM2008344 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006010 Microbes metabolize substances PMDBM2008344 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006011 Microbes metabolize substances PMDBM2008344 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-1435 s CAG-1435 sp003537755 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006012 Microbes metabolize substances PMDBM2008345 n.a. f Anaerovoracaceae g CAG-145 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006013 Microbes metabolize substances PMDBM2008345 n.a. f Anaerovoracaceae g CAG-145 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006014 Microbes metabolize substances PMDBM2008345 n.a. f Anaerovoracaceae g CAG-145 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006015 Microbes metabolize substances PMDBM2008345 n.a. f Anaerovoracaceae g CAG-145 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006016 Microbes metabolize substances PMDBM2008345 n.a. f Anaerovoracaceae g CAG-145 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006017 Microbes metabolize substances PMDBM2008345 n.a. f Anaerovoracaceae g CAG-145 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006018 Microbes metabolize substances PMDBM2008345 n.a. f Anaerovoracaceae g CAG-145 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006021 Microbes metabolize substances PMDBM2008345 n.a. f Anaerovoracaceae g CAG-145 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20006022 Microbes metabolize substances PMDBM2008345 n.a. f Anaerovoracaceae g CAG-145 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006023 Microbes metabolize substances PMDBM2008345 n.a. f Anaerovoracaceae g CAG-145 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006024 Microbes metabolize substances PMDBM2008345 n.a. f Anaerovoracaceae g CAG-145 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006025 Microbes metabolize substances PMDBM2008345 n.a. f Anaerovoracaceae g CAG-145 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006026 Microbes metabolize substances PMDBM2008345 n.a. f Anaerovoracaceae g CAG-145 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006027 Microbes metabolize substances PMDBM2008345 n.a. f Anaerovoracaceae g CAG-145 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006028 Microbes metabolize substances PMDBM2008345 n.a. f Anaerovoracaceae g CAG-145 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006029 Microbes metabolize substances PMDBM2008346 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp000435615 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006030 Microbes metabolize substances PMDBM2008346 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp000435615 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006031 Microbes metabolize substances PMDBM2008346 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp000435615 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006032 Microbes metabolize substances PMDBM2008347 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006033 Microbes metabolize substances PMDBM2008347 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006034 Microbes metabolize substances PMDBM2008347 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006035 Microbes metabolize substances PMDBM2008347 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006036 Microbes metabolize substances PMDBM2008347 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006037 Microbes metabolize substances PMDBM2008347 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006038 Microbes metabolize substances PMDBM2008347 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006041 Microbes metabolize substances PMDBM2008347 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006042 Microbes metabolize substances PMDBM2008347 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006043 Microbes metabolize substances PMDBM2008347 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006044 Microbes metabolize substances PMDBM2008347 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006045 Microbes metabolize substances PMDBM2008347 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006046 Microbes metabolize substances PMDBM2008347 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006047 Microbes metabolize substances PMDBM2008347 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp000435715 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006048 Microbes metabolize substances PMDBM2008348 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp002320005 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006049 Microbes metabolize substances PMDBM2008348 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp002320005 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006050 Microbes metabolize substances PMDBM2008348 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp002320005 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006051 Microbes metabolize substances PMDBM2008348 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp002320005 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006052 Microbes metabolize substances PMDBM2008349 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp003150015 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006053 Microbes metabolize substances PMDBM2008349 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp003150015 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006054 Microbes metabolize substances PMDBM2008349 n.a. f Anaerovoracaceae g CAG-145 s CAG-145 sp003150015 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006055 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006056 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20006057 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006058 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006059 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006061 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006063 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006064 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006065 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006066 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006067 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006068 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006070 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20006073 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20006074 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20006075 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20006076 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006077 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006080 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20006083 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006084 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006087 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006088 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006089 Microbes metabolize substances PMDBM2008350 n.a. f Oscillospiraceae g CAG-170 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006090 Microbes metabolize substances PMDBM2008351 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006091 Microbes metabolize substances PMDBM2008351 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006092 Microbes metabolize substances PMDBM2008351 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006093 Microbes metabolize substances PMDBM2008351 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006094 Microbes metabolize substances PMDBM2008351 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006095 Microbes metabolize substances PMDBM2008351 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006096 Microbes metabolize substances PMDBM2008351 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006099 Microbes metabolize substances PMDBM2008351 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20006100 Microbes metabolize substances PMDBM2008351 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006101 Microbes metabolize substances PMDBM2008351 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006102 Microbes metabolize substances PMDBM2008351 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006103 Microbes metabolize substances PMDBM2008351 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006104 Microbes metabolize substances PMDBM2008351 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006105 Microbes metabolize substances PMDBM2008351 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006106 Microbes metabolize substances PMDBM2008351 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006107 Microbes metabolize substances PMDBM2008351 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000432135 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006108 Microbes metabolize substances PMDBM2008352 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006109 Microbes metabolize substances PMDBM2008352 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006110 Microbes metabolize substances PMDBM2008352 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006111 Microbes metabolize substances PMDBM2008352 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006113 Microbes metabolize substances PMDBM2008352 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006115 Microbes metabolize substances PMDBM2008352 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006116 Microbes metabolize substances PMDBM2008352 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006117 Microbes metabolize substances PMDBM2008352 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006118 Microbes metabolize substances PMDBM2008352 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006121 Microbes metabolize substances PMDBM2008352 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006122 Microbes metabolize substances PMDBM2008352 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006123 Microbes metabolize substances PMDBM2008352 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006124 Microbes metabolize substances PMDBM2008352 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006126 Microbes metabolize substances PMDBM2008352 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006127 Microbes metabolize substances PMDBM2008352 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp000436735 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006128 Microbes metabolize substances PMDBM2008353 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006129 Microbes metabolize substances PMDBM2008353 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006130 Microbes metabolize substances PMDBM2008353 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006131 Microbes metabolize substances PMDBM2008353 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006132 Microbes metabolize substances PMDBM2008353 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006133 Microbes metabolize substances PMDBM2008353 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006134 Microbes metabolize substances PMDBM2008353 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006137 Microbes metabolize substances PMDBM2008353 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20006138 Microbes metabolize substances PMDBM2008353 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006139 Microbes metabolize substances PMDBM2008353 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006140 Microbes metabolize substances PMDBM2008353 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006141 Microbes metabolize substances PMDBM2008353 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006142 Microbes metabolize substances PMDBM2008353 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006143 Microbes metabolize substances PMDBM2008353 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006144 Microbes metabolize substances PMDBM2008353 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006145 Microbes metabolize substances PMDBM2008353 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp002404795 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006146 Microbes metabolize substances PMDBM2008354 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006147 Microbes metabolize substances PMDBM2008354 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006148 Microbes metabolize substances PMDBM2008354 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006149 Microbes metabolize substances PMDBM2008354 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006150 Microbes metabolize substances PMDBM2008354 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006151 Microbes metabolize substances PMDBM2008354 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006152 Microbes metabolize substances PMDBM2008354 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006155 Microbes metabolize substances PMDBM2008354 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006156 Microbes metabolize substances PMDBM2008354 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006157 Microbes metabolize substances PMDBM2008354 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006158 Microbes metabolize substances PMDBM2008354 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006159 Microbes metabolize substances PMDBM2008354 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006160 Microbes metabolize substances PMDBM2008354 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006161 Microbes metabolize substances PMDBM2008354 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006162 Microbes metabolize substances PMDBM2008354 n.a. f Oscillospiraceae g CAG-170 s CAG-170 sp003516765 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006163 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006164 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006165 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006166 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006168 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006170 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006171 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006172 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006173 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006174 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006175 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006177 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20006180 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20006181 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20006182 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006183 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006186 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20006189 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006190 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006193 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006194 Microbes metabolize substances PMDBM2008355 n.a. f Acutalibacteraceae g CAG-177 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006195 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006196 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006197 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006198 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006200 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006202 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006203 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006204 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006205 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006206 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006207 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006209 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20006212 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20006213 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20006214 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006217 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20006220 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006221 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006224 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006225 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006226 Microbes metabolize substances PMDBM2008356 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp000431775 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006227 Microbes metabolize substances PMDBM2008357 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006228 Microbes metabolize substances PMDBM2008357 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006229 Microbes metabolize substances PMDBM2008357 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006230 Microbes metabolize substances PMDBM2008357 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006232 Microbes metabolize substances PMDBM2008357 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006234 Microbes metabolize substances PMDBM2008357 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006235 Microbes metabolize substances PMDBM2008357 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006236 Microbes metabolize substances PMDBM2008357 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006237 Microbes metabolize substances PMDBM2008357 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006240 Microbes metabolize substances PMDBM2008357 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006241 Microbes metabolize substances PMDBM2008357 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006242 Microbes metabolize substances PMDBM2008357 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006243 Microbes metabolize substances PMDBM2008357 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006245 Microbes metabolize substances PMDBM2008357 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006246 Microbes metabolize substances PMDBM2008357 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003514385 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006247 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006248 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006249 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006250 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006252 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006254 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006255 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006256 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006257 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006258 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006259 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006261 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20006264 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20006265 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20006266 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006267 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006270 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20006273 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006274 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006277 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006278 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006279 Microbes metabolize substances PMDBM2008358 n.a. f Acutalibacteraceae g CAG-177 s CAG-177 sp003538135 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006280 Microbes metabolize substances PMDBM2008359 n.a. c Clostridia o 4C28d-15 f DTU072 g CAG-1782 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006281 Microbes metabolize substances PMDBM2008359 n.a. c Clostridia o 4C28d-15 f DTU072 g CAG-1782 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006282 Microbes metabolize substances PMDBM2008359 n.a. c Clostridia o 4C28d-15 f DTU072 g CAG-1782 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006283 Microbes metabolize substances PMDBM2008359 n.a. c Clostridia o 4C28d-15 f DTU072 g CAG-1782 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006284 Microbes metabolize substances PMDBM2008359 n.a. c Clostridia o 4C28d-15 f DTU072 g CAG-1782 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006285 Microbes metabolize substances PMDBM2008359 n.a. c Clostridia o 4C28d-15 f DTU072 g CAG-1782 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006286 Microbes metabolize substances PMDBM2008359 n.a. c Clostridia o 4C28d-15 f DTU072 g CAG-1782 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006289 Microbes metabolize substances PMDBM2008359 n.a. c Clostridia o 4C28d-15 f DTU072 g CAG-1782 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006290 Microbes metabolize substances PMDBM2008359 n.a. c Clostridia o 4C28d-15 f DTU072 g CAG-1782 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006291 Microbes metabolize substances PMDBM2008359 n.a. c Clostridia o 4C28d-15 f DTU072 g CAG-1782 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006292 Microbes metabolize substances PMDBM2008359 n.a. c Clostridia o 4C28d-15 f DTU072 g CAG-1782 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006293 Microbes metabolize substances PMDBM2008359 n.a. c Clostridia o 4C28d-15 f DTU072 g CAG-1782 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006294 Microbes metabolize substances PMDBM2008359 n.a. c Clostridia o 4C28d-15 f DTU072 g CAG-1782 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006295 Microbes metabolize substances PMDBM2008359 n.a. c Clostridia o 4C28d-15 f DTU072 g CAG-1782 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006296 Microbes metabolize substances PMDBM2008359 n.a. c Clostridia o 4C28d-15 f DTU072 g CAG-1782 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006297 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006298 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006299 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006300 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006302 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006304 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006305 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006306 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006307 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006308 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006309 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006311 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20006314 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20006315 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20006316 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006317 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006320 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20006323 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006324 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006327 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006328 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006329 Microbes metabolize substances PMDBM2008360 n.a. f Acutalibacteraceae g CAG-180 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006330 Microbes metabolize substances PMDBM2008361 n.a. f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006331 Microbes metabolize substances PMDBM2008361 n.a. f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006332 Microbes metabolize substances PMDBM2008361 n.a. f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006333 Microbes metabolize substances PMDBM2008361 n.a. f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006334 Microbes metabolize substances PMDBM2008361 n.a. f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006335 Microbes metabolize substances PMDBM2008361 n.a. f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006336 Microbes metabolize substances PMDBM2008361 n.a. f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006339 Microbes metabolize substances PMDBM2008361 n.a. f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006340 Microbes metabolize substances PMDBM2008361 n.a. f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006341 Microbes metabolize substances PMDBM2008361 n.a. f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006342 Microbes metabolize substances PMDBM2008361 n.a. f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006343 Microbes metabolize substances PMDBM2008361 n.a. f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006344 Microbes metabolize substances PMDBM2008361 n.a. f Acutalibacteraceae g CAG-180 s CAG-180 sp000432435 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006345 Microbes metabolize substances PMDBM2008362 n.a. f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006346 Microbes metabolize substances PMDBM2008362 n.a. f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006347 Microbes metabolize substances PMDBM2008362 n.a. f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006348 Microbes metabolize substances PMDBM2008362 n.a. f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006349 Microbes metabolize substances PMDBM2008362 n.a. f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006350 Microbes metabolize substances PMDBM2008362 n.a. f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006351 Microbes metabolize substances PMDBM2008362 n.a. f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006354 Microbes metabolize substances PMDBM2008362 n.a. f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006355 Microbes metabolize substances PMDBM2008362 n.a. f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006356 Microbes metabolize substances PMDBM2008362 n.a. f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006357 Microbes metabolize substances PMDBM2008362 n.a. f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006358 Microbes metabolize substances PMDBM2008362 n.a. f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006359 Microbes metabolize substances PMDBM2008362 n.a. f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006360 Microbes metabolize substances PMDBM2008362 n.a. f Lachnospiraceae g CAG-194 s CAG-194 sp000432915 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006361 Microbes metabolize substances PMDBM2008363 n.a. f Gastranaerophilaceae g CAG-196 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006362 Microbes metabolize substances PMDBM2008363 n.a. f Gastranaerophilaceae g CAG-196 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006363 Microbes metabolize substances PMDBM2008363 n.a. f Gastranaerophilaceae g CAG-196 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006364 Microbes metabolize substances PMDBM2008363 n.a. f Gastranaerophilaceae g CAG-196 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006365 Microbes metabolize substances PMDBM2008363 n.a. f Gastranaerophilaceae g CAG-196 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006366 Microbes metabolize substances PMDBM2008364 n.a. f Gastranaerophilaceae g CAG-196 s CAG-196 sp002102975 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006367 Microbes metabolize substances PMDBM2008364 n.a. f Gastranaerophilaceae g CAG-196 s CAG-196 sp002102975 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006368 Microbes metabolize substances PMDBM2008364 n.a. f Gastranaerophilaceae g CAG-196 s CAG-196 sp002102975 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006369 Microbes metabolize substances PMDBM2008364 n.a. f Gastranaerophilaceae g CAG-196 s CAG-196 sp002102975 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006370 Microbes metabolize substances PMDBM2008365 n.a. f Acutalibacteraceae g CAG-217 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006371 Microbes metabolize substances PMDBM2008365 n.a. f Acutalibacteraceae g CAG-217 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006372 Microbes metabolize substances PMDBM2008365 n.a. f Acutalibacteraceae g CAG-217 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006373 Microbes metabolize substances PMDBM2008365 n.a. f Acutalibacteraceae g CAG-217 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006375 Microbes metabolize substances PMDBM2008365 n.a. f Acutalibacteraceae g CAG-217 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006377 Microbes metabolize substances PMDBM2008365 n.a. f Acutalibacteraceae g CAG-217 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006378 Microbes metabolize substances PMDBM2008365 n.a. f Acutalibacteraceae g CAG-217 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006379 Microbes metabolize substances PMDBM2008365 n.a. f Acutalibacteraceae g CAG-217 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006380 Microbes metabolize substances PMDBM2008365 n.a. f Acutalibacteraceae g CAG-217 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006383 Microbes metabolize substances PMDBM2008365 n.a. f Acutalibacteraceae g CAG-217 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006384 Microbes metabolize substances PMDBM2008365 n.a. f Acutalibacteraceae g CAG-217 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006385 Microbes metabolize substances PMDBM2008365 n.a. f Acutalibacteraceae g CAG-217 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006386 Microbes metabolize substances PMDBM2008365 n.a. f Acutalibacteraceae g CAG-217 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006388 Microbes metabolize substances PMDBM2008365 n.a. f Acutalibacteraceae g CAG-217 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006389 Microbes metabolize substances PMDBM2008365 n.a. f Acutalibacteraceae g CAG-217 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006390 Microbes metabolize substances PMDBM2008366 n.a. f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006391 Microbes metabolize substances PMDBM2008366 n.a. f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006392 Microbes metabolize substances PMDBM2008366 n.a. f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006393 Microbes metabolize substances PMDBM2008366 n.a. f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006394 Microbes metabolize substances PMDBM2008366 n.a. f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006395 Microbes metabolize substances PMDBM2008366 n.a. f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006396 Microbes metabolize substances PMDBM2008366 n.a. f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006399 Microbes metabolize substances PMDBM2008366 n.a. f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006400 Microbes metabolize substances PMDBM2008366 n.a. f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006401 Microbes metabolize substances PMDBM2008366 n.a. f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006402 Microbes metabolize substances PMDBM2008366 n.a. f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006403 Microbes metabolize substances PMDBM2008366 n.a. f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006404 Microbes metabolize substances PMDBM2008366 n.a. f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006405 Microbes metabolize substances PMDBM2008366 n.a. f Acutalibacteraceae g CAG-217 s CAG-217 sp000436335 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006406 Microbes metabolize substances PMDBM2008367 n.a. c Alphaproteobacteria o RF32 f CAG-239 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006407 Microbes metabolize substances PMDBM2008367 n.a. c Alphaproteobacteria o RF32 f CAG-239 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006408 Microbes metabolize substances PMDBM2008367 n.a. c Alphaproteobacteria o RF32 f CAG-239 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006409 Microbes metabolize substances PMDBM2008367 n.a. c Alphaproteobacteria o RF32 f CAG-239 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006410 Microbes metabolize substances PMDBM2008367 n.a. c Alphaproteobacteria o RF32 f CAG-239 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006411 Microbes metabolize substances PMDBM2008367 n.a. c Alphaproteobacteria o RF32 f CAG-239 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006412 Microbes metabolize substances PMDBM2008367 n.a. c Alphaproteobacteria o RF32 f CAG-239 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006415 Microbes metabolize substances PMDBM2008367 n.a. c Alphaproteobacteria o RF32 f CAG-239 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006416 Microbes metabolize substances PMDBM2008367 n.a. c Alphaproteobacteria o RF32 f CAG-239 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006417 Microbes metabolize substances PMDBM2008367 n.a. c Alphaproteobacteria o RF32 f CAG-239 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006418 Microbes metabolize substances PMDBM2008367 n.a. c Alphaproteobacteria o RF32 f CAG-239 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006419 Microbes metabolize substances PMDBM2008367 n.a. c Alphaproteobacteria o RF32 f CAG-239 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006420 Microbes metabolize substances PMDBM2008367 n.a. c Alphaproteobacteria o RF32 f CAG-239 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006421 Microbes metabolize substances PMDBM2008368 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006422 Microbes metabolize substances PMDBM2008368 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006423 Microbes metabolize substances PMDBM2008368 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006424 Microbes metabolize substances PMDBM2008368 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006425 Microbes metabolize substances PMDBM2008369 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006426 Microbes metabolize substances PMDBM2008369 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006427 Microbes metabolize substances PMDBM2008369 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006428 Microbes metabolize substances PMDBM2008369 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006429 Microbes metabolize substances PMDBM2008369 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006430 Microbes metabolize substances PMDBM2008369 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006431 Microbes metabolize substances PMDBM2008369 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006434 Microbes metabolize substances PMDBM2008369 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006435 Microbes metabolize substances PMDBM2008369 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006436 Microbes metabolize substances PMDBM2008369 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006437 Microbes metabolize substances PMDBM2008369 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006438 Microbes metabolize substances PMDBM2008369 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006439 Microbes metabolize substances PMDBM2008369 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006440 Microbes metabolize substances PMDBM2008369 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000434195 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006441 Microbes metabolize substances PMDBM2008370 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000435175 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006442 Microbes metabolize substances PMDBM2008370 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000435175 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006443 Microbes metabolize substances PMDBM2008370 n.a. c Clostridia o TANB77 f CAG-508 g CAG-245 s CAG-245 sp000435175 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006444 Microbes metabolize substances PMDBM2008371 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006445 Microbes metabolize substances PMDBM2008371 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006446 Microbes metabolize substances PMDBM2008371 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006447 Microbes metabolize substances PMDBM2008371 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006448 Microbes metabolize substances PMDBM2008371 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006449 Microbes metabolize substances PMDBM2008371 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006450 Microbes metabolize substances PMDBM2008371 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006453 Microbes metabolize substances PMDBM2008371 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006454 Microbes metabolize substances PMDBM2008371 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006455 Microbes metabolize substances PMDBM2008371 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006456 Microbes metabolize substances PMDBM2008371 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006457 Microbes metabolize substances PMDBM2008371 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006458 Microbes metabolize substances PMDBM2008371 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006459 Microbes metabolize substances PMDBM2008372 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 s CAG-267 sp001917135 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006460 Microbes metabolize substances PMDBM2008372 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 s CAG-267 sp001917135 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006461 Microbes metabolize substances PMDBM2008372 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-267 s CAG-267 sp001917135 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006462 Microbes metabolize substances PMDBM2008373 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006463 Microbes metabolize substances PMDBM2008373 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20006464 Microbes metabolize substances PMDBM2008373 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006465 Microbes metabolize substances PMDBM2008373 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006466 Microbes metabolize substances PMDBM2008373 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006467 Microbes metabolize substances PMDBM2008373 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006468 Microbes metabolize substances PMDBM2008373 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006469 Microbes metabolize substances PMDBM2008373 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006472 Microbes metabolize substances PMDBM2008373 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006473 Microbes metabolize substances PMDBM2008373 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006474 Microbes metabolize substances PMDBM2008373 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006475 Microbes metabolize substances PMDBM2008373 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006476 Microbes metabolize substances PMDBM2008373 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006477 Microbes metabolize substances PMDBM2008373 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006478 Microbes metabolize substances PMDBM2008373 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006479 Microbes metabolize substances PMDBM2008373 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006480 Microbes metabolize substances PMDBM2008374 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006481 Microbes metabolize substances PMDBM2008374 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006482 Microbes metabolize substances PMDBM2008374 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006483 Microbes metabolize substances PMDBM2008374 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006484 Microbes metabolize substances PMDBM2008374 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006485 Microbes metabolize substances PMDBM2008374 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006486 Microbes metabolize substances PMDBM2008374 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006489 Microbes metabolize substances PMDBM2008374 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006490 Microbes metabolize substances PMDBM2008374 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006491 Microbes metabolize substances PMDBM2008374 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006492 Microbes metabolize substances PMDBM2008374 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000431335 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006493 Microbes metabolize substances PMDBM2008375 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006494 Microbes metabolize substances PMDBM2008375 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006495 Microbes metabolize substances PMDBM2008375 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006496 Microbes metabolize substances PMDBM2008375 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006497 Microbes metabolize substances PMDBM2008375 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006498 Microbes metabolize substances PMDBM2008375 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006499 Microbes metabolize substances PMDBM2008375 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006502 Microbes metabolize substances PMDBM2008375 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006503 Microbes metabolize substances PMDBM2008375 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006504 Microbes metabolize substances PMDBM2008375 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006505 Microbes metabolize substances PMDBM2008375 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006506 Microbes metabolize substances PMDBM2008375 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006507 Microbes metabolize substances PMDBM2008375 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000435535 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006508 Microbes metabolize substances PMDBM2008376 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000437215 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006509 Microbes metabolize substances PMDBM2008376 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000437215 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006510 Microbes metabolize substances PMDBM2008376 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000437215 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006511 Microbes metabolize substances PMDBM2008377 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006512 Microbes metabolize substances PMDBM2008377 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006513 Microbes metabolize substances PMDBM2008377 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006514 Microbes metabolize substances PMDBM2008377 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006515 Microbes metabolize substances PMDBM2008377 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006516 Microbes metabolize substances PMDBM2008377 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006517 Microbes metabolize substances PMDBM2008377 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006520 Microbes metabolize substances PMDBM2008377 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006521 Microbes metabolize substances PMDBM2008377 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006522 Microbes metabolize substances PMDBM2008377 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006523 Microbes metabolize substances PMDBM2008377 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006524 Microbes metabolize substances PMDBM2008377 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006525 Microbes metabolize substances PMDBM2008377 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp000438255 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006526 Microbes metabolize substances PMDBM2008378 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006527 Microbes metabolize substances PMDBM2008378 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006528 Microbes metabolize substances PMDBM2008378 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006529 Microbes metabolize substances PMDBM2008378 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20006530 Microbes metabolize substances PMDBM2008378 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006531 Microbes metabolize substances PMDBM2008378 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006532 Microbes metabolize substances PMDBM2008378 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006533 Microbes metabolize substances PMDBM2008378 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006536 Microbes metabolize substances PMDBM2008378 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006537 Microbes metabolize substances PMDBM2008378 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006538 Microbes metabolize substances PMDBM2008378 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006539 Microbes metabolize substances PMDBM2008378 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006540 Microbes metabolize substances PMDBM2008378 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006541 Microbes metabolize substances PMDBM2008378 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916005 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006542 Microbes metabolize substances PMDBM2008379 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006543 Microbes metabolize substances PMDBM2008379 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006544 Microbes metabolize substances PMDBM2008379 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006545 Microbes metabolize substances PMDBM2008379 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006546 Microbes metabolize substances PMDBM2008379 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006547 Microbes metabolize substances PMDBM2008379 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006548 Microbes metabolize substances PMDBM2008379 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006551 Microbes metabolize substances PMDBM2008379 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006552 Microbes metabolize substances PMDBM2008379 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006553 Microbes metabolize substances PMDBM2008379 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006554 Microbes metabolize substances PMDBM2008379 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006555 Microbes metabolize substances PMDBM2008379 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006556 Microbes metabolize substances PMDBM2008379 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916035 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006557 Microbes metabolize substances PMDBM2008380 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916055 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006558 Microbes metabolize substances PMDBM2008380 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916055 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006559 Microbes metabolize substances PMDBM2008380 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916055 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006560 Microbes metabolize substances PMDBM2008381 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006561 Microbes metabolize substances PMDBM2008381 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006562 Microbes metabolize substances PMDBM2008381 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006563 Microbes metabolize substances PMDBM2008381 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006564 Microbes metabolize substances PMDBM2008381 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006565 Microbes metabolize substances PMDBM2008381 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006566 Microbes metabolize substances PMDBM2008381 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006569 Microbes metabolize substances PMDBM2008381 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006570 Microbes metabolize substances PMDBM2008381 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006571 Microbes metabolize substances PMDBM2008381 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006572 Microbes metabolize substances PMDBM2008381 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp001916065 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006573 Microbes metabolize substances PMDBM2008382 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006574 Microbes metabolize substances PMDBM2008382 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006575 Microbes metabolize substances PMDBM2008382 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006576 Microbes metabolize substances PMDBM2008382 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006577 Microbes metabolize substances PMDBM2008382 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006578 Microbes metabolize substances PMDBM2008382 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006579 Microbes metabolize substances PMDBM2008382 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006582 Microbes metabolize substances PMDBM2008382 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006583 Microbes metabolize substances PMDBM2008382 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006584 Microbes metabolize substances PMDBM2008382 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006585 Microbes metabolize substances PMDBM2008382 n.a. c Clostridia o TANB77 f CAG-508 g CAG-269 s CAG-269 sp003525075 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006586 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006588 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20006589 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006591 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006593 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006597 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006601 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006603 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006605 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006607 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006609 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006611 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006615 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20006621 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20006623 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20006625 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20006626 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006627 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006633 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20006639 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20006640 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006642 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006648 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006649 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006650 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006651 Microbes metabolize substances PMDBM2008383 n.a. o Oscillospirales f CAG-272 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20006652 Microbes metabolize substances PMDBM2008384 n.a. o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006653 Microbes metabolize substances PMDBM2008384 n.a. o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006654 Microbes metabolize substances PMDBM2008384 n.a. o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006655 Microbes metabolize substances PMDBM2008384 n.a. o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006656 Microbes metabolize substances PMDBM2008384 n.a. o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006657 Microbes metabolize substances PMDBM2008384 n.a. o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006658 Microbes metabolize substances PMDBM2008384 n.a. o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20006660 Microbes metabolize substances PMDBM2008384 n.a. o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20006661 Microbes metabolize substances PMDBM2008384 n.a. o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20006662 Microbes metabolize substances PMDBM2008384 n.a. o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006663 Microbes metabolize substances PMDBM2008384 n.a. o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006666 Microbes metabolize substances PMDBM2008384 n.a. o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20006670 Microbes metabolize substances PMDBM2008384 n.a. o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006671 Microbes metabolize substances PMDBM2008384 n.a. o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006672 Microbes metabolize substances PMDBM2008384 n.a. o Oscillospirales f CAG-272 g CAG-272 s CAG-272 sp000433515 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006673 Microbes metabolize substances PMDBM2008385 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006674 Microbes metabolize substances PMDBM2008385 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006675 Microbes metabolize substances PMDBM2008385 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006676 Microbes metabolize substances PMDBM2008385 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006677 Microbes metabolize substances PMDBM2008385 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006678 Microbes metabolize substances PMDBM2008385 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006679 Microbes metabolize substances PMDBM2008385 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006682 Microbes metabolize substances PMDBM2008385 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006683 Microbes metabolize substances PMDBM2008385 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006684 Microbes metabolize substances PMDBM2008385 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006685 Microbes metabolize substances PMDBM2008385 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006686 Microbes metabolize substances PMDBM2008385 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006687 Microbes metabolize substances PMDBM2008385 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006688 Microbes metabolize substances PMDBM2008385 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006689 Microbes metabolize substances PMDBM2008386 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000435755 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006690 Microbes metabolize substances PMDBM2008386 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000435755 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006691 Microbes metabolize substances PMDBM2008386 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000435755 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006692 Microbes metabolize substances PMDBM2008387 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006693 Microbes metabolize substances PMDBM2008387 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006694 Microbes metabolize substances PMDBM2008387 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006695 Microbes metabolize substances PMDBM2008387 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006696 Microbes metabolize substances PMDBM2008387 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006697 Microbes metabolize substances PMDBM2008387 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006698 Microbes metabolize substances PMDBM2008387 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006701 Microbes metabolize substances PMDBM2008387 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006702 Microbes metabolize substances PMDBM2008387 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006703 Microbes metabolize substances PMDBM2008387 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006704 Microbes metabolize substances PMDBM2008387 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006705 Microbes metabolize substances PMDBM2008387 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006706 Microbes metabolize substances PMDBM2008387 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006707 Microbes metabolize substances PMDBM2008387 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006708 Microbes metabolize substances PMDBM2008387 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000437855 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006709 Microbes metabolize substances PMDBM2008388 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000438355 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006710 Microbes metabolize substances PMDBM2008388 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000438355 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006711 Microbes metabolize substances PMDBM2008388 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp000438355 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006712 Microbes metabolize substances PMDBM2008389 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003507395 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006713 Microbes metabolize substances PMDBM2008389 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003507395 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006714 Microbes metabolize substances PMDBM2008389 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003507395 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006715 Microbes metabolize substances PMDBM2008389 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003507395 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006716 Microbes metabolize substances PMDBM2008390 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006717 Microbes metabolize substances PMDBM2008390 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006718 Microbes metabolize substances PMDBM2008390 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006719 Microbes metabolize substances PMDBM2008390 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006720 Microbes metabolize substances PMDBM2008390 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006721 Microbes metabolize substances PMDBM2008390 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006722 Microbes metabolize substances PMDBM2008390 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006725 Microbes metabolize substances PMDBM2008390 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006726 Microbes metabolize substances PMDBM2008390 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006727 Microbes metabolize substances PMDBM2008390 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006728 Microbes metabolize substances PMDBM2008390 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006729 Microbes metabolize substances PMDBM2008390 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006730 Microbes metabolize substances PMDBM2008390 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006731 Microbes metabolize substances PMDBM2008390 n.a. c Clostridia o TANB77 f CAG-508 g CAG-273 s CAG-273 sp003534295 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006732 Microbes metabolize substances PMDBM2008391 n.a. o Lachnospirales f CAG-274 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006733 Microbes metabolize substances PMDBM2008391 n.a. o Lachnospirales f CAG-274 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006734 Microbes metabolize substances PMDBM2008391 n.a. o Lachnospirales f CAG-274 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006735 Microbes metabolize substances PMDBM2008391 n.a. o Lachnospirales f CAG-274 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006737 Microbes metabolize substances PMDBM2008391 n.a. o Lachnospirales f CAG-274 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006739 Microbes metabolize substances PMDBM2008391 n.a. o Lachnospirales f CAG-274 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006740 Microbes metabolize substances PMDBM2008391 n.a. o Lachnospirales f CAG-274 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006741 Microbes metabolize substances PMDBM2008391 n.a. o Lachnospirales f CAG-274 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006742 Microbes metabolize substances PMDBM2008391 n.a. o Lachnospirales f CAG-274 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006745 Microbes metabolize substances PMDBM2008391 n.a. o Lachnospirales f CAG-274 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006747 Microbes metabolize substances PMDBM2008391 n.a. o Lachnospirales f CAG-274 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006749 Microbes metabolize substances PMDBM2008391 n.a. o Lachnospirales f CAG-274 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006750 Microbes metabolize substances PMDBM2008391 n.a. o Lachnospirales f CAG-274 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006752 Microbes metabolize substances PMDBM2008391 n.a. o Lachnospirales f CAG-274 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006754 Microbes metabolize substances PMDBM2008391 n.a. o Lachnospirales f CAG-274 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006756 Microbes metabolize substances PMDBM2008392 n.a. o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006757 Microbes metabolize substances PMDBM2008392 n.a. o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006758 Microbes metabolize substances PMDBM2008392 n.a. o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006759 Microbes metabolize substances PMDBM2008392 n.a. o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006760 Microbes metabolize substances PMDBM2008392 n.a. o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006761 Microbes metabolize substances PMDBM2008392 n.a. o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006762 Microbes metabolize substances PMDBM2008392 n.a. o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006765 Microbes metabolize substances PMDBM2008392 n.a. o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006766 Microbes metabolize substances PMDBM2008392 n.a. o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006767 Microbes metabolize substances PMDBM2008392 n.a. o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006768 Microbes metabolize substances PMDBM2008392 n.a. o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006769 Microbes metabolize substances PMDBM2008392 n.a. o Lachnospirales f CAG-274 g CAG-274 s CAG-274 sp000432155 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006770 Microbes metabolize substances PMDBM2008393 n.a. f Muribaculaceae g CAG-279 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006771 Microbes metabolize substances PMDBM2008393 n.a. f Muribaculaceae g CAG-279 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20006772 Microbes metabolize substances PMDBM2008393 n.a. f Muribaculaceae g CAG-279 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006773 Microbes metabolize substances PMDBM2008393 n.a. f Muribaculaceae g CAG-279 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006774 Microbes metabolize substances PMDBM2008393 n.a. f Muribaculaceae g CAG-279 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006775 Microbes metabolize substances PMDBM2008393 n.a. f Muribaculaceae g CAG-279 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006776 Microbes metabolize substances PMDBM2008393 n.a. f Muribaculaceae g CAG-279 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006777 Microbes metabolize substances PMDBM2008393 n.a. f Muribaculaceae g CAG-279 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006780 Microbes metabolize substances PMDBM2008393 n.a. f Muribaculaceae g CAG-279 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006781 Microbes metabolize substances PMDBM2008393 n.a. f Muribaculaceae g CAG-279 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006782 Microbes metabolize substances PMDBM2008393 n.a. f Muribaculaceae g CAG-279 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006783 Microbes metabolize substances PMDBM2008393 n.a. f Muribaculaceae g CAG-279 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006784 Microbes metabolize substances PMDBM2008393 n.a. f Muribaculaceae g CAG-279 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006785 Microbes metabolize substances PMDBM2008393 n.a. f Muribaculaceae g CAG-279 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006786 Microbes metabolize substances PMDBM2008393 n.a. f Muribaculaceae g CAG-279 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006787 Microbes metabolize substances PMDBM2008393 n.a. f Muribaculaceae g CAG-279 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006788 Microbes metabolize substances PMDBM2008394 n.a. f Muribaculaceae g CAG-279 s CAG-279 sp000437795 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006789 Microbes metabolize substances PMDBM2008394 n.a. f Muribaculaceae g CAG-279 s CAG-279 sp000437795 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006790 Microbes metabolize substances PMDBM2008394 n.a. f Muribaculaceae g CAG-279 s CAG-279 sp000437795 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006791 Microbes metabolize substances PMDBM2008394 n.a. f Muribaculaceae g CAG-279 s CAG-279 sp000437795 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006792 Microbes metabolize substances PMDBM2008394 n.a. f Muribaculaceae g CAG-279 s CAG-279 sp000437795 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006793 Microbes metabolize substances PMDBM2008394 n.a. f Muribaculaceae g CAG-279 s CAG-279 sp000437795 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006794 Microbes metabolize substances PMDBM2008394 n.a. f Muribaculaceae g CAG-279 s CAG-279 sp000437795 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006797 Microbes metabolize substances PMDBM2008394 n.a. f Muribaculaceae g CAG-279 s CAG-279 sp000437795 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006798 Microbes metabolize substances PMDBM2008394 n.a. f Muribaculaceae g CAG-279 s CAG-279 sp000437795 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006799 Microbes metabolize substances PMDBM2008394 n.a. f Muribaculaceae g CAG-279 s CAG-279 sp000437795 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006800 Microbes metabolize substances PMDBM2008394 n.a. f Muribaculaceae g CAG-279 s CAG-279 sp000437795 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006801 Microbes metabolize substances PMDBM2008394 n.a. f Muribaculaceae g CAG-279 s CAG-279 sp000437795 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006802 Microbes metabolize substances PMDBM2008394 n.a. f Muribaculaceae g CAG-279 s CAG-279 sp000437795 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006803 Microbes metabolize substances PMDBM2008394 n.a. f Muribaculaceae g CAG-279 s CAG-279 sp000437795 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006804 Microbes metabolize substances PMDBM2008395 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006805 Microbes metabolize substances PMDBM2008395 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20006806 Microbes metabolize substances PMDBM2008395 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006807 Microbes metabolize substances PMDBM2008395 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006808 Microbes metabolize substances PMDBM2008395 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006809 Microbes metabolize substances PMDBM2008395 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006810 Microbes metabolize substances PMDBM2008395 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006811 Microbes metabolize substances PMDBM2008395 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006814 Microbes metabolize substances PMDBM2008395 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006815 Microbes metabolize substances PMDBM2008395 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006816 Microbes metabolize substances PMDBM2008395 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006817 Microbes metabolize substances PMDBM2008395 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006818 Microbes metabolize substances PMDBM2008395 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006819 Microbes metabolize substances PMDBM2008395 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006820 Microbes metabolize substances PMDBM2008395 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006821 Microbes metabolize substances PMDBM2008396 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 s CAG-288 sp000437395 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006822 Microbes metabolize substances PMDBM2008396 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 s CAG-288 sp000437395 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006823 Microbes metabolize substances PMDBM2008396 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 s CAG-288 sp000437395 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006824 Microbes metabolize substances PMDBM2008396 n.a. c Bacilli o RFN20 f CAG-288 g CAG-288 s CAG-288 sp000437395 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006825 Microbes metabolize substances PMDBM2008397 n.a. c Bacilli o RF39 f CAG-302 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20006826 Microbes metabolize substances PMDBM2008397 n.a. c Bacilli o RF39 f CAG-302 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006828 Microbes metabolize substances PMDBM2008397 n.a. c Bacilli o RF39 f CAG-302 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006830 Microbes metabolize substances PMDBM2008397 n.a. c Bacilli o RF39 f CAG-302 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006832 Microbes metabolize substances PMDBM2008398 n.a. c Bacilli o RF39 f CAG-302 g CAG-302 s CAG-302 sp000431795 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006833 Microbes metabolize substances PMDBM2008398 n.a. c Bacilli o RF39 f CAG-302 g CAG-302 s CAG-302 sp000431795 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006834 Microbes metabolize substances PMDBM2008399 n.a. c Bacilli o RF39 f CAG-302 g CAG-302 s CAG-302 sp001916775 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006835 Microbes metabolize substances PMDBM2008399 n.a. c Bacilli o RF39 f CAG-302 g CAG-302 s CAG-302 sp001916775 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006836 Microbes metabolize substances PMDBM2008399 n.a. c Bacilli o RF39 f CAG-302 g CAG-302 s CAG-302 sp001916775 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006837 Microbes metabolize substances PMDBM2008400 n.a. f Lachnospiraceae g CAG-303 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006838 Microbes metabolize substances PMDBM2008400 n.a. f Lachnospiraceae g CAG-303 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006839 Microbes metabolize substances PMDBM2008400 n.a. f Lachnospiraceae g CAG-303 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006840 Microbes metabolize substances PMDBM2008400 n.a. f Lachnospiraceae g CAG-303 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006841 Microbes metabolize substances PMDBM2008401 n.a. f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006842 Microbes metabolize substances PMDBM2008401 n.a. f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006843 Microbes metabolize substances PMDBM2008401 n.a. f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006844 Microbes metabolize substances PMDBM2008401 n.a. f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006846 Microbes metabolize substances PMDBM2008401 n.a. f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006848 Microbes metabolize substances PMDBM2008401 n.a. f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006849 Microbes metabolize substances PMDBM2008401 n.a. f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006850 Microbes metabolize substances PMDBM2008401 n.a. f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006851 Microbes metabolize substances PMDBM2008401 n.a. f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006854 Microbes metabolize substances PMDBM2008401 n.a. f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006855 Microbes metabolize substances PMDBM2008401 n.a. f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006856 Microbes metabolize substances PMDBM2008401 n.a. f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006857 Microbes metabolize substances PMDBM2008401 n.a. f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006859 Microbes metabolize substances PMDBM2008401 n.a. f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20006860 Microbes metabolize substances PMDBM2008401 n.a. f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006861 Microbes metabolize substances PMDBM2008401 n.a. f Lachnospiraceae g CAG-303 s CAG-303 sp000437755 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006862 Microbes metabolize substances PMDBM2008402 n.a. f Gastranaerophilaceae g CAG-306 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20006863 Microbes metabolize substances PMDBM2008402 n.a. f Gastranaerophilaceae g CAG-306 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006864 Microbes metabolize substances PMDBM2008402 n.a. f Gastranaerophilaceae g CAG-306 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006865 Microbes metabolize substances PMDBM2008402 n.a. f Gastranaerophilaceae g CAG-306 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006866 Microbes metabolize substances PMDBM2008402 n.a. f Gastranaerophilaceae g CAG-306 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006867 Microbes metabolize substances PMDBM2008403 n.a. f Gastranaerophilaceae g CAG-306 s CAG-306 sp000980375 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20006868 Microbes metabolize substances PMDBM2008403 n.a. f Gastranaerophilaceae g CAG-306 s CAG-306 sp000980375 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006869 Microbes metabolize substances PMDBM2008403 n.a. f Gastranaerophilaceae g CAG-306 s CAG-306 sp000980375 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006870 Microbes metabolize substances PMDBM2008403 n.a. f Gastranaerophilaceae g CAG-306 s CAG-306 sp000980375 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006871 Microbes metabolize substances PMDBM2008403 n.a. f Gastranaerophilaceae g CAG-306 s CAG-306 sp000980375 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006872 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006873 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20006874 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006875 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006876 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006877 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006878 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006879 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006880 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006881 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006883 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20006886 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20006887 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20006888 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006889 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006893 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20006896 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006897 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006898 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006900 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006902 Microbes metabolize substances PMDBM2008404 n.a. o Acholeplasmatales f CAG-307 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006904 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006905 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006906 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006907 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006908 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006909 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006910 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006911 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006912 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006914 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20006917 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20006918 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20006919 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006922 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20006925 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006926 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006927 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006929 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006930 Microbes metabolize substances PMDBM2008405 n.a. o Acholeplasmatales f CAG-307 g CAG-307 s CAG-307 sp001916215 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20006931 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006933 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006935 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006937 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006941 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006945 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006947 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006949 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006951 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006952 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20006953 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006957 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20006961 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20006962 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20006963 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20006964 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006966 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20006969 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20006972 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006974 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006979 Microbes metabolize substances PMDBM2008406 n.a. o Opitutales f CAG-312 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20006980 Microbes metabolize substances PMDBM2008407 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006981 Microbes metabolize substances PMDBM2008407 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20006982 Microbes metabolize substances PMDBM2008407 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20006983 Microbes metabolize substances PMDBM2008407 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006985 Microbes metabolize substances PMDBM2008407 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20006987 Microbes metabolize substances PMDBM2008407 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006988 Microbes metabolize substances PMDBM2008407 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006989 Microbes metabolize substances PMDBM2008407 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20006990 Microbes metabolize substances PMDBM2008407 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20006993 Microbes metabolize substances PMDBM2008407 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20006994 Microbes metabolize substances PMDBM2008407 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20006995 Microbes metabolize substances PMDBM2008407 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006996 Microbes metabolize substances PMDBM2008407 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp000438015 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20006998 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20006999 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007000 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007001 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007003 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007005 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007006 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007007 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007008 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007009 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007010 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007012 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20007015 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20007016 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20007017 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007020 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20007023 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007024 Microbes metabolize substances PMDBM2008408 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp001917305 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007027 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007028 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20007029 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007030 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007031 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007033 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007035 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007036 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007037 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007038 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007039 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007040 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007042 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20007045 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20007046 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20007047 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007050 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20007053 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007054 Microbes metabolize substances PMDBM2008409 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002405555 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007057 Microbes metabolize substances PMDBM2008410 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002437405 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007058 Microbes metabolize substances PMDBM2008410 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002437405 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007059 Microbes metabolize substances PMDBM2008410 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002437405 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007060 Microbes metabolize substances PMDBM2008410 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002437405 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007061 Microbes metabolize substances PMDBM2008410 n.a. o Opitutales f CAG-312 g CAG-312 s CAG-312 sp002437405 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007062 Microbes metabolize substances PMDBM2008411 n.a. c Bacilli o ML615J-28 f CAG-313 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007064 Microbes metabolize substances PMDBM2008411 n.a. c Bacilli o ML615J-28 f CAG-313 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20007065 Microbes metabolize substances PMDBM2008411 n.a. c Bacilli o ML615J-28 f CAG-313 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007067 Microbes metabolize substances PMDBM2008411 n.a. c Bacilli o ML615J-28 f CAG-313 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007069 Microbes metabolize substances PMDBM2008411 n.a. c Bacilli o ML615J-28 f CAG-313 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007071 Microbes metabolize substances PMDBM2008411 n.a. c Bacilli o ML615J-28 f CAG-313 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007073 Microbes metabolize substances PMDBM2008411 n.a. c Bacilli o ML615J-28 f CAG-313 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007075 Microbes metabolize substances PMDBM2008411 n.a. c Bacilli o ML615J-28 f CAG-313 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007081 Microbes metabolize substances PMDBM2008411 n.a. c Bacilli o ML615J-28 f CAG-313 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007083 Microbes metabolize substances PMDBM2008411 n.a. c Bacilli o ML615J-28 f CAG-313 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007085 Microbes metabolize substances PMDBM2008411 n.a. c Bacilli o ML615J-28 f CAG-313 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007087 Microbes metabolize substances PMDBM2008411 n.a. c Bacilli o ML615J-28 f CAG-313 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007089 Microbes metabolize substances PMDBM2008411 n.a. c Bacilli o ML615J-28 f CAG-313 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007091 Microbes metabolize substances PMDBM2008411 n.a. c Bacilli o ML615J-28 f CAG-313 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007092 Microbes metabolize substances PMDBM2008411 n.a. c Bacilli o ML615J-28 f CAG-313 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007094 Microbes metabolize substances PMDBM2008411 n.a. c Bacilli o ML615J-28 f CAG-313 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007096 Microbes metabolize substances PMDBM2008412 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007097 Microbes metabolize substances PMDBM2008412 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007098 Microbes metabolize substances PMDBM2008412 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007099 Microbes metabolize substances PMDBM2008412 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007100 Microbes metabolize substances PMDBM2008412 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007101 Microbes metabolize substances PMDBM2008412 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007102 Microbes metabolize substances PMDBM2008412 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007105 Microbes metabolize substances PMDBM2008412 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007106 Microbes metabolize substances PMDBM2008412 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007107 Microbes metabolize substances PMDBM2008412 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007108 Microbes metabolize substances PMDBM2008412 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007109 Microbes metabolize substances PMDBM2008412 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007110 Microbes metabolize substances PMDBM2008412 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007111 Microbes metabolize substances PMDBM2008412 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007112 Microbes metabolize substances PMDBM2008412 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp000433035 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007113 Microbes metabolize substances PMDBM2008413 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007114 Microbes metabolize substances PMDBM2008413 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007115 Microbes metabolize substances PMDBM2008413 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007116 Microbes metabolize substances PMDBM2008413 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007117 Microbes metabolize substances PMDBM2008413 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007118 Microbes metabolize substances PMDBM2008413 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007119 Microbes metabolize substances PMDBM2008413 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007122 Microbes metabolize substances PMDBM2008413 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007123 Microbes metabolize substances PMDBM2008413 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007124 Microbes metabolize substances PMDBM2008413 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007125 Microbes metabolize substances PMDBM2008413 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007126 Microbes metabolize substances PMDBM2008413 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007127 Microbes metabolize substances PMDBM2008413 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007128 Microbes metabolize substances PMDBM2008413 n.a. c Bacilli o ML615J-28 f CAG-313 g CAG-313 s CAG-313 sp003539625 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007129 Microbes metabolize substances PMDBM2008414 n.a. c Clostridia o 4C28d-15 f CAG-314 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007130 Microbes metabolize substances PMDBM2008414 n.a. c Clostridia o 4C28d-15 f CAG-314 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007131 Microbes metabolize substances PMDBM2008414 n.a. c Clostridia o 4C28d-15 f CAG-314 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007132 Microbes metabolize substances PMDBM2008414 n.a. c Clostridia o 4C28d-15 f CAG-314 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007134 Microbes metabolize substances PMDBM2008414 n.a. c Clostridia o 4C28d-15 f CAG-314 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007136 Microbes metabolize substances PMDBM2008414 n.a. c Clostridia o 4C28d-15 f CAG-314 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007137 Microbes metabolize substances PMDBM2008414 n.a. c Clostridia o 4C28d-15 f CAG-314 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007138 Microbes metabolize substances PMDBM2008414 n.a. c Clostridia o 4C28d-15 f CAG-314 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007139 Microbes metabolize substances PMDBM2008414 n.a. c Clostridia o 4C28d-15 f CAG-314 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007142 Microbes metabolize substances PMDBM2008414 n.a. c Clostridia o 4C28d-15 f CAG-314 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20007144 Microbes metabolize substances PMDBM2008414 n.a. c Clostridia o 4C28d-15 f CAG-314 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007145 Microbes metabolize substances PMDBM2008414 n.a. c Clostridia o 4C28d-15 f CAG-314 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007147 Microbes metabolize substances PMDBM2008414 n.a. c Clostridia o 4C28d-15 f CAG-314 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007148 Microbes metabolize substances PMDBM2008414 n.a. c Clostridia o 4C28d-15 f CAG-314 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007150 Microbes metabolize substances PMDBM2008414 n.a. c Clostridia o 4C28d-15 f CAG-314 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007152 Microbes metabolize substances PMDBM2008414 n.a. c Clostridia o 4C28d-15 f CAG-314 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007154 Microbes metabolize substances PMDBM2008415 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007155 Microbes metabolize substances PMDBM2008415 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007156 Microbes metabolize substances PMDBM2008415 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007157 Microbes metabolize substances PMDBM2008415 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007158 Microbes metabolize substances PMDBM2008415 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007159 Microbes metabolize substances PMDBM2008415 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007160 Microbes metabolize substances PMDBM2008415 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007163 Microbes metabolize substances PMDBM2008415 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007164 Microbes metabolize substances PMDBM2008415 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007165 Microbes metabolize substances PMDBM2008415 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007166 Microbes metabolize substances PMDBM2008415 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007167 Microbes metabolize substances PMDBM2008415 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007168 Microbes metabolize substances PMDBM2008415 n.a. c Clostridia o 4C28d-15 f CAG-314 g CAG-314 s CAG-314 sp000437915 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007169 Microbes metabolize substances PMDBM2008416 n.a. c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007170 Microbes metabolize substances PMDBM2008416 n.a. c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007171 Microbes metabolize substances PMDBM2008416 n.a. c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007172 Microbes metabolize substances PMDBM2008416 n.a. c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007173 Microbes metabolize substances PMDBM2008416 n.a. c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007174 Microbes metabolize substances PMDBM2008416 n.a. c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007175 Microbes metabolize substances PMDBM2008416 n.a. c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007178 Microbes metabolize substances PMDBM2008416 n.a. c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007179 Microbes metabolize substances PMDBM2008416 n.a. c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007180 Microbes metabolize substances PMDBM2008416 n.a. c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007181 Microbes metabolize substances PMDBM2008416 n.a. c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007182 Microbes metabolize substances PMDBM2008416 n.a. c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007183 Microbes metabolize substances PMDBM2008416 n.a. c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007184 Microbes metabolize substances PMDBM2008416 n.a. c Bacilli o RFN20 f CAG-288 g CAG-345 s CAG-345 sp000433315 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007185 Microbes metabolize substances PMDBM2008417 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007186 Microbes metabolize substances PMDBM2008417 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007187 Microbes metabolize substances PMDBM2008417 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007188 Microbes metabolize substances PMDBM2008417 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007189 Microbes metabolize substances PMDBM2008417 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007190 Microbes metabolize substances PMDBM2008417 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007191 Microbes metabolize substances PMDBM2008417 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007194 Microbes metabolize substances PMDBM2008417 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007195 Microbes metabolize substances PMDBM2008417 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007196 Microbes metabolize substances PMDBM2008417 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007197 Microbes metabolize substances PMDBM2008417 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007198 Microbes metabolize substances PMDBM2008417 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp001940895 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007199 Microbes metabolize substances PMDBM2008418 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007200 Microbes metabolize substances PMDBM2008418 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007201 Microbes metabolize substances PMDBM2008418 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007202 Microbes metabolize substances PMDBM2008418 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007203 Microbes metabolize substances PMDBM2008418 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007204 Microbes metabolize substances PMDBM2008418 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007205 Microbes metabolize substances PMDBM2008418 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007208 Microbes metabolize substances PMDBM2008418 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007209 Microbes metabolize substances PMDBM2008418 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007210 Microbes metabolize substances PMDBM2008418 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007211 Microbes metabolize substances PMDBM2008418 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007212 Microbes metabolize substances PMDBM2008418 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007213 Microbes metabolize substances PMDBM2008418 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007214 Microbes metabolize substances PMDBM2008418 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-349 s CAG-349 sp003539515 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007215 Microbes metabolize substances PMDBM2008419 n.a. f Ruminococcaceae g CAG-353 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007216 Microbes metabolize substances PMDBM2008419 n.a. f Ruminococcaceae g CAG-353 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007217 Microbes metabolize substances PMDBM2008419 n.a. f Ruminococcaceae g CAG-353 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007218 Microbes metabolize substances PMDBM2008419 n.a. f Ruminococcaceae g CAG-353 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007219 Microbes metabolize substances PMDBM2008419 n.a. f Ruminococcaceae g CAG-353 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007220 Microbes metabolize substances PMDBM2008419 n.a. f Ruminococcaceae g CAG-353 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007221 Microbes metabolize substances PMDBM2008419 n.a. f Ruminococcaceae g CAG-353 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007224 Microbes metabolize substances PMDBM2008419 n.a. f Ruminococcaceae g CAG-353 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007225 Microbes metabolize substances PMDBM2008419 n.a. f Ruminococcaceae g CAG-353 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007226 Microbes metabolize substances PMDBM2008419 n.a. f Ruminococcaceae g CAG-353 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007227 Microbes metabolize substances PMDBM2008419 n.a. f Ruminococcaceae g CAG-353 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007228 Microbes metabolize substances PMDBM2008419 n.a. f Ruminococcaceae g CAG-353 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007229 Microbes metabolize substances PMDBM2008419 n.a. f Ruminococcaceae g CAG-353 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007230 Microbes metabolize substances PMDBM2008419 n.a. f Ruminococcaceae g CAG-353 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007231 Microbes metabolize substances PMDBM2008420 n.a. f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007232 Microbes metabolize substances PMDBM2008420 n.a. f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007233 Microbes metabolize substances PMDBM2008420 n.a. f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007234 Microbes metabolize substances PMDBM2008420 n.a. f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007235 Microbes metabolize substances PMDBM2008420 n.a. f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007236 Microbes metabolize substances PMDBM2008420 n.a. f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007237 Microbes metabolize substances PMDBM2008420 n.a. f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007240 Microbes metabolize substances PMDBM2008420 n.a. f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007241 Microbes metabolize substances PMDBM2008420 n.a. f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007242 Microbes metabolize substances PMDBM2008420 n.a. f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007243 Microbes metabolize substances PMDBM2008420 n.a. f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007244 Microbes metabolize substances PMDBM2008420 n.a. f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007245 Microbes metabolize substances PMDBM2008420 n.a. f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007246 Microbes metabolize substances PMDBM2008420 n.a. f Ruminococcaceae g CAG-353 s CAG-353 sp900066885 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007247 Microbes metabolize substances PMDBM2008421 n.a. c Clostridia o TANB77 f CAG-508 g CAG-354 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007248 Microbes metabolize substances PMDBM2008421 n.a. c Clostridia o TANB77 f CAG-508 g CAG-354 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007249 Microbes metabolize substances PMDBM2008421 n.a. c Clostridia o TANB77 f CAG-508 g CAG-354 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007250 Microbes metabolize substances PMDBM2008421 n.a. c Clostridia o TANB77 f CAG-508 g CAG-354 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007251 Microbes metabolize substances PMDBM2008421 n.a. c Clostridia o TANB77 f CAG-508 g CAG-354 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007252 Microbes metabolize substances PMDBM2008421 n.a. c Clostridia o TANB77 f CAG-508 g CAG-354 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007253 Microbes metabolize substances PMDBM2008421 n.a. c Clostridia o TANB77 f CAG-508 g CAG-354 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007256 Microbes metabolize substances PMDBM2008421 n.a. c Clostridia o TANB77 f CAG-508 g CAG-354 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007257 Microbes metabolize substances PMDBM2008421 n.a. c Clostridia o TANB77 f CAG-508 g CAG-354 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007258 Microbes metabolize substances PMDBM2008421 n.a. c Clostridia o TANB77 f CAG-508 g CAG-354 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007259 Microbes metabolize substances PMDBM2008421 n.a. c Clostridia o TANB77 f CAG-508 g CAG-354 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007260 Microbes metabolize substances PMDBM2008421 n.a. c Clostridia o TANB77 f CAG-508 g CAG-354 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007261 Microbes metabolize substances PMDBM2008421 n.a. c Clostridia o TANB77 f CAG-508 g CAG-354 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007262 Microbes metabolize substances PMDBM2008421 n.a. c Clostridia o TANB77 f CAG-508 g CAG-354 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007263 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007264 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20007265 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007266 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007267 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007269 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007271 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20007272 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007273 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007274 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007275 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007276 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007277 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007279 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20007282 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20007283 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20007284 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007285 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007288 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20007291 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007292 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007295 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007296 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007297 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007298 Microbes metabolize substances PMDBM2008422 n.a. o Oscillospirales f CAG-382 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20007299 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007300 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007301 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007302 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007304 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007306 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007307 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007308 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007309 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007310 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007311 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007313 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20007316 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20007317 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20007318 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007319 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007322 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20007325 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007326 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007329 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007330 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007331 Microbes metabolize substances PMDBM2008423 n.a. o Oscillospirales f CAG-272 g CAG-390 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007332 Microbes metabolize substances PMDBM2008424 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007333 Microbes metabolize substances PMDBM2008424 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007334 Microbes metabolize substances PMDBM2008424 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007335 Microbes metabolize substances PMDBM2008424 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007336 Microbes metabolize substances PMDBM2008424 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007337 Microbes metabolize substances PMDBM2008424 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007338 Microbes metabolize substances PMDBM2008424 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20007340 Microbes metabolize substances PMDBM2008424 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20007341 Microbes metabolize substances PMDBM2008424 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20007342 Microbes metabolize substances PMDBM2008424 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007343 Microbes metabolize substances PMDBM2008424 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007346 Microbes metabolize substances PMDBM2008424 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20007350 Microbes metabolize substances PMDBM2008424 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007351 Microbes metabolize substances PMDBM2008424 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007352 Microbes metabolize substances PMDBM2008424 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp000437015 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007353 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007354 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007355 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007356 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007358 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007360 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007361 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007362 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007363 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007364 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007365 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007367 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20007370 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20007371 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20007372 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007373 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007376 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20007379 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007380 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007383 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007384 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007385 Microbes metabolize substances PMDBM2008425 n.a. o Oscillospirales f CAG-272 g CAG-390 s CAG-390 sp003523225 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007386 Microbes metabolize substances PMDBM2008426 n.a. o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007387 Microbes metabolize substances PMDBM2008426 n.a. o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007388 Microbes metabolize substances PMDBM2008426 n.a. o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007389 Microbes metabolize substances PMDBM2008426 n.a. o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007391 Microbes metabolize substances PMDBM2008426 n.a. o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007393 Microbes metabolize substances PMDBM2008426 n.a. o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20007394 Microbes metabolize substances PMDBM2008426 n.a. o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007395 Microbes metabolize substances PMDBM2008426 n.a. o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007396 Microbes metabolize substances PMDBM2008426 n.a. o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007397 Microbes metabolize substances PMDBM2008426 n.a. o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007400 Microbes metabolize substances PMDBM2008426 n.a. o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007401 Microbes metabolize substances PMDBM2008426 n.a. o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007402 Microbes metabolize substances PMDBM2008426 n.a. o Monoglobales f UBA1381 g CAG-41 s CAG-41 sp900066215 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007404 Microbes metabolize substances PMDBM2008427 n.a. f Lachnospiraceae g CAG-411 s CAG-411 sp000437275 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007405 Microbes metabolize substances PMDBM2008427 n.a. f Lachnospiraceae g CAG-411 s CAG-411 sp000437275 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007406 Microbes metabolize substances PMDBM2008427 n.a. f Lachnospiraceae g CAG-411 s CAG-411 sp000437275 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007407 Microbes metabolize substances PMDBM2008428 n.a. c Bacilli o RF39 f CAG-611 g CAG-417 s CAG-417 sp000432835 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007408 Microbes metabolize substances PMDBM2008428 n.a. c Bacilli o RF39 f CAG-611 g CAG-417 s CAG-417 sp000432835 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007409 Microbes metabolize substances PMDBM2008429 n.a. c Bacilli o RF39 f CAG-433 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007410 Microbes metabolize substances PMDBM2008429 n.a. c Bacilli o RF39 f CAG-433 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007411 Microbes metabolize substances PMDBM2008430 n.a. c Bacilli o RF39 f CAG-433 g CAG-433 s CAG-433 sp000433675 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007412 Microbes metabolize substances PMDBM2008430 n.a. c Bacilli o RF39 f CAG-433 g CAG-433 s CAG-433 sp000433675 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007413 Microbes metabolize substances PMDBM2008431 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007414 Microbes metabolize substances PMDBM2008431 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007415 Microbes metabolize substances PMDBM2008431 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007416 Microbes metabolize substances PMDBM2008431 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007417 Microbes metabolize substances PMDBM2008431 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007418 Microbes metabolize substances PMDBM2008431 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007419 Microbes metabolize substances PMDBM2008431 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20007421 Microbes metabolize substances PMDBM2008431 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20007422 Microbes metabolize substances PMDBM2008431 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20007423 Microbes metabolize substances PMDBM2008431 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007426 Microbes metabolize substances PMDBM2008431 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20007430 Microbes metabolize substances PMDBM2008431 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007431 Microbes metabolize substances PMDBM2008431 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007432 Microbes metabolize substances PMDBM2008431 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp000433415 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007433 Microbes metabolize substances PMDBM2008432 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007434 Microbes metabolize substances PMDBM2008432 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007435 Microbes metabolize substances PMDBM2008432 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007436 Microbes metabolize substances PMDBM2008432 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007437 Microbes metabolize substances PMDBM2008432 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007438 Microbes metabolize substances PMDBM2008432 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007439 Microbes metabolize substances PMDBM2008432 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20007441 Microbes metabolize substances PMDBM2008432 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20007442 Microbes metabolize substances PMDBM2008432 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20007443 Microbes metabolize substances PMDBM2008432 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007444 Microbes metabolize substances PMDBM2008432 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007447 Microbes metabolize substances PMDBM2008432 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20007451 Microbes metabolize substances PMDBM2008432 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007452 Microbes metabolize substances PMDBM2008432 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007453 Microbes metabolize substances PMDBM2008432 n.a. o Oscillospirales f CAG-272 g CAG-448 s CAG-448 sp003150135 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20007454 Microbes metabolize substances PMDBM2008433 n.a. c Bacilli o RFN20 f CAG-449 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007456 Microbes metabolize substances PMDBM2008433 n.a. c Bacilli o RFN20 f CAG-449 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20007457 Microbes metabolize substances PMDBM2008433 n.a. c Bacilli o RFN20 f CAG-449 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007459 Microbes metabolize substances PMDBM2008433 n.a. c Bacilli o RFN20 f CAG-449 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007461 Microbes metabolize substances PMDBM2008433 n.a. c Bacilli o RFN20 f CAG-449 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007463 Microbes metabolize substances PMDBM2008433 n.a. c Bacilli o RFN20 f CAG-449 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007465 Microbes metabolize substances PMDBM2008433 n.a. c Bacilli o RFN20 f CAG-449 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007467 Microbes metabolize substances PMDBM2008433 n.a. c Bacilli o RFN20 f CAG-449 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007469 Microbes metabolize substances PMDBM2008433 n.a. c Bacilli o RFN20 f CAG-449 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007471 Microbes metabolize substances PMDBM2008433 n.a. c Bacilli o RFN20 f CAG-449 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007477 Microbes metabolize substances PMDBM2008433 n.a. c Bacilli o RFN20 f CAG-449 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007479 Microbes metabolize substances PMDBM2008433 n.a. c Bacilli o RFN20 f CAG-449 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007481 Microbes metabolize substances PMDBM2008433 n.a. c Bacilli o RFN20 f CAG-449 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007483 Microbes metabolize substances PMDBM2008433 n.a. c Bacilli o RFN20 f CAG-449 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007487 Microbes metabolize substances PMDBM2008433 n.a. c Bacilli o RFN20 f CAG-449 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007489 Microbes metabolize substances PMDBM2008433 n.a. c Bacilli o RFN20 f CAG-449 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007491 Microbes metabolize substances PMDBM2008433 n.a. c Bacilli o RFN20 f CAG-449 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007493 Microbes metabolize substances PMDBM2008434 n.a. c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007494 Microbes metabolize substances PMDBM2008434 n.a. c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007495 Microbes metabolize substances PMDBM2008434 n.a. c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007496 Microbes metabolize substances PMDBM2008434 n.a. c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007497 Microbes metabolize substances PMDBM2008434 n.a. c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007498 Microbes metabolize substances PMDBM2008434 n.a. c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007499 Microbes metabolize substances PMDBM2008434 n.a. c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007502 Microbes metabolize substances PMDBM2008434 n.a. c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007503 Microbes metabolize substances PMDBM2008434 n.a. c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007504 Microbes metabolize substances PMDBM2008434 n.a. c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007505 Microbes metabolize substances PMDBM2008434 n.a. c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007506 Microbes metabolize substances PMDBM2008434 n.a. c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007507 Microbes metabolize substances PMDBM2008434 n.a. c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007508 Microbes metabolize substances PMDBM2008434 n.a. c Bacilli o RFN20 f CAG-449 g CAG-449 s CAG-449 sp000432895 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007509 Microbes metabolize substances PMDBM2008435 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007510 Microbes metabolize substances PMDBM2008435 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007511 Microbes metabolize substances PMDBM2008435 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007512 Microbes metabolize substances PMDBM2008435 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007514 Microbes metabolize substances PMDBM2008435 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007516 Microbes metabolize substances PMDBM2008435 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007517 Microbes metabolize substances PMDBM2008435 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007518 Microbes metabolize substances PMDBM2008435 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007519 Microbes metabolize substances PMDBM2008435 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007522 Microbes metabolize substances PMDBM2008435 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007523 Microbes metabolize substances PMDBM2008435 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007524 Microbes metabolize substances PMDBM2008435 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007525 Microbes metabolize substances PMDBM2008435 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007527 Microbes metabolize substances PMDBM2008435 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007528 Microbes metabolize substances PMDBM2008435 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp000438375 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007529 Microbes metabolize substances PMDBM2008436 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007530 Microbes metabolize substances PMDBM2008436 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007531 Microbes metabolize substances PMDBM2008436 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007532 Microbes metabolize substances PMDBM2008436 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007534 Microbes metabolize substances PMDBM2008436 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007536 Microbes metabolize substances PMDBM2008436 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20007537 Microbes metabolize substances PMDBM2008436 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007538 Microbes metabolize substances PMDBM2008436 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007539 Microbes metabolize substances PMDBM2008436 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007540 Microbes metabolize substances PMDBM2008436 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007543 Microbes metabolize substances PMDBM2008436 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007544 Microbes metabolize substances PMDBM2008436 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007545 Microbes metabolize substances PMDBM2008436 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007546 Microbes metabolize substances PMDBM2008436 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007548 Microbes metabolize substances PMDBM2008436 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007549 Microbes metabolize substances PMDBM2008436 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007550 Microbes metabolize substances PMDBM2008436 n.a. f Lachnospiraceae g CAG-45 s CAG-45 sp900066395 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007551 Microbes metabolize substances PMDBM2008437 n.a. c Bacilli o RF39 f CAG-611 g CAG-451 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007552 Microbes metabolize substances PMDBM2008437 n.a. c Bacilli o RF39 f CAG-611 g CAG-451 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007553 Microbes metabolize substances PMDBM2008438 n.a. c Bacilli o RF39 f CAG-611 g CAG-451 s CAG-451 sp000438295 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007554 Microbes metabolize substances PMDBM2008438 n.a. c Bacilli o RF39 f CAG-611 g CAG-451 s CAG-451 sp000438295 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007555 Microbes metabolize substances PMDBM2008439 n.a. c Clostridia o TANB77 f CAG-508 g CAG-452 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007556 Microbes metabolize substances PMDBM2008439 n.a. c Clostridia o TANB77 f CAG-508 g CAG-452 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007557 Microbes metabolize substances PMDBM2008439 n.a. c Clostridia o TANB77 f CAG-508 g CAG-452 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007558 Microbes metabolize substances PMDBM2008439 n.a. c Clostridia o TANB77 f CAG-508 g CAG-452 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007559 Microbes metabolize substances PMDBM2008440 n.a. c Clostridia o TANB77 f CAG-508 g CAG-452 s CAG-452 sp000434035 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007560 Microbes metabolize substances PMDBM2008440 n.a. c Clostridia o TANB77 f CAG-508 g CAG-452 s CAG-452 sp000434035 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007561 Microbes metabolize substances PMDBM2008440 n.a. c Clostridia o TANB77 f CAG-508 g CAG-452 s CAG-452 sp000434035 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007562 Microbes metabolize substances PMDBM2008440 n.a. c Clostridia o TANB77 f CAG-508 g CAG-452 s CAG-452 sp000434035 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007563 Microbes metabolize substances PMDBM2008441 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007564 Microbes metabolize substances PMDBM2008441 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007565 Microbes metabolize substances PMDBM2008441 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007566 Microbes metabolize substances PMDBM2008441 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007567 Microbes metabolize substances PMDBM2008441 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007568 Microbes metabolize substances PMDBM2008441 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007569 Microbes metabolize substances PMDBM2008441 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007572 Microbes metabolize substances PMDBM2008441 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007573 Microbes metabolize substances PMDBM2008441 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007574 Microbes metabolize substances PMDBM2008441 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007575 Microbes metabolize substances PMDBM2008441 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007576 Microbes metabolize substances PMDBM2008441 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007577 Microbes metabolize substances PMDBM2008441 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007578 Microbes metabolize substances PMDBM2008442 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 s CAG-460 sp000437315 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20007579 Microbes metabolize substances PMDBM2008442 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 s CAG-460 sp000437315 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007580 Microbes metabolize substances PMDBM2008442 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 s CAG-460 sp000437315 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007581 Microbes metabolize substances PMDBM2008443 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 s CAG-460 sp000437355 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007582 Microbes metabolize substances PMDBM2008443 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 s CAG-460 sp000437355 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007583 Microbes metabolize substances PMDBM2008444 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 s CAG-460 sp000438075 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007584 Microbes metabolize substances PMDBM2008444 n.a. c Bacilli o RF39 f CAG-1000 g CAG-460 s CAG-460 sp000438075 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007585 Microbes metabolize substances PMDBM2008445 n.a. f Bacteroidaceae g CAG-462 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007586 Microbes metabolize substances PMDBM2008445 n.a. f Bacteroidaceae g CAG-462 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007587 Microbes metabolize substances PMDBM2008445 n.a. f Bacteroidaceae g CAG-462 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007588 Microbes metabolize substances PMDBM2008445 n.a. f Bacteroidaceae g CAG-462 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007590 Microbes metabolize substances PMDBM2008445 n.a. f Bacteroidaceae g CAG-462 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007592 Microbes metabolize substances PMDBM2008445 n.a. f Bacteroidaceae g CAG-462 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007593 Microbes metabolize substances PMDBM2008445 n.a. f Bacteroidaceae g CAG-462 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007594 Microbes metabolize substances PMDBM2008445 n.a. f Bacteroidaceae g CAG-462 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007595 Microbes metabolize substances PMDBM2008445 n.a. f Bacteroidaceae g CAG-462 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007598 Microbes metabolize substances PMDBM2008445 n.a. f Bacteroidaceae g CAG-462 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20007599 Microbes metabolize substances PMDBM2008445 n.a. f Bacteroidaceae g CAG-462 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007600 Microbes metabolize substances PMDBM2008445 n.a. f Bacteroidaceae g CAG-462 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007601 Microbes metabolize substances PMDBM2008445 n.a. f Bacteroidaceae g CAG-462 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007602 Microbes metabolize substances PMDBM2008445 n.a. f Bacteroidaceae g CAG-462 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007604 Microbes metabolize substances PMDBM2008445 n.a. f Bacteroidaceae g CAG-462 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007605 Microbes metabolize substances PMDBM2008445 n.a. f Bacteroidaceae g CAG-462 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007606 Microbes metabolize substances PMDBM2008445 n.a. f Bacteroidaceae g CAG-462 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007607 Microbes metabolize substances PMDBM2008446 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007608 Microbes metabolize substances PMDBM2008446 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20007609 Microbes metabolize substances PMDBM2008446 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007610 Microbes metabolize substances PMDBM2008446 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007611 Microbes metabolize substances PMDBM2008446 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007613 Microbes metabolize substances PMDBM2008446 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007615 Microbes metabolize substances PMDBM2008446 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007616 Microbes metabolize substances PMDBM2008446 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007617 Microbes metabolize substances PMDBM2008446 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007618 Microbes metabolize substances PMDBM2008446 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007621 Microbes metabolize substances PMDBM2008446 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20007622 Microbes metabolize substances PMDBM2008446 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007623 Microbes metabolize substances PMDBM2008446 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007624 Microbes metabolize substances PMDBM2008446 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007626 Microbes metabolize substances PMDBM2008446 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007627 Microbes metabolize substances PMDBM2008446 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007628 Microbes metabolize substances PMDBM2008446 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp003489705 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007629 Microbes metabolize substances PMDBM2008447 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007630 Microbes metabolize substances PMDBM2008447 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20007631 Microbes metabolize substances PMDBM2008447 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007632 Microbes metabolize substances PMDBM2008447 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007633 Microbes metabolize substances PMDBM2008447 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007635 Microbes metabolize substances PMDBM2008447 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007637 Microbes metabolize substances PMDBM2008447 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007638 Microbes metabolize substances PMDBM2008447 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007639 Microbes metabolize substances PMDBM2008447 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007640 Microbes metabolize substances PMDBM2008447 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007643 Microbes metabolize substances PMDBM2008447 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20007644 Microbes metabolize substances PMDBM2008447 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007645 Microbes metabolize substances PMDBM2008447 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007646 Microbes metabolize substances PMDBM2008447 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007647 Microbes metabolize substances PMDBM2008447 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007649 Microbes metabolize substances PMDBM2008447 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007650 Microbes metabolize substances PMDBM2008447 n.a. f Bacteroidaceae g CAG-462 s CAG-462 sp900291465 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007651 Microbes metabolize substances PMDBM2008448 n.a. c Clostridia o TANB77 f CAG-465 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007652 Microbes metabolize substances PMDBM2008448 n.a. c Clostridia o TANB77 f CAG-465 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007654 Microbes metabolize substances PMDBM2008448 n.a. c Clostridia o TANB77 f CAG-465 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007656 Microbes metabolize substances PMDBM2008449 n.a. c Clostridia o TANB77 f CAG-465 g CAG-465 s CAG-465 sp000433135 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007657 Microbes metabolize substances PMDBM2008449 n.a. c Clostridia o TANB77 f CAG-465 g CAG-465 s CAG-465 sp000433135 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007658 Microbes metabolize substances PMDBM2008450 n.a. c Clostridia o TANB77 f CAG-465 g CAG-465 s CAG-465 sp000433335 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007659 Microbes metabolize substances PMDBM2008450 n.a. c Clostridia o TANB77 f CAG-465 g CAG-465 s CAG-465 sp000433335 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007660 Microbes metabolize substances PMDBM2008451 n.a. c Clostridia o TANB77 f CAG-465 g CAG-465 s CAG-465 sp000433755 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007661 Microbes metabolize substances PMDBM2008451 n.a. c Clostridia o TANB77 f CAG-465 g CAG-465 s CAG-465 sp000433755 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007662 Microbes metabolize substances PMDBM2008452 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007663 Microbes metabolize substances PMDBM2008452 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007664 Microbes metabolize substances PMDBM2008452 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007665 Microbes metabolize substances PMDBM2008452 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007667 Microbes metabolize substances PMDBM2008452 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007669 Microbes metabolize substances PMDBM2008452 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007670 Microbes metabolize substances PMDBM2008452 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007671 Microbes metabolize substances PMDBM2008452 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007672 Microbes metabolize substances PMDBM2008452 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007675 Microbes metabolize substances PMDBM2008452 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007676 Microbes metabolize substances PMDBM2008452 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007677 Microbes metabolize substances PMDBM2008452 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007678 Microbes metabolize substances PMDBM2008452 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007680 Microbes metabolize substances PMDBM2008452 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007681 Microbes metabolize substances PMDBM2008452 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007682 Microbes metabolize substances PMDBM2008452 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007683 Microbes metabolize substances PMDBM2008453 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007684 Microbes metabolize substances PMDBM2008453 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007685 Microbes metabolize substances PMDBM2008453 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007686 Microbes metabolize substances PMDBM2008453 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007687 Microbes metabolize substances PMDBM2008453 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007688 Microbes metabolize substances PMDBM2008453 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007689 Microbes metabolize substances PMDBM2008453 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007692 Microbes metabolize substances PMDBM2008453 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007693 Microbes metabolize substances PMDBM2008453 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007694 Microbes metabolize substances PMDBM2008453 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007695 Microbes metabolize substances PMDBM2008453 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007696 Microbes metabolize substances PMDBM2008453 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007697 Microbes metabolize substances PMDBM2008453 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007698 Microbes metabolize substances PMDBM2008453 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-475 s CAG-475 sp000434435 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007699 Microbes metabolize substances PMDBM2008454 n.a. f Gastranaerophilaceae g CAG-484 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007700 Microbes metabolize substances PMDBM2008454 n.a. f Gastranaerophilaceae g CAG-484 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007701 Microbes metabolize substances PMDBM2008454 n.a. f Gastranaerophilaceae g CAG-484 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007702 Microbes metabolize substances PMDBM2008454 n.a. f Gastranaerophilaceae g CAG-484 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007703 Microbes metabolize substances PMDBM2008454 n.a. f Gastranaerophilaceae g CAG-484 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007704 Microbes metabolize substances PMDBM2008454 n.a. f Gastranaerophilaceae g CAG-484 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007705 Microbes metabolize substances PMDBM2008454 n.a. f Gastranaerophilaceae g CAG-484 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007708 Microbes metabolize substances PMDBM2008454 n.a. f Gastranaerophilaceae g CAG-484 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007709 Microbes metabolize substances PMDBM2008454 n.a. f Gastranaerophilaceae g CAG-484 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007710 Microbes metabolize substances PMDBM2008454 n.a. f Gastranaerophilaceae g CAG-484 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007711 Microbes metabolize substances PMDBM2008454 n.a. f Gastranaerophilaceae g CAG-484 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007712 Microbes metabolize substances PMDBM2008454 n.a. f Gastranaerophilaceae g CAG-484 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007713 Microbes metabolize substances PMDBM2008454 n.a. f Gastranaerophilaceae g CAG-484 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007714 Microbes metabolize substances PMDBM2008454 n.a. f Gastranaerophilaceae g CAG-484 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007715 Microbes metabolize substances PMDBM2008454 n.a. f Gastranaerophilaceae g CAG-484 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007716 Microbes metabolize substances PMDBM2008455 n.a. f Gastranaerophilaceae g CAG-484 s CAG-484 sp000431315 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007717 Microbes metabolize substances PMDBM2008455 n.a. f Gastranaerophilaceae g CAG-484 s CAG-484 sp000431315 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007718 Microbes metabolize substances PMDBM2008455 n.a. f Gastranaerophilaceae g CAG-484 s CAG-484 sp000431315 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007719 Microbes metabolize substances PMDBM2008455 n.a. f Gastranaerophilaceae g CAG-484 s CAG-484 sp000431315 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007720 Microbes metabolize substances PMDBM2008455 n.a. f Gastranaerophilaceae g CAG-484 s CAG-484 sp000431315 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007721 Microbes metabolize substances PMDBM2008456 n.a. f Gastranaerophilaceae g CAG-484 s CAG-484 sp900321895 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007722 Microbes metabolize substances PMDBM2008456 n.a. f Gastranaerophilaceae g CAG-484 s CAG-484 sp900321895 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007723 Microbes metabolize substances PMDBM2008456 n.a. f Gastranaerophilaceae g CAG-484 s CAG-484 sp900321895 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007724 Microbes metabolize substances PMDBM2008456 n.a. f Gastranaerophilaceae g CAG-484 s CAG-484 sp900321895 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007725 Microbes metabolize substances PMDBM2008456 n.a. f Gastranaerophilaceae g CAG-484 s CAG-484 sp900321895 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007726 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007727 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007728 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007729 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007731 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007733 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007734 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007735 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007736 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007737 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007738 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007740 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20007743 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20007744 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20007745 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20007746 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007747 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007750 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20007753 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007754 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007757 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007758 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007759 Microbes metabolize substances PMDBM2008457 n.a. f Muribaculaceae g CAG-485 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007760 Microbes metabolize substances PMDBM2008458 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp000437495 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007761 Microbes metabolize substances PMDBM2008458 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp000437495 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007762 Microbes metabolize substances PMDBM2008458 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp000437495 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007763 Microbes metabolize substances PMDBM2008458 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp000437495 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007764 Microbes metabolize substances PMDBM2008458 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp000437495 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20007765 Microbes metabolize substances PMDBM2008458 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp000437495 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007766 Microbes metabolize substances PMDBM2008458 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp000437495 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007767 Microbes metabolize substances PMDBM2008458 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp000437495 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007768 Microbes metabolize substances PMDBM2008459 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp001701295 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007769 Microbes metabolize substances PMDBM2008459 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp001701295 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007770 Microbes metabolize substances PMDBM2008459 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp001701295 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007771 Microbes metabolize substances PMDBM2008459 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp001701295 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007772 Microbes metabolize substances PMDBM2008459 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp001701295 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007773 Microbes metabolize substances PMDBM2008459 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp001701295 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007774 Microbes metabolize substances PMDBM2008459 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp001701295 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007777 Microbes metabolize substances PMDBM2008459 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp001701295 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20007778 Microbes metabolize substances PMDBM2008459 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp001701295 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007779 Microbes metabolize substances PMDBM2008459 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp001701295 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007780 Microbes metabolize substances PMDBM2008459 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp001701295 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007781 Microbes metabolize substances PMDBM2008459 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp001701295 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007782 Microbes metabolize substances PMDBM2008459 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp001701295 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007783 Microbes metabolize substances PMDBM2008459 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp001701295 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007784 Microbes metabolize substances PMDBM2008459 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp001701295 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007785 Microbes metabolize substances PMDBM2008459 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp001701295 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007786 Microbes metabolize substances PMDBM2008460 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002361235 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007787 Microbes metabolize substances PMDBM2008460 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002361235 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007788 Microbes metabolize substances PMDBM2008460 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002361235 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007789 Microbes metabolize substances PMDBM2008460 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002361235 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007790 Microbes metabolize substances PMDBM2008460 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002361235 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007791 Microbes metabolize substances PMDBM2008460 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002361235 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007792 Microbes metabolize substances PMDBM2008460 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002361235 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007795 Microbes metabolize substances PMDBM2008460 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002361235 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20007796 Microbes metabolize substances PMDBM2008460 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002361235 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007797 Microbes metabolize substances PMDBM2008460 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002361235 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007798 Microbes metabolize substances PMDBM2008460 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002361235 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007799 Microbes metabolize substances PMDBM2008460 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002361235 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007800 Microbes metabolize substances PMDBM2008460 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002361235 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007801 Microbes metabolize substances PMDBM2008460 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002361235 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007802 Microbes metabolize substances PMDBM2008460 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002361235 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007803 Microbes metabolize substances PMDBM2008461 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002491165 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20007804 Microbes metabolize substances PMDBM2008461 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002491165 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007805 Microbes metabolize substances PMDBM2008461 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002491165 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007806 Microbes metabolize substances PMDBM2008461 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002491165 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007807 Microbes metabolize substances PMDBM2008461 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002491165 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007808 Microbes metabolize substances PMDBM2008461 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp002491165 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007809 Microbes metabolize substances PMDBM2008462 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp900321585 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007810 Microbes metabolize substances PMDBM2008462 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp900321585 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007811 Microbes metabolize substances PMDBM2008462 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp900321585 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007812 Microbes metabolize substances PMDBM2008462 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp900321585 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007814 Microbes metabolize substances PMDBM2008462 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp900321585 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007816 Microbes metabolize substances PMDBM2008462 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp900321585 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007817 Microbes metabolize substances PMDBM2008462 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp900321585 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007818 Microbes metabolize substances PMDBM2008462 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp900321585 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007819 Microbes metabolize substances PMDBM2008462 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp900321585 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007822 Microbes metabolize substances PMDBM2008462 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp900321585 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20007823 Microbes metabolize substances PMDBM2008462 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp900321585 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007824 Microbes metabolize substances PMDBM2008462 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp900321585 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007825 Microbes metabolize substances PMDBM2008462 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp900321585 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007826 Microbes metabolize substances PMDBM2008462 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp900321585 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007828 Microbes metabolize substances PMDBM2008462 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp900321585 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20007829 Microbes metabolize substances PMDBM2008462 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp900321585 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007830 Microbes metabolize substances PMDBM2008462 n.a. f Muribaculaceae g CAG-485 s CAG-485 sp900321585 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007831 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007832 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007833 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007834 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007836 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007838 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007839 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007840 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007841 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007842 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007843 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007845 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20007848 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20007849 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20007850 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007851 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007854 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20007857 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007858 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007861 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007862 Microbes metabolize substances PMDBM2008463 n.a. f Acutalibacteraceae g CAG-488 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007863 Microbes metabolize substances PMDBM2008464 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007864 Microbes metabolize substances PMDBM2008464 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007865 Microbes metabolize substances PMDBM2008464 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007866 Microbes metabolize substances PMDBM2008464 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007868 Microbes metabolize substances PMDBM2008464 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007870 Microbes metabolize substances PMDBM2008464 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007871 Microbes metabolize substances PMDBM2008464 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007872 Microbes metabolize substances PMDBM2008464 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007873 Microbes metabolize substances PMDBM2008464 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007876 Microbes metabolize substances PMDBM2008464 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007877 Microbes metabolize substances PMDBM2008464 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007878 Microbes metabolize substances PMDBM2008464 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007879 Microbes metabolize substances PMDBM2008464 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007881 Microbes metabolize substances PMDBM2008464 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007882 Microbes metabolize substances PMDBM2008464 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434055 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007883 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007884 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007885 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007886 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007888 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007890 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007891 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007892 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007893 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007894 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20007895 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007897 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20007900 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20007901 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20007902 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007903 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007906 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20007909 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007910 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007913 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007914 Microbes metabolize substances PMDBM2008465 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp000434915 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007915 Microbes metabolize substances PMDBM2008466 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007916 Microbes metabolize substances PMDBM2008466 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007917 Microbes metabolize substances PMDBM2008466 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007918 Microbes metabolize substances PMDBM2008466 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007920 Microbes metabolize substances PMDBM2008466 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20007922 Microbes metabolize substances PMDBM2008466 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007923 Microbes metabolize substances PMDBM2008466 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007924 Microbes metabolize substances PMDBM2008466 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007925 Microbes metabolize substances PMDBM2008466 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007928 Microbes metabolize substances PMDBM2008466 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007929 Microbes metabolize substances PMDBM2008466 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007930 Microbes metabolize substances PMDBM2008466 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007931 Microbes metabolize substances PMDBM2008466 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007933 Microbes metabolize substances PMDBM2008466 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007934 Microbes metabolize substances PMDBM2008466 n.a. f Acutalibacteraceae g CAG-488 s CAG-488 sp003486665 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007935 Microbes metabolize substances PMDBM2008467 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007936 Microbes metabolize substances PMDBM2008467 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007937 Microbes metabolize substances PMDBM2008467 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007938 Microbes metabolize substances PMDBM2008467 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007939 Microbes metabolize substances PMDBM2008467 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007940 Microbes metabolize substances PMDBM2008467 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007941 Microbes metabolize substances PMDBM2008467 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007944 Microbes metabolize substances PMDBM2008467 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007945 Microbes metabolize substances PMDBM2008467 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007946 Microbes metabolize substances PMDBM2008467 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007947 Microbes metabolize substances PMDBM2008467 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007948 Microbes metabolize substances PMDBM2008467 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007949 Microbes metabolize substances PMDBM2008467 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007950 Microbes metabolize substances PMDBM2008468 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 s CAG-492 sp000434015 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007951 Microbes metabolize substances PMDBM2008468 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 s CAG-492 sp000434015 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007952 Microbes metabolize substances PMDBM2008468 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 s CAG-492 sp000434015 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007953 Microbes metabolize substances PMDBM2008469 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 s CAG-492 sp000434335 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007954 Microbes metabolize substances PMDBM2008469 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 s CAG-492 sp000434335 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007955 Microbes metabolize substances PMDBM2008469 n.a. c Clostridia o TANB77 f CAG-508 g CAG-492 s CAG-492 sp000434335 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007956 Microbes metabolize substances PMDBM2008470 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007957 Microbes metabolize substances PMDBM2008470 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007958 Microbes metabolize substances PMDBM2008470 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007959 Microbes metabolize substances PMDBM2008470 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007960 Microbes metabolize substances PMDBM2008470 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007961 Microbes metabolize substances PMDBM2008470 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007962 Microbes metabolize substances PMDBM2008470 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007965 Microbes metabolize substances PMDBM2008470 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007966 Microbes metabolize substances PMDBM2008470 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20007967 Microbes metabolize substances PMDBM2008470 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007968 Microbes metabolize substances PMDBM2008470 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007969 Microbes metabolize substances PMDBM2008470 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007970 Microbes metabolize substances PMDBM2008470 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007971 Microbes metabolize substances PMDBM2008470 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007972 Microbes metabolize substances PMDBM2008471 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007973 Microbes metabolize substances PMDBM2008471 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007974 Microbes metabolize substances PMDBM2008471 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007975 Microbes metabolize substances PMDBM2008471 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007976 Microbes metabolize substances PMDBM2008471 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007977 Microbes metabolize substances PMDBM2008471 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007978 Microbes metabolize substances PMDBM2008471 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007981 Microbes metabolize substances PMDBM2008471 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007982 Microbes metabolize substances PMDBM2008471 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007983 Microbes metabolize substances PMDBM2008471 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007984 Microbes metabolize substances PMDBM2008471 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007985 Microbes metabolize substances PMDBM2008471 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007986 Microbes metabolize substances PMDBM2008471 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000432275 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20007987 Microbes metabolize substances PMDBM2008472 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20007988 Microbes metabolize substances PMDBM2008472 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20007989 Microbes metabolize substances PMDBM2008472 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20007990 Microbes metabolize substances PMDBM2008472 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007991 Microbes metabolize substances PMDBM2008472 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007992 Microbes metabolize substances PMDBM2008472 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20007993 Microbes metabolize substances PMDBM2008472 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20007996 Microbes metabolize substances PMDBM2008472 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20007997 Microbes metabolize substances PMDBM2008472 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007998 Microbes metabolize substances PMDBM2008472 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20007999 Microbes metabolize substances PMDBM2008472 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008000 Microbes metabolize substances PMDBM2008472 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008001 Microbes metabolize substances PMDBM2008472 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp000436375 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008002 Microbes metabolize substances PMDBM2008473 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008003 Microbes metabolize substances PMDBM2008473 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008004 Microbes metabolize substances PMDBM2008473 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008005 Microbes metabolize substances PMDBM2008473 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008006 Microbes metabolize substances PMDBM2008473 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008007 Microbes metabolize substances PMDBM2008473 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008008 Microbes metabolize substances PMDBM2008473 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008011 Microbes metabolize substances PMDBM2008473 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008012 Microbes metabolize substances PMDBM2008473 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008013 Microbes metabolize substances PMDBM2008473 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008014 Microbes metabolize substances PMDBM2008473 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008015 Microbes metabolize substances PMDBM2008473 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008016 Microbes metabolize substances PMDBM2008473 n.a. c Alphaproteobacteria o RF32 f CAG-239 g CAG-495 s CAG-495 sp001917125 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008017 Microbes metabolize substances PMDBM2008474 n.a. c Clostridia o TANB77 f CAG-508 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008018 Microbes metabolize substances PMDBM2008474 n.a. c Clostridia o TANB77 f CAG-508 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20008019 Microbes metabolize substances PMDBM2008474 n.a. c Clostridia o TANB77 f CAG-508 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008020 Microbes metabolize substances PMDBM2008474 n.a. c Clostridia o TANB77 f CAG-508 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008021 Microbes metabolize substances PMDBM2008474 n.a. c Clostridia o TANB77 f CAG-508 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008023 Microbes metabolize substances PMDBM2008474 n.a. c Clostridia o TANB77 f CAG-508 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008025 Microbes metabolize substances PMDBM2008474 n.a. c Clostridia o TANB77 f CAG-508 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008026 Microbes metabolize substances PMDBM2008474 n.a. c Clostridia o TANB77 f CAG-508 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008027 Microbes metabolize substances PMDBM2008474 n.a. c Clostridia o TANB77 f CAG-508 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008028 Microbes metabolize substances PMDBM2008474 n.a. c Clostridia o TANB77 f CAG-508 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008031 Microbes metabolize substances PMDBM2008474 n.a. c Clostridia o TANB77 f CAG-508 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008032 Microbes metabolize substances PMDBM2008474 n.a. c Clostridia o TANB77 f CAG-508 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008033 Microbes metabolize substances PMDBM2008474 n.a. c Clostridia o TANB77 f CAG-508 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008034 Microbes metabolize substances PMDBM2008474 n.a. c Clostridia o TANB77 f CAG-508 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008036 Microbes metabolize substances PMDBM2008474 n.a. c Clostridia o TANB77 f CAG-508 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008037 Microbes metabolize substances PMDBM2008474 n.a. c Clostridia o TANB77 f CAG-508 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008038 Microbes metabolize substances PMDBM2008474 n.a. c Clostridia o TANB77 f CAG-508 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008039 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008040 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20008041 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008042 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008043 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008045 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008047 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008048 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008049 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008050 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008053 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20008054 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008055 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008056 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008057 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008059 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008060 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008061 Microbes metabolize substances PMDBM2008475 n.a. f Lachnospiraceae g CAG-510 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008062 Microbes metabolize substances PMDBM2008476 n.a. f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008063 Microbes metabolize substances PMDBM2008476 n.a. f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008064 Microbes metabolize substances PMDBM2008476 n.a. f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008065 Microbes metabolize substances PMDBM2008476 n.a. f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008066 Microbes metabolize substances PMDBM2008476 n.a. f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008067 Microbes metabolize substances PMDBM2008476 n.a. f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008068 Microbes metabolize substances PMDBM2008476 n.a. f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008071 Microbes metabolize substances PMDBM2008476 n.a. f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008072 Microbes metabolize substances PMDBM2008476 n.a. f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008073 Microbes metabolize substances PMDBM2008476 n.a. f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008074 Microbes metabolize substances PMDBM2008476 n.a. f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008075 Microbes metabolize substances PMDBM2008476 n.a. f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008076 Microbes metabolize substances PMDBM2008476 n.a. f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008077 Microbes metabolize substances PMDBM2008476 n.a. f Lachnospiraceae g CAG-510 s CAG-510 sp000434615 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008078 Microbes metabolize substances PMDBM2008477 n.a. f Burkholderiaceae g CAG-521 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008079 Microbes metabolize substances PMDBM2008477 n.a. f Burkholderiaceae g CAG-521 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20008080 Microbes metabolize substances PMDBM2008477 n.a. f Burkholderiaceae g CAG-521 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008081 Microbes metabolize substances PMDBM2008477 n.a. f Burkholderiaceae g CAG-521 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008082 Microbes metabolize substances PMDBM2008477 n.a. f Burkholderiaceae g CAG-521 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008083 Microbes metabolize substances PMDBM2008477 n.a. f Burkholderiaceae g CAG-521 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008084 Microbes metabolize substances PMDBM2008477 n.a. f Burkholderiaceae g CAG-521 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008085 Microbes metabolize substances PMDBM2008477 n.a. f Burkholderiaceae g CAG-521 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008088 Microbes metabolize substances PMDBM2008477 n.a. f Burkholderiaceae g CAG-521 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008089 Microbes metabolize substances PMDBM2008477 n.a. f Burkholderiaceae g CAG-521 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008090 Microbes metabolize substances PMDBM2008477 n.a. f Burkholderiaceae g CAG-521 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008091 Microbes metabolize substances PMDBM2008477 n.a. f Burkholderiaceae g CAG-521 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008092 Microbes metabolize substances PMDBM2008478 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008093 Microbes metabolize substances PMDBM2008478 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20008094 Microbes metabolize substances PMDBM2008478 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008095 Microbes metabolize substances PMDBM2008478 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008096 Microbes metabolize substances PMDBM2008478 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008097 Microbes metabolize substances PMDBM2008478 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008098 Microbes metabolize substances PMDBM2008478 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008099 Microbes metabolize substances PMDBM2008478 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008102 Microbes metabolize substances PMDBM2008478 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008103 Microbes metabolize substances PMDBM2008478 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008104 Microbes metabolize substances PMDBM2008478 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008105 Microbes metabolize substances PMDBM2008478 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp000437635 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008106 Microbes metabolize substances PMDBM2008479 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008107 Microbes metabolize substances PMDBM2008479 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20008108 Microbes metabolize substances PMDBM2008479 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008109 Microbes metabolize substances PMDBM2008479 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008110 Microbes metabolize substances PMDBM2008479 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008111 Microbes metabolize substances PMDBM2008479 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008112 Microbes metabolize substances PMDBM2008479 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008113 Microbes metabolize substances PMDBM2008479 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008116 Microbes metabolize substances PMDBM2008479 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008117 Microbes metabolize substances PMDBM2008479 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008118 Microbes metabolize substances PMDBM2008479 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008119 Microbes metabolize substances PMDBM2008479 n.a. f Burkholderiaceae g CAG-521 s CAG-521 sp002329575 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008120 Microbes metabolize substances PMDBM2008480 n.a. c Bacilli o RF39 f CAG-1000 g CAG-533 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008121 Microbes metabolize substances PMDBM2008480 n.a. c Bacilli o RF39 f CAG-1000 g CAG-533 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008122 Microbes metabolize substances PMDBM2008481 n.a. f Erysipelotrichaceae g CAG-536 s CAG-536 sp000434355 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008123 Microbes metabolize substances PMDBM2008481 n.a. f Erysipelotrichaceae g CAG-536 s CAG-536 sp000434355 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008124 Microbes metabolize substances PMDBM2008481 n.a. f Erysipelotrichaceae g CAG-536 s CAG-536 sp000434355 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008125 Microbes metabolize substances PMDBM2008481 n.a. f Erysipelotrichaceae g CAG-536 s CAG-536 sp000434355 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008126 Microbes metabolize substances PMDBM2008482 n.a. f Erysipelotrichaceae g CAG-536 s CAG-536 sp900314505 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008127 Microbes metabolize substances PMDBM2008482 n.a. f Erysipelotrichaceae g CAG-536 s CAG-536 sp900314505 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008128 Microbes metabolize substances PMDBM2008482 n.a. f Erysipelotrichaceae g CAG-536 s CAG-536 sp900314505 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008129 Microbes metabolize substances PMDBM2008482 n.a. f Erysipelotrichaceae g CAG-536 s CAG-536 sp900314505 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008130 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008131 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008132 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008133 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008135 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008137 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008138 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008139 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008140 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008141 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008142 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008144 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20008147 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20008148 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20008149 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20008150 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008151 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008154 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20008157 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008158 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008161 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008162 Microbes metabolize substances PMDBM2008483 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008163 Microbes metabolize substances PMDBM2008484 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 s CAG-552 sp000435495 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20008164 Microbes metabolize substances PMDBM2008484 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 s CAG-552 sp000435495 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008165 Microbes metabolize substances PMDBM2008484 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 s CAG-552 sp000435495 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008166 Microbes metabolize substances PMDBM2008484 n.a. c Clostridia o 4C28d-15 f CAG-552 g CAG-552 s CAG-552 sp000435495 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008167 Microbes metabolize substances PMDBM2008485 n.a. f Acutalibacteraceae g CAG-557 s CAG-557 sp000435275 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008168 Microbes metabolize substances PMDBM2008485 n.a. f Acutalibacteraceae g CAG-557 s CAG-557 sp000435275 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008169 Microbes metabolize substances PMDBM2008485 n.a. f Acutalibacteraceae g CAG-557 s CAG-557 sp000435275 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008170 Microbes metabolize substances PMDBM2008485 n.a. f Acutalibacteraceae g CAG-557 s CAG-557 sp000435275 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008171 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008172 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008173 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008174 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008176 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008178 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20008179 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008180 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008181 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008182 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008183 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008184 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008186 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20008189 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20008190 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20008191 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008192 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008195 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20008198 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008199 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008202 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008203 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008204 Microbes metabolize substances PMDBM2008486 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008205 Microbes metabolize substances PMDBM2008487 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008206 Microbes metabolize substances PMDBM2008487 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008207 Microbes metabolize substances PMDBM2008487 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008208 Microbes metabolize substances PMDBM2008487 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008210 Microbes metabolize substances PMDBM2008487 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008212 Microbes metabolize substances PMDBM2008487 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008213 Microbes metabolize substances PMDBM2008487 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008214 Microbes metabolize substances PMDBM2008487 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008215 Microbes metabolize substances PMDBM2008487 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008218 Microbes metabolize substances PMDBM2008487 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008219 Microbes metabolize substances PMDBM2008487 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008220 Microbes metabolize substances PMDBM2008487 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008221 Microbes metabolize substances PMDBM2008487 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008223 Microbes metabolize substances PMDBM2008487 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008224 Microbes metabolize substances PMDBM2008487 n.a. c Clostridia o Lachnospirales f Lachnospiraceae g CAG-56 s CAG-56 sp900066615 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008225 Microbes metabolize substances PMDBM2008488 n.a. c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008226 Microbes metabolize substances PMDBM2008488 n.a. c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20008227 Microbes metabolize substances PMDBM2008488 n.a. c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008228 Microbes metabolize substances PMDBM2008488 n.a. c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008229 Microbes metabolize substances PMDBM2008488 n.a. c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008230 Microbes metabolize substances PMDBM2008488 n.a. c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008231 Microbes metabolize substances PMDBM2008488 n.a. c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008232 Microbes metabolize substances PMDBM2008488 n.a. c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008235 Microbes metabolize substances PMDBM2008488 n.a. c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008236 Microbes metabolize substances PMDBM2008488 n.a. c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008237 Microbes metabolize substances PMDBM2008488 n.a. c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008238 Microbes metabolize substances PMDBM2008488 n.a. c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008239 Microbes metabolize substances PMDBM2008488 n.a. c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008240 Microbes metabolize substances PMDBM2008488 n.a. c Bacilli o RFN20 f CAG-288 g CAG-568 s CAG-568 sp000434395 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008241 Microbes metabolize substances PMDBM2008489 n.a. Bacilli o RF39 f CAG-1000 g CAG-582 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008242 Microbes metabolize substances PMDBM2008489 n.a. Bacilli o RF39 f CAG-1000 g CAG-582 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008243 Microbes metabolize substances PMDBM2008490 n.a. c Bacilli o RF39 f CAG-1000 g CAG-582 s CAG-582 sp000435515 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008244 Microbes metabolize substances PMDBM2008490 n.a. c Bacilli o RF39 f CAG-1000 g CAG-582 s CAG-582 sp000435515 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008245 Microbes metabolize substances PMDBM2008491 n.a. f Lachnospiraceae g CAG-590 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008246 Microbes metabolize substances PMDBM2008491 n.a. f Lachnospiraceae g CAG-590 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008247 Microbes metabolize substances PMDBM2008491 n.a. f Lachnospiraceae g CAG-590 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008248 Microbes metabolize substances PMDBM2008491 n.a. f Lachnospiraceae g CAG-590 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20008249 Microbes metabolize substances PMDBM2008491 n.a. f Lachnospiraceae g CAG-590 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008250 Microbes metabolize substances PMDBM2008491 n.a. f Lachnospiraceae g CAG-590 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008251 Microbes metabolize substances PMDBM2008491 n.a. f Lachnospiraceae g CAG-590 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008252 Microbes metabolize substances PMDBM2008491 n.a. f Lachnospiraceae g CAG-590 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008255 Microbes metabolize substances PMDBM2008491 n.a. f Lachnospiraceae g CAG-590 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008256 Microbes metabolize substances PMDBM2008491 n.a. f Lachnospiraceae g CAG-590 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008257 Microbes metabolize substances PMDBM2008491 n.a. f Lachnospiraceae g CAG-590 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008258 Microbes metabolize substances PMDBM2008491 n.a. f Lachnospiraceae g CAG-590 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008259 Microbes metabolize substances PMDBM2008491 n.a. f Lachnospiraceae g CAG-590 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008260 Microbes metabolize substances PMDBM2008491 n.a. f Lachnospiraceae g CAG-590 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008261 Microbes metabolize substances PMDBM2008491 n.a. f Lachnospiraceae g CAG-590 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008262 Microbes metabolize substances PMDBM2008491 n.a. f Lachnospiraceae g CAG-590 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008263 Microbes metabolize substances PMDBM2008492 n.a. f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008264 Microbes metabolize substances PMDBM2008492 n.a. f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008265 Microbes metabolize substances PMDBM2008492 n.a. f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008266 Microbes metabolize substances PMDBM2008492 n.a. f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20008267 Microbes metabolize substances PMDBM2008492 n.a. f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008268 Microbes metabolize substances PMDBM2008492 n.a. f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008269 Microbes metabolize substances PMDBM2008492 n.a. f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008270 Microbes metabolize substances PMDBM2008492 n.a. f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008273 Microbes metabolize substances PMDBM2008492 n.a. f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008274 Microbes metabolize substances PMDBM2008492 n.a. f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008275 Microbes metabolize substances PMDBM2008492 n.a. f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008276 Microbes metabolize substances PMDBM2008492 n.a. f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008277 Microbes metabolize substances PMDBM2008492 n.a. f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008278 Microbes metabolize substances PMDBM2008492 n.a. f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008279 Microbes metabolize substances PMDBM2008492 n.a. f Lachnospiraceae g CAG-590 s CAG-590 sp000431135 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008280 Microbes metabolize substances PMDBM2008493 n.a. c Bacilli o RF39 f CAG-433 g CAG-594 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008281 Microbes metabolize substances PMDBM2008493 n.a. c Bacilli o RF39 f CAG-433 g CAG-594 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008282 Microbes metabolize substances PMDBM2008493 n.a. c Bacilli o RF39 f CAG-433 g CAG-594 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008283 Microbes metabolize substances PMDBM2008494 n.a. c Bacilli o RF39 f CAG-433 g CAG-594 s CAG-594 sp000434835 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008284 Microbes metabolize substances PMDBM2008494 n.a. c Bacilli o RF39 f CAG-433 g CAG-594 s CAG-594 sp000434835 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008285 Microbes metabolize substances PMDBM2008495 n.a. f Lachnospiraceae g CAG-603 s CAG-603 sp900066105 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008286 Microbes metabolize substances PMDBM2008495 n.a. f Lachnospiraceae g CAG-603 s CAG-603 sp900066105 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008287 Microbes metabolize substances PMDBM2008495 n.a. f Lachnospiraceae g CAG-603 s CAG-603 sp900066105 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008288 Microbes metabolize substances PMDBM2008495 n.a. f Lachnospiraceae g CAG-603 s CAG-603 sp900066105 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008289 Microbes metabolize substances PMDBM2008495 n.a. f Lachnospiraceae g CAG-603 s CAG-603 sp900066105 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008290 Microbes metabolize substances PMDBM2008496 n.a. c Bacilli o RF39 f CAG-1000 g CAG-605 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008291 Microbes metabolize substances PMDBM2008496 n.a. c Bacilli o RF39 f CAG-1000 g CAG-605 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008292 Microbes metabolize substances PMDBM2008496 n.a. c Bacilli o RF39 f CAG-1000 g CAG-605 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008293 Microbes metabolize substances PMDBM2008497 n.a. c Bacilli o RF39 f CAG-1000 g CAG-605 s CAG-605 sp000433255 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008294 Microbes metabolize substances PMDBM2008497 n.a. c Bacilli o RF39 f CAG-1000 g CAG-605 s CAG-605 sp000433255 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008295 Microbes metabolize substances PMDBM2008498 n.a. c Bacilli o RF39 f CAG-1000 g CAG-605 s CAG-605 sp000433475 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008296 Microbes metabolize substances PMDBM2008498 n.a. c Bacilli o RF39 f CAG-1000 g CAG-605 s CAG-605 sp000433475 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008297 Microbes metabolize substances PMDBM2008499 n.a. c Bacilli o RF39 f CAG-611 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008298 Microbes metabolize substances PMDBM2008499 n.a. c Bacilli o RF39 f CAG-611 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008299 Microbes metabolize substances PMDBM2008499 n.a. c Bacilli o RF39 f CAG-611 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008300 Microbes metabolize substances PMDBM2008499 n.a. c Bacilli o RF39 f CAG-611 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008301 Microbes metabolize substances PMDBM2008499 n.a. c Bacilli o RF39 f CAG-611 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008302 Microbes metabolize substances PMDBM2008499 n.a. c Bacilli o RF39 f CAG-611 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008303 Microbes metabolize substances PMDBM2008499 n.a. c Bacilli o RF39 f CAG-611 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008306 Microbes metabolize substances PMDBM2008499 n.a. c Bacilli o RF39 f CAG-611 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008307 Microbes metabolize substances PMDBM2008499 n.a. c Bacilli o RF39 f CAG-611 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008308 Microbes metabolize substances PMDBM2008499 n.a. c Bacilli o RF39 f CAG-611 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008309 Microbes metabolize substances PMDBM2008499 n.a. c Bacilli o RF39 f CAG-611 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008311 Microbes metabolize substances PMDBM2008499 n.a. c Bacilli o RF39 f CAG-611 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008313 Microbes metabolize substances PMDBM2008500 n.a. c Bacilli o RF39 f CAG-611 g CAG-611 s CAG-611 sp000434175 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008314 Microbes metabolize substances PMDBM2008500 n.a. c Bacilli o RF39 f CAG-611 g CAG-611 s CAG-611 sp000434175 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008315 Microbes metabolize substances PMDBM2008500 n.a. c Bacilli o RF39 f CAG-611 g CAG-611 s CAG-611 sp000434175 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008316 Microbes metabolize substances PMDBM2008501 n.a. f Bacteroidaceae g CAG-617 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008317 Microbes metabolize substances PMDBM2008501 n.a. f Bacteroidaceae g CAG-617 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008318 Microbes metabolize substances PMDBM2008501 n.a. f Bacteroidaceae g CAG-617 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008319 Microbes metabolize substances PMDBM2008501 n.a. f Bacteroidaceae g CAG-617 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008320 Microbes metabolize substances PMDBM2008501 n.a. f Bacteroidaceae g CAG-617 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008321 Microbes metabolize substances PMDBM2008501 n.a. f Bacteroidaceae g CAG-617 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008322 Microbes metabolize substances PMDBM2008501 n.a. f Bacteroidaceae g CAG-617 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008325 Microbes metabolize substances PMDBM2008501 n.a. f Bacteroidaceae g CAG-617 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008326 Microbes metabolize substances PMDBM2008501 n.a. f Bacteroidaceae g CAG-617 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008327 Microbes metabolize substances PMDBM2008501 n.a. f Bacteroidaceae g CAG-617 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008328 Microbes metabolize substances PMDBM2008501 n.a. f Bacteroidaceae g CAG-617 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008329 Microbes metabolize substances PMDBM2008501 n.a. f Bacteroidaceae g CAG-617 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008330 Microbes metabolize substances PMDBM2008501 n.a. f Bacteroidaceae g CAG-617 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008331 Microbes metabolize substances PMDBM2008501 n.a. f Bacteroidaceae g CAG-617 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008332 Microbes metabolize substances PMDBM2008501 n.a. f Bacteroidaceae g CAG-617 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008333 Microbes metabolize substances PMDBM2008502 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000431275 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008334 Microbes metabolize substances PMDBM2008502 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000431275 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008335 Microbes metabolize substances PMDBM2008502 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000431275 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008336 Microbes metabolize substances PMDBM2008502 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000431275 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008337 Microbes metabolize substances PMDBM2008502 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000431275 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008338 Microbes metabolize substances PMDBM2008503 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008339 Microbes metabolize substances PMDBM2008503 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008340 Microbes metabolize substances PMDBM2008503 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008341 Microbes metabolize substances PMDBM2008503 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008342 Microbes metabolize substances PMDBM2008503 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008343 Microbes metabolize substances PMDBM2008503 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008344 Microbes metabolize substances PMDBM2008503 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008347 Microbes metabolize substances PMDBM2008503 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008348 Microbes metabolize substances PMDBM2008503 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008349 Microbes metabolize substances PMDBM2008503 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008350 Microbes metabolize substances PMDBM2008503 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008351 Microbes metabolize substances PMDBM2008503 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008352 Microbes metabolize substances PMDBM2008503 n.a. f Bacteroidaceae g CAG-617 s CAG-617 sp000438115 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008353 Microbes metabolize substances PMDBM2008504 n.a. c Bacilli o RF39 f CAG-1000 g CAG-628 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008354 Microbes metabolize substances PMDBM2008504 n.a. c Bacilli o RF39 f CAG-1000 g CAG-628 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008355 Microbes metabolize substances PMDBM2008505 n.a. c Bacilli o RF39 f CAG-1000 g CAG-628 s CAG-628 sp003524085 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008356 Microbes metabolize substances PMDBM2008505 n.a. c Bacilli o RF39 f CAG-1000 g CAG-628 s CAG-628 sp003524085 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008357 Microbes metabolize substances PMDBM2008506 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008359 Microbes metabolize substances PMDBM2008506 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008361 Microbes metabolize substances PMDBM2008506 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008363 Microbes metabolize substances PMDBM2008506 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008365 Microbes metabolize substances PMDBM2008506 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008367 Microbes metabolize substances PMDBM2008506 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008369 Microbes metabolize substances PMDBM2008506 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008375 Microbes metabolize substances PMDBM2008506 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20008376 Microbes metabolize substances PMDBM2008506 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008378 Microbes metabolize substances PMDBM2008506 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008380 Microbes metabolize substances PMDBM2008506 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008382 Microbes metabolize substances PMDBM2008506 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008384 Microbes metabolize substances PMDBM2008506 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008386 Microbes metabolize substances PMDBM2008506 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008387 Microbes metabolize substances PMDBM2008506 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008389 Microbes metabolize substances PMDBM2008506 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008391 Microbes metabolize substances PMDBM2008507 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 s CAG-631 sp000433015 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008392 Microbes metabolize substances PMDBM2008507 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 s CAG-631 sp000433015 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008393 Microbes metabolize substances PMDBM2008507 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 s CAG-631 sp000433015 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008394 Microbes metabolize substances PMDBM2008507 n.a. c Bacilli o RFN20 f CAG-631 g CAG-631 s CAG-631 sp000433015 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008395 Microbes metabolize substances PMDBM2008508 n.a. f Lachnospiraceae g CAG-632 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008396 Microbes metabolize substances PMDBM2008508 n.a. f Lachnospiraceae g CAG-632 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008397 Microbes metabolize substances PMDBM2008508 n.a. f Lachnospiraceae g CAG-632 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008398 Microbes metabolize substances PMDBM2008508 n.a. f Lachnospiraceae g CAG-632 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008399 Microbes metabolize substances PMDBM2008508 n.a. f Lachnospiraceae g CAG-632 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008400 Microbes metabolize substances PMDBM2008508 n.a. f Lachnospiraceae g CAG-632 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008401 Microbes metabolize substances PMDBM2008508 n.a. f Lachnospiraceae g CAG-632 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008404 Microbes metabolize substances PMDBM2008508 n.a. f Lachnospiraceae g CAG-632 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008405 Microbes metabolize substances PMDBM2008508 n.a. f Lachnospiraceae g CAG-632 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008406 Microbes metabolize substances PMDBM2008508 n.a. f Lachnospiraceae g CAG-632 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008407 Microbes metabolize substances PMDBM2008508 n.a. f Lachnospiraceae g CAG-632 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008408 Microbes metabolize substances PMDBM2008508 n.a. f Lachnospiraceae g CAG-632 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008409 Microbes metabolize substances PMDBM2008508 n.a. f Lachnospiraceae g CAG-632 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008410 Microbes metabolize substances PMDBM2008508 n.a. f Lachnospiraceae g CAG-632 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008411 Microbes metabolize substances PMDBM2008508 n.a. f Lachnospiraceae g CAG-632 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008412 Microbes metabolize substances PMDBM2008509 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008413 Microbes metabolize substances PMDBM2008509 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008414 Microbes metabolize substances PMDBM2008509 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008415 Microbes metabolize substances PMDBM2008509 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008416 Microbes metabolize substances PMDBM2008509 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008417 Microbes metabolize substances PMDBM2008509 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008418 Microbes metabolize substances PMDBM2008509 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008421 Microbes metabolize substances PMDBM2008509 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008422 Microbes metabolize substances PMDBM2008509 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008423 Microbes metabolize substances PMDBM2008509 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008424 Microbes metabolize substances PMDBM2008509 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008425 Microbes metabolize substances PMDBM2008509 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008426 Microbes metabolize substances PMDBM2008509 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008427 Microbes metabolize substances PMDBM2008509 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008428 Microbes metabolize substances PMDBM2008509 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp000431515 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008429 Microbes metabolize substances PMDBM2008510 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008430 Microbes metabolize substances PMDBM2008510 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008431 Microbes metabolize substances PMDBM2008510 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008432 Microbes metabolize substances PMDBM2008510 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008433 Microbes metabolize substances PMDBM2008510 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008434 Microbes metabolize substances PMDBM2008510 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008435 Microbes metabolize substances PMDBM2008510 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008438 Microbes metabolize substances PMDBM2008510 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008439 Microbes metabolize substances PMDBM2008510 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008440 Microbes metabolize substances PMDBM2008510 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008441 Microbes metabolize substances PMDBM2008510 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008442 Microbes metabolize substances PMDBM2008510 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008443 Microbes metabolize substances PMDBM2008510 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008444 Microbes metabolize substances PMDBM2008510 n.a. f Lachnospiraceae g CAG-632 s CAG-632 sp002406015 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008445 Microbes metabolize substances PMDBM2008511 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008446 Microbes metabolize substances PMDBM2008511 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008447 Microbes metabolize substances PMDBM2008511 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008448 Microbes metabolize substances PMDBM2008511 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008449 Microbes metabolize substances PMDBM2008511 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008450 Microbes metabolize substances PMDBM2008511 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008451 Microbes metabolize substances PMDBM2008511 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008454 Microbes metabolize substances PMDBM2008511 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008455 Microbes metabolize substances PMDBM2008511 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008456 Microbes metabolize substances PMDBM2008511 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008457 Microbes metabolize substances PMDBM2008512 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008458 Microbes metabolize substances PMDBM2008512 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008459 Microbes metabolize substances PMDBM2008512 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008460 Microbes metabolize substances PMDBM2008512 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008461 Microbes metabolize substances PMDBM2008512 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008462 Microbes metabolize substances PMDBM2008512 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008463 Microbes metabolize substances PMDBM2008512 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008466 Microbes metabolize substances PMDBM2008512 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008467 Microbes metabolize substances PMDBM2008512 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008468 Microbes metabolize substances PMDBM2008512 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008469 Microbes metabolize substances PMDBM2008512 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008470 Microbes metabolize substances PMDBM2008512 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008471 Microbes metabolize substances PMDBM2008512 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008472 Microbes metabolize substances PMDBM2008512 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008473 Microbes metabolize substances PMDBM2008512 n.a. c Bacilli o ML615J-28 f CAG-698 g CAG-698 s CAG-698 sp000431235 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008474 Microbes metabolize substances PMDBM2008513 n.a. c Bacilli o RF39 f CAG-611 g CAG-710 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008475 Microbes metabolize substances PMDBM2008513 n.a. c Bacilli o RF39 f CAG-611 g CAG-710 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008476 Microbes metabolize substances PMDBM2008513 n.a. c Bacilli o RF39 f CAG-611 g CAG-710 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008477 Microbes metabolize substances PMDBM2008514 n.a. c Bacilli o RF39 f CAG-611 g CAG-710 s CAG-710 sp000432595 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008478 Microbes metabolize substances PMDBM2008514 n.a. c Bacilli o RF39 f CAG-611 g CAG-710 s CAG-710 sp000432595 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008479 Microbes metabolize substances PMDBM2008514 n.a. c Bacilli o RF39 f CAG-611 g CAG-710 s CAG-710 sp000432595 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008480 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008481 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008482 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008483 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008485 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008487 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008488 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008489 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008490 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008491 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008492 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008494 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20008497 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20008498 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20008499 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008500 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008503 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20008506 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008507 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008510 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008511 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008512 Microbes metabolize substances PMDBM2008515 n.a. o Oscillospirales f CAG-272 g CAG-724 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008513 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008514 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008515 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008516 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008518 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008520 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008521 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008522 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008523 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008524 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008525 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008527 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20008530 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20008531 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20008532 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008533 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008536 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20008539 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008540 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008543 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008544 Microbes metabolize substances PMDBM2008516 n.a. o Oscillospirales f CAG-272 g CAG-724 s CAG-724 sp003524145 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008545 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008546 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008547 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008548 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008550 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008552 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008553 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008554 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008555 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008556 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008557 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008559 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20008562 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20008563 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20008564 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008565 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008568 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20008571 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008572 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008575 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008576 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008577 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008578 Microbes metabolize substances PMDBM2008517 n.a. c Clostridia o 4C28d-15 f CAG-727 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20008579 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008580 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20008581 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008582 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008583 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008585 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008587 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008588 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008589 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008590 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008591 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008592 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008594 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20008597 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20008598 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20008599 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008600 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008603 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20008606 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008607 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008610 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008611 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008612 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008613 Microbes metabolize substances PMDBM2008518 n.a. o Christensenellales f CAG-74 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20008616 Microbes metabolize substances PMDBM2008519 n.a. c Bacilli o RF39 f CAG-302 g CAG-762 s CAG-762 sp000432575 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008617 Microbes metabolize substances PMDBM2008519 n.a. c Bacilli o RF39 f CAG-302 g CAG-762 s CAG-762 sp000432575 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008618 Microbes metabolize substances PMDBM2008520 n.a. c Bacilli o RF39 f CAG-1000 g CAG-776 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008619 Microbes metabolize substances PMDBM2008520 n.a. c Bacilli o RF39 f CAG-1000 g CAG-776 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20008620 Microbes metabolize substances PMDBM2008520 n.a. c Bacilli o RF39 f CAG-1000 g CAG-776 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008621 Microbes metabolize substances PMDBM2008520 n.a. c Bacilli o RF39 f CAG-1000 g CAG-776 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008622 Microbes metabolize substances PMDBM2008520 n.a. c Bacilli o RF39 f CAG-1000 g CAG-776 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008623 Microbes metabolize substances PMDBM2008520 n.a. c Bacilli o RF39 f CAG-1000 g CAG-776 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008624 Microbes metabolize substances PMDBM2008520 n.a. c Bacilli o RF39 f CAG-1000 g CAG-776 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008625 Microbes metabolize substances PMDBM2008520 n.a. c Bacilli o RF39 f CAG-1000 g CAG-776 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008628 Microbes metabolize substances PMDBM2008520 n.a. c Bacilli o RF39 f CAG-1000 g CAG-776 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008629 Microbes metabolize substances PMDBM2008520 n.a. c Bacilli o RF39 f CAG-1000 g CAG-776 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008630 Microbes metabolize substances PMDBM2008520 n.a. c Bacilli o RF39 f CAG-1000 g CAG-776 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008631 Microbes metabolize substances PMDBM2008520 n.a. c Bacilli o RF39 f CAG-1000 g CAG-776 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008632 Microbes metabolize substances PMDBM2008520 n.a. c Bacilli o RF39 f CAG-1000 g CAG-776 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008633 Microbes metabolize substances PMDBM2008521 n.a. c Bacilli o RF39 f CAG-1000 g CAG-776 s CAG-776 sp000438195 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008634 Microbes metabolize substances PMDBM2008521 n.a. c Bacilli o RF39 f CAG-1000 g CAG-776 s CAG-776 sp000438195 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008635 Microbes metabolize substances PMDBM2008522 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008636 Microbes metabolize substances PMDBM2008522 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008637 Microbes metabolize substances PMDBM2008522 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008638 Microbes metabolize substances PMDBM2008522 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008639 Microbes metabolize substances PMDBM2008522 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008640 Microbes metabolize substances PMDBM2008522 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008641 Microbes metabolize substances PMDBM2008522 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008644 Microbes metabolize substances PMDBM2008522 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008645 Microbes metabolize substances PMDBM2008522 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008646 Microbes metabolize substances PMDBM2008522 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008647 Microbes metabolize substances PMDBM2008522 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008648 Microbes metabolize substances PMDBM2008522 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008649 Microbes metabolize substances PMDBM2008522 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008650 Microbes metabolize substances PMDBM2008522 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008651 Microbes metabolize substances PMDBM2008522 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp000431495 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008652 Microbes metabolize substances PMDBM2008523 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008653 Microbes metabolize substances PMDBM2008523 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008654 Microbes metabolize substances PMDBM2008523 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008655 Microbes metabolize substances PMDBM2008523 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008657 Microbes metabolize substances PMDBM2008523 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008659 Microbes metabolize substances PMDBM2008523 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008660 Microbes metabolize substances PMDBM2008523 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008661 Microbes metabolize substances PMDBM2008523 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008662 Microbes metabolize substances PMDBM2008523 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008665 Microbes metabolize substances PMDBM2008523 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008666 Microbes metabolize substances PMDBM2008523 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008667 Microbes metabolize substances PMDBM2008523 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20008668 Microbes metabolize substances PMDBM2008523 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008669 Microbes metabolize substances PMDBM2008523 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008671 Microbes metabolize substances PMDBM2008523 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008672 Microbes metabolize substances PMDBM2008523 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008673 Microbes metabolize substances PMDBM2008523 n.a. f Lachnospiraceae g CAG-791 s CAG-791 sp900315055 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008674 Microbes metabolize substances PMDBM2008524 n.a. c Clostridia o TANB77 f CAG-508 g CAG-793 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008675 Microbes metabolize substances PMDBM2008524 n.a. c Clostridia o TANB77 f CAG-508 g CAG-793 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008676 Microbes metabolize substances PMDBM2008525 n.a. c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008677 Microbes metabolize substances PMDBM2008525 n.a. c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008678 Microbes metabolize substances PMDBM2008525 n.a. c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008679 Microbes metabolize substances PMDBM2008525 n.a. c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008680 Microbes metabolize substances PMDBM2008525 n.a. c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008681 Microbes metabolize substances PMDBM2008525 n.a. c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008682 Microbes metabolize substances PMDBM2008525 n.a. c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008685 Microbes metabolize substances PMDBM2008525 n.a. c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008686 Microbes metabolize substances PMDBM2008525 n.a. c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008687 Microbes metabolize substances PMDBM2008525 n.a. c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008688 Microbes metabolize substances PMDBM2008525 n.a. c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008689 Microbes metabolize substances PMDBM2008525 n.a. c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008690 Microbes metabolize substances PMDBM2008525 n.a. c Clostridia o TANB77 f CAG-508 g CAG-793 s CAG-793 sp000433915 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008691 Microbes metabolize substances PMDBM2008526 n.a. f Lachnospiraceae g CAG-81 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008692 Microbes metabolize substances PMDBM2008526 n.a. f Lachnospiraceae g CAG-81 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008693 Microbes metabolize substances PMDBM2008526 n.a. f Lachnospiraceae g CAG-81 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008694 Microbes metabolize substances PMDBM2008526 n.a. f Lachnospiraceae g CAG-81 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008695 Microbes metabolize substances PMDBM2008526 n.a. f Lachnospiraceae g CAG-81 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008696 Microbes metabolize substances PMDBM2008527 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008697 Microbes metabolize substances PMDBM2008527 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20008698 Microbes metabolize substances PMDBM2008527 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008699 Microbes metabolize substances PMDBM2008527 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008700 Microbes metabolize substances PMDBM2008527 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008701 Microbes metabolize substances PMDBM2008527 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008702 Microbes metabolize substances PMDBM2008527 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008703 Microbes metabolize substances PMDBM2008527 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008706 Microbes metabolize substances PMDBM2008527 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008707 Microbes metabolize substances PMDBM2008527 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008708 Microbes metabolize substances PMDBM2008527 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008709 Microbes metabolize substances PMDBM2008527 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008710 Microbes metabolize substances PMDBM2008527 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008711 Microbes metabolize substances PMDBM2008527 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp000435795 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008712 Microbes metabolize substances PMDBM2008528 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp900066055 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008713 Microbes metabolize substances PMDBM2008528 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp900066055 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008714 Microbes metabolize substances PMDBM2008528 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp900066055 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008715 Microbes metabolize substances PMDBM2008528 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp900066055 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008716 Microbes metabolize substances PMDBM2008529 n.a. Lachnospiraceae g CAG-81 s CAG-81 sp900066535 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008717 Microbes metabolize substances PMDBM2008529 n.a. Lachnospiraceae g CAG-81 s CAG-81 sp900066535 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008718 Microbes metabolize substances PMDBM2008529 n.a. Lachnospiraceae g CAG-81 s CAG-81 sp900066535 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008719 Microbes metabolize substances PMDBM2008529 n.a. Lachnospiraceae g CAG-81 s CAG-81 sp900066535 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008720 Microbes metabolize substances PMDBM2008529 n.a. Lachnospiraceae g CAG-81 s CAG-81 sp900066535 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008721 Microbes metabolize substances PMDBM2008529 n.a. Lachnospiraceae g CAG-81 s CAG-81 sp900066535 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008722 Microbes metabolize substances PMDBM2008529 n.a. Lachnospiraceae g CAG-81 s CAG-81 sp900066535 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008723 Microbes metabolize substances PMDBM2008529 n.a. Lachnospiraceae g CAG-81 s CAG-81 sp900066535 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008724 Microbes metabolize substances PMDBM2008529 n.a. Lachnospiraceae g CAG-81 s CAG-81 sp900066535 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008725 Microbes metabolize substances PMDBM2008530 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp900066785 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008726 Microbes metabolize substances PMDBM2008530 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp900066785 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008727 Microbes metabolize substances PMDBM2008530 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp900066785 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008728 Microbes metabolize substances PMDBM2008530 n.a. f Lachnospiraceae g CAG-81 s CAG-81 sp900066785 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008729 Microbes metabolize substances PMDBM2008531 n.a. c Bacilli o RF39 f CAG-822 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008730 Microbes metabolize substances PMDBM2008531 n.a. c Bacilli o RF39 f CAG-822 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008731 Microbes metabolize substances PMDBM2008531 n.a. c Bacilli o RF39 f CAG-822 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20008733 Microbes metabolize substances PMDBM2008531 n.a. c Bacilli o RF39 f CAG-822 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20008734 Microbes metabolize substances PMDBM2008531 n.a. c Bacilli o RF39 f CAG-822 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20008737 Microbes metabolize substances PMDBM2008531 n.a. c Bacilli o RF39 f CAG-822 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20008741 Microbes metabolize substances PMDBM2008531 n.a. c Bacilli o RF39 f CAG-822 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008742 Microbes metabolize substances PMDBM2008531 n.a. c Bacilli o RF39 f CAG-822 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008743 Microbes metabolize substances PMDBM2008531 n.a. c Bacilli o RF39 f CAG-822 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008744 Microbes metabolize substances PMDBM2008532 n.a. c Bacilli o RF39 f CAG-822 g CAG-822 s CAG-822 sp000432855 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20008745 Microbes metabolize substances PMDBM2008532 n.a. c Bacilli o RF39 f CAG-822 g CAG-822 s CAG-822 sp000432855 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008746 Microbes metabolize substances PMDBM2008532 n.a. c Bacilli o RF39 f CAG-822 g CAG-822 s CAG-822 sp000432855 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008747 Microbes metabolize substances PMDBM2008533 n.a. c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008748 Microbes metabolize substances PMDBM2008533 n.a. c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008749 Microbes metabolize substances PMDBM2008533 n.a. c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008750 Microbes metabolize substances PMDBM2008533 n.a. c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008751 Microbes metabolize substances PMDBM2008533 n.a. c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008752 Microbes metabolize substances PMDBM2008533 n.a. c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008753 Microbes metabolize substances PMDBM2008533 n.a. c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008756 Microbes metabolize substances PMDBM2008533 n.a. c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008757 Microbes metabolize substances PMDBM2008533 n.a. c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008758 Microbes metabolize substances PMDBM2008533 n.a. c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008759 Microbes metabolize substances PMDBM2008533 n.a. c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008760 Microbes metabolize substances PMDBM2008533 n.a. c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008761 Microbes metabolize substances PMDBM2008533 n.a. c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008762 Microbes metabolize substances PMDBM2008533 n.a. c Bacilli o RFN20 f CAG-826 g CAG-826 s CAG-826 sp000437235 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008763 Microbes metabolize substances PMDBM2008534 n.a. f Oscillospiraceae g CAG-83 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008764 Microbes metabolize substances PMDBM2008534 n.a. f Oscillospiraceae g CAG-83 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008765 Microbes metabolize substances PMDBM2008534 n.a. f Oscillospiraceae g CAG-83 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008766 Microbes metabolize substances PMDBM2008534 n.a. f Oscillospiraceae g CAG-83 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008767 Microbes metabolize substances PMDBM2008534 n.a. f Oscillospiraceae g CAG-83 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20008768 Microbes metabolize substances PMDBM2008534 n.a. f Oscillospiraceae g CAG-83 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20008769 Microbes metabolize substances PMDBM2008534 n.a. f Oscillospiraceae g CAG-83 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008770 Microbes metabolize substances PMDBM2008534 n.a. f Oscillospiraceae g CAG-83 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008771 Microbes metabolize substances PMDBM2008534 n.a. f Oscillospiraceae g CAG-83 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20008772 Microbes metabolize substances PMDBM2008534 n.a. f Oscillospiraceae g CAG-83 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008773 Microbes metabolize substances PMDBM2008534 n.a. f Oscillospiraceae g CAG-83 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008774 Microbes metabolize substances PMDBM2008534 n.a. f Oscillospiraceae g CAG-83 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008775 Microbes metabolize substances PMDBM2008535 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp000431575 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008776 Microbes metabolize substances PMDBM2008535 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp000431575 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008777 Microbes metabolize substances PMDBM2008535 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp000431575 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008778 Microbes metabolize substances PMDBM2008535 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp000431575 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008779 Microbes metabolize substances PMDBM2008535 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp000431575 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008780 Microbes metabolize substances PMDBM2008536 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp000435555 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008781 Microbes metabolize substances PMDBM2008536 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp000435555 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008782 Microbes metabolize substances PMDBM2008536 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp000435555 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008783 Microbes metabolize substances PMDBM2008537 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp000435975 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008784 Microbes metabolize substances PMDBM2008537 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp000435975 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008785 Microbes metabolize substances PMDBM2008537 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp000435975 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008786 Microbes metabolize substances PMDBM2008538 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp001916855 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008787 Microbes metabolize substances PMDBM2008538 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp001916855 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008788 Microbes metabolize substances PMDBM2008538 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp001916855 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008789 Microbes metabolize substances PMDBM2008539 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp003487665 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20008790 Microbes metabolize substances PMDBM2008539 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp003487665 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008791 Microbes metabolize substances PMDBM2008539 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp003487665 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008792 Microbes metabolize substances PMDBM2008539 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp003487665 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008793 Microbes metabolize substances PMDBM2008539 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp003487665 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008794 Microbes metabolize substances PMDBM2008539 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp003487665 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008795 Microbes metabolize substances PMDBM2008540 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp003539495 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20008796 Microbes metabolize substances PMDBM2008540 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp003539495 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008797 Microbes metabolize substances PMDBM2008540 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp003539495 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008798 Microbes metabolize substances PMDBM2008540 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp003539495 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008799 Microbes metabolize substances PMDBM2008540 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp003539495 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008800 Microbes metabolize substances PMDBM2008541 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp900313295 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008801 Microbes metabolize substances PMDBM2008541 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp900313295 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008802 Microbes metabolize substances PMDBM2008541 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp900313295 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008803 Microbes metabolize substances PMDBM2008541 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp900313295 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008804 Microbes metabolize substances PMDBM2008541 n.a. f Oscillospiraceae g CAG-83 s CAG-83 sp900313295 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008805 Microbes metabolize substances PMDBM2008542 n.a. o Bacteroidales f UBA932 g CAG-831 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008806 Microbes metabolize substances PMDBM2008542 n.a. o Bacteroidales f UBA932 g CAG-831 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008807 Microbes metabolize substances PMDBM2008542 n.a. o Bacteroidales f UBA932 g CAG-831 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008808 Microbes metabolize substances PMDBM2008542 n.a. o Bacteroidales f UBA932 g CAG-831 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008809 Microbes metabolize substances PMDBM2008542 n.a. o Bacteroidales f UBA932 g CAG-831 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008810 Microbes metabolize substances PMDBM2008542 n.a. o Bacteroidales f UBA932 g CAG-831 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008811 Microbes metabolize substances PMDBM2008542 n.a. o Bacteroidales f UBA932 g CAG-831 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008814 Microbes metabolize substances PMDBM2008542 n.a. o Bacteroidales f UBA932 g CAG-831 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20008815 Microbes metabolize substances PMDBM2008542 n.a. o Bacteroidales f UBA932 g CAG-831 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008816 Microbes metabolize substances PMDBM2008542 n.a. o Bacteroidales f UBA932 g CAG-831 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008817 Microbes metabolize substances PMDBM2008542 n.a. o Bacteroidales f UBA932 g CAG-831 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008818 Microbes metabolize substances PMDBM2008542 n.a. o Bacteroidales f UBA932 g CAG-831 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008819 Microbes metabolize substances PMDBM2008542 n.a. o Bacteroidales f UBA932 g CAG-831 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008820 Microbes metabolize substances PMDBM2008542 n.a. o Bacteroidales f UBA932 g CAG-831 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008821 Microbes metabolize substances PMDBM2008542 n.a. o Bacteroidales f UBA932 g CAG-831 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008822 Microbes metabolize substances PMDBM2008542 n.a. o Bacteroidales f UBA932 g CAG-831 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008823 Microbes metabolize substances PMDBM2008543 n.a. o Bacteroidales f UBA932 g CAG-831 s CAG-831 sp000432775 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20008824 Microbes metabolize substances PMDBM2008543 n.a. o Bacteroidales f UBA932 g CAG-831 s CAG-831 sp000432775 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008825 Microbes metabolize substances PMDBM2008543 n.a. o Bacteroidales f UBA932 g CAG-831 s CAG-831 sp000432775 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008826 Microbes metabolize substances PMDBM2008543 n.a. o Bacteroidales f UBA932 g CAG-831 s CAG-831 sp000432775 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008827 Microbes metabolize substances PMDBM2008543 n.a. o Bacteroidales f UBA932 g CAG-831 s CAG-831 sp000432775 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008828 Microbes metabolize substances PMDBM2008543 n.a. o Bacteroidales f UBA932 g CAG-831 s CAG-831 sp000432775 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008829 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008830 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008831 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008832 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008834 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008836 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008837 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008838 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008839 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008840 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008841 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008843 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20008846 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20008847 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20008848 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008849 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008852 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20008855 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008856 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008859 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008860 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008861 Microbes metabolize substances PMDBM2008544 n.a. o Oscillospirales f CAG-272 g CAG-841 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008862 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008863 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008864 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008865 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008867 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008869 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008870 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008871 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008872 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008873 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008874 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008876 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20008879 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20008880 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20008881 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008884 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20008887 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008888 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008891 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008892 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008893 Microbes metabolize substances PMDBM2008545 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp000437375 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008894 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008895 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008896 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008897 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008899 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008901 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008902 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008903 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008904 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008905 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008906 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008908 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20008911 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20008912 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20008913 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008914 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008917 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20008920 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008921 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008924 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008925 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008926 Microbes metabolize substances PMDBM2008546 n.a. o Oscillospirales f CAG-272 g CAG-841 s CAG-841 sp002479075 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008927 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008928 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20008929 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008930 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008931 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008933 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008935 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008936 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008937 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008938 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008939 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20008940 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008942 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20008945 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20008946 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20008947 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20008948 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008949 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008952 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20008955 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008956 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008959 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008960 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008961 Microbes metabolize substances PMDBM2008547 n.a. f Muribaculaceae g CAG-873 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008962 Microbes metabolize substances PMDBM2008548 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp001701165 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008963 Microbes metabolize substances PMDBM2008548 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp001701165 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008964 Microbes metabolize substances PMDBM2008548 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp001701165 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008965 Microbes metabolize substances PMDBM2008548 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp001701165 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008966 Microbes metabolize substances PMDBM2008548 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp001701165 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008967 Microbes metabolize substances PMDBM2008549 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp002493945 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20008968 Microbes metabolize substances PMDBM2008549 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp002493945 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20008969 Microbes metabolize substances PMDBM2008549 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp002493945 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20008970 Microbes metabolize substances PMDBM2008549 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp002493945 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008972 Microbes metabolize substances PMDBM2008549 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp002493945 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20008974 Microbes metabolize substances PMDBM2008549 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp002493945 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008975 Microbes metabolize substances PMDBM2008549 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp002493945 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008976 Microbes metabolize substances PMDBM2008549 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp002493945 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20008977 Microbes metabolize substances PMDBM2008549 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp002493945 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20008980 Microbes metabolize substances PMDBM2008549 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp002493945 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20008981 Microbes metabolize substances PMDBM2008549 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp002493945 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008982 Microbes metabolize substances PMDBM2008549 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp002493945 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008983 Microbes metabolize substances PMDBM2008549 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp002493945 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20008985 Microbes metabolize substances PMDBM2008549 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp002493945 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008986 Microbes metabolize substances PMDBM2008549 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp002493945 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008987 Microbes metabolize substances PMDBM2008549 n.a. f Muribaculaceae g CAG-873 s CAG-873 sp002493945 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008988 Microbes metabolize substances PMDBM2008550 n.a. c Bacilli o RF39 f CAG-611 g CAG-877 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20008989 Microbes metabolize substances PMDBM2008550 n.a. c Bacilli o RF39 f CAG-611 g CAG-877 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20008990 Microbes metabolize substances PMDBM2008550 n.a. c Bacilli o RF39 f CAG-611 g CAG-877 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008991 Microbes metabolize substances PMDBM2008550 n.a. c Bacilli o RF39 f CAG-611 g CAG-877 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008992 Microbes metabolize substances PMDBM2008550 n.a. c Bacilli o RF39 f CAG-611 g CAG-877 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008993 Microbes metabolize substances PMDBM2008551 n.a. c Bacilli o RF39 f CAG-611 g CAG-877 s CAG-877 sp000433455 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20008994 Microbes metabolize substances PMDBM2008551 n.a. c Bacilli o RF39 f CAG-611 g CAG-877 s CAG-877 sp000433455 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20008995 Microbes metabolize substances PMDBM2008551 n.a. c Bacilli o RF39 f CAG-611 g CAG-877 s CAG-877 sp000433455 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008996 Microbes metabolize substances PMDBM2008551 n.a. c Bacilli o RF39 f CAG-611 g CAG-877 s CAG-877 sp000433455 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008997 Microbes metabolize substances PMDBM2008552 n.a. c Bacilli o RF39 f CAG-822 g CAG-878 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008998 Microbes metabolize substances PMDBM2008552 n.a. c Bacilli o RF39 f CAG-822 g CAG-878 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20008999 Microbes metabolize substances PMDBM2008553 n.a. c Bacilli o RF39 f CAG-822 g CAG-878 s CAG-878 sp000432255 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009000 Microbes metabolize substances PMDBM2008553 n.a. c Bacilli o RF39 f CAG-822 g CAG-878 s CAG-878 sp000432255 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009001 Microbes metabolize substances PMDBM2008553 n.a. c Bacilli o RF39 f CAG-822 g CAG-878 s CAG-878 sp000432255 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009002 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009003 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009004 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009005 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009007 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009009 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009010 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009011 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009012 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009013 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009014 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009016 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20009019 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20009020 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20009021 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009022 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009025 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20009028 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009029 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009032 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009033 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009034 Microbes metabolize substances PMDBM2008554 n.a. f Lachnospiraceae g CAG-882 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009035 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009036 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009037 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009038 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009040 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009042 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009043 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009044 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009045 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009046 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009047 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009049 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20009052 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20009053 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20009054 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009055 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009058 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20009061 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009062 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009065 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009066 Microbes metabolize substances PMDBM2008555 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp000435595 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009067 Microbes metabolize substances PMDBM2008556 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009068 Microbes metabolize substances PMDBM2008556 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009069 Microbes metabolize substances PMDBM2008556 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009070 Microbes metabolize substances PMDBM2008556 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009071 Microbes metabolize substances PMDBM2008556 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009072 Microbes metabolize substances PMDBM2008556 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009073 Microbes metabolize substances PMDBM2008556 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009076 Microbes metabolize substances PMDBM2008556 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009077 Microbes metabolize substances PMDBM2008556 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009078 Microbes metabolize substances PMDBM2008556 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009079 Microbes metabolize substances PMDBM2008556 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009080 Microbes metabolize substances PMDBM2008556 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009081 Microbes metabolize substances PMDBM2008556 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009082 Microbes metabolize substances PMDBM2008556 n.a. f Lachnospiraceae g CAG-882 s CAG-882 sp003486385 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009083 Microbes metabolize substances PMDBM2008557 n.a. c Bacilli o RF39 f CAG-822 g CAG-884 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20009084 Microbes metabolize substances PMDBM2008557 n.a. c Bacilli o RF39 f CAG-822 g CAG-884 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009085 Microbes metabolize substances PMDBM2008557 n.a. c Bacilli o RF39 f CAG-822 g CAG-884 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009086 Microbes metabolize substances PMDBM2008557 n.a. c Bacilli o RF39 f CAG-822 g CAG-884 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009087 Microbes metabolize substances PMDBM2008558 n.a. c Bacilli o RF39 f CAG-822 g CAG-884 s CAG-884 sp000433875 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20009088 Microbes metabolize substances PMDBM2008558 n.a. c Bacilli o RF39 f CAG-822 g CAG-884 s CAG-884 sp000433875 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009089 Microbes metabolize substances PMDBM2008558 n.a. c Bacilli o RF39 f CAG-822 g CAG-884 s CAG-884 sp000433875 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009090 Microbes metabolize substances PMDBM2008558 n.a. c Bacilli o RF39 f CAG-822 g CAG-884 s CAG-884 sp000433875 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009094 Microbes metabolize substances PMDBM2008559 n.a. c Clostridia o 4C28d-15 f CAG-917 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009096 Microbes metabolize substances PMDBM2008559 n.a. c Clostridia o 4C28d-15 f CAG-917 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009098 Microbes metabolize substances PMDBM2008559 n.a. c Clostridia o 4C28d-15 f CAG-917 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009100 Microbes metabolize substances PMDBM2008559 n.a. c Clostridia o 4C28d-15 f CAG-917 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009102 Microbes metabolize substances PMDBM2008559 n.a. c Clostridia o 4C28d-15 f CAG-917 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009104 Microbes metabolize substances PMDBM2008559 n.a. c Clostridia o 4C28d-15 f CAG-917 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009106 Microbes metabolize substances PMDBM2008559 n.a. c Clostridia o 4C28d-15 f CAG-917 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009112 Microbes metabolize substances PMDBM2008559 n.a. c Clostridia o 4C28d-15 f CAG-917 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009114 Microbes metabolize substances PMDBM2008559 n.a. c Clostridia o 4C28d-15 f CAG-917 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009116 Microbes metabolize substances PMDBM2008559 n.a. c Clostridia o 4C28d-15 f CAG-917 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009118 Microbes metabolize substances PMDBM2008559 n.a. c Clostridia o 4C28d-15 f CAG-917 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009120 Microbes metabolize substances PMDBM2008559 n.a. c Clostridia o 4C28d-15 f CAG-917 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009122 Microbes metabolize substances PMDBM2008559 n.a. c Clostridia o 4C28d-15 f CAG-917 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009124 Microbes metabolize substances PMDBM2008559 n.a. c Clostridia o 4C28d-15 f CAG-917 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009126 Microbes metabolize substances PMDBM2008560 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009127 Microbes metabolize substances PMDBM2008560 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009128 Microbes metabolize substances PMDBM2008560 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009129 Microbes metabolize substances PMDBM2008560 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009130 Microbes metabolize substances PMDBM2008560 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009131 Microbes metabolize substances PMDBM2008560 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009132 Microbes metabolize substances PMDBM2008560 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009135 Microbes metabolize substances PMDBM2008560 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009136 Microbes metabolize substances PMDBM2008560 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009137 Microbes metabolize substances PMDBM2008560 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009138 Microbes metabolize substances PMDBM2008560 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009139 Microbes metabolize substances PMDBM2008560 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009140 Microbes metabolize substances PMDBM2008560 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009141 Microbes metabolize substances PMDBM2008560 n.a. c Clostridia o 4C28d-15 f CAG-917 g CAG-917 s CAG-917 sp000437555 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009142 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009143 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009144 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009145 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009147 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009149 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009150 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009151 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009152 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009153 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009154 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009156 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20009159 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20009160 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20009161 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009162 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009165 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20009168 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009169 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009172 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009173 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009174 Microbes metabolize substances PMDBM2008561 n.a. f Lachnospiraceae g CAG-95 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009175 Microbes metabolize substances PMDBM2008562 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009176 Microbes metabolize substances PMDBM2008562 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009177 Microbes metabolize substances PMDBM2008562 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009178 Microbes metabolize substances PMDBM2008562 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009179 Microbes metabolize substances PMDBM2008562 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009180 Microbes metabolize substances PMDBM2008562 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009181 Microbes metabolize substances PMDBM2008562 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009184 Microbes metabolize substances PMDBM2008562 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009185 Microbes metabolize substances PMDBM2008562 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009186 Microbes metabolize substances PMDBM2008562 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009187 Microbes metabolize substances PMDBM2008562 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009188 Microbes metabolize substances PMDBM2008562 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009189 Microbes metabolize substances PMDBM2008562 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009190 Microbes metabolize substances PMDBM2008562 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000436115 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009191 Microbes metabolize substances PMDBM2008563 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009192 Microbes metabolize substances PMDBM2008563 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009193 Microbes metabolize substances PMDBM2008563 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009194 Microbes metabolize substances PMDBM2008563 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009195 Microbes metabolize substances PMDBM2008563 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009196 Microbes metabolize substances PMDBM2008563 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009197 Microbes metabolize substances PMDBM2008563 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009200 Microbes metabolize substances PMDBM2008563 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009201 Microbes metabolize substances PMDBM2008563 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009202 Microbes metabolize substances PMDBM2008563 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009203 Microbes metabolize substances PMDBM2008563 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009204 Microbes metabolize substances PMDBM2008563 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009205 Microbes metabolize substances PMDBM2008563 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009206 Microbes metabolize substances PMDBM2008563 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009207 Microbes metabolize substances PMDBM2008563 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp000438155 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009208 Microbes metabolize substances PMDBM2008564 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009209 Microbes metabolize substances PMDBM2008564 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009210 Microbes metabolize substances PMDBM2008564 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009211 Microbes metabolize substances PMDBM2008564 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009212 Microbes metabolize substances PMDBM2008564 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009213 Microbes metabolize substances PMDBM2008564 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009214 Microbes metabolize substances PMDBM2008564 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009217 Microbes metabolize substances PMDBM2008564 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009218 Microbes metabolize substances PMDBM2008564 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009219 Microbes metabolize substances PMDBM2008564 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009220 Microbes metabolize substances PMDBM2008564 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009221 Microbes metabolize substances PMDBM2008564 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009222 Microbes metabolize substances PMDBM2008564 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009223 Microbes metabolize substances PMDBM2008564 n.a. f Lachnospiraceae g CAG-95 s CAG-95 sp900066375 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009224 Microbes metabolize substances PMDBM2008565 n.a. f Acutalibacteraceae g CAG-964 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009225 Microbes metabolize substances PMDBM2008565 n.a. f Acutalibacteraceae g CAG-964 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009226 Microbes metabolize substances PMDBM2008565 n.a. f Acutalibacteraceae g CAG-964 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009227 Microbes metabolize substances PMDBM2008565 n.a. f Acutalibacteraceae g CAG-964 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009228 Microbes metabolize substances PMDBM2008565 n.a. f Acutalibacteraceae g CAG-964 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009229 Microbes metabolize substances PMDBM2008565 n.a. f Acutalibacteraceae g CAG-964 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009230 Microbes metabolize substances PMDBM2008565 n.a. f Acutalibacteraceae g CAG-964 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009233 Microbes metabolize substances PMDBM2008565 n.a. f Acutalibacteraceae g CAG-964 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009234 Microbes metabolize substances PMDBM2008565 n.a. f Acutalibacteraceae g CAG-964 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009235 Microbes metabolize substances PMDBM2008565 n.a. f Acutalibacteraceae g CAG-964 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009236 Microbes metabolize substances PMDBM2008565 n.a. f Acutalibacteraceae g CAG-964 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009237 Microbes metabolize substances PMDBM2008565 n.a. f Acutalibacteraceae g CAG-964 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009238 Microbes metabolize substances PMDBM2008565 n.a. f Acutalibacteraceae g CAG-964 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009239 Microbes metabolize substances PMDBM2008565 n.a. f Acutalibacteraceae g CAG-964 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009240 Microbes metabolize substances PMDBM2008566 n.a. f Acutalibacteraceae g CAG-964 s CAG-964 sp000435335 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009241 Microbes metabolize substances PMDBM2008566 n.a. f Acutalibacteraceae g CAG-964 s CAG-964 sp000435335 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009242 Microbes metabolize substances PMDBM2008566 n.a. f Acutalibacteraceae g CAG-964 s CAG-964 sp000435335 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009243 Microbes metabolize substances PMDBM2008566 n.a. f Acutalibacteraceae g CAG-964 s CAG-964 sp000435335 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009244 Microbes metabolize substances PMDBM2008567 n.a. f Acutalibacteraceae g CAG-964 A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009245 Microbes metabolize substances PMDBM2008567 n.a. f Acutalibacteraceae g CAG-964 A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009246 Microbes metabolize substances PMDBM2008567 n.a. f Acutalibacteraceae g CAG-964 A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009247 Microbes metabolize substances PMDBM2008567 n.a. f Acutalibacteraceae g CAG-964 A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009248 Microbes metabolize substances PMDBM2008567 n.a. f Acutalibacteraceae g CAG-964 A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009249 Microbes metabolize substances PMDBM2008568 n.a. c Alphaproteobacteria o RF32 f CAG-977 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009251 Microbes metabolize substances PMDBM2008568 n.a. c Alphaproteobacteria o RF32 f CAG-977 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009253 Microbes metabolize substances PMDBM2008568 n.a. c Alphaproteobacteria o RF32 f CAG-977 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009255 Microbes metabolize substances PMDBM2008568 n.a. c Alphaproteobacteria o RF32 f CAG-977 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009257 Microbes metabolize substances PMDBM2008568 n.a. c Alphaproteobacteria o RF32 f CAG-977 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009259 Microbes metabolize substances PMDBM2008568 n.a. c Alphaproteobacteria o RF32 f CAG-977 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009261 Microbes metabolize substances PMDBM2008568 n.a. c Alphaproteobacteria o RF32 f CAG-977 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009267 Microbes metabolize substances PMDBM2008568 n.a. c Alphaproteobacteria o RF32 f CAG-977 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009269 Microbes metabolize substances PMDBM2008568 n.a. c Alphaproteobacteria o RF32 f CAG-977 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009271 Microbes metabolize substances PMDBM2008568 n.a. c Alphaproteobacteria o RF32 f CAG-977 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009273 Microbes metabolize substances PMDBM2008568 n.a. c Alphaproteobacteria o RF32 f CAG-977 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009275 Microbes metabolize substances PMDBM2008568 n.a. c Alphaproteobacteria o RF32 f CAG-977 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009277 Microbes metabolize substances PMDBM2008568 n.a. c Alphaproteobacteria o RF32 f CAG-977 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009279 Microbes metabolize substances PMDBM2008568 n.a. c Alphaproteobacteria o RF32 f CAG-977 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009281 Microbes metabolize substances PMDBM2008568 n.a. c Alphaproteobacteria o RF32 f CAG-977 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009283 Microbes metabolize substances PMDBM2008569 n.a. c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009284 Microbes metabolize substances PMDBM2008569 n.a. c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009285 Microbes metabolize substances PMDBM2008569 n.a. c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009286 Microbes metabolize substances PMDBM2008569 n.a. c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009287 Microbes metabolize substances PMDBM2008569 n.a. c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009288 Microbes metabolize substances PMDBM2008569 n.a. c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009289 Microbes metabolize substances PMDBM2008569 n.a. c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009292 Microbes metabolize substances PMDBM2008569 n.a. c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009293 Microbes metabolize substances PMDBM2008569 n.a. c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009294 Microbes metabolize substances PMDBM2008569 n.a. c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009295 Microbes metabolize substances PMDBM2008569 n.a. c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009296 Microbes metabolize substances PMDBM2008569 n.a. c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009297 Microbes metabolize substances PMDBM2008569 n.a. c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009298 Microbes metabolize substances PMDBM2008569 n.a. c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009299 Microbes metabolize substances PMDBM2008569 n.a. c Alphaproteobacteria o RF32 f CAG-977 g CAG-977 s CAG-977 sp000434295 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009300 Microbes metabolize substances PMDBM2008570 n.a. c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009301 Microbes metabolize substances PMDBM2008570 n.a. c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009302 Microbes metabolize substances PMDBM2008570 n.a. c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009303 Microbes metabolize substances PMDBM2008570 n.a. c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009304 Microbes metabolize substances PMDBM2008570 n.a. c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009305 Microbes metabolize substances PMDBM2008570 n.a. c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009306 Microbes metabolize substances PMDBM2008570 n.a. c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009309 Microbes metabolize substances PMDBM2008570 n.a. c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009310 Microbes metabolize substances PMDBM2008570 n.a. c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009311 Microbes metabolize substances PMDBM2008570 n.a. c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009312 Microbes metabolize substances PMDBM2008570 n.a. c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009313 Microbes metabolize substances PMDBM2008570 n.a. c Bacilli o RF39 f CAG-611 g CAG-988 s CAG-988 sp003149915 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009314 Microbes metabolize substances PMDBM2020480 196 Campylobacter fetus A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009315 Microbes metabolize substances PMDBM2020481 198 Campylobacter hyointestinalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009316 Microbes metabolize substances PMDBM2020478 199 Campylobacter A concisus B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009317 Microbes metabolize substances PMDBM2020478 199 Campylobacter A concisus E PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009318 Microbes metabolize substances PMDBM2020478 199 Campylobacter A concisus F PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20009319 Microbes metabolize substances PMDBM2020478 199 Campylobacter A concisus F PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009320 Microbes metabolize substances PMDBM2020478 199 Campylobacter A concisus G PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009321 Microbes metabolize substances PMDBM2020478 199 Campylobacter A concisus I PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009322 Microbes metabolize substances PMDBM2020478 199 Campylobacter A concisus K PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009323 Microbes metabolize substances PMDBM2020478 199 Campylobacter A concisus L PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009324 Microbes metabolize substances PMDBM2020478 199 Campylobacter A concisus P PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009325 Microbes metabolize substances PMDBM2020478 199 Campylobacter A concisus Q PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009326 Microbes metabolize substances PMDBM2020478 199 Campylobacter A concisus R PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009327 Microbes metabolize substances PMDBM2020478 199 Campylobacter A concisus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009328 Microbes metabolize substances PMDBM2020478 199 Campylobacter A concisus W PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009329 Microbes metabolize substances PMDBM2020479 200 Campylobacter A curvus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009330 Microbes metabolize substances PMDBM2008586 n.a. Campylobacter B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009331 Microbes metabolize substances PMDBM2020490 827 Campylobacter B ureolyticus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009332 Microbes metabolize substances PMDBM2008588 n.a. Campylobacter D PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009333 Microbes metabolize substances PMDBM2008588 n.a. Campylobacter D PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009334 Microbes metabolize substances PMDBM2008588 n.a. Campylobacter D PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009335 Microbes metabolize substances PMDBM2008588 n.a. Campylobacter D PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009336 Microbes metabolize substances PMDBM2020477 195 Campylobacter D coli PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009337 Microbes metabolize substances PMDBM2020477 195 Campylobacter D coli A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009338 Microbes metabolize substances PMDBM2020477 195 Campylobacter D coli B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009339 Microbes metabolize substances PMDBM2020482 197 Campylobacter D jejuni PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009340 Microbes metabolize substances PMDBM2020497 1018 Capnocytophaga ochracea PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009341 Microbes metabolize substances PMDBM2020497 1018 Capnocytophaga ochracea PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009342 Microbes metabolize substances PMDBM2020497 1018 Capnocytophaga ochracea PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009343 Microbes metabolize substances PMDBM2020497 1018 Capnocytophaga ochracea PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009344 Microbes metabolize substances PMDBM2020497 1018 Capnocytophaga ochracea PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009345 Microbes metabolize substances PMDBM2020497 1018 Capnocytophaga ochracea PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009346 Microbes metabolize substances PMDBM2020497 1018 Capnocytophaga ochracea PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009349 Microbes metabolize substances PMDBM2020497 1018 Capnocytophaga ochracea PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009350 Microbes metabolize substances PMDBM2020497 1018 Capnocytophaga ochracea PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009351 Microbes metabolize substances PMDBM2020497 1018 Capnocytophaga ochracea PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009352 Microbes metabolize substances PMDBM2020497 1018 Capnocytophaga ochracea PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009353 Microbes metabolize substances PMDBM2020497 1018 Capnocytophaga ochracea PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009354 Microbes metabolize substances PMDBM2020497 1018 Capnocytophaga ochracea PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009355 Microbes metabolize substances PMDBM2020497 1018 Capnocytophaga ochracea PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009356 Microbes metabolize substances PMDBM2020497 1018 Capnocytophaga ochracea PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009357 Microbes metabolize substances PMDBM2020508 194702 Cardiobacterium valvarum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009358 Microbes metabolize substances PMDBM2020508 194702 Cardiobacterium valvarum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009359 Microbes metabolize substances PMDBM2020508 194702 Cardiobacterium valvarum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009360 Microbes metabolize substances PMDBM2020508 194702 Cardiobacterium valvarum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009361 Microbes metabolize substances PMDBM2020508 194702 Cardiobacterium valvarum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009362 Microbes metabolize substances PMDBM2020508 194702 Cardiobacterium valvarum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009363 Microbes metabolize substances PMDBM2020508 194702 Cardiobacterium valvarum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009366 Microbes metabolize substances PMDBM2020508 194702 Cardiobacterium valvarum PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20009367 Microbes metabolize substances PMDBM2020508 194702 Cardiobacterium valvarum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009368 Microbes metabolize substances PMDBM2020508 194702 Cardiobacterium valvarum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009369 Microbes metabolize substances PMDBM2020508 194702 Cardiobacterium valvarum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009370 Microbes metabolize substances PMDBM2020508 194702 Cardiobacterium valvarum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009371 Microbes metabolize substances PMDBM2020508 194702 Cardiobacterium valvarum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009372 Microbes metabolize substances PMDBM2021466 270498 Catabacter hongkongensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009373 Microbes metabolize substances PMDBM2021466 270498 Catabacter hongkongensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009374 Microbes metabolize substances PMDBM2021466 270498 Catabacter hongkongensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009375 Microbes metabolize substances PMDBM2021466 270498 Catabacter hongkongensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009376 Microbes metabolize substances PMDBM2021466 270498 Catabacter hongkongensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009377 Microbes metabolize substances PMDBM2021466 270498 Catabacter hongkongensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009378 Microbes metabolize substances PMDBM2021466 270498 Catabacter hongkongensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009381 Microbes metabolize substances PMDBM2021466 270498 Catabacter hongkongensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009382 Microbes metabolize substances PMDBM2021466 270498 Catabacter hongkongensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009383 Microbes metabolize substances PMDBM2021466 270498 Catabacter hongkongensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009384 Microbes metabolize substances PMDBM2021466 270498 Catabacter hongkongensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009385 Microbes metabolize substances PMDBM2021466 270498 Catabacter hongkongensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009386 Microbes metabolize substances PMDBM2021466 270498 Catabacter hongkongensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009387 Microbes metabolize substances PMDBM2021466 270498 Catabacter hongkongensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009388 Microbes metabolize substances PMDBM2008596 135858 Catenibacterium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009389 Microbes metabolize substances PMDBM2008596 135858 Catenibacterium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009390 Microbes metabolize substances PMDBM2008596 135858 Catenibacterium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009391 Microbes metabolize substances PMDBM2008596 135858 Catenibacterium PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009393 Microbes metabolize substances PMDBM2008596 135858 Catenibacterium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009395 Microbes metabolize substances PMDBM2008596 135858 Catenibacterium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009396 Microbes metabolize substances PMDBM2008596 135858 Catenibacterium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009397 Microbes metabolize substances PMDBM2008596 135858 Catenibacterium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009398 Microbes metabolize substances PMDBM2008596 135858 Catenibacterium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009401 Microbes metabolize substances PMDBM2008596 135858 Catenibacterium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009402 Microbes metabolize substances PMDBM2008596 135858 Catenibacterium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009403 Microbes metabolize substances PMDBM2008596 135858 Catenibacterium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009404 Microbes metabolize substances PMDBM2008596 135858 Catenibacterium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009406 Microbes metabolize substances PMDBM2008596 135858 Catenibacterium PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009407 Microbes metabolize substances PMDBM2008596 135858 Catenibacterium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009408 Microbes metabolize substances PMDBM2008596 135858 Catenibacterium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009409 Microbes metabolize substances PMDBM2020510 100886 Catenibacterium mitsuokai PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009410 Microbes metabolize substances PMDBM2020510 100886 Catenibacterium mitsuokai PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009411 Microbes metabolize substances PMDBM2020510 100886 Catenibacterium mitsuokai PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009412 Microbes metabolize substances PMDBM2020510 100886 Catenibacterium mitsuokai PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009413 Microbes metabolize substances PMDBM2020510 100886 Catenibacterium mitsuokai PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009414 Microbes metabolize substances PMDBM2020510 100886 Catenibacterium mitsuokai PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009415 Microbes metabolize substances PMDBM2020510 100886 Catenibacterium mitsuokai PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009418 Microbes metabolize substances PMDBM2020510 100886 Catenibacterium mitsuokai PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009419 Microbes metabolize substances PMDBM2020510 100886 Catenibacterium mitsuokai PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009420 Microbes metabolize substances PMDBM2020510 100886 Catenibacterium mitsuokai PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009421 Microbes metabolize substances PMDBM2020510 100886 Catenibacterium mitsuokai PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009422 Microbes metabolize substances PMDBM2020510 100886 Catenibacterium mitsuokai PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009423 Microbes metabolize substances PMDBM2020510 100886 Catenibacterium mitsuokai PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009424 Microbes metabolize substances PMDBM2021467 2049022 Catenibacterium sp000437715 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009425 Microbes metabolize substances PMDBM2021467 2049022 Catenibacterium sp000437715 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009426 Microbes metabolize substances PMDBM2021467 2049022 Catenibacterium sp000437715 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009427 Microbes metabolize substances PMDBM2021467 2049022 Catenibacterium sp000437715 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009428 Microbes metabolize substances PMDBM2021467 2049022 Catenibacterium sp000437715 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009429 Microbes metabolize substances PMDBM2021467 2049022 Catenibacterium sp000437715 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009430 Microbes metabolize substances PMDBM2021467 2049022 Catenibacterium sp000437715 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009433 Microbes metabolize substances PMDBM2021467 2049022 Catenibacterium sp000437715 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009434 Microbes metabolize substances PMDBM2021467 2049022 Catenibacterium sp000437715 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009435 Microbes metabolize substances PMDBM2021467 2049022 Catenibacterium sp000437715 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009436 Microbes metabolize substances PMDBM2021467 2049022 Catenibacterium sp000437715 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009437 Microbes metabolize substances PMDBM2021467 2049022 Catenibacterium sp000437715 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009438 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009439 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20009440 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009441 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009442 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009444 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009446 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009447 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009448 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009449 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009450 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009451 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009453 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20009456 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20009457 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20009458 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009461 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20009464 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009465 Microbes metabolize substances PMDBM2008599 75 Caulobacter PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009468 Microbes metabolize substances PMDBM2008600 3031419 Bacteriovoracia PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009469 Microbes metabolize substances PMDBM2008600 3031419 Bacteriovoracia PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20009470 Microbes metabolize substances PMDBM2008600 3031419 Bacteriovoracia PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009471 Microbes metabolize substances PMDBM2008600 3031419 Bacteriovoracia PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009472 Microbes metabolize substances PMDBM2008600 3031419 Bacteriovoracia PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009473 Microbes metabolize substances PMDBM2008600 3031419 Bacteriovoracia PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009474 Microbes metabolize substances PMDBM2008600 3031419 Bacteriovoracia PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009475 Microbes metabolize substances PMDBM2008600 3031419 Bacteriovoracia PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009478 Microbes metabolize substances PMDBM2008600 3031419 Bacteriovoracia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009479 Microbes metabolize substances PMDBM2008600 3031419 Bacteriovoracia PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20009480 Microbes metabolize substances PMDBM2008600 3031419 Bacteriovoracia PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009481 Microbes metabolize substances PMDBM2008600 3031419 Bacteriovoracia PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009482 Microbes metabolize substances PMDBM2008600 3031419 Bacteriovoracia PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009483 Microbes metabolize substances PMDBM2008600 3031419 Bacteriovoracia PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009484 Microbes metabolize substances PMDBM2008600 3031419 Bacteriovoracia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009485 Microbes metabolize substances PMDBM2008600 3031419 Bacteriovoracia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009486 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009487 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20009488 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009489 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009490 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009491 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009492 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009493 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009494 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009495 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009497 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20009500 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20009501 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20009502 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009503 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009506 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20009509 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20009510 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009511 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009512 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009514 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009515 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009516 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009517 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20009518 Microbes metabolize substances PMDBM2020827 158484 Cedecea davisae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009519 Microbes metabolize substances PMDBM2020827 158484 Cedecea davisae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009520 Microbes metabolize substances PMDBM2020827 158484 Cedecea davisae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009521 Microbes metabolize substances PMDBM2020827 158484 Cedecea davisae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009522 Microbes metabolize substances PMDBM2020827 158484 Cedecea davisae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009523 Microbes metabolize substances PMDBM2020827 158484 Cedecea davisae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009524 Microbes metabolize substances PMDBM2020827 158484 Cedecea davisae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009527 Microbes metabolize substances PMDBM2020827 158484 Cedecea davisae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009528 Microbes metabolize substances PMDBM2020827 158484 Cedecea davisae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009529 Microbes metabolize substances PMDBM2020827 158484 Cedecea davisae PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20009530 Microbes metabolize substances PMDBM2020827 158484 Cedecea davisae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009531 Microbes metabolize substances PMDBM2020827 158484 Cedecea davisae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009532 Microbes metabolize substances PMDBM2020827 158484 Cedecea davisae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009533 Microbes metabolize substances PMDBM2020827 158484 Cedecea davisae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009534 Microbes metabolize substances PMDBM2020827 158484 Cedecea davisae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009535 Microbes metabolize substances PMDBM2020827 158484 Cedecea davisae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009536 Microbes metabolize substances PMDBM2020512 1465811 Cellulomonas massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009537 Microbes metabolize substances PMDBM2020512 1465811 Cellulomonas massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009538 Microbes metabolize substances PMDBM2020512 1465811 Cellulomonas massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009539 Microbes metabolize substances PMDBM2020512 1465811 Cellulomonas massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009540 Microbes metabolize substances PMDBM2020512 1465811 Cellulomonas massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009541 Microbes metabolize substances PMDBM2020512 1465811 Cellulomonas massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009542 Microbes metabolize substances PMDBM2020512 1465811 Cellulomonas massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009545 Microbes metabolize substances PMDBM2020512 1465811 Cellulomonas massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009546 Microbes metabolize substances PMDBM2020512 1465811 Cellulomonas massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009547 Microbes metabolize substances PMDBM2020512 1465811 Cellulomonas massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009548 Microbes metabolize substances PMDBM2020512 1465811 Cellulomonas massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009549 Microbes metabolize substances PMDBM2020512 1465811 Cellulomonas massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009550 Microbes metabolize substances PMDBM2020512 1465811 Cellulomonas massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009551 Microbes metabolize substances PMDBM2020512 1465811 Cellulomonas massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009552 Microbes metabolize substances PMDBM2020513 1689271 Cellulomonas timonensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009553 Microbes metabolize substances PMDBM2020513 1689271 Cellulomonas timonensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009554 Microbes metabolize substances PMDBM2020513 1689271 Cellulomonas timonensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009555 Microbes metabolize substances PMDBM2020513 1689271 Cellulomonas timonensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009556 Microbes metabolize substances PMDBM2020513 1689271 Cellulomonas timonensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009557 Microbes metabolize substances PMDBM2020513 1689271 Cellulomonas timonensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009558 Microbes metabolize substances PMDBM2020513 1689271 Cellulomonas timonensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009561 Microbes metabolize substances PMDBM2020513 1689271 Cellulomonas timonensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20009562 Microbes metabolize substances PMDBM2020513 1689271 Cellulomonas timonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009563 Microbes metabolize substances PMDBM2020513 1689271 Cellulomonas timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009564 Microbes metabolize substances PMDBM2020513 1689271 Cellulomonas timonensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009565 Microbes metabolize substances PMDBM2020513 1689271 Cellulomonas timonensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009566 Microbes metabolize substances PMDBM2020513 1689271 Cellulomonas timonensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009567 Microbes metabolize substances PMDBM2020513 1689271 Cellulomonas timonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009568 Microbes metabolize substances PMDBM2020513 1689271 Cellulomonas timonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009569 Microbes metabolize substances PMDBM2008604 698776 Cellulosilyticum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009570 Microbes metabolize substances PMDBM2008604 698776 Cellulosilyticum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009571 Microbes metabolize substances PMDBM2008604 698776 Cellulosilyticum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009572 Microbes metabolize substances PMDBM2008604 698776 Cellulosilyticum PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20009573 Microbes metabolize substances PMDBM2008604 698776 Cellulosilyticum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009574 Microbes metabolize substances PMDBM2008604 698776 Cellulosilyticum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009575 Microbes metabolize substances PMDBM2008604 698776 Cellulosilyticum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009576 Microbes metabolize substances PMDBM2008604 698776 Cellulosilyticum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009579 Microbes metabolize substances PMDBM2008604 698776 Cellulosilyticum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009580 Microbes metabolize substances PMDBM2008604 698776 Cellulosilyticum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009581 Microbes metabolize substances PMDBM2008604 698776 Cellulosilyticum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009582 Microbes metabolize substances PMDBM2008604 698776 Cellulosilyticum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009583 Microbes metabolize substances PMDBM2008604 698776 Cellulosilyticum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009584 Microbes metabolize substances PMDBM2008604 698776 Cellulosilyticum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009585 Microbes metabolize substances PMDBM2008604 698776 Cellulosilyticum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009586 Microbes metabolize substances PMDBM2008605 n.a. Centipeda artemidis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20009587 Microbes metabolize substances PMDBM2008605 n.a. Centipeda artemidis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009588 Microbes metabolize substances PMDBM2008605 n.a. Centipeda artemidis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009589 Microbes metabolize substances PMDBM2008605 n.a. Centipeda artemidis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009590 Microbes metabolize substances PMDBM2008605 n.a. Centipeda artemidis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009591 Microbes metabolize substances PMDBM2008606 n.a. Cetobacterium A PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20009592 Microbes metabolize substances PMDBM2008606 n.a. Cetobacterium A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009593 Microbes metabolize substances PMDBM2008606 n.a. Cetobacterium A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009594 Microbes metabolize substances PMDBM2008606 n.a. Cetobacterium A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009595 Microbes metabolize substances PMDBM2008606 n.a. Cetobacterium A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009596 Microbes metabolize substances PMDBM2020092 188913 Cetobacterium A somerae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009597 Microbes metabolize substances PMDBM2020092 188913 Cetobacterium A somerae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20009598 Microbes metabolize substances PMDBM2020092 188913 Cetobacterium A somerae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009599 Microbes metabolize substances PMDBM2020092 188913 Cetobacterium A somerae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009600 Microbes metabolize substances PMDBM2020092 188913 Cetobacterium A somerae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009601 Microbes metabolize substances PMDBM2020092 188913 Cetobacterium A somerae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009602 Microbes metabolize substances PMDBM2020092 188913 Cetobacterium A somerae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009603 Microbes metabolize substances PMDBM2020092 188913 Cetobacterium A somerae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009606 Microbes metabolize substances PMDBM2020092 188913 Cetobacterium A somerae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20009607 Microbes metabolize substances PMDBM2020092 188913 Cetobacterium A somerae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009608 Microbes metabolize substances PMDBM2020092 188913 Cetobacterium A somerae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009609 Microbes metabolize substances PMDBM2020092 188913 Cetobacterium A somerae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009610 Microbes metabolize substances PMDBM2020092 188913 Cetobacterium A somerae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009611 Microbes metabolize substances PMDBM2020092 188913 Cetobacterium A somerae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009612 Microbes metabolize substances PMDBM2020092 188913 Cetobacterium A somerae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009613 Microbes metabolize substances PMDBM2020092 188913 Cetobacterium A somerae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009614 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009615 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009616 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009617 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009619 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009621 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009622 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009623 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009624 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009625 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009626 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009628 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20009631 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20009632 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20009633 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009634 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009637 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20009640 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009641 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009644 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009645 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009646 Microbes metabolize substances PMDBM2008608 n.a. f Lachnospiraceae g CHH4-2 s CHH4-2 sp002899675 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009647 Microbes metabolize substances PMDBM2020519 626937 Christensenella minuta PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009648 Microbes metabolize substances PMDBM2020519 626937 Christensenella minuta PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009649 Microbes metabolize substances PMDBM2020519 626937 Christensenella minuta PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009650 Microbes metabolize substances PMDBM2020519 626937 Christensenella minuta PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009652 Microbes metabolize substances PMDBM2020519 626937 Christensenella minuta PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009654 Microbes metabolize substances PMDBM2020519 626937 Christensenella minuta PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009655 Microbes metabolize substances PMDBM2020519 626937 Christensenella minuta PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009656 Microbes metabolize substances PMDBM2020519 626937 Christensenella minuta PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009657 Microbes metabolize substances PMDBM2020519 626937 Christensenella minuta PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009660 Microbes metabolize substances PMDBM2020519 626937 Christensenella minuta PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009661 Microbes metabolize substances PMDBM2020519 626937 Christensenella minuta PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009662 Microbes metabolize substances PMDBM2020519 626937 Christensenella minuta PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009663 Microbes metabolize substances PMDBM2020519 626937 Christensenella minuta PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009665 Microbes metabolize substances PMDBM2020519 626937 Christensenella minuta PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009666 Microbes metabolize substances PMDBM2020519 626937 Christensenella minuta PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009667 Microbes metabolize substances PMDBM2021468 1935934 Christensenella sp001678845 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009668 Microbes metabolize substances PMDBM2021468 1935934 Christensenella sp001678845 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009669 Microbes metabolize substances PMDBM2021468 1935934 Christensenella sp001678845 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009670 Microbes metabolize substances PMDBM2021468 1935934 Christensenella sp001678845 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009672 Microbes metabolize substances PMDBM2021468 1935934 Christensenella sp001678845 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009674 Microbes metabolize substances PMDBM2021468 1935934 Christensenella sp001678845 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009675 Microbes metabolize substances PMDBM2021468 1935934 Christensenella sp001678845 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009676 Microbes metabolize substances PMDBM2021468 1935934 Christensenella sp001678845 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009677 Microbes metabolize substances PMDBM2021468 1935934 Christensenella sp001678845 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009680 Microbes metabolize substances PMDBM2021468 1935934 Christensenella sp001678845 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009681 Microbes metabolize substances PMDBM2021468 1935934 Christensenella sp001678845 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009682 Microbes metabolize substances PMDBM2021468 1935934 Christensenella sp001678845 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009683 Microbes metabolize substances PMDBM2021468 1935934 Christensenella sp001678845 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009685 Microbes metabolize substances PMDBM2021468 1935934 Christensenella sp001678845 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009686 Microbes metabolize substances PMDBM2021468 1935934 Christensenella sp001678845 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009687 Microbes metabolize substances PMDBM2021469 1816678 Christensenella A timonensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009688 Microbes metabolize substances PMDBM2021469 1816678 Christensenella A timonensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009689 Microbes metabolize substances PMDBM2021469 1816678 Christensenella A timonensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009690 Microbes metabolize substances PMDBM2021469 1816678 Christensenella A timonensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009691 Microbes metabolize substances PMDBM2021469 1816678 Christensenella A timonensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009692 Microbes metabolize substances PMDBM2021469 1816678 Christensenella A timonensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009693 Microbes metabolize substances PMDBM2021469 1816678 Christensenella A timonensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009696 Microbes metabolize substances PMDBM2021469 1816678 Christensenella A timonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009697 Microbes metabolize substances PMDBM2021469 1816678 Christensenella A timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009698 Microbes metabolize substances PMDBM2021469 1816678 Christensenella A timonensis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20009699 Microbes metabolize substances PMDBM2021469 1816678 Christensenella A timonensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009700 Microbes metabolize substances PMDBM2021469 1816678 Christensenella A timonensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009701 Microbes metabolize substances PMDBM2021469 1816678 Christensenella A timonensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009702 Microbes metabolize substances PMDBM2021469 1816678 Christensenella A timonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009703 Microbes metabolize substances PMDBM2021469 1816678 Christensenella A timonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009704 Microbes metabolize substances PMDBM131 990719 Christensenellaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009705 Microbes metabolize substances PMDBM131 990719 Christensenellaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009706 Microbes metabolize substances PMDBM131 990719 Christensenellaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009707 Microbes metabolize substances PMDBM131 990719 Christensenellaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009708 Microbes metabolize substances PMDBM131 990719 Christensenellaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009709 Microbes metabolize substances PMDBM131 990719 Christensenellaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009710 Microbes metabolize substances PMDBM131 990719 Christensenellaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009713 Microbes metabolize substances PMDBM131 990719 Christensenellaceae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20009714 Microbes metabolize substances PMDBM131 990719 Christensenellaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009715 Microbes metabolize substances PMDBM131 990719 Christensenellaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009716 Microbes metabolize substances PMDBM131 990719 Christensenellaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009717 Microbes metabolize substances PMDBM131 990719 Christensenellaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009718 Microbes metabolize substances PMDBM131 990719 Christensenellaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009719 Microbes metabolize substances PMDBM131 990719 Christensenellaceae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009720 Microbes metabolize substances PMDBM131 990719 Christensenellaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009721 Microbes metabolize substances PMDBM131 990719 Christensenellaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009722 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009723 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20009724 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009725 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009726 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009728 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009730 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009731 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009732 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009733 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009734 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009735 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009737 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20009740 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20009741 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20009742 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20009743 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009744 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009747 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20009750 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20009751 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009752 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009755 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009756 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009757 Microbes metabolize substances PMDBM2008612 3082768 Christensenellales PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009758 Microbes metabolize substances PMDBM2021470 373672 Chryseobacterium gambrini PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009759 Microbes metabolize substances PMDBM2021470 373672 Chryseobacterium gambrini PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20009760 Microbes metabolize substances PMDBM2021470 373672 Chryseobacterium gambrini PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009761 Microbes metabolize substances PMDBM2021470 373672 Chryseobacterium gambrini PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009762 Microbes metabolize substances PMDBM2021470 373672 Chryseobacterium gambrini PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009763 Microbes metabolize substances PMDBM2021470 373672 Chryseobacterium gambrini PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009764 Microbes metabolize substances PMDBM2021470 373672 Chryseobacterium gambrini PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009765 Microbes metabolize substances PMDBM2021470 373672 Chryseobacterium gambrini PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009768 Microbes metabolize substances PMDBM2021470 373672 Chryseobacterium gambrini PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009769 Microbes metabolize substances PMDBM2021470 373672 Chryseobacterium gambrini PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009770 Microbes metabolize substances PMDBM2021470 373672 Chryseobacterium gambrini PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009771 Microbes metabolize substances PMDBM2021470 373672 Chryseobacterium gambrini PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009772 Microbes metabolize substances PMDBM2021470 373672 Chryseobacterium gambrini PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009773 Microbes metabolize substances PMDBM2021470 373672 Chryseobacterium gambrini PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009774 Microbes metabolize substances PMDBM2021470 373672 Chryseobacterium gambrini PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009775 Microbes metabolize substances PMDBM2021470 373672 Chryseobacterium gambrini PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009776 Microbes metabolize substances PMDBM2021471 421530 Chryseobacterium B bovis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009777 Microbes metabolize substances PMDBM2021471 421530 Chryseobacterium B bovis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20009778 Microbes metabolize substances PMDBM2021471 421530 Chryseobacterium B bovis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009779 Microbes metabolize substances PMDBM2021471 421530 Chryseobacterium B bovis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009780 Microbes metabolize substances PMDBM2021471 421530 Chryseobacterium B bovis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009781 Microbes metabolize substances PMDBM2021471 421530 Chryseobacterium B bovis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009782 Microbes metabolize substances PMDBM2021471 421530 Chryseobacterium B bovis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009783 Microbes metabolize substances PMDBM2021471 421530 Chryseobacterium B bovis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009786 Microbes metabolize substances PMDBM2021471 421530 Chryseobacterium B bovis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20009787 Microbes metabolize substances PMDBM2021471 421530 Chryseobacterium B bovis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009788 Microbes metabolize substances PMDBM2021471 421530 Chryseobacterium B bovis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009789 Microbes metabolize substances PMDBM2021471 421530 Chryseobacterium B bovis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009790 Microbes metabolize substances PMDBM2021471 421530 Chryseobacterium B bovis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009791 Microbes metabolize substances PMDBM2021471 421530 Chryseobacterium B bovis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009792 Microbes metabolize substances PMDBM2021471 421530 Chryseobacterium B bovis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009793 Microbes metabolize substances PMDBM2021471 421530 Chryseobacterium B bovis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009794 Microbes metabolize substances PMDBM2021471 421530 Chryseobacterium B bovis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009795 Microbes metabolize substances PMDBM2021472 57706 Citrobacter braakii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009796 Microbes metabolize substances PMDBM2021472 57706 Citrobacter braakii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009797 Microbes metabolize substances PMDBM2021472 57706 Citrobacter braakii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009798 Microbes metabolize substances PMDBM2021472 57706 Citrobacter braakii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009800 Microbes metabolize substances PMDBM2021472 57706 Citrobacter braakii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009802 Microbes metabolize substances PMDBM2021472 57706 Citrobacter braakii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009803 Microbes metabolize substances PMDBM2021472 57706 Citrobacter braakii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009804 Microbes metabolize substances PMDBM2021472 57706 Citrobacter braakii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009805 Microbes metabolize substances PMDBM2021472 57706 Citrobacter braakii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009808 Microbes metabolize substances PMDBM2021472 57706 Citrobacter braakii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009809 Microbes metabolize substances PMDBM2021472 57706 Citrobacter braakii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009810 Microbes metabolize substances PMDBM2021472 57706 Citrobacter braakii PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20009811 Microbes metabolize substances PMDBM2021472 57706 Citrobacter braakii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009812 Microbes metabolize substances PMDBM2021472 57706 Citrobacter braakii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009814 Microbes metabolize substances PMDBM2021472 57706 Citrobacter braakii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009815 Microbes metabolize substances PMDBM2021472 57706 Citrobacter braakii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009816 Microbes metabolize substances PMDBM2021472 57706 Citrobacter braakii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009817 Microbes metabolize substances PMDBM2021473 1914243 Citrobacter europaeus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009818 Microbes metabolize substances PMDBM2021473 1914243 Citrobacter europaeus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009819 Microbes metabolize substances PMDBM2021473 1914243 Citrobacter europaeus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009820 Microbes metabolize substances PMDBM2021473 1914243 Citrobacter europaeus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009821 Microbes metabolize substances PMDBM2021473 1914243 Citrobacter europaeus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009822 Microbes metabolize substances PMDBM2021473 1914243 Citrobacter europaeus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009823 Microbes metabolize substances PMDBM2021473 1914243 Citrobacter europaeus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009826 Microbes metabolize substances PMDBM2021473 1914243 Citrobacter europaeus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009827 Microbes metabolize substances PMDBM2021473 1914243 Citrobacter europaeus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009828 Microbes metabolize substances PMDBM2021473 1914243 Citrobacter europaeus PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20009829 Microbes metabolize substances PMDBM2021473 1914243 Citrobacter europaeus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009830 Microbes metabolize substances PMDBM2021473 1914243 Citrobacter europaeus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009831 Microbes metabolize substances PMDBM2021473 1914243 Citrobacter europaeus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009832 Microbes metabolize substances PMDBM2021473 1914243 Citrobacter europaeus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009833 Microbes metabolize substances PMDBM2021473 1914243 Citrobacter europaeus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009834 Microbes metabolize substances PMDBM2021473 1914243 Citrobacter europaeus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009835 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009836 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009837 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009838 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009839 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009840 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009841 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009844 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20009845 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009846 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009847 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20009848 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009849 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009850 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009851 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009852 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009853 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009854 Microbes metabolize substances PMDBM2021474 1563222 Citrobacter pasteurii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009855 Microbes metabolize substances PMDBM2021474 1563222 Citrobacter pasteurii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009856 Microbes metabolize substances PMDBM2021474 1563222 Citrobacter pasteurii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009857 Microbes metabolize substances PMDBM2021474 1563222 Citrobacter pasteurii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009858 Microbes metabolize substances PMDBM2021474 1563222 Citrobacter pasteurii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009859 Microbes metabolize substances PMDBM2021474 1563222 Citrobacter pasteurii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009860 Microbes metabolize substances PMDBM2021474 1563222 Citrobacter pasteurii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009863 Microbes metabolize substances PMDBM2021474 1563222 Citrobacter pasteurii PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20009864 Microbes metabolize substances PMDBM2021474 1563222 Citrobacter pasteurii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009865 Microbes metabolize substances PMDBM2021474 1563222 Citrobacter pasteurii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009866 Microbes metabolize substances PMDBM2021474 1563222 Citrobacter pasteurii PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20009867 Microbes metabolize substances PMDBM2021474 1563222 Citrobacter pasteurii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009868 Microbes metabolize substances PMDBM2021474 1563222 Citrobacter pasteurii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009869 Microbes metabolize substances PMDBM2021474 1563222 Citrobacter pasteurii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009870 Microbes metabolize substances PMDBM2021474 1563222 Citrobacter pasteurii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009871 Microbes metabolize substances PMDBM2021474 1563222 Citrobacter pasteurii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009872 Microbes metabolize substances PMDBM2021474 1563222 Citrobacter pasteurii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009873 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009874 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009875 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009876 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009877 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009878 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009879 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009880 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009881 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009883 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20009886 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20009887 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20009888 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009889 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009892 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20009895 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20009896 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009897 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009898 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009900 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009901 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009902 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009903 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009904 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009905 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009906 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009907 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009908 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009909 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009912 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009913 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009914 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20009915 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009916 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009917 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009918 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009919 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009920 Microbes metabolize substances PMDBM2020521 1639133 Citrobacter portucalensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009921 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009922 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009923 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009924 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009925 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009926 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009927 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009928 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20009929 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009931 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20009934 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20009935 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20009936 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009937 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009940 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20009943 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20009944 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009945 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009946 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009948 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009949 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009950 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009951 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009952 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009953 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009954 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009955 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009956 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009957 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009960 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009961 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009962 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii A PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20009963 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009964 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009965 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009966 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009967 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009968 Microbes metabolize substances PMDBM2021475 67827 Citrobacter werkmanii A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009969 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009970 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20009971 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009972 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009973 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009975 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20009977 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009978 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009979 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009980 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20009983 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20009984 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20009985 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20009986 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20009987 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009988 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20009990 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20009991 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009992 Microbes metabolize substances PMDBM2008621 n.a. Citrobacter A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20009993 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20009994 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20009995 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20009996 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20009997 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009998 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20009999 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010000 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010003 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20010004 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010005 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010006 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20010007 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010008 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010009 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010010 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010011 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010012 Microbes metabolize substances PMDBM2020044 35703 Citrobacter A amalonaticus D PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010013 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010014 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20010015 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010016 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010017 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010018 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010019 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010020 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010021 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010022 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010024 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20010027 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20010028 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20010029 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20010030 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010031 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010034 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20010037 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20010038 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010039 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010040 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010042 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010043 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010044 Microbes metabolize substances PMDBM2020045 67824 Citrobacter A farmeri PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010065 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010066 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20010067 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010068 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010069 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010070 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010071 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010072 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010075 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20010076 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010077 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010078 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20010079 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010080 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010081 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010082 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010083 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010084 Microbes metabolize substances PMDBM2020093 545 Citrobacter B koseri PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010085 Microbes metabolize substances PMDBM2020527 508460 Cloacibacillus evryensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010086 Microbes metabolize substances PMDBM2020527 508460 Cloacibacillus evryensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010087 Microbes metabolize substances PMDBM2020527 508460 Cloacibacillus evryensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010088 Microbes metabolize substances PMDBM2020527 508460 Cloacibacillus evryensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010089 Microbes metabolize substances PMDBM2020527 508460 Cloacibacillus evryensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010090 Microbes metabolize substances PMDBM2020527 508460 Cloacibacillus evryensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010091 Microbes metabolize substances PMDBM2020527 508460 Cloacibacillus evryensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010094 Microbes metabolize substances PMDBM2020527 508460 Cloacibacillus evryensis PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010095 Microbes metabolize substances PMDBM2020527 508460 Cloacibacillus evryensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010096 Microbes metabolize substances PMDBM2020527 508460 Cloacibacillus evryensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010097 Microbes metabolize substances PMDBM2020527 508460 Cloacibacillus evryensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010098 Microbes metabolize substances PMDBM2020527 508460 Cloacibacillus evryensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010099 Microbes metabolize substances PMDBM2020527 508460 Cloacibacillus evryensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010100 Microbes metabolize substances PMDBM2020527 508460 Cloacibacillus evryensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010101 Microbes metabolize substances PMDBM2020527 508460 Cloacibacillus evryensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010102 Microbes metabolize substances PMDBM2021476 1197717 Cloacibacillus porcorum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010103 Microbes metabolize substances PMDBM2021476 1197717 Cloacibacillus porcorum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010104 Microbes metabolize substances PMDBM2021476 1197717 Cloacibacillus porcorum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010105 Microbes metabolize substances PMDBM2021476 1197717 Cloacibacillus porcorum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010106 Microbes metabolize substances PMDBM2021476 1197717 Cloacibacillus porcorum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010107 Microbes metabolize substances PMDBM2021476 1197717 Cloacibacillus porcorum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010108 Microbes metabolize substances PMDBM2021476 1197717 Cloacibacillus porcorum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010111 Microbes metabolize substances PMDBM2021476 1197717 Cloacibacillus porcorum PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010112 Microbes metabolize substances PMDBM2021476 1197717 Cloacibacillus porcorum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010113 Microbes metabolize substances PMDBM2021476 1197717 Cloacibacillus porcorum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010114 Microbes metabolize substances PMDBM2021476 1197717 Cloacibacillus porcorum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010115 Microbes metabolize substances PMDBM2021476 1197717 Cloacibacillus porcorum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010116 Microbes metabolize substances PMDBM2021476 1197717 Cloacibacillus porcorum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010117 Microbes metabolize substances PMDBM2021476 1197717 Cloacibacillus porcorum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010118 Microbes metabolize substances PMDBM2021476 1197717 Cloacibacillus porcorum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010119 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD2000019 Methamphetamine Therapeutic Substance psychostimulant and sympathomimetic n.a. n.a. n.a. n.a. Amphetamine, norephedrine n.a. unknown activity decreased n.a. n.a. n.a. Through demethylation, Methamphetamine formation Amphetamine, norephedrine and an unknownn metabolite n.a. PMID PMID: 36467581 PMDBI20010120 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD96 Balsalazide Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. unknown activation n.a. n.a. n.a. release 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract. n.a. PMID PMID: 36467581 PMDBI20010121 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD453 Ipsalazide Therapeutic Substance unknown n.a. n.a. n.a. n.a. n.a. n.a. unknown activation n.a. n.a. n.a. release 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract. n.a. PMID PMID: 36467581 PMDBI20010122 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD618 Olsalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. unknown activation n.a. n.a. n.a. release 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract. n.a. PMID PMID: 36467581 PMDBI20010123 Microbes metabolize substances PMDBM689 31979 Clostridiaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010124 Microbes metabolize substances PMDBM689 31979 Clostridiaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010125 Microbes metabolize substances PMDBM689 31979 Clostridiaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010126 Microbes metabolize substances PMDBM689 31979 Clostridiaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010127 Microbes metabolize substances PMDBM689 31979 Clostridiaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010128 Microbes metabolize substances PMDBM689 31979 Clostridiaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010129 Microbes metabolize substances PMDBM689 31979 Clostridiaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010132 Microbes metabolize substances PMDBM689 31979 Clostridiaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010133 Microbes metabolize substances PMDBM689 31979 Clostridiaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010134 Microbes metabolize substances PMDBM689 31979 Clostridiaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010135 Microbes metabolize substances PMDBM689 31979 Clostridiaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010136 Microbes metabolize substances PMDBM689 31979 Clostridiaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010137 Microbes metabolize substances PMDBM2020046 1496 Clostridioides difficile PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010138 Microbes metabolize substances PMDBM2020046 1496 Clostridioides difficile PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010139 Microbes metabolize substances PMDBM2020046 1496 Clostridioides difficile PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010140 Microbes metabolize substances PMDBM2020046 1496 Clostridioides difficile PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite NAPQI n.a. PMID PMID: 36467581 PMDBI20010141 Microbes metabolize substances PMDBM2020046 1496 Clostridioides difficile PMDBD52 Antibiotic Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. "Cause antibiotic-associated diarrhoea(AAD);pseudomembranous colitis(can cause death)" n.a. PMID PMID: 36467581 PMDBI20010142 Microbes metabolize substances PMDBM2020046 1496 Clostridioides difficile PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010143 Microbes metabolize substances PMDBM2020046 1496 Clostridioides difficile PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010144 Microbes metabolize substances PMDBM2020046 1496 Clostridioides difficile A PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010145 Microbes metabolize substances PMDBM2020046 1496 Clostridioides difficile A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010146 Microbes metabolize substances PMDBM2020046 1496 Clostridioides difficile A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010147 Microbes metabolize substances PMDBM2020046 1496 Clostridioides difficile A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010148 Microbes metabolize substances PMDBM2020046 1496 Clostridioides difficile A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010149 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010150 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010151 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD595 Nitrazepam Therapeutic Substance anticonvulsant and hypnotic n.a. n.a. n.a. n.a. n.a. n.a. Nitroreductase activity decreased n.a. n.a. n.a. Involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to nitroreduction n.a. PMID PMID: 36467581 PMDBI20010152 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD812 Sulfasalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Azo reductases activation n.a. n.a. n.a. prodrug activation n.a. PMID PMID: 36467581 PMDBI20010153 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010154 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010156 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010158 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010159 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010160 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010162 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010163 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010164 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. Formation of three thiazole ring-opened metabolites, namely, levametabol-I, II and III n.a. unknown activity increased n.a. n.a. n.a. Through thiazole ring opening閿涘evamisole formation of three thiazole ring-opened metabolites, namely, levametabol-I, II and III n.a. PMID PMID: 36467581 PMDBI20010165 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010168 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD2000019 Methamphetamine Therapeutic Substance psychostimulant and sympathomimetic n.a. n.a. n.a. n.a. Amphetamine, norephedrine n.a. unknown activity decreased n.a. n.a. n.a. activity decreased n.a. PMID PMID: 36467581 PMDBI20010171 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20010174 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20010175 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20010176 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010177 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010181 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20010186 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD96 Balsalazide Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. Azo reductases activation n.a. n.a. n.a. produced by intestinal bacteria release active part-ASA閿涘‘rom prodrug and at the same time, increase the toxicity n.a. PMID PMID: 36467581 PMDBI20010187 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD618 Olsalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Azo reductases toxicity increased n.a. n.a. n.a. Reduction and Release of 5-aminosalicylic acid閿涘he activity increased and the toxicity increased n.a. PMID PMID: 36467581 PMDBI20010189 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD471 Lactulose Therapeutic Substance laxative n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Forming lactic and acetic acidsactive metabolite,the activity and bioavailability were decreased n.a. PMID PMID: 36467581 PMDBI20010191 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010192 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010195 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010197 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010198 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010199 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD403 Glucuronides Environmental Chemicals Environmental Substance n.a. n.a. n.a. n.a. diclofenac,ketoprofen,indomethacin n.a. unknown toxicity increased n.a. n.a. n.a. Increase toxicity n.a. PMID PMID: 36467581 PMDBI20010201 Microbes metabolize substances PMDBM2020047 n.a. Clostridium bolteae WAL 16351,DSM 15670,ATCC BAA-613,CCUG 46953 PMDBD558 Montelukast Therapeutic Substance Drugs for obstructive airway disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20010202 Microbes metabolize substances PMDBM2020047 n.a. Clostridium bolteae WAL 16351,DSM 15670,ATCC BAA-613,CCUG 46953 PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20010203 Microbes metabolize substances PMDBM2021321 n.a. Clostridium ramosum 113-I,VPI 0427,DSM 1402,ATCC 25582,NCIB 10673 PMDBD1407 Rosiglitazone Therapeutic substance Anti-diabetics n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20010204 Microbes metabolize substances PMDBM2020050 n.a. Clostridium saccharolyticum WM1,DSM 2544,ATCC 35040,NRC 2533 PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20010205 Microbes metabolize substances PMDBM2020050 n.a. Clostridium saccharolyticum WM1,DSM 2544,ATCC 35040,NRC 2533 PMDBD558 Montelukast Therapeutic Substance Drugs for obstructive airway disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20010206 Microbes metabolize substances PMDBM2020050 n.a. Clostridium saccharolyticum WM1,DSM 2544,ATCC 35040,NRC 2533 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Biotransformation n.a. PMID PMID: 36467581 PMDBI20010207 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010208 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20010209 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010210 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010211 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20010212 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010213 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010214 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010215 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010218 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010219 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010220 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010221 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010222 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010223 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010224 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010225 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010226 Microbes metabolize substances PMDBM2020532 1561 Clostridium baratii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010227 Microbes metabolize substances PMDBM2021477 1263064 Clostridium bolteae PMDBD2000020 Hydrocortisone acetate Therapeutic Substance immune, inflammatory, and neoplastic conditions n.a. n.a. n.a. n.a. hydrocortisone n.a. unknown activation n.a. n.a. n.a. it was deacetylated to yield hydrocortisone n.a. PMID PMID: 36467581 PMDBI20010228 Microbes metabolize substances PMDBM2021477 1263064 Clostridium bolteae PMDBD249 Dasatinib Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Microbiota species involved in ALL chemotherapeutics metabolism n.a. PMID PMID: 36467581 PMDBI20010229 Microbes metabolize substances PMDBM2020021 1492 Clostridium butyricum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010230 Microbes metabolize substances PMDBM2020021 1492 Clostridium butyricum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010231 Microbes metabolize substances PMDBM2020021 1492 Clostridium butyricum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010232 Microbes metabolize substances PMDBM2020021 1492 Clostridium butyricum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010233 Microbes metabolize substances PMDBM2020021 1492 Clostridium butyricum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010234 Microbes metabolize substances PMDBM2020021 1492 Clostridium butyricum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010235 Microbes metabolize substances PMDBM2020021 1492 Clostridium butyricum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010238 Microbes metabolize substances PMDBM2020021 1492 Clostridium butyricum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010239 Microbes metabolize substances PMDBM2020021 1492 Clostridium butyricum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010240 Microbes metabolize substances PMDBM2020021 1492 Clostridium butyricum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010241 Microbes metabolize substances PMDBM2020021 1492 Clostridium butyricum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010242 Microbes metabolize substances PMDBM2020021 1492 Clostridium butyricum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010243 Microbes metabolize substances PMDBM2020021 1492 Clostridium butyricum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010244 Microbes metabolize substances PMDBM2020021 1492 Clostridium butyricum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010245 Microbes metabolize substances PMDBM2020021 1492 Clostridium butyricum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010246 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010247 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010248 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010249 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010250 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010251 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010252 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010253 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010254 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010256 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20010259 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20010260 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20010261 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010262 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010265 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20010268 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010269 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010270 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010272 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010273 Microbes metabolize substances PMDBM2020911 36834 Clostridium celatum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010274 Microbes metabolize substances PMDBM2020046 1496 Clostridium difficile PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Increased toxicity n.a. PMID PMID: 36467581 PMDBI20010276 Microbes metabolize substances PMDBM2020046 1496 Clostridium difficile PMDBD1342 Paracetamol Therapeutic substance first-line therapy in pain n.a. n.a. n.a. n.a. Acetaminophen sulfate n.a. unknown activity decreased n.a. n.a. n.a. Decreased activity or Increased cellular toxicity n.a. PMID PMID: 36467581 PMDBI20010280 Microbes metabolize substances PMDBM2020540 84024 Clostridium disporicum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010281 Microbes metabolize substances PMDBM2020540 84024 Clostridium disporicum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010282 Microbes metabolize substances PMDBM2020540 84024 Clostridium disporicum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010283 Microbes metabolize substances PMDBM2020540 84024 Clostridium disporicum PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010285 Microbes metabolize substances PMDBM2020540 84024 Clostridium disporicum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010287 Microbes metabolize substances PMDBM2020540 84024 Clostridium disporicum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010288 Microbes metabolize substances PMDBM2020540 84024 Clostridium disporicum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010289 Microbes metabolize substances PMDBM2020540 84024 Clostridium disporicum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010290 Microbes metabolize substances PMDBM2020540 84024 Clostridium disporicum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010293 Microbes metabolize substances PMDBM2020540 84024 Clostridium disporicum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010294 Microbes metabolize substances PMDBM2020540 84024 Clostridium disporicum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010295 Microbes metabolize substances PMDBM2020540 84024 Clostridium disporicum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010296 Microbes metabolize substances PMDBM2020540 84024 Clostridium disporicum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010298 Microbes metabolize substances PMDBM2020540 84024 Clostridium disporicum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010299 Microbes metabolize substances PMDBM2020540 84024 Clostridium disporicum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010300 Microbes metabolize substances PMDBM2020201 1535 Clostridium leptum PMDBD595 Nitrazepam Therapeutic Substance anticonvulsant and hypnotic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. High performance liquid chromatography elution profile of nitrazepam after partial conversion to 7-aminonitrazepam n.a. PMID PMID: 36467581 PMDBI20010301 Microbes metabolize substances PMDBM2020201 1535 Clostridium leptum PMDBD214 Clonazepam Therapeutic Substance Central nervous system agents n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. clonazepam metabolism is primarily reductive in the presence of gut flora and oxidative in its absence. n.a. PMID PMID: 36467581 PMDBI20010306 Microbes metabolize substances PMDBM2021478 137838 Clostridium neonatale PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010307 Microbes metabolize substances PMDBM2021478 137838 Clostridium neonatale PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010308 Microbes metabolize substances PMDBM2021478 137838 Clostridium neonatale PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010309 Microbes metabolize substances PMDBM2021478 137838 Clostridium neonatale PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010311 Microbes metabolize substances PMDBM2021478 137838 Clostridium neonatale PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010313 Microbes metabolize substances PMDBM2021478 137838 Clostridium neonatale PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010314 Microbes metabolize substances PMDBM2021478 137838 Clostridium neonatale PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010315 Microbes metabolize substances PMDBM2021478 137838 Clostridium neonatale PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010316 Microbes metabolize substances PMDBM2021478 137838 Clostridium neonatale PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010319 Microbes metabolize substances PMDBM2021478 137838 Clostridium neonatale PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010320 Microbes metabolize substances PMDBM2021478 137838 Clostridium neonatale PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010321 Microbes metabolize substances PMDBM2021478 137838 Clostridium neonatale PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010322 Microbes metabolize substances PMDBM2021478 137838 Clostridium neonatale PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010324 Microbes metabolize substances PMDBM2021478 137838 Clostridium neonatale PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010325 Microbes metabolize substances PMDBM2021478 137838 Clostridium neonatale PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010326 Microbes metabolize substances PMDBM2021478 137838 Clostridium neonatale PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010327 Microbes metabolize substances PMDBM2021479 1805470 Clostridium nigeriense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010328 Microbes metabolize substances PMDBM2021479 1805470 Clostridium nigeriense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010329 Microbes metabolize substances PMDBM2021479 1805470 Clostridium nigeriense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010330 Microbes metabolize substances PMDBM2021479 1805470 Clostridium nigeriense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010331 Microbes metabolize substances PMDBM2021479 1805470 Clostridium nigeriense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010332 Microbes metabolize substances PMDBM2021479 1805470 Clostridium nigeriense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010333 Microbes metabolize substances PMDBM2021479 1805470 Clostridium nigeriense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010336 Microbes metabolize substances PMDBM2021479 1805470 Clostridium nigeriense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010337 Microbes metabolize substances PMDBM2021479 1805470 Clostridium nigeriense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010338 Microbes metabolize substances PMDBM2021479 1805470 Clostridium nigeriense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010339 Microbes metabolize substances PMDBM2021479 1805470 Clostridium nigeriense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010340 Microbes metabolize substances PMDBM2021479 1805470 Clostridium nigeriense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010341 Microbes metabolize substances PMDBM2021479 1805470 Clostridium nigeriense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010342 Microbes metabolize substances PMDBM2021479 1805470 Clostridium nigeriense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010343 Microbes metabolize substances PMDBM2020551 29363 Clostridium paraputrificum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010344 Microbes metabolize substances PMDBM2020551 29363 Clostridium paraputrificum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010345 Microbes metabolize substances PMDBM2020551 29363 Clostridium paraputrificum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010346 Microbes metabolize substances PMDBM2020551 29363 Clostridium paraputrificum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010347 Microbes metabolize substances PMDBM2020551 29363 Clostridium paraputrificum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010348 Microbes metabolize substances PMDBM2020551 29363 Clostridium paraputrificum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010349 Microbes metabolize substances PMDBM2020551 29363 Clostridium paraputrificum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010352 Microbes metabolize substances PMDBM2020551 29363 Clostridium paraputrificum PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010353 Microbes metabolize substances PMDBM2020551 29363 Clostridium paraputrificum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010354 Microbes metabolize substances PMDBM2020551 29363 Clostridium paraputrificum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010355 Microbes metabolize substances PMDBM2020551 29363 Clostridium paraputrificum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010356 Microbes metabolize substances PMDBM2020551 29363 Clostridium paraputrificum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010357 Microbes metabolize substances PMDBM2020551 29363 Clostridium paraputrificum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010358 Microbes metabolize substances PMDBM2020551 29363 Clostridium paraputrificum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010359 Microbes metabolize substances PMDBM2020551 29363 Clostridium paraputrificum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010360 Microbes metabolize substances PMDBM2020099 1502 Clostridium perfringens PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Metronidazole is metabolized to acetamide in yields of between 8 and 15 per cent by cultures of rat cecal contents or Clostridium perfringens. The yield of acetamide is 6- to 9-fold greater than that of N-(2-hydroxyethyl)-oxamic acid which is also derived from metronidazole. n.a. PMID PMID: 36467581 PMDBI20010362 Microbes metabolize substances PMDBM2020099 1502 Clostridium perfringens PMDBD553 Misonidazole Therapeutic Substance Tumor Hypoxia n.a. n.a. n.a. n.a. N-(2-hydroxyethyl)-oxamic acid and acetamide n.a. unknown toxicity n.a. n.a. n.a. Misonidazole is a 2-nitroimidazole deriva-tive, which is an effective radiosensitiser of hypoxic cellsthat is being tested as an adjunct to radiation therapyin the treatment of human cancer. Misonidazole ismetabolized to its amino derivative [1-(2-aminoimida-zol-1-yl)-3-methoxypropan-2-ol] in pure or mixed cul-tures of the intestinal microbiota and that themetabolite is further metabolized to release CO2. Themetabolite was only seen in the excreta of normal butnot germ-free rats, suggesting that its formation is dueto the intestinal microbiota in vivo. Another studyshowed that mice treated with penicillin for a weekbefore misonidazole administration showed increaseddrug exposure and decreased misonidazole-inducedneurotoxicity n.a. PMID PMID: 36467581 PMDBI20010365 Microbes metabolize substances PMDBM2021321 1547 Clostridium ramosum PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon,Regenerate the active SN-38 in intestinal lumen n.a. PMID PMID: 36467581 PMDBI20010366 Microbes metabolize substances PMDBM2020557 1414720 Clostridium saudiense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010367 Microbes metabolize substances PMDBM2020557 1414720 Clostridium saudiense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010368 Microbes metabolize substances PMDBM2020557 1414720 Clostridium saudiense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010369 Microbes metabolize substances PMDBM2020557 1414720 Clostridium saudiense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010370 Microbes metabolize substances PMDBM2020557 1414720 Clostridium saudiense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010371 Microbes metabolize substances PMDBM2020557 1414720 Clostridium saudiense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010372 Microbes metabolize substances PMDBM2020557 1414720 Clostridium saudiense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010375 Microbes metabolize substances PMDBM2020557 1414720 Clostridium saudiense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010376 Microbes metabolize substances PMDBM2020557 1414720 Clostridium saudiense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010377 Microbes metabolize substances PMDBM2020557 1414720 Clostridium saudiense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010378 Microbes metabolize substances PMDBM2020557 1414720 Clostridium saudiense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010379 Microbes metabolize substances PMDBM2020557 1414720 Clostridium saudiense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010380 Microbes metabolize substances PMDBM2020557 1414720 Clostridium saudiense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010381 Microbes metabolize substances PMDBM2020557 1414720 Clostridium saudiense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010382 Microbes metabolize substances PMDBM2020202 29347 Clostridium scindens PMDBD772 Secoisolariciresinol Therapeutic Substance anticancer n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. unknown activity increased n.a. n.a. n.a. Protective effects against breast cancer n.a. PMID PMID: 36467581 PMDBI20010383 Microbes metabolize substances PMDBM2020202 29347 Clostridium scindens PMDBD259 Dexamethasone Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Microbiota species involved in ALL chemotherapeutics metabolism n.a. PMID PMID: 36467581 PMDBI20010384 Microbes metabolize substances PMDBM2021480 1504 Clostridium septicum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010385 Microbes metabolize substances PMDBM2021480 1504 Clostridium septicum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010386 Microbes metabolize substances PMDBM2021480 1504 Clostridium septicum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010387 Microbes metabolize substances PMDBM2021480 1504 Clostridium septicum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010388 Microbes metabolize substances PMDBM2021480 1504 Clostridium septicum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010389 Microbes metabolize substances PMDBM2021480 1504 Clostridium septicum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010390 Microbes metabolize substances PMDBM2021480 1504 Clostridium septicum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010393 Microbes metabolize substances PMDBM2021480 1504 Clostridium septicum PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010394 Microbes metabolize substances PMDBM2021480 1504 Clostridium septicum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010395 Microbes metabolize substances PMDBM2021480 1504 Clostridium septicum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010396 Microbes metabolize substances PMDBM2021480 1504 Clostridium septicum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010397 Microbes metabolize substances PMDBM2021480 1504 Clostridium septicum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010398 Microbes metabolize substances PMDBM2021480 1504 Clostridium septicum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010399 Microbes metabolize substances PMDBM2021480 1504 Clostridium septicum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010400 Microbes metabolize substances PMDBM2021480 1504 Clostridium septicum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010401 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" a weakly estrogenic compound with potential health n.a. n.a. n.a. n.a. Dihydrodaidzein, equol n.a. unknown activity increased n.a. n.a. n.a. activity increased n.a. PMID PMID: 36467581 PMDBI20010402 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp.HGH 136 PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" a weakly estrogenic compound with potential health n.a. n.a. n.a. n.a. Dihydrodaidzein, equol n.a. unknown activity increased n.a. n.a. n.a. Increased activity by conversion into Dihydrodaidzein, equol, or O-desmethylanolensin (ODMA) n.a. PMID PMID: 36467581 PMDBI20010403 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp000435835 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010404 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp000435835 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010405 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp000435835 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010406 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp000435835 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010407 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp000435835 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010408 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp000435835 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010409 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp000435835 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010412 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp000435835 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010413 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp000435835 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010414 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp000435835 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010415 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp000435835 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010416 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp000435835 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010417 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp000435835 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010418 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp000435835 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010419 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp001916075 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010420 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp001916075 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010421 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp001916075 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010422 Microbes metabolize substances PMDBM2020051 1506 Clostridium sp001916075 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010423 Microbes metabolize substances PMDBM2020204 1509 Clostridium sporogenes PMDBD915 Zonisamide Therapeutic Substance anticonvulsant n.a. n.a. n.a. n.a. 2-sulfamoyalcetylphenol n.a. unknown involved in substrate metabolism n.a. n.a. n.a. It is primarily metabolized to 2-sulfamoyalcetylphenol by reduction of the benzisoxazole ring. n.a. PMID PMID: 36467581 PMDBI20010426 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010427 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010428 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010429 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010430 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010431 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010432 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010433 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010434 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010436 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20010439 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20010440 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20010441 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010442 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010445 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20010448 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010449 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010450 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010452 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010453 Microbes metabolize substances PMDBM2020575 1559 Clostridium tertium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010454 Microbes metabolize substances PMDBM2008646 n.a. Clostridium A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010455 Microbes metabolize substances PMDBM2008646 n.a. Clostridium A PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20010456 Microbes metabolize substances PMDBM2008646 n.a. Clostridium A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010457 Microbes metabolize substances PMDBM2008646 n.a. Clostridium A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010458 Microbes metabolize substances PMDBM2008646 n.a. Clostridium A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010460 Microbes metabolize substances PMDBM2008646 n.a. Clostridium A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010462 Microbes metabolize substances PMDBM2008646 n.a. Clostridium A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010463 Microbes metabolize substances PMDBM2008646 n.a. Clostridium A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010464 Microbes metabolize substances PMDBM2008646 n.a. Clostridium A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010465 Microbes metabolize substances PMDBM2008646 n.a. Clostridium A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010468 Microbes metabolize substances PMDBM2008646 n.a. Clostridium A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010469 Microbes metabolize substances PMDBM2008646 n.a. Clostridium A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010470 Microbes metabolize substances PMDBM2008646 n.a. Clostridium A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010471 Microbes metabolize substances PMDBM2008646 n.a. Clostridium A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010473 Microbes metabolize substances PMDBM2008646 n.a. Clostridium A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010474 Microbes metabolize substances PMDBM2008646 n.a. Clostridium A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010475 Microbes metabolize substances PMDBM2020201 1535 Clostridium A leptum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010476 Microbes metabolize substances PMDBM2020201 1535 Clostridium A leptum PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20010477 Microbes metabolize substances PMDBM2020201 1535 Clostridium A leptum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010478 Microbes metabolize substances PMDBM2020201 1535 Clostridium A leptum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010479 Microbes metabolize substances PMDBM2020201 1535 Clostridium A leptum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010480 Microbes metabolize substances PMDBM2020201 1535 Clostridium A leptum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010481 Microbes metabolize substances PMDBM2020201 1535 Clostridium A leptum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010482 Microbes metabolize substances PMDBM2020201 1535 Clostridium A leptum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010485 Microbes metabolize substances PMDBM2020201 1535 Clostridium A leptum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010486 Microbes metabolize substances PMDBM2020201 1535 Clostridium A leptum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010487 Microbes metabolize substances PMDBM2020201 1535 Clostridium A leptum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010488 Microbes metabolize substances PMDBM2020201 1535 Clostridium A leptum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010489 Microbes metabolize substances PMDBM2020201 1535 Clostridium A leptum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010490 Microbes metabolize substances PMDBM2020201 1535 Clostridium A leptum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010491 Microbes metabolize substances PMDBM2020201 1535 Clostridium A leptum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010492 Microbes metabolize substances PMDBM2020554 1325933 Clostridium AA polynesiense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010493 Microbes metabolize substances PMDBM2020554 1325933 Clostridium AA polynesiense PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20010494 Microbes metabolize substances PMDBM2020554 1325933 Clostridium AA polynesiense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010495 Microbes metabolize substances PMDBM2020554 1325933 Clostridium AA polynesiense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010496 Microbes metabolize substances PMDBM2020554 1325933 Clostridium AA polynesiense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010497 Microbes metabolize substances PMDBM2020554 1325933 Clostridium AA polynesiense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010498 Microbes metabolize substances PMDBM2020554 1325933 Clostridium AA polynesiense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010499 Microbes metabolize substances PMDBM2020554 1325933 Clostridium AA polynesiense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010502 Microbes metabolize substances PMDBM2020554 1325933 Clostridium AA polynesiense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010503 Microbes metabolize substances PMDBM2020554 1325933 Clostridium AA polynesiense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010504 Microbes metabolize substances PMDBM2020554 1325933 Clostridium AA polynesiense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010505 Microbes metabolize substances PMDBM2020554 1325933 Clostridium AA polynesiense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010506 Microbes metabolize substances PMDBM2020554 1325933 Clostridium AA polynesiense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010507 Microbes metabolize substances PMDBM2020554 1325933 Clostridium AA polynesiense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010508 Microbes metabolize substances PMDBM2020554 1325933 Clostridium AA polynesiense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010509 Microbes metabolize substances PMDBM2008649 n.a. Clostridium B PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010510 Microbes metabolize substances PMDBM2008649 n.a. Clostridium B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010511 Microbes metabolize substances PMDBM2008649 n.a. Clostridium B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010512 Microbes metabolize substances PMDBM2008649 n.a. Clostridium B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010513 Microbes metabolize substances PMDBM2020576 1519 Clostridium B tyrobutyricum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010514 Microbes metabolize substances PMDBM2020576 1519 Clostridium B tyrobutyricum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010515 Microbes metabolize substances PMDBM2020576 1519 Clostridium B tyrobutyricum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010516 Microbes metabolize substances PMDBM2020576 1519 Clostridium B tyrobutyricum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010517 Microbes metabolize substances PMDBM2008651 n.a. Clostridium E PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010518 Microbes metabolize substances PMDBM2008651 n.a. Clostridium E PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010519 Microbes metabolize substances PMDBM2008651 n.a. Clostridium E PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010520 Microbes metabolize substances PMDBM2008651 n.a. Clostridium E PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010521 Microbes metabolize substances PMDBM2008651 n.a. Clostridium E PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010522 Microbes metabolize substances PMDBM2008651 n.a. Clostridium E PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010523 Microbes metabolize substances PMDBM2008651 n.a. Clostridium E PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010526 Microbes metabolize substances PMDBM2008651 n.a. Clostridium E PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010527 Microbes metabolize substances PMDBM2008651 n.a. Clostridium E PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010528 Microbes metabolize substances PMDBM2008651 n.a. Clostridium E PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010529 Microbes metabolize substances PMDBM2008651 n.a. Clostridium E PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010530 Microbes metabolize substances PMDBM2008651 n.a. Clostridium E PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010531 Microbes metabolize substances PMDBM2008651 n.a. Clostridium E PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010532 Microbes metabolize substances PMDBM2008651 n.a. Clostridium E PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010533 Microbes metabolize substances PMDBM2020545 1414721 Clostridium E jeddahense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010534 Microbes metabolize substances PMDBM2020545 1414721 Clostridium E jeddahense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010535 Microbes metabolize substances PMDBM2020545 1414721 Clostridium E jeddahense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010536 Microbes metabolize substances PMDBM2020545 1414721 Clostridium E jeddahense PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010538 Microbes metabolize substances PMDBM2020545 1414721 Clostridium E jeddahense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010540 Microbes metabolize substances PMDBM2020545 1414721 Clostridium E jeddahense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010541 Microbes metabolize substances PMDBM2020545 1414721 Clostridium E jeddahense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010542 Microbes metabolize substances PMDBM2020545 1414721 Clostridium E jeddahense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010543 Microbes metabolize substances PMDBM2020545 1414721 Clostridium E jeddahense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010546 Microbes metabolize substances PMDBM2020545 1414721 Clostridium E jeddahense PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010547 Microbes metabolize substances PMDBM2020545 1414721 Clostridium E jeddahense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010548 Microbes metabolize substances PMDBM2020545 1414721 Clostridium E jeddahense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010549 Microbes metabolize substances PMDBM2020545 1414721 Clostridium E jeddahense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010550 Microbes metabolize substances PMDBM2020545 1414721 Clostridium E jeddahense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010552 Microbes metabolize substances PMDBM2020545 1414721 Clostridium E jeddahense PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010553 Microbes metabolize substances PMDBM2020545 1414721 Clostridium E jeddahense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010554 Microbes metabolize substances PMDBM2020545 1414721 Clostridium E jeddahense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010555 Microbes metabolize substances PMDBM2021481 1958780 Clostridium E merdae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010556 Microbes metabolize substances PMDBM2021481 1958780 Clostridium E merdae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010557 Microbes metabolize substances PMDBM2021481 1958780 Clostridium E merdae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010558 Microbes metabolize substances PMDBM2021481 1958780 Clostridium E merdae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010560 Microbes metabolize substances PMDBM2021481 1958780 Clostridium E merdae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010562 Microbes metabolize substances PMDBM2021481 1958780 Clostridium E merdae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010563 Microbes metabolize substances PMDBM2021481 1958780 Clostridium E merdae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010564 Microbes metabolize substances PMDBM2021481 1958780 Clostridium E merdae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010565 Microbes metabolize substances PMDBM2021481 1958780 Clostridium E merdae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010568 Microbes metabolize substances PMDBM2021481 1958780 Clostridium E merdae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010569 Microbes metabolize substances PMDBM2021481 1958780 Clostridium E merdae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010570 Microbes metabolize substances PMDBM2021481 1958780 Clostridium E merdae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010571 Microbes metabolize substances PMDBM2021481 1958780 Clostridium E merdae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010573 Microbes metabolize substances PMDBM2021481 1958780 Clostridium E merdae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010574 Microbes metabolize substances PMDBM2021481 1958780 Clostridium E merdae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010575 Microbes metabolize substances PMDBM2020573 1549 Clostridium E sporosphaeroides PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010576 Microbes metabolize substances PMDBM2020573 1549 Clostridium E sporosphaeroides PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010577 Microbes metabolize substances PMDBM2020573 1549 Clostridium E sporosphaeroides PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010578 Microbes metabolize substances PMDBM2020573 1549 Clostridium E sporosphaeroides PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010580 Microbes metabolize substances PMDBM2020573 1549 Clostridium E sporosphaeroides PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010582 Microbes metabolize substances PMDBM2020573 1549 Clostridium E sporosphaeroides PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010583 Microbes metabolize substances PMDBM2020573 1549 Clostridium E sporosphaeroides PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010584 Microbes metabolize substances PMDBM2020573 1549 Clostridium E sporosphaeroides PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010585 Microbes metabolize substances PMDBM2020573 1549 Clostridium E sporosphaeroides PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010588 Microbes metabolize substances PMDBM2020573 1549 Clostridium E sporosphaeroides PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010589 Microbes metabolize substances PMDBM2020573 1549 Clostridium E sporosphaeroides PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010590 Microbes metabolize substances PMDBM2020573 1549 Clostridium E sporosphaeroides PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010591 Microbes metabolize substances PMDBM2020573 1549 Clostridium E sporosphaeroides PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010593 Microbes metabolize substances PMDBM2020573 1549 Clostridium E sporosphaeroides PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010594 Microbes metabolize substances PMDBM2020573 1549 Clostridium E sporosphaeroides PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010595 Microbes metabolize substances PMDBM2020020 1491 Clostridium F botulinum PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20010596 Microbes metabolize substances PMDBM2020020 1491 Clostridium F botulinum PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010597 Microbes metabolize substances PMDBM2020020 1491 Clostridium F botulinum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010598 Microbes metabolize substances PMDBM2020020 1491 Clostridium F botulinum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010599 Microbes metabolize substances PMDBM2020020 1491 Clostridium F botulinum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010600 Microbes metabolize substances PMDBM2020020 1491 Clostridium F botulinum A PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20010601 Microbes metabolize substances PMDBM2020020 1491 Clostridium F botulinum A PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010602 Microbes metabolize substances PMDBM2020020 1491 Clostridium F botulinum A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010603 Microbes metabolize substances PMDBM2020020 1491 Clostridium F botulinum A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010604 Microbes metabolize substances PMDBM2020020 1491 Clostridium F botulinum A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010605 Microbes metabolize substances PMDBM2020550 1622073 Clostridium F niameyense PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20010606 Microbes metabolize substances PMDBM2020550 1622073 Clostridium F niameyense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010607 Microbes metabolize substances PMDBM2020550 1622073 Clostridium F niameyense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010608 Microbes metabolize substances PMDBM2020550 1622073 Clostridium F niameyense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010609 Microbes metabolize substances PMDBM2021482 1962263 Clostridium F tepidum PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010610 Microbes metabolize substances PMDBM2021482 1962263 Clostridium F tepidum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010611 Microbes metabolize substances PMDBM2021482 1962263 Clostridium F tepidum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010612 Microbes metabolize substances PMDBM2021482 1962263 Clostridium F tepidum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010613 Microbes metabolize substances PMDBM2020537 1494 Clostridium G cochlearium PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20010614 Microbes metabolize substances PMDBM2020537 1494 Clostridium G cochlearium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010615 Microbes metabolize substances PMDBM2020537 1494 Clostridium G cochlearium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010616 Microbes metabolize substances PMDBM2020537 1494 Clostridium G cochlearium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010617 Microbes metabolize substances PMDBM2021250 1513 Clostridium G tetani PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20010618 Microbes metabolize substances PMDBM2021250 1513 Clostridium G tetani PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010619 Microbes metabolize substances PMDBM2021250 1513 Clostridium G tetani PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010620 Microbes metabolize substances PMDBM2021250 1513 Clostridium G tetani PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010621 Microbes metabolize substances PMDBM2021250 1513 Clostridium G tetani PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010622 Microbes metabolize substances PMDBM2021483 1776385 Clostridium H massiliodielmoense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010623 Microbes metabolize substances PMDBM2021483 1776385 Clostridium H massiliodielmoense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010624 Microbes metabolize substances PMDBM2021483 1776385 Clostridium H massiliodielmoense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010625 Microbes metabolize substances PMDBM2021483 1776385 Clostridium H massiliodielmoense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010626 Microbes metabolize substances PMDBM2008662 n.a. Clostridium J PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010627 Microbes metabolize substances PMDBM2008662 n.a. Clostridium J PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010628 Microbes metabolize substances PMDBM2008662 n.a. Clostridium J PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010629 Microbes metabolize substances PMDBM2008662 n.a. Clostridium J PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010630 Microbes metabolize substances PMDBM2008662 n.a. Clostridium J PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010631 Microbes metabolize substances PMDBM2020542 1470356 Clostridium J ihumii PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010632 Microbes metabolize substances PMDBM2020542 1470356 Clostridium J ihumii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010633 Microbes metabolize substances PMDBM2020542 1470356 Clostridium J ihumii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010634 Microbes metabolize substances PMDBM2020542 1470356 Clostridium J ihumii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010635 Microbes metabolize substances PMDBM2020542 1470356 Clostridium J ihumii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010636 Microbes metabolize substances PMDBM2020558 1465809 Clostridium J senegalense PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20010637 Microbes metabolize substances PMDBM2020558 1465809 Clostridium J senegalense PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010638 Microbes metabolize substances PMDBM2020558 1465809 Clostridium J senegalense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010639 Microbes metabolize substances PMDBM2020558 1465809 Clostridium J senegalense PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010640 Microbes metabolize substances PMDBM2020558 1465809 Clostridium J senegalense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010641 Microbes metabolize substances PMDBM2020558 1465809 Clostridium J senegalense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010642 Microbes metabolize substances PMDBM2020051 1506 Clostridium J sp000821305 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010643 Microbes metabolize substances PMDBM2020051 1506 Clostridium J sp000821305 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20010644 Microbes metabolize substances PMDBM2020051 1506 Clostridium J sp000821305 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010645 Microbes metabolize substances PMDBM2020051 1506 Clostridium J sp000821305 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010646 Microbes metabolize substances PMDBM2020051 1506 Clostridium J sp000821305 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010647 Microbes metabolize substances PMDBM2020051 1506 Clostridium J sp000821305 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010648 Microbes metabolize substances PMDBM2020051 1506 Clostridium J sp000821305 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010649 Microbes metabolize substances PMDBM2020051 1506 Clostridium J sp000821305 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010652 Microbes metabolize substances PMDBM2020051 1506 Clostridium J sp000821305 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010653 Microbes metabolize substances PMDBM2020051 1506 Clostridium J sp000821305 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010654 Microbes metabolize substances PMDBM2020051 1506 Clostridium J sp000821305 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010655 Microbes metabolize substances PMDBM2020051 1506 Clostridium J sp000821305 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010656 Microbes metabolize substances PMDBM2020051 1506 Clostridium J sp000821305 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010657 Microbes metabolize substances PMDBM2020051 1506 Clostridium J sp000821305 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010658 Microbes metabolize substances PMDBM2020051 1506 Clostridium J sp000821305 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010659 Microbes metabolize substances PMDBM2020051 1506 Clostridium J sp000821305 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010660 Microbes metabolize substances PMDBM2020051 1506 Clostridium J sp000821305 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010661 Microbes metabolize substances PMDBM2020531 1499689 Clostridium L amazonitimonense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010662 Microbes metabolize substances PMDBM2020531 1499689 Clostridium L amazonitimonense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010663 Microbes metabolize substances PMDBM2020531 1499689 Clostridium L amazonitimonense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010664 Microbes metabolize substances PMDBM2020531 1499689 Clostridium L amazonitimonense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010665 Microbes metabolize substances PMDBM2020531 1499689 Clostridium L amazonitimonense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010666 Microbes metabolize substances PMDBM2020531 1499689 Clostridium L amazonitimonense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010667 Microbes metabolize substances PMDBM2020531 1499689 Clostridium L amazonitimonense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010670 Microbes metabolize substances PMDBM2020531 1499689 Clostridium L amazonitimonense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010671 Microbes metabolize substances PMDBM2020531 1499689 Clostridium L amazonitimonense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010672 Microbes metabolize substances PMDBM2020531 1499689 Clostridium L amazonitimonense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010673 Microbes metabolize substances PMDBM2020531 1499689 Clostridium L amazonitimonense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010674 Microbes metabolize substances PMDBM2020531 1499689 Clostridium L amazonitimonense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010675 Microbes metabolize substances PMDBM2020531 1499689 Clostridium L amazonitimonense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010676 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010677 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010678 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010679 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010681 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010683 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20010684 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010685 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010686 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010687 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010688 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010689 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010691 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20010694 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20010695 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20010696 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20010697 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010698 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010699 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010702 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20010705 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010706 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010709 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010710 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010711 Microbes metabolize substances PMDBM2008667 n.a. Clostridium M PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010712 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010713 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010714 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010715 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20010716 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010717 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010718 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010719 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010720 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010721 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010723 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20010726 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20010727 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20010728 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20010729 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010730 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010731 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010734 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20010737 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010738 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010739 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010741 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010742 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010743 Microbes metabolize substances PMDBM2021484 333367 Clostridium M asparagiforme PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010744 Microbes metabolize substances PMDBM2020047 208479 Clostridium M bolteae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010745 Microbes metabolize substances PMDBM2020047 208479 Clostridium M bolteae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010746 Microbes metabolize substances PMDBM2020047 208479 Clostridium M bolteae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010747 Microbes metabolize substances PMDBM2020047 208479 Clostridium M bolteae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010749 Microbes metabolize substances PMDBM2020047 208479 Clostridium M bolteae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010751 Microbes metabolize substances PMDBM2020047 208479 Clostridium M bolteae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010752 Microbes metabolize substances PMDBM2020047 208479 Clostridium M bolteae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010753 Microbes metabolize substances PMDBM2020047 208479 Clostridium M bolteae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010754 Microbes metabolize substances PMDBM2020047 208479 Clostridium M bolteae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010757 Microbes metabolize substances PMDBM2020047 208479 Clostridium M bolteae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010758 Microbes metabolize substances PMDBM2020047 208479 Clostridium M bolteae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010759 Microbes metabolize substances PMDBM2020047 208479 Clostridium M bolteae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010760 Microbes metabolize substances PMDBM2020047 208479 Clostridium M bolteae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010762 Microbes metabolize substances PMDBM2020047 208479 Clostridium M bolteae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010763 Microbes metabolize substances PMDBM2020047 208479 Clostridium M bolteae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010764 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010765 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010766 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010767 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010769 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010771 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010772 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010773 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010774 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010775 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010776 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010778 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20010781 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20010782 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20010783 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20010784 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010785 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010786 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010789 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20010792 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010793 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010796 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010797 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010798 Microbes metabolize substances PMDBM2020048 358743 Clostridium M citroniae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010799 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010800 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010801 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010802 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010803 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010804 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010805 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010806 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010807 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010809 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20010812 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20010813 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20010814 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20010815 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010816 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010819 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20010822 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010823 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010824 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010826 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010827 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010828 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010829 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010830 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010831 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010832 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010834 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20010836 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010837 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010838 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010839 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010840 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010841 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010843 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20010846 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20010847 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20010848 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010849 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010850 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010853 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20010856 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010857 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010860 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010861 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010862 Microbes metabolize substances PMDBM2021485 1531 Clostridium M clostridioforme A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010863 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010864 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010865 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010866 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20010867 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010868 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010869 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010870 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010873 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20010874 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010875 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010876 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010877 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010878 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010879 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010880 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010881 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010882 Microbes metabolize substances PMDBM2021486 460384 Clostridium M lavalense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010883 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000155435 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010884 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000155435 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010885 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000155435 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010886 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000155435 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010887 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000155435 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010888 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000155435 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010889 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000155435 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010892 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000155435 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20010893 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000155435 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010894 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000155435 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010895 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000155435 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010896 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000155435 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010897 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000155435 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010898 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000155435 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010899 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000155435 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010900 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000155435 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010901 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000431375 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010902 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000431375 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20010903 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000431375 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010904 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000431375 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010905 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000431375 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010906 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000431375 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010907 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000431375 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010908 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000431375 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010911 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000431375 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010912 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000431375 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010913 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000431375 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010914 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000431375 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010915 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000431375 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010916 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000431375 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010917 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp000431375 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010918 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010919 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010920 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010921 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010922 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010923 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010924 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010925 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010926 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010928 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20010931 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20010932 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20010933 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010934 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010937 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20010940 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010941 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010942 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010944 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20010945 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010946 Microbes metabolize substances PMDBM2020051 1506 Clostridium M sp001517625 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010947 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010948 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010949 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010950 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010951 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010952 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010953 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010954 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010955 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010957 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20010960 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20010961 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20010962 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010963 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010966 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20010969 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010970 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010971 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010973 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010974 Microbes metabolize substances PMDBM2020546 1805472 Clostridium P mediterraneense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20010975 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20010976 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20010977 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20010978 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010979 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010980 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20010981 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010982 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20010983 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20010985 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20010988 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20010989 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20010990 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20010991 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20010994 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20010997 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010998 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20010999 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011001 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011002 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011003 Microbes metabolize substances PMDBM2020099 1502 Clostridium P perfringens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011004 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011005 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011006 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011007 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20011008 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011009 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011010 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011011 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011012 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011013 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011015 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20011018 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20011019 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20011020 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011021 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011024 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20011027 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011028 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011029 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011031 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011032 Microbes metabolize substances PMDBM2020051 1506 Clostridium P sp001403635 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011033 Microbes metabolize substances PMDBM2021076 1267 Clostridium P ventriculi PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011034 Microbes metabolize substances PMDBM2021076 1267 Clostridium P ventriculi PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011035 Microbes metabolize substances PMDBM2021076 1267 Clostridium P ventriculi PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011036 Microbes metabolize substances PMDBM2021076 1267 Clostridium P ventriculi PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011037 Microbes metabolize substances PMDBM2021076 1267 Clostridium P ventriculi PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011038 Microbes metabolize substances PMDBM2008681 n.a. Clostridium Q PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011039 Microbes metabolize substances PMDBM2008681 n.a. Clostridium Q PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011040 Microbes metabolize substances PMDBM2008681 n.a. Clostridium Q PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011041 Microbes metabolize substances PMDBM2008681 n.a. Clostridium Q PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011043 Microbes metabolize substances PMDBM2008681 n.a. Clostridium Q PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011045 Microbes metabolize substances PMDBM2008681 n.a. Clostridium Q PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20011046 Microbes metabolize substances PMDBM2008681 n.a. Clostridium Q PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011047 Microbes metabolize substances PMDBM2008681 n.a. Clostridium Q PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011048 Microbes metabolize substances PMDBM2008681 n.a. Clostridium Q PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011049 Microbes metabolize substances PMDBM2008681 n.a. Clostridium Q PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011052 Microbes metabolize substances PMDBM2008681 n.a. Clostridium Q PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011053 Microbes metabolize substances PMDBM2008681 n.a. Clostridium Q PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011054 Microbes metabolize substances PMDBM2008681 n.a. Clostridium Q PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011055 Microbes metabolize substances PMDBM2008681 n.a. Clostridium Q PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011057 Microbes metabolize substances PMDBM2008681 n.a. Clostridium Q PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011058 Microbes metabolize substances PMDBM2008681 n.a. Clostridium Q PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011059 Microbes metabolize substances PMDBM2008681 n.a. Clostridium Q PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011060 Microbes metabolize substances PMDBM2020050 84030 Clostridium Q saccharolyticum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011061 Microbes metabolize substances PMDBM2020050 84030 Clostridium Q saccharolyticum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011062 Microbes metabolize substances PMDBM2020050 84030 Clostridium Q saccharolyticum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011063 Microbes metabolize substances PMDBM2020050 84030 Clostridium Q saccharolyticum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011064 Microbes metabolize substances PMDBM2020050 84030 Clostridium Q saccharolyticum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011065 Microbes metabolize substances PMDBM2020051 1506 Clostridium Q sp000435655 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20011066 Microbes metabolize substances PMDBM2020051 1506 Clostridium Q sp000435655 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011067 Microbes metabolize substances PMDBM2020051 1506 Clostridium Q sp000435655 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011068 Microbes metabolize substances PMDBM2020051 1506 Clostridium Q sp000435655 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011069 Microbes metabolize substances PMDBM2020051 1506 Clostridium Q sp000435655 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011070 Microbes metabolize substances PMDBM2020051 1506 Clostridium Q sp000435655 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011071 Microbes metabolize substances PMDBM2020051 1506 Clostridium Q sp003024715 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20011072 Microbes metabolize substances PMDBM2020051 1506 Clostridium Q sp003024715 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011073 Microbes metabolize substances PMDBM2020051 1506 Clostridium Q sp003024715 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011074 Microbes metabolize substances PMDBM2020051 1506 Clostridium Q sp003024715 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011075 Microbes metabolize substances PMDBM2020205 1512 Clostridium Q symbiosum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011076 Microbes metabolize substances PMDBM2020205 1512 Clostridium Q symbiosum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011077 Microbes metabolize substances PMDBM2020205 1512 Clostridium Q symbiosum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011078 Microbes metabolize substances PMDBM2020205 1512 Clostridium Q symbiosum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011079 Microbes metabolize substances PMDBM2020205 1512 Clostridium Q symbiosum PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20011080 Microbes metabolize substances PMDBM2008686 n.a. Clostridium U PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011081 Microbes metabolize substances PMDBM2008686 n.a. Clostridium U PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011082 Microbes metabolize substances PMDBM2008686 n.a. Clostridium U PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011083 Microbes metabolize substances PMDBM2008686 n.a. Clostridium U PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011084 Microbes metabolize substances PMDBM2021487 89152 Clostridium U hiranonis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011085 Microbes metabolize substances PMDBM2021487 89152 Clostridium U hiranonis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011086 Microbes metabolize substances PMDBM2021487 89152 Clostridium U hiranonis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011087 Microbes metabolize substances PMDBM2021487 89152 Clostridium U hiranonis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011088 Microbes metabolize substances PMDBM2008688 n.a. Clostridium X PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20011089 Microbes metabolize substances PMDBM2008688 n.a. Clostridium X PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011090 Microbes metabolize substances PMDBM2008688 n.a. Clostridium X PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011091 Microbes metabolize substances PMDBM2008688 n.a. Clostridium X PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011092 Microbes metabolize substances PMDBM2008688 n.a. Clostridium X PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011093 Microbes metabolize substances PMDBM2020535 1529 Clostridium X cadaveris PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20011094 Microbes metabolize substances PMDBM2020535 1529 Clostridium X cadaveris PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011095 Microbes metabolize substances PMDBM2020535 1529 Clostridium X cadaveris PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011096 Microbes metabolize substances PMDBM2020535 1529 Clostridium X cadaveris PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011097 Microbes metabolize substances PMDBM2020535 1529 Clostridium X cadaveris PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011098 Microbes metabolize substances PMDBM2008690 n.a. Mahellia PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20011099 Microbes metabolize substances PMDBM2008690 n.a. Mahellia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011100 Microbes metabolize substances PMDBM2008690 n.a. Mahellia PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20011101 Microbes metabolize substances PMDBM2008690 n.a. Mahellia PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011102 Microbes metabolize substances PMDBM2008690 n.a. Mahellia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011103 Microbes metabolize substances PMDBM2008690 n.a. Mahellia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011104 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011105 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011106 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011107 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011109 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011111 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011112 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011113 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011114 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011115 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011116 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011118 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20011121 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20011122 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20011123 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011124 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011127 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20011130 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011131 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011134 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011135 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011136 Microbes metabolize substances PMDBM2008691 n.a. f Lachnospiraceae g COE1 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011137 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011138 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011139 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011140 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011142 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011144 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011145 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011146 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011147 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011148 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011149 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011151 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20011154 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20011155 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20011156 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011157 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011160 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20011163 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011164 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011167 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011168 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011169 Microbes metabolize substances PMDBM2008692 n.a. f Lachnospiraceae g COE1 sp001916965 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011170 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011171 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011172 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011173 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011175 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011177 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011178 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011179 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011180 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011181 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011182 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011184 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20011187 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20011188 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20011189 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011192 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20011195 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011196 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011199 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011200 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011201 Microbes metabolize substances PMDBM2021488 1883426 Cohnella sp900169535 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011202 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011203 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011204 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011205 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011207 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011209 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011210 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011211 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011212 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011213 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011214 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011216 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20011219 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20011220 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20011221 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20011222 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011223 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011226 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20011229 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011230 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011233 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011234 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011235 Microbes metabolize substances PMDBM166 102106 Collinsella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011236 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011237 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011238 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011239 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011240 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011241 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011242 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011243 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011244 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011246 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20011249 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20011250 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20011251 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011252 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011255 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20011258 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011259 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011260 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011262 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens E PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011263 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens E PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011264 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens E PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011265 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens E PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011266 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens E PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011267 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens E PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011268 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens E PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011271 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens E PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011272 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens E PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011273 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens E PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011274 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens E PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011275 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens E PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011276 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens F PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011277 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens F PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011278 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens F PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011279 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens F PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011280 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens F PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011281 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens F PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011282 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens F PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011285 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens F PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011286 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens F PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011287 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens F PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011288 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens F PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011289 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens F PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011290 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011291 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011292 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011293 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011294 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011295 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011296 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011299 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011300 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011301 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011302 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011303 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011304 Microbes metabolize substances PMDBM2020206 74426 Collinsella aerofaciens PMDBD2000017 Anti-axis programmed cell death protein 1 (PD-1) and its ligand (PD-L1) Therapeutic substance immune checkpoint repressing T cell response n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. abundance of Bifidobacterium longum, Collinsella aerofaciens, and Enterococcus faecium was associated with anti-PD1 efficacy in metastatic melanoma patients, while Gopalakrishnan et al. observed higher microbial diversity and increased Ruminococcaceae levels in responding melanoma patients relative to non-responders, together with an enhanced systemic and antitumor immunity n.a. PMID PMID: 36467581 PMDBI20011305 Microbes metabolize substances PMDBM2021489 1907654 Collinsella bouchesdurhonensis PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20011306 Microbes metabolize substances PMDBM2021489 1907654 Collinsella bouchesdurhonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011307 Microbes metabolize substances PMDBM2021489 1907654 Collinsella bouchesdurhonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011308 Microbes metabolize substances PMDBM2021489 1907654 Collinsella bouchesdurhonensis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20011309 Microbes metabolize substances PMDBM2021490 1720204 Collinsella ihuae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011310 Microbes metabolize substances PMDBM2021490 1720204 Collinsella ihuae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011311 Microbes metabolize substances PMDBM2021490 1720204 Collinsella ihuae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011312 Microbes metabolize substances PMDBM2021490 1720204 Collinsella ihuae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011313 Microbes metabolize substances PMDBM2021490 1720204 Collinsella ihuae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011314 Microbes metabolize substances PMDBM2021490 1720204 Collinsella ihuae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011315 Microbes metabolize substances PMDBM2021490 1720204 Collinsella ihuae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011318 Microbes metabolize substances PMDBM2021490 1720204 Collinsella ihuae PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20011319 Microbes metabolize substances PMDBM2021490 1720204 Collinsella ihuae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011320 Microbes metabolize substances PMDBM2021490 1720204 Collinsella ihuae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011321 Microbes metabolize substances PMDBM2021490 1720204 Collinsella ihuae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011322 Microbes metabolize substances PMDBM2021490 1720204 Collinsella ihuae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011323 Microbes metabolize substances PMDBM2021490 1720204 Collinsella ihuae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011324 Microbes metabolize substances PMDBM2020207 147207 Collinsella intestinalis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011325 Microbes metabolize substances PMDBM2020207 147207 Collinsella intestinalis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011326 Microbes metabolize substances PMDBM2020207 147207 Collinsella intestinalis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011327 Microbes metabolize substances PMDBM2020207 147207 Collinsella intestinalis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011328 Microbes metabolize substances PMDBM2020207 147207 Collinsella intestinalis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011329 Microbes metabolize substances PMDBM2020207 147207 Collinsella intestinalis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011330 Microbes metabolize substances PMDBM2020207 147207 Collinsella intestinalis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011333 Microbes metabolize substances PMDBM2020207 147207 Collinsella intestinalis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011334 Microbes metabolize substances PMDBM2020207 147207 Collinsella intestinalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011335 Microbes metabolize substances PMDBM2020207 147207 Collinsella intestinalis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011336 Microbes metabolize substances PMDBM2020207 147207 Collinsella intestinalis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011337 Microbes metabolize substances PMDBM2020207 147207 Collinsella intestinalis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011338 Microbes metabolize substances PMDBM2020207 147207 Collinsella intestinalis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011339 Microbes metabolize substances PMDBM2020207 147207 Collinsella intestinalis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011340 Microbes metabolize substances PMDBM2021491 1871016 Collinsella phocaeensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011341 Microbes metabolize substances PMDBM2021491 1871016 Collinsella phocaeensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011342 Microbes metabolize substances PMDBM2021491 1871016 Collinsella phocaeensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011343 Microbes metabolize substances PMDBM2021491 1871016 Collinsella phocaeensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011344 Microbes metabolize substances PMDBM2021491 1871016 Collinsella phocaeensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011345 Microbes metabolize substances PMDBM2021491 1871016 Collinsella phocaeensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011346 Microbes metabolize substances PMDBM2021491 1871016 Collinsella phocaeensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011349 Microbes metabolize substances PMDBM2021491 1871016 Collinsella phocaeensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011350 Microbes metabolize substances PMDBM2021491 1871016 Collinsella phocaeensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011351 Microbes metabolize substances PMDBM2021491 1871016 Collinsella phocaeensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011352 Microbes metabolize substances PMDBM2021491 1871016 Collinsella phocaeensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011353 Microbes metabolize substances PMDBM2021491 1871016 Collinsella phocaeensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011354 Microbes metabolize substances PMDBM2021491 1871016 Collinsella phocaeensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011355 Microbes metabolize substances PMDBM2021491 1871016 Collinsella phocaeensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011356 Microbes metabolize substances PMDBM2021492 1937461 Collinsella provencensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011357 Microbes metabolize substances PMDBM2021492 1937461 Collinsella provencensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011358 Microbes metabolize substances PMDBM2021492 1937461 Collinsella provencensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011359 Microbes metabolize substances PMDBM2021492 1937461 Collinsella provencensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011360 Microbes metabolize substances PMDBM2021492 1937461 Collinsella provencensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011361 Microbes metabolize substances PMDBM2021492 1937461 Collinsella provencensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011362 Microbes metabolize substances PMDBM2021492 1937461 Collinsella provencensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011365 Microbes metabolize substances PMDBM2021492 1937461 Collinsella provencensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011366 Microbes metabolize substances PMDBM2021492 1937461 Collinsella provencensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011367 Microbes metabolize substances PMDBM2021492 1937461 Collinsella provencensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011368 Microbes metabolize substances PMDBM2021492 1937461 Collinsella provencensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011369 Microbes metabolize substances PMDBM2021492 1937461 Collinsella provencensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011370 Microbes metabolize substances PMDBM2021492 1937461 Collinsella provencensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011371 Microbes metabolize substances PMDBM2021492 1937461 Collinsella provencensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011372 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000434535 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011373 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000434535 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011374 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000434535 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011375 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000434535 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011376 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000434535 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011377 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000434535 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011378 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000434535 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011381 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000434535 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011382 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000434535 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011383 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000434535 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011384 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000434535 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011385 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000434535 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011386 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000763055 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011387 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000763055 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011388 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000763055 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011389 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000763055 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011390 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000763055 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011391 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000763055 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011392 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000763055 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011395 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000763055 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011396 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000763055 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011397 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000763055 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011398 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000763055 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011399 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp000763055 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011400 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002232035 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011401 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002232035 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011402 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002232035 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011403 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002232035 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011405 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002232035 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011407 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002232035 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011408 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002232035 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011409 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002232035 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011410 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002232035 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011413 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002232035 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011414 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002232035 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011415 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002232035 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011416 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002232035 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011418 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002232035 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011419 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002232035 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011420 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002232035 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011421 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002391315 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011422 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002391315 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011423 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002391315 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011424 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002391315 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011425 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002391315 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011426 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002391315 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011427 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002391315 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011430 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002391315 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011431 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002391315 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011432 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002391315 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011433 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002391315 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011434 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp002391315 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011435 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp003487125 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011436 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp003487125 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011437 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp003487125 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011438 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp003487125 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011439 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp003487125 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011440 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp003487125 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011441 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp003487125 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011444 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp003487125 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011445 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp003487125 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011446 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp003487125 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011447 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp003487125 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011448 Microbes metabolize substances PMDBM2020581 1965294 Collinsella sp003487125 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011449 Microbes metabolize substances PMDBM2020024 147206 Collinsella stercoris PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011450 Microbes metabolize substances PMDBM2020024 147206 Collinsella stercoris PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011451 Microbes metabolize substances PMDBM2020024 147206 Collinsella stercoris PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011452 Microbes metabolize substances PMDBM2020024 147206 Collinsella stercoris PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011453 Microbes metabolize substances PMDBM2020024 147206 Collinsella stercoris PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011454 Microbes metabolize substances PMDBM2020024 147206 Collinsella stercoris PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011455 Microbes metabolize substances PMDBM2020024 147206 Collinsella stercoris PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011458 Microbes metabolize substances PMDBM2020024 147206 Collinsella stercoris PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011459 Microbes metabolize substances PMDBM2020024 147206 Collinsella stercoris PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011460 Microbes metabolize substances PMDBM2020024 147206 Collinsella stercoris PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011461 Microbes metabolize substances PMDBM2020024 147206 Collinsella stercoris PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011462 Microbes metabolize substances PMDBM2020024 147206 Collinsella stercoris PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011463 Microbes metabolize substances PMDBM2020024 147206 Collinsella stercoris PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011464 Microbes metabolize substances PMDBM2020024 147206 Collinsella stercoris PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011465 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011466 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011467 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011468 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011469 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011470 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011471 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011472 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011473 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011475 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20011478 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20011479 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20011480 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20011481 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011482 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011485 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20011488 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011489 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011490 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011492 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011493 Microbes metabolize substances PMDBM2021007 626935 Collinsella tanakaei PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011494 Microbes metabolize substances PMDBM2021493 1870987 Collinsella vaginalis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011495 Microbes metabolize substances PMDBM2021493 1870987 Collinsella vaginalis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011496 Microbes metabolize substances PMDBM2021493 1870987 Collinsella vaginalis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011497 Microbes metabolize substances PMDBM2021493 1870987 Collinsella vaginalis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011498 Microbes metabolize substances PMDBM2021493 1870987 Collinsella vaginalis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011499 Microbes metabolize substances PMDBM2021493 1870987 Collinsella vaginalis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011500 Microbes metabolize substances PMDBM2021493 1870987 Collinsella vaginalis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011503 Microbes metabolize substances PMDBM2021493 1870987 Collinsella vaginalis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011504 Microbes metabolize substances PMDBM2021493 1870987 Collinsella vaginalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011505 Microbes metabolize substances PMDBM2021493 1870987 Collinsella vaginalis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011506 Microbes metabolize substances PMDBM2021493 1870987 Collinsella vaginalis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011507 Microbes metabolize substances PMDBM2021493 1870987 Collinsella vaginalis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011508 Microbes metabolize substances PMDBM2021493 1870987 Collinsella vaginalis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011509 Microbes metabolize substances PMDBM2021493 1870987 Collinsella vaginalis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011510 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD636 Paclitaxel "Therapeutic Substance; Herbal Substance" chemotherapeutic agent n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. developmental delay n.a. PMID PMID: 36467581 PMDBI20011511 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD8 5-fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. 5-fluorouridine monophospate n.a. Uracil phosphoribosyltransferase activity increased n.a. n.a. n.a. Lead to sterility n.a. PMID PMID: 36467581 PMDBI20011512 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD1072 Camptothecin Therapeutic substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. production of few dead embryos n.a. PMID PMID: 36467581 PMDBI20011513 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD290 Doxorubicin "Therapeutic Substance; Herbal Substance" chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown no impact n.a. n.a. n.a. No effect on Caenorhabditis elegans n.a. PMID PMID: 36467581 PMDBI20011514 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown no impact n.a. n.a. n.a. No effect on Caenorhabditis elegans n.a. PMID PMID: 36467581 PMDBI20011515 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD535 Methotrexate Therapeutic Substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown no impact n.a. n.a. n.a. No effect on Caenorhabditis elegans n.a. PMID PMID: 36467581 PMDBI20011516 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD829 Temozolomide Therapeutic Substance antitumor n.a. n.a. n.a. n.a. n.a. n.a. unknown no impact n.a. n.a. n.a. No effect on Caenorhabditis elegans n.a. PMID PMID: 36467581 PMDBI20011517 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD1005 5-fluoro-2'-deoxyuridine Therapeutic substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown no impact n.a. n.a. n.a. No effect on Caenorhabditis elegans n.a. PMID PMID: 36467581 PMDBI20011518 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD1316 Neocarzinostatin Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. unknown no impact n.a. n.a. n.a. No effect on Caenorhabditis elegans n.a. PMID PMID: 36467581 PMDBI20011519 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD1431 Sunitinib Therapeutic substance multi-targeted receptor tyrosine kinase (RTK) inhibitor n.a. n.a. n.a. n.a. n.a. n.a. unknown no impact n.a. n.a. n.a. No effect on Caenorhabditis elegans n.a. PMID PMID: 36467581 PMDBI20011520 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD1433 Tamoxifen Therapeutic substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown no impact n.a. n.a. n.a. No effect on Caenorhabditis elegans n.a. PMID PMID: 36467581 PMDBI20011521 Microbes metabolize substances PMDBM2021494 225992 Comamonas kerstersii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011522 Microbes metabolize substances PMDBM2021494 225992 Comamonas kerstersii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011523 Microbes metabolize substances PMDBM2021494 225992 Comamonas kerstersii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011524 Microbes metabolize substances PMDBM2021495 100884 Coprobacillus cateniformis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011525 Microbes metabolize substances PMDBM2021495 100884 Coprobacillus cateniformis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011526 Microbes metabolize substances PMDBM2021495 100884 Coprobacillus cateniformis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011527 Microbes metabolize substances PMDBM2021495 100884 Coprobacillus cateniformis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011529 Microbes metabolize substances PMDBM2021495 100884 Coprobacillus cateniformis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011531 Microbes metabolize substances PMDBM2021495 100884 Coprobacillus cateniformis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011532 Microbes metabolize substances PMDBM2021495 100884 Coprobacillus cateniformis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011533 Microbes metabolize substances PMDBM2021495 100884 Coprobacillus cateniformis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011534 Microbes metabolize substances PMDBM2021495 100884 Coprobacillus cateniformis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011537 Microbes metabolize substances PMDBM2021495 100884 Coprobacillus cateniformis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011538 Microbes metabolize substances PMDBM2021495 100884 Coprobacillus cateniformis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011539 Microbes metabolize substances PMDBM2021495 100884 Coprobacillus cateniformis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011540 Microbes metabolize substances PMDBM2021495 100884 Coprobacillus cateniformis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011542 Microbes metabolize substances PMDBM2021495 100884 Coprobacillus cateniformis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011543 Microbes metabolize substances PMDBM2021495 100884 Coprobacillus cateniformis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011544 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011545 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011546 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011547 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011549 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011551 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011552 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011553 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011554 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011555 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011556 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011558 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20011561 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20011562 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20011563 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011564 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011567 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20011570 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011571 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011574 Microbes metabolize substances PMDBM715 1348911 Coprobacter PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011575 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011576 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011577 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011578 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011580 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011582 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011583 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011584 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011585 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011586 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011587 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011589 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20011592 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20011593 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20011594 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011595 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011598 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20011601 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011602 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011605 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011606 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011607 Microbes metabolize substances PMDBM2021496 1099853 Coprobacter fastidiosus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011608 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011609 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011610 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011611 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011613 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011615 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011616 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011617 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011618 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011619 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20011620 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011622 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20011625 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20011626 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20011627 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011628 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011631 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20011634 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011635 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011638 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011639 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011640 Microbes metabolize substances PMDBM2021497 1501392 Coprobacter secundus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011641 Microbes metabolize substances PMDBM2008714 n.a. Coprococcus A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011642 Microbes metabolize substances PMDBM2008714 n.a. Coprococcus A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011643 Microbes metabolize substances PMDBM2008714 n.a. Coprococcus A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011644 Microbes metabolize substances PMDBM2008714 n.a. Coprococcus A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011645 Microbes metabolize substances PMDBM2008714 n.a. Coprococcus A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011646 Microbes metabolize substances PMDBM2020101 116085 Coprococcus A catus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20011647 Microbes metabolize substances PMDBM2020101 116085 Coprococcus A catus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011648 Microbes metabolize substances PMDBM2020101 116085 Coprococcus A catus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011649 Microbes metabolize substances PMDBM2020101 116085 Coprococcus A catus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011650 Microbes metabolize substances PMDBM2020101 116085 Coprococcus A catus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011651 Microbes metabolize substances PMDBM2008716 n.a. Coprococcus B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011652 Microbes metabolize substances PMDBM2008716 n.a. Coprococcus B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011653 Microbes metabolize substances PMDBM2008716 n.a. Coprococcus B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011654 Microbes metabolize substances PMDBM2008716 n.a. Coprococcus B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011655 Microbes metabolize substances PMDBM2008716 n.a. Coprococcus B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011656 Microbes metabolize substances PMDBM2008716 n.a. Coprococcus B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011657 Microbes metabolize substances PMDBM2008716 n.a. Coprococcus B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011660 Microbes metabolize substances PMDBM2008716 n.a. Coprococcus B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011661 Microbes metabolize substances PMDBM2008716 n.a. Coprococcus B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011662 Microbes metabolize substances PMDBM2008716 n.a. Coprococcus B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011663 Microbes metabolize substances PMDBM2008716 n.a. Coprococcus B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011664 Microbes metabolize substances PMDBM2008716 n.a. Coprococcus B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011665 Microbes metabolize substances PMDBM2008716 n.a. Coprococcus B PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011666 Microbes metabolize substances PMDBM2008716 n.a. Coprococcus B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011667 Microbes metabolize substances PMDBM2008716 n.a. Coprococcus B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011668 Microbes metabolize substances PMDBM2020208 410072 Coprococcus B comes PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011669 Microbes metabolize substances PMDBM2020208 410072 Coprococcus B comes PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011670 Microbes metabolize substances PMDBM2020208 410072 Coprococcus B comes PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011671 Microbes metabolize substances PMDBM2020208 410072 Coprococcus B comes PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011673 Microbes metabolize substances PMDBM2020208 410072 Coprococcus B comes PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20011675 Microbes metabolize substances PMDBM2020208 410072 Coprococcus B comes PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011676 Microbes metabolize substances PMDBM2020208 410072 Coprococcus B comes PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011677 Microbes metabolize substances PMDBM2020208 410072 Coprococcus B comes PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011678 Microbes metabolize substances PMDBM2020208 410072 Coprococcus B comes PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011681 Microbes metabolize substances PMDBM2020208 410072 Coprococcus B comes PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011682 Microbes metabolize substances PMDBM2020208 410072 Coprococcus B comes PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011683 Microbes metabolize substances PMDBM2020208 410072 Coprococcus B comes PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011684 Microbes metabolize substances PMDBM2020208 410072 Coprococcus B comes PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011686 Microbes metabolize substances PMDBM2020208 410072 Coprococcus B comes PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011687 Microbes metabolize substances PMDBM170 33042 Coprococcus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011688 Microbes metabolize substances PMDBM170 33042 Coprococcus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011689 Microbes metabolize substances PMDBM170 33042 Coprococcus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011690 Microbes metabolize substances PMDBM170 33042 Coprococcus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011691 Microbes metabolize substances PMDBM170 33042 Coprococcus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011692 Microbes metabolize substances PMDBM170 33042 Coprococcus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011693 Microbes metabolize substances PMDBM170 33042 Coprococcus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011696 Microbes metabolize substances PMDBM170 33042 Coprococcus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011697 Microbes metabolize substances PMDBM170 33042 Coprococcus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011698 Microbes metabolize substances PMDBM170 33042 Coprococcus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011699 Microbes metabolize substances PMDBM170 33042 Coprococcus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011700 Microbes metabolize substances PMDBM170 33042 Coprococcus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011701 Microbes metabolize substances PMDBM170 33042 Coprococcus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011702 Microbes metabolize substances PMDBM170 33042 Coprococcus PMDBD1460 Tolcapone Therapeutic substance Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity n.a. n.a. n.a. a potential link betweenthe gut microbiome and tolcapone toxicity n.a. PMID PMID: 36467581 PMDBI20011703 Microbes metabolize substances PMDBM170 33042 Coprococcus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011704 Microbes metabolize substances PMDBM170 33042 Coprococcus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011705 Microbes metabolize substances PMDBM2020208 n.a. Coprococcus comes VPI CI-38,ATCC 27758 PMDBD558 Montelukast Therapeutic Substance Drugs for obstructive airway disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Biotransformation n.a. PMID PMID: 36467581 PMDBI20011706 Microbes metabolize substances PMDBM2020588 33043 Coprococcus eutactus A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011707 Microbes metabolize substances PMDBM2020588 33043 Coprococcus eutactus A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011708 Microbes metabolize substances PMDBM2020588 33043 Coprococcus eutactus A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011709 Microbes metabolize substances PMDBM2020588 33043 Coprococcus eutactus A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011710 Microbes metabolize substances PMDBM2020588 33043 Coprococcus eutactus A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011711 Microbes metabolize substances PMDBM2020588 33043 Coprococcus eutactus A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011712 Microbes metabolize substances PMDBM2020588 33043 Coprococcus eutactus A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011715 Microbes metabolize substances PMDBM2020588 33043 Coprococcus eutactus A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011716 Microbes metabolize substances PMDBM2020588 33043 Coprococcus eutactus A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011717 Microbes metabolize substances PMDBM2020588 33043 Coprococcus eutactus A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011718 Microbes metabolize substances PMDBM2020588 33043 Coprococcus eutactus A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011719 Microbes metabolize substances PMDBM2020588 33043 Coprococcus eutactus A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011720 Microbes metabolize substances PMDBM2020588 33043 Coprococcus eutactus A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011721 Microbes metabolize substances PMDBM2020588 33043 Coprococcus eutactus A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011722 Microbes metabolize substances PMDBM2020588 33043 Coprococcus eutactus A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011723 Microbes metabolize substances PMDBM2021498 1263071 Coprococcus eutactus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011724 Microbes metabolize substances PMDBM2021498 1263071 Coprococcus eutactus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011725 Microbes metabolize substances PMDBM2021498 1263071 Coprococcus eutactus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011726 Microbes metabolize substances PMDBM2021498 1263071 Coprococcus eutactus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011727 Microbes metabolize substances PMDBM2021498 1263071 Coprococcus eutactus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011728 Microbes metabolize substances PMDBM2021498 1263071 Coprococcus eutactus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011729 Microbes metabolize substances PMDBM2021498 1263071 Coprococcus eutactus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011732 Microbes metabolize substances PMDBM2021498 1263071 Coprococcus eutactus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011733 Microbes metabolize substances PMDBM2021498 1263071 Coprococcus eutactus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011734 Microbes metabolize substances PMDBM2021498 1263071 Coprococcus eutactus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011735 Microbes metabolize substances PMDBM2021498 1263071 Coprococcus eutactus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011736 Microbes metabolize substances PMDBM2021498 1263071 Coprococcus eutactus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011737 Microbes metabolize substances PMDBM2021498 1263071 Coprococcus eutactus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011738 Microbes metabolize substances PMDBM2021498 1263071 Coprococcus eutactus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011739 Microbes metabolize substances PMDBM2021498 1263071 Coprococcus eutactus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011740 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000154245 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011741 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000154245 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011742 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000154245 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011743 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000154245 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011744 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000154245 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011745 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000154245 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011746 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000154245 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011749 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000154245 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011750 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000154245 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011751 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000154245 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011752 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000154245 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011753 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000154245 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011754 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000154245 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011755 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000154245 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011756 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000154245 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011757 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000433075 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011758 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000433075 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011759 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000433075 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011760 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000433075 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011761 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000433075 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011762 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000433075 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011763 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000433075 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011766 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000433075 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011767 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000433075 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011768 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000433075 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011769 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000433075 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011770 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000433075 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011771 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000433075 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011772 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000433075 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011773 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp000433075 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011774 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp900066115 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011775 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp900066115 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011776 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp900066115 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011777 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp900066115 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011778 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp900066115 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011779 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp900066115 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011780 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp900066115 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011783 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp900066115 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011784 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp900066115 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011785 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp900066115 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011786 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp900066115 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011787 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp900066115 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20011788 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp900066115 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011789 Microbes metabolize substances PMDBM2021499 2049024 Coprococcus sp900066115 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011790 Microbes metabolize substances PMDBM174 84999 Coriobacteriales PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011791 Microbes metabolize substances PMDBM175 1716 Corynebacterium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011792 Microbes metabolize substances PMDBM175 1716 Corynebacterium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011793 Microbes metabolize substances PMDBM175 1716 Corynebacterium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011794 Microbes metabolize substances PMDBM175 1716 Corynebacterium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011795 Microbes metabolize substances PMDBM175 1716 Corynebacterium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011796 Microbes metabolize substances PMDBM175 1716 Corynebacterium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011797 Microbes metabolize substances PMDBM175 1716 Corynebacterium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011800 Microbes metabolize substances PMDBM175 1716 Corynebacterium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011801 Microbes metabolize substances PMDBM175 1716 Corynebacterium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011802 Microbes metabolize substances PMDBM175 1716 Corynebacterium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011803 Microbes metabolize substances PMDBM175 1716 Corynebacterium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011804 Microbes metabolize substances PMDBM175 1716 Corynebacterium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011805 Microbes metabolize substances PMDBM175 1716 Corynebacterium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011806 Microbes metabolize substances PMDBM175 1716 Corynebacterium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011807 Microbes metabolize substances PMDBM2021500 38286 Corynebacterium afermentans PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011808 Microbes metabolize substances PMDBM2021500 38286 Corynebacterium afermentans PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011809 Microbes metabolize substances PMDBM2021500 38286 Corynebacterium afermentans PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011810 Microbes metabolize substances PMDBM2021500 38286 Corynebacterium afermentans PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011811 Microbes metabolize substances PMDBM2021500 38286 Corynebacterium afermentans PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011812 Microbes metabolize substances PMDBM2021500 38286 Corynebacterium afermentans PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011813 Microbes metabolize substances PMDBM2021500 38286 Corynebacterium afermentans PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011816 Microbes metabolize substances PMDBM2021500 38286 Corynebacterium afermentans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011817 Microbes metabolize substances PMDBM2021500 38286 Corynebacterium afermentans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011818 Microbes metabolize substances PMDBM2021500 38286 Corynebacterium afermentans PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011819 Microbes metabolize substances PMDBM2021500 38286 Corynebacterium afermentans PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011820 Microbes metabolize substances PMDBM2021500 38286 Corynebacterium afermentans PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011821 Microbes metabolize substances PMDBM2021018 1697 Corynebacterium ammoniagenes PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011822 Microbes metabolize substances PMDBM2021018 1697 Corynebacterium ammoniagenes PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011823 Microbes metabolize substances PMDBM2021018 1697 Corynebacterium ammoniagenes PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011824 Microbes metabolize substances PMDBM2021018 1697 Corynebacterium ammoniagenes PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011825 Microbes metabolize substances PMDBM2021018 1697 Corynebacterium ammoniagenes PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011826 Microbes metabolize substances PMDBM2021018 1697 Corynebacterium ammoniagenes PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011827 Microbes metabolize substances PMDBM2021018 1697 Corynebacterium ammoniagenes PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011830 Microbes metabolize substances PMDBM2021018 1697 Corynebacterium ammoniagenes PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011831 Microbes metabolize substances PMDBM2021018 1697 Corynebacterium ammoniagenes PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011832 Microbes metabolize substances PMDBM2021018 1697 Corynebacterium ammoniagenes PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011833 Microbes metabolize substances PMDBM2021018 1697 Corynebacterium ammoniagenes PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011834 Microbes metabolize substances PMDBM2021018 1697 Corynebacterium ammoniagenes PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011835 Microbes metabolize substances PMDBM2021027 43765 Corynebacterium amycolatum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011836 Microbes metabolize substances PMDBM2021027 43765 Corynebacterium amycolatum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011837 Microbes metabolize substances PMDBM2021027 43765 Corynebacterium amycolatum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011838 Microbes metabolize substances PMDBM2021027 43765 Corynebacterium amycolatum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011839 Microbes metabolize substances PMDBM2021027 43765 Corynebacterium amycolatum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011840 Microbes metabolize substances PMDBM2021027 43765 Corynebacterium amycolatum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011841 Microbes metabolize substances PMDBM2021027 43765 Corynebacterium amycolatum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011844 Microbes metabolize substances PMDBM2021027 43765 Corynebacterium amycolatum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011845 Microbes metabolize substances PMDBM2021027 43765 Corynebacterium amycolatum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011846 Microbes metabolize substances PMDBM2021027 43765 Corynebacterium amycolatum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011847 Microbes metabolize substances PMDBM2021027 43765 Corynebacterium amycolatum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011848 Microbes metabolize substances PMDBM2021027 43765 Corynebacterium amycolatum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011849 Microbes metabolize substances PMDBM2021027 43765 Corynebacterium amycolatum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011850 Microbes metabolize substances PMDBM2021027 43765 Corynebacterium amycolatum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011851 Microbes metabolize substances PMDBM2020593 169292 Corynebacterium aurimucosum C PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011852 Microbes metabolize substances PMDBM2020593 169292 Corynebacterium aurimucosum C PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011853 Microbes metabolize substances PMDBM2020593 169292 Corynebacterium aurimucosum E PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011854 Microbes metabolize substances PMDBM2020593 169292 Corynebacterium aurimucosum E PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011855 Microbes metabolize substances PMDBM2020593 169292 Corynebacterium aurimucosum E PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011856 Microbes metabolize substances PMDBM2020593 169292 Corynebacterium aurimucosum E PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011857 Microbes metabolize substances PMDBM2020593 169292 Corynebacterium aurimucosum E PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011858 Microbes metabolize substances PMDBM2020593 169292 Corynebacterium aurimucosum E PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011859 Microbes metabolize substances PMDBM2020593 169292 Corynebacterium aurimucosum E PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011862 Microbes metabolize substances PMDBM2020593 169292 Corynebacterium aurimucosum E PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011863 Microbes metabolize substances PMDBM2020593 169292 Corynebacterium aurimucosum E PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011864 Microbes metabolize substances PMDBM2020593 169292 Corynebacterium aurimucosum E PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011865 Microbes metabolize substances PMDBM2020593 169292 Corynebacterium aurimucosum E PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011866 Microbes metabolize substances PMDBM2020593 169292 Corynebacterium aurimucosum E PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011867 Microbes metabolize substances PMDBM2020593 169292 Corynebacterium aurimucosum E PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011868 Microbes metabolize substances PMDBM2020593 169292 Corynebacterium aurimucosum E PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011869 Microbes metabolize substances PMDBM2020594 1720192 Corynebacterium bouchesdurhonense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011870 Microbes metabolize substances PMDBM2020594 1720192 Corynebacterium bouchesdurhonense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011871 Microbes metabolize substances PMDBM2020594 1720192 Corynebacterium bouchesdurhonense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011872 Microbes metabolize substances PMDBM2020594 1720192 Corynebacterium bouchesdurhonense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011873 Microbes metabolize substances PMDBM2020594 1720192 Corynebacterium bouchesdurhonense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011874 Microbes metabolize substances PMDBM2020594 1720192 Corynebacterium bouchesdurhonense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011875 Microbes metabolize substances PMDBM2020594 1720192 Corynebacterium bouchesdurhonense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011878 Microbes metabolize substances PMDBM2020594 1720192 Corynebacterium bouchesdurhonense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011879 Microbes metabolize substances PMDBM2020594 1720192 Corynebacterium bouchesdurhonense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011880 Microbes metabolize substances PMDBM2020594 1720192 Corynebacterium bouchesdurhonense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011881 Microbes metabolize substances PMDBM2020594 1720192 Corynebacterium bouchesdurhonense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011882 Microbes metabolize substances PMDBM2020594 1720192 Corynebacterium bouchesdurhonense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011883 Microbes metabolize substances PMDBM2020594 1720192 Corynebacterium bouchesdurhonense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011884 Microbes metabolize substances PMDBM2020594 1720192 Corynebacterium bouchesdurhonense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011885 Microbes metabolize substances PMDBM2020599 39791 Corynebacterium glucuronolyticum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011886 Microbes metabolize substances PMDBM2021501 1979527 Corynebacterium kefirresidentii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011887 Microbes metabolize substances PMDBM2021501 1979527 Corynebacterium kefirresidentii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011888 Microbes metabolize substances PMDBM2021501 1979527 Corynebacterium kefirresidentii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011889 Microbes metabolize substances PMDBM2021501 1979527 Corynebacterium kefirresidentii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011890 Microbes metabolize substances PMDBM2021501 1979527 Corynebacterium kefirresidentii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011891 Microbes metabolize substances PMDBM2021501 1979527 Corynebacterium kefirresidentii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011892 Microbes metabolize substances PMDBM2021501 1979527 Corynebacterium kefirresidentii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011895 Microbes metabolize substances PMDBM2021501 1979527 Corynebacterium kefirresidentii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011896 Microbes metabolize substances PMDBM2021501 1979527 Corynebacterium kefirresidentii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011897 Microbes metabolize substances PMDBM2021501 1979527 Corynebacterium kefirresidentii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011898 Microbes metabolize substances PMDBM2021501 1979527 Corynebacterium kefirresidentii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011899 Microbes metabolize substances PMDBM2021501 1979527 Corynebacterium kefirresidentii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011900 Microbes metabolize substances PMDBM2021501 1979527 Corynebacterium kefirresidentii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011901 Microbes metabolize substances PMDBM2021501 1979527 Corynebacterium kefirresidentii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011902 Microbes metabolize substances PMDBM2020602 161879 Corynebacterium kroppenstedtii A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011903 Microbes metabolize substances PMDBM2020602 161879 Corynebacterium kroppenstedtii A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011904 Microbes metabolize substances PMDBM2020602 161879 Corynebacterium kroppenstedtii A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011905 Microbes metabolize substances PMDBM2020605 1686286 Corynebacterium phoceense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011906 Microbes metabolize substances PMDBM2020605 1686286 Corynebacterium phoceense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011907 Microbes metabolize substances PMDBM2020605 1686286 Corynebacterium phoceense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011908 Microbes metabolize substances PMDBM2020605 1686286 Corynebacterium phoceense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011909 Microbes metabolize substances PMDBM2020605 1686286 Corynebacterium phoceense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011910 Microbes metabolize substances PMDBM2020605 1686286 Corynebacterium phoceense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011911 Microbes metabolize substances PMDBM2020605 1686286 Corynebacterium phoceense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011914 Microbes metabolize substances PMDBM2020605 1686286 Corynebacterium phoceense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011915 Microbes metabolize substances PMDBM2020605 1686286 Corynebacterium phoceense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011916 Microbes metabolize substances PMDBM2020605 1686286 Corynebacterium phoceense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011917 Microbes metabolize substances PMDBM2020605 1686286 Corynebacterium phoceense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011918 Microbes metabolize substances PMDBM2020605 1686286 Corynebacterium phoceense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011919 Microbes metabolize substances PMDBM2020605 1686286 Corynebacterium phoceense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011920 Microbes metabolize substances PMDBM2020605 1686286 Corynebacterium phoceense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011921 Microbes metabolize substances PMDBM2020606 43769 Corynebacterium propinquum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011922 Microbes metabolize substances PMDBM2020606 43769 Corynebacterium propinquum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011923 Microbes metabolize substances PMDBM2020606 43769 Corynebacterium propinquum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011924 Microbes metabolize substances PMDBM2020606 43769 Corynebacterium propinquum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011925 Microbes metabolize substances PMDBM2020606 43769 Corynebacterium propinquum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011926 Microbes metabolize substances PMDBM2020606 43769 Corynebacterium propinquum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011927 Microbes metabolize substances PMDBM2020606 43769 Corynebacterium propinquum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011930 Microbes metabolize substances PMDBM2020606 43769 Corynebacterium propinquum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011931 Microbes metabolize substances PMDBM2020606 43769 Corynebacterium propinquum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011932 Microbes metabolize substances PMDBM2020606 43769 Corynebacterium propinquum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011933 Microbes metabolize substances PMDBM2020606 43769 Corynebacterium propinquum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011934 Microbes metabolize substances PMDBM2020607 1737425 Corynebacterium provencense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011935 Microbes metabolize substances PMDBM2020607 1737425 Corynebacterium provencense PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20011936 Microbes metabolize substances PMDBM2020607 1737425 Corynebacterium provencense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011937 Microbes metabolize substances PMDBM2020607 1737425 Corynebacterium provencense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011938 Microbes metabolize substances PMDBM2020607 1737425 Corynebacterium provencense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011939 Microbes metabolize substances PMDBM2020607 1737425 Corynebacterium provencense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011940 Microbes metabolize substances PMDBM2020607 1737425 Corynebacterium provencense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011941 Microbes metabolize substances PMDBM2020607 1737425 Corynebacterium provencense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011944 Microbes metabolize substances PMDBM2020607 1737425 Corynebacterium provencense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011945 Microbes metabolize substances PMDBM2020607 1737425 Corynebacterium provencense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011946 Microbes metabolize substances PMDBM2020607 1737425 Corynebacterium provencense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011947 Microbes metabolize substances PMDBM2020607 1737425 Corynebacterium provencense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011948 Microbes metabolize substances PMDBM2020607 1737425 Corynebacterium provencense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011949 Microbes metabolize substances PMDBM2020607 1737425 Corynebacterium provencense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011950 Microbes metabolize substances PMDBM2020607 1737425 Corynebacterium provencense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011951 Microbes metabolize substances PMDBM2021502 146827 Corynebacterium simulans PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011952 Microbes metabolize substances PMDBM2021502 146827 Corynebacterium simulans PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011953 Microbes metabolize substances PMDBM2021502 146827 Corynebacterium simulans PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011954 Microbes metabolize substances PMDBM2021502 146827 Corynebacterium simulans PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011955 Microbes metabolize substances PMDBM2021502 146827 Corynebacterium simulans PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011956 Microbes metabolize substances PMDBM2021502 146827 Corynebacterium simulans PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011957 Microbes metabolize substances PMDBM2021502 146827 Corynebacterium simulans PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011960 Microbes metabolize substances PMDBM2021502 146827 Corynebacterium simulans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011961 Microbes metabolize substances PMDBM2021502 146827 Corynebacterium simulans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011962 Microbes metabolize substances PMDBM2021502 146827 Corynebacterium simulans PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011963 Microbes metabolize substances PMDBM2021502 146827 Corynebacterium simulans PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011964 Microbes metabolize substances PMDBM2021502 146827 Corynebacterium simulans PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011965 Microbes metabolize substances PMDBM2021502 146827 Corynebacterium simulans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011966 Microbes metabolize substances PMDBM2021502 146827 Corynebacterium simulans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011967 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp000755185 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011968 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp000755185 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011969 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp000755185 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011970 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp000755185 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011971 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp000755185 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011972 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp000755185 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011973 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp000755185 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011976 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp000755185 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011977 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp000755185 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011978 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp000755185 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011979 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp000755185 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011980 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp000755185 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011981 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp000755185 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011982 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp000755185 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20011983 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp900169525 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011984 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp900169525 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011985 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp900169525 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20011986 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp900169525 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011987 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp900169525 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011988 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp900169525 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20011989 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp900169525 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20011992 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp900169525 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20011993 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp900169525 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20011994 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp900169525 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011995 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp900169525 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011996 Microbes metabolize substances PMDBM2021503 1720 Corynebacterium sp900169525 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20011997 Microbes metabolize substances PMDBM2020026 43770 Corynebacterium striatum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20011998 Microbes metabolize substances PMDBM2020026 43770 Corynebacterium striatum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20011999 Microbes metabolize substances PMDBM2020026 43770 Corynebacterium striatum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012000 Microbes metabolize substances PMDBM2020026 43770 Corynebacterium striatum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012001 Microbes metabolize substances PMDBM2020026 43770 Corynebacterium striatum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012002 Microbes metabolize substances PMDBM2020026 43770 Corynebacterium striatum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012003 Microbes metabolize substances PMDBM2020026 43770 Corynebacterium striatum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012006 Microbes metabolize substances PMDBM2020026 43770 Corynebacterium striatum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012007 Microbes metabolize substances PMDBM2020026 43770 Corynebacterium striatum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012008 Microbes metabolize substances PMDBM2020026 43770 Corynebacterium striatum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012009 Microbes metabolize substances PMDBM2020026 43770 Corynebacterium striatum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012010 Microbes metabolize substances PMDBM2020026 43770 Corynebacterium striatum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012011 Microbes metabolize substances PMDBM2020026 43770 Corynebacterium striatum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012012 Microbes metabolize substances PMDBM2020026 43770 Corynebacterium striatum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012013 Microbes metabolize substances PMDBM2021504 1871336 Criibacterium bergeronii PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012014 Microbes metabolize substances PMDBM2021504 1871336 Criibacterium bergeronii PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012015 Microbes metabolize substances PMDBM2021504 1871336 Criibacterium bergeronii PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20012017 Microbes metabolize substances PMDBM2021504 1871336 Criibacterium bergeronii PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20012018 Microbes metabolize substances PMDBM2021504 1871336 Criibacterium bergeronii PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20012019 Microbes metabolize substances PMDBM2021504 1871336 Criibacterium bergeronii PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20012020 Microbes metabolize substances PMDBM2021504 1871336 Criibacterium bergeronii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012021 Microbes metabolize substances PMDBM2021504 1871336 Criibacterium bergeronii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012024 Microbes metabolize substances PMDBM2021504 1871336 Criibacterium bergeronii PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20012028 Microbes metabolize substances PMDBM2021504 1871336 Criibacterium bergeronii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012029 Microbes metabolize substances PMDBM2021504 1871336 Criibacterium bergeronii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012030 Microbes metabolize substances PMDBM2021504 1871336 Criibacterium bergeronii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012031 Microbes metabolize substances PMDBM2021505 413503 Cronobacter malonaticus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012032 Microbes metabolize substances PMDBM2021505 413503 Cronobacter malonaticus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012033 Microbes metabolize substances PMDBM2021505 413503 Cronobacter malonaticus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012034 Microbes metabolize substances PMDBM2021505 413503 Cronobacter malonaticus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012035 Microbes metabolize substances PMDBM2021505 413503 Cronobacter malonaticus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012036 Microbes metabolize substances PMDBM2021505 413503 Cronobacter malonaticus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012037 Microbes metabolize substances PMDBM2021505 413503 Cronobacter malonaticus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012040 Microbes metabolize substances PMDBM2021505 413503 Cronobacter malonaticus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012041 Microbes metabolize substances PMDBM2021505 413503 Cronobacter malonaticus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012042 Microbes metabolize substances PMDBM2021505 413503 Cronobacter malonaticus PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20012043 Microbes metabolize substances PMDBM2021505 413503 Cronobacter malonaticus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012044 Microbes metabolize substances PMDBM2021505 413503 Cronobacter malonaticus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012045 Microbes metabolize substances PMDBM2021505 413503 Cronobacter malonaticus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012046 Microbes metabolize substances PMDBM2021505 413503 Cronobacter malonaticus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012047 Microbes metabolize substances PMDBM2021505 413503 Cronobacter malonaticus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012048 Microbes metabolize substances PMDBM2021505 413503 Cronobacter malonaticus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012049 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012050 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012051 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012052 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD471 Lactulose Therapeutic Substance laxative n.a. n.a. n.a. n.a. Monosaccharides n.a. unknown activity decreased n.a. n.a. n.a. Stimulating the growth of beneficial bacteria such as Bifidobacteria and Lactobacilli n.a. PMID PMID: 36467581 PMDBI20012053 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012054 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012055 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012056 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012060 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012061 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012062 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20012063 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012064 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012065 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012066 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012067 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012068 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012069 Microbes metabolize substances PMDBM2020617 119219 Cupriavidus metallidurans PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012070 Microbes metabolize substances PMDBM2020617 119219 Cupriavidus metallidurans PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20012071 Microbes metabolize substances PMDBM2020617 119219 Cupriavidus metallidurans PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012072 Microbes metabolize substances PMDBM2020617 119219 Cupriavidus metallidurans PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012073 Microbes metabolize substances PMDBM2020617 119219 Cupriavidus metallidurans PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012074 Microbes metabolize substances PMDBM2020617 119219 Cupriavidus metallidurans PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012075 Microbes metabolize substances PMDBM2020617 119219 Cupriavidus metallidurans PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012076 Microbes metabolize substances PMDBM2020617 119219 Cupriavidus metallidurans PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012079 Microbes metabolize substances PMDBM2020617 119219 Cupriavidus metallidurans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012080 Microbes metabolize substances PMDBM2020617 119219 Cupriavidus metallidurans PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012081 Microbes metabolize substances PMDBM2020617 119219 Cupriavidus metallidurans PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012082 Microbes metabolize substances PMDBM2020617 119219 Cupriavidus metallidurans PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012083 Microbes metabolize substances PMDBM2020617 119219 Cupriavidus metallidurans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012084 Microbes metabolize substances PMDBM2020617 119219 Cupriavidus metallidurans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012085 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012086 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012087 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012088 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012089 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012090 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012091 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012092 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012093 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012095 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20012098 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20012099 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20012100 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20012101 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012102 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012105 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20012108 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012109 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012110 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012112 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012113 Microbes metabolize substances PMDBM2020620 1747 Cutibacterium acnes PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012114 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012115 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012116 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012117 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012119 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012121 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012122 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012123 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012124 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012125 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012126 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012128 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20012131 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20012132 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20012133 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012136 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20012139 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012140 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012143 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012144 Microbes metabolize substances PMDBM2021316 33010 Cutibacterium avidum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012145 Microbes metabolize substances PMDBM2020621 33011 Cutibacterium granulosum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012146 Microbes metabolize substances PMDBM2020621 33011 Cutibacterium granulosum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012147 Microbes metabolize substances PMDBM2020621 33011 Cutibacterium granulosum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012148 Microbes metabolize substances PMDBM2020621 33011 Cutibacterium granulosum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012149 Microbes metabolize substances PMDBM2008744 n.a. f Ruminococcaceae g D5 s D5 sp900113995 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012150 Microbes metabolize substances PMDBM2008744 n.a. f Ruminococcaceae g D5 s D5 sp900113995 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012151 Microbes metabolize substances PMDBM2008744 n.a. f Ruminococcaceae g D5 s D5 sp900113995 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012152 Microbes metabolize substances PMDBM2008744 n.a. f Ruminococcaceae g D5 s D5 sp900113995 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012153 Microbes metabolize substances PMDBM2008745 1987748 Dakarella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012154 Microbes metabolize substances PMDBM2008745 1987748 Dakarella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012155 Microbes metabolize substances PMDBM2008745 1987748 Dakarella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012156 Microbes metabolize substances PMDBM2008745 1987748 Dakarella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012157 Microbes metabolize substances PMDBM2008745 1987748 Dakarella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012158 Microbes metabolize substances PMDBM2008745 1987748 Dakarella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012159 Microbes metabolize substances PMDBM2008745 1987748 Dakarella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012162 Microbes metabolize substances PMDBM2008745 1987748 Dakarella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012163 Microbes metabolize substances PMDBM2008745 1987748 Dakarella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012164 Microbes metabolize substances PMDBM2008745 1987748 Dakarella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012165 Microbes metabolize substances PMDBM2008745 1987748 Dakarella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012166 Microbes metabolize substances PMDBM2020622 1506471 Dakarella massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012167 Microbes metabolize substances PMDBM2020622 1506471 Dakarella massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012168 Microbes metabolize substances PMDBM2020622 1506471 Dakarella massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012169 Microbes metabolize substances PMDBM2020622 1506471 Dakarella massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012170 Microbes metabolize substances PMDBM2020622 1506471 Dakarella massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012171 Microbes metabolize substances PMDBM2020622 1506471 Dakarella massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012172 Microbes metabolize substances PMDBM2020622 1506471 Dakarella massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012175 Microbes metabolize substances PMDBM2020622 1506471 Dakarella massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012176 Microbes metabolize substances PMDBM2020622 1506471 Dakarella massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012177 Microbes metabolize substances PMDBM2020622 1506471 Dakarella massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012178 Microbes metabolize substances PMDBM2020622 1506471 Dakarella massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012179 Microbes metabolize substances PMDBM2008747 73029 Dechloromonas PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20012180 Microbes metabolize substances PMDBM2008747 73029 Dechloromonas PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012181 Microbes metabolize substances PMDBM2008747 73029 Dechloromonas PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012182 Microbes metabolize substances PMDBM2008747 73029 Dechloromonas PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012183 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012184 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012185 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012186 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012187 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012188 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012189 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012190 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012191 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012193 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20012196 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20012197 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20012198 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012199 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012202 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20012205 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012206 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012207 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012209 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012210 Microbes metabolize substances PMDBM2021506 36740 Dermabacter hominis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012211 Microbes metabolize substances PMDBM2020209 49338 Desulfitobacterium hafniense PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20012212 Microbes metabolize substances PMDBM2020209 49338 Desulfitobacterium hafniense PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20012213 Microbes metabolize substances PMDBM2020209 49338 Desulfitobacterium hafniense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012214 Microbes metabolize substances PMDBM2020209 49338 Desulfitobacterium hafniense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012215 Microbes metabolize substances PMDBM2020209 49338 Desulfitobacterium hafniense PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20012216 Microbes metabolize substances PMDBM2020209 49338 Desulfitobacterium hafniense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012217 Microbes metabolize substances PMDBM2020209 49338 Desulfitobacterium hafniense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012218 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012219 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20012220 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012221 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012222 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012223 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012224 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012225 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012228 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20012229 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012230 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012231 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20012232 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012233 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012234 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012235 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012236 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012237 Microbes metabolize substances PMDBM179 872 Desulfovibrio PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20012238 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012239 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012240 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012241 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012242 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012243 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012244 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012247 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans A PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20012248 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012249 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012250 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012251 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012252 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012253 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012254 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012255 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans A PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20012256 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20012257 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20012258 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012259 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012260 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans PMDBD70 Arsenic Environmental Chemicals Environmental Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Product a more toxic form of arsenic n.a. PMID PMID: 36467581 PMDBI20012261 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012262 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012263 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20012264 Microbes metabolize substances PMDBM2021507 44742 Desulfovibrio fairfieldensis PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20012265 Microbes metabolize substances PMDBM2021507 44742 Desulfovibrio fairfieldensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012266 Microbes metabolize substances PMDBM2021507 44742 Desulfovibrio fairfieldensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012267 Microbes metabolize substances PMDBM2021507 44742 Desulfovibrio fairfieldensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012268 Microbes metabolize substances PMDBM2021507 44742 Desulfovibrio fairfieldensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012269 Microbes metabolize substances PMDBM2021507 44742 Desulfovibrio fairfieldensis PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20012270 Microbes metabolize substances PMDBM2020630 901 Desulfovibrio piger PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012271 Microbes metabolize substances PMDBM2020630 901 Desulfovibrio piger PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012272 Microbes metabolize substances PMDBM2020630 901 Desulfovibrio piger PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012273 Microbes metabolize substances PMDBM2020630 901 Desulfovibrio piger PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012274 Microbes metabolize substances PMDBM2020630 901 Desulfovibrio piger A PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20012275 Microbes metabolize substances PMDBM2020630 901 Desulfovibrio piger A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012276 Microbes metabolize substances PMDBM2020630 901 Desulfovibrio piger A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012277 Microbes metabolize substances PMDBM2020630 901 Desulfovibrio piger A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012278 Microbes metabolize substances PMDBM2020630 901 Desulfovibrio piger A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012279 Microbes metabolize substances PMDBM2020631 885 Desulfovibrio sp002159665 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012280 Microbes metabolize substances PMDBM2020631 885 Desulfovibrio sp002159665 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012281 Microbes metabolize substances PMDBM2020631 885 Desulfovibrio sp900319575 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20012282 Microbes metabolize substances PMDBM2020631 885 Desulfovibrio sp900319575 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012283 Microbes metabolize substances PMDBM2020631 885 Desulfovibrio sp900319575 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012284 Microbes metabolize substances PMDBM740 39948 Dialister PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012285 Microbes metabolize substances PMDBM740 39948 Dialister PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012286 Microbes metabolize substances PMDBM2021508 1263072 Dialister invisus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012287 Microbes metabolize substances PMDBM2021508 1263072 Dialister invisus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012288 Microbes metabolize substances PMDBM2021509 1955814 Dialister sp000434475 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012289 Microbes metabolize substances PMDBM2021509 1955814 Dialister sp000434475 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012290 Microbes metabolize substances PMDBM2021509 1955814 Dialister sp002320515 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012291 Microbes metabolize substances PMDBM2021509 1955814 Dialister sp002320515 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012292 Microbes metabolize substances PMDBM2021509 1955814 Dialister sp900343095 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012293 Microbes metabolize substances PMDBM2021509 1955814 Dialister sp900343095 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012294 Microbes metabolize substances PMDBM2020635 487173 Dialister succinatiphilus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012295 Microbes metabolize substances PMDBM2020635 487173 Dialister succinatiphilus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012296 Microbes metabolize substances PMDBM2020634 39950 Dialister A pneumosintes PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012297 Microbes metabolize substances PMDBM2020634 39950 Dialister A pneumosintes PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012298 Microbes metabolize substances PMDBM2020636 1034346 Dielma fastidiosa PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20012299 Microbes metabolize substances PMDBM2020636 1034346 Dielma fastidiosa PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012300 Microbes metabolize substances PMDBM2020636 1034346 Dielma fastidiosa PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012301 Microbes metabolize substances PMDBM2020636 1034346 Dielma fastidiosa PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012302 Microbes metabolize substances PMDBM2020636 1034346 Dielma fastidiosa PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012303 Microbes metabolize substances PMDBM2008762 n.a. Dielma sp001305055 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012304 Microbes metabolize substances PMDBM2008762 n.a. Dielma sp001305055 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20012305 Microbes metabolize substances PMDBM2008762 n.a. Dielma sp001305055 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012306 Microbes metabolize substances PMDBM2008762 n.a. Dielma sp001305055 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012307 Microbes metabolize substances PMDBM2008762 n.a. Dielma sp001305055 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012308 Microbes metabolize substances PMDBM2008762 n.a. Dielma sp001305055 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012309 Microbes metabolize substances PMDBM2008762 n.a. Dielma sp001305055 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012310 Microbes metabolize substances PMDBM2008762 n.a. Dielma sp001305055 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012313 Microbes metabolize substances PMDBM2008762 n.a. Dielma sp001305055 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012314 Microbes metabolize substances PMDBM2008762 n.a. Dielma sp001305055 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012315 Microbes metabolize substances PMDBM2008762 n.a. Dielma sp001305055 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012316 Microbes metabolize substances PMDBM2008762 n.a. Dielma sp001305055 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012317 Microbes metabolize substances PMDBM2008762 n.a. Dielma sp001305055 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012318 Microbes metabolize substances PMDBM2008762 n.a. Dielma sp001305055 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012319 Microbes metabolize substances PMDBM2008762 n.a. Dielma sp001305055 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012320 Microbes metabolize substances n.a. n.a. digoxin PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" cardiac glycoside n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20012328 Microbes metabolize substances PMDBM2008763 n.a. f Eggerthellaceae g DNF00809 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012329 Microbes metabolize substances PMDBM2008764 n.a. f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012330 Microbes metabolize substances PMDBM2008764 n.a. f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012331 Microbes metabolize substances PMDBM2008764 n.a. f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012332 Microbes metabolize substances PMDBM2008764 n.a. f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012333 Microbes metabolize substances PMDBM2008764 n.a. f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012334 Microbes metabolize substances PMDBM2008764 n.a. f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012335 Microbes metabolize substances PMDBM2008764 n.a. f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012338 Microbes metabolize substances PMDBM2008764 n.a. f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012339 Microbes metabolize substances PMDBM2008764 n.a. f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012340 Microbes metabolize substances PMDBM2008764 n.a. f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012341 Microbes metabolize substances PMDBM2008764 n.a. f Eggerthellaceae g DNF00809 s DNF00809 sp001552935 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012342 Microbes metabolize substances PMDBM182 189330 Dorea PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012343 Microbes metabolize substances PMDBM182 189330 Dorea PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012344 Microbes metabolize substances PMDBM182 189330 Dorea PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012345 Microbes metabolize substances PMDBM182 189330 Dorea PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012347 Microbes metabolize substances PMDBM182 189330 Dorea PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012349 Microbes metabolize substances PMDBM182 189330 Dorea PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20012350 Microbes metabolize substances PMDBM182 189330 Dorea PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012351 Microbes metabolize substances PMDBM182 189330 Dorea PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012352 Microbes metabolize substances PMDBM182 189330 Dorea PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012353 Microbes metabolize substances PMDBM182 189330 Dorea PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012356 Microbes metabolize substances PMDBM182 189330 Dorea PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012357 Microbes metabolize substances PMDBM182 189330 Dorea PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012358 Microbes metabolize substances PMDBM182 189330 Dorea PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012359 Microbes metabolize substances PMDBM182 189330 Dorea PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012361 Microbes metabolize substances PMDBM182 189330 Dorea PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012362 Microbes metabolize substances PMDBM182 189330 Dorea PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012363 Microbes metabolize substances PMDBM182 189330 Dorea PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012364 Microbes metabolize substances PMDBM2008765 n.a. Dorea faecis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012365 Microbes metabolize substances PMDBM2008765 n.a. Dorea faecis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012366 Microbes metabolize substances PMDBM2008765 n.a. Dorea faecis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012367 Microbes metabolize substances PMDBM2008765 n.a. Dorea faecis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012368 Microbes metabolize substances PMDBM2008765 n.a. Dorea faecis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012369 Microbes metabolize substances PMDBM2008765 n.a. Dorea faecis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012370 Microbes metabolize substances PMDBM2008765 n.a. Dorea faecis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012373 Microbes metabolize substances PMDBM2008765 n.a. Dorea faecis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012374 Microbes metabolize substances PMDBM2008765 n.a. Dorea faecis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012375 Microbes metabolize substances PMDBM2008765 n.a. Dorea faecis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012376 Microbes metabolize substances PMDBM2008765 n.a. Dorea faecis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012377 Microbes metabolize substances PMDBM2008765 n.a. Dorea faecis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012378 Microbes metabolize substances PMDBM2008765 n.a. Dorea faecis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012379 Microbes metabolize substances PMDBM2008765 n.a. Dorea faecis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012380 Microbes metabolize substances PMDBM2008765 n.a. Dorea faecis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012381 Microbes metabolize substances PMDBM2020211 39486 Dorea formicigenerans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012382 Microbes metabolize substances PMDBM2020211 39486 Dorea formicigenerans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012383 Microbes metabolize substances PMDBM2020211 39486 Dorea formicigenerans PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012384 Microbes metabolize substances PMDBM2020211 39486 Dorea formicigenerans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012385 Microbes metabolize substances PMDBM2020211 39486 Dorea formicigenerans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012386 Microbes metabolize substances PMDBM2008766 n.a. Dorea hylemonae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012387 Microbes metabolize substances PMDBM2008766 n.a. Dorea hylemonae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012388 Microbes metabolize substances PMDBM2008766 n.a. Dorea hylemonae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012389 Microbes metabolize substances PMDBM2008766 n.a. Dorea hylemonae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012390 Microbes metabolize substances PMDBM2008766 n.a. Dorea hylemonae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012391 Microbes metabolize substances PMDBM2008766 n.a. Dorea hylemonae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012392 Microbes metabolize substances PMDBM2008766 n.a. Dorea hylemonae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012395 Microbes metabolize substances PMDBM2008766 n.a. Dorea hylemonae PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20012396 Microbes metabolize substances PMDBM2008766 n.a. Dorea hylemonae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012397 Microbes metabolize substances PMDBM2008766 n.a. Dorea hylemonae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012398 Microbes metabolize substances PMDBM2008766 n.a. Dorea hylemonae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012399 Microbes metabolize substances PMDBM2008766 n.a. Dorea hylemonae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012400 Microbes metabolize substances PMDBM2008766 n.a. Dorea hylemonae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012401 Microbes metabolize substances PMDBM2008766 n.a. Dorea hylemonae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012402 Microbes metabolize substances PMDBM2008766 n.a. Dorea hylemonae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012403 Microbes metabolize substances PMDBM2008766 n.a. Dorea hylemonae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012404 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20012405 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012406 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012407 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012408 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012409 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012410 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012411 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena B PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012413 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012415 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012416 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012417 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012418 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012421 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012422 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012423 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012424 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012426 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena B PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012427 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012428 Microbes metabolize substances PMDBM2020113 88431 Dorea longicatena B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012429 Microbes metabolize substances PMDBM2021510 2040291 Dorea phocaeense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012430 Microbes metabolize substances PMDBM2021510 2040291 Dorea phocaeense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012431 Microbes metabolize substances PMDBM2021510 2040291 Dorea phocaeense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012432 Microbes metabolize substances PMDBM2021510 2040291 Dorea phocaeense PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20012433 Microbes metabolize substances PMDBM2021510 2040291 Dorea phocaeense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012434 Microbes metabolize substances PMDBM2021510 2040291 Dorea phocaeense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012435 Microbes metabolize substances PMDBM2021510 2040291 Dorea phocaeense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012436 Microbes metabolize substances PMDBM2021510 2040291 Dorea phocaeense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012439 Microbes metabolize substances PMDBM2021510 2040291 Dorea phocaeense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012440 Microbes metabolize substances PMDBM2021510 2040291 Dorea phocaeense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012441 Microbes metabolize substances PMDBM2021510 2040291 Dorea phocaeense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012442 Microbes metabolize substances PMDBM2021510 2040291 Dorea phocaeense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012443 Microbes metabolize substances PMDBM2021510 2040291 Dorea phocaeense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012444 Microbes metabolize substances PMDBM2021510 2040291 Dorea phocaeense PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012445 Microbes metabolize substances PMDBM2021510 2040291 Dorea phocaeense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012446 Microbes metabolize substances PMDBM2021510 2040291 Dorea phocaeense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012447 Microbes metabolize substances PMDBM2008769 n.a. Dorea scindens PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20012448 Microbes metabolize substances PMDBM2008769 n.a. Dorea scindens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012449 Microbes metabolize substances PMDBM2008769 n.a. Dorea scindens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012450 Microbes metabolize substances PMDBM2008769 n.a. Dorea scindens PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012451 Microbes metabolize substances PMDBM2008769 n.a. Dorea scindens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012452 Microbes metabolize substances PMDBM2008769 n.a. Dorea scindens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012453 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000433215 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20012454 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000433215 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012455 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000433215 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012456 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000433215 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012457 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000433215 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012458 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000433215 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012459 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000433535 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012460 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000433535 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012461 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000433535 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012462 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000433535 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012463 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000433535 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20012464 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000433535 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012465 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000433535 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012466 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000433535 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012467 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000433535 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012468 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000433535 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012469 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000765215 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20012470 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000765215 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012471 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000765215 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012472 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000765215 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012473 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000765215 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012474 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp000765215 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012475 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp001185345 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20012476 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp001185345 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012477 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp001185345 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012478 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp001185345 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012479 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp001185345 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012480 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp001185345 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012481 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066555 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012482 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066555 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012483 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066555 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012484 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066555 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012485 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066555 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012486 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066555 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012487 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066555 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012490 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066555 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012491 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066555 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012492 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066555 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012493 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066555 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012494 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066555 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012495 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066555 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012496 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066555 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012497 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066555 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012498 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066765 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012499 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066765 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012500 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066765 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012501 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066765 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012502 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066765 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012503 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066765 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012504 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066765 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012505 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900066765 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012506 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900086625 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20012507 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900086625 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012508 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900086625 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012509 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900086625 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012510 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900086625 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012511 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900086625 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012512 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900240315 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012513 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900240315 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012514 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900240315 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012515 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900240315 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012517 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900240315 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012519 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900240315 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20012520 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900240315 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012521 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900240315 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012522 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900240315 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012523 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900240315 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012526 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900240315 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012527 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900240315 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012528 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900240315 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012529 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900240315 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012531 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900240315 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012532 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900240315 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012533 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900240315 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012534 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900312975 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20012535 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900312975 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012536 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900312975 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012537 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900312975 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012538 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900312975 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012539 Microbes metabolize substances PMDBM2021511 2040332 Dorea sp900312975 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012540 Microbes metabolize substances PMDBM2008779 n.a. o Saccharofermentanales f DTU023 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012541 Microbes metabolize substances PMDBM2008779 n.a. o Saccharofermentanales f DTU023 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012542 Microbes metabolize substances PMDBM2008779 n.a. o Saccharofermentanales f DTU023 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012543 Microbes metabolize substances PMDBM2008779 n.a. o Saccharofermentanales f DTU023 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012544 Microbes metabolize substances PMDBM2008779 n.a. o Saccharofermentanales f DTU023 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012545 Microbes metabolize substances PMDBM2008779 n.a. o Saccharofermentanales f DTU023 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012546 Microbes metabolize substances PMDBM2008779 n.a. o Saccharofermentanales f DTU023 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012549 Microbes metabolize substances PMDBM2008779 n.a. o Saccharofermentanales f DTU023 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20012550 Microbes metabolize substances PMDBM2008779 n.a. o Saccharofermentanales f DTU023 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012551 Microbes metabolize substances PMDBM2008779 n.a. o Saccharofermentanales f DTU023 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012552 Microbes metabolize substances PMDBM2008779 n.a. o Saccharofermentanales f DTU023 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012553 Microbes metabolize substances PMDBM2008779 n.a. o Saccharofermentanales f DTU023 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012554 Microbes metabolize substances PMDBM2008779 n.a. o Saccharofermentanales f DTU023 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012555 Microbes metabolize substances PMDBM2008779 n.a. o Saccharofermentanales f DTU023 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012556 Microbes metabolize substances PMDBM2008779 n.a. o Saccharofermentanales f DTU023 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012557 Microbes metabolize substances PMDBM2008779 n.a. o Saccharofermentanales f DTU023 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012558 Microbes metabolize substances PMDBM2008780 n.a. f Acutalibacteraceae g DTU089 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012559 Microbes metabolize substances PMDBM2008780 n.a. f Acutalibacteraceae g DTU089 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012560 Microbes metabolize substances PMDBM2008780 n.a. f Acutalibacteraceae g DTU089 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012561 Microbes metabolize substances PMDBM2008780 n.a. f Acutalibacteraceae g DTU089 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012563 Microbes metabolize substances PMDBM2008780 n.a. f Acutalibacteraceae g DTU089 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012565 Microbes metabolize substances PMDBM2008780 n.a. f Acutalibacteraceae g DTU089 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012566 Microbes metabolize substances PMDBM2008780 n.a. f Acutalibacteraceae g DTU089 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012567 Microbes metabolize substances PMDBM2008780 n.a. f Acutalibacteraceae g DTU089 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012568 Microbes metabolize substances PMDBM2008780 n.a. f Acutalibacteraceae g DTU089 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012571 Microbes metabolize substances PMDBM2008780 n.a. f Acutalibacteraceae g DTU089 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012572 Microbes metabolize substances PMDBM2008780 n.a. f Acutalibacteraceae g DTU089 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012573 Microbes metabolize substances PMDBM2008780 n.a. f Acutalibacteraceae g DTU089 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012574 Microbes metabolize substances PMDBM2008780 n.a. f Acutalibacteraceae g DTU089 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012576 Microbes metabolize substances PMDBM2008780 n.a. f Acutalibacteraceae g DTU089 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012577 Microbes metabolize substances PMDBM2008780 n.a. f Acutalibacteraceae g DTU089 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012578 Microbes metabolize substances PMDBM2008780 n.a. f Acutalibacteraceae g DTU089 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012579 Microbes metabolize substances PMDBM2008781 n.a. f Acutalibacteraceae g DTU089 A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012580 Microbes metabolize substances PMDBM2008781 n.a. f Acutalibacteraceae g DTU089 A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012581 Microbes metabolize substances PMDBM2008781 n.a. f Acutalibacteraceae g DTU089 A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012582 Microbes metabolize substances PMDBM2008781 n.a. f Acutalibacteraceae g DTU089 A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012583 Microbes metabolize substances PMDBM2008781 n.a. f Acutalibacteraceae g DTU089 A PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012584 Microbes metabolize substances PMDBM2008781 n.a. f Acutalibacteraceae g DTU089 A PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012585 Microbes metabolize substances PMDBM2008781 n.a. f Acutalibacteraceae g DTU089 A PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20012587 Microbes metabolize substances PMDBM2008781 n.a. f Acutalibacteraceae g DTU089 A PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20012588 Microbes metabolize substances PMDBM2008781 n.a. f Acutalibacteraceae g DTU089 A PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20012589 Microbes metabolize substances PMDBM2008781 n.a. f Acutalibacteraceae g DTU089 A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012590 Microbes metabolize substances PMDBM2008781 n.a. f Acutalibacteraceae g DTU089 A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012593 Microbes metabolize substances PMDBM2008781 n.a. f Acutalibacteraceae g DTU089 A PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20012597 Microbes metabolize substances PMDBM2008781 n.a. f Acutalibacteraceae g DTU089 A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012598 Microbes metabolize substances PMDBM2008781 n.a. f Acutalibacteraceae g DTU089 A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012599 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012600 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012601 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012602 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012604 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012606 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012607 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012608 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012609 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012610 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012611 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012613 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20012616 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20012617 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20012618 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012619 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012622 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20012625 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012626 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012629 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012630 Microbes metabolize substances PMDBM2008782 n.a. DTU089 A sp002440045 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012631 Microbes metabolize substances PMDBM2008783 n.a. p Firmicutes G c SHA-98 o DTUO25 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20012632 Microbes metabolize substances PMDBM2008783 n.a. p Firmicutes G c SHA-98 o DTUO25 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20012633 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012634 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20012635 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012636 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012637 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012639 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012641 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012642 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012643 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012644 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012645 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012646 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012648 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20012651 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20012652 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20012653 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20012654 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012655 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012658 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20012661 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012662 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012665 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012666 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012667 Microbes metabolize substances PMDBM2008784 2518495 Duncaniella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012668 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012669 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012670 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012671 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012673 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012675 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012676 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012677 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012678 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012679 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012680 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012682 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20012685 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20012686 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20012687 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012688 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012691 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20012694 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012695 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012698 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012699 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012700 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001689425 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012701 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001701225 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012702 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001701225 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012703 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001701225 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012704 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001701225 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012706 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001701225 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012708 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001701225 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012709 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001701225 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012710 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001701225 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012711 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001701225 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012714 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001701225 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012715 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001701225 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012716 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001701225 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012717 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001701225 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012719 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001701225 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012720 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001701225 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012721 Microbes metabolize substances PMDBM2021512 2518496 Duncaniella sp001701225 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012722 Microbes metabolize substances PMDBM2008787 1980697 Duodenibacillus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012723 Microbes metabolize substances PMDBM2008787 1980697 Duodenibacillus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012724 Microbes metabolize substances PMDBM2008787 1980697 Duodenibacillus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012725 Microbes metabolize substances PMDBM2008787 1980697 Duodenibacillus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012726 Microbes metabolize substances PMDBM2008787 1980697 Duodenibacillus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012727 Microbes metabolize substances PMDBM2008787 1980697 Duodenibacillus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012728 Microbes metabolize substances PMDBM2008787 1980697 Duodenibacillus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012731 Microbes metabolize substances PMDBM2008787 1980697 Duodenibacillus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012732 Microbes metabolize substances PMDBM2008787 1980697 Duodenibacillus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012733 Microbes metabolize substances PMDBM2008787 1980697 Duodenibacillus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012734 Microbes metabolize substances PMDBM2008787 1980697 Duodenibacillus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012735 Microbes metabolize substances PMDBM2008787 1980697 Duodenibacillus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012736 Microbes metabolize substances PMDBM2021513 1852381 Duodenibacillus massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012737 Microbes metabolize substances PMDBM2021513 1852381 Duodenibacillus massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20012738 Microbes metabolize substances PMDBM2021513 1852381 Duodenibacillus massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012739 Microbes metabolize substances PMDBM2021513 1852381 Duodenibacillus massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012740 Microbes metabolize substances PMDBM2021513 1852381 Duodenibacillus massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012741 Microbes metabolize substances PMDBM2021513 1852381 Duodenibacillus massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012742 Microbes metabolize substances PMDBM2021513 1852381 Duodenibacillus massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012743 Microbes metabolize substances PMDBM2021513 1852381 Duodenibacillus massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012746 Microbes metabolize substances PMDBM2021513 1852381 Duodenibacillus massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012747 Microbes metabolize substances PMDBM2021513 1852381 Duodenibacillus massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012748 Microbes metabolize substances PMDBM2021513 1852381 Duodenibacillus massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012749 Microbes metabolize substances PMDBM2021513 1852381 Duodenibacillus massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012750 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012751 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012752 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012753 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012755 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012757 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012758 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012759 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012760 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012761 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012762 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012764 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20012767 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20012768 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20012769 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20012770 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012771 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012774 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20012777 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012778 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012781 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012782 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012783 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012784 Microbes metabolize substances PMDBM2008789 156973 Dysgonomonas PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20012785 Microbes metabolize substances PMDBM2021514 45254 Dysgonomonas capnocytophagoides PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012786 Microbes metabolize substances PMDBM2021514 45254 Dysgonomonas capnocytophagoides PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012787 Microbes metabolize substances PMDBM2021514 45254 Dysgonomonas capnocytophagoides PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012788 Microbes metabolize substances PMDBM2021514 45254 Dysgonomonas capnocytophagoides PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012790 Microbes metabolize substances PMDBM2021514 45254 Dysgonomonas capnocytophagoides PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012792 Microbes metabolize substances PMDBM2021514 45254 Dysgonomonas capnocytophagoides PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012793 Microbes metabolize substances PMDBM2021514 45254 Dysgonomonas capnocytophagoides PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012794 Microbes metabolize substances PMDBM2021514 45254 Dysgonomonas capnocytophagoides PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012795 Microbes metabolize substances PMDBM2021514 45254 Dysgonomonas capnocytophagoides PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012798 Microbes metabolize substances PMDBM2021514 45254 Dysgonomonas capnocytophagoides PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012799 Microbes metabolize substances PMDBM2021514 45254 Dysgonomonas capnocytophagoides PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012800 Microbes metabolize substances PMDBM2021514 45254 Dysgonomonas capnocytophagoides PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012801 Microbes metabolize substances PMDBM2021514 45254 Dysgonomonas capnocytophagoides PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012803 Microbes metabolize substances PMDBM2021514 45254 Dysgonomonas capnocytophagoides PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012804 Microbes metabolize substances PMDBM2021514 45254 Dysgonomonas capnocytophagoides PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012805 Microbes metabolize substances PMDBM2021514 45254 Dysgonomonas capnocytophagoides PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012806 Microbes metabolize substances PMDBM2020642 156974 Dysgonomonas gadei PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012807 Microbes metabolize substances PMDBM2020642 156974 Dysgonomonas gadei PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012808 Microbes metabolize substances PMDBM2020642 156974 Dysgonomonas gadei PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012809 Microbes metabolize substances PMDBM2020642 156974 Dysgonomonas gadei PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012811 Microbes metabolize substances PMDBM2020642 156974 Dysgonomonas gadei PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012813 Microbes metabolize substances PMDBM2020642 156974 Dysgonomonas gadei PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012814 Microbes metabolize substances PMDBM2020642 156974 Dysgonomonas gadei PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012815 Microbes metabolize substances PMDBM2020642 156974 Dysgonomonas gadei PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012816 Microbes metabolize substances PMDBM2020642 156974 Dysgonomonas gadei PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012819 Microbes metabolize substances PMDBM2020642 156974 Dysgonomonas gadei PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20012820 Microbes metabolize substances PMDBM2020642 156974 Dysgonomonas gadei PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012821 Microbes metabolize substances PMDBM2020642 156974 Dysgonomonas gadei PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012822 Microbes metabolize substances PMDBM2020642 156974 Dysgonomonas gadei PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012823 Microbes metabolize substances PMDBM2020642 156974 Dysgonomonas gadei PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012825 Microbes metabolize substances PMDBM2020642 156974 Dysgonomonas gadei PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012826 Microbes metabolize substances PMDBM2020642 156974 Dysgonomonas gadei PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012827 Microbes metabolize substances PMDBM2020642 156974 Dysgonomonas gadei PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012828 Microbes metabolize substances PMDBM2020643 163665 Dysgonomonas mossii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012829 Microbes metabolize substances PMDBM2020643 163665 Dysgonomonas mossii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012830 Microbes metabolize substances PMDBM2020643 163665 Dysgonomonas mossii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012831 Microbes metabolize substances PMDBM2020643 163665 Dysgonomonas mossii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012833 Microbes metabolize substances PMDBM2020643 163665 Dysgonomonas mossii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012835 Microbes metabolize substances PMDBM2020643 163665 Dysgonomonas mossii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012836 Microbes metabolize substances PMDBM2020643 163665 Dysgonomonas mossii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012837 Microbes metabolize substances PMDBM2020643 163665 Dysgonomonas mossii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012838 Microbes metabolize substances PMDBM2020643 163665 Dysgonomonas mossii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012841 Microbes metabolize substances PMDBM2020643 163665 Dysgonomonas mossii PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20012842 Microbes metabolize substances PMDBM2020643 163665 Dysgonomonas mossii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012843 Microbes metabolize substances PMDBM2020643 163665 Dysgonomonas mossii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012844 Microbes metabolize substances PMDBM2020643 163665 Dysgonomonas mossii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012845 Microbes metabolize substances PMDBM2020643 163665 Dysgonomonas mossii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012847 Microbes metabolize substances PMDBM2020643 163665 Dysgonomonas mossii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012848 Microbes metabolize substances PMDBM2020643 163665 Dysgonomonas mossii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012849 Microbes metabolize substances PMDBM2020643 163665 Dysgonomonas mossii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012850 Microbes metabolize substances PMDBM2021515 1891233 Dysgonomonas sp900079735 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012851 Microbes metabolize substances PMDBM2021515 1891233 Dysgonomonas sp900079735 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012852 Microbes metabolize substances PMDBM2021515 1891233 Dysgonomonas sp900079735 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012853 Microbes metabolize substances PMDBM2021515 1891233 Dysgonomonas sp900079735 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012855 Microbes metabolize substances PMDBM2021515 1891233 Dysgonomonas sp900079735 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012857 Microbes metabolize substances PMDBM2021515 1891233 Dysgonomonas sp900079735 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012858 Microbes metabolize substances PMDBM2021515 1891233 Dysgonomonas sp900079735 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012859 Microbes metabolize substances PMDBM2021515 1891233 Dysgonomonas sp900079735 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012860 Microbes metabolize substances PMDBM2021515 1891233 Dysgonomonas sp900079735 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012863 Microbes metabolize substances PMDBM2021515 1891233 Dysgonomonas sp900079735 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20012864 Microbes metabolize substances PMDBM2021515 1891233 Dysgonomonas sp900079735 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012865 Microbes metabolize substances PMDBM2021515 1891233 Dysgonomonas sp900079735 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012866 Microbes metabolize substances PMDBM2021515 1891233 Dysgonomonas sp900079735 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012867 Microbes metabolize substances PMDBM2021515 1891233 Dysgonomonas sp900079735 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012869 Microbes metabolize substances PMDBM2021515 1891233 Dysgonomonas sp900079735 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012870 Microbes metabolize substances PMDBM2021515 1891233 Dysgonomonas sp900079735 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012871 Microbes metabolize substances PMDBM2021515 1891233 Dysgonomonas sp900079735 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012872 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012873 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012874 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012875 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012876 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012877 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012878 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012879 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012880 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012882 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20012885 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20012886 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20012887 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20012888 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012889 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012892 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20012895 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012896 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012897 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012899 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012900 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012901 Microbes metabolize substances PMDBM2020212 636 Edwardsiella tarda PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012902 Microbes metabolize substances PMDBM748 84111 Eggerthella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012903 Microbes metabolize substances PMDBM748 84111 Eggerthella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012904 Microbes metabolize substances PMDBM748 84111 Eggerthella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012905 Microbes metabolize substances PMDBM748 84111 Eggerthella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012906 Microbes metabolize substances PMDBM748 84111 Eggerthella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012907 Microbes metabolize substances PMDBM748 84111 Eggerthella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012908 Microbes metabolize substances PMDBM748 84111 Eggerthella PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" cardiac glycoside n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. cardiac drug inactivation by the human gut bacterium Eggerthella lenta n.a. PMID PMID: 36467581 PMDBI20012910 Microbes metabolize substances PMDBM748 84111 Eggerthella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012913 Microbes metabolize substances PMDBM748 84111 Eggerthella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012914 Microbes metabolize substances PMDBM748 84111 Eggerthella PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20012915 Microbes metabolize substances PMDBM748 84111 Eggerthella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012916 Microbes metabolize substances PMDBM748 84111 Eggerthella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012917 Microbes metabolize substances PMDBM748 84111 Eggerthella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012918 Microbes metabolize substances PMDBM748 84111 Eggerthella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012919 Microbes metabolize substances PMDBM748 84111 Eggerthella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012920 Microbes metabolize substances PMDBM2020213 84112 Eggerthella lenta PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" cardiac glycoside n.a. n.a. n.a. n.a. n.a. n.a. Digoxin reductase activity decreased n.a. n.a. n.a. decreased drug action n.a. PMID PMID: 36467581 PMDBI20012923 Microbes metabolize substances PMDBM2020213 84112 Eggerthella lenta PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012928 Microbes metabolize substances PMDBM2020213 84112 Eggerthella lenta PMDBD772 Secoisolariciresinol Therapeutic Substance anticancer n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. unknown activity increased n.a. n.a. n.a. Protective effects against breast cancer n.a. PMID PMID: 36467581 PMDBI20012931 Microbes metabolize substances PMDBM2020213 84112 Eggerthella lenta PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012932 Microbes metabolize substances PMDBM2020213 84112 Eggerthella lenta PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012936 Microbes metabolize substances PMDBM2008795 1643826 Eggerthellaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012937 Microbes metabolize substances PMDBM2008795 1643826 Eggerthellaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012938 Microbes metabolize substances PMDBM2008795 1643826 Eggerthellaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012939 Microbes metabolize substances PMDBM2008795 1643826 Eggerthellaceae PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20012940 Microbes metabolize substances PMDBM2008795 1643826 Eggerthellaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012941 Microbes metabolize substances PMDBM2008795 1643826 Eggerthellaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012942 Microbes metabolize substances PMDBM2008795 1643826 Eggerthellaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012943 Microbes metabolize substances PMDBM2008795 1643826 Eggerthellaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012946 Microbes metabolize substances PMDBM2008795 1643826 Eggerthellaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012947 Microbes metabolize substances PMDBM2008795 1643826 Eggerthellaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012948 Microbes metabolize substances PMDBM2008795 1643826 Eggerthellaceae PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20012949 Microbes metabolize substances PMDBM2008795 1643826 Eggerthellaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012950 Microbes metabolize substances PMDBM2008795 1643826 Eggerthellaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012951 Microbes metabolize substances PMDBM2008795 1643826 Eggerthellaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012952 Microbes metabolize substances PMDBM2008795 1643826 Eggerthellaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012953 Microbes metabolize substances PMDBM2008795 1643826 Eggerthellaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20012954 Microbes metabolize substances PMDBM2021137 539 Eikenella corrodens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012955 Microbes metabolize substances PMDBM2021137 539 Eikenella corrodens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012956 Microbes metabolize substances PMDBM2021137 539 Eikenella corrodens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012957 Microbes metabolize substances PMDBM2021137 539 Eikenella corrodens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012958 Microbes metabolize substances PMDBM2021137 539 Eikenella corrodens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012959 Microbes metabolize substances PMDBM2021137 539 Eikenella corrodens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012960 Microbes metabolize substances PMDBM2021137 539 Eikenella corrodens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012963 Microbes metabolize substances PMDBM2021137 539 Eikenella corrodens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012964 Microbes metabolize substances PMDBM2021137 539 Eikenella corrodens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012965 Microbes metabolize substances PMDBM2021137 539 Eikenella corrodens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012966 Microbes metabolize substances PMDBM2021137 539 Eikenella corrodens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012967 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20012968 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20012969 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20012970 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20012971 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012973 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20012975 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012976 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012977 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20012978 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012979 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20012980 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20012982 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20012985 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20012986 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20012987 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20012988 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20012991 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20012994 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012995 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20012998 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20012999 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013000 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013001 Microbes metabolize substances PMDBM2008797 1432051 Eisenbergiella PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20013002 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013003 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013004 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013005 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013007 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013009 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013010 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013011 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013012 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20013013 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20013014 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013016 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20013019 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20013020 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20013021 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013022 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013025 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20013028 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013029 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013032 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013033 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013034 Microbes metabolize substances PMDBM2021516 1720294 Eisenbergiella massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013035 Microbes metabolize substances PMDBM2021517 1924109 Eisenbergiella sp900066775 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013036 Microbes metabolize substances PMDBM2021517 1924109 Eisenbergiella sp900066775 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013037 Microbes metabolize substances PMDBM2021517 1924109 Eisenbergiella sp900066775 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013038 Microbes metabolize substances PMDBM2021517 1924109 Eisenbergiella sp900066775 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013040 Microbes metabolize substances PMDBM2021517 1924109 Eisenbergiella sp900066775 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013042 Microbes metabolize substances PMDBM2021517 1924109 Eisenbergiella sp900066775 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013043 Microbes metabolize substances PMDBM2021517 1924109 Eisenbergiella sp900066775 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013044 Microbes metabolize substances PMDBM2021517 1924109 Eisenbergiella sp900066775 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013045 Microbes metabolize substances PMDBM2021517 1924109 Eisenbergiella sp900066775 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013048 Microbes metabolize substances PMDBM2021517 1924109 Eisenbergiella sp900066775 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013049 Microbes metabolize substances PMDBM2021517 1924109 Eisenbergiella sp900066775 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013050 Microbes metabolize substances PMDBM2021517 1924109 Eisenbergiella sp900066775 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013052 Microbes metabolize substances PMDBM2021517 1924109 Eisenbergiella sp900066775 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013053 Microbes metabolize substances PMDBM2021517 1924109 Eisenbergiella sp900066775 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013054 Microbes metabolize substances PMDBM2021517 1924109 Eisenbergiella sp900066775 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013055 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013056 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013057 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013058 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013060 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013062 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013063 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013064 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013065 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20013066 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20013067 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013069 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20013072 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20013073 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20013074 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013075 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013078 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20013081 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013082 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013085 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013086 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013087 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013088 Microbes metabolize substances PMDBM2020054 1432052 Eisenbergiella tayi PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20013089 Microbes metabolize substances PMDBM2008800 641876 Elusimicrobiaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013090 Microbes metabolize substances PMDBM2008800 641876 Elusimicrobiaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013091 Microbes metabolize substances PMDBM2008800 641876 Elusimicrobiaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013092 Microbes metabolize substances PMDBM2008800 641876 Elusimicrobiaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013093 Microbes metabolize substances PMDBM2008800 641876 Elusimicrobiaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013094 Microbes metabolize substances PMDBM2008800 641876 Elusimicrobiaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013095 Microbes metabolize substances PMDBM2008800 641876 Elusimicrobiaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013098 Microbes metabolize substances PMDBM2008800 641876 Elusimicrobiaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013099 Microbes metabolize substances PMDBM2008800 641876 Elusimicrobiaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013100 Microbes metabolize substances PMDBM2008800 641876 Elusimicrobiaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013101 Microbes metabolize substances PMDBM2008800 641876 Elusimicrobiaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013102 Microbes metabolize substances PMDBM2008800 641876 Elusimicrobiaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013103 Microbes metabolize substances PMDBM2008800 641876 Elusimicrobiaceae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013104 Microbes metabolize substances PMDBM2008800 641876 Elusimicrobiaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013105 Microbes metabolize substances PMDBM2008800 641876 Elusimicrobiaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013106 Microbes metabolize substances PMDBM2008801 1926556 Emergencia PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013107 Microbes metabolize substances PMDBM2008801 1926556 Emergencia PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013108 Microbes metabolize substances PMDBM2008801 1926556 Emergencia PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013109 Microbes metabolize substances PMDBM2008801 1926556 Emergencia PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013110 Microbes metabolize substances PMDBM2008801 1926556 Emergencia PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013111 Microbes metabolize substances PMDBM2008801 1926556 Emergencia PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013112 Microbes metabolize substances PMDBM2008801 1926556 Emergencia PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013113 Microbes metabolize substances PMDBM2008801 1926556 Emergencia PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013116 Microbes metabolize substances PMDBM2008801 1926556 Emergencia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013117 Microbes metabolize substances PMDBM2008801 1926556 Emergencia PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013118 Microbes metabolize substances PMDBM2008801 1926556 Emergencia PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013119 Microbes metabolize substances PMDBM2008801 1926556 Emergencia PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013120 Microbes metabolize substances PMDBM2008801 1926556 Emergencia PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013121 Microbes metabolize substances PMDBM2008801 1926556 Emergencia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013122 Microbes metabolize substances PMDBM2008801 1926556 Emergencia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013123 Microbes metabolize substances PMDBM2021518 1926557 Emergencia sp900066695 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013124 Microbes metabolize substances PMDBM2021518 1926557 Emergencia sp900066695 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013125 Microbes metabolize substances PMDBM2021518 1926557 Emergencia sp900066695 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013126 Microbes metabolize substances PMDBM2021518 1926557 Emergencia sp900066695 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013127 Microbes metabolize substances PMDBM2020648 1776384 Emergencia timonensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013128 Microbes metabolize substances PMDBM2020648 1776384 Emergencia timonensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013129 Microbes metabolize substances PMDBM2020648 1776384 Emergencia timonensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013130 Microbes metabolize substances PMDBM2020648 1776384 Emergencia timonensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013131 Microbes metabolize substances PMDBM2020648 1776384 Emergencia timonensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013132 Microbes metabolize substances PMDBM2020648 1776384 Emergencia timonensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013133 Microbes metabolize substances PMDBM2020648 1776384 Emergencia timonensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013134 Microbes metabolize substances PMDBM2020648 1776384 Emergencia timonensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013137 Microbes metabolize substances PMDBM2020648 1776384 Emergencia timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013138 Microbes metabolize substances PMDBM2020648 1776384 Emergencia timonensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013139 Microbes metabolize substances PMDBM2020648 1776384 Emergencia timonensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013140 Microbes metabolize substances PMDBM2020648 1776384 Emergencia timonensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013141 Microbes metabolize substances PMDBM2020648 1776384 Emergencia timonensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013142 Microbes metabolize substances PMDBM2020648 1776384 Emergencia timonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013143 Microbes metabolize substances PMDBM2020648 1776384 Emergencia timonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013144 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013145 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013146 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013147 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013149 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013151 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20013152 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013153 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013154 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013155 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20013156 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20013157 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013159 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20013162 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20013163 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20013164 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013165 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013168 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20013171 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013172 Microbes metabolize substances PMDBM2008804 1472762 Enorma PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013175 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013176 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013177 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013178 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013180 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013182 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013183 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013184 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013185 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20013186 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20013187 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013189 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20013192 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20013193 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20013194 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013195 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013198 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20013201 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013202 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013208 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20013220 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013221 Microbes metabolize substances PMDBM2020650 1472761 Enorma massiliensis A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013222 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013223 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013224 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013225 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013226 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013227 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013228 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013229 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013232 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20013233 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013234 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013235 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20013236 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013237 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013238 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013239 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013240 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013241 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013242 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013243 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013244 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013245 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013246 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013247 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013248 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013249 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20013250 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20013251 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013253 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20013256 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20013257 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20013258 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013261 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20013264 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20013265 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013266 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013267 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013269 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013270 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013271 Microbes metabolize substances PMDBM2021519 881260 Enterobacter bugandensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013272 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013273 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013274 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013275 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013276 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013277 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013278 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013279 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013282 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20013283 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013284 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013285 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20013286 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013287 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013288 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013289 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013290 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013291 Microbes metabolize substances PMDBM2020214 69218 Enterobacter cancerogenus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013292 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013293 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013294 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013295 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013296 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013297 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013298 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013299 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013302 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013303 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013304 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20013305 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013306 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013307 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013308 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013309 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013310 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013311 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013312 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae B PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013313 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013314 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013315 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013316 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013317 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013318 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013321 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013322 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013323 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae B PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20013324 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013325 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013326 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013327 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae B PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013328 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013329 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013330 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae H PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013331 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae H PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013332 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae H PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013333 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae H PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013334 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae H PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013335 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae H PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013336 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae H PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013337 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae H PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013340 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae H PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013341 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae H PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013342 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae H PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20013343 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae H PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013344 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae H PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013345 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae H PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013346 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae H PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013347 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae H PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013348 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae H PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013349 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae K PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013350 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae K PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013351 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae K PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013352 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae K PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013353 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae K PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013354 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae K PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013355 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae K PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013356 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae K PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013359 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae K PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013360 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae K PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013361 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae K PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20013362 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae K PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013363 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae K PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013364 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae K PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013365 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae K PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013366 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae K PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013367 Microbes metabolize substances PMDBM2020029 550 Enterobacter cloacae K PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013368 Microbes metabolize substances PMDBM2008811 n.a. Enterobacter himalayensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013369 Microbes metabolize substances PMDBM2008811 n.a. Enterobacter himalayensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013370 Microbes metabolize substances PMDBM2008811 n.a. Enterobacter himalayensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013371 Microbes metabolize substances PMDBM2008811 n.a. Enterobacter himalayensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013372 Microbes metabolize substances PMDBM2008811 n.a. Enterobacter himalayensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013373 Microbes metabolize substances PMDBM2008811 n.a. Enterobacter himalayensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013374 Microbes metabolize substances PMDBM2008811 n.a. Enterobacter himalayensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013375 Microbes metabolize substances PMDBM2008811 n.a. Enterobacter himalayensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013378 Microbes metabolize substances PMDBM2008811 n.a. Enterobacter himalayensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013379 Microbes metabolize substances PMDBM2008811 n.a. Enterobacter himalayensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013380 Microbes metabolize substances PMDBM2008811 n.a. Enterobacter himalayensis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20013381 Microbes metabolize substances PMDBM2008811 n.a. Enterobacter himalayensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013382 Microbes metabolize substances PMDBM2008811 n.a. Enterobacter himalayensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013383 Microbes metabolize substances PMDBM2008811 n.a. Enterobacter himalayensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013384 Microbes metabolize substances PMDBM2008811 n.a. Enterobacter himalayensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013385 Microbes metabolize substances PMDBM2008811 n.a. Enterobacter himalayensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013386 Microbes metabolize substances PMDBM2008811 n.a. Enterobacter himalayensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013387 Microbes metabolize substances PMDBM2021520 208224 Enterobacter kobei PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013388 Microbes metabolize substances PMDBM2021520 208224 Enterobacter kobei PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013389 Microbes metabolize substances PMDBM2021520 208224 Enterobacter kobei PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013390 Microbes metabolize substances PMDBM2021520 208224 Enterobacter kobei PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013391 Microbes metabolize substances PMDBM2021520 208224 Enterobacter kobei PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013392 Microbes metabolize substances PMDBM2021520 208224 Enterobacter kobei PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013393 Microbes metabolize substances PMDBM2021520 208224 Enterobacter kobei PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013394 Microbes metabolize substances PMDBM2021520 208224 Enterobacter kobei PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013397 Microbes metabolize substances PMDBM2021520 208224 Enterobacter kobei PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013398 Microbes metabolize substances PMDBM2021520 208224 Enterobacter kobei PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013399 Microbes metabolize substances PMDBM2021520 208224 Enterobacter kobei PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20013400 Microbes metabolize substances PMDBM2021520 208224 Enterobacter kobei PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013401 Microbes metabolize substances PMDBM2021520 208224 Enterobacter kobei PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013402 Microbes metabolize substances PMDBM2021520 208224 Enterobacter kobei PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013403 Microbes metabolize substances PMDBM2021520 208224 Enterobacter kobei PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013404 Microbes metabolize substances PMDBM2021520 208224 Enterobacter kobei PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013405 Microbes metabolize substances PMDBM2021520 208224 Enterobacter kobei PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013406 Microbes metabolize substances PMDBM2020653 299767 Enterobacter ludwigii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013407 Microbes metabolize substances PMDBM2020653 299767 Enterobacter ludwigii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013408 Microbes metabolize substances PMDBM2020653 299767 Enterobacter ludwigii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013409 Microbes metabolize substances PMDBM2020653 299767 Enterobacter ludwigii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013410 Microbes metabolize substances PMDBM2020653 299767 Enterobacter ludwigii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013411 Microbes metabolize substances PMDBM2020653 299767 Enterobacter ludwigii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013412 Microbes metabolize substances PMDBM2020653 299767 Enterobacter ludwigii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013413 Microbes metabolize substances PMDBM2020653 299767 Enterobacter ludwigii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013416 Microbes metabolize substances PMDBM2020653 299767 Enterobacter ludwigii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013417 Microbes metabolize substances PMDBM2020653 299767 Enterobacter ludwigii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013418 Microbes metabolize substances PMDBM2020653 299767 Enterobacter ludwigii PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20013419 Microbes metabolize substances PMDBM2020653 299767 Enterobacter ludwigii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013420 Microbes metabolize substances PMDBM2020653 299767 Enterobacter ludwigii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013421 Microbes metabolize substances PMDBM2020653 299767 Enterobacter ludwigii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013422 Microbes metabolize substances PMDBM2020653 299767 Enterobacter ludwigii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013423 Microbes metabolize substances PMDBM2020653 299767 Enterobacter ludwigii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013424 Microbes metabolize substances PMDBM2020653 299767 Enterobacter ludwigii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013425 Microbes metabolize substances PMDBM2020654 539813 Enterobacter mori PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013426 Microbes metabolize substances PMDBM2020654 539813 Enterobacter mori PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013427 Microbes metabolize substances PMDBM2020654 539813 Enterobacter mori PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013428 Microbes metabolize substances PMDBM2020654 539813 Enterobacter mori PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013429 Microbes metabolize substances PMDBM2020654 539813 Enterobacter mori PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013430 Microbes metabolize substances PMDBM2020654 539813 Enterobacter mori PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013431 Microbes metabolize substances PMDBM2020654 539813 Enterobacter mori PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013432 Microbes metabolize substances PMDBM2020654 539813 Enterobacter mori PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013435 Microbes metabolize substances PMDBM2020654 539813 Enterobacter mori PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013436 Microbes metabolize substances PMDBM2020654 539813 Enterobacter mori PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013437 Microbes metabolize substances PMDBM2020654 539813 Enterobacter mori PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20013438 Microbes metabolize substances PMDBM2020654 539813 Enterobacter mori PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013439 Microbes metabolize substances PMDBM2020654 539813 Enterobacter mori PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013440 Microbes metabolize substances PMDBM2020654 539813 Enterobacter mori PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013441 Microbes metabolize substances PMDBM2020654 539813 Enterobacter mori PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013442 Microbes metabolize substances PMDBM2020654 539813 Enterobacter mori PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013443 Microbes metabolize substances PMDBM2020654 539813 Enterobacter mori PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013444 Microbes metabolize substances PMDBM2021521 69220 Enterobacter nimipressuralis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013445 Microbes metabolize substances PMDBM2021521 69220 Enterobacter nimipressuralis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013446 Microbes metabolize substances PMDBM2021521 69220 Enterobacter nimipressuralis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013447 Microbes metabolize substances PMDBM2021521 69220 Enterobacter nimipressuralis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013448 Microbes metabolize substances PMDBM2021521 69220 Enterobacter nimipressuralis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013449 Microbes metabolize substances PMDBM2021521 69220 Enterobacter nimipressuralis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013450 Microbes metabolize substances PMDBM2021521 69220 Enterobacter nimipressuralis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013451 Microbes metabolize substances PMDBM2021521 69220 Enterobacter nimipressuralis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013454 Microbes metabolize substances PMDBM2021521 69220 Enterobacter nimipressuralis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013455 Microbes metabolize substances PMDBM2021521 69220 Enterobacter nimipressuralis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013456 Microbes metabolize substances PMDBM2021521 69220 Enterobacter nimipressuralis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20013457 Microbes metabolize substances PMDBM2021521 69220 Enterobacter nimipressuralis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013458 Microbes metabolize substances PMDBM2021521 69220 Enterobacter nimipressuralis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013459 Microbes metabolize substances PMDBM2021521 69220 Enterobacter nimipressuralis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013460 Microbes metabolize substances PMDBM2021521 69220 Enterobacter nimipressuralis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013461 Microbes metabolize substances PMDBM2021521 69220 Enterobacter nimipressuralis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013462 Microbes metabolize substances PMDBM2021521 69220 Enterobacter nimipressuralis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013463 Microbes metabolize substances PMDBM2008816 n.a. Enterobacter sesami PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013464 Microbes metabolize substances PMDBM2008816 n.a. Enterobacter sesami PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013465 Microbes metabolize substances PMDBM2008816 n.a. Enterobacter sesami PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013466 Microbes metabolize substances PMDBM2008816 n.a. Enterobacter sesami PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013467 Microbes metabolize substances PMDBM2008816 n.a. Enterobacter sesami PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013468 Microbes metabolize substances PMDBM2008816 n.a. Enterobacter sesami PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013469 Microbes metabolize substances PMDBM2008816 n.a. Enterobacter sesami PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013470 Microbes metabolize substances PMDBM2008816 n.a. Enterobacter sesami PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013473 Microbes metabolize substances PMDBM2008816 n.a. Enterobacter sesami PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013474 Microbes metabolize substances PMDBM2008816 n.a. Enterobacter sesami PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013475 Microbes metabolize substances PMDBM2008816 n.a. Enterobacter sesami PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20013476 Microbes metabolize substances PMDBM2008816 n.a. Enterobacter sesami PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013477 Microbes metabolize substances PMDBM2008816 n.a. Enterobacter sesami PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013478 Microbes metabolize substances PMDBM2008816 n.a. Enterobacter sesami PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013479 Microbes metabolize substances PMDBM2008816 n.a. Enterobacter sesami PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013480 Microbes metabolize substances PMDBM2008816 n.a. Enterobacter sesami PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013481 Microbes metabolize substances PMDBM2008816 n.a. Enterobacter sesami PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013482 Microbes metabolize substances PMDBM2021522 1755099 Enterobacter A timonensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013483 Microbes metabolize substances PMDBM2021522 1755099 Enterobacter A timonensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013484 Microbes metabolize substances PMDBM2021522 1755099 Enterobacter A timonensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013485 Microbes metabolize substances PMDBM2021522 1755099 Enterobacter A timonensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013486 Microbes metabolize substances PMDBM2021522 1755099 Enterobacter A timonensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013487 Microbes metabolize substances PMDBM2021522 1755099 Enterobacter A timonensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013488 Microbes metabolize substances PMDBM2021522 1755099 Enterobacter A timonensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013491 Microbes metabolize substances PMDBM2021522 1755099 Enterobacter A timonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013492 Microbes metabolize substances PMDBM2021522 1755099 Enterobacter A timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013493 Microbes metabolize substances PMDBM2021522 1755099 Enterobacter A timonensis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20013494 Microbes metabolize substances PMDBM2021522 1755099 Enterobacter A timonensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013495 Microbes metabolize substances PMDBM2021522 1755099 Enterobacter A timonensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013496 Microbes metabolize substances PMDBM2021522 1755099 Enterobacter A timonensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013497 Microbes metabolize substances PMDBM2021522 1755099 Enterobacter A timonensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013498 Microbes metabolize substances PMDBM2021522 1755099 Enterobacter A timonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013499 Microbes metabolize substances PMDBM2021522 1755099 Enterobacter A timonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013500 Microbes metabolize substances PMDBM2021520 208224 Enterobacter D kobei PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013501 Microbes metabolize substances PMDBM2021520 208224 Enterobacter D kobei PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013502 Microbes metabolize substances PMDBM2021520 208224 Enterobacter D kobei PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013503 Microbes metabolize substances PMDBM2021520 208224 Enterobacter D kobei PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013504 Microbes metabolize substances PMDBM2021520 208224 Enterobacter D kobei PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013505 Microbes metabolize substances PMDBM2021520 208224 Enterobacter D kobei PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013506 Microbes metabolize substances PMDBM2021520 208224 Enterobacter D kobei PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013509 Microbes metabolize substances PMDBM2021520 208224 Enterobacter D kobei PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013510 Microbes metabolize substances PMDBM2021520 208224 Enterobacter D kobei PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013511 Microbes metabolize substances PMDBM2021520 208224 Enterobacter D kobei PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20013512 Microbes metabolize substances PMDBM2021520 208224 Enterobacter D kobei PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013513 Microbes metabolize substances PMDBM2021520 208224 Enterobacter D kobei PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013514 Microbes metabolize substances PMDBM2021520 208224 Enterobacter D kobei PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013515 Microbes metabolize substances PMDBM2021520 208224 Enterobacter D kobei PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013516 Microbes metabolize substances PMDBM2021520 208224 Enterobacter D kobei PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013517 Microbes metabolize substances PMDBM2021520 208224 Enterobacter D kobei PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013518 Microbes metabolize substances PMDBM194 543 Enterobacteriaceae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Modulate the metabolism and pharmacokinetics閿涘otentiated the therapeutic potency,the bioavailability of the drug increased n.a. PMID PMID: 36467581 PMDBI20013519 Microbes metabolize substances PMDBM195 n.a. Enterobacteriales PMDBD18 Acetylsalicylic acid Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. "Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency" n.a. PMID PMID: 36467581 PMDBI20013520 Microbes metabolize substances PMDBM2021154 33945 Enterococcus A avium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013521 Microbes metabolize substances PMDBM2021154 33945 Enterococcus A avium PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013522 Microbes metabolize substances PMDBM2021154 33945 Enterococcus A avium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013523 Microbes metabolize substances PMDBM2021154 33945 Enterococcus A avium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013524 Microbes metabolize substances PMDBM2021154 33945 Enterococcus A avium PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013526 Microbes metabolize substances PMDBM2021154 33945 Enterococcus A avium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013528 Microbes metabolize substances PMDBM2021154 33945 Enterococcus A avium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013529 Microbes metabolize substances PMDBM2021154 33945 Enterococcus A avium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013530 Microbes metabolize substances PMDBM2021154 33945 Enterococcus A avium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013531 Microbes metabolize substances PMDBM2021154 33945 Enterococcus A avium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013534 Microbes metabolize substances PMDBM2021154 33945 Enterococcus A avium PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20013535 Microbes metabolize substances PMDBM2021154 33945 Enterococcus A avium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013536 Microbes metabolize substances PMDBM2021154 33945 Enterococcus A avium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013537 Microbes metabolize substances PMDBM2021154 33945 Enterococcus A avium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013538 Microbes metabolize substances PMDBM2021154 33945 Enterococcus A avium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013540 Microbes metabolize substances PMDBM2021154 33945 Enterococcus A avium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013541 Microbes metabolize substances PMDBM2021154 33945 Enterococcus A avium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013542 Microbes metabolize substances PMDBM2021523 319970 Enterococcus A devriesei PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013543 Microbes metabolize substances PMDBM2021523 319970 Enterococcus A devriesei PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013544 Microbes metabolize substances PMDBM2021523 319970 Enterococcus A devriesei PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013545 Microbes metabolize substances PMDBM2021523 319970 Enterococcus A devriesei PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013546 Microbes metabolize substances PMDBM2021523 319970 Enterococcus A devriesei PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013547 Microbes metabolize substances PMDBM2021523 319970 Enterococcus A devriesei PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013548 Microbes metabolize substances PMDBM2021523 319970 Enterococcus A devriesei PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013549 Microbes metabolize substances PMDBM2021523 319970 Enterococcus A devriesei PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013552 Microbes metabolize substances PMDBM2021523 319970 Enterococcus A devriesei PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013553 Microbes metabolize substances PMDBM2021523 319970 Enterococcus A devriesei PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013554 Microbes metabolize substances PMDBM2021523 319970 Enterococcus A devriesei PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013555 Microbes metabolize substances PMDBM2021523 319970 Enterococcus A devriesei PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013556 Microbes metabolize substances PMDBM2021523 319970 Enterococcus A devriesei PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013557 Microbes metabolize substances PMDBM2021523 319970 Enterococcus A devriesei PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013558 Microbes metabolize substances PMDBM2021523 319970 Enterococcus A devriesei PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013559 Microbes metabolize substances PMDBM2020662 160453 Enterococcus A gilvus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013560 Microbes metabolize substances PMDBM2020662 160453 Enterococcus A gilvus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013561 Microbes metabolize substances PMDBM2020662 160453 Enterococcus A gilvus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013562 Microbes metabolize substances PMDBM2020662 160453 Enterococcus A gilvus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013563 Microbes metabolize substances PMDBM2020662 160453 Enterococcus A gilvus PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20013564 Microbes metabolize substances PMDBM2020662 160453 Enterococcus A gilvus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013565 Microbes metabolize substances PMDBM2020662 160453 Enterococcus A gilvus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013566 Microbes metabolize substances PMDBM2020662 160453 Enterococcus A gilvus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013567 Microbes metabolize substances PMDBM2020662 160453 Enterococcus A gilvus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013570 Microbes metabolize substances PMDBM2020662 160453 Enterococcus A gilvus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013571 Microbes metabolize substances PMDBM2020662 160453 Enterococcus A gilvus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013572 Microbes metabolize substances PMDBM2020662 160453 Enterococcus A gilvus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013573 Microbes metabolize substances PMDBM2020662 160453 Enterococcus A gilvus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013574 Microbes metabolize substances PMDBM2020662 160453 Enterococcus A gilvus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013575 Microbes metabolize substances PMDBM2020662 160453 Enterococcus A gilvus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013576 Microbes metabolize substances PMDBM2020662 160453 Enterococcus A gilvus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013577 Microbes metabolize substances PMDBM2020664 160454 Enterococcus A pallens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013578 Microbes metabolize substances PMDBM2020664 160454 Enterococcus A pallens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013579 Microbes metabolize substances PMDBM2020664 160454 Enterococcus A pallens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013580 Microbes metabolize substances PMDBM2020664 160454 Enterococcus A pallens PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013582 Microbes metabolize substances PMDBM2020664 160454 Enterococcus A pallens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013584 Microbes metabolize substances PMDBM2020664 160454 Enterococcus A pallens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013585 Microbes metabolize substances PMDBM2020664 160454 Enterococcus A pallens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013586 Microbes metabolize substances PMDBM2020664 160454 Enterococcus A pallens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013587 Microbes metabolize substances PMDBM2020664 160454 Enterococcus A pallens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013590 Microbes metabolize substances PMDBM2020664 160454 Enterococcus A pallens PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20013591 Microbes metabolize substances PMDBM2020664 160454 Enterococcus A pallens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013592 Microbes metabolize substances PMDBM2020664 160454 Enterococcus A pallens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013593 Microbes metabolize substances PMDBM2020664 160454 Enterococcus A pallens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013594 Microbes metabolize substances PMDBM2020664 160454 Enterococcus A pallens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013596 Microbes metabolize substances PMDBM2020664 160454 Enterococcus A pallens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013597 Microbes metabolize substances PMDBM2020664 160454 Enterococcus A pallens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013598 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013599 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013600 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013601 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013602 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013604 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013606 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20013607 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013608 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013609 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013610 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013613 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20013614 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013615 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013616 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013617 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013619 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013620 Microbes metabolize substances PMDBM2020666 71452 Enterococcus A raffinosus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013621 Microbes metabolize substances PMDBM2020668 35783 Enterococcus A sp002140655 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013622 Microbes metabolize substances PMDBM2020668 35783 Enterococcus A sp002140655 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013623 Microbes metabolize substances PMDBM2020668 35783 Enterococcus A sp002140655 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013624 Microbes metabolize substances PMDBM2020668 35783 Enterococcus A sp002140655 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013626 Microbes metabolize substances PMDBM2020668 35783 Enterococcus A sp002140655 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013628 Microbes metabolize substances PMDBM2020668 35783 Enterococcus A sp002140655 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20013629 Microbes metabolize substances PMDBM2020668 35783 Enterococcus A sp002140655 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013630 Microbes metabolize substances PMDBM2020668 35783 Enterococcus A sp002140655 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013631 Microbes metabolize substances PMDBM2020668 35783 Enterococcus A sp002140655 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013632 Microbes metabolize substances PMDBM2020668 35783 Enterococcus A sp002140655 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013635 Microbes metabolize substances PMDBM2020668 35783 Enterococcus A sp002140655 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20013636 Microbes metabolize substances PMDBM2020668 35783 Enterococcus A sp002140655 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013637 Microbes metabolize substances PMDBM2020668 35783 Enterococcus A sp002140655 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013638 Microbes metabolize substances PMDBM2020668 35783 Enterococcus A sp002140655 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013640 Microbes metabolize substances PMDBM2020668 35783 Enterococcus A sp002140655 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013641 Microbes metabolize substances PMDBM2020668 35783 Enterococcus A sp002140655 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013642 Microbes metabolize substances PMDBM2020659 53345 Enterococcus B durans PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013643 Microbes metabolize substances PMDBM2020659 53345 Enterococcus B durans PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013644 Microbes metabolize substances PMDBM2020659 53345 Enterococcus B durans PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013645 Microbes metabolize substances PMDBM2020659 53345 Enterococcus B durans PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013646 Microbes metabolize substances PMDBM2020659 53345 Enterococcus B durans PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20013647 Microbes metabolize substances PMDBM2020659 53345 Enterococcus B durans PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013649 Microbes metabolize substances PMDBM2020659 53345 Enterococcus B durans PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013651 Microbes metabolize substances PMDBM2020659 53345 Enterococcus B durans PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20013652 Microbes metabolize substances PMDBM2020659 53345 Enterococcus B durans PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013653 Microbes metabolize substances PMDBM2020659 53345 Enterococcus B durans PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013654 Microbes metabolize substances PMDBM2020659 53345 Enterococcus B durans PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013655 Microbes metabolize substances PMDBM2020659 53345 Enterococcus B durans PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013658 Microbes metabolize substances PMDBM2020659 53345 Enterococcus B durans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013659 Microbes metabolize substances PMDBM2020659 53345 Enterococcus B durans PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013660 Microbes metabolize substances PMDBM2020659 53345 Enterococcus B durans PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013662 Microbes metabolize substances PMDBM2020659 53345 Enterococcus B durans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013663 Microbes metabolize substances PMDBM2020659 53345 Enterococcus B durans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013664 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013665 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013666 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013667 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013668 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20013669 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013671 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013673 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013674 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013675 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013676 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013679 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013680 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013681 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013683 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013684 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013685 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013686 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium B PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013687 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013688 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013689 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium B PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20013690 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium B PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013692 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013694 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013695 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013696 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013697 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013700 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013701 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013702 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013704 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013705 Microbes metabolize substances PMDBM2020033 1352 Enterococcus B faecium B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013706 Microbes metabolize substances PMDBM2020217 1354 Enterococcus B hirae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013707 Microbes metabolize substances PMDBM2020217 1354 Enterococcus B hirae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013708 Microbes metabolize substances PMDBM2020217 1354 Enterococcus B hirae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013709 Microbes metabolize substances PMDBM2020217 1354 Enterococcus B hirae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013710 Microbes metabolize substances PMDBM2020217 1354 Enterococcus B hirae PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20013711 Microbes metabolize substances PMDBM2020217 1354 Enterococcus B hirae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013713 Microbes metabolize substances PMDBM2020217 1354 Enterococcus B hirae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013715 Microbes metabolize substances PMDBM2020217 1354 Enterococcus B hirae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013716 Microbes metabolize substances PMDBM2020217 1354 Enterococcus B hirae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013717 Microbes metabolize substances PMDBM2020217 1354 Enterococcus B hirae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013718 Microbes metabolize substances PMDBM2020217 1354 Enterococcus B hirae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013721 Microbes metabolize substances PMDBM2020217 1354 Enterococcus B hirae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013722 Microbes metabolize substances PMDBM2020217 1354 Enterococcus B hirae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013723 Microbes metabolize substances PMDBM2020217 1354 Enterococcus B hirae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013725 Microbes metabolize substances PMDBM2020217 1354 Enterococcus B hirae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013726 Microbes metabolize substances PMDBM2020217 1354 Enterococcus B hirae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013727 Microbes metabolize substances PMDBM2021524 590158 Enterococcus B pernyi PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013728 Microbes metabolize substances PMDBM2021524 590158 Enterococcus B pernyi PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20013729 Microbes metabolize substances PMDBM2021524 590158 Enterococcus B pernyi PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013730 Microbes metabolize substances PMDBM2021524 590158 Enterococcus B pernyi PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013731 Microbes metabolize substances PMDBM2021524 590158 Enterococcus B pernyi PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013732 Microbes metabolize substances PMDBM2021150 57732 Enterococcus C asini PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013733 Microbes metabolize substances PMDBM2021150 57732 Enterococcus C asini PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013734 Microbes metabolize substances PMDBM2021150 57732 Enterococcus C asini PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013735 Microbes metabolize substances PMDBM2021150 57732 Enterococcus C asini PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013736 Microbes metabolize substances PMDBM2021150 57732 Enterococcus C asini PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013738 Microbes metabolize substances PMDBM2021150 57732 Enterococcus C asini PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013740 Microbes metabolize substances PMDBM2021150 57732 Enterococcus C asini PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013741 Microbes metabolize substances PMDBM2021150 57732 Enterococcus C asini PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013742 Microbes metabolize substances PMDBM2021150 57732 Enterococcus C asini PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013743 Microbes metabolize substances PMDBM2021150 57732 Enterococcus C asini PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013746 Microbes metabolize substances PMDBM2021150 57732 Enterococcus C asini PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20013747 Microbes metabolize substances PMDBM2021150 57732 Enterococcus C asini PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013748 Microbes metabolize substances PMDBM2021150 57732 Enterococcus C asini PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013749 Microbes metabolize substances PMDBM2021150 57732 Enterococcus C asini PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013750 Microbes metabolize substances PMDBM2021150 57732 Enterococcus C asini PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013752 Microbes metabolize substances PMDBM2021150 57732 Enterococcus C asini PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013753 Microbes metabolize substances PMDBM2021150 57732 Enterococcus C asini PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013754 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013755 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013756 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013757 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013758 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20013759 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20013760 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013761 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013762 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013763 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013766 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20013767 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013768 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013769 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013770 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013771 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013772 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013773 Microbes metabolize substances PMDBM2021171 44009 Enterococcus C dispar PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013774 Microbes metabolize substances PMDBM2021525 1640685 Enterococcus C massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013775 Microbes metabolize substances PMDBM2021525 1640685 Enterococcus C massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013776 Microbes metabolize substances PMDBM2021525 1640685 Enterococcus C massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013777 Microbes metabolize substances PMDBM2021525 1640685 Enterococcus C massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013778 Microbes metabolize substances PMDBM2021525 1640685 Enterococcus C massiliensis PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20013779 Microbes metabolize substances PMDBM2021525 1640685 Enterococcus C massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013780 Microbes metabolize substances PMDBM2021525 1640685 Enterococcus C massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013781 Microbes metabolize substances PMDBM2021525 1640685 Enterococcus C massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013782 Microbes metabolize substances PMDBM2021525 1640685 Enterococcus C massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013785 Microbes metabolize substances PMDBM2021525 1640685 Enterococcus C massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013786 Microbes metabolize substances PMDBM2021525 1640685 Enterococcus C massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013787 Microbes metabolize substances PMDBM2021525 1640685 Enterococcus C massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013788 Microbes metabolize substances PMDBM2021525 1640685 Enterococcus C massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013789 Microbes metabolize substances PMDBM2021525 1640685 Enterococcus C massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013790 Microbes metabolize substances PMDBM2021525 1640685 Enterococcus C massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013791 Microbes metabolize substances PMDBM2021525 1640685 Enterococcus C massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013792 Microbes metabolize substances PMDBM2020031 37734 Enterococcus D casseliflavus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013793 Microbes metabolize substances PMDBM2020031 37734 Enterococcus D casseliflavus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013794 Microbes metabolize substances PMDBM2020031 37734 Enterococcus D casseliflavus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013795 Microbes metabolize substances PMDBM2020031 37734 Enterococcus D casseliflavus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013796 Microbes metabolize substances PMDBM2020031 37734 Enterococcus D casseliflavus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013798 Microbes metabolize substances PMDBM2020031 37734 Enterococcus D casseliflavus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013800 Microbes metabolize substances PMDBM2020031 37734 Enterococcus D casseliflavus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013801 Microbes metabolize substances PMDBM2020031 37734 Enterococcus D casseliflavus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013802 Microbes metabolize substances PMDBM2020031 37734 Enterococcus D casseliflavus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013803 Microbes metabolize substances PMDBM2020031 37734 Enterococcus D casseliflavus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013806 Microbes metabolize substances PMDBM2020031 37734 Enterococcus D casseliflavus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013807 Microbes metabolize substances PMDBM2020031 37734 Enterococcus D casseliflavus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013808 Microbes metabolize substances PMDBM2020031 37734 Enterococcus D casseliflavus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013809 Microbes metabolize substances PMDBM2020031 37734 Enterococcus D casseliflavus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013811 Microbes metabolize substances PMDBM2020031 37734 Enterococcus D casseliflavus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013812 Microbes metabolize substances PMDBM2020031 37734 Enterococcus D casseliflavus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013813 Microbes metabolize substances PMDBM2020661 1353 Enterococcus D gallinarum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013814 Microbes metabolize substances PMDBM2020661 1353 Enterococcus D gallinarum PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013815 Microbes metabolize substances PMDBM2020661 1353 Enterococcus D gallinarum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013816 Microbes metabolize substances PMDBM2020661 1353 Enterococcus D gallinarum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013817 Microbes metabolize substances PMDBM2020661 1353 Enterococcus D gallinarum PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013819 Microbes metabolize substances PMDBM2020661 1353 Enterococcus D gallinarum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013821 Microbes metabolize substances PMDBM2020661 1353 Enterococcus D gallinarum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013822 Microbes metabolize substances PMDBM2020661 1353 Enterococcus D gallinarum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013823 Microbes metabolize substances PMDBM2020661 1353 Enterococcus D gallinarum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013824 Microbes metabolize substances PMDBM2020661 1353 Enterococcus D gallinarum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013827 Microbes metabolize substances PMDBM2020661 1353 Enterococcus D gallinarum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013828 Microbes metabolize substances PMDBM2020661 1353 Enterococcus D gallinarum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013829 Microbes metabolize substances PMDBM2020661 1353 Enterococcus D gallinarum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013830 Microbes metabolize substances PMDBM2020661 1353 Enterococcus D gallinarum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013832 Microbes metabolize substances PMDBM2020661 1353 Enterococcus D gallinarum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013833 Microbes metabolize substances PMDBM2020661 1353 Enterococcus D gallinarum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013834 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013835 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013836 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013837 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013838 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013839 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013840 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013841 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20013842 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20013843 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013845 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20013848 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20013849 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20013850 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013851 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013854 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20013857 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013858 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013859 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013861 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013862 Microbes metabolize substances PMDBM2020668 35783 Enterococcus D sp002850555 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013863 Microbes metabolize substances PMDBM2021526 246144 Enterococcus G italicus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013864 Microbes metabolize substances PMDBM2021526 246144 Enterococcus G italicus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013865 Microbes metabolize substances PMDBM2021526 246144 Enterococcus G italicus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013866 Microbes metabolize substances PMDBM2021526 246144 Enterococcus G italicus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013867 Microbes metabolize substances PMDBM2021526 246144 Enterococcus G italicus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013868 Microbes metabolize substances PMDBM2021526 246144 Enterococcus G italicus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013869 Microbes metabolize substances PMDBM2021526 246144 Enterococcus G italicus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013870 Microbes metabolize substances PMDBM2021526 246144 Enterococcus G italicus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013873 Microbes metabolize substances PMDBM2021526 246144 Enterococcus G italicus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013874 Microbes metabolize substances PMDBM2021526 246144 Enterococcus G italicus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013875 Microbes metabolize substances PMDBM2021526 246144 Enterococcus G italicus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013876 Microbes metabolize substances PMDBM2021526 246144 Enterococcus G italicus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013877 Microbes metabolize substances PMDBM2021526 246144 Enterococcus G italicus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013878 Microbes metabolize substances PMDBM2021526 246144 Enterococcus G italicus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013879 Microbes metabolize substances PMDBM2021526 246144 Enterococcus G italicus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013880 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD2000019 Methamphetamine Therapeutic Substance psychostimulant and sympathomimetic n.a. n.a. n.a. n.a. Amphetamine, norephedrine n.a. unknown activity decreased n.a. n.a. n.a. activity decreased n.a. PMID PMID: 36467581 PMDBI20013881 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD718 Quercetin-3-glucoside "Herbal Substance; Dietary Substance" compound n.a. n.a. n.a. n.a. 3,4-dihydroxyphenylacetic-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Eubacterium ramulus and Enterococcus casseliflavus showed that both species are capable of metabolizing quercetin-3-glucoside. Based on the wide occurrence of Eu. Ramulus in the human intestinal tract it is believed that this species plays a dominant role in bacterial transformation of flavonoids n.a. PMID PMID: 36467581 PMDBI20013882 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD2000021 Chloroacetic acid Therapeutic substance Antioxidant n.a. n.a. n.a. n.a. haloacetic-acids n.a. unknown carcinogenic n.a. n.a. n.a. Production of haloacetic acids which can be carcinogenic and genotoxic n.a. PMID PMID: 36467581 PMDBI20013883 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Modulate the metabolism and pharmacokinetics閿涘otentiated the therapeutic potency,the bioavailability of the drug increased n.a. PMID PMID: 36467581 PMDBI20013884 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD18 Acetylsalicylic acid Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. "Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency" n.a. PMID PMID: 36467581 PMDBI20013885 Microbes metabolize substances PMDBM2020657 317735 Enterococcus caccae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013886 Microbes metabolize substances PMDBM2020657 317735 Enterococcus caccae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20013887 Microbes metabolize substances PMDBM2020657 317735 Enterococcus caccae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013888 Microbes metabolize substances PMDBM2020657 317735 Enterococcus caccae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013889 Microbes metabolize substances PMDBM2020657 317735 Enterococcus caccae PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20013890 Microbes metabolize substances PMDBM2020657 317735 Enterococcus caccae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013891 Microbes metabolize substances PMDBM2020657 317735 Enterococcus caccae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013892 Microbes metabolize substances PMDBM2020657 317735 Enterococcus caccae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013893 Microbes metabolize substances PMDBM2020657 317735 Enterococcus caccae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013896 Microbes metabolize substances PMDBM2020657 317735 Enterococcus caccae PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20013897 Microbes metabolize substances PMDBM2020657 317735 Enterococcus caccae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013898 Microbes metabolize substances PMDBM2020657 317735 Enterococcus caccae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013899 Microbes metabolize substances PMDBM2020657 317735 Enterococcus caccae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013900 Microbes metabolize substances PMDBM2020657 317735 Enterococcus caccae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013901 Microbes metabolize substances PMDBM2020657 317735 Enterococcus caccae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013902 Microbes metabolize substances PMDBM2020657 317735 Enterococcus caccae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013903 Microbes metabolize substances PMDBM2020031 37734 Enterococcus casseliflavus PMDBD471 Lactulose Therapeutic Substance laxative n.a. n.a. n.a. n.a. Monosaccharides n.a. unknown activity decreased n.a. n.a. n.a. Stimulating the growth of beneficial bacteria such as Bifidobacteria and Lactobacilli n.a. PMID PMID: 36467581 PMDBI20013904 Microbes metabolize substances PMDBM2020031 37734 Enterococcus casseliflavus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013906 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013907 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013908 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013909 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20013911 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD471 Lactulose Therapeutic Substance laxative n.a. n.a. n.a. n.a. Monosaccharides n.a. unknown activity decreased n.a. n.a. n.a. Stimulating the growth of beneficial bacteria such as Bifidobacteria and Lactobacilli n.a. PMID PMID: 36467581 PMDBI20013912 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013913 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013914 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013915 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013919 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013920 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013921 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013922 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013923 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD772 Secoisolariciresinol Therapeutic Substance anticancer n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. unknown activity increased n.a. n.a. n.a. Protective effects against breast cancer n.a. PMID PMID: 36467581 PMDBI20013924 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013925 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013926 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD1451 Thiopurines Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. unknown activation n.a. n.a. n.a. Microbiota as IBD therapy response biomarker n.a. PMID PMID: 36467581 PMDBI20013927 Microbes metabolize substances PMDBM2020033 1352 Enterococcus faecium PMDBD2000017 Anti-axis programmed cell death protein 1 (PD-1) and its ligand (PD-L1) Therapeutic substance immune checkpoint repressing T cell response n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. abundance of Bifidobacterium longum, Collinsella aerofaciens, and Enterococcus faecium was associated with anti-PD1 efficacy in metastatic melanoma patients, while Gopalakrishnan et al. observed higher microbial diversity and increased Ruminococcaceae levels in responding melanoma patients relative to non-responders, together with an enhanced systemic and antitumor immunity n.a. PMID PMID: 36467581 PMDBI20013928 Microbes metabolize substances PMDBM2020217 1354 Enterococcus hirae PMDBD237 Cyclophosphamide Therapeutic Substance lymphoma and leukemia n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. they were instrumental in the stimulation a Th1 and Th17 immune response. n.a. PMID PMID: 36467581 PMDBI20013929 Microbes metabolize substances PMDBM2008838 n.a. Enterolignans PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" a weakly estrogenic compound with potential health n.a. n.a. n.a. n.a. Dihydrodaidzein, equol n.a. unknown activity increased n.a. n.a. n.a. activity increased n.a. PMID PMID: 36467581 PMDBI20013931 Microbes metabolize substances PMDBM2021527 2070686 Enteroscipio rubneri PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013932 Microbes metabolize substances PMDBM2021527 2070686 Enteroscipio rubneri PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013933 Microbes metabolize substances PMDBM2021527 2070686 Enteroscipio rubneri PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013934 Microbes metabolize substances PMDBM2008840 n.a. f Oscillospiraceae g ER4 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013935 Microbes metabolize substances PMDBM2008840 n.a. f Oscillospiraceae g ER4 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013936 Microbes metabolize substances PMDBM2008840 n.a. f Oscillospiraceae g ER4 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013937 Microbes metabolize substances PMDBM2008840 n.a. f Oscillospiraceae g ER4 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013939 Microbes metabolize substances PMDBM2008840 n.a. f Oscillospiraceae g ER4 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013941 Microbes metabolize substances PMDBM2008840 n.a. f Oscillospiraceae g ER4 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013942 Microbes metabolize substances PMDBM2008840 n.a. f Oscillospiraceae g ER4 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013943 Microbes metabolize substances PMDBM2008840 n.a. f Oscillospiraceae g ER4 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013944 Microbes metabolize substances PMDBM2008840 n.a. f Oscillospiraceae g ER4 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013947 Microbes metabolize substances PMDBM2008840 n.a. f Oscillospiraceae g ER4 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013948 Microbes metabolize substances PMDBM2008840 n.a. f Oscillospiraceae g ER4 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013949 Microbes metabolize substances PMDBM2008840 n.a. f Oscillospiraceae g ER4 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013950 Microbes metabolize substances PMDBM2008840 n.a. f Oscillospiraceae g ER4 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013952 Microbes metabolize substances PMDBM2008840 n.a. f Oscillospiraceae g ER4 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013953 Microbes metabolize substances PMDBM2008840 n.a. f Oscillospiraceae g ER4 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013954 Microbes metabolize substances PMDBM2008840 n.a. f Oscillospiraceae g ER4 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013955 Microbes metabolize substances PMDBM2008841 n.a. f Oscillospiraceae g ER4 s ER4 sp000765235 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013956 Microbes metabolize substances PMDBM2008841 n.a. f Oscillospiraceae g ER4 s ER4 sp000765235 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013957 Microbes metabolize substances PMDBM2008842 n.a. f Oscillospiraceae g ER4 s ER4 sp003522105 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013958 Microbes metabolize substances PMDBM2008842 n.a. f Oscillospiraceae g ER4 s ER4 sp003522105 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013959 Microbes metabolize substances PMDBM2008842 n.a. f Oscillospiraceae g ER4 s ER4 sp003522105 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013960 Microbes metabolize substances PMDBM2008842 n.a. f Oscillospiraceae g ER4 s ER4 sp003522105 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013961 Microbes metabolize substances PMDBM2008842 n.a. f Oscillospiraceae g ER4 s ER4 sp003522105 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013962 Microbes metabolize substances PMDBM2008843 n.a. f Oscillospiraceae g ER4 s ER4 sp900317525 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013963 Microbes metabolize substances PMDBM2008843 n.a. f Oscillospiraceae g ER4 s ER4 sp900317525 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013964 Microbes metabolize substances PMDBM2008843 n.a. f Oscillospiraceae g ER4 s ER4 sp900317525 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20013965 Microbes metabolize substances PMDBM2008843 n.a. f Oscillospiraceae g ER4 s ER4 sp900317525 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013966 Microbes metabolize substances PMDBM2008843 n.a. f Oscillospiraceae g ER4 s ER4 sp900317525 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013967 Microbes metabolize substances PMDBM2008844 3025755 Erysipelatoclostridium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013968 Microbes metabolize substances PMDBM2008844 3025755 Erysipelatoclostridium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013969 Microbes metabolize substances PMDBM2008844 3025755 Erysipelatoclostridium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013970 Microbes metabolize substances PMDBM2008844 3025755 Erysipelatoclostridium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013971 Microbes metabolize substances PMDBM2008844 3025755 Erysipelatoclostridium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013972 Microbes metabolize substances PMDBM2008844 3025755 Erysipelatoclostridium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013973 Microbes metabolize substances PMDBM2008844 3025755 Erysipelatoclostridium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013976 Microbes metabolize substances PMDBM2008844 3025755 Erysipelatoclostridium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20013977 Microbes metabolize substances PMDBM2008844 3025755 Erysipelatoclostridium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013978 Microbes metabolize substances PMDBM2008844 3025755 Erysipelatoclostridium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013979 Microbes metabolize substances PMDBM2008844 3025755 Erysipelatoclostridium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013980 Microbes metabolize substances PMDBM2008844 3025755 Erysipelatoclostridium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013981 Microbes metabolize substances PMDBM2008844 3025755 Erysipelatoclostridium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013982 Microbes metabolize substances PMDBM2008844 3025755 Erysipelatoclostridium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20013983 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20013984 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20013985 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20013986 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013988 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20013990 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013991 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013992 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20013993 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20013996 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20013997 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20013998 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014000 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014001 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014002 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Enhance the irinotecan toxicity n.a. PMID PMID: 36467581 PMDBI20014003 Microbes metabolize substances PMDBM2008845 n.a. Erysipelatoclostridium saccharogumia PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014004 Microbes metabolize substances PMDBM2008845 n.a. Erysipelatoclostridium saccharogumia PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014005 Microbes metabolize substances PMDBM2008845 n.a. Erysipelatoclostridium saccharogumia PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014006 Microbes metabolize substances PMDBM2008845 n.a. Erysipelatoclostridium saccharogumia PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014007 Microbes metabolize substances PMDBM2008845 n.a. Erysipelatoclostridium saccharogumia PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014008 Microbes metabolize substances PMDBM2008845 n.a. Erysipelatoclostridium saccharogumia PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014009 Microbes metabolize substances PMDBM2008845 n.a. Erysipelatoclostridium saccharogumia PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014012 Microbes metabolize substances PMDBM2008845 n.a. Erysipelatoclostridium saccharogumia PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014013 Microbes metabolize substances PMDBM2008845 n.a. Erysipelatoclostridium saccharogumia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014014 Microbes metabolize substances PMDBM2008845 n.a. Erysipelatoclostridium saccharogumia PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014015 Microbes metabolize substances PMDBM2008845 n.a. Erysipelatoclostridium saccharogumia PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014016 Microbes metabolize substances PMDBM2008845 n.a. Erysipelatoclostridium saccharogumia PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014017 Microbes metabolize substances PMDBM2008845 n.a. Erysipelatoclostridium saccharogumia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014018 Microbes metabolize substances PMDBM2008845 n.a. Erysipelatoclostridium saccharogumia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014019 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp000752095 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014020 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp000752095 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014021 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp000752095 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014022 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp002160495 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014023 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp002160495 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014024 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp002160495 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014025 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp002160495 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014027 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp002160495 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014029 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp002160495 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014030 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp002160495 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014031 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp002160495 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014032 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp002160495 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014035 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp002160495 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014036 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp002160495 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014037 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp002160495 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014038 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp002160495 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014040 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp002160495 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014041 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp002160495 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014042 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp002160495 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014043 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp003024675 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014044 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium sp003024675 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014045 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium spiroforme PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014046 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium spiroforme PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20014047 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium spiroforme PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014048 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium spiroforme PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014049 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium spiroforme PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014050 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium spiroforme PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014051 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium spiroforme PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014052 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium spiroforme PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014055 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium spiroforme PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014056 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium spiroforme PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014057 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium spiroforme PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014058 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium spiroforme PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014059 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium spiroforme PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014060 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium spiroforme PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014061 Microbes metabolize substances PMDBM2021320 3025757 Erysipelatoclostridium spiroforme PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014062 Microbes metabolize substances PMDBM204 128827 Erysipelotrichaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014063 Microbes metabolize substances PMDBM204 128827 Erysipelotrichaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014064 Microbes metabolize substances PMDBM204 128827 Erysipelotrichaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014065 Microbes metabolize substances PMDBM204 128827 Erysipelotrichaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014066 Microbes metabolize substances PMDBM204 128827 Erysipelotrichaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014067 Microbes metabolize substances PMDBM204 128827 Erysipelotrichaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014068 Microbes metabolize substances PMDBM204 128827 Erysipelotrichaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014071 Microbes metabolize substances PMDBM204 128827 Erysipelotrichaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014072 Microbes metabolize substances PMDBM204 128827 Erysipelotrichaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014073 Microbes metabolize substances PMDBM204 128827 Erysipelotrichaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014074 Microbes metabolize substances PMDBM204 128827 Erysipelotrichaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014075 Microbes metabolize substances PMDBM204 128827 Erysipelotrichaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014076 Microbes metabolize substances PMDBM204 128827 Erysipelotrichaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014077 Microbes metabolize substances PMDBM2020034 208962 Escherichia albertii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014078 Microbes metabolize substances PMDBM2020034 208962 Escherichia albertii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014079 Microbes metabolize substances PMDBM2020034 208962 Escherichia albertii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014080 Microbes metabolize substances PMDBM2020034 208962 Escherichia albertii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014081 Microbes metabolize substances PMDBM2020034 208962 Escherichia albertii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014082 Microbes metabolize substances PMDBM2020034 208962 Escherichia albertii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014083 Microbes metabolize substances PMDBM2020034 208962 Escherichia albertii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014086 Microbes metabolize substances PMDBM2020034 208962 Escherichia albertii PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20014087 Microbes metabolize substances PMDBM2020034 208962 Escherichia albertii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014088 Microbes metabolize substances PMDBM2020034 208962 Escherichia albertii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014089 Microbes metabolize substances PMDBM2020034 208962 Escherichia albertii PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20014090 Microbes metabolize substances PMDBM2020034 208962 Escherichia albertii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014091 Microbes metabolize substances PMDBM2020034 208962 Escherichia albertii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014092 Microbes metabolize substances PMDBM2020034 208962 Escherichia albertii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014093 Microbes metabolize substances PMDBM2020034 208962 Escherichia albertii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014094 Microbes metabolize substances PMDBM2020034 208962 Escherichia albertii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014095 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20014096 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20014097 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD471 Lactulose Therapeutic Substance laxative n.a. n.a. n.a. n.a. lactic and acetic acids n.a. unknown side effect n.a. n.a. n.a. The drug is hydrolyzed by several kinds of intestinal bacteria (lactobacillus, bacteroides and E. coli) to form lactic and acetic acids, which lower the pH of the intestinal contents . At the lower pH, ammonia and the other amines present in the gastroin-testinal tract become protonated and tend to be excreted in faeces, the accentuated elimination of these amines is responsible for the laxative effect of lactulose n.a. PMID PMID: 36467581 PMDBI20014099 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" bacteriostatic n.a. n.a. n.a. n.a. toxic-metabolites n.a. unknown toxicity n.a. n.a. n.a. Coliforms generate toxic metabolites for chloramphenicol n.a. PMID PMID: 36467581 PMDBI20014102 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. trifluorothymine n.a. unknown activity decreased n.a. n.a. n.a. MDM deglycosylation of the oral anticancer drug trifluridine leads to its premature inactivation, since trifluorothymine is no longer active n.a. PMID PMID: 36467581 PMDBI20014103 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD2000022 Doxifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. 5-fluorouracil n.a. unknown toxicity increased n.a. n.a. n.a. 5-Fluorouracil Premature activation may cause intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014104 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD2000023 Tretazicar(CB1954) Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. Nitroreductase toxicity increased n.a. n.a. n.a. enhance Tretazicar cytotoxicity n.a. PMID PMID: 36467581 PMDBI20014106 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" Cardiac drugs n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Result in an increase of gas metabolism pathways(side effect of metformin) n.a. PMID PMID: 36467581 PMDBI20014107 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD610 NSAIDs Therapeutic Substance compound n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. "Yield harmful metabolites,cause the formation of ulcers in the gut;" n.a. PMID PMID: 36467581 PMDBI20014109 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD812 Sulfasalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. "sulfapyridine; 5-aminosalicylate" n.a. Azo reductases activation n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes n.a. PMID PMID: 36467581 PMDBI20014110 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD636 Paclitaxel "Therapeutic Substance; Herbal Substance" chemotherapeutic agent n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. developmental delay n.a. PMID PMID: 36467581 PMDBI20014111 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD8 5-fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. 5-fluorouridine monophospate n.a. Uracil phosphoribosyltransferase activity increased n.a. n.a. n.a. Lead to sterility n.a. PMID PMID: 36467581 PMDBI20014112 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1005 5-fluoro-2'-deoxyuridine Therapeutic substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. completely sterile n.a. PMID PMID: 36467581 PMDBI20014113 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1072 Camptothecin Therapeutic substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. production of few dead embryos n.a. PMID PMID: 36467581 PMDBI20014114 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD200 Cladribine "Therapeutic Substance; Herbal Substance" chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20014115 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD290 Doxorubicin "Therapeutic Substance; Herbal Substance" chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20014116 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20014117 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20014118 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1006 5-fluorocytosine Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Increase chemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20014119 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1038 AQ4N Therapeutic substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Increase cemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20014120 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD866 Tretazicar Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Increase hemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20014121 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1142 Daunorubicin Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20014122 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1198 Fludarabine de phosphate Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Increase hemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20014123 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1232 Idarubicin Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20014124 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1275 Menadione Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20014125 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1300 Mitoxantrone Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20014126 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1436 Tegafur Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Increase hemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20014127 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1489 Vidarabine Therapeutic substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20014130 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD535 Methotrexate Therapeutic Substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown no impact n.a. n.a. n.a. No effect on Caenorhabditis elegans n.a. PMID PMID: 36467581 PMDBI20014131 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD829 Temozolomide Therapeutic Substance antitumor n.a. n.a. n.a. n.a. n.a. n.a. unknown no impact n.a. n.a. n.a. No effect on Caenorhabditis elegans n.a. PMID PMID: 36467581 PMDBI20014132 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1316 Neocarzinostatin Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. unknown no impact n.a. n.a. n.a. No effect on Caenorhabditis elegans n.a. PMID PMID: 36467581 PMDBI20014133 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1431 Sunitinib Therapeutic substance multi-targeted receptor tyrosine kinase (RTK) inhibitor n.a. n.a. n.a. n.a. n.a. n.a. unknown no impact n.a. n.a. n.a. No effect on Caenorhabditis elegans n.a. PMID PMID: 36467581 PMDBI20014134 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1433 Tamoxifen Therapeutic substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown no impact n.a. n.a. n.a. No effect on Caenorhabditis elegans n.a. PMID PMID: 36467581 PMDBI20014135 Microbes metabolize substances PMDBM2020035 585034 Escherichia coli IAI1 PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20014136 Microbes metabolize substances PMDBM2020035 585034 Escherichia coli IAI1 PMDBD558 Montelukast Therapeutic Substance Drugs for obstructive airway disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Biotransformation n.a. PMID PMID: 36467581 PMDBI20014137 Microbes metabolize substances PMDBM2020035 n.a. Escherichia coli ATCC25922 PMDBD565 Nabumetone Therapeutic Substance NSAID n.a. n.a. n.a. n.a. 4-(6-methoxy-2-naphthyl)-butan-2-ol n.a. unknown activity decreased n.a. n.a. n.a. probably lower bioavailability n.a. PMID PMID: 36467581 PMDBI20014138 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD36 Amiodarone Therapeutic Substance anti-arrhythmic n.a. n.a. n.a. n.a. desethylamiodarone n.a. unknown activity increased n.a. n.a. n.a. Absorption increase n.a. PMID PMID: 36467581 PMDBI20014139 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD1436 Tegafur Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20014140 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD1198 Fludarabine de phosphate Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20014141 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD1006 5-fluorocytosine Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20014142 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD1008 6-Mercaptopurine-2deoxyriboside Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20014143 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD2000024 Banoxantrone(AQ4N) Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20014144 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD2000023 Tretazicar(CB1954) Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20014145 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD200 Cladribine "Therapeutic Substance; Herbal Substance" chemotherapeutic n.a. n.a. n.a. n.a. chlorinated purine base n.a. unknown activity decreased n.a. n.a. n.a. it may be that an extracellular activation of cladribine by E. coli along with residual free enzymes from dead bacteria, disables its therapeutic potential. n.a. PMID PMID: 36467581 PMDBI20014146 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD1489 Vidarabine Therapeutic substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20014147 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. The decrease of drug efficacy is related to the enzyme enzymatic activity in E.coli n.a. PMID PMID: 36467581 PMDBI20014148 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD290 Doxorubicin "Therapeutic Substance; Herbal Substance" chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20014149 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD1142 Daunorubicin Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20014150 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD1232 Idarubicin Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20014151 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD2000025 Etoposide phosphate Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20014152 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD1300 Mitoxantrone Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20014153 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD1498 é“?Lapachone Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20014154 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD1275 Menadione Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20014155 Microbes metabolize substances PMDBM2020035 562 Escherichia coli D PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014156 Microbes metabolize substances PMDBM2020035 562 Escherichia coli D PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014157 Microbes metabolize substances PMDBM2020035 562 Escherichia coli D PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014158 Microbes metabolize substances PMDBM2020035 562 Escherichia coli D PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014159 Microbes metabolize substances PMDBM2020035 562 Escherichia coli D PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014160 Microbes metabolize substances PMDBM2020035 562 Escherichia coli D PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014161 Microbes metabolize substances PMDBM2020035 562 Escherichia coli D PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014164 Microbes metabolize substances PMDBM2020035 562 Escherichia coli D PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014165 Microbes metabolize substances PMDBM2020035 562 Escherichia coli D PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20014166 Microbes metabolize substances PMDBM2020035 562 Escherichia coli D PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014167 Microbes metabolize substances PMDBM2020035 562 Escherichia coli D PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014168 Microbes metabolize substances PMDBM2020035 562 Escherichia coli D PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014169 Microbes metabolize substances PMDBM2020035 562 Escherichia coli D PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014170 Microbes metabolize substances PMDBM2020035 562 Escherichia coli D PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014171 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014172 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014173 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014174 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014175 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014176 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014177 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014180 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20014181 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20014182 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014183 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014184 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20014185 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014186 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014187 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014188 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014189 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014190 Microbes metabolize substances PMDBM2020684 564 Escherichia fergusonii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014191 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014192 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014193 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014194 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014195 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014196 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014197 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20014198 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20014199 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014201 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20014204 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20014205 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20014206 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20014207 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014208 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014211 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20014214 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20014215 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014216 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014217 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014219 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014220 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014221 Microbes metabolize substances PMDBM2021528 1499973 Escherichia marmotae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014222 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014223 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014224 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014225 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014226 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014227 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014228 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20014229 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20014230 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014232 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20014235 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20014236 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20014237 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014238 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014241 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20014244 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20014245 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014246 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014247 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014249 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014250 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014251 Microbes metabolize substances PMDBM2020055 1884818 Escherichia sp000208585 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014252 Microbes metabolize substances PMDBM2008856 2 Eubacteria PMDBD96 Balsalazide Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. unknown activation n.a. n.a. n.a. release 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract. n.a. PMID PMID: 36467581 PMDBI20014253 Microbes metabolize substances PMDBM2008856 2 Eubacteria PMDBD453 Ipsalazide Therapeutic Substance unknown n.a. n.a. n.a. n.a. n.a. n.a. unknown activation n.a. n.a. n.a. release 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract. n.a. PMID PMID: 36467581 PMDBI20014254 Microbes metabolize substances PMDBM2008856 2 Eubacteria PMDBD618 Olsalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. unknown activation n.a. n.a. n.a. release 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract. n.a. PMID PMID: 36467581 PMDBI20014255 Microbes metabolize substances PMDBM216 1730 Eubacterium PMDBD595 Nitrazepam Therapeutic Substance anticonvulsant and hypnotic n.a. n.a. n.a. n.a. n.a. n.a. Nitroreductase activity decreased n.a. n.a. n.a. Involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to nitroreduction n.a. PMID PMID: 36467581 PMDBI20014256 Microbes metabolize substances PMDBM216 1730 Eubacterium PMDBD408 Glycyrrhizin Herbal Substance hepatoprotective n.a. n.a. n.a. n.a. 18-beta-glycyrrhetinic acid n.a. unknown activity increased n.a. n.a. n.a. activity increased n.a. PMID PMID: 36467581 PMDBI20014257 Microbes metabolize substances PMDBM216 1730 Eubacterium PMDBD96 Balsalazide Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. Azo reductases activation n.a. n.a. n.a. produced by intestinal bacteria release active part-ASA閿涘‘rom prodrug and at the same time, increase the toxicity n.a. PMID PMID: 36467581 PMDBI20014258 Microbes metabolize substances PMDBM216 1730 Eubacterium PMDBD618 Olsalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Azo reductases toxicity increased n.a. n.a. n.a. Reduction and Release of 5-aminosalicylic acid閿涘he activity increased and the toxicity increased n.a. PMID PMID: 36467581 PMDBI20014260 Microbes metabolize substances PMDBM216 1730 Eubacterium PMDBD812 Sulfasalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. "sulfapyridine; 5-aminosalicylate" n.a. Azo reductases activation n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 4-ASA by gut microbes n.a. PMID PMID: 36467581 PMDBI20014261 Microbes metabolize substances PMDBM2020223 n.a. Eubacterium rectale A1-86,DSM 17629,NCIMB 14373 PMDBD558 Montelukast Therapeutic Substance Drugs for obstructive airway disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Biotransformation n.a. PMID PMID: 36467581 PMDBI20014262 Microbes metabolize substances PMDBM2021529 53442 Eubacterium callanderi PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014263 Microbes metabolize substances PMDBM2021529 53442 Eubacterium callanderi PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014264 Microbes metabolize substances PMDBM2021529 53442 Eubacterium callanderi PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014265 Microbes metabolize substances PMDBM2021529 53442 Eubacterium callanderi PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014266 Microbes metabolize substances PMDBM2021529 53442 Eubacterium callanderi PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014267 Microbes metabolize substances PMDBM2021529 53442 Eubacterium callanderi PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014268 Microbes metabolize substances PMDBM2021529 53442 Eubacterium callanderi PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014271 Microbes metabolize substances PMDBM2021529 53442 Eubacterium callanderi PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014272 Microbes metabolize substances PMDBM2021529 53442 Eubacterium callanderi PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014273 Microbes metabolize substances PMDBM2021529 53442 Eubacterium callanderi PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014274 Microbes metabolize substances PMDBM2021529 53442 Eubacterium callanderi PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014275 Microbes metabolize substances PMDBM2021529 53442 Eubacterium callanderi PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014276 Microbes metabolize substances PMDBM2020213 84112 Eubacterium lentum PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" cardiac glycoside n.a. n.a. n.a. n.a. dihydrodigoxin n.a. Digoxin reductase involved in substrate metabolism n.a. n.a. n.a. Reaction contingent on the correct strain of E. lentum and inhibited by dietary arginine n.a. PMID PMID: 36467581 PMDBI20014277 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014278 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20014279 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014280 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014281 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014282 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014283 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014284 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014287 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20014288 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014289 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014290 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014291 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014292 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014293 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum PMDBD772 Secoisolariciresinol Therapeutic Substance anticancer n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. unknown activity increased n.a. n.a. n.a. Protective effects against breast cancer n.a. PMID PMID: 36467581 PMDBI20014294 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014295 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014296 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014297 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014298 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014299 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014300 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014303 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014304 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014305 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014306 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014307 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014308 Microbes metabolize substances PMDBM2020222 39490 Eubacterium ramulus PMDBD386 Genistein "Therapeutic Substance; Herbal Substance" antineoplastic and antitumor n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Genistein was completely degraded by E. ramulus via 6'-hydroxy-O-desmethylangolensin to 2-(4-hydroxyphenyl)-propionic acid. Dihydrogenistein was neither observed as an intermediate in this transformation nor converted itself by growing cells or cell-free extracts of E. ramulus. Genistein-7-O-glucoside was partially transformed by way of genistein to the product 2-(4-hydroxyphenyl)-propionic acid n.a. PMID PMID: 36467581 PMDBI20014309 Microbes metabolize substances PMDBM2020222 39490 Eubacterium ramulus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014310 Microbes metabolize substances PMDBM2020222 39490 Eubacterium ramulus PMDBD718 Quercetin-3-glucoside "Herbal Substance; Dietary Substance" compound n.a. n.a. n.a. n.a. 3,4-dihydroxyphenylacetic-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Eubacterium ramulus and Enterococcus casseliflavus showed that both species are capable of metabolizing quercetin-3-glucoside. Based on the wide occurrence of Eu. Ramulus in the human intestinal tract it is believed that this species plays a dominant role in bacterial transformation of flavonoids n.a. PMID PMID: 36467581 PMDBI20014313 Microbes metabolize substances PMDBM2020222 39490 Eubacterium ramulus PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" a weakly estrogenic compound with potential health n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. genistein is more susceptible to breakdown by gut microorganisms than daidzein. n.a. PMID PMID: 36467581 PMDBI20014314 Microbes metabolize substances PMDBM2020222 39490 Eubacterium ramulus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20014315 Microbes metabolize substances PMDBM2020223 39491 Eubacterium rectale PMDBD668 Picosulfuric acid Therapeutic Substance compound n.a. n.a. n.a. n.a. free diphenol[4,49-(pyridin-2-ylmethanediyl)diphenol] n.a. unknown activity increased n.a. n.a. n.a. "Have a laxative effect;drug interaction:antibiotics inhibits the transformation" n.a. PMID PMID: 36467581 PMDBI20014316 Microbes metabolize substances PMDBM2020057 n.a. Eubacterium sp. Strain GLH PMDBD408 Glycyrrhizin Herbal Substance hepatoprotective n.a. n.a. n.a. n.a. 18-beta-glycyrrhetinic-acid n.a. unknown activity increased n.a. n.a. n.a. Increased activity by conversion into 18-beta-glycyrrhetinic acid n.a. PMID PMID: 36467581 PMDBI20014317 Microbes metabolize substances PMDBM2020057 n.a. Eubacterium. sp.strain GLH57 PMDBD408 Glycyrrhizin Herbal Substance hepatoprotective n.a. n.a. n.a. n.a. 18-beta-glycyrrhetinic acid n.a. unknown activity increased n.a. n.a. n.a. Through hydrolysis閿涘瓘lycyrrhizin formation 18-ç?glycyrrhetinic acid n.a. PMID PMID: 36467581 PMDBI20014318 Microbes metabolize substances PMDBM2008863 n.a. Eubacterium A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014319 Microbes metabolize substances PMDBM2008863 n.a. Eubacterium A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014320 Microbes metabolize substances PMDBM2008863 n.a. Eubacterium A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014321 Microbes metabolize substances PMDBM2008863 n.a. Eubacterium A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014322 Microbes metabolize substances PMDBM2008864 n.a. Eubacterium E PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014323 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014324 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014325 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014326 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014327 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014328 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014329 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014332 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014333 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014334 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014335 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014336 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014337 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014338 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014339 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014340 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014341 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014342 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014343 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014346 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014347 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014348 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014349 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014350 Microbes metabolize substances PMDBM2020120 1263078 Eubacterium E hallii A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014351 Microbes metabolize substances PMDBM2020057 142586 Eubacterium E sp002161065 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014352 Microbes metabolize substances PMDBM2020057 142586 Eubacterium E sp002161065 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014353 Microbes metabolize substances PMDBM2020057 142586 Eubacterium E sp002161065 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014354 Microbes metabolize substances PMDBM2020057 142586 Eubacterium E sp002161065 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20014355 Microbes metabolize substances PMDBM2020057 142586 Eubacterium E sp002161065 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014356 Microbes metabolize substances PMDBM2020057 142586 Eubacterium E sp002161065 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014357 Microbes metabolize substances PMDBM2020057 142586 Eubacterium E sp002161065 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014358 Microbes metabolize substances PMDBM2020057 142586 Eubacterium E sp002161065 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014361 Microbes metabolize substances PMDBM2020057 142586 Eubacterium E sp002161065 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014362 Microbes metabolize substances PMDBM2020057 142586 Eubacterium E sp002161065 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014363 Microbes metabolize substances PMDBM2020057 142586 Eubacterium E sp002161065 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014364 Microbes metabolize substances PMDBM2020057 142586 Eubacterium E sp002161065 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014365 Microbes metabolize substances PMDBM2020057 142586 Eubacterium E sp002161065 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014366 Microbes metabolize substances PMDBM2020057 142586 Eubacterium E sp002161065 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014367 Microbes metabolize substances PMDBM2008868 n.a. Eubacterium F PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014368 Microbes metabolize substances PMDBM2008868 n.a. Eubacterium F PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014369 Microbes metabolize substances PMDBM2008868 n.a. Eubacterium F PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014370 Microbes metabolize substances PMDBM2008868 n.a. Eubacterium F PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014371 Microbes metabolize substances PMDBM2008868 n.a. Eubacterium F PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014372 Microbes metabolize substances PMDBM2008868 n.a. Eubacterium F PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014373 Microbes metabolize substances PMDBM2008868 n.a. Eubacterium F PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014376 Microbes metabolize substances PMDBM2008868 n.a. Eubacterium F PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014377 Microbes metabolize substances PMDBM2008868 n.a. Eubacterium F PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014378 Microbes metabolize substances PMDBM2008868 n.a. Eubacterium F PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014379 Microbes metabolize substances PMDBM2008868 n.a. Eubacterium F PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014380 Microbes metabolize substances PMDBM2008868 n.a. Eubacterium F PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014381 Microbes metabolize substances PMDBM2008868 n.a. Eubacterium F PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014382 Microbes metabolize substances PMDBM2008868 n.a. Eubacterium F PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014383 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000433735 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014384 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000433735 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014385 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000433735 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014386 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000433735 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014387 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000433735 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014388 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000433735 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014389 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000433735 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014392 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000433735 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014393 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000433735 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014394 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000433735 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014395 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000433735 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014396 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000433735 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014397 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000433735 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014398 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000433735 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014399 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000434115 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014400 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000434115 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014401 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000434115 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014402 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000434115 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014403 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000434115 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014404 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000434115 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014405 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000434115 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014408 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000434115 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014409 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000434115 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014410 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000434115 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014411 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000434115 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014412 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000434115 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014413 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000434115 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014414 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp000434115 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014415 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp003491505 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014416 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp003491505 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014417 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp003491505 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014418 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp003491505 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014419 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp003491505 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014420 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp003491505 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014421 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp003491505 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014424 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp003491505 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014425 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp003491505 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014426 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp003491505 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014427 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp003491505 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014428 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp003491505 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014429 Microbes metabolize substances PMDBM2020057 142586 Eubacterium F sp003491505 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014430 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014431 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014432 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014433 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014435 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014437 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014438 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014439 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014440 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20014441 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20014442 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014444 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20014447 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20014448 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20014449 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014450 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014453 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20014456 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014457 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014460 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014461 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014462 Microbes metabolize substances PMDBM2008872 n.a. Eubacterium G PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014463 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000432355 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014464 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000432355 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014465 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000432355 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014466 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000432355 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014467 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000432355 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014468 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000432355 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014469 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000432355 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014472 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000432355 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014473 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000432355 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014474 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000432355 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014475 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000432355 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014476 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000432355 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014477 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000432355 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014478 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000432355 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014479 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000432355 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014480 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000434315 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014481 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000434315 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014482 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000434315 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014483 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000434315 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014484 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000434315 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014485 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000434315 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014486 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000434315 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014489 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000434315 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014490 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000434315 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014491 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000434315 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014492 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000434315 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014493 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000434315 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014494 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000434315 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014495 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000434315 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014496 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000434315 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014497 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000435815 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014498 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000435815 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014499 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000435815 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014500 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000435815 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014501 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000435815 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014502 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000435815 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014503 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000435815 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014506 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000435815 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014507 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000435815 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014508 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000435815 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014509 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000435815 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014510 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000435815 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014511 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000435815 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014512 Microbes metabolize substances PMDBM2020057 142586 Eubacterium G sp000435815 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014513 Microbes metabolize substances PMDBM2020122 39496 Eubacterium G ventriosum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014514 Microbes metabolize substances PMDBM2020122 39496 Eubacterium G ventriosum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014515 Microbes metabolize substances PMDBM2020122 39496 Eubacterium G ventriosum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014516 Microbes metabolize substances PMDBM2020122 39496 Eubacterium G ventriosum PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20014517 Microbes metabolize substances PMDBM2020122 39496 Eubacterium G ventriosum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014518 Microbes metabolize substances PMDBM2020122 39496 Eubacterium G ventriosum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014519 Microbes metabolize substances PMDBM2020122 39496 Eubacterium G ventriosum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014520 Microbes metabolize substances PMDBM2020122 39496 Eubacterium G ventriosum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014523 Microbes metabolize substances PMDBM2020122 39496 Eubacterium G ventriosum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014524 Microbes metabolize substances PMDBM2020122 39496 Eubacterium G ventriosum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014525 Microbes metabolize substances PMDBM2020122 39496 Eubacterium G ventriosum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014526 Microbes metabolize substances PMDBM2020122 39496 Eubacterium G ventriosum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014527 Microbes metabolize substances PMDBM2020122 39496 Eubacterium G ventriosum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014528 Microbes metabolize substances PMDBM2020122 39496 Eubacterium G ventriosum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014529 Microbes metabolize substances PMDBM2020122 39496 Eubacterium G ventriosum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014530 Microbes metabolize substances PMDBM2020122 39496 Eubacterium G ventriosum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014531 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014532 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014533 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014534 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014536 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014538 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20014539 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014540 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014541 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014542 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014545 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014546 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014547 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20014548 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014549 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014551 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014552 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014553 Microbes metabolize substances PMDBM2008877 n.a. Eubacterium I PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014554 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014555 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014556 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014557 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus A PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20014558 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014559 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014560 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014561 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014564 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014565 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014566 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014567 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014568 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014569 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014570 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014571 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014572 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014573 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20014574 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014575 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014576 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20014577 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014578 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014579 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014580 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014583 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014584 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014585 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20014586 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014587 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014588 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014589 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014590 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014591 Microbes metabolize substances PMDBM2020222 39490 Eubacterium I ramulus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014592 Microbes metabolize substances PMDBM2020057 142586 Eubacterium I sp900066595 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014593 Microbes metabolize substances PMDBM2020057 142586 Eubacterium I sp900066595 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20014594 Microbes metabolize substances PMDBM2020057 142586 Eubacterium I sp900066595 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014595 Microbes metabolize substances PMDBM2020057 142586 Eubacterium I sp900066595 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014596 Microbes metabolize substances PMDBM2020057 142586 Eubacterium I sp900066595 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014597 Microbes metabolize substances PMDBM2020057 142586 Eubacterium I sp900066595 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014598 Microbes metabolize substances PMDBM2020057 142586 Eubacterium I sp900066595 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014599 Microbes metabolize substances PMDBM2020057 142586 Eubacterium I sp900066595 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014602 Microbes metabolize substances PMDBM2020057 142586 Eubacterium I sp900066595 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014603 Microbes metabolize substances PMDBM2020057 142586 Eubacterium I sp900066595 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20014604 Microbes metabolize substances PMDBM2020057 142586 Eubacterium I sp900066595 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014605 Microbes metabolize substances PMDBM2020057 142586 Eubacterium I sp900066595 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014606 Microbes metabolize substances PMDBM2020057 142586 Eubacterium I sp900066595 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014607 Microbes metabolize substances PMDBM2020057 142586 Eubacterium I sp900066595 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014608 Microbes metabolize substances PMDBM2020057 142586 Eubacterium I sp900066595 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014609 Microbes metabolize substances PMDBM2020057 142586 Eubacterium I sp900066595 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014610 Microbes metabolize substances PMDBM2008881 n.a. Eubacterium J PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014611 Microbes metabolize substances PMDBM2008881 n.a. Eubacterium J PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014612 Microbes metabolize substances PMDBM2008881 n.a. Eubacterium J PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014613 Microbes metabolize substances PMDBM2008881 n.a. Eubacterium J PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014614 Microbes metabolize substances PMDBM2008881 n.a. Eubacterium J PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014615 Microbes metabolize substances PMDBM2008881 n.a. Eubacterium J PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014616 Microbes metabolize substances PMDBM2008881 n.a. Eubacterium J PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014619 Microbes metabolize substances PMDBM2008881 n.a. Eubacterium J PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014620 Microbes metabolize substances PMDBM2008881 n.a. Eubacterium J PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014621 Microbes metabolize substances PMDBM2008881 n.a. Eubacterium J PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014622 Microbes metabolize substances PMDBM2008881 n.a. Eubacterium J PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014623 Microbes metabolize substances PMDBM2008881 n.a. Eubacterium J PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014624 Microbes metabolize substances PMDBM2008881 n.a. Eubacterium J PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014625 Microbes metabolize substances PMDBM2008881 n.a. Eubacterium J PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014626 Microbes metabolize substances PMDBM2008881 n.a. Eubacterium J PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014627 Microbes metabolize substances PMDBM2008882 n.a. Eubacterium M PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014628 Microbes metabolize substances PMDBM2008882 n.a. Eubacterium M PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014629 Microbes metabolize substances PMDBM2008882 n.a. Eubacterium M PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014630 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014631 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014632 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014633 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014635 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014637 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014638 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014639 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014640 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20014641 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20014642 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014644 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20014647 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20014648 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20014649 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014650 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014653 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20014656 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014657 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014660 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014661 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014662 Microbes metabolize substances PMDBM2008883 n.a. Eubacterium R PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014663 Microbes metabolize substances PMDBM2021530 290054 Eubacterium R coprostanoligenes PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014664 Microbes metabolize substances PMDBM2021530 290054 Eubacterium R coprostanoligenes PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014665 Microbes metabolize substances PMDBM2021530 290054 Eubacterium R coprostanoligenes PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014666 Microbes metabolize substances PMDBM2021530 290054 Eubacterium R coprostanoligenes PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014667 Microbes metabolize substances PMDBM2021530 290054 Eubacterium R coprostanoligenes PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014668 Microbes metabolize substances PMDBM2021530 290054 Eubacterium R coprostanoligenes PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014669 Microbes metabolize substances PMDBM2021530 290054 Eubacterium R coprostanoligenes PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014672 Microbes metabolize substances PMDBM2021530 290054 Eubacterium R coprostanoligenes PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014673 Microbes metabolize substances PMDBM2021530 290054 Eubacterium R coprostanoligenes PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014674 Microbes metabolize substances PMDBM2021530 290054 Eubacterium R coprostanoligenes PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014675 Microbes metabolize substances PMDBM2021530 290054 Eubacterium R coprostanoligenes PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014676 Microbes metabolize substances PMDBM2021530 290054 Eubacterium R coprostanoligenes PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014677 Microbes metabolize substances PMDBM2021530 290054 Eubacterium R coprostanoligenes PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014678 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000431535 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014679 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000431535 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014680 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000431535 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014681 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000431535 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014682 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000431535 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014683 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000431535 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014684 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000431535 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014687 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000431535 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014688 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000431535 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014689 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000431535 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014690 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000431535 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014691 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000431535 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014692 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000431535 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014693 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000431535 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014694 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000433975 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014695 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000433975 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014696 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000433975 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014697 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000433975 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014698 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000433975 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014699 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000433975 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014700 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000433975 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014703 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000433975 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014704 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000433975 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014705 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000433975 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014706 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000433975 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014707 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000433975 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014708 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000434995 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014709 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000434995 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014710 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000434995 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014711 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000434995 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014712 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000434995 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014713 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000434995 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014714 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000434995 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014717 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000434995 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014718 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000434995 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014719 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000434995 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014720 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000434995 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014721 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000434995 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014722 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000434995 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014723 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000434995 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014724 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000436835 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014725 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000436835 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014726 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000436835 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014727 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000436835 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014729 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000436835 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014731 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000436835 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014732 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000436835 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014733 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000436835 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014734 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000436835 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014737 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000436835 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014738 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000436835 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014739 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000436835 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014740 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000436835 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014742 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp000436835 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014743 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014744 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014745 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014746 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014747 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014748 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014749 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20014750 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20014751 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014753 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20014756 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20014757 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20014758 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014759 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014762 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20014765 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014766 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014767 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014769 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014770 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014771 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp002493325 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014772 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp003526845 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014773 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp003526845 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014774 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp003526845 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014775 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp003526845 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014776 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp003526845 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014777 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp003526845 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014778 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp003526845 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014781 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp003526845 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014782 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp003526845 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014783 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp003526845 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014784 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp003526845 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014785 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp003526845 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014786 Microbes metabolize substances PMDBM2020057 142586 Eubacterium R sp003526845 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014787 Microbes metabolize substances PMDBM2008891 33986 Exiguobacterium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014788 Microbes metabolize substances PMDBM2008891 33986 Exiguobacterium PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20014789 Microbes metabolize substances PMDBM2008891 33986 Exiguobacterium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014790 Microbes metabolize substances PMDBM2008891 33986 Exiguobacterium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014791 Microbes metabolize substances PMDBM2008891 33986 Exiguobacterium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014792 Microbes metabolize substances PMDBM2008891 33986 Exiguobacterium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014793 Microbes metabolize substances PMDBM2008891 33986 Exiguobacterium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014794 Microbes metabolize substances PMDBM2008891 33986 Exiguobacterium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014797 Microbes metabolize substances PMDBM2008891 33986 Exiguobacterium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014798 Microbes metabolize substances PMDBM2008891 33986 Exiguobacterium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014799 Microbes metabolize substances PMDBM2008891 33986 Exiguobacterium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014800 Microbes metabolize substances PMDBM2008891 33986 Exiguobacterium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014801 Microbes metabolize substances PMDBM2008891 33986 Exiguobacterium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014802 Microbes metabolize substances PMDBM2008891 33986 Exiguobacterium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014803 Microbes metabolize substances PMDBM2008891 33986 Exiguobacterium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014804 Microbes metabolize substances PMDBM2008892 n.a. Exiguobacterium A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014805 Microbes metabolize substances PMDBM2008892 n.a. Exiguobacterium A PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20014806 Microbes metabolize substances PMDBM2008892 n.a. Exiguobacterium A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014807 Microbes metabolize substances PMDBM2008892 n.a. Exiguobacterium A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014808 Microbes metabolize substances PMDBM2008892 n.a. Exiguobacterium A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014809 Microbes metabolize substances PMDBM2008892 n.a. Exiguobacterium A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014810 Microbes metabolize substances PMDBM2008892 n.a. Exiguobacterium A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014811 Microbes metabolize substances PMDBM2008892 n.a. Exiguobacterium A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014814 Microbes metabolize substances PMDBM2008892 n.a. Exiguobacterium A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014815 Microbes metabolize substances PMDBM2008892 n.a. Exiguobacterium A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014816 Microbes metabolize substances PMDBM2008892 n.a. Exiguobacterium A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014817 Microbes metabolize substances PMDBM2008892 n.a. Exiguobacterium A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014818 Microbes metabolize substances PMDBM2008892 n.a. Exiguobacterium A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014819 Microbes metabolize substances PMDBM2008892 n.a. Exiguobacterium A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014820 Microbes metabolize substances PMDBM2008892 n.a. Exiguobacterium A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014821 Microbes metabolize substances PMDBM2008893 1582879 Ezakiella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014822 Microbes metabolize substances PMDBM2008893 1582879 Ezakiella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014823 Microbes metabolize substances PMDBM2008893 1582879 Ezakiella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014824 Microbes metabolize substances PMDBM2008893 1582879 Ezakiella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014825 Microbes metabolize substances PMDBM2008893 1582879 Ezakiella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014826 Microbes metabolize substances PMDBM2008893 1582879 Ezakiella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014827 Microbes metabolize substances PMDBM2008893 1582879 Ezakiella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014830 Microbes metabolize substances PMDBM2008893 1582879 Ezakiella PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20014831 Microbes metabolize substances PMDBM2008893 1582879 Ezakiella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014832 Microbes metabolize substances PMDBM2008893 1582879 Ezakiella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014833 Microbes metabolize substances PMDBM2008893 1582879 Ezakiella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014834 Microbes metabolize substances PMDBM2008893 1582879 Ezakiella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014835 Microbes metabolize substances PMDBM2008893 1582879 Ezakiella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014836 Microbes metabolize substances PMDBM2008893 1582879 Ezakiella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014837 Microbes metabolize substances PMDBM2008893 1582879 Ezakiella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014838 Microbes metabolize substances PMDBM2021531 46507 Ezakiella coagulans PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014839 Microbes metabolize substances PMDBM2021531 46507 Ezakiella coagulans PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014840 Microbes metabolize substances PMDBM2021531 46507 Ezakiella coagulans PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014841 Microbes metabolize substances PMDBM2021531 46507 Ezakiella coagulans PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014842 Microbes metabolize substances PMDBM2021531 46507 Ezakiella coagulans PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014843 Microbes metabolize substances PMDBM2021531 46507 Ezakiella coagulans PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014844 Microbes metabolize substances PMDBM2021531 46507 Ezakiella coagulans PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014847 Microbes metabolize substances PMDBM2021531 46507 Ezakiella coagulans PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20014848 Microbes metabolize substances PMDBM2021531 46507 Ezakiella coagulans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014849 Microbes metabolize substances PMDBM2021531 46507 Ezakiella coagulans PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014850 Microbes metabolize substances PMDBM2021531 46507 Ezakiella coagulans PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014851 Microbes metabolize substances PMDBM2021531 46507 Ezakiella coagulans PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014852 Microbes metabolize substances PMDBM2021531 46507 Ezakiella coagulans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014853 Microbes metabolize substances PMDBM2021531 46507 Ezakiella coagulans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014854 Microbes metabolize substances PMDBM2021532 1852374 Ezakiella massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014855 Microbes metabolize substances PMDBM2021532 1852374 Ezakiella massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014856 Microbes metabolize substances PMDBM2021532 1852374 Ezakiella massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014857 Microbes metabolize substances PMDBM2021532 1852374 Ezakiella massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014858 Microbes metabolize substances PMDBM2021532 1852374 Ezakiella massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014859 Microbes metabolize substances PMDBM2021532 1852374 Ezakiella massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014860 Microbes metabolize substances PMDBM2021532 1852374 Ezakiella massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014863 Microbes metabolize substances PMDBM2021532 1852374 Ezakiella massiliensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20014864 Microbes metabolize substances PMDBM2021532 1852374 Ezakiella massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014865 Microbes metabolize substances PMDBM2021532 1852374 Ezakiella massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014866 Microbes metabolize substances PMDBM2021532 1852374 Ezakiella massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014867 Microbes metabolize substances PMDBM2021532 1852374 Ezakiella massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014868 Microbes metabolize substances PMDBM2021532 1852374 Ezakiella massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014869 Microbes metabolize substances PMDBM2021532 1852374 Ezakiella massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014870 Microbes metabolize substances PMDBM2021532 1852374 Ezakiella massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014871 Microbes metabolize substances PMDBM2008896 n.a. f Acutalibacteraceae g An172 s An172 sp002160515 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014872 Microbes metabolize substances PMDBM2008896 n.a. f Acutalibacteraceae g An172 s An172 sp002160515 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014873 Microbes metabolize substances PMDBM2008896 n.a. f Acutalibacteraceae g An172 s An172 sp002160515 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014874 Microbes metabolize substances PMDBM2008896 n.a. f Acutalibacteraceae g An172 s An172 sp002160515 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014875 Microbes metabolize substances PMDBM2008896 n.a. f Acutalibacteraceae g An172 s An172 sp002160515 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014876 Microbes metabolize substances PMDBM2008896 n.a. f Acutalibacteraceae g An172 s An172 sp002160515 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014877 Microbes metabolize substances PMDBM2008896 n.a. f Acutalibacteraceae g An172 s An172 sp002160515 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014880 Microbes metabolize substances PMDBM2008896 n.a. f Acutalibacteraceae g An172 s An172 sp002160515 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014881 Microbes metabolize substances PMDBM2008896 n.a. f Acutalibacteraceae g An172 s An172 sp002160515 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014882 Microbes metabolize substances PMDBM2008896 n.a. f Acutalibacteraceae g An172 s An172 sp002160515 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014883 Microbes metabolize substances PMDBM2008896 n.a. f Acutalibacteraceae g An172 s An172 sp002160515 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014884 Microbes metabolize substances PMDBM2008896 n.a. f Acutalibacteraceae g An172 s An172 sp002160515 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014885 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014886 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20014887 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014888 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014889 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014891 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014893 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014894 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014895 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014896 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20014897 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20014898 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014900 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20014903 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20014904 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20014905 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014906 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014909 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20014912 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014913 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014916 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014917 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014918 Microbes metabolize substances PMDBM2008897 n.a. f Acutalibacteraceae g An200 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014919 Microbes metabolize substances PMDBM2008898 n.a. f Acutalibacteraceae g An200 s An200 sp003268275 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20014920 Microbes metabolize substances PMDBM2008898 n.a. f Acutalibacteraceae g An200 s An200 sp003268275 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014921 Microbes metabolize substances PMDBM2008898 n.a. f Acutalibacteraceae g An200 s An200 sp003268275 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014922 Microbes metabolize substances PMDBM2008898 n.a. f Acutalibacteraceae g An200 s An200 sp003268275 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014923 Microbes metabolize substances PMDBM2008898 n.a. f Acutalibacteraceae g An200 s An200 sp003268275 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014924 Microbes metabolize substances PMDBM2008898 n.a. f Acutalibacteraceae g An200 s An200 sp003268275 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20014925 Microbes metabolize substances PMDBM2008898 n.a. f Acutalibacteraceae g An200 s An200 sp003268275 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20014926 Microbes metabolize substances PMDBM2008898 n.a. f Acutalibacteraceae g An200 s An200 sp003268275 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20014928 Microbes metabolize substances PMDBM2008898 n.a. f Acutalibacteraceae g An200 s An200 sp003268275 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20014929 Microbes metabolize substances PMDBM2008898 n.a. f Acutalibacteraceae g An200 s An200 sp003268275 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20014930 Microbes metabolize substances PMDBM2008898 n.a. f Acutalibacteraceae g An200 s An200 sp003268275 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014931 Microbes metabolize substances PMDBM2008898 n.a. f Acutalibacteraceae g An200 s An200 sp003268275 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014934 Microbes metabolize substances PMDBM2008898 n.a. f Acutalibacteraceae g An200 s An200 sp003268275 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20014938 Microbes metabolize substances PMDBM2008898 n.a. f Acutalibacteraceae g An200 s An200 sp003268275 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014939 Microbes metabolize substances PMDBM2008898 n.a. f Acutalibacteraceae g An200 s An200 sp003268275 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014940 Microbes metabolize substances PMDBM2008898 n.a. f Acutalibacteraceae g An200 s An200 sp003268275 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20014941 Microbes metabolize substances PMDBM2008899 n.a. f Bacteroidaceae g 43-108 s 43-108 sp001915545 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014942 Microbes metabolize substances PMDBM2008899 n.a. f Bacteroidaceae g 43-108 s 43-108 sp001915545 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014943 Microbes metabolize substances PMDBM2008899 n.a. f Bacteroidaceae g 43-108 s 43-108 sp001915545 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014944 Microbes metabolize substances PMDBM2008899 n.a. f Bacteroidaceae g 43-108 s 43-108 sp001915545 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014946 Microbes metabolize substances PMDBM2008899 n.a. f Bacteroidaceae g 43-108 s 43-108 sp001915545 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014948 Microbes metabolize substances PMDBM2008899 n.a. f Bacteroidaceae g 43-108 s 43-108 sp001915545 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014949 Microbes metabolize substances PMDBM2008899 n.a. f Bacteroidaceae g 43-108 s 43-108 sp001915545 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014950 Microbes metabolize substances PMDBM2008899 n.a. f Bacteroidaceae g 43-108 s 43-108 sp001915545 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014951 Microbes metabolize substances PMDBM2008899 n.a. f Bacteroidaceae g 43-108 s 43-108 sp001915545 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014954 Microbes metabolize substances PMDBM2008899 n.a. f Bacteroidaceae g 43-108 s 43-108 sp001915545 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014955 Microbes metabolize substances PMDBM2008899 n.a. f Bacteroidaceae g 43-108 s 43-108 sp001915545 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014956 Microbes metabolize substances PMDBM2008899 n.a. f Bacteroidaceae g 43-108 s 43-108 sp001915545 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014957 Microbes metabolize substances PMDBM2008899 n.a. f Bacteroidaceae g 43-108 s 43-108 sp001915545 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014959 Microbes metabolize substances PMDBM2008899 n.a. f Bacteroidaceae g 43-108 s 43-108 sp001915545 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014960 Microbes metabolize substances PMDBM2008899 n.a. f Bacteroidaceae g 43-108 s 43-108 sp001915545 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014961 Microbes metabolize substances PMDBM2008899 n.a. f Bacteroidaceae g 43-108 s 43-108 sp001915545 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014962 Microbes metabolize substances PMDBM2008900 n.a. f Lachnospiraceae g An181 s An181 sp002160325 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20014963 Microbes metabolize substances PMDBM2008900 n.a. f Lachnospiraceae g An181 s An181 sp002160325 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20014964 Microbes metabolize substances PMDBM2008900 n.a. f Lachnospiraceae g An181 s An181 sp002160325 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20014965 Microbes metabolize substances PMDBM2008900 n.a. f Lachnospiraceae g An181 s An181 sp002160325 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014967 Microbes metabolize substances PMDBM2008900 n.a. f Lachnospiraceae g An181 s An181 sp002160325 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20014969 Microbes metabolize substances PMDBM2008900 n.a. f Lachnospiraceae g An181 s An181 sp002160325 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20014970 Microbes metabolize substances PMDBM2008900 n.a. f Lachnospiraceae g An181 s An181 sp002160325 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014971 Microbes metabolize substances PMDBM2008900 n.a. f Lachnospiraceae g An181 s An181 sp002160325 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014972 Microbes metabolize substances PMDBM2008900 n.a. f Lachnospiraceae g An181 s An181 sp002160325 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20014973 Microbes metabolize substances PMDBM2008900 n.a. f Lachnospiraceae g An181 s An181 sp002160325 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20014976 Microbes metabolize substances PMDBM2008900 n.a. f Lachnospiraceae g An181 s An181 sp002160325 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014977 Microbes metabolize substances PMDBM2008900 n.a. f Lachnospiraceae g An181 s An181 sp002160325 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014978 Microbes metabolize substances PMDBM2008900 n.a. f Lachnospiraceae g An181 s An181 sp002160325 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014979 Microbes metabolize substances PMDBM2008900 n.a. f Lachnospiraceae g An181 s An181 sp002160325 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20014981 Microbes metabolize substances PMDBM2008900 n.a. f Lachnospiraceae g An181 s An181 sp002160325 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014982 Microbes metabolize substances PMDBM2008900 n.a. f Lachnospiraceae g An181 s An181 sp002160325 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014983 Microbes metabolize substances PMDBM2008900 n.a. f Lachnospiraceae g An181 s An181 sp002160325 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014984 Microbes metabolize substances PMDBM2008901 n.a. f Megasphaeraceae g 28L s 28L sp000177555 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014985 Microbes metabolize substances PMDBM2008901 n.a. f Megasphaeraceae g 28L s 28L sp000177555 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014986 Microbes metabolize substances PMDBM2008901 n.a. f Megasphaeraceae g 28L s 28L sp000177555 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014987 Microbes metabolize substances PMDBM2008902 n.a. f Synergistaceae g An23 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014988 Microbes metabolize substances PMDBM2008902 n.a. f Synergistaceae g An23 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014989 Microbes metabolize substances PMDBM2008902 n.a. f Synergistaceae g An23 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014990 Microbes metabolize substances PMDBM2008902 n.a. f Synergistaceae g An23 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014991 Microbes metabolize substances PMDBM2008903 n.a. f Bacteroidaceae g F0040 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014992 Microbes metabolize substances PMDBM2008903 n.a. f Bacteroidaceae g F0040 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014993 Microbes metabolize substances PMDBM2008903 n.a. f Bacteroidaceae g F0040 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014994 Microbes metabolize substances PMDBM2008904 n.a. f Bacteroidaceae g F0040 s F0040 sp000318095 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20014995 Microbes metabolize substances PMDBM2008904 n.a. f Bacteroidaceae g F0040 s F0040 sp000318095 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20014996 Microbes metabolize substances PMDBM2008904 n.a. f Bacteroidaceae g F0040 s F0040 sp000318095 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20014997 Microbes metabolize substances PMDBM2008904 n.a. f Bacteroidaceae g F0040 s F0040 sp000318095 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014998 Microbes metabolize substances PMDBM2008904 n.a. f Bacteroidaceae g F0040 s F0040 sp000318095 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20014999 Microbes metabolize substances PMDBM2008905 n.a. f Bacteroidaceae g F0040 s F0040 sp900095835 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015000 Microbes metabolize substances PMDBM2008905 n.a. f Bacteroidaceae g F0040 s F0040 sp900095835 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015001 Microbes metabolize substances PMDBM2008905 n.a. f Bacteroidaceae g F0040 s F0040 sp900095835 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015002 Microbes metabolize substances PMDBM2008905 n.a. f Bacteroidaceae g F0040 s F0040 sp900095835 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015003 Microbes metabolize substances PMDBM2008905 n.a. f Bacteroidaceae g F0040 s F0040 sp900095835 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015004 Microbes metabolize substances PMDBM2008906 n.a. f Veillonellaceae g F0422 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015005 Microbes metabolize substances PMDBM2008907 n.a. f Veillonellaceae g F0422 s F0422 sp001553345 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015006 Microbes metabolize substances PMDBM2008908 n.a. o Bacteroidales f F082 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015007 Microbes metabolize substances PMDBM2008908 n.a. o Bacteroidales f F082 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015008 Microbes metabolize substances PMDBM2008908 n.a. o Bacteroidales f F082 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015009 Microbes metabolize substances PMDBM2008908 n.a. o Bacteroidales f F082 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015010 Microbes metabolize substances PMDBM2008908 n.a. o Bacteroidales f F082 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015011 Microbes metabolize substances PMDBM2008908 n.a. o Bacteroidales f F082 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015012 Microbes metabolize substances PMDBM2008908 n.a. o Bacteroidales f F082 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015015 Microbes metabolize substances PMDBM2008908 n.a. o Bacteroidales f F082 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20015016 Microbes metabolize substances PMDBM2008908 n.a. o Bacteroidales f F082 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015017 Microbes metabolize substances PMDBM2008908 n.a. o Bacteroidales f F082 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015018 Microbes metabolize substances PMDBM2008908 n.a. o Bacteroidales f F082 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015019 Microbes metabolize substances PMDBM2008908 n.a. o Bacteroidales f F082 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015020 Microbes metabolize substances PMDBM2008908 n.a. o Bacteroidales f F082 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015021 Microbes metabolize substances PMDBM2008908 n.a. o Bacteroidales f F082 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015022 Microbes metabolize substances PMDBM2008908 n.a. o Bacteroidales f F082 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015023 Microbes metabolize substances PMDBM2008908 n.a. o Bacteroidales f F082 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015024 Microbes metabolize substances PMDBM2008909 n.a. o Bacteroidales f F082 g F082 s F082 sp002633315 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015025 Microbes metabolize substances PMDBM2008909 n.a. o Bacteroidales f F082 g F082 s F082 sp002633315 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015026 Microbes metabolize substances PMDBM2008909 n.a. o Bacteroidales f F082 g F082 s F082 sp002633315 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015027 Microbes metabolize substances PMDBM2008909 n.a. o Bacteroidales f F082 g F082 s F082 sp002633315 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015028 Microbes metabolize substances PMDBM2008909 n.a. o Bacteroidales f F082 g F082 s F082 sp002633315 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015029 Microbes metabolize substances PMDBM2008909 n.a. o Bacteroidales f F082 g F082 s F082 sp002633315 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015030 Microbes metabolize substances PMDBM2008909 n.a. o Bacteroidales f F082 g F082 s F082 sp002633315 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015033 Microbes metabolize substances PMDBM2008909 n.a. o Bacteroidales f F082 g F082 s F082 sp002633315 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20015034 Microbes metabolize substances PMDBM2008909 n.a. o Bacteroidales f F082 g F082 s F082 sp002633315 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015035 Microbes metabolize substances PMDBM2008909 n.a. o Bacteroidales f F082 g F082 s F082 sp002633315 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015036 Microbes metabolize substances PMDBM2008909 n.a. o Bacteroidales f F082 g F082 s F082 sp002633315 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015037 Microbes metabolize substances PMDBM2008909 n.a. o Bacteroidales f F082 g F082 s F082 sp002633315 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015038 Microbes metabolize substances PMDBM2008909 n.a. o Bacteroidales f F082 g F082 s F082 sp002633315 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015039 Microbes metabolize substances PMDBM2008909 n.a. o Bacteroidales f F082 g F082 s F082 sp002633315 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015040 Microbes metabolize substances PMDBM2008909 n.a. o Bacteroidales f F082 g F082 s F082 sp002633315 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015041 Microbes metabolize substances PMDBM2008909 n.a. o Bacteroidales f F082 g F082 s F082 sp002633315 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015042 Microbes metabolize substances PMDBM2008910 n.a. f Oscillospiraceae g F23-B02 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015043 Microbes metabolize substances PMDBM2008910 n.a. f Oscillospiraceae g F23-B02 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015044 Microbes metabolize substances PMDBM2008910 n.a. f Oscillospiraceae g F23-B02 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015045 Microbes metabolize substances PMDBM2008910 n.a. f Oscillospiraceae g F23-B02 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015047 Microbes metabolize substances PMDBM2008910 n.a. f Oscillospiraceae g F23-B02 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015049 Microbes metabolize substances PMDBM2008910 n.a. f Oscillospiraceae g F23-B02 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015050 Microbes metabolize substances PMDBM2008910 n.a. f Oscillospiraceae g F23-B02 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015051 Microbes metabolize substances PMDBM2008910 n.a. f Oscillospiraceae g F23-B02 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015052 Microbes metabolize substances PMDBM2008910 n.a. f Oscillospiraceae g F23-B02 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015055 Microbes metabolize substances PMDBM2008910 n.a. f Oscillospiraceae g F23-B02 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20015056 Microbes metabolize substances PMDBM2008910 n.a. f Oscillospiraceae g F23-B02 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015057 Microbes metabolize substances PMDBM2008910 n.a. f Oscillospiraceae g F23-B02 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015058 Microbes metabolize substances PMDBM2008910 n.a. f Oscillospiraceae g F23-B02 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015059 Microbes metabolize substances PMDBM2008910 n.a. f Oscillospiraceae g F23-B02 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015061 Microbes metabolize substances PMDBM2008910 n.a. f Oscillospiraceae g F23-B02 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015062 Microbes metabolize substances PMDBM2008910 n.a. f Oscillospiraceae g F23-B02 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015063 Microbes metabolize substances PMDBM2008911 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015064 Microbes metabolize substances PMDBM2008911 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015065 Microbes metabolize substances PMDBM2008911 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015066 Microbes metabolize substances PMDBM2008911 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015067 Microbes metabolize substances PMDBM2008911 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015068 Microbes metabolize substances PMDBM2008911 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015069 Microbes metabolize substances PMDBM2008911 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015072 Microbes metabolize substances PMDBM2008911 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015073 Microbes metabolize substances PMDBM2008911 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015074 Microbes metabolize substances PMDBM2008911 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015075 Microbes metabolize substances PMDBM2008911 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015076 Microbes metabolize substances PMDBM2008911 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015077 Microbes metabolize substances PMDBM2008911 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015078 Microbes metabolize substances PMDBM2008911 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp000431075 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015079 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015080 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015081 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015082 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015083 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015084 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015085 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015086 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015087 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015089 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20015092 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20015093 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20015094 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015095 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015098 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20015101 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015102 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015103 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015105 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015106 Microbes metabolize substances PMDBM2008912 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp001916715 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015107 Microbes metabolize substances PMDBM2008913 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015108 Microbes metabolize substances PMDBM2008913 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015109 Microbes metabolize substances PMDBM2008913 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015110 Microbes metabolize substances PMDBM2008913 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015111 Microbes metabolize substances PMDBM2008913 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015112 Microbes metabolize substances PMDBM2008913 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015113 Microbes metabolize substances PMDBM2008913 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015116 Microbes metabolize substances PMDBM2008913 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015117 Microbes metabolize substances PMDBM2008913 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015118 Microbes metabolize substances PMDBM2008913 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015119 Microbes metabolize substances PMDBM2008913 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015120 Microbes metabolize substances PMDBM2008913 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015121 Microbes metabolize substances PMDBM2008913 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015122 Microbes metabolize substances PMDBM2008913 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp002472405 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015123 Microbes metabolize substances PMDBM2008914 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015124 Microbes metabolize substances PMDBM2008914 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015125 Microbes metabolize substances PMDBM2008914 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015126 Microbes metabolize substances PMDBM2008914 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015127 Microbes metabolize substances PMDBM2008914 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015128 Microbes metabolize substances PMDBM2008914 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015129 Microbes metabolize substances PMDBM2008914 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015132 Microbes metabolize substances PMDBM2008914 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015133 Microbes metabolize substances PMDBM2008914 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015134 Microbes metabolize substances PMDBM2008914 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015135 Microbes metabolize substances PMDBM2008914 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015136 Microbes metabolize substances PMDBM2008914 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015137 Microbes metabolize substances PMDBM2008914 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015138 Microbes metabolize substances PMDBM2008914 n.a. f Oscillospiraceae g F23-B02 s F23-B02 sp003533405 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015139 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015140 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20015141 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015142 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015143 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015145 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015147 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015148 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015149 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015150 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015151 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015152 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015154 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20015157 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20015158 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20015159 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015160 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015163 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20015166 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015167 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015170 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015171 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015172 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015173 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" reduce the activity of the patient's immune system n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Incubation of F. prausnitzii with tacrolimus led to production of two compounds (the major one named M1), M1 is a C-9 keto-reduction product of tacrolimus. Pharmacological activity testing using human peripheral blood mononuclear cells demonstrated that M1 is 15-fold less potent than tacrolimus as an immunosuppressant. n.a. PMID PMID: 36467581 PMDBI20015174 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD214 Clonazepam Therapeutic Substance Central nervous system agents n.a. n.a. n.a. n.a. clonazepam-M1 n.a. unknown activity decreased n.a. n.a. n.a. Accelerate clonazepam metabolism and reduce drug efficacy n.a. PMID PMID: 36467581 PMDBI20015175 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" cardiac glycoside n.a. n.a. n.a. n.a. dihydrodigoxin n.a. unknown involved in substrate metabolism n.a. n.a. n.a. inactivation n.a. PMID PMID: 36467581 PMDBI20015176 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" antimicrobial n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20015177 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD1166 Dolasetron Therapeutic substance antinauseant and antiemetic n.a. n.a. n.a. n.a. duloxetine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20015178 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20015179 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" fungal infections n.a. n.a. n.a. n.a. ketoprofen n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20015180 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. ketoprofen n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20015181 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD477 Levonorgestrel Therapeutic Substance contraception and hormone n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20015182 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD563 Mycophenolate mofetil Therapeutic Substance inosine monophosphate dehydrogenase inhibitor n.a. n.a. n.a. n.a. mycophenolic-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20015183 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD1318 Nicardipine Therapeutic substance effective in the treatment of angina and coronary spasms without showing cardiodepressant effects n.a. n.a. n.a. n.a. aminonicardipine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20015184 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD1376 Praziquantel Therapeutic substance Anti-infection n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20015185 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD1421 Spironolactone Therapeutic substance diuretic and also antihypertensive effects n.a. n.a. n.a. n.a. 7æµ?thiospironolactone n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20015186 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD816 Sulindac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. sulindac-M2 n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20015187 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD1493 Vorinostat Therapeutic substance Anti-cancer n.a. n.a. n.a. n.a. vorinostat-M1 n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20015188 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD1460 Tolcapone Therapeutic substance Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity n.a. n.a. n.a. a potential link betweenthe gut microbiome and tolcapone toxicity n.a. PMID PMID: 36467581 PMDBI20015189 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii C PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015190 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii C PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015191 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii C PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015192 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii C PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015193 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii C PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015194 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii C PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015195 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii C PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015198 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii C PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015199 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii C PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015200 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii C PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015201 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii C PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015202 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii C PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015203 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii C PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015204 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii C PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015205 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii D PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015206 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii D PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015207 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii D PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20015209 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii D PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20015210 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii D PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20015211 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii D PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015212 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii D PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015215 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii D PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20015219 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii D PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015220 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii D PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015221 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015222 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015223 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015224 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015226 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015228 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015229 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015230 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015231 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015232 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015233 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015235 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20015238 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20015239 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20015240 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015241 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015244 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20015247 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015248 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015251 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015252 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015253 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii E PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015254 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii F PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015255 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii F PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015256 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii F PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015257 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii F PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015258 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii F PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015259 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii F PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015260 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii F PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015263 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii F PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015264 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii F PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015265 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii F PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015266 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii F PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015267 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii F PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015268 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii F PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015269 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii F PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015270 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii G PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015271 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii G PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015272 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii G PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015273 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii G PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015274 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii G PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015275 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii G PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015276 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii G PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015279 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii G PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015280 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii G PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015281 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii G PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015282 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii G PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015283 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii G PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015284 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015285 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015286 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015287 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015288 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015289 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015290 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015291 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015292 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015294 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20015297 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20015298 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20015299 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015300 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015303 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20015306 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015307 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015308 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015310 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015311 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii H PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015312 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii I PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015313 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii I PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015314 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii I PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015315 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii I PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015316 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii I PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015317 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii I PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015318 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii I PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015321 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii I PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015322 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii I PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015323 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii I PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015324 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii I PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015325 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii I PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015326 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii I PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015327 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii I PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015328 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015329 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015330 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015331 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015332 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015333 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015334 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015335 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015336 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015338 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20015341 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20015342 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20015343 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015344 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015347 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20015350 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015351 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015352 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015354 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015355 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii J PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015356 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii K PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015357 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii K PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015358 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii K PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015359 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii K PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015360 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii K PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015361 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii K PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015362 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii K PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015365 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii K PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015366 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii K PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015367 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii K PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015368 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii K PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015369 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii K PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015370 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii K PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015371 Microbes metabolize substances PMDBM2021533 1971605 Faecalibacterium sp003449675 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015372 Microbes metabolize substances PMDBM2021533 1971605 Faecalibacterium sp003449675 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015373 Microbes metabolize substances PMDBM2021533 1971605 Faecalibacterium sp003449675 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015374 Microbes metabolize substances PMDBM2021533 1971605 Faecalibacterium sp003449675 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015376 Microbes metabolize substances PMDBM2021533 1971605 Faecalibacterium sp003449675 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015378 Microbes metabolize substances PMDBM2021533 1971605 Faecalibacterium sp003449675 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015379 Microbes metabolize substances PMDBM2021533 1971605 Faecalibacterium sp003449675 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015380 Microbes metabolize substances PMDBM2021533 1971605 Faecalibacterium sp003449675 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015381 Microbes metabolize substances PMDBM2021533 1971605 Faecalibacterium sp003449675 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015384 Microbes metabolize substances PMDBM2021533 1971605 Faecalibacterium sp003449675 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015385 Microbes metabolize substances PMDBM2021533 1971605 Faecalibacterium sp003449675 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015386 Microbes metabolize substances PMDBM2021533 1971605 Faecalibacterium sp003449675 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015387 Microbes metabolize substances PMDBM2021533 1971605 Faecalibacterium sp003449675 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015389 Microbes metabolize substances PMDBM2021533 1971605 Faecalibacterium sp003449675 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015390 Microbes metabolize substances PMDBM2021533 1971605 Faecalibacterium sp003449675 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015391 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015392 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20015393 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015394 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015395 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015397 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015399 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20015400 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015401 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015402 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015403 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015404 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015405 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015407 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20015410 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20015411 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20015412 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20015413 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015414 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015417 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20015420 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015421 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015424 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015425 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015426 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015427 Microbes metabolize substances PMDBM2008925 2005359 Faecalicatena PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20015428 Microbes metabolize substances PMDBM2021534 39482 Faecalicatena contorta B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015429 Microbes metabolize substances PMDBM2021534 39482 Faecalicatena contorta B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015430 Microbes metabolize substances PMDBM2021534 39482 Faecalicatena contorta B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015431 Microbes metabolize substances PMDBM2021534 39482 Faecalicatena contorta B PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015433 Microbes metabolize substances PMDBM2021534 39482 Faecalicatena contorta B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015435 Microbes metabolize substances PMDBM2021534 39482 Faecalicatena contorta B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015436 Microbes metabolize substances PMDBM2021534 39482 Faecalicatena contorta B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015437 Microbes metabolize substances PMDBM2021534 39482 Faecalicatena contorta B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015438 Microbes metabolize substances PMDBM2021534 39482 Faecalicatena contorta B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015441 Microbes metabolize substances PMDBM2021534 39482 Faecalicatena contorta B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015442 Microbes metabolize substances PMDBM2021534 39482 Faecalicatena contorta B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015443 Microbes metabolize substances PMDBM2021534 39482 Faecalicatena contorta B PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20015444 Microbes metabolize substances PMDBM2021534 39482 Faecalicatena contorta B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015445 Microbes metabolize substances PMDBM2021534 39482 Faecalicatena contorta B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015447 Microbes metabolize substances PMDBM2021534 39482 Faecalicatena contorta B PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015448 Microbes metabolize substances PMDBM2021534 39482 Faecalicatena contorta B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015449 Microbes metabolize substances PMDBM2021534 39482 Faecalicatena contorta B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015450 Microbes metabolize substances PMDBM2021535 2726362 Faecalicatena faecis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015451 Microbes metabolize substances PMDBM2021535 2726362 Faecalicatena faecis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015452 Microbes metabolize substances PMDBM2021535 2726362 Faecalicatena faecis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015453 Microbes metabolize substances PMDBM2021535 2726362 Faecalicatena faecis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015455 Microbes metabolize substances PMDBM2021535 2726362 Faecalicatena faecis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015457 Microbes metabolize substances PMDBM2021535 2726362 Faecalicatena faecis PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20015458 Microbes metabolize substances PMDBM2021535 2726362 Faecalicatena faecis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015459 Microbes metabolize substances PMDBM2021535 2726362 Faecalicatena faecis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015460 Microbes metabolize substances PMDBM2021535 2726362 Faecalicatena faecis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015461 Microbes metabolize substances PMDBM2021535 2726362 Faecalicatena faecis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015464 Microbes metabolize substances PMDBM2021535 2726362 Faecalicatena faecis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015465 Microbes metabolize substances PMDBM2021535 2726362 Faecalicatena faecis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015466 Microbes metabolize substances PMDBM2021535 2726362 Faecalicatena faecis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015467 Microbes metabolize substances PMDBM2021535 2726362 Faecalicatena faecis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015469 Microbes metabolize substances PMDBM2021535 2726362 Faecalicatena faecis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015470 Microbes metabolize substances PMDBM2021536 290055 Faecalicatena fissicatena PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015471 Microbes metabolize substances PMDBM2021536 290055 Faecalicatena fissicatena PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015472 Microbes metabolize substances PMDBM2021536 290055 Faecalicatena fissicatena PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015473 Microbes metabolize substances PMDBM2021536 290055 Faecalicatena fissicatena PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015475 Microbes metabolize substances PMDBM2021536 290055 Faecalicatena fissicatena PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015477 Microbes metabolize substances PMDBM2021536 290055 Faecalicatena fissicatena PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015478 Microbes metabolize substances PMDBM2021536 290055 Faecalicatena fissicatena PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015479 Microbes metabolize substances PMDBM2021536 290055 Faecalicatena fissicatena PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015480 Microbes metabolize substances PMDBM2021536 290055 Faecalicatena fissicatena PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015483 Microbes metabolize substances PMDBM2021536 290055 Faecalicatena fissicatena PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015484 Microbes metabolize substances PMDBM2021536 290055 Faecalicatena fissicatena PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015485 Microbes metabolize substances PMDBM2021536 290055 Faecalicatena fissicatena PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20015486 Microbes metabolize substances PMDBM2021536 290055 Faecalicatena fissicatena PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015487 Microbes metabolize substances PMDBM2021536 290055 Faecalicatena fissicatena PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015489 Microbes metabolize substances PMDBM2021536 290055 Faecalicatena fissicatena PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015490 Microbes metabolize substances PMDBM2021536 290055 Faecalicatena fissicatena PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015491 Microbes metabolize substances PMDBM2021536 290055 Faecalicatena fissicatena PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015492 Microbes metabolize substances PMDBM2008929 n.a. Faecalicatena glycyrrhizinilyticum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015493 Microbes metabolize substances PMDBM2008929 n.a. Faecalicatena glycyrrhizinilyticum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015494 Microbes metabolize substances PMDBM2008929 n.a. Faecalicatena glycyrrhizinilyticum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015495 Microbes metabolize substances PMDBM2008929 n.a. Faecalicatena glycyrrhizinilyticum PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015497 Microbes metabolize substances PMDBM2008929 n.a. Faecalicatena glycyrrhizinilyticum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015499 Microbes metabolize substances PMDBM2008929 n.a. Faecalicatena glycyrrhizinilyticum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015500 Microbes metabolize substances PMDBM2008929 n.a. Faecalicatena glycyrrhizinilyticum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015501 Microbes metabolize substances PMDBM2008929 n.a. Faecalicatena glycyrrhizinilyticum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015502 Microbes metabolize substances PMDBM2008929 n.a. Faecalicatena glycyrrhizinilyticum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015505 Microbes metabolize substances PMDBM2008929 n.a. Faecalicatena glycyrrhizinilyticum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015506 Microbes metabolize substances PMDBM2008929 n.a. Faecalicatena glycyrrhizinilyticum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015507 Microbes metabolize substances PMDBM2008929 n.a. Faecalicatena glycyrrhizinilyticum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015508 Microbes metabolize substances PMDBM2008929 n.a. Faecalicatena glycyrrhizinilyticum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015510 Microbes metabolize substances PMDBM2008929 n.a. Faecalicatena glycyrrhizinilyticum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015511 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015512 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015513 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015514 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015516 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015518 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015519 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015520 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015521 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015522 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015523 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015525 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20015528 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20015529 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20015530 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015531 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015534 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20015537 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015538 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015541 Microbes metabolize substances PMDBM2008930 n.a. Faecalicatena gnavus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015542 Microbes metabolize substances PMDBM2008931 n.a. Faecalicatena lactaris PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015543 Microbes metabolize substances PMDBM2008931 n.a. Faecalicatena lactaris PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015544 Microbes metabolize substances PMDBM2008931 n.a. Faecalicatena lactaris PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015545 Microbes metabolize substances PMDBM2008931 n.a. Faecalicatena lactaris PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015546 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015547 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015548 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015549 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015551 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015553 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015554 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015555 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015556 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015557 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015558 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015560 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20015563 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20015564 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20015565 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015566 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015569 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20015572 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015573 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015576 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015577 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015578 Microbes metabolize substances PMDBM2021537 1544 Faecalicatena orotica PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015579 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp000509105 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015580 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp000509105 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015581 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp000509105 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015582 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp000509105 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015584 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp000509105 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015586 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp000509105 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015587 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp000509105 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015588 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp000509105 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015589 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp000509105 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015592 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp000509105 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015593 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp000509105 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015594 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp000509105 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20015595 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp000509105 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015596 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp000509105 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015598 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp000509105 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015599 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp000509105 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015600 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp000509105 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015601 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp001487105 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015602 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp001487105 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015603 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp001487105 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015604 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp001487105 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015605 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp001487105 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015606 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp001487105 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015607 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp001487105 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015608 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp001487105 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015609 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp001487105 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015610 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp002314255 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015611 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp002314255 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015612 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp002314255 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015613 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp002314255 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20015614 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp002314255 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015615 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp002314255 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015616 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp002314255 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015617 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp002314255 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015620 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp002314255 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015621 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp002314255 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015622 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp002314255 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015623 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp002314255 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015624 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp002314255 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015625 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp002314255 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015626 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp002314255 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015627 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp900066545 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015628 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp900066545 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015629 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp900066545 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015630 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp900066545 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015632 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp900066545 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015634 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp900066545 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015635 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp900066545 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015636 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp900066545 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015637 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp900066545 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015640 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp900066545 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015641 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp900066545 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015642 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp900066545 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015643 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp900066545 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015645 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp900066545 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015646 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp900066545 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015647 Microbes metabolize substances PMDBM2021538 2005360 Faecalicatena sp900066545 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015648 Microbes metabolize substances PMDBM2008937 n.a. Faecalicatena torques PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20015649 Microbes metabolize substances PMDBM2008937 n.a. Faecalicatena torques PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20015650 Microbes metabolize substances PMDBM2008937 n.a. Faecalicatena torques PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015651 Microbes metabolize substances PMDBM2008937 n.a. Faecalicatena torques PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015652 Microbes metabolize substances PMDBM2008937 n.a. Faecalicatena torques PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015653 Microbes metabolize substances PMDBM2008937 n.a. Faecalicatena torques PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015654 Microbes metabolize substances PMDBM2008938 1573536 Faecalicoccus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015655 Microbes metabolize substances PMDBM2008938 1573536 Faecalicoccus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20015656 Microbes metabolize substances PMDBM2008938 1573536 Faecalicoccus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015657 Microbes metabolize substances PMDBM2008938 1573536 Faecalicoccus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015658 Microbes metabolize substances PMDBM2008938 1573536 Faecalicoccus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015659 Microbes metabolize substances PMDBM2008938 1573536 Faecalicoccus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015660 Microbes metabolize substances PMDBM2008938 1573536 Faecalicoccus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015661 Microbes metabolize substances PMDBM2008938 1573536 Faecalicoccus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015664 Microbes metabolize substances PMDBM2008938 1573536 Faecalicoccus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015665 Microbes metabolize substances PMDBM2008938 1573536 Faecalicoccus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015666 Microbes metabolize substances PMDBM2008938 1573536 Faecalicoccus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015667 Microbes metabolize substances PMDBM2008938 1573536 Faecalicoccus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015668 Microbes metabolize substances PMDBM2008938 1573536 Faecalicoccus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015669 Microbes metabolize substances PMDBM2008938 1573536 Faecalicoccus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015670 Microbes metabolize substances PMDBM2008938 1573536 Faecalicoccus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015671 Microbes metabolize substances PMDBM2008938 1573536 Faecalicoccus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015672 Microbes metabolize substances PMDBM2021323 1323 Faecalicoccus pleomorphus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015673 Microbes metabolize substances PMDBM2021323 1323 Faecalicoccus pleomorphus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015674 Microbes metabolize substances PMDBM2021323 1323 Faecalicoccus pleomorphus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015675 Microbes metabolize substances PMDBM2021323 1323 Faecalicoccus pleomorphus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015676 Microbes metabolize substances PMDBM2021323 1323 Faecalicoccus pleomorphus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015677 Microbes metabolize substances PMDBM2021323 1323 Faecalicoccus pleomorphus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015678 Microbes metabolize substances PMDBM2021323 1323 Faecalicoccus pleomorphus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015681 Microbes metabolize substances PMDBM2021323 1323 Faecalicoccus pleomorphus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015682 Microbes metabolize substances PMDBM2021323 1323 Faecalicoccus pleomorphus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015683 Microbes metabolize substances PMDBM2021323 1323 Faecalicoccus pleomorphus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015684 Microbes metabolize substances PMDBM2021323 1323 Faecalicoccus pleomorphus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015685 Microbes metabolize substances PMDBM2021323 1323 Faecalicoccus pleomorphus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015686 Microbes metabolize substances PMDBM2021323 1323 Faecalicoccus pleomorphus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015687 Microbes metabolize substances PMDBM2021323 1323 Faecalicoccus pleomorphus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015688 Microbes metabolize substances PMDBM2021324 39483 Faecalitalea cylindroides PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015689 Microbes metabolize substances PMDBM2021324 39483 Faecalitalea cylindroides PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20015690 Microbes metabolize substances PMDBM2021324 39483 Faecalitalea cylindroides PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015691 Microbes metabolize substances PMDBM2021324 39483 Faecalitalea cylindroides PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015692 Microbes metabolize substances PMDBM2021324 39483 Faecalitalea cylindroides PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015693 Microbes metabolize substances PMDBM2021324 39483 Faecalitalea cylindroides PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015694 Microbes metabolize substances PMDBM2021324 39483 Faecalitalea cylindroides PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015695 Microbes metabolize substances PMDBM2021324 39483 Faecalitalea cylindroides PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015698 Microbes metabolize substances PMDBM2021324 39483 Faecalitalea cylindroides PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015699 Microbes metabolize substances PMDBM2021324 39483 Faecalitalea cylindroides PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015700 Microbes metabolize substances PMDBM2021324 39483 Faecalitalea cylindroides PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015701 Microbes metabolize substances PMDBM2021324 39483 Faecalitalea cylindroides PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015702 Microbes metabolize substances PMDBM2021324 39483 Faecalitalea cylindroides PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015703 Microbes metabolize substances PMDBM2021324 39483 Faecalitalea cylindroides PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015704 Microbes metabolize substances PMDBM2021324 39483 Faecalitalea cylindroides PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015705 Microbes metabolize substances PMDBM2021539 82135 Fannyhessea vaginae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015706 Microbes metabolize substances PMDBM2021539 82135 Fannyhessea vaginae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015707 Microbes metabolize substances PMDBM2021539 82135 Fannyhessea vaginae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015708 Microbes metabolize substances PMDBM2021539 82135 Fannyhessea vaginae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015709 Microbes metabolize substances PMDBM2021539 82135 Fannyhessea vaginae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015710 Microbes metabolize substances PMDBM2021539 82135 Fannyhessea vaginae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015711 Microbes metabolize substances PMDBM2021539 82135 Fannyhessea vaginae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015714 Microbes metabolize substances PMDBM2021539 82135 Fannyhessea vaginae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015715 Microbes metabolize substances PMDBM2021539 82135 Fannyhessea vaginae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015716 Microbes metabolize substances PMDBM2021539 82135 Fannyhessea vaginae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015717 Microbes metabolize substances PMDBM2021539 82135 Fannyhessea vaginae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015718 Microbes metabolize substances PMDBM2021539 82135 Fannyhessea vaginae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015719 Microbes metabolize substances PMDBM2021539 82135 Fannyhessea vaginae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015720 Microbes metabolize substances PMDBM2008941 1686313 Fenollaria PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20015721 Microbes metabolize substances PMDBM2008941 1686313 Fenollaria PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015722 Microbes metabolize substances PMDBM2008941 1686313 Fenollaria PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015723 Microbes metabolize substances PMDBM2021540 938288 Fenollaria massiliensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20015724 Microbes metabolize substances PMDBM2021540 938288 Fenollaria massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015725 Microbes metabolize substances PMDBM2021540 938288 Fenollaria massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015726 Microbes metabolize substances PMDBM2020704 1723384 Fenollaria timonensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20015727 Microbes metabolize substances PMDBM2020704 1723384 Fenollaria timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015728 Microbes metabolize substances PMDBM2021541 1562970 Fermentimonas massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015729 Microbes metabolize substances PMDBM2021541 1562970 Fermentimonas massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015730 Microbes metabolize substances PMDBM2021541 1562970 Fermentimonas massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015731 Microbes metabolize substances PMDBM2021541 1562970 Fermentimonas massiliensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015733 Microbes metabolize substances PMDBM2021541 1562970 Fermentimonas massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015735 Microbes metabolize substances PMDBM2021541 1562970 Fermentimonas massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015736 Microbes metabolize substances PMDBM2021541 1562970 Fermentimonas massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015737 Microbes metabolize substances PMDBM2021541 1562970 Fermentimonas massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015738 Microbes metabolize substances PMDBM2021541 1562970 Fermentimonas massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015741 Microbes metabolize substances PMDBM2021541 1562970 Fermentimonas massiliensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20015742 Microbes metabolize substances PMDBM2021541 1562970 Fermentimonas massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015743 Microbes metabolize substances PMDBM2021541 1562970 Fermentimonas massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015744 Microbes metabolize substances PMDBM2021541 1562970 Fermentimonas massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015745 Microbes metabolize substances PMDBM2021541 1562970 Fermentimonas massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015747 Microbes metabolize substances PMDBM2021541 1562970 Fermentimonas massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015748 Microbes metabolize substances PMDBM2021541 1562970 Fermentimonas massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015749 Microbes metabolize substances PMDBM2021541 1562970 Fermentimonas massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015750 Microbes metabolize substances PMDBM2021542 28122 FibrobacterA intestinalis PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20015751 Microbes metabolize substances PMDBM2021542 28122 FibrobacterA intestinalis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015752 Microbes metabolize substances PMDBM2021542 28122 FibrobacterA intestinalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015753 Microbes metabolize substances PMDBM2021542 28122 FibrobacterA intestinalis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015754 Microbes metabolize substances PMDBM2021542 28122 FibrobacterA intestinalis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015755 Microbes metabolize substances PMDBM2008946 44259 Filifactor PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015756 Microbes metabolize substances PMDBM2008946 44259 Filifactor PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015757 Microbes metabolize substances PMDBM2008946 44259 Filifactor PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015758 Microbes metabolize substances PMDBM2008946 44259 Filifactor PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015759 Microbes metabolize substances PMDBM2008947 150022 Finegoldia PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015760 Microbes metabolize substances PMDBM2008947 150022 Finegoldia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015761 Microbes metabolize substances PMDBM2008947 150022 Finegoldia PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015762 Microbes metabolize substances PMDBM2008947 150022 Finegoldia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015763 Microbes metabolize substances PMDBM2008947 150022 Finegoldia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015764 Microbes metabolize substances PMDBM2020706 1260 Finegoldia magna PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015765 Microbes metabolize substances PMDBM2020706 1260 Finegoldia magna PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015766 Microbes metabolize substances PMDBM2020706 1260 Finegoldia magna PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015767 Microbes metabolize substances PMDBM2020706 1260 Finegoldia magna PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015768 Microbes metabolize substances PMDBM2020706 1260 Finegoldia magna PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015769 Microbes metabolize substances PMDBM2020706 1260 Finegoldia magna F PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015770 Microbes metabolize substances PMDBM2020706 1260 Finegoldia magna F PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015771 Microbes metabolize substances PMDBM2020706 1260 Finegoldia magna F PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015772 Microbes metabolize substances PMDBM2020706 1260 Finegoldia magna F PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015773 Microbes metabolize substances PMDBM2020706 1260 Finegoldia magna F PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015774 Microbes metabolize substances PMDBM2020706 1260 Finegoldia magna H PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015775 Microbes metabolize substances PMDBM2020706 1260 Finegoldia magna H PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015776 Microbes metabolize substances PMDBM2020706 1260 Finegoldia magna H PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015777 Microbes metabolize substances PMDBM2020706 1260 Finegoldia magna H PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015778 Microbes metabolize substances PMDBM2020706 1260 Finegoldia magna H PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015779 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015780 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015781 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015782 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015784 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015786 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015787 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015788 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015789 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015790 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015791 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015793 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20015796 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20015797 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20015798 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015799 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015802 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20015805 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015806 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015809 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015810 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015811 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015812 Microbes metabolize substances PMDBM2008951 n.a. o Oscillospirales f CAG-272 g Firm-07 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20015813 Microbes metabolize substances PMDBM2008952 n.a. o Christensenellales f CAG-74 g Firm-10 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015814 Microbes metabolize substances PMDBM2008952 n.a. o Christensenellales f CAG-74 g Firm-10 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015815 Microbes metabolize substances PMDBM2008952 n.a. o Christensenellales f CAG-74 g Firm-10 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015816 Microbes metabolize substances PMDBM2008952 n.a. o Christensenellales f CAG-74 g Firm-10 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015817 Microbes metabolize substances PMDBM2008952 n.a. o Christensenellales f CAG-74 g Firm-10 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015818 Microbes metabolize substances PMDBM2008952 n.a. o Christensenellales f CAG-74 g Firm-10 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015819 Microbes metabolize substances PMDBM2008952 n.a. o Christensenellales f CAG-74 g Firm-10 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20015821 Microbes metabolize substances PMDBM2008952 n.a. o Christensenellales f CAG-74 g Firm-10 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20015822 Microbes metabolize substances PMDBM2008952 n.a. o Christensenellales f CAG-74 g Firm-10 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20015823 Microbes metabolize substances PMDBM2008952 n.a. o Christensenellales f CAG-74 g Firm-10 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015824 Microbes metabolize substances PMDBM2008952 n.a. o Christensenellales f CAG-74 g Firm-10 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015827 Microbes metabolize substances PMDBM2008952 n.a. o Christensenellales f CAG-74 g Firm-10 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20015830 Microbes metabolize substances PMDBM2008952 n.a. o Christensenellales f CAG-74 g Firm-10 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20015832 Microbes metabolize substances PMDBM2008952 n.a. o Christensenellales f CAG-74 g Firm-10 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015833 Microbes metabolize substances PMDBM2008952 n.a. o Christensenellales f CAG-74 g Firm-10 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015834 Microbes metabolize substances PMDBM2008952 n.a. o Christensenellales f CAG-74 g Firm-10 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015835 Microbes metabolize substances PMDBM2008952 n.a. o Christensenellales f CAG-74 g Firm-10 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20015836 Microbes metabolize substances PMDBM2008953 n.a. o Monoglobales f Firm-18 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015837 Microbes metabolize substances PMDBM2008953 n.a. o Monoglobales f Firm-18 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015838 Microbes metabolize substances PMDBM2008953 n.a. o Monoglobales f Firm-18 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015839 Microbes metabolize substances PMDBM2008953 n.a. o Monoglobales f Firm-18 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015840 Microbes metabolize substances PMDBM2008953 n.a. o Monoglobales f Firm-18 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015841 Microbes metabolize substances PMDBM2008953 n.a. o Monoglobales f Firm-18 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015842 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD627 Oxaliplatin Therapeutic Substance chemotherapy agent n.a. n.a. n.a. n.a. n.a. n.a. unknown Reduce the side effects of drugs n.a. n.a. n.a. Hydrogenated water-induced changes in the gut microbiota significantly improve mechanical hyperalgesia caused by oxaliplatin. Oxaliplatin, a chemotherapeutic agent, can cause severe pain by mechanical hyperalgesia. Mice treated with hydrogen-rich water showed significant changes in the richness and æµ?diversity of the gut microbiota. High abundance of Firmicutes and Tenericutes and low abundance of Bacteroidetes were observed. The expression of TNF-æµ?and IL-6 (P<0.05) was reduced with hydrogen-rich water treatment. Such change in expression is believed to improve chemotherapy-induced neuropathic pain. n.a. PMID PMID: 36467581 PMDBI20015843 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD237 Cyclophosphamide Therapeutic Substance lymphoma and leukemia n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Stimulate the generation of T helper 17 (pT(H)17) cells and memory T(H)1 immune responses n.a. PMID PMID: 36467581 PMDBI20015845 Microbes metabolize substances PMDBM2008954 n.a. f Planococcaceae g FJAT-21963 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20015846 Microbes metabolize substances PMDBM2008954 n.a. f Planococcaceae g FJAT-21963 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015847 Microbes metabolize substances PMDBM2008954 n.a. f Planococcaceae g FJAT-21963 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015848 Microbes metabolize substances PMDBM2008954 n.a. f Planococcaceae g FJAT-21963 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015849 Microbes metabolize substances PMDBM2008955 n.a. f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015850 Microbes metabolize substances PMDBM2008955 n.a. f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015851 Microbes metabolize substances PMDBM2008955 n.a. f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015852 Microbes metabolize substances PMDBM2008955 n.a. f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015853 Microbes metabolize substances PMDBM2008955 n.a. f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015854 Microbes metabolize substances PMDBM2008955 n.a. f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015855 Microbes metabolize substances PMDBM2008955 n.a. f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015858 Microbes metabolize substances PMDBM2008955 n.a. f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015859 Microbes metabolize substances PMDBM2008955 n.a. f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015860 Microbes metabolize substances PMDBM2008955 n.a. f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015861 Microbes metabolize substances PMDBM2008955 n.a. f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015862 Microbes metabolize substances PMDBM2008955 n.a. f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015863 Microbes metabolize substances PMDBM2008955 n.a. f Bacillaceae A g FJAT-27916 s FJAT-27916 sp001183965 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015864 Microbes metabolize substances PMDBM2020707 1522309 Flaviflexus massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015865 Microbes metabolize substances PMDBM2020707 1522309 Flaviflexus massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015866 Microbes metabolize substances PMDBM2020707 1522309 Flaviflexus massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015867 Microbes metabolize substances PMDBM2020707 1522309 Flaviflexus massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015868 Microbes metabolize substances PMDBM2021543 428988 Flavobacterium lindanitolerans PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015869 Microbes metabolize substances PMDBM2021543 428988 Flavobacterium lindanitolerans PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20015870 Microbes metabolize substances PMDBM2021543 428988 Flavobacterium lindanitolerans PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015871 Microbes metabolize substances PMDBM2021543 428988 Flavobacterium lindanitolerans PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015872 Microbes metabolize substances PMDBM2021543 428988 Flavobacterium lindanitolerans PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20015873 Microbes metabolize substances PMDBM2021543 428988 Flavobacterium lindanitolerans PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015874 Microbes metabolize substances PMDBM2021543 428988 Flavobacterium lindanitolerans PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015875 Microbes metabolize substances PMDBM2021543 428988 Flavobacterium lindanitolerans PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015876 Microbes metabolize substances PMDBM2021543 428988 Flavobacterium lindanitolerans PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015879 Microbes metabolize substances PMDBM2021543 428988 Flavobacterium lindanitolerans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015880 Microbes metabolize substances PMDBM2021543 428988 Flavobacterium lindanitolerans PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015881 Microbes metabolize substances PMDBM2021543 428988 Flavobacterium lindanitolerans PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015882 Microbes metabolize substances PMDBM2021543 428988 Flavobacterium lindanitolerans PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015883 Microbes metabolize substances PMDBM2021543 428988 Flavobacterium lindanitolerans PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015884 Microbes metabolize substances PMDBM2021543 428988 Flavobacterium lindanitolerans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015885 Microbes metabolize substances PMDBM2021543 428988 Flavobacterium lindanitolerans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015886 Microbes metabolize substances PMDBM2008958 946234 Flavonifractor PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20015887 Microbes metabolize substances PMDBM2008958 946234 Flavonifractor PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20015888 Microbes metabolize substances PMDBM2008958 946234 Flavonifractor PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015889 Microbes metabolize substances PMDBM2008958 946234 Flavonifractor PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015890 Microbes metabolize substances PMDBM2008958 946234 Flavonifractor PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015891 Microbes metabolize substances PMDBM2008958 946234 Flavonifractor PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015892 Microbes metabolize substances PMDBM2008958 946234 Flavonifractor PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015893 Microbes metabolize substances PMDBM2020710 292800 Flavonifractor plautii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015894 Microbes metabolize substances PMDBM2020710 292800 Flavonifractor plautii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015895 Microbes metabolize substances PMDBM2020710 292800 Flavonifractor plautii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015896 Microbes metabolize substances PMDBM2020710 292800 Flavonifractor plautii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015897 Microbes metabolize substances PMDBM2020710 292800 Flavonifractor plautii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015898 Microbes metabolize substances PMDBM2020710 292800 Flavonifractor plautii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015899 Microbes metabolize substances PMDBM2020710 292800 Flavonifractor plautii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015900 Microbes metabolize substances PMDBM2020710 292800 Flavonifractor plautii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015901 Microbes metabolize substances PMDBM2021544 2049025 Flavonifractor sp900199495 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015902 Microbes metabolize substances PMDBM2021544 2049025 Flavonifractor sp900199495 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015903 Microbes metabolize substances PMDBM2021544 2049025 Flavonifractor sp900199495 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015904 Microbes metabolize substances PMDBM2021544 2049025 Flavonifractor sp900199495 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015905 Microbes metabolize substances PMDBM2021544 2049025 Flavonifractor sp900199495 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015906 Microbes metabolize substances PMDBM2008961 1940255 Fournierella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015907 Microbes metabolize substances PMDBM2008961 1940255 Fournierella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015908 Microbes metabolize substances PMDBM2008961 1940255 Fournierella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015909 Microbes metabolize substances PMDBM2008961 1940255 Fournierella PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015911 Microbes metabolize substances PMDBM2008961 1940255 Fournierella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015913 Microbes metabolize substances PMDBM2008961 1940255 Fournierella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015914 Microbes metabolize substances PMDBM2008961 1940255 Fournierella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015915 Microbes metabolize substances PMDBM2008961 1940255 Fournierella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015916 Microbes metabolize substances PMDBM2008961 1940255 Fournierella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015919 Microbes metabolize substances PMDBM2008961 1940255 Fournierella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015920 Microbes metabolize substances PMDBM2008961 1940255 Fournierella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015921 Microbes metabolize substances PMDBM2008961 1940255 Fournierella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015922 Microbes metabolize substances PMDBM2008961 1940255 Fournierella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015924 Microbes metabolize substances PMDBM2008961 1940255 Fournierella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015925 Microbes metabolize substances PMDBM2008961 1940255 Fournierella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015926 Microbes metabolize substances PMDBM2008961 1940255 Fournierella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015927 Microbes metabolize substances PMDBM2020711 1650663 Fournierella massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015928 Microbes metabolize substances PMDBM2020711 1650663 Fournierella massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015929 Microbes metabolize substances PMDBM2020711 1650663 Fournierella massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015930 Microbes metabolize substances PMDBM2020711 1650663 Fournierella massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015931 Microbes metabolize substances PMDBM2020711 1650663 Fournierella massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015932 Microbes metabolize substances PMDBM2020711 1650663 Fournierella massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015933 Microbes metabolize substances PMDBM2020711 1650663 Fournierella massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015936 Microbes metabolize substances PMDBM2020711 1650663 Fournierella massiliensis PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20015937 Microbes metabolize substances PMDBM2020711 1650663 Fournierella massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015938 Microbes metabolize substances PMDBM2020711 1650663 Fournierella massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015939 Microbes metabolize substances PMDBM2020711 1650663 Fournierella massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015940 Microbes metabolize substances PMDBM2020711 1650663 Fournierella massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015941 Microbes metabolize substances PMDBM2020711 1650663 Fournierella massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015942 Microbes metabolize substances PMDBM2020711 1650663 Fournierella massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015943 Microbes metabolize substances PMDBM2020711 1650663 Fournierella massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015944 Microbes metabolize substances PMDBM2020711 1650663 Fournierella massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015945 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015946 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20015947 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015948 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015949 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015950 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015951 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015952 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015955 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20015956 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015957 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015958 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20015959 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015960 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015961 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015962 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015963 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015964 Microbes metabolize substances PMDBM2021545 357240 Franconibacter helveticus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015965 Microbes metabolize substances PMDBM2008964 5506 fusarium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015966 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20015967 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20015968 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20015969 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015971 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20015973 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015974 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015975 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20015976 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015977 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20015978 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20015980 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20015983 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20015984 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20015985 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20015986 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20015989 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20015992 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015993 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20015996 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20015997 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015998 Microbes metabolize substances PMDBM2008965 1407607 Fusicatenibacter PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20015999 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016000 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016001 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016002 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016004 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016006 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20016007 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016008 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016009 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016010 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20016011 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20016012 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016014 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20016017 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20016018 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20016019 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016022 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20016025 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016026 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016029 Microbes metabolize substances PMDBM2020717 1150298 Fusicatenibacter saccharivorans PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016030 Microbes metabolize substances PMDBM242 32066 Fusobacteria PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite NAPQI n.a. PMID PMID: 36467581 PMDBI20016031 Microbes metabolize substances PMDBM2020225 n.a. Fusobacterium nucleatum subsp. nucleatum 1612A,VPI 4355,DSM 15643,ATCC 25586,CCUG 32989,CIP 101130,JCM 8532,LMG 13131 PMDBD558 Montelukast Therapeutic Substance Drugs for obstructive airway disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Biotransformation n.a. PMID PMID: 36467581 PMDBI20016032 Microbes metabolize substances PMDBM2020225 n.a. Fusobacterium nucleatum subsp. nucleatum 1612A,VPI 4355,DSM 15643,ATCC 25586,CCUG 32989,CIP 101130,JCM 8532,LMG 13131 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Biotransformation n.a. PMID PMID: 36467581 PMDBI20016033 Microbes metabolize substances PMDBM2020225 n.a. Fusobacterium nucleatum subsp. nucleatum 1612A,VPI 4355,DSM 15643,ATCC 25586,CCUG 32989,CIP 101130,JCM 8532,LMG 13131 PMDBD731 Ranitidine "Therapeutic Substance; Herbal Substance" Drugs for acid related disorders n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Biotransformation n.a. PMID PMID: 36467581 PMDBI20016034 Microbes metabolize substances PMDBM2020722 76859 Fusobacterium animalis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016035 Microbes metabolize substances PMDBM2020722 76859 Fusobacterium animalis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016036 Microbes metabolize substances PMDBM2020722 76859 Fusobacterium animalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016037 Microbes metabolize substances PMDBM2020722 76859 Fusobacterium animalis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016038 Microbes metabolize substances PMDBM2020722 76859 Fusobacterium animalis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016039 Microbes metabolize substances PMDBM2020719 1852365 Fusobacterium massiliense PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016040 Microbes metabolize substances PMDBM2020719 1852365 Fusobacterium massiliense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016041 Microbes metabolize substances PMDBM2020719 1852365 Fusobacterium massiliense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016042 Microbes metabolize substances PMDBM2020719 1852365 Fusobacterium massiliense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016043 Microbes metabolize substances PMDBM2020719 1852365 Fusobacterium massiliense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016044 Microbes metabolize substances PMDBM2020225 851 Fusobacterium nucleatum PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016045 Microbes metabolize substances PMDBM2020225 851 Fusobacterium nucleatum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016046 Microbes metabolize substances PMDBM2020225 851 Fusobacterium nucleatum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016047 Microbes metabolize substances PMDBM2020225 851 Fusobacterium nucleatum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016048 Microbes metabolize substances PMDBM2020225 851 Fusobacterium nucleatum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016049 Microbes metabolize substances PMDBM2020225 851 Fusobacterium nucleatum E PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016050 Microbes metabolize substances PMDBM2020225 851 Fusobacterium nucleatum E PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016051 Microbes metabolize substances PMDBM2020225 851 Fusobacterium nucleatum E PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016052 Microbes metabolize substances PMDBM2020225 851 Fusobacterium nucleatum E PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016053 Microbes metabolize substances PMDBM2020225 851 Fusobacterium nucleatum E PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016054 Microbes metabolize substances PMDBM2020726 860 Fusobacterium periodonticum B PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016055 Microbes metabolize substances PMDBM2020726 860 Fusobacterium periodonticum B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016056 Microbes metabolize substances PMDBM2020726 860 Fusobacterium periodonticum B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016057 Microbes metabolize substances PMDBM2020726 860 Fusobacterium periodonticum B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016058 Microbes metabolize substances PMDBM2020726 860 Fusobacterium periodonticum B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016059 Microbes metabolize substances PMDBM2020726 860 Fusobacterium periodonticum D PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016060 Microbes metabolize substances PMDBM2020726 860 Fusobacterium periodonticum D PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016061 Microbes metabolize substances PMDBM2020726 860 Fusobacterium periodonticum D PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016062 Microbes metabolize substances PMDBM2020726 860 Fusobacterium periodonticum D PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016063 Microbes metabolize substances PMDBM2020726 860 Fusobacterium periodonticum D PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016064 Microbes metabolize substances PMDBM2020723 76857 Fusobacterium polymorphum PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016065 Microbes metabolize substances PMDBM2020723 76857 Fusobacterium polymorphum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016066 Microbes metabolize substances PMDBM2020723 76857 Fusobacterium polymorphum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016067 Microbes metabolize substances PMDBM2020723 76857 Fusobacterium polymorphum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016068 Microbes metabolize substances PMDBM2020723 76857 Fusobacterium polymorphum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016069 Microbes metabolize substances PMDBM2020728 68766 Fusobacterium sp000235465 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016070 Microbes metabolize substances PMDBM2020728 68766 Fusobacterium sp000235465 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016071 Microbes metabolize substances PMDBM2020728 68766 Fusobacterium sp000235465 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016072 Microbes metabolize substances PMDBM2020724 155615 Fusobacterium vincentii PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016073 Microbes metabolize substances PMDBM2020724 155615 Fusobacterium vincentii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016074 Microbes metabolize substances PMDBM2020724 155615 Fusobacterium vincentii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016075 Microbes metabolize substances PMDBM2020724 155615 Fusobacterium vincentii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016076 Microbes metabolize substances PMDBM2020724 155615 Fusobacterium vincentii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016077 Microbes metabolize substances PMDBM2008977 n.a. Fusobacterium A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016078 Microbes metabolize substances PMDBM2008977 n.a. Fusobacterium A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016079 Microbes metabolize substances PMDBM2008977 n.a. Fusobacterium A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016080 Microbes metabolize substances PMDBM2008977 n.a. Fusobacterium A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016081 Microbes metabolize substances PMDBM2008977 n.a. Fusobacterium A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016082 Microbes metabolize substances PMDBM2008977 n.a. Fusobacterium A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016083 Microbes metabolize substances PMDBM2008977 n.a. Fusobacterium A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016086 Microbes metabolize substances PMDBM2008977 n.a. Fusobacterium A PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016087 Microbes metabolize substances PMDBM2008977 n.a. Fusobacterium A PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20016088 Microbes metabolize substances PMDBM2008977 n.a. Fusobacterium A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016089 Microbes metabolize substances PMDBM2008977 n.a. Fusobacterium A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016090 Microbes metabolize substances PMDBM2008977 n.a. Fusobacterium A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016091 Microbes metabolize substances PMDBM2008977 n.a. Fusobacterium A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016092 Microbes metabolize substances PMDBM2008977 n.a. Fusobacterium A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016093 Microbes metabolize substances PMDBM2008977 n.a. Fusobacterium A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016094 Microbes metabolize substances PMDBM2008977 n.a. Fusobacterium A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016095 Microbes metabolize substances PMDBM2008977 n.a. Fusobacterium A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016096 Microbes metabolize substances PMDBM2020720 850 Fusobacterium A mortiferum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016097 Microbes metabolize substances PMDBM2020720 850 Fusobacterium A mortiferum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016098 Microbes metabolize substances PMDBM2020720 850 Fusobacterium A mortiferum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016099 Microbes metabolize substances PMDBM2020720 850 Fusobacterium A mortiferum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016100 Microbes metabolize substances PMDBM2020720 850 Fusobacterium A mortiferum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016101 Microbes metabolize substances PMDBM2020728 68766 Fusobacterium A sp900015295 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016102 Microbes metabolize substances PMDBM2020728 68766 Fusobacterium A sp900015295 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016103 Microbes metabolize substances PMDBM2020728 68766 Fusobacterium A sp900015295 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016104 Microbes metabolize substances PMDBM2020728 68766 Fusobacterium A sp900015295 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016105 Microbes metabolize substances PMDBM2020728 68766 Fusobacterium A sp900015295 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016106 Microbes metabolize substances PMDBM2020728 68766 Fusobacterium A sp900015295 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016107 Microbes metabolize substances PMDBM2020728 68766 Fusobacterium A sp900015295 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016108 Microbes metabolize substances PMDBM2020728 68766 Fusobacterium A sp900015295 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016109 Microbes metabolize substances PMDBM2020728 68766 Fusobacterium A sp900015295 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016110 Microbes metabolize substances PMDBM2020729 861 Fusobacterium A ulcerans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016111 Microbes metabolize substances PMDBM2020729 861 Fusobacterium A ulcerans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016112 Microbes metabolize substances PMDBM2020729 861 Fusobacterium A ulcerans PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016113 Microbes metabolize substances PMDBM2020729 861 Fusobacterium A ulcerans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016114 Microbes metabolize substances PMDBM2020729 861 Fusobacterium A ulcerans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016115 Microbes metabolize substances PMDBM2020729 861 Fusobacterium A ulcerans PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20016116 Microbes metabolize substances PMDBM2020730 856 Fusobacterium A varium A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016117 Microbes metabolize substances PMDBM2020730 856 Fusobacterium A varium A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016118 Microbes metabolize substances PMDBM2020730 856 Fusobacterium A varium A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016119 Microbes metabolize substances PMDBM2020730 856 Fusobacterium A varium A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016120 Microbes metabolize substances PMDBM2020730 856 Fusobacterium A varium A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016121 Microbes metabolize substances PMDBM2020730 856 Fusobacterium A varium B PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016122 Microbes metabolize substances PMDBM2020730 856 Fusobacterium A varium B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016123 Microbes metabolize substances PMDBM2020730 856 Fusobacterium A varium B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016124 Microbes metabolize substances PMDBM2020730 856 Fusobacterium A varium B PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016125 Microbes metabolize substances PMDBM2020730 856 Fusobacterium A varium B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016126 Microbes metabolize substances PMDBM2020730 856 Fusobacterium A varium B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016127 Microbes metabolize substances PMDBM2020730 856 Fusobacterium A varium B PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20016128 Microbes metabolize substances PMDBM2008983 n.a. Fusobacterium B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016129 Microbes metabolize substances PMDBM2008983 n.a. Fusobacterium B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016130 Microbes metabolize substances PMDBM2008983 n.a. Fusobacterium B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016131 Microbes metabolize substances PMDBM2008983 n.a. Fusobacterium B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016132 Microbes metabolize substances PMDBM2008983 n.a. Fusobacterium B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016133 Microbes metabolize substances PMDBM2008983 n.a. Fusobacterium B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016134 Microbes metabolize substances PMDBM2008983 n.a. Fusobacterium B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016137 Microbes metabolize substances PMDBM2008983 n.a. Fusobacterium B PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016138 Microbes metabolize substances PMDBM2008983 n.a. Fusobacterium B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016139 Microbes metabolize substances PMDBM2008983 n.a. Fusobacterium B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016140 Microbes metabolize substances PMDBM2008983 n.a. Fusobacterium B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016141 Microbes metabolize substances PMDBM2008983 n.a. Fusobacterium B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016142 Microbes metabolize substances PMDBM2008983 n.a. Fusobacterium B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016143 Microbes metabolize substances PMDBM2008983 n.a. Fusobacterium B PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016144 Microbes metabolize substances PMDBM2008983 n.a. Fusobacterium B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016145 Microbes metabolize substances PMDBM2008983 n.a. Fusobacterium B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016146 Microbes metabolize substances PMDBM2020718 849 Fusobacterium C gonidiaformans PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016147 Microbes metabolize substances PMDBM2020718 849 Fusobacterium C gonidiaformans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016148 Microbes metabolize substances PMDBM2020718 849 Fusobacterium C gonidiaformans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016149 Microbes metabolize substances PMDBM2020718 849 Fusobacterium C gonidiaformans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016150 Microbes metabolize substances PMDBM2020718 849 Fusobacterium C gonidiaformans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016151 Microbes metabolize substances PMDBM2020095 859 Fusobacterium C necrophorum PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016152 Microbes metabolize substances PMDBM2020095 859 Fusobacterium C necrophorum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016153 Microbes metabolize substances PMDBM2020095 859 Fusobacterium C necrophorum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016154 Microbes metabolize substances PMDBM2020095 859 Fusobacterium C necrophorum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016155 Microbes metabolize substances PMDBM2020095 859 Fusobacterium C necrophorum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016156 Microbes metabolize substances PMDBM2020095 859 Fusobacterium C necrophorum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016157 Microbes metabolize substances PMDBM2008986 1911312 Gabonibacter PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016158 Microbes metabolize substances PMDBM2008986 1911312 Gabonibacter PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016159 Microbes metabolize substances PMDBM2008986 1911312 Gabonibacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016160 Microbes metabolize substances PMDBM2008986 1911312 Gabonibacter PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016161 Microbes metabolize substances PMDBM2008986 1911312 Gabonibacter PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016162 Microbes metabolize substances PMDBM2008986 1911312 Gabonibacter PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016163 Microbes metabolize substances PMDBM2021546 1720195 Gabonibacter massiliensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016164 Microbes metabolize substances PMDBM2021546 1720195 Gabonibacter massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016165 Microbes metabolize substances PMDBM2021546 1720195 Gabonibacter massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016166 Microbes metabolize substances PMDBM2021546 1720195 Gabonibacter massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016167 Microbes metabolize substances PMDBM2021546 1720195 Gabonibacter massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016168 Microbes metabolize substances PMDBM2021546 1720195 Gabonibacter massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016169 Microbes metabolize substances PMDBM2008988 218204 Garciella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016170 Microbes metabolize substances PMDBM2008988 218204 Garciella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016171 Microbes metabolize substances PMDBM2008988 218204 Garciella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016172 Microbes metabolize substances PMDBM2008989 3022868 Gastranaerophilaceae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20016173 Microbes metabolize substances PMDBM2008989 3022868 Gastranaerophilaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016174 Microbes metabolize substances PMDBM2008989 3022868 Gastranaerophilaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016175 Microbes metabolize substances PMDBM2008989 3022868 Gastranaerophilaceae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016176 Microbes metabolize substances PMDBM2008989 3022868 Gastranaerophilaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016177 Microbes metabolize substances PMDBM2008989 3022868 Gastranaerophilaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016178 Microbes metabolize substances PMDBM2008990 1906119 Gastranaerophilales PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20016179 Microbes metabolize substances PMDBM2008990 1906119 Gastranaerophilales PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016180 Microbes metabolize substances PMDBM2008990 1906119 Gastranaerophilales PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016181 Microbes metabolize substances PMDBM2008990 1906119 Gastranaerophilales PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016182 Microbes metabolize substances PMDBM2008990 1906119 Gastranaerophilales PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016183 Microbes metabolize substances PMDBM2021547 1906137 Gastranaerophilus phascolarctosicola PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016184 Microbes metabolize substances PMDBM2021547 1906137 Gastranaerophilus phascolarctosicola PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016185 Microbes metabolize substances PMDBM2021547 1906137 Gastranaerophilus phascolarctosicola PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016186 Microbes metabolize substances PMDBM2021547 1906137 Gastranaerophilus phascolarctosicola PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016187 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016188 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20016189 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016190 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016191 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016193 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016195 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016196 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016197 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016198 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20016199 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20016200 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016202 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20016205 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20016206 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20016207 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016208 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016211 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20016214 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016215 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016218 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016219 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016220 Microbes metabolize substances PMDBM2008992 n.a. f Lachnospiraceae g GCA-900066135 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016221 Microbes metabolize substances PMDBM2008993 n.a. f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016222 Microbes metabolize substances PMDBM2008993 n.a. f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20016223 Microbes metabolize substances PMDBM2008993 n.a. f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016224 Microbes metabolize substances PMDBM2008993 n.a. f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016225 Microbes metabolize substances PMDBM2008993 n.a. f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016227 Microbes metabolize substances PMDBM2008993 n.a. f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016229 Microbes metabolize substances PMDBM2008993 n.a. f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016230 Microbes metabolize substances PMDBM2008993 n.a. f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016231 Microbes metabolize substances PMDBM2008993 n.a. f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016232 Microbes metabolize substances PMDBM2008993 n.a. f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016235 Microbes metabolize substances PMDBM2008993 n.a. f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016236 Microbes metabolize substances PMDBM2008993 n.a. f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016237 Microbes metabolize substances PMDBM2008993 n.a. f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016238 Microbes metabolize substances PMDBM2008993 n.a. f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016240 Microbes metabolize substances PMDBM2008993 n.a. f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016241 Microbes metabolize substances PMDBM2008993 n.a. f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016242 Microbes metabolize substances PMDBM2008993 n.a. f Lachnospiraceae g GCA-900066135 s GCA-900066135 sp900066135 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016243 Microbes metabolize substances PMDBM2008994 n.a. f Peptostreptococcaceae g GCA-900066495 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016244 Microbes metabolize substances PMDBM2008994 n.a. f Peptostreptococcaceae g GCA-900066495 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016245 Microbes metabolize substances PMDBM2008994 n.a. f Peptostreptococcaceae g GCA-900066495 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016246 Microbes metabolize substances PMDBM2008994 n.a. f Peptostreptococcaceae g GCA-900066495 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016247 Microbes metabolize substances PMDBM2008994 n.a. f Peptostreptococcaceae g GCA-900066495 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016248 Microbes metabolize substances PMDBM2008994 n.a. f Peptostreptococcaceae g GCA-900066495 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016249 Microbes metabolize substances PMDBM2008994 n.a. f Peptostreptococcaceae g GCA-900066495 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016252 Microbes metabolize substances PMDBM2008994 n.a. f Peptostreptococcaceae g GCA-900066495 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016253 Microbes metabolize substances PMDBM2008994 n.a. f Peptostreptococcaceae g GCA-900066495 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016254 Microbes metabolize substances PMDBM2008994 n.a. f Peptostreptococcaceae g GCA-900066495 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016255 Microbes metabolize substances PMDBM2008994 n.a. f Peptostreptococcaceae g GCA-900066495 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016256 Microbes metabolize substances PMDBM2008994 n.a. f Peptostreptococcaceae g GCA-900066495 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016257 Microbes metabolize substances PMDBM2008994 n.a. f Peptostreptococcaceae g GCA-900066495 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016258 Microbes metabolize substances PMDBM2008994 n.a. f Peptostreptococcaceae g GCA-900066495 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016259 Microbes metabolize substances PMDBM2008995 n.a. f Peptostreptococcaceae g GCA-900066495 s GCA-900066495 sp900066495 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20016260 Microbes metabolize substances PMDBM2008995 n.a. f Peptostreptococcaceae g GCA-900066495 s GCA-900066495 sp900066495 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016261 Microbes metabolize substances PMDBM2008995 n.a. f Peptostreptococcaceae g GCA-900066495 s GCA-900066495 sp900066495 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016262 Microbes metabolize substances PMDBM2008995 n.a. f Peptostreptococcaceae g GCA-900066495 s GCA-900066495 sp900066495 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016263 Microbes metabolize substances PMDBM2008995 n.a. f Peptostreptococcaceae g GCA-900066495 s GCA-900066495 sp900066495 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016264 Microbes metabolize substances PMDBM2008996 n.a. f Lachnospiraceae g GCA-900066575 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20016265 Microbes metabolize substances PMDBM2008996 n.a. f Lachnospiraceae g GCA-900066575 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016266 Microbes metabolize substances PMDBM2008996 n.a. f Lachnospiraceae g GCA-900066575 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016267 Microbes metabolize substances PMDBM2008996 n.a. f Lachnospiraceae g GCA-900066575 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016268 Microbes metabolize substances PMDBM2008996 n.a. f Lachnospiraceae g GCA-900066575 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016269 Microbes metabolize substances PMDBM2008996 n.a. f Lachnospiraceae g GCA-900066575 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016270 Microbes metabolize substances PMDBM2008997 n.a. f Lachnospiraceae g GCA-900066575 s GCA-900066575 sp002160765 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016271 Microbes metabolize substances PMDBM2008997 n.a. f Lachnospiraceae g GCA-900066575 s GCA-900066575 sp002160765 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016272 Microbes metabolize substances PMDBM2008997 n.a. f Lachnospiraceae g GCA-900066575 s GCA-900066575 sp002160765 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016273 Microbes metabolize substances PMDBM2008998 n.a. f Lachnospiraceae g GCA-900066575 s GCA-900066575 sp900066385 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20016274 Microbes metabolize substances PMDBM2008998 n.a. f Lachnospiraceae g GCA-900066575 s GCA-900066575 sp900066385 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016275 Microbes metabolize substances PMDBM2008998 n.a. f Lachnospiraceae g GCA-900066575 s GCA-900066575 sp900066385 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016276 Microbes metabolize substances PMDBM2008998 n.a. f Lachnospiraceae g GCA-900066575 s GCA-900066575 sp900066385 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016277 Microbes metabolize substances PMDBM2008998 n.a. f Lachnospiraceae g GCA-900066575 s GCA-900066575 sp900066385 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016278 Microbes metabolize substances PMDBM2008999 n.a. f Lachnospiraceae g GCA-900066755 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016279 Microbes metabolize substances PMDBM2008999 n.a. f Lachnospiraceae g GCA-900066755 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20016280 Microbes metabolize substances PMDBM2008999 n.a. f Lachnospiraceae g GCA-900066755 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016281 Microbes metabolize substances PMDBM2008999 n.a. f Lachnospiraceae g GCA-900066755 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016282 Microbes metabolize substances PMDBM2008999 n.a. f Lachnospiraceae g GCA-900066755 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016284 Microbes metabolize substances PMDBM2008999 n.a. f Lachnospiraceae g GCA-900066755 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016286 Microbes metabolize substances PMDBM2008999 n.a. f Lachnospiraceae g GCA-900066755 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016287 Microbes metabolize substances PMDBM2008999 n.a. f Lachnospiraceae g GCA-900066755 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016288 Microbes metabolize substances PMDBM2008999 n.a. f Lachnospiraceae g GCA-900066755 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016289 Microbes metabolize substances PMDBM2008999 n.a. f Lachnospiraceae g GCA-900066755 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016292 Microbes metabolize substances PMDBM2008999 n.a. f Lachnospiraceae g GCA-900066755 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016293 Microbes metabolize substances PMDBM2008999 n.a. f Lachnospiraceae g GCA-900066755 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016294 Microbes metabolize substances PMDBM2008999 n.a. f Lachnospiraceae g GCA-900066755 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016295 Microbes metabolize substances PMDBM2008999 n.a. f Lachnospiraceae g GCA-900066755 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016297 Microbes metabolize substances PMDBM2008999 n.a. f Lachnospiraceae g GCA-900066755 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016298 Microbes metabolize substances PMDBM2008999 n.a. f Lachnospiraceae g GCA-900066755 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016299 Microbes metabolize substances PMDBM2008999 n.a. f Lachnospiraceae g GCA-900066755 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016300 Microbes metabolize substances PMDBM2009000 n.a. f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016301 Microbes metabolize substances PMDBM2009000 n.a. f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016302 Microbes metabolize substances PMDBM2009000 n.a. f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016303 Microbes metabolize substances PMDBM2009000 n.a. f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016305 Microbes metabolize substances PMDBM2009000 n.a. f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016307 Microbes metabolize substances PMDBM2009000 n.a. f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016308 Microbes metabolize substances PMDBM2009000 n.a. f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016309 Microbes metabolize substances PMDBM2009000 n.a. f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016310 Microbes metabolize substances PMDBM2009000 n.a. f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016313 Microbes metabolize substances PMDBM2009000 n.a. f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016314 Microbes metabolize substances PMDBM2009000 n.a. f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016315 Microbes metabolize substances PMDBM2009000 n.a. f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016316 Microbes metabolize substances PMDBM2009000 n.a. f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016318 Microbes metabolize substances PMDBM2009000 n.a. f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016319 Microbes metabolize substances PMDBM2009000 n.a. f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016320 Microbes metabolize substances PMDBM2009000 n.a. f Lachnospiraceae g GCA-900066755 s GCA-900066755 sp900066755 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016321 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016322 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20016323 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016324 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016325 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016327 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016329 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016330 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016331 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016332 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20016333 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20016334 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016336 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20016339 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20016340 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20016341 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016342 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016345 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20016348 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016349 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016352 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016353 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016354 Microbes metabolize substances PMDBM2009001 n.a. o Christensenellales f GCA-900066905 g GCA-900066905 s GCA-900066905 sp900066905 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016355 Microbes metabolize substances PMDBM2009002 n.a. f Peptostreptococcaceae g GCA-900066935 s GCA-900066935 sp900066925 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20016356 Microbes metabolize substances PMDBM2009002 n.a. f Peptostreptococcaceae g GCA-900066935 s GCA-900066935 sp900066925 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016357 Microbes metabolize substances PMDBM2009002 n.a. f Peptostreptococcaceae g GCA-900066935 s GCA-900066935 sp900066925 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016358 Microbes metabolize substances PMDBM2009002 n.a. f Peptostreptococcaceae g GCA-900066935 s GCA-900066935 sp900066925 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016359 Microbes metabolize substances PMDBM2009002 n.a. f Peptostreptococcaceae g GCA-900066935 s GCA-900066935 sp900066925 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016360 Microbes metabolize substances PMDBM2009002 n.a. f Peptostreptococcaceae g GCA-900066935 s GCA-900066935 sp900066925 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016361 Microbes metabolize substances PMDBM2009003 n.a. f Acutalibacteraceae g GCA-900066995 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016362 Microbes metabolize substances PMDBM2009003 n.a. f Acutalibacteraceae g GCA-900066995 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016363 Microbes metabolize substances PMDBM2009003 n.a. f Acutalibacteraceae g GCA-900066995 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016364 Microbes metabolize substances PMDBM2009004 n.a. f Acutalibacteraceae g GCA-900066995 s GCA-900066995 sp900291955 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016365 Microbes metabolize substances PMDBM2009004 n.a. f Acutalibacteraceae g GCA-900066995 s GCA-900066995 sp900291955 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016366 Microbes metabolize substances PMDBM2009004 n.a. f Acutalibacteraceae g GCA-900066995 s GCA-900066995 sp900291955 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016367 Microbes metabolize substances PMDBM2009004 n.a. f Acutalibacteraceae g GCA-900066995 s GCA-900066995 sp900291955 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016368 Microbes metabolize substances PMDBM784 1378 Gemella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016369 Microbes metabolize substances PMDBM784 1378 Gemella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016370 Microbes metabolize substances PMDBM784 1378 Gemella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016371 Microbes metabolize substances PMDBM784 1378 Gemella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016372 Microbes metabolize substances PMDBM784 1378 Gemella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016373 Microbes metabolize substances PMDBM784 1378 Gemella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016374 Microbes metabolize substances PMDBM784 1378 Gemella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016377 Microbes metabolize substances PMDBM784 1378 Gemella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016378 Microbes metabolize substances PMDBM784 1378 Gemella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016379 Microbes metabolize substances PMDBM784 1378 Gemella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016380 Microbes metabolize substances PMDBM784 1378 Gemella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016381 Microbes metabolize substances PMDBM784 1378 Gemella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016382 Microbes metabolize substances PMDBM784 1378 Gemella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016383 Microbes metabolize substances PMDBM784 1378 Gemella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016384 Microbes metabolize substances PMDBM2020733 1379 Gemella haemolysans B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016385 Microbes metabolize substances PMDBM2020733 1379 Gemella haemolysans B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016386 Microbes metabolize substances PMDBM2020733 1379 Gemella haemolysans B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016387 Microbes metabolize substances PMDBM2020733 1379 Gemella haemolysans B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016388 Microbes metabolize substances PMDBM2020733 1379 Gemella haemolysans B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016389 Microbes metabolize substances PMDBM2020733 1379 Gemella haemolysans B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016390 Microbes metabolize substances PMDBM2020733 1379 Gemella haemolysans B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016393 Microbes metabolize substances PMDBM2020733 1379 Gemella haemolysans B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016394 Microbes metabolize substances PMDBM2020733 1379 Gemella haemolysans B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016395 Microbes metabolize substances PMDBM2020733 1379 Gemella haemolysans B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016396 Microbes metabolize substances PMDBM2020733 1379 Gemella haemolysans B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016397 Microbes metabolize substances PMDBM2020733 1379 Gemella haemolysans B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016398 Microbes metabolize substances PMDBM2020733 1379 Gemella haemolysans B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016399 Microbes metabolize substances PMDBM2020734 29391 Gemella morbillorum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016400 Microbes metabolize substances PMDBM2020734 29391 Gemella morbillorum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016401 Microbes metabolize substances PMDBM2020734 29391 Gemella morbillorum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016402 Microbes metabolize substances PMDBM2020734 29391 Gemella morbillorum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016403 Microbes metabolize substances PMDBM2020734 29391 Gemella morbillorum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016404 Microbes metabolize substances PMDBM2020734 29391 Gemella morbillorum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016405 Microbes metabolize substances PMDBM2020734 29391 Gemella morbillorum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016408 Microbes metabolize substances PMDBM2020734 29391 Gemella morbillorum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016409 Microbes metabolize substances PMDBM2020734 29391 Gemella morbillorum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016410 Microbes metabolize substances PMDBM2020734 29391 Gemella morbillorum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016411 Microbes metabolize substances PMDBM2020734 29391 Gemella morbillorum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016412 Microbes metabolize substances PMDBM2020734 29391 Gemella morbillorum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016413 Microbes metabolize substances PMDBM2020734 29391 Gemella morbillorum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016414 Microbes metabolize substances PMDBM2020734 29391 Gemella morbillorum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016415 Microbes metabolize substances PMDBM2020735 84135 Gemella sanguinis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016416 Microbes metabolize substances PMDBM2020735 84135 Gemella sanguinis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016417 Microbes metabolize substances PMDBM2020735 84135 Gemella sanguinis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016418 Microbes metabolize substances PMDBM2020735 84135 Gemella sanguinis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016419 Microbes metabolize substances PMDBM2020735 84135 Gemella sanguinis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016420 Microbes metabolize substances PMDBM2020735 84135 Gemella sanguinis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016421 Microbes metabolize substances PMDBM2020735 84135 Gemella sanguinis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016424 Microbes metabolize substances PMDBM2020735 84135 Gemella sanguinis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016425 Microbes metabolize substances PMDBM2020735 84135 Gemella sanguinis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016426 Microbes metabolize substances PMDBM2020735 84135 Gemella sanguinis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016427 Microbes metabolize substances PMDBM2020735 84135 Gemella sanguinis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016428 Microbes metabolize substances PMDBM2020735 84135 Gemella sanguinis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016429 Microbes metabolize substances PMDBM2020735 84135 Gemella sanguinis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016430 Microbes metabolize substances PMDBM2020735 84135 Gemella sanguinis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016431 Microbes metabolize substances PMDBM2021325 1966354 Gemella sp002871655 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016432 Microbes metabolize substances PMDBM2021325 1966354 Gemella sp002871655 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016433 Microbes metabolize substances PMDBM2021325 1966354 Gemella sp002871655 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016434 Microbes metabolize substances PMDBM2021325 1966354 Gemella sp002871655 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016435 Microbes metabolize substances PMDBM2021325 1966354 Gemella sp002871655 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016436 Microbes metabolize substances PMDBM2021325 1966354 Gemella sp002871655 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016437 Microbes metabolize substances PMDBM2021325 1966354 Gemella sp002871655 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016440 Microbes metabolize substances PMDBM2021325 1966354 Gemella sp002871655 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016441 Microbes metabolize substances PMDBM2021325 1966354 Gemella sp002871655 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016442 Microbes metabolize substances PMDBM2021325 1966354 Gemella sp002871655 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016443 Microbes metabolize substances PMDBM2021325 1966354 Gemella sp002871655 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016444 Microbes metabolize substances PMDBM2021325 1966354 Gemella sp002871655 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016445 Microbes metabolize substances PMDBM2021325 1966354 Gemella sp002871655 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016446 Microbes metabolize substances PMDBM2021325 1966354 Gemella sp002871655 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016447 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016448 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016449 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016450 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016452 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016454 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016455 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016456 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016457 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20016458 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20016459 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016461 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20016464 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20016465 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20016466 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016467 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016470 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20016473 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016474 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016477 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016478 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016479 Microbes metabolize substances PMDBM248 204475 Gemmiger PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016480 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016481 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016482 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016483 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016485 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016487 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016488 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016489 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016490 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016493 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016494 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016495 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016496 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016498 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD1166 Dolasetron Therapeutic substance antinauseant and antiemetic n.a. n.a. n.a. n.a. duloxetine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20016499 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD1227 Hydrocortisone Therapeutic substance immune, inflammatory, and neoplastic conditions n.a. n.a. n.a. n.a. 20beta-dihydrocortisone n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20016500 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" fungal infections n.a. n.a. n.a. n.a. ketoprofen n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20016501 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD477 Levonorgestrel Therapeutic Substance contraception and hormone n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20016502 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" lower the risk of cardiovascular disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20016503 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD1298 Misoprostol Therapeutic substance reduce the risk of NSAID induced gastric ulcers n.a. n.a. n.a. n.a. misoprostol-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20016504 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD563 Mycophenolate mofetil Therapeutic Substance inosine monophosphate dehydrogenase inhibitor n.a. n.a. n.a. n.a. mycophenolic-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20016505 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD1318 Nicardipine Therapeutic substance effective in the treatment of angina and coronary spasms without showing cardiodepressant effects n.a. n.a. n.a. n.a. aminonicardipine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20016506 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD1376 Praziquantel Therapeutic substance Anti-infection n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20016507 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD1406 Ropinirole Therapeutic substance Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20016508 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD1421 Spironolactone Therapeutic substance diuretic and also antihypertensive effects n.a. n.a. n.a. n.a. 7æµ?thiospironolactone n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20016509 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD812 Sulfasalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. sulfapyridine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20016510 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD816 Sulindac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. sulindac-M2 n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20016511 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016512 Microbes metabolize substances PMDBM2020738 745368 Gemmiger formicilis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016513 Microbes metabolize substances PMDBM2021548 2049027 Gemmiger sp003476825 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016514 Microbes metabolize substances PMDBM2021548 2049027 Gemmiger sp003476825 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016515 Microbes metabolize substances PMDBM2021548 2049027 Gemmiger sp003476825 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016516 Microbes metabolize substances PMDBM2021548 2049027 Gemmiger sp003476825 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016518 Microbes metabolize substances PMDBM2021548 2049027 Gemmiger sp003476825 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016520 Microbes metabolize substances PMDBM2021548 2049027 Gemmiger sp003476825 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016521 Microbes metabolize substances PMDBM2021548 2049027 Gemmiger sp003476825 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016522 Microbes metabolize substances PMDBM2021548 2049027 Gemmiger sp003476825 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016523 Microbes metabolize substances PMDBM2021548 2049027 Gemmiger sp003476825 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016526 Microbes metabolize substances PMDBM2021548 2049027 Gemmiger sp003476825 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016527 Microbes metabolize substances PMDBM2021548 2049027 Gemmiger sp003476825 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016528 Microbes metabolize substances PMDBM2021548 2049027 Gemmiger sp003476825 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016529 Microbes metabolize substances PMDBM2021548 2049027 Gemmiger sp003476825 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016531 Microbes metabolize substances PMDBM2009011 n.a. Gemmiger variabile PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016532 Microbes metabolize substances PMDBM2009011 n.a. Gemmiger variabile PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016533 Microbes metabolize substances PMDBM2009011 n.a. Gemmiger variabile PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016534 Microbes metabolize substances PMDBM2009011 n.a. Gemmiger variabile PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016536 Microbes metabolize substances PMDBM2009011 n.a. Gemmiger variabile PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016538 Microbes metabolize substances PMDBM2009011 n.a. Gemmiger variabile PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016539 Microbes metabolize substances PMDBM2009011 n.a. Gemmiger variabile PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016540 Microbes metabolize substances PMDBM2009011 n.a. Gemmiger variabile PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016541 Microbes metabolize substances PMDBM2009011 n.a. Gemmiger variabile PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016544 Microbes metabolize substances PMDBM2009011 n.a. Gemmiger variabile PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016545 Microbes metabolize substances PMDBM2009011 n.a. Gemmiger variabile PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016546 Microbes metabolize substances PMDBM2009011 n.a. Gemmiger variabile PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016547 Microbes metabolize substances PMDBM2009011 n.a. Gemmiger variabile PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016549 Microbes metabolize substances PMDBM2009011 n.a. Gemmiger variabile PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016550 Microbes metabolize substances PMDBM2009011 n.a. Gemmiger variabile PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016551 Microbes metabolize substances PMDBM2021549 66228 Gleimia europaea A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016552 Microbes metabolize substances PMDBM2021549 66228 Gleimia europaea A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016553 Microbes metabolize substances PMDBM2021549 66228 Gleimia europaea A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016554 Microbes metabolize substances PMDBM2021549 66228 Gleimia europaea A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016555 Microbes metabolize substances PMDBM2021549 66228 Gleimia europaea A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016556 Microbes metabolize substances PMDBM2021549 66228 Gleimia europaea A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016557 Microbes metabolize substances PMDBM2021549 66228 Gleimia europaea A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016560 Microbes metabolize substances PMDBM2021549 66228 Gleimia europaea A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016561 Microbes metabolize substances PMDBM2021549 66228 Gleimia europaea A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016562 Microbes metabolize substances PMDBM2021549 66228 Gleimia europaea A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016563 Microbes metabolize substances PMDBM2021549 66228 Gleimia europaea A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016564 Microbes metabolize substances PMDBM2021549 66228 Gleimia europaea A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016565 Microbes metabolize substances PMDBM2021549 66228 Gleimia europaea A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016566 Microbes metabolize substances PMDBM2021549 66228 Gleimia europaea A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016567 Microbes metabolize substances PMDBM2009013 n.a. f Paenibacillaceae g GM2 s GM2 sp900069005 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016568 Microbes metabolize substances PMDBM2009013 n.a. f Paenibacillaceae g GM2 s GM2 sp900069005 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016569 Microbes metabolize substances PMDBM2009013 n.a. f Paenibacillaceae g GM2 s GM2 sp900069005 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016570 Microbes metabolize substances PMDBM2009013 n.a. f Paenibacillaceae g GM2 s GM2 sp900069005 PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20016571 Microbes metabolize substances PMDBM2009013 n.a. f Paenibacillaceae g GM2 s GM2 sp900069005 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016573 Microbes metabolize substances PMDBM2009013 n.a. f Paenibacillaceae g GM2 s GM2 sp900069005 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016575 Microbes metabolize substances PMDBM2009013 n.a. f Paenibacillaceae g GM2 s GM2 sp900069005 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016576 Microbes metabolize substances PMDBM2009013 n.a. f Paenibacillaceae g GM2 s GM2 sp900069005 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016577 Microbes metabolize substances PMDBM2009013 n.a. f Paenibacillaceae g GM2 s GM2 sp900069005 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016578 Microbes metabolize substances PMDBM2009013 n.a. f Paenibacillaceae g GM2 s GM2 sp900069005 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016581 Microbes metabolize substances PMDBM2009013 n.a. f Paenibacillaceae g GM2 s GM2 sp900069005 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016582 Microbes metabolize substances PMDBM2009013 n.a. f Paenibacillaceae g GM2 s GM2 sp900069005 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016583 Microbes metabolize substances PMDBM2009013 n.a. f Paenibacillaceae g GM2 s GM2 sp900069005 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016584 Microbes metabolize substances PMDBM2009013 n.a. f Paenibacillaceae g GM2 s GM2 sp900069005 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016586 Microbes metabolize substances PMDBM2009013 n.a. f Paenibacillaceae g GM2 s GM2 sp900069005 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016587 Microbes metabolize substances PMDBM2009013 n.a. f Paenibacillaceae g GM2 s GM2 sp900069005 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016588 Microbes metabolize substances PMDBM249 644652 Gordonibacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016589 Microbes metabolize substances PMDBM249 644652 Gordonibacter PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20016590 Microbes metabolize substances PMDBM249 644652 Gordonibacter PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016591 Microbes metabolize substances PMDBM249 644652 Gordonibacter PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016592 Microbes metabolize substances PMDBM249 644652 Gordonibacter PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016593 Microbes metabolize substances PMDBM2021550 1841863 Gordonibacter massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016594 Microbes metabolize substances PMDBM2021550 1841863 Gordonibacter massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016595 Microbes metabolize substances PMDBM2021550 1841863 Gordonibacter massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016596 Microbes metabolize substances PMDBM2021550 1841863 Gordonibacter massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016597 Microbes metabolize substances PMDBM2021550 1841863 Gordonibacter massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016598 Microbes metabolize substances PMDBM2021550 1841863 Gordonibacter massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016599 Microbes metabolize substances PMDBM2021550 1841863 Gordonibacter massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016602 Microbes metabolize substances PMDBM2021550 1841863 Gordonibacter massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016603 Microbes metabolize substances PMDBM2021550 1841863 Gordonibacter massiliensis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20016604 Microbes metabolize substances PMDBM2021550 1841863 Gordonibacter massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016605 Microbes metabolize substances PMDBM2021550 1841863 Gordonibacter massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016606 Microbes metabolize substances PMDBM2021550 1841863 Gordonibacter massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016607 Microbes metabolize substances PMDBM2021550 1841863 Gordonibacter massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016608 Microbes metabolize substances PMDBM2021550 1841863 Gordonibacter massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016609 Microbes metabolize substances PMDBM2021550 1841863 Gordonibacter massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016610 Microbes metabolize substances PMDBM2020743 471189 Gordonibacter pamelaeae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016611 Microbes metabolize substances PMDBM2020743 471189 Gordonibacter pamelaeae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016612 Microbes metabolize substances PMDBM2020743 471189 Gordonibacter pamelaeae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016613 Microbes metabolize substances PMDBM2020743 471189 Gordonibacter pamelaeae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016614 Microbes metabolize substances PMDBM2020743 471189 Gordonibacter pamelaeae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016615 Microbes metabolize substances PMDBM2020743 471189 Gordonibacter pamelaeae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016616 Microbes metabolize substances PMDBM2020743 471189 Gordonibacter pamelaeae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016619 Microbes metabolize substances PMDBM2020743 471189 Gordonibacter pamelaeae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016620 Microbes metabolize substances PMDBM2020743 471189 Gordonibacter pamelaeae PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20016621 Microbes metabolize substances PMDBM2020743 471189 Gordonibacter pamelaeae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016622 Microbes metabolize substances PMDBM2020743 471189 Gordonibacter pamelaeae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016623 Microbes metabolize substances PMDBM2020743 471189 Gordonibacter pamelaeae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016624 Microbes metabolize substances PMDBM2020743 471189 Gordonibacter pamelaeae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016625 Microbes metabolize substances PMDBM2020743 471189 Gordonibacter pamelaeae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016626 Microbes metabolize substances PMDBM2020058 1335613 Gordonibacter urolithinfaciens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016627 Microbes metabolize substances PMDBM2020058 1335613 Gordonibacter urolithinfaciens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016628 Microbes metabolize substances PMDBM2020058 1335613 Gordonibacter urolithinfaciens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016629 Microbes metabolize substances PMDBM2020058 1335613 Gordonibacter urolithinfaciens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016630 Microbes metabolize substances PMDBM2020058 1335613 Gordonibacter urolithinfaciens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016631 Microbes metabolize substances PMDBM2020058 1335613 Gordonibacter urolithinfaciens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016632 Microbes metabolize substances PMDBM2020058 1335613 Gordonibacter urolithinfaciens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016635 Microbes metabolize substances PMDBM2020058 1335613 Gordonibacter urolithinfaciens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016636 Microbes metabolize substances PMDBM2020058 1335613 Gordonibacter urolithinfaciens PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20016637 Microbes metabolize substances PMDBM2020058 1335613 Gordonibacter urolithinfaciens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016638 Microbes metabolize substances PMDBM2020058 1335613 Gordonibacter urolithinfaciens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016639 Microbes metabolize substances PMDBM2020058 1335613 Gordonibacter urolithinfaciens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016640 Microbes metabolize substances PMDBM2020058 1335613 Gordonibacter urolithinfaciens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016641 Microbes metabolize substances PMDBM2020058 1335613 Gordonibacter urolithinfaciens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016642 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016643 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016644 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016645 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016646 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016647 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016648 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20016649 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20016650 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016652 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20016655 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20016656 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20016657 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016658 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016661 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20016664 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016665 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016666 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016668 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016669 Microbes metabolize substances PMDBM2020744 1689269 Gorillibacterium timonense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016670 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016671 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20016672 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016673 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016674 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016676 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016678 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016679 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016680 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016681 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20016682 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20016683 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016685 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20016688 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20016689 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20016690 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016691 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016694 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20016697 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016698 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016701 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016702 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016703 Microbes metabolize substances PMDBM2020746 1564956 Gracilibacillus massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016704 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016705 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20016706 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016707 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016708 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016709 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016710 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016711 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20016712 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20016713 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016715 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20016718 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20016719 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20016720 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016721 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016724 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20016727 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20016728 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016729 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016730 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016732 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016733 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016734 Microbes metabolize substances PMDBM2020747 1816696 Gracilibacillus timonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016735 Microbes metabolize substances PMDBM2009020 117563 Granulicatella PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20016736 Microbes metabolize substances PMDBM2009020 117563 Granulicatella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016737 Microbes metabolize substances PMDBM2009020 117563 Granulicatella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016738 Microbes metabolize substances PMDBM2009020 117563 Granulicatella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016739 Microbes metabolize substances PMDBM2009020 117563 Granulicatella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016740 Microbes metabolize substances PMDBM2009020 117563 Granulicatella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016741 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016742 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20016743 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016744 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016745 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016747 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016749 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20016750 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016751 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016752 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016753 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016756 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016757 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016758 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016759 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016761 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016762 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016763 Microbes metabolize substances PMDBM2020749 46124 Granulicatella adiacens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016764 Microbes metabolize substances PMDBM2021551 2049028 Granulicatella sp001071995 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016765 Microbes metabolize substances PMDBM2021551 2049028 Granulicatella sp001071995 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20016766 Microbes metabolize substances PMDBM2021551 2049028 Granulicatella sp001071995 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016767 Microbes metabolize substances PMDBM2021551 2049028 Granulicatella sp001071995 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016768 Microbes metabolize substances PMDBM2021551 2049028 Granulicatella sp001071995 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016770 Microbes metabolize substances PMDBM2021551 2049028 Granulicatella sp001071995 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20016772 Microbes metabolize substances PMDBM2021551 2049028 Granulicatella sp001071995 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016773 Microbes metabolize substances PMDBM2021551 2049028 Granulicatella sp001071995 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016774 Microbes metabolize substances PMDBM2021551 2049028 Granulicatella sp001071995 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016775 Microbes metabolize substances PMDBM2021551 2049028 Granulicatella sp001071995 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016778 Microbes metabolize substances PMDBM2021551 2049028 Granulicatella sp001071995 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20016779 Microbes metabolize substances PMDBM2021551 2049028 Granulicatella sp001071995 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016780 Microbes metabolize substances PMDBM2021551 2049028 Granulicatella sp001071995 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016781 Microbes metabolize substances PMDBM2021551 2049028 Granulicatella sp001071995 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016783 Microbes metabolize substances PMDBM2021551 2049028 Granulicatella sp001071995 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016784 Microbes metabolize substances PMDBM2021551 2049028 Granulicatella sp001071995 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016785 Microbes metabolize substances PMDBM2021551 2049028 Granulicatella sp001071995 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016786 Microbes metabolize substances PMDBM2021259 673 Grimontia hollisae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016787 Microbes metabolize substances PMDBM2021259 673 Grimontia hollisae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20016788 Microbes metabolize substances PMDBM2021259 673 Grimontia hollisae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20016789 Microbes metabolize substances PMDBM2021259 673 Grimontia hollisae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016790 Microbes metabolize substances PMDBM2021259 673 Grimontia hollisae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016791 Microbes metabolize substances PMDBM2021259 673 Grimontia hollisae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20016792 Microbes metabolize substances PMDBM2021259 673 Grimontia hollisae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016795 Microbes metabolize substances PMDBM2021259 673 Grimontia hollisae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016796 Microbes metabolize substances PMDBM2021259 673 Grimontia hollisae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016797 Microbes metabolize substances PMDBM2021259 673 Grimontia hollisae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016798 Microbes metabolize substances PMDBM2021259 673 Grimontia hollisae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016799 Microbes metabolize substances PMDBM2021259 673 Grimontia hollisae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016800 Microbes metabolize substances PMDBM2021259 673 Grimontia hollisae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20016801 Microbes metabolize substances PMDBM2021259 673 Grimontia hollisae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016802 Microbes metabolize substances PMDBM2021259 673 Grimontia hollisae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20016803 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20016804 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20016805 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD711 Prontosil Therapeutic Substance antibacterial n.a. n.a. n.a. n.a. n.a. n.a. Azo reductases activation n.a. n.a. n.a. The conversion of prontosil and neoprontosil to sulfanilamide by aid of azoreductase enzyme produced by the large intestinal microbiota, it was discovered that the antibacterial action of prontosil was due to the molecule sulfanilamide n.a. PMID PMID: 36467581 PMDBI20016806 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000026 Saponins Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Lactobacillus brevis crude enzyme activation n.a. n.a. n.a. Aescin is a prodrug. The crude enzyme of human intestinal bacteria and Lactobacillus brevis can extract aescin Deacylaescinoside I, the product of glycoside ia transformation, has antitumor activity and is a potential antitumor drug candidate. n.a. PMID PMID: 36467581 PMDBI20016807 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000027 Ethanol Therapeutic Substance compound n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Extrahepatic ethanol metabolism takes place via microbial oxidation in the colon by ADH, mediated by aerobic and facultative anaerobic bacteria. Ciprofloxacin treatment decreased the ethanol elimination rate by 9.4%, with a concomitant decrease in intestinal aerobic and facultative anaerobic bacteria, fecal ADH activity, and acetaldehyde production. n.a. PMID PMID: 36467581 PMDBI20016808 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD358 Flucytosine Therapeutic Substance antifungals n.a. n.a. n.a. n.a. 5-fluorouracil n.a. unknown toxicity increased n.a. n.a. n.a. toxicity increased n.a. PMID PMID: 36467581 PMDBI20016809 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" inhibitor n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Fluoxetine was shown to be mainly eliminated through biodegradation. n.a. PMID PMID: 36467581 PMDBI20016810 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000028 L-carnitine Therapeutic Substance compound n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. The gut microbiota converts dietary choline and L-carnitine to trimethylamine (TMA), which is further metabolized by the flavine monooxygenase system in the liver to produce the toxic metabolite TMA-N-oxide (TMAO). n.a. PMID PMID: 36467581 PMDBI20016811 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000029 Indicine N-oxide Therapeutic substance compound n.a. n.a. n.a. n.a. N-oxide n.a. unknown activation n.a. n.a. n.a. In humans and rabbits, the gut microbiota plays a major role in the metabolic reduction of indicine N-oxide into indicine, a pyrrolizidine alkaloid N-oxide with antitumor activity but without the toxic effects of other pyrrolizidine alkaloids n.a. PMID PMID: 36467581 PMDBI20016812 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD461 Isosorbide dinitrate "Therapeutic Substance; Herbal Substance" organic nitrates for the treatment of angina pec-toris n.a. n.a. n.a. n.a. mononitrates and isosorbide n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Generate glyceryl-1,3-dinitrate, glyceryl-1,2-dinitrate, glyceryl-1-mononitrate, and glyceryl-2-mononitrate n.a. PMID PMID: 36467581 PMDBI20016813 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" lower the risk of cardiovascular disease n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. This study shows that gut microbes increase the conversion of lovastatin to active metabolites. The plasma concentration of the active hydroxyl acid metabolite of lovastatin is significantly lower in antibiotic-treated rats than in controls. n.a. PMID PMID: 36467581 PMDBI20016814 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000030 L-tryptophan Therapeutic Substance amino acid n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Gut bacteria metabolize L-tryptophan into many products, including the antioxidant indole-3-propionic acid, the neurotransmitter tryptamine, and indole. Hydroxylation and sulfation of indole by hepatic enzymes generate the uremic toxin indoxyl sulfate. n.a. PMID PMID: 36467581 PMDBI20016815 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" Cardiac drugs n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Gut microbes play a role in metformin pharmacology as oral metformin is more effective than intravenous one. Although this observation has been reported, the interaction is not clearly understood. n.a. PMID PMID: 36467581 PMDBI20016816 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD492 Loperamide oxide Therapeutic Substance Anti閳ユ亯iarrheal medication n.a. n.a. n.a. n.a. n.a. n.a. n.a. LOPOX reductase activation n.a. n.a. n.a. Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humansn.a. PMID PMID: 36467581 PMDBI20016818 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD1271 Mefenamic Acid Therapeutic substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Mefenamic acid was shown to be mainly eliminated through biodegradation. A study compared the biodegradation potential of three degrading microbial consortia: an ammonium-nitrite-oxidizing consortium, a nitrite-oxidizing consortium, and a heterotrophic consortium. The ammonium-nitrite-oxidizing consortium showed the highest ability (85%) to biodegrade mefenamic acid, followed by the heterotrophic consortium (66%). n.a. PMID PMID: 36467581 PMDBI20016819 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000031 Methylmercuric chloride Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity decreased n.a. n.a. n.a. Metabolism of methylmercuric chloride by the gut microbiota reduces the tissue content of mercury and thus its toxicity. n.a. PMID PMID: 36467581 PMDBI20016820 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000032 Metoprolol Therapeutic Substance beta-blocker n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Metoprolol removal was shown to be mainly through biodegradation. A study compared the biodegradation potential of three degrading microbial consortia: an ammonium-nitrite-oxidizing consortium, a nitrite-oxidizing consortium, and a heterotrophic consortium. The degradation of metoprolol was shown to be mainly by ammonium-nitrite-oxidizing (64%) and heterotrophic (58%) consortia. n.a. PMID PMID: 36467581 PMDBI20016821 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000033 Phosphatidylcholine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. unknown Induced disease n.a. n.a. n.a. Gut microbiota-dependent metabolism of dietary phosphatidylcholine is believed to increase cardiovascular disease (CVD) pathogenesis. Three metabolites of the dietary lipid phosphatidylcholine: choline, trimethylamine N-oxide (TMAO), and betaine were shown to predict risk for CVD. Suppression of intestinal microbiota in atherosclerosis-prone mice inhibited dietary-choline-enhanced atherosclerosis. n.a. PMID PMID: 36467581 PMDBI20016822 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD750 Risperidone Therapeutic Substance second-generation antipsychotic (SGA) n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. the oxidative dealkylation at the piperidine nitrogen and the scission of the isoxazole in the benzisoxazole ring system. n.a. PMID PMID: 36467581 PMDBI20016823 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000034 Phospholipase A2 Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. phospholipase A2Platelet activation factor and lipopolysaccharide (LPS) can induce an increase in group II phospholipase A2 (PLA2-II) activity. This induction was found to be dependent on gut bacteria, n.a. PMID PMID: 36467581 PMDBI20016824 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD755 Rosuvastatin Therapeutic Substance lipid-lowering drug n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Variability in FXR receptor signaling n.a. PMID PMID: 36467581 PMDBI20016825 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD816 Sulindac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. sulindac sulfide n.a. unknown activity increased n.a. n.a. n.a. activity increased n.a. PMID PMID: 36467581 PMDBI20016826 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD813 Sulfinpyrazone Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. sulindac sulfide n.a. unknown activity increased n.a. n.a. n.a. Through reduction閿涘ulindac and Sulfinpyrazone formation of their sulfide products--sulindac sulfide, sulinpyrzone sulfide n.a. PMID PMID: 36467581 PMDBI20016828 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000035 Xylose Therapeutic Substance nutritional usage n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Sulindac, a nonsteroid anti-inflammatory analgesic, is reduced by the human gut microbiota to sulindac sulfide(active constituent ). n.a. PMID PMID: 36467581 PMDBI20016829 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD619 Omeprazole Therapeutic Substance gastric acid-related disorders n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. It is presumable that omeprazole is also reduced to sulfide metabolites by gut flora n.a. PMID PMID: 36467581 PMDBI20016830 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD731 Ranitidine "Therapeutic Substance; Herbal Substance" Drugs for acid related disorders n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. metabolism occurred via cleavage of an N-oxide bond within the molecule with the resultant loss of an oxygen atom, although further metabolic reactions are possible. Such metabolism may in part be responsible for the poor bioavailability of ranitidine from the colon. n.a. PMID PMID: 36467581 PMDBI20016831 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD95 Baicalin Herbal Substance anti-inflammatory n.a. n.a. n.a. n.a. baicalein n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Baicalin was transformed to baicalein readily by the rat gastric and caecal contents. When baicalin was administered orally to conventional rats, an appreciable amount of baicalein was recovered in their gastrointestinal tracts. Moreover, baicalein was efficiently conjugated to baicalin in rat intestinal and hepatic microsomes. These results indicate that baicalin itself is poorly absorbed from the rat gut, but is hydrolysed to baicalein by intestinal bacteria and then restored to its original form from the absorbed baicalein in the body. n.a. PMID PMID: 36467581 PMDBI20016832 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000014 Sulphinpyrazone Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. unknown activation n.a. n.a. n.a. Sulphide formation n.a. PMID PMID: 36467581 PMDBI20016834 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20016835 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20016836 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD553 Misonidazole Therapeutic Substance Tumor Hypoxia n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. The radiation sensitizer misonidazole is metabolized to its amino derivative [1-(2-aminoimidazol-1-yl)-3-methoxypropan-2-o1] in pure or mixed cultures of the intestinal microflora. n.a. PMID PMID: 36467581 PMDBI20016837 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000036 Insulin Therapeutic Substance Blood glucose control n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. can be degraded in rat caecal contents閿涘he degradation of calcitonin was much faster than that of insulin. The degradation of insulin was fastest at pH 6.8. Protease inhibitors such as camostat and aprotinin inhibited the degradation of insulin and calcitonin in rat caecal contents, which was consistent with the high chymotrypsin activity of these contents. n.a. PMID PMID: 36467581 PMDBI20016838 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD137 Calcitonin Therapeutic Substance calcitonin n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. can be degraded in rat caecal contents閿涘he degradation of calcitonin was much faster than that of insulin. The degradation of insulin was fastest at pH 6.8. Protease inhibitors such as camostat and aprotinin inhibited the degradation of insulin and calcitonin in rat caecal contents, which was consistent with the high chymotrypsin activity of these contents. n.a. PMID PMID: 36467581 PMDBI20016841 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD580 Neoprontosil Therapeutic Substance anti閳ユ亼nfective n.a. n.a. n.a. n.a. n.a. n.a. unknown activation n.a. n.a. n.a. when given orally is largely reduced to sulphanilamide by the gut flora before absorption. n.a. PMID PMID: 36467581 PMDBI20016842 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" Cardiac drugs n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Association with secondary BA and absorption n.a. PMID PMID: 36467581 PMDBI20016843 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD915 Zonisamide Therapeutic Substance anticonvulsant n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Association with secondary BA and absorption n.a. PMID PMID: 36467581 PMDBI20016844 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. m-tyrosine, m-tyramine, m-hydroxyphenylacetic acid n.a. unknown activity decreased n.a. n.a. n.a. Through dehydroxylation閿涘evodopa formation m-tyrosine, m-tyramine, m-hydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20016845 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000037 Hespesidin Therapeutic substance "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. Hesperetin n.a. unknown activity increased n.a. n.a. n.a. Through deglycosylation閿涘瓛espesidin formation Hesperetin n.a. PMID PMID: 36467581 PMDBI20016846 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000038 Glyceryl trinitrate Therapeutic Substance angina pectoris n.a. n.a. n.a. n.a. Glyceryl-1,3-dinitrate, glyceryl-1,2-dinitrate, glyceryl-1-mononitrate n.a. unknown activity decreased n.a. n.a. n.a. Through denitration閿涘瓘lyceryl trinitrate formation Glyceryl-1,3-dinitrate, glyceryl-1,2-dinitrate, glyceryl-1-mononitrate, and glyceryl-2-mononitrate n.a. PMID PMID: 36467581 PMDBI20016847 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. N-(2-hydroxyethyl)-oxamic acid and acetamide n.a. unknown toxicity n.a. n.a. n.a. Through reduction閿涘etronidazole formation N-(2-hydroxyethyl)-oxamic acid and acetamide閿涘robably increase its liver toxicity n.a. PMID PMID: 36467581 PMDBI20016849 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD602 Nizatidine Therapeutic Substance antiulcerotics n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Through N-Oxide bond cleavage閿涘瓕ecreased intestinal absorption and systemic bioavailability n.a. PMID PMID: 36467581 PMDBI20016852 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD618 Olsalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. 5-aminosalicylic-acid n.a. unknown activity decreased n.a. n.a. n.a. Increased activity or causing side effects such as anorexia nausea n.a. PMID PMID: 36467581 PMDBI20016854 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" bacteriostatic n.a. n.a. n.a. n.a. p-aminphenyl-2-amino-1, 3-propanediol n.a. unknown Induced disease n.a. n.a. n.a. Through amine formation and hydrolysis p-aminphenyl-2-amino-1, 3-propanediol閿涘nducing bone marrow aplasia n.a. PMID PMID: 36467581 PMDBI20016855 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl)uracil n.a. unknown toxicity n.a. n.a. n.a. (E)-5-(2-bromovinyl)uracil can inactivate a key liver enzyme,leadingto lethal toxicity of 5-fluorouracil when coadministered with 5-fluorouracil n.a. PMID PMID: 36467581 PMDBI20016856 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD595 Nitrazepam Therapeutic Substance anticonvulsant and hypnotic n.a. n.a. n.a. n.a. 7-aminonitrazepam n.a. unknown teratogenic n.a. n.a. n.a. Through nitroreduction-aminonitrazepam閿涘nducing teratogenicity n.a. PMID PMID: 36467581 PMDBI20016860 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000039 2-Amino-3-methylimidazo(4,5-f)quinoline(IQ) Therapeutic substance chemicalcompounds n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity n.a. n.a. n.a. production of toxic or carcinogenic metabolites n.a. PMID PMID: 36467581 PMDBI20016861 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000040 Arbutin Therapeutic Substance anti-infective n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity n.a. n.a. n.a. production of toxic or carcinogenic metabolites n.a. PMID PMID: 36467581 PMDBI20016862 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD385 Geniposide Herbal Substance Geniposide has significant effects on digestive system, cardiovascular system and central nervous system diseases. Geniposide also has certain anti-inflammatory and soft tissue injury effects. n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity n.a. n.a. n.a. production of toxic or carcinogenic metabolites n.a. PMID PMID: 36467581 PMDBI20016863 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity n.a. n.a. n.a. production of toxic or carcinogenic metabolites n.a. PMID PMID: 36467581 PMDBI20016865 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000041 Butyl paraben Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity decreased n.a. n.a. n.a. Decreased toxicity or detoxication n.a. PMID PMID: 36467581 PMDBI20016866 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD1326 Ochratoxin A Environmental Chemicals compound n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity decreased n.a. n.a. n.a. Decreased toxicity or detoxication n.a. PMID PMID: 36467581 PMDBI20016867 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000042 Zearalenone Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity decreased n.a. n.a. n.a. Decreased toxicity or detoxication n.a. PMID PMID: 36467581 PMDBI20016868 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity n.a. n.a. n.a. Species variation in metabolism and toxicity n.a. PMID PMID: 36467581 PMDBI20016869 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000043 Sulfotransferase Therapeutic substance enzyme n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Modulation of hepatic and intestinal drug-metabolizing enzymes n.a. PMID PMID: 36467581 PMDBI20016875 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD812 Sulfasalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. 5-aminosalicyclic acid and sulfapyridine n.a. unknown activation n.a. n.a. n.a. "Produces active 5-aminosalicyclic acid and sulfapyridine; the latter is systemically absorbed, causing side effects" n.a. PMID PMID: 36467581 PMDBI20016876 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD96 Balsalazide Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. sulfapyridine and 4-aminobenzoyl-beta-alanine n.a. unknown activation n.a. n.a. n.a. "Produces active 6-aminosalicyclic acid and sulfapyridine; the latter is systemically absorbed, causing side effects" n.a. PMID PMID: 36467581 PMDBI20016880 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD657 Phenacetin Therapeutic Substance analgesic n.a. n.a. n.a. n.a. p-phenetidin n.a. unknown side effect n.a. n.a. n.a. Converts to p-phenetidin, which correlates with methemoglobinemia, one of the complications of the use of phenacetin, and with nephritis that accompanies chronic cardiac activity n.a. PMID PMID: 36467581 PMDBI20016884 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD214 Clonazepam Therapeutic Substance Central nervous system agents n.a. n.a. n.a. n.a. 7-aminoclonazepam n.a. Nitroreductase teratogenic n.a. n.a. n.a. Produces 7-aminonitrazepam, a teratogenic metabolite n.a. PMID PMID: 36467581 PMDBI20016891 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" cardiac glycoside n.a. n.a. n.a. n.a. Dihydrodigoxin and dihydrodigoxigenin n.a. unknown activity decreased n.a. n.a. n.a. metabolites not active such as dihy-drodigoxin or its aglycone, dihydrodigoxigenin n.a. PMID PMID: 36467581 PMDBI20016894 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD87 Azetirelin Therapeutic Substance thyrotropin-releasing hormone (TRH) ana-logue n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Bacterial degradation in the gastrointestinal tract contributes to low oral bioavailability n.a. PMID PMID: 36467581 PMDBI20016896 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD695 Potassium oxonate Environmental Chemicals unknown n.a. n.a. n.a. n.a. cyanuric acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. potassium oxonate converts to cyanuric acid and that one of theroutes is the direct conversion to cyanuric acid by gut microbiotain the caecum n.a. PMID PMID: 36467581 PMDBI20016897 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD420 Hesperidin "Therapeutic Substance; Herbal Substance" anti-allergy n.a. n.a. n.a. n.a. hesperitin n.a. unknown activation n.a. n.a. n.a. Converts to hesperitin, showing activated antiallergic activity hesperidin may be a prodrug, which is metabolised to hesperetin by intestinalbacteria. n.a. PMID PMID: 36467581 PMDBI20016899 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000019 Methamphetamine Therapeutic Substance psychostimulant and sympathomimetic n.a. n.a. n.a. n.a. amphetamine n.a. unknown no impact n.a. n.a. n.a. The differences seen in theextent of metabolism between caecal and rectal contents are prob-ably a reflection of the differences in the amount of material fromthesetworegionsusedintheincubations,ratherthanafundamen-taldifferenceintheactivityoftheirmicrobiota.Thistransformationis probably of little consequence in man since metham-phetamine is quite efficiently absorbed in the upper portion ofthe gut. n.a. PMID PMID: 36467581 PMDBI20016902 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. Acetylated 5-ASA n.a. unknown involved in substrate metabolism n.a. n.a. n.a. less than 3.4% of 5-ASA was acetylated in in vitro suspensionsof either guinea-pig caecal contents or faeces from rats, dogs orhumans. n.a. PMID PMID: 36467581 PMDBI20016903 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000044 succinylsulfathiazole Therapeutic substance antibacterial n.a. n.a. n.a. n.a. n.a. n.a. unknown activation n.a. n.a. n.a. The sulfa drug succinylsulfathiazole is itself inactive and poorlyabsorbed from the gastrointestinal tract, but is converted byintestinal bacteria to sulfathiazole, which has strongantibacterial actio n.a. PMID PMID: 36467581 PMDBI20016904 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000045 Nitroglycerin(glyceryl trinitrate) Therapeutic substance angina pectoris n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Isosorbide dinitrate in addition to other metabolic pathwayscan be metabolised in vitro by anaerobic intestinal microorgan-isms of both rat and man. Themetabolic pathway involves step-wise denitration to produce iso-meric mononitrates and isosorbide. In the same study a comparisonwith the rate ofin vitrometabolism in human faecal microbiota wasperformed. n.a. PMID PMID: 36467581 PMDBI20016906 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" a weakly estrogenic compound with potential health n.a. n.a. n.a. n.a. dihydrodaidzein and equol n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Converts to hesperitin, showing activated antiallergic activity hesperidin may be a prodrug, which is metabolised to hesperetin by intestinalbacteria. n.a. PMID PMID: 36467581 PMDBI20016907 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. "Acetaminophen toxicity is associated with elevated levels of p-cresol, which competes with acetaminophen on the o-sulfonation metabolism. p-cresol is produced by some members of the bacterial community; thus, establishing an assessment of microbiome activity was suggested as a guideline prior to the administration of acetamniophen." n.a. PMID PMID: 36467581 PMDBI20016911 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20016912 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20016913 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD124 Bromazepam Therapeutic Substance anti-anxiety disorders n.a. n.a. n.a. n.a. n.a. n.a. Nitroreductase carcinogenic n.a. n.a. n.a. "Antibiotic pretreatment can abolish enzyme activity; Nitrazepam is metabolized into 7-aminonitrazepam, which undergoes host hepati" n.a. PMID PMID: 36467581 PMDBI20016915 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000046 Benzodiazepines Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Nitroreductase carcinogenic n.a. n.a. n.a. "Antibiotic pretreatment can abolish enzyme activity; Nitrazepam is metabolized into 7-aminonitrazepam, which undergoes host hepati" n.a. PMID PMID: 36467581 PMDBI20016916 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20016917 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20016918 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD1081 Carnitine Dietary Substances quaternary ammonium compound n.a. n.a. n.a. n.a. n.a. n.a. Carnitine oxygenase (Rieske-type oxygenase/reductase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20016919 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD1237 Indigestible polysaccharides Dietary Substances unknown n.a. n.a. n.a. n.a. n.a. n.a. butyryl-CoA:acetate CoA transferase involved in substrate metabolism n.a. n.a. n.a. Production of short chain fatty acids n.a. PMID PMID: 36467581 PMDBI20016921 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD1263 L-tyrosine Dietary Substances amino acid n.a. n.a. n.a. n.a. n.a. n.a. Decarboxylase involved in substrate metabolism n.a. n.a. n.a. Bacterial production of p-cresol, which is sulfated by the host. P-cresol competes with acetaminophen for sulfation. n.a. PMID PMID: 36467581 PMDBI20016922 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD485 Linoleic acid Herbal Substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Linoleate isomerase involved in substrate metabolism n.a. n.a. n.a. Production of conjugated linoleic acid from food-derived lactobacilli n.a. PMID PMID: 36467581 PMDBI20016924 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD136 Caffeic acid Herbal Substance compound n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Present in high levels in herbs such as thyme n.a. PMID PMID: 36467581 PMDBI20016926 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD1273 Melamine Dietary Substances compound n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Conversion to cyanuric acid, which cocrystallizes with melamine in kidneys n.a. PMID PMID: 36467581 PMDBI20016927 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD1327 Oleic acid Dietary Substances a naturally occurring fatty acid n.a. n.a. n.a. n.a. n.a. n.a. N-acylsynthase involved in substrate metabolism n.a. n.a. n.a. Products are able to modulate GPCRs n.a. PMID PMID: 36467581 PMDBI20016928 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD1026 Amino acids Dietary Substances Amino acids n.a. n.a. n.a. n.a. n.a. n.a. Peptide synthetase involved in substrate metabolism n.a. n.a. n.a. Dipeiptide aldehyde produced can inhibit human cathepsins L n.a. PMID PMID: 36467581 PMDBI20016929 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20016930 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD1058 Bile acids Dietary Substances compound n.a. n.a. n.a. n.a. n.a. n.a. Bile salt hydrolyase involved in substrate metabolism n.a. n.a. n.a. Further metabolism by-7-dehydroxylase important n.a. PMID PMID: 36467581 PMDBI20016942 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD478 Levosimendan Therapeutic Substance Levosimendan is used to manage acutely decompensated congestive heart failur n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. reducing substrate n.a. PMID PMID: 36467581 PMDBI20016943 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD300 Eltrombopag Therapeutic Substance Eltrombopag is a thrombopoietin receptor agonist used to treat thrombocytopenia or aplastic anemia associated with various etiologies. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20016944 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD535 Methotrexate Therapeutic Substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Methotrexate, a chemotherapeutic agent,is an early example of a drug being biotransformed viahydrolysis by intestinal flora. Incubation of radiolabelled[3H]-methotrexate with CDF1 mouse cecal contentsresulted in at least three metabolites including 4-amino-4-deoxy-n10-methylpteroic acid (APA). The metabolitewas also found in urine and feces of mice administeredthe drug n.a. PMID PMID: 36467581 PMDBI20016945 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000047 Sodium picosulfate Therapeutic Substance laxative n.a. n.a. n.a. n.a. 4,40-dihydroxydiphenyl-(2-pyridyl)-methane n.a. unknown activation n.a. n.a. n.a. the laxative sodiumpicosulfate, which is administered as a bisulfate, needsintestinal bacteria converting it into 4,40-dihydroxydi-phenyl-(2 pyridyl)-methane to make it be active n.a. PMID PMID: 36467581 PMDBI20016946 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. Levametabol-I,-II,-and-III n.a. unknown activity increased n.a. n.a. n.a. Levametabol-I is responsible for anti-colon cancer activity n.a. PMID PMID: 36467581 PMDBI20016954 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD253 Deleobuvir Therapeutic Substance under investigation in clinical trial n.a. n.a. n.a. n.a. CD6168 n.a. unknown activity decreased n.a. n.a. n.a. Reductive metabolism to CD6168,The activity and bioavailability were decreased n.a. PMID PMID: 36467581 PMDBI20016956 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD307 Epacadostat Therapeutic Substance Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others. n.a. n.a. n.a. n.a. M11 n.a. unknown activity decreased n.a. n.a. n.a. Amidine metabolite of epacadostat (M11),the activity and bioavailability were decreased n.a. PMID PMID: 36467581 PMDBI20016960 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD560 Morphine "Therapeutic Substance; Herbal Substance" opioid agonist n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Hydrolysis of glucuronide,drug activity and toxicity increased n.a. PMID PMID: 36467581 PMDBI20016964 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD39 Amlodipine Therapeutic Substance antihypertensive n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Co-antibiotic increase metabolism,the activity and bioavailability of the drug increased n.a. PMID PMID: 36467581 PMDBI20016969 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD107 Berberine Herbal Substance antifungal infections and as antidiarrheal n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Gut microbes increase berberinebioavailability by converting it into anabsorbable form. n.a. PMID PMID: 36467581 PMDBI20016971 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD299 Ellagic acid "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Gut microbes increase ellagic acid's activity n.a. PMID PMID: 36467581 PMDBI20016972 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000048 Grape Seed Polyphenol Extract (GPSE) Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. unknown activation n.a. n.a. n.a. The intestinal microbiota convertsGSPE to active metabolite n.a. PMID PMID: 36467581 PMDBI20016974 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD627 Oxaliplatin Therapeutic Substance chemotherapy agent n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Gut microbes increase oxaliplatin's toxicity n.a. PMID PMID: 36467581 PMDBI20016975 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000049 Cycasin Therapeutic substance compound n.a. n.a. n.a. n.a. methylazoxymethano n.a. unknown toxicity n.a. n.a. n.a. Members of the gut microbiota hydrolyze cycasin into the carcinogenic derivative, methylazoxymethanol,Microbiome-inducedhydrolysis leading todirect toxic effect n.a. PMID PMID: 36467581 PMDBI20016976 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000050 2-methoxy esterone Therapeutic substance Anti-angiogenic n.a. n.a. n.a. n.a. n.a. n.a. unknown activation n.a. n.a. n.a. Oxidoreduction anddemethylation resultingin activation of prodrug n.a. PMID PMID: 36467581 PMDBI20016977 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000051 Chlorogenic acid Therapeutic Substance Antioxidant n.a. n.a. n.a. n.a. 3-hydroxycinnamic-acid-and3-(3-hydroxyphenyl)propionic-acid n.a. unknown activity increased n.a. n.a. n.a. Microbial metabolism resultingin potentiated clinical effect n.a. PMID PMID: 36467581 PMDBI20016978 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000052 Soy-derived phytoestrogens Therapeutic substance Xeno-estrogens n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity n.a. n.a. n.a. According to the type ofmicrobiota present, toxicity or lower action may result. n.a. PMID PMID: 36467581 PMDBI20016979 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000053 Heterocyclic aromaticamines (HAAs) Therapeutic substance Carcinogenic agents n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Enhancement of CYP450activity, deconjugation ofHAAs and consequentincreased mutagenicactivity n.a. PMID PMID: 36467581 PMDBI20016980 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016981 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016982 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20016984 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD1019 Aflatoxin B1 Environmental Chemicals Carcinogenic mycotoxins n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity n.a. n.a. n.a. Potentiated toxic effects n.a. PMID PMID: 36467581 PMDBI20016996 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD290 Doxorubicin "Therapeutic Substance; Herbal Substance" chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown side effect n.a. n.a. n.a. The enteric microbiota was found to play a major role in doxorubicin-induced mucositis. Targeting themicrobiota reduced damage. n.a. PMID PMID: 36467581 PMDBI20017003 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000054 7-ethyl-10-hydroxycamptothecin(SN-38) Therapeutic substance antineoplastic n.a. n.a. n.a. n.a. SN-38-glucuronide n.a. unknown toxicity decreased n.a. n.a. n.a. lower intestinal tract toxicity induced by NSAIDs n.a. PMID PMID: 36467581 PMDBI20017006 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000016 PD-1 inhibitors Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Gut microbes enhance the activity of PD-1 inhibitors n.a. PMID PMID: 36467581 PMDBI20017008 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD237 Cyclophosphamide Therapeutic Substance lymphoma and leukemia n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Enhancement of activity n.a. PMID PMID: 36467581 PMDBI20017010 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000055 NaringNnin Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. unknown inactivation n.a. n.a. n.a. Drug inactivation n.a. PMID PMID: 36467581 PMDBI20017012 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD588 Nifedipine "Therapeutic Substance; Herbal Substance" calcium channel blocker n.a. n.a. n.a. n.a. n.a. n.a. unknown inactivation n.a. n.a. n.a. Gut microbes metabolize metabolism, affecting its bioavailability and efficacy. n.a. PMID PMID: 36467581 PMDBI20017018 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD452 Ipilimumab Therapeutic Substance a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity decreased n.a. n.a. n.a. Decreased toxicity n.a. PMID PMID: 36467581 PMDBI20017033 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000056 Lovastatine Therapeutic Substance Hypolipidemics n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. altered pharmacokinetics n.a. PMID PMID: 36467581 PMDBI20017039 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD471 Lactulose Therapeutic Substance laxative n.a. n.a. n.a. n.a. n.a. n.a. unknown Beneficial bacteria increased n.a. n.a. n.a. stimulating the growth of beneficial bacteria n.a. PMID PMID: 36467581 PMDBI20017048 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD2000057 Cisplatin Therapeutic Substance Antitumor n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. The increase of reactive oxygen species produced by bone marrow cells can improve the anti-tumor activity of drugs n.a. PMID PMID: 36467581 PMDBI20017056 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD600 Nitroglycerin Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. "Glyceryl-1,3-dinitrate; glyceryl-1,2-dinitrate; glyceryl-1-mononitrate; glyceryl-2-mononitrate" n.a. unknown activity decreased n.a. n.a. n.a. Decreased activity n.a. PMID PMID: 36467581 PMDBI20017057 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD279 Dihydroxyphenylalanine (DOPA) Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. "m-tyramine; m-hydroxylphenylacetic acid" n.a. unknown activity increased n.a. n.a. n.a. Increased activity n.a. PMID PMID: 36467581 PMDBI20017059 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD9 7-ethyl-10-hydroxycamptothecin Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. "SN-38G;cyanuric acid" n.a. unknown toxicity increased n.a. n.a. n.a. Metabolites are harmful to the host n.a. PMID PMID: 36467581 PMDBI20017060 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD610 NSAIDs Therapeutic Substance compound n.a. n.a. n.a. n.a. "SN-38G; ;cyanuric acid" n.a. unknown toxicity increased n.a. n.a. n.a. Metabolites are harmful to the host n.a. PMID PMID: 36467581 PMDBI20017061 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD662 Phenoxyethanol Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. "SN-38G ;cyanuric acid" n.a. unknown toxicity increased n.a. n.a. n.a. Metabolites are harmful to the host n.a. PMID PMID: 36467581 PMDBI20017063 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD810 Sulfanilamide "Therapeutic Substance; Herbal Substance" anti-infective n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Contribute to therapeutic concentrations n.a. PMID PMID: 36467581 PMDBI20017068 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Cause mitochondrial and endo plasmic reticulum stress, compromise mucosal integrity and promote inflammation n.a. PMID PMID: 36467581 PMDBI20017078 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD245 Daidzin "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. daidzein,calycosin n.a. unknown activity increased n.a. n.a. n.a. Drug interaction:Antibiotic inhibits the metabolism of isoflavone glycosides n.a. PMID PMID: 36467581 PMDBI20017079 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD714 Puerarin "Therapeutic Substance; Herbal Substance" Herbal n.a. n.a. n.a. n.a. daidzein,calycosin n.a. unknown activity increased n.a. n.a. n.a. Drug interaction:Antibiotic inhibits the metabolism of isoflavone glycosides n.a. PMID PMID: 36467581 PMDBI20017082 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Affect the pharmacokinetics n.a. PMID PMID: 36467581 PMDBI20017088 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD776 Sennosides Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. rheinanthrone n.a. unknown activity increased n.a. n.a. n.a. "Product a purgative compound;drug interaction:antibioticsé—挎稑娼廻loramphenicol, streptomycin, and rifampiciné—挎稑鈥漬hibits the biotransformation" n.a. PMID PMID: 36467581 PMDBI20017092 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD430 Hippuric acid Environmental Chemicals Environmental Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Drug concentration in urine is reduced in either germ-free mice or in mice treated with antibiotics n.a. PMID PMID: 36467581 PMDBI20017099 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD90 Azo dyes Environmental Chemicals Environmental Substance n.a. n.a. n.a. n.a. mutagenic bis-aniline benzidine n.a. unknown toxicity increased n.a. n.a. n.a. Increase carcinogen exposure n.a. PMID PMID: 36467581 PMDBI20017100 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD540 Methylmercury Environmental Chemicals compound n.a. n.a. n.a. n.a. inorganic mercury n.a. unknown toxicity decreased n.a. n.a. n.a. Lead to less toxicity,facilitate mercury excretion n.a. PMID PMID: 36467581 PMDBI20017118 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD123 Brivudine Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. additional bromovinyluracil n.a. DYPD toxicity increased n.a. n.a. n.a. "Hepatotoxicity; bromovinyluracil prevents clearance of 5-FU" n.a. PMID PMID: 36467581 PMDBI20017124 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD453 Ipsalazide Therapeutic Substance unknown n.a. n.a. n.a. n.a. local 5-ASA n.a. unknown activity increased n.a. n.a. n.a. Prodrug activation: local 5-ASA release n.a. PMID PMID: 36467581 PMDBI20017127 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD668 Picosulfuric acid Therapeutic Substance compound n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Solubility increase n.a. PMID PMID: 36467581 PMDBI20017129 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD808 Sulfadiazine Therapeutic Substance antibiotic n.a. n.a. n.a. n.a. local 5-ASA n.a. unknown activity increased n.a. n.a. n.a. Prodrug activation: local 5-ASA release n.a. PMID PMID: 36467581 PMDBI20017131 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD36 Amiodarone Therapeutic Substance anti-arrhythmic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Increased bioavailability of active metabolite n.a. PMID PMID: 36467581 PMDBI20017132 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD221 Codeine "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Reformation of active metabolite n.a. PMID PMID: 36467581 PMDBI20017134 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD527 Metamfetamine Therapeutic Substance psychostimulant and sympathomimetic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Change to inactive metabolite n.a. PMID PMID: 36467581 PMDBI20017138 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD315 Estradiol "Therapeutic Substance; Herbal Substance" Herbal n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. "Greater absroption of estrogens;develop estrogen-driven cancer" n.a. PMID PMID: 36467581 PMDBI20017140 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD825 Taurine conjugated bile acid Environmental Chemicals Environmental Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Contribute to the etiology of cancer n.a. PMID PMID: 36467581 PMDBI20017141 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD30 Altretamine Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. "Cause diarrhea and kidney damage;interaction" n.a. PMID PMID: 36467581 PMDBI20017153 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD270 Dietary choline Dietary Substance Dietary Substance n.a. n.a. n.a. n.a. trimethylamine-N-oxide(TMAO) n.a. unknown toxicity increased n.a. n.a. n.a. Interfer with drug pharmacokinetics and pharmacodynamics n.a. PMID PMID: 36467581 PMDBI20017154 Microbes metabolize substances PMDBM2009024 n.a. Gut microbes PMDBD475 Levocarnitine "Therapeutic Substance; Herbal Substance" Herbal n.a. n.a. n.a. n.a. trimethylamine-N-oxide(TMAO) n.a. unknown toxicity increased n.a. n.a. n.a. Interfer with drug pharmacokinetics and pharmacodynamics n.a. PMID PMID: 36467581 PMDBI20017157 Microbes metabolize substances PMDBM2020754 735 Haemophilus A parahaemolyticus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017158 Microbes metabolize substances PMDBM2020754 735 Haemophilus A parahaemolyticus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017159 Microbes metabolize substances PMDBM2020754 735 Haemophilus A parahaemolyticus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017160 Microbes metabolize substances PMDBM2020754 735 Haemophilus A parahaemolyticus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017161 Microbes metabolize substances PMDBM2020754 735 Haemophilus A parahaemolyticus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017162 Microbes metabolize substances PMDBM2020754 735 Haemophilus A parahaemolyticus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017163 Microbes metabolize substances PMDBM2020754 735 Haemophilus A parahaemolyticus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017166 Microbes metabolize substances PMDBM2020754 735 Haemophilus A parahaemolyticus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017167 Microbes metabolize substances PMDBM2020754 735 Haemophilus A parahaemolyticus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017168 Microbes metabolize substances PMDBM2020754 735 Haemophilus A parahaemolyticus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017169 Microbes metabolize substances PMDBM2020754 735 Haemophilus A parahaemolyticus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017170 Microbes metabolize substances PMDBM2020754 735 Haemophilus A parahaemolyticus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017171 Microbes metabolize substances PMDBM2020754 735 Haemophilus A parahaemolyticus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017172 Microbes metabolize substances PMDBM2020754 735 Haemophilus A parahaemolyticus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017173 Microbes metabolize substances PMDBM2020754 735 Haemophilus A parahaemolyticus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017174 Microbes metabolize substances PMDBM2020755 736 Haemophilus A paraphrohaemolyticus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017175 Microbes metabolize substances PMDBM2020755 736 Haemophilus A paraphrohaemolyticus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017176 Microbes metabolize substances PMDBM2020755 736 Haemophilus A paraphrohaemolyticus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017177 Microbes metabolize substances PMDBM2020755 736 Haemophilus A paraphrohaemolyticus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017178 Microbes metabolize substances PMDBM2020755 736 Haemophilus A paraphrohaemolyticus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017179 Microbes metabolize substances PMDBM2020755 736 Haemophilus A paraphrohaemolyticus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017180 Microbes metabolize substances PMDBM2020755 736 Haemophilus A paraphrohaemolyticus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017183 Microbes metabolize substances PMDBM2020755 736 Haemophilus A paraphrohaemolyticus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017184 Microbes metabolize substances PMDBM2020755 736 Haemophilus A paraphrohaemolyticus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017185 Microbes metabolize substances PMDBM2020755 736 Haemophilus A paraphrohaemolyticus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017186 Microbes metabolize substances PMDBM2020755 736 Haemophilus A paraphrohaemolyticus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017187 Microbes metabolize substances PMDBM2020755 736 Haemophilus A paraphrohaemolyticus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017188 Microbes metabolize substances PMDBM2020755 736 Haemophilus A paraphrohaemolyticus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017189 Microbes metabolize substances PMDBM2020755 736 Haemophilus A paraphrohaemolyticus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017190 Microbes metabolize substances PMDBM2020755 736 Haemophilus A paraphrohaemolyticus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017191 Microbes metabolize substances PMDBM2020757 1078480 Haemophilus A sputorum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017192 Microbes metabolize substances PMDBM2020757 1078480 Haemophilus A sputorum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017193 Microbes metabolize substances PMDBM2020757 1078480 Haemophilus A sputorum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017194 Microbes metabolize substances PMDBM2020757 1078480 Haemophilus A sputorum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017195 Microbes metabolize substances PMDBM2020757 1078480 Haemophilus A sputorum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017196 Microbes metabolize substances PMDBM2020757 1078480 Haemophilus A sputorum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017197 Microbes metabolize substances PMDBM2020757 1078480 Haemophilus A sputorum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017200 Microbes metabolize substances PMDBM2020757 1078480 Haemophilus A sputorum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017201 Microbes metabolize substances PMDBM2020757 1078480 Haemophilus A sputorum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017202 Microbes metabolize substances PMDBM2020757 1078480 Haemophilus A sputorum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017203 Microbes metabolize substances PMDBM2020757 1078480 Haemophilus A sputorum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017204 Microbes metabolize substances PMDBM2020757 1078480 Haemophilus A sputorum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017205 Microbes metabolize substances PMDBM2020757 1078480 Haemophilus A sputorum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017206 Microbes metabolize substances PMDBM2020757 1078480 Haemophilus A sputorum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017207 Microbes metabolize substances PMDBM2009028 n.a. Haemophilus D PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017208 Microbes metabolize substances PMDBM2009028 n.a. Haemophilus D PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017209 Microbes metabolize substances PMDBM2009028 n.a. Haemophilus D PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017210 Microbes metabolize substances PMDBM2009028 n.a. Haemophilus D PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017211 Microbes metabolize substances PMDBM2009028 n.a. Haemophilus D PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017212 Microbes metabolize substances PMDBM2009028 n.a. Haemophilus D PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017213 Microbes metabolize substances PMDBM2009028 n.a. Haemophilus D PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017216 Microbes metabolize substances PMDBM2009028 n.a. Haemophilus D PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017217 Microbes metabolize substances PMDBM2009028 n.a. Haemophilus D PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017218 Microbes metabolize substances PMDBM2009028 n.a. Haemophilus D PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017219 Microbes metabolize substances PMDBM2009028 n.a. Haemophilus D PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017220 Microbes metabolize substances PMDBM2009028 n.a. Haemophilus D PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017221 Microbes metabolize substances PMDBM2009028 n.a. Haemophilus D PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017222 Microbes metabolize substances PMDBM2009028 n.a. Haemophilus D PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017223 Microbes metabolize substances PMDBM2009028 n.a. Haemophilus D PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017224 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017225 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017226 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017227 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017228 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017229 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017230 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017233 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017234 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017235 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017236 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017237 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017238 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017239 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017240 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017241 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae J PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017242 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae J PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017243 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae J PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017244 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae J PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017245 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae J PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017246 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae J PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017247 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae J PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017250 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae J PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017251 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae J PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017252 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae J PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017253 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae J PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017254 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae J PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017255 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae J PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017256 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae J PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017257 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae J PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017258 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae K PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017259 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae K PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017260 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae K PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017261 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae K PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017262 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae K PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017263 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae K PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017264 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae K PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017267 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae K PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017268 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae K PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017269 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae K PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017270 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae K PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017271 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae K PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017272 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae K PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017273 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae K PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017274 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae K PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017275 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae L PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017276 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae L PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017277 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae L PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017278 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae L PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017279 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae L PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017280 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae L PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017281 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae L PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017284 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae L PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017285 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae L PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017286 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae L PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017287 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae L PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017288 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae L PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017289 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae L PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017290 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae L PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017291 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae L PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017292 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae M PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017293 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae M PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017294 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae M PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017295 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae M PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017296 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae M PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017297 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae M PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017298 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae M PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017301 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae M PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017302 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae M PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017303 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae M PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017304 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae M PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017305 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae M PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017306 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae M PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017307 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae M PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017308 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae M PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017309 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae N PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017310 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae N PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017311 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae N PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017312 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae N PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017313 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae N PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017314 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae N PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017315 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae N PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017318 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae N PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017319 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae N PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017320 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae N PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017321 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae N PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017322 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae N PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017323 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae N PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017324 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae N PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017325 Microbes metabolize substances PMDBM2020126 729 Haemophilus D parainfluenzae N PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017326 Microbes metabolize substances PMDBM2020756 249188 Haemophilus D pittmaniae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017327 Microbes metabolize substances PMDBM2020756 249188 Haemophilus D pittmaniae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017328 Microbes metabolize substances PMDBM2020756 249188 Haemophilus D pittmaniae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017329 Microbes metabolize substances PMDBM2020756 249188 Haemophilus D pittmaniae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017330 Microbes metabolize substances PMDBM2020756 249188 Haemophilus D pittmaniae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017331 Microbes metabolize substances PMDBM2020756 249188 Haemophilus D pittmaniae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017332 Microbes metabolize substances PMDBM2020756 249188 Haemophilus D pittmaniae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017335 Microbes metabolize substances PMDBM2020756 249188 Haemophilus D pittmaniae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017336 Microbes metabolize substances PMDBM2020756 249188 Haemophilus D pittmaniae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017337 Microbes metabolize substances PMDBM2020756 249188 Haemophilus D pittmaniae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017338 Microbes metabolize substances PMDBM2020756 249188 Haemophilus D pittmaniae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017339 Microbes metabolize substances PMDBM2020756 249188 Haemophilus D pittmaniae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017340 Microbes metabolize substances PMDBM2020756 249188 Haemophilus D pittmaniae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017341 Microbes metabolize substances PMDBM2020756 249188 Haemophilus D pittmaniae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017342 Microbes metabolize substances PMDBM2021552 67859 Haemophilus influenzae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017343 Microbes metabolize substances PMDBM2021552 67859 Haemophilus influenzae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017344 Microbes metabolize substances PMDBM2021552 67859 Haemophilus influenzae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017345 Microbes metabolize substances PMDBM2021552 67859 Haemophilus influenzae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017346 Microbes metabolize substances PMDBM2021552 67859 Haemophilus influenzae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017347 Microbes metabolize substances PMDBM2021552 67859 Haemophilus influenzae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017348 Microbes metabolize substances PMDBM2021552 67859 Haemophilus influenzae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017351 Microbes metabolize substances PMDBM2021552 67859 Haemophilus influenzae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20017352 Microbes metabolize substances PMDBM2021552 67859 Haemophilus influenzae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017353 Microbes metabolize substances PMDBM2021552 67859 Haemophilus influenzae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017354 Microbes metabolize substances PMDBM2021552 67859 Haemophilus influenzae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017355 Microbes metabolize substances PMDBM2021552 67859 Haemophilus influenzae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017356 Microbes metabolize substances PMDBM2021552 67859 Haemophilus influenzae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017357 Microbes metabolize substances PMDBM2021552 67859 Haemophilus influenzae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017358 Microbes metabolize substances PMDBM2021552 67859 Haemophilus influenzae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017359 Microbes metabolize substances PMDBM2021553 740 Haemophilus sp002998595 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017360 Microbes metabolize substances PMDBM2021553 740 Haemophilus sp002998595 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017361 Microbes metabolize substances PMDBM2021553 740 Haemophilus sp002998595 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017362 Microbes metabolize substances PMDBM2021553 740 Haemophilus sp002998595 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017363 Microbes metabolize substances PMDBM2021553 740 Haemophilus sp002998595 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017364 Microbes metabolize substances PMDBM2021553 740 Haemophilus sp002998595 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017365 Microbes metabolize substances PMDBM2021553 740 Haemophilus sp002998595 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017368 Microbes metabolize substances PMDBM2021553 740 Haemophilus sp002998595 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017369 Microbes metabolize substances PMDBM2021553 740 Haemophilus sp002998595 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017370 Microbes metabolize substances PMDBM2021553 740 Haemophilus sp002998595 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017371 Microbes metabolize substances PMDBM2021553 740 Haemophilus sp002998595 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017372 Microbes metabolize substances PMDBM2021553 740 Haemophilus sp002998595 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017373 Microbes metabolize substances PMDBM2021553 740 Haemophilus sp002998595 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017374 Microbes metabolize substances PMDBM2021553 740 Haemophilus sp002998595 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017375 Microbes metabolize substances PMDBM2021553 740 Haemophilus sp002998595 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017376 Microbes metabolize substances PMDBM2020758 569 Hafnia alvei PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017377 Microbes metabolize substances PMDBM2020758 569 Hafnia alvei PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017378 Microbes metabolize substances PMDBM2020758 569 Hafnia alvei PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017379 Microbes metabolize substances PMDBM2020758 569 Hafnia alvei PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017380 Microbes metabolize substances PMDBM2020758 569 Hafnia alvei PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017381 Microbes metabolize substances PMDBM2020758 569 Hafnia alvei PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017382 Microbes metabolize substances PMDBM2020758 569 Hafnia alvei PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017385 Microbes metabolize substances PMDBM2020758 569 Hafnia alvei PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017386 Microbes metabolize substances PMDBM2020758 569 Hafnia alvei PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017387 Microbes metabolize substances PMDBM2020758 569 Hafnia alvei PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017388 Microbes metabolize substances PMDBM2020758 569 Hafnia alvei PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017389 Microbes metabolize substances PMDBM2020758 569 Hafnia alvei PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017390 Microbes metabolize substances PMDBM2020758 569 Hafnia alvei PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017391 Microbes metabolize substances PMDBM2020758 569 Hafnia alvei PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017392 Microbes metabolize substances PMDBM2020758 569 Hafnia alvei PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017393 Microbes metabolize substances PMDBM2020759 546367 Hafnia paralvei PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017394 Microbes metabolize substances PMDBM2020759 546367 Hafnia paralvei PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017395 Microbes metabolize substances PMDBM2020759 546367 Hafnia paralvei PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017396 Microbes metabolize substances PMDBM2020759 546367 Hafnia paralvei PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20017397 Microbes metabolize substances PMDBM2020759 546367 Hafnia paralvei PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017398 Microbes metabolize substances PMDBM2020759 546367 Hafnia paralvei PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017399 Microbes metabolize substances PMDBM2020759 546367 Hafnia paralvei PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017400 Microbes metabolize substances PMDBM2020759 546367 Hafnia paralvei PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017403 Microbes metabolize substances PMDBM2020759 546367 Hafnia paralvei PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017404 Microbes metabolize substances PMDBM2020759 546367 Hafnia paralvei PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017405 Microbes metabolize substances PMDBM2020759 546367 Hafnia paralvei PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017406 Microbes metabolize substances PMDBM2020759 546367 Hafnia paralvei PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017407 Microbes metabolize substances PMDBM2020759 546367 Hafnia paralvei PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017408 Microbes metabolize substances PMDBM2020759 546367 Hafnia paralvei PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017409 Microbes metabolize substances PMDBM2020759 546367 Hafnia paralvei PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017410 Microbes metabolize substances PMDBM2020759 546367 Hafnia paralvei PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017411 Microbes metabolize substances PMDBM2021554 1476858 Haloferax massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017412 Microbes metabolize substances PMDBM2021554 1476858 Haloferax massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017413 Microbes metabolize substances PMDBM2021554 1476858 Haloferax massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017414 Microbes metabolize substances PMDBM2021554 1476858 Haloferax massiliensis PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20017415 Microbes metabolize substances PMDBM2021554 1476858 Haloferax massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017416 Microbes metabolize substances PMDBM2021554 1476858 Haloferax massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017417 Microbes metabolize substances PMDBM2021554 1476858 Haloferax massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017418 Microbes metabolize substances PMDBM2021554 1476858 Haloferax massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017421 Microbes metabolize substances PMDBM2021554 1476858 Haloferax massiliensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20017422 Microbes metabolize substances PMDBM2021554 1476858 Haloferax massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017423 Microbes metabolize substances PMDBM2021554 1476858 Haloferax massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017424 Microbes metabolize substances PMDBM2021554 1476858 Haloferax massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017425 Microbes metabolize substances PMDBM2021554 1476858 Haloferax massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017426 Microbes metabolize substances PMDBM2021554 1476858 Haloferax massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017427 Microbes metabolize substances PMDBM2021555 368624 Halorubrum lipolyticum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017428 Microbes metabolize substances PMDBM2021555 368624 Halorubrum lipolyticum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017429 Microbes metabolize substances PMDBM2021555 368624 Halorubrum lipolyticum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017430 Microbes metabolize substances PMDBM2021555 368624 Halorubrum lipolyticum PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20017431 Microbes metabolize substances PMDBM2021555 368624 Halorubrum lipolyticum PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017433 Microbes metabolize substances PMDBM2021555 368624 Halorubrum lipolyticum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017435 Microbes metabolize substances PMDBM2021555 368624 Halorubrum lipolyticum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017436 Microbes metabolize substances PMDBM2021555 368624 Halorubrum lipolyticum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017437 Microbes metabolize substances PMDBM2021555 368624 Halorubrum lipolyticum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017438 Microbes metabolize substances PMDBM2021555 368624 Halorubrum lipolyticum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017441 Microbes metabolize substances PMDBM2021555 368624 Halorubrum lipolyticum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017442 Microbes metabolize substances PMDBM2021555 368624 Halorubrum lipolyticum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017443 Microbes metabolize substances PMDBM2021555 368624 Halorubrum lipolyticum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017445 Microbes metabolize substances PMDBM2021555 368624 Halorubrum lipolyticum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017446 Microbes metabolize substances PMDBM2009042 n.a. Helcococcaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017447 Microbes metabolize substances PMDBM2009042 n.a. Helcococcaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017448 Microbes metabolize substances PMDBM2009042 n.a. Helcococcaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017449 Microbes metabolize substances PMDBM2009042 n.a. Helcococcaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017450 Microbes metabolize substances PMDBM2020226 210 Helicobacter pylori PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. m-hydroxyphenylacetic n.a. Amino acid ddecarboxylase activity decreased n.a. n.a. n.a. Dehydroxylation, absorption decrease, metabolism increase n.a. PMID PMID: 36467581 PMDBI20017452 Microbes metabolize substances PMDBM2020226 210 Helicobacter pylori BU PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017453 Microbes metabolize substances PMDBM2020226 210 Helicobacter pylori BU PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017454 Microbes metabolize substances PMDBM2020226 210 Helicobacter pylori BU PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017455 Microbes metabolize substances PMDBM2020226 210 Helicobacter pylori BU PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017456 Microbes metabolize substances PMDBM2020226 210 Helicobacter pylori C PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017457 Microbes metabolize substances PMDBM2020226 210 Helicobacter pylori C PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017458 Microbes metabolize substances PMDBM2020226 210 Helicobacter pylori C PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017459 Microbes metabolize substances PMDBM2020226 210 Helicobacter pylori C PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017460 Microbes metabolize substances PMDBM2021556 95150 Helicobacter A rappini PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017461 Microbes metabolize substances PMDBM2021556 95150 Helicobacter A rappini PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017462 Microbes metabolize substances PMDBM2021556 95150 Helicobacter A rappini PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017463 Microbes metabolize substances PMDBM2021556 95150 Helicobacter A rappini PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017464 Microbes metabolize substances PMDBM794 72293 Helicobacteraceae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017465 Microbes metabolize substances PMDBM794 72293 Helicobacteraceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017466 Microbes metabolize substances PMDBM794 72293 Helicobacteraceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017467 Microbes metabolize substances PMDBM794 72293 Helicobacteraceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017468 Microbes metabolize substances PMDBM794 72293 Helicobacteraceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017469 Microbes metabolize substances PMDBM794 72293 Helicobacteraceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017470 Microbes metabolize substances PMDBM2021557 218 Helicobacter B sp001854545 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017471 Microbes metabolize substances PMDBM2021557 218 Helicobacter B sp001854545 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017472 Microbes metabolize substances PMDBM2021557 218 Helicobacter B sp001854545 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017473 Microbes metabolize substances PMDBM2021557 218 Helicobacter B sp001854545 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017474 Microbes metabolize substances PMDBM2021557 218 Helicobacter B sp001854545 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017475 Microbes metabolize substances PMDBM2020764 213 Helicobacter C cinaedi PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017476 Microbes metabolize substances PMDBM2009048 n.a. Helicobacter D PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017477 Microbes metabolize substances PMDBM2021557 218 Helicobacter F sp002287135 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017478 Microbes metabolize substances PMDBM2021557 218 Helicobacter F sp002287135 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017479 Microbes metabolize substances PMDBM2021557 218 Helicobacter F sp002287135 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017480 Microbes metabolize substances PMDBM2021557 218 Helicobacter F sp002287135 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017481 Microbes metabolize substances PMDBM797 1573535 Holdemanella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017482 Microbes metabolize substances PMDBM797 1573535 Holdemanella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017483 Microbes metabolize substances PMDBM797 1573535 Holdemanella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017484 Microbes metabolize substances PMDBM797 1573535 Holdemanella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017485 Microbes metabolize substances PMDBM797 1573535 Holdemanella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017486 Microbes metabolize substances PMDBM797 1573535 Holdemanella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017487 Microbes metabolize substances PMDBM797 1573535 Holdemanella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017490 Microbes metabolize substances PMDBM797 1573535 Holdemanella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017491 Microbes metabolize substances PMDBM797 1573535 Holdemanella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017492 Microbes metabolize substances PMDBM797 1573535 Holdemanella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017493 Microbes metabolize substances PMDBM797 1573535 Holdemanella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017494 Microbes metabolize substances PMDBM797 1573535 Holdemanella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017495 Microbes metabolize substances PMDBM797 1573535 Holdemanella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017496 Microbes metabolize substances PMDBM797 1573535 Holdemanella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017497 Microbes metabolize substances PMDBM797 1573535 Holdemanella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017498 Microbes metabolize substances PMDBM2021391 1735 Holdemanella biformis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017499 Microbes metabolize substances PMDBM2021391 1735 Holdemanella biformis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017500 Microbes metabolize substances PMDBM2021391 1735 Holdemanella biformis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017501 Microbes metabolize substances PMDBM2021391 1735 Holdemanella biformis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017502 Microbes metabolize substances PMDBM2021558 1971762 Holdemanella sp002299315 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017503 Microbes metabolize substances PMDBM2021558 1971762 Holdemanella sp002299315 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20017504 Microbes metabolize substances PMDBM2021558 1971762 Holdemanella sp002299315 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017505 Microbes metabolize substances PMDBM2021558 1971762 Holdemanella sp002299315 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017506 Microbes metabolize substances PMDBM2021558 1971762 Holdemanella sp002299315 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017507 Microbes metabolize substances PMDBM2021558 1971762 Holdemanella sp002299315 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017508 Microbes metabolize substances PMDBM2021558 1971762 Holdemanella sp002299315 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017509 Microbes metabolize substances PMDBM2021558 1971762 Holdemanella sp002299315 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017512 Microbes metabolize substances PMDBM2021558 1971762 Holdemanella sp002299315 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017513 Microbes metabolize substances PMDBM2021558 1971762 Holdemanella sp002299315 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017514 Microbes metabolize substances PMDBM2021558 1971762 Holdemanella sp002299315 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017515 Microbes metabolize substances PMDBM2021558 1971762 Holdemanella sp002299315 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017516 Microbes metabolize substances PMDBM2021558 1971762 Holdemanella sp002299315 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017517 Microbes metabolize substances PMDBM2021558 1971762 Holdemanella sp002299315 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017518 Microbes metabolize substances PMDBM2021558 1971762 Holdemanella sp002299315 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017519 Microbes metabolize substances PMDBM798 61170 Holdemania PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. Compound K n.a. unknown activity increased n.a. n.a. n.a. Drug interaction:antibiotics inhibits the metabolism n.a. PMID PMID: 36467581 PMDBI20017520 Microbes metabolize substances PMDBM2020773 61171 Holdemania filiformis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20017521 Microbes metabolize substances PMDBM2020773 61171 Holdemania filiformis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017522 Microbes metabolize substances PMDBM2020773 61171 Holdemania filiformis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017523 Microbes metabolize substances PMDBM2020773 61171 Holdemania filiformis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017524 Microbes metabolize substances PMDBM2020773 61171 Holdemania filiformis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017525 Microbes metabolize substances PMDBM2020773 61171 Holdemania filiformis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017526 Microbes metabolize substances PMDBM2020773 61171 Holdemania filiformis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017527 Microbes metabolize substances PMDBM2020773 61171 Holdemania filiformis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017528 Microbes metabolize substances PMDBM2020773 61171 Holdemania filiformis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017529 Microbes metabolize substances PMDBM2020773 61171 Holdemania filiformis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017530 Microbes metabolize substances PMDBM2020774 1468449 Holdemania massiliensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017531 Microbes metabolize substances PMDBM2020774 1468449 Holdemania massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017532 Microbes metabolize substances PMDBM2020774 1468449 Holdemania massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017533 Microbes metabolize substances PMDBM2020774 1468449 Holdemania massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017534 Microbes metabolize substances PMDBM2020774 1468449 Holdemania massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017535 Microbes metabolize substances PMDBM2020774 1468449 Holdemania massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017536 Microbes metabolize substances PMDBM2020774 1468449 Holdemania massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017537 Microbes metabolize substances PMDBM2020774 1468449 Holdemania massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017538 Microbes metabolize substances PMDBM2020774 1468449 Holdemania massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017539 Microbes metabolize substances PMDBM2020060 2049029 Holdemania sp900120005 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017540 Microbes metabolize substances PMDBM2020060 2049029 Holdemania sp900120005 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017541 Microbes metabolize substances PMDBM2020060 2049029 Holdemania sp900120005 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017542 Microbes metabolize substances PMDBM2020060 2049029 Holdemania sp900120005 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017543 Microbes metabolize substances PMDBM2020060 2049029 Holdemania sp900120005 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017544 Microbes metabolize substances PMDBM2020060 2049029 Holdemania sp900120005 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017545 Microbes metabolize substances PMDBM2020060 2049029 Holdemania sp900120005 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017546 Microbes metabolize substances PMDBM2020060 2049029 Holdemania sp900120005 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017547 Microbes metabolize substances PMDBM2020060 2049029 Holdemania sp900120005 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017548 Microbes metabolize substances PMDBM2009055 n.a. f Ruminococcaceae g HUN007 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017549 Microbes metabolize substances PMDBM2009055 n.a. f Ruminococcaceae g HUN007 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017550 Microbes metabolize substances PMDBM2009055 n.a. f Ruminococcaceae g HUN007 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017551 Microbes metabolize substances PMDBM2009055 n.a. f Ruminococcaceae g HUN007 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017552 Microbes metabolize substances PMDBM2009055 n.a. f Ruminococcaceae g HUN007 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017553 Microbes metabolize substances PMDBM2009055 n.a. f Ruminococcaceae g HUN007 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017554 Microbes metabolize substances PMDBM2009055 n.a. f Ruminococcaceae g HUN007 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017557 Microbes metabolize substances PMDBM2009055 n.a. f Ruminococcaceae g HUN007 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017558 Microbes metabolize substances PMDBM2009055 n.a. f Ruminococcaceae g HUN007 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017559 Microbes metabolize substances PMDBM2009055 n.a. f Ruminococcaceae g HUN007 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017560 Microbes metabolize substances PMDBM2009055 n.a. f Ruminococcaceae g HUN007 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017561 Microbes metabolize substances PMDBM2009055 n.a. f Ruminococcaceae g HUN007 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017562 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017563 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017564 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017565 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017567 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017569 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20017570 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017571 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017572 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017573 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20017574 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20017575 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017577 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20017580 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20017581 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20017582 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20017583 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20017584 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017585 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017588 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20017591 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017592 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017595 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017596 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017597 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017598 Microbes metabolize substances PMDBM2009056 1649459 Hungatella PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20017599 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017600 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20017601 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017602 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017603 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017605 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017607 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017608 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017609 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017610 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20017611 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20017612 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017614 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20017617 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20017618 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20017619 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20017620 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017621 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017624 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20017627 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017628 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017631 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017632 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017633 Microbes metabolize substances PMDBM2021559 1096246 Hungatella effluvii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017634 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017635 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20017636 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017637 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017638 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017640 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017642 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20017643 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017644 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017645 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017646 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20017647 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20017648 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017650 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20017653 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20017654 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20017655 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20017656 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017657 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017660 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20017663 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017664 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017667 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017668 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017669 Microbes metabolize substances PMDBM2021560 154046 Hungatella hathewayi PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017670 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017671 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017672 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017673 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017674 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017675 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017676 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20017677 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20017678 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017680 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20017683 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20017684 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20017685 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20017686 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017687 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017690 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20017693 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017694 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017695 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017697 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017698 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017699 Microbes metabolize substances PMDBM2021561 2613924 Hungatella sp000526575 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017700 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017701 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017702 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017703 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017705 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017707 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20017708 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017709 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017710 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017711 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20017712 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20017713 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017715 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20017718 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20017719 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20017720 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017721 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017724 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20017727 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017728 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017731 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017732 Microbes metabolize substances PMDBM2009060 n.a. Hungatella A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017733 Microbes metabolize substances PMDBM2021560 154046 Hungatella A hathewayi PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017734 Microbes metabolize substances PMDBM2021560 154046 Hungatella A hathewayi PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017735 Microbes metabolize substances PMDBM2021560 154046 Hungatella A hathewayi PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017736 Microbes metabolize substances PMDBM2021560 154046 Hungatella A hathewayi PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017738 Microbes metabolize substances PMDBM2021560 154046 Hungatella A hathewayi PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017740 Microbes metabolize substances PMDBM2021560 154046 Hungatella A hathewayi PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017741 Microbes metabolize substances PMDBM2021560 154046 Hungatella A hathewayi PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017742 Microbes metabolize substances PMDBM2021560 154046 Hungatella A hathewayi PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017743 Microbes metabolize substances PMDBM2021560 154046 Hungatella A hathewayi PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017746 Microbes metabolize substances PMDBM2021560 154046 Hungatella A hathewayi PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017747 Microbes metabolize substances PMDBM2021560 154046 Hungatella A hathewayi PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017748 Microbes metabolize substances PMDBM2021560 154046 Hungatella A hathewayi PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017749 Microbes metabolize substances PMDBM2021560 154046 Hungatella A hathewayi PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017751 Microbes metabolize substances PMDBM2021560 154046 Hungatella A hathewayi PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017752 Microbes metabolize substances PMDBM2021560 154046 Hungatella A hathewayi PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017753 Microbes metabolize substances PMDBM2021560 154046 Hungatella A hathewayi PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017754 Microbes metabolize substances PMDBM2009062 596767 Hydrogenoanaerobacterium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017755 Microbes metabolize substances PMDBM2009062 596767 Hydrogenoanaerobacterium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017756 Microbes metabolize substances PMDBM2009062 596767 Hydrogenoanaerobacterium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017757 Microbes metabolize substances PMDBM2009062 596767 Hydrogenoanaerobacterium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017758 Microbes metabolize substances PMDBM802 1505657 Intestinibacter PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017759 Microbes metabolize substances PMDBM802 1505657 Intestinibacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017760 Microbes metabolize substances PMDBM802 1505657 Intestinibacter PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20017761 Microbes metabolize substances PMDBM802 1505657 Intestinibacter PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017762 Microbes metabolize substances PMDBM802 1505657 Intestinibacter PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017763 Microbes metabolize substances PMDBM2020776 261299 Intestinibacter bartlettii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017764 Microbes metabolize substances PMDBM2020776 261299 Intestinibacter bartlettii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017765 Microbes metabolize substances PMDBM2020776 261299 Intestinibacter bartlettii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017766 Microbes metabolize substances PMDBM2020776 261299 Intestinibacter bartlettii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017767 Microbes metabolize substances PMDBM2020776 261299 Intestinibacter bartlettii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017768 Microbes metabolize substances PMDBM2020776 261299 Intestinibacter bartlettii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017769 Microbes metabolize substances PMDBM2020776 261299 Intestinibacter bartlettii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017772 Microbes metabolize substances PMDBM2020776 261299 Intestinibacter bartlettii PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20017773 Microbes metabolize substances PMDBM2020776 261299 Intestinibacter bartlettii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017774 Microbes metabolize substances PMDBM2020776 261299 Intestinibacter bartlettii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017775 Microbes metabolize substances PMDBM2020776 261299 Intestinibacter bartlettii PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20017776 Microbes metabolize substances PMDBM2020776 261299 Intestinibacter bartlettii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017777 Microbes metabolize substances PMDBM2020776 261299 Intestinibacter bartlettii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017778 Microbes metabolize substances PMDBM2020776 261299 Intestinibacter bartlettii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017779 Microbes metabolize substances PMDBM2020776 261299 Intestinibacter bartlettii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017780 Microbes metabolize substances PMDBM2020776 261299 Intestinibacter bartlettii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017781 Microbes metabolize substances PMDBM803 1392389 Intestinimonas PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017782 Microbes metabolize substances PMDBM803 1392389 Intestinimonas PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017783 Microbes metabolize substances PMDBM803 1392389 Intestinimonas PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017784 Microbes metabolize substances PMDBM803 1392389 Intestinimonas PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017786 Microbes metabolize substances PMDBM803 1392389 Intestinimonas PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017788 Microbes metabolize substances PMDBM803 1392389 Intestinimonas PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017789 Microbes metabolize substances PMDBM803 1392389 Intestinimonas PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017790 Microbes metabolize substances PMDBM803 1392389 Intestinimonas PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017791 Microbes metabolize substances PMDBM803 1392389 Intestinimonas PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017794 Microbes metabolize substances PMDBM803 1392389 Intestinimonas PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20017795 Microbes metabolize substances PMDBM803 1392389 Intestinimonas PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017796 Microbes metabolize substances PMDBM803 1392389 Intestinimonas PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017797 Microbes metabolize substances PMDBM803 1392389 Intestinimonas PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017798 Microbes metabolize substances PMDBM803 1392389 Intestinimonas PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017800 Microbes metabolize substances PMDBM803 1392389 Intestinimonas PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017801 Microbes metabolize substances PMDBM803 1392389 Intestinimonas PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017802 Microbes metabolize substances PMDBM803 1392389 Intestinimonas PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017803 Microbes metabolize substances PMDBM2020777 1297617 Intestinimonas butyriciproducens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017804 Microbes metabolize substances PMDBM2020777 1297617 Intestinimonas butyriciproducens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017805 Microbes metabolize substances PMDBM2020777 1297617 Intestinimonas butyriciproducens PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017806 Microbes metabolize substances PMDBM2020777 1297617 Intestinimonas butyriciproducens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017807 Microbes metabolize substances PMDBM2020777 1297617 Intestinimonas butyriciproducens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017808 Microbes metabolize substances PMDBM2021562 1673721 Intestinimonas massiliensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20017809 Microbes metabolize substances PMDBM2021562 1673721 Intestinimonas massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017810 Microbes metabolize substances PMDBM2021562 1673721 Intestinimonas massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017811 Microbes metabolize substances PMDBM2021562 1673721 Intestinimonas massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017812 Microbes metabolize substances PMDBM2021562 1673721 Intestinimonas massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017813 Microbes metabolize substances PMDBM2021562 1673721 Intestinimonas massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017814 Microbes metabolize substances PMDBM2020780 428712 Jonquetella anthropi PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017815 Microbes metabolize substances PMDBM2020780 428712 Jonquetella anthropi PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017816 Microbes metabolize substances PMDBM2020780 428712 Jonquetella anthropi PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017817 Microbes metabolize substances PMDBM2020780 428712 Jonquetella anthropi PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017818 Microbes metabolize substances PMDBM2009067 n.a. f Muribaculaceae g K10 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017819 Microbes metabolize substances PMDBM2009067 n.a. f Muribaculaceae g K10 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017820 Microbes metabolize substances PMDBM2009067 n.a. f Muribaculaceae g K10 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017821 Microbes metabolize substances PMDBM2009067 n.a. f Muribaculaceae g K10 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017822 Microbes metabolize substances PMDBM2009067 n.a. f Muribaculaceae g K10 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017823 Microbes metabolize substances PMDBM2009067 n.a. f Muribaculaceae g K10 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017824 Microbes metabolize substances PMDBM2009067 n.a. f Muribaculaceae g K10 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017827 Microbes metabolize substances PMDBM2009067 n.a. f Muribaculaceae g K10 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20017828 Microbes metabolize substances PMDBM2009067 n.a. f Muribaculaceae g K10 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017829 Microbes metabolize substances PMDBM2009067 n.a. f Muribaculaceae g K10 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017830 Microbes metabolize substances PMDBM2009067 n.a. f Muribaculaceae g K10 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017831 Microbes metabolize substances PMDBM2009067 n.a. f Muribaculaceae g K10 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017832 Microbes metabolize substances PMDBM2009067 n.a. f Muribaculaceae g K10 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017833 Microbes metabolize substances PMDBM2009067 n.a. f Muribaculaceae g K10 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017834 Microbes metabolize substances PMDBM2009067 n.a. f Muribaculaceae g K10 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017835 Microbes metabolize substances PMDBM2009067 n.a. f Muribaculaceae g K10 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017836 Microbes metabolize substances PMDBM2009068 n.a. f Muribaculaceae g K10 s K10 sp001689515 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017837 Microbes metabolize substances PMDBM2009068 n.a. f Muribaculaceae g K10 s K10 sp001689515 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017838 Microbes metabolize substances PMDBM2009068 n.a. f Muribaculaceae g K10 s K10 sp001689515 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017839 Microbes metabolize substances PMDBM2009068 n.a. f Muribaculaceae g K10 s K10 sp001689515 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017840 Microbes metabolize substances PMDBM2009068 n.a. f Muribaculaceae g K10 s K10 sp001689515 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017841 Microbes metabolize substances PMDBM2009069 n.a. f Muribaculaceae g K10 s K10 sp001941205 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017842 Microbes metabolize substances PMDBM2009069 n.a. f Muribaculaceae g K10 s K10 sp001941205 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017843 Microbes metabolize substances PMDBM2009069 n.a. f Muribaculaceae g K10 s K10 sp001941205 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017844 Microbes metabolize substances PMDBM2009069 n.a. f Muribaculaceae g K10 s K10 sp001941205 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017845 Microbes metabolize substances PMDBM2009069 n.a. f Muribaculaceae g K10 s K10 sp001941205 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017846 Microbes metabolize substances PMDBM2009069 n.a. f Muribaculaceae g K10 s K10 sp001941205 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017847 Microbes metabolize substances PMDBM2009069 n.a. f Muribaculaceae g K10 s K10 sp001941205 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017850 Microbes metabolize substances PMDBM2009069 n.a. f Muribaculaceae g K10 s K10 sp001941205 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017851 Microbes metabolize substances PMDBM2009069 n.a. f Muribaculaceae g K10 s K10 sp001941205 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017852 Microbes metabolize substances PMDBM2009069 n.a. f Muribaculaceae g K10 s K10 sp001941205 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017853 Microbes metabolize substances PMDBM2009069 n.a. f Muribaculaceae g K10 s K10 sp001941205 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017854 Microbes metabolize substances PMDBM2009069 n.a. f Muribaculaceae g K10 s K10 sp001941205 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017855 Microbes metabolize substances PMDBM2009069 n.a. f Muribaculaceae g K10 s K10 sp001941205 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017856 Microbes metabolize substances PMDBM2009069 n.a. f Muribaculaceae g K10 s K10 sp001941205 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017857 Microbes metabolize substances PMDBM2009069 n.a. f Muribaculaceae g K10 s K10 sp001941205 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017858 Microbes metabolize substances PMDBM2009070 n.a. f Peptoniphilaceae g KA00134 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017859 Microbes metabolize substances PMDBM2009070 n.a. f Peptoniphilaceae g KA00134 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017860 Microbes metabolize substances PMDBM2009070 n.a. f Peptoniphilaceae g KA00134 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017861 Microbes metabolize substances PMDBM2009071 n.a. f Fastidiosipilaceae g KA00274 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20017862 Microbes metabolize substances PMDBM2009071 n.a. f Fastidiosipilaceae g KA00274 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017863 Microbes metabolize substances PMDBM2009071 n.a. f Fastidiosipilaceae g KA00274 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017864 Microbes metabolize substances PMDBM2009071 n.a. f Fastidiosipilaceae g KA00274 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017865 Microbes metabolize substances PMDBM2009071 n.a. f Fastidiosipilaceae g KA00274 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017866 Microbes metabolize substances PMDBM2009071 n.a. f Fastidiosipilaceae g KA00274 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017867 Microbes metabolize substances PMDBM2009072 1472763 Kallipyga PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017868 Microbes metabolize substances PMDBM2009072 1472763 Kallipyga PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017869 Microbes metabolize substances PMDBM2009072 1472763 Kallipyga PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017870 Microbes metabolize substances PMDBM2009072 1472763 Kallipyga PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017871 Microbes metabolize substances PMDBM2009072 1472763 Kallipyga PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017872 Microbes metabolize substances PMDBM2009072 1472763 Kallipyga PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017873 Microbes metabolize substances PMDBM2009072 1472763 Kallipyga PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017876 Microbes metabolize substances PMDBM2009072 1472763 Kallipyga PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017877 Microbes metabolize substances PMDBM2009072 1472763 Kallipyga PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017878 Microbes metabolize substances PMDBM2009072 1472763 Kallipyga PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017879 Microbes metabolize substances PMDBM2009072 1472763 Kallipyga PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017880 Microbes metabolize substances PMDBM2009072 1472763 Kallipyga PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017881 Microbes metabolize substances PMDBM2009072 1472763 Kallipyga PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017882 Microbes metabolize substances PMDBM2009072 1472763 Kallipyga PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017883 Microbes metabolize substances PMDBM2020781 1686287 Kallipyga gabonensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017884 Microbes metabolize substances PMDBM2020781 1686287 Kallipyga gabonensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017885 Microbes metabolize substances PMDBM2020781 1686287 Kallipyga gabonensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017886 Microbes metabolize substances PMDBM2020781 1686287 Kallipyga gabonensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017887 Microbes metabolize substances PMDBM2020781 1686287 Kallipyga gabonensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017888 Microbes metabolize substances PMDBM2020781 1686287 Kallipyga gabonensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017889 Microbes metabolize substances PMDBM2020781 1686287 Kallipyga gabonensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017892 Microbes metabolize substances PMDBM2020781 1686287 Kallipyga gabonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017893 Microbes metabolize substances PMDBM2020781 1686287 Kallipyga gabonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017894 Microbes metabolize substances PMDBM2020781 1686287 Kallipyga gabonensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017895 Microbes metabolize substances PMDBM2020781 1686287 Kallipyga gabonensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017896 Microbes metabolize substances PMDBM2020781 1686287 Kallipyga gabonensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017897 Microbes metabolize substances PMDBM2020781 1686287 Kallipyga gabonensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017898 Microbes metabolize substances PMDBM2020781 1686287 Kallipyga gabonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017899 Microbes metabolize substances PMDBM2020781 1686287 Kallipyga gabonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017900 Microbes metabolize substances PMDBM2021272 1472764 Kallipyga massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017901 Microbes metabolize substances PMDBM2021272 1472764 Kallipyga massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017902 Microbes metabolize substances PMDBM2021272 1472764 Kallipyga massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017903 Microbes metabolize substances PMDBM2021272 1472764 Kallipyga massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017904 Microbes metabolize substances PMDBM2021272 1472764 Kallipyga massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017905 Microbes metabolize substances PMDBM2021272 1472764 Kallipyga massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017906 Microbes metabolize substances PMDBM2021272 1472764 Kallipyga massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017909 Microbes metabolize substances PMDBM2021272 1472764 Kallipyga massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017910 Microbes metabolize substances PMDBM2021272 1472764 Kallipyga massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017911 Microbes metabolize substances PMDBM2021272 1472764 Kallipyga massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017912 Microbes metabolize substances PMDBM2021272 1472764 Kallipyga massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017913 Microbes metabolize substances PMDBM2021272 1472764 Kallipyga massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017914 Microbes metabolize substances PMDBM2021272 1472764 Kallipyga massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017915 Microbes metabolize substances PMDBM2021272 1472764 Kallipyga massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017916 Microbes metabolize substances PMDBM2021272 1472764 Kallipyga massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017917 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017918 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20017919 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017920 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017921 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017922 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017923 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017924 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20017925 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20017926 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017928 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20017931 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20017932 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20017933 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017936 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20017939 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017940 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017941 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017943 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017944 Microbes metabolize substances PMDBM2009075 n.a. f Lachnospiraceae g KLE1615 s KLE1615 sp900066985 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017945 Microbes metabolize substances PMDBM2009076 n.a. f Erysipelatoclostridiaceae g KLE1796 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017946 Microbes metabolize substances PMDBM2009076 n.a. f Erysipelatoclostridiaceae g KLE1796 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017947 Microbes metabolize substances PMDBM2009076 n.a. f Erysipelatoclostridiaceae g KLE1796 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017948 Microbes metabolize substances PMDBM2009076 n.a. f Erysipelatoclostridiaceae g KLE1796 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017950 Microbes metabolize substances PMDBM2009076 n.a. f Erysipelatoclostridiaceae g KLE1796 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017952 Microbes metabolize substances PMDBM2009076 n.a. f Erysipelatoclostridiaceae g KLE1796 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017953 Microbes metabolize substances PMDBM2009076 n.a. f Erysipelatoclostridiaceae g KLE1796 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017954 Microbes metabolize substances PMDBM2009076 n.a. f Erysipelatoclostridiaceae g KLE1796 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017955 Microbes metabolize substances PMDBM2009076 n.a. f Erysipelatoclostridiaceae g KLE1796 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017958 Microbes metabolize substances PMDBM2009076 n.a. f Erysipelatoclostridiaceae g KLE1796 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017959 Microbes metabolize substances PMDBM2009076 n.a. f Erysipelatoclostridiaceae g KLE1796 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017960 Microbes metabolize substances PMDBM2009076 n.a. f Erysipelatoclostridiaceae g KLE1796 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017961 Microbes metabolize substances PMDBM2009076 n.a. f Erysipelatoclostridiaceae g KLE1796 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017963 Microbes metabolize substances PMDBM2009076 n.a. f Erysipelatoclostridiaceae g KLE1796 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017964 Microbes metabolize substances PMDBM2009076 n.a. f Erysipelatoclostridiaceae g KLE1796 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017965 Microbes metabolize substances PMDBM2009076 n.a. f Erysipelatoclostridiaceae g KLE1796 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017966 Microbes metabolize substances PMDBM2009077 n.a. f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017967 Microbes metabolize substances PMDBM2009077 n.a. f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017968 Microbes metabolize substances PMDBM2009077 n.a. f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017969 Microbes metabolize substances PMDBM2009077 n.a. f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017971 Microbes metabolize substances PMDBM2009077 n.a. f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017973 Microbes metabolize substances PMDBM2009077 n.a. f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017974 Microbes metabolize substances PMDBM2009077 n.a. f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017975 Microbes metabolize substances PMDBM2009077 n.a. f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20017976 Microbes metabolize substances PMDBM2009077 n.a. f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20017979 Microbes metabolize substances PMDBM2009077 n.a. f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20017980 Microbes metabolize substances PMDBM2009077 n.a. f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20017981 Microbes metabolize substances PMDBM2009077 n.a. f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017982 Microbes metabolize substances PMDBM2009077 n.a. f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20017984 Microbes metabolize substances PMDBM2009077 n.a. f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20017985 Microbes metabolize substances PMDBM2009077 n.a. f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017986 Microbes metabolize substances PMDBM2009077 n.a. f Erysipelatoclostridiaceae g KLE1796 s KLE1796 sp001580115 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20017987 Microbes metabolize substances PMDBM255 570 Klebsiella PMDBD1273 Melamine Dietary Substances compound n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. The gut microbiota deaminates melamine to generate ammonia and cyanuric acid. Cyanuric acid forms an insoluble complex with melamine in vivo, leading to renal toxicity. Klebsiella species are associated with cyanuric acid production. n.a. PMID PMID: 36467581 PMDBI20017988 Microbes metabolize substances PMDBM255 570 Klebsiella PMDBD662 Phenoxyethanol Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. cyanuric acid n.a. unknown toxicity increased n.a. n.a. n.a. Lead to renal toxicity n.a. PMID PMID: 36467581 PMDBI20017989 Microbes metabolize substances PMDBM2020129 575 Klebsiella planticola PMDBD1273 Melamine Dietary Substances compound n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Conversion to cyanuric acid, which cocrystallizes with melamine in kidneys and leads to renal toxicity. n.a. PMID PMID: 36467581 PMDBI20017990 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20017991 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20017992 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20017993 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20017994 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017996 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20017998 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD471 Lactulose Therapeutic Substance laxative n.a. n.a. n.a. n.a. Monosaccharides n.a. unknown activity decreased n.a. n.a. n.a. Stimulating the growth of beneficial bacteria such as Bifidobacteria and Lactobacilli n.a. PMID PMID: 36467581 PMDBI20017999 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018000 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018001 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018002 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018006 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018007 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018008 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20018009 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018010 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018012 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018013 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018014 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018015 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD1273 Melamine Dietary Substances compound n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Conversion to cyanuric acid, which cocrystallizes with melamine in kidneys and leads to renal toxicity. n.a. PMID PMID: 36467581 PMDBI20018016 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018017 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018018 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018019 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018020 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018022 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018024 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018025 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018026 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018027 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018030 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20018031 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018032 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018033 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20018034 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018035 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018037 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018038 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018039 Microbes metabolize substances PMDBM2020787 1463165 Klebsiella quasipneumoniae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018040 Microbes metabolize substances PMDBM2021563 2026240 Klebsiella quasivariicola PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018041 Microbes metabolize substances PMDBM2021563 2026240 Klebsiella quasivariicola PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018042 Microbes metabolize substances PMDBM2021563 2026240 Klebsiella quasivariicola PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018043 Microbes metabolize substances PMDBM2021563 2026240 Klebsiella quasivariicola PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018044 Microbes metabolize substances PMDBM2021563 2026240 Klebsiella quasivariicola PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018045 Microbes metabolize substances PMDBM2021563 2026240 Klebsiella quasivariicola PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018046 Microbes metabolize substances PMDBM2021563 2026240 Klebsiella quasivariicola PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018047 Microbes metabolize substances PMDBM2021563 2026240 Klebsiella quasivariicola PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018050 Microbes metabolize substances PMDBM2021563 2026240 Klebsiella quasivariicola PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018051 Microbes metabolize substances PMDBM2021563 2026240 Klebsiella quasivariicola PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018052 Microbes metabolize substances PMDBM2021563 2026240 Klebsiella quasivariicola PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018053 Microbes metabolize substances PMDBM2021563 2026240 Klebsiella quasivariicola PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018054 Microbes metabolize substances PMDBM2021563 2026240 Klebsiella quasivariicola PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018055 Microbes metabolize substances PMDBM2021563 2026240 Klebsiella quasivariicola PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018056 Microbes metabolize substances PMDBM2021563 2026240 Klebsiella quasivariicola PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018057 Microbes metabolize substances PMDBM2020062 577 Klebsiella terrigena PMDBD1273 Melamine Dietary Substances compound n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Conversion to cyanuric acid, which cocrystallizes with melamine in kidneys and leads to renal toxicity. n.a. PMID PMID: 36467581 PMDBI20018058 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018059 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018060 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018061 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018062 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018064 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018066 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018067 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018068 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018069 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018072 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20018073 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018074 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018075 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20018076 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018077 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018079 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018080 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018081 Microbes metabolize substances PMDBM2020791 244366 Klebsiella variicola PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018082 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018083 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018084 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018085 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018086 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018088 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018090 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018091 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018092 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018093 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018096 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20018097 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018098 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018099 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018100 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018102 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018103 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018104 Microbes metabolize substances PMDBM2009081 n.a. Klebsiella A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018105 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018106 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018107 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018108 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018109 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018111 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018113 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018114 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018115 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018116 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018119 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20018120 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20018121 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018122 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018123 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20018124 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018125 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018127 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018128 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018129 Microbes metabolize substances PMDBM2021564 2058152 Klebsiella A grimontii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018130 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018131 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018132 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018133 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018134 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018136 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018138 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018139 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018140 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018141 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018144 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20018145 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018146 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018147 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20018148 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018149 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018151 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018152 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018153 Microbes metabolize substances PMDBM2020786 1134687 Klebsiella A michiganensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018154 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018155 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018156 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018157 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018158 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018159 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018160 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018163 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20018164 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20018165 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018166 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018167 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20018168 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018169 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018170 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018171 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018172 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018173 Microbes metabolize substances PMDBM2020097 571 Klebsiella A oxytoca PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018174 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018175 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018176 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018177 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018178 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018180 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018182 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018183 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018184 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018185 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018188 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20018189 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018190 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018191 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20018192 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018193 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018195 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018196 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018197 Microbes metabolize substances PMDBM2009085 n.a. Klebsiella B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018198 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018199 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018200 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018201 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018202 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018203 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018204 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018205 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018208 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20018209 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018210 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018211 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20018212 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018213 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018214 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018215 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018216 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018217 Microbes metabolize substances PMDBM2020785 548 Klebsiella B aerogenes PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018218 Microbes metabolize substances PMDBM2009087 579 Kluyvera PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018219 Microbes metabolize substances PMDBM2009087 579 Kluyvera PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018220 Microbes metabolize substances PMDBM2009087 579 Kluyvera PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018221 Microbes metabolize substances PMDBM2009087 579 Kluyvera PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018222 Microbes metabolize substances PMDBM2009087 579 Kluyvera PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018223 Microbes metabolize substances PMDBM2009087 579 Kluyvera PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018224 Microbes metabolize substances PMDBM2009087 579 Kluyvera PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018225 Microbes metabolize substances PMDBM2009087 579 Kluyvera PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018228 Microbes metabolize substances PMDBM2009087 579 Kluyvera PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20018229 Microbes metabolize substances PMDBM2009087 579 Kluyvera PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018230 Microbes metabolize substances PMDBM2009087 579 Kluyvera PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018231 Microbes metabolize substances PMDBM2009087 579 Kluyvera PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018232 Microbes metabolize substances PMDBM2009087 579 Kluyvera PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018233 Microbes metabolize substances PMDBM2009087 579 Kluyvera PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018234 Microbes metabolize substances PMDBM2009087 579 Kluyvera PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018235 Microbes metabolize substances PMDBM2009087 579 Kluyvera PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018236 Microbes metabolize substances PMDBM2009087 579 Kluyvera PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018237 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018238 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018239 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018240 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018241 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018243 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018245 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018246 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018247 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018248 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018251 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20018252 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20018253 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018254 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018255 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20018256 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018257 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018259 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018260 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018261 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018262 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018263 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018264 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018265 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018266 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018267 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018268 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018269 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018272 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20018273 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20018274 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018275 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018276 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20018277 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018278 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018279 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018280 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018281 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018282 Microbes metabolize substances PMDBM2020792 51288 Kluyvera ascorbata B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018283 Microbes metabolize substances PMDBM2020797 72000 Kocuria rhizophila B PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018284 Microbes metabolize substances PMDBM2020797 72000 Kocuria rhizophila B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018285 Microbes metabolize substances PMDBM2020797 72000 Kocuria rhizophila B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018286 Microbes metabolize substances PMDBM2020797 72000 Kocuria rhizophila B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018287 Microbes metabolize substances PMDBM2020797 72000 Kocuria rhizophila B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018288 Microbes metabolize substances PMDBM2021565 208223 Kosakonia cowanii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018289 Microbes metabolize substances PMDBM2021565 208223 Kosakonia cowanii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018290 Microbes metabolize substances PMDBM2021565 208223 Kosakonia cowanii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018291 Microbes metabolize substances PMDBM2021565 208223 Kosakonia cowanii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018292 Microbes metabolize substances PMDBM2021565 208223 Kosakonia cowanii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018293 Microbes metabolize substances PMDBM2021565 208223 Kosakonia cowanii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018294 Microbes metabolize substances PMDBM2021565 208223 Kosakonia cowanii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018295 Microbes metabolize substances PMDBM2021565 208223 Kosakonia cowanii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018298 Microbes metabolize substances PMDBM2021565 208223 Kosakonia cowanii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018299 Microbes metabolize substances PMDBM2021565 208223 Kosakonia cowanii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018300 Microbes metabolize substances PMDBM2021565 208223 Kosakonia cowanii PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20018301 Microbes metabolize substances PMDBM2021565 208223 Kosakonia cowanii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018302 Microbes metabolize substances PMDBM2021565 208223 Kosakonia cowanii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018303 Microbes metabolize substances PMDBM2021565 208223 Kosakonia cowanii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018304 Microbes metabolize substances PMDBM2021565 208223 Kosakonia cowanii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018305 Microbes metabolize substances PMDBM2021565 208223 Kosakonia cowanii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018306 Microbes metabolize substances PMDBM2021565 208223 Kosakonia cowanii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018307 Microbes metabolize substances PMDBM2020799 1033739 Kurthia massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018308 Microbes metabolize substances PMDBM2020799 1033739 Kurthia massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018309 Microbes metabolize substances PMDBM2020799 1033739 Kurthia massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018310 Microbes metabolize substances PMDBM2020799 1033739 Kurthia massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018311 Microbes metabolize substances PMDBM2020800 1033740 Kurthia senegalensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018312 Microbes metabolize substances PMDBM2020800 1033740 Kurthia senegalensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018313 Microbes metabolize substances PMDBM2020800 1033740 Kurthia senegalensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018314 Microbes metabolize substances PMDBM2020800 1033740 Kurthia senegalensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018315 Microbes metabolize substances PMDBM2021385 1963358 Kurthia sp002418445 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018316 Microbes metabolize substances PMDBM2021385 1963358 Kurthia sp002418445 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018317 Microbes metabolize substances PMDBM2021385 1963358 Kurthia sp002418445 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018318 Microbes metabolize substances PMDBM2021385 1963358 Kurthia sp002418445 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018319 Microbes metabolize substances PMDBM2020803 467210 Lachnoanaerobaculum saburreum A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018320 Microbes metabolize substances PMDBM2020803 467210 Lachnoanaerobaculum saburreum A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018321 Microbes metabolize substances PMDBM2020803 467210 Lachnoanaerobaculum saburreum A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018322 Microbes metabolize substances PMDBM2020803 467210 Lachnoanaerobaculum saburreum A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018323 Microbes metabolize substances PMDBM2020803 467210 Lachnoanaerobaculum saburreum A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018324 Microbes metabolize substances PMDBM2020803 467210 Lachnoanaerobaculum saburreum A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018325 Microbes metabolize substances PMDBM2020803 467210 Lachnoanaerobaculum saburreum A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018328 Microbes metabolize substances PMDBM2020803 467210 Lachnoanaerobaculum saburreum A PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20018329 Microbes metabolize substances PMDBM2020803 467210 Lachnoanaerobaculum saburreum A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018330 Microbes metabolize substances PMDBM2020803 467210 Lachnoanaerobaculum saburreum A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018331 Microbes metabolize substances PMDBM2020803 467210 Lachnoanaerobaculum saburreum A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018332 Microbes metabolize substances PMDBM2020803 467210 Lachnoanaerobaculum saburreum A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018333 Microbes metabolize substances PMDBM2020803 467210 Lachnoanaerobaculum saburreum A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018334 Microbes metabolize substances PMDBM2020803 467210 Lachnoanaerobaculum saburreum A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018335 Microbes metabolize substances PMDBM2021566 2049030 Lachnoanaerobaculum sp000296385 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018336 Microbes metabolize substances PMDBM2021566 2049030 Lachnoanaerobaculum sp000296385 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018337 Microbes metabolize substances PMDBM2021566 2049030 Lachnoanaerobaculum sp000296385 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018338 Microbes metabolize substances PMDBM2021566 2049030 Lachnoanaerobaculum sp000296385 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018339 Microbes metabolize substances PMDBM2021566 2049030 Lachnoanaerobaculum sp000296385 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018340 Microbes metabolize substances PMDBM2021566 2049030 Lachnoanaerobaculum sp000296385 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018341 Microbes metabolize substances PMDBM2021566 2049030 Lachnoanaerobaculum sp000296385 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018344 Microbes metabolize substances PMDBM2021566 2049030 Lachnoanaerobaculum sp000296385 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20018345 Microbes metabolize substances PMDBM2021566 2049030 Lachnoanaerobaculum sp000296385 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018346 Microbes metabolize substances PMDBM2021566 2049030 Lachnoanaerobaculum sp000296385 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018347 Microbes metabolize substances PMDBM2021566 2049030 Lachnoanaerobaculum sp000296385 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018348 Microbes metabolize substances PMDBM2021566 2049030 Lachnoanaerobaculum sp000296385 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018349 Microbes metabolize substances PMDBM2021566 2049030 Lachnoanaerobaculum sp000296385 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018350 Microbes metabolize substances PMDBM2021566 2049030 Lachnoanaerobaculum sp000296385 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018351 Microbes metabolize substances PMDBM2021566 2049030 Lachnoanaerobaculum sp000296385 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018352 Microbes metabolize substances PMDBM2021566 2049030 Lachnoanaerobaculum sp000296385 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018353 Microbes metabolize substances PMDBM2021567 617123 Lachnoanaerobaculum umeaense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018354 Microbes metabolize substances PMDBM2021567 617123 Lachnoanaerobaculum umeaense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018355 Microbes metabolize substances PMDBM2021567 617123 Lachnoanaerobaculum umeaense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018356 Microbes metabolize substances PMDBM2021567 617123 Lachnoanaerobaculum umeaense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018357 Microbes metabolize substances PMDBM2021567 617123 Lachnoanaerobaculum umeaense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018358 Microbes metabolize substances PMDBM2021567 617123 Lachnoanaerobaculum umeaense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018359 Microbes metabolize substances PMDBM2021567 617123 Lachnoanaerobaculum umeaense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018362 Microbes metabolize substances PMDBM2021567 617123 Lachnoanaerobaculum umeaense PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20018363 Microbes metabolize substances PMDBM2021567 617123 Lachnoanaerobaculum umeaense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018364 Microbes metabolize substances PMDBM2021567 617123 Lachnoanaerobaculum umeaense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018365 Microbes metabolize substances PMDBM2021567 617123 Lachnoanaerobaculum umeaense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018366 Microbes metabolize substances PMDBM2021567 617123 Lachnoanaerobaculum umeaense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018367 Microbes metabolize substances PMDBM2021567 617123 Lachnoanaerobaculum umeaense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018368 Microbes metabolize substances PMDBM2021567 617123 Lachnoanaerobaculum umeaense PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018369 Microbes metabolize substances PMDBM2021567 617123 Lachnoanaerobaculum umeaense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018370 Microbes metabolize substances PMDBM2021567 617123 Lachnoanaerobaculum umeaense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018371 Microbes metabolize substances PMDBM2009097 140625 Lachnobacterium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018372 Microbes metabolize substances PMDBM2009097 140625 Lachnobacterium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018373 Microbes metabolize substances PMDBM2009097 140625 Lachnobacterium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018374 Microbes metabolize substances PMDBM2009097 140625 Lachnobacterium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018375 Microbes metabolize substances PMDBM2009097 140625 Lachnobacterium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018376 Microbes metabolize substances PMDBM2009097 140625 Lachnobacterium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018377 Microbes metabolize substances PMDBM2009097 140625 Lachnobacterium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018380 Microbes metabolize substances PMDBM2009097 140625 Lachnobacterium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018381 Microbes metabolize substances PMDBM2009097 140625 Lachnobacterium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018382 Microbes metabolize substances PMDBM2009097 140625 Lachnobacterium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018383 Microbes metabolize substances PMDBM2009097 140625 Lachnobacterium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018384 Microbes metabolize substances PMDBM2009097 140625 Lachnobacterium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018385 Microbes metabolize substances PMDBM2009097 140625 Lachnobacterium PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018386 Microbes metabolize substances PMDBM2009097 140625 Lachnobacterium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018387 Microbes metabolize substances PMDBM2009097 140625 Lachnobacterium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018388 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018389 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018390 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018391 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018392 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018393 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018394 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018395 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018396 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018398 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20018401 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20018402 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20018403 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018404 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018407 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20018410 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018411 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018412 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018414 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018415 Microbes metabolize substances PMDBM809 1506553 Lachnoclostridium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018416 Microbes metabolize substances PMDBM2021568 66219 Lachnoclostridium phytofermentans A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018417 Microbes metabolize substances PMDBM2021568 66219 Lachnoclostridium phytofermentans A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018418 Microbes metabolize substances PMDBM2021568 66219 Lachnoclostridium phytofermentans A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018419 Microbes metabolize substances PMDBM2021568 66219 Lachnoclostridium phytofermentans A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018420 Microbes metabolize substances PMDBM2021568 66219 Lachnoclostridium phytofermentans A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018421 Microbes metabolize substances PMDBM2021568 66219 Lachnoclostridium phytofermentans A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018422 Microbes metabolize substances PMDBM2021568 66219 Lachnoclostridium phytofermentans A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018425 Microbes metabolize substances PMDBM2021568 66219 Lachnoclostridium phytofermentans A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018426 Microbes metabolize substances PMDBM2021568 66219 Lachnoclostridium phytofermentans A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018427 Microbes metabolize substances PMDBM2021568 66219 Lachnoclostridium phytofermentans A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018428 Microbes metabolize substances PMDBM2021568 66219 Lachnoclostridium phytofermentans A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018429 Microbes metabolize substances PMDBM2021568 66219 Lachnoclostridium phytofermentans A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018430 Microbes metabolize substances PMDBM2021568 66219 Lachnoclostridium phytofermentans A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018431 Microbes metabolize substances PMDBM2021568 66219 Lachnoclostridium phytofermentans A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018432 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018433 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018434 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018435 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018437 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018439 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018440 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018441 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018442 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018443 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018444 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018446 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20018449 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20018450 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20018451 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018452 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018455 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20018458 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018459 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018462 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018463 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium sp900078195 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018464 Microbes metabolize substances PMDBM2009100 n.a. Lachnoclostridium A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018465 Microbes metabolize substances PMDBM2009100 n.a. Lachnoclostridium A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018466 Microbes metabolize substances PMDBM2009100 n.a. Lachnoclostridium A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018467 Microbes metabolize substances PMDBM2009100 n.a. Lachnoclostridium A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018468 Microbes metabolize substances PMDBM2009100 n.a. Lachnoclostridium A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018469 Microbes metabolize substances PMDBM2009100 n.a. Lachnoclostridium A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018470 Microbes metabolize substances PMDBM2009100 n.a. Lachnoclostridium A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018473 Microbes metabolize substances PMDBM2009100 n.a. Lachnoclostridium A PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20018474 Microbes metabolize substances PMDBM2009100 n.a. Lachnoclostridium A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018475 Microbes metabolize substances PMDBM2009100 n.a. Lachnoclostridium A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018476 Microbes metabolize substances PMDBM2009100 n.a. Lachnoclostridium A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018477 Microbes metabolize substances PMDBM2009100 n.a. Lachnoclostridium A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018478 Microbes metabolize substances PMDBM2009100 n.a. Lachnoclostridium A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018479 Microbes metabolize substances PMDBM2009100 n.a. Lachnoclostridium A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018480 Microbes metabolize substances PMDBM2009100 n.a. Lachnoclostridium A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018481 Microbes metabolize substances PMDBM2009100 n.a. Lachnoclostridium A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018482 Microbes metabolize substances PMDBM2021570 1926283 Lachnoclostridium A edouardi PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20018483 Microbes metabolize substances PMDBM2021570 1926283 Lachnoclostridium A edouardi PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018484 Microbes metabolize substances PMDBM2021570 1926283 Lachnoclostridium A edouardi PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018485 Microbes metabolize substances PMDBM2021570 1926283 Lachnoclostridium A edouardi PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018486 Microbes metabolize substances PMDBM2021570 1926283 Lachnoclostridium A edouardi PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018487 Microbes metabolize substances PMDBM2021570 1926283 Lachnoclostridium A edouardi PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018488 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium A sp002160755 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018489 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium A sp002160755 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018490 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium A sp002160755 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018491 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium A sp002160755 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018492 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium A sp002160755 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018493 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium A sp002160755 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018494 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium A sp002160755 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018497 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium A sp002160755 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018498 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium A sp002160755 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018499 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium A sp002160755 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018500 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium A sp002160755 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018501 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium A sp002160755 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018502 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium A sp002160755 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018503 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium A sp002160755 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018504 Microbes metabolize substances PMDBM2021569 2028282 Lachnoclostridium A sp002160755 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018505 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018506 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018507 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018508 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20018509 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018510 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018511 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018512 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018513 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018514 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018516 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20018519 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20018520 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20018521 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018522 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018525 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20018528 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018529 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018530 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018532 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018533 Microbes metabolize substances PMDBM810 28050 Lachnospira PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018534 Microbes metabolize substances PMDBM2021322 39485 Lachnospira eligens B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018535 Microbes metabolize substances PMDBM2021322 39485 Lachnospira eligens B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018536 Microbes metabolize substances PMDBM2021322 39485 Lachnospira eligens B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018537 Microbes metabolize substances PMDBM2021322 39485 Lachnospira eligens B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018538 Microbes metabolize substances PMDBM2021322 39485 Lachnospira eligens B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018539 Microbes metabolize substances PMDBM2021322 39485 Lachnospira eligens B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018540 Microbes metabolize substances PMDBM2021322 39485 Lachnospira eligens B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018543 Microbes metabolize substances PMDBM2021322 39485 Lachnospira eligens B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018544 Microbes metabolize substances PMDBM2021322 39485 Lachnospira eligens B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018545 Microbes metabolize substances PMDBM2021322 39485 Lachnospira eligens B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018546 Microbes metabolize substances PMDBM2021322 39485 Lachnospira eligens B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018547 Microbes metabolize substances PMDBM2021322 39485 Lachnospira eligens B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018548 Microbes metabolize substances PMDBM2021322 39485 Lachnospira eligens B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018549 Microbes metabolize substances PMDBM2021571 706562 Lachnospira rogosae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018550 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436475 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018551 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436475 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018552 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436475 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20018554 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436475 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20018555 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436475 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20018556 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436475 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018559 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436475 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20018563 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436475 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018564 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436475 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018565 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436535 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018566 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436535 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018567 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436535 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20018569 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436535 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20018570 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436535 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20018571 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436535 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018572 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436535 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018575 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436535 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20018579 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436535 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018580 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000436535 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018581 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000437735 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018582 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000437735 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018583 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000437735 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018584 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000437735 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20018585 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000437735 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018586 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000437735 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018587 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000437735 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018588 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000437735 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018591 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000437735 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018592 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000437735 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018593 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000437735 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018594 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000437735 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018595 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000437735 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018596 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000437735 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018597 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000437735 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018598 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp000437735 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20018599 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp003537285 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018600 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp003537285 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018601 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp003537285 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20018603 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp003537285 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20018604 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp003537285 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20018605 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp003537285 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018606 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp003537285 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018609 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp003537285 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20018613 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp003537285 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018614 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp003537285 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018615 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp900316325 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018616 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp900316325 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018617 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp900316325 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018618 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp900316325 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018619 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp900316325 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018620 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp900316325 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018621 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp900316325 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018624 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp900316325 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018625 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp900316325 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018626 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp900316325 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018627 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp900316325 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018628 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp900316325 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018629 Microbes metabolize substances PMDBM2021572 2049031 Lachnospira sp900316325 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018630 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018631 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018632 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018633 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018634 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018636 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018638 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20018639 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018640 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018641 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018642 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018643 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018644 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018646 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20018649 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20018650 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20018651 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20018652 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20018653 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018654 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018657 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20018660 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20018661 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018662 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018665 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018666 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD214 Clonazepam Therapeutic Substance Central nervous system agents n.a. n.a. n.a. n.a. clonazepam-M1 n.a. unknown activity decreased n.a. n.a. n.a. Accelerate clonazepam metabolism and reduce drug efficacy n.a. PMID PMID: 36467581 PMDBI20018667 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018668 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018669 Microbes metabolize substances PMDBM263 186803 Lachnospiraceae PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20018670 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018671 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018672 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018673 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018674 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018676 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018678 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20018679 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018680 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018681 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018682 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018683 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018684 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018686 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20018689 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20018690 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20018691 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018692 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018695 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20018698 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018699 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018702 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018703 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018704 Microbes metabolize substances PMDBM2009110 3085636 Lachnospirales PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018705 Microbes metabolize substances PMDBM267 186826 Lactobacillales PMDBD2000019 Methamphetamine Therapeutic Substance psychostimulant and sympathomimetic n.a. n.a. n.a. n.a. Amphetamine, norephedrine n.a. unknown activity decreased n.a. n.a. n.a. Through demethylation, Methamphetamine formation Amphetamine, norephedrine and an unknownn metabolite n.a. PMID PMID: 36467581 PMDBI20018706 Microbes metabolize substances PMDBM2009111 n.a. Lactobacillus B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018707 Microbes metabolize substances PMDBM2009111 n.a. Lactobacillus B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018708 Microbes metabolize substances PMDBM2009111 n.a. Lactobacillus B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018709 Microbes metabolize substances PMDBM2009111 n.a. Lactobacillus B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018710 Microbes metabolize substances PMDBM2009111 n.a. Lactobacillus B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018711 Microbes metabolize substances PMDBM2009111 n.a. Lactobacillus B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018712 Microbes metabolize substances PMDBM2009111 n.a. Lactobacillus B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018715 Microbes metabolize substances PMDBM2009111 n.a. Lactobacillus B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018716 Microbes metabolize substances PMDBM2009111 n.a. Lactobacillus B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018717 Microbes metabolize substances PMDBM2009111 n.a. Lactobacillus B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018718 Microbes metabolize substances PMDBM2009111 n.a. Lactobacillus B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018719 Microbes metabolize substances PMDBM2021573 1601 Lactobacillus B agilis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018720 Microbes metabolize substances PMDBM2021573 1601 Lactobacillus B agilis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018721 Microbes metabolize substances PMDBM2021573 1601 Lactobacillus B agilis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018722 Microbes metabolize substances PMDBM2021573 1601 Lactobacillus B agilis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018724 Microbes metabolize substances PMDBM2021573 1601 Lactobacillus B agilis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018726 Microbes metabolize substances PMDBM2021573 1601 Lactobacillus B agilis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018727 Microbes metabolize substances PMDBM2021573 1601 Lactobacillus B agilis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018728 Microbes metabolize substances PMDBM2021573 1601 Lactobacillus B agilis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018729 Microbes metabolize substances PMDBM2021573 1601 Lactobacillus B agilis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018732 Microbes metabolize substances PMDBM2021573 1601 Lactobacillus B agilis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018733 Microbes metabolize substances PMDBM2021573 1601 Lactobacillus B agilis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018734 Microbes metabolize substances PMDBM2021573 1601 Lactobacillus B agilis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018735 Microbes metabolize substances PMDBM2021573 1601 Lactobacillus B agilis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018737 Microbes metabolize substances PMDBM2021573 1601 Lactobacillus B agilis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018738 Microbes metabolize substances PMDBM2021574 1605 Lactobacillus B animalis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018739 Microbes metabolize substances PMDBM2021574 1605 Lactobacillus B animalis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018740 Microbes metabolize substances PMDBM2021574 1605 Lactobacillus B animalis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018741 Microbes metabolize substances PMDBM2021574 1605 Lactobacillus B animalis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018742 Microbes metabolize substances PMDBM2021574 1605 Lactobacillus B animalis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018743 Microbes metabolize substances PMDBM2021574 1605 Lactobacillus B animalis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018744 Microbes metabolize substances PMDBM2021574 1605 Lactobacillus B animalis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018747 Microbes metabolize substances PMDBM2021574 1605 Lactobacillus B animalis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018748 Microbes metabolize substances PMDBM2021574 1605 Lactobacillus B animalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018749 Microbes metabolize substances PMDBM2021574 1605 Lactobacillus B animalis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018750 Microbes metabolize substances PMDBM2021574 1605 Lactobacillus B animalis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018751 Microbes metabolize substances PMDBM2021574 1605 Lactobacillus B animalis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018752 Microbes metabolize substances PMDBM2021574 1605 Lactobacillus B animalis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018753 Microbes metabolize substances PMDBM2021574 1605 Lactobacillus B animalis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018754 Microbes metabolize substances PMDBM2021575 1622 Lactobacillu B murinus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018755 Microbes metabolize substances PMDBM2021575 1622 Lactobacillu B murinus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018756 Microbes metabolize substances PMDBM2021575 1622 Lactobacillu B murinus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018757 Microbes metabolize substances PMDBM2021575 1622 Lactobacillu B murinus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018758 Microbes metabolize substances PMDBM2021575 1622 Lactobacillu B murinus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018759 Microbes metabolize substances PMDBM2021575 1622 Lactobacillu B murinus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018760 Microbes metabolize substances PMDBM2021575 1622 Lactobacillu B murinus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018763 Microbes metabolize substances PMDBM2021575 1622 Lactobacillu B murinus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018764 Microbes metabolize substances PMDBM2021575 1622 Lactobacillu B murinus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018765 Microbes metabolize substances PMDBM2021575 1622 Lactobacillu B murinus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018766 Microbes metabolize substances PMDBM2021575 1622 Lactobacillu B murinus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018767 Microbes metabolize substances PMDBM2021575 1622 Lactobacillu B murinus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018768 Microbes metabolize substances PMDBM2021575 1622 Lactobacillu B murinus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018769 Microbes metabolize substances PMDBM2021575 1622 Lactobacillu B murinus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018770 Microbes metabolize substances PMDBM2021576 1623 Lactobacillu B ruminis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018771 Microbes metabolize substances PMDBM2021576 1623 Lactobacillu B ruminis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018772 Microbes metabolize substances PMDBM2021576 1623 Lactobacillu B ruminis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018773 Microbes metabolize substances PMDBM2021576 1623 Lactobacillu B ruminis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018774 Microbes metabolize substances PMDBM2021576 1623 Lactobacillu B ruminis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018775 Microbes metabolize substances PMDBM2021576 1623 Lactobacillu B ruminis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018776 Microbes metabolize substances PMDBM2021576 1623 Lactobacillu B ruminis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018779 Microbes metabolize substances PMDBM2021576 1623 Lactobacillu B ruminis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018780 Microbes metabolize substances PMDBM2021576 1623 Lactobacillu B ruminis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018781 Microbes metabolize substances PMDBM2021576 1623 Lactobacillu B ruminis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018782 Microbes metabolize substances PMDBM2021576 1623 Lactobacillu B ruminis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018783 Microbes metabolize substances PMDBM2021576 1623 Lactobacillu B ruminis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018784 Microbes metabolize substances PMDBM2021255 1624 Lactobacillus B salivarius PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018785 Microbes metabolize substances PMDBM2021255 1624 Lactobacillus B salivarius PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018786 Microbes metabolize substances PMDBM2009117 n.a. Lactobacillus C PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018787 Microbes metabolize substances PMDBM2009117 n.a. Lactobacillus C PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018788 Microbes metabolize substances PMDBM2009117 n.a. Lactobacillus C PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018789 Microbes metabolize substances PMDBM2009117 n.a. Lactobacillus C PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018790 Microbes metabolize substances PMDBM2009117 n.a. Lactobacillus C PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018791 Microbes metabolize substances PMDBM2009117 n.a. Lactobacillus C PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018792 Microbes metabolize substances PMDBM2009117 n.a. Lactobacillus C PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018793 Microbes metabolize substances PMDBM2009117 n.a. Lactobacillus C PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018796 Microbes metabolize substances PMDBM2009117 n.a. Lactobacillus C PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018797 Microbes metabolize substances PMDBM2009117 n.a. Lactobacillus C PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018798 Microbes metabolize substances PMDBM2009117 n.a. Lactobacillus C PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018799 Microbes metabolize substances PMDBM2009117 n.a. Lactobacillus C PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018800 Microbes metabolize substances PMDBM2009117 n.a. Lactobacillus C PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018801 Microbes metabolize substances PMDBM2009117 n.a. Lactobacillus C PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018802 Microbes metabolize substances PMDBM2009117 n.a. Lactobacillus C PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018803 Microbes metabolize substances PMDBM2021329 1597 Lactobacillus C paracasei PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018804 Microbes metabolize substances PMDBM2021329 1597 Lactobacillus C paracasei PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018805 Microbes metabolize substances PMDBM2021329 1597 Lactobacillus C paracasei PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018806 Microbes metabolize substances PMDBM2021329 1597 Lactobacillus C paracasei PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018807 Microbes metabolize substances PMDBM2021329 1597 Lactobacillus C paracasei PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018808 Microbes metabolize substances PMDBM2021329 1597 Lactobacillus C paracasei PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018809 Microbes metabolize substances PMDBM2021329 1597 Lactobacillus C paracasei PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018810 Microbes metabolize substances PMDBM2021329 1597 Lactobacillus C paracasei PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018813 Microbes metabolize substances PMDBM2021329 1597 Lactobacillus C paracasei PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018814 Microbes metabolize substances PMDBM2021329 1597 Lactobacillus C paracasei PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018815 Microbes metabolize substances PMDBM2021329 1597 Lactobacillus C paracasei PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018816 Microbes metabolize substances PMDBM2021329 1597 Lactobacillus C paracasei PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018817 Microbes metabolize substances PMDBM2021329 1597 Lactobacillus C paracasei PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018818 Microbes metabolize substances PMDBM2021329 1597 Lactobacillus C paracasei PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018819 Microbes metabolize substances PMDBM2021329 1597 Lactobacillus C paracasei PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018820 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018821 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018822 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018823 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018824 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018826 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018828 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018829 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018830 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018831 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018832 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018833 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018835 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20018838 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20018839 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20018840 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018841 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018844 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20018847 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018848 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018851 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018852 Microbes metabolize substances PMDBM2021326 47715 Lactobacillus C rhamnosus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018853 Microbes metabolize substances PMDBM2021577 931533 Lactobacillus C saniviri PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018854 Microbes metabolize substances PMDBM2021577 931533 Lactobacillus C saniviri PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018855 Microbes metabolize substances PMDBM2021577 931533 Lactobacillus C saniviri PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018856 Microbes metabolize substances PMDBM2021577 931533 Lactobacillus C saniviri PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018857 Microbes metabolize substances PMDBM2021577 931533 Lactobacillus C saniviri PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018858 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018859 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018860 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018861 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018862 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018864 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018866 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018867 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018868 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018869 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018870 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018871 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018873 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20018876 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20018877 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20018878 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018879 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018882 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20018885 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018886 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018889 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018890 Microbes metabolize substances PMDBM2021578 57037 Lactobacillus C zeae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018891 Microbes metabolize substances PMDBM2021579 28038 Lactobacillus D curvatus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018892 Microbes metabolize substances PMDBM2021579 28038 Lactobacillus D curvatus PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20018893 Microbes metabolize substances PMDBM2021579 28038 Lactobacillus D curvatus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018894 Microbes metabolize substances PMDBM2021580 1599 Lactobacillus D sakei PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018895 Microbes metabolize substances PMDBM2021580 1599 Lactobacillus D sakei PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018896 Microbes metabolize substances PMDBM2021580 1599 Lactobacillus D sakei PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018897 Microbes metabolize substances PMDBM2021580 1599 Lactobacillus D sakei PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018898 Microbes metabolize substances PMDBM2021328 1610 Lactobacillus E coryniformis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018899 Microbes metabolize substances PMDBM2021328 1610 Lactobacillus E coryniformis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018900 Microbes metabolize substances PMDBM2021328 1610 Lactobacillus E coryniformis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018901 Microbes metabolize substances PMDBM2021581 1589 Lactobacillus F pentosus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018902 Microbes metabolize substances PMDBM2021581 1589 Lactobacillus F pentosus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018903 Microbes metabolize substances PMDBM2021581 1589 Lactobacillus F pentosus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018904 Microbes metabolize substances PMDBM2021581 1589 Lactobacillus F pentosus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018905 Microbes metabolize substances PMDBM2021581 1589 Lactobacillus F pentosus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018907 Microbes metabolize substances PMDBM2021581 1589 Lactobacillus F pentosus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018909 Microbes metabolize substances PMDBM2021581 1589 Lactobacillus F pentosus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018910 Microbes metabolize substances PMDBM2021581 1589 Lactobacillus F pentosus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018911 Microbes metabolize substances PMDBM2021581 1589 Lactobacillus F pentosus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018912 Microbes metabolize substances PMDBM2021581 1589 Lactobacillus F pentosus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018915 Microbes metabolize substances PMDBM2021581 1589 Lactobacillus F pentosus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018916 Microbes metabolize substances PMDBM2021581 1589 Lactobacillus F pentosus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018917 Microbes metabolize substances PMDBM2021581 1589 Lactobacillus F pentosus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018919 Microbes metabolize substances PMDBM2021254 1590 Lactobacillus F plantarum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018920 Microbes metabolize substances PMDBM2021254 1590 Lactobacillus F plantarum PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018921 Microbes metabolize substances PMDBM2021254 1590 Lactobacillus F plantarum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018922 Microbes metabolize substances PMDBM2021254 1590 Lactobacillus F plantarum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018923 Microbes metabolize substances PMDBM2021254 1590 Lactobacillus F plantarum PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018925 Microbes metabolize substances PMDBM2021254 1590 Lactobacillus F plantarum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018927 Microbes metabolize substances PMDBM2021254 1590 Lactobacillus F plantarum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018928 Microbes metabolize substances PMDBM2021254 1590 Lactobacillus F plantarum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018929 Microbes metabolize substances PMDBM2021254 1590 Lactobacillus F plantarum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018930 Microbes metabolize substances PMDBM2021254 1590 Lactobacillus F plantarum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018933 Microbes metabolize substances PMDBM2021254 1590 Lactobacillus F plantarum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20018934 Microbes metabolize substances PMDBM2021254 1590 Lactobacillus F plantarum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018935 Microbes metabolize substances PMDBM2021254 1590 Lactobacillus F plantarum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018936 Microbes metabolize substances PMDBM2021254 1590 Lactobacillus F plantarum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018938 Microbes metabolize substances PMDBM2021254 1590 Lactobacillus F plantarum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20018939 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018940 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018941 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018942 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018943 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20018944 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018945 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018946 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018947 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018948 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018949 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20018951 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20018954 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20018955 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20018956 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018959 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20018962 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018963 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018964 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20018966 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018967 Microbes metabolize substances PMDBM2021330 1580 Lactobacillus G brevis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018968 Microbes metabolize substances PMDBM2021582 1581 Lactobacillus G buchneri PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018969 Microbes metabolize substances PMDBM2021582 1581 Lactobacillus G buchneri PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018970 Microbes metabolize substances PMDBM2021582 1581 Lactobacillus G buchneri PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018971 Microbes metabolize substances PMDBM2021582 1581 Lactobacillus G buchneri PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018972 Microbes metabolize substances PMDBM2021582 1581 Lactobacillus G buchneri PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018973 Microbes metabolize substances PMDBM2021582 1581 Lactobacillus G buchneri PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018974 Microbes metabolize substances PMDBM2021582 1581 Lactobacillus G buchneri PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20018975 Microbes metabolize substances PMDBM2021582 1581 Lactobacillus G buchneri PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20018977 Microbes metabolize substances PMDBM2021582 1581 Lactobacillus G buchneri PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20018978 Microbes metabolize substances PMDBM2021582 1581 Lactobacillus G buchneri PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20018979 Microbes metabolize substances PMDBM2021582 1581 Lactobacillus G buchneri PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20018982 Microbes metabolize substances PMDBM2021582 1581 Lactobacillus G buchneri PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20018986 Microbes metabolize substances PMDBM2021582 1581 Lactobacillus G buchneri PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018987 Microbes metabolize substances PMDBM2021582 1581 Lactobacillus G buchneri PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20018988 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20018989 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20018990 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20018991 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20018992 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20018993 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018995 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20018997 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018998 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20018999 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019000 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019001 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019002 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019004 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20019007 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20019008 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20019009 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019012 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20019015 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019016 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019019 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019020 Microbes metabolize substances PMDBM2021371 1588 Lactobacillus G hilgardii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019021 Microbes metabolize substances PMDBM2021583 33962 Lactobacillus G kefiri PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019022 Microbes metabolize substances PMDBM2021583 33962 Lactobacillus G kefiri PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019023 Microbes metabolize substances PMDBM2021583 33962 Lactobacillus G kefiri PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019024 Microbes metabolize substances PMDBM2021583 33962 Lactobacillus G kefiri PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019025 Microbes metabolize substances PMDBM2021583 33962 Lactobacillus G kefiri PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019026 Microbes metabolize substances PMDBM2021583 33962 Lactobacillus G kefiri PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019027 Microbes metabolize substances PMDBM2021583 33962 Lactobacillus G kefiri PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019028 Microbes metabolize substances PMDBM2021583 33962 Lactobacillus G kefiri PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20019030 Microbes metabolize substances PMDBM2021583 33962 Lactobacillus G kefiri PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20019031 Microbes metabolize substances PMDBM2021583 33962 Lactobacillus G kefiri PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20019032 Microbes metabolize substances PMDBM2021583 33962 Lactobacillus G kefiri PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019035 Microbes metabolize substances PMDBM2021583 33962 Lactobacillus G kefiri PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20019039 Microbes metabolize substances PMDBM2021583 33962 Lactobacillus G kefiri PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019040 Microbes metabolize substances PMDBM2021583 33962 Lactobacillus G kefiri PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019041 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019042 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019043 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019044 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019045 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019047 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019049 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019050 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019051 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019052 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019053 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019054 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019056 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20019059 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20019060 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20019061 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019064 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20019067 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019068 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019071 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019072 Microbes metabolize substances PMDBM2021584 152331 Lactobacillus G parabuchneri PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019073 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019074 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019075 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019076 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019077 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019079 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019081 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019082 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019083 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019084 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019085 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019086 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019088 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20019091 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20019092 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20019093 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019096 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20019099 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019100 Microbes metabolize substances PMDBM2021585 390842 Lactobacillus G parafarraginis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019103 Microbes metabolize substances PMDBM2021586 1625 Lactobacillus G sanfranciscensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019104 Microbes metabolize substances PMDBM2021587 931534 Lactobacillus G senioris PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019105 Microbes metabolize substances PMDBM2021587 931534 Lactobacillus G senioris PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019106 Microbes metabolize substances PMDBM2021587 931534 Lactobacillus G senioris PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019107 Microbes metabolize substances PMDBM2021587 931534 Lactobacillus G senioris PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019108 Microbes metabolize substances PMDBM2009135 n.a. Lactobacillus H PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019109 Microbes metabolize substances PMDBM2009135 n.a. Lactobacillus H PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019110 Microbes metabolize substances PMDBM2009135 n.a. Lactobacillus H PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019111 Microbes metabolize substances PMDBM2009135 n.a. Lactobacillus H PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019112 Microbes metabolize substances PMDBM2009135 n.a. Lactobacillus H PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019113 Microbes metabolize substances PMDBM2009135 n.a. Lactobacillus H PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019114 Microbes metabolize substances PMDBM2009135 n.a. Lactobacillus H PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019115 Microbes metabolize substances PMDBM2009135 n.a. Lactobacillus H PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019116 Microbes metabolize substances PMDBM2009135 n.a. Lactobacillus H PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019117 Microbes metabolize substances PMDBM2021588 227943 Lactobacillus H antri PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019118 Microbes metabolize substances PMDBM2021588 227943 Lactobacillus H antri PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019119 Microbes metabolize substances PMDBM2021588 227943 Lactobacillus H antri PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019120 Microbes metabolize substances PMDBM2021588 227943 Lactobacillus H antri PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019121 Microbes metabolize substances PMDBM2021588 227943 Lactobacillus H antri PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019122 Microbes metabolize substances PMDBM2021588 227943 Lactobacillus H antri PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019123 Microbes metabolize substances PMDBM2021588 227943 Lactobacillus H antri PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019124 Microbes metabolize substances PMDBM2021588 227943 Lactobacillus H antri PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019127 Microbes metabolize substances PMDBM2021588 227943 Lactobacillus H antri PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019128 Microbes metabolize substances PMDBM2021588 227943 Lactobacillus H antri PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019129 Microbes metabolize substances PMDBM2021588 227943 Lactobacillus H antri PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019130 Microbes metabolize substances PMDBM2021588 227943 Lactobacillus H antri PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019131 Microbes metabolize substances PMDBM2021588 227943 Lactobacillus H antri PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019132 Microbes metabolize substances PMDBM2021588 227943 Lactobacillus H antri PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019133 Microbes metabolize substances PMDBM2021588 227943 Lactobacillus H antri PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019134 Microbes metabolize substances PMDBM2021589 1613 Lactobacillus H fermentum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019135 Microbes metabolize substances PMDBM2021589 1613 Lactobacillus H fermentum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019136 Microbes metabolize substances PMDBM2021589 1613 Lactobacillus H fermentum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019137 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019138 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019139 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019140 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019141 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019142 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019143 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019144 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019145 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019147 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20019150 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20019151 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20019152 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019153 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019156 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20019159 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019160 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019161 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019163 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019164 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019165 Microbes metabolize substances PMDBM2021590 97478 Lactobacillus H mucosae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019166 Microbes metabolize substances PMDBM2021591 1632 Lactobacillus H oris PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019167 Microbes metabolize substances PMDBM2021591 1632 Lactobacillus H oris PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019168 Microbes metabolize substances PMDBM2021591 1632 Lactobacillus H oris PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019169 Microbes metabolize substances PMDBM2021591 1632 Lactobacillus H oris PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019170 Microbes metabolize substances PMDBM2021591 1632 Lactobacillus H oris PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20019171 Microbes metabolize substances PMDBM2021591 1632 Lactobacillus H oris PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019172 Microbes metabolize substances PMDBM2021591 1632 Lactobacillus H oris PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019173 Microbes metabolize substances PMDBM2021591 1632 Lactobacillus H oris PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019174 Microbes metabolize substances PMDBM2021591 1632 Lactobacillus H oris PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019177 Microbes metabolize substances PMDBM2021591 1632 Lactobacillus H oris PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019178 Microbes metabolize substances PMDBM2021591 1632 Lactobacillus H oris PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019179 Microbes metabolize substances PMDBM2021591 1632 Lactobacillus H oris PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019180 Microbes metabolize substances PMDBM2021591 1632 Lactobacillus H oris PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019181 Microbes metabolize substances PMDBM2021591 1632 Lactobacillus H oris PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019182 Microbes metabolize substances PMDBM2021591 1632 Lactobacillus H oris PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019183 Microbes metabolize substances PMDBM2021591 1632 Lactobacillus H oris PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019184 Microbes metabolize substances PMDBM2021592 1633 Lactobacillus H vaginalis A PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019185 Microbes metabolize substances PMDBM2021592 1633 Lactobacillus H vaginalis A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019186 Microbes metabolize substances PMDBM2021592 1633 Lactobacillus H vaginalis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019187 Microbes metabolize substances PMDBM2021592 1633 Lactobacillus H vaginalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019188 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019189 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019190 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019191 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019193 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019195 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019196 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019197 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019198 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019199 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019200 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019202 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20019205 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20019206 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20019207 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019208 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019211 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20019214 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019215 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019218 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019219 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019220 Microbes metabolize substances PMDBM2021593 304207 Lactobacillus J harbinensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019221 Microbes metabolize substances PMDBM2021594 1612 Lactobacillus K farciminis A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019222 Microbes metabolize substances PMDBM2021594 1612 Lactobacillus K farciminis A PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019223 Microbes metabolize substances PMDBM2021594 1612 Lactobacillus K farciminis A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019224 Microbes metabolize substances PMDBM2021594 1612 Lactobacillus K farciminis A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019225 Microbes metabolize substances PMDBM2021594 1612 Lactobacillus K farciminis A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019227 Microbes metabolize substances PMDBM2021594 1612 Lactobacillus K farciminis A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019229 Microbes metabolize substances PMDBM2021594 1612 Lactobacillus K farciminis A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019230 Microbes metabolize substances PMDBM2021594 1612 Lactobacillus K farciminis A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019231 Microbes metabolize substances PMDBM2021594 1612 Lactobacillus K farciminis A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019232 Microbes metabolize substances PMDBM2021594 1612 Lactobacillus K farciminis A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019235 Microbes metabolize substances PMDBM2021594 1612 Lactobacillus K farciminis A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019236 Microbes metabolize substances PMDBM2021594 1612 Lactobacillus K farciminis A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019237 Microbes metabolize substances PMDBM2021594 1612 Lactobacillus K farciminis A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019239 Microbes metabolize substances PMDBM2021595 51664 Lactobacillus L dextrinicus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019240 Microbes metabolize substances PMDBM2021595 51664 Lactobacillus L dextrinicus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019241 Microbes metabolize substances PMDBM2021595 51664 Lactobacillus L dextrinicus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019242 Microbes metabolize substances PMDBM2021595 51664 Lactobacillus L dextrinicus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019243 Microbes metabolize substances PMDBM2021595 51664 Lactobacillus L dextrinicus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019244 Microbes metabolize substances PMDBM2021595 51664 Lactobacillus L dextrinicus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019245 Microbes metabolize substances PMDBM2021595 51664 Lactobacillus L dextrinicus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019248 Microbes metabolize substances PMDBM2021595 51664 Lactobacillus L dextrinicus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019249 Microbes metabolize substances PMDBM2021595 51664 Lactobacillus L dextrinicus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019250 Microbes metabolize substances PMDBM2021595 51664 Lactobacillus L dextrinicus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019251 Microbes metabolize substances PMDBM2021595 51664 Lactobacillus L dextrinicus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019252 Microbes metabolize substances PMDBM2021595 51664 Lactobacillus L dextrinicus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019253 Microbes metabolize substances PMDBM2021595 51664 Lactobacillus L dextrinicus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019254 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019255 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019256 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019257 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20019259 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD2000019 Methamphetamine Therapeutic Substance psychostimulant and sympathomimetic n.a. n.a. n.a. n.a. Amphetamine, norephedrine n.a. unknown activity decreased n.a. n.a. n.a. Through demethylation, Methamphetamine formation Amphetamine, norephedrine and an unknownn metabolite n.a. PMID PMID: 36467581 PMDBI20019260 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019261 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019262 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019264 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019267 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD471 Lactulose Therapeutic Substance laxative n.a. n.a. n.a. n.a. lactic and acetic acids n.a. unknown side effect n.a. n.a. n.a. The drug is hydrolyzed by several kinds of intestinal bacteria (lactobacillus, bacteroides and E. coli) to form lactic and acetic acids, which lower the pH of the intestinal contents . At the lower pH, ammonia and the other amines present in the gastroin-testinal tract become protonated and tend to be excreted in faeces, the accentuated elimination of these amines is responsible for the laxative effect of lactulose n.a. PMID PMID: 36467581 PMDBI20019269 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019270 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019272 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" Cardiac drugs n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Affecting the pharmacokinetics and pharmacodynamics, and increasing the risk of myopathy n.a. PMID PMID: 36467581 PMDBI20019274 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019275 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019276 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019277 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019279 Microbes metabolize substances PMDBM268 1578 Lactobacillus PMDBD18 Acetylsalicylic acid Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. "Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency" n.a. PMID PMID: 36467581 PMDBI20019281 Microbes metabolize substances PMDBM2020133 n.a. Lactobacillus gasseri AM 63,DSM 20243,ATCC 33323,NCDO 2233,NCIB 11718 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Biotransformation n.a. PMID PMID: 36467581 PMDBI20019282 Microbes metabolize substances PMDBM2021329 n.a. Lactobacillus paracasei LPC-37,ATCC SD5275 PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20019283 Microbes metabolize substances PMDBM2021329 n.a. Lactobacillus paracasei LPC-37,ATCC SD5275 PMDBD1407 Rosiglitazone Therapeutic substance Anti-diabetics n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20019284 Microbes metabolize substances PMDBM2021254 n.a. Lactobacillus plantarum WCFS1,LMG 9211,NCIMB 8826 PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20019285 Microbes metabolize substances PMDBM2020119 1579 Lactobacillus acidophilus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019286 Microbes metabolize substances PMDBM2020119 1579 Lactobacillus acidophilus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019287 Microbes metabolize substances PMDBM2020119 1579 Lactobacillus acidophilus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019288 Microbes metabolize substances PMDBM2020119 1579 Lactobacillus acidophilus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019289 Microbes metabolize substances PMDBM2020119 1579 Lactobacillus acidophilus PMDBD2000058 Salicin Therapeutic Substance compound n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. The gut microbe, Lactobacillus acidophilus, catalytically unwraps plant glucosides, such as salicin, to make deglucosylated bioactive aglycones available to human tissues. n.a. PMID PMID: 36467581 PMDBI20019290 Microbes metabolize substances PMDBM2020119 1579 Lactobacillus acidophilus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019291 Microbes metabolize substances PMDBM2020119 1579 Lactobacillus acidophilus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019293 Microbes metabolize substances PMDBM2020119 1579 Lactobacillus acidophilus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019295 Microbes metabolize substances PMDBM2020123 83683 Lactobacillus amylolyticus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019296 Microbes metabolize substances PMDBM2020123 83683 Lactobacillus amylolyticus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019297 Microbes metabolize substances PMDBM2021596 1263084 Lactobacillus amylovorus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019298 Microbes metabolize substances PMDBM2021596 1263084 Lactobacillus amylovorus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019299 Microbes metabolize substances PMDBM2021596 1263084 Lactobacillus amylovorus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019300 Microbes metabolize substances PMDBM2020816 303541 Lactobacillus apis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019301 Microbes metabolize substances PMDBM2020816 303541 Lactobacillus apis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019302 Microbes metabolize substances PMDBM2020816 303541 Lactobacillus apis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019303 Microbes metabolize substances PMDBM2020816 303541 Lactobacillus apis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019304 Microbes metabolize substances PMDBM2020816 303541 Lactobacillus apis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019305 Microbes metabolize substances PMDBM2020816 303541 Lactobacillus apis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019306 Microbes metabolize substances PMDBM2020817 47770 Lactobacillus crispatus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019307 Microbes metabolize substances PMDBM2020817 47770 Lactobacillus crispatus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019308 Microbes metabolize substances PMDBM2020817 47770 Lactobacillus crispatus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019309 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019310 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019311 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019312 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019313 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019314 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019315 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019318 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019319 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019320 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019321 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019322 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019323 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019324 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019325 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019326 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019327 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019328 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019329 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019330 Microbes metabolize substances PMDBM2020132 1584 Lactobacillus delbrueckii A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019331 Microbes metabolize substances PMDBM2021597 52242 Lactobacillus gallinarum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019332 Microbes metabolize substances PMDBM2021597 52242 Lactobacillus gallinarum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019333 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019334 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019335 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019336 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019337 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019338 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019339 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019340 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019341 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019343 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20019346 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20019347 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20019348 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019351 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20019354 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019355 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019356 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019358 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019359 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019360 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019361 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019362 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019363 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri A PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019364 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri A PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019365 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri A PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20019367 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri A PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20019368 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri A PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20019369 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019372 Microbes metabolize substances PMDBM2020133 1596 Lactobacillus gasseri A PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20019376 Microbes metabolize substances PMDBM2020820 1587 Lactobacillus helveticus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019377 Microbes metabolize substances PMDBM2020820 1587 Lactobacillus helveticus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019378 Microbes metabolize substances PMDBM2021598 1203033 Lactobacillus hominis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019379 Microbes metabolize substances PMDBM2021598 1203033 Lactobacillus hominis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019380 Microbes metabolize substances PMDBM2021598 1203033 Lactobacillus hominis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20019382 Microbes metabolize substances PMDBM2021598 1203033 Lactobacillus hominis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20019383 Microbes metabolize substances PMDBM2021598 1203033 Lactobacillus hominis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20019384 Microbes metabolize substances PMDBM2021598 1203033 Lactobacillus hominis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019387 Microbes metabolize substances PMDBM2021598 1203033 Lactobacillus hominis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20019391 Microbes metabolize substances PMDBM2021598 1203033 Lactobacillus hominis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019392 Microbes metabolize substances PMDBM2020821 147802 Lactobacillus iners PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019393 Microbes metabolize substances PMDBM2020822 151781 Lactobacillus intestinalis PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20019394 Microbes metabolize substances PMDBM2020822 151781 Lactobacillus intestinalis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019395 Microbes metabolize substances PMDBM2020822 151781 Lactobacillus intestinalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019396 Microbes metabolize substances PMDBM2020822 151781 Lactobacillus intestinalis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019397 Microbes metabolize substances PMDBM2020125 109790 Lactobacillus jenseniis A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019398 Microbes metabolize substances PMDBM2020125 109790 Lactobacillus jenseniis A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019399 Microbes metabolize substances PMDBM2020130 33959 Lactobacillus johnsonii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019400 Microbes metabolize substances PMDBM2020130 33959 Lactobacillus johnsonii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019401 Microbes metabolize substances PMDBM2020130 33959 Lactobacillus johnsonii PMDBD237 Cyclophosphamide Therapeutic Substance lymphoma and leukemia n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. they were instrumental in the stimulation a Th1 and Th17 immune response. n.a. PMID PMID: 36467581 PMDBI20019402 Microbes metabolize substances PMDBM2020823 227944 Lactobacillus kalixensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019403 Microbes metabolize substances PMDBM2020823 227944 Lactobacillus kalixensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019404 Microbes metabolize substances PMDBM2020823 227944 Lactobacillus kalixensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019405 Microbes metabolize substances PMDBM2020823 227944 Lactobacillus kalixensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019406 Microbes metabolize substances PMDBM2020823 227944 Lactobacillus kalixensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019407 Microbes metabolize substances PMDBM2020823 227944 Lactobacillus kalixensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019408 Microbes metabolize substances PMDBM2020823 227944 Lactobacillus kalixensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019411 Microbes metabolize substances PMDBM2020823 227944 Lactobacillus kalixensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019412 Microbes metabolize substances PMDBM2020823 227944 Lactobacillus kalixensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019413 Microbes metabolize substances PMDBM2020823 227944 Lactobacillus kalixensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019414 Microbes metabolize substances PMDBM2020823 227944 Lactobacillus kalixensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019415 Microbes metabolize substances PMDBM2020823 227944 Lactobacillus kalixensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019416 Microbes metabolize substances PMDBM277 1622 Lactobacillus murinus PMDBD237 Cyclophosphamide Therapeutic Substance lymphoma and leukemia n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. they were instrumental in the stimulation a Th1 and Th17 immune response. n.a. PMID PMID: 36467581 PMDBI20019417 Microbes metabolize substances PMDBM2020131 227945 Lactobacillus ultunensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019418 Microbes metabolize substances PMDBM2020131 227945 Lactobacillus ultunensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019419 Microbes metabolize substances PMDBM2020131 227945 Lactobacillus ultunensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019420 Microbes metabolize substances PMDBM2020131 227945 Lactobacillus ultunensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019421 Microbes metabolize substances PMDBM2020131 227945 Lactobacillus ultunensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019422 Microbes metabolize substances PMDBM2020131 227945 Lactobacillus ultunensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019423 Microbes metabolize substances PMDBM2020131 227945 Lactobacillus ultunensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019426 Microbes metabolize substances PMDBM2020131 227945 Lactobacillus ultunensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019427 Microbes metabolize substances PMDBM2020131 227945 Lactobacillus ultunensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019428 Microbes metabolize substances PMDBM2020131 227945 Lactobacillus ultunensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019429 Microbes metabolize substances PMDBM2020131 227945 Lactobacillus ultunensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019430 Microbes metabolize substances PMDBM2020131 227945 Lactobacillus ultunensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019431 Microbes metabolize substances PMDBM2020131 227945 Lactobacillus ultunensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019432 Microbes metabolize substances PMDBM285 1357 Lactococcus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019433 Microbes metabolize substances PMDBM285 1357 Lactococcus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019434 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis subsp. lactis IL1403,CIRM BIA 96,CNRZ 1342 PMDBD2000059 Roflumilast Therapeutic Substance Drugs for obstructive airway disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20019435 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019436 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019437 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019438 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019439 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019440 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019441 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019444 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019445 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019446 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019447 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019448 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019449 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019450 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019451 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019452 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019453 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019454 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019455 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019456 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019457 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019460 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019461 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019462 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019463 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019464 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019465 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019466 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019467 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis E PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019468 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis E PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019469 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis E PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019470 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis E PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019471 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis E PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019472 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019473 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019474 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019475 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019476 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019477 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019478 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019481 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019482 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019483 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019484 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019485 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019486 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019487 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019488 Microbes metabolize substances PMDBM2020830 1358 Lactococcus lactis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019489 Microbes metabolize substances PMDBM2021599 1940789 Lactococcus petauri PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019490 Microbes metabolize substances PMDBM2021599 1940789 Lactococcus petauri PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019491 Microbes metabolize substances PMDBM2021599 1940789 Lactococcus petauri PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019492 Microbes metabolize substances PMDBM2021599 1940789 Lactococcus petauri PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019493 Microbes metabolize substances PMDBM2021599 1940789 Lactococcus petauri PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019494 Microbes metabolize substances PMDBM2021599 1940789 Lactococcus petauri PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019495 Microbes metabolize substances PMDBM2021599 1940789 Lactococcus petauri PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019498 Microbes metabolize substances PMDBM2021599 1940789 Lactococcus petauri PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019499 Microbes metabolize substances PMDBM2021599 1940789 Lactococcus petauri PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019500 Microbes metabolize substances PMDBM2021599 1940789 Lactococcus petauri PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019501 Microbes metabolize substances PMDBM2021599 1940789 Lactococcus petauri PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019502 Microbes metabolize substances PMDBM2021599 1940789 Lactococcus petauri PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019503 Microbes metabolize substances PMDBM2021599 1940789 Lactococcus petauri PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019504 Microbes metabolize substances PMDBM2021599 1940789 Lactococcus petauri PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019505 Microbes metabolize substances PMDBM2021600 1364 Lactococcus piscium C PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019506 Microbes metabolize substances PMDBM2021600 1364 Lactococcus piscium C PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019507 Microbes metabolize substances PMDBM2021600 1364 Lactococcus piscium C PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019508 Microbes metabolize substances PMDBM2021600 1364 Lactococcus piscium C PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019509 Microbes metabolize substances PMDBM2021600 1364 Lactococcus piscium C PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019510 Microbes metabolize substances PMDBM2021600 1364 Lactococcus piscium C PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019511 Microbes metabolize substances PMDBM2021600 1364 Lactococcus piscium C PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019514 Microbes metabolize substances PMDBM2021600 1364 Lactococcus piscium C PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019515 Microbes metabolize substances PMDBM2021600 1364 Lactococcus piscium C PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019516 Microbes metabolize substances PMDBM2021600 1364 Lactococcus piscium C PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019517 Microbes metabolize substances PMDBM2021600 1364 Lactococcus piscium C PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019518 Microbes metabolize substances PMDBM2021600 1364 Lactococcus piscium C PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019519 Microbes metabolize substances PMDBM2021289 1366 Lactococcus raffinolactis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019520 Microbes metabolize substances PMDBM2021289 1366 Lactococcus raffinolactis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019521 Microbes metabolize substances PMDBM2021289 1366 Lactococcus raffinolactis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019522 Microbes metabolize substances PMDBM2021289 1366 Lactococcus raffinolactis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019523 Microbes metabolize substances PMDBM2021289 1366 Lactococcus raffinolactis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019524 Microbes metabolize substances PMDBM2021289 1366 Lactococcus raffinolactis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019525 Microbes metabolize substances PMDBM2021289 1366 Lactococcus raffinolactis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019528 Microbes metabolize substances PMDBM2021289 1366 Lactococcus raffinolactis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019529 Microbes metabolize substances PMDBM2021289 1366 Lactococcus raffinolactis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019530 Microbes metabolize substances PMDBM2021289 1366 Lactococcus raffinolactis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019531 Microbes metabolize substances PMDBM2021289 1366 Lactococcus raffinolactis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019532 Microbes metabolize substances PMDBM2021289 1366 Lactococcus raffinolactis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019533 Microbes metabolize substances PMDBM2021289 1366 Lactococcus raffinolactis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019534 Microbes metabolize substances PMDBM2021289 1366 Lactococcus raffinolactis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019535 Microbes metabolize substances PMDBM2020065 341220 Lactonifactor longoviformis PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20019536 Microbes metabolize substances PMDBM2020065 341220 Lactonifactor longoviformis PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20019537 Microbes metabolize substances PMDBM2020065 341220 Lactonifactor longoviformis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019538 Microbes metabolize substances PMDBM2020065 341220 Lactonifactor longoviformis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019539 Microbes metabolize substances PMDBM2020065 341220 Lactonifactor longoviformis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019540 Microbes metabolize substances PMDBM2020065 341220 Lactonifactor longoviformis PMDBD772 Secoisolariciresinol Therapeutic Substance anticancer n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. unknown activity increased n.a. n.a. n.a. Protective effects against breast cancer n.a. PMID PMID: 36467581 PMDBI20019541 Microbes metabolize substances PMDBM2020065 341220 Lactonifactor longoviformis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019542 Microbes metabolize substances PMDBM2020065 341220 Lactonifactor longoviformis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019543 Microbes metabolize substances PMDBM2020831 1689303 Lagierella massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019544 Microbes metabolize substances PMDBM2020831 1689303 Lagierella massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019545 Microbes metabolize substances PMDBM2020831 1689303 Lagierella massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019546 Microbes metabolize substances PMDBM2020831 1689303 Lagierella massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019547 Microbes metabolize substances PMDBM2020831 1689303 Lagierella massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019548 Microbes metabolize substances PMDBM2009172 2767353 Lancefieldella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019549 Microbes metabolize substances PMDBM2009172 2767353 Lancefieldella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019550 Microbes metabolize substances PMDBM2009172 2767353 Lancefieldella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019551 Microbes metabolize substances PMDBM2009172 2767353 Lancefieldella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019552 Microbes metabolize substances PMDBM2009172 2767353 Lancefieldella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019553 Microbes metabolize substances PMDBM2009172 2767353 Lancefieldella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019554 Microbes metabolize substances PMDBM2009172 2767353 Lancefieldella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019557 Microbes metabolize substances PMDBM2009172 2767353 Lancefieldella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019558 Microbes metabolize substances PMDBM2009172 2767353 Lancefieldella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019559 Microbes metabolize substances PMDBM2009172 2767353 Lancefieldella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019560 Microbes metabolize substances PMDBM2009172 2767353 Lancefieldella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019561 Microbes metabolize substances PMDBM2009172 2767353 Lancefieldella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019562 Microbes metabolize substances PMDBM2009172 2767353 Lancefieldella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019563 Microbes metabolize substances PMDBM2009172 2767353 Lancefieldella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019564 Microbes metabolize substances PMDBM2009172 2767353 Lancefieldella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019565 Microbes metabolize substances PMDBM2021601 1382 Lancefieldella parvula PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019566 Microbes metabolize substances PMDBM2021601 1382 Lancefieldella parvula PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019567 Microbes metabolize substances PMDBM2021601 1382 Lancefieldella parvula PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019568 Microbes metabolize substances PMDBM2021601 1382 Lancefieldella parvula PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019569 Microbes metabolize substances PMDBM2021601 1382 Lancefieldella parvula PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019570 Microbes metabolize substances PMDBM2021601 1382 Lancefieldella parvula PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019571 Microbes metabolize substances PMDBM2021601 1382 Lancefieldella parvula PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019574 Microbes metabolize substances PMDBM2021601 1382 Lancefieldella parvula PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019575 Microbes metabolize substances PMDBM2021601 1382 Lancefieldella parvula PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019576 Microbes metabolize substances PMDBM2021601 1382 Lancefieldella parvula PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019577 Microbes metabolize substances PMDBM2021601 1382 Lancefieldella parvula PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019578 Microbes metabolize substances PMDBM2021601 1382 Lancefieldella parvula PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019579 Microbes metabolize substances PMDBM2021602 1383 Lancefieldella rimae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019580 Microbes metabolize substances PMDBM2021602 1383 Lancefieldella rimae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019581 Microbes metabolize substances PMDBM2021602 1383 Lancefieldella rimae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019582 Microbes metabolize substances PMDBM2021602 1383 Lancefieldella rimae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019583 Microbes metabolize substances PMDBM2021602 1383 Lancefieldella rimae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019584 Microbes metabolize substances PMDBM2021602 1383 Lancefieldella rimae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019585 Microbes metabolize substances PMDBM2021602 1383 Lancefieldella rimae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019588 Microbes metabolize substances PMDBM2021602 1383 Lancefieldella rimae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019589 Microbes metabolize substances PMDBM2021602 1383 Lancefieldella rimae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019590 Microbes metabolize substances PMDBM2021602 1383 Lancefieldella rimae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019591 Microbes metabolize substances PMDBM2021602 1383 Lancefieldella rimae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019592 Microbes metabolize substances PMDBM2021602 1383 Lancefieldella rimae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019593 Microbes metabolize substances PMDBM2021602 1383 Lancefieldella rimae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019594 Microbes metabolize substances PMDBM2021602 1383 Lancefieldella rimae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019595 Microbes metabolize substances PMDBM2009175 n.a. Lancefieldella sp000564995 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019596 Microbes metabolize substances PMDBM2009175 n.a. Lancefieldella sp000564995 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019597 Microbes metabolize substances PMDBM2009175 n.a. Lancefieldella sp000564995 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019598 Microbes metabolize substances PMDBM2009175 n.a. Lancefieldella sp000564995 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019599 Microbes metabolize substances PMDBM2009175 n.a. Lancefieldella sp000564995 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019600 Microbes metabolize substances PMDBM2009175 n.a. Lancefieldella sp000564995 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019601 Microbes metabolize substances PMDBM2009175 n.a. Lancefieldella sp000564995 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019604 Microbes metabolize substances PMDBM2009175 n.a. Lancefieldella sp000564995 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019605 Microbes metabolize substances PMDBM2009175 n.a. Lancefieldella sp000564995 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019606 Microbes metabolize substances PMDBM2009175 n.a. Lancefieldella sp000564995 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019607 Microbes metabolize substances PMDBM2009175 n.a. Lancefieldella sp000564995 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019608 Microbes metabolize substances PMDBM2009175 n.a. Lancefieldella sp000564995 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019609 Microbes metabolize substances PMDBM2009175 n.a. Lancefieldella sp000564995 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019610 Microbes metabolize substances PMDBM2009175 n.a. Lancefieldella sp000564995 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019611 Microbes metabolize substances PMDBM2009175 n.a. Lancefieldella sp000564995 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019612 Microbes metabolize substances PMDBM2021238 168471 Laribacter hongkongensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019613 Microbes metabolize substances PMDBM2021238 168471 Laribacter hongkongensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019614 Microbes metabolize substances PMDBM2021238 168471 Laribacter hongkongensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019615 Microbes metabolize substances PMDBM2021238 168471 Laribacter hongkongensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019616 Microbes metabolize substances PMDBM2021238 168471 Laribacter hongkongensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019617 Microbes metabolize substances PMDBM2021238 168471 Laribacter hongkongensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019618 Microbes metabolize substances PMDBM2021238 168471 Laribacter hongkongensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019619 Microbes metabolize substances PMDBM2021238 168471 Laribacter hongkongensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019622 Microbes metabolize substances PMDBM2021238 168471 Laribacter hongkongensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019623 Microbes metabolize substances PMDBM2021238 168471 Laribacter hongkongensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019624 Microbes metabolize substances PMDBM2021238 168471 Laribacter hongkongensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019625 Microbes metabolize substances PMDBM2021238 168471 Laribacter hongkongensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019626 Microbes metabolize substances PMDBM2021238 168471 Laribacter hongkongensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019627 Microbes metabolize substances PMDBM2021238 168471 Laribacter hongkongensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019628 Microbes metabolize substances PMDBM2009177 1847725 Lawsonella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019629 Microbes metabolize substances PMDBM2009177 1847725 Lawsonella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019630 Microbes metabolize substances PMDBM2009177 1847725 Lawsonella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019631 Microbes metabolize substances PMDBM2009177 1847725 Lawsonella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019632 Microbes metabolize substances PMDBM2009177 1847725 Lawsonella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019633 Microbes metabolize substances PMDBM2009177 1847725 Lawsonella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019634 Microbes metabolize substances PMDBM2009177 1847725 Lawsonella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019637 Microbes metabolize substances PMDBM2009177 1847725 Lawsonella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019638 Microbes metabolize substances PMDBM2009177 1847725 Lawsonella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019639 Microbes metabolize substances PMDBM2009177 1847725 Lawsonella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019640 Microbes metabolize substances PMDBM2009177 1847725 Lawsonella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019641 Microbes metabolize substances PMDBM2009177 1847725 Lawsonella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019642 Microbes metabolize substances PMDBM2021603 1528099 Lawsonella clevelandensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019643 Microbes metabolize substances PMDBM2021603 1528099 Lawsonella clevelandensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019644 Microbes metabolize substances PMDBM2021603 1528099 Lawsonella clevelandensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019645 Microbes metabolize substances PMDBM2021603 1528099 Lawsonella clevelandensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019646 Microbes metabolize substances PMDBM2021603 1528099 Lawsonella clevelandensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019647 Microbes metabolize substances PMDBM2021603 1528099 Lawsonella clevelandensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019648 Microbes metabolize substances PMDBM2021603 1528099 Lawsonella clevelandensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019651 Microbes metabolize substances PMDBM2021603 1528099 Lawsonella clevelandensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20019652 Microbes metabolize substances PMDBM2021603 1528099 Lawsonella clevelandensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019653 Microbes metabolize substances PMDBM2021603 1528099 Lawsonella clevelandensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019654 Microbes metabolize substances PMDBM2021603 1528099 Lawsonella clevelandensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019655 Microbes metabolize substances PMDBM2021603 1528099 Lawsonella clevelandensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019656 Microbes metabolize substances PMDBM2021603 1528099 Lawsonella clevelandensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019657 Microbes metabolize substances PMDBM2009179 2172004 Lawsonibacter PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019658 Microbes metabolize substances PMDBM2009179 2172004 Lawsonibacter PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019659 Microbes metabolize substances PMDBM2009179 2172004 Lawsonibacter PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019660 Microbes metabolize substances PMDBM2009179 2172004 Lawsonibacter PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019662 Microbes metabolize substances PMDBM2009179 2172004 Lawsonibacter PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019664 Microbes metabolize substances PMDBM2009179 2172004 Lawsonibacter PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20019665 Microbes metabolize substances PMDBM2009179 2172004 Lawsonibacter PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019666 Microbes metabolize substances PMDBM2009179 2172004 Lawsonibacter PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019667 Microbes metabolize substances PMDBM2009179 2172004 Lawsonibacter PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019668 Microbes metabolize substances PMDBM2009179 2172004 Lawsonibacter PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019671 Microbes metabolize substances PMDBM2009179 2172004 Lawsonibacter PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019672 Microbes metabolize substances PMDBM2009179 2172004 Lawsonibacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019673 Microbes metabolize substances PMDBM2009179 2172004 Lawsonibacter PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019674 Microbes metabolize substances PMDBM2009179 2172004 Lawsonibacter PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019676 Microbes metabolize substances PMDBM2009179 2172004 Lawsonibacter PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019677 Microbes metabolize substances PMDBM2009179 2172004 Lawsonibacter PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019678 Microbes metabolize substances PMDBM2009179 2172004 Lawsonibacter PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019679 Microbes metabolize substances PMDBM2021604 2108523 Lawsonibacter asaccharolyticus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019680 Microbes metabolize substances PMDBM2021604 2108523 Lawsonibacter asaccharolyticus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019681 Microbes metabolize substances PMDBM2021604 2108523 Lawsonibacter asaccharolyticus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019682 Microbes metabolize substances PMDBM2021604 2108523 Lawsonibacter asaccharolyticus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019683 Microbes metabolize substances PMDBM2021604 2108523 Lawsonibacter asaccharolyticus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019684 Microbes metabolize substances PMDBM2021604 2108523 Lawsonibacter asaccharolyticus PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20019685 Microbes metabolize substances PMDBM2021604 2108523 Lawsonibacter asaccharolyticus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019686 Microbes metabolize substances PMDBM2021604 2108523 Lawsonibacter asaccharolyticus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019687 Microbes metabolize substances PMDBM2021604 2108523 Lawsonibacter asaccharolyticus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019688 Microbes metabolize substances PMDBM2021604 2108523 Lawsonibacter asaccharolyticus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019689 Microbes metabolize substances PMDBM2021604 2108523 Lawsonibacter asaccharolyticus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019690 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp000177015 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019691 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp000177015 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019692 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp000177015 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019693 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp000177015 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019695 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp000177015 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019697 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp000177015 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019698 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp000177015 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019699 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp000177015 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019700 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp000177015 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019703 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp000177015 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019704 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp000177015 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019705 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp000177015 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019706 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp000177015 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019708 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp000177015 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019709 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp000177015 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019710 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp000177015 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019711 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp002160305 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019712 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp002160305 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019713 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp002160305 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019714 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp002160305 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019715 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp002160305 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019717 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp002160305 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019719 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp002160305 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019720 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp002160305 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019721 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp002160305 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019722 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp002160305 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019725 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp002160305 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019726 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp002160305 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019727 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp002160305 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019729 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp002160305 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019730 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp002160305 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019731 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp002160305 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019732 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp900066645 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019733 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp900066645 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019734 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp900066645 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019735 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp900066645 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019736 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp900066645 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019737 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp900066825 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019738 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp900066825 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019739 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp900066825 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019740 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp900066825 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019741 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp900066825 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019742 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp900066825 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019743 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp900066825 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019744 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp900066825 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019745 Microbes metabolize substances PMDBM2021605 2185275 Lawsonibacter sp900066825 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019746 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019747 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019748 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019749 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019750 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019751 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019752 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019755 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20019756 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20019757 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019758 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019759 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20019760 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019761 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019762 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019763 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20019764 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019765 Microbes metabolize substances PMDBM2020833 83655 Leclercia adecarboxylata C PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019766 Microbes metabolize substances PMDBM2020834 82981 Leminorella grimontii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019767 Microbes metabolize substances PMDBM2020834 82981 Leminorella grimontii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019768 Microbes metabolize substances PMDBM2020834 82981 Leminorella grimontii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019769 Microbes metabolize substances PMDBM2020834 82981 Leminorella grimontii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019771 Microbes metabolize substances PMDBM2020834 82981 Leminorella grimontii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019773 Microbes metabolize substances PMDBM2020834 82981 Leminorella grimontii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019774 Microbes metabolize substances PMDBM2020834 82981 Leminorella grimontii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019775 Microbes metabolize substances PMDBM2020834 82981 Leminorella grimontii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019776 Microbes metabolize substances PMDBM2020834 82981 Leminorella grimontii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019779 Microbes metabolize substances PMDBM2020834 82981 Leminorella grimontii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019780 Microbes metabolize substances PMDBM2020834 82981 Leminorella grimontii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019781 Microbes metabolize substances PMDBM2020834 82981 Leminorella grimontii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019782 Microbes metabolize substances PMDBM2020834 82981 Leminorella grimontii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019784 Microbes metabolize substances PMDBM2020834 82981 Leminorella grimontii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019785 Microbes metabolize substances PMDBM2020834 82981 Leminorella grimontii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019786 Microbes metabolize substances PMDBM2021606 158841 Leminorella richardii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019787 Microbes metabolize substances PMDBM2021606 158841 Leminorella richardii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019788 Microbes metabolize substances PMDBM2021606 158841 Leminorella richardii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019789 Microbes metabolize substances PMDBM2021606 158841 Leminorella richardii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019791 Microbes metabolize substances PMDBM2021606 158841 Leminorella richardii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019793 Microbes metabolize substances PMDBM2021606 158841 Leminorella richardii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019794 Microbes metabolize substances PMDBM2021606 158841 Leminorella richardii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019795 Microbes metabolize substances PMDBM2021606 158841 Leminorella richardii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019796 Microbes metabolize substances PMDBM2021606 158841 Leminorella richardii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019799 Microbes metabolize substances PMDBM2021606 158841 Leminorella richardii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019800 Microbes metabolize substances PMDBM2021606 158841 Leminorella richardii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019801 Microbes metabolize substances PMDBM2021606 158841 Leminorella richardii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019802 Microbes metabolize substances PMDBM2021606 158841 Leminorella richardii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019804 Microbes metabolize substances PMDBM2021606 158841 Leminorella richardii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019805 Microbes metabolize substances PMDBM2021606 158841 Leminorella richardii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019806 Microbes metabolize substances PMDBM2009188 32067 Leptotrichia PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019807 Microbes metabolize substances PMDBM2009188 32067 Leptotrichia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019808 Microbes metabolize substances PMDBM2009188 32067 Leptotrichia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019809 Microbes metabolize substances PMDBM2020839 157687 Leptotrichia wadei PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019810 Microbes metabolize substances PMDBM2020839 157687 Leptotrichia wadei PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019811 Microbes metabolize substances PMDBM2020839 157687 Leptotrichia wadei PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019812 Microbes metabolize substances PMDBM2020839 157687 Leptotrichia wadei PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019813 Microbes metabolize substances PMDBM2020839 157687 Leptotrichia wadei PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019814 Microbes metabolize substances PMDBM2020839 157687 Leptotrichia wadei PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019815 Microbes metabolize substances PMDBM2020839 157687 Leptotrichia wadei PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019818 Microbes metabolize substances PMDBM2020839 157687 Leptotrichia wadei PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019819 Microbes metabolize substances PMDBM2020839 157687 Leptotrichia wadei PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019820 Microbes metabolize substances PMDBM2020839 157687 Leptotrichia wadei PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019821 Microbes metabolize substances PMDBM2020839 157687 Leptotrichia wadei PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019822 Microbes metabolize substances PMDBM2020839 157687 Leptotrichia wadei PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019823 Microbes metabolize substances PMDBM288 1243 Leuconostoc PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019824 Microbes metabolize substances PMDBM288 1243 Leuconostoc PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019825 Microbes metabolize substances PMDBM288 1243 Leuconostoc PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019826 Microbes metabolize substances PMDBM288 1243 Leuconostoc PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019827 Microbes metabolize substances PMDBM288 1243 Leuconostoc PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019828 Microbes metabolize substances PMDBM288 1243 Leuconostoc PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019829 Microbes metabolize substances PMDBM288 1243 Leuconostoc PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019832 Microbes metabolize substances PMDBM288 1243 Leuconostoc PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019833 Microbes metabolize substances PMDBM288 1243 Leuconostoc PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019834 Microbes metabolize substances PMDBM288 1243 Leuconostoc PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019835 Microbes metabolize substances PMDBM288 1243 Leuconostoc PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019836 Microbes metabolize substances PMDBM288 1243 Leuconostoc PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019837 Microbes metabolize substances PMDBM288 1243 Leuconostoc PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019838 Microbes metabolize substances PMDBM2020841 33964 Leuconostoc citreum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019839 Microbes metabolize substances PMDBM2020844 1246 Leuconostoc lactis B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019840 Microbes metabolize substances PMDBM2020845 1245 Leuconostoc mesenteroides PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019841 Microbes metabolize substances PMDBM2020845 1245 Leuconostoc mesenteroides PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019842 Microbes metabolize substances PMDBM2020845 1245 Leuconostoc mesenteroides PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019843 Microbes metabolize substances PMDBM2020845 1245 Leuconostoc mesenteroides PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019844 Microbes metabolize substances PMDBM2020845 1245 Leuconostoc mesenteroides PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019845 Microbes metabolize substances PMDBM2020845 1245 Leuconostoc mesenteroides PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019846 Microbes metabolize substances PMDBM2020845 1245 Leuconostoc mesenteroides PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019849 Microbes metabolize substances PMDBM2020845 1245 Leuconostoc mesenteroides PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019850 Microbes metabolize substances PMDBM2020845 1245 Leuconostoc mesenteroides PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019851 Microbes metabolize substances PMDBM2020845 1245 Leuconostoc mesenteroides PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019852 Microbes metabolize substances PMDBM2020845 1245 Leuconostoc mesenteroides PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019853 Microbes metabolize substances PMDBM2021607 938289 Levyella massiliensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20019854 Microbes metabolize substances PMDBM2021607 938289 Levyella massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019855 Microbes metabolize substances PMDBM2021607 938289 Levyella massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019856 Microbes metabolize substances PMDBM2021607 938289 Levyella massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019857 Microbes metabolize substances PMDBM2021607 938289 Levyella massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019858 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019859 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019860 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019861 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019863 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20019865 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019866 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019867 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019868 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019869 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20019870 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019872 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20019875 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20019876 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20019877 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019878 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019881 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20019884 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019885 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019888 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019889 Microbes metabolize substances PMDBM2009194 2082587 Libanicoccus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019890 Microbes metabolize substances PMDBM2021608 1871022 Libanicoccus massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019891 Microbes metabolize substances PMDBM2021608 1871022 Libanicoccus massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019892 Microbes metabolize substances PMDBM2021608 1871022 Libanicoccus massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019893 Microbes metabolize substances PMDBM2021608 1871022 Libanicoccus massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019894 Microbes metabolize substances PMDBM2021608 1871022 Libanicoccus massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019895 Microbes metabolize substances PMDBM2021608 1871022 Libanicoccus massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019896 Microbes metabolize substances PMDBM2021608 1871022 Libanicoccus massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019899 Microbes metabolize substances PMDBM2021608 1871022 Libanicoccus massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019900 Microbes metabolize substances PMDBM2021608 1871022 Libanicoccus massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019901 Microbes metabolize substances PMDBM2021608 1871022 Libanicoccus massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019902 Microbes metabolize substances PMDBM2021608 1871022 Libanicoccus massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019903 Microbes metabolize substances PMDBM2021608 1871022 Libanicoccus massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019904 Microbes metabolize substances PMDBM2020135 1641 Listeria grayi PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019905 Microbes metabolize substances PMDBM2020135 1641 Listeria grayi PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019906 Microbes metabolize substances PMDBM2020135 1641 Listeria grayi PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019907 Microbes metabolize substances PMDBM2020135 1641 Listeria grayi PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019908 Microbes metabolize substances PMDBM2020135 1641 Listeria grayi PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019909 Microbes metabolize substances PMDBM2020135 1641 Listeria grayi PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019910 Microbes metabolize substances PMDBM2020135 1641 Listeria grayi PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019911 Microbes metabolize substances PMDBM2020135 1641 Listeria grayi PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019914 Microbes metabolize substances PMDBM2020135 1641 Listeria grayi PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019915 Microbes metabolize substances PMDBM2020135 1641 Listeria grayi PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019916 Microbes metabolize substances PMDBM2020135 1641 Listeria grayi PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019917 Microbes metabolize substances PMDBM2020135 1641 Listeria grayi PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019918 Microbes metabolize substances PMDBM2020135 1641 Listeria grayi PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019919 Microbes metabolize substances PMDBM2020135 1641 Listeria grayi PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019920 Microbes metabolize substances PMDBM2020847 1642 Listeria innocua PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019921 Microbes metabolize substances PMDBM2020847 1642 Listeria innocua PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019922 Microbes metabolize substances PMDBM2020847 1642 Listeria innocua PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019923 Microbes metabolize substances PMDBM2020847 1642 Listeria innocua PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019924 Microbes metabolize substances PMDBM2020847 1642 Listeria innocua PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019925 Microbes metabolize substances PMDBM2020847 1642 Listeria innocua PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019926 Microbes metabolize substances PMDBM2020847 1642 Listeria innocua PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019927 Microbes metabolize substances PMDBM2020847 1642 Listeria innocua PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019930 Microbes metabolize substances PMDBM2020847 1642 Listeria innocua PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019931 Microbes metabolize substances PMDBM2020847 1642 Listeria innocua PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019932 Microbes metabolize substances PMDBM2020847 1642 Listeria innocua PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019933 Microbes metabolize substances PMDBM2020847 1642 Listeria innocua PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019934 Microbes metabolize substances PMDBM2020847 1642 Listeria innocua PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019935 Microbes metabolize substances PMDBM2020847 1642 Listeria innocua PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019936 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019937 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes B PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019938 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019939 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019940 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019941 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019942 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019943 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019946 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019947 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019948 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019949 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019950 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019951 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019952 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019953 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019954 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019955 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019956 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019957 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019958 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019959 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019962 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019963 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019964 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019965 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20019966 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019967 Microbes metabolize substances PMDBM2020848 1639 Listeria monocytogenes PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019968 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD200 Cladribine "Therapeutic Substance; Herbal Substance" chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20019969 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD866 Tretazicar Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Increase hemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20019970 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD1142 Daunorubicin Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20019971 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD1198 Fludarabine de phosphate Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. Increase hemotherapeutic drug cytotoxicity in vitro. n.a. PMID PMID: 36467581 PMDBI20019972 Microbes metabolize substances PMDBM2020066 n.a. Listeria welshimeri serovar 6B SLCC533410 PMDBD1198 Fludarabine de phosphate Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20019973 Microbes metabolize substances PMDBM2020066 n.a. Listeria welshimeri serovar 6B SLCC533410 PMDBD866 Tretazicar Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20019974 Microbes metabolize substances PMDBM2020066 n.a. Listeria welshimeri serovar 6B SLCC533410 PMDBD200 Cladribine "Therapeutic Substance; Herbal Substance" chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20019975 Microbes metabolize substances PMDBM2020066 n.a. Listeria welshimeri serovar 6B SLCC533410 PMDBD1142 Daunorubicin Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. unknown n.a. PMID PMID: 36467581 PMDBI20019976 Microbes metabolize substances PMDBM2009201 n.a. Luminal bacteria PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. unknown side effect n.a. n.a. n.a. Interaction of the oral NSAID, indomethacin, with gut microbes resulted in damage to the intestinalmucosa. n.a. PMID PMID: 36467581 PMDBI20019977 Microbes metabolize substances PMDBM2009202 n.a. Lysinibacillus C PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20019978 Microbes metabolize substances PMDBM2009202 n.a. Lysinibacillus C PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019979 Microbes metabolize substances PMDBM2009202 n.a. Lysinibacillus C PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019980 Microbes metabolize substances PMDBM2009202 n.a. Lysinibacillus C PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20019981 Microbes metabolize substances PMDBM2009203 1981028 Mailhella PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20019982 Microbes metabolize substances PMDBM2009203 1981028 Mailhella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019983 Microbes metabolize substances PMDBM2009203 1981028 Mailhella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019984 Microbes metabolize substances PMDBM2021609 1981029 Mailhella sp003150275 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20019985 Microbes metabolize substances PMDBM2021609 1981029 Mailhella sp003150275 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20019986 Microbes metabolize substances PMDBM2021609 1981029 Mailhella sp003150275 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019987 Microbes metabolize substances PMDBM2021609 1981029 Mailhella sp003150275 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019988 Microbes metabolize substances PMDBM2009205 558415 Marinilabiliaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20019989 Microbes metabolize substances PMDBM2009205 558415 Marinilabiliaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20019990 Microbes metabolize substances PMDBM2009205 558415 Marinilabiliaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20019991 Microbes metabolize substances PMDBM2009205 558415 Marinilabiliaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019992 Microbes metabolize substances PMDBM2009205 558415 Marinilabiliaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019993 Microbes metabolize substances PMDBM2009205 558415 Marinilabiliaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20019994 Microbes metabolize substances PMDBM2009205 558415 Marinilabiliaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20019997 Microbes metabolize substances PMDBM2009205 558415 Marinilabiliaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20019998 Microbes metabolize substances PMDBM2009205 558415 Marinilabiliaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20019999 Microbes metabolize substances PMDBM2009205 558415 Marinilabiliaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020000 Microbes metabolize substances PMDBM2009205 558415 Marinilabiliaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020001 Microbes metabolize substances PMDBM2009205 558415 Marinilabiliaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020002 Microbes metabolize substances PMDBM2009205 558415 Marinilabiliaceae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020003 Microbes metabolize substances PMDBM2009205 558415 Marinilabiliaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020004 Microbes metabolize substances PMDBM2009205 558415 Marinilabiliaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020005 Microbes metabolize substances PMDBM2009206 n.a. Marseille-P3106 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20020006 Microbes metabolize substances PMDBM2009206 n.a. Marseille-P3106 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020007 Microbes metabolize substances PMDBM2009206 n.a. Marseille-P3106 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020008 Microbes metabolize substances PMDBM2009206 n.a. Marseille-P3106 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020009 Microbes metabolize substances PMDBM2009206 n.a. Marseille-P3106 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020010 Microbes metabolize substances PMDBM2009206 n.a. Marseille-P3106 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020011 Microbes metabolize substances PMDBM2009207 n.a. Marseille-P3106 sp900169975 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20020012 Microbes metabolize substances PMDBM2009207 n.a. Marseille-P3106 sp900169975 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020013 Microbes metabolize substances PMDBM2009207 n.a. Marseille-P3106 sp900169975 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020014 Microbes metabolize substances PMDBM2009207 n.a. Marseille-P3106 sp900169975 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020015 Microbes metabolize substances PMDBM2009207 n.a. Marseille-P3106 sp900169975 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020016 Microbes metabolize substances PMDBM2009207 n.a. Marseille-P3106 sp900169975 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020017 Microbes metabolize substances PMDBM2009208 n.a. Marseille-P4683 sp900232885 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020018 Microbes metabolize substances PMDBM2009208 n.a. Marseille-P4683 sp900232885 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020019 Microbes metabolize substances PMDBM2009208 n.a. Marseille-P4683 sp900232885 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020020 Microbes metabolize substances PMDBM2009208 n.a. Marseille-P4683 sp900232885 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020021 Microbes metabolize substances PMDBM2009208 n.a. Marseille-P4683 sp900232885 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020022 Microbes metabolize substances PMDBM2009208 n.a. Marseille-P4683 sp900232885 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020023 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020024 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020025 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020026 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020028 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020030 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020031 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020032 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020033 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20020034 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20020035 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020037 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20020040 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20020041 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20020042 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020043 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020046 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20020049 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20020050 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020051 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020054 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020055 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020056 Microbes metabolize substances PMDBM2009209 248744 Marvinbryantia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020057 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020058 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020059 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020060 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020062 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020064 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020065 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020066 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020067 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20020068 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20020069 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020071 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20020074 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20020075 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20020076 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020077 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020080 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20020083 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020084 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020087 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020088 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020089 Microbes metabolize substances PMDBM2020136 168384 Marvinbryantia formatexigens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020090 Microbes metabolize substances PMDBM2021610 2496532 Marvinbryantia sp900066075 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020091 Microbes metabolize substances PMDBM2021610 2496532 Marvinbryantia sp900066075 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020092 Microbes metabolize substances PMDBM2021610 2496532 Marvinbryantia sp900066075 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020093 Microbes metabolize substances PMDBM2021610 2496532 Marvinbryantia sp900066075 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020094 Microbes metabolize substances PMDBM2021610 2496532 Marvinbryantia sp900066075 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020095 Microbes metabolize substances PMDBM2021610 2496532 Marvinbryantia sp900066075 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020096 Microbes metabolize substances PMDBM2021610 2496532 Marvinbryantia sp900066075 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020099 Microbes metabolize substances PMDBM2021610 2496532 Marvinbryantia sp900066075 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020100 Microbes metabolize substances PMDBM2021610 2496532 Marvinbryantia sp900066075 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020101 Microbes metabolize substances PMDBM2021610 2496532 Marvinbryantia sp900066075 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20020102 Microbes metabolize substances PMDBM2021610 2496532 Marvinbryantia sp900066075 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020103 Microbes metabolize substances PMDBM2021610 2496532 Marvinbryantia sp900066075 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020104 Microbes metabolize substances PMDBM2021610 2496532 Marvinbryantia sp900066075 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020105 Microbes metabolize substances PMDBM2021610 2496532 Marvinbryantia sp900066075 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020106 Microbes metabolize substances PMDBM2021610 2496532 Marvinbryantia sp900066075 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020107 Microbes metabolize substances PMDBM2021610 2496532 Marvinbryantia sp900066075 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020108 Microbes metabolize substances PMDBM2009212 n.a. Massilibacillaceae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20020109 Microbes metabolize substances PMDBM2009212 n.a. Massilibacillaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020110 Microbes metabolize substances PMDBM2009212 n.a. Massilibacillaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020111 Microbes metabolize substances PMDBM2009212 n.a. Massilibacillaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020112 Microbes metabolize substances PMDBM2009212 n.a. Massilibacillaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020113 Microbes metabolize substances PMDBM2020855 1632858 Massilibacterium senegalense PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20020114 Microbes metabolize substances PMDBM2020855 1632858 Massilibacterium senegalense PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20020115 Microbes metabolize substances PMDBM2020855 1632858 Massilibacterium senegalense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020116 Microbes metabolize substances PMDBM2020855 1632858 Massilibacterium senegalense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020117 Microbes metabolize substances PMDBM2020855 1632858 Massilibacterium senegalense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020118 Microbes metabolize substances PMDBM2021611 1987501 Massilimaliae timonensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020119 Microbes metabolize substances PMDBM2021611 1987501 Massilimaliae timonensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20020120 Microbes metabolize substances PMDBM2021611 1987501 Massilimaliae timonensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020121 Microbes metabolize substances PMDBM2021611 1987501 Massilimaliae timonensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020122 Microbes metabolize substances PMDBM2021611 1987501 Massilimaliae timonensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020124 Microbes metabolize substances PMDBM2021611 1987501 Massilimaliae timonensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020126 Microbes metabolize substances PMDBM2021611 1987501 Massilimaliae timonensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020127 Microbes metabolize substances PMDBM2021611 1987501 Massilimaliae timonensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020128 Microbes metabolize substances PMDBM2021611 1987501 Massilimaliae timonensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020129 Microbes metabolize substances PMDBM2021611 1987501 Massilimaliae timonensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020132 Microbes metabolize substances PMDBM2021611 1987501 Massilimaliae timonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020133 Microbes metabolize substances PMDBM2021611 1987501 Massilimaliae timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020134 Microbes metabolize substances PMDBM2021611 1987501 Massilimaliae timonensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020135 Microbes metabolize substances PMDBM2021611 1987501 Massilimaliae timonensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020137 Microbes metabolize substances PMDBM2021611 1987501 Massilimaliae timonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020138 Microbes metabolize substances PMDBM2021611 1987501 Massilimaliae timonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020139 Microbes metabolize substances PMDBM2021612 1870991 Massilioclostridium coli PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020140 Microbes metabolize substances PMDBM2021612 1870991 Massilioclostridium coli PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020141 Microbes metabolize substances PMDBM2021612 1870991 Massilioclostridium coli PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020142 Microbes metabolize substances PMDBM2021612 1870991 Massilioclostridium coli PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020144 Microbes metabolize substances PMDBM2021612 1870991 Massilioclostridium coli PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020146 Microbes metabolize substances PMDBM2021612 1870991 Massilioclostridium coli PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020147 Microbes metabolize substances PMDBM2021612 1870991 Massilioclostridium coli PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020148 Microbes metabolize substances PMDBM2021612 1870991 Massilioclostridium coli PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020149 Microbes metabolize substances PMDBM2021612 1870991 Massilioclostridium coli PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020152 Microbes metabolize substances PMDBM2021612 1870991 Massilioclostridium coli PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020153 Microbes metabolize substances PMDBM2021612 1870991 Massilioclostridium coli PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020154 Microbes metabolize substances PMDBM2021612 1870991 Massilioclostridium coli PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020155 Microbes metabolize substances PMDBM2021612 1870991 Massilioclostridium coli PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020157 Microbes metabolize substances PMDBM2009216 n.a. Massilioclostridium methylpentosum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020158 Microbes metabolize substances PMDBM2009216 n.a. Massilioclostridium methylpentosum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020159 Microbes metabolize substances PMDBM2009216 n.a. Massilioclostridium methylpentosum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020160 Microbes metabolize substances PMDBM2009216 n.a. Massilioclostridium methylpentosum PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020162 Microbes metabolize substances PMDBM2009216 n.a. Massilioclostridium methylpentosum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020164 Microbes metabolize substances PMDBM2009216 n.a. Massilioclostridium methylpentosum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020165 Microbes metabolize substances PMDBM2009216 n.a. Massilioclostridium methylpentosum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020166 Microbes metabolize substances PMDBM2009216 n.a. Massilioclostridium methylpentosum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020167 Microbes metabolize substances PMDBM2009216 n.a. Massilioclostridium methylpentosum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020170 Microbes metabolize substances PMDBM2009216 n.a. Massilioclostridium methylpentosum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020171 Microbes metabolize substances PMDBM2009216 n.a. Massilioclostridium methylpentosum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020172 Microbes metabolize substances PMDBM2009216 n.a. Massilioclostridium methylpentosum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020173 Microbes metabolize substances PMDBM2009216 n.a. Massilioclostridium methylpentosum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020175 Microbes metabolize substances PMDBM2021613 1924111 Massiliomicrobiota sp002160815 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020176 Microbes metabolize substances PMDBM2021613 1924111 Massiliomicrobiota sp002160815 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20020177 Microbes metabolize substances PMDBM2021613 1924111 Massiliomicrobiota sp002160815 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020178 Microbes metabolize substances PMDBM2021613 1924111 Massiliomicrobiota sp002160815 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020179 Microbes metabolize substances PMDBM2021613 1924111 Massiliomicrobiota sp002160815 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020180 Microbes metabolize substances PMDBM2021613 1924111 Massiliomicrobiota sp002160815 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020181 Microbes metabolize substances PMDBM2021613 1924111 Massiliomicrobiota sp002160815 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020182 Microbes metabolize substances PMDBM2021613 1924111 Massiliomicrobiota sp002160815 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020185 Microbes metabolize substances PMDBM2021613 1924111 Massiliomicrobiota sp002160815 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020186 Microbes metabolize substances PMDBM2021613 1924111 Massiliomicrobiota sp002160815 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020187 Microbes metabolize substances PMDBM2021613 1924111 Massiliomicrobiota sp002160815 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020188 Microbes metabolize substances PMDBM2021613 1924111 Massiliomicrobiota sp002160815 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020189 Microbes metabolize substances PMDBM2021613 1924111 Massiliomicrobiota sp002160815 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020190 Microbes metabolize substances PMDBM2021613 1924111 Massiliomicrobiota sp002160815 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020191 Microbes metabolize substances PMDBM2021613 1924111 Massiliomicrobiota sp002160815 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020192 Microbes metabolize substances PMDBM2021331 1776392 Massiliomicrobiota timonensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020193 Microbes metabolize substances PMDBM2021331 1776392 Massiliomicrobiota timonensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20020194 Microbes metabolize substances PMDBM2021331 1776392 Massiliomicrobiota timonensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020195 Microbes metabolize substances PMDBM2021331 1776392 Massiliomicrobiota timonensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020196 Microbes metabolize substances PMDBM2021331 1776392 Massiliomicrobiota timonensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020197 Microbes metabolize substances PMDBM2021331 1776392 Massiliomicrobiota timonensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020198 Microbes metabolize substances PMDBM2021331 1776392 Massiliomicrobiota timonensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020199 Microbes metabolize substances PMDBM2021331 1776392 Massiliomicrobiota timonensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020202 Microbes metabolize substances PMDBM2021331 1776392 Massiliomicrobiota timonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020203 Microbes metabolize substances PMDBM2021331 1776392 Massiliomicrobiota timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020204 Microbes metabolize substances PMDBM2021331 1776392 Massiliomicrobiota timonensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020205 Microbes metabolize substances PMDBM2021331 1776392 Massiliomicrobiota timonensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020206 Microbes metabolize substances PMDBM2021331 1776392 Massiliomicrobiota timonensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020207 Microbes metabolize substances PMDBM2021331 1776392 Massiliomicrobiota timonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020208 Microbes metabolize substances PMDBM2021331 1776392 Massiliomicrobiota timonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020209 Microbes metabolize substances PMDBM2009219 158846 Megamonas PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020210 Microbes metabolize substances PMDBM2009219 158846 Megamonas PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20020211 Microbes metabolize substances PMDBM2009219 158846 Megamonas PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020212 Microbes metabolize substances PMDBM2009219 158846 Megamonas PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020213 Microbes metabolize substances PMDBM2009219 158846 Megamonas PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020214 Microbes metabolize substances PMDBM2009219 158846 Megamonas PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020215 Microbes metabolize substances PMDBM2009219 158846 Megamonas PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020216 Microbes metabolize substances PMDBM2009219 158846 Megamonas PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020219 Microbes metabolize substances PMDBM2009219 158846 Megamonas PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020220 Microbes metabolize substances PMDBM2009219 158846 Megamonas PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020221 Microbes metabolize substances PMDBM2009219 158846 Megamonas PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020222 Microbes metabolize substances PMDBM2009219 158846 Megamonas PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020223 Microbes metabolize substances PMDBM2009219 158846 Megamonas PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020224 Microbes metabolize substances PMDBM2009219 158846 Megamonas PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020225 Microbes metabolize substances PMDBM2009219 158846 Megamonas PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020226 Microbes metabolize substances PMDBM2020857 437897 Megamonas funiformis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020227 Microbes metabolize substances PMDBM2020857 437897 Megamonas funiformis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020228 Microbes metabolize substances PMDBM2020857 437897 Megamonas funiformis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020229 Microbes metabolize substances PMDBM2020857 437897 Megamonas funiformis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020230 Microbes metabolize substances PMDBM2020858 158847 Megamonas hypermegale PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020231 Microbes metabolize substances PMDBM2020858 158847 Megamonas hypermegale PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20020232 Microbes metabolize substances PMDBM2020858 158847 Megamonas hypermegale PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020233 Microbes metabolize substances PMDBM2020858 158847 Megamonas hypermegale PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020234 Microbes metabolize substances PMDBM2020858 158847 Megamonas hypermegale PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020235 Microbes metabolize substances PMDBM2020858 158847 Megamonas hypermegale PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020236 Microbes metabolize substances PMDBM2020858 158847 Megamonas hypermegale PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020237 Microbes metabolize substances PMDBM2020858 158847 Megamonas hypermegale PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020240 Microbes metabolize substances PMDBM2020858 158847 Megamonas hypermegale PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020241 Microbes metabolize substances PMDBM2020858 158847 Megamonas hypermegale PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020242 Microbes metabolize substances PMDBM2020858 158847 Megamonas hypermegale PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020243 Microbes metabolize substances PMDBM2020858 158847 Megamonas hypermegale PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020244 Microbes metabolize substances PMDBM2020858 158847 Megamonas hypermegale PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020245 Microbes metabolize substances PMDBM836 906 Megasphaera PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20020246 Microbes metabolize substances PMDBM836 906 Megasphaera PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020247 Microbes metabolize substances PMDBM836 906 Megasphaera PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020248 Microbes metabolize substances PMDBM836 906 Megasphaera PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020249 Microbes metabolize substances PMDBM836 906 Megasphaera PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020250 Microbes metabolize substances PMDBM2020138 907 Megasphaera elsdenii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020251 Microbes metabolize substances PMDBM2020138 907 Megasphaera elsdenii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020252 Microbes metabolize substances PMDBM2020138 907 Megasphaera elsdenii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020253 Microbes metabolize substances PMDBM2020138 907 Megasphaera elsdenii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020254 Microbes metabolize substances PMDBM2020861 1232428 Megasphaera massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020255 Microbes metabolize substances PMDBM2020861 1232428 Megasphaera massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020256 Microbes metabolize substances PMDBM2020861 1232428 Megasphaera massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020257 Microbes metabolize substances PMDBM2020861 1232428 Megasphaera massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020258 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp000417505 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020259 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp000417505 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20020260 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp000417505 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020261 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp000417505 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020262 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp001546855 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20020263 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp001546855 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020264 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp001546855 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020265 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp001546855 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020266 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp001546855 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020267 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp002319965 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020268 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp002319965 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020269 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp002319965 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020270 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp002319965 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020271 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp900066485 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20020272 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp900066485 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020273 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp900066485 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020274 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp900066485 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020275 Microbes metabolize substances PMDBM2021614 2023260 Megasphaera sp900066485 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020276 Microbes metabolize substances PMDBM2009228 1935200 Merdibacter PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020277 Microbes metabolize substances PMDBM2009228 1935200 Merdibacter PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20020278 Microbes metabolize substances PMDBM2009228 1935200 Merdibacter PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020279 Microbes metabolize substances PMDBM2009228 1935200 Merdibacter PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020280 Microbes metabolize substances PMDBM2009228 1935200 Merdibacter PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020282 Microbes metabolize substances PMDBM2009228 1935200 Merdibacter PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020284 Microbes metabolize substances PMDBM2009228 1935200 Merdibacter PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020285 Microbes metabolize substances PMDBM2009228 1935200 Merdibacter PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020286 Microbes metabolize substances PMDBM2009228 1935200 Merdibacter PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020287 Microbes metabolize substances PMDBM2009228 1935200 Merdibacter PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020290 Microbes metabolize substances PMDBM2009228 1935200 Merdibacter PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020291 Microbes metabolize substances PMDBM2009228 1935200 Merdibacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020292 Microbes metabolize substances PMDBM2009228 1935200 Merdibacter PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020293 Microbes metabolize substances PMDBM2009228 1935200 Merdibacter PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020295 Microbes metabolize substances PMDBM2009228 1935200 Merdibacter PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020296 Microbes metabolize substances PMDBM2009228 1935200 Merdibacter PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020297 Microbes metabolize substances PMDBM2009229 n.a. Metakosakonia intermedia PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020298 Microbes metabolize substances PMDBM2009229 n.a. Metakosakonia intermedia PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020299 Microbes metabolize substances PMDBM2009229 n.a. Metakosakonia intermedia PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020300 Microbes metabolize substances PMDBM2009229 n.a. Metakosakonia intermedia PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020302 Microbes metabolize substances PMDBM2009229 n.a. Metakosakonia intermedia PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020304 Microbes metabolize substances PMDBM2009229 n.a. Metakosakonia intermedia PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020305 Microbes metabolize substances PMDBM2009229 n.a. Metakosakonia intermedia PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020306 Microbes metabolize substances PMDBM2009229 n.a. Metakosakonia intermedia PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020307 Microbes metabolize substances PMDBM2009229 n.a. Metakosakonia intermedia PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020310 Microbes metabolize substances PMDBM2009229 n.a. Metakosakonia intermedia PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020311 Microbes metabolize substances PMDBM2009229 n.a. Metakosakonia intermedia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020312 Microbes metabolize substances PMDBM2009229 n.a. Metakosakonia intermedia PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20020313 Microbes metabolize substances PMDBM2009229 n.a. Metakosakonia intermedia PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020314 Microbes metabolize substances PMDBM2009229 n.a. Metakosakonia intermedia PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020316 Microbes metabolize substances PMDBM2009229 n.a. Metakosakonia intermedia PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020317 Microbes metabolize substances PMDBM2009229 n.a. Metakosakonia intermedia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020318 Microbes metabolize substances PMDBM2009229 n.a. Metakosakonia intermedia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020319 Microbes metabolize substances PMDBM2009230 n.a. Metakosakonia intestini PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020320 Microbes metabolize substances PMDBM2009230 n.a. Metakosakonia intestini PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020321 Microbes metabolize substances PMDBM2009230 n.a. Metakosakonia intestini PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020322 Microbes metabolize substances PMDBM2009230 n.a. Metakosakonia intestini PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020323 Microbes metabolize substances PMDBM2009230 n.a. Metakosakonia intestini PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020324 Microbes metabolize substances PMDBM2009230 n.a. Metakosakonia intestini PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020325 Microbes metabolize substances PMDBM2009230 n.a. Metakosakonia intestini PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020328 Microbes metabolize substances PMDBM2009230 n.a. Metakosakonia intestini PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20020329 Microbes metabolize substances PMDBM2009230 n.a. Metakosakonia intestini PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020330 Microbes metabolize substances PMDBM2009230 n.a. Metakosakonia intestini PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020331 Microbes metabolize substances PMDBM2009230 n.a. Metakosakonia intestini PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20020332 Microbes metabolize substances PMDBM2009230 n.a. Metakosakonia intestini PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020333 Microbes metabolize substances PMDBM2009230 n.a. Metakosakonia intestini PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020334 Microbes metabolize substances PMDBM2009230 n.a. Metakosakonia intestini PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020335 Microbes metabolize substances PMDBM2009230 n.a. Metakosakonia intestini PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020336 Microbes metabolize substances PMDBM2009230 n.a. Metakosakonia intestini PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020337 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020338 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20020339 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020340 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020341 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020343 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020345 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020346 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020347 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020348 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020351 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20020352 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020353 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020354 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20020355 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020356 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020358 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020359 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020360 Microbes metabolize substances PMDBM2021615 1485952 Metakosakonia massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020361 Microbes metabolize substances PMDBM2009232 n.a. Metakosakonia sp002377245 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020362 Microbes metabolize substances PMDBM2009232 n.a. Metakosakonia sp002377245 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020363 Microbes metabolize substances PMDBM2009232 n.a. Metakosakonia sp002377245 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020364 Microbes metabolize substances PMDBM2009232 n.a. Metakosakonia sp002377245 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020366 Microbes metabolize substances PMDBM2009232 n.a. Metakosakonia sp002377245 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020368 Microbes metabolize substances PMDBM2009232 n.a. Metakosakonia sp002377245 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020369 Microbes metabolize substances PMDBM2009232 n.a. Metakosakonia sp002377245 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020370 Microbes metabolize substances PMDBM2009232 n.a. Metakosakonia sp002377245 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020371 Microbes metabolize substances PMDBM2009232 n.a. Metakosakonia sp002377245 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020374 Microbes metabolize substances PMDBM2009232 n.a. Metakosakonia sp002377245 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020375 Microbes metabolize substances PMDBM2009232 n.a. Metakosakonia sp002377245 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020376 Microbes metabolize substances PMDBM2009232 n.a. Metakosakonia sp002377245 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20020377 Microbes metabolize substances PMDBM2009232 n.a. Metakosakonia sp002377245 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020378 Microbes metabolize substances PMDBM2009232 n.a. Metakosakonia sp002377245 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020380 Microbes metabolize substances PMDBM2009232 n.a. Metakosakonia sp002377245 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020381 Microbes metabolize substances PMDBM2009232 n.a. Metakosakonia sp002377245 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020382 Microbes metabolize substances PMDBM2009232 n.a. Metakosakonia sp002377245 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020383 Microbes metabolize substances PMDBM2021616 2098 Metamycoplasma hominis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020384 Microbes metabolize substances PMDBM2021616 2098 Metamycoplasma hominis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020385 Microbes metabolize substances PMDBM2009234 n.a. Methanobacterium sp000499765 PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20020386 Microbes metabolize substances PMDBM2009234 n.a. Methanobacterium sp000499765 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020387 Microbes metabolize substances PMDBM2009234 n.a. Methanobacterium sp000499765 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020388 Microbes metabolize substances PMDBM2009234 n.a. Methanobacterium sp000499765 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020389 Microbes metabolize substances PMDBM2009235 n.a. Methanobrevibacter A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020390 Microbes metabolize substances PMDBM2009235 n.a. Methanobrevibacter A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020391 Microbes metabolize substances PMDBM2021617 66851 Methanobrevibacter A oralis PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20020392 Microbes metabolize substances PMDBM2021617 66851 Methanobrevibacter A oralis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020393 Microbes metabolize substances PMDBM2021617 66851 Methanobrevibacter A oralis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020394 Microbes metabolize substances PMDBM2021617 66851 Methanobrevibacter A oralis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020395 Microbes metabolize substances PMDBM2021618 2173 Methanobrevibacter A smithii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020396 Microbes metabolize substances PMDBM2021618 2173 Methanobrevibacter A smithii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020397 Microbes metabolize substances PMDBM2021618 2173 Methanobrevibacter A smithii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020398 Microbes metabolize substances PMDBM2021618 2173 Methanobrevibacter A smithii A PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20020399 Microbes metabolize substances PMDBM2021618 2173 Methanobrevibacter A smithii A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020400 Microbes metabolize substances PMDBM2021618 2173 Methanobrevibacter A smithii A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020401 Microbes metabolize substances PMDBM2021618 2173 Methanobrevibacter A smithii A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020402 Microbes metabolize substances PMDBM2021619 190976 Methanobrevibacter A woesei PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20020403 Microbes metabolize substances PMDBM2021619 190976 Methanobrevibacter A woesei PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020404 Microbes metabolize substances PMDBM2021619 190976 Methanobrevibacter A woesei PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020405 Microbes metabolize substances PMDBM2009240 2192 Methanocorpusculum PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20020406 Microbes metabolize substances PMDBM2009240 2192 Methanocorpusculum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020407 Microbes metabolize substances PMDBM2009240 2192 Methanocorpusculum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020408 Microbes metabolize substances PMDBM2009241 n.a. Methanomassiliicoccus A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020409 Microbes metabolize substances PMDBM2009241 n.a. Methanomassiliicoccus A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020410 Microbes metabolize substances PMDBM2009241 n.a. Methanomassiliicoccus A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020411 Microbes metabolize substances PMDBM2009241 n.a. Methanomassiliicoccus A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020412 Microbes metabolize substances PMDBM2009241 n.a. Methanomassiliicoccus A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020413 Microbes metabolize substances PMDBM2009241 n.a. Methanomassiliicoccus A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020414 Microbes metabolize substances PMDBM2009241 n.a. Methanomassiliicoccus A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020417 Microbes metabolize substances PMDBM2009241 n.a. Methanomassiliicoccus A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020418 Microbes metabolize substances PMDBM2009241 n.a. Methanomassiliicoccus A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020419 Microbes metabolize substances PMDBM2009241 n.a. Methanomassiliicoccus A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020420 Microbes metabolize substances PMDBM2021620 1406512 Methanomassiliicoccus A intestinalis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020421 Microbes metabolize substances PMDBM2021620 1406512 Methanomassiliicoccus A intestinalis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020422 Microbes metabolize substances PMDBM2021620 1406512 Methanomassiliicoccus A intestinalis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020423 Microbes metabolize substances PMDBM2021620 1406512 Methanomassiliicoccus A intestinalis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020424 Microbes metabolize substances PMDBM2021620 1406512 Methanomassiliicoccus A intestinalis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020425 Microbes metabolize substances PMDBM2021620 1406512 Methanomassiliicoccus A intestinalis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020426 Microbes metabolize substances PMDBM2021620 1406512 Methanomassiliicoccus A intestinalis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020429 Microbes metabolize substances PMDBM2021620 1406512 Methanomassiliicoccus A intestinalis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020430 Microbes metabolize substances PMDBM2021620 1406512 Methanomassiliicoccus A intestinalis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020431 Microbes metabolize substances PMDBM2021620 1406512 Methanomassiliicoccus A intestinalis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020432 Microbes metabolize substances PMDBM2009243 2517203 Methanomethylophilaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020433 Microbes metabolize substances PMDBM2009243 2517203 Methanomethylophilaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020434 Microbes metabolize substances PMDBM2009243 2517203 Methanomethylophilaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020435 Microbes metabolize substances PMDBM2009243 2517203 Methanomethylophilaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020436 Microbes metabolize substances PMDBM2009243 2517203 Methanomethylophilaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020437 Microbes metabolize substances PMDBM2009243 2517203 Methanomethylophilaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020438 Microbes metabolize substances PMDBM2009243 2517203 Methanomethylophilaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020441 Microbes metabolize substances PMDBM2009243 2517203 Methanomethylophilaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020442 Microbes metabolize substances PMDBM2009243 2517203 Methanomethylophilaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020443 Microbes metabolize substances PMDBM2009243 2517203 Methanomethylophilaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020444 Microbes metabolize substances PMDBM2009243 2517203 Methanomethylophilaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020445 Microbes metabolize substances PMDBM2021621 1077256 Methanosphaera cuniculi PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020446 Microbes metabolize substances PMDBM2021621 1077256 Methanosphaera cuniculi PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020447 Microbes metabolize substances PMDBM2009245 n.a. Methanosphaera sp900322125 PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20020448 Microbes metabolize substances PMDBM2009245 n.a. Methanosphaera sp900322125 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020449 Microbes metabolize substances PMDBM2009245 n.a. Methanosphaera sp900322125 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020450 Microbes metabolize substances PMDBM2021622 2317 Methanosphaera stadtmanae PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20020451 Microbes metabolize substances PMDBM2021622 2317 Methanosphaera stadtmanae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020452 Microbes metabolize substances PMDBM2021622 2317 Methanosphaera stadtmanae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020453 Microbes metabolize substances PMDBM2021623 409 Methylobacterium sp002778835 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020454 Microbes metabolize substances PMDBM2021623 409 Methylobacterium sp002778835 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020455 Microbes metabolize substances PMDBM2021623 409 Methylobacterium sp002778835 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020456 Microbes metabolize substances PMDBM2021623 409 Methylobacterium sp002778835 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020457 Microbes metabolize substances PMDBM2021623 409 Methylobacterium sp002778835 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020458 Microbes metabolize substances PMDBM2021623 409 Methylobacterium sp002778835 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020459 Microbes metabolize substances PMDBM2021623 409 Methylobacterium sp002778835 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020462 Microbes metabolize substances PMDBM2021623 409 Methylobacterium sp002778835 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020463 Microbes metabolize substances PMDBM2021623 409 Methylobacterium sp002778835 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20020464 Microbes metabolize substances PMDBM2021623 409 Methylobacterium sp002778835 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020465 Microbes metabolize substances PMDBM2021623 409 Methylobacterium sp002778835 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020466 Microbes metabolize substances PMDBM2021623 409 Methylobacterium sp002778835 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020467 Microbes metabolize substances PMDBM2021623 409 Methylobacterium sp002778835 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020468 Microbes metabolize substances PMDBM2021623 409 Methylobacterium sp002778835 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020469 Microbes metabolize substances PMDBM2020228 1270 Micrococcus luteus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20020470 Microbes metabolize substances PMDBM2020228 1270 Micrococcus luteus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020471 Microbes metabolize substances PMDBM2020228 1270 Micrococcus luteus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020472 Microbes metabolize substances PMDBM2020228 1270 Micrococcus luteus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020473 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020474 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020475 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020476 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020477 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020478 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020479 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20020480 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20020481 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020483 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20020486 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20020487 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20020488 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020489 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020492 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20020495 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020496 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020497 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020499 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020500 Microbes metabolize substances PMDBM2020872 1033741 Microvirga massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020501 Microbes metabolize substances PMDBM2009249 52225 Mitsuokella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020502 Microbes metabolize substances PMDBM2009249 52225 Mitsuokella PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20020503 Microbes metabolize substances PMDBM2009249 52225 Mitsuokella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020504 Microbes metabolize substances PMDBM2009249 52225 Mitsuokella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020505 Microbes metabolize substances PMDBM2009249 52225 Mitsuokella PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020507 Microbes metabolize substances PMDBM2009249 52225 Mitsuokella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020509 Microbes metabolize substances PMDBM2009249 52225 Mitsuokella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020510 Microbes metabolize substances PMDBM2009249 52225 Mitsuokella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020511 Microbes metabolize substances PMDBM2009249 52225 Mitsuokella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020512 Microbes metabolize substances PMDBM2009249 52225 Mitsuokella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020515 Microbes metabolize substances PMDBM2009249 52225 Mitsuokella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020516 Microbes metabolize substances PMDBM2009249 52225 Mitsuokella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020517 Microbes metabolize substances PMDBM2009249 52225 Mitsuokella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020518 Microbes metabolize substances PMDBM2009249 52225 Mitsuokella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020520 Microbes metabolize substances PMDBM2009249 52225 Mitsuokella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020521 Microbes metabolize substances PMDBM2009249 52225 Mitsuokella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020522 Microbes metabolize substances PMDBM2009249 52225 Mitsuokella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020523 Microbes metabolize substances PMDBM2020873 187979 Mitsuokella jalaludinii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20020524 Microbes metabolize substances PMDBM2020873 187979 Mitsuokella jalaludinii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020525 Microbes metabolize substances PMDBM2020873 187979 Mitsuokella jalaludinii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020526 Microbes metabolize substances PMDBM2020873 187979 Mitsuokella jalaludinii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020527 Microbes metabolize substances PMDBM2020873 187979 Mitsuokella jalaludinii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020528 Microbes metabolize substances PMDBM2020873 187979 Mitsuokella jalaludinii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020529 Microbes metabolize substances PMDBM2020874 52226 Mitsuokella multacida PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20020530 Microbes metabolize substances PMDBM2020874 52226 Mitsuokella multacida PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020531 Microbes metabolize substances PMDBM2020874 52226 Mitsuokella multacida PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020532 Microbes metabolize substances PMDBM2020874 52226 Mitsuokella multacida PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020533 Microbes metabolize substances PMDBM2020874 52226 Mitsuokella multacida PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020534 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020535 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20020536 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020537 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020538 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020539 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020540 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020541 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20020542 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20020543 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020545 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20020548 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20020549 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20020550 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20020551 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020552 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020555 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20020558 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020559 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020560 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020562 Microbes metabolize substances PMDBM2020875 1522310 Mobilicoccus massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020563 Microbes metabolize substances PMDBM2009253 2050 Mobiluncus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020564 Microbes metabolize substances PMDBM2009253 2050 Mobiluncus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020565 Microbes metabolize substances PMDBM2009253 2050 Mobiluncus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020566 Microbes metabolize substances PMDBM2009253 2050 Mobiluncus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020567 Microbes metabolize substances PMDBM2009253 2050 Mobiluncus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020568 Microbes metabolize substances PMDBM2009253 2050 Mobiluncus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020569 Microbes metabolize substances PMDBM2009253 2050 Mobiluncus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020572 Microbes metabolize substances PMDBM2009253 2050 Mobiluncus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020573 Microbes metabolize substances PMDBM2009253 2050 Mobiluncus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020574 Microbes metabolize substances PMDBM2009253 2050 Mobiluncus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020575 Microbes metabolize substances PMDBM2009253 2050 Mobiluncus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020576 Microbes metabolize substances PMDBM2009253 2050 Mobiluncus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020577 Microbes metabolize substances PMDBM2009253 2050 Mobiluncus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020578 Microbes metabolize substances PMDBM2009253 2050 Mobiluncus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020579 Microbes metabolize substances PMDBM2021624 158849 Moellerella wisconsensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020580 Microbes metabolize substances PMDBM2021624 158849 Moellerella wisconsensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020581 Microbes metabolize substances PMDBM2021624 158849 Moellerella wisconsensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020582 Microbes metabolize substances PMDBM2021624 158849 Moellerella wisconsensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020583 Microbes metabolize substances PMDBM2021624 158849 Moellerella wisconsensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020584 Microbes metabolize substances PMDBM2021624 158849 Moellerella wisconsensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020585 Microbes metabolize substances PMDBM2021624 158849 Moellerella wisconsensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020588 Microbes metabolize substances PMDBM2021624 158849 Moellerella wisconsensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20020589 Microbes metabolize substances PMDBM2021624 158849 Moellerella wisconsensis PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20020590 Microbes metabolize substances PMDBM2021624 158849 Moellerella wisconsensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020591 Microbes metabolize substances PMDBM2021624 158849 Moellerella wisconsensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020592 Microbes metabolize substances PMDBM2021624 158849 Moellerella wisconsensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020593 Microbes metabolize substances PMDBM2021624 158849 Moellerella wisconsensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020594 Microbes metabolize substances PMDBM2021624 158849 Moellerella wisconsensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020595 Microbes metabolize substances PMDBM2021624 158849 Moellerella wisconsensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020596 Microbes metabolize substances PMDBM2021624 158849 Moellerella wisconsensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020597 Microbes metabolize substances PMDBM2009255 86331 Mogibacterium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020598 Microbes metabolize substances PMDBM2009255 86331 Mogibacterium PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020599 Microbes metabolize substances PMDBM2009255 86331 Mogibacterium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020600 Microbes metabolize substances PMDBM2009255 86331 Mogibacterium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020601 Microbes metabolize substances PMDBM2021625 1816679 Mogibacterium massiliense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020602 Microbes metabolize substances PMDBM2021625 1816679 Mogibacterium massiliense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020603 Microbes metabolize substances PMDBM2021625 1816679 Mogibacterium massiliense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020604 Microbes metabolize substances PMDBM2021626 2049035 Mogibacterium sp002299625 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020605 Microbes metabolize substances PMDBM2021626 2049035 Mogibacterium sp002299625 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020606 Microbes metabolize substances PMDBM2021626 2049035 Mogibacterium sp002299625 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020607 Microbes metabolize substances PMDBM2021626 2049035 Mogibacterium sp900315625 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020608 Microbes metabolize substances PMDBM2021626 2049035 Mogibacterium sp900315625 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020609 Microbes metabolize substances PMDBM2021626 2049035 Mogibacterium sp900315625 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020610 Microbes metabolize substances PMDBM2021626 2049035 Mogibacterium sp900315625 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020611 Microbes metabolize substances PMDBM2021626 2049035 Mogibacterium sp900315625 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020612 Microbes metabolize substances PMDBM2009259 n.a. Mogibacterium timonense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020613 Microbes metabolize substances PMDBM2009259 n.a. Mogibacterium timonense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020614 Microbes metabolize substances PMDBM2009259 n.a. Mogibacterium timonense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020615 Microbes metabolize substances PMDBM2009259 n.a. Mogibacterium timonense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020616 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020617 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020618 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020619 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020621 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020623 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020624 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020625 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020626 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20020627 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20020628 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020630 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20020633 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20020634 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20020635 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20020636 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020637 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020640 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20020643 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020644 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020647 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020648 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020649 Microbes metabolize substances PMDBM2009260 3085657 Monoglobaceae PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20020650 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020651 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20020652 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020653 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020654 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020656 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020658 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20020659 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020660 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020661 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020662 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20020663 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20020664 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020666 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20020669 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20020670 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20020671 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020672 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020675 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20020678 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020679 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020682 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020683 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020684 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020685 Microbes metabolize substances PMDBM2009261 3085656 Monoglobales PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20020686 Microbes metabolize substances PMDBM2009262 2039302 Monoglobus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020687 Microbes metabolize substances PMDBM2009262 2039302 Monoglobus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020688 Microbes metabolize substances PMDBM2009262 2039302 Monoglobus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020689 Microbes metabolize substances PMDBM2009262 2039302 Monoglobus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020690 Microbes metabolize substances PMDBM2009262 2039302 Monoglobus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020691 Microbes metabolize substances PMDBM2009262 2039302 Monoglobus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020692 Microbes metabolize substances PMDBM2009262 2039302 Monoglobus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020695 Microbes metabolize substances PMDBM2009262 2039302 Monoglobus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020696 Microbes metabolize substances PMDBM2009262 2039302 Monoglobus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020697 Microbes metabolize substances PMDBM2009262 2039302 Monoglobus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020698 Microbes metabolize substances PMDBM2009262 2039302 Monoglobus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020699 Microbes metabolize substances PMDBM2009262 2039302 Monoglobus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020700 Microbes metabolize substances PMDBM2009262 2039302 Monoglobus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020701 Microbes metabolize substances PMDBM2009262 2039302 Monoglobus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020702 Microbes metabolize substances PMDBM2021627 1981510 Monoglobus pectinilyticus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020703 Microbes metabolize substances PMDBM2021627 1981510 Monoglobus pectinilyticus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020704 Microbes metabolize substances PMDBM2021627 1981510 Monoglobus pectinilyticus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020705 Microbes metabolize substances PMDBM2021627 1981510 Monoglobus pectinilyticus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020706 Microbes metabolize substances PMDBM2021627 1981510 Monoglobus pectinilyticus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020707 Microbes metabolize substances PMDBM2021627 1981510 Monoglobus pectinilyticus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020708 Microbes metabolize substances PMDBM2021627 1981510 Monoglobus pectinilyticus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020711 Microbes metabolize substances PMDBM2021627 1981510 Monoglobus pectinilyticus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020712 Microbes metabolize substances PMDBM2021627 1981510 Monoglobus pectinilyticus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020713 Microbes metabolize substances PMDBM2021627 1981510 Monoglobus pectinilyticus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020714 Microbes metabolize substances PMDBM2021627 1981510 Monoglobus pectinilyticus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020715 Microbes metabolize substances PMDBM2021627 1981510 Monoglobus pectinilyticus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020716 Microbes metabolize substances PMDBM2021627 1981510 Monoglobus pectinilyticus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020717 Microbes metabolize substances PMDBM2021627 1981510 Monoglobus pectinilyticus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020718 Microbes metabolize substances PMDBM2020229 582 Morganella morganii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020719 Microbes metabolize substances PMDBM2020229 582 Morganella morganii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020720 Microbes metabolize substances PMDBM2020229 582 Morganella morganii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020721 Microbes metabolize substances PMDBM2020229 582 Morganella morganii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020722 Microbes metabolize substances PMDBM2020229 582 Morganella morganii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020723 Microbes metabolize substances PMDBM2020229 582 Morganella morganii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020724 Microbes metabolize substances PMDBM2020229 582 Morganella morganii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020727 Microbes metabolize substances PMDBM2020229 582 Morganella morganii PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20020728 Microbes metabolize substances PMDBM2020229 582 Morganella morganii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020729 Microbes metabolize substances PMDBM2020229 582 Morganella morganii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020730 Microbes metabolize substances PMDBM2020229 582 Morganella morganii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020731 Microbes metabolize substances PMDBM2020229 582 Morganella morganii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020732 Microbes metabolize substances PMDBM2020229 582 Morganella morganii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020733 Microbes metabolize substances PMDBM2020229 582 Morganella morganii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020734 Microbes metabolize substances PMDBM2020229 582 Morganella morganii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020735 Microbes metabolize substances PMDBM2020229 582 Morganella morganii A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020736 Microbes metabolize substances PMDBM2020229 582 Morganella morganii A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020737 Microbes metabolize substances PMDBM2020229 582 Morganella morganii A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020738 Microbes metabolize substances PMDBM2020229 582 Morganella morganii A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020739 Microbes metabolize substances PMDBM2020229 582 Morganella morganii A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020740 Microbes metabolize substances PMDBM2020229 582 Morganella morganii A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020741 Microbes metabolize substances PMDBM2020229 582 Morganella morganii A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020744 Microbes metabolize substances PMDBM2020229 582 Morganella morganii A PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20020745 Microbes metabolize substances PMDBM2020229 582 Morganella morganii A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020746 Microbes metabolize substances PMDBM2020229 582 Morganella morganii A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020747 Microbes metabolize substances PMDBM2020229 582 Morganella morganii A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020748 Microbes metabolize substances PMDBM2020229 582 Morganella morganii A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020749 Microbes metabolize substances PMDBM2020229 582 Morganella morganii A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020750 Microbes metabolize substances PMDBM2020229 582 Morganella morganii A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020751 Microbes metabolize substances PMDBM2020229 582 Morganella morganii A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020752 Microbes metabolize substances PMDBM2020229 582 Morganella morganii B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020753 Microbes metabolize substances PMDBM2020229 582 Morganella morganii B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020754 Microbes metabolize substances PMDBM2020229 582 Morganella morganii B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020755 Microbes metabolize substances PMDBM2020229 582 Morganella morganii B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020756 Microbes metabolize substances PMDBM2020229 582 Morganella morganii B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020757 Microbes metabolize substances PMDBM2020229 582 Morganella morganii B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020758 Microbes metabolize substances PMDBM2020229 582 Morganella morganii B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020761 Microbes metabolize substances PMDBM2020229 582 Morganella morganii B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020762 Microbes metabolize substances PMDBM2020229 582 Morganella morganii B PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20020763 Microbes metabolize substances PMDBM2020229 582 Morganella morganii B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020764 Microbes metabolize substances PMDBM2020229 582 Morganella morganii B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020765 Microbes metabolize substances PMDBM2020229 582 Morganella morganii B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020766 Microbes metabolize substances PMDBM2020229 582 Morganella morganii B PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020767 Microbes metabolize substances PMDBM2009266 n.a. f Acutalibacteraceae g MS4 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020768 Microbes metabolize substances PMDBM2009266 n.a. f Acutalibacteraceae g MS4 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020769 Microbes metabolize substances PMDBM2009266 n.a. f Acutalibacteraceae g MS4 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020770 Microbes metabolize substances PMDBM2009266 n.a. f Acutalibacteraceae g MS4 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020771 Microbes metabolize substances PMDBM2009266 n.a. f Acutalibacteraceae g MS4 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020772 Microbes metabolize substances PMDBM2009266 n.a. f Acutalibacteraceae g MS4 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020773 Microbes metabolize substances PMDBM2009266 n.a. f Acutalibacteraceae g MS4 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020776 Microbes metabolize substances PMDBM2009266 n.a. f Acutalibacteraceae g MS4 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020777 Microbes metabolize substances PMDBM2009266 n.a. f Acutalibacteraceae g MS4 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020778 Microbes metabolize substances PMDBM2009266 n.a. f Acutalibacteraceae g MS4 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020779 Microbes metabolize substances PMDBM2009266 n.a. f Acutalibacteraceae g MS4 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020780 Microbes metabolize substances PMDBM2009266 n.a. f Acutalibacteraceae g MS4 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020781 Microbes metabolize substances PMDBM2009266 n.a. f Acutalibacteraceae g MS4 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020782 Microbes metabolize substances PMDBM2009266 n.a. f Acutalibacteraceae g MS4 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020783 Microbes metabolize substances PMDBM2009266 n.a. f Acutalibacteraceae g MS4 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020784 Microbes metabolize substances PMDBM2009267 n.a. f Acutalibacteraceae g MS4 s MS4 sp000752215 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020785 Microbes metabolize substances PMDBM2009267 n.a. f Acutalibacteraceae g MS4 s MS4 sp000752215 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020786 Microbes metabolize substances PMDBM2009267 n.a. f Acutalibacteraceae g MS4 s MS4 sp000752215 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020787 Microbes metabolize substances PMDBM2009267 n.a. f Acutalibacteraceae g MS4 s MS4 sp000752215 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020788 Microbes metabolize substances PMDBM2009267 n.a. f Acutalibacteraceae g MS4 s MS4 sp000752215 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020789 Microbes metabolize substances PMDBM2009267 n.a. f Acutalibacteraceae g MS4 s MS4 sp000752215 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020790 Microbes metabolize substances PMDBM2009267 n.a. f Acutalibacteraceae g MS4 s MS4 sp000752215 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020793 Microbes metabolize substances PMDBM2009267 n.a. f Acutalibacteraceae g MS4 s MS4 sp000752215 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020794 Microbes metabolize substances PMDBM2009267 n.a. f Acutalibacteraceae g MS4 s MS4 sp000752215 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020795 Microbes metabolize substances PMDBM2009267 n.a. f Acutalibacteraceae g MS4 s MS4 sp000752215 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020796 Microbes metabolize substances PMDBM2009267 n.a. f Acutalibacteraceae g MS4 s MS4 sp000752215 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020797 Microbes metabolize substances PMDBM2009267 n.a. f Acutalibacteraceae g MS4 s MS4 sp000752215 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020798 Microbes metabolize substances PMDBM2009267 n.a. f Acutalibacteraceae g MS4 s MS4 sp000752215 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020799 Microbes metabolize substances PMDBM2009267 n.a. f Acutalibacteraceae g MS4 s MS4 sp000752215 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020800 Microbes metabolize substances PMDBM2009267 n.a. f Acutalibacteraceae g MS4 s MS4 sp000752215 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020801 Microbes metabolize substances PMDBM2009268 n.a. f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020802 Microbes metabolize substances PMDBM2009268 n.a. f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020803 Microbes metabolize substances PMDBM2009268 n.a. f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020804 Microbes metabolize substances PMDBM2009268 n.a. f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020805 Microbes metabolize substances PMDBM2009268 n.a. f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020806 Microbes metabolize substances PMDBM2009268 n.a. f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020807 Microbes metabolize substances PMDBM2009268 n.a. f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020810 Microbes metabolize substances PMDBM2009268 n.a. f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20020811 Microbes metabolize substances PMDBM2009268 n.a. f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020812 Microbes metabolize substances PMDBM2009268 n.a. f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020813 Microbes metabolize substances PMDBM2009268 n.a. f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020814 Microbes metabolize substances PMDBM2009268 n.a. f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020815 Microbes metabolize substances PMDBM2009268 n.a. f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020816 Microbes metabolize substances PMDBM2009268 n.a. f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020817 Microbes metabolize substances PMDBM2009268 n.a. f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020818 Microbes metabolize substances PMDBM2009268 n.a. f Tepidimicrobiaceae g Mt11 s Mt11 sp001282665 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020819 Microbes metabolize substances PMDBM2009269 1161127 Murdochiella PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20020820 Microbes metabolize substances PMDBM2009269 1161127 Murdochiella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020821 Microbes metabolize substances PMDBM2009269 1161127 Murdochiella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020822 Microbes metabolize substances PMDBM2009269 1161127 Murdochiella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020823 Microbes metabolize substances PMDBM2009269 1161127 Murdochiella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020824 Microbes metabolize substances PMDBM2020883 1673723 Murdochiella massiliensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20020825 Microbes metabolize substances PMDBM2020883 1673723 Murdochiella massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020826 Microbes metabolize substances PMDBM2020883 1673723 Murdochiella massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020827 Microbes metabolize substances PMDBM2020883 1673723 Murdochiella massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020828 Microbes metabolize substances PMDBM2020883 1673723 Murdochiella massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020829 Microbes metabolize substances PMDBM2020884 1852373 Murdochiella vaginalis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20020830 Microbes metabolize substances PMDBM2020884 1852373 Murdochiella vaginalis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020831 Microbes metabolize substances PMDBM2020884 1852373 Murdochiella vaginalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020832 Microbes metabolize substances PMDBM2020884 1852373 Murdochiella vaginalis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020833 Microbes metabolize substances PMDBM2020884 1852373 Murdochiella vaginalis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020834 Microbes metabolize substances PMDBM2020884 1852373 Murdochiella vaginalis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020835 Microbes metabolize substances PMDBM2009272 2005473 Muribaculaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020836 Microbes metabolize substances PMDBM2009272 2005473 Muribaculaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020837 Microbes metabolize substances PMDBM2009272 2005473 Muribaculaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020838 Microbes metabolize substances PMDBM2009272 2005473 Muribaculaceae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020840 Microbes metabolize substances PMDBM2009272 2005473 Muribaculaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020842 Microbes metabolize substances PMDBM2009272 2005473 Muribaculaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020843 Microbes metabolize substances PMDBM2009272 2005473 Muribaculaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020844 Microbes metabolize substances PMDBM2009272 2005473 Muribaculaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020845 Microbes metabolize substances PMDBM2009272 2005473 Muribaculaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020848 Microbes metabolize substances PMDBM2009272 2005473 Muribaculaceae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20020849 Microbes metabolize substances PMDBM2009272 2005473 Muribaculaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020850 Microbes metabolize substances PMDBM2009272 2005473 Muribaculaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020851 Microbes metabolize substances PMDBM2009272 2005473 Muribaculaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020852 Microbes metabolize substances PMDBM2009272 2005473 Muribaculaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020854 Microbes metabolize substances PMDBM2009272 2005473 Muribaculaceae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020855 Microbes metabolize substances PMDBM2009272 2005473 Muribaculaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020856 Microbes metabolize substances PMDBM2009272 2005473 Muribaculaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020857 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020858 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020859 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020860 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020862 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020864 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020865 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020866 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020867 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20020868 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20020869 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020871 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20020874 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20020875 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20020876 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020877 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020880 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20020883 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020884 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020887 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020888 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020889 Microbes metabolize substances PMDBM2020885 1796646 Muribaculum intestinale PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020890 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp001701195 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020891 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp001701195 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020892 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp001701195 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020893 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp001701195 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020895 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp001701195 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020897 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp001701195 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020898 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp001701195 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020899 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp001701195 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020900 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp001701195 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020903 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp001701195 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020904 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp001701195 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020905 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp001701195 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020906 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp001701195 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020908 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp001701195 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020909 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp001701195 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020910 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp001701195 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020911 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002358615 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020912 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002358615 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020913 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002358615 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020914 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002358615 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020916 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002358615 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020918 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002358615 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020919 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002358615 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020920 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002358615 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020921 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002358615 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020924 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002358615 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020925 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002358615 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020926 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002358615 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020927 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002358615 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020929 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002358615 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020930 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002358615 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020931 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002358615 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020932 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002473395 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020933 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002473395 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020934 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002473395 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020935 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002473395 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020936 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002473395 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020937 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002473395 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020938 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002473395 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020939 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002473395 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020940 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002492595 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020941 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002492595 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020942 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002492595 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020943 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002492595 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020944 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002492595 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020945 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002492595 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020946 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002492595 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020949 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002492595 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20020950 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002492595 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020951 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002492595 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020952 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002492595 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020953 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002492595 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020954 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002492595 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020955 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002492595 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020956 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002492595 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020957 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp002492595 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020958 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp003150235 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020959 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp003150235 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020960 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp003150235 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020961 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp003150235 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020963 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp003150235 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020965 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp003150235 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020966 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp003150235 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020967 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp003150235 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020968 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp003150235 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020971 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp003150235 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20020972 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp003150235 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20020973 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp003150235 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020974 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp003150235 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20020976 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp003150235 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20020977 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp003150235 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020978 Microbes metabolize substances PMDBM2021628 1918611 Muribaculum sp003150235 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20020979 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20020980 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20020981 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20020982 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020984 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20020986 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20020987 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020988 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020989 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20020990 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20020991 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20020992 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20020994 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20020997 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20020998 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20020999 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021000 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021003 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20021006 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20021007 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021008 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021011 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021012 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021013 Microbes metabolize substances PMDBM2020887 1337051 Murimonas intestini PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021014 Microbes metabolize substances PMDBM2020888 1764 Mycobacterium avium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021015 Microbes metabolize substances PMDBM2020888 1764 Mycobacterium avium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021016 Microbes metabolize substances PMDBM2020888 1764 Mycobacterium avium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021017 Microbes metabolize substances PMDBM2020888 1764 Mycobacterium avium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021018 Microbes metabolize substances PMDBM2020888 1764 Mycobacterium avium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021019 Microbes metabolize substances PMDBM2020888 1764 Mycobacterium avium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021020 Microbes metabolize substances PMDBM2020888 1764 Mycobacterium avium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021023 Microbes metabolize substances PMDBM2020888 1764 Mycobacterium avium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021024 Microbes metabolize substances PMDBM2020888 1764 Mycobacterium avium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021025 Microbes metabolize substances PMDBM2020888 1764 Mycobacterium avium PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20021026 Microbes metabolize substances PMDBM2020888 1764 Mycobacterium avium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021027 Microbes metabolize substances PMDBM2020888 1764 Mycobacterium avium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021028 Microbes metabolize substances PMDBM2020888 1764 Mycobacterium avium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021029 Microbes metabolize substances PMDBM2020888 1764 Mycobacterium avium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021030 Microbes metabolize substances PMDBM2020888 1764 Mycobacterium avium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021031 Microbes metabolize substances PMDBM2020889 1773 Mycobacterium tuberculosis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021032 Microbes metabolize substances PMDBM2020889 1773 Mycobacterium tuberculosis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021033 Microbes metabolize substances PMDBM2020889 1773 Mycobacterium tuberculosis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021034 Microbes metabolize substances PMDBM2020889 1773 Mycobacterium tuberculosis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021035 Microbes metabolize substances PMDBM2020889 1773 Mycobacterium tuberculosis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021036 Microbes metabolize substances PMDBM2020889 1773 Mycobacterium tuberculosis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021037 Microbes metabolize substances PMDBM2020889 1773 Mycobacterium tuberculosis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021040 Microbes metabolize substances PMDBM2020889 1773 Mycobacterium tuberculosis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021041 Microbes metabolize substances PMDBM2020889 1773 Mycobacterium tuberculosis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021042 Microbes metabolize substances PMDBM2020889 1773 Mycobacterium tuberculosis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20021043 Microbes metabolize substances PMDBM2020889 1773 Mycobacterium tuberculosis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021044 Microbes metabolize substances PMDBM2020889 1773 Mycobacterium tuberculosis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021045 Microbes metabolize substances PMDBM2020889 1773 Mycobacterium tuberculosis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021046 Microbes metabolize substances PMDBM2020889 1773 Mycobacterium tuberculosis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021047 Microbes metabolize substances PMDBM2020889 1773 Mycobacterium tuberculosis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021048 Microbes metabolize substances PMDBM2020889 1773 Mycobacterium tuberculosis PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20021049 Microbes metabolize substances PMDBM299 2093 Mycoplasma PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. Have deleterious effects on its therapeutic efficacy n.a. PMID PMID: 36467581 PMDBI20021050 Microbes metabolize substances PMDBM299 2093 Mycoplasma PMDBD355 Floxuridine Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021051 Microbes metabolize substances PMDBM299 2093 Mycoplasma PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021053 Microbes metabolize substances PMDBM300 2100 Mycoplasma hyorhinis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. unknown activity decreased n.a. n.a. n.a. coplasma hyorhinis decrease gemcitabine's activity n.a. PMID PMID: 36467581 PMDBI20021055 Microbes metabolize substances PMDBM2009282 2790998 Mycoplasmoidaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021056 Microbes metabolize substances PMDBM2009282 2790998 Mycoplasmoidaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021057 Microbes metabolize substances PMDBM2009283 n.a. f Lachnospiraceae g NC2004 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021058 Microbes metabolize substances PMDBM2009283 n.a. f Lachnospiraceae g NC2004 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021059 Microbes metabolize substances PMDBM2009283 n.a. f Lachnospiraceae g NC2004 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021060 Microbes metabolize substances PMDBM2009283 n.a. f Lachnospiraceae g NC2004 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021061 Microbes metabolize substances PMDBM2009283 n.a. f Lachnospiraceae g NC2004 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021062 Microbes metabolize substances PMDBM2009283 n.a. f Lachnospiraceae g NC2004 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021063 Microbes metabolize substances PMDBM2009283 n.a. f Lachnospiraceae g NC2004 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021066 Microbes metabolize substances PMDBM2009283 n.a. f Lachnospiraceae g NC2004 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021067 Microbes metabolize substances PMDBM2009283 n.a. f Lachnospiraceae g NC2004 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021068 Microbes metabolize substances PMDBM2009283 n.a. f Lachnospiraceae g NC2004 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021069 Microbes metabolize substances PMDBM2009283 n.a. f Lachnospiraceae g NC2004 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021070 Microbes metabolize substances PMDBM2009283 n.a. f Lachnospiraceae g NC2004 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021071 Microbes metabolize substances PMDBM2009283 n.a. f Lachnospiraceae g NC2004 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021072 Microbes metabolize substances PMDBM2009283 n.a. f Lachnospiraceae g NC2004 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021073 Microbes metabolize substances PMDBM2009284 1980693 Negativibacillus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021074 Microbes metabolize substances PMDBM2009284 1980693 Negativibacillus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20021075 Microbes metabolize substances PMDBM2009284 1980693 Negativibacillus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021076 Microbes metabolize substances PMDBM2009284 1980693 Negativibacillus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021077 Microbes metabolize substances PMDBM2009284 1980693 Negativibacillus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021078 Microbes metabolize substances PMDBM2009284 1980693 Negativibacillus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021079 Microbes metabolize substances PMDBM2009284 1980693 Negativibacillus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021080 Microbes metabolize substances PMDBM2009284 1980693 Negativibacillus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021083 Microbes metabolize substances PMDBM2009284 1980693 Negativibacillus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021084 Microbes metabolize substances PMDBM2009284 1980693 Negativibacillus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021085 Microbes metabolize substances PMDBM2009284 1980693 Negativibacillus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021086 Microbes metabolize substances PMDBM2009284 1980693 Negativibacillus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021087 Microbes metabolize substances PMDBM2009284 1980693 Negativibacillus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021088 Microbes metabolize substances PMDBM2009284 1980693 Negativibacillus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021089 Microbes metabolize substances PMDBM2009284 1980693 Negativibacillus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021090 Microbes metabolize substances PMDBM2009284 1980693 Negativibacillus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021091 Microbes metabolize substances PMDBM2021629 1871035 Negativibacillus massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021092 Microbes metabolize substances PMDBM2021629 1871035 Negativibacillus massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021093 Microbes metabolize substances PMDBM2021629 1871035 Negativibacillus massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021094 Microbes metabolize substances PMDBM2021629 1871035 Negativibacillus massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021095 Microbes metabolize substances PMDBM2021629 1871035 Negativibacillus massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021096 Microbes metabolize substances PMDBM2021630 1980694 Negativibacillus sp000435195 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021097 Microbes metabolize substances PMDBM2021630 1980694 Negativibacillus sp000435195 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021098 Microbes metabolize substances PMDBM2021630 1980694 Negativibacillus sp000435195 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021099 Microbes metabolize substances PMDBM2021630 1980694 Negativibacillus sp000435195 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021100 Microbes metabolize substances PMDBM2021630 1980694 Negativibacillus sp000435195 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021101 Microbes metabolize substances PMDBM2009287 n.a. Negativicoccaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021102 Microbes metabolize substances PMDBM2009288 909928 Negativicoccus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021103 Microbes metabolize substances PMDBM2021631 1702287 Negativicoccus massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021104 Microbes metabolize substances PMDBM2021631 1702287 Negativicoccus massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021105 Microbes metabolize substances PMDBM2021632 620903 Negativicoccus succinicivorans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021106 Microbes metabolize substances PMDBM2021633 485 Neisseria gonorrhoeae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021107 Microbes metabolize substances PMDBM2021633 485 Neisseria gonorrhoeae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021108 Microbes metabolize substances PMDBM2021633 485 Neisseria gonorrhoeae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021109 Microbes metabolize substances PMDBM2021633 485 Neisseria gonorrhoeae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021110 Microbes metabolize substances PMDBM2021633 485 Neisseria gonorrhoeae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021111 Microbes metabolize substances PMDBM2021633 485 Neisseria gonorrhoeae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021112 Microbes metabolize substances PMDBM2021633 485 Neisseria gonorrhoeae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021115 Microbes metabolize substances PMDBM2021633 485 Neisseria gonorrhoeae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021116 Microbes metabolize substances PMDBM2021633 485 Neisseria gonorrhoeae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021117 Microbes metabolize substances PMDBM2021633 485 Neisseria gonorrhoeae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021118 Microbes metabolize substances PMDBM2021633 485 Neisseria gonorrhoeae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021119 Microbes metabolize substances PMDBM2021304 496 Neisseria macacae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021120 Microbes metabolize substances PMDBM2021304 496 Neisseria macacae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021121 Microbes metabolize substances PMDBM2021304 496 Neisseria macacae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021122 Microbes metabolize substances PMDBM2021304 496 Neisseria macacae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021123 Microbes metabolize substances PMDBM2021304 496 Neisseria macacae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021124 Microbes metabolize substances PMDBM2021304 496 Neisseria macacae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021125 Microbes metabolize substances PMDBM2021304 496 Neisseria macacae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021128 Microbes metabolize substances PMDBM2021304 496 Neisseria macacae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021129 Microbes metabolize substances PMDBM2021304 496 Neisseria macacae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021130 Microbes metabolize substances PMDBM2021304 496 Neisseria macacae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021131 Microbes metabolize substances PMDBM2021304 496 Neisseria macacae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021132 Microbes metabolize substances PMDBM2021304 496 Neisseria macacae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021133 Microbes metabolize substances PMDBM2021634 192066 Neisseria sp000186165 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021134 Microbes metabolize substances PMDBM2021634 192066 Neisseria sp000186165 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021135 Microbes metabolize substances PMDBM2021634 192066 Neisseria sp000186165 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021136 Microbes metabolize substances PMDBM2021634 192066 Neisseria sp000186165 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021137 Microbes metabolize substances PMDBM2021634 192066 Neisseria sp000186165 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021138 Microbes metabolize substances PMDBM2021634 192066 Neisseria sp000186165 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021139 Microbes metabolize substances PMDBM2021634 192066 Neisseria sp000186165 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021142 Microbes metabolize substances PMDBM2021634 192066 Neisseria sp000186165 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021143 Microbes metabolize substances PMDBM2021634 192066 Neisseria sp000186165 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021144 Microbes metabolize substances PMDBM2021634 192066 Neisseria sp000186165 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021145 Microbes metabolize substances PMDBM2021634 192066 Neisseria sp000186165 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021146 Microbes metabolize substances PMDBM2021634 192066 Neisseria sp000186165 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021147 Microbes metabolize substances PMDBM2021306 28449 Neisseria subflava B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021148 Microbes metabolize substances PMDBM2021306 28449 Neisseria subflava B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021149 Microbes metabolize substances PMDBM2021306 28449 Neisseria subflava B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021150 Microbes metabolize substances PMDBM2021306 28449 Neisseria subflava B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021151 Microbes metabolize substances PMDBM2021306 28449 Neisseria subflava B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021152 Microbes metabolize substances PMDBM2021306 28449 Neisseria subflava B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021153 Microbes metabolize substances PMDBM2021306 28449 Neisseria subflava B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021156 Microbes metabolize substances PMDBM2021306 28449 Neisseria subflava B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021157 Microbes metabolize substances PMDBM2021306 28449 Neisseria subflava B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021158 Microbes metabolize substances PMDBM2021306 28449 Neisseria subflava B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021159 Microbes metabolize substances PMDBM2021306 28449 Neisseria subflava B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021160 Microbes metabolize substances PMDBM2021306 28449 Neisseria subflava B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021161 Microbes metabolize substances PMDBM2020141 495 Neisseria D elongata PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021162 Microbes metabolize substances PMDBM2020141 495 Neisseria D elongata PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021163 Microbes metabolize substances PMDBM2020141 495 Neisseria D elongata PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021164 Microbes metabolize substances PMDBM2020141 495 Neisseria D elongata PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021165 Microbes metabolize substances PMDBM2020141 495 Neisseria D elongata PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021166 Microbes metabolize substances PMDBM2020141 495 Neisseria D elongata PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021167 Microbes metabolize substances PMDBM2020141 495 Neisseria D elongata PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021170 Microbes metabolize substances PMDBM2020141 495 Neisseria D elongata PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021171 Microbes metabolize substances PMDBM2020141 495 Neisseria D elongata PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021172 Microbes metabolize substances PMDBM2020141 495 Neisseria D elongata PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021173 Microbes metabolize substances PMDBM2020141 495 Neisseria D elongata PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021174 Microbes metabolize substances PMDBM2021635 2041842 Neobitarella massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021175 Microbes metabolize substances PMDBM2021635 2041842 Neobitarella massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021176 Microbes metabolize substances PMDBM2021635 2041842 Neobitarella massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021177 Microbes metabolize substances PMDBM2021635 2041842 Neobitarella massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021178 Microbes metabolize substances PMDBM2021635 2041842 Neobitarella massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021179 Microbes metabolize substances PMDBM2021635 2041842 Neobitarella massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021180 Microbes metabolize substances PMDBM2021635 2041842 Neobitarella massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021183 Microbes metabolize substances PMDBM2021635 2041842 Neobitarella massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021184 Microbes metabolize substances PMDBM2021635 2041842 Neobitarella massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021185 Microbes metabolize substances PMDBM2021635 2041842 Neobitarella massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021186 Microbes metabolize substances PMDBM2021635 2041842 Neobitarella massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021187 Microbes metabolize substances PMDBM2021635 2041842 Neobitarella massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021188 Microbes metabolize substances PMDBM2021635 2041842 Neobitarella massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021189 Microbes metabolize substances PMDBM2021635 2041842 Neobitarella massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021190 Microbes metabolize substances PMDBM2021635 2041842 Neobitarella massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021191 Microbes metabolize substances PMDBM2020898 1673724 Neofamilia massiliensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20021192 Microbes metabolize substances PMDBM2020898 1673724 Neofamilia massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021193 Microbes metabolize substances PMDBM2020898 1673724 Neofamilia massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021194 Microbes metabolize substances PMDBM2020898 1673724 Neofamilia massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021195 Microbes metabolize substances PMDBM2020898 1673724 Neofamilia massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021196 Microbes metabolize substances PMDBM2020898 1673724 Neofamilia massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021197 Microbes metabolize substances PMDBM2020899 1232429 Nesterenkonia massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20021198 Microbes metabolize substances PMDBM2020899 1232429 Nesterenkonia massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021199 Microbes metabolize substances PMDBM2020899 1232429 Nesterenkonia massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021200 Microbes metabolize substances PMDBM2020899 1232429 Nesterenkonia massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021201 Microbes metabolize substances PMDBM2009299 1973274 Niameybacter PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021202 Microbes metabolize substances PMDBM2009299 1973274 Niameybacter PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021203 Microbes metabolize substances PMDBM2009299 1973274 Niameybacter PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021204 Microbes metabolize substances PMDBM2009299 1973274 Niameybacter PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021205 Microbes metabolize substances PMDBM2009299 1973274 Niameybacter PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021206 Microbes metabolize substances PMDBM2009299 1973274 Niameybacter PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021207 Microbes metabolize substances PMDBM2009299 1973274 Niameybacter PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021210 Microbes metabolize substances PMDBM2009299 1973274 Niameybacter PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20021211 Microbes metabolize substances PMDBM2009299 1973274 Niameybacter PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021212 Microbes metabolize substances PMDBM2009299 1973274 Niameybacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021213 Microbes metabolize substances PMDBM2009299 1973274 Niameybacter PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021214 Microbes metabolize substances PMDBM2009299 1973274 Niameybacter PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021215 Microbes metabolize substances PMDBM2009299 1973274 Niameybacter PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021216 Microbes metabolize substances PMDBM2009299 1973274 Niameybacter PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021217 Microbes metabolize substances PMDBM2009299 1973274 Niameybacter PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021218 Microbes metabolize substances PMDBM2009299 1973274 Niameybacter PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021219 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021220 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20021221 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021222 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021223 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021224 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021225 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021226 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20021227 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20021228 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021230 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20021233 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20021234 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20021235 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021236 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021239 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20021242 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021243 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021244 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021246 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021247 Microbes metabolize substances PMDBM2020901 1522317 Nigerium massiliense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021248 Microbes metabolize substances PMDBM2021636 1917880 Nissabacter archeti PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021249 Microbes metabolize substances PMDBM2021636 1917880 Nissabacter archeti PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20021250 Microbes metabolize substances PMDBM2021636 1917880 Nissabacter archeti PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021251 Microbes metabolize substances PMDBM2021636 1917880 Nissabacter archeti PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021252 Microbes metabolize substances PMDBM2021636 1917880 Nissabacter archeti PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021253 Microbes metabolize substances PMDBM2021636 1917880 Nissabacter archeti PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021254 Microbes metabolize substances PMDBM2021636 1917880 Nissabacter archeti PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021255 Microbes metabolize substances PMDBM2021636 1917880 Nissabacter archeti PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021258 Microbes metabolize substances PMDBM2021636 1917880 Nissabacter archeti PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021259 Microbes metabolize substances PMDBM2021636 1917880 Nissabacter archeti PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021260 Microbes metabolize substances PMDBM2021636 1917880 Nissabacter archeti PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021261 Microbes metabolize substances PMDBM2021636 1917880 Nissabacter archeti PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021262 Microbes metabolize substances PMDBM2021636 1917880 Nissabacter archeti PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021263 Microbes metabolize substances PMDBM2021636 1917880 Nissabacter archeti PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021264 Microbes metabolize substances PMDBM2021636 1917880 Nissabacter archeti PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021265 Microbes metabolize substances PMDBM2021636 1917880 Nissabacter archeti PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021266 Microbes metabolize substances PMDBM2021637 1964367 Nissabacter sp002858715 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021267 Microbes metabolize substances PMDBM2021637 1964367 Nissabacter sp002858715 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20021268 Microbes metabolize substances PMDBM2021637 1964367 Nissabacter sp002858715 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021269 Microbes metabolize substances PMDBM2021637 1964367 Nissabacter sp002858715 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021270 Microbes metabolize substances PMDBM2021637 1964367 Nissabacter sp002858715 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021271 Microbes metabolize substances PMDBM2021637 1964367 Nissabacter sp002858715 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021272 Microbes metabolize substances PMDBM2021637 1964367 Nissabacter sp002858715 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021273 Microbes metabolize substances PMDBM2021637 1964367 Nissabacter sp002858715 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021276 Microbes metabolize substances PMDBM2021637 1964367 Nissabacter sp002858715 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021277 Microbes metabolize substances PMDBM2021637 1964367 Nissabacter sp002858715 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021278 Microbes metabolize substances PMDBM2021637 1964367 Nissabacter sp002858715 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021279 Microbes metabolize substances PMDBM2021637 1964367 Nissabacter sp002858715 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021280 Microbes metabolize substances PMDBM2021637 1964367 Nissabacter sp002858715 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021281 Microbes metabolize substances PMDBM2021637 1964367 Nissabacter sp002858715 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021282 Microbes metabolize substances PMDBM2021637 1964367 Nissabacter sp002858715 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021283 Microbes metabolize substances PMDBM2021637 1964367 Nissabacter sp002858715 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021284 Microbes metabolize substances PMDBM2009303 n.a. f Oscillospiraceae g NK3B98 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20021285 Microbes metabolize substances PMDBM2009303 n.a. f Oscillospiraceae g NK3B98 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021286 Microbes metabolize substances PMDBM2009303 n.a. f Oscillospiraceae g NK3B98 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021287 Microbes metabolize substances PMDBM2009303 n.a. f Oscillospiraceae g NK3B98 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021288 Microbes metabolize substances PMDBM2009303 n.a. f Oscillospiraceae g NK3B98 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021289 Microbes metabolize substances PMDBM2009303 n.a. f Oscillospiraceae g NK3B98 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021290 Microbes metabolize substances PMDBM2009304 n.a. f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021291 Microbes metabolize substances PMDBM2009304 n.a. f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021292 Microbes metabolize substances PMDBM2009304 n.a. f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021293 Microbes metabolize substances PMDBM2009304 n.a. f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021294 Microbes metabolize substances PMDBM2009304 n.a. f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021295 Microbes metabolize substances PMDBM2009304 n.a. f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021296 Microbes metabolize substances PMDBM2009304 n.a. f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021299 Microbes metabolize substances PMDBM2009304 n.a. f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021300 Microbes metabolize substances PMDBM2009304 n.a. f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021301 Microbes metabolize substances PMDBM2009304 n.a. f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021302 Microbes metabolize substances PMDBM2009304 n.a. f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021303 Microbes metabolize substances PMDBM2009304 n.a. f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021304 Microbes metabolize substances PMDBM2009304 n.a. f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021305 Microbes metabolize substances PMDBM2009304 n.a. f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021306 Microbes metabolize substances PMDBM2009304 n.a. f Lachnospiraceae g NK4A136 s NK4A136 sp002314855 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021307 Microbes metabolize substances PMDBM2020903 1232430 Nosocomiicoccus massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20021308 Microbes metabolize substances PMDBM2020903 1232430 Nosocomiicoccus massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021309 Microbes metabolize substances PMDBM2020903 1232430 Nosocomiicoccus massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021310 Microbes metabolize substances PMDBM2020903 1232430 Nosocomiicoccus massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021311 Microbes metabolize substances PMDBM2020904 1465823 Noviherbaspirillum massiliense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021312 Microbes metabolize substances PMDBM2020904 1465823 Noviherbaspirillum massiliense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021313 Microbes metabolize substances PMDBM2020904 1465823 Noviherbaspirillum massiliense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021314 Microbes metabolize substances PMDBM2020904 1465823 Noviherbaspirillum massiliense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021315 Microbes metabolize substances PMDBM2020904 1465823 Noviherbaspirillum massiliense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021316 Microbes metabolize substances PMDBM2020904 1465823 Noviherbaspirillum massiliense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021317 Microbes metabolize substances PMDBM2020904 1465823 Noviherbaspirillum massiliense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021320 Microbes metabolize substances PMDBM2020904 1465823 Noviherbaspirillum massiliense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021321 Microbes metabolize substances PMDBM2020904 1465823 Noviherbaspirillum massiliense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021322 Microbes metabolize substances PMDBM2020904 1465823 Noviherbaspirillum massiliense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021323 Microbes metabolize substances PMDBM2020904 1465823 Noviherbaspirillum massiliense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021324 Microbes metabolize substances PMDBM2020904 1465823 Noviherbaspirillum massiliense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021325 Microbes metabolize substances PMDBM2020904 1465823 Noviherbaspirillum massiliense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021326 Microbes metabolize substances PMDBM2021638 1522315 Numidum massiliense PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20021327 Microbes metabolize substances PMDBM2021638 1522315 Numidum massiliense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021328 Microbes metabolize substances PMDBM2021638 1522315 Numidum massiliense PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20021329 Microbes metabolize substances PMDBM2021638 1522315 Numidum massiliense PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021330 Microbes metabolize substances PMDBM2021638 1522315 Numidum massiliense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021331 Microbes metabolize substances PMDBM2021638 1522315 Numidum massiliense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021332 Microbes metabolize substances PMDBM2020907 405946 Oceanobacillus caeni PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20021333 Microbes metabolize substances PMDBM2020907 405946 Oceanobacillus caeni PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021334 Microbes metabolize substances PMDBM2020907 405946 Oceanobacillus caeni PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021335 Microbes metabolize substances PMDBM2020907 405946 Oceanobacillus caeni PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021336 Microbes metabolize substances PMDBM2020907 405946 Oceanobacillus caeni PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021337 Microbes metabolize substances PMDBM2020908 1462527 Oceanobacillus jeddahense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021338 Microbes metabolize substances PMDBM2020908 1462527 Oceanobacillus jeddahense PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20021339 Microbes metabolize substances PMDBM2020908 1462527 Oceanobacillus jeddahense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021340 Microbes metabolize substances PMDBM2020908 1462527 Oceanobacillus jeddahense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021341 Microbes metabolize substances PMDBM2020908 1462527 Oceanobacillus jeddahense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021342 Microbes metabolize substances PMDBM2020908 1462527 Oceanobacillus jeddahense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021343 Microbes metabolize substances PMDBM2020908 1462527 Oceanobacillus jeddahense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021344 Microbes metabolize substances PMDBM2020908 1462527 Oceanobacillus jeddahense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021347 Microbes metabolize substances PMDBM2020908 1462527 Oceanobacillus jeddahense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021348 Microbes metabolize substances PMDBM2020908 1462527 Oceanobacillus jeddahense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021349 Microbes metabolize substances PMDBM2020908 1462527 Oceanobacillus jeddahense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021350 Microbes metabolize substances PMDBM2020908 1462527 Oceanobacillus jeddahense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021351 Microbes metabolize substances PMDBM2020908 1462527 Oceanobacillus jeddahense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021352 Microbes metabolize substances PMDBM2020908 1462527 Oceanobacillus jeddahense PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021353 Microbes metabolize substances PMDBM2020908 1462527 Oceanobacillus jeddahense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021354 Microbes metabolize substances PMDBM2020908 1462527 Oceanobacillus jeddahense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021355 Microbes metabolize substances PMDBM2020909 1465765 Oceanobacillus massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021356 Microbes metabolize substances PMDBM2020909 1465765 Oceanobacillus massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20021357 Microbes metabolize substances PMDBM2020909 1465765 Oceanobacillus massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021358 Microbes metabolize substances PMDBM2020909 1465765 Oceanobacillus massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021359 Microbes metabolize substances PMDBM2020909 1465765 Oceanobacillus massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021360 Microbes metabolize substances PMDBM2020909 1465765 Oceanobacillus massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021361 Microbes metabolize substances PMDBM2020909 1465765 Oceanobacillus massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021362 Microbes metabolize substances PMDBM2020909 1465765 Oceanobacillus massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021365 Microbes metabolize substances PMDBM2020909 1465765 Oceanobacillus massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021366 Microbes metabolize substances PMDBM2020909 1465765 Oceanobacillus massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021367 Microbes metabolize substances PMDBM2020909 1465765 Oceanobacillus massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021368 Microbes metabolize substances PMDBM2020909 1465765 Oceanobacillus massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021369 Microbes metabolize substances PMDBM2020909 1465765 Oceanobacillus massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021370 Microbes metabolize substances PMDBM2020909 1465765 Oceanobacillus massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021371 Microbes metabolize substances PMDBM2020909 1465765 Oceanobacillus massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021372 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021373 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20021374 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021375 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021376 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021378 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021380 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021381 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021382 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021383 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20021384 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20021385 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021387 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20021390 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20021391 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20021392 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20021393 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021394 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021397 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20021400 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021401 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021404 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021405 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021406 Microbes metabolize substances PMDBM302 283168 Odoribacter PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021407 Microbes metabolize substances PMDBM2021639 1263089 Odoribacter laneus PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20021408 Microbes metabolize substances PMDBM2021639 1263089 Odoribacter laneus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021409 Microbes metabolize substances PMDBM2021639 1263089 Odoribacter laneus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021410 Microbes metabolize substances PMDBM2021639 1263089 Odoribacter laneus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021411 Microbes metabolize substances PMDBM2021639 1263089 Odoribacter laneus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021412 Microbes metabolize substances PMDBM2021639 1263089 Odoribacter laneus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021413 Microbes metabolize substances PMDBM2021550 1841863 Odoribacter massiliensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20021414 Microbes metabolize substances PMDBM2021550 1841863 Odoribacter massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021415 Microbes metabolize substances PMDBM2021550 1841863 Odoribacter massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021416 Microbes metabolize substances PMDBM2021550 1841863 Odoribacter massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021417 Microbes metabolize substances PMDBM2021550 1841863 Odoribacter massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021418 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021419 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021420 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021421 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021422 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021423 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021424 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20021425 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20021426 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021428 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20021431 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20021432 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20021433 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20021434 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021437 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20021440 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021441 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021442 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021444 Microbes metabolize substances PMDBM2020230 28118 Odoribacter splanchnicus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021445 Microbes metabolize substances PMDBM2009313 n.a. f Erysipelotrichaceae g OEMR01 s OEMR01 sp900199515 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021446 Microbes metabolize substances PMDBM2009313 n.a. f Erysipelotrichaceae g OEMR01 s OEMR01 sp900199515 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021447 Microbes metabolize substances PMDBM2009313 n.a. f Erysipelotrichaceae g OEMR01 s OEMR01 sp900199515 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021448 Microbes metabolize substances PMDBM2009313 n.a. f Erysipelotrichaceae g OEMR01 s OEMR01 sp900199515 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021449 Microbes metabolize substances PMDBM2020912 1776381 Olegusella massiliensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021450 Microbes metabolize substances PMDBM2020912 1776381 Olegusella massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021451 Microbes metabolize substances PMDBM2020912 1776381 Olegusella massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021452 Microbes metabolize substances PMDBM2020912 1776381 Olegusella massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021453 Microbes metabolize substances PMDBM2020912 1776381 Olegusella massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021454 Microbes metabolize substances PMDBM2020912 1776381 Olegusella massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021455 Microbes metabolize substances PMDBM2020912 1776381 Olegusella massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021456 Microbes metabolize substances PMDBM2020912 1776381 Olegusella massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021457 Microbes metabolize substances PMDBM2020912 1776381 Olegusella massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021458 Microbes metabolize substances PMDBM2020915 2042683 Olsenella sp001457795 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021459 Microbes metabolize substances PMDBM2020915 2042683 Olsenella sp001457795 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021460 Microbes metabolize substances PMDBM2020915 2042683 Olsenella sp001457795 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021461 Microbes metabolize substances PMDBM2020915 2042683 Olsenella sp001457795 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021462 Microbes metabolize substances PMDBM2020915 2042683 Olsenella sp001457795 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021463 Microbes metabolize substances PMDBM2020915 2042683 Olsenella sp001457795 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021464 Microbes metabolize substances PMDBM2020915 2042683 Olsenella sp001457795 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021467 Microbes metabolize substances PMDBM2020915 2042683 Olsenella sp001457795 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021468 Microbes metabolize substances PMDBM2020915 2042683 Olsenella sp001457795 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021469 Microbes metabolize substances PMDBM2020915 2042683 Olsenella sp001457795 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021470 Microbes metabolize substances PMDBM2020915 2042683 Olsenella sp001457795 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021471 Microbes metabolize substances PMDBM2020915 2042683 Olsenella sp001457795 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021472 Microbes metabolize substances PMDBM2009316 n.a. Olsenella B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021473 Microbes metabolize substances PMDBM2009316 n.a. Olsenella B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021474 Microbes metabolize substances PMDBM2009316 n.a. Olsenella B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021475 Microbes metabolize substances PMDBM2009316 n.a. Olsenella B PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021477 Microbes metabolize substances PMDBM2009316 n.a. Olsenella B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021479 Microbes metabolize substances PMDBM2009316 n.a. Olsenella B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021480 Microbes metabolize substances PMDBM2009316 n.a. Olsenella B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021481 Microbes metabolize substances PMDBM2009316 n.a. Olsenella B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021482 Microbes metabolize substances PMDBM2009316 n.a. Olsenella B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021485 Microbes metabolize substances PMDBM2009316 n.a. Olsenella B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021486 Microbes metabolize substances PMDBM2009316 n.a. Olsenella B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021487 Microbes metabolize substances PMDBM2009316 n.a. Olsenella B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021488 Microbes metabolize substances PMDBM2009316 n.a. Olsenella B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021490 Microbes metabolize substances PMDBM2009316 n.a. Olsenella B PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021491 Microbes metabolize substances PMDBM2009316 n.a. Olsenella B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021492 Microbes metabolize substances PMDBM2009316 n.a. Olsenella B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021493 Microbes metabolize substances PMDBM2009317 n.a. Olsenella B sp000752675 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021494 Microbes metabolize substances PMDBM2009317 n.a. Olsenella B sp000752675 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021495 Microbes metabolize substances PMDBM2009317 n.a. Olsenella B sp000752675 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021496 Microbes metabolize substances PMDBM2009317 n.a. Olsenella B sp000752675 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021498 Microbes metabolize substances PMDBM2009317 n.a. Olsenella B sp000752675 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021500 Microbes metabolize substances PMDBM2009317 n.a. Olsenella B sp000752675 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021501 Microbes metabolize substances PMDBM2009317 n.a. Olsenella B sp000752675 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021502 Microbes metabolize substances PMDBM2009317 n.a. Olsenella B sp000752675 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021503 Microbes metabolize substances PMDBM2009317 n.a. Olsenella B sp000752675 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021506 Microbes metabolize substances PMDBM2009317 n.a. Olsenella B sp000752675 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021507 Microbes metabolize substances PMDBM2009317 n.a. Olsenella B sp000752675 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021508 Microbes metabolize substances PMDBM2009317 n.a. Olsenella B sp000752675 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021509 Microbes metabolize substances PMDBM2009317 n.a. Olsenella B sp000752675 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021511 Microbes metabolize substances PMDBM2009317 n.a. Olsenella B sp000752675 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021512 Microbes metabolize substances PMDBM2009317 n.a. Olsenella B sp000752675 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021513 Microbes metabolize substances PMDBM2009318 n.a. Olsenella C PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021514 Microbes metabolize substances PMDBM2009318 n.a. Olsenella C PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021515 Microbes metabolize substances PMDBM2009318 n.a. Olsenella C PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021516 Microbes metabolize substances PMDBM2009318 n.a. Olsenella C PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021517 Microbes metabolize substances PMDBM2009318 n.a. Olsenella C PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021518 Microbes metabolize substances PMDBM2009318 n.a. Olsenella C PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021519 Microbes metabolize substances PMDBM2009318 n.a. Olsenella C PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021522 Microbes metabolize substances PMDBM2009318 n.a. Olsenella C PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20021523 Microbes metabolize substances PMDBM2009318 n.a. Olsenella C PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021524 Microbes metabolize substances PMDBM2009318 n.a. Olsenella C PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021525 Microbes metabolize substances PMDBM2009318 n.a. Olsenella C PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021526 Microbes metabolize substances PMDBM2009318 n.a. Olsenella C PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021527 Microbes metabolize substances PMDBM2009318 n.a. Olsenella C PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021528 Microbes metabolize substances PMDBM2009318 n.a. Olsenella C PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021529 Microbes metabolize substances PMDBM2009318 n.a. Olsenella C PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021530 Microbes metabolize substances PMDBM2009319 n.a. Olsenella E PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021531 Microbes metabolize substances PMDBM2009319 n.a. Olsenella E PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021532 Microbes metabolize substances PMDBM2009319 n.a. Olsenella E PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021533 Microbes metabolize substances PMDBM2009319 n.a. Olsenella E PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021534 Microbes metabolize substances PMDBM2009319 n.a. Olsenella E PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021535 Microbes metabolize substances PMDBM2009319 n.a. Olsenella E PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021536 Microbes metabolize substances PMDBM2009319 n.a. Olsenella E PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021539 Microbes metabolize substances PMDBM2009319 n.a. Olsenella E PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021540 Microbes metabolize substances PMDBM2009319 n.a. Olsenella E PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021541 Microbes metabolize substances PMDBM2009319 n.a. Olsenella E PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021542 Microbes metabolize substances PMDBM2009319 n.a. Olsenella E PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021543 Microbes metabolize substances PMDBM2009319 n.a. Olsenella E PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021544 Microbes metabolize substances PMDBM2021640 1852386 Olsenella E provencensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021545 Microbes metabolize substances PMDBM2021640 1852386 Olsenella E provencensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021546 Microbes metabolize substances PMDBM2021640 1852386 Olsenella E provencensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021547 Microbes metabolize substances PMDBM2021640 1852386 Olsenella E provencensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021548 Microbes metabolize substances PMDBM2021640 1852386 Olsenella E provencensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021549 Microbes metabolize substances PMDBM2021640 1852386 Olsenella E provencensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021550 Microbes metabolize substances PMDBM2021640 1852386 Olsenella E provencensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021553 Microbes metabolize substances PMDBM2021640 1852386 Olsenella E provencensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021554 Microbes metabolize substances PMDBM2021640 1852386 Olsenella E provencensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021555 Microbes metabolize substances PMDBM2021640 1852386 Olsenella E provencensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021556 Microbes metabolize substances PMDBM2021640 1852386 Olsenella E provencensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021557 Microbes metabolize substances PMDBM2021640 1852386 Olsenella E provencensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021558 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002159735 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021559 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002159735 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021560 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002159735 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021561 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002159735 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021562 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002159735 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021563 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002159735 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021564 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002159735 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021567 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002159735 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021568 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002159735 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021569 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002159735 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021570 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002159735 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021571 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002159735 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021572 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002160255 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021573 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002160255 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021574 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002160255 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021575 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002160255 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021576 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002160255 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021577 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002160255 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021578 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002160255 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021581 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002160255 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021582 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002160255 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021583 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002160255 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021584 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002160255 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021585 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp002160255 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021586 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021587 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021588 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021589 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021590 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021591 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021592 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20021593 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20021594 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021596 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20021599 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20021600 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20021601 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021602 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021605 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20021608 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021609 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021610 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp003150175 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021612 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp900119915 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021613 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp900119915 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021614 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp900119915 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021615 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp900119915 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021616 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp900119915 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021617 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp900119915 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021618 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp900119915 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021621 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp900119915 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021622 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp900119915 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021623 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp900119915 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021624 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp900119915 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021625 Microbes metabolize substances PMDBM2020915 2042683 Olsenella E sp900119915 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021626 Microbes metabolize substances PMDBM2009325 265975 Oribacterium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021627 Microbes metabolize substances PMDBM2009325 265975 Oribacterium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021628 Microbes metabolize substances PMDBM2009325 265975 Oribacterium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021629 Microbes metabolize substances PMDBM2009325 265975 Oribacterium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021630 Microbes metabolize substances PMDBM2009325 265975 Oribacterium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021631 Microbes metabolize substances PMDBM2009325 265975 Oribacterium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021632 Microbes metabolize substances PMDBM2009325 265975 Oribacterium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021635 Microbes metabolize substances PMDBM2009325 265975 Oribacterium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021636 Microbes metabolize substances PMDBM2009325 265975 Oribacterium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021637 Microbes metabolize substances PMDBM2009325 265975 Oribacterium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021638 Microbes metabolize substances PMDBM2009325 265975 Oribacterium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021639 Microbes metabolize substances PMDBM2009325 265975 Oribacterium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021640 Microbes metabolize substances PMDBM2009325 265975 Oribacterium PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021641 Microbes metabolize substances PMDBM2009325 265975 Oribacterium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021642 Microbes metabolize substances PMDBM2009325 265975 Oribacterium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021643 Microbes metabolize substances PMDBM2021309 237576 Oribacterium sinus PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20021644 Microbes metabolize substances PMDBM2021309 237576 Oribacterium sinus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021645 Microbes metabolize substances PMDBM2021309 237576 Oribacterium sinus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021646 Microbes metabolize substances PMDBM2021309 237576 Oribacterium sinus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021647 Microbes metabolize substances PMDBM2021309 237576 Oribacterium sinus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021648 Microbes metabolize substances PMDBM2021309 237576 Oribacterium sinus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021649 Microbes metabolize substances PMDBM305 459786 Oscillibacter PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20021650 Microbes metabolize substances PMDBM305 459786 Oscillibacter PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20021651 Microbes metabolize substances PMDBM305 459786 Oscillibacter PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20021652 Microbes metabolize substances PMDBM305 459786 Oscillibacter PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20021653 Microbes metabolize substances PMDBM305 459786 Oscillibacter PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021654 Microbes metabolize substances PMDBM305 459786 Oscillibacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021655 Microbes metabolize substances PMDBM305 459786 Oscillibacter PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021656 Microbes metabolize substances PMDBM305 459786 Oscillibacter PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. Compound K n.a. unknown activity increased n.a. n.a. n.a. Drug interaction:antibiotics inhibits the metabolism n.a. PMID PMID: 36467581 PMDBI20021657 Microbes metabolize substances PMDBM305 459786 Oscillibacter PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021658 Microbes metabolize substances PMDBM305 459786 Oscillibacter PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021659 Microbes metabolize substances PMDBM2020917 1263547 Oscillibacter ruminantium PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20021660 Microbes metabolize substances PMDBM2020917 1263547 Oscillibacter ruminantium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021661 Microbes metabolize substances PMDBM2020917 1263547 Oscillibacter ruminantium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021662 Microbes metabolize substances PMDBM2020917 1263547 Oscillibacter ruminantium PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021663 Microbes metabolize substances PMDBM2020917 1263547 Oscillibacter ruminantium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021664 Microbes metabolize substances PMDBM2020917 1263547 Oscillibacter ruminantium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021665 Microbes metabolize substances PMDBM2020067 1945593 Oscillibacter sp000436875 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021666 Microbes metabolize substances PMDBM2020067 1945593 Oscillibacter sp000436875 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021667 Microbes metabolize substances PMDBM2020067 1945593 Oscillibacter sp000436875 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021668 Microbes metabolize substances PMDBM2020067 1945593 Oscillibacter sp000436875 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021669 Microbes metabolize substances PMDBM2020067 1945593 Oscillibacter sp000436875 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021670 Microbes metabolize substances PMDBM2020067 1945593 Oscillibacter sp001916835 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021671 Microbes metabolize substances PMDBM2020067 1945593 Oscillibacter sp001916835 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021672 Microbes metabolize substances PMDBM2020067 1945593 Oscillibacter sp001916835 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021673 Microbes metabolize substances PMDBM2020067 1945593 Oscillibacter sp001916835 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021674 Microbes metabolize substances PMDBM2020067 1945593 Oscillibacter sp001916835 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021675 Microbes metabolize substances PMDBM2020067 1945593 Oscillibacter sp900066435 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20021676 Microbes metabolize substances PMDBM2020067 1945593 Oscillibacter sp900066435 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20021677 Microbes metabolize substances PMDBM2020067 1945593 Oscillibacter sp900066435 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021678 Microbes metabolize substances PMDBM2020067 1945593 Oscillibacter sp900066435 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021679 Microbes metabolize substances PMDBM2020067 1945593 Oscillibacter sp900066435 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021680 Microbes metabolize substances PMDBM2020067 1945593 Oscillibacter sp900066435 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021681 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021682 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20021683 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021684 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021685 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021687 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021689 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20021690 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021691 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021692 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021693 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021696 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20021697 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20021698 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021699 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021700 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20021701 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021702 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021704 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021705 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021706 Microbes metabolize substances PMDBM2009331 216572 Oscillospiraceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021707 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021708 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021709 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021710 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021712 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021714 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20021715 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021716 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021717 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021718 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20021719 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20021720 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021722 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20021725 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20021726 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20021727 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021728 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021731 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20021734 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021735 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021738 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021739 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021740 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021741 Microbes metabolize substances PMDBM2009332 186802 Oscillospirales PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20021742 Microbes metabolize substances PMDBM2009333 846 Oxalobacter PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021743 Microbes metabolize substances PMDBM2009333 846 Oxalobacter PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20021744 Microbes metabolize substances PMDBM2009333 846 Oxalobacter PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021745 Microbes metabolize substances PMDBM2009333 846 Oxalobacter PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021746 Microbes metabolize substances PMDBM2009333 846 Oxalobacter PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20021747 Microbes metabolize substances PMDBM2009333 846 Oxalobacter PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021748 Microbes metabolize substances PMDBM2009333 846 Oxalobacter PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021749 Microbes metabolize substances PMDBM2009333 846 Oxalobacter PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021750 Microbes metabolize substances PMDBM2009333 846 Oxalobacter PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021753 Microbes metabolize substances PMDBM2009333 846 Oxalobacter PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20021754 Microbes metabolize substances PMDBM2009333 846 Oxalobacter PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021755 Microbes metabolize substances PMDBM2009333 846 Oxalobacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021756 Microbes metabolize substances PMDBM2009333 846 Oxalobacter PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021757 Microbes metabolize substances PMDBM2009333 846 Oxalobacter PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021758 Microbes metabolize substances PMDBM2009333 846 Oxalobacter PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021759 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021760 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes A PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20021761 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021762 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021763 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021764 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021765 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021766 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021769 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes A PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20021770 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021771 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021772 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021773 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021774 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021775 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021776 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021777 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021778 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021779 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021780 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021781 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021784 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021785 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021786 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021787 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021788 Microbes metabolize substances PMDBM2020920 847 Oxalobacter formigenes B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021789 Microbes metabolize substances PMDBM2009336 n.a. Paenibacillus A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021790 Microbes metabolize substances PMDBM2009336 n.a. Paenibacillus A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021791 Microbes metabolize substances PMDBM2009336 n.a. Paenibacillus A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021792 Microbes metabolize substances PMDBM2009336 n.a. Paenibacillus A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021793 Microbes metabolize substances PMDBM2009336 n.a. Paenibacillus A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021794 Microbes metabolize substances PMDBM2009336 n.a. Paenibacillus A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021795 Microbes metabolize substances PMDBM2009336 n.a. Paenibacillus A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021798 Microbes metabolize substances PMDBM2009336 n.a. Paenibacillus A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021799 Microbes metabolize substances PMDBM2009336 n.a. Paenibacillus A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021800 Microbes metabolize substances PMDBM2009336 n.a. Paenibacillus A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021801 Microbes metabolize substances PMDBM2009336 n.a. Paenibacillus A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021802 Microbes metabolize substances PMDBM2009336 n.a. Paenibacillus A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021803 Microbes metabolize substances PMDBM2009336 n.a. Paenibacillus A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021804 Microbes metabolize substances PMDBM2009336 n.a. Paenibacillus A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021805 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021806 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021807 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021808 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021810 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021812 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021813 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021814 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021815 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20021816 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20021817 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021819 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20021822 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20021823 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20021824 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021825 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021828 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20021831 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021832 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021835 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021836 Microbes metabolize substances PMDBM2020928 1776378 Paenibacillus A phocaensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021853 Microbes metabolize substances PMDBM2020931 1737426 Paenibacillus A senegalimassiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021854 Microbes metabolize substances PMDBM2020931 1737426 Paenibacillus A senegalimassiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021855 Microbes metabolize substances PMDBM2020931 1737426 Paenibacillus A senegalimassiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021856 Microbes metabolize substances PMDBM2020931 1737426 Paenibacillus A senegalimassiliensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021858 Microbes metabolize substances PMDBM2020931 1737426 Paenibacillus A senegalimassiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021860 Microbes metabolize substances PMDBM2020931 1737426 Paenibacillus A senegalimassiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021861 Microbes metabolize substances PMDBM2020931 1737426 Paenibacillus A senegalimassiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021862 Microbes metabolize substances PMDBM2020931 1737426 Paenibacillus A senegalimassiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021863 Microbes metabolize substances PMDBM2020931 1737426 Paenibacillus A senegalimassiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021866 Microbes metabolize substances PMDBM2020931 1737426 Paenibacillus A senegalimassiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021867 Microbes metabolize substances PMDBM2020931 1737426 Paenibacillus A senegalimassiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021868 Microbes metabolize substances PMDBM2020931 1737426 Paenibacillus A senegalimassiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021869 Microbes metabolize substances PMDBM2020931 1737426 Paenibacillus A senegalimassiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021871 Microbes metabolize substances PMDBM2020931 1737426 Paenibacillus A senegalimassiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021872 Microbes metabolize substances PMDBM2020931 1737426 Paenibacillus A senegalimassiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021873 Microbes metabolize substances PMDBM2009339 n.a. Paenibacillus B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021874 Microbes metabolize substances PMDBM2009339 n.a. Paenibacillus B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021875 Microbes metabolize substances PMDBM2009339 n.a. Paenibacillus B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021876 Microbes metabolize substances PMDBM2009339 n.a. Paenibacillus B PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021878 Microbes metabolize substances PMDBM2009339 n.a. Paenibacillus B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021880 Microbes metabolize substances PMDBM2009339 n.a. Paenibacillus B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021881 Microbes metabolize substances PMDBM2009339 n.a. Paenibacillus B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021882 Microbes metabolize substances PMDBM2009339 n.a. Paenibacillus B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021883 Microbes metabolize substances PMDBM2009339 n.a. Paenibacillus B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021886 Microbes metabolize substances PMDBM2009339 n.a. Paenibacillus B PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20021887 Microbes metabolize substances PMDBM2009339 n.a. Paenibacillus B PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20021888 Microbes metabolize substances PMDBM2009339 n.a. Paenibacillus B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021889 Microbes metabolize substances PMDBM2009339 n.a. Paenibacillus B PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20021890 Microbes metabolize substances PMDBM2009339 n.a. Paenibacillus B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021891 Microbes metabolize substances PMDBM2009339 n.a. Paenibacillus B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021893 Microbes metabolize substances PMDBM2009339 n.a. Paenibacillus B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021894 Microbes metabolize substances PMDBM2009339 n.a. Paenibacillus B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021895 Microbes metabolize substances PMDBM2021641 49283 Paenibacillus B thiaminolyticus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021896 Microbes metabolize substances PMDBM2021641 49283 Paenibacillus B thiaminolyticus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021897 Microbes metabolize substances PMDBM2021641 49283 Paenibacillus B thiaminolyticus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021898 Microbes metabolize substances PMDBM2021641 49283 Paenibacillus B thiaminolyticus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021900 Microbes metabolize substances PMDBM2021641 49283 Paenibacillus B thiaminolyticus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021902 Microbes metabolize substances PMDBM2021641 49283 Paenibacillus B thiaminolyticus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021903 Microbes metabolize substances PMDBM2021641 49283 Paenibacillus B thiaminolyticus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021904 Microbes metabolize substances PMDBM2021641 49283 Paenibacillus B thiaminolyticus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021905 Microbes metabolize substances PMDBM2021641 49283 Paenibacillus B thiaminolyticus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021908 Microbes metabolize substances PMDBM2021641 49283 Paenibacillus B thiaminolyticus PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20021909 Microbes metabolize substances PMDBM2021641 49283 Paenibacillus B thiaminolyticus PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20021910 Microbes metabolize substances PMDBM2021641 49283 Paenibacillus B thiaminolyticus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021911 Microbes metabolize substances PMDBM2021641 49283 Paenibacillus B thiaminolyticus PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20021912 Microbes metabolize substances PMDBM2021641 49283 Paenibacillus B thiaminolyticus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021913 Microbes metabolize substances PMDBM2021641 49283 Paenibacillus B thiaminolyticus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021915 Microbes metabolize substances PMDBM2021641 49283 Paenibacillus B thiaminolyticus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021916 Microbes metabolize substances PMDBM2021641 49283 Paenibacillus B thiaminolyticus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021917 Microbes metabolize substances PMDBM2021373 58172 Paenibacillus F sp000411255 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021918 Microbes metabolize substances PMDBM2021373 58172 Paenibacillus F sp000411255 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021919 Microbes metabolize substances PMDBM2021373 58172 Paenibacillus F sp000411255 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021920 Microbes metabolize substances PMDBM2021373 58172 Paenibacillus F sp000411255 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021921 Microbes metabolize substances PMDBM2021373 58172 Paenibacillus F sp000411255 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021922 Microbes metabolize substances PMDBM2021373 58172 Paenibacillus F sp000411255 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021923 Microbes metabolize substances PMDBM2021373 58172 Paenibacillus F sp000411255 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021926 Microbes metabolize substances PMDBM2021373 58172 Paenibacillus F sp000411255 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021927 Microbes metabolize substances PMDBM2021373 58172 Paenibacillus F sp000411255 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20021928 Microbes metabolize substances PMDBM2021373 58172 Paenibacillus F sp000411255 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021929 Microbes metabolize substances PMDBM2021373 58172 Paenibacillus F sp000411255 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021930 Microbes metabolize substances PMDBM2021373 58172 Paenibacillus F sp000411255 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021931 Microbes metabolize substances PMDBM2021373 58172 Paenibacillus F sp000411255 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021932 Microbes metabolize substances PMDBM2021373 58172 Paenibacillus F sp000411255 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021933 Microbes metabolize substances PMDBM2020930 1465766 Paenibacillus L senegalensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021934 Microbes metabolize substances PMDBM2020930 1465766 Paenibacillus L senegalensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021935 Microbes metabolize substances PMDBM2020930 1465766 Paenibacillus L senegalensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021936 Microbes metabolize substances PMDBM2020930 1465766 Paenibacillus L senegalensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021937 Microbes metabolize substances PMDBM2020930 1465766 Paenibacillus L senegalensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021938 Microbes metabolize substances PMDBM2020930 1465766 Paenibacillus L senegalensis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20021939 Microbes metabolize substances PMDBM2020930 1465766 Paenibacillus L senegalensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021940 Microbes metabolize substances PMDBM2020930 1465766 Paenibacillus L senegalensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021941 Microbes metabolize substances PMDBM2020930 1465766 Paenibacillus L senegalensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021942 Microbes metabolize substances PMDBM2020922 1274374 Paenibacillus P antibioticophila PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021943 Microbes metabolize substances PMDBM2020922 1274374 Paenibacillus P antibioticophila PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021944 Microbes metabolize substances PMDBM2020922 1274374 Paenibacillus P antibioticophila PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021945 Microbes metabolize substances PMDBM2020922 1274374 Paenibacillus P antibioticophila PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021947 Microbes metabolize substances PMDBM2020922 1274374 Paenibacillus P antibioticophila PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021949 Microbes metabolize substances PMDBM2020922 1274374 Paenibacillus P antibioticophila PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021950 Microbes metabolize substances PMDBM2020922 1274374 Paenibacillus P antibioticophila PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021951 Microbes metabolize substances PMDBM2020922 1274374 Paenibacillus P antibioticophila PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021952 Microbes metabolize substances PMDBM2020922 1274374 Paenibacillus P antibioticophila PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021955 Microbes metabolize substances PMDBM2020922 1274374 Paenibacillus P antibioticophila PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021956 Microbes metabolize substances PMDBM2020922 1274374 Paenibacillus P antibioticophila PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021957 Microbes metabolize substances PMDBM2020922 1274374 Paenibacillus P antibioticophila PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021958 Microbes metabolize substances PMDBM2020922 1274374 Paenibacillus P antibioticophila PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021960 Microbes metabolize substances PMDBM2020922 1274374 Paenibacillus P antibioticophila PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021961 Microbes metabolize substances PMDBM2020922 1274374 Paenibacillus P antibioticophila PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021962 Microbes metabolize substances PMDBM2020926 687436 Paenibacillus Q ihumii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021963 Microbes metabolize substances PMDBM2020926 687436 Paenibacillus Q ihumii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021964 Microbes metabolize substances PMDBM2020926 687436 Paenibacillus Q ihumii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021965 Microbes metabolize substances PMDBM2020926 687436 Paenibacillus Q ihumii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021967 Microbes metabolize substances PMDBM2020926 687436 Paenibacillus Q ihumii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021969 Microbes metabolize substances PMDBM2020926 687436 Paenibacillus Q ihumii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021970 Microbes metabolize substances PMDBM2020926 687436 Paenibacillus Q ihumii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021971 Microbes metabolize substances PMDBM2020926 687436 Paenibacillus Q ihumii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021972 Microbes metabolize substances PMDBM2020926 687436 Paenibacillus Q ihumii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021975 Microbes metabolize substances PMDBM2020926 687436 Paenibacillus Q ihumii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021976 Microbes metabolize substances PMDBM2020926 687436 Paenibacillus Q ihumii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021977 Microbes metabolize substances PMDBM2020926 687436 Paenibacillus Q ihumii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021978 Microbes metabolize substances PMDBM2020926 687436 Paenibacillus Q ihumii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021980 Microbes metabolize substances PMDBM2020926 687436 Paenibacillus Q ihumii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20021981 Microbes metabolize substances PMDBM2020926 687436 Paenibacillus Q ihumii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021982 Microbes metabolize substances PMDBM2020926 687436 Paenibacillus Q ihumii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20021983 Microbes metabolize substances PMDBM2021642 1451 Paenibacillus amylolyticus C PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20021984 Microbes metabolize substances PMDBM2021642 1451 Paenibacillus amylolyticus C PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20021985 Microbes metabolize substances PMDBM2021642 1451 Paenibacillus amylolyticus C PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20021986 Microbes metabolize substances PMDBM2021642 1451 Paenibacillus amylolyticus C PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021988 Microbes metabolize substances PMDBM2021642 1451 Paenibacillus amylolyticus C PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20021990 Microbes metabolize substances PMDBM2021642 1451 Paenibacillus amylolyticus C PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021991 Microbes metabolize substances PMDBM2021642 1451 Paenibacillus amylolyticus C PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021992 Microbes metabolize substances PMDBM2021642 1451 Paenibacillus amylolyticus C PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20021993 Microbes metabolize substances PMDBM2021642 1451 Paenibacillus amylolyticus C PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20021996 Microbes metabolize substances PMDBM2021642 1451 Paenibacillus amylolyticus C PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20021997 Microbes metabolize substances PMDBM2021642 1451 Paenibacillus amylolyticus C PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20021998 Microbes metabolize substances PMDBM2021642 1451 Paenibacillus amylolyticus C PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20021999 Microbes metabolize substances PMDBM2021642 1451 Paenibacillus amylolyticus C PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022001 Microbes metabolize substances PMDBM2021642 1451 Paenibacillus amylolyticus C PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022002 Microbes metabolize substances PMDBM2021642 1451 Paenibacillus amylolyticus C PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022003 Microbes metabolize substances PMDBM2021642 1451 Paenibacillus amylolyticus C PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022004 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022005 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022006 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022007 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022009 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022011 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022012 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022013 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022014 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022015 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022016 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022018 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20022021 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20022022 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20022023 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022024 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022027 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20022030 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022031 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022034 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022035 Microbes metabolize substances PMDBM2020925 1232431 Paenibacillus ihuae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022036 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022037 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022038 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022039 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022041 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022043 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022044 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022045 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022046 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022047 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022048 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022050 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20022053 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20022054 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20022055 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022056 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022059 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20022062 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022063 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022066 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022067 Microbes metabolize substances PMDBM2021311 228574 Paenibacillus lactis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022068 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022069 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022070 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022071 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022073 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022075 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022076 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022077 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022078 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022079 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022080 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022082 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20022085 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20022086 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20022087 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022088 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022091 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20022094 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20022095 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022096 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022099 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022100 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022101 Microbes metabolize substances PMDBM2021643 1401 Paenibacillus lautus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022102 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022103 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022104 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022105 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022107 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022109 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022110 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022111 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022112 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022113 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022114 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022116 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20022119 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20022120 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20022121 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022122 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022125 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20022128 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022129 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022132 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022133 Microbes metabolize substances PMDBM2021644 189426 Paenibacillus odorifer PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022134 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022135 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022136 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022137 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022139 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022141 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022142 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022143 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022144 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022145 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022146 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022148 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20022151 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20022152 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20022153 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022154 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022157 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20022160 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022161 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022164 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022165 Microbes metabolize substances PMDBM2021645 136407 Paenibacillus polymyxa PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022166 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022167 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022168 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022169 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20022170 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022172 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022174 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022175 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022176 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022177 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022178 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022179 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022181 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20022184 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20022185 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20022186 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022187 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022190 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20022193 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022194 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022197 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022198 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022199 Microbes metabolize substances PMDBM2020939 1816681 PaenibacilluU tuaregi PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022200 Microbes metabolize substances PMDBM2020940 1505 Paeniclostridium sordellii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022201 Microbes metabolize substances PMDBM2020940 1505 Paeniclostridium sordellii PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20022202 Microbes metabolize substances PMDBM2020940 1505 Paeniclostridium sordellii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022203 Microbes metabolize substances PMDBM2020940 1505 Paeniclostridium sordellii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022204 Microbes metabolize substances PMDBM2020940 1505 Paeniclostridium sordellii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022205 Microbes metabolize substances PMDBM2020940 1505 Paeniclostridium sordellii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022206 Microbes metabolize substances PMDBM2021646 1932001 Paenisporosarcina A sp000411295 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022207 Microbes metabolize substances PMDBM2021646 1932001 Paenisporosarcina A sp000411295 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022208 Microbes metabolize substances PMDBM2021646 1932001 Paenisporosarcina A sp000411295 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022209 Microbes metabolize substances PMDBM2021646 1932001 Paenisporosarcina A sp000411295 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022210 Microbes metabolize substances PMDBM2021646 1932001 Paenisporosarcina A sp000411295 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022211 Microbes metabolize substances PMDBM2021646 1932001 Paenisporosarcina A sp000411295 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022212 Microbes metabolize substances PMDBM2021646 1932001 Paenisporosarcina A sp000411295 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022213 Microbes metabolize substances PMDBM2021646 1932001 Paenisporosarcina A sp000411295 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022216 Microbes metabolize substances PMDBM2021646 1932001 Paenisporosarcina A sp000411295 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022217 Microbes metabolize substances PMDBM2021646 1932001 Paenisporosarcina A sp000411295 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022218 Microbes metabolize substances PMDBM2021646 1932001 Paenisporosarcina A sp000411295 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022219 Microbes metabolize substances PMDBM2021646 1932001 Paenisporosarcina A sp000411295 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022220 Microbes metabolize substances PMDBM2021646 1932001 Paenisporosarcina A sp000411295 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022221 Microbes metabolize substances PMDBM2021646 1932001 Paenisporosarcina A sp000411295 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022222 Microbes metabolize substances PMDBM2009354 2005523 Paludibacteraceae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20022223 Microbes metabolize substances PMDBM2009354 2005523 Paludibacteraceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022224 Microbes metabolize substances PMDBM2009354 2005523 Paludibacteraceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022225 Microbes metabolize substances PMDBM2009354 2005523 Paludibacteraceae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022226 Microbes metabolize substances PMDBM2009354 2005523 Paludibacteraceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022227 Microbes metabolize substances PMDBM2009354 2005523 Paludibacteraceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022228 Microbes metabolize substances PMDBM2020945 549 Pantoea agglomerans PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022229 Microbes metabolize substances PMDBM2020945 549 Pantoea agglomerans PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022230 Microbes metabolize substances PMDBM2020945 549 Pantoea agglomerans PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022231 Microbes metabolize substances PMDBM2020945 549 Pantoea agglomerans PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022232 Microbes metabolize substances PMDBM2020945 549 Pantoea agglomerans PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022233 Microbes metabolize substances PMDBM2020945 549 Pantoea agglomerans PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022234 Microbes metabolize substances PMDBM2020945 549 Pantoea agglomerans PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022235 Microbes metabolize substances PMDBM2020945 549 Pantoea agglomerans PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022238 Microbes metabolize substances PMDBM2020945 549 Pantoea agglomerans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022239 Microbes metabolize substances PMDBM2020945 549 Pantoea agglomerans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022240 Microbes metabolize substances PMDBM2020945 549 Pantoea agglomerans PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022241 Microbes metabolize substances PMDBM2020945 549 Pantoea agglomerans PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022242 Microbes metabolize substances PMDBM2020945 549 Pantoea agglomerans PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022243 Microbes metabolize substances PMDBM2020945 549 Pantoea agglomerans PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022244 Microbes metabolize substances PMDBM2020945 549 Pantoea agglomerans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022245 Microbes metabolize substances PMDBM2020945 549 Pantoea agglomerans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022246 Microbes metabolize substances PMDBM2020142 553 Pantoea ananatis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022247 Microbes metabolize substances PMDBM2020142 553 Pantoea ananatis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022248 Microbes metabolize substances PMDBM2020142 553 Pantoea ananatis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022249 Microbes metabolize substances PMDBM2020142 553 Pantoea ananatis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022250 Microbes metabolize substances PMDBM2020142 553 Pantoea ananatis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022251 Microbes metabolize substances PMDBM2020142 553 Pantoea ananatis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022252 Microbes metabolize substances PMDBM2020142 553 Pantoea ananatis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022255 Microbes metabolize substances PMDBM2020142 553 Pantoea ananatis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20022256 Microbes metabolize substances PMDBM2020142 553 Pantoea ananatis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022257 Microbes metabolize substances PMDBM2020142 553 Pantoea ananatis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022258 Microbes metabolize substances PMDBM2020142 553 Pantoea ananatis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022259 Microbes metabolize substances PMDBM2020142 553 Pantoea ananatis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022260 Microbes metabolize substances PMDBM2020142 553 Pantoea ananatis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022261 Microbes metabolize substances PMDBM2020142 553 Pantoea ananatis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022262 Microbes metabolize substances PMDBM2020142 553 Pantoea ananatis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022263 Microbes metabolize substances PMDBM2020142 553 Pantoea ananatis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022264 Microbes metabolize substances PMDBM2021647 470931 Pantoea anthophila PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022265 Microbes metabolize substances PMDBM2021647 470931 Pantoea anthophila PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022266 Microbes metabolize substances PMDBM2021647 470931 Pantoea anthophila PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022267 Microbes metabolize substances PMDBM2021647 470931 Pantoea anthophila PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022268 Microbes metabolize substances PMDBM2021647 470931 Pantoea anthophila PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022269 Microbes metabolize substances PMDBM2021647 470931 Pantoea anthophila PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022270 Microbes metabolize substances PMDBM2021647 470931 Pantoea anthophila PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022271 Microbes metabolize substances PMDBM2021647 470931 Pantoea anthophila PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022274 Microbes metabolize substances PMDBM2021647 470931 Pantoea anthophila PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022275 Microbes metabolize substances PMDBM2021647 470931 Pantoea anthophila PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022276 Microbes metabolize substances PMDBM2021647 470931 Pantoea anthophila PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022277 Microbes metabolize substances PMDBM2021647 470931 Pantoea anthophila PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022278 Microbes metabolize substances PMDBM2021647 470931 Pantoea anthophila PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022279 Microbes metabolize substances PMDBM2021647 470931 Pantoea anthophila PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022280 Microbes metabolize substances PMDBM2021647 470931 Pantoea anthophila PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022281 Microbes metabolize substances PMDBM2021647 470931 Pantoea anthophila PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022282 Microbes metabolize substances PMDBM2021648 472694 Pantoea brenneri PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022283 Microbes metabolize substances PMDBM2021648 472694 Pantoea brenneri PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022284 Microbes metabolize substances PMDBM2021648 472694 Pantoea brenneri PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022285 Microbes metabolize substances PMDBM2021648 472694 Pantoea brenneri PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022286 Microbes metabolize substances PMDBM2021648 472694 Pantoea brenneri PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022287 Microbes metabolize substances PMDBM2021648 472694 Pantoea brenneri PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022288 Microbes metabolize substances PMDBM2021648 472694 Pantoea brenneri PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022289 Microbes metabolize substances PMDBM2021648 472694 Pantoea brenneri PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022292 Microbes metabolize substances PMDBM2021648 472694 Pantoea brenneri PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022293 Microbes metabolize substances PMDBM2021648 472694 Pantoea brenneri PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022294 Microbes metabolize substances PMDBM2021648 472694 Pantoea brenneri PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022295 Microbes metabolize substances PMDBM2021648 472694 Pantoea brenneri PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022296 Microbes metabolize substances PMDBM2021648 472694 Pantoea brenneri PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022297 Microbes metabolize substances PMDBM2021648 472694 Pantoea brenneri PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022298 Microbes metabolize substances PMDBM2021648 472694 Pantoea brenneri PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022299 Microbes metabolize substances PMDBM2021648 472694 Pantoea brenneri PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022300 Microbes metabolize substances PMDBM2021649 472705 Pantoea conspicua PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022301 Microbes metabolize substances PMDBM2021649 472705 Pantoea conspicua PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022302 Microbes metabolize substances PMDBM2021649 472705 Pantoea conspicua PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022303 Microbes metabolize substances PMDBM2021649 472705 Pantoea conspicua PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022304 Microbes metabolize substances PMDBM2021649 472705 Pantoea conspicua PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022305 Microbes metabolize substances PMDBM2021649 472705 Pantoea conspicua PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022306 Microbes metabolize substances PMDBM2021649 472705 Pantoea conspicua PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022307 Microbes metabolize substances PMDBM2021649 472705 Pantoea conspicua PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022310 Microbes metabolize substances PMDBM2021649 472705 Pantoea conspicua PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022311 Microbes metabolize substances PMDBM2021649 472705 Pantoea conspicua PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022312 Microbes metabolize substances PMDBM2021649 472705 Pantoea conspicua PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022313 Microbes metabolize substances PMDBM2021649 472705 Pantoea conspicua PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022314 Microbes metabolize substances PMDBM2021649 472705 Pantoea conspicua PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022315 Microbes metabolize substances PMDBM2021649 472705 Pantoea conspicua PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022316 Microbes metabolize substances PMDBM2021649 472705 Pantoea conspicua PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022317 Microbes metabolize substances PMDBM2021649 472705 Pantoea conspicua PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022318 Microbes metabolize substances PMDBM2021650 472695 Pantoea septica PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022319 Microbes metabolize substances PMDBM2021650 472695 Pantoea septica PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022320 Microbes metabolize substances PMDBM2021650 472695 Pantoea septica PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022321 Microbes metabolize substances PMDBM2021650 472695 Pantoea septica PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022322 Microbes metabolize substances PMDBM2021650 472695 Pantoea septica PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022323 Microbes metabolize substances PMDBM2021650 472695 Pantoea septica PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022324 Microbes metabolize substances PMDBM2021650 472695 Pantoea septica PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022325 Microbes metabolize substances PMDBM2021650 472695 Pantoea septica PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022328 Microbes metabolize substances PMDBM2021650 472695 Pantoea septica PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022329 Microbes metabolize substances PMDBM2021650 472695 Pantoea septica PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022330 Microbes metabolize substances PMDBM2021650 472695 Pantoea septica PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022331 Microbes metabolize substances PMDBM2021650 472695 Pantoea septica PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022332 Microbes metabolize substances PMDBM2021650 472695 Pantoea septica PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022333 Microbes metabolize substances PMDBM2021650 472695 Pantoea septica PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022334 Microbes metabolize substances PMDBM2021650 472695 Pantoea septica PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022335 Microbes metabolize substances PMDBM2021650 472695 Pantoea septica PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022336 Microbes metabolize substances PMDBM2021651 69393 Pantoea sp002920175 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022337 Microbes metabolize substances PMDBM2021651 69393 Pantoea sp002920175 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022338 Microbes metabolize substances PMDBM2021651 69393 Pantoea sp002920175 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022339 Microbes metabolize substances PMDBM2021651 69393 Pantoea sp002920175 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022340 Microbes metabolize substances PMDBM2021651 69393 Pantoea sp002920175 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022341 Microbes metabolize substances PMDBM2021651 69393 Pantoea sp002920175 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022342 Microbes metabolize substances PMDBM2021651 69393 Pantoea sp002920175 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022343 Microbes metabolize substances PMDBM2021651 69393 Pantoea sp002920175 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022346 Microbes metabolize substances PMDBM2021651 69393 Pantoea sp002920175 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022347 Microbes metabolize substances PMDBM2021651 69393 Pantoea sp002920175 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022348 Microbes metabolize substances PMDBM2021651 69393 Pantoea sp002920175 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022349 Microbes metabolize substances PMDBM2021651 69393 Pantoea sp002920175 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022350 Microbes metabolize substances PMDBM2021651 69393 Pantoea sp002920175 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022351 Microbes metabolize substances PMDBM2021651 69393 Pantoea sp002920175 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022352 Microbes metabolize substances PMDBM2021651 69393 Pantoea sp002920175 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022353 Microbes metabolize substances PMDBM2021651 69393 Pantoea sp002920175 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022354 Microbes metabolize substances PMDBM2021652 470934 Pantoea vagans A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022355 Microbes metabolize substances PMDBM2021652 470934 Pantoea vagans A PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022356 Microbes metabolize substances PMDBM2021652 470934 Pantoea vagans A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022357 Microbes metabolize substances PMDBM2021652 470934 Pantoea vagans A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022358 Microbes metabolize substances PMDBM2021652 470934 Pantoea vagans A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022359 Microbes metabolize substances PMDBM2021652 470934 Pantoea vagans A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022360 Microbes metabolize substances PMDBM2021652 470934 Pantoea vagans A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022361 Microbes metabolize substances PMDBM2021652 470934 Pantoea vagans A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022364 Microbes metabolize substances PMDBM2021652 470934 Pantoea vagans A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022365 Microbes metabolize substances PMDBM2021652 470934 Pantoea vagans A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022366 Microbes metabolize substances PMDBM2021652 470934 Pantoea vagans A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022367 Microbes metabolize substances PMDBM2021652 470934 Pantoea vagans A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022368 Microbes metabolize substances PMDBM2021652 470934 Pantoea vagans A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022369 Microbes metabolize substances PMDBM2021652 470934 Pantoea vagans A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022370 Microbes metabolize substances PMDBM2021652 470934 Pantoea vagans A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022371 Microbes metabolize substances PMDBM2021653 665913 Pantoea B calida PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022372 Microbes metabolize substances PMDBM2021653 665913 Pantoea B calida PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022373 Microbes metabolize substances PMDBM2021653 665913 Pantoea B calida PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022374 Microbes metabolize substances PMDBM2021653 665913 Pantoea B calida PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022375 Microbes metabolize substances PMDBM2021653 665913 Pantoea B calida PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022376 Microbes metabolize substances PMDBM2021653 665913 Pantoea B calida PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022377 Microbes metabolize substances PMDBM2021653 665913 Pantoea B calida PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022380 Microbes metabolize substances PMDBM2021653 665913 Pantoea B calida PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022381 Microbes metabolize substances PMDBM2021653 665913 Pantoea B calida PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022382 Microbes metabolize substances PMDBM2021653 665913 Pantoea B calida PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20022383 Microbes metabolize substances PMDBM2021653 665913 Pantoea B calida PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022384 Microbes metabolize substances PMDBM2021653 665913 Pantoea B calida PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022385 Microbes metabolize substances PMDBM2021653 665913 Pantoea B calida PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022386 Microbes metabolize substances PMDBM2021653 665913 Pantoea B calida PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022387 Microbes metabolize substances PMDBM2021653 665913 Pantoea B calida PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022388 Microbes metabolize substances PMDBM2021653 665913 Pantoea B calida PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022389 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022390 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022391 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022392 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022393 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022395 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022397 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022398 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022399 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022400 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022401 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022402 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022404 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20022407 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20022408 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20022409 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20022410 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022411 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022414 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20022417 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022418 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022421 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022422 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022423 Microbes metabolize substances PMDBM308 375288 Parabacteroides PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022424 Microbes metabolize substances PMDBM2021654 1936995 Parabacteroides bouchesdurhonensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022425 Microbes metabolize substances PMDBM2021654 1936995 Parabacteroides bouchesdurhonensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022426 Microbes metabolize substances PMDBM2021654 1936995 Parabacteroides bouchesdurhonensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022427 Microbes metabolize substances PMDBM2021654 1936995 Parabacteroides bouchesdurhonensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022429 Microbes metabolize substances PMDBM2021654 1936995 Parabacteroides bouchesdurhonensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022431 Microbes metabolize substances PMDBM2021654 1936995 Parabacteroides bouchesdurhonensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022432 Microbes metabolize substances PMDBM2021654 1936995 Parabacteroides bouchesdurhonensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022433 Microbes metabolize substances PMDBM2021654 1936995 Parabacteroides bouchesdurhonensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022434 Microbes metabolize substances PMDBM2021654 1936995 Parabacteroides bouchesdurhonensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022437 Microbes metabolize substances PMDBM2021654 1936995 Parabacteroides bouchesdurhonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022438 Microbes metabolize substances PMDBM2021654 1936995 Parabacteroides bouchesdurhonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022439 Microbes metabolize substances PMDBM2021654 1936995 Parabacteroides bouchesdurhonensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022440 Microbes metabolize substances PMDBM2021654 1936995 Parabacteroides bouchesdurhonensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022442 Microbes metabolize substances PMDBM2021654 1936995 Parabacteroides bouchesdurhonensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022443 Microbes metabolize substances PMDBM2021654 1936995 Parabacteroides bouchesdurhonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022444 Microbes metabolize substances PMDBM2021654 1936995 Parabacteroides bouchesdurhonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022445 Microbes metabolize substances PMDBM2020948 871327 Parabacteroides chinchillae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022446 Microbes metabolize substances PMDBM2020948 871327 Parabacteroides chinchillae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022447 Microbes metabolize substances PMDBM2020948 871327 Parabacteroides chinchillae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022448 Microbes metabolize substances PMDBM2020948 871327 Parabacteroides chinchillae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022450 Microbes metabolize substances PMDBM2020948 871327 Parabacteroides chinchillae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022452 Microbes metabolize substances PMDBM2020948 871327 Parabacteroides chinchillae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022453 Microbes metabolize substances PMDBM2020948 871327 Parabacteroides chinchillae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022454 Microbes metabolize substances PMDBM2020948 871327 Parabacteroides chinchillae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022455 Microbes metabolize substances PMDBM2020948 871327 Parabacteroides chinchillae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022458 Microbes metabolize substances PMDBM2020948 871327 Parabacteroides chinchillae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022459 Microbes metabolize substances PMDBM2020948 871327 Parabacteroides chinchillae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022460 Microbes metabolize substances PMDBM2020948 871327 Parabacteroides chinchillae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022461 Microbes metabolize substances PMDBM2020948 871327 Parabacteroides chinchillae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022463 Microbes metabolize substances PMDBM2020948 871327 Parabacteroides chinchillae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022464 Microbes metabolize substances PMDBM2020948 871327 Parabacteroides chinchillae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022465 Microbes metabolize substances PMDBM2020948 871327 Parabacteroides chinchillae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022466 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022467 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022468 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022469 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022470 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022471 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022472 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022473 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022474 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022476 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20022479 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20022480 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20022481 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022484 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20022487 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022488 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022489 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022491 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. unknown toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022494 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" antimicrobial n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20022495 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD477 Levonorgestrel Therapeutic Substance contraception and hormone n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20022496 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" lower the risk of cardiovascular disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20022497 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD1298 Misoprostol Therapeutic substance reduce the risk of NSAID induced gastric ulcers n.a. n.a. n.a. n.a. misoprostol-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20022498 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD1376 Praziquantel Therapeutic substance Anti-infection n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20022499 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD750 Risperidone Therapeutic Substance second-generation antipsychotic (SGA) n.a. n.a. n.a. n.a. risperidone-M1 n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20022500 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD812 Sulfasalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. sulfapyridine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20022501 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD1460 Tolcapone Therapeutic substance Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. a potential link betweenthe gut microbiome and tolcapone toxicity n.a. PMID PMID: 36467581 PMDBI20022502 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022503 Microbes metabolize substances PMDBM2020231 823 Parabacteroides distasonis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022504 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022505 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022506 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022507 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022508 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022510 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022512 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022513 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022514 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022515 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022516 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022517 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022519 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20022522 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20022523 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20022524 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022525 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022528 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20022531 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022532 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022535 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022536 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022537 Microbes metabolize substances PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022538 Microbes metabolize substances PMDBM2020949 574930 Parabacteroides gordonii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022539 Microbes metabolize substances PMDBM2020949 574930 Parabacteroides gordonii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022540 Microbes metabolize substances PMDBM2020949 574930 Parabacteroides gordonii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022541 Microbes metabolize substances PMDBM2020949 574930 Parabacteroides gordonii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022542 Microbes metabolize substances PMDBM2020949 574930 Parabacteroides gordonii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022544 Microbes metabolize substances PMDBM2020949 574930 Parabacteroides gordonii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022546 Microbes metabolize substances PMDBM2020949 574930 Parabacteroides gordonii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022547 Microbes metabolize substances PMDBM2020949 574930 Parabacteroides gordonii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022548 Microbes metabolize substances PMDBM2020949 574930 Parabacteroides gordonii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022549 Microbes metabolize substances PMDBM2020949 574930 Parabacteroides gordonii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022552 Microbes metabolize substances PMDBM2020949 574930 Parabacteroides gordonii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022553 Microbes metabolize substances PMDBM2020949 574930 Parabacteroides gordonii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022554 Microbes metabolize substances PMDBM2020949 574930 Parabacteroides gordonii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022555 Microbes metabolize substances PMDBM2020949 574930 Parabacteroides gordonii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022557 Microbes metabolize substances PMDBM2020949 574930 Parabacteroides gordonii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022558 Microbes metabolize substances PMDBM2020949 574930 Parabacteroides gordonii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022559 Microbes metabolize substances PMDBM2020949 574930 Parabacteroides gordonii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022560 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022561 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022562 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022563 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022565 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022567 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022568 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022569 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022570 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022571 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022572 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022574 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20022577 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20022578 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20022579 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022580 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022583 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20022586 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022587 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022590 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022591 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022592 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022593 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD439 Imatinib Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown activation n.a. n.a. n.a. Microbiota as ALL chemotherapy response biomarker n.a. PMID PMID: 36467581 PMDBI20022594 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022595 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022596 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022597 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022599 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022601 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022602 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022603 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022604 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022605 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022606 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022608 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20022611 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20022612 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20022613 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022614 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022617 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20022620 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022621 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022624 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022625 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022626 Microbes metabolize substances PMDBM2020233 46503 Parabacteroides merdae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022627 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022628 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022629 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022630 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022631 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022633 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022635 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022636 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022637 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022638 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022639 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022640 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022642 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20022645 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20022646 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20022647 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022648 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022651 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20022654 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022655 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022658 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp000436495 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022659 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022660 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022661 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022662 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022663 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022665 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022667 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022668 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022669 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022670 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022671 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022672 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022674 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20022677 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20022678 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20022679 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022680 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022683 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20022686 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022687 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022690 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022691 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022692 Microbes metabolize substances PMDBM2021360 1869337 Parabacteroides sp900155425 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022693 Microbes metabolize substances PMDBM2021655 1871013 Parabacteroides timonensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022694 Microbes metabolize substances PMDBM2021655 1871013 Parabacteroides timonensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022695 Microbes metabolize substances PMDBM2021655 1871013 Parabacteroides timonensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022696 Microbes metabolize substances PMDBM2021655 1871013 Parabacteroides timonensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022697 Microbes metabolize substances PMDBM2021655 1871013 Parabacteroides timonensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022699 Microbes metabolize substances PMDBM2021655 1871013 Parabacteroides timonensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022701 Microbes metabolize substances PMDBM2021655 1871013 Parabacteroides timonensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022702 Microbes metabolize substances PMDBM2021655 1871013 Parabacteroides timonensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022703 Microbes metabolize substances PMDBM2021655 1871013 Parabacteroides timonensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022704 Microbes metabolize substances PMDBM2021655 1871013 Parabacteroides timonensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022707 Microbes metabolize substances PMDBM2021655 1871013 Parabacteroides timonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022708 Microbes metabolize substances PMDBM2021655 1871013 Parabacteroides timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022709 Microbes metabolize substances PMDBM2021655 1871013 Parabacteroides timonensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022710 Microbes metabolize substances PMDBM2021655 1871013 Parabacteroides timonensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022712 Microbes metabolize substances PMDBM2021655 1871013 Parabacteroides timonensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022713 Microbes metabolize substances PMDBM2021655 1871013 Parabacteroides timonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022714 Microbes metabolize substances PMDBM2021655 1871013 Parabacteroides timonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022715 Microbes metabolize substances PMDBM2009024 n.a. Parabacteroidesdistasonis PMDBD2000020 Hydrocortisone acetate Therapeutic Substance immune, inflammatory, and neoplastic conditions n.a. n.a. n.a. n.a. hydrocortisone n.a. unknown activation n.a. n.a. n.a. it was deacetylated to yield hydrocortisone n.a. PMID PMID: 36467581 PMDBI20022716 Microbes metabolize substances PMDBM2009370 n.a. Paraclostridium massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022717 Microbes metabolize substances PMDBM2009370 n.a. Paraclostridium massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022718 Microbes metabolize substances PMDBM2009370 n.a. Paraclostridium massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022719 Microbes metabolize substances PMDBM2009370 n.a. Paraclostridium massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022720 Microbes metabolize substances PMDBM2009370 n.a. Paraclostridium massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022721 Microbes metabolize substances PMDBM2009370 n.a. Paraclostridium massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022722 Microbes metabolize substances PMDBM2009370 n.a. Paraclostridium massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022723 Microbes metabolize substances PMDBM2009370 n.a. Paraclostridium massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022726 Microbes metabolize substances PMDBM2009370 n.a. Paraclostridium massiliensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20022727 Microbes metabolize substances PMDBM2009370 n.a. Paraclostridium massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022728 Microbes metabolize substances PMDBM2009370 n.a. Paraclostridium massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022729 Microbes metabolize substances PMDBM2009370 n.a. Paraclostridium massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022730 Microbes metabolize substances PMDBM2009370 n.a. Paraclostridium massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022731 Microbes metabolize substances PMDBM2009370 n.a. Paraclostridium massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022732 Microbes metabolize substances PMDBM2009370 n.a. Paraclostridium massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022733 Microbes metabolize substances PMDBM2009370 n.a. Paraclostridium massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022734 Microbes metabolize substances PMDBM2009370 n.a. Paraclostridium massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022735 Microbes metabolize substances PMDBM2009371 2518497 Paramuribaculum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022736 Microbes metabolize substances PMDBM2009371 2518497 Paramuribaculum PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022737 Microbes metabolize substances PMDBM2009371 2518497 Paramuribaculum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022738 Microbes metabolize substances PMDBM2009371 2518497 Paramuribaculum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022739 Microbes metabolize substances PMDBM2009371 2518497 Paramuribaculum PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022741 Microbes metabolize substances PMDBM2009371 2518497 Paramuribaculum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022743 Microbes metabolize substances PMDBM2009371 2518497 Paramuribaculum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022744 Microbes metabolize substances PMDBM2009371 2518497 Paramuribaculum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022745 Microbes metabolize substances PMDBM2009371 2518497 Paramuribaculum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022746 Microbes metabolize substances PMDBM2009371 2518497 Paramuribaculum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022749 Microbes metabolize substances PMDBM2009371 2518497 Paramuribaculum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022750 Microbes metabolize substances PMDBM2009371 2518497 Paramuribaculum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022751 Microbes metabolize substances PMDBM2009371 2518497 Paramuribaculum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022752 Microbes metabolize substances PMDBM2009371 2518497 Paramuribaculum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022754 Microbes metabolize substances PMDBM2009371 2518497 Paramuribaculum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022755 Microbes metabolize substances PMDBM2009371 2518497 Paramuribaculum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022756 Microbes metabolize substances PMDBM2009371 2518497 Paramuribaculum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022757 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp000431155 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022758 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp000431155 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022759 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp000431155 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022760 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp000431155 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022761 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp000431155 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022762 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp001689535 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022763 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp001689535 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022764 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp001689535 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022765 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp001689535 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022766 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp001689535 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022768 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp001689535 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022770 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp001689535 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022771 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp001689535 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022772 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp001689535 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022773 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp001689535 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022776 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp001689535 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022777 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp001689535 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022778 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp001689535 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022780 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp001689535 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022781 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp001689535 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022782 Microbes metabolize substances PMDBM2021656 2518501 Paramuribaculum sp001689535 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022783 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022784 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022785 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022786 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022788 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022790 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022791 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022792 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022793 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022794 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20022795 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022797 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20022800 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20022801 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20022802 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20022803 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022804 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022807 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20022810 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022811 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022814 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022815 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022816 Microbes metabolize substances PMDBM870 577309 Paraprevotella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022817 Microbes metabolize substances PMDBM2021657 1263095 Paraprevotella clara PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022818 Microbes metabolize substances PMDBM2021657 1263095 Paraprevotella clara PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022819 Microbes metabolize substances PMDBM2021657 1263095 Paraprevotella clara PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022820 Microbes metabolize substances PMDBM2021657 1263095 Paraprevotella clara PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022821 Microbes metabolize substances PMDBM2021657 1263095 Paraprevotella clara PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022822 Microbes metabolize substances PMDBM2021657 1263095 Paraprevotella clara PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022823 Microbes metabolize substances PMDBM2021657 1263095 Paraprevotella clara PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022826 Microbes metabolize substances PMDBM2021657 1263095 Paraprevotella clara PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022827 Microbes metabolize substances PMDBM2021657 1263095 Paraprevotella clara PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022828 Microbes metabolize substances PMDBM2021657 1263095 Paraprevotella clara PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022829 Microbes metabolize substances PMDBM2021657 1263095 Paraprevotella clara PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022830 Microbes metabolize substances PMDBM2021657 1263095 Paraprevotella clara PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022831 Microbes metabolize substances PMDBM2021314 454155 Paraprevotella xylaniphila PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022832 Microbes metabolize substances PMDBM2021314 454155 Paraprevotella xylaniphila PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022833 Microbes metabolize substances PMDBM2021314 454155 Paraprevotella xylaniphila PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022834 Microbes metabolize substances PMDBM2021314 454155 Paraprevotella xylaniphila PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022836 Microbes metabolize substances PMDBM2021314 454155 Paraprevotella xylaniphila PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022838 Microbes metabolize substances PMDBM2021314 454155 Paraprevotella xylaniphila PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022839 Microbes metabolize substances PMDBM2021314 454155 Paraprevotella xylaniphila PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022840 Microbes metabolize substances PMDBM2021314 454155 Paraprevotella xylaniphila PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022841 Microbes metabolize substances PMDBM2021314 454155 Paraprevotella xylaniphila PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022844 Microbes metabolize substances PMDBM2021314 454155 Paraprevotella xylaniphila PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022845 Microbes metabolize substances PMDBM2021314 454155 Paraprevotella xylaniphila PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022846 Microbes metabolize substances PMDBM2021314 454155 Paraprevotella xylaniphila PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022847 Microbes metabolize substances PMDBM2021314 454155 Paraprevotella xylaniphila PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022849 Microbes metabolize substances PMDBM2021314 454155 Paraprevotella xylaniphila PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022850 Microbes metabolize substances PMDBM2021314 454155 Paraprevotella xylaniphila PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022851 Microbes metabolize substances PMDBM2021314 454155 Paraprevotella xylaniphila PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022852 Microbes metabolize substances PMDBM2020960 78258 Parascardovia denticolens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022853 Microbes metabolize substances PMDBM2020960 78258 Parascardovia denticolens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022854 Microbes metabolize substances PMDBM2020960 78258 Parascardovia denticolens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022855 Microbes metabolize substances PMDBM2020960 78258 Parascardovia denticolens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022856 Microbes metabolize substances PMDBM2020960 78258 Parascardovia denticolens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022857 Microbes metabolize substances PMDBM2020960 78258 Parascardovia denticolens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022858 Microbes metabolize substances PMDBM2020960 78258 Parascardovia denticolens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022861 Microbes metabolize substances PMDBM2020960 78258 Parascardovia denticolens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022862 Microbes metabolize substances PMDBM2020960 78258 Parascardovia denticolens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022863 Microbes metabolize substances PMDBM2020960 78258 Parascardovia denticolens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022864 Microbes metabolize substances PMDBM2020960 78258 Parascardovia denticolens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022865 Microbes metabolize substances PMDBM2020960 78258 Parascardovia denticolens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022866 Microbes metabolize substances PMDBM315 577310 Parasutterella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022867 Microbes metabolize substances PMDBM315 577310 Parasutterella PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022868 Microbes metabolize substances PMDBM315 577310 Parasutterella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022869 Microbes metabolize substances PMDBM315 577310 Parasutterella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022870 Microbes metabolize substances PMDBM315 577310 Parasutterella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022871 Microbes metabolize substances PMDBM315 577310 Parasutterella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022872 Microbes metabolize substances PMDBM315 577310 Parasutterella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022873 Microbes metabolize substances PMDBM315 577310 Parasutterella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022876 Microbes metabolize substances PMDBM315 577310 Parasutterella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022877 Microbes metabolize substances PMDBM315 577310 Parasutterella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022878 Microbes metabolize substances PMDBM315 577310 Parasutterella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022879 Microbes metabolize substances PMDBM315 577310 Parasutterella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022880 Microbes metabolize substances PMDBM2021317 487175 Parasutterella excrementihominis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022881 Microbes metabolize substances PMDBM2021317 487175 Parasutterella excrementihominis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022882 Microbes metabolize substances PMDBM2021317 487175 Parasutterella excrementihominis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022883 Microbes metabolize substances PMDBM2021317 487175 Parasutterella excrementihominis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022884 Microbes metabolize substances PMDBM2021317 487175 Parasutterella excrementihominis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022885 Microbes metabolize substances PMDBM2021317 487175 Parasutterella excrementihominis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022886 Microbes metabolize substances PMDBM2021317 487175 Parasutterella excrementihominis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022887 Microbes metabolize substances PMDBM2021317 487175 Parasutterella excrementihominis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022890 Microbes metabolize substances PMDBM2021317 487175 Parasutterella excrementihominis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022891 Microbes metabolize substances PMDBM2021317 487175 Parasutterella excrementihominis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022892 Microbes metabolize substances PMDBM2021317 487175 Parasutterella excrementihominis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022893 Microbes metabolize substances PMDBM2021317 487175 Parasutterella excrementihominis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022894 Microbes metabolize substances PMDBM2021658 2049037 Parasutterella sp000980495 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022895 Microbes metabolize substances PMDBM2021658 2049037 Parasutterella sp000980495 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20022896 Microbes metabolize substances PMDBM2021658 2049037 Parasutterella sp000980495 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022897 Microbes metabolize substances PMDBM2021658 2049037 Parasutterella sp000980495 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022898 Microbes metabolize substances PMDBM2021658 2049037 Parasutterella sp000980495 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022899 Microbes metabolize substances PMDBM2021658 2049037 Parasutterella sp000980495 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022900 Microbes metabolize substances PMDBM2021658 2049037 Parasutterella sp000980495 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022901 Microbes metabolize substances PMDBM2021658 2049037 Parasutterella sp000980495 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022904 Microbes metabolize substances PMDBM2021658 2049037 Parasutterella sp000980495 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022905 Microbes metabolize substances PMDBM2021658 2049037 Parasutterella sp000980495 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022906 Microbes metabolize substances PMDBM2021658 2049037 Parasutterella sp000980495 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022907 Microbes metabolize substances PMDBM2021658 2049037 Parasutterella sp000980495 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022908 Microbes metabolize substances PMDBM2009379 543311 Parvimonas PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022909 Microbes metabolize substances PMDBM2009379 543311 Parvimonas PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022910 Microbes metabolize substances PMDBM2021318 33033 Parvimonas micra PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022911 Microbes metabolize substances PMDBM2021318 33033 Parvimonas micra PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022912 Microbes metabolize substances PMDBM2021318 33033 Parvimonas micra PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022913 Microbes metabolize substances PMDBM2021318 33033 Parvimonas micra PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022914 Microbes metabolize substances PMDBM2021659 1944660 Parvimonas sp001553085 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022915 Microbes metabolize substances PMDBM2021659 1944660 Parvimonas sp001553085 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20022916 Microbes metabolize substances PMDBM2021659 1944660 Parvimonas sp001553085 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022917 Microbes metabolize substances PMDBM2021659 1944660 Parvimonas sp001553085 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022918 Microbes metabolize substances PMDBM2009382 2740557 Pauljensenia PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022919 Microbes metabolize substances PMDBM2009382 2740557 Pauljensenia PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022920 Microbes metabolize substances PMDBM2009382 2740557 Pauljensenia PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022921 Microbes metabolize substances PMDBM2009382 2740557 Pauljensenia PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022923 Microbes metabolize substances PMDBM2009382 2740557 Pauljensenia PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022925 Microbes metabolize substances PMDBM2009382 2740557 Pauljensenia PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022926 Microbes metabolize substances PMDBM2009382 2740557 Pauljensenia PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022927 Microbes metabolize substances PMDBM2009382 2740557 Pauljensenia PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022928 Microbes metabolize substances PMDBM2009382 2740557 Pauljensenia PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022931 Microbes metabolize substances PMDBM2009382 2740557 Pauljensenia PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022932 Microbes metabolize substances PMDBM2009382 2740557 Pauljensenia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022933 Microbes metabolize substances PMDBM2009382 2740557 Pauljensenia PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022934 Microbes metabolize substances PMDBM2009382 2740557 Pauljensenia PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022936 Microbes metabolize substances PMDBM2009382 2740557 Pauljensenia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022937 Microbes metabolize substances PMDBM2009382 2740557 Pauljensenia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022938 Microbes metabolize substances PMDBM2009383 n.a. Pauljensenia bouchesdurhonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022939 Microbes metabolize substances PMDBM2009383 n.a. Pauljensenia bouchesdurhonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022940 Microbes metabolize substances PMDBM2009383 n.a. Pauljensenia bouchesdurhonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022941 Microbes metabolize substances PMDBM2009384 n.a. Pauljensenia cardiffensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022942 Microbes metabolize substances PMDBM2009384 n.a. Pauljensenia cardiffensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022943 Microbes metabolize substances PMDBM2009384 n.a. Pauljensenia cardiffensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022944 Microbes metabolize substances PMDBM2009384 n.a. Pauljensenia cardiffensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022945 Microbes metabolize substances PMDBM2009384 n.a. Pauljensenia cardiffensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022946 Microbes metabolize substances PMDBM2009384 n.a. Pauljensenia cardiffensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022947 Microbes metabolize substances PMDBM2009384 n.a. Pauljensenia cardiffensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022950 Microbes metabolize substances PMDBM2009384 n.a. Pauljensenia cardiffensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022951 Microbes metabolize substances PMDBM2009384 n.a. Pauljensenia cardiffensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022952 Microbes metabolize substances PMDBM2009384 n.a. Pauljensenia cardiffensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022953 Microbes metabolize substances PMDBM2009384 n.a. Pauljensenia cardiffensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022954 Microbes metabolize substances PMDBM2009384 n.a. Pauljensenia cardiffensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022955 Microbes metabolize substances PMDBM2009384 n.a. Pauljensenia cardiffensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022956 Microbes metabolize substances PMDBM2009384 n.a. Pauljensenia cardiffensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022957 Microbes metabolize substances PMDBM2009385 n.a. Pauljensenia keddieii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022958 Microbes metabolize substances PMDBM2009385 n.a. Pauljensenia keddieii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022959 Microbes metabolize substances PMDBM2009385 n.a. Pauljensenia keddieii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022960 Microbes metabolize substances PMDBM2009385 n.a. Pauljensenia keddieii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022961 Microbes metabolize substances PMDBM2009385 n.a. Pauljensenia keddieii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022962 Microbes metabolize substances PMDBM2009385 n.a. Pauljensenia keddieii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022963 Microbes metabolize substances PMDBM2009385 n.a. Pauljensenia keddieii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022966 Microbes metabolize substances PMDBM2009385 n.a. Pauljensenia keddieii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022967 Microbes metabolize substances PMDBM2009385 n.a. Pauljensenia keddieii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022968 Microbes metabolize substances PMDBM2009385 n.a. Pauljensenia keddieii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022969 Microbes metabolize substances PMDBM2009385 n.a. Pauljensenia keddieii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022970 Microbes metabolize substances PMDBM2009385 n.a. Pauljensenia keddieii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022971 Microbes metabolize substances PMDBM2009385 n.a. Pauljensenia keddieii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022972 Microbes metabolize substances PMDBM2009385 n.a. Pauljensenia keddieii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022973 Microbes metabolize substances PMDBM2009386 n.a. Pauljensenia polynesiensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022974 Microbes metabolize substances PMDBM2009386 n.a. Pauljensenia polynesiensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022975 Microbes metabolize substances PMDBM2009386 n.a. Pauljensenia polynesiensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022976 Microbes metabolize substances PMDBM2009386 n.a. Pauljensenia polynesiensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022977 Microbes metabolize substances PMDBM2009386 n.a. Pauljensenia polynesiensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022978 Microbes metabolize substances PMDBM2009386 n.a. Pauljensenia polynesiensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022979 Microbes metabolize substances PMDBM2009386 n.a. Pauljensenia polynesiensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20022982 Microbes metabolize substances PMDBM2009386 n.a. Pauljensenia polynesiensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20022983 Microbes metabolize substances PMDBM2009386 n.a. Pauljensenia polynesiensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20022984 Microbes metabolize substances PMDBM2009386 n.a. Pauljensenia polynesiensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022985 Microbes metabolize substances PMDBM2009386 n.a. Pauljensenia polynesiensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022986 Microbes metabolize substances PMDBM2009386 n.a. Pauljensenia polynesiensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20022987 Microbes metabolize substances PMDBM2009386 n.a. Pauljensenia polynesiensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022988 Microbes metabolize substances PMDBM2009386 n.a. Pauljensenia polynesiensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20022989 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20022990 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20022991 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20022992 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022994 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20022996 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022997 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022998 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20022999 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023000 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023001 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023003 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20023006 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20023007 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20023008 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023009 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023012 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20023015 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023016 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023019 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023020 Microbes metabolize substances PMDBM2009387 n.a. Pauljensenia radingae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023021 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000278725 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023022 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000278725 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023023 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000278725 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023024 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000278725 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023025 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000278725 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023026 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000278725 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023027 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000278725 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023030 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000278725 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023031 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000278725 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023032 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000278725 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023033 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000278725 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023034 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000278725 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023035 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000278725 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023036 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000278725 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023037 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000308055 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023038 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000308055 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023039 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000308055 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023040 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000308055 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023041 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000308055 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023042 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000308055 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023043 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000308055 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023046 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000308055 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023047 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000308055 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023048 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000308055 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023049 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000308055 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023050 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000308055 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023051 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000308055 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023052 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000308055 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023053 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000411415 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023054 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000411415 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023055 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000411415 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023056 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000411415 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023057 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000411415 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023058 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000411415 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023059 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000411415 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023062 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000411415 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023063 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000411415 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023064 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000411415 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023065 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000411415 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023066 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000411415 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023067 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000411415 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023068 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000411415 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023069 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000758755 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023070 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000758755 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023071 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000758755 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023072 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp000758755 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023073 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp001838165 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023074 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp001838165 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023075 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp001838165 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023076 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp001838165 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023077 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp001838165 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023078 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp001838165 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023079 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp001838165 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023082 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp001838165 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023083 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp001838165 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023084 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp001838165 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023085 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp001838165 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023086 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp001838165 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023087 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp001838165 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023088 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia sp001838165 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023089 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia turicensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023090 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia turicensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023091 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia turicensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023092 Microbes metabolize substances PMDBM2021660 2953801 Pauljensenia turicensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023093 Microbes metabolize substances PMDBM2020966 1254 Pediococcus acidilactici PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023094 Microbes metabolize substances PMDBM2020966 1254 Pediococcus acidilactici PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023095 Microbes metabolize substances PMDBM2020966 1254 Pediococcus acidilactici PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023096 Microbes metabolize substances PMDBM2020966 1254 Pediococcus acidilactici PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023098 Microbes metabolize substances PMDBM2020966 1254 Pediococcus acidilactici PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023100 Microbes metabolize substances PMDBM2020966 1254 Pediococcus acidilactici PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023101 Microbes metabolize substances PMDBM2020966 1254 Pediococcus acidilactici PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023102 Microbes metabolize substances PMDBM2020966 1254 Pediococcus acidilactici PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023103 Microbes metabolize substances PMDBM2020966 1254 Pediococcus acidilactici PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023106 Microbes metabolize substances PMDBM2020966 1254 Pediococcus acidilactici PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023107 Microbes metabolize substances PMDBM2020966 1254 Pediococcus acidilactici PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023108 Microbes metabolize substances PMDBM2020966 1254 Pediococcus acidilactici PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023110 Microbes metabolize substances PMDBM2020966 1254 Pediococcus acidilactici PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023111 Microbes metabolize substances PMDBM2020966 1254 Pediococcus acidilactici PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023112 Microbes metabolize substances PMDBM2020967 1255 Pediococcus pentosaceus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023113 Microbes metabolize substances PMDBM2009396 n.a. o Christensenellales f CAG-138 g PeH17 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023114 Microbes metabolize substances PMDBM2009396 n.a. o Christensenellales f CAG-138 g PeH17 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023115 Microbes metabolize substances PMDBM2009396 n.a. o Christensenellales f CAG-138 g PeH17 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023116 Microbes metabolize substances PMDBM2009396 n.a. o Christensenellales f CAG-138 g PeH17 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023117 Microbes metabolize substances PMDBM2009396 n.a. o Christensenellales f CAG-138 g PeH17 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023118 Microbes metabolize substances PMDBM2009396 n.a. o Christensenellales f CAG-138 g PeH17 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023119 Microbes metabolize substances PMDBM2009397 n.a. o Christensenellales f CAG-138 g PeH17 s PeH17 sp000435055 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20023120 Microbes metabolize substances PMDBM2009397 n.a. o Christensenellales f CAG-138 g PeH17 s PeH17 sp000435055 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023121 Microbes metabolize substances PMDBM2009397 n.a. o Christensenellales f CAG-138 g PeH17 s PeH17 sp000435055 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023122 Microbes metabolize substances PMDBM2009397 n.a. o Christensenellales f CAG-138 g PeH17 s PeH17 sp000435055 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023123 Microbes metabolize substances PMDBM2009397 n.a. o Christensenellales f CAG-138 g PeH17 s PeH17 sp000435055 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023124 Microbes metabolize substances PMDBM2009397 n.a. o Christensenellales f CAG-138 g PeH17 s PeH17 sp000435055 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023125 Microbes metabolize substances PMDBM2021661 1414851 Pelistega indica PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023126 Microbes metabolize substances PMDBM2021661 1414851 Pelistega indica PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023127 Microbes metabolize substances PMDBM2021661 1414851 Pelistega indica PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023128 Microbes metabolize substances PMDBM2021661 1414851 Pelistega indica PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023129 Microbes metabolize substances PMDBM2021661 1414851 Pelistega indica PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023130 Microbes metabolize substances PMDBM2021661 1414851 Pelistega indica PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023131 Microbes metabolize substances PMDBM2021661 1414851 Pelistega indica PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023134 Microbes metabolize substances PMDBM2021661 1414851 Pelistega indica PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023135 Microbes metabolize substances PMDBM2021661 1414851 Pelistega indica PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023136 Microbes metabolize substances PMDBM2021661 1414851 Pelistega indica PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023137 Microbes metabolize substances PMDBM2021661 1414851 Pelistega indica PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023138 Microbes metabolize substances PMDBM2021661 1414851 Pelistega indica PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023139 Microbes metabolize substances PMDBM876 186807 Peptococcaceae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20023140 Microbes metabolize substances PMDBM876 186807 Peptococcaceae PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20023141 Microbes metabolize substances PMDBM876 186807 Peptococcaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023142 Microbes metabolize substances PMDBM876 186807 Peptococcaceae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023143 Microbes metabolize substances PMDBM876 186807 Peptococcaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023144 Microbes metabolize substances PMDBM876 186807 Peptococcaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023145 Microbes metabolize substances PMDBM2021662 2741 Peptococcus niger PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023146 Microbes metabolize substances PMDBM2021662 2741 Peptococcus niger PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023147 Microbes metabolize substances PMDBM2021662 2741 Peptococcus niger PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20023149 Microbes metabolize substances PMDBM2021662 2741 Peptococcus niger PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20023150 Microbes metabolize substances PMDBM2021662 2741 Peptococcus niger PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20023151 Microbes metabolize substances PMDBM2021662 2741 Peptococcus niger PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20023152 Microbes metabolize substances PMDBM2021662 2741 Peptococcus niger PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023155 Microbes metabolize substances PMDBM2021662 2741 Peptococcus niger PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20023159 Microbes metabolize substances PMDBM2021662 2741 Peptococcus niger PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023160 Microbes metabolize substances PMDBM2021662 2741 Peptococcus niger PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023161 Microbes metabolize substances PMDBM2009400 n.a. Peptoniphilus A PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023162 Microbes metabolize substances PMDBM2009400 n.a. Peptoniphilus A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023163 Microbes metabolize substances PMDBM2009400 n.a. Peptoniphilus A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023164 Microbes metabolize substances PMDBM2009400 n.a. Peptoniphilus A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023165 Microbes metabolize substances PMDBM2020971 1465756 Peptoniphilus A grossensis B PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023166 Microbes metabolize substances PMDBM2020971 1465756 Peptoniphilus A grossensis B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023167 Microbes metabolize substances PMDBM2020971 1465756 Peptoniphilus A grossensis B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023168 Microbes metabolize substances PMDBM2020971 1465756 Peptoniphilus A grossensis B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023169 Microbes metabolize substances PMDBM2020972 54005 Peptoniphilus A harei PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023170 Microbes metabolize substances PMDBM2020972 54005 Peptoniphilus A harei PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023171 Microbes metabolize substances PMDBM2020972 54005 Peptoniphilus A harei PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023172 Microbes metabolize substances PMDBM2020972 54005 Peptoniphilus A harei PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023173 Microbes metabolize substances PMDBM2020972 54005 Peptoniphilus A harei A PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023174 Microbes metabolize substances PMDBM2020972 54005 Peptoniphilus A harei A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023175 Microbes metabolize substances PMDBM2020972 54005 Peptoniphilus A harei A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023176 Microbes metabolize substances PMDBM2020972 54005 Peptoniphilus A harei A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023177 Microbes metabolize substances PMDBM2020973 33031 Peptoniphilus A lacrimalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023178 Microbes metabolize substances PMDBM2020975 1720298 Peptoniphilus A phoceensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023179 Microbes metabolize substances PMDBM2020975 1720298 Peptoniphilus A phoceensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023180 Microbes metabolize substances PMDBM2020975 1720298 Peptoniphilus A phoceensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023181 Microbes metabolize substances PMDBM2020975 1720298 Peptoniphilus A phoceensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023182 Microbes metabolize substances PMDBM2021663 1175452 Peptoniphilus A rhinitidis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023183 Microbes metabolize substances PMDBM2021663 1175452 Peptoniphilus A rhinitidis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023184 Microbes metabolize substances PMDBM2021663 1175452 Peptoniphilus A rhinitidis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023185 Microbes metabolize substances PMDBM2021663 1175452 Peptoniphilus A rhinitidis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023186 Microbes metabolize substances PMDBM2020976 1465757 Peptoniphilus A senegalensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023187 Microbes metabolize substances PMDBM2020976 1465757 Peptoniphilus A senegalensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023188 Microbes metabolize substances PMDBM2020976 1465757 Peptoniphilus A senegalensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023189 Microbes metabolize substances PMDBM2020976 1465757 Peptoniphilus A senegalensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023190 Microbes metabolize substances PMDBM2021664 1971214 Peptoniphilus A sp900099555 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023191 Microbes metabolize substances PMDBM2021664 1971214 Peptoniphilus A sp900099555 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023192 Microbes metabolize substances PMDBM2021664 1971214 Peptoniphilus A sp900099555 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023193 Microbes metabolize substances PMDBM2009409 n.a. Peptoniphilus B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023194 Microbes metabolize substances PMDBM2009409 n.a. Peptoniphilus B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023195 Microbes metabolize substances PMDBM2009409 n.a. Peptoniphilus B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023196 Microbes metabolize substances PMDBM2020970 507750 Peptoniphilus B duerdenii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023197 Microbes metabolize substances PMDBM2020970 507750 Peptoniphilus B duerdenii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023198 Microbes metabolize substances PMDBM2020970 507750 Peptoniphilus B duerdenii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023199 Microbes metabolize substances PMDBM2021664 1971214 Peptoniphilus B sp000478985 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023200 Microbes metabolize substances PMDBM2021664 1971214 Peptoniphilus B sp000478985 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023201 Microbes metabolize substances PMDBM2021664 1971214 Peptoniphilus B sp000478985 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023202 Microbes metabolize substances PMDBM2021664 1971214 Peptoniphilus B sp000478985 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023203 Microbes metabolize substances PMDBM2009412 n.a. Peptoniphilus C PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20023204 Microbes metabolize substances PMDBM2009412 n.a. Peptoniphilus C PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023205 Microbes metabolize substances PMDBM2009412 n.a. Peptoniphilus C PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023206 Microbes metabolize substances PMDBM2009412 n.a. Peptoniphilus C PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023207 Microbes metabolize substances PMDBM2009412 n.a. Peptoniphilus C PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023208 Microbes metabolize substances PMDBM2021665 1871017 Peptoniphilus C urinimassiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023209 Microbes metabolize substances PMDBM2021665 1871017 Peptoniphilus C urinimassiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023210 Microbes metabolize substances PMDBM2021665 1871017 Peptoniphilus C urinimassiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023211 Microbes metabolize substances PMDBM2020974 1472765 Peptoniphilus E obesi PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023212 Microbes metabolize substances PMDBM2020974 1472765 Peptoniphilus E obesi PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023213 Microbes metabolize substances PMDBM2020974 1472765 Peptoniphilus E obesi PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023214 Microbes metabolize substances PMDBM880 1257 Peptostreptococcus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023215 Microbes metabolize substances PMDBM880 1257 Peptostreptococcus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023216 Microbes metabolize substances PMDBM880 1257 Peptostreptococcus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023217 Microbes metabolize substances PMDBM880 1257 Peptostreptococcus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023218 Microbes metabolize substances PMDBM880 1257 Peptostreptococcus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023219 Microbes metabolize substances PMDBM880 1257 Peptostreptococcus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023220 Microbes metabolize substances PMDBM880 1257 Peptostreptococcus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023223 Microbes metabolize substances PMDBM880 1257 Peptostreptococcus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023224 Microbes metabolize substances PMDBM880 1257 Peptostreptococcus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023225 Microbes metabolize substances PMDBM880 1257 Peptostreptococcus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023226 Microbes metabolize substances PMDBM880 1257 Peptostreptococcus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023227 Microbes metabolize substances PMDBM880 1257 Peptostreptococcus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023228 Microbes metabolize substances PMDBM880 1257 Peptostreptococcus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023229 Microbes metabolize substances PMDBM880 1257 Peptostreptococcus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023230 Microbes metabolize substances PMDBM2020234 1261 Peptostreptococcus anaerobius PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023231 Microbes metabolize substances PMDBM2020234 1261 Peptostreptococcus anaerobius PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023232 Microbes metabolize substances PMDBM2020234 1261 Peptostreptococcus anaerobius PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023233 Microbes metabolize substances PMDBM2020234 1261 Peptostreptococcus anaerobius PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023234 Microbes metabolize substances PMDBM2020234 1261 Peptostreptococcus anaerobius PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023235 Microbes metabolize substances PMDBM2020234 1261 Peptostreptococcus anaerobius PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023236 Microbes metabolize substances PMDBM2020234 1261 Peptostreptococcus anaerobius PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023239 Microbes metabolize substances PMDBM2020234 1261 Peptostreptococcus anaerobius PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023240 Microbes metabolize substances PMDBM2020234 1261 Peptostreptococcus anaerobius PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023241 Microbes metabolize substances PMDBM2020234 1261 Peptostreptococcus anaerobius PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023242 Microbes metabolize substances PMDBM2020234 1261 Peptostreptococcus anaerobius PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023243 Microbes metabolize substances PMDBM2020234 1261 Peptostreptococcus anaerobius PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023244 Microbes metabolize substances PMDBM2020234 1261 Peptostreptococcus anaerobius PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023245 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023246 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023247 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023248 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023249 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023250 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023251 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023254 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20023255 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023256 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023257 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023258 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023259 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023260 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023261 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023262 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023263 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023264 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023265 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023266 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023267 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023268 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023271 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023272 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023273 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023274 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023275 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023276 Microbes metabolize substances PMDBM2020978 215200 Peptostreptococcus russellii A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023277 Microbes metabolize substances PMDBM2021666 1262 Peptostreptococcus sp000758885 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023278 Microbes metabolize substances PMDBM2021666 1262 Peptostreptococcus sp000758885 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023279 Microbes metabolize substances PMDBM2021666 1262 Peptostreptococcus sp000758885 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023280 Microbes metabolize substances PMDBM2021666 1262 Peptostreptococcus sp000758885 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023281 Microbes metabolize substances PMDBM2020156 341694 Peptostreptococcus stomatis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023282 Microbes metabolize substances PMDBM2020156 341694 Peptostreptococcus stomatis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023283 Microbes metabolize substances PMDBM2020156 341694 Peptostreptococcus stomatis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023284 Microbes metabolize substances PMDBM2020156 341694 Peptostreptococcus stomatis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023285 Microbes metabolize substances PMDBM2020156 341694 Peptostreptococcus stomatis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023286 Microbes metabolize substances PMDBM2020156 341694 Peptostreptococcus stomatis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023287 Microbes metabolize substances PMDBM2020156 341694 Peptostreptococcus stomatis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023290 Microbes metabolize substances PMDBM2020156 341694 Peptostreptococcus stomatis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023291 Microbes metabolize substances PMDBM2020156 341694 Peptostreptococcus stomatis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023292 Microbes metabolize substances PMDBM2020156 341694 Peptostreptococcus stomatis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023293 Microbes metabolize substances PMDBM2020156 341694 Peptostreptococcus stomatis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023294 Microbes metabolize substances PMDBM2020156 341694 Peptostreptococcus stomatis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023295 Microbes metabolize substances PMDBM2020156 341694 Peptostreptococcus stomatis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023296 Microbes metabolize substances PMDBM2020156 341694 Peptostreptococcus stomatis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023297 Microbes metabolize substances PMDBM322 33024 Phascolarctobacterium PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20023298 Microbes metabolize substances PMDBM322 33024 Phascolarctobacterium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023299 Microbes metabolize substances PMDBM322 33024 Phascolarctobacterium PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20023300 Microbes metabolize substances PMDBM322 33024 Phascolarctobacterium PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023301 Microbes metabolize substances PMDBM2020979 33025 Phascolarctobacterium faecium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023302 Microbes metabolize substances PMDBM2020979 33025 Phascolarctobacterium faecium PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023303 Microbes metabolize substances PMDBM2021667 2049039 Phascolarctobacterium sp000436095 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20023304 Microbes metabolize substances PMDBM2021667 2049039 Phascolarctobacterium sp000436095 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023305 Microbes metabolize substances PMDBM2021667 2049039 Phascolarctobacterium sp000436095 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20023306 Microbes metabolize substances PMDBM2021667 2049039 Phascolarctobacterium sp000436095 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023307 Microbes metabolize substances PMDBM2009422 n.a. Phascolarctobacterium A PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20023308 Microbes metabolize substances PMDBM2009422 n.a. Phascolarctobacterium A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023309 Microbes metabolize substances PMDBM2009422 n.a. Phascolarctobacterium A PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20023310 Microbes metabolize substances PMDBM2009422 n.a. Phascolarctobacterium A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023311 Microbes metabolize substances PMDBM2020980 626940 Phascolarctobacterium A succinatutens A PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20023312 Microbes metabolize substances PMDBM2020980 626940 Phascolarctobacterium A succinatutens A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023313 Microbes metabolize substances PMDBM2020980 626940 Phascolarctobacterium A succinatutens A PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20023314 Microbes metabolize substances PMDBM2020980 626940 Phascolarctobacterium A succinatutens A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023315 Microbes metabolize substances PMDBM2020980 626940 Phascolarctobacterium A succinatutens PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20023316 Microbes metabolize substances PMDBM2020980 626940 Phascolarctobacterium A succinatutens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023317 Microbes metabolize substances PMDBM2009425 n.a. o Christensenellales f CAG-138 g Phil1 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023318 Microbes metabolize substances PMDBM2009425 n.a. o Christensenellales f CAG-138 g Phil1 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023319 Microbes metabolize substances PMDBM2009425 n.a. o Christensenellales f CAG-138 g Phil1 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023320 Microbes metabolize substances PMDBM2009425 n.a. o Christensenellales f CAG-138 g Phil1 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023321 Microbes metabolize substances PMDBM2009425 n.a. o Christensenellales f CAG-138 g Phil1 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023322 Microbes metabolize substances PMDBM2009425 n.a. o Christensenellales f CAG-138 g Phil1 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023323 Microbes metabolize substances PMDBM2009425 n.a. o Christensenellales f CAG-138 g Phil1 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023326 Microbes metabolize substances PMDBM2009425 n.a. o Christensenellales f CAG-138 g Phil1 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023327 Microbes metabolize substances PMDBM2009425 n.a. o Christensenellales f CAG-138 g Phil1 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023328 Microbes metabolize substances PMDBM2009425 n.a. o Christensenellales f CAG-138 g Phil1 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023329 Microbes metabolize substances PMDBM2009425 n.a. o Christensenellales f CAG-138 g Phil1 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023330 Microbes metabolize substances PMDBM2009425 n.a. o Christensenellales f CAG-138 g Phil1 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023331 Microbes metabolize substances PMDBM2009425 n.a. o Christensenellales f CAG-138 g Phil1 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023332 Microbes metabolize substances PMDBM2009425 n.a. o Christensenellales f CAG-138 g Phil1 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023333 Microbes metabolize substances PMDBM2009425 n.a. o Christensenellales f CAG-138 g Phil1 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023334 Microbes metabolize substances PMDBM2009426 n.a. o Christensenellales f CAG-138 g Phil1 s Phil1 sp001940855 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023335 Microbes metabolize substances PMDBM2009426 n.a. o Christensenellales f CAG-138 g Phil1 s Phil1 sp001940855 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023336 Microbes metabolize substances PMDBM2009426 n.a. o Christensenellales f CAG-138 g Phil1 s Phil1 sp001940855 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023337 Microbes metabolize substances PMDBM2009426 n.a. o Christensenellales f CAG-138 g Phil1 s Phil1 sp001940855 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023338 Microbes metabolize substances PMDBM2021668 2897707 Phocea massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023339 Microbes metabolize substances PMDBM2021668 2897707 Phocea massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023340 Microbes metabolize substances PMDBM2021668 2897707 Phocea massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023341 Microbes metabolize substances PMDBM2021668 2897707 Phocea massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023342 Microbes metabolize substances PMDBM2021669 1944646 Phoenicibacter massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023343 Microbes metabolize substances PMDBM2009429 28100 Phyllobacterium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023344 Microbes metabolize substances PMDBM2009429 28100 Phyllobacterium PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20023345 Microbes metabolize substances PMDBM2009429 28100 Phyllobacterium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023346 Microbes metabolize substances PMDBM2009429 28100 Phyllobacterium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023347 Microbes metabolize substances PMDBM2009429 28100 Phyllobacterium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023348 Microbes metabolize substances PMDBM2009429 28100 Phyllobacterium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023349 Microbes metabolize substances PMDBM2009429 28100 Phyllobacterium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023350 Microbes metabolize substances PMDBM2009429 28100 Phyllobacterium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023353 Microbes metabolize substances PMDBM2009429 28100 Phyllobacterium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023354 Microbes metabolize substances PMDBM2009429 28100 Phyllobacterium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023355 Microbes metabolize substances PMDBM2009429 28100 Phyllobacterium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023356 Microbes metabolize substances PMDBM2009429 28100 Phyllobacterium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023357 Microbes metabolize substances PMDBM2009429 28100 Phyllobacterium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023358 Microbes metabolize substances PMDBM2009429 28100 Phyllobacterium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023359 Microbes metabolize substances PMDBM2021670 1977564 Pigmentiphaga sp002188635 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023360 Microbes metabolize substances PMDBM2021670 1977564 Pigmentiphaga sp002188635 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20023361 Microbes metabolize substances PMDBM2021670 1977564 Pigmentiphaga sp002188635 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023362 Microbes metabolize substances PMDBM2021670 1977564 Pigmentiphaga sp002188635 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023363 Microbes metabolize substances PMDBM2021670 1977564 Pigmentiphaga sp002188635 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023364 Microbes metabolize substances PMDBM2021670 1977564 Pigmentiphaga sp002188635 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023365 Microbes metabolize substances PMDBM2021670 1977564 Pigmentiphaga sp002188635 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023366 Microbes metabolize substances PMDBM2021670 1977564 Pigmentiphaga sp002188635 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023369 Microbes metabolize substances PMDBM2021670 1977564 Pigmentiphaga sp002188635 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023370 Microbes metabolize substances PMDBM2021670 1977564 Pigmentiphaga sp002188635 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023371 Microbes metabolize substances PMDBM2021670 1977564 Pigmentiphaga sp002188635 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023372 Microbes metabolize substances PMDBM2021670 1977564 Pigmentiphaga sp002188635 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023373 Microbes metabolize substances PMDBM2021670 1977564 Pigmentiphaga sp002188635 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023374 Microbes metabolize substances PMDBM2009431 n.a. Planomicrobium massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20023375 Microbes metabolize substances PMDBM2009431 n.a. Planomicrobium massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023376 Microbes metabolize substances PMDBM2009431 n.a. Planomicrobium massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023377 Microbes metabolize substances PMDBM2009431 n.a. Planomicrobium massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023378 Microbes metabolize substances PMDBM2020235 703 Plesiomonas shigelloides PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023379 Microbes metabolize substances PMDBM2020235 703 Plesiomonas shigelloides PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20023380 Microbes metabolize substances PMDBM2020235 703 Plesiomonas shigelloides PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023381 Microbes metabolize substances PMDBM2020235 703 Plesiomonas shigelloides PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023382 Microbes metabolize substances PMDBM2020235 703 Plesiomonas shigelloides PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023383 Microbes metabolize substances PMDBM2020235 703 Plesiomonas shigelloides PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023384 Microbes metabolize substances PMDBM2020235 703 Plesiomonas shigelloides PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023385 Microbes metabolize substances PMDBM2020235 703 Plesiomonas shigelloides PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023388 Microbes metabolize substances PMDBM2020235 703 Plesiomonas shigelloides PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023389 Microbes metabolize substances PMDBM2020235 703 Plesiomonas shigelloides PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023390 Microbes metabolize substances PMDBM2020235 703 Plesiomonas shigelloides PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023391 Microbes metabolize substances PMDBM2020235 703 Plesiomonas shigelloides PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023392 Microbes metabolize substances PMDBM2020235 703 Plesiomonas shigelloides PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023393 Microbes metabolize substances PMDBM2020235 703 Plesiomonas shigelloides PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023394 Microbes metabolize substances PMDBM2020235 703 Plesiomonas shigelloides PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023395 Microbes metabolize substances PMDBM2020235 703 Plesiomonas shigelloides PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023396 Microbes metabolize substances PMDBM2021671 61647 Pluralibacter gergoviae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023397 Microbes metabolize substances PMDBM2021671 61647 Pluralibacter gergoviae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20023398 Microbes metabolize substances PMDBM2021671 61647 Pluralibacter gergoviae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023399 Microbes metabolize substances PMDBM2021671 61647 Pluralibacter gergoviae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023400 Microbes metabolize substances PMDBM2021671 61647 Pluralibacter gergoviae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023401 Microbes metabolize substances PMDBM2021671 61647 Pluralibacter gergoviae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023402 Microbes metabolize substances PMDBM2021671 61647 Pluralibacter gergoviae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023403 Microbes metabolize substances PMDBM2021671 61647 Pluralibacter gergoviae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023406 Microbes metabolize substances PMDBM2021671 61647 Pluralibacter gergoviae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023407 Microbes metabolize substances PMDBM2021671 61647 Pluralibacter gergoviae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023408 Microbes metabolize substances PMDBM2021671 61647 Pluralibacter gergoviae PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20023409 Microbes metabolize substances PMDBM2021671 61647 Pluralibacter gergoviae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023410 Microbes metabolize substances PMDBM2021671 61647 Pluralibacter gergoviae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023411 Microbes metabolize substances PMDBM2021671 61647 Pluralibacter gergoviae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023412 Microbes metabolize substances PMDBM2021671 61647 Pluralibacter gergoviae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023413 Microbes metabolize substances PMDBM2021671 61647 Pluralibacter gergoviae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023414 Microbes metabolize substances PMDBM2021671 61647 Pluralibacter gergoviae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023415 Microbes metabolize substances PMDBM886 836 Porphyromonas PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023416 Microbes metabolize substances PMDBM886 836 Porphyromonas PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023417 Microbes metabolize substances PMDBM886 836 Porphyromonas PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023418 Microbes metabolize substances PMDBM886 836 Porphyromonas PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023419 Microbes metabolize substances PMDBM886 836 Porphyromonas PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023420 Microbes metabolize substances PMDBM886 836 Porphyromonas PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023421 Microbes metabolize substances PMDBM886 836 Porphyromonas PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023424 Microbes metabolize substances PMDBM886 836 Porphyromonas PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023425 Microbes metabolize substances PMDBM886 836 Porphyromonas PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023426 Microbes metabolize substances PMDBM886 836 Porphyromonas PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023427 Microbes metabolize substances PMDBM886 836 Porphyromonas PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023428 Microbes metabolize substances PMDBM886 836 Porphyromonas PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023429 Microbes metabolize substances PMDBM886 836 Porphyromonas PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023430 Microbes metabolize substances PMDBM886 836 Porphyromonas PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023431 Microbes metabolize substances PMDBM886 836 Porphyromonas PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023432 Microbes metabolize substances PMDBM886 836 Porphyromonas PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023433 Microbes metabolize substances PMDBM2020988 28123 Porphyromonas asaccharolytica PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023434 Microbes metabolize substances PMDBM2020988 28123 Porphyromonas asaccharolytica PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023435 Microbes metabolize substances PMDBM2020988 28123 Porphyromonas asaccharolytica PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023436 Microbes metabolize substances PMDBM2020988 28123 Porphyromonas asaccharolytica PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023437 Microbes metabolize substances PMDBM2020988 28123 Porphyromonas asaccharolytica PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023438 Microbes metabolize substances PMDBM2020988 28123 Porphyromonas asaccharolytica PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023439 Microbes metabolize substances PMDBM2020989 501496 Porphyromonas bennonis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023440 Microbes metabolize substances PMDBM2020989 501496 Porphyromonas bennonis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023441 Microbes metabolize substances PMDBM2020989 501496 Porphyromonas bennonis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023442 Microbes metabolize substances PMDBM2020989 501496 Porphyromonas bennonis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023443 Microbes metabolize substances PMDBM2020989 501496 Porphyromonas bennonis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023444 Microbes metabolize substances PMDBM2020989 501496 Porphyromonas bennonis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023445 Microbes metabolize substances PMDBM2020989 501496 Porphyromonas bennonis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023448 Microbes metabolize substances PMDBM2020989 501496 Porphyromonas bennonis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023449 Microbes metabolize substances PMDBM2020989 501496 Porphyromonas bennonis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023450 Microbes metabolize substances PMDBM2020989 501496 Porphyromonas bennonis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023451 Microbes metabolize substances PMDBM2020989 501496 Porphyromonas bennonis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023452 Microbes metabolize substances PMDBM2020989 501496 Porphyromonas bennonis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023453 Microbes metabolize substances PMDBM2020989 501496 Porphyromonas bennonis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023454 Microbes metabolize substances PMDBM2020989 501496 Porphyromonas bennonis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023455 Microbes metabolize substances PMDBM2020989 501496 Porphyromonas bennonis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023456 Microbes metabolize substances PMDBM2020990 28124 Porphyromonas endodontalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023457 Microbes metabolize substances PMDBM2020990 28124 Porphyromonas endodontalis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023458 Microbes metabolize substances PMDBM2020990 28124 Porphyromonas endodontalis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023459 Microbes metabolize substances PMDBM2020990 28124 Porphyromonas endodontalis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023460 Microbes metabolize substances PMDBM2020236 837 Porphyromonas gingivalis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023461 Microbes metabolize substances PMDBM2020236 837 Porphyromonas gingivalis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023462 Microbes metabolize substances PMDBM2020236 837 Porphyromonas gingivalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023463 Microbes metabolize substances PMDBM2020236 837 Porphyromonas gingivalis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023464 Microbes metabolize substances PMDBM2020236 837 Porphyromonas gingivalis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023465 Microbes metabolize substances PMDBM2020236 837 Porphyromonas gingivalis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023466 Microbes metabolize substances PMDBM2020992 322095 Porphyromonas somerae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023467 Microbes metabolize substances PMDBM2020992 322095 Porphyromonas somerae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023468 Microbes metabolize substances PMDBM2020992 322095 Porphyromonas somerae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023469 Microbes metabolize substances PMDBM2020992 322095 Porphyromonas somerae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023470 Microbes metabolize substances PMDBM2020992 322095 Porphyromonas somerae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023471 Microbes metabolize substances PMDBM2020992 322095 Porphyromonas somerae A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023472 Microbes metabolize substances PMDBM2020992 322095 Porphyromonas somerae A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023473 Microbes metabolize substances PMDBM2020992 322095 Porphyromonas somerae A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023474 Microbes metabolize substances PMDBM2020992 322095 Porphyromonas somerae A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023475 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023476 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023477 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023478 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023479 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023480 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023481 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023482 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023483 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023485 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20023488 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20023489 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20023490 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023491 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023494 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20023497 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023498 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023499 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023501 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023502 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023503 Microbes metabolize substances PMDBM2021361 1924944 Porphyromonas sp001808555 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023504 Microbes metabolize substances PMDBM2020166 281920 Porphyromonas uenonis A PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023505 Microbes metabolize substances PMDBM2020166 281920 Porphyromonas uenonis A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023506 Microbes metabolize substances PMDBM2020166 281920 Porphyromonas uenonis A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023507 Microbes metabolize substances PMDBM2020166 281920 Porphyromonas uenonis A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023508 Microbes metabolize substances PMDBM2020166 281920 Porphyromonas uenonis A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023509 Microbes metabolize substances PMDBM2020166 281920 Porphyromonas uenonis A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023510 Microbes metabolize substances PMDBM2020166 281920 Porphyromonas uenonis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023511 Microbes metabolize substances PMDBM2020166 281920 Porphyromonas uenonis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023512 Microbes metabolize substances PMDBM2020166 281920 Porphyromonas uenonis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023513 Microbes metabolize substances PMDBM2020166 281920 Porphyromonas uenonis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023514 Microbes metabolize substances PMDBM2020166 281920 Porphyromonas uenonis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023515 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023516 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20023517 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023518 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023519 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023521 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023523 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20023524 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023525 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023526 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023527 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023528 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023529 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023531 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20023534 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20023535 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20023536 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023537 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023538 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023541 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20023544 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023545 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023548 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023549 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023550 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023551 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20023552 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD812 Sulfasalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. "sulfapyridine; 5-aminosalicylate" n.a. Azo reductases activation n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes n.a. PMID PMID: 36467581 PMDBI20023553 Microbes metabolize substances PMDBM2020993 419005 Prevotella amnii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023554 Microbes metabolize substances PMDBM2020993 419005 Prevotella amnii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023555 Microbes metabolize substances PMDBM2020993 419005 Prevotella amnii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023556 Microbes metabolize substances PMDBM2020993 419005 Prevotella amnii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023557 Microbes metabolize substances PMDBM2020993 419005 Prevotella amnii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023558 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023559 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023560 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023561 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023563 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023565 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023566 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023567 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023568 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023569 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023570 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023572 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20023575 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20023576 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20023577 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023578 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023581 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20023584 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023585 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023588 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023589 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023590 Microbes metabolize substances PMDBM2021672 242750 Prevotella bergensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023591 Microbes metabolize substances PMDBM2020995 28125 Prevotella bivia PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023592 Microbes metabolize substances PMDBM2020995 28125 Prevotella bivia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023593 Microbes metabolize substances PMDBM2020995 28125 Prevotella bivia PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023594 Microbes metabolize substances PMDBM2020995 28125 Prevotella bivia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023595 Microbes metabolize substances PMDBM2020995 28125 Prevotella bivia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023596 Microbes metabolize substances PMDBM2020998 28126 Prevotella buccae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023597 Microbes metabolize substances PMDBM2020998 28126 Prevotella buccae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023598 Microbes metabolize substances PMDBM2020998 28126 Prevotella buccae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023599 Microbes metabolize substances PMDBM2020998 28126 Prevotella buccae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023601 Microbes metabolize substances PMDBM2020998 28126 Prevotella buccae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023603 Microbes metabolize substances PMDBM2020998 28126 Prevotella buccae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023604 Microbes metabolize substances PMDBM2020998 28126 Prevotella buccae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023605 Microbes metabolize substances PMDBM2020998 28126 Prevotella buccae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023606 Microbes metabolize substances PMDBM2020998 28126 Prevotella buccae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023609 Microbes metabolize substances PMDBM2020998 28126 Prevotella buccae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023610 Microbes metabolize substances PMDBM2020998 28126 Prevotella buccae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023611 Microbes metabolize substances PMDBM2020998 28126 Prevotella buccae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023612 Microbes metabolize substances PMDBM2020998 28126 Prevotella buccae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023614 Microbes metabolize substances PMDBM2020998 28126 Prevotella buccae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023615 Microbes metabolize substances PMDBM2020998 28126 Prevotella buccae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023616 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023617 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023618 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023619 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023621 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023623 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023624 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023625 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023626 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023627 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023628 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023630 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20023633 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20023634 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20023635 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023636 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023639 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20023642 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023643 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023646 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023647 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023648 Microbes metabolize substances PMDBM2021673 28127 Prevotella buccalis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023649 Microbes metabolize substances PMDBM2021674 1703337 Prevotella colorans PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023650 Microbes metabolize substances PMDBM2021674 1703337 Prevotella colorans PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023651 Microbes metabolize substances PMDBM2021674 1703337 Prevotella colorans PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023652 Microbes metabolize substances PMDBM2021674 1703337 Prevotella colorans PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023654 Microbes metabolize substances PMDBM2021674 1703337 Prevotella colorans PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023656 Microbes metabolize substances PMDBM2021674 1703337 Prevotella colorans PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023657 Microbes metabolize substances PMDBM2021674 1703337 Prevotella colorans PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023658 Microbes metabolize substances PMDBM2021674 1703337 Prevotella colorans PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023659 Microbes metabolize substances PMDBM2021674 1703337 Prevotella colorans PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023662 Microbes metabolize substances PMDBM2021674 1703337 Prevotella colorans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023663 Microbes metabolize substances PMDBM2021674 1703337 Prevotella colorans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023664 Microbes metabolize substances PMDBM2021674 1703337 Prevotella colorans PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023665 Microbes metabolize substances PMDBM2021674 1703337 Prevotella colorans PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023667 Microbes metabolize substances PMDBM2021674 1703337 Prevotella colorans PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023668 Microbes metabolize substances PMDBM2021674 1703337 Prevotella colorans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023669 Microbes metabolize substances PMDBM2021674 1703337 Prevotella colorans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023670 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023671 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023672 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023673 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023675 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023677 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD2000060 Nivolumab Therapeutic Substance Anticancer n.a. n.a. n.a. n.a. n.a. n.a. unknown activity increased n.a. n.a. n.a. high frequency of specific memory CD8+ T cell and natural killer cell subset in the periphery. n.a. PMID PMID: 36467581 PMDBI20023678 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023679 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023680 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023681 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023684 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023685 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023686 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023687 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023689 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD2000061 Carboplatin Therapeutic Substance antineoplastic alkylating n.a. n.a. n.a. n.a. n.a. n.a. unknown side effect n.a. n.a. n.a. In a rat model, carboplatin-induced intestinal mucositis was reduced after metronidazole treatment, which was intended to target the anaerobic P. copri. n.a. PMID PMID: 36467581 PMDBI20023690 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023691 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" cardiac glycoside n.a. n.a. n.a. n.a. dihydrodigoxin n.a. unknown involved in substrate metabolism n.a. n.a. n.a. inactivation n.a. PMID PMID: 36467581 PMDBI20023692 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" antimicrobial n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20023693 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD1166 Dolasetron Therapeutic substance antinauseant and antiemetic n.a. n.a. n.a. n.a. duloxetine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20023694 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20023695 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" fungal infections n.a. n.a. n.a. n.a. ketoprofen n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20023696 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. ketoprofen n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20023697 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD477 Levonorgestrel Therapeutic Substance contraception and hormone n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20023698 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" lower the risk of cardiovascular disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20023699 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD1298 Misoprostol Therapeutic substance reduce the risk of NSAID induced gastric ulcers n.a. n.a. n.a. n.a. misoprostol-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20023700 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD563 Mycophenolate mofetil Therapeutic Substance inosine monophosphate dehydrogenase inhibitor n.a. n.a. n.a. n.a. mycophenolic-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20023701 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD1376 Praziquantel Therapeutic substance Anti-infection n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20023702 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD750 Risperidone Therapeutic Substance second-generation antipsychotic (SGA) n.a. n.a. n.a. n.a. risperidone-M1 n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20023703 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD1421 Spironolactone Therapeutic substance diuretic and also antihypertensive effects n.a. n.a. n.a. n.a. 7æµ?thiospironolactone n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20023704 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD1467 Torsemide Therapeutic substance loop diuretic n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20023705 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023706 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023707 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023708 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023709 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023710 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023712 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023714 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023715 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023716 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023717 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023720 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023721 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023722 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023723 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023725 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023726 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023727 Microbes metabolize substances PMDBM2020237 165179 Prevotella copri A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023728 Microbes metabolize substances PMDBM2021000 28128 Prevotella corporis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023729 Microbes metabolize substances PMDBM2021000 28128 Prevotella corporis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023730 Microbes metabolize substances PMDBM2021000 28128 Prevotella corporis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023731 Microbes metabolize substances PMDBM2021000 28128 Prevotella corporis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023732 Microbes metabolize substances PMDBM2021003 28129 Prevotella denticola PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023733 Microbes metabolize substances PMDBM2021003 28129 Prevotella denticola PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023734 Microbes metabolize substances PMDBM2021003 28129 Prevotella denticola PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023735 Microbes metabolize substances PMDBM2021003 28129 Prevotella denticola PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023736 Microbes metabolize substances PMDBM2021003 28129 Prevotella denticola PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023737 Microbes metabolize substances PMDBM2021003 28129 Prevotella denticola PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023738 Microbes metabolize substances PMDBM2021003 28129 Prevotella denticola PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023741 Microbes metabolize substances PMDBM2021003 28129 Prevotella denticola PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023742 Microbes metabolize substances PMDBM2021003 28129 Prevotella denticola PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023743 Microbes metabolize substances PMDBM2021003 28129 Prevotella denticola PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023744 Microbes metabolize substances PMDBM2021003 28129 Prevotella denticola PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023745 Microbes metabolize substances PMDBM2021003 28129 Prevotella denticola PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023746 Microbes metabolize substances PMDBM2021003 28129 Prevotella denticola PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023747 Microbes metabolize substances PMDBM2021003 28129 Prevotella denticola PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023748 Microbes metabolize substances PMDBM2021003 28129 Prevotella denticola PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023749 Microbes metabolize substances PMDBM2021004 28130 Prevotella disiens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023750 Microbes metabolize substances PMDBM2021004 28130 Prevotella disiens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023751 Microbes metabolize substances PMDBM2021004 28130 Prevotella disiens PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023752 Microbes metabolize substances PMDBM2021006 28131 Prevotella intermedia PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023753 Microbes metabolize substances PMDBM2021006 28131 Prevotella intermedia PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023754 Microbes metabolize substances PMDBM2021006 28131 Prevotella intermedia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023755 Microbes metabolize substances PMDBM2021006 28131 Prevotella intermedia PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023756 Microbes metabolize substances PMDBM2021006 28131 Prevotella intermedia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023757 Microbes metabolize substances PMDBM2021006 28131 Prevotella intermedia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023758 Microbes metabolize substances PMDBM2021675 1177574 Prevotella jejuni PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023759 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023760 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023761 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023762 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023764 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023766 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023767 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023768 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023769 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023770 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023771 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023773 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20023776 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20023777 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20023778 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023779 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023782 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20023785 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023786 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023789 Microbes metabolize substances PMDBM2021676 1776379 Prevotella lascolaii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023790 Microbes metabolize substances PMDBM2021009 28132 Prevotella melaninogenica PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023791 Microbes metabolize substances PMDBM2021009 28132 Prevotella melaninogenica PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023792 Microbes metabolize substances PMDBM2021009 28132 Prevotella melaninogenica PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023793 Microbes metabolize substances PMDBM2021009 28132 Prevotella melaninogenica PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023794 Microbes metabolize substances PMDBM2021009 28132 Prevotella melaninogenica PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023795 Microbes metabolize substances PMDBM2021677 310514 Prevotella multisaccharivorax PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023796 Microbes metabolize substances PMDBM2021677 310514 Prevotella multisaccharivorax PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023797 Microbes metabolize substances PMDBM2021677 310514 Prevotella multisaccharivorax PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023798 Microbes metabolize substances PMDBM2021677 310514 Prevotella multisaccharivorax PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023800 Microbes metabolize substances PMDBM2021677 310514 Prevotella multisaccharivorax PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023802 Microbes metabolize substances PMDBM2021677 310514 Prevotella multisaccharivorax PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023803 Microbes metabolize substances PMDBM2021677 310514 Prevotella multisaccharivorax PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023804 Microbes metabolize substances PMDBM2021677 310514 Prevotella multisaccharivorax PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023805 Microbes metabolize substances PMDBM2021677 310514 Prevotella multisaccharivorax PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023808 Microbes metabolize substances PMDBM2021677 310514 Prevotella multisaccharivorax PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023809 Microbes metabolize substances PMDBM2021677 310514 Prevotella multisaccharivorax PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023810 Microbes metabolize substances PMDBM2021677 310514 Prevotella multisaccharivorax PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023811 Microbes metabolize substances PMDBM2021677 310514 Prevotella multisaccharivorax PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023813 Microbes metabolize substances PMDBM2021677 310514 Prevotella multisaccharivorax PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023814 Microbes metabolize substances PMDBM2021677 310514 Prevotella multisaccharivorax PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023815 Microbes metabolize substances PMDBM2021677 310514 Prevotella multisaccharivorax PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023816 Microbes metabolize substances PMDBM2021012 28133 Prevotella nigrescens PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023817 Microbes metabolize substances PMDBM2021012 28133 Prevotella nigrescens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023818 Microbes metabolize substances PMDBM2021012 28133 Prevotella nigrescens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023819 Microbes metabolize substances PMDBM2021012 28133 Prevotella nigrescens PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023820 Microbes metabolize substances PMDBM2021012 28133 Prevotella nigrescens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023821 Microbes metabolize substances PMDBM2021012 28133 Prevotella nigrescens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023822 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023823 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023824 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023825 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023827 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023829 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023830 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023831 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023832 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023833 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023834 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023836 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20023839 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20023840 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20023841 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023842 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023845 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20023848 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023849 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023852 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023853 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023854 Microbes metabolize substances PMDBM2021341 28134 Prevotella oralis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023855 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023856 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023857 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023858 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023860 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023862 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023863 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023864 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023865 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023868 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023869 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023870 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023871 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023873 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023874 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023875 Microbes metabolize substances PMDBM2021333 228604 Prevotella salivae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023876 Microbes metabolize substances PMDBM2021333 228604 Prevotella salivae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023877 Microbes metabolize substances PMDBM2021333 228604 Prevotella salivae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023878 Microbes metabolize substances PMDBM2021333 228604 Prevotella salivae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023880 Microbes metabolize substances PMDBM2021333 228604 Prevotella salivae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023882 Microbes metabolize substances PMDBM2021333 228604 Prevotella salivae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023883 Microbes metabolize substances PMDBM2021333 228604 Prevotella salivae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023884 Microbes metabolize substances PMDBM2021333 228604 Prevotella salivae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023885 Microbes metabolize substances PMDBM2021333 228604 Prevotella salivae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023888 Microbes metabolize substances PMDBM2021333 228604 Prevotella salivae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023889 Microbes metabolize substances PMDBM2021333 228604 Prevotella salivae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023890 Microbes metabolize substances PMDBM2021333 228604 Prevotella salivae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023891 Microbes metabolize substances PMDBM2021333 228604 Prevotella salivae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023893 Microbes metabolize substances PMDBM2021333 228604 Prevotella salivae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023894 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000431975 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023895 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000431975 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023896 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000431975 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023897 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000431975 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023899 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000431975 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023901 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000431975 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023902 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000431975 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023903 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000431975 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023904 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000431975 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023907 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000431975 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023908 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000431975 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023909 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000431975 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023910 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000431975 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023912 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000431975 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023913 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000431975 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023914 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023915 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023916 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023917 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023919 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023921 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023922 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023923 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023924 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023925 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20023926 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023928 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20023931 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20023932 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20023933 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20023934 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023935 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023938 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20023941 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023942 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023945 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023946 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000433175 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023947 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434515 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023948 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434515 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023949 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434515 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023950 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434515 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023952 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434515 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023954 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434515 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023955 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434515 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023956 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434515 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023957 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434515 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023960 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434515 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20023961 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434515 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023962 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434515 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023963 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434515 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023965 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434515 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023966 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434515 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023967 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434515 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023968 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434975 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023969 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434975 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023970 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434975 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023971 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434975 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023973 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434975 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023975 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434975 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023976 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434975 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023977 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434975 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023978 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434975 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20023981 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434975 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20023982 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434975 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023983 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434975 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20023985 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434975 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20023986 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434975 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023987 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000434975 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20023988 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000435635 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20023989 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000435635 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20023990 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000435635 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20023991 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000435635 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023993 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000435635 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20023995 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000435635 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023996 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000435635 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023997 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000435635 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20023998 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000435635 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024001 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000435635 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024002 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000435635 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024003 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000435635 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024004 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000435635 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024006 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000435635 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024007 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000435635 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024008 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000435635 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024009 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000435635 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20024010 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024011 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024012 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024013 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024015 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024017 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024018 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024019 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024020 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20024021 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20024022 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024024 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20024027 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20024028 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20024029 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024030 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024033 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20024036 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024037 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024040 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024041 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024042 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436035 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024043 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436595 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024044 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436595 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024045 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436595 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024046 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436595 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024048 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436595 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024050 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436595 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024051 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436595 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024052 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436595 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024053 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436595 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024056 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436595 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20024057 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436595 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024058 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436595 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024059 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436595 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024060 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436595 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024062 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436595 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024063 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436595 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024064 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436595 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024065 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436695 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024066 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436695 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024067 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436695 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024068 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436695 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024070 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436695 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024072 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436695 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024073 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436695 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024074 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436695 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024075 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436695 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024078 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436695 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024079 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436695 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024080 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436695 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024081 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436695 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024083 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436695 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024084 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436915 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024085 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436915 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024086 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436915 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024087 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436915 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024089 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436915 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024091 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436915 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024092 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436915 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024093 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436915 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024094 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436915 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024097 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436915 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20024098 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436915 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024099 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436915 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024100 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436915 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024101 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436915 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024103 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436915 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024104 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436915 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024105 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000436915 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024106 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000834015 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024107 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000834015 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024108 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000834015 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024109 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000834015 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024111 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000834015 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024113 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000834015 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024114 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000834015 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024115 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000834015 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024116 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000834015 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024119 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000834015 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20024120 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000834015 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024121 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000834015 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024122 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000834015 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024123 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000834015 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024125 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000834015 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024126 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000834015 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024127 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp000834015 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024128 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp001275135 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024129 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp001275135 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024130 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp001275135 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024131 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp001275135 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024133 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp001275135 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024135 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp001275135 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024136 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp001275135 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024137 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp001275135 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024138 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp001275135 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024141 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp001275135 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20024142 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp001275135 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024143 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp001275135 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024144 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp001275135 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024145 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp001275135 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024147 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp001275135 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024148 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp001275135 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024149 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp001275135 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024150 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251295 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024151 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251295 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024152 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251295 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024153 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251295 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024155 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251295 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024157 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251295 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024158 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251295 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024159 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251295 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024160 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251295 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024163 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251295 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20024164 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251295 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024165 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251295 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024166 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251295 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024167 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251295 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024169 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251295 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024170 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251295 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024171 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251295 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024172 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024173 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024174 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024175 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024176 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024177 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024178 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20024179 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20024180 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024182 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20024185 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20024186 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20024187 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024190 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20024193 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024194 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024195 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024197 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024198 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024199 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251365 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024200 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251385 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024201 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251385 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024202 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251385 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024203 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251385 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024205 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251385 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024207 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251385 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024208 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251385 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024209 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251385 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024210 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251385 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024213 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251385 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024214 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251385 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024215 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251385 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024216 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251385 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024218 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251385 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024219 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251385 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024220 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002251385 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024221 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002265625 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024222 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002265625 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024223 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002265625 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024224 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002265625 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024226 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002265625 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024228 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002265625 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024229 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002265625 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024230 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002265625 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024231 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002265625 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024234 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002265625 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024235 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002265625 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024236 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002265625 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024237 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002265625 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024239 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002265625 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024240 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002265625 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024241 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002265625 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024242 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299275 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024243 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299275 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024244 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299275 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024245 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299275 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024246 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299275 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024247 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299275 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024248 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299275 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024251 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299275 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024252 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299275 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024253 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299275 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024254 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299275 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024255 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299275 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024256 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299275 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024257 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299275 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024258 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299275 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024259 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299635 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024260 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299635 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024261 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299635 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024262 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299635 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024264 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299635 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024266 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299635 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024267 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299635 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024268 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299635 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024269 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299635 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024272 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299635 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024273 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299635 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024274 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299635 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024275 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299635 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024277 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299635 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024278 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299635 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024279 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002299635 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024280 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002300055 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024281 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002300055 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024282 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002300055 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024283 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002300055 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024284 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002300055 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024285 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002350355 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024286 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002350355 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024287 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002350355 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024288 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002350355 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024290 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002350355 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024292 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002350355 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024293 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002350355 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024294 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002350355 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024295 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002350355 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024298 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002350355 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024299 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002350355 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024300 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002350355 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024301 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002350355 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024303 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002350355 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024304 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002350355 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024305 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002350355 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024306 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002480935 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024307 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002480935 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024308 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002480935 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024309 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002480935 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024311 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002480935 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024313 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002480935 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024314 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002480935 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024315 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002480935 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024316 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002480935 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024319 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002480935 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024320 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002480935 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024321 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002480935 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024322 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002480935 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024324 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002480935 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024325 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002480935 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024326 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002480935 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024327 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002481295 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024328 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002481295 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024329 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002481295 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024330 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002481295 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024332 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002481295 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024334 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002481295 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024335 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002481295 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024336 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002481295 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024337 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002481295 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024340 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002481295 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024341 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002481295 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024342 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002481295 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024343 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002481295 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024345 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002481295 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024346 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002481295 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024347 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp002481295 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024348 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp003447235 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024349 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp003447235 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024350 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp003447235 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024351 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp003447235 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024352 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp003447235 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024353 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp003447235 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024354 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900290275 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024355 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900290275 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024356 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900290275 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024357 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900290275 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024359 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900290275 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024361 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900290275 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024362 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900290275 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024363 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900290275 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024364 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900290275 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024367 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900290275 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024368 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900290275 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024369 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900290275 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024370 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900290275 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024372 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900290275 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024373 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900290275 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024374 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900290275 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024375 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024376 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024377 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024378 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024380 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024382 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024383 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024384 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024385 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20024386 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20024387 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024389 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20024392 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20024393 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20024394 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024395 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024398 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20024401 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024402 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024405 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024406 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024407 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900313215 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024408 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900315955 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024409 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900315955 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024410 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900315955 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024411 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900315955 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024413 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900315955 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024415 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900315955 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024416 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900315955 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024417 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900315955 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024418 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900315955 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024421 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900315955 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024422 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900315955 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024423 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900315955 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024424 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900315955 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024426 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900315955 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024427 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900315955 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024428 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900315955 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024429 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900316565 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024430 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900316565 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024431 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900316565 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024432 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900316565 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024434 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900316565 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024436 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900316565 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024437 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900316565 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024438 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900316565 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024439 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900316565 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024442 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900316565 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024443 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900316565 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024444 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900316565 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024446 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900316565 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024447 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900316565 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024448 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900316565 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024449 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024450 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024451 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024452 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024454 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024456 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024457 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024458 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024459 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20024460 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20024461 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024463 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20024466 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20024467 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20024468 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024469 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024472 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20024475 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024476 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024479 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024480 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024481 Microbes metabolize substances PMDBM2021016 59823 Prevotella sp900317685 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024482 Microbes metabolize substances PMDBM2021678 1263103 Prevotella stercorea PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024483 Microbes metabolize substances PMDBM2021678 1263103 Prevotella stercorea PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024484 Microbes metabolize substances PMDBM2021678 1263103 Prevotella stercorea PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024485 Microbes metabolize substances PMDBM2021678 1263103 Prevotella stercorea PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024486 Microbes metabolize substances PMDBM2021678 1263103 Prevotella stercorea PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024487 Microbes metabolize substances PMDBM2021678 1263103 Prevotella stercorea PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024488 Microbes metabolize substances PMDBM2021678 1263103 Prevotella stercorea PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024489 Microbes metabolize substances PMDBM2021678 1263103 Prevotella stercorea PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024490 Microbes metabolize substances PMDBM2021678 1263103 Prevotella stercorea PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024491 Microbes metabolize substances PMDBM2021338 386414 Prevotella timonensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024492 Microbes metabolize substances PMDBM2021338 386414 Prevotella timonensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024493 Microbes metabolize substances PMDBM2021338 386414 Prevotella timonensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024494 Microbes metabolize substances PMDBM2021338 386414 Prevotella timonensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024496 Microbes metabolize substances PMDBM2021338 386414 Prevotella timonensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024498 Microbes metabolize substances PMDBM2021338 386414 Prevotella timonensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024499 Microbes metabolize substances PMDBM2021338 386414 Prevotella timonensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024500 Microbes metabolize substances PMDBM2021338 386414 Prevotella timonensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024501 Microbes metabolize substances PMDBM2021338 386414 Prevotella timonensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024504 Microbes metabolize substances PMDBM2021338 386414 Prevotella timonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024505 Microbes metabolize substances PMDBM2021338 386414 Prevotella timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024506 Microbes metabolize substances PMDBM2021338 386414 Prevotella timonensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024507 Microbes metabolize substances PMDBM2021338 386414 Prevotella timonensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024509 Microbes metabolize substances PMDBM2021338 386414 Prevotella timonensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024510 Microbes metabolize substances PMDBM2021338 386414 Prevotella timonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024511 Microbes metabolize substances PMDBM2021338 386414 Prevotella timonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024512 Microbes metabolize substances PMDBM2021017 28137 Prevotella veroralis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024513 Microbes metabolize substances PMDBM2021017 28137 Prevotella veroralis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024514 Microbes metabolize substances PMDBM2021017 28137 Prevotella veroralis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024515 Microbes metabolize substances PMDBM2021017 28137 Prevotella veroralis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024516 Microbes metabolize substances PMDBM2021017 28137 Prevotella veroralis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024517 Microbes metabolize substances PMDBM2021017 28137 Prevotella veroralis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024518 Microbes metabolize substances PMDBM2021017 28137 Prevotella veroralis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024521 Microbes metabolize substances PMDBM2021017 28137 Prevotella veroralis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024522 Microbes metabolize substances PMDBM2021017 28137 Prevotella veroralis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024523 Microbes metabolize substances PMDBM2021017 28137 Prevotella veroralis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024524 Microbes metabolize substances PMDBM2021017 28137 Prevotella veroralis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024525 Microbes metabolize substances PMDBM2021017 28137 Prevotella veroralis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024526 Microbes metabolize substances PMDBM2021017 28137 Prevotella veroralis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024527 Microbes metabolize substances PMDBM2021017 28137 Prevotella veroralis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024528 Microbes metabolize substances PMDBM2009485 1926672 Prevotellamassilia PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024529 Microbes metabolize substances PMDBM2009485 1926672 Prevotellamassilia PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024530 Microbes metabolize substances PMDBM2009485 1926672 Prevotellamassilia PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024531 Microbes metabolize substances PMDBM2009485 1926672 Prevotellamassilia PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024532 Microbes metabolize substances PMDBM2009485 1926672 Prevotellamassilia PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024533 Microbes metabolize substances PMDBM2009485 1926672 Prevotellamassilia PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024534 Microbes metabolize substances PMDBM2009485 1926672 Prevotellamassilia PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024537 Microbes metabolize substances PMDBM2009485 1926672 Prevotellamassilia PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024538 Microbes metabolize substances PMDBM2009485 1926672 Prevotellamassilia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024539 Microbes metabolize substances PMDBM2009485 1926672 Prevotellamassilia PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024540 Microbes metabolize substances PMDBM2009485 1926672 Prevotellamassilia PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024541 Microbes metabolize substances PMDBM2009485 1926672 Prevotellamassilia PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024542 Microbes metabolize substances PMDBM2009485 1926672 Prevotellamassilia PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024543 Microbes metabolize substances PMDBM2009485 1926672 Prevotellamassilia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024544 Microbes metabolize substances PMDBM2009485 1926672 Prevotellamassilia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024545 Microbes metabolize substances PMDBM2021679 1926673 Prevotellamassilia sp000437675 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024546 Microbes metabolize substances PMDBM2021679 1926673 Prevotellamassilia sp000437675 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024547 Microbes metabolize substances PMDBM2021679 1926673 Prevotellamassilia sp000437675 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024548 Microbes metabolize substances PMDBM2021679 1926673 Prevotellamassilia sp000437675 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024549 Microbes metabolize substances PMDBM2021679 1926673 Prevotellamassilia sp000437675 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024550 Microbes metabolize substances PMDBM2021680 1852370 Prevotellamassilia timonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024551 Microbes metabolize substances PMDBM2021680 1852370 Prevotellamassilia timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024552 Microbes metabolize substances PMDBM2021680 1852370 Prevotellamassilia timonensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024553 Microbes metabolize substances PMDBM2021680 1852370 Prevotellamassilia timonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024554 Microbes metabolize substances PMDBM2021680 1852370 Prevotellamassilia timonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024555 Microbes metabolize substances PMDBM336 31957 Propionibacteriaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024556 Microbes metabolize substances PMDBM336 31957 Propionibacteriaceae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20024557 Microbes metabolize substances PMDBM336 31957 Propionibacteriaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024558 Microbes metabolize substances PMDBM336 31957 Propionibacteriaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024559 Microbes metabolize substances PMDBM336 31957 Propionibacteriaceae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024561 Microbes metabolize substances PMDBM336 31957 Propionibacteriaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024563 Microbes metabolize substances PMDBM336 31957 Propionibacteriaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024564 Microbes metabolize substances PMDBM336 31957 Propionibacteriaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024565 Microbes metabolize substances PMDBM336 31957 Propionibacteriaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024566 Microbes metabolize substances PMDBM336 31957 Propionibacteriaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024569 Microbes metabolize substances PMDBM336 31957 Propionibacteriaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024570 Microbes metabolize substances PMDBM336 31957 Propionibacteriaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024571 Microbes metabolize substances PMDBM336 31957 Propionibacteriaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024573 Microbes metabolize substances PMDBM2021020 1744 Propionibacterium freudenreichii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024574 Microbes metabolize substances PMDBM2021020 1744 Propionibacterium freudenreichii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024575 Microbes metabolize substances PMDBM2021020 1744 Propionibacterium freudenreichii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024576 Microbes metabolize substances PMDBM2021020 1744 Propionibacterium freudenreichii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024577 Microbes metabolize substances PMDBM2021020 1744 Propionibacterium freudenreichii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024578 Microbes metabolize substances PMDBM2021020 1744 Propionibacterium freudenreichii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024579 Microbes metabolize substances PMDBM2021020 1744 Propionibacterium freudenreichii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024582 Microbes metabolize substances PMDBM2021020 1744 Propionibacterium freudenreichii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024583 Microbes metabolize substances PMDBM2021020 1744 Propionibacterium freudenreichii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024584 Microbes metabolize substances PMDBM2021020 1744 Propionibacterium freudenreichii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024585 Microbes metabolize substances PMDBM2021020 1744 Propionibacterium freudenreichii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024586 Microbes metabolize substances PMDBM2021020 1744 Propionibacterium freudenreichii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024587 Microbes metabolize substances PMDBM2021020 1744 Propionibacterium freudenreichii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024588 Microbes metabolize substances PMDBM2021025 584 Proteus mirabilis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024589 Microbes metabolize substances PMDBM2021025 584 Proteus mirabilis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024590 Microbes metabolize substances PMDBM2021025 584 Proteus mirabilis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024591 Microbes metabolize substances PMDBM2021025 584 Proteus mirabilis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024593 Microbes metabolize substances PMDBM2021025 584 Proteus mirabilis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024595 Microbes metabolize substances PMDBM2021025 584 Proteus mirabilis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024596 Microbes metabolize substances PMDBM2021025 584 Proteus mirabilis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024597 Microbes metabolize substances PMDBM2021025 584 Proteus mirabilis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024598 Microbes metabolize substances PMDBM2021025 584 Proteus mirabilis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024601 Microbes metabolize substances PMDBM2021025 584 Proteus mirabilis PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20024602 Microbes metabolize substances PMDBM2021025 584 Proteus mirabilis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024603 Microbes metabolize substances PMDBM2021025 584 Proteus mirabilis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024604 Microbes metabolize substances PMDBM2021025 584 Proteus mirabilis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024606 Microbes metabolize substances PMDBM2021025 584 Proteus mirabilis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024607 Microbes metabolize substances PMDBM2021025 584 Proteus mirabilis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024608 Microbes metabolize substances PMDBM2021025 584 Proteus mirabilis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024609 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024610 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20024611 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024612 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024613 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024615 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024617 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024618 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024619 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024620 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024623 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20024624 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024625 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024626 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20024627 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024628 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024630 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024631 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024632 Microbes metabolize substances PMDBM2020239 102862 Proteus penneri PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024633 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024634 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024635 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024636 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024638 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024640 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024641 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024642 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024643 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024646 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20024647 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20024648 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024649 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024650 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024651 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024653 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024654 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024655 Microbes metabolize substances PMDBM2009490 n.a. Proteus sp001722135 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024656 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024657 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024658 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024659 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024661 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024663 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024664 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024665 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024666 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024669 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20024670 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20024671 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024672 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024673 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024674 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024676 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024677 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024678 Microbes metabolize substances PMDBM2021681 1574161 Proteus terrae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024679 Microbes metabolize substances PMDBM2021026 585 Proteus vulgaris A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024680 Microbes metabolize substances PMDBM2021026 585 Proteus vulgaris A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024681 Microbes metabolize substances PMDBM2021026 585 Proteus vulgaris A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024682 Microbes metabolize substances PMDBM2021026 585 Proteus vulgaris A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024684 Microbes metabolize substances PMDBM2021026 585 Proteus vulgaris A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024686 Microbes metabolize substances PMDBM2021026 585 Proteus vulgaris A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024687 Microbes metabolize substances PMDBM2021026 585 Proteus vulgaris A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024688 Microbes metabolize substances PMDBM2021026 585 Proteus vulgaris A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024689 Microbes metabolize substances PMDBM2021026 585 Proteus vulgaris A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024692 Microbes metabolize substances PMDBM2021026 585 Proteus vulgaris A PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20024693 Microbes metabolize substances PMDBM2021026 585 Proteus vulgaris A PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20024694 Microbes metabolize substances PMDBM2021026 585 Proteus vulgaris A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024695 Microbes metabolize substances PMDBM2021026 585 Proteus vulgaris A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024696 Microbes metabolize substances PMDBM2021026 585 Proteus vulgaris A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024697 Microbes metabolize substances PMDBM2021026 585 Proteus vulgaris A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024699 Microbes metabolize substances PMDBM2021026 585 Proteus vulgaris A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024700 Microbes metabolize substances PMDBM2021026 585 Proteus vulgaris A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024701 Microbes metabolize substances PMDBM2021682 1841868 Provencibacterium massiliense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024702 Microbes metabolize substances PMDBM2021682 1841868 Provencibacterium massiliense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024703 Microbes metabolize substances PMDBM2021682 1841868 Provencibacterium massiliense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024704 Microbes metabolize substances PMDBM2021682 1841868 Provencibacterium massiliense PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024706 Microbes metabolize substances PMDBM2021682 1841868 Provencibacterium massiliense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024708 Microbes metabolize substances PMDBM2021682 1841868 Provencibacterium massiliense PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20024709 Microbes metabolize substances PMDBM2021682 1841868 Provencibacterium massiliense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024710 Microbes metabolize substances PMDBM2021682 1841868 Provencibacterium massiliense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024711 Microbes metabolize substances PMDBM2021682 1841868 Provencibacterium massiliense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024712 Microbes metabolize substances PMDBM2021682 1841868 Provencibacterium massiliense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024715 Microbes metabolize substances PMDBM2021682 1841868 Provencibacterium massiliense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024716 Microbes metabolize substances PMDBM2021682 1841868 Provencibacterium massiliense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024717 Microbes metabolize substances PMDBM2021682 1841868 Provencibacterium massiliense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024718 Microbes metabolize substances PMDBM2021682 1841868 Provencibacterium massiliense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024720 Microbes metabolize substances PMDBM2021682 1841868 Provencibacterium massiliense PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024721 Microbes metabolize substances PMDBM2021682 1841868 Provencibacterium massiliense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024722 Microbes metabolize substances PMDBM2021682 1841868 Provencibacterium massiliense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024723 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024724 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024725 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024726 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20024727 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024728 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024729 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024730 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024733 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20024734 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20024735 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024736 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024737 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024738 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024739 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024740 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024741 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024742 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024743 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024744 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024745 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024746 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024747 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024748 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024749 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024752 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20024753 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20024754 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024755 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024756 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024757 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024758 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024759 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024760 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024761 Microbes metabolize substances PMDBM2020240 126385 Providencia alcalifaciens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024762 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri C PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024763 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri C PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024764 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri C PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024765 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri C PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024766 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri C PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024767 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri C PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024768 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri C PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024771 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri C PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20024772 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri C PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20024773 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri C PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024774 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri C PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024775 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri C PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024776 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri C PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024777 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri C PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024778 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri C PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024779 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri C PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024780 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri D PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024781 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri D PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024782 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri D PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024783 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri D PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024784 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri D PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024785 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri D PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024786 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri D PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024789 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri D PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20024790 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri D PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20024791 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri D PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024792 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri D PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024793 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri D PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024794 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri D PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024795 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri D PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024796 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri D PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024797 Microbes metabolize substances PMDBM2020241 587 Providencia rettgeri D PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024798 Microbes metabolize substances PMDBM2021340 158850 Providencia rustigianii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024799 Microbes metabolize substances PMDBM2021340 158850 Providencia rustigianii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024800 Microbes metabolize substances PMDBM2021340 158850 Providencia rustigianii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024801 Microbes metabolize substances PMDBM2021340 158850 Providencia rustigianii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024802 Microbes metabolize substances PMDBM2021340 158850 Providencia rustigianii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024803 Microbes metabolize substances PMDBM2021340 158850 Providencia rustigianii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024804 Microbes metabolize substances PMDBM2021340 158850 Providencia rustigianii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024807 Microbes metabolize substances PMDBM2021340 158850 Providencia rustigianii PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20024808 Microbes metabolize substances PMDBM2021340 158850 Providencia rustigianii PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20024809 Microbes metabolize substances PMDBM2021340 158850 Providencia rustigianii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024810 Microbes metabolize substances PMDBM2021340 158850 Providencia rustigianii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024811 Microbes metabolize substances PMDBM2021340 158850 Providencia rustigianii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024812 Microbes metabolize substances PMDBM2021340 158850 Providencia rustigianii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024813 Microbes metabolize substances PMDBM2021340 158850 Providencia rustigianii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024814 Microbes metabolize substances PMDBM2021340 158850 Providencia rustigianii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024815 Microbes metabolize substances PMDBM2021340 158850 Providencia rustigianii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024816 Microbes metabolize substances PMDBM2021340 158850 Providencia rustigianii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024817 Microbes metabolize substances PMDBM2020242 588 Providencia stuartii B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024818 Microbes metabolize substances PMDBM2020242 588 Providencia stuartii B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024819 Microbes metabolize substances PMDBM2020242 588 Providencia stuartii B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024820 Microbes metabolize substances PMDBM2020242 588 Providencia stuartii B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024821 Microbes metabolize substances PMDBM2020242 588 Providencia stuartii B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024822 Microbes metabolize substances PMDBM2020242 588 Providencia stuartii B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024823 Microbes metabolize substances PMDBM2020242 588 Providencia stuartii B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024826 Microbes metabolize substances PMDBM2020242 588 Providencia stuartii B PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20024827 Microbes metabolize substances PMDBM2020242 588 Providencia stuartii B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024828 Microbes metabolize substances PMDBM2020242 588 Providencia stuartii B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024829 Microbes metabolize substances PMDBM2020242 588 Providencia stuartii B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024830 Microbes metabolize substances PMDBM2020242 588 Providencia stuartii B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024831 Microbes metabolize substances PMDBM2020242 588 Providencia stuartii B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024832 Microbes metabolize substances PMDBM2020242 588 Providencia stuartii B PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024833 Microbes metabolize substances PMDBM2020242 588 Providencia stuartii B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024834 Microbes metabolize substances PMDBM2020242 588 Providencia stuartii B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024835 Microbes metabolize substances PMDBM2021683 2055881 Pseudescherichia sp002298805 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024836 Microbes metabolize substances PMDBM2021683 2055881 Pseudescherichia sp002298805 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024837 Microbes metabolize substances PMDBM2021683 2055881 Pseudescherichia sp002298805 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024838 Microbes metabolize substances PMDBM2021683 2055881 Pseudescherichia sp002298805 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024839 Microbes metabolize substances PMDBM2021683 2055881 Pseudescherichia sp002298805 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024840 Microbes metabolize substances PMDBM2021683 2055881 Pseudescherichia sp002298805 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024841 Microbes metabolize substances PMDBM2021683 2055881 Pseudescherichia sp002298805 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024844 Microbes metabolize substances PMDBM2021683 2055881 Pseudescherichia sp002298805 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024845 Microbes metabolize substances PMDBM2021683 2055881 Pseudescherichia sp002298805 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024846 Microbes metabolize substances PMDBM2021683 2055881 Pseudescherichia sp002298805 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024847 Microbes metabolize substances PMDBM2021683 2055881 Pseudescherichia sp002298805 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024848 Microbes metabolize substances PMDBM2021683 2055881 Pseudescherichia sp002298805 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024849 Microbes metabolize substances PMDBM2021683 2055881 Pseudescherichia sp002298805 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024850 Microbes metabolize substances PMDBM2021683 2055881 Pseudescherichia sp002298805 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024851 Microbes metabolize substances PMDBM2021683 2055881 Pseudescherichia sp002298805 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024852 Microbes metabolize substances PMDBM2021684 566 Pseudescherichia vulneris PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024853 Microbes metabolize substances PMDBM2021684 566 Pseudescherichia vulneris PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024854 Microbes metabolize substances PMDBM2021684 566 Pseudescherichia vulneris PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024855 Microbes metabolize substances PMDBM2021684 566 Pseudescherichia vulneris PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024856 Microbes metabolize substances PMDBM2021684 566 Pseudescherichia vulneris PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024857 Microbes metabolize substances PMDBM2021684 566 Pseudescherichia vulneris PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024858 Microbes metabolize substances PMDBM2021684 566 Pseudescherichia vulneris PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024861 Microbes metabolize substances PMDBM2021684 566 Pseudescherichia vulneris PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024862 Microbes metabolize substances PMDBM2021684 566 Pseudescherichia vulneris PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024863 Microbes metabolize substances PMDBM2021684 566 Pseudescherichia vulneris PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024864 Microbes metabolize substances PMDBM2021684 566 Pseudescherichia vulneris PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024865 Microbes metabolize substances PMDBM2021684 566 Pseudescherichia vulneris PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024866 Microbes metabolize substances PMDBM2021684 566 Pseudescherichia vulneris PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024867 Microbes metabolize substances PMDBM2021684 566 Pseudescherichia vulneris PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024868 Microbes metabolize substances PMDBM2021684 566 Pseudescherichia vulneris PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024869 Microbes metabolize substances PMDBM2009502 n.a. Pseudobutyrivibrio fibrisolvens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024870 Microbes metabolize substances PMDBM2009502 n.a. Pseudobutyrivibrio fibrisolvens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024871 Microbes metabolize substances PMDBM2009502 n.a. Pseudobutyrivibrio fibrisolvens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024872 Microbes metabolize substances PMDBM2009502 n.a. Pseudobutyrivibrio fibrisolvens PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024874 Microbes metabolize substances PMDBM2009502 n.a. Pseudobutyrivibrio fibrisolvens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024876 Microbes metabolize substances PMDBM2009502 n.a. Pseudobutyrivibrio fibrisolvens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024877 Microbes metabolize substances PMDBM2009502 n.a. Pseudobutyrivibrio fibrisolvens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024878 Microbes metabolize substances PMDBM2009502 n.a. Pseudobutyrivibrio fibrisolvens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024879 Microbes metabolize substances PMDBM2009502 n.a. Pseudobutyrivibrio fibrisolvens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024882 Microbes metabolize substances PMDBM2009502 n.a. Pseudobutyrivibrio fibrisolvens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024883 Microbes metabolize substances PMDBM2009502 n.a. Pseudobutyrivibrio fibrisolvens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024884 Microbes metabolize substances PMDBM2009502 n.a. Pseudobutyrivibrio fibrisolvens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024885 Microbes metabolize substances PMDBM2009502 n.a. Pseudobutyrivibrio fibrisolvens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024887 Microbes metabolize substances PMDBM2009502 n.a. Pseudobutyrivibrio fibrisolvens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024888 Microbes metabolize substances PMDBM2009502 n.a. Pseudobutyrivibrio fibrisolvens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024889 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024890 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024891 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024892 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024894 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024896 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024897 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024898 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024899 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20024900 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20024901 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024903 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20024906 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20024907 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20024908 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20024909 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024910 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024913 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20024916 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024917 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024920 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024921 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024922 Microbes metabolize substances PMDBM2009503 1017280 Pseudoflavonifractor PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024923 Microbes metabolize substances PMDBM2020174 106588 Pseudoflavonifractor capillosus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024924 Microbes metabolize substances PMDBM2020174 106588 Pseudoflavonifractor capillosus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20024925 Microbes metabolize substances PMDBM2020174 106588 Pseudoflavonifractor capillosus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024926 Microbes metabolize substances PMDBM2020174 106588 Pseudoflavonifractor capillosus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024927 Microbes metabolize substances PMDBM2020174 106588 Pseudoflavonifractor capillosus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024929 Microbes metabolize substances PMDBM2020174 106588 Pseudoflavonifractor capillosus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20024931 Microbes metabolize substances PMDBM2020174 106588 Pseudoflavonifractor capillosus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024932 Microbes metabolize substances PMDBM2020174 106588 Pseudoflavonifractor capillosus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024933 Microbes metabolize substances PMDBM2020174 106588 Pseudoflavonifractor capillosus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024934 Microbes metabolize substances PMDBM2020174 106588 Pseudoflavonifractor capillosus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024937 Microbes metabolize substances PMDBM2020174 106588 Pseudoflavonifractor capillosus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024938 Microbes metabolize substances PMDBM2020174 106588 Pseudoflavonifractor capillosus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024939 Microbes metabolize substances PMDBM2020174 106588 Pseudoflavonifractor capillosus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024940 Microbes metabolize substances PMDBM2020174 106588 Pseudoflavonifractor capillosus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024942 Microbes metabolize substances PMDBM2020174 106588 Pseudoflavonifractor capillosus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20024943 Microbes metabolize substances PMDBM2020174 106588 Pseudoflavonifractor capillosus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024944 Microbes metabolize substances PMDBM2020174 106588 Pseudoflavonifractor capillosus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024945 Microbes metabolize substances PMDBM2021685 47886 Pseudomonas B luteola PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024946 Microbes metabolize substances PMDBM2021685 47886 Pseudomonas B luteola PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20024947 Microbes metabolize substances PMDBM2021685 47886 Pseudomonas B luteola PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024948 Microbes metabolize substances PMDBM2021685 47886 Pseudomonas B luteola PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024949 Microbes metabolize substances PMDBM2021685 47886 Pseudomonas B luteola PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024950 Microbes metabolize substances PMDBM2021685 47886 Pseudomonas B luteola PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024951 Microbes metabolize substances PMDBM2021685 47886 Pseudomonas B luteola PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024952 Microbes metabolize substances PMDBM2021685 47886 Pseudomonas B luteola PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024955 Microbes metabolize substances PMDBM2021685 47886 Pseudomonas B luteola PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024956 Microbes metabolize substances PMDBM2021685 47886 Pseudomonas B luteola PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024957 Microbes metabolize substances PMDBM2021685 47886 Pseudomonas B luteola PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024958 Microbes metabolize substances PMDBM2021685 47886 Pseudomonas B luteola PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024959 Microbes metabolize substances PMDBM2021685 47886 Pseudomonas B luteola PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024960 Microbes metabolize substances PMDBM2021685 47886 Pseudomonas B luteola PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024961 Microbes metabolize substances PMDBM2021685 47886 Pseudomonas B luteola PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024962 Microbes metabolize substances PMDBM345 135621 Pseudomonadaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024963 Microbes metabolize substances PMDBM345 135621 Pseudomonadaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024964 Microbes metabolize substances PMDBM345 135621 Pseudomonadaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024965 Microbes metabolize substances PMDBM345 135621 Pseudomonadaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024966 Microbes metabolize substances PMDBM345 135621 Pseudomonadaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024967 Microbes metabolize substances PMDBM345 135621 Pseudomonadaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024968 Microbes metabolize substances PMDBM345 135621 Pseudomonadaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024971 Microbes metabolize substances PMDBM345 135621 Pseudomonadaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024972 Microbes metabolize substances PMDBM345 135621 Pseudomonadaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024973 Microbes metabolize substances PMDBM345 135621 Pseudomonadaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024974 Microbes metabolize substances PMDBM345 135621 Pseudomonadaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024975 Microbes metabolize substances PMDBM345 135621 Pseudomonadaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024976 Microbes metabolize substances PMDBM345 135621 Pseudomonadaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024977 Microbes metabolize substances PMDBM345 135621 Pseudomonadaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20024978 Microbes metabolize substances PMDBM2020151 287 Pseudomonas E aeruginosa PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024979 Microbes metabolize substances PMDBM2020151 287 Pseudomonas E aeruginosa PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024980 Microbes metabolize substances PMDBM2020151 287 Pseudomonas E aeruginosa PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024981 Microbes metabolize substances PMDBM2020151 287 Pseudomonas E aeruginosa PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024982 Microbes metabolize substances PMDBM2020151 287 Pseudomonas E aeruginosa PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024983 Microbes metabolize substances PMDBM2020151 287 Pseudomonas E aeruginosa PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024984 Microbes metabolize substances PMDBM2020151 287 Pseudomonas E aeruginosa PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20024987 Microbes metabolize substances PMDBM2020151 287 Pseudomonas E aeruginosa PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20024988 Microbes metabolize substances PMDBM2020151 287 Pseudomonas E aeruginosa PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20024989 Microbes metabolize substances PMDBM2020151 287 Pseudomonas E aeruginosa PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024990 Microbes metabolize substances PMDBM2020151 287 Pseudomonas E aeruginosa PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024991 Microbes metabolize substances PMDBM2020151 287 Pseudomonas E aeruginosa PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20024992 Microbes metabolize substances PMDBM2021686 359110 Pseudomonas E extremaustralis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20024993 Microbes metabolize substances PMDBM2021686 359110 Pseudomonas E extremaustralis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20024994 Microbes metabolize substances PMDBM2021686 359110 Pseudomonas E extremaustralis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20024995 Microbes metabolize substances PMDBM2021686 359110 Pseudomonas E extremaustralis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20024996 Microbes metabolize substances PMDBM2021686 359110 Pseudomonas E extremaustralis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024997 Microbes metabolize substances PMDBM2021686 359110 Pseudomonas E extremaustralis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024998 Microbes metabolize substances PMDBM2021686 359110 Pseudomonas E extremaustralis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20024999 Microbes metabolize substances PMDBM2021686 359110 Pseudomonas E extremaustralis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025002 Microbes metabolize substances PMDBM2021686 359110 Pseudomonas E extremaustralis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025003 Microbes metabolize substances PMDBM2021686 359110 Pseudomonas E extremaustralis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025004 Microbes metabolize substances PMDBM2021686 359110 Pseudomonas E extremaustralis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025005 Microbes metabolize substances PMDBM2021686 359110 Pseudomonas E extremaustralis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025006 Microbes metabolize substances PMDBM2021686 359110 Pseudomonas E extremaustralis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025007 Microbes metabolize substances PMDBM2021686 359110 Pseudomonas E extremaustralis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025008 Microbes metabolize substances PMDBM2021686 359110 Pseudomonas E extremaustralis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025009 Microbes metabolize substances PMDBM2021034 296 Pseudomonas E fragi B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025010 Microbes metabolize substances PMDBM2021034 296 Pseudomonas E fragi B PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20025011 Microbes metabolize substances PMDBM2021034 296 Pseudomonas E fragi B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025012 Microbes metabolize substances PMDBM2021034 296 Pseudomonas E fragi B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025013 Microbes metabolize substances PMDBM2021034 296 Pseudomonas E fragi B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025014 Microbes metabolize substances PMDBM2021034 296 Pseudomonas E fragi B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025015 Microbes metabolize substances PMDBM2021034 296 Pseudomonas E fragi B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025016 Microbes metabolize substances PMDBM2021034 296 Pseudomonas E fragi B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025019 Microbes metabolize substances PMDBM2021034 296 Pseudomonas E fragi B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025020 Microbes metabolize substances PMDBM2021034 296 Pseudomonas E fragi B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025021 Microbes metabolize substances PMDBM2021034 296 Pseudomonas E fragi B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025022 Microbes metabolize substances PMDBM2021034 296 Pseudomonas E fragi B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025023 Microbes metabolize substances PMDBM2021034 296 Pseudomonas E fragi B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025024 Microbes metabolize substances PMDBM2021034 296 Pseudomonas E fragi B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025025 Microbes metabolize substances PMDBM2021034 296 Pseudomonas E fragi B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025026 Microbes metabolize substances PMDBM2021687 47880 Pseudomonas E fulva PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025027 Microbes metabolize substances PMDBM2021687 47880 Pseudomonas E fulva PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025028 Microbes metabolize substances PMDBM2021687 47880 Pseudomonas E fulva PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025029 Microbes metabolize substances PMDBM2021687 47880 Pseudomonas E fulva PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025030 Microbes metabolize substances PMDBM2021687 47880 Pseudomonas E fulva PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025031 Microbes metabolize substances PMDBM2021687 47880 Pseudomonas E fulva PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025032 Microbes metabolize substances PMDBM2021687 47880 Pseudomonas E fulva PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025035 Microbes metabolize substances PMDBM2021687 47880 Pseudomonas E fulva PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025036 Microbes metabolize substances PMDBM2021687 47880 Pseudomonas E fulva PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025037 Microbes metabolize substances PMDBM2021687 47880 Pseudomonas E fulva PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025038 Microbes metabolize substances PMDBM2021687 47880 Pseudomonas E fulva PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025039 Microbes metabolize substances PMDBM2021687 47880 Pseudomonas E fulva PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025040 Microbes metabolize substances PMDBM2021687 47880 Pseudomonas E fulva PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025041 Microbes metabolize substances PMDBM2021687 47880 Pseudomonas E fulva PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025042 Microbes metabolize substances PMDBM2021035 522492 Pseudomonas E massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025043 Microbes metabolize substances PMDBM2021035 522492 Pseudomonas E massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025044 Microbes metabolize substances PMDBM2021035 522492 Pseudomonas E massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025045 Microbes metabolize substances PMDBM2021035 522492 Pseudomonas E massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025046 Microbes metabolize substances PMDBM2021035 522492 Pseudomonas E massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025047 Microbes metabolize substances PMDBM2021035 522492 Pseudomonas E massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025048 Microbes metabolize substances PMDBM2021035 522492 Pseudomonas E massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025051 Microbes metabolize substances PMDBM2021035 522492 Pseudomonas E massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025052 Microbes metabolize substances PMDBM2021035 522492 Pseudomonas E massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025053 Microbes metabolize substances PMDBM2021035 522492 Pseudomonas E massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025054 Microbes metabolize substances PMDBM2021035 522492 Pseudomonas E massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025055 Microbes metabolize substances PMDBM2021035 522492 Pseudomonas E massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025056 Microbes metabolize substances PMDBM2021035 522492 Pseudomonas E massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025057 Microbes metabolize substances PMDBM2021035 522492 Pseudomonas E massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025058 Microbes metabolize substances PMDBM2020155 303 Pseudomonas E putida P PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025059 Microbes metabolize substances PMDBM2020155 303 Pseudomonas E putida P PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025060 Microbes metabolize substances PMDBM2020155 303 Pseudomonas E putida P PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025061 Microbes metabolize substances PMDBM2020155 303 Pseudomonas E putida P PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025062 Microbes metabolize substances PMDBM2020155 303 Pseudomonas E putida P PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025063 Microbes metabolize substances PMDBM2020155 303 Pseudomonas E putida P PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025064 Microbes metabolize substances PMDBM2020155 303 Pseudomonas E putida P PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025067 Microbes metabolize substances PMDBM2020155 303 Pseudomonas E putida P PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025068 Microbes metabolize substances PMDBM2020155 303 Pseudomonas E putida P PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025069 Microbes metabolize substances PMDBM2020155 303 Pseudomonas E putida P PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025070 Microbes metabolize substances PMDBM2020155 303 Pseudomonas E putida P PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025071 Microbes metabolize substances PMDBM2020155 303 Pseudomonas E putida P PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025072 Microbes metabolize substances PMDBM2020155 303 Pseudomonas E putida P PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025073 Microbes metabolize substances PMDBM2020155 303 Pseudomonas E putida P PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025074 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025075 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025076 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025077 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025078 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025079 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025080 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025083 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025084 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025085 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20025086 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025087 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025088 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025089 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD3 2,8-DHQ (including 2,4-DHQ) Environmental Chemicals Environmental Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. Drug is involved in the pathogenicity of bacteria n.a. PMID PMID: 36467581 PMDBI20025090 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025091 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025092 Microbes metabolize substances PMDBM2021688 53408 Pseudomonas citronellolis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025093 Microbes metabolize substances PMDBM2021688 53408 Pseudomonas citronellolis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025094 Microbes metabolize substances PMDBM2021688 53408 Pseudomonas citronellolis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025095 Microbes metabolize substances PMDBM2021688 53408 Pseudomonas citronellolis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025096 Microbes metabolize substances PMDBM2021688 53408 Pseudomonas citronellolis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025097 Microbes metabolize substances PMDBM2021688 53408 Pseudomonas citronellolis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025098 Microbes metabolize substances PMDBM2021688 53408 Pseudomonas citronellolis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025101 Microbes metabolize substances PMDBM2021688 53408 Pseudomonas citronellolis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025102 Microbes metabolize substances PMDBM2021688 53408 Pseudomonas citronellolis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025103 Microbes metabolize substances PMDBM2021688 53408 Pseudomonas citronellolis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20025104 Microbes metabolize substances PMDBM2021688 53408 Pseudomonas citronellolis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025105 Microbes metabolize substances PMDBM2021688 53408 Pseudomonas citronellolis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025106 Microbes metabolize substances PMDBM2021688 53408 Pseudomonas citronellolis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025107 Microbes metabolize substances PMDBM2021688 53408 Pseudomonas citronellolis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025108 Microbes metabolize substances PMDBM2021688 53408 Pseudomonas citronellolis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025109 Microbes metabolize substances PMDBM2020155 303 Pseudomonas putida PMDBD30 Altretamine Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. unknown toxicity increased n.a. n.a. n.a. "Lead to similar toxic effects as seen with melamine;Substrate similar(no evidence)" n.a. PMID PMID: 36467581 PMDBI20025110 Microbes metabolize substances PMDBM2009513 1929305 Pygmaiobacter PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025111 Microbes metabolize substances PMDBM2009513 1929305 Pygmaiobacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025112 Microbes metabolize substances PMDBM2009513 1929305 Pygmaiobacter PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025113 Microbes metabolize substances PMDBM2009513 1929305 Pygmaiobacter PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025114 Microbes metabolize substances PMDBM2009513 1929305 Pygmaiobacter PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025115 Microbes metabolize substances PMDBM2021689 1917873 Pygmaiobacter massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025116 Microbes metabolize substances PMDBM2021689 1917873 Pygmaiobacter massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025117 Microbes metabolize substances PMDBM2021689 1917873 Pygmaiobacter massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025118 Microbes metabolize substances PMDBM2021689 1917873 Pygmaiobacter massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025119 Microbes metabolize substances PMDBM2021689 1917873 Pygmaiobacter massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025120 Microbes metabolize substances PMDBM2021689 1917873 Pygmaiobacter massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025121 Microbes metabolize substances PMDBM2021689 1917873 Pygmaiobacter massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025124 Microbes metabolize substances PMDBM2021689 1917873 Pygmaiobacter massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025125 Microbes metabolize substances PMDBM2021689 1917873 Pygmaiobacter massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025126 Microbes metabolize substances PMDBM2021689 1917873 Pygmaiobacter massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025127 Microbes metabolize substances PMDBM2021689 1917873 Pygmaiobacter massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025128 Microbes metabolize substances PMDBM2021689 1917873 Pygmaiobacter massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025129 Microbes metabolize substances PMDBM2021689 1917873 Pygmaiobacter massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025130 Microbes metabolize substances PMDBM2021689 1917873 Pygmaiobacter massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025131 Microbes metabolize substances PMDBM2009515 638847 Pyramidobacter PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025132 Microbes metabolize substances PMDBM2009515 638847 Pyramidobacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025133 Microbes metabolize substances PMDBM2009515 638847 Pyramidobacter PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025134 Microbes metabolize substances PMDBM2009515 638847 Pyramidobacter PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025135 Microbes metabolize substances PMDBM2009515 638847 Pyramidobacter PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025136 Microbes metabolize substances PMDBM2021046 638849 Pyramidobacter piscolens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025137 Microbes metabolize substances PMDBM2021046 638849 Pyramidobacter piscolens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025138 Microbes metabolize substances PMDBM2021046 638849 Pyramidobacter piscolens PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025139 Microbes metabolize substances PMDBM2021046 638849 Pyramidobacter piscolens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025140 Microbes metabolize substances PMDBM2021046 638849 Pyramidobacter piscolens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025141 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025142 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025143 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025144 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025146 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025148 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025149 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025150 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025151 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025152 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025153 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025155 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20025158 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20025159 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20025160 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025161 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025164 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20025167 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025168 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025171 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025172 Microbes metabolize substances PMDBM2009517 n.a. o Oscillospirales f CAG-272 g QALR01 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025173 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025174 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025175 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025176 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025178 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025180 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025181 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025182 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025183 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025184 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025185 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025187 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20025190 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20025191 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20025192 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025193 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025196 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20025199 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025200 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025203 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025204 Microbes metabolize substances PMDBM2009518 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025205 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025206 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025207 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025208 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025210 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025212 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025213 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025214 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025215 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025216 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025217 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025219 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20025222 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20025223 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20025224 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025225 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025228 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20025231 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025232 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025235 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025236 Microbes metabolize substances PMDBM2009519 n.a. c Clostridia o 4C28d-15 f CAG-727 g QALS01 s QALS01 sp003150575 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025237 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025238 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025239 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025240 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025244 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025248 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025249 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025250 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025251 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025253 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025255 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025257 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20025262 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20025264 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20025266 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025268 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025274 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20025280 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025281 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025285 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025286 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025288 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025290 Microbes metabolize substances PMDBM2009520 n.a. o Christensenellales f QALW01 g QALW01 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20025291 Microbes metabolize substances PMDBM2009521 n.a. o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025292 Microbes metabolize substances PMDBM2009521 n.a. o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025293 Microbes metabolize substances PMDBM2009521 n.a. o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025294 Microbes metabolize substances PMDBM2009521 n.a. o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025295 Microbes metabolize substances PMDBM2009521 n.a. o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025296 Microbes metabolize substances PMDBM2009521 n.a. o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025297 Microbes metabolize substances PMDBM2009521 n.a. o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20025299 Microbes metabolize substances PMDBM2009521 n.a. o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20025300 Microbes metabolize substances PMDBM2009521 n.a. o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20025301 Microbes metabolize substances PMDBM2009521 n.a. o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025304 Microbes metabolize substances PMDBM2009521 n.a. o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20025308 Microbes metabolize substances PMDBM2009521 n.a. o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025309 Microbes metabolize substances PMDBM2009521 n.a. o Christensenellales f QALW01 g QALW01 s QALW01 sp003150515 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025310 Microbes metabolize substances PMDBM2009522 n.a. o Coriobacteriales f QAMH01 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025311 Microbes metabolize substances PMDBM2009522 n.a. o Coriobacteriales f QAMH01 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025312 Microbes metabolize substances PMDBM2009522 n.a. o Coriobacteriales f QAMH01 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025313 Microbes metabolize substances PMDBM2009522 n.a. o Coriobacteriales f QAMH01 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025314 Microbes metabolize substances PMDBM2009522 n.a. o Coriobacteriales f QAMH01 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025315 Microbes metabolize substances PMDBM2009522 n.a. o Coriobacteriales f QAMH01 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025316 Microbes metabolize substances PMDBM2009522 n.a. o Coriobacteriales f QAMH01 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025319 Microbes metabolize substances PMDBM2009522 n.a. o Coriobacteriales f QAMH01 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025320 Microbes metabolize substances PMDBM2009522 n.a. o Coriobacteriales f QAMH01 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025321 Microbes metabolize substances PMDBM2009522 n.a. o Coriobacteriales f QAMH01 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025322 Microbes metabolize substances PMDBM2009522 n.a. o Coriobacteriales f QAMH01 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025323 Microbes metabolize substances PMDBM2009522 n.a. o Coriobacteriales f QAMH01 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025324 Microbes metabolize substances PMDBM2009522 n.a. o Coriobacteriales f QAMH01 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025325 Microbes metabolize substances PMDBM2009523 n.a. o Coriobacteriales f QAMH01 g QAMH01 s QAMH01 sp003149935 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025326 Microbes metabolize substances PMDBM2009523 n.a. o Coriobacteriales f QAMH01 g QAMH01 s QAMH01 sp003149935 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025327 Microbes metabolize substances PMDBM2009523 n.a. o Coriobacteriales f QAMH01 g QAMH01 s QAMH01 sp003149935 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025328 Microbes metabolize substances PMDBM2009524 n.a. f Gastranaerophilaceae g QAMI01 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025329 Microbes metabolize substances PMDBM2009524 n.a. f Gastranaerophilaceae g QAMI01 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025330 Microbes metabolize substances PMDBM2009524 n.a. f Gastranaerophilaceae g QAMI01 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025331 Microbes metabolize substances PMDBM2009524 n.a. f Gastranaerophilaceae g QAMI01 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025332 Microbes metabolize substances PMDBM2009524 n.a. f Gastranaerophilaceae g QAMI01 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025333 Microbes metabolize substances PMDBM2009524 n.a. f Gastranaerophilaceae g QAMI01 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025334 Microbes metabolize substances PMDBM2009524 n.a. f Gastranaerophilaceae g QAMI01 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025335 Microbes metabolize substances PMDBM2009524 n.a. f Gastranaerophilaceae g QAMI01 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025336 Microbes metabolize substances PMDBM2009524 n.a. f Gastranaerophilaceae g QAMI01 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025338 Microbes metabolize substances PMDBM2009524 n.a. f Gastranaerophilaceae g QAMI01 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025340 Microbes metabolize substances PMDBM2009524 n.a. f Gastranaerophilaceae g QAMI01 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025341 Microbes metabolize substances PMDBM2009524 n.a. f Gastranaerophilaceae g QAMI01 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025342 Microbes metabolize substances PMDBM2009524 n.a. f Gastranaerophilaceae g QAMI01 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025343 Microbes metabolize substances PMDBM2009524 n.a. f Gastranaerophilaceae g QAMI01 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025348 Microbes metabolize substances PMDBM2009524 n.a. f Gastranaerophilaceae g QAMI01 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025349 Microbes metabolize substances PMDBM2009524 n.a. f Gastranaerophilaceae g QAMI01 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025353 Microbes metabolize substances PMDBM2009525 n.a. f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025354 Microbes metabolize substances PMDBM2009525 n.a. f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025355 Microbes metabolize substances PMDBM2009525 n.a. f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025356 Microbes metabolize substances PMDBM2009525 n.a. f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025358 Microbes metabolize substances PMDBM2009525 n.a. f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025360 Microbes metabolize substances PMDBM2009525 n.a. f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025361 Microbes metabolize substances PMDBM2009525 n.a. f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025362 Microbes metabolize substances PMDBM2009525 n.a. f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025363 Microbes metabolize substances PMDBM2009525 n.a. f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025366 Microbes metabolize substances PMDBM2009525 n.a. f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025367 Microbes metabolize substances PMDBM2009525 n.a. f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025368 Microbes metabolize substances PMDBM2009525 n.a. f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025369 Microbes metabolize substances PMDBM2009525 n.a. f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025371 Microbes metabolize substances PMDBM2009525 n.a. f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025372 Microbes metabolize substances PMDBM2009525 n.a. f Ruminococcaceae g QAMM01 s QAMM01 sp003150405 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025373 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025375 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20025376 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025378 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025380 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025382 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025384 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025386 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025388 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025390 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025391 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025392 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025396 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20025400 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20025401 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20025402 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025404 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025407 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20025410 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20025411 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025413 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025418 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025420 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025422 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025424 Microbes metabolize substances PMDBM2009526 n.a. o Oscillospirales f QAMX01 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20025425 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025426 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025427 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025428 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025430 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025432 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025433 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025434 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025435 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025436 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025437 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025439 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20025442 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20025443 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20025444 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025445 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025448 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20025451 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20025452 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025453 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025456 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025457 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025458 Microbes metabolize substances PMDBM2009527 n.a. o Oscillospirales f QAMX01 g QAMX01 s QAMX01 sp003149835 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025459 Microbes metabolize substances PMDBM2009528 n.a. f Christensenellaceae g QANA01 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025460 Microbes metabolize substances PMDBM2009528 n.a. f Christensenellaceae g QANA01 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025461 Microbes metabolize substances PMDBM2009528 n.a. f Christensenellaceae g QANA01 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025462 Microbes metabolize substances PMDBM2009528 n.a. f Christensenellaceae g QANA01 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025463 Microbes metabolize substances PMDBM2009528 n.a. f Christensenellaceae g QANA01 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025464 Microbes metabolize substances PMDBM2009528 n.a. f Christensenellaceae g QANA01 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025465 Microbes metabolize substances PMDBM2009528 n.a. f Christensenellaceae g QANA01 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025468 Microbes metabolize substances PMDBM2009528 n.a. f Christensenellaceae g QANA01 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025469 Microbes metabolize substances PMDBM2009528 n.a. f Christensenellaceae g QANA01 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025470 Microbes metabolize substances PMDBM2009528 n.a. f Christensenellaceae g QANA01 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025471 Microbes metabolize substances PMDBM2009528 n.a. f Christensenellaceae g QANA01 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025472 Microbes metabolize substances PMDBM2009529 n.a. o Christensenellales f QAND01 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025473 Microbes metabolize substances PMDBM2009529 n.a. o Christensenellales f QAND01 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20025474 Microbes metabolize substances PMDBM2009529 n.a. o Christensenellales f QAND01 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025475 Microbes metabolize substances PMDBM2009529 n.a. o Christensenellales f QAND01 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025476 Microbes metabolize substances PMDBM2009529 n.a. o Christensenellales f QAND01 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025477 Microbes metabolize substances PMDBM2009529 n.a. o Christensenellales f QAND01 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025478 Microbes metabolize substances PMDBM2009529 n.a. o Christensenellales f QAND01 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025479 Microbes metabolize substances PMDBM2009529 n.a. o Christensenellales f QAND01 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025482 Microbes metabolize substances PMDBM2009529 n.a. o Christensenellales f QAND01 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025483 Microbes metabolize substances PMDBM2009529 n.a. o Christensenellales f QAND01 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025484 Microbes metabolize substances PMDBM2009529 n.a. o Christensenellales f QAND01 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025485 Microbes metabolize substances PMDBM2009529 n.a. o Christensenellales f QAND01 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025486 Microbes metabolize substances PMDBM2009529 n.a. o Christensenellales f QAND01 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025487 Microbes metabolize substances PMDBM2009529 n.a. o Christensenellales f QAND01 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025488 Microbes metabolize substances PMDBM2009530 n.a. f Ruminococcaceae g QANG01 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025489 Microbes metabolize substances PMDBM2009530 n.a. f Ruminococcaceae g QANG01 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025490 Microbes metabolize substances PMDBM2009530 n.a. f Ruminococcaceae g QANG01 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025491 Microbes metabolize substances PMDBM2009531 n.a. f Neisseriaceae g QFNR01 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025492 Microbes metabolize substances PMDBM2009531 n.a. f Neisseriaceae g QFNR01 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025493 Microbes metabolize substances PMDBM2009531 n.a. f Neisseriaceae g QFNR01 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025494 Microbes metabolize substances PMDBM2009531 n.a. f Neisseriaceae g QFNR01 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025495 Microbes metabolize substances PMDBM2009531 n.a. f Neisseriaceae g QFNR01 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025496 Microbes metabolize substances PMDBM2009531 n.a. f Neisseriaceae g QFNR01 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025497 Microbes metabolize substances PMDBM2009531 n.a. f Neisseriaceae g QFNR01 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025500 Microbes metabolize substances PMDBM2009531 n.a. f Neisseriaceae g QFNR01 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025501 Microbes metabolize substances PMDBM2009531 n.a. f Neisseriaceae g QFNR01 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025502 Microbes metabolize substances PMDBM2009531 n.a. f Neisseriaceae g QFNR01 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025503 Microbes metabolize substances PMDBM2009532 n.a. f Gastranaerophilaceae g QHMH01 s QHMH01 sp003258795 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025504 Microbes metabolize substances PMDBM2009532 n.a. f Gastranaerophilaceae g QHMH01 s QHMH01 sp003258795 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025505 Microbes metabolize substances PMDBM2009532 n.a. f Gastranaerophilaceae g QHMH01 s QHMH01 sp003258795 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025506 Microbes metabolize substances PMDBM2009532 n.a. f Gastranaerophilaceae g QHMH01 s QHMH01 sp003258795 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025507 Microbes metabolize substances PMDBM2009532 n.a. f Gastranaerophilaceae g QHMH01 s QHMH01 sp003258795 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025508 Microbes metabolize substances PMDBM2020159 1873497 Rahnella sp003263545 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025509 Microbes metabolize substances PMDBM2020159 1873497 Rahnella sp003263545 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20025510 Microbes metabolize substances PMDBM2020159 1873497 Rahnella sp003263545 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025511 Microbes metabolize substances PMDBM2020159 1873497 Rahnella sp003263545 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025512 Microbes metabolize substances PMDBM2020159 1873497 Rahnella sp003263545 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025514 Microbes metabolize substances PMDBM2020159 1873497 Rahnella sp003263545 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025516 Microbes metabolize substances PMDBM2020159 1873497 Rahnella sp003263545 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025517 Microbes metabolize substances PMDBM2020159 1873497 Rahnella sp003263545 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025518 Microbes metabolize substances PMDBM2020159 1873497 Rahnella sp003263545 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025519 Microbes metabolize substances PMDBM2020159 1873497 Rahnella sp003263545 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025522 Microbes metabolize substances PMDBM2020159 1873497 Rahnella sp003263545 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025523 Microbes metabolize substances PMDBM2020159 1873497 Rahnella sp003263545 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025524 Microbes metabolize substances PMDBM2020159 1873497 Rahnella sp003263545 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025525 Microbes metabolize substances PMDBM2020159 1873497 Rahnella sp003263545 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025527 Microbes metabolize substances PMDBM2020159 1873497 Rahnella sp003263545 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025528 Microbes metabolize substances PMDBM2020159 1873497 Rahnella sp003263545 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025529 Microbes metabolize substances PMDBM2020159 1873497 Rahnella sp003263545 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025530 Microbes metabolize substances PMDBM2021048 329 Ralstonia pickettii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025531 Microbes metabolize substances PMDBM2021048 329 Ralstonia pickettii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20025532 Microbes metabolize substances PMDBM2021048 329 Ralstonia pickettii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025533 Microbes metabolize substances PMDBM2021048 329 Ralstonia pickettii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025534 Microbes metabolize substances PMDBM2021048 329 Ralstonia pickettii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025535 Microbes metabolize substances PMDBM2021048 329 Ralstonia pickettii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025536 Microbes metabolize substances PMDBM2021048 329 Ralstonia pickettii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025537 Microbes metabolize substances PMDBM2021048 329 Ralstonia pickettii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025540 Microbes metabolize substances PMDBM2021048 329 Ralstonia pickettii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025541 Microbes metabolize substances PMDBM2021048 329 Ralstonia pickettii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025542 Microbes metabolize substances PMDBM2021048 329 Ralstonia pickettii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025543 Microbes metabolize substances PMDBM2021048 329 Ralstonia pickettii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025544 Microbes metabolize substances PMDBM2021048 329 Ralstonia pickettii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025545 Microbes metabolize substances PMDBM2021048 329 Ralstonia pickettii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025546 Microbes metabolize substances PMDBM2021048 329 Ralstonia pickettii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025547 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025548 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20025549 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025550 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025551 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025553 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025555 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025556 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025557 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025558 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025561 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20025562 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20025563 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025564 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025565 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20025566 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025567 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025569 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025570 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025571 Microbes metabolize substances PMDBM2021050 54291 Raoultella ornithinolytica PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025572 Microbes metabolize substances PMDBM2020186 575 Raoultella planticola PMDBD290 Doxorubicin "Therapeutic Substance; Herbal Substance" chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. unknown inactivation n.a. n.a. n.a. Raoultella planticola and otherEnterobacteriaceae increasedoxorubicin metabolism. n.a. PMID PMID: 36467581 PMDBI20025574 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025575 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025576 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025577 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025579 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025581 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025582 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025583 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025584 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025585 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025586 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025588 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20025591 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20025592 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20025593 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20025594 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025595 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025598 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20025601 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025602 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025605 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025606 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025607 Microbes metabolize substances PMDBM2009536 n.a. o Bacteroidales f UBA932 g RC9 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025608 Microbes metabolize substances PMDBM2009537 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025609 Microbes metabolize substances PMDBM2009537 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025610 Microbes metabolize substances PMDBM2009537 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025611 Microbes metabolize substances PMDBM2009537 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025613 Microbes metabolize substances PMDBM2009537 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025615 Microbes metabolize substances PMDBM2009537 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025616 Microbes metabolize substances PMDBM2009537 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025617 Microbes metabolize substances PMDBM2009537 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025618 Microbes metabolize substances PMDBM2009537 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025621 Microbes metabolize substances PMDBM2009537 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025622 Microbes metabolize substances PMDBM2009537 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025623 Microbes metabolize substances PMDBM2009537 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025625 Microbes metabolize substances PMDBM2009537 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025626 Microbes metabolize substances PMDBM2009537 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025627 Microbes metabolize substances PMDBM2009537 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000431015 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025628 Microbes metabolize substances PMDBM2009538 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025629 Microbes metabolize substances PMDBM2009538 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025630 Microbes metabolize substances PMDBM2009538 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025631 Microbes metabolize substances PMDBM2009538 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025632 Microbes metabolize substances PMDBM2009538 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025633 Microbes metabolize substances PMDBM2009538 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025634 Microbes metabolize substances PMDBM2009538 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025637 Microbes metabolize substances PMDBM2009538 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025638 Microbes metabolize substances PMDBM2009538 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025639 Microbes metabolize substances PMDBM2009538 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025640 Microbes metabolize substances PMDBM2009538 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025641 Microbes metabolize substances PMDBM2009538 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025642 Microbes metabolize substances PMDBM2009538 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025643 Microbes metabolize substances PMDBM2009538 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025644 Microbes metabolize substances PMDBM2009538 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432515 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025645 Microbes metabolize substances PMDBM2009539 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025646 Microbes metabolize substances PMDBM2009539 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025647 Microbes metabolize substances PMDBM2009539 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025648 Microbes metabolize substances PMDBM2009539 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025649 Microbes metabolize substances PMDBM2009539 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025650 Microbes metabolize substances PMDBM2009539 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025651 Microbes metabolize substances PMDBM2009539 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025654 Microbes metabolize substances PMDBM2009539 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025655 Microbes metabolize substances PMDBM2009539 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025656 Microbes metabolize substances PMDBM2009539 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025657 Microbes metabolize substances PMDBM2009539 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025658 Microbes metabolize substances PMDBM2009539 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025659 Microbes metabolize substances PMDBM2009539 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025660 Microbes metabolize substances PMDBM2009539 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000432655 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025661 Microbes metabolize substances PMDBM2009540 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025662 Microbes metabolize substances PMDBM2009540 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025663 Microbes metabolize substances PMDBM2009540 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025664 Microbes metabolize substances PMDBM2009540 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025666 Microbes metabolize substances PMDBM2009540 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025668 Microbes metabolize substances PMDBM2009540 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025669 Microbes metabolize substances PMDBM2009540 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025670 Microbes metabolize substances PMDBM2009540 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025671 Microbes metabolize substances PMDBM2009540 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025674 Microbes metabolize substances PMDBM2009540 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025675 Microbes metabolize substances PMDBM2009540 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025676 Microbes metabolize substances PMDBM2009540 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025677 Microbes metabolize substances PMDBM2009540 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025679 Microbes metabolize substances PMDBM2009540 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025680 Microbes metabolize substances PMDBM2009540 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025681 Microbes metabolize substances PMDBM2009540 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000433355 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025682 Microbes metabolize substances PMDBM2009541 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025683 Microbes metabolize substances PMDBM2009541 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025684 Microbes metabolize substances PMDBM2009541 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025685 Microbes metabolize substances PMDBM2009541 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025686 Microbes metabolize substances PMDBM2009541 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025687 Microbes metabolize substances PMDBM2009541 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025688 Microbes metabolize substances PMDBM2009541 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025691 Microbes metabolize substances PMDBM2009541 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025692 Microbes metabolize substances PMDBM2009541 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025693 Microbes metabolize substances PMDBM2009541 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025694 Microbes metabolize substances PMDBM2009541 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025695 Microbes metabolize substances PMDBM2009541 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025696 Microbes metabolize substances PMDBM2009541 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025697 Microbes metabolize substances PMDBM2009541 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025698 Microbes metabolize substances PMDBM2009541 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000434935 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025699 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025700 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025701 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025702 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025703 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025704 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025705 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025706 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025707 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025709 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20025712 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20025713 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20025714 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025715 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025718 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20025721 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025722 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025723 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025725 Microbes metabolize substances PMDBM2009542 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp000435075 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025726 Microbes metabolize substances PMDBM2009543 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025727 Microbes metabolize substances PMDBM2009543 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025728 Microbes metabolize substances PMDBM2009543 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025729 Microbes metabolize substances PMDBM2009543 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025730 Microbes metabolize substances PMDBM2009543 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025731 Microbes metabolize substances PMDBM2009543 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025732 Microbes metabolize substances PMDBM2009543 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025735 Microbes metabolize substances PMDBM2009543 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025736 Microbes metabolize substances PMDBM2009543 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025737 Microbes metabolize substances PMDBM2009543 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025738 Microbes metabolize substances PMDBM2009543 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025739 Microbes metabolize substances PMDBM2009543 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025740 Microbes metabolize substances PMDBM2009543 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025741 Microbes metabolize substances PMDBM2009543 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025742 Microbes metabolize substances PMDBM2009543 n.a. o Bacteroidales f UBA932 g RC9 s RC9 sp001915575 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025743 Microbes metabolize substances PMDBM2009544 n.a. f Paludibacteraceae g RF16 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025744 Microbes metabolize substances PMDBM2009544 n.a. f Paludibacteraceae g RF16 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025745 Microbes metabolize substances PMDBM2009544 n.a. f Paludibacteraceae g RF16 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025746 Microbes metabolize substances PMDBM2009544 n.a. f Paludibacteraceae g RF16 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025748 Microbes metabolize substances PMDBM2009544 n.a. f Paludibacteraceae g RF16 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025750 Microbes metabolize substances PMDBM2009544 n.a. f Paludibacteraceae g RF16 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025751 Microbes metabolize substances PMDBM2009544 n.a. f Paludibacteraceae g RF16 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025752 Microbes metabolize substances PMDBM2009544 n.a. f Paludibacteraceae g RF16 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025753 Microbes metabolize substances PMDBM2009544 n.a. f Paludibacteraceae g RF16 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025756 Microbes metabolize substances PMDBM2009544 n.a. f Paludibacteraceae g RF16 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20025757 Microbes metabolize substances PMDBM2009544 n.a. f Paludibacteraceae g RF16 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025758 Microbes metabolize substances PMDBM2009544 n.a. f Paludibacteraceae g RF16 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025759 Microbes metabolize substances PMDBM2009544 n.a. f Paludibacteraceae g RF16 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025760 Microbes metabolize substances PMDBM2009544 n.a. f Paludibacteraceae g RF16 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025762 Microbes metabolize substances PMDBM2009544 n.a. f Paludibacteraceae g RF16 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025763 Microbes metabolize substances PMDBM2009544 n.a. f Paludibacteraceae g RF16 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025764 Microbes metabolize substances PMDBM2009544 n.a. f Paludibacteraceae g RF16 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025765 Microbes metabolize substances PMDBM2009545 n.a. c Alphaproteobacteria o RF32 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025766 Microbes metabolize substances PMDBM2009545 n.a. c Alphaproteobacteria o RF32 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025767 Microbes metabolize substances PMDBM2009545 n.a. c Alphaproteobacteria o RF32 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025768 Microbes metabolize substances PMDBM2009545 n.a. c Alphaproteobacteria o RF32 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025769 Microbes metabolize substances PMDBM2009545 n.a. c Alphaproteobacteria o RF32 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025770 Microbes metabolize substances PMDBM2009545 n.a. c Alphaproteobacteria o RF32 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025771 Microbes metabolize substances PMDBM2009545 n.a. c Alphaproteobacteria o RF32 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025774 Microbes metabolize substances PMDBM2009545 n.a. c Alphaproteobacteria o RF32 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025775 Microbes metabolize substances PMDBM2009545 n.a. c Alphaproteobacteria o RF32 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025776 Microbes metabolize substances PMDBM2009545 n.a. c Alphaproteobacteria o RF32 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025777 Microbes metabolize substances PMDBM2009545 n.a. c Alphaproteobacteria o RF32 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025778 Microbes metabolize substances PMDBM2009546 n.a. c Kiritimatiellae o RFP12 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20025779 Microbes metabolize substances PMDBM2009546 n.a. c Kiritimatiellae o RFP12 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20025780 Microbes metabolize substances PMDBM2009546 n.a. c Kiritimatiellae o RFP12 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025781 Microbes metabolize substances PMDBM2009546 n.a. c Kiritimatiellae o RFP12 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025782 Microbes metabolize substances PMDBM2009546 n.a. c Kiritimatiellae o RFP12 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025783 Microbes metabolize substances PMDBM2009547 75787 Rhodocyclaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025784 Microbes metabolize substances PMDBM2009547 75787 Rhodocyclaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025785 Microbes metabolize substances PMDBM2009547 75787 Rhodocyclaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025786 Microbes metabolize substances PMDBM2009547 75787 Rhodocyclaceae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025788 Microbes metabolize substances PMDBM2009547 75787 Rhodocyclaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025790 Microbes metabolize substances PMDBM2009547 75787 Rhodocyclaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025791 Microbes metabolize substances PMDBM2009547 75787 Rhodocyclaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025792 Microbes metabolize substances PMDBM2009547 75787 Rhodocyclaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025793 Microbes metabolize substances PMDBM2009547 75787 Rhodocyclaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025796 Microbes metabolize substances PMDBM2009547 75787 Rhodocyclaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025797 Microbes metabolize substances PMDBM2009547 75787 Rhodocyclaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025798 Microbes metabolize substances PMDBM2009547 75787 Rhodocyclaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025800 Microbes metabolize substances PMDBM2021059 28139 Rikenella microfusus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025801 Microbes metabolize substances PMDBM2021059 28139 Rikenella microfusus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025802 Microbes metabolize substances PMDBM2021059 28139 Rikenella microfusus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025803 Microbes metabolize substances PMDBM2021059 28139 Rikenella microfusus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025804 Microbes metabolize substances PMDBM2021059 28139 Rikenella microfusus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025805 Microbes metabolize substances PMDBM2021059 28139 Rikenella microfusus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025806 Microbes metabolize substances PMDBM2021059 28139 Rikenella microfusus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025809 Microbes metabolize substances PMDBM2021059 28139 Rikenella microfusus PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20025810 Microbes metabolize substances PMDBM2021059 28139 Rikenella microfusus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025811 Microbes metabolize substances PMDBM2021059 28139 Rikenella microfusus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025812 Microbes metabolize substances PMDBM2021059 28139 Rikenella microfusus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025813 Microbes metabolize substances PMDBM2021059 28139 Rikenella microfusus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025814 Microbes metabolize substances PMDBM2021059 28139 Rikenella microfusus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025815 Microbes metabolize substances PMDBM2021059 28139 Rikenella microfusus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025816 Microbes metabolize substances PMDBM2021059 28139 Rikenella microfusus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025817 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025818 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025819 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025820 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025822 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025824 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025825 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025826 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025827 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025828 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025829 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025831 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20025834 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20025835 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20025836 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20025837 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025838 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025841 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20025844 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025845 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025848 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025849 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD2000015 Anti-cytotoxic T-lymphocyte-associated antigen 4(CTLA-4) Therapeutic substance negative regulators of T cell proliferation and functions n.a. n.a. n.a. n.a. n.a. n.a. unknown side effect n.a. n.a. n.a. resistance to anti-CTLA-4-induced colitis n.a. PMID PMID: 36467581 PMDBI20025850 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025851 Microbes metabolize substances PMDBM351 171550 Rikenellaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025852 Microbes metabolize substances PMDBM2021060 1329796 Risungbinella massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20025853 Microbes metabolize substances PMDBM2021060 1329796 Risungbinella massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025854 Microbes metabolize substances PMDBM2021060 1329796 Risungbinella massiliensis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20025855 Microbes metabolize substances PMDBM2021060 1329796 Risungbinella massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025856 Microbes metabolize substances PMDBM2021060 1329796 Risungbinella massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025857 Microbes metabolize substances PMDBM2021060 1329796 Risungbinella massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025858 Microbes metabolize substances PMDBM2009550 n.a. f Enterobacteriaceae g RIT-PI-d PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025859 Microbes metabolize substances PMDBM2009550 n.a. f Enterobacteriaceae g RIT-PI-d PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025860 Microbes metabolize substances PMDBM2009550 n.a. f Enterobacteriaceae g RIT-PI-d PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025861 Microbes metabolize substances PMDBM2009550 n.a. f Enterobacteriaceae g RIT-PI-d PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025863 Microbes metabolize substances PMDBM2009550 n.a. f Enterobacteriaceae g RIT-PI-d PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025865 Microbes metabolize substances PMDBM2009550 n.a. f Enterobacteriaceae g RIT-PI-d PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025866 Microbes metabolize substances PMDBM2009550 n.a. f Enterobacteriaceae g RIT-PI-d PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025867 Microbes metabolize substances PMDBM2009550 n.a. f Enterobacteriaceae g RIT-PI-d PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025868 Microbes metabolize substances PMDBM2009550 n.a. f Enterobacteriaceae g RIT-PI-d PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025871 Microbes metabolize substances PMDBM2009550 n.a. f Enterobacteriaceae g RIT-PI-d PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025872 Microbes metabolize substances PMDBM2009550 n.a. f Enterobacteriaceae g RIT-PI-d PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025873 Microbes metabolize substances PMDBM2009550 n.a. f Enterobacteriaceae g RIT-PI-d PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20025874 Microbes metabolize substances PMDBM2009550 n.a. f Enterobacteriaceae g RIT-PI-d PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025875 Microbes metabolize substances PMDBM2009550 n.a. f Enterobacteriaceae g RIT-PI-d PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025877 Microbes metabolize substances PMDBM2009550 n.a. f Enterobacteriaceae g RIT-PI-d PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025878 Microbes metabolize substances PMDBM2009550 n.a. f Enterobacteriaceae g RIT-PI-d PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025879 Microbes metabolize substances PMDBM2009550 n.a. f Enterobacteriaceae g RIT-PI-d PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025880 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025881 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20025882 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025883 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025884 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025886 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025888 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025889 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025890 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025891 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025892 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025893 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025895 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20025898 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20025899 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20025900 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025901 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025904 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20025907 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025908 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025911 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025912 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025913 Microbes metabolize substances PMDBM2009551 588605 Robinsoniella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025914 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025915 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025916 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025917 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025919 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025921 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025922 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025923 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025924 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025925 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025926 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025928 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20025931 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20025932 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20025933 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025934 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025937 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20025940 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025941 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025944 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20025945 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025946 Microbes metabolize substances PMDBM2021061 180332 Robinsoniella peoriensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025947 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025948 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20025949 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025950 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025951 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025953 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025955 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025956 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025957 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025958 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025961 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20025962 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20025963 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025964 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025965 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025966 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025968 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025969 Microbes metabolize substances PMDBM2009553 n.a. Romboutsia dakarense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025970 Microbes metabolize substances PMDBM2021690 1776391 Romboutsia timonensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025971 Microbes metabolize substances PMDBM2021690 1776391 Romboutsia timonensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20025972 Microbes metabolize substances PMDBM2021690 1776391 Romboutsia timonensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025973 Microbes metabolize substances PMDBM2021690 1776391 Romboutsia timonensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025974 Microbes metabolize substances PMDBM2021690 1776391 Romboutsia timonensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025975 Microbes metabolize substances PMDBM2021690 1776391 Romboutsia timonensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025976 Microbes metabolize substances PMDBM2021690 1776391 Romboutsia timonensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025977 Microbes metabolize substances PMDBM2021690 1776391 Romboutsia timonensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20025980 Microbes metabolize substances PMDBM2021690 1776391 Romboutsia timonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20025981 Microbes metabolize substances PMDBM2021690 1776391 Romboutsia timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20025982 Microbes metabolize substances PMDBM2021690 1776391 Romboutsia timonensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025983 Microbes metabolize substances PMDBM2021690 1776391 Romboutsia timonensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025984 Microbes metabolize substances PMDBM2021690 1776391 Romboutsia timonensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20025985 Microbes metabolize substances PMDBM2021690 1776391 Romboutsia timonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025986 Microbes metabolize substances PMDBM2021690 1776391 Romboutsia timonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20025987 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20025988 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20025989 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20025990 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025992 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20025994 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025995 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025996 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20025997 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025998 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20025999 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026001 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20026004 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20026005 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20026006 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026007 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026010 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20026013 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026014 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026017 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026018 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026019 Microbes metabolize substances PMDBM353 841 Roseburia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026020 Microbes metabolize substances PMDBM2020162 301302 Roseburia faecis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. unknown toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026021 Microbes metabolize substances PMDBM2020162 301302 Roseburia faecis PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" cardiac glycoside n.a. n.a. n.a. n.a. dihydrodigoxin n.a. unknown involved in substrate metabolism n.a. n.a. n.a. inactivation n.a. PMID PMID: 36467581 PMDBI20026023 Microbes metabolize substances PMDBM2020162 301302 Roseburia faecis PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" antimicrobial n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026024 Microbes metabolize substances PMDBM2020162 301302 Roseburia faecis PMDBD1166 Dolasetron Therapeutic substance antinauseant and antiemetic n.a. n.a. n.a. n.a. duloxetine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026025 Microbes metabolize substances PMDBM2020162 301302 Roseburia faecis PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" fungal infections n.a. n.a. n.a. n.a. ketoprofen n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026026 Microbes metabolize substances PMDBM2020162 301302 Roseburia faecis PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" lower the risk of cardiovascular disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026027 Microbes metabolize substances PMDBM2020162 301302 Roseburia faecis PMDBD1298 Misoprostol Therapeutic substance reduce the risk of NSAID induced gastric ulcers n.a. n.a. n.a. n.a. misoprostol-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026028 Microbes metabolize substances PMDBM2020162 301302 Roseburia faecis PMDBD1318 Nicardipine Therapeutic substance effective in the treatment of angina and coronary spasms without showing cardiodepressant effects n.a. n.a. n.a. n.a. aminonicardipine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026029 Microbes metabolize substances PMDBM2020162 301302 Roseburia faecis PMDBD1376 Praziquantel Therapeutic substance Anti-infection n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026030 Microbes metabolize substances PMDBM2020162 301302 Roseburia faecis PMDBD750 Risperidone Therapeutic Substance second-generation antipsychotic (SGA) n.a. n.a. n.a. n.a. risperidone-M1 n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026031 Microbes metabolize substances PMDBM2020162 301302 Roseburia faecis PMDBD1406 Ropinirole Therapeutic substance Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026032 Microbes metabolize substances PMDBM2020162 301302 Roseburia faecis PMDBD816 Sulindac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. sulindac-M2 n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026033 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026034 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026035 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026036 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026038 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026040 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026041 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026042 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026043 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20026044 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20026045 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026047 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20026050 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20026051 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20026052 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026053 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026056 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20026059 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026060 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026063 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026064 Microbes metabolize substances PMDBM2020244 301301 Roseburia hominis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026065 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026066 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026067 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026068 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026069 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026071 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026073 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026074 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026075 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026076 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20026077 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20026078 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026080 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20026083 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20026084 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20026085 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026088 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20026091 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026092 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026095 Microbes metabolize substances PMDBM2020189 166486 Roseburia intestinalis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026096 Microbes metabolize substances PMDBM2020163 360807 Roseburia inulinivorans PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026097 Microbes metabolize substances PMDBM2020163 360807 Roseburia inulinivorans PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026098 Microbes metabolize substances PMDBM2020163 360807 Roseburia inulinivorans PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026099 Microbes metabolize substances PMDBM2020163 360807 Roseburia inulinivorans PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026100 Microbes metabolize substances PMDBM2020163 360807 Roseburia inulinivorans PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026101 Microbes metabolize substances PMDBM2020163 360807 Roseburia inulinivorans PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026102 Microbes metabolize substances PMDBM2020163 360807 Roseburia inulinivorans PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026105 Microbes metabolize substances PMDBM2020163 360807 Roseburia inulinivorans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026106 Microbes metabolize substances PMDBM2020163 360807 Roseburia inulinivorans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026107 Microbes metabolize substances PMDBM2020163 360807 Roseburia inulinivorans PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026108 Microbes metabolize substances PMDBM2020163 360807 Roseburia inulinivorans PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026109 Microbes metabolize substances PMDBM2020163 360807 Roseburia inulinivorans PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026110 Microbes metabolize substances PMDBM2020163 360807 Roseburia inulinivorans PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026111 Microbes metabolize substances PMDBM2020163 360807 Roseburia inulinivorans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026112 Microbes metabolize substances PMDBM2020163 360807 Roseburia inulinivorans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026113 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026114 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026115 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026116 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026117 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026118 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026119 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20026120 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20026121 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026123 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20026126 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20026127 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20026128 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026129 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026132 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20026135 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026136 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026137 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026139 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026140 Microbes metabolize substances PMDBM2021691 2049040 Roseburia sp003483745 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026141 Microbes metabolize substances PMDBM2009556 32207 Rothia PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026142 Microbes metabolize substances PMDBM2009556 32207 Rothia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026143 Microbes metabolize substances PMDBM2009556 32207 Rothia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026144 Microbes metabolize substances PMDBM2009556 32207 Rothia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026145 Microbes metabolize substances PMDBM2021346 172042 Rothia aeria PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026146 Microbes metabolize substances PMDBM2021346 172042 Rothia aeria PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026147 Microbes metabolize substances PMDBM2021346 172042 Rothia aeria PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20026148 Microbes metabolize substances PMDBM2021065 2047 Rothia dentocariosa PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026149 Microbes metabolize substances PMDBM2020164 43675 Rothia mucilaginosa PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026150 Microbes metabolize substances PMDBM2020164 43675 Rothia mucilaginosa PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026151 Microbes metabolize substances PMDBM2020164 43675 Rothia mucilaginosa A PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026152 Microbes metabolize substances PMDBM2020164 43675 Rothia mucilaginosa A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026153 Microbes metabolize substances PMDBM2020164 43675 Rothia mucilaginosa B PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026154 Microbes metabolize substances PMDBM2020164 43675 Rothia mucilaginosa B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026155 Microbes metabolize substances PMDBM2009562 n.a. Rothia sp001808955 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026156 Microbes metabolize substances PMDBM2009562 n.a. Rothia sp001808955 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026157 Microbes metabolize substances PMDBM2009563 n.a. c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026158 Microbes metabolize substances PMDBM2009563 n.a. c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026159 Microbes metabolize substances PMDBM2009563 n.a. c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026160 Microbes metabolize substances PMDBM2009563 n.a. c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026161 Microbes metabolize substances PMDBM2009563 n.a. c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026162 Microbes metabolize substances PMDBM2009563 n.a. c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026163 Microbes metabolize substances PMDBM2009563 n.a. c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026166 Microbes metabolize substances PMDBM2009563 n.a. c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026167 Microbes metabolize substances PMDBM2009563 n.a. c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026168 Microbes metabolize substances PMDBM2009563 n.a. c Alphaproteobacteria o Rs-D84 f Rs-D84 g Rs-D84 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026169 Microbes metabolize substances PMDBM2021692 1631346 Rubeoparvulum massiliense PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026170 Microbes metabolize substances PMDBM2021692 1631346 Rubeoparvulum massiliense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026171 Microbes metabolize substances PMDBM2021692 1631346 Rubeoparvulum massiliense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026172 Microbes metabolize substances PMDBM2021692 1631346 Rubeoparvulum massiliense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026173 Microbes metabolize substances PMDBM2021693 2070688 Rubneribacter badeniensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026174 Microbes metabolize substances PMDBM2021693 2070688 Rubneribacter badeniensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026175 Microbes metabolize substances PMDBM2021693 2070688 Rubneribacter badeniensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026176 Microbes metabolize substances PMDBM2009566 n.a. f Eggerthellaceae g RUG013 s RUG013 sp001486445 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026177 Microbes metabolize substances PMDBM2009566 n.a. f Eggerthellaceae g RUG013 s RUG013 sp001486445 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026178 Microbes metabolize substances PMDBM2009566 n.a. f Eggerthellaceae g RUG013 s RUG013 sp001486445 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026179 Microbes metabolize substances PMDBM2009566 n.a. f Eggerthellaceae g RUG013 s RUG013 sp001486445 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026180 Microbes metabolize substances PMDBM2009566 n.a. f Eggerthellaceae g RUG013 s RUG013 sp001486445 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026181 Microbes metabolize substances PMDBM2009566 n.a. f Eggerthellaceae g RUG013 s RUG013 sp001486445 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026182 Microbes metabolize substances PMDBM2009566 n.a. f Eggerthellaceae g RUG013 s RUG013 sp001486445 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026185 Microbes metabolize substances PMDBM2009566 n.a. f Eggerthellaceae g RUG013 s RUG013 sp001486445 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026186 Microbes metabolize substances PMDBM2009566 n.a. f Eggerthellaceae g RUG013 s RUG013 sp001486445 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026187 Microbes metabolize substances PMDBM2009566 n.a. f Eggerthellaceae g RUG013 s RUG013 sp001486445 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026188 Microbes metabolize substances PMDBM2009566 n.a. f Eggerthellaceae g RUG013 s RUG013 sp001486445 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026189 Microbes metabolize substances PMDBM2009566 n.a. f Eggerthellaceae g RUG013 s RUG013 sp001486445 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026190 Microbes metabolize substances PMDBM2009566 n.a. f Eggerthellaceae g RUG013 s RUG013 sp001486445 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026191 Microbes metabolize substances PMDBM2009567 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026192 Microbes metabolize substances PMDBM2009567 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026193 Microbes metabolize substances PMDBM2009567 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026194 Microbes metabolize substances PMDBM2009567 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026196 Microbes metabolize substances PMDBM2009567 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026198 Microbes metabolize substances PMDBM2009567 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026199 Microbes metabolize substances PMDBM2009567 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026200 Microbes metabolize substances PMDBM2009567 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026201 Microbes metabolize substances PMDBM2009567 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026204 Microbes metabolize substances PMDBM2009567 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026205 Microbes metabolize substances PMDBM2009567 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026206 Microbes metabolize substances PMDBM2009567 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026208 Microbes metabolize substances PMDBM2009567 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026209 Microbes metabolize substances PMDBM2009567 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026210 Microbes metabolize substances PMDBM2009567 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026211 Microbes metabolize substances PMDBM2009568 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 s RUG131 sp900315885 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026212 Microbes metabolize substances PMDBM2009568 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 s RUG131 sp900315885 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026213 Microbes metabolize substances PMDBM2009568 n.a. c Bacilli o RFN20 f CAG-826 g RUG131 s RUG131 sp900315885 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026214 Microbes metabolize substances PMDBM2009569 n.a. f Acutalibacteraceae g RUG420 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026215 Microbes metabolize substances PMDBM2009569 n.a. f Acutalibacteraceae g RUG420 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026216 Microbes metabolize substances PMDBM2009569 n.a. f Acutalibacteraceae g RUG420 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026217 Microbes metabolize substances PMDBM2009569 n.a. f Acutalibacteraceae g RUG420 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026219 Microbes metabolize substances PMDBM2009569 n.a. f Acutalibacteraceae g RUG420 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026221 Microbes metabolize substances PMDBM2009569 n.a. f Acutalibacteraceae g RUG420 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026222 Microbes metabolize substances PMDBM2009569 n.a. f Acutalibacteraceae g RUG420 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026223 Microbes metabolize substances PMDBM2009569 n.a. f Acutalibacteraceae g RUG420 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026224 Microbes metabolize substances PMDBM2009569 n.a. f Acutalibacteraceae g RUG420 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026227 Microbes metabolize substances PMDBM2009569 n.a. f Acutalibacteraceae g RUG420 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026228 Microbes metabolize substances PMDBM2009569 n.a. f Acutalibacteraceae g RUG420 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026229 Microbes metabolize substances PMDBM2009569 n.a. f Acutalibacteraceae g RUG420 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026230 Microbes metabolize substances PMDBM2009569 n.a. f Acutalibacteraceae g RUG420 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026232 Microbes metabolize substances PMDBM2009569 n.a. f Acutalibacteraceae g RUG420 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026233 Microbes metabolize substances PMDBM2009569 n.a. f Acutalibacteraceae g RUG420 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026234 Microbes metabolize substances PMDBM2009570 n.a. o Christensenellales f CAG-138 g RUG472 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026235 Microbes metabolize substances PMDBM2009570 n.a. o Christensenellales f CAG-138 g RUG472 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026236 Microbes metabolize substances PMDBM2009570 n.a. o Christensenellales f CAG-138 g RUG472 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026237 Microbes metabolize substances PMDBM2009570 n.a. o Christensenellales f CAG-138 g RUG472 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026238 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026239 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026240 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026241 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026242 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026244 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026246 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026247 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026248 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026249 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20026250 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20026251 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026253 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20026256 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20026257 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20026258 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026259 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026262 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20026265 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026266 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026269 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026270 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026271 Microbes metabolize substances PMDBM2009571 n.a. o Christensenellales f CAG-74 g RUG563 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026272 Microbes metabolize substances PMDBM2009572 n.a. c Bacilli o RF39 f CAG-302 g RUG705 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026273 Microbes metabolize substances PMDBM2009572 n.a. c Bacilli o RF39 f CAG-302 g RUG705 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026274 Microbes metabolize substances PMDBM2009572 n.a. c Bacilli o RF39 f CAG-302 g RUG705 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026275 Microbes metabolize substances PMDBM2009572 n.a. c Bacilli o RF39 f CAG-302 g RUG705 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026276 Microbes metabolize substances PMDBM2009572 n.a. c Bacilli o RF39 f CAG-302 g RUG705 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026277 Microbes metabolize substances PMDBM2009572 n.a. c Bacilli o RF39 f CAG-302 g RUG705 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026278 Microbes metabolize substances PMDBM2009572 n.a. c Bacilli o RF39 f CAG-302 g RUG705 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026281 Microbes metabolize substances PMDBM2009572 n.a. c Bacilli o RF39 f CAG-302 g RUG705 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026282 Microbes metabolize substances PMDBM2009572 n.a. c Bacilli o RF39 f CAG-302 g RUG705 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026283 Microbes metabolize substances PMDBM2009572 n.a. c Bacilli o RF39 f CAG-302 g RUG705 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026284 Microbes metabolize substances PMDBM2009572 n.a. c Bacilli o RF39 f CAG-302 g RUG705 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026285 Microbes metabolize substances PMDBM2009572 n.a. c Bacilli o RF39 f CAG-302 g RUG705 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026286 Microbes metabolize substances PMDBM2009572 n.a. c Bacilli o RF39 f CAG-302 g RUG705 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026287 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026288 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026289 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026290 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026292 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026294 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026295 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026296 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026297 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20026298 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20026299 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026301 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20026304 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20026305 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20026306 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026307 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026310 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20026313 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026314 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026317 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026318 Microbes metabolize substances PMDBM2009573 n.a. f Acutalibacteraceae g RUG806 s RUG806 sp900313475 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026319 Microbes metabolize substances PMDBM2009574 n.a. c Bacilli o RF39 f CAG-822 g RUG832 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026320 Microbes metabolize substances PMDBM2009574 n.a. c Bacilli o RF39 f CAG-822 g RUG832 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026321 Microbes metabolize substances PMDBM2009574 n.a. c Bacilli o RF39 f CAG-822 g RUG832 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026322 Microbes metabolize substances PMDBM2009575 n.a. f Gastranaerophilaceae g RUG841 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026323 Microbes metabolize substances PMDBM2009575 n.a. f Gastranaerophilaceae g RUG841 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026324 Microbes metabolize substances PMDBM2009575 n.a. f Gastranaerophilaceae g RUG841 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026325 Microbes metabolize substances PMDBM2009575 n.a. f Gastranaerophilaceae g RUG841 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026326 Microbes metabolize substances PMDBM2009575 n.a. f Gastranaerophilaceae g RUG841 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026327 Microbes metabolize substances PMDBM2009575 n.a. f Gastranaerophilaceae g RUG841 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026328 Microbes metabolize substances PMDBM2009576 n.a. f Gastranaerophilaceae g RUG841 s RUG841 sp900313795 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026329 Microbes metabolize substances PMDBM2009576 n.a. f Gastranaerophilaceae g RUG841 s RUG841 sp900313795 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026330 Microbes metabolize substances PMDBM2009576 n.a. f Gastranaerophilaceae g RUG841 s RUG841 sp900313795 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026331 Microbes metabolize substances PMDBM2009576 n.a. f Gastranaerophilaceae g RUG841 s RUG841 sp900313795 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026332 Microbes metabolize substances PMDBM2009576 n.a. f Gastranaerophilaceae g RUG841 s RUG841 sp900313795 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026333 Microbes metabolize substances PMDBM2009576 n.a. f Gastranaerophilaceae g RUG841 s RUG841 sp900313795 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026334 Microbes metabolize substances PMDBM2009577 n.a. Ruminiclostridium C PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20026335 Microbes metabolize substances PMDBM2009577 n.a. Ruminiclostridium C PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20026336 Microbes metabolize substances PMDBM2009577 n.a. Ruminiclostridium C PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20026338 Microbes metabolize substances PMDBM2009577 n.a. Ruminiclostridium C PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20026339 Microbes metabolize substances PMDBM2009577 n.a. Ruminiclostridium C PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20026340 Microbes metabolize substances PMDBM2009577 n.a. Ruminiclostridium C PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20026341 Microbes metabolize substances PMDBM2009577 n.a. Ruminiclostridium C PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026344 Microbes metabolize substances PMDBM2009577 n.a. Ruminiclostridium C PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20026347 Microbes metabolize substances PMDBM2009577 n.a. Ruminiclostridium C PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20026349 Microbes metabolize substances PMDBM2009577 n.a. Ruminiclostridium C PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026350 Microbes metabolize substances PMDBM2009577 n.a. Ruminiclostridium C PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026351 Microbes metabolize substances PMDBM2009577 n.a. Ruminiclostridium C PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026352 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium C sp000435295 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026353 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium C sp000435295 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20026354 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium C sp000435295 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20026355 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium C sp000435295 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026356 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium C sp000435295 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026357 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium C sp000435295 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026358 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026359 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026360 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026361 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026363 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026365 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026366 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026367 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026368 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20026369 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20026370 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026372 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20026375 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20026376 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20026377 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026378 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026381 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20026384 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026385 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026388 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026389 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026390 Microbes metabolize substances PMDBM2009579 n.a. Ruminiclostridium E PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026391 Microbes metabolize substances PMDBM2020693 39492 Ruminiclostridium E siraeum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026392 Microbes metabolize substances PMDBM2020693 39492 Ruminiclostridium E siraeum PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026393 Microbes metabolize substances PMDBM2020693 39492 Ruminiclostridium E siraeum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026394 Microbes metabolize substances PMDBM2020693 39492 Ruminiclostridium E siraeum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026395 Microbes metabolize substances PMDBM2020693 39492 Ruminiclostridium E siraeum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026396 Microbes metabolize substances PMDBM2020693 39492 Ruminiclostridium E siraeum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026397 Microbes metabolize substances PMDBM2020693 39492 Ruminiclostridium E siraeum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026398 Microbes metabolize substances PMDBM2020693 39492 Ruminiclostridium E siraeum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026401 Microbes metabolize substances PMDBM2020693 39492 Ruminiclostridium E siraeum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026402 Microbes metabolize substances PMDBM2020693 39492 Ruminiclostridium E siraeum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026403 Microbes metabolize substances PMDBM2020693 39492 Ruminiclostridium E siraeum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026404 Microbes metabolize substances PMDBM2020693 39492 Ruminiclostridium E siraeum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026405 Microbes metabolize substances PMDBM2020693 39492 Ruminiclostridium E siraeum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026406 Microbes metabolize substances PMDBM2020693 39492 Ruminiclostridium E siraeum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026407 Microbes metabolize substances PMDBM2020693 39492 Ruminiclostridium E siraeum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026408 Microbes metabolize substances PMDBM2020693 39492 Ruminiclostridium E siraeum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026409 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium E sp003512525 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026410 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium E sp003512525 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026411 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium E sp003512525 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026412 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium E sp003512525 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026413 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium E sp003512525 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026414 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium E sp003512525 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026415 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium E sp003512525 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026418 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium E sp003512525 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026419 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium E sp003512525 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026420 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium E sp003512525 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026421 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium E sp003512525 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026422 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium E sp003512525 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026423 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium E sp003512525 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026424 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium E sp003512525 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026425 Microbes metabolize substances PMDBM2021069 2053608 Ruminiclostridium E sp003512525 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026426 Microbes metabolize substances PMDBM2009582 n.a. Ruminobacter A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026427 Microbes metabolize substances PMDBM2009582 n.a. Ruminobacter A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026428 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026429 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026430 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026431 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026432 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026434 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026436 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026437 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026438 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026439 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20026440 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20026441 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026443 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20026446 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20026447 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20026448 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026449 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026452 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20026455 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20026456 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026457 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026460 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026461 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026462 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026463 Microbes metabolize substances PMDBM357 541000 Ruminococcaceae PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20026464 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000432335 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026465 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000432335 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026466 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000432335 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026467 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000432335 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026469 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000432335 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026471 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000432335 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026472 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000432335 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026473 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000432335 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026474 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000432335 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026477 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000432335 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026478 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000432335 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026479 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000432335 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026480 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000432335 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026482 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000432335 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026483 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000432335 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026484 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000432335 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026485 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000437095 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026486 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000437095 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026487 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000437095 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026488 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000437095 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026490 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000437095 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026492 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000437095 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026493 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000437095 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026494 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000437095 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026495 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000437095 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026498 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000437095 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026499 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000437095 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026500 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000437095 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026501 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000437095 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026503 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000437095 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026504 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000437095 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026505 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp000437095 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026506 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp003011855 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026507 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp003011855 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026508 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp003011855 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026509 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp003011855 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026511 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp003011855 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026513 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp003011855 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026514 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp003011855 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026515 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp003011855 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026516 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp003011855 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026519 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp003011855 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026520 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp003011855 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026521 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp003011855 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026522 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp003011855 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026524 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp003011855 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026525 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp003011855 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026526 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus A sp003011855 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026527 Microbes metabolize substances PMDBM2009586 n.a. Ruminococcus C PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026528 Microbes metabolize substances PMDBM2009586 n.a. Ruminococcus C PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026529 Microbes metabolize substances PMDBM2009586 n.a. Ruminococcus C PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026530 Microbes metabolize substances PMDBM2009586 n.a. Ruminococcus C PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026531 Microbes metabolize substances PMDBM2009586 n.a. Ruminococcus C PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026532 Microbes metabolize substances PMDBM2009586 n.a. Ruminococcus C PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026533 Microbes metabolize substances PMDBM2009586 n.a. Ruminococcus C PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026534 Microbes metabolize substances PMDBM2009586 n.a. Ruminococcus C PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026537 Microbes metabolize substances PMDBM2009586 n.a. Ruminococcus C PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026538 Microbes metabolize substances PMDBM2009586 n.a. Ruminococcus C PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026539 Microbes metabolize substances PMDBM2009586 n.a. Ruminococcus C PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026540 Microbes metabolize substances PMDBM2009586 n.a. Ruminococcus C PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026541 Microbes metabolize substances PMDBM2009586 n.a. Ruminococcus C PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026542 Microbes metabolize substances PMDBM2009586 n.a. Ruminococcus C PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026543 Microbes metabolize substances PMDBM2009586 n.a. Ruminococcus C PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026544 Microbes metabolize substances PMDBM2009586 n.a. Ruminococcus C PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026545 Microbes metabolize substances PMDBM2021071 40519 Ruminococcus C callidus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026546 Microbes metabolize substances PMDBM2021071 40519 Ruminococcus C callidus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026547 Microbes metabolize substances PMDBM2021071 40519 Ruminococcus C callidus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026548 Microbes metabolize substances PMDBM2021071 40519 Ruminococcus C callidus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026549 Microbes metabolize substances PMDBM2021071 40519 Ruminococcus C callidus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026550 Microbes metabolize substances PMDBM2021071 40519 Ruminococcus C callidus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026551 Microbes metabolize substances PMDBM2021071 40519 Ruminococcus C callidus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026554 Microbes metabolize substances PMDBM2021071 40519 Ruminococcus C callidus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026555 Microbes metabolize substances PMDBM2021071 40519 Ruminococcus C callidus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026556 Microbes metabolize substances PMDBM2021071 40519 Ruminococcus C callidus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026557 Microbes metabolize substances PMDBM2021071 40519 Ruminococcus C callidus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026558 Microbes metabolize substances PMDBM2021071 40519 Ruminococcus C callidus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026559 Microbes metabolize substances PMDBM2021071 40519 Ruminococcus C callidus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026560 Microbes metabolize substances PMDBM2021071 40519 Ruminococcus C callidus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026561 Microbes metabolize substances PMDBM2021071 40519 Ruminococcus C callidus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026562 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000433635 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026563 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000433635 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026564 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000433635 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026565 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000433635 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026566 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000433635 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026567 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000433635 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026568 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000433635 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026571 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000433635 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026572 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000433635 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026573 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000433635 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026574 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000433635 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026575 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000433635 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026576 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000433635 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026577 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000433635 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026578 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000433635 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026579 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437175 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026580 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437175 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026581 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437175 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026582 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437175 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026583 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437175 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026584 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437175 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026585 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437175 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026588 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437175 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026589 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437175 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026590 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437175 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026591 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437175 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026592 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437175 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026593 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437175 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026594 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437175 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026595 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437175 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026596 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437255 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026597 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437255 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026598 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437255 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026599 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437255 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026600 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437255 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026601 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437255 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026602 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437255 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026605 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437255 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026606 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437255 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026607 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437255 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026608 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437255 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026609 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437255 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026610 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437255 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026611 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437255 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026612 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000437255 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026613 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000980705 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026614 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000980705 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026615 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000980705 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026616 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000980705 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026617 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000980705 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026618 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000980705 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026619 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000980705 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026622 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000980705 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026623 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000980705 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026624 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000980705 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026625 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000980705 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026626 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000980705 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026627 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000980705 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026628 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000980705 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026629 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus C sp000980705 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026630 Microbes metabolize substances PMDBM2009592 n.a. Ruminococcus D PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026631 Microbes metabolize substances PMDBM2009592 n.a. Ruminococcus D PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026632 Microbes metabolize substances PMDBM2009592 n.a. Ruminococcus D PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026633 Microbes metabolize substances PMDBM2009592 n.a. Ruminococcus D PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026634 Microbes metabolize substances PMDBM2009592 n.a. Ruminococcus D PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026635 Microbes metabolize substances PMDBM2009592 n.a. Ruminococcus D PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026636 Microbes metabolize substances PMDBM2009592 n.a. Ruminococcus D PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026637 Microbes metabolize substances PMDBM2009592 n.a. Ruminococcus D PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026640 Microbes metabolize substances PMDBM2009592 n.a. Ruminococcus D PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026641 Microbes metabolize substances PMDBM2009592 n.a. Ruminococcus D PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026642 Microbes metabolize substances PMDBM2009592 n.a. Ruminococcus D PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026643 Microbes metabolize substances PMDBM2009592 n.a. Ruminococcus D PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026644 Microbes metabolize substances PMDBM2009592 n.a. Ruminococcus D PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026645 Microbes metabolize substances PMDBM2009592 n.a. Ruminococcus D PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026646 Microbes metabolize substances PMDBM2009592 n.a. Ruminococcus D PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026647 Microbes metabolize substances PMDBM2009592 n.a. Ruminococcus D PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026648 Microbes metabolize substances PMDBM2009592 n.a. Ruminococcus D PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20026649 Microbes metabolize substances PMDBM2021394 1160721 Ruminococcus D bicirculans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026650 Microbes metabolize substances PMDBM2021394 1160721 Ruminococcus D bicirculans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026651 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus D sp000434695 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026652 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus D sp000434695 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026653 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus D sp000434695 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026654 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus D sp000434695 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026655 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus D sp000434695 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026656 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus D sp000434695 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026657 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus D sp000434695 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026660 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus D sp000434695 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026661 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus D sp000434695 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026662 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus D sp000434695 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026663 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus D sp000434695 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026664 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus D sp000434695 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026665 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus D sp000434695 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026666 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus D sp000434695 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026667 Microbes metabolize substances PMDBM2009595 n.a. Ruminococcus E PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026668 Microbes metabolize substances PMDBM2009595 n.a. Ruminococcus E PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026669 Microbes metabolize substances PMDBM2009595 n.a. Ruminococcus E PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026670 Microbes metabolize substances PMDBM2020246 40518 Ruminococcus E bromii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026671 Microbes metabolize substances PMDBM2020246 40518 Ruminococcus E bromii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026672 Microbes metabolize substances PMDBM2020246 40518 Ruminococcus E bromii A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026673 Microbes metabolize substances PMDBM2020246 40518 Ruminococcus E bromii A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026674 Microbes metabolize substances PMDBM2020246 40518 Ruminococcus E bromii A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026675 Microbes metabolize substances PMDBM2020246 40518 Ruminococcus E bromii B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026676 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp002493635 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026677 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp002493635 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026678 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp002493635 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026679 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp002493635 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026680 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp002493635 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026681 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp002493635 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026682 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp002493635 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026685 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp002493635 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026686 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp002493635 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026687 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp002493635 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026688 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp002493635 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026689 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp003521625 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026690 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp003521625 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026691 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp003526955 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026692 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp900314705 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026693 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp900314705 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026694 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp900314705 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026695 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp900314705 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026696 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp900314705 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026697 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus E sp900314705 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026698 Microbes metabolize substances PMDBM2021072 1161942 Ruminococcus F champanellensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026699 Microbes metabolize substances PMDBM2021072 1161942 Ruminococcus F champanellensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026700 Microbes metabolize substances PMDBM2021072 1161942 Ruminococcus F champanellensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026701 Microbes metabolize substances PMDBM2021072 1161942 Ruminococcus F champanellensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026702 Microbes metabolize substances PMDBM2021072 1161942 Ruminococcus F champanellensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026703 Microbes metabolize substances PMDBM2021072 1161942 Ruminococcus F champanellensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026704 Microbes metabolize substances PMDBM2021072 1161942 Ruminococcus F champanellensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026707 Microbes metabolize substances PMDBM2021072 1161942 Ruminococcus F champanellensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026708 Microbes metabolize substances PMDBM2021072 1161942 Ruminococcus F champanellensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026709 Microbes metabolize substances PMDBM2021072 1161942 Ruminococcus F champanellensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026710 Microbes metabolize substances PMDBM2021072 1161942 Ruminococcus F champanellensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026711 Microbes metabolize substances PMDBM2021072 1161942 Ruminococcus F champanellensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026712 Microbes metabolize substances PMDBM2021072 1161942 Ruminococcus F champanellensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026713 Microbes metabolize substances PMDBM2021072 1161942 Ruminococcus F champanellensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026714 Microbes metabolize substances PMDBM2021073 438033 Ruminococcus G gauvreauii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026715 Microbes metabolize substances PMDBM2021073 438033 Ruminococcus G gauvreauii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026716 Microbes metabolize substances PMDBM2021073 438033 Ruminococcus G gauvreauii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026717 Microbes metabolize substances PMDBM2021073 438033 Ruminococcus G gauvreauii PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026719 Microbes metabolize substances PMDBM2021073 438033 Ruminococcus G gauvreauii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026721 Microbes metabolize substances PMDBM2021073 438033 Ruminococcus G gauvreauii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026722 Microbes metabolize substances PMDBM2021073 438033 Ruminococcus G gauvreauii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026723 Microbes metabolize substances PMDBM2021073 438033 Ruminococcus G gauvreauii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026724 Microbes metabolize substances PMDBM2021073 438033 Ruminococcus G gauvreauii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026727 Microbes metabolize substances PMDBM2021073 438033 Ruminococcus G gauvreauii PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20026728 Microbes metabolize substances PMDBM2021073 438033 Ruminococcus G gauvreauii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026729 Microbes metabolize substances PMDBM2021073 438033 Ruminococcus G gauvreauii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026730 Microbes metabolize substances PMDBM2021073 438033 Ruminococcus G gauvreauii PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20026731 Microbes metabolize substances PMDBM2021073 438033 Ruminococcus G gauvreauii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026732 Microbes metabolize substances PMDBM2021073 438033 Ruminococcus G gauvreauii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026734 Microbes metabolize substances PMDBM2021073 438033 Ruminococcus G gauvreauii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026735 Microbes metabolize substances PMDBM2021073 438033 Ruminococcus G gauvreauii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026736 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026737 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026738 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026739 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026740 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026741 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026742 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026743 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026746 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026747 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026748 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026749 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026750 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026751 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. Compound K n.a. unknown activity increased n.a. n.a. n.a. Drug interaction:antibiotics inhibits the metabolism n.a. PMID PMID: 36467581 PMDBI20026752 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026753 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026754 Microbes metabolize substances PMDBM2020247 n.a. Ruminococcus gnavus VPI C7-9,ATCC 29149 PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20026755 Microbes metabolize substances PMDBM2020247 n.a. Ruminococcus gnavus VPI C7-9,ATCC 29149 PMDBD2000059 Roflumilast Therapeutic Substance Drugs for obstructive airway disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Biotransformation n.a. PMID PMID: 36467581 PMDBI20026756 Microbes metabolize substances PMDBM2020246 40518 Ruminococcus bromii PMDBD1166 Dolasetron Therapeutic substance antinauseant and antiemetic n.a. n.a. n.a. n.a. duloxetine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026757 Microbes metabolize substances PMDBM2020246 40518 Ruminococcus bromii PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026758 Microbes metabolize substances PMDBM2020246 40518 Ruminococcus bromii PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" fungal infections n.a. n.a. n.a. n.a. ketoprofen n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026759 Microbes metabolize substances PMDBM2020246 40518 Ruminococcus bromii PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" lower the risk of cardiovascular disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026760 Microbes metabolize substances PMDBM2020246 40518 Ruminococcus bromii PMDBD1298 Misoprostol Therapeutic substance reduce the risk of NSAID induced gastric ulcers n.a. n.a. n.a. n.a. misoprostol-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026761 Microbes metabolize substances PMDBM2020246 40518 Ruminococcus bromii PMDBD563 Mycophenolate mofetil Therapeutic Substance inosine monophosphate dehydrogenase inhibitor n.a. n.a. n.a. n.a. mycophenolic-acid n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026762 Microbes metabolize substances PMDBM2020246 40518 Ruminococcus bromii PMDBD1318 Nicardipine Therapeutic substance effective in the treatment of angina and coronary spasms without showing cardiodepressant effects n.a. n.a. n.a. n.a. aminonicardipine n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026763 Microbes metabolize substances PMDBM2020246 40518 Ruminococcus bromii PMDBD1376 Praziquantel Therapeutic substance Anti-infection n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026764 Microbes metabolize substances PMDBM2020246 40518 Ruminococcus bromii PMDBD1406 Ropinirole Therapeutic substance Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. affect substrate metabolism n.a. PMID PMID: 36467581 PMDBI20026765 Microbes metabolize substances PMDBM2020247 33038 Ruminococcus gnavus PMDBD812 Sulfasalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. "sulfapyridine; 5-aminosalicylate" n.a. Azo reductases activation n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 3-ASA by gut microbes n.a. PMID PMID: 36467581 PMDBI20026766 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus sp002438605 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026767 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus sp002438605 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026768 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus sp002438605 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026769 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus sp002438605 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026770 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus sp002438605 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026771 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus sp002438605 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026772 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus sp002438605 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026775 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus sp002438605 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026776 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus sp002438605 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026777 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus sp002438605 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026778 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus sp002438605 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026779 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus sp002438605 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026780 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus sp002438605 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026781 Microbes metabolize substances PMDBM2020199 41978 Ruminococcus sp002438605 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026782 Microbes metabolize substances PMDBM2009607 1905344 Ruthenibacterium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026783 Microbes metabolize substances PMDBM2009607 1905344 Ruthenibacterium PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026784 Microbes metabolize substances PMDBM2009607 1905344 Ruthenibacterium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026785 Microbes metabolize substances PMDBM2009607 1905344 Ruthenibacterium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026786 Microbes metabolize substances PMDBM2009607 1905344 Ruthenibacterium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026787 Microbes metabolize substances PMDBM2009607 1905344 Ruthenibacterium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026788 Microbes metabolize substances PMDBM2009607 1905344 Ruthenibacterium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026789 Microbes metabolize substances PMDBM2009607 1905344 Ruthenibacterium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026792 Microbes metabolize substances PMDBM2009607 1905344 Ruthenibacterium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026793 Microbes metabolize substances PMDBM2009607 1905344 Ruthenibacterium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026794 Microbes metabolize substances PMDBM2009607 1905344 Ruthenibacterium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026795 Microbes metabolize substances PMDBM2009607 1905344 Ruthenibacterium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026796 Microbes metabolize substances PMDBM2009607 1905344 Ruthenibacterium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026797 Microbes metabolize substances PMDBM2009607 1905344 Ruthenibacterium PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026798 Microbes metabolize substances PMDBM2009607 1905344 Ruthenibacterium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026799 Microbes metabolize substances PMDBM2009607 1905344 Ruthenibacterium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026800 Microbes metabolize substances PMDBM2021074 1550024 Ruthenibacterium lactatiformans PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026801 Microbes metabolize substances PMDBM2021074 1550024 Ruthenibacterium lactatiformans PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026802 Microbes metabolize substances PMDBM2021074 1550024 Ruthenibacterium lactatiformans PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026803 Microbes metabolize substances PMDBM2021074 1550024 Ruthenibacterium lactatiformans PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026805 Microbes metabolize substances PMDBM2021074 1550024 Ruthenibacterium lactatiformans PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026807 Microbes metabolize substances PMDBM2021074 1550024 Ruthenibacterium lactatiformans PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20026808 Microbes metabolize substances PMDBM2021074 1550024 Ruthenibacterium lactatiformans PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026809 Microbes metabolize substances PMDBM2021074 1550024 Ruthenibacterium lactatiformans PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026810 Microbes metabolize substances PMDBM2021074 1550024 Ruthenibacterium lactatiformans PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026811 Microbes metabolize substances PMDBM2021074 1550024 Ruthenibacterium lactatiformans PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026814 Microbes metabolize substances PMDBM2021074 1550024 Ruthenibacterium lactatiformans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026815 Microbes metabolize substances PMDBM2021074 1550024 Ruthenibacterium lactatiformans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026816 Microbes metabolize substances PMDBM2021074 1550024 Ruthenibacterium lactatiformans PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20026817 Microbes metabolize substances PMDBM2021074 1550024 Ruthenibacterium lactatiformans PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026818 Microbes metabolize substances PMDBM2021074 1550024 Ruthenibacterium lactatiformans PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026820 Microbes metabolize substances PMDBM2021074 1550024 Ruthenibacterium lactatiformans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026821 Microbes metabolize substances PMDBM2021074 1550024 Ruthenibacterium lactatiformans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026822 Microbes metabolize substances PMDBM2021069 2053608 Ruthenibacterium sp003149955 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026823 Microbes metabolize substances PMDBM2021069 2053608 Ruthenibacterium sp003149955 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026824 Microbes metabolize substances PMDBM2021069 2053608 Ruthenibacterium sp003149955 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026825 Microbes metabolize substances PMDBM2021069 2053608 Ruthenibacterium sp003149955 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026826 Microbes metabolize substances PMDBM2021069 2053608 Ruthenibacterium sp003149955 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026827 Microbes metabolize substances PMDBM2021069 2053608 Ruthenibacterium sp003149955 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026828 Microbes metabolize substances PMDBM2021069 2053608 Ruthenibacterium sp003149955 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026831 Microbes metabolize substances PMDBM2021069 2053608 Ruthenibacterium sp003149955 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20026832 Microbes metabolize substances PMDBM2021069 2053608 Ruthenibacterium sp003149955 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026833 Microbes metabolize substances PMDBM2021069 2053608 Ruthenibacterium sp003149955 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026834 Microbes metabolize substances PMDBM2021069 2053608 Ruthenibacterium sp003149955 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026835 Microbes metabolize substances PMDBM2021069 2053608 Ruthenibacterium sp003149955 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026836 Microbes metabolize substances PMDBM2021069 2053608 Ruthenibacterium sp003149955 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026837 Microbes metabolize substances PMDBM2021069 2053608 Ruthenibacterium sp003149955 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026838 Microbes metabolize substances PMDBM2021069 2053608 Ruthenibacterium sp003149955 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026839 Microbes metabolize substances PMDBM2021069 2053608 Ruthenibacterium sp003149955 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026840 Microbes metabolize substances PMDBM2009610 n.a. f Anaerovoracaceae g S5-A14a PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026841 Microbes metabolize substances PMDBM2009610 n.a. f Anaerovoracaceae g S5-A14a PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026842 Microbes metabolize substances PMDBM2009610 n.a. f Anaerovoracaceae g S5-A14a PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026843 Microbes metabolize substances PMDBM2009610 n.a. f Anaerovoracaceae g S5-A14a PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026844 Microbes metabolize substances PMDBM2009611 n.a. f Anaerovoracaceae g S5-A14a s S5-A14a sp000758905 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026845 Microbes metabolize substances PMDBM2009611 n.a. f Anaerovoracaceae g S5-A14a s S5-A14a sp000758905 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026846 Microbes metabolize substances PMDBM2009611 n.a. f Anaerovoracaceae g S5-A14a s S5-A14a sp000758905 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026847 Microbes metabolize substances PMDBM2009612 2171986 Saccharimonadaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026848 Microbes metabolize substances PMDBM2021694 1771309 Salinicola tamaricis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026849 Microbes metabolize substances PMDBM2021694 1771309 Salinicola tamaricis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026850 Microbes metabolize substances PMDBM2021694 1771309 Salinicola tamaricis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026851 Microbes metabolize substances PMDBM2021694 1771309 Salinicola tamaricis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026852 Microbes metabolize substances PMDBM2021694 1771309 Salinicola tamaricis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026853 Microbes metabolize substances PMDBM2021694 1771309 Salinicola tamaricis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026854 Microbes metabolize substances PMDBM2021694 1771309 Salinicola tamaricis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026857 Microbes metabolize substances PMDBM2021694 1771309 Salinicola tamaricis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026858 Microbes metabolize substances PMDBM2021694 1771309 Salinicola tamaricis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026859 Microbes metabolize substances PMDBM2021694 1771309 Salinicola tamaricis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026860 Microbes metabolize substances PMDBM2021694 1771309 Salinicola tamaricis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026861 Microbes metabolize substances PMDBM2021694 1771309 Salinicola tamaricis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026862 Microbes metabolize substances PMDBM2021694 1771309 Salinicola tamaricis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026863 Microbes metabolize substances PMDBM2021694 1771309 Salinicola tamaricis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026864 Microbes metabolize substances PMDBM2020218 54736 Salmonella bongori PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026865 Microbes metabolize substances PMDBM2020218 54736 Salmonella bongori PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026866 Microbes metabolize substances PMDBM2020218 54736 Salmonella bongori PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026867 Microbes metabolize substances PMDBM2020218 54736 Salmonella bongori PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026869 Microbes metabolize substances PMDBM2020218 54736 Salmonella bongori PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026871 Microbes metabolize substances PMDBM2020218 54736 Salmonella bongori PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026872 Microbes metabolize substances PMDBM2020218 54736 Salmonella bongori PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026873 Microbes metabolize substances PMDBM2020218 54736 Salmonella bongori PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026874 Microbes metabolize substances PMDBM2020218 54736 Salmonella bongori PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026877 Microbes metabolize substances PMDBM2020218 54736 Salmonella bongori PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026878 Microbes metabolize substances PMDBM2020218 54736 Salmonella bongori PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026879 Microbes metabolize substances PMDBM2020218 54736 Salmonella bongori PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20026880 Microbes metabolize substances PMDBM2020218 54736 Salmonella bongori PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026881 Microbes metabolize substances PMDBM2020218 54736 Salmonella bongori PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026883 Microbes metabolize substances PMDBM2020218 54736 Salmonella bongori PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026884 Microbes metabolize substances PMDBM2020218 54736 Salmonella bongori PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026885 Microbes metabolize substances PMDBM2020218 54736 Salmonella bongori PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026886 Microbes metabolize substances PMDBM2020168 28901 Salmonella enterica PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026887 Microbes metabolize substances PMDBM2020168 28901 Salmonella enterica PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026888 Microbes metabolize substances PMDBM2020168 28901 Salmonella enterica PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026889 Microbes metabolize substances PMDBM2020168 28901 Salmonella enterica PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026891 Microbes metabolize substances PMDBM2020168 28901 Salmonella enterica PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20026893 Microbes metabolize substances PMDBM2020168 28901 Salmonella enterica PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026894 Microbes metabolize substances PMDBM2020168 28901 Salmonella enterica PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026895 Microbes metabolize substances PMDBM2020168 28901 Salmonella enterica PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026896 Microbes metabolize substances PMDBM2020168 28901 Salmonella enterica PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026899 Microbes metabolize substances PMDBM2020168 28901 Salmonella enterica PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026900 Microbes metabolize substances PMDBM2020168 28901 Salmonella enterica PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026901 Microbes metabolize substances PMDBM2020168 28901 Salmonella enterica PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20026902 Microbes metabolize substances PMDBM2020168 28901 Salmonella enterica PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026903 Microbes metabolize substances PMDBM2020168 28901 Salmonella enterica PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026905 Microbes metabolize substances PMDBM2020168 28901 Salmonella enterica PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026906 Microbes metabolize substances PMDBM2020168 28901 Salmonella enterica PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026907 Microbes metabolize substances PMDBM2020168 28901 Salmonella enterica PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026908 Microbes metabolize substances PMDBM2021261 90371 Salmonella typhimurium PMDBD812 Sulfasalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. "sulfapyridine; 5-aminosalicylate" n.a. Azo reductases activation n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes n.a. PMID PMID: 36467581 PMDBI20026909 Microbes metabolize substances PMDBM2021078 230143 Scardovia wiggsiae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026910 Microbes metabolize substances PMDBM2021078 230143 Scardovia wiggsiae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026911 Microbes metabolize substances PMDBM2021078 230143 Scardovia wiggsiae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026912 Microbes metabolize substances PMDBM2021078 230143 Scardovia wiggsiae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026913 Microbes metabolize substances PMDBM2021078 230143 Scardovia wiggsiae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026914 Microbes metabolize substances PMDBM2021078 230143 Scardovia wiggsiae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026915 Microbes metabolize substances PMDBM2021078 230143 Scardovia wiggsiae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026918 Microbes metabolize substances PMDBM2021078 230143 Scardovia wiggsiae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026919 Microbes metabolize substances PMDBM2021078 230143 Scardovia wiggsiae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026920 Microbes metabolize substances PMDBM2021078 230143 Scardovia wiggsiae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026921 Microbes metabolize substances PMDBM2021078 230143 Scardovia wiggsiae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026922 Microbes metabolize substances PMDBM2021078 230143 Scardovia wiggsiae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026923 Microbes metabolize substances PMDBM2021695 1960295 Sedimentibacter sp003457065 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026924 Microbes metabolize substances PMDBM2021695 1960295 Sedimentibacter sp003457065 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026925 Microbes metabolize substances PMDBM2021695 1960295 Sedimentibacter sp003457065 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026926 Microbes metabolize substances PMDBM2021695 1960295 Sedimentibacter sp003457065 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026927 Microbes metabolize substances PMDBM2021695 1960295 Sedimentibacter sp003457065 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026928 Microbes metabolize substances PMDBM2021695 1960295 Sedimentibacter sp003457065 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026929 Microbes metabolize substances PMDBM2021695 1960295 Sedimentibacter sp003457065 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026932 Microbes metabolize substances PMDBM2021695 1960295 Sedimentibacter sp003457065 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20026933 Microbes metabolize substances PMDBM2021695 1960295 Sedimentibacter sp003457065 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026934 Microbes metabolize substances PMDBM2021695 1960295 Sedimentibacter sp003457065 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026935 Microbes metabolize substances PMDBM2021695 1960295 Sedimentibacter sp003457065 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026936 Microbes metabolize substances PMDBM2021695 1960295 Sedimentibacter sp003457065 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026937 Microbes metabolize substances PMDBM2021695 1960295 Sedimentibacter sp003457065 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026938 Microbes metabolize substances PMDBM2021695 1960295 Sedimentibacter sp003457065 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026939 Microbes metabolize substances PMDBM2021695 1960295 Sedimentibacter sp003457065 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026940 Microbes metabolize substances PMDBM2009619 n.a. Selenomonas A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026941 Microbes metabolize substances PMDBM2009619 n.a. Selenomonas A PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026942 Microbes metabolize substances PMDBM2009619 n.a. Selenomonas A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026943 Microbes metabolize substances PMDBM2009619 n.a. Selenomonas A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026944 Microbes metabolize substances PMDBM2009619 n.a. Selenomonas A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026945 Microbes metabolize substances PMDBM2009619 n.a. Selenomonas A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026946 Microbes metabolize substances PMDBM2009619 n.a. Selenomonas A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026947 Microbes metabolize substances PMDBM2009619 n.a. Selenomonas A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026950 Microbes metabolize substances PMDBM2009619 n.a. Selenomonas A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026951 Microbes metabolize substances PMDBM2009619 n.a. Selenomonas A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026952 Microbes metabolize substances PMDBM2009619 n.a. Selenomonas A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026953 Microbes metabolize substances PMDBM2009619 n.a. Selenomonas A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026954 Microbes metabolize substances PMDBM2009619 n.a. Selenomonas A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026955 Microbes metabolize substances PMDBM2009619 n.a. Selenomonas A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026956 Microbes metabolize substances PMDBM2021083 416586 Selenomonas C bovis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026957 Microbes metabolize substances PMDBM2021083 416586 Selenomonas C bovis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026958 Microbes metabolize substances PMDBM2021083 416586 Selenomonas C bovis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026959 Microbes metabolize substances PMDBM2021083 416586 Selenomonas C bovis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026960 Microbes metabolize substances PMDBM2021083 416586 Selenomonas C bovis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026961 Microbes metabolize substances PMDBM2021083 416586 Selenomonas C bovis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026962 Microbes metabolize substances PMDBM2021083 416586 Selenomonas C bovis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026963 Microbes metabolize substances PMDBM2021083 416586 Selenomonas C bovis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026966 Microbes metabolize substances PMDBM2021083 416586 Selenomonas C bovis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026967 Microbes metabolize substances PMDBM2021083 416586 Selenomonas C bovis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026968 Microbes metabolize substances PMDBM2021083 416586 Selenomonas C bovis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026969 Microbes metabolize substances PMDBM2021083 416586 Selenomonas C bovis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026970 Microbes metabolize substances PMDBM2021083 416586 Selenomonas C bovis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026971 Microbes metabolize substances PMDBM2021083 416586 Selenomonas C bovis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026972 Microbes metabolize substances PMDBM2021083 416586 Selenomonas C bovis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026973 Microbes metabolize substances PMDBM2021696 2053611 Selenomonas C sp002351185 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026974 Microbes metabolize substances PMDBM2021696 2053611 Selenomonas C sp002351185 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026975 Microbes metabolize substances PMDBM2021696 2053611 Selenomonas C sp002351185 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026976 Microbes metabolize substances PMDBM2021696 2053611 Selenomonas C sp002351185 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026977 Microbes metabolize substances PMDBM2021696 2053611 Selenomonas C sp002351185 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026978 Microbes metabolize substances PMDBM2009622 1843491 Selenomonadaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20026979 Microbes metabolize substances PMDBM2009622 1843491 Selenomonadaceae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20026980 Microbes metabolize substances PMDBM2009622 1843491 Selenomonadaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20026981 Microbes metabolize substances PMDBM2009622 1843491 Selenomonadaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20026982 Microbes metabolize substances PMDBM2009622 1843491 Selenomonadaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026983 Microbes metabolize substances PMDBM2009622 1843491 Selenomonadaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026984 Microbes metabolize substances PMDBM2009622 1843491 Selenomonadaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20026985 Microbes metabolize substances PMDBM2009622 1843491 Selenomonadaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20026988 Microbes metabolize substances PMDBM2009622 1843491 Selenomonadaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026989 Microbes metabolize substances PMDBM2009622 1843491 Selenomonadaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026990 Microbes metabolize substances PMDBM2009622 1843491 Selenomonadaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026991 Microbes metabolize substances PMDBM2009622 1843491 Selenomonadaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026992 Microbes metabolize substances PMDBM2009622 1843491 Selenomonadaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20026993 Microbes metabolize substances PMDBM2009622 1843491 Selenomonadaceae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026994 Microbes metabolize substances PMDBM2009622 1843491 Selenomonadaceae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20026995 Microbes metabolize substances PMDBM2021090 1653434 Sellimonas intestinalis PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20026996 Microbes metabolize substances PMDBM2021090 1653434 Sellimonas intestinalis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20026997 Microbes metabolize substances PMDBM2021090 1653434 Sellimonas intestinalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20026998 Microbes metabolize substances PMDBM2021090 1653434 Sellimonas intestinalis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20026999 Microbes metabolize substances PMDBM2021090 1653434 Sellimonas intestinalis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027000 Microbes metabolize substances PMDBM2021090 1653434 Sellimonas intestinalis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027001 Microbes metabolize substances PMDBM2021697 2021466 Sellimonas sp002161525 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20027002 Microbes metabolize substances PMDBM2021697 2021466 Sellimonas sp002161525 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027003 Microbes metabolize substances PMDBM2021697 2021466 Sellimonas sp002161525 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027004 Microbes metabolize substances PMDBM2021697 2021466 Sellimonas sp002161525 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027005 Microbes metabolize substances PMDBM2021697 2021466 Sellimonas sp002161525 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027006 Microbes metabolize substances PMDBM2021697 2021466 Sellimonas sp002161525 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027007 Microbes metabolize substances PMDBM2009625 1473205 Senegalimassilia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027008 Microbes metabolize substances PMDBM2021091 1473216 Senegalimassilia anaerobia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027009 Microbes metabolize substances PMDBM2021093 614 Serratia liquefaciens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027010 Microbes metabolize substances PMDBM2021093 614 Serratia liquefaciens PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027011 Microbes metabolize substances PMDBM2021093 614 Serratia liquefaciens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027012 Microbes metabolize substances PMDBM2021093 614 Serratia liquefaciens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027013 Microbes metabolize substances PMDBM2021093 614 Serratia liquefaciens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027014 Microbes metabolize substances PMDBM2021093 614 Serratia liquefaciens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027015 Microbes metabolize substances PMDBM2021093 614 Serratia liquefaciens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027016 Microbes metabolize substances PMDBM2021093 614 Serratia liquefaciens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027019 Microbes metabolize substances PMDBM2021093 614 Serratia liquefaciens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027020 Microbes metabolize substances PMDBM2021093 614 Serratia liquefaciens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027021 Microbes metabolize substances PMDBM2021093 614 Serratia liquefaciens PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20027022 Microbes metabolize substances PMDBM2021093 614 Serratia liquefaciens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027023 Microbes metabolize substances PMDBM2021093 614 Serratia liquefaciens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027024 Microbes metabolize substances PMDBM2021093 614 Serratia liquefaciens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027025 Microbes metabolize substances PMDBM2021093 614 Serratia liquefaciens PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027026 Microbes metabolize substances PMDBM2021093 614 Serratia liquefaciens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027027 Microbes metabolize substances PMDBM2021093 614 Serratia liquefaciens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027028 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens I PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027029 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens I PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027030 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens I PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027031 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens I PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027032 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens I PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027033 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens I PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027034 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens I PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027035 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens I PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027038 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens I PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027039 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens I PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027040 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens I PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20027041 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens I PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027042 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens I PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027043 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens I PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027044 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens I PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027045 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens I PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027046 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens I PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027047 Microbes metabolize substances PMDBM2009628 n.a. Serratia sp001642805 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027048 Microbes metabolize substances PMDBM2009628 n.a. Serratia sp001642805 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027049 Microbes metabolize substances PMDBM2009628 n.a. Serratia sp001642805 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027050 Microbes metabolize substances PMDBM2009628 n.a. Serratia sp001642805 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027051 Microbes metabolize substances PMDBM2009628 n.a. Serratia sp001642805 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027052 Microbes metabolize substances PMDBM2009628 n.a. Serratia sp001642805 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027053 Microbes metabolize substances PMDBM2009628 n.a. Serratia sp001642805 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027056 Microbes metabolize substances PMDBM2009628 n.a. Serratia sp001642805 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027057 Microbes metabolize substances PMDBM2009628 n.a. Serratia sp001642805 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027058 Microbes metabolize substances PMDBM2009628 n.a. Serratia sp001642805 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20027059 Microbes metabolize substances PMDBM2009628 n.a. Serratia sp001642805 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027060 Microbes metabolize substances PMDBM2009628 n.a. Serratia sp001642805 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027061 Microbes metabolize substances PMDBM2009628 n.a. Serratia sp001642805 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027062 Microbes metabolize substances PMDBM2009628 n.a. Serratia sp001642805 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027063 Microbes metabolize substances PMDBM2009628 n.a. Serratia sp001642805 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027064 Microbes metabolize substances PMDBM2009628 n.a. Serratia sp001642805 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027065 Microbes metabolize substances PMDBM2021698 300181 Serratia ureilytica PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027066 Microbes metabolize substances PMDBM2021698 300181 Serratia ureilytica PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027067 Microbes metabolize substances PMDBM2021698 300181 Serratia ureilytica PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027068 Microbes metabolize substances PMDBM2021698 300181 Serratia ureilytica PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027069 Microbes metabolize substances PMDBM2021698 300181 Serratia ureilytica PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027070 Microbes metabolize substances PMDBM2021698 300181 Serratia ureilytica PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027071 Microbes metabolize substances PMDBM2021698 300181 Serratia ureilytica PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027074 Microbes metabolize substances PMDBM2021698 300181 Serratia ureilytica PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027075 Microbes metabolize substances PMDBM2021698 300181 Serratia ureilytica PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027076 Microbes metabolize substances PMDBM2021698 300181 Serratia ureilytica PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20027077 Microbes metabolize substances PMDBM2021698 300181 Serratia ureilytica PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027078 Microbes metabolize substances PMDBM2021698 300181 Serratia ureilytica PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027079 Microbes metabolize substances PMDBM2021698 300181 Serratia ureilytica PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027080 Microbes metabolize substances PMDBM2021698 300181 Serratia ureilytica PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027081 Microbes metabolize substances PMDBM2021698 300181 Serratia ureilytica PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027082 Microbes metabolize substances PMDBM2021698 300181 Serratia ureilytica PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027083 Microbes metabolize substances PMDBM2020227 84109 Slackia exigua PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027084 Microbes metabolize substances PMDBM2009631 n.a. Slackia A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027085 Microbes metabolize substances PMDBM2009631 n.a. Slackia A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027086 Microbes metabolize substances PMDBM2009631 n.a. Slackia A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027087 Microbes metabolize substances PMDBM2009631 n.a. Slackia A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027088 Microbes metabolize substances PMDBM2009631 n.a. Slackia A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027089 Microbes metabolize substances PMDBM2009631 n.a. Slackia A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027090 Microbes metabolize substances PMDBM2009631 n.a. Slackia A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027093 Microbes metabolize substances PMDBM2009631 n.a. Slackia A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027094 Microbes metabolize substances PMDBM2009631 n.a. Slackia A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027095 Microbes metabolize substances PMDBM2009631 n.a. Slackia A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027096 Microbes metabolize substances PMDBM2009631 n.a. Slackia A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027097 Microbes metabolize substances PMDBM2021351 626934 Slackia A piriformis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027098 Microbes metabolize substances PMDBM2009633 168808 Sneathia PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027099 Microbes metabolize substances PMDBM2009633 168808 Sneathia PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027100 Microbes metabolize substances PMDBM2009633 168808 Sneathia PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20027102 Microbes metabolize substances PMDBM2009633 168808 Sneathia PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20027103 Microbes metabolize substances PMDBM2009633 168808 Sneathia PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20027104 Microbes metabolize substances PMDBM2009633 168808 Sneathia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027107 Microbes metabolize substances PMDBM2009633 168808 Sneathia PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20027111 Microbes metabolize substances PMDBM2021699 187101 Sneathia amnii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027112 Microbes metabolize substances PMDBM2021699 187101 Sneathia amnii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027113 Microbes metabolize substances PMDBM2021699 187101 Sneathia amnii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027114 Microbes metabolize substances PMDBM2021699 187101 Sneathia amnii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027115 Microbes metabolize substances PMDBM2021699 187101 Sneathia amnii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027116 Microbes metabolize substances PMDBM2021699 187101 Sneathia amnii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027117 Microbes metabolize substances PMDBM2021699 187101 Sneathia amnii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027120 Microbes metabolize substances PMDBM2021699 187101 Sneathia amnii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027121 Microbes metabolize substances PMDBM2021699 187101 Sneathia amnii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027122 Microbes metabolize substances PMDBM2021699 187101 Sneathia amnii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027123 Microbes metabolize substances PMDBM2021699 187101 Sneathia amnii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027124 Microbes metabolize substances PMDBM2021699 187101 Sneathia amnii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027125 Microbes metabolize substances PMDBM2021699 187101 Sneathia amnii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027126 Microbes metabolize substances PMDBM2021699 187101 Sneathia amnii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027127 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027128 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027129 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027130 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027131 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027132 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027133 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027134 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027135 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027137 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20027140 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20027141 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20027142 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027143 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027146 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20027149 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027150 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027151 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027153 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027154 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027155 Microbes metabolize substances PMDBM2021104 40543 Sneathia sanguinegens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027156 Microbes metabolize substances PMDBM2009636 123375 Solobacterium PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027157 Microbes metabolize substances PMDBM2009636 123375 Solobacterium PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027158 Microbes metabolize substances PMDBM2009636 123375 Solobacterium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027159 Microbes metabolize substances PMDBM2009636 123375 Solobacterium PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027161 Microbes metabolize substances PMDBM2009636 123375 Solobacterium PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027163 Microbes metabolize substances PMDBM2009636 123375 Solobacterium PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027164 Microbes metabolize substances PMDBM2009636 123375 Solobacterium PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027165 Microbes metabolize substances PMDBM2009636 123375 Solobacterium PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027166 Microbes metabolize substances PMDBM2009636 123375 Solobacterium PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027169 Microbes metabolize substances PMDBM2009636 123375 Solobacterium PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027170 Microbes metabolize substances PMDBM2009636 123375 Solobacterium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027171 Microbes metabolize substances PMDBM2009636 123375 Solobacterium PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027172 Microbes metabolize substances PMDBM2009636 123375 Solobacterium PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027174 Microbes metabolize substances PMDBM2009636 123375 Solobacterium PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027175 Microbes metabolize substances PMDBM2009636 123375 Solobacterium PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027176 Microbes metabolize substances PMDBM2009636 123375 Solobacterium PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027177 Microbes metabolize substances PMDBM2021105 102148 Solobacterium moorei PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027178 Microbes metabolize substances PMDBM2021105 102148 Solobacterium moorei PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027179 Microbes metabolize substances PMDBM2021105 102148 Solobacterium moorei PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027180 Microbes metabolize substances PMDBM2021105 102148 Solobacterium moorei PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027181 Microbes metabolize substances PMDBM2021105 102148 Solobacterium moorei PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027182 Microbes metabolize substances PMDBM2021700 2060878 Solobacterium sp900290205 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027183 Microbes metabolize substances PMDBM2021700 2060878 Solobacterium sp900290205 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027184 Microbes metabolize substances PMDBM2021700 2060878 Solobacterium sp900290205 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027185 Microbes metabolize substances PMDBM2021700 2060878 Solobacterium sp900290205 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027186 Microbes metabolize substances PMDBM2021700 2060878 Solobacterium sp900290205 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027187 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027188 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027189 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027190 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027192 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned �L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of �L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the �L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027194 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027195 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027196 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027197 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027198 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027199 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027201 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20027204 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20027205 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20027208 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20027211 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027212 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027215 Microbes metabolize substances PMDBM944 13687 Sphingomonas PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20027216 Microbes metabolize substances PMDBM2021701 862134 Sphingomonas ginsenosidimutans PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027217 Microbes metabolize substances PMDBM2021701 862134 Sphingomonas ginsenosidimutans PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027218 Microbes metabolize substances PMDBM2021701 862134 Sphingomonas ginsenosidimutans PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027219 Microbes metabolize substances PMDBM2021701 862134 Sphingomonas ginsenosidimutans PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027220 Microbes metabolize substances PMDBM2021701 862134 Sphingomonas ginsenosidimutans PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027221 Microbes metabolize substances PMDBM2021701 862134 Sphingomonas ginsenosidimutans PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027222 Microbes metabolize substances PMDBM2021701 862134 Sphingomonas ginsenosidimutans PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027225 Microbes metabolize substances PMDBM2021701 862134 Sphingomonas ginsenosidimutans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027226 Microbes metabolize substances PMDBM2021701 862134 Sphingomonas ginsenosidimutans PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20027227 Microbes metabolize substances PMDBM2021701 862134 Sphingomonas ginsenosidimutans PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027228 Microbes metabolize substances PMDBM2021701 862134 Sphingomonas ginsenosidimutans PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027229 Microbes metabolize substances PMDBM2021701 862134 Sphingomonas ginsenosidimutans PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027230 Microbes metabolize substances PMDBM2009640 n.a. f Sphaerochaetaceae g Spiro-01 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027231 Microbes metabolize substances PMDBM2009640 n.a. f Sphaerochaetaceae g Spiro-01 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027232 Microbes metabolize substances PMDBM2009640 n.a. f Sphaerochaetaceae g Spiro-01 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027233 Microbes metabolize substances PMDBM2009640 n.a. f Sphaerochaetaceae g Spiro-01 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027234 Microbes metabolize substances PMDBM2009640 n.a. f Sphaerochaetaceae g Spiro-01 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027235 Microbes metabolize substances PMDBM2009640 n.a. f Sphaerochaetaceae g Spiro-01 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027236 Microbes metabolize substances PMDBM2009640 n.a. f Sphaerochaetaceae g Spiro-01 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027237 Microbes metabolize substances PMDBM2009640 n.a. f Sphaerochaetaceae g Spiro-01 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027240 Microbes metabolize substances PMDBM2009640 n.a. f Sphaerochaetaceae g Spiro-01 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027241 Microbes metabolize substances PMDBM2009640 n.a. f Sphaerochaetaceae g Spiro-01 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027242 Microbes metabolize substances PMDBM2009640 n.a. f Sphaerochaetaceae g Spiro-01 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027243 Microbes metabolize substances PMDBM2009640 n.a. f Sphaerochaetaceae g Spiro-01 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027244 Microbes metabolize substances PMDBM2009640 n.a. f Sphaerochaetaceae g Spiro-01 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027245 Microbes metabolize substances PMDBM2009640 n.a. f Sphaerochaetaceae g Spiro-01 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027246 Microbes metabolize substances PMDBM2009640 n.a. f Sphaerochaetaceae g Spiro-01 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027247 Microbes metabolize substances PMDBM2009640 n.a. f Sphaerochaetaceae g Spiro-01 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027248 Microbes metabolize substances PMDBM2009641 n.a. f Sphaerochaetaceae g Spiro-02 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027249 Microbes metabolize substances PMDBM2009641 n.a. f Sphaerochaetaceae g Spiro-02 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027250 Microbes metabolize substances PMDBM2009641 n.a. f Sphaerochaetaceae g Spiro-02 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027251 Microbes metabolize substances PMDBM2009641 n.a. f Sphaerochaetaceae g Spiro-02 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027252 Microbes metabolize substances PMDBM2009641 n.a. f Sphaerochaetaceae g Spiro-02 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027253 Microbes metabolize substances PMDBM2009641 n.a. f Sphaerochaetaceae g Spiro-02 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027254 Microbes metabolize substances PMDBM2009641 n.a. f Sphaerochaetaceae g Spiro-02 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027255 Microbes metabolize substances PMDBM2009641 n.a. f Sphaerochaetaceae g Spiro-02 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027258 Microbes metabolize substances PMDBM2009641 n.a. f Sphaerochaetaceae g Spiro-02 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027259 Microbes metabolize substances PMDBM2009641 n.a. f Sphaerochaetaceae g Spiro-02 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027260 Microbes metabolize substances PMDBM2009641 n.a. f Sphaerochaetaceae g Spiro-02 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027261 Microbes metabolize substances PMDBM2009641 n.a. f Sphaerochaetaceae g Spiro-02 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027262 Microbes metabolize substances PMDBM2009641 n.a. f Sphaerochaetaceae g Spiro-02 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027263 Microbes metabolize substances PMDBM2009641 n.a. f Sphaerochaetaceae g Spiro-02 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027264 Microbes metabolize substances PMDBM2009641 n.a. f Sphaerochaetaceae g Spiro-02 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027265 Microbes metabolize substances PMDBM2009641 n.a. f Sphaerochaetaceae g Spiro-02 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027266 Microbes metabolize substances PMDBM2021702 165813 Sporanaerobacter acetigenes PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027267 Microbes metabolize substances PMDBM2021702 165813 Sporanaerobacter acetigenes PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027268 Microbes metabolize substances PMDBM2021702 165813 Sporanaerobacter acetigenes PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027269 Microbes metabolize substances PMDBM2009643 2077 Sporolactobacillus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027270 Microbes metabolize substances PMDBM2009643 2077 Sporolactobacillus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027271 Microbes metabolize substances PMDBM2009643 2077 Sporolactobacillus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027272 Microbes metabolize substances PMDBM2009643 2077 Sporolactobacillus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027273 Microbes metabolize substances PMDBM2009643 2077 Sporolactobacillus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027274 Microbes metabolize substances PMDBM2021703 42858 Staphylococcus A lentus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027275 Microbes metabolize substances PMDBM2021703 42858 Staphylococcus A lentus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027276 Microbes metabolize substances PMDBM2021703 42858 Staphylococcus A lentus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027277 Microbes metabolize substances PMDBM2021703 42858 Staphylococcus A lentus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027278 Microbes metabolize substances PMDBM2021703 42858 Staphylococcus A lentus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027279 Microbes metabolize substances PMDBM2021703 42858 Staphylococcus A lentus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027280 Microbes metabolize substances PMDBM2021703 42858 Staphylococcus A lentus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027281 Microbes metabolize substances PMDBM2021703 42858 Staphylococcus A lentus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027284 Microbes metabolize substances PMDBM2021703 42858 Staphylococcus A lentus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027285 Microbes metabolize substances PMDBM2021703 42858 Staphylococcus A lentus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027286 Microbes metabolize substances PMDBM2021703 42858 Staphylococcus A lentus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027287 Microbes metabolize substances PMDBM2021703 42858 Staphylococcus A lentus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027288 Microbes metabolize substances PMDBM2021703 42858 Staphylococcus A lentus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027289 Microbes metabolize substances PMDBM2021703 42858 Staphylococcus A lentus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027290 Microbes metabolize substances PMDBM2021704 985002 Staphylococcus argenteus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027291 Microbes metabolize substances PMDBM2021704 985002 Staphylococcus argenteus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027292 Microbes metabolize substances PMDBM2021704 985002 Staphylococcus argenteus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027293 Microbes metabolize substances PMDBM2021704 985002 Staphylococcus argenteus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027294 Microbes metabolize substances PMDBM2020177 1280 Staphylococcus aureus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027295 Microbes metabolize substances PMDBM2020177 1280 Staphylococcus aureus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027296 Microbes metabolize substances PMDBM2020177 1280 Staphylococcus aureus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027297 Microbes metabolize substances PMDBM2020177 1280 Staphylococcus aureus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027298 Microbes metabolize substances PMDBM2021113 29388 Staphylococcus capitis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027299 Microbes metabolize substances PMDBM2021113 29388 Staphylococcus capitis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027300 Microbes metabolize substances PMDBM2021113 29388 Staphylococcus capitis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027301 Microbes metabolize substances PMDBM2021113 29388 Staphylococcus capitis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027302 Microbes metabolize substances PMDBM2020178 1282 Staphylococcus epidermidis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027303 Microbes metabolize substances PMDBM2020178 1282 Staphylococcus epidermidis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027304 Microbes metabolize substances PMDBM2020178 1282 Staphylococcus epidermidis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027305 Microbes metabolize substances PMDBM2020178 1282 Staphylococcus epidermidis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027306 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus A PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027307 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus A PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027308 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus A PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027309 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus A PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20027311 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus A PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20027312 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus A PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20027313 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027316 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus A PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20027320 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027321 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" Parkinson's n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase activity decreased n.a. n.a. n.a. gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases, Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson閳ユç?disease patients. n.a. PMID PMID: 36467581 PMDBI20027322 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027323 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027324 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20027326 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20027327 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20027328 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027331 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20027335 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027336 Microbes metabolize substances PMDBM2021117 1283 Staphylococcus haemolyticus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027337 Microbes metabolize substances PMDBM2021118 1290 Staphylococcus hominis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027338 Microbes metabolize substances PMDBM2021118 1290 Staphylococcus hominis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027339 Microbes metabolize substances PMDBM2021118 1290 Staphylococcus hominis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027340 Microbes metabolize substances PMDBM2021118 1290 Staphylococcus hominis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027341 Microbes metabolize substances PMDBM2021120 28035 Staphylococcus lugdunensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027342 Microbes metabolize substances PMDBM2021120 28035 Staphylococcus lugdunensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027343 Microbes metabolize substances PMDBM2021120 28035 Staphylococcus lugdunensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027344 Microbes metabolize substances PMDBM2021120 28035 Staphylococcus lugdunensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027345 Microbes metabolize substances PMDBM2021121 214473 Staphylococcus nepalensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027346 Microbes metabolize substances PMDBM2021121 214473 Staphylococcus nepalensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027347 Microbes metabolize substances PMDBM2021121 214473 Staphylococcus nepalensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027348 Microbes metabolize substances PMDBM2021121 214473 Staphylococcus nepalensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20027350 Microbes metabolize substances PMDBM2021121 214473 Staphylococcus nepalensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20027351 Microbes metabolize substances PMDBM2021121 214473 Staphylococcus nepalensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20027352 Microbes metabolize substances PMDBM2021121 214473 Staphylococcus nepalensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027355 Microbes metabolize substances PMDBM2021121 214473 Staphylococcus nepalensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20027359 Microbes metabolize substances PMDBM2021121 214473 Staphylococcus nepalensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027360 Microbes metabolize substances PMDBM2021121 214473 Staphylococcus nepalensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027361 Microbes metabolize substances PMDBM2021705 1295 Staphylococcus schleiferi PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027362 Microbes metabolize substances PMDBM2021705 1295 Staphylococcus schleiferi PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027363 Microbes metabolize substances PMDBM2021705 1295 Staphylococcus schleiferi PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027364 Microbes metabolize substances PMDBM2021705 1295 Staphylococcus schleiferi PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027365 Microbes metabolize substances PMDBM2021130 1292 Staphylococcus warneri PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027366 Microbes metabolize substances PMDBM2021130 1292 Staphylococcus warneri PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027367 Microbes metabolize substances PMDBM2021130 1292 Staphylococcus warneri PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027368 Microbes metabolize substances PMDBM2021130 1292 Staphylococcus warneri PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20027370 Microbes metabolize substances PMDBM2021130 1292 Staphylococcus warneri PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20027371 Microbes metabolize substances PMDBM2021130 1292 Staphylococcus warneri PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20027372 Microbes metabolize substances PMDBM2021130 1292 Staphylococcus warneri PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027375 Microbes metabolize substances PMDBM2021130 1292 Staphylococcus warneri PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20027379 Microbes metabolize substances PMDBM2021130 1292 Staphylococcus warneri PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027380 Microbes metabolize substances PMDBM2021130 1292 Staphylococcus warneri PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027381 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus B PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027382 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus B PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027383 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus B PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027384 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus B PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20027386 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus B PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20027387 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus B PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20027388 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027391 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus B PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20027395 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027396 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027397 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027398 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027399 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027400 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20027402 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20027403 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20027404 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027407 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20027411 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027412 Microbes metabolize substances PMDBM2021131 1288 Staphylococcus xylosus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027413 Microbes metabolize substances PMDBM952 40323 Stenotrophomonas PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027414 Microbes metabolize substances PMDBM952 40323 Stenotrophomonas PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027415 Microbes metabolize substances PMDBM952 40323 Stenotrophomonas PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027416 Microbes metabolize substances PMDBM952 40323 Stenotrophomonas PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027417 Microbes metabolize substances PMDBM952 40323 Stenotrophomonas PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20027418 Microbes metabolize substances PMDBM952 40323 Stenotrophomonas PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027419 Microbes metabolize substances PMDBM952 40323 Stenotrophomonas PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027420 Microbes metabolize substances PMDBM952 40323 Stenotrophomonas PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027421 Microbes metabolize substances PMDBM952 40323 Stenotrophomonas PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027424 Microbes metabolize substances PMDBM952 40323 Stenotrophomonas PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027425 Microbes metabolize substances PMDBM952 40323 Stenotrophomonas PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20027426 Microbes metabolize substances PMDBM952 40323 Stenotrophomonas PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027427 Microbes metabolize substances PMDBM952 40323 Stenotrophomonas PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027428 Microbes metabolize substances PMDBM952 40323 Stenotrophomonas PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027429 Microbes metabolize substances PMDBM952 40323 Stenotrophomonas PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027430 Microbes metabolize substances PMDBM2021706 1450134 Stenotrophomonas bentonitica PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027431 Microbes metabolize substances PMDBM2021706 1450134 Stenotrophomonas bentonitica PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027432 Microbes metabolize substances PMDBM2021706 1450134 Stenotrophomonas bentonitica PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027433 Microbes metabolize substances PMDBM2021706 1450134 Stenotrophomonas bentonitica PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027434 Microbes metabolize substances PMDBM2021706 1450134 Stenotrophomonas bentonitica PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027435 Microbes metabolize substances PMDBM2021706 1450134 Stenotrophomonas bentonitica PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027436 Microbes metabolize substances PMDBM2021706 1450134 Stenotrophomonas bentonitica PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027439 Microbes metabolize substances PMDBM2021706 1450134 Stenotrophomonas bentonitica PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027440 Microbes metabolize substances PMDBM2021706 1450134 Stenotrophomonas bentonitica PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027441 Microbes metabolize substances PMDBM2021706 1450134 Stenotrophomonas bentonitica PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027442 Microbes metabolize substances PMDBM2021706 1450134 Stenotrophomonas bentonitica PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027443 Microbes metabolize substances PMDBM2021706 1450134 Stenotrophomonas bentonitica PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027444 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027445 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027446 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027447 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027448 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027449 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027450 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027453 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027454 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027455 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027456 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027457 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027458 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AK PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027459 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AK PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027460 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AK PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027461 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AK PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027462 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AK PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027463 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AK PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027464 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AK PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027465 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AK PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027468 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AK PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027469 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AK PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20027470 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AK PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027471 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AK PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027472 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AK PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027473 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AK PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027474 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AM PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027475 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AM PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027476 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AM PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027477 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AM PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027478 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AM PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027479 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AM PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027480 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AM PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027481 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AM PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027484 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AM PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027485 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AM PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20027486 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AM PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027487 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AM PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027488 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AM PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027489 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia AM PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027490 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia F PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027491 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia F PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027492 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia F PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027493 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia F PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027494 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia F PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027495 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia F PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027496 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia F PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027497 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia F PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027500 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia F PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027501 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia F PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20027502 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia F PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027503 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia F PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027504 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia F PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027505 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia F PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027506 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia S PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027507 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia S PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027508 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia S PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027509 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia S PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027510 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia S PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027511 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia S PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027512 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia S PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027513 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia S PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027516 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia S PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027517 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia S PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20027518 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia S PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027519 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia S PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027520 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia S PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027521 Microbes metabolize substances PMDBM2021132 40324 Stenotrophomonas maltophilia S PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027522 Microbes metabolize substances PMDBM2021707 69392 Stenotrophomonas sp003028475 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027523 Microbes metabolize substances PMDBM2021707 69392 Stenotrophomonas sp003028475 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027524 Microbes metabolize substances PMDBM2021707 69392 Stenotrophomonas sp003028475 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027525 Microbes metabolize substances PMDBM2021707 69392 Stenotrophomonas sp003028475 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027526 Microbes metabolize substances PMDBM2021707 69392 Stenotrophomonas sp003028475 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20027527 Microbes metabolize substances PMDBM2021707 69392 Stenotrophomonas sp003028475 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027528 Microbes metabolize substances PMDBM2021707 69392 Stenotrophomonas sp003028475 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027529 Microbes metabolize substances PMDBM2021707 69392 Stenotrophomonas sp003028475 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027530 Microbes metabolize substances PMDBM2021707 69392 Stenotrophomonas sp003028475 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027533 Microbes metabolize substances PMDBM2021707 69392 Stenotrophomonas sp003028475 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027534 Microbes metabolize substances PMDBM2021707 69392 Stenotrophomonas sp003028475 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20027535 Microbes metabolize substances PMDBM2021707 69392 Stenotrophomonas sp003028475 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027536 Microbes metabolize substances PMDBM2021707 69392 Stenotrophomonas sp003028475 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027537 Microbes metabolize substances PMDBM2021707 69392 Stenotrophomonas sp003028475 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027538 Microbes metabolize substances PMDBM2021707 69392 Stenotrophomonas sp003028475 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027539 Microbes metabolize substances PMDBM2009660 1213720 Stomatobaculum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027540 Microbes metabolize substances PMDBM2009660 1213720 Stomatobaculum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027541 Microbes metabolize substances PMDBM2009660 1213720 Stomatobaculum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027542 Microbes metabolize substances PMDBM2009660 1213720 Stomatobaculum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027543 Microbes metabolize substances PMDBM2009660 1213720 Stomatobaculum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027544 Microbes metabolize substances PMDBM2009660 1213720 Stomatobaculum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027545 Microbes metabolize substances PMDBM2009660 1213720 Stomatobaculum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027548 Microbes metabolize substances PMDBM2009660 1213720 Stomatobaculum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027549 Microbes metabolize substances PMDBM2009660 1213720 Stomatobaculum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027550 Microbes metabolize substances PMDBM2009660 1213720 Stomatobaculum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027551 Microbes metabolize substances PMDBM2009660 1213720 Stomatobaculum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027552 Microbes metabolize substances PMDBM2009660 1213720 Stomatobaculum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027553 Microbes metabolize substances PMDBM2009660 1213720 Stomatobaculum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027554 Microbes metabolize substances PMDBM2009660 1213720 Stomatobaculum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027555 Microbes metabolize substances PMDBM2009660 1213720 Stomatobaculum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027556 Microbes metabolize substances PMDBM2021134 796942 Stomatobaculum longum PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027557 Microbes metabolize substances PMDBM2021134 796942 Stomatobaculum longum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027558 Microbes metabolize substances PMDBM2021134 796942 Stomatobaculum longum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027559 Microbes metabolize substances PMDBM2021134 796942 Stomatobaculum longum PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027560 Microbes metabolize substances PMDBM2021134 796942 Stomatobaculum longum PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027561 Microbes metabolize substances PMDBM2021134 796942 Stomatobaculum longum PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027562 Microbes metabolize substances PMDBM2021134 796942 Stomatobaculum longum PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027565 Microbes metabolize substances PMDBM2021134 796942 Stomatobaculum longum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027566 Microbes metabolize substances PMDBM2021134 796942 Stomatobaculum longum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027567 Microbes metabolize substances PMDBM2021134 796942 Stomatobaculum longum PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027568 Microbes metabolize substances PMDBM2021134 796942 Stomatobaculum longum PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027569 Microbes metabolize substances PMDBM2021134 796942 Stomatobaculum longum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027570 Microbes metabolize substances PMDBM2021134 796942 Stomatobaculum longum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027571 Microbes metabolize substances PMDBM2021134 796942 Stomatobaculum longum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027572 Microbes metabolize substances PMDBM2009662 n.a. Stomatobaculum naviforme PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20027573 Microbes metabolize substances PMDBM2009662 n.a. Stomatobaculum naviforme PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027574 Microbes metabolize substances PMDBM2009662 n.a. Stomatobaculum naviforme PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027575 Microbes metabolize substances PMDBM2009662 n.a. Stomatobaculum naviforme PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027576 Microbes metabolize substances PMDBM2009662 n.a. Stomatobaculum naviforme PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027577 Microbes metabolize substances PMDBM2009662 n.a. Stomatobaculum naviforme PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027578 Microbes metabolize substances PMDBM2021708 1984869 Stomatobaculum sp002892395 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20027579 Microbes metabolize substances PMDBM2021708 1984869 Stomatobaculum sp002892395 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027580 Microbes metabolize substances PMDBM2021708 1984869 Stomatobaculum sp002892395 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027581 Microbes metabolize substances PMDBM2021708 1984869 Stomatobaculum sp002892395 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027582 Microbes metabolize substances PMDBM2021709 1470350 Stoquefichus massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027583 Microbes metabolize substances PMDBM2021709 1470350 Stoquefichus massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027584 Microbes metabolize substances PMDBM2021709 1470350 Stoquefichus massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027585 Microbes metabolize substances PMDBM2021709 1470350 Stoquefichus massiliensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027587 Microbes metabolize substances PMDBM2021709 1470350 Stoquefichus massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027589 Microbes metabolize substances PMDBM2021709 1470350 Stoquefichus massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027590 Microbes metabolize substances PMDBM2021709 1470350 Stoquefichus massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027591 Microbes metabolize substances PMDBM2021709 1470350 Stoquefichus massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027592 Microbes metabolize substances PMDBM2021709 1470350 Stoquefichus massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027595 Microbes metabolize substances PMDBM2021709 1470350 Stoquefichus massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027596 Microbes metabolize substances PMDBM2021709 1470350 Stoquefichus massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027597 Microbes metabolize substances PMDBM2021709 1470350 Stoquefichus massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027598 Microbes metabolize substances PMDBM2021709 1470350 Stoquefichus massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027600 Microbes metabolize substances PMDBM2021709 1470350 Stoquefichus massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027601 Microbes metabolize substances PMDBM2021709 1470350 Stoquefichus massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027602 Microbes metabolize substances PMDBM2009665 n.a. Stoquefichus sp001244545 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027603 Microbes metabolize substances PMDBM2009665 n.a. Stoquefichus sp001244545 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027604 Microbes metabolize substances PMDBM2009665 n.a. Stoquefichus sp001244545 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027605 Microbes metabolize substances PMDBM2009665 n.a. Stoquefichus sp001244545 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027607 Microbes metabolize substances PMDBM2009665 n.a. Stoquefichus sp001244545 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027609 Microbes metabolize substances PMDBM2009665 n.a. Stoquefichus sp001244545 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027610 Microbes metabolize substances PMDBM2009665 n.a. Stoquefichus sp001244545 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027611 Microbes metabolize substances PMDBM2009665 n.a. Stoquefichus sp001244545 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027612 Microbes metabolize substances PMDBM2009665 n.a. Stoquefichus sp001244545 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027615 Microbes metabolize substances PMDBM2009665 n.a. Stoquefichus sp001244545 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027616 Microbes metabolize substances PMDBM2009665 n.a. Stoquefichus sp001244545 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027617 Microbes metabolize substances PMDBM2009665 n.a. Stoquefichus sp001244545 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027619 Microbes metabolize substances PMDBM2009665 n.a. Stoquefichus sp001244545 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027620 Microbes metabolize substances PMDBM2009665 n.a. Stoquefichus sp001244545 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027621 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027622 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027623 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027624 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20027625 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027626 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027627 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027628 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027631 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027632 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027633 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027634 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027635 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027636 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027637 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027638 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027639 Microbes metabolize substances PMDBM2020254 n.a. Streptococcus salivarius 275,DSM 20560,ATCC 7073,NCTC 8618 PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Bioaccumulation n.a. PMID PMID: 36467581 PMDBI20027640 Microbes metabolize substances PMDBM2020254 n.a. Streptococcus salivarius 275,DSM 20560,ATCC 7073,NCTC 8618 PMDBD558 Montelukast Therapeutic Substance Drugs for obstructive airway disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Biotransformation n.a. PMID PMID: 36467581 PMDBI20027642 Microbes metabolize substances PMDBM2020254 n.a. Streptococcus salivarius 275,DSM 20560,ATCC 7073,NCTC 8618 PMDBD2000059 Roflumilast Therapeutic Substance Drugs for obstructive airway disease n.a. n.a. n.a. n.a. n.a. n.a. unknown involved in substrate metabolism n.a. n.a. n.a. Biotransformation n.a. PMID PMID: 36467581 PMDBI20027643 Microbes metabolize substances PMDBM2020251 1311 Streptococcus agalactiae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027644 Microbes metabolize substances PMDBM2020251 1311 Streptococcus agalactiae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027645 Microbes metabolize substances PMDBM2020251 1311 Streptococcus agalactiae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20027647 Microbes metabolize substances PMDBM2020251 1311 Streptococcus agalactiae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20027648 Microbes metabolize substances PMDBM2020251 1311 Streptococcus agalactiae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20027649 Microbes metabolize substances PMDBM2020251 1311 Streptococcus agalactiae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027650 Microbes metabolize substances PMDBM2020251 1311 Streptococcus agalactiae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027653 Microbes metabolize substances PMDBM2020251 1311 Streptococcus agalactiae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20027657 Microbes metabolize substances PMDBM2020251 1311 Streptococcus agalactiae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027658 Microbes metabolize substances PMDBM2020251 1311 Streptococcus agalactiae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027659 Microbes metabolize substances PMDBM2020251 1311 Streptococcus agalactiae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027660 Microbes metabolize substances PMDBM2020179 1328 Streptococcus anginosus C PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027661 Microbes metabolize substances PMDBM2020179 1328 Streptococcus anginosus C PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027662 Microbes metabolize substances PMDBM2020179 1328 Streptococcus anginosus C PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027663 Microbes metabolize substances PMDBM2020179 1328 Streptococcus anginosus C PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027664 Microbes metabolize substances PMDBM2020179 1328 Streptococcus anginosus C PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027665 Microbes metabolize substances PMDBM2020179 1328 Streptococcus anginosus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027666 Microbes metabolize substances PMDBM2020179 1328 Streptococcus anginosus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027667 Microbes metabolize substances PMDBM2020179 1328 Streptococcus anginosus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027668 Microbes metabolize substances PMDBM2020179 1328 Streptococcus anginosus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027669 Microbes metabolize substances PMDBM2020179 1328 Streptococcus anginosus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027670 Microbes metabolize substances PMDBM2021136 76860 Streptococcus constellatus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027671 Microbes metabolize substances PMDBM2021136 76860 Streptococcus constellatus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027672 Microbes metabolize substances PMDBM2021136 76860 Streptococcus constellatus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027673 Microbes metabolize substances PMDBM2021136 76860 Streptococcus constellatus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027674 Microbes metabolize substances PMDBM2021136 76860 Streptococcus constellatus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027675 Microbes metabolize substances PMDBM2021353 1335 Streptococcus equinus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027676 Microbes metabolize substances PMDBM2021353 1335 Streptococcus equinus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027677 Microbes metabolize substances PMDBM2021353 1335 Streptococcus equinus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027678 Microbes metabolize substances PMDBM2021353 1335 Streptococcus equinus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027679 Microbes metabolize substances PMDBM2021353 1335 Streptococcus equinus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027680 Microbes metabolize substances PMDBM2021353 1335 Streptococcus equinus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027681 Microbes metabolize substances PMDBM2021353 1335 Streptococcus equinus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027684 Microbes metabolize substances PMDBM2021353 1335 Streptococcus equinus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027685 Microbes metabolize substances PMDBM2021353 1335 Streptococcus equinus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027686 Microbes metabolize substances PMDBM2021353 1335 Streptococcus equinus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027687 Microbes metabolize substances PMDBM2021353 1335 Streptococcus equinus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027688 Microbes metabolize substances PMDBM2021353 1335 Streptococcus equinus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027689 Microbes metabolize substances PMDBM2021353 1335 Streptococcus equinus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027690 Microbes metabolize substances PMDBM2021353 1335 Streptococcus equinus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027691 Microbes metabolize substances PMDBM2021353 1335 Streptococcus equinus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027692 Microbes metabolize substances PMDBM2021143 1302 Streptococcus gordonii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027693 Microbes metabolize substances PMDBM2021143 1302 Streptococcus gordonii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027694 Microbes metabolize substances PMDBM2021143 1302 Streptococcus gordonii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027695 Microbes metabolize substances PMDBM2021143 1302 Streptococcus gordonii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027696 Microbes metabolize substances PMDBM2021143 1302 Streptococcus gordonii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027697 Microbes metabolize substances PMDBM2020181 102684 Streptococcus infantarius PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027698 Microbes metabolize substances PMDBM2020181 102684 Streptococcus infantarius PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027699 Microbes metabolize substances PMDBM2020181 102684 Streptococcus infantarius PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027700 Microbes metabolize substances PMDBM2020181 102684 Streptococcus infantarius PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027701 Microbes metabolize substances PMDBM2020181 102684 Streptococcus infantarius PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027702 Microbes metabolize substances PMDBM2020181 102684 Streptococcus infantarius PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027703 Microbes metabolize substances PMDBM2020181 102684 Streptococcus infantarius PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027706 Microbes metabolize substances PMDBM2020181 102684 Streptococcus infantarius PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027707 Microbes metabolize substances PMDBM2020181 102684 Streptococcus infantarius PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027708 Microbes metabolize substances PMDBM2020181 102684 Streptococcus infantarius PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027709 Microbes metabolize substances PMDBM2020181 102684 Streptococcus infantarius PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027710 Microbes metabolize substances PMDBM2020181 102684 Streptococcus infantarius PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027711 Microbes metabolize substances PMDBM2020181 102684 Streptococcus infantarius PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027712 Microbes metabolize substances PMDBM2020181 102684 Streptococcus infantarius PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027713 Microbes metabolize substances PMDBM2020181 102684 Streptococcus infantarius PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027714 Microbes metabolize substances PMDBM2020182 68892 Streptococcus infantiI PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027715 Microbes metabolize substances PMDBM2020182 68892 Streptococcus infantiI PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027716 Microbes metabolize substances PMDBM2020182 68892 Streptococcus infantiI PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027717 Microbes metabolize substances PMDBM2020182 68892 Streptococcus infantiI PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027718 Microbes metabolize substances PMDBM2020182 68892 Streptococcus infantiI PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027719 Microbes metabolize substances PMDBM2021145 150055 Streptococcus lutetiensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027720 Microbes metabolize substances PMDBM2021145 150055 Streptococcus lutetiensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027721 Microbes metabolize substances PMDBM2021145 150055 Streptococcus lutetiensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027722 Microbes metabolize substances PMDBM2021145 150055 Streptococcus lutetiensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027723 Microbes metabolize substances PMDBM2021145 150055 Streptococcus lutetiensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027724 Microbes metabolize substances PMDBM2021145 150055 Streptococcus lutetiensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027725 Microbes metabolize substances PMDBM2021145 150055 Streptococcus lutetiensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027728 Microbes metabolize substances PMDBM2021145 150055 Streptococcus lutetiensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027729 Microbes metabolize substances PMDBM2021145 150055 Streptococcus lutetiensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027730 Microbes metabolize substances PMDBM2021145 150055 Streptococcus lutetiensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027731 Microbes metabolize substances PMDBM2021145 150055 Streptococcus lutetiensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027732 Microbes metabolize substances PMDBM2021145 150055 Streptococcus lutetiensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027733 Microbes metabolize substances PMDBM2021145 150055 Streptococcus lutetiensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027734 Microbes metabolize substances PMDBM2021145 150055 Streptococcus lutetiensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027735 Microbes metabolize substances PMDBM2021148 28037 Streptococcus mitis AC PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027736 Microbes metabolize substances PMDBM2021148 28037 Streptococcus mitis AC PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027737 Microbes metabolize substances PMDBM2021148 28037 Streptococcus mitis AC PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027738 Microbes metabolize substances PMDBM2021148 28037 Streptococcus mitis AC PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027739 Microbes metabolize substances PMDBM2021148 28037 Streptococcus mitis AC PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027740 Microbes metabolize substances PMDBM2021148 28037 Streptococcus mitis D PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027741 Microbes metabolize substances PMDBM2021148 28037 Streptococcus mitis D PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027742 Microbes metabolize substances PMDBM2021148 28037 Streptococcus mitis D PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027743 Microbes metabolize substances PMDBM2021148 28037 Streptococcus mitis D PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027744 Microbes metabolize substances PMDBM2021148 28037 Streptococcus mitis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027745 Microbes metabolize substances PMDBM2021148 28037 Streptococcus mitis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027746 Microbes metabolize substances PMDBM2021148 28037 Streptococcus mitis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027747 Microbes metabolize substances PMDBM2021148 28037 Streptococcus mitis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027748 Microbes metabolize substances PMDBM2020183 1309 Streptococcus mutans PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027749 Microbes metabolize substances PMDBM2020183 1309 Streptococcus mutans PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027750 Microbes metabolize substances PMDBM2020183 1309 Streptococcus mutans PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027751 Microbes metabolize substances PMDBM2020183 1309 Streptococcus mutans PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027752 Microbes metabolize substances PMDBM2020183 1309 Streptococcus mutans PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027753 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis AE PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027754 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis AE PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027755 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis AE PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027756 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis AE PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027757 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis E PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027758 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis E PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027759 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis E PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027760 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis E PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027761 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis E PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027762 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027763 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis S PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027764 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027765 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis S PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027766 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027767 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis S PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027768 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027769 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis S PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027770 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027771 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis S PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027772 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis V PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027773 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis V PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027774 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis V PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027775 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis V PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027776 Microbes metabolize substances PMDBM2021149 1303 Streptococcus oralis V PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027777 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027778 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027779 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027780 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis B PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027782 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027784 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027785 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027786 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027787 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027790 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027791 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027792 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027793 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027795 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis B PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027796 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027797 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027798 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027799 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027800 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027801 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027802 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027803 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027804 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027805 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027806 Microbes metabolize substances PMDBM2020252 1318 Streptococcus parasanguinis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027807 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027808 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027809 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027810 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027812 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027814 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027815 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027816 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027817 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027818 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027819 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027821 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20027824 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20027825 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20027826 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027827 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027830 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20027833 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027834 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027837 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027838 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027839 Microbes metabolize substances PMDBM2021152 197614 Streptococcus pasteurianus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027840 Microbes metabolize substances PMDBM2021356 68891 Streptococcus peroris PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027841 Microbes metabolize substances PMDBM2021356 68891 Streptococcus peroris PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027842 Microbes metabolize substances PMDBM2021356 68891 Streptococcus peroris PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027843 Microbes metabolize substances PMDBM2021356 68891 Streptococcus peroris PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027844 Microbes metabolize substances PMDBM2021356 68891 Streptococcus peroris PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027845 Microbes metabolize substances PMDBM2021155 257758 Streptococcus pseudopneumoniae O PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027846 Microbes metabolize substances PMDBM2021155 257758 Streptococcus pseudopneumoniae O PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027847 Microbes metabolize substances PMDBM2021155 257758 Streptococcus pseudopneumoniae O PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027848 Microbes metabolize substances PMDBM2021155 257758 Streptococcus pseudopneumoniae O PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027849 Microbes metabolize substances PMDBM2021155 257758 Streptococcus pseudopneumoniae O PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027850 Microbes metabolize substances PMDBM2020253 1314 Streptococcus pyogenes PMDBD810 Sulfanilamide "Therapeutic Substance; Herbal Substance" anti-infective n.a. n.a. n.a. n.a. sulfanilamide n.a. unknown activity increased n.a. n.a. n.a. "Exhibit potent antibacterial activity;drug interaction:antibiotics suppresses the conversion" n.a. PMID PMID: 36467581 PMDBI20027851 Microbes metabolize substances PMDBM2020254 1304 Streptococcus salivarius PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027852 Microbes metabolize substances PMDBM2020254 1304 Streptococcus salivarius PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027853 Microbes metabolize substances PMDBM2020254 1304 Streptococcus salivarius PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027854 Microbes metabolize substances PMDBM2020254 1304 Streptococcus salivarius PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027855 Microbes metabolize substances PMDBM2020254 1304 Streptococcus salivarius PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027856 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp000187445 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027857 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp000187445 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027858 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp000187445 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027859 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp000187445 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027860 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp000187445 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027861 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp000411475 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027862 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp000411475 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027863 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp000411475 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027864 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp000411475 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027865 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp000411475 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027866 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp000479315 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027867 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp000479315 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027868 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp000479315 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027869 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp000479315 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027870 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp000479315 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027871 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp001556435 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027872 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp001556435 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027873 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp001556435 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027874 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp001556435 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027875 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp001556435 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027876 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp002300045 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027877 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp002300045 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027878 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp002300045 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027879 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp002300045 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027880 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp002300045 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027881 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp002300045 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027882 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp002300045 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027885 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp002300045 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027886 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp002300045 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027887 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp002300045 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027888 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp002300045 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027889 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp002300045 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027890 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp002300045 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027891 Microbes metabolize substances PMDBM2021157 1306 Streptococcus sp002300045 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027892 Microbes metabolize substances PMDBM2020255 1308 Streptococcus thermophilus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027893 Microbes metabolize substances PMDBM2020255 1308 Streptococcus thermophilus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027894 Microbes metabolize substances PMDBM2020255 1308 Streptococcus thermophilus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027895 Microbes metabolize substances PMDBM2020255 1308 Streptococcus thermophilus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027896 Microbes metabolize substances PMDBM2020255 1308 Streptococcus thermophilus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027897 Microbes metabolize substances PMDBM2021163 1852387 Streptococcus timonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027898 Microbes metabolize substances PMDBM2021163 1852387 Streptococcus timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027899 Microbes metabolize substances PMDBM2021163 1852387 Streptococcus timonensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027900 Microbes metabolize substances PMDBM2021163 1852387 Streptococcus timonensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027901 Microbes metabolize substances PMDBM2021163 1852387 Streptococcus timonensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027902 Microbes metabolize substances PMDBM2021165 1343 Streptococcus vestibularis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027903 Microbes metabolize substances PMDBM2021165 1343 Streptococcus vestibularis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027904 Microbes metabolize substances PMDBM2021165 1343 Streptococcus vestibularis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027905 Microbes metabolize substances PMDBM2021165 1343 Streptococcus vestibularis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027906 Microbes metabolize substances PMDBM2021165 1343 Streptococcus vestibularis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027907 Microbes metabolize substances PMDBM2021710 1888 Streptomyces albus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027908 Microbes metabolize substances PMDBM2021710 1888 Streptomyces albus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027909 Microbes metabolize substances PMDBM2021710 1888 Streptomyces albus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027910 Microbes metabolize substances PMDBM2021710 1888 Streptomyces albus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027911 Microbes metabolize substances PMDBM2021710 1888 Streptomyces albus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027912 Microbes metabolize substances PMDBM2021710 1888 Streptomyces albus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027913 Microbes metabolize substances PMDBM2021710 1888 Streptomyces albus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027914 Microbes metabolize substances PMDBM2021710 1888 Streptomyces albus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027917 Microbes metabolize substances PMDBM2021710 1888 Streptomyces albus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027918 Microbes metabolize substances PMDBM2021710 1888 Streptomyces albus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027919 Microbes metabolize substances PMDBM2021710 1888 Streptomyces albus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027920 Microbes metabolize substances PMDBM2021710 1888 Streptomyces albus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027921 Microbes metabolize substances PMDBM2021710 1888 Streptomyces albus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027922 Microbes metabolize substances PMDBM2021710 1888 Streptomyces albus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20027923 Microbes metabolize substances PMDBM2009693 674963 Succinatimonas PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027924 Microbes metabolize substances PMDBM2009693 674963 Succinatimonas PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027925 Microbes metabolize substances PMDBM2009693 674963 Succinatimonas PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027926 Microbes metabolize substances PMDBM2009693 674963 Succinatimonas PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027927 Microbes metabolize substances PMDBM2009693 674963 Succinatimonas PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027928 Microbes metabolize substances PMDBM2021168 626938 Succinatimonas hippei PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027929 Microbes metabolize substances PMDBM2021168 626938 Succinatimonas hippei PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027930 Microbes metabolize substances PMDBM2021168 626938 Succinatimonas hippei PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027931 Microbes metabolize substances PMDBM2021168 626938 Succinatimonas hippei PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027932 Microbes metabolize substances PMDBM2021168 626938 Succinatimonas hippei PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027933 Microbes metabolize substances PMDBM2009695 40840 Succiniclasticum PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027934 Microbes metabolize substances PMDBM2009695 40840 Succiniclasticum PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027935 Microbes metabolize substances PMDBM2009695 40840 Succiniclasticum PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027936 Microbes metabolize substances PMDBM2009695 40840 Succiniclasticum PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027937 Microbes metabolize substances PMDBM2009695 40840 Succiniclasticum PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027938 Microbes metabolize substances PMDBM2009695 40840 Succiniclasticum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027939 Microbes metabolize substances PMDBM2009695 40840 Succiniclasticum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027940 Microbes metabolize substances PMDBM2009695 40840 Succiniclasticum PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027941 Microbes metabolize substances PMDBM2021711 2775030 Succiniclasticum sp900314855 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027942 Microbes metabolize substances PMDBM2021711 2775030 Succiniclasticum sp900314855 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027943 Microbes metabolize substances PMDBM2021711 2775030 Succiniclasticum sp900314855 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027944 Microbes metabolize substances PMDBM2021711 2775030 Succiniclasticum sp900314855 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027945 Microbes metabolize substances PMDBM2021711 2775030 Succiniclasticum sp900315805 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027946 Microbes metabolize substances PMDBM2021711 2775030 Succiniclasticum sp900315805 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027947 Microbes metabolize substances PMDBM2021711 2775030 Succiniclasticum sp900315805 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027948 Microbes metabolize substances PMDBM2021711 2775030 Succiniclasticum sp900315805 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027949 Microbes metabolize substances PMDBM2021711 2775030 Succiniclasticum sp900316935 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20027950 Microbes metabolize substances PMDBM2021711 2775030 Succiniclasticum sp900316935 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027951 Microbes metabolize substances PMDBM2021711 2775030 Succiniclasticum sp900316935 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027952 Microbes metabolize substances PMDBM2021711 2775030 Succiniclasticum sp900316935 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20027953 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027954 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027955 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027956 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027958 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20027960 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027961 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027962 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027963 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027964 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20027965 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027967 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20027970 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20027971 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20027972 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027973 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027976 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20027979 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027980 Microbes metabolize substances PMDBM2009699 83770 Succinivibrio PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027983 Microbes metabolize substances PMDBM2021712 2053619 Succinivibrio sp000431835 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027984 Microbes metabolize substances PMDBM2021712 2053619 Succinivibrio sp000431835 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027985 Microbes metabolize substances PMDBM2021712 2053619 Succinivibrio sp003456415 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20027986 Microbes metabolize substances PMDBM2021712 2053619 Succinivibrio sp003456415 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20027987 Microbes metabolize substances PMDBM2021712 2053619 Succinivibrio sp003456415 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20027988 Microbes metabolize substances PMDBM2021712 2053619 Succinivibrio sp003456415 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027989 Microbes metabolize substances PMDBM2021712 2053619 Succinivibrio sp003456415 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027990 Microbes metabolize substances PMDBM2021712 2053619 Succinivibrio sp003456415 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20027991 Microbes metabolize substances PMDBM2021712 2053619 Succinivibrio sp003456415 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20027994 Microbes metabolize substances PMDBM2021712 2053619 Succinivibrio sp003456415 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20027995 Microbes metabolize substances PMDBM2021712 2053619 Succinivibrio sp003456415 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20027996 Microbes metabolize substances PMDBM2021712 2053619 Succinivibrio sp003456415 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027997 Microbes metabolize substances PMDBM2021712 2053619 Succinivibrio sp003456415 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027998 Microbes metabolize substances PMDBM2021712 2053619 Succinivibrio sp003456415 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20027999 Microbes metabolize substances PMDBM397 40544 Sutterella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028000 Microbes metabolize substances PMDBM397 40544 Sutterella PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20028001 Microbes metabolize substances PMDBM397 40544 Sutterella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028002 Microbes metabolize substances PMDBM397 40544 Sutterella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028003 Microbes metabolize substances PMDBM397 40544 Sutterella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028004 Microbes metabolize substances PMDBM397 40544 Sutterella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028005 Microbes metabolize substances PMDBM397 40544 Sutterella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028006 Microbes metabolize substances PMDBM397 40544 Sutterella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028009 Microbes metabolize substances PMDBM397 40544 Sutterella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028010 Microbes metabolize substances PMDBM397 40544 Sutterella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028011 Microbes metabolize substances PMDBM397 40544 Sutterella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028012 Microbes metabolize substances PMDBM397 40544 Sutterella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028013 Microbes metabolize substances PMDBM397 40544 Sutterella PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. Compound K n.a. unknown activity increased n.a. n.a. n.a. Drug interaction:antibiotics inhibits the metabolism n.a. PMID PMID: 36467581 PMDBI20028014 Microbes metabolize substances PMDBM2021369 437898 Sutterella parvirubra PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028015 Microbes metabolize substances PMDBM2021369 437898 Sutterella parvirubra PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028016 Microbes metabolize substances PMDBM2021369 437898 Sutterella parvirubra PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028017 Microbes metabolize substances PMDBM2021369 437898 Sutterella parvirubra PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028018 Microbes metabolize substances PMDBM2021369 437898 Sutterella parvirubra PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028019 Microbes metabolize substances PMDBM2021369 437898 Sutterella parvirubra PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028020 Microbes metabolize substances PMDBM2021369 437898 Sutterella parvirubra PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028023 Microbes metabolize substances PMDBM2021369 437898 Sutterella parvirubra PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028024 Microbes metabolize substances PMDBM2021369 437898 Sutterella parvirubra PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028025 Microbes metabolize substances PMDBM2021369 437898 Sutterella parvirubra PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028026 Microbes metabolize substances PMDBM2021369 437898 Sutterella parvirubra PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028027 Microbes metabolize substances PMDBM2021172 40545 Sutterella wadsworthensis A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028028 Microbes metabolize substances PMDBM2021172 40545 Sutterella wadsworthensis B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028029 Microbes metabolize substances PMDBM2021172 40545 Sutterella wadsworthensis B PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20028030 Microbes metabolize substances PMDBM2021172 40545 Sutterella wadsworthensis B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028031 Microbes metabolize substances PMDBM2021172 40545 Sutterella wadsworthensis B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028032 Microbes metabolize substances PMDBM2021172 40545 Sutterella wadsworthensis B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028033 Microbes metabolize substances PMDBM2021172 40545 Sutterella wadsworthensis B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028034 Microbes metabolize substances PMDBM2021172 40545 Sutterella wadsworthensis B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028035 Microbes metabolize substances PMDBM2021172 40545 Sutterella wadsworthensis B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028038 Microbes metabolize substances PMDBM2021172 40545 Sutterella wadsworthensis B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028039 Microbes metabolize substances PMDBM2021172 40545 Sutterella wadsworthensis B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028040 Microbes metabolize substances PMDBM2021172 40545 Sutterella wadsworthensis B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028041 Microbes metabolize substances PMDBM2021172 40545 Sutterella wadsworthensis B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028042 Microbes metabolize substances PMDBM2009705 n.a. f Lachnospiraceae g SZUA-378 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028043 Microbes metabolize substances PMDBM2009705 n.a. f Lachnospiraceae g SZUA-378 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20028044 Microbes metabolize substances PMDBM2009705 n.a. f Lachnospiraceae g SZUA-378 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028045 Microbes metabolize substances PMDBM2009705 n.a. f Lachnospiraceae g SZUA-378 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028046 Microbes metabolize substances PMDBM2009705 n.a. f Lachnospiraceae g SZUA-378 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028047 Microbes metabolize substances PMDBM2009705 n.a. f Lachnospiraceae g SZUA-378 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028048 Microbes metabolize substances PMDBM2009705 n.a. f Lachnospiraceae g SZUA-378 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028049 Microbes metabolize substances PMDBM2009705 n.a. f Lachnospiraceae g SZUA-378 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028052 Microbes metabolize substances PMDBM2009705 n.a. f Lachnospiraceae g SZUA-378 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028053 Microbes metabolize substances PMDBM2009705 n.a. f Lachnospiraceae g SZUA-378 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028054 Microbes metabolize substances PMDBM2009705 n.a. f Lachnospiraceae g SZUA-378 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028055 Microbes metabolize substances PMDBM2009705 n.a. f Lachnospiraceae g SZUA-378 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028056 Microbes metabolize substances PMDBM2009705 n.a. f Lachnospiraceae g SZUA-378 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028057 Microbes metabolize substances PMDBM2009705 n.a. f Lachnospiraceae g SZUA-378 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028058 Microbes metabolize substances PMDBM2009705 n.a. f Lachnospiraceae g SZUA-378 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028059 Microbes metabolize substances PMDBM2009706 n.a. c Clostridia o TANB77 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028060 Microbes metabolize substances PMDBM2009706 n.a. c Clostridia o TANB77 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028061 Microbes metabolize substances PMDBM2009706 n.a. c Clostridia o TANB77 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028062 Microbes metabolize substances PMDBM2009706 n.a. c Clostridia o TANB77 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028063 Microbes metabolize substances PMDBM2009706 n.a. c Clostridia o TANB77 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028064 Microbes metabolize substances PMDBM2009706 n.a. c Clostridia o TANB77 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028065 Microbes metabolize substances PMDBM2009706 n.a. c Clostridia o TANB77 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028068 Microbes metabolize substances PMDBM2009706 n.a. c Clostridia o TANB77 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028069 Microbes metabolize substances PMDBM2009706 n.a. c Clostridia o TANB77 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028070 Microbes metabolize substances PMDBM2009706 n.a. c Clostridia o TANB77 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028071 Microbes metabolize substances PMDBM2009706 n.a. c Clostridia o TANB77 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028072 Microbes metabolize substances PMDBM2009706 n.a. c Clostridia o TANB77 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028073 Microbes metabolize substances PMDBM2009706 n.a. c Clostridia o TANB77 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028074 Microbes metabolize substances PMDBM2009707 n.a. c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028075 Microbes metabolize substances PMDBM2009707 n.a. c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028076 Microbes metabolize substances PMDBM2009707 n.a. c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028077 Microbes metabolize substances PMDBM2009707 n.a. c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028078 Microbes metabolize substances PMDBM2009707 n.a. c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028079 Microbes metabolize substances PMDBM2009707 n.a. c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028080 Microbes metabolize substances PMDBM2009707 n.a. c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028083 Microbes metabolize substances PMDBM2009707 n.a. c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028084 Microbes metabolize substances PMDBM2009707 n.a. c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028085 Microbes metabolize substances PMDBM2009707 n.a. c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028086 Microbes metabolize substances PMDBM2009707 n.a. c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028087 Microbes metabolize substances PMDBM2009707 n.a. c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028088 Microbes metabolize substances PMDBM2009707 n.a. c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028089 Microbes metabolize substances PMDBM2009707 n.a. c Bacilli o ML615J-28 f CAG-698 g Tener-01 s Tener-01 sp001940985 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028090 Microbes metabolize substances PMDBM965 544448 Tenericutes PMDBD627 Oxaliplatin Therapeutic Substance chemotherapy agent n.a. n.a. n.a. n.a. n.a. n.a. unknown Reduce the side effects of drugs n.a. n.a. n.a. Hydrogenated water-induced changes in the gut microbiota significantly improve mechanical hyperalgesia caused by oxaliplatin. Oxaliplatin, a chemotherapeutic agent, can cause severe pain by mechanical hyperalgesia. Mice treated with hydrogen-rich water showed significant changes in the richness and æµ?diversity of the gut microbiota. High abundance of Firmicutes and Tenericutes and low abundance of Bacteroidetes were observed. The expression of TNF-æµ?and IL-6 (P<0.05) was reduced with hydrogen-rich water treatment. Such change in expression is believed to improve chemotherapy-induced neuropathic pain. n.a. PMID PMID: 36467581 PMDBI20028091 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028092 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20028093 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028094 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028095 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028096 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028097 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028098 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028099 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028100 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028102 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028105 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028106 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028107 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20028108 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028109 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028112 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028115 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028116 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028117 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028119 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028120 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028121 Microbes metabolize substances PMDBM2009708 1505652 Terrisporobacter PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028122 Microbes metabolize substances PMDBM2021178 36841 Terrisporobacter glycolicus A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028123 Microbes metabolize substances PMDBM2021178 36841 Terrisporobacter glycolicus A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028124 Microbes metabolize substances PMDBM2021178 36841 Terrisporobacter glycolicus A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028125 Microbes metabolize substances PMDBM2021178 36841 Terrisporobacter glycolicus A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028126 Microbes metabolize substances PMDBM2021178 36841 Terrisporobacter glycolicus A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028127 Microbes metabolize substances PMDBM2021178 36841 Terrisporobacter glycolicus A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028128 Microbes metabolize substances PMDBM2021178 36841 Terrisporobacter glycolicus A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028131 Microbes metabolize substances PMDBM2021178 36841 Terrisporobacter glycolicus A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028132 Microbes metabolize substances PMDBM2021178 36841 Terrisporobacter glycolicus A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028133 Microbes metabolize substances PMDBM2021178 36841 Terrisporobacter glycolicus A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028134 Microbes metabolize substances PMDBM2021178 36841 Terrisporobacter glycolicus A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028135 Microbes metabolize substances PMDBM2021178 36841 Terrisporobacter glycolicus A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028136 Microbes metabolize substances PMDBM2021178 36841 Terrisporobacter glycolicus A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028137 Microbes metabolize substances PMDBM2021178 36841 Terrisporobacter glycolicus A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028138 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028139 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20028140 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028141 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028142 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028143 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028144 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028145 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028146 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028147 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028149 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028152 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028153 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028154 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028155 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028158 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028161 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028162 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028163 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028165 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028166 Microbes metabolize substances PMDBM2021713 1577792 Terrisporobacter othiniensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028167 Microbes metabolize substances PMDBM2021180 1522311 Tessaracoccus massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028168 Microbes metabolize substances PMDBM2021180 1522311 Tessaracoccus massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20028169 Microbes metabolize substances PMDBM2021180 1522311 Tessaracoccus massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028170 Microbes metabolize substances PMDBM2021180 1522311 Tessaracoccus massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028171 Microbes metabolize substances PMDBM2021180 1522311 Tessaracoccus massiliensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028173 Microbes metabolize substances PMDBM2021180 1522311 Tessaracoccus massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028175 Microbes metabolize substances PMDBM2021180 1522311 Tessaracoccus massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028176 Microbes metabolize substances PMDBM2021180 1522311 Tessaracoccus massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028177 Microbes metabolize substances PMDBM2021180 1522311 Tessaracoccus massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028178 Microbes metabolize substances PMDBM2021180 1522311 Tessaracoccus massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028181 Microbes metabolize substances PMDBM2021180 1522311 Tessaracoccus massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028182 Microbes metabolize substances PMDBM2021180 1522311 Tessaracoccus massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028183 Microbes metabolize substances PMDBM2021180 1522311 Tessaracoccus massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028184 Microbes metabolize substances PMDBM2021180 1522311 Tessaracoccus massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028186 Microbes metabolize substances PMDBM2021180 1522311 Tessaracoccus massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028187 Microbes metabolize substances PMDBM2021180 1522311 Tessaracoccus massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028188 Microbes metabolize substances PMDBM2021180 1522311 Tessaracoccus massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028189 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028190 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028191 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028192 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028194 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028196 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028197 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028198 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028199 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028200 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028201 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028203 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028206 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028207 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028208 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028209 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028212 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028215 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028216 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028219 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028220 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028221 Microbes metabolize substances PMDBM2009712 n.a. f Lachnospiraceae g TF01-11 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028222 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028223 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028224 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028225 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028227 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028229 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028230 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028231 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028232 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028233 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028234 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028236 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028239 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028240 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028241 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028242 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028245 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028248 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028249 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028252 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028253 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028254 Microbes metabolize substances PMDBM2009713 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp000436755 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028255 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028256 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028257 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028258 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028260 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028262 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028263 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028264 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028265 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028266 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028267 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028269 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028272 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028273 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028274 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028275 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028278 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028281 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028282 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028285 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028286 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028287 Microbes metabolize substances PMDBM2009714 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001414325 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028288 Microbes metabolize substances PMDBM2009715 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028289 Microbes metabolize substances PMDBM2009715 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028290 Microbes metabolize substances PMDBM2009715 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028291 Microbes metabolize substances PMDBM2009715 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028292 Microbes metabolize substances PMDBM2009715 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028293 Microbes metabolize substances PMDBM2009715 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028294 Microbes metabolize substances PMDBM2009715 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028297 Microbes metabolize substances PMDBM2009715 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028298 Microbes metabolize substances PMDBM2009715 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028299 Microbes metabolize substances PMDBM2009715 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028300 Microbes metabolize substances PMDBM2009715 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028301 Microbes metabolize substances PMDBM2009715 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028302 Microbes metabolize substances PMDBM2009715 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028303 Microbes metabolize substances PMDBM2009715 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp001916135 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028304 Microbes metabolize substances PMDBM2009716 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028305 Microbes metabolize substances PMDBM2009716 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028306 Microbes metabolize substances PMDBM2009716 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028307 Microbes metabolize substances PMDBM2009716 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028309 Microbes metabolize substances PMDBM2009716 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028311 Microbes metabolize substances PMDBM2009716 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20028312 Microbes metabolize substances PMDBM2009716 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028313 Microbes metabolize substances PMDBM2009716 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028314 Microbes metabolize substances PMDBM2009716 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028315 Microbes metabolize substances PMDBM2009716 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028318 Microbes metabolize substances PMDBM2009716 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028319 Microbes metabolize substances PMDBM2009716 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028320 Microbes metabolize substances PMDBM2009716 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028321 Microbes metabolize substances PMDBM2009716 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028323 Microbes metabolize substances PMDBM2009716 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028324 Microbes metabolize substances PMDBM2009716 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003149875 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028325 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028326 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028327 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028328 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028329 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028330 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028331 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028332 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028333 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028335 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028338 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028339 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028340 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028341 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028344 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028347 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028348 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028349 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028351 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028352 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028353 Microbes metabolize substances PMDBM2009717 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003524945 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028354 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028355 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20028356 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028357 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028358 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028359 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028360 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028361 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028362 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028363 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028365 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028368 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028369 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028370 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028371 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028374 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028377 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028378 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028379 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028381 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028382 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028383 Microbes metabolize substances PMDBM2009718 n.a. f Lachnospiraceae g TF01-11 s TF01-11 sp003529475 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028384 Microbes metabolize substances PMDBM2021714 1922205 Thalassobacillus sp001368835 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028385 Microbes metabolize substances PMDBM2021714 1922205 Thalassobacillus sp001368835 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20028386 Microbes metabolize substances PMDBM2021714 1922205 Thalassobacillus sp001368835 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028387 Microbes metabolize substances PMDBM2021714 1922205 Thalassobacillus sp001368835 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028388 Microbes metabolize substances PMDBM2021714 1922205 Thalassobacillus sp001368835 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028389 Microbes metabolize substances PMDBM2021714 1922205 Thalassobacillus sp001368835 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028390 Microbes metabolize substances PMDBM2021714 1922205 Thalassobacillus sp001368835 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028391 Microbes metabolize substances PMDBM2021714 1922205 Thalassobacillus sp001368835 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028394 Microbes metabolize substances PMDBM2021714 1922205 Thalassobacillus sp001368835 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028395 Microbes metabolize substances PMDBM2021714 1922205 Thalassobacillus sp001368835 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028396 Microbes metabolize substances PMDBM2021714 1922205 Thalassobacillus sp001368835 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028397 Microbes metabolize substances PMDBM2021714 1922205 Thalassobacillus sp001368835 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028398 Microbes metabolize substances PMDBM2021714 1922205 Thalassobacillus sp001368835 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028399 Microbes metabolize substances PMDBM2021714 1922205 Thalassobacillus sp001368835 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028400 Microbes metabolize substances PMDBM2021714 1922205 Thalassobacillus sp001368835 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028401 Microbes metabolize substances PMDBM2021714 1922205 Thalassobacillus sp001368835 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028402 Microbes metabolize substances PMDBM2021715 1501391 Tidjanibacter inops PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20028403 Microbes metabolize substances PMDBM2021715 1501391 Tidjanibacter inops PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028404 Microbes metabolize substances PMDBM2021715 1501391 Tidjanibacter inops PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028405 Microbes metabolize substances PMDBM2021715 1501391 Tidjanibacter inops PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028406 Microbes metabolize substances PMDBM2021715 1501391 Tidjanibacter inops PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028407 Microbes metabolize substances PMDBM2021184 1465825 Timonella senegalensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028408 Microbes metabolize substances PMDBM2021184 1465825 Timonella senegalensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028409 Microbes metabolize substances PMDBM2021184 1465825 Timonella senegalensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028410 Microbes metabolize substances PMDBM2021184 1465825 Timonella senegalensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028411 Microbes metabolize substances PMDBM2021184 1465825 Timonella senegalensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028412 Microbes metabolize substances PMDBM2021184 1465825 Timonella senegalensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028413 Microbes metabolize substances PMDBM2021184 1465825 Timonella senegalensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028416 Microbes metabolize substances PMDBM2021184 1465825 Timonella senegalensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028417 Microbes metabolize substances PMDBM2021184 1465825 Timonella senegalensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028418 Microbes metabolize substances PMDBM2021184 1465825 Timonella senegalensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028419 Microbes metabolize substances PMDBM2021184 1465825 Timonella senegalensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028420 Microbes metabolize substances PMDBM2021184 1465825 Timonella senegalensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028421 Microbes metabolize substances PMDBM2021184 1465825 Timonella senegalensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028422 Microbes metabolize substances PMDBM2021184 1465825 Timonella senegalensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028423 Microbes metabolize substances PMDBM2021716 41274 Tissierella sp002266425 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20028424 Microbes metabolize substances PMDBM2021716 41274 Tissierella sp002266425 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20028425 Microbes metabolize substances PMDBM2021716 41274 Tissierella sp002266425 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028426 Microbes metabolize substances PMDBM2021716 41274 Tissierella sp002266425 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028427 Microbes metabolize substances PMDBM2021716 41274 Tissierella sp002266425 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028428 Microbes metabolize substances PMDBM2021716 41274 Tissierella sp002266425 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028429 Microbes metabolize substances PMDBM2009723 n.a. f Saccharimonadaceae g TM7x PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20028430 Microbes metabolize substances PMDBM2009723 n.a. f Saccharimonadaceae g TM7x PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028431 Microbes metabolize substances PMDBM2009724 1929045 Traorella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028432 Microbes metabolize substances PMDBM2009724 1929045 Traorella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028433 Microbes metabolize substances PMDBM2009724 1929045 Traorella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028434 Microbes metabolize substances PMDBM2009724 1929045 Traorella PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20028435 Microbes metabolize substances PMDBM2009724 1929045 Traorella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028436 Microbes metabolize substances PMDBM2009724 1929045 Traorella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028437 Microbes metabolize substances PMDBM2009724 1929045 Traorella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028438 Microbes metabolize substances PMDBM2009724 1929045 Traorella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028441 Microbes metabolize substances PMDBM2009724 1929045 Traorella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028442 Microbes metabolize substances PMDBM2009724 1929045 Traorella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028443 Microbes metabolize substances PMDBM2009724 1929045 Traorella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028444 Microbes metabolize substances PMDBM2009724 1929045 Traorella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028445 Microbes metabolize substances PMDBM2009724 1929045 Traorella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028446 Microbes metabolize substances PMDBM2009725 n.a. Treponema D PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028447 Microbes metabolize substances PMDBM2009725 n.a. Treponema D PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028448 Microbes metabolize substances PMDBM2009725 n.a. Treponema D PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028449 Microbes metabolize substances PMDBM2009725 n.a. Treponema D PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028450 Microbes metabolize substances PMDBM2009725 n.a. Treponema D PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028451 Microbes metabolize substances PMDBM2009725 n.a. Treponema D PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028452 Microbes metabolize substances PMDBM2009725 n.a. Treponema D PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028455 Microbes metabolize substances PMDBM2009725 n.a. Treponema D PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028456 Microbes metabolize substances PMDBM2009725 n.a. Treponema D PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028457 Microbes metabolize substances PMDBM2009725 n.a. Treponema D PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028458 Microbes metabolize substances PMDBM2009725 n.a. Treponema D PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028459 Microbes metabolize substances PMDBM2009725 n.a. Treponema D PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028460 Microbes metabolize substances PMDBM2009725 n.a. Treponema D PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028461 Microbes metabolize substances PMDBM2009725 n.a. Treponema D PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028462 Microbes metabolize substances PMDBM2009725 n.a. Treponema D PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028463 Microbes metabolize substances PMDBM2021717 225004 Treponema D berlinense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028464 Microbes metabolize substances PMDBM2021717 225004 Treponema D berlinense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028465 Microbes metabolize substances PMDBM2021717 225004 Treponema D berlinense PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028466 Microbes metabolize substances PMDBM2021717 225004 Treponema D berlinense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028467 Microbes metabolize substances PMDBM2021717 225004 Treponema D berlinense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028468 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002449305 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028469 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002449305 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028470 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002449305 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028471 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002449305 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028472 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002449305 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028473 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002449305 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028474 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002449305 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028477 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002449305 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028478 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002449305 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028479 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002449305 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028480 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002449305 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028481 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002449305 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028482 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002449305 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028483 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002449305 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028484 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002478955 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028485 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002478955 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028486 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002478955 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028487 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002478955 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028488 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002478955 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028489 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002478955 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028490 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002478955 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028493 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002478955 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028494 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002478955 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028495 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002478955 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028496 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002478955 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028497 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002478955 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028498 Microbes metabolize substances PMDBM2021718 166 Treponema D sp002478955 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028499 Microbes metabolize substances PMDBM2021188 167 Treponema D succinifaciens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028500 Microbes metabolize substances PMDBM2021188 167 Treponema D succinifaciens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028501 Microbes metabolize substances PMDBM2021188 167 Treponema D succinifaciens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028502 Microbes metabolize substances PMDBM2021188 167 Treponema D succinifaciens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028503 Microbes metabolize substances PMDBM2021188 167 Treponema D succinifaciens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028504 Microbes metabolize substances PMDBM2021188 167 Treponema D succinifaciens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028505 Microbes metabolize substances PMDBM2021188 167 Treponema D succinifaciens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028508 Microbes metabolize substances PMDBM2021188 167 Treponema D succinifaciens PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028509 Microbes metabolize substances PMDBM2021188 167 Treponema D succinifaciens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028510 Microbes metabolize substances PMDBM2021188 167 Treponema D succinifaciens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028511 Microbes metabolize substances PMDBM2021188 167 Treponema D succinifaciens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028512 Microbes metabolize substances PMDBM2021188 167 Treponema D succinifaciens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028513 Microbes metabolize substances PMDBM2021188 167 Treponema D succinifaciens PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028514 Microbes metabolize substances PMDBM2021188 167 Treponema D succinifaciens PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028515 Microbes metabolize substances PMDBM2021191 154288 Turicibacter sanguinis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028516 Microbes metabolize substances PMDBM2021191 154288 Turicibacter sanguinis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20028517 Microbes metabolize substances PMDBM2021191 154288 Turicibacter sanguinis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028518 Microbes metabolize substances PMDBM2021191 154288 Turicibacter sanguinis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028519 Microbes metabolize substances PMDBM2021191 154288 Turicibacter sanguinis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028520 Microbes metabolize substances PMDBM2021191 154288 Turicibacter sanguinis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028521 Microbes metabolize substances PMDBM2021191 154288 Turicibacter sanguinis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028522 Microbes metabolize substances PMDBM2021191 154288 Turicibacter sanguinis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028525 Microbes metabolize substances PMDBM2021191 154288 Turicibacter sanguinis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028526 Microbes metabolize substances PMDBM2021191 154288 Turicibacter sanguinis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028527 Microbes metabolize substances PMDBM2021191 154288 Turicibacter sanguinis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028528 Microbes metabolize substances PMDBM2021191 154288 Turicibacter sanguinis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028529 Microbes metabolize substances PMDBM2021191 154288 Turicibacter sanguinis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028530 Microbes metabolize substances PMDBM2021191 154288 Turicibacter sanguinis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028531 Microbes metabolize substances PMDBM2021191 154288 Turicibacter sanguinis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028532 Microbes metabolize substances PMDBM2021719 2049042 Turicibacter sp001543345 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028533 Microbes metabolize substances PMDBM2021719 2049042 Turicibacter sp001543345 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20028534 Microbes metabolize substances PMDBM2021719 2049042 Turicibacter sp001543345 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028535 Microbes metabolize substances PMDBM2021719 2049042 Turicibacter sp001543345 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028536 Microbes metabolize substances PMDBM2021719 2049042 Turicibacter sp001543345 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028537 Microbes metabolize substances PMDBM2021719 2049042 Turicibacter sp001543345 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028538 Microbes metabolize substances PMDBM2021719 2049042 Turicibacter sp001543345 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028539 Microbes metabolize substances PMDBM2021719 2049042 Turicibacter sp001543345 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028542 Microbes metabolize substances PMDBM2021719 2049042 Turicibacter sp001543345 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028543 Microbes metabolize substances PMDBM2021719 2049042 Turicibacter sp001543345 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028544 Microbes metabolize substances PMDBM2021719 2049042 Turicibacter sp001543345 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028545 Microbes metabolize substances PMDBM2021719 2049042 Turicibacter sp001543345 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028546 Microbes metabolize substances PMDBM2021719 2049042 Turicibacter sp001543345 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028547 Microbes metabolize substances PMDBM2021719 2049042 Turicibacter sp001543345 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028548 Microbes metabolize substances PMDBM2021719 2049042 Turicibacter sp001543345 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028549 Microbes metabolize substances PMDBM2009732 1918598 Turicimonas PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028550 Microbes metabolize substances PMDBM2009732 1918598 Turicimonas PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20028551 Microbes metabolize substances PMDBM2009732 1918598 Turicimonas PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028552 Microbes metabolize substances PMDBM2009732 1918598 Turicimonas PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028553 Microbes metabolize substances PMDBM2009732 1918598 Turicimonas PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028554 Microbes metabolize substances PMDBM2009732 1918598 Turicimonas PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028555 Microbes metabolize substances PMDBM2009732 1918598 Turicimonas PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028556 Microbes metabolize substances PMDBM2009732 1918598 Turicimonas PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028559 Microbes metabolize substances PMDBM2009732 1918598 Turicimonas PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028560 Microbes metabolize substances PMDBM2009732 1918598 Turicimonas PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028561 Microbes metabolize substances PMDBM2009732 1918598 Turicimonas PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028562 Microbes metabolize substances PMDBM2009732 1918598 Turicimonas PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028563 Microbes metabolize substances PMDBM2021194 1796652 Turicimonas muris PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028564 Microbes metabolize substances PMDBM2021194 1796652 Turicimonas muris PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20028565 Microbes metabolize substances PMDBM2021194 1796652 Turicimonas muris PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028566 Microbes metabolize substances PMDBM2021194 1796652 Turicimonas muris PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028567 Microbes metabolize substances PMDBM2021194 1796652 Turicimonas muris PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028568 Microbes metabolize substances PMDBM2021194 1796652 Turicimonas muris PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028569 Microbes metabolize substances PMDBM2021194 1796652 Turicimonas muris PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028570 Microbes metabolize substances PMDBM2021194 1796652 Turicimonas muris PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028573 Microbes metabolize substances PMDBM2021194 1796652 Turicimonas muris PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028574 Microbes metabolize substances PMDBM2021194 1796652 Turicimonas muris PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028575 Microbes metabolize substances PMDBM2021194 1796652 Turicimonas muris PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028576 Microbes metabolize substances PMDBM2021194 1796652 Turicimonas muris PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028577 Microbes metabolize substances PMDBM2009734 n.a. f Lachnospiraceae g TWA4 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20028578 Microbes metabolize substances PMDBM2009734 n.a. f Lachnospiraceae g TWA4 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028579 Microbes metabolize substances PMDBM2009734 n.a. f Lachnospiraceae g TWA4 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028580 Microbes metabolize substances PMDBM2009734 n.a. f Lachnospiraceae g TWA4 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20028581 Microbes metabolize substances PMDBM2009734 n.a. f Lachnospiraceae g TWA4 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028582 Microbes metabolize substances PMDBM2009734 n.a. f Lachnospiraceae g TWA4 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028583 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028584 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20028585 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028586 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028587 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028589 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028591 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20028592 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028593 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028594 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028595 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028596 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028597 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028599 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028602 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028603 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028604 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028605 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028608 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028611 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028612 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028615 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028616 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028617 Microbes metabolize substances PMDBM2009735 1506577 Tyzzerella PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028618 Microbes metabolize substances PMDBM2020549 29361 Tyzzerella nexilis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028619 Microbes metabolize substances PMDBM2020549 29361 Tyzzerella nexilis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20028620 Microbes metabolize substances PMDBM2020549 29361 Tyzzerella nexilis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028621 Microbes metabolize substances PMDBM2020549 29361 Tyzzerella nexilis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028622 Microbes metabolize substances PMDBM2020549 29361 Tyzzerella nexilis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028623 Microbes metabolize substances PMDBM2020549 29361 Tyzzerella nexilis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028624 Microbes metabolize substances PMDBM2020549 29361 Tyzzerella nexilis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028625 Microbes metabolize substances PMDBM2020549 29361 Tyzzerella nexilis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028628 Microbes metabolize substances PMDBM2020549 29361 Tyzzerella nexilis PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20028629 Microbes metabolize substances PMDBM2020549 29361 Tyzzerella nexilis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028630 Microbes metabolize substances PMDBM2020549 29361 Tyzzerella nexilis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028631 Microbes metabolize substances PMDBM2020549 29361 Tyzzerella nexilis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028632 Microbes metabolize substances PMDBM2020549 29361 Tyzzerella nexilis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028633 Microbes metabolize substances PMDBM2020549 29361 Tyzzerella nexilis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028634 Microbes metabolize substances PMDBM2020549 29361 Tyzzerella nexilis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028635 Microbes metabolize substances PMDBM2020549 29361 Tyzzerella nexilis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028636 Microbes metabolize substances PMDBM2020549 29361 Tyzzerella nexilis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028637 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000209385 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028638 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000209385 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028639 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000209385 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028640 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000209385 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028641 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000209385 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028642 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000209385 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028643 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000209385 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028646 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000209385 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028647 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000209385 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028648 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000209385 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028649 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000209385 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028650 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000209385 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028651 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000209385 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028652 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000209385 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028653 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000411335 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028654 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000411335 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028655 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000411335 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028656 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000411335 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028657 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000411335 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028658 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000411335 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028659 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000411335 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028662 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000411335 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028663 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000411335 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028664 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000411335 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028665 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000411335 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028666 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000411335 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028667 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000411335 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028668 Microbes metabolize substances PMDBM2021720 2053632 Tyzzerella sp000411335 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028669 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028670 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028671 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028672 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028674 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028676 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028677 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028678 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028679 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028680 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028681 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028683 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028686 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028687 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028688 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028689 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028692 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028695 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028696 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028699 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028700 Microbes metabolize substances PMDBM2009739 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028701 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028702 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028703 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028704 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028706 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028708 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028709 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028710 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028711 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028712 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028713 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028715 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028718 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028719 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028720 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028721 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028724 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028727 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028728 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028731 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028732 Microbes metabolize substances PMDBM2009740 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA10281 s UBA10281 sp000437515 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028733 Microbes metabolize substances PMDBM2009741 n.a. c Kiritimatiellae o RFP12 f UBA1067 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20028734 Microbes metabolize substances PMDBM2009741 n.a. c Kiritimatiellae o RFP12 f UBA1067 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028735 Microbes metabolize substances PMDBM2009741 n.a. c Kiritimatiellae o RFP12 f UBA1067 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028736 Microbes metabolize substances PMDBM2009741 n.a. c Kiritimatiellae o RFP12 f UBA1067 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028737 Microbes metabolize substances PMDBM2009741 n.a. c Kiritimatiellae o RFP12 f UBA1067 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028738 Microbes metabolize substances PMDBM2009741 n.a. c Kiritimatiellae o RFP12 f UBA1067 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028739 Microbes metabolize substances PMDBM2009741 n.a. c Kiritimatiellae o RFP12 f UBA1067 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028740 Microbes metabolize substances PMDBM2009741 n.a. c Kiritimatiellae o RFP12 f UBA1067 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028742 Microbes metabolize substances PMDBM2009741 n.a. c Kiritimatiellae o RFP12 f UBA1067 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028743 Microbes metabolize substances PMDBM2009741 n.a. c Kiritimatiellae o RFP12 f UBA1067 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028744 Microbes metabolize substances PMDBM2009741 n.a. c Kiritimatiellae o RFP12 f UBA1067 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028747 Microbes metabolize substances PMDBM2009741 n.a. c Kiritimatiellae o RFP12 f UBA1067 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028751 Microbes metabolize substances PMDBM2009741 n.a. c Kiritimatiellae o RFP12 f UBA1067 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028752 Microbes metabolize substances PMDBM2009741 n.a. c Kiritimatiellae o RFP12 f UBA1067 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028753 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028754 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028755 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028756 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028758 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028760 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028761 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028762 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028763 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028764 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028765 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028767 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028770 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028771 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028772 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20028773 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028774 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028777 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028780 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028781 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028784 Microbes metabolize substances PMDBM2009742 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028785 Microbes metabolize substances PMDBM2009743 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028786 Microbes metabolize substances PMDBM2009743 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028787 Microbes metabolize substances PMDBM2009743 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028788 Microbes metabolize substances PMDBM2009743 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028789 Microbes metabolize substances PMDBM2009743 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028790 Microbes metabolize substances PMDBM2009743 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028791 Microbes metabolize substances PMDBM2009743 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028793 Microbes metabolize substances PMDBM2009743 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028794 Microbes metabolize substances PMDBM2009743 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028795 Microbes metabolize substances PMDBM2009743 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20028796 Microbes metabolize substances PMDBM2009743 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028797 Microbes metabolize substances PMDBM2009743 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028800 Microbes metabolize substances PMDBM2009743 n.a. c Clostridia o 4C28d-15 f CAG-552 g UBA10677 s UBA10677 sp003533505 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028804 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028805 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028806 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028807 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028809 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028811 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028812 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028813 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028814 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028815 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028816 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028818 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028821 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028822 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028823 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028824 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028827 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028830 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028831 Microbes metabolize substances PMDBM2009744 n.a. f Acutalibacteraceae g UBA1081 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028834 Microbes metabolize substances PMDBM2009745 n.a. f Saccharimonadaceae g UBA1103 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028835 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028836 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028837 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028838 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028840 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028842 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028843 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028844 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028845 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028846 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028847 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028849 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028852 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028853 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028854 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028857 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028860 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028861 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028864 Microbes metabolize substances PMDBM2009746 n.a. o Victivallales f UBA1829 g UBA11452 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20028865 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028866 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028867 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028868 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028870 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028872 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028873 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028874 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028875 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028876 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028877 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028879 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028882 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028883 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028884 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028885 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028888 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028891 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028892 Microbes metabolize substances PMDBM2009747 n.a. o Victivallales f UBA1829 g UBA11452 s UBA11452 sp003526375 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028895 Microbes metabolize substances PMDBM2009748 n.a. o Bacteroidales f UBA11471 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028896 Microbes metabolize substances PMDBM2009748 n.a. o Bacteroidales f UBA11471 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028897 Microbes metabolize substances PMDBM2009748 n.a. o Bacteroidales f UBA11471 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028898 Microbes metabolize substances PMDBM2009748 n.a. o Bacteroidales f UBA11471 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028900 Microbes metabolize substances PMDBM2009748 n.a. o Bacteroidales f UBA11471 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028902 Microbes metabolize substances PMDBM2009748 n.a. o Bacteroidales f UBA11471 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028903 Microbes metabolize substances PMDBM2009748 n.a. o Bacteroidales f UBA11471 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028904 Microbes metabolize substances PMDBM2009748 n.a. o Bacteroidales f UBA11471 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028905 Microbes metabolize substances PMDBM2009748 n.a. o Bacteroidales f UBA11471 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028908 Microbes metabolize substances PMDBM2009748 n.a. o Bacteroidales f UBA11471 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028909 Microbes metabolize substances PMDBM2009748 n.a. o Bacteroidales f UBA11471 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028910 Microbes metabolize substances PMDBM2009748 n.a. o Bacteroidales f UBA11471 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028911 Microbes metabolize substances PMDBM2009748 n.a. o Bacteroidales f UBA11471 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028913 Microbes metabolize substances PMDBM2009748 n.a. o Bacteroidales f UBA11471 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028914 Microbes metabolize substances PMDBM2009748 n.a. o Bacteroidales f UBA11471 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028915 Microbes metabolize substances PMDBM2009748 n.a. o Bacteroidales f UBA11471 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028916 Microbes metabolize substances PMDBM2009749 n.a. o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028917 Microbes metabolize substances PMDBM2009749 n.a. o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028918 Microbes metabolize substances PMDBM2009749 n.a. o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028919 Microbes metabolize substances PMDBM2009749 n.a. o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028921 Microbes metabolize substances PMDBM2009749 n.a. o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20028923 Microbes metabolize substances PMDBM2009749 n.a. o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028924 Microbes metabolize substances PMDBM2009749 n.a. o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028925 Microbes metabolize substances PMDBM2009749 n.a. o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028926 Microbes metabolize substances PMDBM2009749 n.a. o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028929 Microbes metabolize substances PMDBM2009749 n.a. o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028930 Microbes metabolize substances PMDBM2009749 n.a. o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028931 Microbes metabolize substances PMDBM2009749 n.a. o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028932 Microbes metabolize substances PMDBM2009749 n.a. o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028934 Microbes metabolize substances PMDBM2009749 n.a. o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20028935 Microbes metabolize substances PMDBM2009749 n.a. o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028936 Microbes metabolize substances PMDBM2009749 n.a. o Bacteroidales f UBA11471 g UBA11471 s UBA11471 sp000434215 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028937 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028938 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028939 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028940 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028941 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028942 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028943 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028944 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028945 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028947 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028950 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028951 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028952 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028953 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028956 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028959 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028960 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028961 Microbes metabolize substances PMDBM2009750 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11475 s UBA11475 sp003538975 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028963 Microbes metabolize substances PMDBM2009751 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11490 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028964 Microbes metabolize substances PMDBM2009751 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11490 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028965 Microbes metabolize substances PMDBM2009751 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11490 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028966 Microbes metabolize substances PMDBM2009752 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11490 s UBA11490 sp003524095 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028967 Microbes metabolize substances PMDBM2009752 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11490 s UBA11490 sp003524095 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028968 Microbes metabolize substances PMDBM2009752 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11490 s UBA11490 sp003524095 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028969 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028970 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20028971 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20028972 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20028973 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028974 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028975 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20028976 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028977 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20028978 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20028980 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20028983 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20028984 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20028985 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20028986 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20028989 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20028992 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028993 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028994 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20028996 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028997 Microbes metabolize substances PMDBM2009753 n.a. o Oscillospirales f CAG-272 g UBA11512 s UBA11512 sp003522145 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20028998 Microbes metabolize substances PMDBM2009754 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11517 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20028999 Microbes metabolize substances PMDBM2009754 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11517 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029000 Microbes metabolize substances PMDBM2009754 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11517 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029001 Microbes metabolize substances PMDBM2009754 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11517 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029002 Microbes metabolize substances PMDBM2009754 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11517 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029003 Microbes metabolize substances PMDBM2009754 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11517 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029004 Microbes metabolize substances PMDBM2009754 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11517 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029007 Microbes metabolize substances PMDBM2009754 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11517 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029008 Microbes metabolize substances PMDBM2009754 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11517 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029009 Microbes metabolize substances PMDBM2009754 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11517 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029010 Microbes metabolize substances PMDBM2009754 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11517 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029011 Microbes metabolize substances PMDBM2009754 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA11517 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029012 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029013 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20029014 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029015 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029016 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029018 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029020 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029021 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029022 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029023 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029024 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029025 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029027 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20029030 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20029031 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20029032 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029033 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029036 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20029039 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029040 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029043 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029044 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029045 Microbes metabolize substances PMDBM2009755 n.a. o Christensenellales f CAG-74 g UBA11524 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029046 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029047 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20029048 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029049 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029050 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029052 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029054 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029055 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029056 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029057 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029058 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029059 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029061 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20029064 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20029065 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20029066 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029067 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029070 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20029073 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029074 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029077 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029078 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029079 Microbes metabolize substances PMDBM2009756 n.a. o Christensenellales f CAG-74 g UBA11524 s UBA11524 sp000437595 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029080 Microbes metabolize substances PMDBM2009757 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029081 Microbes metabolize substances PMDBM2009757 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029082 Microbes metabolize substances PMDBM2009757 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029083 Microbes metabolize substances PMDBM2009757 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029084 Microbes metabolize substances PMDBM2009757 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029085 Microbes metabolize substances PMDBM2009757 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029086 Microbes metabolize substances PMDBM2009757 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029089 Microbes metabolize substances PMDBM2009757 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029090 Microbes metabolize substances PMDBM2009757 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029091 Microbes metabolize substances PMDBM2009757 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029092 Microbes metabolize substances PMDBM2009757 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029093 Microbes metabolize substances PMDBM2009757 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029094 Microbes metabolize substances PMDBM2009757 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029095 Microbes metabolize substances PMDBM2009757 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029096 Microbes metabolize substances PMDBM2009757 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA11549 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029097 Microbes metabolize substances PMDBM2009758 n.a. f Elusimicrobiaceae g UBA1174 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029098 Microbes metabolize substances PMDBM2009758 n.a. f Elusimicrobiaceae g UBA1174 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029099 Microbes metabolize substances PMDBM2009758 n.a. f Elusimicrobiaceae g UBA1174 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029100 Microbes metabolize substances PMDBM2009758 n.a. f Elusimicrobiaceae g UBA1174 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029101 Microbes metabolize substances PMDBM2009758 n.a. f Elusimicrobiaceae g UBA1174 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029102 Microbes metabolize substances PMDBM2009758 n.a. f Elusimicrobiaceae g UBA1174 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029103 Microbes metabolize substances PMDBM2009758 n.a. f Elusimicrobiaceae g UBA1174 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029106 Microbes metabolize substances PMDBM2009758 n.a. f Elusimicrobiaceae g UBA1174 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029107 Microbes metabolize substances PMDBM2009758 n.a. f Elusimicrobiaceae g UBA1174 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029108 Microbes metabolize substances PMDBM2009758 n.a. f Elusimicrobiaceae g UBA1174 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029109 Microbes metabolize substances PMDBM2009758 n.a. f Elusimicrobiaceae g UBA1174 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029110 Microbes metabolize substances PMDBM2009758 n.a. f Elusimicrobiaceae g UBA1174 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029111 Microbes metabolize substances PMDBM2009758 n.a. f Elusimicrobiaceae g UBA1174 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029112 Microbes metabolize substances PMDBM2009758 n.a. f Elusimicrobiaceae g UBA1174 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029113 Microbes metabolize substances PMDBM2009758 n.a. f Elusimicrobiaceae g UBA1174 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029117 Microbes metabolize substances PMDBM2009758 n.a. f Elusimicrobiaceae g UBA1174 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20029119 Microbes metabolize substances PMDBM2009758 n.a. f Elusimicrobiaceae g UBA1174 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029122 Microbes metabolize substances PMDBM2009759 n.a. f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029123 Microbes metabolize substances PMDBM2009759 n.a. f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029124 Microbes metabolize substances PMDBM2009759 n.a. f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20029126 Microbes metabolize substances PMDBM2009759 n.a. f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20029127 Microbes metabolize substances PMDBM2009759 n.a. f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20029128 Microbes metabolize substances PMDBM2009759 n.a. f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029129 Microbes metabolize substances PMDBM2009759 n.a. f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029132 Microbes metabolize substances PMDBM2009759 n.a. f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20029136 Microbes metabolize substances PMDBM2009759 n.a. f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029137 Microbes metabolize substances PMDBM2009759 n.a. f Lachnospiraceae g UBA11774 s UBA11774 sp003507655 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029138 Microbes metabolize substances PMDBM2009760 n.a. f Paludibacteraceae g UBA1181 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029139 Microbes metabolize substances PMDBM2009760 n.a. f Paludibacteraceae g UBA1181 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029140 Microbes metabolize substances PMDBM2009760 n.a. f Paludibacteraceae g UBA1181 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029141 Microbes metabolize substances PMDBM2009760 n.a. f Paludibacteraceae g UBA1181 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029143 Microbes metabolize substances PMDBM2009760 n.a. f Paludibacteraceae g UBA1181 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029145 Microbes metabolize substances PMDBM2009760 n.a. f Paludibacteraceae g UBA1181 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029146 Microbes metabolize substances PMDBM2009760 n.a. f Paludibacteraceae g UBA1181 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029147 Microbes metabolize substances PMDBM2009760 n.a. f Paludibacteraceae g UBA1181 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029148 Microbes metabolize substances PMDBM2009760 n.a. f Paludibacteraceae g UBA1181 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029151 Microbes metabolize substances PMDBM2009760 n.a. f Paludibacteraceae g UBA1181 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029152 Microbes metabolize substances PMDBM2009760 n.a. f Paludibacteraceae g UBA1181 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029153 Microbes metabolize substances PMDBM2009760 n.a. f Paludibacteraceae g UBA1181 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029155 Microbes metabolize substances PMDBM2009760 n.a. f Paludibacteraceae g UBA1181 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029156 Microbes metabolize substances PMDBM2009760 n.a. f Paludibacteraceae g UBA1181 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029157 Microbes metabolize substances PMDBM2009760 n.a. f Paludibacteraceae g UBA1181 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029158 Microbes metabolize substances PMDBM2009761 n.a. f Anaerovoracaceae g UBA1191 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029159 Microbes metabolize substances PMDBM2009761 n.a. f Anaerovoracaceae g UBA1191 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029160 Microbes metabolize substances PMDBM2009761 n.a. f Anaerovoracaceae g UBA1191 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029161 Microbes metabolize substances PMDBM2009761 n.a. f Anaerovoracaceae g UBA1191 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20029162 Microbes metabolize substances PMDBM2009761 n.a. f Anaerovoracaceae g UBA1191 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029163 Microbes metabolize substances PMDBM2009761 n.a. f Anaerovoracaceae g UBA1191 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029164 Microbes metabolize substances PMDBM2009761 n.a. f Anaerovoracaceae g UBA1191 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029165 Microbes metabolize substances PMDBM2009761 n.a. f Anaerovoracaceae g UBA1191 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029168 Microbes metabolize substances PMDBM2009761 n.a. f Anaerovoracaceae g UBA1191 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20029169 Microbes metabolize substances PMDBM2009761 n.a. f Anaerovoracaceae g UBA1191 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029170 Microbes metabolize substances PMDBM2009761 n.a. f Anaerovoracaceae g UBA1191 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20029171 Microbes metabolize substances PMDBM2009761 n.a. f Anaerovoracaceae g UBA1191 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029172 Microbes metabolize substances PMDBM2009761 n.a. f Anaerovoracaceae g UBA1191 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029173 Microbes metabolize substances PMDBM2009761 n.a. f Anaerovoracaceae g UBA1191 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029174 Microbes metabolize substances PMDBM2009761 n.a. f Anaerovoracaceae g UBA1191 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029175 Microbes metabolize substances PMDBM2009761 n.a. f Anaerovoracaceae g UBA1191 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029176 Microbes metabolize substances PMDBM2009762 n.a. f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029177 Microbes metabolize substances PMDBM2009762 n.a. f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029178 Microbes metabolize substances PMDBM2009762 n.a. f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029179 Microbes metabolize substances PMDBM2009762 n.a. f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029180 Microbes metabolize substances PMDBM2009762 n.a. f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20029181 Microbes metabolize substances PMDBM2009762 n.a. f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029182 Microbes metabolize substances PMDBM2009762 n.a. f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20029183 Microbes metabolize substances PMDBM2009762 n.a. f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029184 Microbes metabolize substances PMDBM2009762 n.a. f Anaerovoracaceae g UBA1191 s UBA1191 sp900066305 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029185 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029186 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029187 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029188 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029190 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029192 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029193 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029194 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029195 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029196 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029197 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029199 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20029202 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20029203 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20029204 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029207 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20029210 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029211 Microbes metabolize substances PMDBM2009763 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA11940 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029214 Microbes metabolize substances PMDBM2009764 n.a. c Bacilli o RF39 f CAG-1000 g UBA11963 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029215 Microbes metabolize substances PMDBM2009764 n.a. c Bacilli o RF39 f CAG-1000 g UBA11963 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029216 Microbes metabolize substances PMDBM2009764 n.a. c Bacilli o RF39 f CAG-1000 g UBA11963 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029217 Microbes metabolize substances PMDBM2009765 n.a. o Oscillospirales f CAG-382 g UBA1206 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029218 Microbes metabolize substances PMDBM2009765 n.a. o Oscillospirales f CAG-382 g UBA1206 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029219 Microbes metabolize substances PMDBM2009765 n.a. o Oscillospirales f CAG-382 g UBA1206 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20029221 Microbes metabolize substances PMDBM2009765 n.a. o Oscillospirales f CAG-382 g UBA1206 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20029222 Microbes metabolize substances PMDBM2009765 n.a. o Oscillospirales f CAG-382 g UBA1206 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20029223 Microbes metabolize substances PMDBM2009765 n.a. o Oscillospirales f CAG-382 g UBA1206 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029226 Microbes metabolize substances PMDBM2009765 n.a. o Oscillospirales f CAG-382 g UBA1206 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20029230 Microbes metabolize substances PMDBM2009765 n.a. o Oscillospirales f CAG-382 g UBA1206 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029231 Microbes metabolize substances PMDBM2009765 n.a. o Oscillospirales f CAG-382 g UBA1206 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029232 Microbes metabolize substances PMDBM2009766 n.a. o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029233 Microbes metabolize substances PMDBM2009766 n.a. o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029234 Microbes metabolize substances PMDBM2009766 n.a. o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20029236 Microbes metabolize substances PMDBM2009766 n.a. o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20029237 Microbes metabolize substances PMDBM2009766 n.a. o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20029238 Microbes metabolize substances PMDBM2009766 n.a. o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029239 Microbes metabolize substances PMDBM2009766 n.a. o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029242 Microbes metabolize substances PMDBM2009766 n.a. o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20029246 Microbes metabolize substances PMDBM2009766 n.a. o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029247 Microbes metabolize substances PMDBM2009766 n.a. o Oscillospirales f CAG-382 g UBA1206 s UBA1206 sp000433115 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029248 Microbes metabolize substances PMDBM2009767 n.a. o Bacteroidales f P3 g UBA1219 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20029249 Microbes metabolize substances PMDBM2009767 n.a. o Bacteroidales f P3 g UBA1219 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029250 Microbes metabolize substances PMDBM2009767 n.a. o Bacteroidales f P3 g UBA1219 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029251 Microbes metabolize substances PMDBM2009767 n.a. o Bacteroidales f P3 g UBA1219 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029252 Microbes metabolize substances PMDBM2009767 n.a. o Bacteroidales f P3 g UBA1219 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029253 Microbes metabolize substances PMDBM2009768 n.a. f Acutalibacteraceae g UBA1227 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029254 Microbes metabolize substances PMDBM2009768 n.a. f Acutalibacteraceae g UBA1227 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029255 Microbes metabolize substances PMDBM2009768 n.a. f Acutalibacteraceae g UBA1227 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029256 Microbes metabolize substances PMDBM2009768 n.a. f Acutalibacteraceae g UBA1227 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029257 Microbes metabolize substances PMDBM2009768 n.a. f Acutalibacteraceae g UBA1227 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029258 Microbes metabolize substances PMDBM2009768 n.a. f Acutalibacteraceae g UBA1227 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029259 Microbes metabolize substances PMDBM2009768 n.a. f Acutalibacteraceae g UBA1227 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029262 Microbes metabolize substances PMDBM2009768 n.a. f Acutalibacteraceae g UBA1227 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029263 Microbes metabolize substances PMDBM2009768 n.a. f Acutalibacteraceae g UBA1227 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029264 Microbes metabolize substances PMDBM2009768 n.a. f Acutalibacteraceae g UBA1227 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029265 Microbes metabolize substances PMDBM2009768 n.a. f Acutalibacteraceae g UBA1227 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029266 Microbes metabolize substances PMDBM2009768 n.a. f Acutalibacteraceae g UBA1227 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029267 Microbes metabolize substances PMDBM2009768 n.a. f Acutalibacteraceae g UBA1227 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029268 Microbes metabolize substances PMDBM2009768 n.a. f Acutalibacteraceae g UBA1227 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029269 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029270 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029271 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029272 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029273 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029274 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029275 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029278 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20029279 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029280 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029281 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029282 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029283 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029284 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029285 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029286 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029287 Microbes metabolize substances PMDBM2009770 n.a. c Clostridia o TANB77 f UBA1234 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029289 Microbes metabolize substances PMDBM2009770 n.a. c Clostridia o TANB77 f UBA1234 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029291 Microbes metabolize substances PMDBM2009770 n.a. c Clostridia o TANB77 f UBA1234 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029292 Microbes metabolize substances PMDBM2009770 n.a. c Clostridia o TANB77 f UBA1234 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029294 Microbes metabolize substances PMDBM2009770 n.a. c Clostridia o TANB77 f UBA1234 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029296 Microbes metabolize substances PMDBM2009771 n.a. c Clostridia o 4C28d-15 f UBA1242 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029297 Microbes metabolize substances PMDBM2009771 n.a. c Clostridia o 4C28d-15 f UBA1242 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029298 Microbes metabolize substances PMDBM2009771 n.a. c Clostridia o 4C28d-15 f UBA1242 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029299 Microbes metabolize substances PMDBM2009771 n.a. c Clostridia o 4C28d-15 f UBA1242 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029300 Microbes metabolize substances PMDBM2009771 n.a. c Clostridia o 4C28d-15 f UBA1242 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029301 Microbes metabolize substances PMDBM2009771 n.a. c Clostridia o 4C28d-15 f UBA1242 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029302 Microbes metabolize substances PMDBM2009771 n.a. c Clostridia o 4C28d-15 f UBA1242 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029305 Microbes metabolize substances PMDBM2009771 n.a. c Clostridia o 4C28d-15 f UBA1242 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029306 Microbes metabolize substances PMDBM2009771 n.a. c Clostridia o 4C28d-15 f UBA1242 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029307 Microbes metabolize substances PMDBM2009771 n.a. c Clostridia o 4C28d-15 f UBA1242 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029308 Microbes metabolize substances PMDBM2009771 n.a. c Clostridia o 4C28d-15 f UBA1242 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029309 Microbes metabolize substances PMDBM2009771 n.a. c Clostridia o 4C28d-15 f UBA1242 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029310 Microbes metabolize substances PMDBM2009771 n.a. c Clostridia o 4C28d-15 f UBA1242 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029311 Microbes metabolize substances PMDBM2009771 n.a. c Clostridia o 4C28d-15 f UBA1242 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029312 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029313 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029314 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029315 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029317 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029319 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029320 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029321 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029322 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029323 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029324 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029326 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20029329 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20029330 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20029331 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20029332 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029333 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029336 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20029339 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029340 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029343 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029344 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029345 Microbes metabolize substances PMDBM2009772 n.a. c Clostridia o UBA1212 f UBA1255 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029346 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029347 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029348 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029349 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029351 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029353 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029354 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029355 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029356 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029357 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029358 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029360 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20029363 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20029364 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20029365 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029366 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029369 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20029372 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029373 Microbes metabolize substances PMDBM2009773 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029376 Microbes metabolize substances PMDBM2009774 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029377 Microbes metabolize substances PMDBM2009774 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029378 Microbes metabolize substances PMDBM2009774 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029379 Microbes metabolize substances PMDBM2009774 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029381 Microbes metabolize substances PMDBM2009774 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029383 Microbes metabolize substances PMDBM2009774 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029384 Microbes metabolize substances PMDBM2009774 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029385 Microbes metabolize substances PMDBM2009774 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029386 Microbes metabolize substances PMDBM2009774 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029389 Microbes metabolize substances PMDBM2009774 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029390 Microbes metabolize substances PMDBM2009774 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029391 Microbes metabolize substances PMDBM2009774 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029392 Microbes metabolize substances PMDBM2009774 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA1259 s UBA1259 sp003523255 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029394 Microbes metabolize substances PMDBM2009775 n.a. f Ruminococcaceae g UBA1375 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029395 Microbes metabolize substances PMDBM2009775 n.a. f Ruminococcaceae g UBA1375 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029396 Microbes metabolize substances PMDBM2009775 n.a. f Ruminococcaceae g UBA1375 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029397 Microbes metabolize substances PMDBM2009775 n.a. f Ruminococcaceae g UBA1375 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029398 Microbes metabolize substances PMDBM2009775 n.a. f Ruminococcaceae g UBA1375 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029399 Microbes metabolize substances PMDBM2009776 n.a. f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029400 Microbes metabolize substances PMDBM2009776 n.a. f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029401 Microbes metabolize substances PMDBM2009776 n.a. f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029402 Microbes metabolize substances PMDBM2009776 n.a. f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029403 Microbes metabolize substances PMDBM2009776 n.a. f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029404 Microbes metabolize substances PMDBM2009776 n.a. f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029405 Microbes metabolize substances PMDBM2009776 n.a. f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029408 Microbes metabolize substances PMDBM2009776 n.a. f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029409 Microbes metabolize substances PMDBM2009776 n.a. f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029410 Microbes metabolize substances PMDBM2009776 n.a. f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029411 Microbes metabolize substances PMDBM2009776 n.a. f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029412 Microbes metabolize substances PMDBM2009776 n.a. f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029413 Microbes metabolize substances PMDBM2009776 n.a. f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029414 Microbes metabolize substances PMDBM2009776 n.a. f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029415 Microbes metabolize substances PMDBM2009776 n.a. f Ruminococcaceae g UBA1375 s UBA1375 sp002305795 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029416 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029418 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029420 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029422 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029426 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029430 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029432 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029434 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029436 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029438 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029440 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029444 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20029450 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20029452 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20029454 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029456 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029462 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20029468 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029470 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029476 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029477 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029479 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029481 Microbes metabolize substances PMDBM2009777 n.a. o Monoglobales f UBA1381 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20029482 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029483 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029484 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029485 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029487 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029489 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029490 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029491 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029492 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029493 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029494 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029496 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20029499 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20029500 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20029501 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029502 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029505 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20029508 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029509 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029512 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029513 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029514 Microbes metabolize substances PMDBM2009778 n.a. o Lachnospirales f UBA1390 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029515 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029516 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029517 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029518 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029520 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029522 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029523 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029524 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029525 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029526 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029527 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029529 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20029532 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20029533 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20029534 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029535 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029538 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20029541 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029542 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029545 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029546 Microbes metabolize substances PMDBM2009779 n.a. o Lachnospirales f UBA1390 g UBA1390 s UBA1390 sp002305315 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029547 Microbes metabolize substances PMDBM2009780 n.a. f Ruminococcaceae g UBA1394 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029548 Microbes metabolize substances PMDBM2009780 n.a. f Ruminococcaceae g UBA1394 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029549 Microbes metabolize substances PMDBM2009780 n.a. f Ruminococcaceae g UBA1394 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029550 Microbes metabolize substances PMDBM2009780 n.a. f Ruminococcaceae g UBA1394 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029551 Microbes metabolize substances PMDBM2009780 n.a. f Ruminococcaceae g UBA1394 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029552 Microbes metabolize substances PMDBM2009780 n.a. f Ruminococcaceae g UBA1394 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029553 Microbes metabolize substances PMDBM2009780 n.a. f Ruminococcaceae g UBA1394 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029556 Microbes metabolize substances PMDBM2009780 n.a. f Ruminococcaceae g UBA1394 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029557 Microbes metabolize substances PMDBM2009780 n.a. f Ruminococcaceae g UBA1394 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029558 Microbes metabolize substances PMDBM2009780 n.a. f Ruminococcaceae g UBA1394 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029559 Microbes metabolize substances PMDBM2009780 n.a. f Ruminococcaceae g UBA1394 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029560 Microbes metabolize substances PMDBM2009780 n.a. f Ruminococcaceae g UBA1394 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029561 Microbes metabolize substances PMDBM2009780 n.a. f Ruminococcaceae g UBA1394 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029562 Microbes metabolize substances PMDBM2009780 n.a. f Ruminococcaceae g UBA1394 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029563 Microbes metabolize substances PMDBM2009781 n.a. f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029564 Microbes metabolize substances PMDBM2009781 n.a. f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029565 Microbes metabolize substances PMDBM2009781 n.a. f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029566 Microbes metabolize substances PMDBM2009781 n.a. f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029567 Microbes metabolize substances PMDBM2009781 n.a. f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029568 Microbes metabolize substances PMDBM2009781 n.a. f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029569 Microbes metabolize substances PMDBM2009781 n.a. f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029572 Microbes metabolize substances PMDBM2009781 n.a. f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029573 Microbes metabolize substances PMDBM2009781 n.a. f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029574 Microbes metabolize substances PMDBM2009781 n.a. f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029575 Microbes metabolize substances PMDBM2009781 n.a. f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029576 Microbes metabolize substances PMDBM2009781 n.a. f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029577 Microbes metabolize substances PMDBM2009781 n.a. f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029578 Microbes metabolize substances PMDBM2009781 n.a. f Ruminococcaceae g UBA1394 s UBA1394 sp900066845 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029579 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029580 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029581 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029582 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029584 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029586 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029587 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029588 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029589 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029590 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029591 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029593 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20029596 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20029597 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20029598 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029599 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029602 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20029605 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029606 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029609 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029610 Microbes metabolize substances PMDBM2009782 n.a. c Lentisphaeria o UBA1407 f UBA1407 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029611 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029612 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029613 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029614 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029616 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029618 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029619 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029620 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029621 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029622 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029623 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029625 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20029628 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20029629 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20029630 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029631 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029634 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20029637 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029638 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029641 Microbes metabolize substances PMDBM2009783 n.a. f Ruminococcaceae g UBA1409 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029642 Microbes metabolize substances PMDBM2009784 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029643 Microbes metabolize substances PMDBM2009784 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029644 Microbes metabolize substances PMDBM2009784 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029645 Microbes metabolize substances PMDBM2009784 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029646 Microbes metabolize substances PMDBM2009784 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029647 Microbes metabolize substances PMDBM2009784 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029648 Microbes metabolize substances PMDBM2009784 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029651 Microbes metabolize substances PMDBM2009784 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029652 Microbes metabolize substances PMDBM2009784 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029653 Microbes metabolize substances PMDBM2009784 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029654 Microbes metabolize substances PMDBM2009784 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029655 Microbes metabolize substances PMDBM2009784 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002338885 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029656 Microbes metabolize substances PMDBM2009785 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029657 Microbes metabolize substances PMDBM2009785 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029658 Microbes metabolize substances PMDBM2009785 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029659 Microbes metabolize substances PMDBM2009785 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029660 Microbes metabolize substances PMDBM2009785 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029661 Microbes metabolize substances PMDBM2009785 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029662 Microbes metabolize substances PMDBM2009785 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029665 Microbes metabolize substances PMDBM2009785 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029666 Microbes metabolize substances PMDBM2009785 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029667 Microbes metabolize substances PMDBM2009785 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029668 Microbes metabolize substances PMDBM2009785 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029669 Microbes metabolize substances PMDBM2009785 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029670 Microbes metabolize substances PMDBM2009785 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029671 Microbes metabolize substances PMDBM2009785 n.a. f Ruminococcaceae g UBA1409 s UBA1409 sp002491605 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029672 Microbes metabolize substances PMDBM2009786 n.a. f Acutalibacteraceae g UBA1417 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029673 Microbes metabolize substances PMDBM2009786 n.a. f Acutalibacteraceae g UBA1417 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20029674 Microbes metabolize substances PMDBM2009786 n.a. f Acutalibacteraceae g UBA1417 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029675 Microbes metabolize substances PMDBM2009786 n.a. f Acutalibacteraceae g UBA1417 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029676 Microbes metabolize substances PMDBM2009786 n.a. f Acutalibacteraceae g UBA1417 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029678 Microbes metabolize substances PMDBM2009786 n.a. f Acutalibacteraceae g UBA1417 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029680 Microbes metabolize substances PMDBM2009786 n.a. f Acutalibacteraceae g UBA1417 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029681 Microbes metabolize substances PMDBM2009786 n.a. f Acutalibacteraceae g UBA1417 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029682 Microbes metabolize substances PMDBM2009786 n.a. f Acutalibacteraceae g UBA1417 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029683 Microbes metabolize substances PMDBM2009786 n.a. f Acutalibacteraceae g UBA1417 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029686 Microbes metabolize substances PMDBM2009786 n.a. f Acutalibacteraceae g UBA1417 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029687 Microbes metabolize substances PMDBM2009786 n.a. f Acutalibacteraceae g UBA1417 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029688 Microbes metabolize substances PMDBM2009786 n.a. f Acutalibacteraceae g UBA1417 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029689 Microbes metabolize substances PMDBM2009786 n.a. f Acutalibacteraceae g UBA1417 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029691 Microbes metabolize substances PMDBM2009786 n.a. f Acutalibacteraceae g UBA1417 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029692 Microbes metabolize substances PMDBM2009786 n.a. f Acutalibacteraceae g UBA1417 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029693 Microbes metabolize substances PMDBM2009786 n.a. f Acutalibacteraceae g UBA1417 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029694 Microbes metabolize substances PMDBM2009787 n.a. f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029695 Microbes metabolize substances PMDBM2009787 n.a. f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029696 Microbes metabolize substances PMDBM2009787 n.a. f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029697 Microbes metabolize substances PMDBM2009787 n.a. f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029699 Microbes metabolize substances PMDBM2009787 n.a. f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029701 Microbes metabolize substances PMDBM2009787 n.a. f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029702 Microbes metabolize substances PMDBM2009787 n.a. f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029703 Microbes metabolize substances PMDBM2009787 n.a. f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029704 Microbes metabolize substances PMDBM2009787 n.a. f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029707 Microbes metabolize substances PMDBM2009787 n.a. f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029708 Microbes metabolize substances PMDBM2009787 n.a. f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029709 Microbes metabolize substances PMDBM2009787 n.a. f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029711 Microbes metabolize substances PMDBM2009787 n.a. f Acutalibacteraceae g UBA1417 s UBA1417 sp003531055 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029712 Microbes metabolize substances PMDBM2009788 n.a. f Elusimicrobiaceae g UBA1436 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029713 Microbes metabolize substances PMDBM2009788 n.a. f Elusimicrobiaceae g UBA1436 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029714 Microbes metabolize substances PMDBM2009788 n.a. f Elusimicrobiaceae g UBA1436 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029715 Microbes metabolize substances PMDBM2009788 n.a. f Elusimicrobiaceae g UBA1436 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029716 Microbes metabolize substances PMDBM2009788 n.a. f Elusimicrobiaceae g UBA1436 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029717 Microbes metabolize substances PMDBM2009788 n.a. f Elusimicrobiaceae g UBA1436 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029718 Microbes metabolize substances PMDBM2009788 n.a. f Elusimicrobiaceae g UBA1436 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029721 Microbes metabolize substances PMDBM2009788 n.a. f Elusimicrobiaceae g UBA1436 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029722 Microbes metabolize substances PMDBM2009788 n.a. f Elusimicrobiaceae g UBA1436 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029723 Microbes metabolize substances PMDBM2009788 n.a. f Elusimicrobiaceae g UBA1436 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029724 Microbes metabolize substances PMDBM2009788 n.a. f Elusimicrobiaceae g UBA1436 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029725 Microbes metabolize substances PMDBM2009788 n.a. f Elusimicrobiaceae g UBA1436 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029726 Microbes metabolize substances PMDBM2009788 n.a. f Elusimicrobiaceae g UBA1436 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029727 Microbes metabolize substances PMDBM2009788 n.a. f Elusimicrobiaceae g UBA1436 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029728 Microbes metabolize substances PMDBM2009789 n.a. f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029729 Microbes metabolize substances PMDBM2009789 n.a. f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029730 Microbes metabolize substances PMDBM2009789 n.a. f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029731 Microbes metabolize substances PMDBM2009789 n.a. f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029732 Microbes metabolize substances PMDBM2009789 n.a. f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029733 Microbes metabolize substances PMDBM2009789 n.a. f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029734 Microbes metabolize substances PMDBM2009789 n.a. f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029737 Microbes metabolize substances PMDBM2009789 n.a. f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029738 Microbes metabolize substances PMDBM2009789 n.a. f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029739 Microbes metabolize substances PMDBM2009789 n.a. f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029740 Microbes metabolize substances PMDBM2009789 n.a. f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029741 Microbes metabolize substances PMDBM2009789 n.a. f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029742 Microbes metabolize substances PMDBM2009789 n.a. f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029743 Microbes metabolize substances PMDBM2009789 n.a. f Elusimicrobiaceae g UBA1436 s UBA1436 sp002329395 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029744 Microbes metabolize substances PMDBM2009790 n.a. c Negativicutes o UBA1444 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20029745 Microbes metabolize substances PMDBM2009790 n.a. c Negativicutes o UBA1444 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20029746 Microbes metabolize substances PMDBM2009790 n.a. c Negativicutes o UBA1444 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20029747 Microbes metabolize substances PMDBM2009790 n.a. c Negativicutes o UBA1444 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029748 Microbes metabolize substances PMDBM2009790 n.a. c Negativicutes o UBA1444 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029749 Microbes metabolize substances PMDBM2009791 n.a. o Christensenellales f CAG-138 g UBA1685 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029750 Microbes metabolize substances PMDBM2009791 n.a. o Christensenellales f CAG-138 g UBA1685 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20029751 Microbes metabolize substances PMDBM2009791 n.a. o Christensenellales f CAG-138 g UBA1685 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029752 Microbes metabolize substances PMDBM2009791 n.a. o Christensenellales f CAG-138 g UBA1685 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029753 Microbes metabolize substances PMDBM2009791 n.a. o Christensenellales f CAG-138 g UBA1685 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029754 Microbes metabolize substances PMDBM2009791 n.a. o Christensenellales f CAG-138 g UBA1685 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029755 Microbes metabolize substances PMDBM2009791 n.a. o Christensenellales f CAG-138 g UBA1685 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029756 Microbes metabolize substances PMDBM2009791 n.a. o Christensenellales f CAG-138 g UBA1685 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029759 Microbes metabolize substances PMDBM2009791 n.a. o Christensenellales f CAG-138 g UBA1685 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029760 Microbes metabolize substances PMDBM2009791 n.a. o Christensenellales f CAG-138 g UBA1685 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029761 Microbes metabolize substances PMDBM2009791 n.a. o Christensenellales f CAG-138 g UBA1685 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029762 Microbes metabolize substances PMDBM2009791 n.a. o Christensenellales f CAG-138 g UBA1685 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029763 Microbes metabolize substances PMDBM2009791 n.a. o Christensenellales f CAG-138 g UBA1685 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029764 Microbes metabolize substances PMDBM2009791 n.a. o Christensenellales f CAG-138 g UBA1685 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029765 Microbes metabolize substances PMDBM2009791 n.a. o Christensenellales f CAG-138 g UBA1685 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029766 Microbes metabolize substances PMDBM2009791 n.a. o Christensenellales f CAG-138 g UBA1685 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029767 Microbes metabolize substances PMDBM2009792 n.a. o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029768 Microbes metabolize substances PMDBM2009792 n.a. o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20029769 Microbes metabolize substances PMDBM2009792 n.a. o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029770 Microbes metabolize substances PMDBM2009792 n.a. o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029771 Microbes metabolize substances PMDBM2009792 n.a. o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029772 Microbes metabolize substances PMDBM2009792 n.a. o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029773 Microbes metabolize substances PMDBM2009792 n.a. o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029774 Microbes metabolize substances PMDBM2009792 n.a. o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029777 Microbes metabolize substances PMDBM2009792 n.a. o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029778 Microbes metabolize substances PMDBM2009792 n.a. o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029779 Microbes metabolize substances PMDBM2009792 n.a. o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029780 Microbes metabolize substances PMDBM2009792 n.a. o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029781 Microbes metabolize substances PMDBM2009792 n.a. o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029782 Microbes metabolize substances PMDBM2009792 n.a. o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029783 Microbes metabolize substances PMDBM2009792 n.a. o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029784 Microbes metabolize substances PMDBM2009792 n.a. o Christensenellales f CAG-138 g UBA1685 s UBA1685 sp002320595 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029785 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029786 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20029787 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029788 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029789 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029791 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029793 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029794 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029795 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029796 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029797 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029798 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029800 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20029803 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20029804 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20029805 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029806 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029809 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20029812 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029813 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029816 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029817 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029818 Microbes metabolize substances PMDBM2009793 n.a. f Acutalibacteraceae g UBA1691 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029819 Microbes metabolize substances PMDBM2009794 n.a. f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029820 Microbes metabolize substances PMDBM2009794 n.a. f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029821 Microbes metabolize substances PMDBM2009794 n.a. f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029822 Microbes metabolize substances PMDBM2009794 n.a. f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029824 Microbes metabolize substances PMDBM2009794 n.a. f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029826 Microbes metabolize substances PMDBM2009794 n.a. f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029827 Microbes metabolize substances PMDBM2009794 n.a. f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029828 Microbes metabolize substances PMDBM2009794 n.a. f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029829 Microbes metabolize substances PMDBM2009794 n.a. f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029832 Microbes metabolize substances PMDBM2009794 n.a. f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029833 Microbes metabolize substances PMDBM2009794 n.a. f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029834 Microbes metabolize substances PMDBM2009794 n.a. f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029835 Microbes metabolize substances PMDBM2009794 n.a. f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029837 Microbes metabolize substances PMDBM2009794 n.a. f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029838 Microbes metabolize substances PMDBM2009794 n.a. f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029839 Microbes metabolize substances PMDBM2009794 n.a. f Acutalibacteraceae g UBA1691 s UBA1691 sp002320555 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029840 Microbes metabolize substances PMDBM2009795 n.a. o Bacteroidales f P3 g UBA1711 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029841 Microbes metabolize substances PMDBM2009795 n.a. o Bacteroidales f P3 g UBA1711 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029842 Microbes metabolize substances PMDBM2009795 n.a. o Bacteroidales f P3 g UBA1711 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029843 Microbes metabolize substances PMDBM2009795 n.a. o Bacteroidales f P3 g UBA1711 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029845 Microbes metabolize substances PMDBM2009795 n.a. o Bacteroidales f P3 g UBA1711 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029847 Microbes metabolize substances PMDBM2009795 n.a. o Bacteroidales f P3 g UBA1711 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029848 Microbes metabolize substances PMDBM2009795 n.a. o Bacteroidales f P3 g UBA1711 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029849 Microbes metabolize substances PMDBM2009795 n.a. o Bacteroidales f P3 g UBA1711 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029850 Microbes metabolize substances PMDBM2009795 n.a. o Bacteroidales f P3 g UBA1711 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029853 Microbes metabolize substances PMDBM2009795 n.a. o Bacteroidales f P3 g UBA1711 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20029854 Microbes metabolize substances PMDBM2009795 n.a. o Bacteroidales f P3 g UBA1711 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029855 Microbes metabolize substances PMDBM2009795 n.a. o Bacteroidales f P3 g UBA1711 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029857 Microbes metabolize substances PMDBM2009795 n.a. o Bacteroidales f P3 g UBA1711 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029858 Microbes metabolize substances PMDBM2009795 n.a. o Bacteroidales f P3 g UBA1711 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029859 Microbes metabolize substances PMDBM2009795 n.a. o Bacteroidales f P3 g UBA1711 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029860 Microbes metabolize substances PMDBM2009796 n.a. f Lachnospiraceae g UBA1712 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029861 Microbes metabolize substances PMDBM2009796 n.a. f Lachnospiraceae g UBA1712 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029862 Microbes metabolize substances PMDBM2009796 n.a. f Lachnospiraceae g UBA1712 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029863 Microbes metabolize substances PMDBM2009796 n.a. f Lachnospiraceae g UBA1712 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029864 Microbes metabolize substances PMDBM2009796 n.a. f Lachnospiraceae g UBA1712 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029865 Microbes metabolize substances PMDBM2009796 n.a. f Lachnospiraceae g UBA1712 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029866 Microbes metabolize substances PMDBM2009796 n.a. f Lachnospiraceae g UBA1712 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029869 Microbes metabolize substances PMDBM2009796 n.a. f Lachnospiraceae g UBA1712 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029870 Microbes metabolize substances PMDBM2009796 n.a. f Lachnospiraceae g UBA1712 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029871 Microbes metabolize substances PMDBM2009796 n.a. f Lachnospiraceae g UBA1712 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029872 Microbes metabolize substances PMDBM2009796 n.a. f Lachnospiraceae g UBA1712 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029873 Microbes metabolize substances PMDBM2009796 n.a. f Lachnospiraceae g UBA1712 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029874 Microbes metabolize substances PMDBM2009796 n.a. f Lachnospiraceae g UBA1712 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029875 Microbes metabolize substances PMDBM2009796 n.a. f Lachnospiraceae g UBA1712 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029876 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029877 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029878 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029879 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029881 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029883 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029884 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029885 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029886 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029887 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029888 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029890 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20029893 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20029894 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20029895 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029898 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20029901 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029902 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029905 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029906 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029907 Microbes metabolize substances PMDBM2009797 n.a. c Lentisphaeria o UBA1407 f UBA1407 g UBA1724 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20029908 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029909 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029910 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029911 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029913 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029915 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029916 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029917 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029918 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029919 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029920 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029922 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20029925 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20029926 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20029927 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029928 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029931 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20029934 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20029935 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029936 Microbes metabolize substances PMDBM2009798 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA1731 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029939 Microbes metabolize substances PMDBM2009799 n.a. o Victivallales f UBA1829 g UBA1732 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029940 Microbes metabolize substances PMDBM2009799 n.a. o Victivallales f UBA1829 g UBA1732 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029941 Microbes metabolize substances PMDBM2009799 n.a. o Victivallales f UBA1829 g UBA1732 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029942 Microbes metabolize substances PMDBM2009799 n.a. o Victivallales f UBA1829 g UBA1732 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029943 Microbes metabolize substances PMDBM2009799 n.a. o Victivallales f UBA1829 g UBA1732 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029944 Microbes metabolize substances PMDBM2009799 n.a. o Victivallales f UBA1829 g UBA1732 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029945 Microbes metabolize substances PMDBM2009799 n.a. o Victivallales f UBA1829 g UBA1732 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029948 Microbes metabolize substances PMDBM2009799 n.a. o Victivallales f UBA1829 g UBA1732 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029949 Microbes metabolize substances PMDBM2009799 n.a. o Victivallales f UBA1829 g UBA1732 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029950 Microbes metabolize substances PMDBM2009799 n.a. o Victivallales f UBA1829 g UBA1732 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029951 Microbes metabolize substances PMDBM2009799 n.a. o Victivallales f UBA1829 g UBA1732 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029952 Microbes metabolize substances PMDBM2009799 n.a. o Victivallales f UBA1829 g UBA1732 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029953 Microbes metabolize substances PMDBM2009800 n.a. c Bacilli o ML615J-28 f CAG-313 g UBA1737 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029954 Microbes metabolize substances PMDBM2009800 n.a. c Bacilli o ML615J-28 f CAG-313 g UBA1737 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029955 Microbes metabolize substances PMDBM2009800 n.a. c Bacilli o ML615J-28 f CAG-313 g UBA1737 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029956 Microbes metabolize substances PMDBM2009800 n.a. c Bacilli o ML615J-28 f CAG-313 g UBA1737 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029957 Microbes metabolize substances PMDBM2009800 n.a. c Bacilli o ML615J-28 f CAG-313 g UBA1737 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029958 Microbes metabolize substances PMDBM2009800 n.a. c Bacilli o ML615J-28 f CAG-313 g UBA1737 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029959 Microbes metabolize substances PMDBM2009800 n.a. c Bacilli o ML615J-28 f CAG-313 g UBA1737 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029962 Microbes metabolize substances PMDBM2009800 n.a. c Bacilli o ML615J-28 f CAG-313 g UBA1737 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029963 Microbes metabolize substances PMDBM2009800 n.a. c Bacilli o ML615J-28 f CAG-313 g UBA1737 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029964 Microbes metabolize substances PMDBM2009800 n.a. c Bacilli o ML615J-28 f CAG-313 g UBA1737 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029965 Microbes metabolize substances PMDBM2009800 n.a. c Bacilli o ML615J-28 f CAG-313 g UBA1737 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029966 Microbes metabolize substances PMDBM2009800 n.a. c Bacilli o ML615J-28 f CAG-313 g UBA1737 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029967 Microbes metabolize substances PMDBM2009800 n.a. c Bacilli o ML615J-28 f CAG-313 g UBA1737 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20029968 Microbes metabolize substances PMDBM2009800 n.a. c Bacilli o ML615J-28 f CAG-313 g UBA1737 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029969 Microbes metabolize substances PMDBM2009800 n.a. c Bacilli o ML615J-28 f CAG-313 g UBA1737 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20029970 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20029971 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20029972 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20029973 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029975 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20029977 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029978 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029979 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20029980 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029981 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20029982 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20029984 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20029987 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20029988 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20029989 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20029990 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20029993 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20029996 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20029997 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030000 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030001 Microbes metabolize substances PMDBM2009801 n.a. o Oscillospirales f CAG-272 g UBA1740 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030002 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030003 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030004 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030005 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030007 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030009 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030010 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030011 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030012 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030015 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20030016 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030017 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030018 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20030019 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030020 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030022 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030023 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030024 Microbes metabolize substances PMDBM2009802 n.a. f Oscillospiraceae g UBA1777 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030025 Microbes metabolize substances PMDBM2009803 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030026 Microbes metabolize substances PMDBM2009803 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20030027 Microbes metabolize substances PMDBM2009803 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030028 Microbes metabolize substances PMDBM2009803 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030029 Microbes metabolize substances PMDBM2009803 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030030 Microbes metabolize substances PMDBM2009803 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030031 Microbes metabolize substances PMDBM2009803 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030032 Microbes metabolize substances PMDBM2009803 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030035 Microbes metabolize substances PMDBM2009803 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030036 Microbes metabolize substances PMDBM2009803 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030037 Microbes metabolize substances PMDBM2009803 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030038 Microbes metabolize substances PMDBM2009803 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030039 Microbes metabolize substances PMDBM2009803 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030040 Microbes metabolize substances PMDBM2009803 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030041 Microbes metabolize substances PMDBM2009803 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp002320035 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030042 Microbes metabolize substances PMDBM2009804 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030043 Microbes metabolize substances PMDBM2009804 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030044 Microbes metabolize substances PMDBM2009804 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030045 Microbes metabolize substances PMDBM2009804 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030046 Microbes metabolize substances PMDBM2009804 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030047 Microbes metabolize substances PMDBM2009804 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030048 Microbes metabolize substances PMDBM2009804 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030051 Microbes metabolize substances PMDBM2009804 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030052 Microbes metabolize substances PMDBM2009804 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030053 Microbes metabolize substances PMDBM2009804 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030054 Microbes metabolize substances PMDBM2009804 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030055 Microbes metabolize substances PMDBM2009804 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030056 Microbes metabolize substances PMDBM2009804 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030057 Microbes metabolize substances PMDBM2009804 n.a. f Oscillospiraceae g UBA1777 s UBA1777 sp003150355 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030058 Microbes metabolize substances PMDBM2009805 n.a. f Bacteroidaceae g UBA1786 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030059 Microbes metabolize substances PMDBM2009805 n.a. f Bacteroidaceae g UBA1786 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030060 Microbes metabolize substances PMDBM2009805 n.a. f Bacteroidaceae g UBA1786 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030061 Microbes metabolize substances PMDBM2009805 n.a. f Bacteroidaceae g UBA1786 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030063 Microbes metabolize substances PMDBM2009805 n.a. f Bacteroidaceae g UBA1786 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030065 Microbes metabolize substances PMDBM2009805 n.a. f Bacteroidaceae g UBA1786 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030066 Microbes metabolize substances PMDBM2009805 n.a. f Bacteroidaceae g UBA1786 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030067 Microbes metabolize substances PMDBM2009805 n.a. f Bacteroidaceae g UBA1786 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030068 Microbes metabolize substances PMDBM2009805 n.a. f Bacteroidaceae g UBA1786 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030071 Microbes metabolize substances PMDBM2009805 n.a. f Bacteroidaceae g UBA1786 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030072 Microbes metabolize substances PMDBM2009805 n.a. f Bacteroidaceae g UBA1786 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030073 Microbes metabolize substances PMDBM2009805 n.a. f Bacteroidaceae g UBA1786 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030074 Microbes metabolize substances PMDBM2009805 n.a. f Bacteroidaceae g UBA1786 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030076 Microbes metabolize substances PMDBM2009805 n.a. f Bacteroidaceae g UBA1786 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030077 Microbes metabolize substances PMDBM2009805 n.a. f Bacteroidaceae g UBA1786 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030078 Microbes metabolize substances PMDBM2009805 n.a. f Bacteroidaceae g UBA1786 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030079 Microbes metabolize substances PMDBM2009806 n.a. o Flavobacteriales f UBA1820 g UBA1820 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20030080 Microbes metabolize substances PMDBM2009806 n.a. o Flavobacteriales f UBA1820 g UBA1820 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030081 Microbes metabolize substances PMDBM2009806 n.a. o Flavobacteriales f UBA1820 g UBA1820 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030082 Microbes metabolize substances PMDBM2009806 n.a. o Flavobacteriales f UBA1820 g UBA1820 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030083 Microbes metabolize substances PMDBM2009807 n.a. o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp002314265 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20030084 Microbes metabolize substances PMDBM2009807 n.a. o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp002314265 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030085 Microbes metabolize substances PMDBM2009807 n.a. o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp002314265 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030086 Microbes metabolize substances PMDBM2009807 n.a. o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp002314265 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030087 Microbes metabolize substances PMDBM2009807 n.a. o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp002314265 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030088 Microbes metabolize substances PMDBM2009807 n.a. o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp002314265 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030089 Microbes metabolize substances PMDBM2009808 n.a. o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp003150615 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20030090 Microbes metabolize substances PMDBM2009808 n.a. o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp003150615 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030091 Microbes metabolize substances PMDBM2009808 n.a. o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp003150615 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030092 Microbes metabolize substances PMDBM2009808 n.a. o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp003150615 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030093 Microbes metabolize substances PMDBM2009808 n.a. o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp003150615 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030094 Microbes metabolize substances PMDBM2009808 n.a. o Flavobacteriales f UBA1820 g UBA1820 s UBA1820 sp003150615 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030095 Microbes metabolize substances PMDBM2009809 n.a. f Dialisteraceae g UBA1822 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030096 Microbes metabolize substances PMDBM2009810 n.a. f Dialisteraceae g UBA1822 s UBA1822 sp002314995 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030097 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030099 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20030100 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030102 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030104 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030108 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030112 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030114 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030116 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030118 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030120 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030122 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030126 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20030132 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20030134 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20030136 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20030137 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030139 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030145 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20030151 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030153 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030159 Microbes metabolize substances PMDBM2009811 n.a. o Victivallales f UBA1829 g UBA1829 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20030161 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030162 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030163 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030164 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030166 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030168 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030169 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030170 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030171 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030172 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030173 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030175 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20030178 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20030179 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20030180 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030181 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030184 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20030187 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030188 Microbes metabolize substances PMDBM2009812 n.a. o Victivallales f UBA1829 g UBA1829 s UBA1829 sp002338895 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030191 Microbes metabolize substances PMDBM2009813 n.a. f Lachnospiraceae g UBA2727 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030192 Microbes metabolize substances PMDBM2009813 n.a. f Lachnospiraceae g UBA2727 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030193 Microbes metabolize substances PMDBM2009813 n.a. f Lachnospiraceae g UBA2727 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030194 Microbes metabolize substances PMDBM2009813 n.a. f Lachnospiraceae g UBA2727 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030195 Microbes metabolize substances PMDBM2009813 n.a. f Lachnospiraceae g UBA2727 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030196 Microbes metabolize substances PMDBM2009813 n.a. f Lachnospiraceae g UBA2727 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030197 Microbes metabolize substances PMDBM2009813 n.a. f Lachnospiraceae g UBA2727 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030200 Microbes metabolize substances PMDBM2009813 n.a. f Lachnospiraceae g UBA2727 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030201 Microbes metabolize substances PMDBM2009813 n.a. f Lachnospiraceae g UBA2727 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030202 Microbes metabolize substances PMDBM2009813 n.a. f Lachnospiraceae g UBA2727 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030203 Microbes metabolize substances PMDBM2009813 n.a. f Lachnospiraceae g UBA2727 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030204 Microbes metabolize substances PMDBM2009813 n.a. f Lachnospiraceae g UBA2727 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030205 Microbes metabolize substances PMDBM2009814 n.a. f Succinivibrionaceae g UBA2804 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030206 Microbes metabolize substances PMDBM2009815 n.a. f Lachnospiraceae g UBA2821 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030207 Microbes metabolize substances PMDBM2009815 n.a. f Lachnospiraceae g UBA2821 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030208 Microbes metabolize substances PMDBM2009815 n.a. f Lachnospiraceae g UBA2821 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030209 Microbes metabolize substances PMDBM2009815 n.a. f Lachnospiraceae g UBA2821 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030210 Microbes metabolize substances PMDBM2009815 n.a. f Lachnospiraceae g UBA2821 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030211 Microbes metabolize substances PMDBM2009815 n.a. f Lachnospiraceae g UBA2821 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030212 Microbes metabolize substances PMDBM2009815 n.a. f Lachnospiraceae g UBA2821 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030215 Microbes metabolize substances PMDBM2009815 n.a. f Lachnospiraceae g UBA2821 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030216 Microbes metabolize substances PMDBM2009815 n.a. f Lachnospiraceae g UBA2821 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030217 Microbes metabolize substances PMDBM2009815 n.a. f Lachnospiraceae g UBA2821 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030218 Microbes metabolize substances PMDBM2009815 n.a. f Lachnospiraceae g UBA2821 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030219 Microbes metabolize substances PMDBM2009815 n.a. f Lachnospiraceae g UBA2821 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030220 Microbes metabolize substances PMDBM2009815 n.a. f Lachnospiraceae g UBA2821 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030221 Microbes metabolize substances PMDBM2009815 n.a. f Lachnospiraceae g UBA2821 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030222 Microbes metabolize substances PMDBM2009816 n.a. f Saccharimonadaceae g UBA2834 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030223 Microbes metabolize substances PMDBM2009817 n.a. f Lachnospiraceae g UBA2856 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030224 Microbes metabolize substances PMDBM2009817 n.a. f Lachnospiraceae g UBA2856 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030225 Microbes metabolize substances PMDBM2009817 n.a. f Lachnospiraceae g UBA2856 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030226 Microbes metabolize substances PMDBM2009817 n.a. f Lachnospiraceae g UBA2856 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030227 Microbes metabolize substances PMDBM2009817 n.a. f Lachnospiraceae g UBA2856 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030228 Microbes metabolize substances PMDBM2009817 n.a. f Lachnospiraceae g UBA2856 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030229 Microbes metabolize substances PMDBM2009817 n.a. f Lachnospiraceae g UBA2856 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030232 Microbes metabolize substances PMDBM2009817 n.a. f Lachnospiraceae g UBA2856 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030233 Microbes metabolize substances PMDBM2009817 n.a. f Lachnospiraceae g UBA2856 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030234 Microbes metabolize substances PMDBM2009817 n.a. f Lachnospiraceae g UBA2856 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030235 Microbes metabolize substances PMDBM2009817 n.a. f Lachnospiraceae g UBA2856 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030236 Microbes metabolize substances PMDBM2009817 n.a. f Lachnospiraceae g UBA2856 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030237 Microbes metabolize substances PMDBM2009817 n.a. f Lachnospiraceae g UBA2856 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030238 Microbes metabolize substances PMDBM2009817 n.a. f Lachnospiraceae g UBA2856 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030239 Microbes metabolize substances PMDBM2009817 n.a. f Lachnospiraceae g UBA2856 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030241 Microbes metabolize substances PMDBM2009818 n.a. f Lachnospiraceae g UBA2882 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20030242 Microbes metabolize substances PMDBM2009818 n.a. f Lachnospiraceae g UBA2882 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030243 Microbes metabolize substances PMDBM2009818 n.a. f Lachnospiraceae g UBA2882 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030244 Microbes metabolize substances PMDBM2009818 n.a. f Lachnospiraceae g UBA2882 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030245 Microbes metabolize substances PMDBM2009818 n.a. f Lachnospiraceae g UBA2882 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030246 Microbes metabolize substances PMDBM2009818 n.a. f Lachnospiraceae g UBA2882 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030247 Microbes metabolize substances PMDBM2009818 n.a. f Lachnospiraceae g UBA2882 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030250 Microbes metabolize substances PMDBM2009818 n.a. f Lachnospiraceae g UBA2882 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030251 Microbes metabolize substances PMDBM2009818 n.a. f Lachnospiraceae g UBA2882 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030252 Microbes metabolize substances PMDBM2009818 n.a. f Lachnospiraceae g UBA2882 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20030253 Microbes metabolize substances PMDBM2009818 n.a. f Lachnospiraceae g UBA2882 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030254 Microbes metabolize substances PMDBM2009818 n.a. f Lachnospiraceae g UBA2882 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030255 Microbes metabolize substances PMDBM2009818 n.a. f Lachnospiraceae g UBA2882 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030256 Microbes metabolize substances PMDBM2009818 n.a. f Lachnospiraceae g UBA2882 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030257 Microbes metabolize substances PMDBM2009818 n.a. f Lachnospiraceae g UBA2882 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030258 Microbes metabolize substances PMDBM2009819 n.a. f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030259 Microbes metabolize substances PMDBM2009819 n.a. f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030260 Microbes metabolize substances PMDBM2009819 n.a. f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030261 Microbes metabolize substances PMDBM2009819 n.a. f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030263 Microbes metabolize substances PMDBM2009819 n.a. f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030265 Microbes metabolize substances PMDBM2009819 n.a. f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030266 Microbes metabolize substances PMDBM2009819 n.a. f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030267 Microbes metabolize substances PMDBM2009819 n.a. f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030268 Microbes metabolize substances PMDBM2009819 n.a. f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030271 Microbes metabolize substances PMDBM2009819 n.a. f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030272 Microbes metabolize substances PMDBM2009819 n.a. f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030273 Microbes metabolize substances PMDBM2009819 n.a. f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030274 Microbes metabolize substances PMDBM2009819 n.a. f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030276 Microbes metabolize substances PMDBM2009819 n.a. f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030277 Microbes metabolize substances PMDBM2009819 n.a. f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030278 Microbes metabolize substances PMDBM2009819 n.a. f Lachnospiraceae g UBA2882 s UBA2882 sp002362385 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030279 Microbes metabolize substances PMDBM2009820 n.a. f Gastranaerophilaceae g UBA2883 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20030280 Microbes metabolize substances PMDBM2009820 n.a. f Gastranaerophilaceae g UBA2883 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030281 Microbes metabolize substances PMDBM2009820 n.a. f Gastranaerophilaceae g UBA2883 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030282 Microbes metabolize substances PMDBM2009820 n.a. f Gastranaerophilaceae g UBA2883 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030283 Microbes metabolize substances PMDBM2009820 n.a. f Gastranaerophilaceae g UBA2883 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030284 Microbes metabolize substances PMDBM2009820 n.a. f Gastranaerophilaceae g UBA2883 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030285 Microbes metabolize substances PMDBM2009821 n.a. f Gastranaerophilaceae g UBA2883 s UBA2883 sp002103075 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20030286 Microbes metabolize substances PMDBM2009821 n.a. f Gastranaerophilaceae g UBA2883 s UBA2883 sp002103075 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030287 Microbes metabolize substances PMDBM2009821 n.a. f Gastranaerophilaceae g UBA2883 s UBA2883 sp002103075 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030288 Microbes metabolize substances PMDBM2009821 n.a. f Gastranaerophilaceae g UBA2883 s UBA2883 sp002103075 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030289 Microbes metabolize substances PMDBM2009821 n.a. f Gastranaerophilaceae g UBA2883 s UBA2883 sp002103075 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030290 Microbes metabolize substances PMDBM2009821 n.a. f Gastranaerophilaceae g UBA2883 s UBA2883 sp002103075 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030291 Microbes metabolize substances PMDBM2009822 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030292 Microbes metabolize substances PMDBM2009822 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030293 Microbes metabolize substances PMDBM2009822 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030294 Microbes metabolize substances PMDBM2009822 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030295 Microbes metabolize substances PMDBM2009822 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030296 Microbes metabolize substances PMDBM2009822 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030297 Microbes metabolize substances PMDBM2009822 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030300 Microbes metabolize substances PMDBM2009822 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030301 Microbes metabolize substances PMDBM2009822 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030302 Microbes metabolize substances PMDBM2009822 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030303 Microbes metabolize substances PMDBM2009822 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030304 Microbes metabolize substances PMDBM2009822 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030305 Microbes metabolize substances PMDBM2009822 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030306 Microbes metabolize substances PMDBM2009822 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030307 Microbes metabolize substances PMDBM2009822 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030308 Microbes metabolize substances PMDBM2009823 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030309 Microbes metabolize substances PMDBM2009823 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030310 Microbes metabolize substances PMDBM2009823 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030311 Microbes metabolize substances PMDBM2009823 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030312 Microbes metabolize substances PMDBM2009823 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030313 Microbes metabolize substances PMDBM2009823 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030314 Microbes metabolize substances PMDBM2009823 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030317 Microbes metabolize substances PMDBM2009823 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030318 Microbes metabolize substances PMDBM2009823 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030319 Microbes metabolize substances PMDBM2009823 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030320 Microbes metabolize substances PMDBM2009823 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030321 Microbes metabolize substances PMDBM2009823 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030322 Microbes metabolize substances PMDBM2009823 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030323 Microbes metabolize substances PMDBM2009823 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030324 Microbes metabolize substances PMDBM2009823 n.a. c Alphaproteobacteria o RF32 f CAG-977 g UBA2903 s UBA2903 sp002349565 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030325 Microbes metabolize substances PMDBM2009824 n.a. f Selenomonadaceae g UBA2913 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030326 Microbes metabolize substances PMDBM2009824 n.a. f Selenomonadaceae g UBA2913 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20030327 Microbes metabolize substances PMDBM2009824 n.a. f Selenomonadaceae g UBA2913 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030328 Microbes metabolize substances PMDBM2009824 n.a. f Selenomonadaceae g UBA2913 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030329 Microbes metabolize substances PMDBM2009824 n.a. f Selenomonadaceae g UBA2913 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030330 Microbes metabolize substances PMDBM2009824 n.a. f Selenomonadaceae g UBA2913 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030331 Microbes metabolize substances PMDBM2009824 n.a. f Selenomonadaceae g UBA2913 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030332 Microbes metabolize substances PMDBM2009824 n.a. f Selenomonadaceae g UBA2913 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030335 Microbes metabolize substances PMDBM2009824 n.a. f Selenomonadaceae g UBA2913 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030336 Microbes metabolize substances PMDBM2009824 n.a. f Selenomonadaceae g UBA2913 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030337 Microbes metabolize substances PMDBM2009824 n.a. f Selenomonadaceae g UBA2913 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030338 Microbes metabolize substances PMDBM2009824 n.a. f Selenomonadaceae g UBA2913 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030339 Microbes metabolize substances PMDBM2009824 n.a. f Selenomonadaceae g UBA2913 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030340 Microbes metabolize substances PMDBM2009824 n.a. f Selenomonadaceae g UBA2913 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030341 Microbes metabolize substances PMDBM2009824 n.a. f Selenomonadaceae g UBA2913 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030342 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030343 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20030344 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030345 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030346 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030347 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030348 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030349 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030350 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030351 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030353 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20030356 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20030357 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20030358 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030359 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030362 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20030365 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030366 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030367 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030369 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030370 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030371 Microbes metabolize substances PMDBM2009825 n.a. f Muribaculaceae g UBA3263 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030372 Microbes metabolize substances PMDBM2009826 n.a. o Mycoplasmatales f UBA3375 g UBA3375 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030373 Microbes metabolize substances PMDBM2009826 n.a. o Mycoplasmatales f UBA3375 g UBA3375 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030374 Microbes metabolize substances PMDBM2009826 n.a. o Mycoplasmatales f UBA3375 g UBA3375 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030375 Microbes metabolize substances PMDBM2009827 n.a. o Bacteroidales f P3 g UBA3388 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030376 Microbes metabolize substances PMDBM2009827 n.a. o Bacteroidales f P3 g UBA3388 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030377 Microbes metabolize substances PMDBM2009827 n.a. o Bacteroidales f P3 g UBA3388 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030378 Microbes metabolize substances PMDBM2009827 n.a. o Bacteroidales f P3 g UBA3388 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030379 Microbes metabolize substances PMDBM2009827 n.a. o Bacteroidales f P3 g UBA3388 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030380 Microbes metabolize substances PMDBM2009827 n.a. o Bacteroidales f P3 g UBA3388 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030381 Microbes metabolize substances PMDBM2009827 n.a. o Bacteroidales f P3 g UBA3388 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030384 Microbes metabolize substances PMDBM2009827 n.a. o Bacteroidales f P3 g UBA3388 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20030385 Microbes metabolize substances PMDBM2009827 n.a. o Bacteroidales f P3 g UBA3388 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030386 Microbes metabolize substances PMDBM2009827 n.a. o Bacteroidales f P3 g UBA3388 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030387 Microbes metabolize substances PMDBM2009827 n.a. o Bacteroidales f P3 g UBA3388 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030388 Microbes metabolize substances PMDBM2009827 n.a. o Bacteroidales f P3 g UBA3388 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030389 Microbes metabolize substances PMDBM2009827 n.a. o Bacteroidales f P3 g UBA3388 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030390 Microbes metabolize substances PMDBM2009827 n.a. o Bacteroidales f P3 g UBA3388 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030391 Microbes metabolize substances PMDBM2009827 n.a. o Bacteroidales f P3 g UBA3388 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030392 Microbes metabolize substances PMDBM2009828 n.a. o Bacteroidales f P3 g UBA3388 s UBA3388 sp002358835 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20030393 Microbes metabolize substances PMDBM2009828 n.a. o Bacteroidales f P3 g UBA3388 s UBA3388 sp002358835 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030394 Microbes metabolize substances PMDBM2009828 n.a. o Bacteroidales f P3 g UBA3388 s UBA3388 sp002358835 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030395 Microbes metabolize substances PMDBM2009828 n.a. o Bacteroidales f P3 g UBA3388 s UBA3388 sp002358835 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030396 Microbes metabolize substances PMDBM2009828 n.a. o Bacteroidales f P3 g UBA3388 s UBA3388 sp002358835 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030397 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030398 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030399 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030400 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030402 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030404 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030405 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030406 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030407 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030408 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030409 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030411 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20030414 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20030415 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20030416 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030417 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030420 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20030423 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030424 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030427 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030428 Microbes metabolize substances PMDBM2009829 n.a. c Kiritimatiellae o RFP12 f UBA1067 g UBA3624 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030429 Microbes metabolize substances PMDBM2009830 n.a. c Bacilli o RF39 f CAG-822 g UBA3631 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030430 Microbes metabolize substances PMDBM2009830 n.a. c Bacilli o RF39 f CAG-822 g UBA3631 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030431 Microbes metabolize substances PMDBM2009831 n.a. c Clostridia o 4C28d-15 f UBA3700 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030432 Microbes metabolize substances PMDBM2009831 n.a. c Clostridia o 4C28d-15 f UBA3700 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030433 Microbes metabolize substances PMDBM2009831 n.a. c Clostridia o 4C28d-15 f UBA3700 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030434 Microbes metabolize substances PMDBM2009831 n.a. c Clostridia o 4C28d-15 f UBA3700 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030435 Microbes metabolize substances PMDBM2009831 n.a. c Clostridia o 4C28d-15 f UBA3700 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030436 Microbes metabolize substances PMDBM2009831 n.a. c Clostridia o 4C28d-15 f UBA3700 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030437 Microbes metabolize substances PMDBM2009831 n.a. c Clostridia o 4C28d-15 f UBA3700 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030440 Microbes metabolize substances PMDBM2009831 n.a. c Clostridia o 4C28d-15 f UBA3700 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030441 Microbes metabolize substances PMDBM2009831 n.a. c Clostridia o 4C28d-15 f UBA3700 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030442 Microbes metabolize substances PMDBM2009831 n.a. c Clostridia o 4C28d-15 f UBA3700 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030443 Microbes metabolize substances PMDBM2009831 n.a. c Clostridia o 4C28d-15 f UBA3700 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030444 Microbes metabolize substances PMDBM2009831 n.a. c Clostridia o 4C28d-15 f UBA3700 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030445 Microbes metabolize substances PMDBM2009831 n.a. c Clostridia o 4C28d-15 f UBA3700 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030446 Microbes metabolize substances PMDBM2009831 n.a. c Clostridia o 4C28d-15 f UBA3700 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030447 Microbes metabolize substances PMDBM2009832 n.a. c Bacilli o RF39 f CAG-611 g UBA3789 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030448 Microbes metabolize substances PMDBM2009832 n.a. c Bacilli o RF39 f CAG-611 g UBA3789 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030449 Microbes metabolize substances PMDBM2009832 n.a. c Bacilli o RF39 f CAG-611 g UBA3789 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030450 Microbes metabolize substances PMDBM2009832 n.a. c Bacilli o RF39 f CAG-611 g UBA3789 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030451 Microbes metabolize substances PMDBM2009832 n.a. c Bacilli o RF39 f CAG-611 g UBA3789 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030452 Microbes metabolize substances PMDBM2009832 n.a. c Bacilli o RF39 f CAG-611 g UBA3789 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030453 Microbes metabolize substances PMDBM2009832 n.a. c Bacilli o RF39 f CAG-611 g UBA3789 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030456 Microbes metabolize substances PMDBM2009832 n.a. c Bacilli o RF39 f CAG-611 g UBA3789 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030457 Microbes metabolize substances PMDBM2009832 n.a. c Bacilli o RF39 f CAG-611 g UBA3789 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030458 Microbes metabolize substances PMDBM2009832 n.a. c Bacilli o RF39 f CAG-611 g UBA3789 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030459 Microbes metabolize substances PMDBM2009832 n.a. c Bacilli o RF39 f CAG-611 g UBA3789 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030460 Microbes metabolize substances PMDBM2009832 n.a. c Bacilli o RF39 f CAG-611 g UBA3789 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030461 Microbes metabolize substances PMDBM2009833 n.a. f Ruminococcaceae g UBA3818 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20030462 Microbes metabolize substances PMDBM2009833 n.a. f Ruminococcaceae g UBA3818 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030463 Microbes metabolize substances PMDBM2009833 n.a. f Ruminococcaceae g UBA3818 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030464 Microbes metabolize substances PMDBM2009833 n.a. f Ruminococcaceae g UBA3818 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030465 Microbes metabolize substances PMDBM2009833 n.a. f Ruminococcaceae g UBA3818 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030466 Microbes metabolize substances PMDBM2009833 n.a. f Ruminococcaceae g UBA3818 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030467 Microbes metabolize substances PMDBM2009833 n.a. f Ruminococcaceae g UBA3818 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030468 Microbes metabolize substances PMDBM2009833 n.a. f Ruminococcaceae g UBA3818 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030469 Microbes metabolize substances PMDBM2009833 n.a. f Ruminococcaceae g UBA3818 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030470 Microbes metabolize substances PMDBM2009834 n.a. c Dehalobacteriia o UBA4068 f UBA4068 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030471 Microbes metabolize substances PMDBM2009834 n.a. c Dehalobacteriia o UBA4068 f UBA4068 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030472 Microbes metabolize substances PMDBM2009834 n.a. c Dehalobacteriia o UBA4068 f UBA4068 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030473 Microbes metabolize substances PMDBM2009834 n.a. c Dehalobacteriia o UBA4068 f UBA4068 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030474 Microbes metabolize substances PMDBM2009834 n.a. c Dehalobacteriia o UBA4068 f UBA4068 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030475 Microbes metabolize substances PMDBM2009834 n.a. c Dehalobacteriia o UBA4068 f UBA4068 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030476 Microbes metabolize substances PMDBM2009834 n.a. c Dehalobacteriia o UBA4068 f UBA4068 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030479 Microbes metabolize substances PMDBM2009834 n.a. c Dehalobacteriia o UBA4068 f UBA4068 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20030480 Microbes metabolize substances PMDBM2009834 n.a. c Dehalobacteriia o UBA4068 f UBA4068 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030481 Microbes metabolize substances PMDBM2009834 n.a. c Dehalobacteriia o UBA4068 f UBA4068 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030482 Microbes metabolize substances PMDBM2009834 n.a. c Dehalobacteriia o UBA4068 f UBA4068 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030483 Microbes metabolize substances PMDBM2009834 n.a. c Dehalobacteriia o UBA4068 f UBA4068 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030484 Microbes metabolize substances PMDBM2009834 n.a. c Dehalobacteriia o UBA4068 f UBA4068 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030485 Microbes metabolize substances PMDBM2009835 n.a. o Bradymonadales f UBA4248 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20030486 Microbes metabolize substances PMDBM2009835 n.a. o Bradymonadales f UBA4248 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030487 Microbes metabolize substances PMDBM2009835 n.a. o Bradymonadales f UBA4248 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030488 Microbes metabolize substances PMDBM2009835 n.a. o Bradymonadales f UBA4248 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030489 Microbes metabolize substances PMDBM2009835 n.a. o Bradymonadales f UBA4248 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030490 Microbes metabolize substances PMDBM2009836 n.a. f Bacteroidaceae g UBA4334 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030491 Microbes metabolize substances PMDBM2009836 n.a. f Bacteroidaceae g UBA4334 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030492 Microbes metabolize substances PMDBM2009836 n.a. f Bacteroidaceae g UBA4334 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030493 Microbes metabolize substances PMDBM2009836 n.a. f Bacteroidaceae g UBA4334 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030494 Microbes metabolize substances PMDBM2009836 n.a. f Bacteroidaceae g UBA4334 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030495 Microbes metabolize substances PMDBM2009836 n.a. f Bacteroidaceae g UBA4334 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030496 Microbes metabolize substances PMDBM2009836 n.a. f Bacteroidaceae g UBA4334 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030499 Microbes metabolize substances PMDBM2009836 n.a. f Bacteroidaceae g UBA4334 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030500 Microbes metabolize substances PMDBM2009836 n.a. f Bacteroidaceae g UBA4334 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030501 Microbes metabolize substances PMDBM2009836 n.a. f Bacteroidaceae g UBA4334 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030502 Microbes metabolize substances PMDBM2009836 n.a. f Bacteroidaceae g UBA4334 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030503 Microbes metabolize substances PMDBM2009836 n.a. f Bacteroidaceae g UBA4334 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030504 Microbes metabolize substances PMDBM2009836 n.a. f Bacteroidaceae g UBA4334 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030505 Microbes metabolize substances PMDBM2009836 n.a. f Bacteroidaceae g UBA4334 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030506 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030507 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030508 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030509 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030511 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030513 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030514 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030515 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030516 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030517 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030518 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030520 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20030523 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20030524 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20030525 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20030526 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030527 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030530 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20030533 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030534 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030537 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030538 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030539 Microbes metabolize substances PMDBM2009837 n.a. f Bacteroidaceae g UBA4372 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030540 Microbes metabolize substances PMDBM2009838 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA4626 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030541 Microbes metabolize substances PMDBM2009838 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA4626 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030542 Microbes metabolize substances PMDBM2009838 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA4626 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030543 Microbes metabolize substances PMDBM2009838 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA4626 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030544 Microbes metabolize substances PMDBM2009838 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA4626 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030545 Microbes metabolize substances PMDBM2009838 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA4626 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030547 Microbes metabolize substances PMDBM2009838 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA4626 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030549 Microbes metabolize substances PMDBM2009838 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA4626 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030550 Microbes metabolize substances PMDBM2009838 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA4626 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030551 Microbes metabolize substances PMDBM2009838 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA4626 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030552 Microbes metabolize substances PMDBM2009838 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA4626 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030555 Microbes metabolize substances PMDBM2009838 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA4626 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030556 Microbes metabolize substances PMDBM2009838 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA4626 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030557 Microbes metabolize substances PMDBM2009838 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA4626 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030558 Microbes metabolize substances PMDBM2009838 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA4626 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030560 Microbes metabolize substances PMDBM2009838 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA4626 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030561 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030562 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030563 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030564 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030565 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030566 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030567 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030568 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030569 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030571 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20030574 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20030575 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20030576 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030579 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20030582 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030583 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030584 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030586 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030587 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030588 Microbes metabolize substances PMDBM2009839 n.a. f Butyricicoccaceae g UBA4644 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030589 Microbes metabolize substances PMDBM2009840 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA4675 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030590 Microbes metabolize substances PMDBM2009840 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA4675 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030591 Microbes metabolize substances PMDBM2009840 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA4675 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030592 Microbes metabolize substances PMDBM2009840 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA4675 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030593 Microbes metabolize substances PMDBM2009840 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA4675 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030594 Microbes metabolize substances PMDBM2009840 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA4675 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030595 Microbes metabolize substances PMDBM2009840 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA4675 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030598 Microbes metabolize substances PMDBM2009840 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA4675 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030599 Microbes metabolize substances PMDBM2009840 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA4675 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030600 Microbes metabolize substances PMDBM2009840 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA4675 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030601 Microbes metabolize substances PMDBM2009840 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA4675 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030602 Microbes metabolize substances PMDBM2009840 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA4675 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030603 Microbes metabolize substances PMDBM2009840 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA4675 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030604 Microbes metabolize substances PMDBM2009840 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA4675 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030605 Microbes metabolize substances PMDBM2009841 n.a. p Eremiobacterota c UBP9 o UBA4705 f UBA4705 g UBA4705 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030606 Microbes metabolize substances PMDBM2009841 n.a. p Eremiobacterota c UBP9 o UBA4705 f UBA4705 g UBA4705 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030607 Microbes metabolize substances PMDBM2009841 n.a. p Eremiobacterota c UBP9 o UBA4705 f UBA4705 g UBA4705 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030608 Microbes metabolize substances PMDBM2009841 n.a. p Eremiobacterota c UBP9 o UBA4705 f UBA4705 g UBA4705 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030609 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030610 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030611 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030612 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030614 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030616 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20030617 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030618 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030619 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030620 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030621 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030622 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030624 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20030627 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20030628 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20030629 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030630 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030633 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20030636 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030637 Microbes metabolize substances PMDBM2009842 n.a. o Monoglobales f UBA1381 g UBA4716 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030640 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030641 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030642 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030643 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030645 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030647 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030648 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030649 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030650 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030651 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030652 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030654 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20030657 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20030658 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20030659 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030660 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030663 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20030666 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030667 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030670 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030671 Microbes metabolize substances PMDBM2009843 n.a. c Bacilli o RFN20 f CAG-826 g UBA4855 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030672 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030673 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030674 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030675 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030676 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030677 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030678 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030679 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030680 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030682 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20030685 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20030686 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20030687 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030688 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030691 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20030694 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20030695 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030696 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030697 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030699 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030700 Microbes metabolize substances PMDBM2009844 n.a. f Acutalibacteraceae g UBA4871 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030701 Microbes metabolize substances PMDBM2009845 n.a. o Caldanaerobiales f UBA4877 g UBA4877 s UBA4877 sp002399345 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030702 Microbes metabolize substances PMDBM2009846 n.a. c Bacilli o RFN20 f CAG-826 g UBA4951 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030703 Microbes metabolize substances PMDBM2009846 n.a. c Bacilli o RFN20 f CAG-826 g UBA4951 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20030704 Microbes metabolize substances PMDBM2009846 n.a. c Bacilli o RFN20 f CAG-826 g UBA4951 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030705 Microbes metabolize substances PMDBM2009846 n.a. c Bacilli o RFN20 f CAG-826 g UBA4951 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030706 Microbes metabolize substances PMDBM2009846 n.a. c Bacilli o RFN20 f CAG-826 g UBA4951 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030708 Microbes metabolize substances PMDBM2009846 n.a. c Bacilli o RFN20 f CAG-826 g UBA4951 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030710 Microbes metabolize substances PMDBM2009846 n.a. c Bacilli o RFN20 f CAG-826 g UBA4951 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030711 Microbes metabolize substances PMDBM2009846 n.a. c Bacilli o RFN20 f CAG-826 g UBA4951 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030712 Microbes metabolize substances PMDBM2009846 n.a. c Bacilli o RFN20 f CAG-826 g UBA4951 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030713 Microbes metabolize substances PMDBM2009846 n.a. c Bacilli o RFN20 f CAG-826 g UBA4951 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030716 Microbes metabolize substances PMDBM2009846 n.a. c Bacilli o RFN20 f CAG-826 g UBA4951 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030717 Microbes metabolize substances PMDBM2009846 n.a. c Bacilli o RFN20 f CAG-826 g UBA4951 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030718 Microbes metabolize substances PMDBM2009846 n.a. c Bacilli o RFN20 f CAG-826 g UBA4951 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030719 Microbes metabolize substances PMDBM2009846 n.a. c Bacilli o RFN20 f CAG-826 g UBA4951 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030721 Microbes metabolize substances PMDBM2009846 n.a. c Bacilli o RFN20 f CAG-826 g UBA4951 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030722 Microbes metabolize substances PMDBM2009846 n.a. c Bacilli o RFN20 f CAG-826 g UBA4951 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030723 Microbes metabolize substances PMDBM2009847 n.a. c Bacilli o RF39 f CAG-822 g UBA5026 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030724 Microbes metabolize substances PMDBM2009847 n.a. c Bacilli o RF39 f CAG-822 g UBA5026 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030725 Microbes metabolize substances PMDBM2009848 n.a. o Christensenellales f CAG-138 g UBA5394 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030726 Microbes metabolize substances PMDBM2009848 n.a. o Christensenellales f CAG-138 g UBA5394 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030727 Microbes metabolize substances PMDBM2009848 n.a. o Christensenellales f CAG-138 g UBA5394 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030728 Microbes metabolize substances PMDBM2009848 n.a. o Christensenellales f CAG-138 g UBA5394 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030729 Microbes metabolize substances PMDBM2009848 n.a. o Christensenellales f CAG-138 g UBA5394 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030730 Microbes metabolize substances PMDBM2009849 n.a. o Christensenellales f CAG-138 g UBA5394 s UBA5394 sp003150565 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030731 Microbes metabolize substances PMDBM2009849 n.a. o Christensenellales f CAG-138 g UBA5394 s UBA5394 sp003150565 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030732 Microbes metabolize substances PMDBM2009849 n.a. o Christensenellales f CAG-138 g UBA5394 s UBA5394 sp003150565 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030733 Microbes metabolize substances PMDBM2009849 n.a. o Christensenellales f CAG-138 g UBA5394 s UBA5394 sp003150565 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030734 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030735 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030736 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030737 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030739 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030741 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030742 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030743 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030744 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030745 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030746 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030748 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20030751 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20030752 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20030753 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030754 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030757 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20030760 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030761 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030764 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030765 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030766 Microbes metabolize substances PMDBM2009850 n.a. f Lachnospiraceae g UBA5416 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030767 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030768 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030769 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030770 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030772 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030774 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030775 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030776 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030777 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030778 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030779 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030781 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20030784 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20030785 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20030786 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20030787 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030788 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030791 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20030794 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030795 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030798 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030799 Microbes metabolize substances PMDBM2009851 n.a. f Oscillospiraceae g UBA5446 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030800 Microbes metabolize substances PMDBM2009852 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA5489 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030801 Microbes metabolize substances PMDBM2009852 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA5489 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030802 Microbes metabolize substances PMDBM2009852 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA5489 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030803 Microbes metabolize substances PMDBM2009853 n.a. f Dialisteraceae g UBA5809 s UBA5809 sp002417965 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030804 Microbes metabolize substances PMDBM2009854 n.a. f Ruminococcaceae g UBA5884 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030805 Microbes metabolize substances PMDBM2009854 n.a. f Ruminococcaceae g UBA5884 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030806 Microbes metabolize substances PMDBM2009854 n.a. f Ruminococcaceae g UBA5884 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030807 Microbes metabolize substances PMDBM2009854 n.a. f Ruminococcaceae g UBA5884 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030808 Microbes metabolize substances PMDBM2009854 n.a. f Ruminococcaceae g UBA5884 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030809 Microbes metabolize substances PMDBM2009854 n.a. f Ruminococcaceae g UBA5884 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030810 Microbes metabolize substances PMDBM2009854 n.a. f Ruminococcaceae g UBA5884 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030813 Microbes metabolize substances PMDBM2009854 n.a. f Ruminococcaceae g UBA5884 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030814 Microbes metabolize substances PMDBM2009854 n.a. f Ruminococcaceae g UBA5884 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030815 Microbes metabolize substances PMDBM2009854 n.a. f Ruminococcaceae g UBA5884 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030816 Microbes metabolize substances PMDBM2009854 n.a. f Ruminococcaceae g UBA5884 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030817 Microbes metabolize substances PMDBM2009854 n.a. f Ruminococcaceae g UBA5884 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030818 Microbes metabolize substances PMDBM2009854 n.a. f Ruminococcaceae g UBA5884 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030819 Microbes metabolize substances PMDBM2009854 n.a. f Ruminococcaceae g UBA5884 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030820 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030821 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20030822 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030823 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030824 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030826 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030828 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030829 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030830 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030831 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030832 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030833 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030835 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20030838 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20030839 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20030840 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030841 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030844 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20030847 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030848 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030851 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030852 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030853 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030854 Microbes metabolize substances PMDBM2009855 n.a. f Acutalibacteraceae g UBA5905 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20030855 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030856 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030857 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030858 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030860 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030862 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030863 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030864 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030865 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030866 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030867 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030869 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20030872 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20030873 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20030874 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030875 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030878 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20030881 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030882 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030885 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030886 Microbes metabolize substances PMDBM2009856 n.a. f Acutalibacteraceae g UBA5905 s UBA5905 sp002437905 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030887 Microbes metabolize substances PMDBM2009857 n.a. f Sphaerochaetaceae g UBA5920 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030888 Microbes metabolize substances PMDBM2009857 n.a. f Sphaerochaetaceae g UBA5920 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20030889 Microbes metabolize substances PMDBM2009857 n.a. f Sphaerochaetaceae g UBA5920 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030890 Microbes metabolize substances PMDBM2009857 n.a. f Sphaerochaetaceae g UBA5920 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030891 Microbes metabolize substances PMDBM2009857 n.a. f Sphaerochaetaceae g UBA5920 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030893 Microbes metabolize substances PMDBM2009857 n.a. f Sphaerochaetaceae g UBA5920 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030895 Microbes metabolize substances PMDBM2009857 n.a. f Sphaerochaetaceae g UBA5920 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030896 Microbes metabolize substances PMDBM2009857 n.a. f Sphaerochaetaceae g UBA5920 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030897 Microbes metabolize substances PMDBM2009857 n.a. f Sphaerochaetaceae g UBA5920 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030898 Microbes metabolize substances PMDBM2009857 n.a. f Sphaerochaetaceae g UBA5920 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030901 Microbes metabolize substances PMDBM2009857 n.a. f Sphaerochaetaceae g UBA5920 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030902 Microbes metabolize substances PMDBM2009857 n.a. f Sphaerochaetaceae g UBA5920 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030903 Microbes metabolize substances PMDBM2009857 n.a. f Sphaerochaetaceae g UBA5920 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030904 Microbes metabolize substances PMDBM2009857 n.a. f Sphaerochaetaceae g UBA5920 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030906 Microbes metabolize substances PMDBM2009857 n.a. f Sphaerochaetaceae g UBA5920 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030907 Microbes metabolize substances PMDBM2009857 n.a. f Sphaerochaetaceae g UBA5920 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030908 Microbes metabolize substances PMDBM2009857 n.a. f Sphaerochaetaceae g UBA5920 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030909 Microbes metabolize substances PMDBM2009858 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA6345 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030910 Microbes metabolize substances PMDBM2009859 n.a. f Erysipelotrichaceae g UBA636 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030911 Microbes metabolize substances PMDBM2009859 n.a. f Erysipelotrichaceae g UBA636 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030912 Microbes metabolize substances PMDBM2009859 n.a. f Erysipelotrichaceae g UBA636 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030913 Microbes metabolize substances PMDBM2009859 n.a. f Erysipelotrichaceae g UBA636 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030914 Microbes metabolize substances PMDBM2009859 n.a. f Erysipelotrichaceae g UBA636 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030915 Microbes metabolize substances PMDBM2009859 n.a. f Erysipelotrichaceae g UBA636 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030916 Microbes metabolize substances PMDBM2009859 n.a. f Erysipelotrichaceae g UBA636 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030919 Microbes metabolize substances PMDBM2009859 n.a. f Erysipelotrichaceae g UBA636 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030920 Microbes metabolize substances PMDBM2009859 n.a. f Erysipelotrichaceae g UBA636 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20030921 Microbes metabolize substances PMDBM2009859 n.a. f Erysipelotrichaceae g UBA636 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030922 Microbes metabolize substances PMDBM2009859 n.a. f Erysipelotrichaceae g UBA636 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030923 Microbes metabolize substances PMDBM2009859 n.a. f Erysipelotrichaceae g UBA636 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030924 Microbes metabolize substances PMDBM2009859 n.a. f Erysipelotrichaceae g UBA636 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030925 Microbes metabolize substances PMDBM2009859 n.a. f Erysipelotrichaceae g UBA636 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030926 Microbes metabolize substances PMDBM2009859 n.a. f Erysipelotrichaceae g UBA636 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030927 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030928 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030929 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030930 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030931 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030932 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030933 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030934 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030935 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030937 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20030940 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20030941 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20030942 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030945 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20030948 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030949 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030950 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030952 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030953 Microbes metabolize substances PMDBM2009860 n.a. f Bacteroidaceae g UBA6382 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030954 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030955 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030956 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030957 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030959 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030961 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030962 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030963 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030964 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030965 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030966 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20030968 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20030971 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20030972 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20030973 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20030974 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20030977 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20030980 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030981 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20030984 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20030985 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030986 Microbes metabolize substances PMDBM2009861 n.a. f Bacteroidaceae g UBA6398 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20030987 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20030988 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20030989 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20030990 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030992 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20030994 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030995 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030996 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20030997 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030998 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20030999 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031001 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20031004 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20031005 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20031006 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031009 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20031012 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031013 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031016 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031017 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031018 Microbes metabolize substances PMDBM2009862 n.a. f Bacteroidaceae g UBA6398 s UBA6398 sp003150315 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031019 Microbes metabolize substances PMDBM2009863 n.a. c Bacilli o RF39 f CAG-302 g UBA6414 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031020 Microbes metabolize substances PMDBM2009863 n.a. c Bacilli o RF39 f CAG-302 g UBA6414 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031021 Microbes metabolize substances PMDBM2009863 n.a. c Bacilli o RF39 f CAG-302 g UBA6414 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031022 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031024 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031026 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031028 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031032 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031036 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031038 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031040 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031042 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031043 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031044 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031048 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20031052 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20031053 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20031054 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031056 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031060 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20031063 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20031064 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031066 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031071 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031072 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031074 Microbes metabolize substances PMDBM2009864 n.a. o Oscillospirales f UBA644 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031076 Microbes metabolize substances PMDBM2009865 n.a. o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031077 Microbes metabolize substances PMDBM2009865 n.a. o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031078 Microbes metabolize substances PMDBM2009865 n.a. o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031079 Microbes metabolize substances PMDBM2009865 n.a. o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031080 Microbes metabolize substances PMDBM2009865 n.a. o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031081 Microbes metabolize substances PMDBM2009865 n.a. o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031082 Microbes metabolize substances PMDBM2009865 n.a. o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20031084 Microbes metabolize substances PMDBM2009865 n.a. o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20031085 Microbes metabolize substances PMDBM2009865 n.a. o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20031086 Microbes metabolize substances PMDBM2009865 n.a. o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031087 Microbes metabolize substances PMDBM2009865 n.a. o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031090 Microbes metabolize substances PMDBM2009865 n.a. o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20031094 Microbes metabolize substances PMDBM2009865 n.a. o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031095 Microbes metabolize substances PMDBM2009865 n.a. o Oscillospirales f UBA644 g UBA644 s UBA644 sp002299265 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031096 Microbes metabolize substances PMDBM2009866 n.a. o Oscillospirales f UBA644 A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031097 Microbes metabolize substances PMDBM2009866 n.a. o Oscillospirales f UBA644 A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031098 Microbes metabolize substances PMDBM2009866 n.a. o Oscillospirales f UBA644 A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031099 Microbes metabolize substances PMDBM2009866 n.a. o Oscillospirales f UBA644 A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031100 Microbes metabolize substances PMDBM2009866 n.a. o Oscillospirales f UBA644 A PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031101 Microbes metabolize substances PMDBM2009866 n.a. o Oscillospirales f UBA644 A PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031102 Microbes metabolize substances PMDBM2009866 n.a. o Oscillospirales f UBA644 A PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20031104 Microbes metabolize substances PMDBM2009866 n.a. o Oscillospirales f UBA644 A PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20031105 Microbes metabolize substances PMDBM2009866 n.a. o Oscillospirales f UBA644 A PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20031106 Microbes metabolize substances PMDBM2009866 n.a. o Oscillospirales f UBA644 A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031107 Microbes metabolize substances PMDBM2009866 n.a. o Oscillospirales f UBA644 A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031110 Microbes metabolize substances PMDBM2009866 n.a. o Oscillospirales f UBA644 A PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20031114 Microbes metabolize substances PMDBM2009866 n.a. o Oscillospirales f UBA644 A PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031115 Microbes metabolize substances PMDBM2009866 n.a. o Oscillospirales f UBA644 A PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031116 Microbes metabolize substances PMDBM2009867 n.a. f Acutalibacteraceae g UBA6857 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031117 Microbes metabolize substances PMDBM2009867 n.a. f Acutalibacteraceae g UBA6857 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031118 Microbes metabolize substances PMDBM2009867 n.a. f Acutalibacteraceae g UBA6857 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031119 Microbes metabolize substances PMDBM2009867 n.a. f Acutalibacteraceae g UBA6857 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031121 Microbes metabolize substances PMDBM2009867 n.a. f Acutalibacteraceae g UBA6857 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031123 Microbes metabolize substances PMDBM2009867 n.a. f Acutalibacteraceae g UBA6857 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031124 Microbes metabolize substances PMDBM2009867 n.a. f Acutalibacteraceae g UBA6857 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031125 Microbes metabolize substances PMDBM2009867 n.a. f Acutalibacteraceae g UBA6857 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031126 Microbes metabolize substances PMDBM2009867 n.a. f Acutalibacteraceae g UBA6857 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031129 Microbes metabolize substances PMDBM2009867 n.a. f Acutalibacteraceae g UBA6857 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031130 Microbes metabolize substances PMDBM2009867 n.a. f Acutalibacteraceae g UBA6857 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031131 Microbes metabolize substances PMDBM2009867 n.a. f Acutalibacteraceae g UBA6857 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031132 Microbes metabolize substances PMDBM2009867 n.a. f Acutalibacteraceae g UBA6857 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031134 Microbes metabolize substances PMDBM2009867 n.a. f Acutalibacteraceae g UBA6857 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031135 Microbes metabolize substances PMDBM2009867 n.a. f Acutalibacteraceae g UBA6857 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031136 Microbes metabolize substances PMDBM2009868 n.a. f Gastranaerophilaceae g UBA6984 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031137 Microbes metabolize substances PMDBM2009868 n.a. f Gastranaerophilaceae g UBA6984 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031138 Microbes metabolize substances PMDBM2009868 n.a. f Gastranaerophilaceae g UBA6984 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031139 Microbes metabolize substances PMDBM2009868 n.a. f Gastranaerophilaceae g UBA6984 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031140 Microbes metabolize substances PMDBM2009868 n.a. f Gastranaerophilaceae g UBA6984 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031141 Microbes metabolize substances PMDBM2009869 n.a. f Gastranaerophilaceae g UBA6984 s UBA6984 sp003258725 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031142 Microbes metabolize substances PMDBM2009869 n.a. f Gastranaerophilaceae g UBA6984 s UBA6984 sp003258725 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031143 Microbes metabolize substances PMDBM2009869 n.a. f Gastranaerophilaceae g UBA6984 s UBA6984 sp003258725 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031144 Microbes metabolize substances PMDBM2009869 n.a. f Gastranaerophilaceae g UBA6984 s UBA6984 sp003258725 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031145 Microbes metabolize substances PMDBM2009869 n.a. f Gastranaerophilaceae g UBA6984 s UBA6984 sp003258725 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031146 Microbes metabolize substances PMDBM2009870 n.a. c Clostridia o TANB77 f CAG-508 g UBA7001 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031147 Microbes metabolize substances PMDBM2009870 n.a. c Clostridia o TANB77 f CAG-508 g UBA7001 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031148 Microbes metabolize substances PMDBM2009870 n.a. c Clostridia o TANB77 f CAG-508 g UBA7001 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031149 Microbes metabolize substances PMDBM2009870 n.a. c Clostridia o TANB77 f CAG-508 g UBA7001 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031150 Microbes metabolize substances PMDBM2009870 n.a. c Clostridia o TANB77 f CAG-508 g UBA7001 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031151 Microbes metabolize substances PMDBM2009870 n.a. c Clostridia o TANB77 f CAG-508 g UBA7001 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031152 Microbes metabolize substances PMDBM2009870 n.a. c Clostridia o TANB77 f CAG-508 g UBA7001 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031155 Microbes metabolize substances PMDBM2009870 n.a. c Clostridia o TANB77 f CAG-508 g UBA7001 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031156 Microbes metabolize substances PMDBM2009870 n.a. c Clostridia o TANB77 f CAG-508 g UBA7001 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031157 Microbes metabolize substances PMDBM2009870 n.a. c Clostridia o TANB77 f CAG-508 g UBA7001 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031158 Microbes metabolize substances PMDBM2009870 n.a. c Clostridia o TANB77 f CAG-508 g UBA7001 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031159 Microbes metabolize substances PMDBM2009870 n.a. c Clostridia o TANB77 f CAG-508 g UBA7001 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031160 Microbes metabolize substances PMDBM2009870 n.a. c Clostridia o TANB77 f CAG-508 g UBA7001 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031161 Microbes metabolize substances PMDBM2009870 n.a. c Clostridia o TANB77 f CAG-508 g UBA7001 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031162 Microbes metabolize substances PMDBM2009871 n.a. o Acholeplasmatales f CAG-307 g UBA7004 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031163 Microbes metabolize substances PMDBM2009871 n.a. o Acholeplasmatales f CAG-307 g UBA7004 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031164 Microbes metabolize substances PMDBM2009871 n.a. o Acholeplasmatales f CAG-307 g UBA7004 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031165 Microbes metabolize substances PMDBM2009871 n.a. o Acholeplasmatales f CAG-307 g UBA7004 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031166 Microbes metabolize substances PMDBM2009871 n.a. o Acholeplasmatales f CAG-307 g UBA7004 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031167 Microbes metabolize substances PMDBM2009871 n.a. o Acholeplasmatales f CAG-307 g UBA7004 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031168 Microbes metabolize substances PMDBM2009871 n.a. o Acholeplasmatales f CAG-307 g UBA7004 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031171 Microbes metabolize substances PMDBM2009871 n.a. o Acholeplasmatales f CAG-307 g UBA7004 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031172 Microbes metabolize substances PMDBM2009871 n.a. o Acholeplasmatales f CAG-307 g UBA7004 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031173 Microbes metabolize substances PMDBM2009871 n.a. o Acholeplasmatales f CAG-307 g UBA7004 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031174 Microbes metabolize substances PMDBM2009871 n.a. o Acholeplasmatales f CAG-307 g UBA7004 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031175 Microbes metabolize substances PMDBM2009871 n.a. o Acholeplasmatales f CAG-307 g UBA7004 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031176 Microbes metabolize substances PMDBM2009871 n.a. o Acholeplasmatales f CAG-307 g UBA7004 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031177 Microbes metabolize substances PMDBM2009871 n.a. o Acholeplasmatales f CAG-307 g UBA7004 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031178 Microbes metabolize substances PMDBM2009871 n.a. o Acholeplasmatales f CAG-307 g UBA7004 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031179 Microbes metabolize substances PMDBM2009872 n.a. c Bacilli o RF39 f CAG-611 g UBA7057 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031180 Microbes metabolize substances PMDBM2009872 n.a. c Bacilli o RF39 f CAG-611 g UBA7057 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031181 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031182 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20031183 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031184 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031185 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031187 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031189 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20031190 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031191 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031192 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031193 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031194 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031195 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031197 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20031200 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20031201 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20031202 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20031203 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031204 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031207 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20031210 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031211 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031214 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031215 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031216 Microbes metabolize substances PMDBM2009873 n.a. f Lachnospiraceae g UBA7096 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031217 Microbes metabolize substances PMDBM2009874 n.a. f Lachnospiraceae g UBA7096 s UBA7096 sp002492425 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031218 Microbes metabolize substances PMDBM2009874 n.a. f Lachnospiraceae g UBA7096 s UBA7096 sp002492425 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031219 Microbes metabolize substances PMDBM2009874 n.a. f Lachnospiraceae g UBA7096 s UBA7096 sp002492425 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031220 Microbes metabolize substances PMDBM2009874 n.a. f Lachnospiraceae g UBA7096 s UBA7096 sp002492425 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031221 Microbes metabolize substances PMDBM2009875 n.a. o Christensenellales f UBA1750 g UBA7102 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031222 Microbes metabolize substances PMDBM2009875 n.a. o Christensenellales f UBA1750 g UBA7102 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20031223 Microbes metabolize substances PMDBM2009875 n.a. o Christensenellales f UBA1750 g UBA7102 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031224 Microbes metabolize substances PMDBM2009875 n.a. o Christensenellales f UBA1750 g UBA7102 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031225 Microbes metabolize substances PMDBM2009875 n.a. o Christensenellales f UBA1750 g UBA7102 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031227 Microbes metabolize substances PMDBM2009875 n.a. o Christensenellales f UBA1750 g UBA7102 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031229 Microbes metabolize substances PMDBM2009875 n.a. o Christensenellales f UBA1750 g UBA7102 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031230 Microbes metabolize substances PMDBM2009875 n.a. o Christensenellales f UBA1750 g UBA7102 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031231 Microbes metabolize substances PMDBM2009875 n.a. o Christensenellales f UBA1750 g UBA7102 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031232 Microbes metabolize substances PMDBM2009875 n.a. o Christensenellales f UBA1750 g UBA7102 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031235 Microbes metabolize substances PMDBM2009875 n.a. o Christensenellales f UBA1750 g UBA7102 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031236 Microbes metabolize substances PMDBM2009875 n.a. o Christensenellales f UBA1750 g UBA7102 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031237 Microbes metabolize substances PMDBM2009875 n.a. o Christensenellales f UBA1750 g UBA7102 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031238 Microbes metabolize substances PMDBM2009875 n.a. o Christensenellales f UBA1750 g UBA7102 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031240 Microbes metabolize substances PMDBM2009875 n.a. o Christensenellales f UBA1750 g UBA7102 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031241 Microbes metabolize substances PMDBM2009875 n.a. o Christensenellales f UBA1750 g UBA7102 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031242 Microbes metabolize substances PMDBM2009875 n.a. o Christensenellales f UBA1750 g UBA7102 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031243 Microbes metabolize substances PMDBM2009876 n.a. f Lachnospiraceae g UBA7160 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031244 Microbes metabolize substances PMDBM2009876 n.a. f Lachnospiraceae g UBA7160 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031245 Microbes metabolize substances PMDBM2009876 n.a. f Lachnospiraceae g UBA7160 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031246 Microbes metabolize substances PMDBM2009876 n.a. f Lachnospiraceae g UBA7160 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031248 Microbes metabolize substances PMDBM2009876 n.a. f Lachnospiraceae g UBA7160 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031250 Microbes metabolize substances PMDBM2009876 n.a. f Lachnospiraceae g UBA7160 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031251 Microbes metabolize substances PMDBM2009876 n.a. f Lachnospiraceae g UBA7160 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031252 Microbes metabolize substances PMDBM2009876 n.a. f Lachnospiraceae g UBA7160 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031253 Microbes metabolize substances PMDBM2009876 n.a. f Lachnospiraceae g UBA7160 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031256 Microbes metabolize substances PMDBM2009876 n.a. f Lachnospiraceae g UBA7160 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031257 Microbes metabolize substances PMDBM2009876 n.a. f Lachnospiraceae g UBA7160 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031258 Microbes metabolize substances PMDBM2009876 n.a. f Lachnospiraceae g UBA7160 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031259 Microbes metabolize substances PMDBM2009876 n.a. f Lachnospiraceae g UBA7160 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031261 Microbes metabolize substances PMDBM2009876 n.a. f Lachnospiraceae g UBA7160 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031262 Microbes metabolize substances PMDBM2009876 n.a. f Lachnospiraceae g UBA7160 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031263 Microbes metabolize substances PMDBM2009876 n.a. f Lachnospiraceae g UBA7160 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031264 Microbes metabolize substances PMDBM2009876 n.a. f Lachnospiraceae g UBA7160 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20031265 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031266 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20031267 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031268 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031269 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031271 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031273 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031274 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031275 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031276 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031277 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031278 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031280 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20031283 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20031284 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20031285 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20031286 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031287 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031290 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20031293 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031294 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031297 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031298 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031299 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031300 Microbes metabolize substances PMDBM2009877 n.a. f Muribaculaceae g UBA7173 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20031301 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031302 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031303 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031304 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031306 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031308 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031309 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031310 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031311 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031312 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031313 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031315 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20031318 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20031319 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20031320 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031321 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031324 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20031327 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031328 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031331 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031332 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031333 Microbes metabolize substances PMDBM2009878 n.a. f Muribaculaceae g UBA7173 s UBA7173 sp001701135 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031334 Microbes metabolize substances PMDBM2009879 n.a. f Muribaculaceae g UBA7173 A PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031335 Microbes metabolize substances PMDBM2009879 n.a. f Muribaculaceae g UBA7173 A PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031336 Microbes metabolize substances PMDBM2009879 n.a. f Muribaculaceae g UBA7173 A PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031337 Microbes metabolize substances PMDBM2009879 n.a. f Muribaculaceae g UBA7173 A PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031339 Microbes metabolize substances PMDBM2009879 n.a. f Muribaculaceae g UBA7173 A PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031341 Microbes metabolize substances PMDBM2009879 n.a. f Muribaculaceae g UBA7173 A PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031342 Microbes metabolize substances PMDBM2009879 n.a. f Muribaculaceae g UBA7173 A PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031343 Microbes metabolize substances PMDBM2009879 n.a. f Muribaculaceae g UBA7173 A PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031344 Microbes metabolize substances PMDBM2009879 n.a. f Muribaculaceae g UBA7173 A PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031347 Microbes metabolize substances PMDBM2009879 n.a. f Muribaculaceae g UBA7173 A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031348 Microbes metabolize substances PMDBM2009879 n.a. f Muribaculaceae g UBA7173 A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031349 Microbes metabolize substances PMDBM2009879 n.a. f Muribaculaceae g UBA7173 A PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031350 Microbes metabolize substances PMDBM2009879 n.a. f Muribaculaceae g UBA7173 A PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031352 Microbes metabolize substances PMDBM2009879 n.a. f Muribaculaceae g UBA7173 A PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031353 Microbes metabolize substances PMDBM2009880 n.a. f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031354 Microbes metabolize substances PMDBM2009880 n.a. f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031355 Microbes metabolize substances PMDBM2009880 n.a. f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031356 Microbes metabolize substances PMDBM2009880 n.a. f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031358 Microbes metabolize substances PMDBM2009880 n.a. f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031360 Microbes metabolize substances PMDBM2009880 n.a. f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031361 Microbes metabolize substances PMDBM2009880 n.a. f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031362 Microbes metabolize substances PMDBM2009880 n.a. f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031363 Microbes metabolize substances PMDBM2009880 n.a. f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031366 Microbes metabolize substances PMDBM2009880 n.a. f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031367 Microbes metabolize substances PMDBM2009880 n.a. f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031368 Microbes metabolize substances PMDBM2009880 n.a. f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031369 Microbes metabolize substances PMDBM2009880 n.a. f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031371 Microbes metabolize substances PMDBM2009880 n.a. f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031372 Microbes metabolize substances PMDBM2009880 n.a. f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031373 Microbes metabolize substances PMDBM2009880 n.a. f Muribaculaceae g UBA7173 A s UBA7173 A sp001915385 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031374 Microbes metabolize substances PMDBM2009881 n.a. f Lachnospiraceae g UBA7182 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031375 Microbes metabolize substances PMDBM2009881 n.a. f Lachnospiraceae g UBA7182 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031376 Microbes metabolize substances PMDBM2009881 n.a. f Lachnospiraceae g UBA7182 PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20031377 Microbes metabolize substances PMDBM2009881 n.a. f Lachnospiraceae g UBA7182 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031378 Microbes metabolize substances PMDBM2009881 n.a. f Lachnospiraceae g UBA7182 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031379 Microbes metabolize substances PMDBM2009881 n.a. f Lachnospiraceae g UBA7182 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031380 Microbes metabolize substances PMDBM2009882 n.a. f Peptococcaceae g UBA7185 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20031381 Microbes metabolize substances PMDBM2009882 n.a. f Peptococcaceae g UBA7185 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031382 Microbes metabolize substances PMDBM2009882 n.a. f Peptococcaceae g UBA7185 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031383 Microbes metabolize substances PMDBM2009882 n.a. f Peptococcaceae g UBA7185 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031384 Microbes metabolize substances PMDBM2009883 n.a. c Bacilli o RFN20 f CAG-826 g UBA733 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031385 Microbes metabolize substances PMDBM2009883 n.a. c Bacilli o RFN20 f CAG-826 g UBA733 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031386 Microbes metabolize substances PMDBM2009883 n.a. c Bacilli o RFN20 f CAG-826 g UBA733 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031387 Microbes metabolize substances PMDBM2009883 n.a. c Bacilli o RFN20 f CAG-826 g UBA733 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031389 Microbes metabolize substances PMDBM2009883 n.a. c Bacilli o RFN20 f CAG-826 g UBA733 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031391 Microbes metabolize substances PMDBM2009883 n.a. c Bacilli o RFN20 f CAG-826 g UBA733 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031392 Microbes metabolize substances PMDBM2009883 n.a. c Bacilli o RFN20 f CAG-826 g UBA733 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031393 Microbes metabolize substances PMDBM2009883 n.a. c Bacilli o RFN20 f CAG-826 g UBA733 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031394 Microbes metabolize substances PMDBM2009883 n.a. c Bacilli o RFN20 f CAG-826 g UBA733 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031397 Microbes metabolize substances PMDBM2009883 n.a. c Bacilli o RFN20 f CAG-826 g UBA733 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031398 Microbes metabolize substances PMDBM2009883 n.a. c Bacilli o RFN20 f CAG-826 g UBA733 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031399 Microbes metabolize substances PMDBM2009883 n.a. c Bacilli o RFN20 f CAG-826 g UBA733 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031400 Microbes metabolize substances PMDBM2009883 n.a. c Bacilli o RFN20 f CAG-826 g UBA733 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031402 Microbes metabolize substances PMDBM2009883 n.a. c Bacilli o RFN20 f CAG-826 g UBA733 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031403 Microbes metabolize substances PMDBM2009883 n.a. c Bacilli o RFN20 f CAG-826 g UBA733 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031404 Microbes metabolize substances PMDBM2009883 n.a. c Bacilli o RFN20 f CAG-826 g UBA733 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031405 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031406 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031407 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031408 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031410 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031412 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031413 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031414 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031415 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031416 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031417 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031419 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20031422 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20031423 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20031424 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20031425 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031426 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031429 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20031432 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031433 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031436 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031437 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031438 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031439 Microbes metabolize substances PMDBM2009884 n.a. f Acutalibacteraceae g UBA737 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20031440 Microbes metabolize substances PMDBM2009885 n.a. f Acutalibacteraceae g UBA737 s UBA737 sp002431945 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031441 Microbes metabolize substances PMDBM2009885 n.a. f Acutalibacteraceae g UBA737 s UBA737 sp002431945 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031442 Microbes metabolize substances PMDBM2009885 n.a. f Acutalibacteraceae g UBA737 s UBA737 sp002431945 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031443 Microbes metabolize substances PMDBM2009885 n.a. f Acutalibacteraceae g UBA737 s UBA737 sp002431945 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031445 Microbes metabolize substances PMDBM2009885 n.a. f Acutalibacteraceae g UBA737 s UBA737 sp002431945 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031447 Microbes metabolize substances PMDBM2009885 n.a. f Acutalibacteraceae g UBA737 s UBA737 sp002431945 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031448 Microbes metabolize substances PMDBM2009885 n.a. f Acutalibacteraceae g UBA737 s UBA737 sp002431945 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031449 Microbes metabolize substances PMDBM2009885 n.a. f Acutalibacteraceae g UBA737 s UBA737 sp002431945 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031450 Microbes metabolize substances PMDBM2009885 n.a. f Acutalibacteraceae g UBA737 s UBA737 sp002431945 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031453 Microbes metabolize substances PMDBM2009885 n.a. f Acutalibacteraceae g UBA737 s UBA737 sp002431945 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031454 Microbes metabolize substances PMDBM2009885 n.a. f Acutalibacteraceae g UBA737 s UBA737 sp002431945 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031455 Microbes metabolize substances PMDBM2009885 n.a. f Acutalibacteraceae g UBA737 s UBA737 sp002431945 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031456 Microbes metabolize substances PMDBM2009885 n.a. f Acutalibacteraceae g UBA737 s UBA737 sp002431945 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031458 Microbes metabolize substances PMDBM2009885 n.a. f Acutalibacteraceae g UBA737 s UBA737 sp002431945 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031459 Microbes metabolize substances PMDBM2009885 n.a. f Acutalibacteraceae g UBA737 s UBA737 sp002431945 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031460 Microbes metabolize substances PMDBM2009886 n.a. f Oscillospiraceae g UBA738 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031461 Microbes metabolize substances PMDBM2009886 n.a. f Oscillospiraceae g UBA738 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031462 Microbes metabolize substances PMDBM2009886 n.a. f Oscillospiraceae g UBA738 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031463 Microbes metabolize substances PMDBM2009886 n.a. f Oscillospiraceae g UBA738 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031464 Microbes metabolize substances PMDBM2009886 n.a. f Oscillospiraceae g UBA738 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031465 Microbes metabolize substances PMDBM2009886 n.a. f Oscillospiraceae g UBA738 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031466 Microbes metabolize substances PMDBM2009886 n.a. f Oscillospiraceae g UBA738 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031469 Microbes metabolize substances PMDBM2009886 n.a. f Oscillospiraceae g UBA738 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20031470 Microbes metabolize substances PMDBM2009886 n.a. f Oscillospiraceae g UBA738 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031471 Microbes metabolize substances PMDBM2009886 n.a. f Oscillospiraceae g UBA738 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031472 Microbes metabolize substances PMDBM2009886 n.a. f Oscillospiraceae g UBA738 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031473 Microbes metabolize substances PMDBM2009886 n.a. f Oscillospiraceae g UBA738 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031474 Microbes metabolize substances PMDBM2009886 n.a. f Oscillospiraceae g UBA738 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031475 Microbes metabolize substances PMDBM2009886 n.a. f Oscillospiraceae g UBA738 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031476 Microbes metabolize substances PMDBM2009886 n.a. f Oscillospiraceae g UBA738 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031477 Microbes metabolize substances PMDBM2009886 n.a. f Oscillospiraceae g UBA738 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031478 Microbes metabolize substances PMDBM2009887 n.a. f Oscillospiraceae g UBA738 s UBA738 sp003522945 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031479 Microbes metabolize substances PMDBM2009887 n.a. f Oscillospiraceae g UBA738 s UBA738 sp003522945 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031480 Microbes metabolize substances PMDBM2009887 n.a. f Oscillospiraceae g UBA738 s UBA738 sp003522945 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031481 Microbes metabolize substances PMDBM2009887 n.a. f Oscillospiraceae g UBA738 s UBA738 sp003522945 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031482 Microbes metabolize substances PMDBM2009887 n.a. f Oscillospiraceae g UBA738 s UBA738 sp003522945 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031483 Microbes metabolize substances PMDBM2009887 n.a. f Oscillospiraceae g UBA738 s UBA738 sp003522945 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031484 Microbes metabolize substances PMDBM2009887 n.a. f Oscillospiraceae g UBA738 s UBA738 sp003522945 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031487 Microbes metabolize substances PMDBM2009887 n.a. f Oscillospiraceae g UBA738 s UBA738 sp003522945 PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20031488 Microbes metabolize substances PMDBM2009887 n.a. f Oscillospiraceae g UBA738 s UBA738 sp003522945 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031489 Microbes metabolize substances PMDBM2009887 n.a. f Oscillospiraceae g UBA738 s UBA738 sp003522945 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031490 Microbes metabolize substances PMDBM2009887 n.a. f Oscillospiraceae g UBA738 s UBA738 sp003522945 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031491 Microbes metabolize substances PMDBM2009887 n.a. f Oscillospiraceae g UBA738 s UBA738 sp003522945 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031492 Microbes metabolize substances PMDBM2009887 n.a. f Oscillospiraceae g UBA738 s UBA738 sp003522945 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031493 Microbes metabolize substances PMDBM2009887 n.a. f Oscillospiraceae g UBA738 s UBA738 sp003522945 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031494 Microbes metabolize substances PMDBM2009887 n.a. f Oscillospiraceae g UBA738 s UBA738 sp003522945 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031495 Microbes metabolize substances PMDBM2009887 n.a. f Oscillospiraceae g UBA738 s UBA738 sp003522945 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031496 Microbes metabolize substances PMDBM2009888 n.a. c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031497 Microbes metabolize substances PMDBM2009888 n.a. c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031498 Microbes metabolize substances PMDBM2009888 n.a. c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031499 Microbes metabolize substances PMDBM2009888 n.a. c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031500 Microbes metabolize substances PMDBM2009888 n.a. c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031501 Microbes metabolize substances PMDBM2009888 n.a. c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031502 Microbes metabolize substances PMDBM2009888 n.a. c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031505 Microbes metabolize substances PMDBM2009888 n.a. c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031506 Microbes metabolize substances PMDBM2009888 n.a. c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031507 Microbes metabolize substances PMDBM2009888 n.a. c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031508 Microbes metabolize substances PMDBM2009888 n.a. c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031509 Microbes metabolize substances PMDBM2009888 n.a. c Alphaproteobacteria o RF32 f UBA3637 g UBA7488 s UBA7488 sp002477185 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031510 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031511 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031512 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031513 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031515 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031517 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031518 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031519 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031520 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031521 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031522 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031524 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20031527 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20031528 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20031529 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031530 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031533 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20031536 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031537 Microbes metabolize substances PMDBM2009889 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031540 Microbes metabolize substances PMDBM2009890 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031541 Microbes metabolize substances PMDBM2009890 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031542 Microbes metabolize substances PMDBM2009890 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031543 Microbes metabolize substances PMDBM2009890 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031545 Microbes metabolize substances PMDBM2009890 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031547 Microbes metabolize substances PMDBM2009890 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031548 Microbes metabolize substances PMDBM2009890 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031549 Microbes metabolize substances PMDBM2009890 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031550 Microbes metabolize substances PMDBM2009890 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031553 Microbes metabolize substances PMDBM2009890 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031554 Microbes metabolize substances PMDBM2009890 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031555 Microbes metabolize substances PMDBM2009890 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031556 Microbes metabolize substances PMDBM2009890 n.a. c Clostridia o 4C28d-15 f CAG-727 g UBA7597 s UBA7597 sp003448195 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031558 Microbes metabolize substances PMDBM2009891 n.a. c Bacilli o RFN20 f CAG-288 g UBA7642 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031559 Microbes metabolize substances PMDBM2009891 n.a. c Bacilli o RFN20 f CAG-288 g UBA7642 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031560 Microbes metabolize substances PMDBM2009891 n.a. c Bacilli o RFN20 f CAG-288 g UBA7642 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031561 Microbes metabolize substances PMDBM2009891 n.a. c Bacilli o RFN20 f CAG-288 g UBA7642 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031563 Microbes metabolize substances PMDBM2009891 n.a. c Bacilli o RFN20 f CAG-288 g UBA7642 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031565 Microbes metabolize substances PMDBM2009891 n.a. c Bacilli o RFN20 f CAG-288 g UBA7642 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031566 Microbes metabolize substances PMDBM2009891 n.a. c Bacilli o RFN20 f CAG-288 g UBA7642 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031567 Microbes metabolize substances PMDBM2009891 n.a. c Bacilli o RFN20 f CAG-288 g UBA7642 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031568 Microbes metabolize substances PMDBM2009891 n.a. c Bacilli o RFN20 f CAG-288 g UBA7642 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031571 Microbes metabolize substances PMDBM2009891 n.a. c Bacilli o RFN20 f CAG-288 g UBA7642 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031572 Microbes metabolize substances PMDBM2009891 n.a. c Bacilli o RFN20 f CAG-288 g UBA7642 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031573 Microbes metabolize substances PMDBM2009891 n.a. c Bacilli o RFN20 f CAG-288 g UBA7642 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031574 Microbes metabolize substances PMDBM2009891 n.a. c Bacilli o RFN20 f CAG-288 g UBA7642 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031576 Microbes metabolize substances PMDBM2009891 n.a. c Bacilli o RFN20 f CAG-288 g UBA7642 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031577 Microbes metabolize substances PMDBM2009891 n.a. c Bacilli o RFN20 f CAG-288 g UBA7642 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031579 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031580 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031581 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031582 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031584 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031586 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031587 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031588 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031589 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031590 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031591 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031593 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20031596 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20031597 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20031598 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031599 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031602 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20031605 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031606 Microbes metabolize substances PMDBM2009892 n.a. f Atopobiaceae g UBA7748 s UBA7748 sp900314535 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031609 Microbes metabolize substances PMDBM2009893 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA7862 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031610 Microbes metabolize substances PMDBM2009893 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA7862 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031611 Microbes metabolize substances PMDBM2009894 n.a. f Gastranaerophilaceae g UBA791 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031612 Microbes metabolize substances PMDBM2009894 n.a. f Gastranaerophilaceae g UBA791 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031613 Microbes metabolize substances PMDBM2009894 n.a. f Gastranaerophilaceae g UBA791 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031614 Microbes metabolize substances PMDBM2009894 n.a. f Gastranaerophilaceae g UBA791 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031615 Microbes metabolize substances PMDBM2009895 n.a. f Ruminococcaceae g UBA866 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031616 Microbes metabolize substances PMDBM2009895 n.a. f Ruminococcaceae g UBA866 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031617 Microbes metabolize substances PMDBM2009895 n.a. f Ruminococcaceae g UBA866 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031618 Microbes metabolize substances PMDBM2009895 n.a. f Ruminococcaceae g UBA866 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031620 Microbes metabolize substances PMDBM2009895 n.a. f Ruminococcaceae g UBA866 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031622 Microbes metabolize substances PMDBM2009895 n.a. f Ruminococcaceae g UBA866 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031623 Microbes metabolize substances PMDBM2009895 n.a. f Ruminococcaceae g UBA866 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031624 Microbes metabolize substances PMDBM2009895 n.a. f Ruminococcaceae g UBA866 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031625 Microbes metabolize substances PMDBM2009895 n.a. f Ruminococcaceae g UBA866 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031628 Microbes metabolize substances PMDBM2009895 n.a. f Ruminococcaceae g UBA866 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031629 Microbes metabolize substances PMDBM2009895 n.a. f Ruminococcaceae g UBA866 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031630 Microbes metabolize substances PMDBM2009895 n.a. f Ruminococcaceae g UBA866 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031631 Microbes metabolize substances PMDBM2009895 n.a. f Ruminococcaceae g UBA866 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031633 Microbes metabolize substances PMDBM2009895 n.a. f Ruminococcaceae g UBA866 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031637 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031644 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031645 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031648 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20031651 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20031652 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20031658 Microbes metabolize substances PMDBM2009769 n.a. o Bacteroidales f UBA932 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20031668 Microbes metabolize substances PMDBM2009896 n.a. f Lachnospiraceae g UBA9414 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20031669 Microbes metabolize substances PMDBM2009896 n.a. f Lachnospiraceae g UBA9414 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031670 Microbes metabolize substances PMDBM2009896 n.a. f Lachnospiraceae g UBA9414 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031671 Microbes metabolize substances PMDBM2009896 n.a. f Lachnospiraceae g UBA9414 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031672 Microbes metabolize substances PMDBM2009896 n.a. f Lachnospiraceae g UBA9414 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031673 Microbes metabolize substances PMDBM2009896 n.a. f Lachnospiraceae g UBA9414 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031674 Microbes metabolize substances PMDBM2009897 n.a. f Acutalibacteraceae g UBA945 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031675 Microbes metabolize substances PMDBM2009897 n.a. f Acutalibacteraceae g UBA945 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031676 Microbes metabolize substances PMDBM2009897 n.a. f Acutalibacteraceae g UBA945 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031677 Microbes metabolize substances PMDBM2009897 n.a. f Acutalibacteraceae g UBA945 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031679 Microbes metabolize substances PMDBM2009897 n.a. f Acutalibacteraceae g UBA945 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031681 Microbes metabolize substances PMDBM2009897 n.a. f Acutalibacteraceae g UBA945 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031682 Microbes metabolize substances PMDBM2009897 n.a. f Acutalibacteraceae g UBA945 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031683 Microbes metabolize substances PMDBM2009897 n.a. f Acutalibacteraceae g UBA945 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031684 Microbes metabolize substances PMDBM2009897 n.a. f Acutalibacteraceae g UBA945 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031687 Microbes metabolize substances PMDBM2009897 n.a. f Acutalibacteraceae g UBA945 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031688 Microbes metabolize substances PMDBM2009897 n.a. f Acutalibacteraceae g UBA945 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031689 Microbes metabolize substances PMDBM2009897 n.a. f Acutalibacteraceae g UBA945 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031691 Microbes metabolize substances PMDBM2009897 n.a. f Acutalibacteraceae g UBA945 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031692 Microbes metabolize substances PMDBM2009898 n.a. f Ruminococcaceae g UBA946 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031693 Microbes metabolize substances PMDBM2009898 n.a. f Ruminococcaceae g UBA946 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031694 Microbes metabolize substances PMDBM2009898 n.a. f Ruminococcaceae g UBA946 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031695 Microbes metabolize substances PMDBM2009898 n.a. f Ruminococcaceae g UBA946 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031696 Microbes metabolize substances PMDBM2009898 n.a. f Ruminococcaceae g UBA946 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031697 Microbes metabolize substances PMDBM2009898 n.a. f Ruminococcaceae g UBA946 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031698 Microbes metabolize substances PMDBM2009898 n.a. f Ruminococcaceae g UBA946 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031701 Microbes metabolize substances PMDBM2009898 n.a. f Ruminococcaceae g UBA946 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031702 Microbes metabolize substances PMDBM2009898 n.a. f Ruminococcaceae g UBA946 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031703 Microbes metabolize substances PMDBM2009898 n.a. f Ruminococcaceae g UBA946 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031704 Microbes metabolize substances PMDBM2009898 n.a. f Ruminococcaceae g UBA946 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031705 Microbes metabolize substances PMDBM2009898 n.a. f Ruminococcaceae g UBA946 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031706 Microbes metabolize substances PMDBM2009898 n.a. f Ruminococcaceae g UBA946 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031707 Microbes metabolize substances PMDBM2009898 n.a. f Ruminococcaceae g UBA946 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031708 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031709 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031710 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031711 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031713 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031715 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031716 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031717 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031718 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031719 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031720 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031722 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20031725 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20031726 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20031727 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031728 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031731 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20031734 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031735 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031738 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031739 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031740 Microbes metabolize substances PMDBM2009899 n.a. f Oscillospiraceae g UBA9475 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031741 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031742 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031743 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031744 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031746 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031748 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031749 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031750 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031751 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031752 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031753 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031755 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20031758 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20031759 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20031760 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031761 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031764 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20031767 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031768 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031771 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031772 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031773 Microbes metabolize substances PMDBM2009900 n.a. f Lachnospiraceae g UBA9502 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031774 Microbes metabolize substances PMDBM2009901 n.a. f Lachnospiraceae g UBA9502 s UBA9502 sp003506385 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031775 Microbes metabolize substances PMDBM2009901 n.a. f Lachnospiraceae g UBA9502 s UBA9502 sp003506385 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031776 Microbes metabolize substances PMDBM2009901 n.a. f Lachnospiraceae g UBA9502 s UBA9502 sp003506385 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031777 Microbes metabolize substances PMDBM2009901 n.a. f Lachnospiraceae g UBA9502 s UBA9502 sp003506385 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031778 Microbes metabolize substances PMDBM2009901 n.a. f Lachnospiraceae g UBA9502 s UBA9502 sp003506385 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031779 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031780 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20031781 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031782 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031783 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031785 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031787 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD2000012 Amphetamine Therapeutic Substance attention-deficit/hyperactivity disorders (ADHD) n.a. n.a. n.a. n.a. n.a. n.a. Tyramine oxidase activity increased n.a. n.a. n.a. The obtained results will be crucial in designing a surrogate molecule for amphetamine that can help either in improving the efficacy and bioavailability of the amphetamine drug via competitive inhibition or in redesigning the drug for better pharmacological effects. This study will also have useful clinical implications in reducing the gut microbiota caused variation in the drug response among different populations. n.a. PMID PMID: 36467581 PMDBI20031788 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031789 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031790 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031791 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031792 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031793 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031795 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20031798 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20031799 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20031800 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031801 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031804 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20031807 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031808 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031811 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031812 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031813 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031814 Microbes metabolize substances PMDBM2009902 n.a. o Monoglobales f UBA9506 g UBA9506 PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20031815 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031816 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20031817 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031818 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031819 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031821 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20031823 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031824 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031825 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031826 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031827 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031828 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031830 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20031833 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20031834 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20031835 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031836 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031839 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20031842 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031843 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031846 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031847 Microbes metabolize substances PMDBM2009903 n.a. o Monoglobales f UBA9506 g UBA9506 s UBA9506 sp003506415 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031848 Microbes metabolize substances PMDBM2009904 n.a. o Opitutales f UBA953 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031849 Microbes metabolize substances PMDBM2009904 n.a. o Opitutales f UBA953 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031850 Microbes metabolize substances PMDBM2009904 n.a. o Opitutales f UBA953 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031851 Microbes metabolize substances PMDBM2009904 n.a. o Opitutales f UBA953 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031852 Microbes metabolize substances PMDBM2009904 n.a. o Opitutales f UBA953 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031853 Microbes metabolize substances PMDBM2009904 n.a. o Opitutales f UBA953 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031854 Microbes metabolize substances PMDBM2009904 n.a. o Opitutales f UBA953 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031857 Microbes metabolize substances PMDBM2009904 n.a. o Opitutales f UBA953 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031858 Microbes metabolize substances PMDBM2009904 n.a. o Opitutales f UBA953 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031859 Microbes metabolize substances PMDBM2009904 n.a. o Opitutales f UBA953 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031860 Microbes metabolize substances PMDBM2009904 n.a. o Opitutales f UBA953 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031861 Microbes metabolize substances PMDBM2009905 n.a. f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031862 Microbes metabolize substances PMDBM2009905 n.a. f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031863 Microbes metabolize substances PMDBM2009905 n.a. f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031864 Microbes metabolize substances PMDBM2009905 n.a. f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031865 Microbes metabolize substances PMDBM2009905 n.a. f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031866 Microbes metabolize substances PMDBM2009905 n.a. f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031867 Microbes metabolize substances PMDBM2009905 n.a. f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031870 Microbes metabolize substances PMDBM2009905 n.a. f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031871 Microbes metabolize substances PMDBM2009905 n.a. f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031872 Microbes metabolize substances PMDBM2009905 n.a. f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031873 Microbes metabolize substances PMDBM2009905 n.a. f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031874 Microbes metabolize substances PMDBM2009905 n.a. f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031875 Microbes metabolize substances PMDBM2009905 n.a. f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031876 Microbes metabolize substances PMDBM2009905 n.a. f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031877 Microbes metabolize substances PMDBM2009905 n.a. f Sphaerochaetaceae g UBA9732 s UBA9732 sp001940825 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031878 Microbes metabolize substances PMDBM2009906 n.a. o Opitutales f UBA9783 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031879 Microbes metabolize substances PMDBM2009906 n.a. o Opitutales f UBA9783 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031880 Microbes metabolize substances PMDBM2009907 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA9845 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031881 Microbes metabolize substances PMDBM2009907 n.a. c Clostridia o 4C28d-15 f UBA1242 g UBA9845 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031882 Microbes metabolize substances PMDBM2009908 n.a. f Lachnospiraceae g UC5-1-2E3 s UC5-1-2E3 sp001304875 PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20031883 Microbes metabolize substances PMDBM2009908 n.a. f Lachnospiraceae g UC5-1-2E3 s UC5-1-2E3 sp001304875 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031884 Microbes metabolize substances PMDBM2009908 n.a. f Lachnospiraceae g UC5-1-2E3 s UC5-1-2E3 sp001304875 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031885 Microbes metabolize substances PMDBM2009908 n.a. f Lachnospiraceae g UC5-1-2E3 s UC5-1-2E3 sp001304875 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031886 Microbes metabolize substances PMDBM2009908 n.a. f Lachnospiraceae g UC5-1-2E3 s UC5-1-2E3 sp001304875 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031887 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031888 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031889 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031890 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031891 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031892 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031893 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031894 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031895 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031897 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20031900 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20031901 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20031902 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031903 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031906 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20031909 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031910 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031911 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031913 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031914 Microbes metabolize substances PMDBM2009909 n.a. o Oscillospirales f CAG-382 g UCG-010 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031915 Microbes metabolize substances PMDBM2009910 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150115 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031916 Microbes metabolize substances PMDBM2009910 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150115 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031917 Microbes metabolize substances PMDBM2009910 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150115 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031918 Microbes metabolize substances PMDBM2009910 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150115 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031919 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031920 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031921 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031922 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031923 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031924 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031925 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031926 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20031927 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031929 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20031932 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20031933 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20031934 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031935 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031938 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20031941 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031942 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031943 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031945 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031946 Microbes metabolize substances PMDBM2009911 n.a. o Oscillospirales f CAG-382 g UCG-010 s UCG-010 sp003150215 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031947 Microbes metabolize substances PMDBM2021199 134821 Ureaplasma parvum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031948 Microbes metabolize substances PMDBM2021199 134821 Ureaplasma parvum PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031949 Microbes metabolize substances PMDBM2021199 134821 Ureaplasma parvum PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031950 Microbes metabolize substances PMDBM2021721 1870994 Urmitella timonensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031951 Microbes metabolize substances PMDBM2021721 1870994 Urmitella timonensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031952 Microbes metabolize substances PMDBM2009914 n.a. f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031953 Microbes metabolize substances PMDBM2009914 n.a. f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20031954 Microbes metabolize substances PMDBM2009914 n.a. f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031955 Microbes metabolize substances PMDBM2009914 n.a. f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031956 Microbes metabolize substances PMDBM2009914 n.a. f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031957 Microbes metabolize substances PMDBM2009914 n.a. f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031958 Microbes metabolize substances PMDBM2009914 n.a. f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031959 Microbes metabolize substances PMDBM2009914 n.a. f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031962 Microbes metabolize substances PMDBM2009914 n.a. f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031963 Microbes metabolize substances PMDBM2009914 n.a. f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031964 Microbes metabolize substances PMDBM2009914 n.a. f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031965 Microbes metabolize substances PMDBM2009914 n.a. f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031966 Microbes metabolize substances PMDBM2009914 n.a. f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031967 Microbes metabolize substances PMDBM2009914 n.a. f Lachnospiraceae g V9D3004 s V9D3004 sp002349525 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031968 Microbes metabolize substances PMDBM2009915 2737 Vagococcus PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20031969 Microbes metabolize substances PMDBM2009915 2737 Vagococcus PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20031970 Microbes metabolize substances PMDBM2009915 2737 Vagococcus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031971 Microbes metabolize substances PMDBM2009915 2737 Vagococcus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031972 Microbes metabolize substances PMDBM2009915 2737 Vagococcus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031973 Microbes metabolize substances PMDBM2009915 2737 Vagococcus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031974 Microbes metabolize substances PMDBM2021722 519472 Vagococcus teuberi PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20031975 Microbes metabolize substances PMDBM2021722 519472 Vagococcus teuberi PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031976 Microbes metabolize substances PMDBM2021722 519472 Vagococcus teuberi PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20031977 Microbes metabolize substances PMDBM2021722 519472 Vagococcus teuberi PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031978 Microbes metabolize substances PMDBM2021722 519472 Vagococcus teuberi PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20031979 Microbes metabolize substances PMDBM2021722 519472 Vagococcus teuberi PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20031980 Microbes metabolize substances PMDBM2009917 184869 Varibaculum PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031981 Microbes metabolize substances PMDBM2009917 184869 Varibaculum PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031982 Microbes metabolize substances PMDBM2021205 184870 Varibaculum cambriense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031983 Microbes metabolize substances PMDBM2021205 184870 Varibaculum cambriense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031984 Microbes metabolize substances PMDBM2021205 184870 Varibaculum cambriense A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031985 Microbes metabolize substances PMDBM2021205 184870 Varibaculum cambriense A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031986 Microbes metabolize substances PMDBM2021205 184870 Varibaculum cambriense B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20031987 Microbes metabolize substances PMDBM2021205 184870 Varibaculum cambriense B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20031988 Microbes metabolize substances PMDBM2021205 184870 Varibaculum cambriense B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20031989 Microbes metabolize substances PMDBM2021205 184870 Varibaculum cambriense B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031990 Microbes metabolize substances PMDBM2021205 184870 Varibaculum cambriense B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031991 Microbes metabolize substances PMDBM2021205 184870 Varibaculum cambriense B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20031992 Microbes metabolize substances PMDBM2021205 184870 Varibaculum cambriense B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20031995 Microbes metabolize substances PMDBM2021205 184870 Varibaculum cambriense B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20031996 Microbes metabolize substances PMDBM2021205 184870 Varibaculum cambriense B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20031997 Microbes metabolize substances PMDBM2021205 184870 Varibaculum cambriense B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031998 Microbes metabolize substances PMDBM2021205 184870 Varibaculum cambriense B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20031999 Microbes metabolize substances PMDBM2021205 184870 Varibaculum cambriense B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032000 Microbes metabolize substances PMDBM2021723 1895474 Varibaculum sp900106855 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032001 Microbes metabolize substances PMDBM2021723 1895474 Varibaculum sp900106855 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032002 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032003 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032004 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032005 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032006 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032007 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032008 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20032009 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20032010 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032012 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20032015 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20032016 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20032017 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20032018 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032019 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032022 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20032025 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032026 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032027 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032029 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032030 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032031 Microbes metabolize substances PMDBM2021724 1964383 Varibaculum A timonense PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032032 Microbes metabolize substances PMDBM982 29465 Veillonella PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032033 Microbes metabolize substances PMDBM2021207 39777 Veillonella atypica PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032034 Microbes metabolize substances PMDBM2020265 39778 Veillonella dispar PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032035 Microbes metabolize substances PMDBM2020265 39778 Veillonella dispar A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032036 Microbes metabolize substances PMDBM2021725 1911679 Veillonella infantium PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032037 Microbes metabolize substances PMDBM2020257 29466 Veillonella parvula PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032038 Microbes metabolize substances PMDBM2020257 29466 Veillonella parvula A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032039 Microbes metabolize substances PMDBM2021726 423477 Veillonella rogosae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032040 Microbes metabolize substances PMDBM2021212 1926307 Veillonella sp. 32 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032041 Microbes metabolize substances PMDBM2021212 1926307 Veillonella sp002959755 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032042 Microbes metabolize substances PMDBM2021264 1110546 Veillonella tobetsuensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032043 Microbes metabolize substances PMDBM2009932 n.a. Veillonella A PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20032044 Microbes metabolize substances PMDBM2009932 n.a. Veillonella A PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032045 Microbes metabolize substances PMDBM2009932 n.a. Veillonella A PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032046 Microbes metabolize substances PMDBM2021209 464322 Veillonella A magna PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032047 Microbes metabolize substances PMDBM2021727 1502943 Veillonella A seminalis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032048 Microbes metabolize substances PMDBM2021212 1926307 Veillonella A sp000431435 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032049 Microbes metabolize substances PMDBM2009936 1843489 Veillonellales PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20032050 Microbes metabolize substances PMDBM2009936 1843489 Veillonellales PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032051 Microbes metabolize substances PMDBM2020258 666 Vibrio cholerae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032052 Microbes metabolize substances PMDBM2020258 666 Vibrio cholerae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032053 Microbes metabolize substances PMDBM2020258 666 Vibrio cholerae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032054 Microbes metabolize substances PMDBM2020258 666 Vibrio cholerae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032055 Microbes metabolize substances PMDBM2020258 666 Vibrio cholerae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032056 Microbes metabolize substances PMDBM2020258 666 Vibrio cholerae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032057 Microbes metabolize substances PMDBM2020258 666 Vibrio cholerae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032060 Microbes metabolize substances PMDBM2020258 666 Vibrio cholerae PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20032061 Microbes metabolize substances PMDBM2020258 666 Vibrio cholerae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032062 Microbes metabolize substances PMDBM2020258 666 Vibrio cholerae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032063 Microbes metabolize substances PMDBM2020258 666 Vibrio cholerae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032064 Microbes metabolize substances PMDBM2020258 666 Vibrio cholerae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032065 Microbes metabolize substances PMDBM2020258 666 Vibrio cholerae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032066 Microbes metabolize substances PMDBM2020258 666 Vibrio cholerae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032067 Microbes metabolize substances PMDBM2020258 666 Vibrio cholerae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032068 Microbes metabolize substances PMDBM2020258 666 Vibrio cholerae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032069 Microbes metabolize substances PMDBM2021217 676 Vibrio fluvialis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032070 Microbes metabolize substances PMDBM2021217 676 Vibrio fluvialis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032071 Microbes metabolize substances PMDBM2021217 676 Vibrio fluvialis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032072 Microbes metabolize substances PMDBM2021217 676 Vibrio fluvialis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032073 Microbes metabolize substances PMDBM2021217 676 Vibrio fluvialis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032074 Microbes metabolize substances PMDBM2021217 676 Vibrio fluvialis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032075 Microbes metabolize substances PMDBM2021217 676 Vibrio fluvialis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032078 Microbes metabolize substances PMDBM2021217 676 Vibrio fluvialis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20032079 Microbes metabolize substances PMDBM2021217 676 Vibrio fluvialis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032080 Microbes metabolize substances PMDBM2021217 676 Vibrio fluvialis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032081 Microbes metabolize substances PMDBM2021217 676 Vibrio fluvialis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20032082 Microbes metabolize substances PMDBM2021217 676 Vibrio fluvialis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032083 Microbes metabolize substances PMDBM2021217 676 Vibrio fluvialis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032084 Microbes metabolize substances PMDBM2021217 676 Vibrio fluvialis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032085 Microbes metabolize substances PMDBM2021217 676 Vibrio fluvialis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032086 Microbes metabolize substances PMDBM2021217 676 Vibrio fluvialis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032087 Microbes metabolize substances PMDBM2021217 676 Vibrio fluvialis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032088 Microbes metabolize substances PMDBM2020269 29494 Vibrio furnissii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032089 Microbes metabolize substances PMDBM2020269 29494 Vibrio furnissii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032090 Microbes metabolize substances PMDBM2020269 29494 Vibrio furnissii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032091 Microbes metabolize substances PMDBM2020269 29494 Vibrio furnissii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032092 Microbes metabolize substances PMDBM2020269 29494 Vibrio furnissii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032093 Microbes metabolize substances PMDBM2020269 29494 Vibrio furnissii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032094 Microbes metabolize substances PMDBM2020269 29494 Vibrio furnissii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032097 Microbes metabolize substances PMDBM2020269 29494 Vibrio furnissii PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20032098 Microbes metabolize substances PMDBM2020269 29494 Vibrio furnissii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032099 Microbes metabolize substances PMDBM2020269 29494 Vibrio furnissii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032100 Microbes metabolize substances PMDBM2020269 29494 Vibrio furnissii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032101 Microbes metabolize substances PMDBM2020269 29494 Vibrio furnissii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032102 Microbes metabolize substances PMDBM2020269 29494 Vibrio furnissii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032103 Microbes metabolize substances PMDBM2020269 29494 Vibrio furnissii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032104 Microbes metabolize substances PMDBM2020269 29494 Vibrio furnissii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032105 Microbes metabolize substances PMDBM2020269 29494 Vibrio furnissii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032106 Microbes metabolize substances PMDBM2021728 1481663 Vibrio metoecus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032107 Microbes metabolize substances PMDBM2021728 1481663 Vibrio metoecus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032108 Microbes metabolize substances PMDBM2021728 1481663 Vibrio metoecus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032109 Microbes metabolize substances PMDBM2021728 1481663 Vibrio metoecus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032110 Microbes metabolize substances PMDBM2021728 1481663 Vibrio metoecus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032111 Microbes metabolize substances PMDBM2021728 1481663 Vibrio metoecus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032112 Microbes metabolize substances PMDBM2021728 1481663 Vibrio metoecus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032115 Microbes metabolize substances PMDBM2021728 1481663 Vibrio metoecus PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20032116 Microbes metabolize substances PMDBM2021728 1481663 Vibrio metoecus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032117 Microbes metabolize substances PMDBM2021728 1481663 Vibrio metoecus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032118 Microbes metabolize substances PMDBM2021728 1481663 Vibrio metoecus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032119 Microbes metabolize substances PMDBM2021728 1481663 Vibrio metoecus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032120 Microbes metabolize substances PMDBM2021728 1481663 Vibrio metoecus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032121 Microbes metabolize substances PMDBM2021728 1481663 Vibrio metoecus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032122 Microbes metabolize substances PMDBM2021728 1481663 Vibrio metoecus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032123 Microbes metabolize substances PMDBM2021728 1481663 Vibrio metoecus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032124 Microbes metabolize substances PMDBM2021220 670 Vibrio parahaemolyticus PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20032125 Microbes metabolize substances PMDBM2021220 670 Vibrio parahaemolyticus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032126 Microbes metabolize substances PMDBM2021220 670 Vibrio parahaemolyticus PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20032127 Microbes metabolize substances PMDBM2021220 670 Vibrio parahaemolyticus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032128 Microbes metabolize substances PMDBM2021220 670 Vibrio parahaemolyticus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032129 Microbes metabolize substances PMDBM2021220 670 Vibrio parahaemolyticus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032130 Microbes metabolize substances PMDBM2021267 672 Vibrio vulnificus PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032131 Microbes metabolize substances PMDBM2021267 672 Vibrio vulnificus PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032132 Microbes metabolize substances PMDBM2021267 672 Vibrio vulnificus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032133 Microbes metabolize substances PMDBM2021267 672 Vibrio vulnificus PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032134 Microbes metabolize substances PMDBM2021267 672 Vibrio vulnificus PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032135 Microbes metabolize substances PMDBM2021267 672 Vibrio vulnificus PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032136 Microbes metabolize substances PMDBM2021267 672 Vibrio vulnificus PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032139 Microbes metabolize substances PMDBM2021267 672 Vibrio vulnificus PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20032140 Microbes metabolize substances PMDBM2021267 672 Vibrio vulnificus PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032141 Microbes metabolize substances PMDBM2021267 672 Vibrio vulnificus PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032142 Microbes metabolize substances PMDBM2021267 672 Vibrio vulnificus PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032143 Microbes metabolize substances PMDBM2021267 672 Vibrio vulnificus PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032144 Microbes metabolize substances PMDBM2021267 672 Vibrio vulnificus PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032145 Microbes metabolize substances PMDBM2021267 672 Vibrio vulnificus PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032146 Microbes metabolize substances PMDBM2021267 672 Vibrio vulnificus PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032147 Microbes metabolize substances PMDBM2021267 672 Vibrio vulnificus PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032148 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032149 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032150 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032151 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20032153 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20032155 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032156 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032157 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032158 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20032159 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20032160 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032162 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20032165 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20032166 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20032167 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032168 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032171 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20032174 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032175 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032178 Microbes metabolize substances PMDBM2009940 255528 Victivallaceae PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20032179 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032180 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032181 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032182 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20032184 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20032186 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032187 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032188 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032189 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20032190 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20032191 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032193 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20032196 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20032197 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20032198 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032199 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032202 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20032205 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032206 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032209 Microbes metabolize substances PMDBM409 172900 Victivallis PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" analgesics n.a. n.a. n.a. n.a. n.a. n.a. "UGT1A; SULT1A3" toxicity decreased n.a. n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" n.a. PMID PMID: 36467581 PMDBI20032210 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032211 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032212 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032213 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20032215 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20032217 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032218 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032219 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032220 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20032221 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20032222 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032224 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20032227 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20032228 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20032229 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032230 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032233 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20032236 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032237 Microbes metabolize substances PMDBM2021729 2049020 Victivallis sp002998355 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032240 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032241 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032242 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032243 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD2000002 Poncirin Therapeutic substance unknown n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20032245 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. Alpha-L-rhamnosidase involved in substrate metabolism n.a. n.a. n.a. Of the tested natural product constituents, the cloned æµ?L-rhamnosidase hydrolyzed rutin most potently, followed by poncirin, naringin, and ginsenoside Re. However, it was unable to hydrolyze quercitrin. This is the first report describing the cloning, expression, and characterization of æµ?L-rhamnosidase, a flavonoid rhamnoglycosidemetabolizing enzyme, from bifidobacteria. Based on these findings, the æµ?L-rhamnosidase of intestinal bacteria such as B. dentium seem to be more effective in hydrolyzing (1-->6) bonds than (1-->2) bonds of rhamnoglycosides, and may play an important role in the metabolism and pharmacological effect of rhamnoglycosides. n.a. PMID PMID: 36467581 PMDBI20032247 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032248 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032249 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032250 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20032251 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20032252 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032254 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20032257 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20032258 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20032259 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032260 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032263 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20032266 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032267 Microbes metabolize substances PMDBM2020072 172901 Victivallis vadensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032270 Microbes metabolize substances PMDBM2021224 1462526 Virgibacillus massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032271 Microbes metabolize substances PMDBM2021224 1462526 Virgibacillus massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20032272 Microbes metabolize substances PMDBM2021224 1462526 Virgibacillus massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032273 Microbes metabolize substances PMDBM2021224 1462526 Virgibacillus massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032274 Microbes metabolize substances PMDBM2021224 1462526 Virgibacillus massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032275 Microbes metabolize substances PMDBM2021224 1462526 Virgibacillus massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032276 Microbes metabolize substances PMDBM2021224 1462526 Virgibacillus massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032277 Microbes metabolize substances PMDBM2021224 1462526 Virgibacillus massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032280 Microbes metabolize substances PMDBM2021224 1462526 Virgibacillus massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032281 Microbes metabolize substances PMDBM2021224 1462526 Virgibacillus massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032282 Microbes metabolize substances PMDBM2021224 1462526 Virgibacillus massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032283 Microbes metabolize substances PMDBM2021224 1462526 Virgibacillus massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032284 Microbes metabolize substances PMDBM2021224 1462526 Virgibacillus massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032285 Microbes metabolize substances PMDBM2021224 1462526 Virgibacillus massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032286 Microbes metabolize substances PMDBM2020910 171693 Virgibacillus picturae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032287 Microbes metabolize substances PMDBM2020910 171693 Virgibacillus picturae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20032288 Microbes metabolize substances PMDBM2020910 171693 Virgibacillus picturae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032289 Microbes metabolize substances PMDBM2020910 171693 Virgibacillus picturae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032290 Microbes metabolize substances PMDBM2020910 171693 Virgibacillus picturae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032291 Microbes metabolize substances PMDBM2020910 171693 Virgibacillus picturae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032292 Microbes metabolize substances PMDBM2020910 171693 Virgibacillus picturae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032293 Microbes metabolize substances PMDBM2020910 171693 Virgibacillus picturae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032296 Microbes metabolize substances PMDBM2020910 171693 Virgibacillus picturae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032297 Microbes metabolize substances PMDBM2020910 171693 Virgibacillus picturae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032298 Microbes metabolize substances PMDBM2020910 171693 Virgibacillus picturae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032299 Microbes metabolize substances PMDBM2020910 171693 Virgibacillus picturae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032300 Microbes metabolize substances PMDBM2020910 171693 Virgibacillus picturae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032301 Microbes metabolize substances PMDBM2020910 171693 Virgibacillus picturae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032302 Microbes metabolize substances PMDBM2020910 171693 Virgibacillus picturae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032303 Microbes metabolize substances PMDBM2021226 1689272 Vitreoscilla massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032304 Microbes metabolize substances PMDBM2021226 1689272 Vitreoscilla massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032305 Microbes metabolize substances PMDBM2021226 1689272 Vitreoscilla massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032306 Microbes metabolize substances PMDBM2021226 1689272 Vitreoscilla massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032307 Microbes metabolize substances PMDBM2021226 1689272 Vitreoscilla massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032308 Microbes metabolize substances PMDBM2021226 1689272 Vitreoscilla massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032309 Microbes metabolize substances PMDBM2021226 1689272 Vitreoscilla massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032312 Microbes metabolize substances PMDBM2021226 1689272 Vitreoscilla massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032313 Microbes metabolize substances PMDBM2021226 1689272 Vitreoscilla massiliensis PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20032314 Microbes metabolize substances PMDBM2021226 1689272 Vitreoscilla massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032315 Microbes metabolize substances PMDBM2021226 1689272 Vitreoscilla massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032316 Microbes metabolize substances PMDBM2021226 1689272 Vitreoscilla massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032317 Microbes metabolize substances PMDBM2020271 137591 Weissella cibaria PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032318 Microbes metabolize substances PMDBM2020271 137591 Weissella cibaria PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032319 Microbes metabolize substances PMDBM2020271 137591 Weissella cibaria PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032320 Microbes metabolize substances PMDBM2020271 137591 Weissella cibaria PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032321 Microbes metabolize substances PMDBM2020271 137591 Weissella cibaria PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032322 Microbes metabolize substances PMDBM2020271 137591 Weissella cibaria PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032323 Microbes metabolize substances PMDBM2020271 137591 Weissella cibaria PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032326 Microbes metabolize substances PMDBM2020271 137591 Weissella cibaria PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032327 Microbes metabolize substances PMDBM2020271 137591 Weissella cibaria PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032328 Microbes metabolize substances PMDBM2020271 137591 Weissella cibaria PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032329 Microbes metabolize substances PMDBM2020271 137591 Weissella cibaria PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032330 Microbes metabolize substances PMDBM2020271 137591 Weissella cibaria PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032331 Microbes metabolize substances PMDBM2020260 1583 Weissella confusa PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032332 Microbes metabolize substances PMDBM2020260 1583 Weissella confusa PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032333 Microbes metabolize substances PMDBM2020260 1583 Weissella confusa PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032334 Microbes metabolize substances PMDBM2020260 1583 Weissella confusa PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032335 Microbes metabolize substances PMDBM2020260 1583 Weissella confusa PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032336 Microbes metabolize substances PMDBM2020260 1583 Weissella confusa PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032337 Microbes metabolize substances PMDBM2020260 1583 Weissella confusa PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032340 Microbes metabolize substances PMDBM2020260 1583 Weissella confusa PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032341 Microbes metabolize substances PMDBM2020260 1583 Weissella confusa PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032342 Microbes metabolize substances PMDBM2020260 1583 Weissella confusa PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032343 Microbes metabolize substances PMDBM2020260 1583 Weissella confusa PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032344 Microbes metabolize substances PMDBM2021390 1249 Weissella paramesenteroides PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032345 Microbes metabolize substances PMDBM2021229 1629 Weissella viridescens PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032346 Microbes metabolize substances PMDBM2021229 1629 Weissella viridescens PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032347 Microbes metabolize substances PMDBM2021229 1629 Weissella viridescens PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032348 Microbes metabolize substances PMDBM2021229 1629 Weissella viridescens PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032349 Microbes metabolize substances PMDBM2021229 1629 Weissella viridescens PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032350 Microbes metabolize substances PMDBM2021229 1629 Weissella viridescens PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032351 Microbes metabolize substances PMDBM2021229 1629 Weissella viridescens PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032354 Microbes metabolize substances PMDBM2021229 1629 Weissella viridescens PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032355 Microbes metabolize substances PMDBM2021229 1629 Weissella viridescens PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032356 Microbes metabolize substances PMDBM2021229 1629 Weissella viridescens PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032357 Microbes metabolize substances PMDBM2021229 1629 Weissella viridescens PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032358 Microbes metabolize substances PMDBM2021730 33007 Winkia neuii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032359 Microbes metabolize substances PMDBM2021730 33007 Winkia neuii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032360 Microbes metabolize substances PMDBM2021730 33007 Winkia neuii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032361 Microbes metabolize substances PMDBM2021730 33007 Winkia neuii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032362 Microbes metabolize substances PMDBM2021730 33007 Winkia neuii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032363 Microbes metabolize substances PMDBM2021730 33007 Winkia neuii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032364 Microbes metabolize substances PMDBM2021730 33007 Winkia neuii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032367 Microbes metabolize substances PMDBM2021730 33007 Winkia neuii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032368 Microbes metabolize substances PMDBM2021730 33007 Winkia neuii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032369 Microbes metabolize substances PMDBM2021730 33007 Winkia neuii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032370 Microbes metabolize substances PMDBM2021730 33007 Winkia neuii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032371 Microbes metabolize substances PMDBM2021730 33007 Winkia neuii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032372 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032373 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032374 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032375 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032376 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032377 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032378 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20032379 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20032380 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032382 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20032385 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20032386 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20032387 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032388 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032391 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20032394 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032395 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032396 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032398 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032399 Microbes metabolize substances PMDBM2021731 2692120 Winkia sp002849225 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032400 Microbes metabolize substances PMDBM2021230 1720302 Xanthomonas B massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032401 Microbes metabolize substances PMDBM2021230 1720302 Xanthomonas B massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032402 Microbes metabolize substances PMDBM2021230 1720302 Xanthomonas B massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032403 Microbes metabolize substances PMDBM2021230 1720302 Xanthomonas B massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032404 Microbes metabolize substances PMDBM2021230 1720302 Xanthomonas B massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032405 Microbes metabolize substances PMDBM2021230 1720302 Xanthomonas B massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032406 Microbes metabolize substances PMDBM2021230 1720302 Xanthomonas B massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032409 Microbes metabolize substances PMDBM2021230 1720302 Xanthomonas B massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032410 Microbes metabolize substances PMDBM2021230 1720302 Xanthomonas B massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032411 Microbes metabolize substances PMDBM2021230 1720302 Xanthomonas B massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032412 Microbes metabolize substances PMDBM2021230 1720302 Xanthomonas B massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032413 Microbes metabolize substances PMDBM2021732 263819 Yersinia aleksiciae PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032414 Microbes metabolize substances PMDBM2021732 263819 Yersinia aleksiciae PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20032415 Microbes metabolize substances PMDBM2021732 263819 Yersinia aleksiciae PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032416 Microbes metabolize substances PMDBM2021732 263819 Yersinia aleksiciae PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032417 Microbes metabolize substances PMDBM2021732 263819 Yersinia aleksiciae PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032418 Microbes metabolize substances PMDBM2021732 263819 Yersinia aleksiciae PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032419 Microbes metabolize substances PMDBM2021732 263819 Yersinia aleksiciae PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032420 Microbes metabolize substances PMDBM2021732 263819 Yersinia aleksiciae PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032423 Microbes metabolize substances PMDBM2021732 263819 Yersinia aleksiciae PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032424 Microbes metabolize substances PMDBM2021732 263819 Yersinia aleksiciae PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032425 Microbes metabolize substances PMDBM2021732 263819 Yersinia aleksiciae PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032426 Microbes metabolize substances PMDBM2021732 263819 Yersinia aleksiciae PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032427 Microbes metabolize substances PMDBM2021732 263819 Yersinia aleksiciae PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032428 Microbes metabolize substances PMDBM2021732 263819 Yersinia aleksiciae PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032429 Microbes metabolize substances PMDBM2021732 263819 Yersinia aleksiciae PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032430 Microbes metabolize substances PMDBM2021732 263819 Yersinia aleksiciae PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032431 Microbes metabolize substances PMDBM2021231 634 Yersinia bercovieri PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032432 Microbes metabolize substances PMDBM2021231 634 Yersinia bercovieri PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20032433 Microbes metabolize substances PMDBM2021231 634 Yersinia bercovieri PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032434 Microbes metabolize substances PMDBM2021231 634 Yersinia bercovieri PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032435 Microbes metabolize substances PMDBM2021231 634 Yersinia bercovieri PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032436 Microbes metabolize substances PMDBM2021231 634 Yersinia bercovieri PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032437 Microbes metabolize substances PMDBM2021231 634 Yersinia bercovieri PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032438 Microbes metabolize substances PMDBM2021231 634 Yersinia bercovieri PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032441 Microbes metabolize substances PMDBM2021231 634 Yersinia bercovieri PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032442 Microbes metabolize substances PMDBM2021231 634 Yersinia bercovieri PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032443 Microbes metabolize substances PMDBM2021231 634 Yersinia bercovieri PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032444 Microbes metabolize substances PMDBM2021231 634 Yersinia bercovieri PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032445 Microbes metabolize substances PMDBM2021231 634 Yersinia bercovieri PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032446 Microbes metabolize substances PMDBM2021231 634 Yersinia bercovieri PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032447 Microbes metabolize substances PMDBM2021231 634 Yersinia bercovieri PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032448 Microbes metabolize substances PMDBM2021231 634 Yersinia bercovieri PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032449 Microbes metabolize substances PMDBM2020192 630 Yersinia enterocolitica PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032450 Microbes metabolize substances PMDBM2020192 630 Yersinia enterocolitica PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20032451 Microbes metabolize substances PMDBM2020192 630 Yersinia enterocolitica PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032452 Microbes metabolize substances PMDBM2020192 630 Yersinia enterocolitica PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032453 Microbes metabolize substances PMDBM2020192 630 Yersinia enterocolitica PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032454 Microbes metabolize substances PMDBM2020192 630 Yersinia enterocolitica PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032455 Microbes metabolize substances PMDBM2020192 630 Yersinia enterocolitica PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032456 Microbes metabolize substances PMDBM2020192 630 Yersinia enterocolitica PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032459 Microbes metabolize substances PMDBM2020192 630 Yersinia enterocolitica PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20032460 Microbes metabolize substances PMDBM2020192 630 Yersinia enterocolitica PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032461 Microbes metabolize substances PMDBM2020192 630 Yersinia enterocolitica PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032462 Microbes metabolize substances PMDBM2020192 630 Yersinia enterocolitica PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032463 Microbes metabolize substances PMDBM2020192 630 Yersinia enterocolitica PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032464 Microbes metabolize substances PMDBM2020192 630 Yersinia enterocolitica PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032465 Microbes metabolize substances PMDBM2020192 630 Yersinia enterocolitica PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032466 Microbes metabolize substances PMDBM2020192 630 Yersinia enterocolitica PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032467 Microbes metabolize substances PMDBM2020192 630 Yersinia enterocolitica PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032468 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032469 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20032470 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032471 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032472 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032473 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032474 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032475 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032478 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20032479 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032480 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032481 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032482 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032483 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032484 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032485 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032486 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032487 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii C PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032488 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii C PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20032489 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii C PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032490 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii C PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032491 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii C PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032492 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii C PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032493 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii C PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032494 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii C PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032497 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii C PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20032498 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii C PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032499 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii C PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032500 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii C PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032501 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii C PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032502 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii C PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032503 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii C PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032504 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii C PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032505 Microbes metabolize substances PMDBM2021279 29484 Yersinia frederiksenii C PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032506 Microbes metabolize substances PMDBM2021269 631 Yersinia intermedia PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032507 Microbes metabolize substances PMDBM2021269 631 Yersinia intermedia PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20032508 Microbes metabolize substances PMDBM2021269 631 Yersinia intermedia PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032509 Microbes metabolize substances PMDBM2021269 631 Yersinia intermedia PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032510 Microbes metabolize substances PMDBM2021269 631 Yersinia intermedia PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032511 Microbes metabolize substances PMDBM2021269 631 Yersinia intermedia PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032512 Microbes metabolize substances PMDBM2021269 631 Yersinia intermedia PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032513 Microbes metabolize substances PMDBM2021269 631 Yersinia intermedia PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032516 Microbes metabolize substances PMDBM2021269 631 Yersinia intermedia PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20032517 Microbes metabolize substances PMDBM2021269 631 Yersinia intermedia PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032518 Microbes metabolize substances PMDBM2021269 631 Yersinia intermedia PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032519 Microbes metabolize substances PMDBM2021269 631 Yersinia intermedia PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032520 Microbes metabolize substances PMDBM2021269 631 Yersinia intermedia PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032521 Microbes metabolize substances PMDBM2021269 631 Yersinia intermedia PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032522 Microbes metabolize substances PMDBM2021269 631 Yersinia intermedia PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032523 Microbes metabolize substances PMDBM2021269 631 Yersinia intermedia PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032524 Microbes metabolize substances PMDBM2021269 631 Yersinia intermedia PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032525 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032526 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20032527 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032528 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032529 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032530 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032531 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032532 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD446 Indomethacin Therapeutic Substance NSAID n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20032533 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD263 Diclofenac Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity n.a. n.a. n.a. Re-activation,toxicity n.a. PMID PMID: 36467581 PMDBI20032534 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032536 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. 7-ethyl-10-hydroxycamptothecin n.a. Beta-glucuronidase side effect n.a. n.a. n.a. CPT-11 to its active form (7-ethyl-10-hydroxycamptothecin)which is then converted back to its active form by bacterial beta-glucuronidase enzyme that exerts toxicity, thus diarrhea n.a. PMID PMID: 36467581 PMDBI20032539 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD2000010 Serotonin dopamine Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase involved in substrate metabolism n.a. n.a. n.a. metabolic substrate n.a. PMID PMID: 36467581 PMDBI20032540 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD2000011 Nitrotoluene Therapeutic substance compound n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase carcinogenic n.a. n.a. n.a. Genotoxic/Carcinogenic compound formed in meat and fish during cooking n.a. PMID PMID: 36467581 PMDBI20032541 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20032542 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032543 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032546 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucuronidase toxicity increased n.a. n.a. n.a. Hydrolysis of the glycosidicbon, Release of ketoprofen from glucuronides n.a. PMID PMID: 36467581 PMDBI20032549 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032550 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032551 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032553 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032554 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032555 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032556 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii B PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032557 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii B PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20032558 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii B PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032559 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii B PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032560 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii B PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032561 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii B PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032562 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii B PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032563 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii B PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032566 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii B PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20032567 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii B PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032568 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii B PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032569 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii B PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032570 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii B PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032571 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii B PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032572 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii B PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032573 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii B PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032574 Microbes metabolize substances PMDBM2021232 28152 Yersinia kristensenii B PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032575 Microbes metabolize substances PMDBM2021733 419257 Yersinia massiliensis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032576 Microbes metabolize substances PMDBM2021733 419257 Yersinia massiliensis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20032577 Microbes metabolize substances PMDBM2021733 419257 Yersinia massiliensis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032578 Microbes metabolize substances PMDBM2021733 419257 Yersinia massiliensis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032579 Microbes metabolize substances PMDBM2021733 419257 Yersinia massiliensis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032580 Microbes metabolize substances PMDBM2021733 419257 Yersinia massiliensis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032581 Microbes metabolize substances PMDBM2021733 419257 Yersinia massiliensis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032582 Microbes metabolize substances PMDBM2021733 419257 Yersinia massiliensis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032585 Microbes metabolize substances PMDBM2021733 419257 Yersinia massiliensis PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" amino acid commonly found n.a. n.a. n.a. n.a. n.a. n.a. Tryptophanase involved in substrate metabolism n.a. n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule n.a. PMID PMID: 36467581 PMDBI20032586 Microbes metabolize substances PMDBM2021733 419257 Yersinia massiliensis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032587 Microbes metabolize substances PMDBM2021733 419257 Yersinia massiliensis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032588 Microbes metabolize substances PMDBM2021733 419257 Yersinia massiliensis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032589 Microbes metabolize substances PMDBM2021733 419257 Yersinia massiliensis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032590 Microbes metabolize substances PMDBM2021733 419257 Yersinia massiliensis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032591 Microbes metabolize substances PMDBM2021733 419257 Yersinia massiliensis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032592 Microbes metabolize substances PMDBM2021733 419257 Yersinia massiliensis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032593 Microbes metabolize substances PMDBM2021733 419257 Yersinia massiliensis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032594 Microbes metabolize substances PMDBM2021734 33060 Yersinia mollaretii PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032595 Microbes metabolize substances PMDBM2021734 33060 Yersinia mollaretii PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20032596 Microbes metabolize substances PMDBM2021734 33060 Yersinia mollaretii PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032597 Microbes metabolize substances PMDBM2021734 33060 Yersinia mollaretii PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032598 Microbes metabolize substances PMDBM2021734 33060 Yersinia mollaretii PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032599 Microbes metabolize substances PMDBM2021734 33060 Yersinia mollaretii PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032600 Microbes metabolize substances PMDBM2021734 33060 Yersinia mollaretii PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032601 Microbes metabolize substances PMDBM2021734 33060 Yersinia mollaretii PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032604 Microbes metabolize substances PMDBM2021734 33060 Yersinia mollaretii PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032605 Microbes metabolize substances PMDBM2021734 33060 Yersinia mollaretii PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032606 Microbes metabolize substances PMDBM2021734 33060 Yersinia mollaretii PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032607 Microbes metabolize substances PMDBM2021734 33060 Yersinia mollaretii PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032608 Microbes metabolize substances PMDBM2021734 33060 Yersinia mollaretii PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032609 Microbes metabolize substances PMDBM2021734 33060 Yersinia mollaretii PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032610 Microbes metabolize substances PMDBM2021734 33060 Yersinia mollaretii PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032611 Microbes metabolize substances PMDBM2021734 33060 Yersinia mollaretii PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032612 Microbes metabolize substances PMDBM2021270 632 Yersinia pestis PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032613 Microbes metabolize substances PMDBM2021270 632 Yersinia pestis PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20032614 Microbes metabolize substances PMDBM2021270 632 Yersinia pestis PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032615 Microbes metabolize substances PMDBM2021270 632 Yersinia pestis PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032616 Microbes metabolize substances PMDBM2021270 632 Yersinia pestis PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032617 Microbes metabolize substances PMDBM2021270 632 Yersinia pestis PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032618 Microbes metabolize substances PMDBM2021270 632 Yersinia pestis PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032619 Microbes metabolize substances PMDBM2021270 632 Yersinia pestis PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032622 Microbes metabolize substances PMDBM2021270 632 Yersinia pestis PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032623 Microbes metabolize substances PMDBM2021270 632 Yersinia pestis PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032624 Microbes metabolize substances PMDBM2021270 632 Yersinia pestis PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032625 Microbes metabolize substances PMDBM2021270 632 Yersinia pestis PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032626 Microbes metabolize substances PMDBM2021270 632 Yersinia pestis PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032627 Microbes metabolize substances PMDBM2021270 632 Yersinia pestis PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032628 Microbes metabolize substances PMDBM2021270 632 Yersinia pestis PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032629 Microbes metabolize substances PMDBM2021270 632 Yersinia pestis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032630 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" Herbal Substance n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase toxicity n.a. n.a. n.a. the gastriointestinal flora are obligatory for the reactions which lead to the release of toxic amounts of cyanide from amygdalin (laetrile). n.a. PMID PMID: 36467581 PMDBI20032631 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. Carboxylesterase side effect n.a. n.a. n.a. aspirin is metabolized by the intestinal flora, and the main metabolite is salicylic acid,The interaction between amoxicillin and aspirin mediated by the intestinal flora may affect the efficacy of aspirin and cause more significant adverse effects. n.a. PMID PMID: 36467581 PMDBI20032632 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD2000001 Ginsenoside Therapeutic substance reproductive system in animal testicles n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. activation n.a. PMID PMID: 36467581 PMDBI20032633 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacillus sp. 52 and Bacteroides sp. 45 could metabolize rutin to quercetin 3-O-glucoside and leucocyanidin.Bacteroides sp. 42 and Veillonella sp. 32 could conver rutin to leucocyanidin. Bacteroides sp. 22 could hydrolyze rutin to quercetin-3-O-glucoside. n.a. PMID PMID: 36467581 PMDBI20032634 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD2000003 Steviol glycosides Therapeutic Substance unknown n.a. n.a. n.a. n.a. Steviol glycosides n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032635 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD2000004 Rebaudioside A Therapeutic Substance compound n.a. n.a. n.a. n.a. rebaudioside A n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032636 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD2000005 Stevioside Therapeutic Substance compound n.a. n.a. n.a. n.a. steviol n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Bacteroides species are primarily responsible for hydrolysis of Steviol glycosides, stevioside and rebaudioside A, to steviol via their beta-glucosidase activity. n.a. PMID PMID: 36467581 PMDBI20032637 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD2000006 Isoquercetin閿涘湨uercitin-3-glucoside) Therapeutic substance n.a. n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. Beta-glucosidase involved in substrate metabolism n.a. n.a. n.a. Through deglycosylation閿涘瓥soquercetin閿涘湨uercitin-3-glucoside閿涘‘ormation Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. PMID PMID: 36467581 PMDBI20032640 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD189 Choline "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. Glycyl radical enzymes (choline TMA-lyase) Induced disease n.a. n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO n.a. PMID PMID: 36467581 PMDBI20032641 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032642 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032643 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD525 Mesalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase activity decreased n.a. n.a. n.a. Forming acetylated 5-aminosalicylic acid by acetylating,The activity increased and the efficacy decreased n.a. PMID PMID: 36467581 PMDBI20032644 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD2000007 Anthocyanins Therapeutic substance Potential anticancer, anti-oxidant and anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032645 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD1214 Genistin Dietary Substances Anti-cancer, estrogenic and antiatherosclerotic n.a. n.a. n.a. n.a. genistein n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032646 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. naringenin n.a. Beta-glucosidase activation n.a. n.a. n.a. Microbial hydrolysisleading to activationof prodrug n.a. PMID PMID: 36467581 PMDBI20032647 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032648 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032649 Microbes metabolize substances PMDBM2021392 158877 Yokenella regensburgei PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032650 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032651 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032652 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032653 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032654 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032655 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp000433095 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032656 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp000433095 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032657 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp000433095 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032658 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp000433095 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032659 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp000433095 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032660 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp000437435 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032661 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp000437435 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032662 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp000437435 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032663 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp000437435 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032664 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp000437435 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032665 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp000438175 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032666 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp000438175 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032667 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp000438175 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032668 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp000438175 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032669 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp000438175 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032670 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp001765415 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032671 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp001765415 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032672 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp001765415 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032673 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp001765415 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032674 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp001917115 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032675 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp001917115 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032676 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp001917115 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032677 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp001917115 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032678 Microbes metabolize substances PMDBM2021735 1906169 f Gastranaerophilaceae g Zag1 s Zag1 sp001917115 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032679 Microbes metabolize substances PMDBM2021736 1906167 f Gastranaerophilaceae g Zag111 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032680 Microbes metabolize substances PMDBM2021736 1906167 f Gastranaerophilaceae g Zag111 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032681 Microbes metabolize substances PMDBM2021736 1906167 f Gastranaerophilaceae g Zag111 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032682 Microbes metabolize substances PMDBM2021736 1906167 f Gastranaerophilaceae g Zag111 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032683 Microbes metabolize substances PMDBM2021736 1906167 f Gastranaerophilaceae g Zag111 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032684 Microbes metabolize substances PMDBM2021736 1906167 f Gastranaerophilaceae g Zag111 s Zag111 sp002102825 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032685 Microbes metabolize substances PMDBM2021736 1906167 f Gastranaerophilaceae g Zag111 s Zag111 sp002102825 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032686 Microbes metabolize substances PMDBM2021736 1906167 f Gastranaerophilaceae g Zag111 s Zag111 sp002102825 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032687 Microbes metabolize substances PMDBM2021736 1906167 f Gastranaerophilaceae g Zag111 s Zag111 sp002102825 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032688 Microbes metabolize substances PMDBM2021736 1906167 f Gastranaerophilaceae g Zag111 s Zag111 sp002102825 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032689 Microbes metabolize substances PMDBM2021736 1906167 f Gastranaerophilaceae g Zag111 s Zag111 sp002103105 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032690 Microbes metabolize substances PMDBM2021736 1906167 f Gastranaerophilaceae g Zag111 s Zag111 sp002103105 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032691 Microbes metabolize substances PMDBM2021736 1906167 f Gastranaerophilaceae g Zag111 s Zag111 sp003258735 PMDBD788 Sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. Phosphorylysases involved in substrate metabolism n.a. n.a. n.a. Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) n.a. PMID PMID: 36467581 PMDBI20032692 Microbes metabolize substances PMDBM2021736 1906167 f Gastranaerophilaceae g Zag111 s Zag111 sp003258735 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. Uracil phosphoribosyltransferase involved in substrate metabolism n.a. n.a. n.a. 5-fluorouridine monophospate produced is RNA damaging n.a. PMID PMID: 36467581 PMDBI20032693 Microbes metabolize substances PMDBM2021736 1906167 f Gastranaerophilaceae g Zag111 s Zag111 sp003258735 PMDBD141 Capecitabine Therapeutic Substance chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. n.a. n.a. n.a. n.a. degylcocapecitabine n.a. Uridine phosphorylase toxicity n.a. n.a. n.a. causing a potential contributor to their undefined intestinal toxicity n.a. PMID PMID: 36467581 PMDBI20032694 Microbes metabolize substances PMDBM2021736 1906167 f Gastranaerophilaceae g Zag111 s Zag111 sp003258735 PMDBD872 Trifluridine Therapeutic Substance deglycosylation n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032695 Microbes metabolize substances PMDBM2021736 1906167 f Gastranaerophilaceae g Zag111 s Zag111 sp003258735 PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. nucleoside phosphorylases activity decreased n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity n.a. PMID PMID: 36467581 PMDBI20032696 Microbes metabolize substances PMDBM2009971 n.a. fecal microbiota PMDBD1384 Progesterone Therapeutic substance hormone 65 M and 1% tween and DMSO in slurry n.a. n.a. n.a. 5æµ? and 5ç?pregnanolone Reduction and dehydoxylation n.a. inactivation human faecal slurry n.a. n.a. n.a. Metabolism significantly decreased the concentration by a 28-minute half-life period PMID PMID: 32806503 PMDBI20032697 Microbes metabolize substances PMDBM2009971 n.a. fecal microbiota PMDBD477 LevonorGestrel Therapeutic Substance contraception and hormone 65 M and 1% tween and DMSO in slurry n.a. n.a. n.a. tetrahydro- and hydroxy- derivatives, sulfate and glucuronide conjugations Reduction and dehydoxylation n.a. inactivation human faecal slurry n.a. n.a. n.a. Metabolism significantly decreased the concentration by a 240-minute half-life period PMID PMID: 32806503 PMDBI20032698 Microbes metabolize substances PMDBM2009971 n.a. fecal microbiota PMDBD2000062 Medroxyprogesterone Acetate Therapeutic substance hormone 65 M and 1% tween and DMSO in slurry n.a. n.a. n.a. 5ç?dihydro MPA and tetrahydro MPA Reduction and dehydoxylation n.a. inactivation human faecal slurry n.a. n.a. attack the polar ketone bond on aromatic ring A of the hormone Metabolism significantly decreased the concentration by a 644-minute half-life period PMID PMID: 32806503 PMDBI20032699 n.a. PMDBM216 1730 Eubacterium PMDBD2000063 Irinotecan (CPT-11) Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterial ç?glucuronidase reactivated SN-38G to SN-38 in the gut, inducing significant intestinal toxicity and diarrhoea. PMID "PMID:35277453; PMID: 18927500" PMDBI20032700 n.a. PMDBM141 1485 Clostridium PMDBD2000063 Irinotecan (CPT-11) Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterial ç?glucuronidase reactivated SN-38G to SN-38 in the gut, inducing significant intestinal toxicity and diarrhoea. PMID "PMID:35277453; PMID: 18927501" PMDBI20032701 n.a. PMDBM359 1263 Ruminococcus PMDBD2000063 Irinotecan (CPT-11) Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterial ç?glucuronidase reactivated SN-38G to SN-38 in the gut, inducing significant intestinal toxicity and diarrhoea. PMID "PMID:35277453; PMID: 18927502" PMDBI20032702 n.a. PMDBM2020035 562 Escherichia coli PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterial vitamins B6and B9, ribonucleotide metabolism, and deoxynucleotide imbalance increased the efficacy of 5-FU. PMID "PMID:35277453; PMID: 28431245" PMDBI20032703 n.a. PMDBM2020225 851 Fusobacterium nucleatum. PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. F. nucleatumactivated TLR4/MYD88-dependent pathway to switch CRC cells from apoptosis to autophagy and promote chemoresistance. PMID "PMID:35277453; PMID: 28753429" PMDBI20032704 n.a. PMDBM2020035 562 Escherichia coli PMDBD355 Floxuridine Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "E. coliOP50 increased the efficacy of FUDR;Comamonasdecreased the efficacy of FUDR." PMID "PMID:35277453; PMID: 28431244" PMDBI20032705 n.a. PMDBM713 283 Comamonas PMDBD355 Floxuridine Therapeutic Substance Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "E. coliOP50 increased the efficacy of FUDR;Comamonasdecreased the efficacy of FUDR." PMID "PMID:35277453; PMID: 28431244" PMDBI20032707 n.a. PMDBM300 2100 Mycoplasma hyorhinis PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterial long isoform cytidine deaminase metabolised gemcitabine into its inactive form. PMID "PMID:35277453; PMID: 28912244" PMDBI20032708 n.a. PMDBM246 1236 Gammaproteobacteria PMDBD384 Gemcitabine Therapeutic Substance chemotherapy n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterial long isoform cytidine deaminase metabolised gemcitabine into its inactive form. PMID "PMID:35277453; PMID: 28912244" PMDBI20032709 n.a. PMDBM2020217 1354 Enterococcus hirae PMDBD237 Cyclophosphamide Therapeutic Substance lymphoma and leukemia n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. L. johnsoniiandE. hiraetranslocated into mesenteric lymph nodes and spleen to stimulate Th1 and Th17 immune response on CTX treatment. PMID "PMID:35277453; PMID: 24264990" PMDBI20032710 n.a. PMDBM2020270 487174 Barnesiella intestinihominis PMDBD237 Cyclophosphamide Therapeutic Substance lymphoma and leukemia n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. B. intestinihominispromoted infiltration of IFN-ç»?producing 绾î„æ¹­T cells in cancer lesions on treatment with CTX. PMID "PMID:35277453; PMID: 27717798" PMDBI20032711 n.a. PMDBM2020130 33959 Lactobacillus johnsonii PMDBD237 Cyclophosphamide Therapeutic Substance lymphoma and leukemia n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. L. johnsoniiandE. hiraetranslocated into mesenteric lymph nodes and spleen to stimulate Th1 and Th17 immune response on CTX treatment. PMID "PMID:35277453; PMID: 24264990" PMDBI20032712 n.a. PMDBM2009973 n.a. Unspecified PMDBD627 Oxaliplatin Therapeutic Substance chemotherapy agent n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Modulation of MYD88-dependent signalling pathway primed intratumoral myeloid cells for ROS production. PMID "PMID:35277453; PMID: 24505616" PMDBI20032713 n.a. PMDBM2020008 817 Bacteroides fragilis PMDBD627 Oxaliplatin Therapeutic Substance chemotherapy agent n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Epithelial cell apoptosis induced by oxaliplatin plus immunogenic commensals stimulated TFH cells to interact with B cells for IgG2b response and enhanced anticancer effector/memory CD8+ T cells. PMID "PMID:35277453; PMID: 32451498" PMDBI20032714 n.a. PMDBM2009974 n.a. Butyrate-producing bacteria PMDBD627 Oxaliplatin Therapeutic Substance chemotherapy agent n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Butyrate activated CD8+ T cells via ID2-dependent IL-12 signalling to promote anticancer immune response. PMID "PMID:35277453; PMID: 33761313" PMDBI20032715 n.a. PMDBM204 128827 Erysipelotrichaceae PMDBD627 Oxaliplatin Therapeutic Substance chemotherapy agent n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Epithelial cell apoptosis induced by oxaliplatin plus immunogenic commensals stimulated TFH cells to interact with B cells for IgG2b response and enhanced anticancer effector/memory CD8+ T cells. PMID "PMID:35277453; PMID: 32451498" PMDBI20032716 n.a. PMDBM2009975 n.a. Gram-negative bacteria with LPS component PMDBD627 Oxaliplatin Therapeutic Substance chemotherapy agent n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbial LPS interacted with TLR4 on macrophages causing hyperalgesia. PMID "PMID:35277453; PMID: 28714953" PMDBI20032717 n.a. PMDBM2009973 n.a. Unspecified PMDBD2000057 Cisplatin Therapeutic Substance Antitumor n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Modulation of MYD88-dependent signalling pathway primed intratumoral myeloid cells for ROS production. PMID "PMID:35277453; PMID: 24505616" PMDBI20032718 n.a. PMDBM2020008 817 Bacteroides fragilis PMDBD2000064 Anti-CTLA-4 mAbs Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Stimulation of CD11b+ DCs improved IL-12閳ユ徆ependent Th1 immune response for enhanced antitumour immune response. PMID "PMID:35277453; PMID: 26541610" PMDBI20032719 n.a. PMDBM2020472 292 Burkholderia cepacia PMDBD2000064 Anti-CTLA-4 mAbs Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Stimulation of CD11b+ DCs improved IL-12閳ユ徆ependent Th1 immune response for enhanced antitumour immune response. PMID "PMID:35277453; PMID: 26541610" PMDBI20032720 n.a. PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD2000064 Anti-CTLA-4 mAbs Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Stimulation of CD11b+ DCs improved IL-12閳ユ徆ependent Th1 immune response for enhanced antitumour immune response. PMID "PMID:35277453; PMID: 26541610" PMDBI20032721 n.a. PMDBM87 1678 Bifidobacterium PMDBD2000064 Anti-CTLA-4 mAbs Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bifidobacteriumenhanced the suppressive functions of Treg cells to minimise immunopathology induced by treatment. PMID "PMID:35277453; PMID: 29255057" PMDBI20032722 n.a. PMDBM2020442 1694 Bifidobacterium pseudolongum PMDBD2000064 Anti-CTLA-4 mAbs Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterial-derived inosine acted on adenosine 2A receptors to stimulate Th1 response in the presence of costimulations from DCs and enhanced tumour shrinkage. PMID "PMID:35277453; PMID: 32792462" PMDBI20032723 n.a. PMDBM2020266 239935 Akkermansia muciniphila PMDBD2000064 Anti-CTLA-4 mAbs Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterial-derived inosine acted on adenosine 2A receptors to stimulate Th1 response in the presence of costimulations from DCs and enhanced tumour shrinkage. PMID "PMID:35277453; PMID: 32792462" PMDBI20032724 n.a. PMDBM2020013 1685 Bifidobacterium breve PMDBD2000065 Anti-PD-1/PD-L1 mAbs Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bifidobacteriumactivated DCs for CD8+ T cell priming and infiltration in the tumour microenvironment to enhance anticancer immune response of treatment. Bifidobacteriumcould also secrete hippurate and reduce PD-1 molecule expression to activate NK cells for anticancer effects. PMID "PMID:35277453; PMID: 26541606, PMID: 34516769" PMDBI20032725 n.a. PMDBM2020193 216816 Bifidobacterium longum PMDBD2000065 Anti-PD-1/PD-L1 mAbs Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bifidobacteriumactivated DCs for CD8+ T cell priming and infiltration in the tumour microenvironment to enhance anticancer immune response of treatment. Bifidobacteriumcould also secrete hippurate and reduce PD-1 molecule expression to activate NK cells for anticancer effects. PMID "PMID:35277453; PMID: 26541606, PMID: 34516769" PMDBI20032726 n.a. PMDBM2021326 n.a. Lactobacillus rhamnosusGG PMDBD2000065 Anti-PD-1/PD-L1 mAbs Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. LGG activated DCs via cGAS-STING-TBK1-IRF7-IFN-ç?cascade to enhance CD8+ T cell activity against tumour cells. PMID "PMID:35277453; PMID: 33685966" PMDBI20032728 n.a. PMDBM2020217 n.a. Bacteriophage-infectingEnterococcus hirae PMDBD2000065 Anti-PD-1/PD-L1 mAbs Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. TMP of bacteriophage-infectingE. hiraestimulated memory CD8+ Tcell cross-reaction with cancer antigen PSMB4 protein. PMID "PMID:35277453; PMID: 32820119" PMDBI20032729 n.a. PMDBM2020213 84112 Eggerthella lenta PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" cardiac glycoside n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Promotion PMID PMID: 34497420 PMDBI20032730 n.a. PMDBM2020050 84030 Clostridium saccharolyticum PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Inhibition PMID PMID: 34497420 PMDBI20032731 n.a. PMDBM2020035 585034 Escherichia coli IAI1 PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Inhibition PMID PMID: 34497420 PMDBI20032732 n.a. PMDBM2020008 817 Bacteroides fragilis PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Previously known PMID PMID: 34497420 PMDBI20032733 n.a. PMDBM2020050 84030 Clostridium saccharolyticum PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Previously known PMID PMID: 34497420 PMDBI20032734 n.a. PMDBM2020267 n.a. Bacteroides uniformis HM715 PMDBD558 Montelukast Therapeutic Substance Drugs for obstructive airway disease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Promotion PMID PMID: 34497420 PMDBI20032735 n.a. PMDBM2021321 1547 Clostridium ramosum PMDBD812 Sulfasalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Inhibition PMID PMID: 34497420 PMDBI20032736 n.a. PMDBM2020035 585034 Escherichia coli IAI1 PMDBD731 Ranitidine "Therapeutic Substance; Herbal Substance" Drugs for acid related disorders n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Inhibition PMID PMID: 34497420 PMDBI20032737 n.a. PMDBM103 1682 Bifidobacterium longum subsp. infantis PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Previously known PMID PMID: 34497420 PMDBI20032738 n.a. PMDBM2020249 33039 Ruminococcus torques PMDBD812 Sulfasalazine Therapeutic Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Inhibition PMID PMID: 34497420 PMDBI20032739 n.a. PMDBM2020830 1358 Lactococcus lactis PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Therapeutic Substance; Herbal Substance" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Promotion PMID PMID: 34497420 PMDBI20032740 n.a. PMDBM2020249 33039 Ruminococcus torques PMDBD2000066 Tolmetin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Inhibition PMID PMID: 34497420 PMDBI20032741 n.a. PMDBM2020249 33039 Ruminococcus torques PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" cardiac glycoside n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Inhibition PMID PMID: 34497420 PMDBI20032742 n.a. PMDBM279 1590 Lactobacillus plantarum PMDBD2000066 Tolmetin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Inhibition PMID PMID: 34497420 PMDBI20032743 n.a. PMDBM2020268 821 Bacteroides vulgatus PMDBD755 Rosuvastatin Therapeutic Substance lipid-lowering drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Promotion PMID PMID: 34497420 PMDBI20032744 n.a. PMDBM2020035 585034 Escherichia coli IAI1 PMDBD1407 Rosiglitazone Therapeutic substance Anti-diabetics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Inhibition PMID PMID: 34497420 PMDBI20032745 n.a. PMDBM2020035 585034 Escherichia coli IAI1 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" cardiac glycoside n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Inhibition PMID PMID: 34497420 PMDBI20032746 n.a. PMDBM2020830 1358 Lactococcus lactis PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Promotion PMID PMID: 34497420 PMDBI20032747 n.a. PMDBM103 1682 Bifidobacterium longum subsp. Infantis PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Inhibition PMID PMID: 34497420 PMDBI20032748 n.a. PMDBM2020223 39491 Eubacterium rectale PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Inhibition PMID PMID: 34497420 PMDBI20032749 n.a. PMDBM2020035 585034 Escherichia coli IAI1 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Inhibition PMID PMID: 34497420 PMDBI20032750 n.a. PMDBM2020213 84112 Eggerthella lenta PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Inhibition PMID PMID: 34497420 PMDBI20032751 n.a. PMDBM2020267 n.a. Bacteroides uniformis HM716 PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" Cardiac drugs n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Excluded PMID PMID: 34497420 PMDBI20032752 n.a. PMDBM2020133 1596 Lactobacillus gasseri PMDBD69 Aripiprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Excluded PMID PMID: 34497420 PMDBI20032753 n.a. PMDBM2020035 585034 Escherichia coli IAI1 PMDBD69 Aripiprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Excluded PMID PMID: 34497420 PMDBI20032754 n.a. PMDBM2020223 39491 Eubacterium rectale PMDBD294 Duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Growth Inhibition PMID PMID: 34497420 PMDBI20032755 n.a. PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Depleted and Inhibits PMID PMID: 34497420 PMDBI20032756 n.a. PMDBM2020267 820 Bacteroides uniformis PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Depleted and Inhibits PMID PMID: 34497420 PMDBI20032757 n.a. PMDBM2020267 n.a. Bacteroides uniformis HM715 PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Depleted and Inhibits PMID PMID: 34497420 PMDBI20032758 n.a. PMDBM2020267 n.a. Bacteroides uniformis HM716 PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Depleted and Inhibits PMID PMID: 34497420 PMDBI20032759 n.a. PMDBM2021321 1547 Clostridium ramosum PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Depleted and Inhibits PMID PMID: 34497420 PMDBI20032760 n.a. PMDBM2020213 84112 Eggerthella lenta PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Depleted and Inhibits PMID PMID: 34497420 PMDBI20032761 n.a. PMDBM2020223 39491 Eubacterium rectale PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Depleted and Inhibits PMID PMID: 34497420 PMDBI20032762 n.a. PMDBM2020225 851 Fusobacterium nucleatum PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. Depleted and Inhibits PMID PMID: 34497420 PMDBI20032763 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000067 Amphotericin B Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032764 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000068 Anidulafungin (LY303366) Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster2) PMID PMID: 35314781 PMDBI20032765 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000069 Broxyquinoline Therapeutic Substance n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032766 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000070 Butoconazole Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster2) PMID PMID: 35314781 PMDBI20032767 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster2) PMID PMID: 35314781 PMDBI20032768 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000071 Caspofungin Acetate Therapeutic substance n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster2) PMID PMID: 35314781 PMDBI20032769 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000072 Cetrimonium Bromide (CTAB) Therapeutic Substance Phase 2 n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032770 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000073 Cetylpyridinium Chloride Therapeutic substance n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032771 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032772 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000074 Chlorquinaldol Therapeutic Substance n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032773 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032774 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000075 Cloxiquine Therapeutic substance n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032775 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000076 Evans Blue Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster2) PMID PMID: 35314781 PMDBI20032776 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000077 Everolimus (RAD001) Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032777 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000078 Fenticonazole Nitrate Therapeutic substance n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster2) PMID PMID: 35314781 PMDBI20032778 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD358 Flucytosine Therapeutic Substance antifungals n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster2) PMID PMID: 35314781 PMDBI20032779 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000079 Fluorouracil (5-Fluoracil, 5-FU) Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032780 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000080 Isavuconazole Therapeutic Substance Phase 3 n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032781 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032782 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000081 Micafungin Sodium Therapeutic substance n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster2) PMID PMID: 35314781 PMDBI20032783 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster2) PMID PMID: 35314781 PMDBI20032784 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000082 Miconazole Nitrate Therapeutic substance n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster2) PMID PMID: 35314781 PMDBI20032785 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000083 Miltefosine Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032786 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000084 Mitoxantrone 2HCl Therapeutic substance n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster2) PMID PMID: 35314781 PMDBI20032787 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000085 Natamycin Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032788 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000086 Nitroxoline Therapeutic Substance Patented n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032789 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000087 Nystatin (Fungicidin) Therapeutic substance n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032790 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000088 Octenidine Dihydrochloride Therapeutic substance n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032791 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000089 Olanexidine Hydrochloride semihydrate Therapeutic Substance Registered Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032792 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000090 Perifosine (KRX-0401) Therapeutic Substance Phase 1 n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032793 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000091 Piroctone Olamine Therapeutic substance n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032794 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD1372 Posaconazole Therapeutic substance Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032795 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000092 Rapamycin (Sirolimus) Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032796 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000093 Ridaforolimus (Deforolimus, MK-8669) Therapeutic substance n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032797 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster2) PMID PMID: 35314781 PMDBI20032798 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD807 Sulconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster2) PMID PMID: 35314781 PMDBI20032799 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000094 Tavaborole (AN-2690) Therapeutic Substance n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032800 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000095 Temsirolimus (CCI-779, NSC 683864) Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032801 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032802 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032803 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000096 Zinc Pyrithione Therapeutic Substance Investigational Drug n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032804 Substances alter microbe abundance PMDBM2009982 n.a. SeMeCos culture PMDBD2000097 Zotarolimus(ABT-578) Therapeutic substance n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) n.a. n.a. n.a. n.a. n.a. in vitro n.a. n.a. n.a. increase in auxotrophy independent of the number or type of auxotrophy (cluster3) PMID PMID: 35314781 PMDBI20032805 n.a. PMDBM2021218 n.a. Vibrio harveyi MTCC 3438 PMDBD2000098 (1-(4-chlorophenoxy)-3-[(4, 6-dimethyl-2-pyrimidinyl) thio]-2- propanol) Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27141809" PMDBI20032806 n.a. PMDBM2020177 n.a. Staphylococcus aureus 8325-4 PMDBD2000099 (10R,11R)-Hydnocarpin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26273725" PMDBI20032807 n.a. PMDBM2020177 n.a. Staphylococcus aureus 8325-4 PMDBD2000100 (10R,11R)-Hydnocarpin D Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26273725" PMDBI20032808 n.a. PMDBM2020177 n.a. Staphylococcus aureus 8325-4 PMDBD2000101 (10S,11S)-Hydnocarpin D Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26273725" PMDBI20032809 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000102 (1E)-1-{[(1E)-prop-1-ene-1-sulfinyl]sulfanyl}prop-1-ene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032810 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000103 (1R,2S,7R,3E,11E)-2,18-diacetoxycembra-3,8(19),11,15(17)-tetraen-7-ol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20032811 n.a. PMDBM2021218 n.a. Vibrio harveyi PHY-2A PMDBD2000103 (1R,2S,7R,3E,11E)-2,18-diacetoxycembra-3,8(19),11,15(17)-tetraen-7-ol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20032812 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000104 (1R,2S,7R,3E,8E,11E)-2,18-diacetoxycembra-3,8,11,15(17)-tetraen-7-ol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20032813 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000104 (1R,2S,7R,3E,8E,11E)-2,18-diacetoxycembra-3,8,11,15(17)-tetraen-7-ol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20032814 n.a. PMDBM2021218 n.a. Vibrio harveyi PHY-2A PMDBD2000104 (1R,2S,7R,3E,8E,11E)-2,18-diacetoxycembra-3,8,11,15(17)-tetraen-7-ol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20032815 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000105 (1R,2S,7R,8R)-2,18-diacetoxyasperdiol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20032816 n.a. PMDBM2021218 n.a. Vibrio harveyi PHY-2A PMDBD2000105 (1R,2S,7R,8R)-2,18-diacetoxyasperdiol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20032817 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000106 (1R,3S,7R,8S,11S,12R)-3-hydroxy-1,4,8-trimethyl-12-(propan-2-yl)tricyclo[9.3.0.0]tetradec-4-en-6-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21384863" PMDBI20032818 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000107 (1R,4R,8S,11S,12R)-4-hydroxy-1,4,8-trimethyl-12-(propan-2-yl)tricyclo[9.3.0.0]tetradec-3(7)-en-6-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21384863" PMDBI20032819 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000108 (1Z)-(2-phenylethylidene)-lambda4-sulfanyliumolate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20032820 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000108 (1Z)-(2-phenylethylidene)-lambda4-sulfanyliumolate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20032821 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000109 (1Z)-(prop-2-en-1-ylidene)-lambda4-sulfanyliumolate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20032822 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000109 (1Z)-(prop-2-en-1-ylidene)-lambda4-sulfanyliumolate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032823 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000109 (1Z)-(prop-2-en-1-ylidene)-lambda4-sulfanyliumolate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20032824 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000110 (1Z)-ethylidene-lambda4-sulfanyliumolate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032825 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000110 (1Z)-ethylidene-lambda4-sulfanyliumolate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20032826 n.a. "PMID: 30581775; PMID: 26526453" 210007 Streptococcus mutans UA159 PMDBD2000111 (2-(4-chlorophenyl)- 4-{[(6-methyl-2-pyridinyl)amino]methylene}-1,3-oxazol- 5(4H)-one) Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032827 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000112 (2-{[(2-phenylethyl)sulfanyl]sulfinyl}ethyl)benzene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20032828 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000112 (2-{[(2-phenylethyl)sulfanyl]sulfinyl}ethyl)benzene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032829 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000113 (2E)-1-(1 ,3 -benzodioxol-5-yl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20032830 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000113 (2E)-1-(1 ,3 -benzodioxol-5-yl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032831 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000113 (2E)-1-(1 ,3 -benzodioxol-5-yl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032832 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000113 (2E)-1-(1 ,3 -benzodioxol-5-yl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032833 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000113 (2E)-1-(1 ,3 -benzodioxol-5-yl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032834 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000114 (2E)-1-(1,3-benzodioxol-5-yl)-3-(2-chloro-quinolin-3-yl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20032835 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000114 (2E)-1-(1,3-benzodioxol-5-yl)-3-(2-chloro-quinolin-3-yl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032836 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000114 (2E)-1-(1,3-benzodioxol-5-yl)-3-(2-chloro-quinolin-3-yl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032837 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000114 (2E)-1-(1,3-benzodioxol-5-yl)-3-(2-chloro-quinolin-3-yl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032838 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000114 (2E)-1-(1,3-benzodioxol-5-yl)-3-(2-chloro-quinolin-3-yl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032839 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000115 (2E)-1-(1,3-benzodioxol-5-yl)-3-[5-(2-nitro-phenyl)-furan-2-yl]-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20032840 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000115 (2E)-1-(1,3-benzodioxol-5-yl)-3-[5-(2-nitro-phenyl)-furan-2-yl]-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032841 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000115 (2E)-1-(1,3-benzodioxol-5-yl)-3-[5-(2-nitro-phenyl)-furan-2-yl]-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032842 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000115 (2E)-1-(1,3-benzodioxol-5-yl)-3-[5-(2-nitro-phenyl)-furan-2-yl]-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032843 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000115 (2E)-1-(1,3-benzodioxol-5-yl)-3-[5-(2-nitro-phenyl)-furan-2-yl]-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032844 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000116 (2E)-1-(2 ,4 ,5 -trimethoxyphenyl)-3-(2-chloro-6-methoxy-quinolin-3-yl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20032845 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000116 (2E)-1-(2 ,4 ,5 -trimethoxyphenyl)-3-(2-chloro-6-methoxy-quinolin-3-yl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032846 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000116 (2E)-1-(2 ,4 ,5 -trimethoxyphenyl)-3-(2-chloro-6-methoxy-quinolin-3-yl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032847 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000116 (2E)-1-(2 ,4 ,5 -trimethoxyphenyl)-3-(2-chloro-6-methoxy-quinolin-3-yl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032848 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000116 (2E)-1-(2 ,4 ,5 -trimethoxyphenyl)-3-(2-chloro-6-methoxy-quinolin-3-yl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032849 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000117 (2E)-1-(2 ,4 ,5 -trimethoxyphenyl)-3-(2-chloro-quinolin-3-yl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20032850 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000117 (2E)-1-(2 ,4 ,5 -trimethoxyphenyl)-3-(2-chloro-quinolin-3-yl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032851 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000117 (2E)-1-(2 ,4 ,5 -trimethoxyphenyl)-3-(2-chloro-quinolin-3-yl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032852 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000117 (2E)-1-(2 ,4 ,5 -trimethoxyphenyl)-3-(2-chloro-quinolin-3-yl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032853 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000117 (2E)-1-(2 ,4 ,5 -trimethoxyphenyl)-3-(2-chloro-quinolin-3-yl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032854 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000118 (2E)-1-(2 ,4 ,5 -trimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20032855 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000118 (2E)-1-(2 ,4 ,5 -trimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032856 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000118 (2E)-1-(2 ,4 ,5 -trimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032857 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000118 (2E)-1-(2 ,4 ,5 -trimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032858 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000118 (2E)-1-(2 ,4 ,5 -trimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032859 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000119 (2E)-1-(2 ,5 -dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20032860 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000119 (2E)-1-(2 ,5 -dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032861 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000119 (2E)-1-(2 ,5 -dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032862 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000119 (2E)-1-(2 ,5 -dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032863 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000119 (2E)-1-(2 ,5 -dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032864 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000120 (2E)-1-(2 ,5 -dimethoxyphenyl)-3-[2,5-dimethyl-1-(3-trifluoromethyl-phenyl)-1H-pirrol-3-yl]-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20032865 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000120 (2E)-1-(2 ,5 -dimethoxyphenyl)-3-[2,5-dimethyl-1-(3-trifluoromethyl-phenyl)-1H-pirrol-3-yl]-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032866 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000120 (2E)-1-(2 ,5 -dimethoxyphenyl)-3-[2,5-dimethyl-1-(3-trifluoromethyl-phenyl)-1H-pirrol-3-yl]-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032867 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000120 (2E)-1-(2 ,5 -dimethoxyphenyl)-3-[2,5-dimethyl-1-(3-trifluoromethyl-phenyl)-1H-pirrol-3-yl]-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032868 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000120 (2E)-1-(2 ,5 -dimethoxyphenyl)-3-[2,5-dimethyl-1-(3-trifluoromethyl-phenyl)-1H-pirrol-3-yl]-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032869 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000121 (2E)-1-(3 ,4 ,5 -trimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20032870 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000121 (2E)-1-(3 ,4 ,5 -trimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032871 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000121 (2E)-1-(3 ,4 ,5 -trimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032872 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000121 (2E)-1-(3 ,4 ,5 -trimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032873 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000121 (2E)-1-(3 ,4 ,5 -trimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032874 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000122 (2E)-1-(3 ,4 -dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20032875 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000122 (2E)-1-(3 ,4 -dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032876 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000122 (2E)-1-(3 ,4 -dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032877 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000122 (2E)-1-(3 ,4 -dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032878 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000122 (2E)-1-(3 ,4 -dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032879 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000123 (2E)-1-(3 ,5 -dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20032880 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000123 (2E)-1-(3 ,5 -dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032881 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000123 (2E)-1-(3 ,5 -dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032882 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000123 (2E)-1-(3 ,5 -dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032883 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000123 (2E)-1-(3 ,5 -dimethoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032884 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000124 (2E)-1-(3 -methoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20032885 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000124 (2E)-1-(3 -methoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032886 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000124 (2E)-1-(3 -methoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032887 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000124 (2E)-1-(3 -methoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032888 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000124 (2E)-1-(3 -methoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032889 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000125 (2E)-1-(4 -methoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20032890 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000125 (2E)-1-(4 -methoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032891 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000125 (2E)-1-(4 -methoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032892 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000125 (2E)-1-(4 -methoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032893 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000125 (2E)-1-(4 -methoxyphenyl)-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032894 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000126 (2E)-1-(5-clorotiophen-2-yl)-3-(3-methoxy-4-benzyloxi-phenyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20032895 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000126 (2E)-1-(5-clorotiophen-2-yl)-3-(3-methoxy-4-benzyloxi-phenyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032896 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000126 (2E)-1-(5-clorotiophen-2-yl)-3-(3-methoxy-4-benzyloxi-phenyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032897 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000126 (2E)-1-(5-clorotiophen-2-yl)-3-(3-methoxy-4-benzyloxi-phenyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032898 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000126 (2E)-1-(5-clorotiophen-2-yl)-3-(3-methoxy-4-benzyloxi-phenyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032899 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000127 (2E)-1-[4 -(1H-imidazol-1-yl)phenyl]-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20032900 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000127 (2E)-1-[4 -(1H-imidazol-1-yl)phenyl]-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032901 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000127 (2E)-1-[4 -(1H-imidazol-1-yl)phenyl]-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032902 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000127 (2E)-1-[4 -(1H-imidazol-1-yl)phenyl]-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032903 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000127 (2E)-1-[4 -(1H-imidazol-1-yl)phenyl]-3-(2-naphthyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032904 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000128 (2E)-1-[4 -(1H-imidazol-1-yl)phenyl]-3-(3-methoxy-4-benzyloxi-phenyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20032905 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000128 (2E)-1-[4 -(1H-imidazol-1-yl)phenyl]-3-(3-methoxy-4-benzyloxi-phenyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032906 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000128 (2E)-1-[4 -(1H-imidazol-1-yl)phenyl]-3-(3-methoxy-4-benzyloxi-phenyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032907 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000128 (2E)-1-[4 -(1H-imidazol-1-yl)phenyl]-3-(3-methoxy-4-benzyloxi-phenyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032908 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000128 (2E)-1-[4 -(1H-imidazol-1-yl)phenyl]-3-(3-methoxy-4-benzyloxi-phenyl)-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032909 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2000129 (2E)-1-[4-(3-nitropyridin-2-yl)piperazin-1-yl]-3-phenylprop-2-en-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27838185" PMDBI20032910 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2000130 (2E)-1-[4-(4-nitrophenyl)piperazin-1-yl]-3-phenylprop-2-en-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27838185" PMDBI20032911 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU7 PMDBD2000131 (2E)-3-(3-hydroxy-4-methoxyphenyl)-1-phenylprop-2-en-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20032912 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU38 PMDBD2000131 (2E)-3-(3-hydroxy-4-methoxyphenyl)-1-phenylprop-2-en-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20032913 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU48 PMDBD2000131 (2E)-3-(3-hydroxy-4-methoxyphenyl)-1-phenylprop-2-en-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20032914 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU7 PMDBD2000132 (2E)-3-(4-Hydroxy-3-methoxyphenyl)-1-phenyl-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20032915 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU38 PMDBD2000132 (2E)-3-(4-Hydroxy-3-methoxyphenyl)-1-phenyl-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20032916 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU48 PMDBD2000132 (2E)-3-(4-Hydroxy-3-methoxyphenyl)-1-phenyl-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20032917 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 (MRSA) PMDBD2000133 (2E)-5-[(1S,2R,4aR,8aR)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl]-3-formylpent-2-enoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28692914" PMDBI20032918 n.a. "PMID: 30581775; PMID: 28692914" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000133 (2E)-5-[(1S,2R,4aR,8aR)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl]-3-formylpent-2-enoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032919 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000134 (2E)-N -(2 -hydroxy-5 -bromo-benzilidene)-3,4,5-trimethoxybenzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20032920 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000134 (2E)-N -(2 -hydroxy-5 -bromo-benzilidene)-3,4,5-trimethoxybenzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032921 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000134 (2E)-N -(2 -hydroxy-5 -bromo-benzilidene)-3,4,5-trimethoxybenzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032922 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000134 (2E)-N -(2 -hydroxy-5 -bromo-benzilidene)-3,4,5-trimethoxybenzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20032923 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000134 (2E)-N -(2 -hydroxy-5 -bromo-benzilidene)-3,4,5-trimethoxybenzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032924 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2000135 (2E)-N-(6-nitro-1,3-benzothiazol-2-yl)-3-phenylprop-2-enamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27838185" PMDBI20032925 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2000136 (2E)-N-[3-(1H-imidazol-1-yl)propyl]-3-phenylprop-2-enamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27838185" PMDBI20032926 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2000137 (2E)-N-[3-(1H-indol-3-yl)propyl]-3-phenylprop-2-enamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27838185" PMDBI20032927 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2000138 (2-methyl-5-nitro-1H-imidazol-1-yl)methyl (2E)-3-phenylprop-2-enoate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27838185" PMDBI20032928 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000139 (2R)-2-amino-3-(2,3-dihydro-1H-inden-2-yl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032929 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000139 (2R)-2-amino-3-(2,3-dihydro-1H-inden-2-yl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032930 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000139 (2R)-2-amino-3-(2,3-dihydro-1H-inden-2-yl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032931 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000140 (2R)-2-amino-3-(2-phenylethanesulfinyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20032932 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000140 (2R)-2-amino-3-(2-phenylethanesulfinyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032933 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000141 (2R)-2-amino-3-(benzenesulfinyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20032934 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000141 (2R)-2-amino-3-(benzenesulfinyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032935 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000141 (2R)-2-amino-3-(benzenesulfinyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20032936 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000142 (2R)-2-amino-3-(thiophene-2-sulfinyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20032937 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000142 (2R)-2-amino-3-(thiophene-2-sulfinyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032938 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000142 (2R)-2-amino-3-(thiophene-2-sulfinyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20032939 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000143 (2R)-2-amino-3-[(4-chlorophenyl)methanesulfinyl]propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20032940 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000143 (2R)-2-amino-3-[(4-chlorophenyl)methanesulfinyl]propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032941 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000143 (2R)-2-amino-3-[(4-chlorophenyl)methanesulfinyl]propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20032942 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000144 (2R)-2-amino-3-[(4-methylphenyl)methanesulfinyl]propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20032943 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000144 (2R)-2-amino-3-[(4-methylphenyl)methanesulfinyl]propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20032944 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000144 (2R)-2-amino-3-[(4-methylphenyl)methanesulfinyl]propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20032945 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000145 (2R)-2-amino-3-phenylmethanesulfinylpropanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20032946 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000146 (2R)-2-amino-4-phenylbutanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032947 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000147 (2R)-2-amino-5-(1-nitrocarbamimidamido)pentanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032948 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000147 (2R)-2-amino-5-(1-nitrocarbamimidamido)pentanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032949 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000148 (2R)-2-amino-6-acetamidohexanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032950 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000148 (2R)-2-amino-6-acetamidohexanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032951 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000149 (2R,3E)-2-Amino-4-phenyl-3-butenoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032952 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000149 (2R,3E)-2-Amino-4-phenyl-3-butenoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032953 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000149 (2R,3E)-2-Amino-4-phenyl-3-butenoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032954 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000150 (2S)-2-amino-3-(1,3-thiazol-4-yl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032955 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000150 (2S)-2-amino-3-(1,3-thiazol-4-yl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032956 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000151 (2S)-2-amino-3-(4-tert-butylphenyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032957 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000152 (2S)-2-amino-3-(tert-butylsulfanyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032958 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000152 (2S)-2-amino-3-(tert-butylsulfanyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032959 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000153 (2S)-2-amino-4-bromopent-4-enoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032960 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000153 (2S)-2-amino-4-bromopent-4-enoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032961 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000153 (2S)-2-amino-4-bromopent-4-enoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032962 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000154 (2S,3R,4S,5S,6R)-3-(2-(1H-Indol-3-yl)acetamido)-6-(acetoxymethyl)tetrahydro-2H-pyran-2,4,5-triyl triacetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20032963 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000155 (2S,3R,4S,5S,6R)-6-(Acetoxymethyl)-3-(2-(4-(trifluoromethyl)phenyl)acetamido)tetrahydro-2H-pyran-2,4,5-triyltriacetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20032964 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000156 (2S,3R,4S,5S,6R)-6-(Acetoxymethyl)-3-(2-(4-bromophenyl)acetamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20032965 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000157 (2S,3R,4S,5S,6R)-6-(Acetoxymethyl)-3-(2-(4-chlorophenyl)acetamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20032966 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000158 (2S,3R,4S,5S,6R)-6-(Acetoxymethyl)-3-(2-(4-fluorophenyl)acetamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20032967 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000159 (2S,3R,4S,5S,6R)-6-(Acetoxymethyl)-3-(2-(4-methoxyphenyl)acetamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20032968 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000160 (2S,3R,4S,5S,6R)-6-(Acetoxymethyl)-3-(3-oxohexanamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20032969 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000161 (2S,3R,4S,5S,6R)-6-(Acetoxymethyl)-3-(3-oxooctanamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20032970 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000162 (2S,3R,4S,5S,6R)-6-(Acetoxymethyl)-3-butyramidotetrahydro-2H-pyran-2,4,5-triyl triacetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20032971 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000163 (2S,3R,4S,5S,6R)-6-(Acetoxymethyl)-3-decanamidotetrahydro-2H-pyran-2,4,5-triyl triacetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20032972 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000164 (2S,3R,4S,5S,6R)-6-(Acetoxymethyl)-3-dodecanamidotetrahydro-2H-pyran-2,4,5-triyl triacetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20032973 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000165 (2S,3R,4S,5S,6R)-6-(Acetoxymethyl)-3-octanamidotetrahydro-2H-pyran-2,4,5-triyl triacetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20032974 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (ATCC BAA 44) PMDBD2000166 (2Z)-N-hexyl-2-hydroxy-3-[4-(trifluoromethyl)phenyl]prop-2-enamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28537316" PMDBI20032975 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000167 (3R)-4-(4-acetylphenyl)-3-aminobutan-2-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032976 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000167 (3R)-4-(4-acetylphenyl)-3-aminobutan-2-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032977 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000168 (3R)-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20032978 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2000169 (5E)-5-decylidene-1,3-thiazolidine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24078467" PMDBI20032979 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2000170 (5E)-5-dodecylidene-1,3-thiazolidine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24078467" PMDBI20032980 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2000171 (5E)-5-hexylidene-1,3-thiazolidine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24078467" PMDBI20032981 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2000172 (5E)-5-octylidene-1,3-thiazolidine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24078467" PMDBI20032982 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2000173 (5E)-5-undecylidene-1,3-thiazolidine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24078467" PMDBI20032983 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2000174 (5-nitrofuran-2-yl)methyl (2E)-3-phenylprop-2-enoate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27838185" PMDBI20032984 n.a. "PMID: 30581775; PMID: 27220074" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000175 (5S)-1,7-bis(4-hydroxyphenyl)-5-O- -D- apiofuranosyl(1 6)- -D-glucopyranosyloxyheptan-3-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20032985 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (ATCC BAA 44) PMDBD2000176 (5Z)-2-(1,1-dichloro-2-phenylethyl)-5-{[4-(trifluoromethyl)phenyl]methylidene}-1,3-oxazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28537316" PMDBI20032986 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (ATCC BAA 43 300) PMDBD2000176 (5Z)-2-(1,1-dichloro-2-phenylethyl)-5-{[4-(trifluoromethyl)phenyl]methylidene}-1,3-oxazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28537316" PMDBI20032987 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (ATCC BAA 1685) PMDBD2000176 (5Z)-2-(1,1-dichloro-2-phenylethyl)-5-{[4-(trifluoromethyl)phenyl]methylidene}-1,3-oxazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28537316" PMDBI20032988 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (ATCC BAA 1770) PMDBD2000176 (5Z)-2-(1,1-dichloro-2-phenylethyl)-5-{[4-(trifluoromethyl)phenyl]methylidene}-1,3-oxazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28537316" PMDBI20032989 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (ATCC BAA 44) PMDBD2000177 (5Z)-2-(1,1-dichloro-3,3-dimethylbutyl)-5-(phenylmethylidene)-1,3-oxazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28537316" PMDBI20032990 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (ATCC BAA 44) PMDBD2000178 (5Z)-2-(1,1-dichloro-3,3-dimethylbutyl)-5-[(3-methoxyphenyl)methylidene]-1,3-oxazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28537316" PMDBI20032991 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (ATCC BAA 44) PMDBD2000179 (5Z)-2-(1,1-dichloro-3,3-dimethylbutyl)-5-{[4-(trifluoromethyl)phenyl]methylidene}-1,3-oxazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28537316" PMDBI20032992 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (ATCC BAA 43 300) PMDBD2000179 (5Z)-2-(1,1-dichloro-3,3-dimethylbutyl)-5-{[4-(trifluoromethyl)phenyl]methylidene}-1,3-oxazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28537316" PMDBI20032993 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (ATCC BAA 1685) PMDBD2000179 (5Z)-2-(1,1-dichloro-3,3-dimethylbutyl)-5-{[4-(trifluoromethyl)phenyl]methylidene}-1,3-oxazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28537316" PMDBI20032994 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (ATCC BAA 1770) PMDBD2000179 (5Z)-2-(1,1-dichloro-3,3-dimethylbutyl)-5-{[4-(trifluoromethyl)phenyl]methylidene}-1,3-oxazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28537316" PMDBI20032995 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (ATCC BAA 44) PMDBD2000180 (5Z)-2-(1,1-dichloro-7-methyloctyl)-5-{[4-(trifluoromethyl)phenyl]methylidene}-1,3-oxazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28537316" PMDBI20032996 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (ATCC BAA 44) PMDBD2000181 (5Z)-2-(1,1-dichlorobut-3-yn-1-yl)-5-{[4-(trifluoromethyl)phenyl]methylidene}-1,3-oxazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28537316" PMDBI20032997 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (ATCC BAA 44) PMDBD2000182 (5Z)-2-(1,1-dichloropropyl)-5-{[4-(trifluoromethyl)phenyl]methylidene}-1,3-oxazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28537316" PMDBI20032998 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (ATCC BAA 44) PMDBD2000183 (5Z)-2-(2,2-dimethylpropyl)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-oxazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28537316" PMDBI20032999 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (ATCC BAA 44) PMDBD2000184 (5Z)-2-tert-butyl-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-oxazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28537316" PMDBI20033000 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000185 (5Z)-4-Bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15470704" PMDBI20033001 n.a. PMDBM2020075 470 Acinetobacter baumannii Not Specified PMDBD2000186 (E)-1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl]-3-phenyl-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24117391" PMDBI20033002 n.a. "PMID: 30581775; PMID: 24117391" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000186 (E)-1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl]-3-phenyl-2-propen-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033003 n.a. PMDBM2020258 n.a. Vibrio cholerae CIP 106859 PMDBD2000187 (E)-3-Decen-2-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21249192" PMDBI20033004 n.a. PMDBM2021218 n.a. Vibrio harveyi BB125 PMDBD2000187 (E)-3-Decen-2-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21249192" PMDBI20033005 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU7 PMDBD2000188 (E)-Chalcone Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033006 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU38 PMDBD2000188 (E)-Chalcone Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033007 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU48 PMDBD2000188 (E)-Chalcone Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033008 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2000189 (furan-2-yl)methyl (2E)-3-phenylprop-2-enoate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27838185" PMDBI20033009 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000190 (R)-2,3-Diaminopropanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033010 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000190 (R)-2,3-Diaminopropanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033011 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000191 (R)-2-Amino-3-biphenyl-3-yl-propionic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033012 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000192 (R)-2-amino-3-cyclohexylpropanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033013 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000192 (R)-2-amino-3-cyclohexylpropanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033014 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000192 (R)-2-amino-3-cyclohexylpropanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033015 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000193 (R)-2-amino-3-cyclopentylpropanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033016 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000193 (R)-2-amino-3-cyclopentylpropanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033017 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000193 (R)-2-amino-3-cyclopentylpropanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033018 n.a. PMDBM2020035 n.a. Escherichia coli HM22 PMDBD2000194 (RW)2-NH2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21622798" PMDBI20033019 n.a. PMDBM2020035 n.a. Escherichia coli HM22 PMDBD2000195 (RW)3-NH2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21622798" PMDBI20033020 n.a. PMDBM2020035 n.a. Escherichia coli HM22 PMDBD2000196 (RW)4D Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21622798" PMDBI20033021 n.a. PMDBM2020035 n.a. Escherichia coli HM22 PMDBD2000197 (RW)4-NH2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21622798" PMDBI20033022 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000198 (Z)-3-(bromomethylene) isobenzofuran-1(3H)-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19098295" PMDBI20033023 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000199 (Z)-3-bromo-5-(bromomethylene) furan-2(5H)-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19098295" PMDBI20033024 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000200 (Z)-4-bromo-5-(bromomethylene)-3-(1-bromobutyl)-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033025 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000201 (Z)-4-bromo-5-(bromomethylene)-3-(1-bromoethyl)-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033026 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000202 (Z)-4-bromo-5-(bromomethylene)-3-(1-bromohexyl)-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033027 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000203 (Z)-4-bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033028 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000204 (Z)-4-bromo-5-(bromomethylene)-3-ethyl-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033029 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000205 (Z)-4-bromo-5-(bromomethylene)-3-hexyl-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033030 n.a. "PMID: 30581775; PMID: 23029239" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000206 (Z)-4-bromo-5-(bromomethylene)-3-methylfuran-2(5H)-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033031 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000207 (Z)-5-(bromomethylene)-3-(hydroxymethyl]thiophen-2(5H)- one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27214405" PMDBI20033032 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000208 (Z)-5-(chloromethylene) furan-2(5H)-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19098295" PMDBI20033033 n.a. PMDBM2020620 1747 Propionibacterium acnes LMG 16711 PMDBD2000209 (Z)-5-decylidenethiazolidine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24251377" PMDBI20033034 n.a. PMDBM2020620 1747 Propionibacterium acnes LMG 16711 PMDBD2000210 (Z)-5-octylidenethiazolidine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24251377" PMDBI20033035 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000211 [(ethanesulfinyl)sulfanyl]ethane Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033036 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2000212 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethyl (2E)-3-phenylprop-2-enoate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27838185" PMDBI20033037 n.a. PMDBM2020035 n.a. Escherichia coli MT102 PMDBD2000213 1-(2-Chloroacetyl)-5-methylindoline-2,3-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033038 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MH602 PMDBD2000213 1-(2-Chloroacetyl)-5-methylindoline-2,3-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033039 n.a. PMDBM2020035 n.a. Escherichia coli MT102 PMDBD2000214 1-(2-Chloroacetyl)indoline-2,3-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033040 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MH602 PMDBD2000214 1-(2-Chloroacetyl)indoline-2,3-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033041 n.a. "PMID: 30581775; PMID: 19855933" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000215 1-(3,5-dinitrophenyl)ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033042 n.a. "PMID: 30581775; PMID: 19855933" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000216 1-(4-amino-2-hydroxyphenyl)ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033043 n.a. PMDBM2020183 1309 Streptococcus mutans NG8 PMDBD2000217 1-(4-chlorophenyl)-3-m-tolyurea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033044 n.a. PMDBM2020183 n.a. Streptococcus mutans 5SM PMDBD2000217 1-(4-chlorophenyl)-3-m-tolyurea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033045 n.a. PMDBM2020183 n.a. Streptococcus mutans 4SM PMDBD2000218 1-(4-chlorophenyl)-3-p-tolyurea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033046 n.a. PMDBM2020183 n.a. Streptococcus mutans 5SM PMDBD2000218 1-(4-chlorophenyl)-3-p-tolyurea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033047 n.a. PMDBM2020183 n.a. Streptococcus mutans MTCC 497 PMDBD2000218 1-(4-chlorophenyl)-3-p-tolyurea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033048 n.a. PMDBM2020183 n.a. Streptococcus mutans MTCC 497 PMDBD2000219 1-(4-methoxyphenyl)-3-m-tolyurea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033049 n.a. PMDBM2020183 1309 Streptococcus mutans NG8 PMDBD2000219 1-(4-methoxyphenyl)-3-m-tolyurea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033050 n.a. PMDBM2020183 n.a. Streptococcus mutans 4SM PMDBD2000219 1-(4-methoxyphenyl)-3-m-tolyurea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033051 n.a. PMDBM2020183 n.a. Streptococcus mutans 5SM PMDBD2000219 1-(4-methoxyphenyl)-3-m-tolyurea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033052 n.a. PMDBM2020183 1309 Streptococcus mutans NG8 PMDBD2000220 1-(4-methoxyphenyl)-3-p-tolyurea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033053 n.a. PMDBM2020183 n.a. Streptococcus mutans 4SM PMDBD2000220 1-(4-methoxyphenyl)-3-p-tolyurea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033054 n.a. PMDBM2020183 n.a. Streptococcus mutans 5SM PMDBD2000220 1-(4-methoxyphenyl)-3-p-tolyurea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033055 n.a. "PMID: 30581775; PMID: 19855933" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000221 1-(6-aminopyridin-3-yl)ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033056 n.a. "PMID: 30581775; PMID: 19855933" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000222 1-(pyrazin-2-yl)ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033057 n.a. "PMID: 30581775; PMID: 19855933" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000223 1-(pyridin-4-yl)ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033058 n.a. PMDBM2020075 470 Acinetobacter baumannii Not Specified PMDBD2000224 1,1,6,6,7,7-hexahydroxy-5,5-diisopropyl-3,3-dimethyl-2,2-binaphthalene-8,8-dicarbaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24117391" PMDBI20033059 n.a. "PMID: 30581775; PMID: 24117391" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000224 1,1,6,6,7,7-hexahydroxy-5,5-diisopropyl-3,3-dimethyl-2,2-binaphthalene-8,8-dicarbaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033060 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000225 1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033061 n.a. PMDBM2020080 1423 Bacillus subtilis 168 PMDBD2000226 1,3-bis[3-chloro-5-(1,3-dichloropropane-2-yloxy)-2(5H)-furanone-4-ylsulfonyl]propane Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26085951" PMDBI20033062 n.a. PMDBM2020080 n.a. Bacillus subtilis MTCC 121 PMDBD2000227 1,3-dimethyl-6-(4-methylphenyl)-5-[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl]-1H,2H,3H,4H,5H,6H-pyrimido[4,5-d][1,3]diazine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28209374" PMDBI20033063 n.a. PMDBM2020228 n.a. Micrococcus luteus MTCC 2470 PMDBD2000227 1,3-dimethyl-6-(4-methylphenyl)-5-[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl]-1H,2H,3H,4H,5H,6H-pyrimido[4,5-d][1,3]diazine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28209374" PMDBI20033064 n.a. PMDBM2020177 n.a. Staphylococcus aureus MTCC 96 PMDBD2000227 1,3-dimethyl-6-(4-methylphenyl)-5-[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl]-1H,2H,3H,4H,5H,6H-pyrimido[4,5-d][1,3]diazine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28209374" PMDBI20033065 n.a. PMDBM2020177 n.a. Staphylococcus aureus MLS16 MTCC 2940 PMDBD2000227 1,3-dimethyl-6-(4-methylphenyl)-5-[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl]-1H,2H,3H,4H,5H,6H-pyrimido[4,5-d][1,3]diazine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28209374" PMDBI20033066 n.a. PMDBM2020080 n.a. Bacillus subtilis MTCC 121 PMDBD2000228 1,3-dimethyl-6-(4-methylphenyl)-5-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]-1H,2H,3H,4H,5H,6H-pyrimido[4,5-d][1,3]diazine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28209374" PMDBI20033067 n.a. PMDBM2020228 n.a. Micrococcus luteus MTCC 2470 PMDBD2000228 1,3-dimethyl-6-(4-methylphenyl)-5-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]-1H,2H,3H,4H,5H,6H-pyrimido[4,5-d][1,3]diazine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28209374" PMDBI20033068 n.a. PMDBM2020177 n.a. Staphylococcus aureus MTCC 96 PMDBD2000228 1,3-dimethyl-6-(4-methylphenyl)-5-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]-1H,2H,3H,4H,5H,6H-pyrimido[4,5-d][1,3]diazine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28209374" PMDBI20033069 n.a. PMDBM2020177 n.a. Staphylococcus aureus MLS16 MTCC 2940 PMDBD2000228 1,3-dimethyl-6-(4-methylphenyl)-5-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]-1H,2H,3H,4H,5H,6H-pyrimido[4,5-d][1,3]diazine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28209374" PMDBI20033070 n.a. PMDBM2020183 1309 Streptococcus mutans NG8 PMDBD2000229 1,3-dim-tolyurea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033071 n.a. PMDBM2020183 n.a. Streptococcus mutans 4SM PMDBD2000229 1,3-dim-tolyurea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033072 n.a. PMDBM2020183 n.a. Streptococcus mutans 5SM PMDBD2000229 1,3-dim-tolyurea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033073 n.a. PMDBM2020183 n.a. Streptococcus mutans MTCC 497 PMDBD2000229 1,3-dim-tolyurea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033074 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000230 1-[2-(2,4-dichlorophenyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20033075 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000230 1-[2-(2,4-dichlorophenyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20033076 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000230 1-[2-(2,4-dichlorophenyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20033077 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000230 1-[2-(2,4-dichlorophenyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20033078 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000230 1-[2-(2,4-dichlorophenyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033079 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000231 1-[2-(2-nitrophenyl)-5-phenyl-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20033080 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000231 1-[2-(2-nitrophenyl)-5-phenyl-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20033081 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000231 1-[2-(2-nitrophenyl)-5-phenyl-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20033082 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000231 1-[2-(2-nitrophenyl)-5-phenyl-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20033083 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000231 1-[2-(2-nitrophenyl)-5-phenyl-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033084 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000232 1-[2-(3,5-dichlorophenyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20033085 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000232 1-[2-(3,5-dichlorophenyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20033086 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000232 1-[2-(3,5-dichlorophenyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20033087 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000232 1-[2-(3,5-dichlorophenyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20033088 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000232 1-[2-(3,5-dichlorophenyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033089 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000233 1-[2-(3-bromo-4-hydroxy-5-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20033090 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000233 1-[2-(3-bromo-4-hydroxy-5-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20033091 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000233 1-[2-(3-bromo-4-hydroxy-5-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20033092 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000233 1-[2-(3-bromo-4-hydroxy-5-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20033093 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000233 1-[2-(3-bromo-4-hydroxy-5-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033094 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000234 1-[2-(naphthalen-1-yl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20033095 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000234 1-[2-(naphthalen-1-yl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20033096 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000234 1-[2-(naphthalen-1-yl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20033097 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000234 1-[2-(naphthalen-1-yl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20033098 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000234 1-[2-(naphthalen-1-yl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl]ethanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033099 n.a. PMDBM2020080 n.a. Bacillus subtilis MTCC 121 PMDBD2000235 1-{2-[(E)-2-(4-chlorophenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033100 n.a. PMDBM2020035 n.a. Escherichia coli MTCC 739 PMDBD2000235 1-{2-[(E)-2-(4-chlorophenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033101 n.a. PMDBM2020186 n.a. Klebsiella planticola MTCC 530 PMDBD2000235 1-{2-[(E)-2-(4-chlorophenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033102 n.a. PMDBM2020228 n.a. Micrococcus luteus MTCC 2470 PMDBD2000235 1-{2-[(E)-2-(4-chlorophenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033103 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MTCC 2453 PMDBD2000235 1-{2-[(E)-2-(4-chlorophenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033104 n.a. PMDBM2020177 n.a. Staphylococcus aureus MTCC 96 PMDBD2000235 1-{2-[(E)-2-(4-chlorophenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033105 n.a. PMDBM2020177 n.a. Staphylococcus aureus MLS16 MTCC 2940 PMDBD2000235 1-{2-[(E)-2-(4-chlorophenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033106 n.a. PMDBM2020080 n.a. Bacillus subtilis MTCC 121 PMDBD2000236 1-{2-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033107 n.a. PMDBM2020035 n.a. Escherichia coli MTCC 739 PMDBD2000236 1-{2-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033108 n.a. PMDBM2020186 n.a. Klebsiella planticola MTCC 530 PMDBD2000236 1-{2-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033109 n.a. PMDBM2020228 n.a. Micrococcus luteus MTCC 2470 PMDBD2000236 1-{2-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033110 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MTCC 2453 PMDBD2000236 1-{2-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033111 n.a. PMDBM2020177 n.a. Staphylococcus aureus MTCC 96 PMDBD2000236 1-{2-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033112 n.a. PMDBM2020177 n.a. Staphylococcus aureus MLS16 MTCC 2940 PMDBD2000236 1-{2-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033113 n.a. PMDBM2020080 n.a. Bacillus subtilis MTCC 121 PMDBD2000237 1-{2-[(E)-2-(4-methoxyphenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033114 n.a. PMDBM2020035 n.a. Escherichia coli MTCC 739 PMDBD2000237 1-{2-[(E)-2-(4-methoxyphenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033115 n.a. PMDBM2020228 n.a. Micrococcus luteus MTCC 2470 PMDBD2000237 1-{2-[(E)-2-(4-methoxyphenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033116 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MTCC 2453 PMDBD2000237 1-{2-[(E)-2-(4-methoxyphenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033117 n.a. PMDBM2020177 n.a. Staphylococcus aureus MTCC 96 PMDBD2000237 1-{2-[(E)-2-(4-methoxyphenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033118 n.a. PMDBM2020177 n.a. Staphylococcus aureus MLS16 MTCC 2940 PMDBD2000237 1-{2-[(E)-2-(4-methoxyphenyl)ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033119 n.a. PMDBM2020080 n.a. Bacillus subtilis MTCC 121 PMDBD2000238 1-{2-[(E)-2-[3,5-bis(trifluoromethyl)phenyl]ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033120 n.a. PMDBM2020035 n.a. Escherichia coli MTCC 739 PMDBD2000238 1-{2-[(E)-2-[3,5-bis(trifluoromethyl)phenyl]ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033121 n.a. PMDBM2020186 n.a. Klebsiella planticola MTCC 530 PMDBD2000238 1-{2-[(E)-2-[3,5-bis(trifluoromethyl)phenyl]ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033122 n.a. PMDBM2020228 n.a. Micrococcus luteus MTCC 2470 PMDBD2000238 1-{2-[(E)-2-[3,5-bis(trifluoromethyl)phenyl]ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033123 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MTCC 2453 PMDBD2000238 1-{2-[(E)-2-[3,5-bis(trifluoromethyl)phenyl]ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033124 n.a. PMDBM2020177 n.a. Staphylococcus aureus MTCC 96 PMDBD2000238 1-{2-[(E)-2-[3,5-bis(trifluoromethyl)phenyl]ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033125 n.a. PMDBM2020177 n.a. Staphylococcus aureus MLS16 MTCC 2940 PMDBD2000238 1-{2-[(E)-2-[3,5-bis(trifluoromethyl)phenyl]ethenyl]-4-phenylquinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033126 n.a. PMDBM2020080 n.a. Bacillus subtilis MTCC 121 PMDBD2000239 1-{4-phenyl-2-[(E)-2-[4-(trifluoromethoxy)phenyl]ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033127 n.a. PMDBM2020035 n.a. Escherichia coli MTCC 739 PMDBD2000239 1-{4-phenyl-2-[(E)-2-[4-(trifluoromethoxy)phenyl]ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033128 n.a. PMDBM2020186 n.a. Klebsiella planticola MTCC 530 PMDBD2000239 1-{4-phenyl-2-[(E)-2-[4-(trifluoromethoxy)phenyl]ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033129 n.a. PMDBM2020228 n.a. Micrococcus luteus MTCC 2470 PMDBD2000239 1-{4-phenyl-2-[(E)-2-[4-(trifluoromethoxy)phenyl]ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033130 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MTCC 2453 PMDBD2000239 1-{4-phenyl-2-[(E)-2-[4-(trifluoromethoxy)phenyl]ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033131 n.a. PMDBM2020177 n.a. Staphylococcus aureus MTCC 96 PMDBD2000239 1-{4-phenyl-2-[(E)-2-[4-(trifluoromethoxy)phenyl]ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033132 n.a. PMDBM2020177 n.a. Staphylococcus aureus MLS16 MTCC 2940 PMDBD2000239 1-{4-phenyl-2-[(E)-2-[4-(trifluoromethoxy)phenyl]ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033133 n.a. PMDBM2020080 n.a. Bacillus subtilis MTCC 121 PMDBD2000240 1-{6-nitro-4-phenyl-2-[(E)-2-(3,4,5-trimethoxyphenyl)ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033134 n.a. PMDBM2020035 n.a. Escherichia coli MTCC 739 PMDBD2000240 1-{6-nitro-4-phenyl-2-[(E)-2-(3,4,5-trimethoxyphenyl)ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033135 n.a. PMDBM2020186 n.a. Klebsiella planticola MTCC 530 PMDBD2000240 1-{6-nitro-4-phenyl-2-[(E)-2-(3,4,5-trimethoxyphenyl)ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033136 n.a. PMDBM2020228 n.a. Micrococcus luteus MTCC 2470 PMDBD2000240 1-{6-nitro-4-phenyl-2-[(E)-2-(3,4,5-trimethoxyphenyl)ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033137 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MTCC 2453 PMDBD2000240 1-{6-nitro-4-phenyl-2-[(E)-2-(3,4,5-trimethoxyphenyl)ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033138 n.a. PMDBM2020177 n.a. Staphylococcus aureus MTCC 96 PMDBD2000240 1-{6-nitro-4-phenyl-2-[(E)-2-(3,4,5-trimethoxyphenyl)ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033139 n.a. PMDBM2020177 n.a. Staphylococcus aureus MLS16 MTCC 2940 PMDBD2000240 1-{6-nitro-4-phenyl-2-[(E)-2-(3,4,5-trimethoxyphenyl)ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033140 n.a. PMDBM2020080 n.a. Bacillus subtilis MTCC 121 PMDBD2000241 1-{6-nitro-4-phenyl-2-[(E)-2-[4-(trifluoromethoxy)phenyl]ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033141 n.a. PMDBM2020035 n.a. Escherichia coli MTCC 739 PMDBD2000241 1-{6-nitro-4-phenyl-2-[(E)-2-[4-(trifluoromethoxy)phenyl]ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033142 n.a. PMDBM2020186 n.a. Klebsiella planticola MTCC 530 PMDBD2000241 1-{6-nitro-4-phenyl-2-[(E)-2-[4-(trifluoromethoxy)phenyl]ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033143 n.a. PMDBM2020228 n.a. Micrococcus luteus MTCC 2470 PMDBD2000241 1-{6-nitro-4-phenyl-2-[(E)-2-[4-(trifluoromethoxy)phenyl]ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033144 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MTCC 2453 PMDBD2000241 1-{6-nitro-4-phenyl-2-[(E)-2-[4-(trifluoromethoxy)phenyl]ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033145 n.a. PMDBM2020177 n.a. Staphylococcus aureus MTCC 96 PMDBD2000241 1-{6-nitro-4-phenyl-2-[(E)-2-[4-(trifluoromethoxy)phenyl]ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033146 n.a. PMDBM2020177 n.a. Staphylococcus aureus MLS16 MTCC 2940 PMDBD2000241 1-{6-nitro-4-phenyl-2-[(E)-2-[4-(trifluoromethoxy)phenyl]ethenyl]quinolin-3-yl}ethan-1-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25465871" PMDBI20033147 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000242 1010cys Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21377727" PMDBI20033148 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000243 11(R)-hydroxy-12(20)-en-knightal Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20033149 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000243 11(R)-hydroxy-12(20)-en-knightal Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20033150 n.a. PMDBM2021218 n.a. Vibrio harveyi PHY-2A PMDBD2000243 11(R)-hydroxy-12(20)-en-knightal Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20033151 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000244 11(R)-hydroxy-12(20)-en-knightol acetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20033152 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000244 11(R)-hydroxy-12(20)-en-knightol acetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20033153 n.a. PMDBM2021218 n.a. Vibrio harveyi PHY-2A PMDBD2000244 11(R)-hydroxy-12(20)-en-knightol acetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20033154 n.a. "PMID: 30581775; PMID: 24944053" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000245 12-hydroxy decyl beta-maltose Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033155 n.a. "PMID: 30581775; PMID: 18318842" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000246 12-methyltetradecanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033156 n.a. PMDBM2021248 n.a. Candida albicans NCIM-3471 PMDBD2000247 13-(2-chloro-6-methoxyquinolin-3-yl)-3,3-dimethyl-1H,2H,3H,4H,4aH,6H,11H,13H,13aH-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033157 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa NCIM-2036 PMDBD2000247 13-(2-chloro-6-methoxyquinolin-3-yl)-3,3-dimethyl-1H,2H,3H,4H,4aH,6H,11H,13H,13aH-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033158 n.a. PMDBM2021248 n.a. Candida albicans NCIM-3471 PMDBD2000248 13-(2-chloro-6-methylquinolin-3-yl)-3,3-dimethyl-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033159 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa NCIM-2036 PMDBD2000248 13-(2-chloro-6-methylquinolin-3-yl)-3,3-dimethyl-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033160 n.a. PMDBM2021248 n.a. Candida albicans NCIM-3471 PMDBD2000249 13-(2-chloro-7-methoxyquinolin-3-yl)-3,3-dimethyl-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033161 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa NCIM-2036 PMDBD2000249 13-(2-chloro-7-methoxyquinolin-3-yl)-3,3-dimethyl-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033162 n.a. PMDBM2021248 n.a. Candida albicans NCIM-3471 PMDBD2000250 13-(2-chloro-7-methylquinolin-3-yl)-3,3-dimethyl-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033163 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa NCIM-2036 PMDBD2000250 13-(2-chloro-7-methylquinolin-3-yl)-3,3-dimethyl-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033164 n.a. PMDBM2021248 n.a. Candida albicans NCIM-3471 PMDBD2000251 13-(2-chloro-8a-methyl-4a,8a-dihydroquinolin-3-yl)-3,3-dimethyl-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033165 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa NCIM-2036 PMDBD2000251 13-(2-chloro-8a-methyl-4a,8a-dihydroquinolin-3-yl)-3,3-dimethyl-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033166 n.a. PMDBM2021248 n.a. Candida albicans NCIM-3471 PMDBD2000252 13-(2-chloroquinolin-3-yl)-3,3-dimethyl-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033167 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa NCIM-2036 PMDBD2000252 13-(2-chloroquinolin-3-yl)-3,3-dimethyl-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033168 n.a. PMDBM2021248 n.a. Candida albicans NCIM-3471 PMDBD2000253 13-{7-methoxy-[1,2,3,4]tetrazolo[1,5-a]quinolin-4-yl}-3,3-dimethyl-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033169 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa NCIM-2036 PMDBD2000253 13-{7-methoxy-[1,2,3,4]tetrazolo[1,5-a]quinolin-4-yl}-3,3-dimethyl-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033170 n.a. PMDBM2021248 n.a. Candida albicans NCIM-3471 PMDBD2000254 13-{8-methoxy-[1,2,3,4]tetrazolo[1,5-a]quinolin-4-yl}-3,3-dimethyl-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033171 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa NCIM-2036 PMDBD2000254 13-{8-methoxy-[1,2,3,4]tetrazolo[1,5-a]quinolin-4-yl}-3,3-dimethyl-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033172 n.a. "PMID: 30581775; PMID: 18318842" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000255 13-methyltetradecanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033173 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MH602 PMDBD2000256 14,15,29,30-Tetrahydro-5H,20H-dibenzo[h,s]bis([1,2,3]triazolo)[5,1-c:5 ,1 -n][1,4,7,12,15,18]hexaazacyclodocosine-6,12,13,21,27,28(7H,22H)-hexaone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033174 n.a. "PMID: 30581775; PMID: 19152987" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000257 14-alpha-lipoyl andrographolide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033175 n.a. "PMID: 30581775; PMID: 19152987" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000258 14-dehydroxy-11,12-didehydroandrographolide- 3,19-bis(succinic acid) potasium sodium salt Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033176 n.a. "PMID: 30581775; PMID: 19152987" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000259 14-Glycinyl andrographolide hydrochloride Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033177 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 29213 PMDBD2000260 16P Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26571297" PMDBI20033178 n.a. PMDBM2020177 n.a. Staphylococcus aureus XJ75302 (MRSA) PMDBD2000260 16P Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26571297" PMDBI20033179 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 14990 PMDBD2000260 16P Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26571297" PMDBI20033180 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis XJ75284 (MRSE) PMDBD2000260 16P Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26571297" PMDBI20033181 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 29213 PMDBD2000261 16P-AC Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26571297" PMDBI20033182 n.a. PMDBM2020177 n.a. Staphylococcus aureus XJ75302 (MRSA) PMDBD2000261 16P-AC Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26571297" PMDBI20033183 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 14990 PMDBD2000261 16P-AC Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26571297" PMDBI20033184 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis XJ75284 (MRSE) PMDBD2000261 16P-AC Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26571297" PMDBI20033185 n.a. PMDBM2020177 n.a. Staphylococcus aureus MR23 (MRSA) PMDBD2000262 17-Deacetyl norgestimate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20033186 n.a. PMDBM2020177 n.a. Staphylococcus aureus MS3 (MSSA) PMDBD2000262 17-Deacetyl norgestimate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20033187 n.a. PMDBM2020177 n.a. Staphylococcus aureus MS4-5 (MSSA) PMDBD2000262 17-Deacetyl norgestimate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20033188 n.a. PMDBM2020177 n.a. Staphylococcus aureus MS18 (MSSA) PMDBD2000262 17-Deacetyl norgestimate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20033189 n.a. PMDBM2020177 n.a. Staphylococcus aureus SH1000 (MSSA) PMDBD2000262 17-Deacetyl norgestimate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20033190 n.a. PMDBM2020177 n.a. Staphylococcus aureus MR2 (MRSA) PMDBD2000262 17-Deacetyl norgestimate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20033191 n.a. PMDBM2020177 n.a. Staphylococcus aureus MR4 (MRSA) PMDBD2000262 17-Deacetyl norgestimate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20033192 n.a. PMDBM2020177 n.a. Staphylococcus aureus MR11 (MRSA) PMDBD2000262 17-Deacetyl norgestimate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20033193 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis SE4 PMDBD2000262 17-Deacetyl norgestimate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20033194 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis SE21 PMDBD2000262 17-Deacetyl norgestimate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20033195 n.a. PMDBM2020183 n.a. Streptococcus mutans MTCC 497 PMDBD2000263 1-mesityl-3(4-nitrophenyl)urea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033196 n.a. PMDBM2020183 n.a. Streptococcus mutans 5SM PMDBD2000263 1-mesityl-3(4-nitrophenyl)urea Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27375583" PMDBI20033197 n.a. "PMID: 30581775; PMID: 19855933" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000264 1-methanesulfonyl-4-methylbenzene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033198 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000265 1-methyl-4-({[(4-methylphenyl)methyl]disulfanyl}methyl)benzene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20033199 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000265 1-methyl-4-({[(4-methylphenyl)methyl]disulfanyl}methyl)benzene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033200 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000265 1-methyl-4-({[(4-methylphenyl)methyl]disulfanyl}methyl)benzene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20033201 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000266 2- geranyloxy-1-(2-methylbutanoyl)phloroglucinol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20033202 n.a. PMDBM2020177 n.a. Staphylococcus aureus L32 (MRSA) PMDBD2000266 2- geranyloxy-1-(2-methylbutanoyl)phloroglucinol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20033203 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000266 2- geranyloxy-1-(2-methylbutanoyl)phloroglucinol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20033204 n.a. "PMID: 30581775; PMID: 27731921" 652611 Pseudomonas aeruginosa PA14 PMDBD2000267 2-((3,4-dichlorophenyl)sulfonyl)-4-(1H-tetrazol-1-yl)pyrimidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033205 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MH602 PMDBD2000268 2-(2-(2-Azidoacetamido)-5-bromophenyl)-2-oxo-N-(prop-2-yn-1-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033206 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MH602 PMDBD2000269 2-(2-(2-Azidoacetamido)-5-fluorophenyl)-2-oxo-N-( prop-2-yn-1-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033207 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MH602 PMDBD2000270 2-(2-(2-Azidoacetamido)-5-methylphenyl)-2-oxo-N-(prop-2-yn-1-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033208 n.a. PMDBM2020035 n.a. Escherichia coli MT102 PMDBD2000271 2-(2-(2-Azidoacetamido)-5-nitrophenyl)-2-oxo-N-(prop-2-yn-1-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033209 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MH602 PMDBD2000271 2-(2-(2-Azidoacetamido)-5-nitrophenyl)-2-oxo-N-(prop-2-yn-1-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033210 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MH602 PMDBD2000272 2-(2-(2-Azidoacetamido)phenyl)-2-oxo-N-(prop-2-yn-1-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033211 n.a. PMDBM2020035 n.a. Escherichia coli MT102 PMDBD2000273 2-(2-(2-Chloroacetamido)-5-fluorophenyl)-2-oxo-N-( prop-2-yn-1-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033212 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MH602 PMDBD2000273 2-(2-(2-Chloroacetamido)-5-fluorophenyl)-2-oxo-N-( prop-2-yn-1-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033213 n.a. PMDBM2020035 n.a. Escherichia coli MT102 PMDBD2000274 2-(2-(2-Chloroacetamido)-5-methylphenyl)-2-oxo-N-( prop-2-yn- 1-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033214 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MH602 PMDBD2000274 2-(2-(2-Chloroacetamido)-5-methylphenyl)-2-oxo-N-( prop-2-yn- 1-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033215 n.a. PMDBM2020035 n.a. Escherichia coli MT102 PMDBD2000275 2-(2-(2-Chloroacetamido)-5-nitrophenyl)-2-oxo-N-( prop-2-yn-1-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033216 n.a. PMDBM2020035 n.a. Escherichia coli MT102 PMDBD2000276 2-(2-(2-Chloroacetamido)phenyl )-2-oxo-N-( prop-2-yn-1-yl )acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033217 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MH602 PMDBD2000276 2-(2-(2-Chloroacetamido)phenyl )-2-oxo-N-( prop-2-yn-1-yl )acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033218 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2000277 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-yl (2E)-3-phenylprop-2-enoate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27838185" PMDBI20033219 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000278 2-(2-chloro-5-fluorophenyl)-5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033220 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000278 2-(2-chloro-5-fluorophenyl)-5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033221 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43866 (MRSA) PMDBD2000278 2-(2-chloro-5-fluorophenyl)-5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033222 n.a. PMDBM2010041 n.a. Streptococcus epidermidis ATCC 35984 PMDBD2000278 2-(2-chloro-5-fluorophenyl)-5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033223 n.a. PMDBM2021266 n.a. Vibrio anguillarum LMG4411 PMDBD2000279 2-(2-Thienylsulfonyl)ethanethioamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19778962" PMDBI20033224 n.a. PMDBM2021267 n.a. Vibrio vulnificus LMG 16867 PMDBD2000279 2-(2-Thienylsulfonyl)ethanethioamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19778962" PMDBI20033225 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000280 2-(4-(Trifluoromethyl)phenyl)-N-((2R,3R,4S,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033226 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000281 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(2,4-dichlorophenyl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033227 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000281 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(2,4-dichlorophenyl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033228 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43866 (MRSA) PMDBD2000281 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(2,4-dichlorophenyl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033229 n.a. PMDBM2010041 n.a. Streptococcus epidermidis ATCC 35984 PMDBD2000281 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(2,4-dichlorophenyl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033230 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000282 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033231 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000282 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033232 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43866 (MRSA) PMDBD2000282 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033233 n.a. PMDBM2010041 n.a. Streptococcus epidermidis ATCC 35984 PMDBD2000282 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033234 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000283 2-(4,5-dibromo-1-methyl-1H-pyrrol-2yl)-5-(4-nitrophenyl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033235 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000283 2-(4,5-dibromo-1-methyl-1H-pyrrol-2yl)-5-(4-nitrophenyl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033236 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43866 (MRSA) PMDBD2000283 2-(4,5-dibromo-1-methyl-1H-pyrrol-2yl)-5-(4-nitrophenyl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033237 n.a. PMDBM2010041 n.a. Streptococcus epidermidis ATCC 35984 PMDBD2000283 2-(4,5-dibromo-1-methyl-1H-pyrrol-2yl)-5-(4-nitrophenyl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033238 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000284 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(ethylthio)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033239 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000284 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(ethylthio)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033240 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43866 (MRSA) PMDBD2000284 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(ethylthio)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033241 n.a. PMDBM2010041 n.a. Streptococcus epidermidis ATCC 35984 PMDBD2000284 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(ethylthio)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033242 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000285 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(methylthio)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033243 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000285 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(methylthio)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033244 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43866 (MRSA) PMDBD2000285 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(methylthio)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033245 n.a. PMDBM2010041 n.a. Streptococcus epidermidis ATCC 35984 PMDBD2000285 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(methylthio)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033246 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000286 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(phenylthio)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033247 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000286 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(phenylthio)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033248 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43866 (MRSA) PMDBD2000286 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(phenylthio)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033249 n.a. PMDBM2010041 n.a. Streptococcus epidermidis ATCC 35984 PMDBD2000286 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(phenylthio)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033250 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000287 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033251 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000287 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033252 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43866 (MRSA) PMDBD2000287 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033253 n.a. PMDBM2010041 n.a. Streptococcus epidermidis ATCC 35984 PMDBD2000287 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033254 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000288 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-phenyl-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033255 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000288 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-phenyl-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033256 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43866 (MRSA) PMDBD2000288 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-phenyl-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033257 n.a. PMDBM2010041 n.a. Streptococcus epidermidis ATCC 35984 PMDBD2000288 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-phenyl-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033258 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000289 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-styryl-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033259 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000289 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-styryl-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033260 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43866 (MRSA) PMDBD2000289 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-styryl-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033261 n.a. PMDBM2010041 n.a. Streptococcus epidermidis ATCC 35984 PMDBD2000289 2-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-5-styryl-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033262 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000290 2-(4-Bromophenyl)-N-((2R,3R,4S,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033263 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000291 2-(4-Chlorophenyl)-5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033264 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000291 2-(4-Chlorophenyl)-5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033265 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43866 (MRSA) PMDBD2000291 2-(4-Chlorophenyl)-5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033266 n.a. PMDBM2010041 n.a. Streptococcus epidermidis ATCC 35984 PMDBD2000291 2-(4-Chlorophenyl)-5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033267 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000292 2-(4-Chlorophenyl)-N-((2R,3R,4S,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033268 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000293 2-(4-Fluorophenyl)-N-((2R,3R,4S,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033269 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000294 2-(4-Methoxyphenyl)-N-((2R,3R,4S,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033270 n.a. PMDBM2021143 1302 Streptococcus gordonii ATCC 10558 PMDBD2000295 2-(4-methoxyphenyl)-N-(3-{[2-(4-methoxyphenyl)ethyl]imino}-1,4-dihydro-2-quinox alinylidene)ethanamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26482298" PMDBI20033271 n.a. "PMID: 30581775; PMID: 26482298" 210007 Streptococcus mutans UA159 PMDBD2000295 2-(4-methoxyphenyl)-N-(3-{[2-(4-methoxyphenyl)ethyl]imino}-1,4-dihydro-2-quinox alinylidene)ethanamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033272 n.a. PMDBM2020184 888807 Streptococcus sanguinis ATCC 10556 PMDBD2000295 2-(4-methoxyphenyl)-N-(3-{[2-(4-methoxyphenyl)ethyl]imino}-1,4-dihydro-2-quinox alinylidene)ethanamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26482298" PMDBI20033273 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000296 2-(5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole-2-yl)phenol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033274 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000296 2-(5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole-2-yl)phenol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033275 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43866 (MRSA) PMDBD2000296 2-(5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole-2-yl)phenol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033276 n.a. PMDBM2010041 n.a. Streptococcus epidermidis ATCC 35984 PMDBD2000296 2-(5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole-2-yl)phenol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033277 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MH602 PMDBD2000297 2-(5-Bromo-2-(2-chloroacetamido)phenyl )-2-oxo-N-( prop-2-yn-1-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033278 n.a. PMDBM2020035 n.a. Escherichia coli MT102 PMDBD2000298 2-(5-Chloro-2-(2-chloroacetamido)phenyl )-2-oxo-N-( prop-2-yn-1-yl)acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033279 n.a. PMDBM2020261 644 Aeromonas hydrophila isolated from a biofouled RO membrane system PMDBD2000299 2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20140298" PMDBI20033280 n.a. PMDBM2020758 n.a. Hafnia alvei O71 PMDBD2000299 2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20140298" PMDBI20033281 n.a. PMDBM2020758 n.a. Hafnia alvei O71 é“»æŠalI PMDBD2000299 2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20140298" PMDBI20033282 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000300 2-(Aminomethyl)-L-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033283 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000300 2-(Aminomethyl)-L-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033284 n.a. "PMID: 30581775; PMID: 27731921" 652611 Pseudomonas aeruginosa PA14 PMDBD2000301 2-(hexylsulfonyl)-4-(1H-1,2,3-triazol-1-yl)pyrimidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033285 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000302 2-(Trifluoromethyl)-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033286 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000302 2-(Trifluoromethyl)-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033287 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000302 2-(Trifluoromethyl)-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033288 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 9027 PMDBD2000303 2,2 -Dipyridyl Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26557964" PMDBI20033289 n.a. "PMID: 30581775; PMID: 26557964" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000303 2,2 -Dipyridyl Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033290 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAK01 PMDBD2000303 2,2 -Dipyridyl Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26557964" PMDBI20033291 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAK02 PMDBD2000303 2,2 -Dipyridyl Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26557964" PMDBI20033292 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAK03 PMDBD2000303 2,2 -Dipyridyl Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26557964" PMDBI20033293 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2000303 2,2 -Dipyridyl Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26557964" PMDBI20033294 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000303 2,2 -Dipyridyl Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26557964" PMDBI20033295 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000304 2,3,4,5,6-Pentafluoro-L-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033296 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000304 2,3,4,5,6-Pentafluoro-L-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033297 n.a. PMDBM2020177 n.a. Staphylococcus aureus 8325-4 PMDBD2000305 2,3-Dehydrosilybin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26273725" PMDBI20033298 n.a. PMDBM2020177 n.a. Staphylococcus aureus Xen 31 (MRSA) PMDBD2000306 2,3-dihydroxybenzoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25319566" PMDBI20033299 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000307 2,4,5-Trifluorophenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033300 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000307 2,4,5-Trifluorophenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033301 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000308 2,4-Dichlorophenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033302 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000309 2,4-Difluorophenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033303 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000309 2,4-Difluorophenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033304 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000310 2,4-Dimethylphenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033305 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000310 2,4-Dimethylphenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033306 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000310 2,4-Dimethylphenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033307 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000311 2,4-Dinitro-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033308 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000312 2,5-bis(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033309 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000312 2,5-bis(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033310 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43866 (MRSA) PMDBD2000312 2,5-bis(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033311 n.a. PMDBM2010041 n.a. Streptococcus epidermidis ATCC 35984 PMDBD2000312 2,5-bis(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033312 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000313 2-amino-3-(2-nitrophenyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033313 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000314 2-amino-3-(3-chlorophenyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033314 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000314 2-amino-3-(3-chlorophenyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033315 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000314 2-amino-3-(3-chlorophenyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033316 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000315 2-amino-3-(3-nitrophenyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033317 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000315 2-amino-3-(3-nitrophenyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033318 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000316 2-amino-3-(4-methylbenzenesulfinyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20033319 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000316 2-amino-3-(4-methylbenzenesulfinyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033320 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000316 2-amino-3-(4-methylbenzenesulfinyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20033321 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000317 2-amino-3-(prop-2-ene-1-sulfinyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033322 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000318 2-amino-3-(propane-1-sulfinyl)propanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033323 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD2000319 2-amino-4-chlorobenzoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20033324 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2000319 2-amino-4-chlorobenzoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20033325 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD2000319 2-amino-4-chlorobenzoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20033326 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD2000319 2-amino-4-chlorobenzoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20033327 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000320 2-amino-5-methoxy-5-oxopentanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033328 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000320 2-amino-5-methoxy-5-oxopentanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033329 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD2000321 2-amino-6-chlorobenzoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20033330 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2000321 2-amino-6-chlorobenzoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20033331 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD2000321 2-amino-6-chlorobenzoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20033332 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD2000321 2-amino-6-chlorobenzoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20033333 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD2000322 2-amino-6-fluorobenzoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20033334 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2000322 2-amino-6-fluorobenzoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20033335 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD2000322 2-amino-6-fluorobenzoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20033336 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD2000322 2-amino-6-fluorobenzoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20033337 n.a. "PMID: 30581775; PMID: 26294263" 210007 Streptococcus mutans UA159 PMDBD2000323 2-amino-imidazole/ triazole conjugate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033338 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000324 2-Benzyl-5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033339 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000324 2-Benzyl-5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033340 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43866 (MRSA) PMDBD2000324 2-Benzyl-5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033341 n.a. PMDBM2010041 n.a. Streptococcus epidermidis ATCC 35984 PMDBD2000324 2-Benzyl-5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033342 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 29213 PMDBD2000325 2-bromo-4-methyl-6-(3,4,5-tribromo-1H-pyrrole-2-carbonyl)phenol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15784315" PMDBI20033343 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis DSM 3269 PMDBD2000325 2-bromo-4-methyl-6-(3,4,5-tribromo-1H-pyrrole-2-carbonyl)phenol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15784315" PMDBI20033344 n.a. "PMID: 30581775; PMID: 24023921" 652611 Pseudomonas aeruginosa PA14 PMDBD2000326 2-bromodecanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033345 n.a. "PMID: 30581775; PMID: 24023921" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000326 2-bromodecanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033346 n.a. "PMID: 30581775; PMID: 24023921" 652611 Pseudomonas aeruginosa PA14 PMDBD2000327 2-bromohexanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033347 n.a. "PMID: 30581775; PMID: 24023921" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000327 2-bromohexanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033348 n.a. "PMID: 30581775; PMID: 24023921" 652611 Pseudomonas aeruginosa PA14 PMDBD2000328 2-bromooctanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033349 n.a. "PMID: 30581775; PMID: 24023921" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000328 2-bromooctanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033350 n.a. "PMID: 30581775; PMID: 20211885" 210007 Streptococcus mutans UA159 PMDBD2000329 2C-4 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033351 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000330 2-Carbamoylphenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033352 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000330 2-Carbamoylphenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033353 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000330 2-Carbamoylphenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033354 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000331 2-Chloro-DL-Phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033355 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000332 2-Cyano-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033356 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000333 2-Fluoro-L-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033357 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000334 2-geranyloxy-1-(2-methylpropanoyl)phloroglucinol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20033358 n.a. PMDBM2020177 n.a. Staphylococcus aureus L32 (MRSA) PMDBD2000334 2-geranyloxy-1-(2-methylpropanoyl)phloroglucinol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20033359 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000334 2-geranyloxy-1-(2-methylpropanoyl)phloroglucinol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20033360 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000335 2-geranyloxy-4,6-dihydroxybenzophenone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20033361 n.a. PMDBM2020177 n.a. Staphylococcus aureus L32 (MRSA) PMDBD2000335 2-geranyloxy-4,6-dihydroxybenzophenone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20033362 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000335 2-geranyloxy-4,6-dihydroxybenzophenone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20033363 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000336 2-Hexylmaleic anhydride Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033364 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU7 PMDBD2000337 2-Hydroxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033365 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU38 PMDBD2000337 2-Hydroxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033366 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU48 PMDBD2000337 2-Hydroxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033367 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000338 2-Methoxy-4-propylphenol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27808174" PMDBI20033368 n.a. PMDBM2021266 n.a. Vibrio anguillarum LMG 4411 PMDBD2000339 2-methoxy-cinnamaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18793453" PMDBI20033369 n.a. PMDBM2021267 n.a. Vibrio vulnificus LMG 16867 PMDBD2000339 2-methoxy-cinnamaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18793453" PMDBI20033370 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000340 2-Methoxy-D-Phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033371 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000340 2-Methoxy-D-Phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033372 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000340 2-Methoxy-D-Phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033373 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000341 2-Methoxyhydroquinone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27808174" PMDBI20033374 n.a. PMDBM2021266 n.a. Vibrio anguillarum LMG 4411 PMDBD2000342 2-Nitro-cinnamaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18793453" PMDBI20033375 n.a. PMDBM2021267 n.a. Vibrio vulnificus LMG 16867 PMDBD2000342 2-Nitro-cinnamaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18793453" PMDBI20033376 n.a. PMDBM2020258 n.a. Vibrio cholerae CIP 106856 PMDBD2000342 2-Nitro-cinnamaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21249192" PMDBI20033377 n.a. PMDBM2021218 n.a. Vibrio harveyi BB122 PMDBD2000342 2-Nitro-cinnamaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21249192" PMDBI20033378 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000343 2-oxindole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033379 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000344 2-phenylethane-1-SO-thioperoxol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20033380 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000345 3-(1-Naphthyl)-D-Alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033381 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000345 3-(1-Naphthyl)-D-Alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033382 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000346 3-(2-Furyl)-D-alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033383 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000346 3-(2-Furyl)-D-alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033384 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000346 3-(2-Furyl)-D-alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033385 n.a. PMDBM2020075 575584 Acinetobacter baumannii 19606 PMDBD2000347 3-(2-Furylmethyl)-2-{[(5-hydroxy-1H-pyrazol-3-yl)methyl]sulfanyl}-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25313216" PMDBI20033386 n.a. "PMID: 30581775; PMID: 25313216" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000347 3-(2-Furylmethyl)-2-{[(5-hydroxy-1H-pyrazol-3-yl)methyl]sulfanyl}-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033387 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium JSG210 PMDBD2000347 3-(2-Furylmethyl)-2-{[(5-hydroxy-1H-pyrazol-3-yl)methyl]sulfanyl}-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25313216" PMDBI20033388 n.a. PMDBM2021737 n.a. Salmonella Typhi JSG624 PMDBD2000347 3-(2-Furylmethyl)-2-{[(5-hydroxy-1H-pyrazol-3-yl)methyl]sulfanyl}-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25313216" PMDBI20033389 n.a. PMDBM2020177 1280 Staphylococcus aureus USA300 PMDBD2000347 3-(2-Furylmethyl)-2-{[(5-hydroxy-1H-pyrazol-3-yl)methyl]sulfanyl}-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25313216" PMDBI20033390 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000348 3-(2-Naphthyl)alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033391 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000348 3-(2-Naphthyl)alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033392 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000349 3-(2-Naphthyl)-D-alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033393 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000349 3-(2-Naphthyl)-D-alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033394 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000349 3-(2-Naphthyl)-D-alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033395 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000350 3-(2-Pyridinyl)alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033396 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000350 3-(2-Pyridinyl)alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033397 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000351 3-(2-Thienyl)alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033398 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000351 3-(2-Thienyl)alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033399 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000351 3-(2-Thienyl)alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033400 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000352 3-(2-Thienyl)-D-alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033401 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000352 3-(2-Thienyl)-D-alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033402 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000352 3-(2-Thienyl)-D-alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033403 n.a. PMDBM2020032 n.a. Enterococcus faecalis ATCC 51299 (VRE) PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033404 n.a. PMDBM2020032 n.a. Enterococcus faecalis F217 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033405 n.a. PMDBM2020032 n.a. Enterococcus faecalis F317 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033406 n.a. PMDBM2020032 n.a. Enterococcus faecalis ATCC 51575 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033407 n.a. PMDBM2020032 n.a. Enterococcus faecalis F177 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033408 n.a. PMDBM2020033 n.a. Enterococcus faecium EF208 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033409 n.a. PMDBM2020033 n.a. Enterococcus faecium 1401 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033410 n.a. PMDBM2020033 n.a. Enterococcus faecium EF1509 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033411 n.a. PMDBM2020033 n.a. Enterococcus faecium F1181 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033412 n.a. PMDBM2020661 n.a. Enterococcus gallinarum 2392 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033413 n.a. PMDBM2020035 1322345 Escherichia coli ATCC 25922 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033414 n.a. "PMID: 30581775; PMID: 19651903" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033415 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033416 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-47263 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033417 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-58336 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033418 n.a. PMDBM2020177 n.a. Staphylococcus aureus MSSA PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033419 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-27687 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033420 n.a. PMDBM2020177 93061 Staphylococcus aureus NCTC 8325 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033421 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-14234 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033422 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-24102 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033423 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-33548 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033424 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-35392 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033425 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-43349 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033426 n.a. PMDBM2020177 1242971 Staphylococcus aureus MW2 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033427 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-22733 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033428 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-38230 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033429 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-49404 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033430 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-44081 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033431 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-24209 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033432 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-1094 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033433 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-23542 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033434 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033435 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis GTC 18972 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033436 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis O-47 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033437 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-41 (CoNS) PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033438 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-45 (CoNS) PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033439 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-48 (CoNS) PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033440 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-47 (CoNS) PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033441 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-40 (CoNS) PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033442 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-46 (CoNS) PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033443 n.a. PMDBM2020178 1282 Staphylococcus epidermidis 1457 PMDBD2000353 3-(3-fluorophenyl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033444 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000354 3-(3-Pyridinyl)alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033445 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000354 3-(3-Pyridinyl)alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033446 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000354 3-(3-Pyridinyl)alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033447 n.a. PMDBM2020032 n.a. Enterococcus faecalis ATCC 51299 (VRE) PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033448 n.a. PMDBM2020032 n.a. Enterococcus faecalis F217 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033449 n.a. PMDBM2020032 n.a. Enterococcus faecalis F317 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033450 n.a. PMDBM2020032 n.a. Enterococcus faecalis ATCC 51575 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033451 n.a. PMDBM2020032 n.a. Enterococcus faecalis F177 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033452 n.a. PMDBM2020033 n.a. Enterococcus faecium EF208 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033453 n.a. PMDBM2020033 n.a. Enterococcus faecium 1401 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033454 n.a. PMDBM2020033 n.a. Enterococcus faecium EF1509 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033455 n.a. PMDBM2020033 n.a. Enterococcus faecium F1181 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033456 n.a. PMDBM2020661 n.a. Enterococcus gallinarum 2392 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033457 n.a. PMDBM2020035 1322345 Escherichia coli ATCC 25922 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033458 n.a. "PMID: 30581775; PMID: 19651903" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033459 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033460 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-47263 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033461 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-58336 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033462 n.a. PMDBM2020177 n.a. Staphylococcus aureus MSSA PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033463 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-27687 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033464 n.a. PMDBM2020177 93061 Staphylococcus aureus NCTC 8325 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033465 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-14234 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033466 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-24102 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033467 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-33548 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033468 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-35392 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033469 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-23542 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033470 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-43349 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033471 n.a. PMDBM2020177 1242971 Staphylococcus aureus MW2 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033472 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-22733 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033473 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-38230 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033474 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-49404 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033475 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-44081 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033476 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-24209 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033477 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-1094 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033478 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033479 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis GTC 18972 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033480 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis O-47 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033481 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-41 (CoNS) PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033482 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-45 (CoNS) PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033483 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-48 (CoNS) PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033484 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-47 (CoNS) PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033485 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-40 (CoNS) PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033486 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-46 (CoNS) PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033487 n.a. PMDBM2020178 1282 Staphylococcus epidermidis 1457 PMDBD2000355 3-(4-fluorophenyl)-5-(3-(allyloxy)-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033488 n.a. PMDBM2020032 n.a. Enterococcus faecalis ATCC 51299 (VRE) PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033489 n.a. PMDBM2020032 n.a. Enterococcus faecalis F217 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033490 n.a. PMDBM2020032 n.a. Enterococcus faecalis F317 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033491 n.a. PMDBM2020032 n.a. Enterococcus faecalis ATCC 51575 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033492 n.a. PMDBM2020032 n.a. Enterococcus faecalis F177 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033493 n.a. PMDBM2020033 n.a. Enterococcus faecium EF208 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033494 n.a. PMDBM2020033 n.a. Enterococcus faecium 1401 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033495 n.a. PMDBM2020033 n.a. Enterococcus faecium EF1509 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033496 n.a. PMDBM2020033 n.a. Enterococcus faecium F1181 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033497 n.a. PMDBM2020661 n.a. Enterococcus gallinarum 2392 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033498 n.a. PMDBM2020035 1322345 Escherichia coli ATCC 25922 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033499 n.a. "PMID: 30581775; PMID: 19651903" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033500 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033501 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-47263 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033502 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-58336 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033503 n.a. PMDBM2020177 n.a. Staphylococcus aureus MSSA PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033504 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-27687 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033505 n.a. PMDBM2020177 93061 Staphylococcus aureus NCTC 8325 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033506 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-14234 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033507 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-24102 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033508 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-33548 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033509 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-35392 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033510 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-23542 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033511 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-43349 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033512 n.a. PMDBM2020177 1242971 Staphylococcus aureus MW2 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033513 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-22733 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033514 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-38230 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033515 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-49404 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033516 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-44081 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033517 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-24209 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033518 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-1094 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033519 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033520 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis GTC 18972 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033521 n.a. PMDBM2020178 1282 Staphylococcus epidermidis 1457 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033522 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis O-47 PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033523 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-41 (CoNS) PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033524 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-45 (CoNS) PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033525 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-48 (CoNS) PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033526 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-47 (CoNS) PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033527 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-40 (CoNS) PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033528 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-46 (CoNS) PMDBD2000356 3-(4-fluorophenyl)-5-(3-ethoxy- 4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033529 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000357 3-(4-Pyridinyl)alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033530 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000357 3-(4-Pyridinyl)alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033531 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000358 3-(Aminomethyl)-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033532 n.a. PMDBM2020032 n.a. Enterococcus faecalis ATCC 51299 (VRE) PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033533 n.a. PMDBM2020032 n.a. Enterococcus faecalis F217 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033534 n.a. PMDBM2020032 n.a. Enterococcus faecalis F317 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033535 n.a. PMDBM2020032 n.a. Enterococcus faecalis ATCC 51575 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033536 n.a. PMDBM2020032 n.a. Enterococcus faecalis F177 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033537 n.a. PMDBM2020033 n.a. Enterococcus faecium EF208 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033538 n.a. PMDBM2020033 n.a. Enterococcus faecium 1401 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033539 n.a. PMDBM2020033 n.a. Enterococcus faecium EF1509 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033540 n.a. PMDBM2020033 n.a. Enterococcus faecium F1181 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033541 n.a. PMDBM2020661 n.a. Enterococcus gallinarum 2392 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033542 n.a. PMDBM2020035 1322345 Escherichia coli ATCC 25922 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033543 n.a. "PMID: 30581775; PMID: 19651903" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033544 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033545 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-47263 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033546 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-58336 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033547 n.a. PMDBM2020177 n.a. Staphylococcus aureus MSSA PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033548 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-27687 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033549 n.a. PMDBM2020177 93061 Staphylococcus aureus NCTC 8325 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033550 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-14234 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033551 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-24102 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033552 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-33548 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033553 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-35392 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033554 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-23542 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033555 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-43349 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033556 n.a. PMDBM2020177 1242971 Staphylococcus aureus MW2 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033557 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-22733 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033558 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-38230 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033559 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-49404 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033560 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-44081 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033561 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-24209 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033562 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-1094 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033563 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033564 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis GTC 18972 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033565 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis O-47 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033566 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-41 (CoNS) PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033567 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-45 (CoNS) PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033568 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-48 (CoNS) PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033569 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-47 (CoNS) PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033570 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-40 (CoNS) PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033571 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis WTBF-46 (CoNS) PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033572 n.a. PMDBM2020178 1282 Staphylococcus epidermidis 1457 PMDBD2000359 3-(pyridin-3-yl)-5-(3-ethoxy-4-hydroxybenzylidene)-2-thioxothiazolidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19651903" PMDBI20033573 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000360 3-(Trifluoromethyl)phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033574 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000360 3-(Trifluoromethyl)phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033575 n.a. PMDBM2021248 n.a. Candida albicans NCIM-3471 PMDBD2000361 3,3-dimethyl-13-{[1,2,3,4]tetrazolo[1,5-a]quinolin-4-yl}-2H,4H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033576 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa NCIM-2036 PMDBD2000361 3,3-dimethyl-13-{[1,2,3,4]tetrazolo[1,5-a]quinolin-4-yl}-2H,4H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033577 n.a. PMDBM2021248 n.a. Candida albicans NCIM-3471 PMDBD2000362 3,3-dimethyl-13-{7-methyl-[1,2,3,4]tetrazolo[1,5-a]quinolin-4-yl}-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033578 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa NCIM-2036 PMDBD2000362 3,3-dimethyl-13-{7-methyl-[1,2,3,4]tetrazolo[1,5-a]quinolin-4-yl}-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033579 n.a. PMDBM2021248 n.a. Candida albicans NCIM-3471 PMDBD2000363 3,3-dimethyl-13-{8-methyl-[1,2,3,4]tetrazolo[1,5-a]quinolin-4-yl}-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033580 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa NCIM-2036 PMDBD2000363 3,3-dimethyl-13-{8-methyl-[1,2,3,4]tetrazolo[1,5-a]quinolin-4-yl}-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033581 n.a. PMDBM2021248 n.a. Candida albicans NCIM-3471 PMDBD2000364 3,3-dimethyl-13-{9-methyl-[1,2,3,4]tetrazolo[1,5-a]quinolin-4-yl}-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033582 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa NCIM-2036 PMDBD2000364 3,3-dimethyl-13-{9-methyl-[1,2,3,4]tetrazolo[1,5-a]quinolin-4-yl}-1H,2H,3H,4H,6H,11H,13H-indazolo[1,2-b]phthalazine-1,6,11-trione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923699" PMDBI20033583 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000365 3,3-Diphenyl-D-alanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033584 n.a. PMDBM2020080 1423 Bacillus subtilis 168 PMDBD2000366 3,4-Dichloro-5-[(1,3-dichloropropan-2-yloxy)]-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25335695" PMDBI20033585 n.a. PMDBM2020080 1423 Bacillus subtilis 168 PMDBD2000367 3,4-Dichloro-5-[(4-methylphenylsulfonyl)]-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25335695" PMDBI20033586 n.a. PMDBM2020258 n.a. Vibrio cholerae CIP 106857 PMDBD2000368 3,4-Dichloro-cinnamaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21249192" PMDBI20033587 n.a. PMDBM2021218 n.a. Vibrio harveyi BB123 PMDBD2000368 3,4-Dichloro-cinnamaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21249192" PMDBI20033588 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000369 3,4-Dichlorophenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033589 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU7 PMDBD2000370 3,4-Dimethoxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033590 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU38 PMDBD2000370 3,4-Dimethoxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033591 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU48 PMDBD2000370 3,4-Dimethoxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033592 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000371 3,5-dibromotyrosined Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033593 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000372 3,5-Difluoro-dl-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033594 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000373 3,5-Diiodotyrosine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033595 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000373 3,5-Diiodotyrosine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033596 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000373 3,5-Diiodotyrosine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033597 n.a. "PMID: 30581775; PMID: 24944053" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000374 3,5-Dimethyl benzyl dodecyl beta-maltoside Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033598 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000375 3,5-dimethylaniline Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25537269" PMDBI20033599 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000376 3-[(prop-2-ene-1-sulfinyl)sulfanyl]prop-1-ene Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033600 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000376 3-[(prop-2-ene-1-sulfinyl)sulfanyl]prop-1-ene Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20033601 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 (MRSA) PMDBD2000377 3-{2-[(1S,2R,4aR,8aR)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl]ethyl}-5-methylidene-N-phenyl-2,5-dihydrofuran-2-amine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28692914" PMDBI20033602 n.a. "PMID: 30581775; PMID: 28692914" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000377 3-{2-[(1S,2R,4aR,8aR)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl]ethyl}-5-methylidene-N-phenyl-2,5-dihydrofuran-2-amine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033603 n.a. PMDBM2021025 n.a. Proteus mirabilis ATCC 12453 PMDBD2000378 3-{2-[(1S,2R,4aR,8aR)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl]ethyl}-N-(2-fluorophenyl)-5-methylidene-2,5-dihydrofuran-2-amine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28692914" PMDBI20033604 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 (MRSA) PMDBD2000378 3-{2-[(1S,2R,4aR,8aR)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl]ethyl}-N-(2-fluorophenyl)-5-methylidene-2,5-dihydrofuran-2-amine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28692914" PMDBI20033605 n.a. "PMID: 30581775; PMID: 28692914" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000378 3-{2-[(1S,2R,4aR,8aR)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl]ethyl}-N-(2-fluorophenyl)-5-methylidene-2,5-dihydrofuran-2-amine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033606 n.a. PMDBM2021025 n.a. Proteus mirabilis ATCC 12453 PMDBD2000379 3-{2-[(1S,2R,4aR,8aR)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl]ethyl}-N-(3-fluorophenyl)-5-methylidene-2,5-dihydrofuran-2-amine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28692914" PMDBI20033607 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 (MRSA) PMDBD2000379 3-{2-[(1S,2R,4aR,8aR)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl]ethyl}-N-(3-fluorophenyl)-5-methylidene-2,5-dihydrofuran-2-amine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28692914" PMDBI20033608 n.a. "PMID: 30581775; PMID: 28692914" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000379 3-{2-[(1S,2R,4aR,8aR)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl]ethyl}-N-(3-fluorophenyl)-5-methylidene-2,5-dihydrofuran-2-amine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033609 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000380 3-Amino-4-(2,4-difluorophenyl)-2-butanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033610 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000380 3-Amino-4-(2,4-difluorophenyl)-2-butanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033611 n.a. "PMID: 30581775; PMID: 26186595" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000381 3beta-Hydroxyolean-12-en-28-al 3-p-coumarate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033612 n.a. PMDBM2020080 1423 Bacillus subtilis 168 PMDBD2000382 3-bromo-5-methoxy-4-[(4-methylphenylsulfanyl)]-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25335695" PMDBI20033613 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000383 3-Bromophenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033614 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000384 3-Carbamoylphenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033615 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000384 3-Carbamoylphenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033616 n.a. PMDBM2020080 1423 Bacillus subtilis 168 PMDBD2000385 3-Chloro-5-[(2-chloroethoxy)]-4-[(4-methylphenylsulfanyl)]-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25335695" PMDBI20033617 n.a. PMDBM2020080 1423 Bacillus subtilis 168 PMDBD2000386 3-chloro-5-hydroxy-4-[(4-methylphenylsulfanyl)]-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25335695" PMDBI20033618 n.a. PMDBM2020080 1423 Bacillus subtilis 168 PMDBD2000387 3-chloro-5-hydroxy-4-[(4-methylphenylsulfonyl)]-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25335695" PMDBI20033619 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000388 3-Chlorotyrosine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033620 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000388 3-Chlorotyrosine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033621 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000389 3-fluoroaniline Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25537269" PMDBI20033622 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000390 3-Fluoro-DL-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033623 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000390 3-Fluoro-DL-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033624 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000391 3-geranyl-1-(2-methylbutanoyl)phloroglucinol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20033625 n.a. PMDBM2020177 n.a. Staphylococcus aureus L32 (MRSA) PMDBD2000391 3-geranyl-1-(2-methylbutanoyl)phloroglucinol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20033626 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000391 3-geranyl-1-(2-methylbutanoyl)phloroglucinol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20033627 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000392 3-geranyl-1-(2-methylpropanoyl)phloroglucinol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20033628 n.a. PMDBM2020177 n.a. Staphylococcus aureus L32 (MRSA) PMDBD2000392 3-geranyl-1-(2-methylpropanoyl)phloroglucinol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20033629 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000392 3-geranyl-1-(2-methylpropanoyl)phloroglucinol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20033630 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000393 3-hexyl-4-bromo-5-methylene-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033631 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000394 3-hexyl-5-bromomethylene-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033632 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU7 PMDBD2000395 3-hydroxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033633 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU38 PMDBD2000395 3-hydroxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033634 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU48 PMDBD2000395 3-hydroxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033635 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000396 3-Hydroxyphenylalanine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033636 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000396 3-Hydroxyphenylalanine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033637 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000396 3-Hydroxyphenylalanine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033638 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000397 3-Hydroxytyrosine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033639 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000398 3-indolylacetonitrile Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033640 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000399 3-Iodotyrosine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033641 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000399 3-Iodotyrosine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033642 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU7 PMDBD2000400 3-Methoxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033643 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU38 PMDBD2000400 3-Methoxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033644 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU48 PMDBD2000400 3-Methoxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033645 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000401 3-Methoxy-D-Phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033646 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000401 3-Methoxy-D-Phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033647 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000402 3-Methyl-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033648 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000402 3-Methyl-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033649 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000402 3-Methyl-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033650 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000403 3-Nitro-D-tyrosine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033651 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000403 3-Nitro-D-tyrosine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033652 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000403 3-Nitro-D-tyrosine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033653 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000404 3-Nitrophenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033654 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000404 3-Nitrophenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033655 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000404 3-Nitrophenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033656 n.a. PMDBM2021738 n.a. Aeromonas sobria B1 PMDBD2000405 3-oxo-C6-HSL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27118073" PMDBI20033657 n.a. PMDBM2021093 n.a. Serratia liquefaciens A2 PMDBD2000405 3-oxo-C6-HSL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27118073" PMDBI20033658 n.a. PMDBM2020758 n.a. Hafnia alvei H4 PMDBD2000406 3-oxo-C8-HSL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28379194" PMDBI20033659 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-USA300 PMDBD2000407 3-tetra- decanoyltetronic Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27999062" PMDBI20033660 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-BH1CC PMDBD2000407 3-tetra- decanoyltetronic Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27999062" PMDBI20033661 n.a. PMDBM2020177 n.a. Staphylococcus aureus MSSA-BH48 PMDBD2000407 3-tetra- decanoyltetronic Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27999062" PMDBI20033662 n.a. PMDBM2020177 n.a. Staphylococcus aureus MSSA-SH1000 PMDBD2000407 3-tetra- decanoyltetronic Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27999062" PMDBI20033663 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-USA300 PMDBD2000408 3-tetradecanoylthiotetronic Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27999062" PMDBI20033664 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-BH1CC PMDBD2000408 3-tetradecanoylthiotetronic Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27999062" PMDBI20033665 n.a. PMDBM2020177 n.a. Staphylococcus aureus MSSA-BH48 PMDBD2000408 3-tetradecanoylthiotetronic Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27999062" PMDBI20033666 n.a. PMDBM2020177 n.a. Staphylococcus aureus MSSA-SH1000 PMDBD2000408 3-tetradecanoylthiotetronic Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27999062" PMDBI20033667 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000409 4 alpha, 5 alpha-epoxy-10 alpha, 14H-1-epi-inuviscolide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26394911" PMDBI20033668 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000410 4-(2-(5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazol-2-yl)vinyl)-2-methoxyphenol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033669 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000410 4-(2-(5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazol-2-yl)vinyl)-2-methoxyphenol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033670 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43866 (MRSA) PMDBD2000410 4-(2-(5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazol-2-yl)vinyl)-2-methoxyphenol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033671 n.a. PMDBM2010041 n.a. Streptococcus epidermidis ATCC 35984 PMDBD2000410 4-(2-(5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazol-2-yl)vinyl)-2-methoxyphenol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033672 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000411 4-(2-methybutyryl)-4H-tomentosin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26394911" PMDBI20033673 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000412 4-(5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole-2-yl)aniline Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033674 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000412 4-(5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole-2-yl)aniline Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033675 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43866 (MRSA) PMDBD2000412 4-(5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole-2-yl)aniline Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033676 n.a. PMDBM2010041 n.a. Streptococcus epidermidis ATCC 35984 PMDBD2000412 4-(5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole-2-yl)aniline Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033677 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000413 4-(Aminomethyl)-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033678 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000413 4-(Aminomethyl)-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033679 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000414 4-(Trifluoromethyl)-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033680 n.a. PMDBM2020005 n.a. Bacillus cereus 407 PMDBD2000415 4,5-dihydroxy-2,3-pentanedione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17169556" PMDBI20033681 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000415 4,5-dihydroxy-2,3-pentanedione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25101248" PMDBI20033682 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000416 4-Acetamido-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033683 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000416 4-Acetamido-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033684 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000417 4-Amino-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033685 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000417 4-Amino-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033686 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000418 4-Benzoylphenylalanine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033687 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000418 4-Benzoylphenylalanine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033688 n.a. PMDBM2020080 1423 Bacillus subtilis 168 PMDBD2000419 4-Benzyl-sulfonyl-5-hydroxy-3-chloro-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26085951" PMDBI20033689 n.a. PMDBM2020178 1282 Staphylococcus epidermidis 1457 PMDBD2000420 4-bromo-5-(bromomethylene)-3-(1-( 2-propynyloxy)butyl)-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19620329" PMDBI20033690 n.a. PMDBM2020178 1282 Staphylococcus epidermidis 1457 PMDBD2000421 4-bromo-5-(bromomethylene)-3-(1-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)butyl)-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19620329" PMDBI20033691 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000422 4-bromo-5-(bromomethylene)-3-(1-acetoxybutyl)-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033692 n.a. PMDBM2020178 1282 Staphylococcus epidermidis 1457 PMDBD2000423 4-bromo-5-(bromomethylene)-3-(1-bromobutyl)-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19620329" PMDBI20033693 n.a. PMDBM2020080 1423 Bacillus subtilis Not Specified PMDBD2000424 4-bromo-5-(bromomethylene)-3-butyl-2(5H)- furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19620329" PMDBI20033694 n.a. PMDBM2020177 n.a. Staphylococcus aureus SA113 PMDBD2000424 4-bromo-5-(bromomethylene)-3-butyl-2(5H)- furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19620329" PMDBI20033695 n.a. PMDBM2020177 n.a. Staphylococcus aureus Newman PMDBD2000424 4-bromo-5-(bromomethylene)-3-butyl-2(5H)- furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19620329" PMDBI20033696 n.a. PMDBM2020178 1282 Staphylococcus epidermidis 1457 PMDBD2000424 4-bromo-5-(bromomethylene)-3-butyl-2(5H)- furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19620329" PMDBI20033697 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 1457 (éˆçŒ§ca) PMDBD2000424 4-bromo-5-(bromomethylene)-3-butyl-2(5H)- furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19620329" PMDBI20033698 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 47 PMDBD2000424 4-bromo-5-(bromomethylene)-3-butyl-2(5H)- furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19620329" PMDBI20033699 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 47 (éˆçŒ§ca) PMDBD2000424 4-bromo-5-(bromomethylene)-3-butyl-2(5H)- furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19620329" PMDBI20033700 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000425 4-bromo-5-(dibromomethylene)-3-(1-acetoxyoethyl)-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033701 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000426 4-bromo-5-(dibromomethylene)-3-(1-bromoethyl)-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033702 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000427 4-bromo-5-(dibromomethylene)-3-ethyl-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033703 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000428 4-bromoaniline Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25537269" PMDBI20033704 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000429 4-Bromo-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033705 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000429 4-Bromo-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033706 n.a. "PMID: 30581775; PMID: 19585989" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000430 4-Br-PHL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033707 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000431 4-Chloro-2-fluoro-DL-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033708 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000431 4-Chloro-2-fluoro-DL-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033709 n.a. "PMID: 30581775; PMID: 28350449" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000432 4-chloro-7-(trifluoromethyl)quinoline Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033710 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000433 4-chloroaniline Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25537269" PMDBI20033711 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU7 PMDBD2000434 4-Chlorochalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033712 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU38 PMDBD2000434 4-Chlorochalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033713 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU48 PMDBD2000434 4-Chlorochalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033714 n.a. PMDBM2020219 n.a. Serratia marcescens ATCC 27117 PMDBD2000435 4-chloroquinoline Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28350449" PMDBI20033715 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000436 4-Cyanophenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033716 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000436 4-Cyanophenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033717 n.a. PMDBM2021266 n.a. Vibrio anguillarum LMG 4411 PMDBD2000437 4-dimethyl-amino-cinnamaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18793453" PMDBI20033718 n.a. PMDBM2021267 n.a. Vibrio vulnificus LMG 16867 PMDBD2000437 4-dimethyl-amino-cinnamaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18793453" PMDBI20033719 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000438 4-Ethylcatechol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27808174" PMDBI20033720 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000439 4-Ethylguaiacol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27808174" PMDBI20033721 n.a. PMDBM2021218 n.a. Vibrio harveyi BB170 PMDBD2000440 4-Fluoro-(S)-4,5-Dihydroxypentane-2,3-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24637781" PMDBI20033722 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000441 4-Fluoro-2-methyl-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033723 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000441 4-Fluoro-2-methyl-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033724 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000442 4-Fluoro-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033725 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000442 4-Fluoro-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033726 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000443 4-fluoroindole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033727 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000444 4H-tomentosin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26394911" PMDBI20033728 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2000445 4-Hydroxy benzoate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24067082" PMDBI20033729 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000446 4-hydroxy coumarin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20033730 n.a. "PMID: 30581775; PMID: 25085732" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000447 4-Hydroxy-2,5-dimethyl-3(2H)-furanone Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033731 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU7 PMDBD2000448 4-Hydroxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033732 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU38 PMDBD2000448 4-Hydroxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033733 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU48 PMDBD2000448 4-Hydroxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033734 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000449 4-Iodo-d-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033735 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000449 4-Iodo-d-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033736 n.a. "PMID: 30581775; PMID: 19855933" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000450 4-methanesulfonylaniline Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033737 n.a. PMDBM2021266 n.a. Vibrio anguillarum LMG4411 PMDBD2000451 4-Methoxycarbonylphenylboronic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19778962" PMDBI20033738 n.a. PMDBM2021216 n.a. Vibrio campbellii LMG21363 PMDBD2000451 4-Methoxycarbonylphenylboronic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19778962" PMDBI20033739 n.a. PMDBM2020258 n.a. Vibrio cholerae NCTC8457 PMDBD2000451 4-Methoxycarbonylphenylboronic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19778962" PMDBI20033740 n.a. PMDBM2021267 n.a. Vibrio vulnificus LMG 16867 PMDBD2000451 4-Methoxycarbonylphenylboronic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19778962" PMDBI20033741 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU7 PMDBD2000452 4-Methoxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033742 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU38 PMDBD2000452 4-Methoxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033743 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU48 PMDBD2000452 4-Methoxychalcone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20033744 n.a. PMDBM2021266 n.a. Vibrio anguillarum LMG 4411 PMDBD2000453 4-methoxy-cinnamaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18793453" PMDBI20033745 n.a. PMDBM2021267 n.a. Vibrio vulnificus LMG 16867 PMDBD2000453 4-methoxy-cinnamaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18793453" PMDBI20033746 n.a. "PMID: 30581775; PMID: 24944053" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000454 4-Methyl benzyl dodecyl beta-maltoside Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033747 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000455 4-Methylphenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033748 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000455 4-Methylphenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033749 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000455 4-Methylphenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033750 n.a. PMDBM2021267 n.a. Vibrio vulnificus LMG 16867 PMDBD2000456 4-nitro-cinnamaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18793453" PMDBI20033751 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000457 4-Nitro-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033752 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000457 4-Nitro-D-phenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20033753 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD2000458 4-nitropyridine N -oxide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20033754 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2000458 4-nitropyridine N -oxide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20033755 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD2000458 4-nitropyridine N -oxide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20033756 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD2000458 4-nitropyridine N -oxide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20033757 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000459 4-Phenyl-N-((2R,3R,4S,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)butanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033758 n.a. "PMID: 30581775; PMID: 24944053" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000460 4-tertiary butyl benzyl decyl beta-maltoside Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033759 n.a. "PMID: 30581775; PMID: 24944053" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000461 4-tertiary butyl benzyl dodecyl beta-maltoside Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033760 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000462 5 alpha-Epoxyalantolactone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26394911" PMDBI20033761 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-USA300 PMDBD2000463 5- hydroxyethyl-3-tetradecanoyltetramic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27999062" PMDBI20033762 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA-BH1CC PMDBD2000463 5- hydroxyethyl-3-tetradecanoyltetramic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27999062" PMDBI20033763 n.a. PMDBM2020177 n.a. Staphylococcus aureus MSSA-BH48 PMDBD2000463 5- hydroxyethyl-3-tetradecanoyltetramic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27999062" PMDBI20033764 n.a. PMDBM2020177 n.a. Staphylococcus aureus MSSA-SH1000 PMDBD2000463 5- hydroxyethyl-3-tetradecanoyltetramic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27999062" PMDBI20033765 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000464 5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole-2-thiol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033766 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000464 5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole-2-thiol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033767 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43866 (MRSA) PMDBD2000464 5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole-2-thiol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033768 n.a. PMDBM2010041 n.a. Streptococcus epidermidis ATCC 35984 PMDBD2000464 5-(4,5-dibromo-1-methyl-1H-pyrrol-2-yl)-1,3,4-oxadiazole-2-thiol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26125599" PMDBI20033769 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000465 5-(dibromomethylene)-3-(1-acetoxyethyl)-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033770 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000466 5-(dibromomethylene)-3-(1-bromobutyl)-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033771 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000467 5-(dibromomethylene)-3-(1-bromoethyl)-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033772 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000468 5-(dibromomethylene)-3-butyl-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033773 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000469 5-(dibromomethylene)-3-ethyl-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033774 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000470 5-(dibromomethylene)-3-hexyl-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20033775 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD2000471 5,7,8,4-Tetramethoxyflavone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26140409" PMDBI20033776 n.a. PMDBM2021248 n.a. Candida albicans BWP17 PMDBD2000472 5,8,11,14-Eicosatetraynoic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20033777 n.a. PMDBM2021248 n.a. Candida albicans Ca-115 PMDBD2000472 5,8,11,14-Eicosatetraynoic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20033778 n.a. PMDBM2021248 n.a. Candida albicans Ca-116 PMDBD2000472 5,8,11,14-Eicosatetraynoic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20033779 n.a. PMDBM2021248 n.a. Candida albicans Ca-117 PMDBD2000472 5,8,11,14-Eicosatetraynoic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20033780 n.a. PMDBM2021248 n.a. Candida albicans Ca-119 PMDBD2000472 5,8,11,14-Eicosatetraynoic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20033781 n.a. PMDBM2021248 n.a. Candida albicans Ca-120 PMDBD2000472 5,8,11,14-Eicosatetraynoic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20033782 n.a. PMDBM2021248 n.a. Candida albicans Ca-121 PMDBD2000472 5,8,11,14-Eicosatetraynoic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20033783 n.a. PMDBM2021248 n.a. Candida albicans Ca-122 PMDBD2000472 5,8,11,14-Eicosatetraynoic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20033784 n.a. PMDBM2021248 n.a. Candida albicans Ca-125 PMDBD2000472 5,8,11,14-Eicosatetraynoic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20033785 n.a. PMDBM2021248 n.a. Candida albicans Ca-126 PMDBD2000472 5,8,11,14-Eicosatetraynoic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20033786 n.a. PMDBM2021248 n.a. Candida albicans Ca-127 PMDBD2000472 5,8,11,14-Eicosatetraynoic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20033787 n.a. PMDBM2021248 n.a. Candida albicans Ca-137 PMDBD2000472 5,8,11,14-Eicosatetraynoic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20033788 n.a. "PMID: 30581775; PMID: 24485124" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000473 5-Bicyclic brominated furanones Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033789 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MH602 PMDBD2000474 5-Bromo-1-(2-chloroacetyl)indoline-2,3-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033790 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000475 5-Bromoindole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25287229" PMDBI20033791 n.a. PMDBM2021738 n.a. Aeromonas sobria B1 PMDBD2000476 5-bromomethylene-2 (5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27118073" PMDBI20033792 n.a. PMDBM2021093 n.a. Serratia liquefaciens A2 PMDBD2000476 5-bromomethylene-2 (5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27118073" PMDBI20033793 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MH602 PMDBD2000477 5-Chloro-1-(2-chloroacetyl)indoline-2,3-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28654117" PMDBI20033794 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000478 5-Chloroindole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25287229" PMDBI20033795 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2000479 5-decyl-1,3-thiazolidine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24078467" PMDBI20033796 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD1006 5-Fluorocytosine Therapeutic substance chemotherapeutic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20033797 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000480 5-fluoroindole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033798 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000481 5-fluorooxiindole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033799 n.a. "PMID: 30581775; PMID: 28261183" 652611 Pseudomonas aeruginosa PA14 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033800 n.a. "PMID: 30581775; PMID: 28261183" 208964 Pseudomonas aeruginosa PAO1 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033801 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (A5) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033802 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (A11) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033803 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (B2) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033804 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (B3) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033805 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (B8) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033806 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (B11) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033807 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (C5) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033808 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (D7) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033809 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (D10) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033810 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (E9) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033811 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (F3) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033812 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (F5) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033813 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (A1) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033814 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (A8) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033815 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (A9) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033816 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (B4) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033817 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (B6) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033818 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (B7) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033819 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (B10) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033820 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (C1) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033821 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (C2) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033822 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (C3) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033823 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (C4) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033824 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (C6) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033825 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (C8) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033826 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (C9) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033827 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (C11) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033828 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (C12 PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033829 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (D5) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033830 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (D6) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033831 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (D8) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033832 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (D11) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033833 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (D12) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033834 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (E2) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033835 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (E3) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033836 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (E5) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033837 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (E6) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033838 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (E8) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033839 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (E10) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033840 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (E11) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033841 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (F7) PMDBD8 5-Fluorouracil Therapeutic Substance antineoplastic antimetabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20033842 n.a. PMDBM2020080 1423 Bacillus subtilis 168 PMDBD2000482 5-Hydroxy-4-[(4-methylphenyl)sulfonyl]-3-chloro-2(5H)-furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26085951" PMDBI20033843 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2000483 5-octyl-1,3-thiazolidine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24078467" PMDBI20033844 n.a. PMDBM2020080 n.a. Bacillus subtilis MTCC 121 PMDBD2000484 6-(4-chlorophenyl)-1,3-dimethyl-5-[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl]-1H,2H,3H,4H,5H,6H-pyrimido[4,5-d][1,3]diazine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28209374" PMDBI20033845 n.a. PMDBM2020228 n.a. Micrococcus luteus MTCC 2470 PMDBD2000484 6-(4-chlorophenyl)-1,3-dimethyl-5-[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl]-1H,2H,3H,4H,5H,6H-pyrimido[4,5-d][1,3]diazine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28209374" PMDBI20033846 n.a. PMDBM2020177 n.a. Staphylococcus aureus MTCC 96 PMDBD2000484 6-(4-chlorophenyl)-1,3-dimethyl-5-[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl]-1H,2H,3H,4H,5H,6H-pyrimido[4,5-d][1,3]diazine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28209374" PMDBI20033847 n.a. PMDBM2020177 n.a. Staphylococcus aureus MLS16 MTCC 2940 PMDBD2000484 6-(4-chlorophenyl)-1,3-dimethyl-5-[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl]-1H,2H,3H,4H,5H,6H-pyrimido[4,5-d][1,3]diazine-2,4-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28209374" PMDBI20033848 n.a. PMDBM2020100 n.a. Klebsiella pneumoniae ATCC 13882 PMDBD2000485 6-Amino Penicillinic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28692914" PMDBI20033849 n.a. PMDBM2021025 n.a. Proteus mirabilis ATCC 12453 PMDBD2000485 6-Amino Penicillinic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28692914" PMDBI20033850 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 (MRSA) PMDBD2000485 6-Amino Penicillinic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28692914" PMDBI20033851 n.a. "PMID: 30581775; PMID: 28692914" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000485 6-Amino Penicillinic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20033852 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2000486 6-Aminoflavone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21930760" PMDBI20033853 n.a. "PMID: 30581775; PMID: 24485124" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000487 6-Bicyclic brominated furanones Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033854 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000488 6-Chloroindole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25287229" PMDBI20033855 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000489 6-Chlorooxindole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25287229" PMDBI20033856 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000490 6-fluoroindole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033857 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000491 6-Gingerol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25728862" PMDBI20033858 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2000492 6-hydroxyflavone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21930760" PMDBI20033859 n.a. "PMID: 30581775; PMID: 26149536" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000493 6-MO-LF11-215 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033860 n.a. "PMID: 30581775; PMID: 26149536" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000494 6-MO-LF11-227 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033861 n.a. "PMID: 30581775; PMID: 26149536" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000495 6-MO-LF11-322 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033862 n.a. "PMID: 30581775; PMID: 24485124" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000496 7-Bicyclic brominated furanones Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033863 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000497 7-bromoindole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033864 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000498 7-chloroindole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033865 n.a. PMDBM2020219 n.a. Serratia marcescens ATCC 27117 PMDBD2000499 7-chloroquinolin-4-ol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28350449" PMDBI20033866 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000500 7-fluoroindole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033867 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000501 7-fluoroindoline-2,3-dione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033868 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000502 7-formylindole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033869 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000503 7-hydroxyindole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033870 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000504 7-methoxyindole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033871 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000505 7-methylindole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033872 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000506 7-nitroindole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033873 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 29213 PMDBD2000507 7P-AC Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26571297" PMDBI20033874 n.a. PMDBM2020177 n.a. Staphylococcus aureus XJ75302 (MRSA) PMDBD2000507 7P-AC Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26571297" PMDBI20033875 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 14990 PMDBD2000507 7P-AC Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26571297" PMDBI20033876 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis XJ75284 (MRSE) PMDBD2000507 7P-AC Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26571297" PMDBI20033877 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000508 8-fluoroquinoline Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033878 n.a. PMDBM2020236 1403335 Porphyromonas gingivalis 381 PMDBD2000509 9-hydroxy-2-propyl-4H-pyrido[1,2-a]pyrimidin-4-one Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19778324" PMDBI20033879 n.a. PMDBM2021248 n.a. Candida albicans BWP17 PMDBD2000510 A-3 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20033880 n.a. PMDBM2020183 n.a. Streptococcus mutans JM11 PMDBD2000511 AAP2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19878192" PMDBI20033881 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD2000512 Abacavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Reverse transcriptase n.a. PMID "PMID: 30581775; PMID: 8760340" PMDBI20033886 n.a. "PMID: 30581775; PMID: 27220074" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000513 Aceroside VIII Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033887 n.a. PMDBM2021025 n.a. Proteus mirabilis NSM6 PMDBD2000514 Acetohydroxamic Acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 9760002" PMDBI20033888 n.a. PMDBM2020785 548 Enterobacter aerogenes Not Specified PMDBD2000514 Acetohydroxamic Acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Urease subunit alpha n.a. PMID "PMID: 30581775; PMID: 11101668" PMDBI20033892 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000515 Acetycholine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26092919" PMDBI20033893 n.a. PMDBM2010183 n.a. Human herpesvirus 1 17 PMDBD2000516 Aciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Thymidine kinase n.a. PMID "PMID: 30581775; PMID: 9989588" PMDBI20033895 n.a. PMDBM2010184 n.a. Varicella-zoster virus Dumas PMDBD2000516 Aciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA polymerase catalytic subunit n.a. PMID "PMID: 30581775; PMID: 16638752" PMDBI20033904 n.a. "PMID: 30581775; PMID: 24944053" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000517 Adamantane dodecyl beta-maltoside Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033905 n.a. PMDBM2010185 n.a. Hepatitis B virus D Not Specified PMDBD1018 Adefovir Dipivoxil Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Protein P n.a. PMID "PMID: 30581775; PMID: 14647052" PMDBI20033909 n.a. PMDBM2021739 5482 Candida tropicalis Not Specified PMDBD2000518 AFP1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21736910" PMDBI20033910 n.a. "PMID: 30581775; PMID: 22314537" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000519 Ajoene Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033911 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa CF438 PMDBD2000519 Ajoene Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22314537" PMDBI20033912 n.a. PMDBM2021740 211586 Shewanella oneidensis MR-1 PMDBD22 Albendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Fumarate reductase flavoprotein subunit n.a. PMID "PMID: 30581775; PMID: 6518278" PMDBI20033913 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20033914 n.a. PMDBM2021248 n.a. Candida albicans 14053 PMDBD2000520 Allicin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21924600" PMDBI20033915 n.a. "PMID: 30581775; PMID: 24459829" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000520 Allicin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20033916 n.a. PMDBM2021025 n.a. Proteus mirabilis ATCC 12453 PMDBD2000520 Allicin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25837813" PMDBI20033917 n.a. PMDBM2021025 n.a. Proteus mirabilis Clinical isolate 1 PMDBD2000520 Allicin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25837813" PMDBI20033918 n.a. PMDBM2021025 n.a. Proteus mirabilis Clinical isolate 2 PMDBD2000520 Allicin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25837813" PMDBI20033919 n.a. PMDBM2021242 714 Actinobacillus actinomycetemcomitans Not Specified PMDBD2000521 Aloe Vera Gel Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28050502" PMDBI20033920 n.a. PMDBM2010193 n.a. Clostridium bacilli Not Specified PMDBD2000521 Aloe Vera Gel Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28050502" PMDBI20033921 n.a. PMDBM2010194 n.a. Staphlococcus aureus Not Specified PMDBD2000521 Aloe Vera Gel Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28050502" PMDBI20033922 n.a. PMDBM2020183 1309 Streptococcus mutans Not Specified PMDBD2000521 Aloe Vera Gel Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28050502" PMDBI20033923 n.a. PMDBM2020183 n.a. Streptococcus mutans LMG 14558 PMDBD2000522 Aloe-emodin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17220400" PMDBI20033924 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000523 alpha-costic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26394911" PMDBI20033925 n.a. PMDBM2021741 n.a. Cryptococcus neoformans B3501 PMDBD2000524 alpha-Defensin-3 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17057089" PMDBI20033926 n.a. PMDBM2021248 5476 Candida albicans DAY185 PMDBD2000525 alpha-Humulene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 2815533" PMDBI20033927 n.a. PMDBM2021248 5476 Candida albicans DAY185 PMDBD2000526 alpha-Longipinene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28155334" PMDBI20033928 n.a. "PMID: 30581775; PMID: 2834324" 176279 Staphylococcus epidermidis RP62A PMDBD2000527 alpha-mangostin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020178 PMDBI20033929 n.a. PMDBM2020005 n.a. Bacillus cereus var. mycoides 0042 PMDBD2000528 alpha-Pinene Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20033930 n.a. PMDBM2020035 n.a. Escherichia coli 582 PMDBD2000528 alpha-Pinene Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20033931 n.a. PMDBM2021742 n.a. Pichia anomala 8061Mo PMDBD2000528 alpha-pinene Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20033932 n.a. PMDBM2021248 5476 Candida albicans DAY185 PMDBD2000528 alpha-Pinene Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28155334" PMDBI20033933 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538P PMDBD2000529 alpha-tocopherol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28869803" PMDBI20033934 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 PMDBD2000529 alpha-tocopherol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28869803" PMDBI20033935 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 33591 PMDBD2000529 alpha-tocopherol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28869803" PMDBI20033936 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 29213 PMDBD2000529 alpha-tocopherol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28869803" PMDBI20033937 n.a. PMDBM2010204 n.a. Influenza A virus A PMDBD32 Amantadine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Matrix protein 2 n.a. PMID "PMID: 30581775; PMID: 7688826" PMDBI20033938 n.a. PMDBM2010205 n.a. Influenza A virus Ann Arbor PMDBD32 Amantadine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Matrix protein 2 n.a. PMID "PMID: 30581775; PMID: 7688826" PMDBI20033939 n.a. PMDBM2010206 n.a. Influenza A virus 6 PMDBD32 Amantadine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Matrix protein 2 n.a. PMID "PMID: 30581775; PMID: 7688826" PMDBI20033940 n.a. PMDBM2010207 n.a. Influenza A virus 1960 H2N2 PMDBD32 Amantadine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Matrix protein 2 n.a. PMID "PMID: 30581775; PMID: 7688826" PMDBI20033961 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000530 Amikacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S12 n.a. PMID "PMID: 30581775; PMID: 10702385" PMDBI20033962 n.a. PMDBM2020035 n.a. Escherichia coli ER20477 PMDBD2000530 Amikacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20033963 n.a. PMDBM2020035 n.a. Escherichia coli ER14169 PMDBD2000530 Amikacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20033964 n.a. PMDBM2020229 n.a. Morganella morganii ER14229 PMDBD2000530 Amikacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20033965 n.a. PMDBM2021026 n.a. Proteus vulgaris ER35441 PMDBD2000530 Amikacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20033966 n.a. PMDBM2020242 n.a. Providencia stuartii ER21870 PMDBD2000530 Amikacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20033967 n.a. PMDBM2020242 n.a. Providencia stuartii ER08274 PMDBD2000530 Amikacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20033968 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD2000530 Amikacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 16S rRNA n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20033975 n.a. PMDBM2020035 n.a. Escherichia coli 8 PMDBD2000531 Amikacin disulfate salt Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24159313" PMDBI20033976 n.a. PMDBM2020035 n.a. Escherichia coli 9 PMDBD2000531 Amikacin disulfate salt Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24159313" PMDBI20033977 n.a. PMDBM2020035 n.a. Escherichia coli 10 PMDBD2000531 Amikacin disulfate salt Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24159313" PMDBI20033978 n.a. PMDBM2020035 n.a. Escherichia coli 31 PMDBD2000531 Amikacin disulfate salt Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24159313" PMDBI20033979 n.a. PMDBM2020035 n.a. Escherichia coli 1583 PMDBD2000531 Amikacin disulfate salt Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24159313" PMDBI20033980 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000532 Aminocyclopropane Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25537269" PMDBI20033981 n.a. PMDBM2020889 1773 Mycobacterium tuberculosis Not Specified PMDBD2000533 Aminosalicylic Acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20033983 n.a. PMDBM2020080 n.a. Bacillus subtilis ATCC 39087 PMDBD39 Amlodipine Therapeutic Substance antihypertensive n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25038633" PMDBI20033984 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 12461003" PMDBI20033985 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 12461003" PMDBI20033990 n.a. PMDBM2020080 n.a. Bacillus subtilis ATCC 39087 PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25038633" PMDBI20033991 n.a. PMDBM2020848 n.a. Listeria monocytogenes 568 PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20033992 n.a. PMDBM2020848 169963 Listeria monocytogenes EGD-e PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20033993 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2a PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20033994 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2b PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20033995 n.a. PMDBM2021248 5476 Candida albicans Not Specified PMDBD2000067 Amphotericin B Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Ergosterol n.a. PMID "PMID: 30581775; PMID: 16086075" PMDBI20033998 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000067 Amphotericin B Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20033999 n.a. PMDBM2021248 n.a. Candida albicans ATCC SC5314 PMDBD2000067 Amphotericin B Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24195531" PMDBI20034001 n.a. PMDBM2021153 1313 Streptococcus pneumoniae Not Specified PMDBD1031 Ampicillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034002 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD1031 Ampicillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034006 n.a. "PMID: 30581775; PMID: 7447421" 171101 Streptococcus pneumoniae R6 PMDBD1031 Ampicillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID PMDBM2021153 PMDBI20034013 n.a. "PMID: 30581775; PMID: 24705563" 208964 Pseudomonas aeruginosa PAO1 PMDBD1031 Ampicillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034014 n.a. PMDBM2020080 n.a. Bacillus subtilis ATCC 39087 PMDBD1031 Ampicillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25038633" PMDBI20034015 n.a. PMDBM2020848 n.a. Listeria monocytogenes 568 PMDBD1031 Ampicillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034016 n.a. PMDBM2020848 169963 Listeria monocytogenes EGD-e PMDBD1031 Ampicillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034017 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2a PMDBD1031 Ampicillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034018 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2b PMDBD1031 Ampicillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034019 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 (MRSA) PMDBD1031 Ampicillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25764489" PMDBI20034021 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD2000534 Amprenavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Pol polyprotein n.a. PMID "PMID: 30581775; PMID: 10390223" PMDBI20034025 n.a. PMDBM2021743 425011 Aspergillus niger CBS 513.88 PMDBD2000535 Anidulafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 1,3-beta-glucan synthase component FKS1 n.a. PMID "PMID: 30581775; PMID: 16960253" PMDBI20034026 n.a. PMDBM2021743 n.a. Aspergillus niger FGSC A1513 PMDBD2000535 Anidulafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 1,3-beta-glucan synthase component FKS1 n.a. PMID "PMID: 30581775; PMID: 16960253" PMDBI20034035 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000536 Aniline Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25537269" PMDBI20034036 n.a. PMDBM2020183 n.a. Streptococcus mutans LMG 14558 PMDBD2000537 Anthraflavic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17220400" PMDBI20034037 n.a. PMDBM2020080 n.a. Bacillus subtilis ATCC 6051 PMDBD2000538 Anthranilate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28819217" PMDBI20034038 n.a. "PMID: 30581775; PMID: 28819217" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000538 Anthranilate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034039 n.a. PMDBM2021261 90371 Salmonella enterica serovar Typhimurium SL1344 PMDBD2000538 Anthranilate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28819217" PMDBI20034040 n.a. PMDBM2021267 914127 Vibrio vulnificus M06-24/O PMDBD2000538 Anthranilate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28819217" PMDBI20034041 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000539 Apigenin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20034042 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD2000539 Apigenin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20034043 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2000539 Apigenin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21930760" PMDBI20034044 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD62 Apramycin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 16S rRNA n.a. PMID "PMID: 30581775; PMID: 1915283" PMDBI20034046 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000540 Arbekacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S12 n.a. PMID "PMID: 30581775; PMID: 320034" PMDBI20034050 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000541 Asperdiol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20034051 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000541 Asperdiol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20034052 n.a. PMDBM2021218 n.a. Vibrio harveyi PHY-2A PMDBD2000541 Asperdiol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20034053 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000542 Asperdiol acetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20034054 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000542 Asperdiol acetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20034055 n.a. PMDBM2021218 n.a. Vibrio harveyi PHY-2A PMDBD2000542 Asperdiol acetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20034056 n.a. PMDBM2021248 n.a. Candida albicans GDH 2346 PMDBD1044 Aspirin Therapeutic substance pain and fever due to various causes n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 14693516" PMDBI20034057 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD1045 Atazanavir Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Pol polyprotein n.a. PMID "PMID: 30581775; PMID: 11752352" PMDBI20034058 n.a. PMDBM2010236 n.a. Human immunodeficiency virus Not Specified PMDBD1045 Atazanavir Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: HIV-1 protease n.a. PMID "PMID: 30581775; PMID: 15585441" PMDBI20034072 n.a. PMDBM2021744 36329 Plasmodium falciparum isolate 3D7 PMDBD79 Atovaquone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydroorotate dehydrogenase (quinone), mitochondrial n.a. PMID "PMID: 30581775; PMID: 7726490" PMDBI20034074 n.a. PMDBM2021744 5833 Plasmodium falciparum Not Specified PMDBD79 Atovaquone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Cytochrome b n.a. PMID "PMID: 30581775; PMID: 10447880" PMDBI20034086 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20034087 n.a. PMDBM2020178 1282 Staphylococcus epidermidis 1457 PMDBD2000543 Autoinducer-2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16369005" PMDBI20034088 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20034089 n.a. PMDBM2020029 550 Enterobacter cloacae Not Specified PMDBD2000544 Avibactam Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Beta-lactamase n.a. PMID "PMID: 30581775; PMID: 22041508" PMDBI20034090 n.a. PMDBM2020035 562 Escherichia coli Not Specified PMDBD2000544 Avibactam Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Beta-lactamase SHV-2 n.a. PMID "PMID: 30581775; PMID: 22041508" PMDBI20034094 n.a. PMDBM2020100 573 Klebsiella pneumoniae Not Specified PMDBD2000544 Avibactam Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Class D OXA-48 carbapenemase n.a. PMID "PMID: 30581775; PMID: 22041508" PMDBI20034097 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000544 Avibactam Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Extended-spectrum beta-lactamase PER-1 n.a. PMID "PMID: 30581775; PMID: 22041508" PMDBI20034099 n.a. PMDBM2021153 1313 Streptococcus pneumoniae Not Specified PMDBD2000545 Azidocillin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034100 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD2000545 Azidocillin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034104 n.a. "PMID: 30581775; PMID: 7447421" 171101 Streptococcus pneumoniae R6 PMDBD2000545 Azidocillin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID PMDBM2021153 PMDBI20034108 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa OMU 91008 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 8983885" PMDBI20034109 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAO 2001-2 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 8983885" PMDBI20034110 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 50S ribosomal protein L4 n.a. PMID "PMID: 30581775; PMID: 12000992" PMDBI20034112 n.a. PMDBM2010245 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 23S rRNA n.a. PMID "PMID: 30581775; PMID: 12183262" PMDBI20034116 n.a. PMDBM2020888 1235988 Mycobacterium avium 101 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15561879" PMDBI20034117 n.a. "PMID: 30581775; PMID: 15561879" 243243 Mycobacterium avium 104 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020888 PMDBI20034118 n.a. PMDBM2020888 n.a. Mycobacterium avium 109 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15561879" PMDBI20034119 n.a. PMDBM2020888 n.a. Mycobacterium avium A5 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15561879" PMDBI20034127 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034128 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034129 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034130 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034131 n.a. PMDBM2020151 1279007 Pseudomonas aeruginosa PA1 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21127154" PMDBI20034132 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA2 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21127154" PMDBI20034133 n.a. "PMID: 30581775; PMID: 21127154" 208964 Pseudomonas aeruginosa PAO1 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034134 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23070152" PMDBI20034135 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA 10 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24426177" PMDBI20034136 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA 21 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24426177" PMDBI20034137 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MTCC 2488 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27000525" PMDBI20034138 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD1049 Azlocillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 10090000" PMDBI20034139 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD1049 Azlocillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 10090000" PMDBI20034144 n.a. PMDBM2020848 n.a. Listeria monocytogenes 568 PMDBD1049 Azlocillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034145 n.a. PMDBM2020848 169963 Listeria monocytogenes EGD-e PMDBD1049 Azlocillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034146 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2a PMDBD1049 Azlocillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034147 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2b PMDBD1049 Azlocillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034148 n.a. PMDBM2020080 1423 Bacillus subtilis 168 PMDBD91 Aztreonam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 2244291" PMDBI20034151 n.a. PMDBM2020520 546 Citrobacter freundii Not Specified PMDBD91 Aztreonam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Beta-lactamase n.a. PMID "PMID: 30581775; PMID: 16048994" PMDBI20034158 n.a. PMDBM2021589 n.a. Lactobacillus fermenti ATCC 9338 PMDBD2000546 Bac8C Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24309076" PMDBI20034159 n.a. "PMID: 30581775; PMID: 24309076" 210007 Streptococcus mutans UA159 PMDBD2000546 Bac8C Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20034160 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD2000547 Bacalin hydrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034161 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2000547 Bacalin hydrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034162 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD2000547 Bacalin hydrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034163 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD2000547 Bacalin hydrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034164 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD2000548 Bacampicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20034165 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD2000548 Bacampicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20034168 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20034169 n.a. PMDBM2021245 n.a. Burkholderia pseudomallei H777 PMDBD2000549 Bactenecin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23785532" PMDBI20034170 n.a. "PMID: 30581775; PMID: 18330563" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000550 Baicalein Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034171 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD2000550 Baicalein Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034172 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2000550 Baicalein Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034173 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD2000550 Baicalein Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034174 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD2000550 Baicalein Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034176 n.a. PMDBM2020177 n.a. Staphylococcus aureus 17413 PMDBD2000550 Baicalein Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27128436" PMDBI20034177 n.a. PMDBM2020177 n.a. Staphylococcus aureus 17546 PMDBD2000550 Baicalein Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27128436" PMDBI20034178 n.a. PMDBM2020177 n.a. Staphylococcus aureus 17624 PMDBD2000550 Baicalein Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27128436" PMDBI20034179 n.a. PMDBM2020177 n.a. Staphylococcus aureus 18558 PMDBD2000550 Baicalein Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27128436" PMDBI20034180 n.a. PMDBM2020177 n.a. Staphylococcus aureus 18565 PMDBD2000550 Baicalein Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27128436" PMDBI20034181 n.a. PMDBM2020177 n.a. Staphylococcus aureus 18791 PMDBD2000550 Baicalein Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27128436" PMDBI20034182 n.a. "PMID: 30581775; PMID: 18330563" 208964 Pseudomonas aeruginosa PAO1 PMDBD95 Baicalin Herbal Substance anti-inflammatory n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034183 n.a. PMDBM2020889 1773 Mycobacterium tuberculosis Not Specified PMDBD2000551 Bedaquiline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: ATP synthase subunit c n.a. PMID "PMID: 30581775; PMID: 17496888" PMDBI20034184 n.a. PMDBM2020258 n.a. Vibrio cholerae CIP 106858 PMDBD2000552 Benzalacetone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21249192" PMDBI20034185 n.a. PMDBM2021218 n.a. Vibrio harveyi BB124 PMDBD2000552 Benzalacetone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21249192" PMDBI20034186 n.a. PMDBM2021633 485 Neisseria gonorrhoeae Not Specified PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2 n.a. PMID "PMID: 30581775; PMID: 3245263" PMDBI20034187 n.a. PMDBM2020848 n.a. Listeria monocytogenes 568 PMDBD100 Benzathine Benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034188 n.a. PMDBM2020848 169963 Listeria monocytogenes EGD-e PMDBD100 Benzathine Benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034189 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2a PMDBD100 Benzathine Benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034190 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2b PMDBD100 Benzathine Benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034191 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20034192 n.a. PMDBM2020075 470 Acinetobacter baumannii Not Specified PMDBD2000553 Benzenesul-fonamide,4-amino-N-methyl-N-[3-(3,4,7,8-tetrahydro-2,4-dioxo-2H-thiopyrano[4,3-d]pyrimidin-1(5H)-yl)propyl Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24117391" PMDBI20034193 n.a. "PMID: 30581775; PMID: 24117391" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000553 Benzenesul-fonamide,4-amino-N-methyl-N-[3-(3,4,7,8-tetrahydro-2,4-dioxo-2H-thiopyrano[4,3-d]pyrimidin-1(5H)-yl)propyl Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034194 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20034195 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000554 Benzocaine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25537269" PMDBI20034196 n.a. "PMID: 30581775; PMID: 24944053" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000555 Benzophenonyl decyl beta-maltoside Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034197 n.a. PMDBM2020620 1747 Propionibacterium acnes LMG 16711 PMDBD2000556 Benzoylperoxide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24251377" PMDBI20034198 n.a. PMDBM2020620 n.a. Propionibacterium acnes LMG 16712 PMDBD2000556 Benzoylperoxide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24251377" PMDBI20034199 n.a. PMDBM2020620 n.a. Propionibacterium acnes LMG 16715 PMDBD2000556 Benzoylperoxide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24251377" PMDBI20034200 n.a. "PMID: 30581775; PMID: 24944053" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000557 Benzyl decyl beta-maltoside Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034201 n.a. PMDBM2020177 1280 Staphylococcus aureus USA300 PMDBD2000558 Benzylpenicillin Therapeutic Substance Phase 3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 3245263" PMDBI20034202 n.a. PMDBM2020035 562 Escherichia coli Not Specified PMDBD2000558 Benzylpenicillin Therapeutic Substance Phase 3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Beta-lactamase TEM n.a. PMID "PMID: 30581775; PMID: 3257523" PMDBI20034203 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2000559 Bergamottin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23891936" PMDBI20034204 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD2000560 Besifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 20030427" PMDBI20034206 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD2000560 Besifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 20030427" PMDBI20034208 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD2000560 Besifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 20030427" PMDBI20034210 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD2000560 Besifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 20030427" PMDBI20034212 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae serotype 4 ATCC BAA-334 PMDBD2000560 Besifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 20030427" PMDBI20034214 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae serotype 4 TIGR4 PMDBD2000560 Besifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 20030427" PMDBI20034216 n.a. "PMID: 30581775; PMID: 22318906" 176279 Staphylococcus epidermidis RP62A PMDBD2000561 beta-6-20-G3K6 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020178 PMDBI20034217 n.a. PMDBM2021248 5476 Candida albicans DAY185 PMDBD2000562 beta-Caryophyllene Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28155334" PMDBI20034218 n.a. PMDBM2021741 n.a. Cryptococcus neoformans B3501 PMDBD2000563 beta-Defensin-1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17057089" PMDBI20034219 n.a. PMDBM2021741 n.a. Cryptococcus neoformans B3501 PMDBD2000564 beta-Defensin-3 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17057089" PMDBI20034220 n.a. PMDBM2021248 5476 Candida albicans DAY185 PMDBD2000565 beta-Pinene Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28155334" PMDBI20034221 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2000566 beta-sitosterol glucoside Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23891936" PMDBI20034222 n.a. PMDBM2021745 690163 Acinetobacter sp. VTT E-022166 PMDBD2000567 Betulin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24944110" PMDBI20034223 n.a. PMDBM2020379 n.a. Bacillus amyloliquefaciens VTT E-052804 PMDBD2000567 Betulin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24944110" PMDBI20034224 n.a. PMDBM2020759 n.a. Hafnia paralvei VTT E-113185 PMDBD2000567 Betulin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24944110" PMDBI20034225 n.a. PMDBM2020906 n.a. Obesumbacterium proteus VTT E-113187 PMDBD2000567 Betulin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24944110" PMDBI20034226 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa VTT E-082794 PMDBD2000567 Betulin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24944110" PMDBI20034227 n.a. PMDBM2021746 n.a. Pseudomonas libaniensis VTT E-052840 PMDBD2000567 Betulin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24944110" PMDBI20034228 n.a. PMDBM2020219 n.a. Serratia marcescens VTT E-031888 PMDBD2000567 Betulin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24944110" PMDBI20034229 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2000568 Betulinic acid Therapeutic Substance Phase 1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24067082" PMDBI20034230 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD2000569 Bevirimat Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Gag-Pol polyprotein n.a. PMID "PMID: 30581775; PMID: 18043758" PMDBI20034231 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25302529" PMDBI20034232 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2000570 Biphenyl Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25007234" PMDBI20034233 n.a. "PMID: 30581775; PMID: 22715388" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000571 Bis[(4-methylphenyl)methyl] disulfide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034234 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD2000572 BisEDT-RIP Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15572191" PMDBI20034235 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis MRSE PMDBD2000572 BisEDT-RIP Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15572191" PMDBI20034236 n.a. PMDBM2021248 n.a. Candida albicans No 90029 PMDBD2000573 Bismuth oxide nanoparticle Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23637533" PMDBI20034237 n.a. PMDBM2020005 n.a. Bacillus cereus 407 PMDBD2000574 Bis-O-acetyl-4,5-dihydroxy-2,3-pentanedione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17169556" PMDBI20034238 n.a. PMDBM2021245 n.a. Burkholderia pseudomallei H777 PMDBD2000575 BMAP-18 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23785532" PMDBI20034239 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Pa5 PMDBD2000576 BMAP-27 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20034240 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Pa9 PMDBD2000576 BMAP-27 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20034241 n.a. PMDBM2020177 n.a. Staphylococcus aureus Sa7 PMDBD2000576 BMAP-27 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20034242 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia Sm109 PMDBD2000576 BMAP-27 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20034243 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia Sm143 PMDBD2000576 BMAP-27 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20034244 n.a. PMDBM2020177 n.a. Staphylococcus aureus Smith diffuse (SD) PMDBD2000577 BMAP-28 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16621147" PMDBI20034245 n.a. "PMID: 30581775; PMID: 18430491" 1201292 Enterococcus faecalis ATCC 29212 PMDBD2000577 BMAP-28 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20034246 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 PMDBD2000577 BMAP-28 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18430491" PMDBI20034247 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Pa5 PMDBD2000577 BMAP-28 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20034248 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Pa9 PMDBD2000577 BMAP-28 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20034249 n.a. PMDBM2020177 n.a. Staphylococcus aureus Sa4 PMDBD2000577 BMAP-28 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20034250 n.a. PMDBM2020177 n.a. Staphylococcus aureus Sa7 PMDBD2000577 BMAP-28 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20034251 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia Sm109 PMDBD2000577 BMAP-28 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20034252 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia Sm143 PMDBD2000577 BMAP-28 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20034253 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000577 BMAP-28 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26238597" PMDBI20034254 n.a. PMDBM2021248 n.a. Candida albicans CA-5 PMDBD2000577 BMAP-28 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26238597" PMDBI20034255 n.a. PMDBM2021248 n.a. Candida albicans CA-6 PMDBD2000577 BMAP-28 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26238597" PMDBI20034256 n.a. PMDBM2021747 n.a. Candida glabrata CG-4 PMDBD2000577 BMAP-28 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26238597" PMDBI20034257 n.a. PMDBM2021748 n.a. Candida krusei CK-1 PMDBD2000577 BMAP-28 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26238597" PMDBI20034258 n.a. PMDBM2021748 n.a. Candida krusei CK-2 PMDBD2000577 BMAP-28 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26238597" PMDBI20034259 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD2000578 Brecanavir Therapeutic Substance Discontinued in Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Pol polyprotein n.a. PMID "PMID: 30581775; PMID: 16723584" PMDBI20034262 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000579 Bromohexylmaleic anhydride Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20580562" PMDBI20034263 n.a. "PMID: 30581775; PMID: 16159245" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000580 Bromophenyl AHL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034264 n.a. PMDBM2021248 n.a. Candida albicans BWP17-DPP3-GFP PMDBD2000581 BS-34 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22174935" PMDBI20034265 n.a. PMDBM2020219 n.a. Serratia marcescens ATCC 27117 PMDBD2000582 Butane-1,4-diamine Therapeutic Substance Discontinued in Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28350449" PMDBI20034266 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2000583 Butanol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24688528" PMDBI20034267 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU7 PMDBD2000584 Butein Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20034268 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU38 PMDBD2000584 Butein Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20034269 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU48 PMDBD2000584 Butein Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20034270 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD132 Butenafine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20034271 n.a. PMDBM2021248 5476 Candida albicans Not Specified PMDBD2000070 Butoconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Ergosterol n.a. PMID "PMID: 30581775; PMID: 2184984" PMDBI20034272 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20034273 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000585 Butyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 2401679" PMDBI20034274 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000585 Butyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20034275 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000585 Butyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20034276 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000585 Butyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20034277 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000585 Butyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20034278 n.a. PMDBM2021190 1435056 Trueperella pyogenes TP8 PMDBD2000586 C12HSL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28144921" PMDBI20034279 n.a. "PMID: 30581775; PMID: 17060534" 210007 Streptococcus mutans UA159 PMDBD2000587 C16-33 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20034280 n.a. PMDBM2020184 n.a. Streptococcus sanguinis NY101 PMDBD2000587 C16-33 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17060534" PMDBI20034281 n.a. PMDBM2021143 n.a. Streptococcus gordonii Challis (DL1) PMDBD2000588 C16G2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17060534" PMDBI20034282 n.a. "PMID: 30581775; PMID: 17060534" 210007 Streptococcus mutans UA159 PMDBD2000588 C16G2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20034283 n.a. PMDBM2020184 n.a. Streptococcus sanguinis NY101 PMDBD2000588 C16G2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17060534" PMDBI20034284 n.a. PMDBM2020183 n.a. Streptococcus mutans UA140 PMDBD2000588 C16G2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21860239" PMDBI20034285 n.a. PMDBM2021738 n.a. Aeromonas sobria B1 PMDBD2000589 C4-HSL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27118073" PMDBI20034286 n.a. PMDBM2021093 n.a. Serratia liquefaciens A2 PMDBD2000589 C4-HSL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27118073" PMDBI20034287 n.a. PMDBM2020758 n.a. Hafnia alvei H4 PMDBD2000589 C4-HSL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28379194" PMDBI20034288 n.a. PMDBM2021260 n.a. Pseudomonas chlororaphis 30-84R PMDBD2000590 C6-HSL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16897305" PMDBI20034289 n.a. PMDBM2021260 n.a. Pseudomonas chlororaphis 30-84Z PMDBD2000590 C6-HSL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16897305" PMDBI20034290 n.a. PMDBM2021738 n.a. Aeromonas sobria B1 PMDBD2000590 C6-HSL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27118073" PMDBI20034291 n.a. PMDBM2021093 n.a. Serratia liquefaciens A2 PMDBD2000590 C6-HSL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27118073" PMDBI20034292 n.a. PMDBM2020758 n.a. Hafnia alvei H4 PMDBD2000590 C6-HSL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28379194" PMDBI20034293 n.a. PMDBM2021190 1435056 Trueperella pyogenes TP8 PMDBD2000591 C8-HSL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28144921" PMDBI20034294 n.a. "PMID: 30581775; PMID: 24958247" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000592 Cadmium Ion Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034295 n.a. PMDBM2020177 n.a. Staphylococcus aureus UAMS-1 PMDBD136 Caffeic Acid Herbal Substance compound n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22242149" PMDBI20034296 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD136 Caffeic Acid Herbal Substance compound n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24067082" PMDBI20034297 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 9027 PMDBD136 Caffeic Acid Herbal Substance compound n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26370951" PMDBI20034298 n.a. "PMID: 30581775; PMID: 26000026" 208964 Pseudomonas aeruginosa PAO1 PMDBD1069 Caffeine Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034299 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD2000593 Calanolide A Therapeutic Substance Phase 1 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Gag-Pol polyprotein n.a. PMID "PMID: 30581775; PMID: 11366704" PMDBI20034301 n.a. PMDBM2020069 n.a. Pseudomonas fluorescens H2S PMDBD2000594 Calcium chloride Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 2624463" PMDBI20034302 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 PMDBD2000595 CAMA Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23070152" PMDBI20034303 n.a. PMDBM2021248 5476 Candida albicans DAY185 PMDBD2000596 Camphene Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28155334" PMDBI20034304 n.a. PMDBM2020889 1773 Mycobacterium tuberculosis Not Specified PMDBD2000597 Capreomycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 70S ribosome n.a. PMID "PMID: 30581775; PMID: 16857584" PMDBI20034306 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000598 Carabrol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26394911" PMDBI20034307 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000599 Carabrone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26394911" PMDBI20034308 n.a. PMDBM2020035 511145 Escherichia coli MG1655 PMDBD2000600 Carbonyl cyanide m-chlorophenylhydrazone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24176982" PMDBI20034309 n.a. "PMID: 30581775; PMID: 24176982" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000600 Carbonyl cyanide m-chlorophenylhydrazone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034310 n.a. PMDBM2020177 n.a. Staphylococcus aureus NCTC strain 8532 PMDBD2000600 Carbonyl cyanide m-chlorophenylhydrazone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24176982" PMDBI20034311 n.a. PMDBM2020472 n.a. Burkholderia cepacia ATCC 17759 PMDBD2000601 Carboxymethyl chitosan Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20034312 n.a. PMDBM2020035 n.a. Escherichia coli ATCC 25312 PMDBD2000601 Carboxymethyl chitosan Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20034313 n.a. PMDBM2020797 378753 Kocuria rhizophila ATCC 9341 PMDBD2000601 Carboxymethyl chitosan Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20034314 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 9027 PMDBD2000601 Carboxymethyl chitosan Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20034315 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2000601 Carboxymethyl chitosan Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20034316 n.a. "PMID: 30581775; PMID: 28756196" 176280 Staphylococcus epidermidis ATCC 12228 PMDBD2000601 Carboxymethyl chitosan Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020178 PMDBI20034317 n.a. PMDBM2020183 n.a. Streptococcus mutans LMG 14558 PMDBD2000602 Carminic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17220400" PMDBI20034318 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000603 Carnitine hydrochloride Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20034319 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000603 Carnitine hydrochloride Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20034320 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000603 Carnitine hydrochloride Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20034321 n.a. "PMID: 30581775; PMID: 24094824" 210007 Streptococcus mutans UA159 PMDBD2000604 Carolacton Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20034322 n.a. PMDBM2021749 243365 Chromobacterium violaceum ATCC 12472 PMDBD2000605 Carvacrol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24691035" PMDBI20034323 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000605 Carvacrol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24691035" PMDBI20034324 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium DT104 PMDBD2000605 Carvacrol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24691035" PMDBI20034325 n.a. PMDBM2020177 n.a. Staphylococcus aureus BMA/FR/032/0074 PMDBD2000605 Carvacrol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24691035" PMDBI20034326 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000605 Carvacrol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27808174" PMDBI20034327 n.a. "PMID: 30581775; PMID: 28233286" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000605 Carvacrol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20034328 n.a. PMDBM2021248 1182531 Candida albicans 3153A PMDBD2000606 Caspofungin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 12384370" PMDBI20034329 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2000607 cat-AGE-RK1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24056098" PMDBI20034330 n.a. "PMID: 30581775; PMID: 24056098" 481805 Escherichia coli ATCC 8739 PMDBD2000607 cat-AGE-RK1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020035 PMDBI20034331 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2000607 cat-AGE-RK1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24056098" PMDBI20034332 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2000608 cat-AGE-RK2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24056098" PMDBI20034333 n.a. "PMID: 30581775; PMID: 24056098" 481805 Escherichia coli ATCC 8739 PMDBD2000608 cat-AGE-RK2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020035 PMDBI20034334 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2000608 cat-AGE-RK2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24056098" PMDBI20034335 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD2000609 Catechin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034336 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2000609 Catechin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034337 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD2000609 Catechin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034338 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD2000609 Catechin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034339 n.a. "PMID: 30581775; PMID: 19854927" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000609 Catechin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034340 n.a. PMDBM2021137 539 Eikenella corrodens 1073 PMDBD2000609 Catechin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21150103" PMDBI20034341 n.a. PMDBM2021137 539 Eikenella corrodens 1073 PMDBD2000610 Catechin gallate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21150103" PMDBI20034342 n.a. "PMID: 30581775; PMID: 18591225" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000611 Cathelicidin Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034343 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000611 Cathelicidin Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20002576" PMDBI20034344 n.a. PMDBM2021242 714 Aggregatibacter actinomycetemcomitans JP2 PMDBD2000611 Cathelicidin Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23836819" PMDBI20034345 n.a. PMDBM2021242 1035194 Aggregatibacter actinomycetemcomitans Y4 PMDBD2000611 Cathelicidin Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23836819" PMDBI20034346 n.a. PMDBM2021242 n.a. Aggregatibacter actinomycetemcomitans VT726 PMDBD2000611 Cathelicidin Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23836819" PMDBI20034347 n.a. PMDBM2021242 n.a. Aggregatibacter actinomycetemcomitans ATCC 29532 PMDBD2000611 Cathelicidin Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23836819" PMDBI20034348 n.a. PMDBM2021242 n.a. Aggregatibacter actinomycetemcomitans ATCC 33384 PMDBD2000611 Cathelicidin Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23836819" PMDBI20034349 n.a. PMDBM2021242 n.a. Aggregatibacter actinomycetemcomitans VT726ltx- PMDBD2000611 Cathelicidin Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23836819" PMDBI20034350 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 PMDBD2000612 Cecropin (1-7)-melittin A (2-9) amide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23070152" PMDBI20034351 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000613 Cecropin B Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23732798" PMDBI20034352 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000614 Cefacetrile Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 2722720" PMDBI20034356 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD1083 Cefaclor Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 1622180" PMDBI20034357 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD1083 Cefaclor Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 1622180" PMDBI20034358 n.a. PMDBM2021153 1313 Streptococcus pneumoniae Not Specified PMDBD1083 Cefaclor Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 1622180" PMDBI20034365 n.a. PMDBM2020848 n.a. Listeria monocytogenes 568 PMDBD1083 Cefaclor Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034366 n.a. PMDBM2020848 169963 Listeria monocytogenes EGD-e PMDBD1083 Cefaclor Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034367 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2a PMDBD1083 Cefaclor Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034368 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2b PMDBD1083 Cefaclor Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034369 n.a. PMDBM2021153 1313 Streptococcus pneumoniae Not Specified PMDBD154 Cefadroxil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034370 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD154 Cefadroxil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034373 n.a. "PMID: 30581775; PMID: 7447421" 171101 Streptococcus pneumoniae R6 PMDBD154 Cefadroxil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID PMDBM2021153 PMDBI20034378 n.a. PMDBM2020848 n.a. Listeria monocytogenes 568 PMDBD2000615 Cefalonium Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034379 n.a. PMDBM2020848 169963 Listeria monocytogenes EGD-e PMDBD2000615 Cefalonium Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034380 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2a PMDBD2000615 Cefalonium Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034381 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2b PMDBD2000615 Cefalonium Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034382 n.a. PMDBM2020177 n.a. Staphylococcus aureus Mu50 PMDBD2000615 Cefalonium Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20034383 n.a. PMDBM2010320 n.a. Streptomyces sp. R61 PMDBD2000616 Cefalotin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: D-alanyl-D-alanine carboxypeptidase n.a. PMID "PMID: 30581775; PMID: 105727" PMDBI20034385 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD2000616 Cefalotin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 7027927" PMDBI20034386 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD2000616 Cefalotin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 7027927" PMDBI20034387 n.a. PMDBM2021153 1313 Streptococcus pneumoniae Not Specified PMDBD2000616 Cefalotin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034388 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD2000616 Cefalotin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034392 n.a. "PMID: 30581775; PMID: 7447421" 171101 Streptococcus pneumoniae R6 PMDBD2000616 Cefalotin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID PMDBM2021153 PMDBI20034397 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000616 Cefalotin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Beta-lactamase n.a. PMID "PMID: 30581775; PMID: 15689162" PMDBI20034408 n.a. PMDBM2020008 817 Bacteroides fragilis Not Specified PMDBD2000617 Cefamandole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2 n.a. PMID "PMID: 30581775; PMID: 3266730" PMDBI20034409 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD2000618 Cefapirin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 808545" PMDBI20034410 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD2000618 Cefapirin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 808545" PMDBI20034415 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000619 Cefazolin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 2722720" PMDBI20034425 n.a. PMDBM2020177 n.a. Staphylococcus aureus Mu50 PMDBD2000619 Cefazolin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20034426 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD2000620 Cefditoren Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 15308278" PMDBI20034427 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD2000620 Cefditoren Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 15308278" PMDBI20034432 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD2000620 Cefditoren Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 17724158" PMDBI20034433 n.a. "PMID: 30581775; PMID: 17724158" 171101 Streptococcus pneumoniae R6 PMDBD2000620 Cefditoren Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID PMDBM2021153 PMDBI20034434 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD1085 Cefepime Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 8150771" PMDBI20034436 n.a. PMDBM2010322 n.a. Candida spp. Not Specified PMDBD1085 Cefepime Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25631674" PMDBI20034437 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000621 Cefepime Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2 n.a. PMID "PMID: 30581775; PMID: 8150771" PMDBI20034439 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2 n.a. PMID "PMID: 30581775; PMID: 16940068" PMDBI20034440 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2 n.a. PMID "PMID: 30581775; PMID: 16940068" PMDBI20034441 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2 n.a. PMID "PMID: 30581775; PMID: 16940068" PMDBI20034442 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2 n.a. PMID "PMID: 30581775; PMID: 16940068" PMDBI20034447 n.a. PMDBM2020080 n.a. Bacillus subtilis ATCC 39087 PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25038633" PMDBI20034448 n.a. PMDBM2020848 n.a. Listeria monocytogenes 568 PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034449 n.a. PMDBM2020848 169963 Listeria monocytogenes EGD-e PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034450 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2a PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034451 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2b PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034452 n.a. PMDBM2020100 n.a. Klebsiella pneumoniae ATCC 13882 PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28692914" PMDBI20034453 n.a. PMDBM2021025 n.a. Proteus mirabilis ATCC 12453 PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28692914" PMDBI20034454 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 (MRSA) PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28692914" PMDBI20034455 n.a. "PMID: 30581775; PMID: 28692914" 1257041 Streptococcus mutans ATCC 25175 PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20034456 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD2000622 Cefmenoxime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 6941742" PMDBI20034457 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD2000622 Cefmenoxime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 6941742" PMDBI20034458 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000622 Cefmenoxime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Peptidoglycan synthase FtsI n.a. PMID "PMID: 30581775; PMID: 6941742" PMDBI20034463 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000623 Cefmetazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 3898066" PMDBI20034468 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD2000623 Cefmetazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin binding protein 2a n.a. PMID "PMID: 30581775; PMID: 3915273" PMDBI20034469 n.a. PMDBM2020848 n.a. Listeria monocytogenes 568 PMDBD2000623 Cefmetazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034470 n.a. PMDBM2020848 169963 Listeria monocytogenes EGD-e PMDBD2000623 Cefmetazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034471 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2a PMDBD2000623 Cefmetazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034472 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2b PMDBD2000623 Cefmetazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034473 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000624 Cefonicid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 6376452" PMDBI20034478 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD160 Cefoperazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 6448021" PMDBI20034485 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD160 Cefoperazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1B n.a. PMID "PMID: 30581775; PMID: 6448021" PMDBI20034486 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 15692 PMDBD160 Cefoperazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 6448021" PMDBI20034487 n.a. "PMID: 30581775; PMID: 6448021" 208964 Pseudomonas aeruginosa PAO1 PMDBD160 Cefoperazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID PMDBM2020151 PMDBI20034488 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa 1C PMDBD160 Cefoperazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 6448021" PMDBI20034489 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PRS 101 PMDBD160 Cefoperazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 6448021" PMDBI20034490 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa LMG 12228 PMDBD160 Cefoperazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 6448021" PMDBI20034491 n.a. PMDBM2020008 817 Bacteroides fragilis Not Specified PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2 n.a. PMID "PMID: 30581775; PMID: 3266730" PMDBI20034493 n.a. PMDBM2020080 1423 Bacillus subtilis 168 PMDBD1087 Cefotaxime Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 6338822" PMDBI20034494 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD1087 Cefotaxime Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034498 n.a. "PMID: 30581775; PMID: 7447421" 171101 Streptococcus pneumoniae R6 PMDBD1087 Cefotaxime Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID PMDBM2021153 PMDBI20034506 n.a. PMDBM2020075 470 Acinetobacter baumannii Not Specified PMDBD1087 Cefotaxime Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Beta-lactamase n.a. PMID "PMID: 30581775; PMID: 20547808" PMDBI20034507 n.a. PMDBM2020848 n.a. Listeria monocytogenes 568 PMDBD1087 Cefotaxime Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034508 n.a. PMDBM2020848 169963 Listeria monocytogenes EGD-e PMDBD1087 Cefotaxime Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034509 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2a PMDBD1087 Cefotaxime Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034510 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2b PMDBD1087 Cefotaxime Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034511 n.a. PMDBM2021153 1313 Streptococcus pneumoniae Not Specified PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 6573313" PMDBI20034512 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD2000625 Cefotiam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 8592992" PMDBI20034513 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD2000625 Cefotiam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 8592992" PMDBI20034518 n.a. PMDBM2020848 n.a. Listeria monocytogenes 568 PMDBD2000625 Cefotiam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034519 n.a. PMDBM2020848 169963 Listeria monocytogenes EGD-e PMDBD2000625 Cefotiam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034520 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2a PMDBD2000625 Cefotiam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034521 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2b PMDBD2000625 Cefotiam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034522 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD1088 Cefoxitin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 368000" PMDBI20034529 n.a. PMDBM2021153 1313 Streptococcus pneumoniae Not Specified PMDBD1088 Cefoxitin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034530 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD1088 Cefoxitin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034534 n.a. "PMID: 30581775; PMID: 7447421" 171101 Streptococcus pneumoniae R6 PMDBD1088 Cefoxitin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID PMDBM2021153 PMDBI20034538 n.a. PMDBM2020848 n.a. Listeria monocytogenes 568 PMDBD1088 Cefoxitin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034539 n.a. PMDBM2020848 169963 Listeria monocytogenes EGD-e PMDBD1088 Cefoxitin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034540 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2a PMDBD1088 Cefoxitin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034541 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2b PMDBD1088 Cefoxitin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034542 n.a. PMDBM2020177 n.a. Staphylococcus aureus Mu50 PMDBD1088 Cefoxitin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20034543 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD2000626 Cefpiramide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin binding protein 2a n.a. PMID "PMID: 30581775; PMID: 1864279" PMDBI20034544 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000626 Cefpiramide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 3943292" PMDBI20034547 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000626 Cefpiramide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1B n.a. PMID "PMID: 30581775; PMID: 3943292" PMDBI20034548 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 15692 PMDBD2000626 Cefpiramide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 3943292" PMDBI20034549 n.a. "PMID: 30581775; PMID: 3943292" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000626 Cefpiramide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID PMDBM2020151 PMDBI20034550 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa 1C PMDBD2000626 Cefpiramide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 3943292" PMDBI20034551 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PRS 101 PMDBD2000626 Cefpiramide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 3943292" PMDBI20034552 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa LMG 12228 PMDBD2000626 Cefpiramide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 3943292" PMDBI20034572 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000627 Cefpodoxime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Peptidoglycan synthase FtsI n.a. PMID "PMID: 30581775; PMID: 12041787" PMDBI20034573 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae serotype 4 ATCC BAA-334 PMDBD1091 Cefprozil Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 11959556" PMDBI20034576 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae serotype 4 TIGR4 PMDBD1091 Cefprozil Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 11959556" PMDBI20034579 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 6413485" PMDBI20034583 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2 n.a. PMID "PMID: 30581775; PMID: 6413485" PMDBI20034585 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 15692 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: D-alanyl-D-alanine endopeptidase n.a. PMID "PMID: 30581775; PMID: 6413485" PMDBI20034586 n.a. "PMID: 30581775; PMID: 6413485" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: D-alanyl-D-alanine endopeptidase n.a. PMID PMDBM2020151 PMDBI20034587 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa 1C PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: D-alanyl-D-alanine endopeptidase n.a. PMID "PMID: 30581775; PMID: 6413485" PMDBI20034588 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PRS 101 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: D-alanyl-D-alanine endopeptidase n.a. PMID "PMID: 30581775; PMID: 6413485" PMDBI20034589 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa LMG 12228 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: D-alanyl-D-alanine endopeptidase n.a. PMID "PMID: 30581775; PMID: 6413485" PMDBI20034590 n.a. PMDBM2021153 1313 Streptococcus pneumoniae Not Specified PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 6413485" PMDBI20034591 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 6413485" PMDBI20034592 n.a. "PMID: 30581775; PMID: 6413485" 171101 Streptococcus pneumoniae R6 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID PMDBM2021153 PMDBI20034593 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia SM33 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 14693533" PMDBI20034594 n.a. PMDBM2020035 n.a. Escherichia coli ER20477 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20034595 n.a. PMDBM2020035 n.a. Escherichia coli ER14169 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20034596 n.a. PMDBM2020229 n.a. Morganella morganii ER14229 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20034597 n.a. PMDBM2020229 n.a. Morganella morganii ER89472 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20034598 n.a. PMDBM2021026 n.a. Proteus vulgaris ER35441 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20034599 n.a. PMDBM2021026 n.a. Proteus vulgaris ER50120 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20034600 n.a. PMDBM2020242 n.a. Providencia stuartii ER21870 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20034601 n.a. PMDBM2020242 n.a. Providencia stuartii ER08274 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20034602 n.a. PMDBM2021245 n.a. Burkholderia pseudomallei H777 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23785532" PMDBI20034603 n.a. PMDBM2020035 n.a. Escherichia coli E42 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25189202" PMDBI20034604 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000628 Ceftazidime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25285879" PMDBI20034606 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD2000629 Ceftazidime hydrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034607 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2000629 Ceftazidime hydrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034608 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD2000629 Ceftazidime hydrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034609 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD2000629 Ceftazidime hydrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034610 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000630 Ceftizoxime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 7018389" PMDBI20034613 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD2000630 Ceftizoxime Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: MecA PBP2' (penicillin binding protein 2') n.a. PMID "PMID: 30581775; PMID: 15716453" PMDBI20034614 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD1096 Ceftobiprole Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Peptidoglycan synthase FtsI n.a. PMID "PMID: 30581775; PMID: 17470659" PMDBI20034615 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD1096 Ceftobiprole Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: MecA n.a. PMID "PMID: 30581775; PMID: 17470659" PMDBI20034616 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae serotype 4 ATCC BAA-334 PMDBD1096 Ceftobiprole Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2x n.a. PMID "PMID: 30581775; PMID: 17470659" PMDBI20034617 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae serotype 4 TIGR4 PMDBD1096 Ceftobiprole Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2x n.a. PMID "PMID: 30581775; PMID: 17470659" PMDBI20034618 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD1097 Ceftriaxone Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 20704258" PMDBI20034619 n.a. "PMID: 30581775; PMID: 20704258" 171101 Streptococcus pneumoniae R6 PMDBD1097 Ceftriaxone Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID PMDBM2021153 PMDBI20034620 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD1098 Cefuroxime Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 7968655" PMDBI20034621 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD1098 Cefuroxime Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 7968655" PMDBI20034626 n.a. PMDBM2020848 n.a. Listeria monocytogenes 568 PMDBD1098 Cefuroxime Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034627 n.a. PMDBM2020848 169963 Listeria monocytogenes EGD-e PMDBD1098 Cefuroxime Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034628 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2a PMDBD1098 Cefuroxime Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034629 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2b PMDBD1098 Cefuroxime Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034630 n.a. PMDBM2021153 1313 Streptococcus pneumoniae Not Specified PMDBD2000631 Cephalexin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034631 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD2000631 Cephalexin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034635 n.a. "PMID: 30581775; PMID: 7447421" 171101 Streptococcus pneumoniae R6 PMDBD2000631 Cephalexin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID PMDBM2021153 PMDBI20034641 n.a. PMDBM2020080 n.a. Bacillus subtilis ATCC 39087 PMDBD2000631 Cephalexin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25038633" PMDBI20034642 n.a. PMDBM2020385 279010 Bacillus licheniformis DSM 13 PMDBD2000632 Cephaloglycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2A n.a. PMID "PMID: 30581775; PMID: 7565098" PMDBI20034643 n.a. "PMID: 30581775; PMID: 7565098" 279010 Bacillus licheniformis ATCC 14580 PMDBD2000632 Cephaloglycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2A n.a. PMID PMDBM2020385 PMDBI20034644 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000633 Cerulenin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 3-oxoacyl-[acyl-carrier-protein] synthase 3 n.a. PMID "PMID: 30581775; PMID: 791237" PMDBI20034658 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000634 Cerulenin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 3-oxoacyl-[acyl-carrier-protein] synthase 1 n.a. PMID "PMID: 30581775; PMID: 791237" PMDBI20034665 n.a. PMDBM2021248 n.a. Candida albicans BWP17 PMDBD2000635 CGP-37157 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20034666 n.a. PMDBM2021248 n.a. Candida albicans Ca-115 PMDBD2000635 CGP-37157 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20034667 n.a. PMDBM2021248 n.a. Candida albicans Ca-116 PMDBD2000635 CGP-37157 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20034668 n.a. PMDBM2021248 n.a. Candida albicans Ca-117 PMDBD2000635 CGP-37157 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20034669 n.a. PMDBM2021248 n.a. Candida albicans Ca-119 PMDBD2000635 CGP-37157 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20034670 n.a. PMDBM2021248 n.a. Candida albicans Ca-120 PMDBD2000635 CGP-37157 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20034671 n.a. PMDBM2021248 n.a. Candida albicans Ca-121 PMDBD2000635 CGP-37157 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20034672 n.a. PMDBM2021248 n.a. Candida albicans Ca-122 PMDBD2000635 CGP-37157 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20034673 n.a. PMDBM2021248 n.a. Candida albicans Ca-125 PMDBD2000635 CGP-37157 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20034674 n.a. PMDBM2021248 n.a. Candida albicans Ca-126 PMDBD2000635 CGP-37157 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20034675 n.a. PMDBM2021248 n.a. Candida albicans Ca-127 PMDBD2000635 CGP-37157 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20034676 n.a. PMDBM2021248 n.a. Candida albicans Ca-137 PMDBD2000635 CGP-37157 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20034677 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD2000636 Ch Dhvar5 ads Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25818458" PMDBI20034678 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD2000637 Ch GG Nt-Dhvar5 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25818458" PMDBI20034679 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538P PMDBD2000638 Chelerythrine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22182580" PMDBI20034680 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000638 Chelerythrine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22182580" PMDBI20034681 n.a. PMDBM2020035 n.a. Escherichia coli K-12 MG 1655 PMDBD2000639 Chitosan Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20089325" PMDBI20034682 n.a. PMDBM2020177 n.a. Staphylococcus aureus A7510 PMDBD2000639 Chitosan Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20089325" PMDBI20034683 n.a. PMDBM2021750 746128 Aspergillus fumigatus DBM 4057 PMDBD2000639 Chitosan Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27660214" PMDBI20034684 n.a. PMDBM2020035 562 Escherichia coli Not Specified PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" bacteriostatic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dr hemagglutinin structural subunit n.a. PMID "PMID: 30581775; PMID: 1670929" PMDBI20034685 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" bacteriostatic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 50S ribosomal protein L16 n.a. PMID "PMID: 30581775; PMID: 3549294" PMDBI20034688 n.a. PMDBM2020482 n.a. Campylobacter jejuni M129 PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" bacteriostatic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17259368" PMDBI20034689 n.a. PMDBM2020482 n.a. Campylobacter jejuni F38011 PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" bacteriostatic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17259368" PMDBI20034691 n.a. PMDBM2020080 n.a. Bacillus subtilis ATCC 39087 PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" bacteriostatic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25038633" PMDBI20034692 n.a. PMDBM2020183 n.a. Streptococcus mutans ATCC 10449 PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16595638" PMDBI20034693 n.a. PMDBM2020183 n.a. Streptococcus mutans LMG 14558 PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17220400" PMDBI20034694 n.a. "PMID: 30581775; PMID: 22281025" 210007 Streptococcus mutans UA159 PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20034695 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20034696 n.a. PMDBM2020177 n.a. Staphylococcus aureus RN1HG PMDBD2000640 Chlorhexidine acetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20034697 n.a. "PMID: 30581775; PMID: 25624759" 210007 Streptococcus mutans UA159 PMDBD2000640 Chlorhexidine acetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20034698 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20034699 n.a. PMDBM2020035 511145 Escherichia coli MG1655 PMDBD2000641 Chlorpromazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24176982" PMDBI20034700 n.a. "PMID: 30581775; PMID: 24176982" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000641 Chlorpromazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034701 n.a. PMDBM2020177 n.a. Staphylococcus aureus NCTC strain 8532 PMDBD2000641 Chlorpromazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24176982" PMDBI20034702 n.a. "PMID: 30581775; PMID: 24958247" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000642 Chromate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034703 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2000643 Chrysin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21930760" PMDBI20034704 n.a. PMDBM2020183 n.a. Streptococcus mutans LMG 14558 PMDBD2000644 Chrysophanol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17220400" PMDBI20034705 n.a. "PMID: 30581775; PMID: 21852522" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000644 Chrysophanol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034706 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia GIMT1.118 PMDBD2000644 Chrysophanol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21852522" PMDBI20034707 n.a. "PMID: 30581775; PMID: 22281025" 210007 Streptococcus mutans UA159 PMDBD2000645 Chrysophsin-1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20034708 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000646 Ciclopirox ethanolamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20034709 n.a. PMDBM2010341 n.a. Human herpesvirus 5 Not Specified PMDBD2000647 Cidofovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA polymerase catalytic subunit n.a. PMID "PMID: 30581775; PMID: 16048917" PMDBI20034715 n.a. PMDBM2021266 n.a. Vibrio anguillarum LMG 4411 PMDBD2000648 Cinnamaldehyde Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18793453" PMDBI20034716 n.a. PMDBM2021267 n.a. Vibrio vulnificus LMG 16867 PMDBD2000648 Cinnamaldehyde Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18793453" PMDBI20034717 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD2000648 Cinnamaldehyde Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034718 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2000648 Cinnamaldehyde Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034719 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD2000648 Cinnamaldehyde Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034720 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD2000648 Cinnamaldehyde Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034721 n.a. PMDBM2020258 n.a. Vibrio cholerae CIP 106855 PMDBD2000648 Cinnamaldehyde Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21249192" PMDBI20034722 n.a. PMDBM2021218 n.a. Vibrio harveyi BB121 PMDBD2000648 Cinnamaldehyde Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21249192" PMDBI20034723 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000649 Cinnamic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23210926" PMDBI20034724 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2000649 Cinnamic Acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27838185" PMDBI20034725 n.a. "PMID: 30581775; PMID: 26263486" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000650 Cinnamon oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034726 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD197 Cinoxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 9293187" PMDBI20034727 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD197 Cinoxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 9293187" PMDBI20034728 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD197 Cinoxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 9293187" PMDBI20034729 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD197 Cinoxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 9293187" PMDBI20034742 n.a. PMDBM2020080 1423 Bacillus subtilis 168 PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit B n.a. PMID "PMID: 30581775; PMID: 7074800" PMDBI20034743 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 7574516" PMDBI20034744 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 9056011" PMDBI20034745 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 9056011" PMDBI20034746 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 9056011" PMDBI20034747 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 9056011" PMDBI20034760 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 14623007" PMDBI20034761 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia SM33 PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 14693533" PMDBI20034762 n.a. PMDBM2020035 n.a. Escherichia coli ER20477 PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20034763 n.a. PMDBM2020035 n.a. Escherichia coli ER14169 PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20034764 n.a. PMDBM2020229 n.a. Morganella morganii ER14229 PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20034765 n.a. PMDBM2021026 n.a. Proteus vulgaris ER35441 PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20034766 n.a. PMDBM2021026 n.a. Proteus vulgaris ER50120 PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20034767 n.a. PMDBM2020242 n.a. Providencia stuartii ER08274 PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15528892" PMDBI20034772 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 16337789" PMDBI20034798 n.a. PMDBM2020035 562 Escherichia coli Not Specified PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Multidrug resistance protein MdtK n.a. PMID "PMID: 30581775; PMID: 18591276" PMDBI20034799 n.a. "PMID: 30581775; PMID: 22884365" 208964 Pseudomonas aeruginosa PAO1 PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034800 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23070152" PMDBI20034801 n.a. PMDBM2020889 1773 Mycobacterium tuberculosis Not Specified PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Gyrase A n.a. PMID "PMID: 30581775; PMID: 23275348" PMDBI20034803 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25285879" PMDBI20034805 n.a. PMDBM2020177 n.a. Staphylococcus aureus Xen 30 (MRSA) PMDBD1118 Ciprofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25853255" PMDBI20034806 n.a. PMDBM2020035 n.a. Escherichia coli 8 PMDBD2000651 Ciprofloxacin lactate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24159313" PMDBI20034807 n.a. PMDBM2020035 n.a. Escherichia coli 9 PMDBD2000651 Ciprofloxacin lactate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24159313" PMDBI20034808 n.a. PMDBM2020035 n.a. Escherichia coli 10 PMDBD2000651 Ciprofloxacin lactate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24159313" PMDBI20034809 n.a. PMDBM2020035 n.a. Escherichia coli 31 PMDBD2000651 Ciprofloxacin lactate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24159313" PMDBI20034810 n.a. PMDBM2020035 n.a. Escherichia coli 1583 PMDBD2000651 Ciprofloxacin lactate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24159313" PMDBI20034811 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD2000652 Ciprofloxacin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 9293187" PMDBI20034812 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD2000652 Ciprofloxacin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 9293187" PMDBI20034813 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD2000652 Ciprofloxacin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 9293187" PMDBI20034814 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD2000652 Ciprofloxacin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 9293187" PMDBI20034827 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000653 cis-2-dodecenoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23948468" PMDBI20034828 n.a. PMDBM2021248 n.a. Candida albicans CA546 PMDBD2000653 cis-2-dodecenoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23948468" PMDBI20034829 n.a. "PMID: 30581775; PMID: 24134835" 652611 Pseudomonas aeruginosa PA14 PMDBD2000653 cis-2-dodecenoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034830 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000654 cis-4-Hydroxy-L-proline Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20034831 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2000655 cis-Stillbene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25007234" PMDBI20034832 n.a. PMDBM2020027 n.a. Cronobacter sakazakii ATCC 29544 PMDBD2000656 Citral Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28233814" PMDBI20034833 n.a. PMDBM2020177 n.a. Staphylococcus aureus Smith diffuse (SD) PMDBD2000657 Citropin 1.1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16289474" PMDBI20034834 n.a. PMDBM2020250 623 Shigella flexneri Not Specified PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 50S ribosomal protein L10 n.a. PMID "PMID: 30581775; PMID: 8540733" PMDBI20034836 n.a. PMDBM2020888 1235988 Mycobacterium avium 101 PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15561879" PMDBI20034837 n.a. "PMID: 30581775; PMID: 15561879" 243243 Mycobacterium avium 104 PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020888 PMDBI20034838 n.a. PMDBM2020888 n.a. Mycobacterium avium 109 PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15561879" PMDBI20034839 n.a. PMDBM2020888 n.a. Mycobacterium avium A5 PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15561879" PMDBI20034843 n.a. PMDBM2020005 n.a. Bacillus cereus var. mycoides 0042 PMDBD2000658 Clary sage Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20034844 n.a. PMDBM2020035 n.a. Escherichia coli 582 PMDBD2000658 Clary sage Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20034845 n.a. PMDBM2021742 n.a. Pichia anomala 8061Mo PMDBD2000658 Clary sage Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20034846 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2000659 Clary sage oil Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20034847 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD2000660 Clavulanate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Beta-lactamase n.a. PMID "PMID: 30581775; PMID: 16127048" PMDBI20034853 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD1122 Clindamycin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 23S rRNA n.a. PMID "PMID: 30581775; PMID: 11677599" PMDBI20034854 n.a. PMDBM2020250 623 Shigella flexneri Not Specified PMDBD1122 Clindamycin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 50S ribosomal protein L10 n.a. PMID "PMID: 30581775; PMID: 11677599" PMDBI20034857 n.a. PMDBM2020620 1747 Propionibacterium acnes LMG 16711 PMDBD1122 Clindamycin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24251377" PMDBI20034858 n.a. PMDBM2020620 n.a. Propionibacterium acnes LMG 16712 PMDBD1122 Clindamycin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24251377" PMDBI20034859 n.a. PMDBM2020620 n.a. Propionibacterium acnes LMG 16715 PMDBD1122 Clindamycin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24251377" PMDBI20034860 n.a. PMDBM2020250 623 Shigella flexneri Not Specified PMDBD1122 Clindamycin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 50S ribosomal protein L10 n.a. PMID "PMID: 30581775; PMID: 11677599" PMDBI20034863 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 2368971" PMDBI20034864 n.a. PMDBM2021751 235909 Geobacillus kaustophilus HTA426 PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" antimicrobial n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Uncharacterized oxidoreductase CzcO-like n.a. PMID "PMID: 30581775; PMID: 6286358" PMDBI20034867 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD2000662 Clomocycline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 16S rRNA n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20034868 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000662 Clomocycline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S4 n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20034874 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20034875 n.a. PMDBM2020183 1309 Streptococcus mutans Not Specified PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27764679" PMDBI20034876 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa p43 PMDBD2000663 Clove oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26517484" PMDBI20034877 n.a. PMDBM2020151 1231933 Pseudomonas aeruginosa p49 PMDBD2000663 Clove oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26517484" PMDBI20034878 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa p50 PMDBD2000663 Clove oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26517484" PMDBI20034879 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa p154 PMDBD2000663 Clove oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26517484" PMDBI20034880 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa p124 PMDBD2000663 Clove oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26517484" PMDBI20034881 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa p123 PMDBD2000663 Clove oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26517484" PMDBI20034882 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa p99 PMDBD2000663 Clove oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26517484" PMDBI20034883 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa p151 PMDBD2000663 Clove oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26517484" PMDBI20034884 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa p131 PMDBD2000663 Clove oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26517484" PMDBI20034885 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa p121 PMDBD2000663 Clove oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26517484" PMDBI20034886 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa p98 PMDBD2000663 Clove oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26517484" PMDBI20034887 n.a. PMDBM2020035 511145 Escherichia coli MG1655 PMDBD2000663 Clove oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27808174" PMDBI20034888 n.a. PMDBM2020035 n.a. Escherichia coli TG1 PMDBD2000663 Clove oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27808174" PMDBI20034889 n.a. "PMID: 30581775; PMID: 28233286" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000663 Clove oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20034890 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD2000664 Cloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 6810758" PMDBI20034891 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD2000664 Cloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 6810758" PMDBI20034892 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000664 Cloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Cell division protein n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034893 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD2000664 Cloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2a n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034894 n.a. "PMID: 30581775; PMID: 7447421" 171101 Streptococcus pneumoniae R6 PMDBD2000664 Cloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2a n.a. PMID PMDBM2021153 PMDBI20034895 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae serotype 4 ATCC BAA-334 PMDBD2000664 Cloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034896 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae serotype 4 TIGR4 PMDBD2000664 Cloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034897 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000664 Cloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Beta-lactamase n.a. PMID "PMID: 30581775; PMID: 15631796" PMDBI20034906 n.a. PMDBM2020035 n.a. Escherichia coli O6:H1 ( ATCC 700928) PMDBD2000664 Cloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: D-alanyl-D-alanine carboxypeptidase DacA n.a. PMID "PMID: 30581775; PMID: 20726582" PMDBI20034907 n.a. PMDBM2020035 n.a. Escherichia coli O6:H1 (strain CFT073 / ATCC 700928 / UPEC) O6:H1 ( CFT073 ) PMDBD2000664 Cloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: D-alanyl-D-alanine carboxypeptidase DacA n.a. PMID "PMID: 30581775; PMID: 20726582" PMDBI20034908 n.a. PMDBM2020035 n.a. Escherichia coli O6:H1 (strain CFT073 / ATCC 700928 / UPEC) O6:H1 ( UPEC) PMDBD2000664 Cloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: D-alanyl-D-alanine carboxypeptidase DacA n.a. PMID "PMID: 30581775; PMID: 20726582" PMDBI20034909 n.a. PMDBM2020848 n.a. Listeria monocytogenes 568 PMDBD2000664 Cloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034910 n.a. PMDBM2020848 169963 Listeria monocytogenes EGD-e PMDBD2000664 Cloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034911 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2a PMDBD2000664 Cloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034912 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2b PMDBD2000664 Cloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20034913 n.a. PMDBM2021248 n.a. Candida albicans BWP17 PMDBD1128 Clozapine Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20034914 n.a. "PMID: 30581775; PMID: 24958247" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000665 Cobalt Ion Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034915 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000666 Coladonin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20034916 n.a. PMDBM2020889 1773 Mycobacterium tuberculosis Not Specified PMDBD2000667 Colistin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28162983" PMDBI20034917 n.a. PMDBM2020035 n.a. Escherichia coli 8 PMDBD2000668 Colistin sodium methanesulfonate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24159313" PMDBI20034918 n.a. PMDBM2020035 n.a. Escherichia coli 9 PMDBD2000668 Colistin sodium methanesulfonate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24159313" PMDBI20034919 n.a. PMDBM2020035 n.a. Escherichia coli 10 PMDBD2000668 Colistin sodium methanesulfonate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24159313" PMDBI20034920 n.a. PMDBM2020035 n.a. Escherichia coli 31 PMDBD2000668 Colistin sodium methanesulfonate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24159313" PMDBI20034921 n.a. PMDBM2020035 n.a. Escherichia coli 1583 PMDBD2000668 Colistin sodium methanesulfonate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24159313" PMDBI20034922 n.a. PMDBM2020177 n.a. Staphylococcus aureus MTCC3160 PMDBD2000669 Colostrum Hexasaccharide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25645850" PMDBI20034923 n.a. PMDBM2021248 n.a. Candida albicans SBC156 PMDBD2000670 Competence Stimulating Peptide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25505189" PMDBI20034924 n.a. PMDBM2010366 n.a. Streptomyces gordonii DL1 PMDBD2000670 Competence Stimulating Peptide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25505189" PMDBI20034925 n.a. PMDBM2020472 n.a. Burkholderia cepacia ATCC 17759 PMDBD2000671 Copper sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20034926 n.a. PMDBM2020035 n.a. Escherichia coli ATCC 25312 PMDBD2000671 Copper sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20034927 n.a. PMDBM2020797 378753 Kocuria rhizophila ATCC 9341 PMDBD2000671 Copper sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20034928 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 9027 PMDBD2000671 Copper sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20034929 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2000671 Copper sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20034930 n.a. "PMID: 30581775; PMID: 28756196" 176280 Staphylococcus epidermidis ATCC 12228 PMDBD2000671 Copper sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020178 PMDBI20034931 n.a. "PMID: 30581775; PMID: 27696655" 652611 Pseudomonas aeruginosa PA14 PMDBD2000672 Coprinuslactone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034932 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000673 Coumarin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20034933 n.a. PMDBM2020212 636 Edwardsiella tarda Not Specified PMDBD2000673 Coumarin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25672848" PMDBI20034934 n.a. PMDBM2020035 n.a. Escherichia coli MUH76317 PMDBD2000673 Coumarin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25672848" PMDBI20034935 n.a. "PMID: 30581775; PMID: 25672848" 652611 Pseudomonas aeruginosa PA14 PMDBD2000673 Coumarin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034936 n.a. PMDBM2020177 n.a. Staphylococcus aureus NCDO949 PMDBD2000673 Coumarin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25672848" PMDBI20034937 n.a. PMDBM2021266 55601 Vibrio anguillarum Not Specified PMDBD2000673 Coumarin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25672848" PMDBI20034938 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000674 Coumarin-3-carboxylic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20034939 n.a. "PMID: 30581775; PMID: 23791670" 431947 Porphyromonas gingivalis ATCC 33277 PMDBD2000675 cov-GK7-NH2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020236 PMDBI20034940 n.a. "PMID: 30581775; PMID: 23791670" 431947 Porphyromonas gingivalis ATCC 33277 PMDBD2000676 cov-GL13K Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020236 PMDBI20034941 n.a. "PMID: 30581775; PMID: 18591225" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000677 CRAMP Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034942 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 9027 PMDBD2000678 Crocin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26370951" PMDBI20034943 n.a. PMDBM2021143 n.a. Streptococcus gordonii Challis (DL1) PMDBD2000679 CSP Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17060534" PMDBI20034944 n.a. "PMID: 30581775; PMID: 17060534" 210007 Streptococcus mutans UA159 PMDBD2000679 CSP Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20034945 n.a. PMDBM2020184 n.a. Streptococcus sanguinis NY101 PMDBD2000679 CSP Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17060534" PMDBI20034946 n.a. PMDBM2021143 n.a. Streptococcus gordonii Challis (DL1) PMDBD2000680 CSP-C16 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17060534" PMDBI20034947 n.a. "PMID: 30581775; PMID: 17060534" 210007 Streptococcus mutans UA159 PMDBD2000680 CSP-C16 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20034948 n.a. PMDBM2020184 n.a. Streptococcus sanguinis NY101 PMDBD2000680 CSP-C16 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17060534" PMDBI20034949 n.a. "PMID: 30581775; PMID: 18284200" 208964 Pseudomonas aeruginosa PAO1 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034950 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034951 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034952 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034953 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20034954 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21930760" PMDBI20034955 n.a. PMDBM2021218 n.a. Vibrio harveyi MTCC 3438 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23354447" PMDBI20034956 n.a. PMDBM2021220 n.a. Vibrio parahaemolyticus ATCC 17802 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23354447" PMDBI20034957 n.a. PMDBM2021267 n.a. Vibrio vulnificus MTCC 1145 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23354447" PMDBI20034958 n.a. "PMID: 30581775; PMID: 23778072" 210007 Streptococcus mutans UA159 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20034959 n.a. PMDBM2020035 n.a. Escherichia coli ATCC 10536 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24262582" PMDBI20034960 n.a. PMDBM2021025 n.a. Proteus mirabilis ATCC 7002 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24262582" PMDBI20034962 n.a. PMDBM2020219 n.a. Serratia marcescens FJ584421 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24262582" PMDBI20034963 n.a. PMDBM2020261 n.a. Aeromonas hydrophila NA1 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20034964 n.a. PMDBM2020261 n.a. Aeromonas hydrophila LBA2 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20034965 n.a. PMDBM2020520 n.a. Citrobacter freundii R2A5 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20034966 n.a. PMDBM2020214 n.a. Enterobacter cancerogenus LBA4 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20034967 n.a. PMDBM2010380 n.a. Enterobacter ludwigi SWA1 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20034968 n.a. PMDBM2020791 n.a. Klebsiella variicola SWA2 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20034969 n.a. PMDBM2020153 n.a. Pseudomonas japonica TSA3 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20034970 n.a. PMDBM2021050 n.a. Raoultella ornithinolytica TSA7 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20034971 n.a. PMDBM2020219 n.a. Serratia marcescens SWA6 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20034972 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa P5d PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27108548" PMDBI20034974 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28473808" PMDBI20034975 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000681 CWR11 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23758173" PMDBI20034976 n.a. PMDBM2020100 n.a. Klebsiella pneumoniae PUFST23 PMDBD2000682 Cyanidin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27162376" PMDBI20034977 n.a. "PMID: 30581775; PMID: 27539815" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000682 Cyanidin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20034978 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD2000683 Cyclacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin binding protein 2a n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034979 n.a. PMDBM2021153 1313 Streptococcus pneumoniae Not Specified PMDBD2000683 Cyclacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034980 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD2000683 Cyclacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20034981 n.a. "PMID: 30581775; PMID: 7447421" 171101 Streptococcus pneumoniae R6 PMDBD2000683 Cyclacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID PMDBM2021153 PMDBI20034982 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD2000683 Cyclacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20034983 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD2000683 Cyclacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20034986 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAO1 (ATCC 27853) PMDBD2000684 cyclo(Trp-Ser) Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28000767" PMDBI20034987 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000685 Cyclobutanamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25537269" PMDBI20034988 n.a. PMDBM2010388 n.a. Firmicutes Not Specified PMDBD237 cyclophosphamide Therapeutic Substance lymphoma and leukemia n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24264990" PMDBI20034989 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000686 Cycloserine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: D-alanine--D-alanine ligase A n.a. PMID "PMID: 30581775; PMID: 11073937" PMDBI20034991 n.a. PMDBM2020888 1764 Mycobacterium avium Not Specified PMDBD2000686 Cycloserine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Alanine racemase n.a. PMID "PMID: 30581775; PMID: 12499203" PMDBI20035000 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000687 Cycloserine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: D-alanine--D-alanine ligase A n.a. PMID "PMID: 30581775; PMID: 11073937" PMDBI20035002 n.a. PMDBM2020888 1764 Mycobacterium avium Not Specified PMDBD2000687 Cycloserine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Alanine racemase n.a. PMID "PMID: 30581775; PMID: 12499203" PMDBI20035011 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 9027 PMDBD2000688 Cynarin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26370951" PMDBI20035012 n.a. "PMID: 30581775; PMID: 25761937" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000689 D, L- K6L9 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035013 n.a. PMDBM2020177 n.a. Staphylococcus aureus N315 (MRSA) PMDBD2000690 D/L-Aspartate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20035014 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000691 D-2-aminoadipic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035015 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000691 D-2-aminoadipic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035016 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000692 D-2-Methylphenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035017 n.a. PMDBM2010391 n.a. Hepatitis C Virus Not Specified PMDBD2000693 Daclatasvir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Nonstructural Protein 5A (NS5A) n.a. PMID "PMID: 30581775; PMID: 23896281" PMDBI20035018 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" a weakly estrogenic compound with potential health n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21930760" PMDBI20035019 n.a. PMDBM2021752 29387 Staphylococcus epidermis Not Specified PMDBD2000694 D-Alanine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25001104" PMDBI20035020 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD1137 Dalbavancin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27896496" PMDBI20035021 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis MRSE PMDBD1137 Dalbavancin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27896496" PMDBI20035022 n.a. PMDBM2020033 1352 Enterococcus faecium Not Specified PMDBD2000695 Dalfopristin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Streptogramin A acetyltransferase n.a. PMID "PMID: 30581775; PMID: 20428664" PMDBI20035023 n.a. PMDBM2020183 n.a. Streptococcus mutans LMG 14558 PMDBD2000696 Danthron Therapeutic Substance Withdrawn from market n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17220400" PMDBI20035024 n.a. PMDBM2021753 272631 Mycobacterium leprae TN PMDBD1139 Dapsone Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Inactive dihydropteroate synthase 2 n.a. PMID "PMID: 30581775; PMID: 10439322" PMDBI20035031 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 PMDBD2000697 Daptomycin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23070152" PMDBI20035032 n.a. PMDBM2020177 n.a. Staphylococcus aureus Strain Smith diffuse PMDBD2000697 Daptomycin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23262356" PMDBI20035033 n.a. PMDBM2020177 n.a. Staphylococcus aureus Mu50 PMDBD2000697 Daptomycin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20035034 n.a. PMDBM2010236 n.a. Human immunodeficiency virus Not Specified PMDBD1141 Darunavir Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: HIV-1 protease n.a. PMID "PMID: 30581775; PMID: 15917527" PMDBI20035040 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD2000698 DASamP1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22445495" PMDBI20035041 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000699 D-Asparagine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035042 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000699 D-Asparagine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035043 n.a. PMDBM2020177 n.a. Staphylococcus aureus N315 (MRSA) PMDBD2000700 D-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20035044 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000701 D-Aspartic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035045 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000701 D-Aspartic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035046 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000702 D-Citrulline Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035047 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000702 D-Citrulline Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035048 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000703 D-Cystine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035049 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000703 D-Cystine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035050 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000703 D-Cystine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035051 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD2000704 DD13 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15215107" PMDBI20035052 n.a. PMDBM2021022 1977903 Propionibacterium acnes Not Specified PMDBD2000705 Decanediol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27188522" PMDBI20035053 n.a. "PMID: 30581775; PMID: 24944053" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000706 Decyl beta-maltoside Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035054 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD2000707 Delavirdine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Reverse transcriptase/RNaseH n.a. PMID "PMID: 30581775; PMID: 8815692" PMDBI20035058 n.a. "PMID: 30581775; PMID: 27539815" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000708 Delphinidin Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035059 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD1145 Demeclocycline Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S4 n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20035063 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000709 den-SB056 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26614437" PMDBI20035064 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000709 den-SB056 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26614437" PMDBI20035065 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000710 den-SB056-1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26614437" PMDBI20035066 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000710 den-SB056-1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26614437" PMDBI20035067 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000711 Dephnetin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20035068 n.a. PMDBM2021754 224324 Aquifex aeolicus VF5 PMDBD1148 Desipramine Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Transporter n.a. PMID "PMID: 30581775; PMID: 10592235" PMDBI20035069 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD2000712 Dezocine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 1361946" PMDBI20035070 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD2000712 Dezocine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 1361946" PMDBI20035071 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD2000712 Dezocine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 1361946" PMDBI20035072 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD2000712 Dezocine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 1361946" PMDBI20035109 n.a. PMDBM2021248 n.a. Candida albicans CA02045 PMDBD2000713 dF17-6K Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16524895" PMDBI20035110 n.a. PMDBM2021739 n.a. Candida tropicalis CT72241607 PMDBD2000713 dF17-6K Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16524895" PMDBI20035111 n.a. PMDBM2021248 n.a. Candida albicans CA02045 PMDBD2000714 dF21-10K Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16524895" PMDBI20035112 n.a. PMDBM2021739 n.a. Candida tropicalis CT72241607 PMDBD2000714 dF21-10K Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16524895" PMDBI20035113 n.a. "PMID: 30581775; PMID: 25246957" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000715 D-galactose cluster Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035114 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000716 D-glutamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035115 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000716 D-glutamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035116 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000717 D-Histidine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035117 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000717 D-Histidine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035118 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD1154 Diazepam Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26241210" PMDBI20035119 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD1154 Diazepam Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26241210" PMDBI20035120 n.a. "PMID: 30581775; PMID: 22715388" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000718 Dibenzyl disulphide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035121 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000718 Dibenzyl disulphide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20035122 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000718 Dibenzyl disulphide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20035123 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000718 Dibenzyl disulphide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20035124 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000719 Dibenzyl sulphide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20035125 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000719 Dibenzyl sulphide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20035126 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000719 Dibenzyl sulphide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20035127 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD2000720 Dichloromethane Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26004723" PMDBI20035128 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2000721 Dicinnamyl Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25007234" PMDBI20035129 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000722 Diclofenac sodium Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27328521" PMDBI20035130 n.a. PMDBM2020848 n.a. Listeria monocytogenes serotype 4a HCC23 PMDBD2000723 Dicloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 (Pbp 3) (Pspb20) n.a. PMID "PMID: 30581775; PMID: 2115510" PMDBI20035132 n.a. PMDBM2021153 1313 Streptococcus pneumoniae Not Specified PMDBD2000723 Dicloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20035133 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD2000723 Dicloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20035137 n.a. "PMID: 30581775; PMID: 7447421" 171101 Streptococcus pneumoniae R6 PMDBD2000723 Dicloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID PMDBM2021153 PMDBI20035141 n.a. PMDBM2020848 n.a. Listeria monocytogenes 568 PMDBD2000723 Dicloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20035142 n.a. PMDBM2020848 169963 Listeria monocytogenes EGD-e PMDBD2000723 Dicloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20035143 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2a PMDBD2000723 Dicloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20035144 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2b PMDBD2000723 Dicloxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20035145 n.a. PMDBM2021245 28450 Burkholderia pseudomallei KHW PMDBD2000724 Dicyclohexylamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20035006" PMDBI20035146 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD2000725 Didanosine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Reverse transcriptase/RNaseH n.a. PMID "PMID: 30581775; PMID: 1379914" PMDBI20035150 n.a. PMDBM2020213 84112 Eggerthella lenta Not Specified PMDBD276 digoxin "Therapeutic Substance; Herbal Substance" cardiac glycoside n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 2759492" PMDBI20035152 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538P PMDBD2000726 DiHydroxyBenzoFuran Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22182580" PMDBI20035153 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000726 DiHydroxyBenzoFuran Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22182580" PMDBI20035154 n.a. PMDBM2021137 539 Eikenella corrodens 1073 PMDBD2000727 Dihydroxybenzoic Acid (2,3-DHBA) Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21150103" PMDBI20035155 n.a. PMDBM2021137 539 Eikenella corrodens 1073 PMDBD2000728 Dihydroxybenzoic Acid (2,4-DHBA) Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21150103" PMDBI20035156 n.a. PMDBM2021137 539 Eikenella corrodens 1073 PMDBD2000729 Dihydroxybenzoic Acid (3,4-DHBA) Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21150103" PMDBI20035157 n.a. "PMID: 30581775; PMID: 26149536" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000730 Di-MB-LF11-215 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035158 n.a. "PMID: 30581775; PMID: 26149536" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000731 Di-MB-LF11-322 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035159 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PDO100 PMDBD2000732 Dimethyl Sulfoxide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27645245" PMDBI20035160 n.a. "PMID: 30581775; PMID: 27645245" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000732 Dimethyl Sulfoxide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035161 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2000733 Diphenyl diselenide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25189816" PMDBI20035162 n.a. "PMID: 30581775; PMID: 22715388" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000734 Diphenyl disulphide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035163 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000734 Diphenyl disulphide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20035164 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000734 Diphenyl disulphide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20035165 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000734 Diphenyl disulphide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20035166 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2000735 Diphenyl methane Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25007234" PMDBI20035167 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 23S rRNA n.a. PMID "PMID: 30581775; PMID: 8478301" PMDBI20035172 n.a. PMDBM2020075 470 Acinetobacter baumannii Not Specified PMDBD2000736 DispersinB-KSL-W wound gel Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24445333" PMDBI20035173 n.a. PMDBM2010403 n.a. Coagulase- negative staphylococci CoNS PMDBD2000736 DispersinB-KSL-W wound gel Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24445333" PMDBI20035174 n.a. PMDBM2020100 573 Klebsiella pneumoniae Not Specified PMDBD2000736 DispersinB-KSL-W wound gel Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24445333" PMDBI20035175 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD2000736 DispersinB-KSL-W wound gel Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24445333" PMDBI20035176 n.a. PMDBM2020178 1282 Staphylococcus epidermidis Not Specified PMDBD2000736 DispersinB-KSL-W wound gel Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24445333" PMDBI20035177 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAO1 (ATCC 27853) PMDBD2000737 Diterpene phytol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25103916" PMDBI20035178 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000738 Djenkolic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20035179 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000738 Djenkolic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20035180 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000738 Djenkolic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20035181 n.a. PMDBM2020075 n.a. Acinetobacter baumannii SENTRY C8 PMDBD2000739 DJK5 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25699603" PMDBI20035182 n.a. PMDBM2020035 1045010 Escherichia coli O157 PMDBD2000739 DJK5 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25699603" PMDBI20035183 n.a. PMDBM2020100 n.a. Klebsiella pneumoniae ATTC 13883 PMDBD2000739 DJK5 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25699603" PMDBI20035184 n.a. "PMID: 30581775; PMID: 25699603" 652611 Pseudomonas aeruginosa PA14 PMDBD2000739 DJK5 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035185 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium isolate 14028S PMDBD2000739 DJK5 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25699603" PMDBI20035186 n.a. PMDBM2020075 n.a. Acinetobacter baumannii SENTRY C8 PMDBD2000740 DJK6 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25699603" PMDBI20035187 n.a. PMDBM2020035 1045010 Escherichia coli O157 PMDBD2000740 DJK6 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25699603" PMDBI20035188 n.a. PMDBM2020100 n.a. Klebsiella pneumoniae ATTC 13883 PMDBD2000740 DJK6 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25699603" PMDBI20035189 n.a. "PMID: 30581775; PMID: 25699603" 652611 Pseudomonas aeruginosa PA14 PMDBD2000740 DJK6 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035190 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium isolate 14028S PMDBD2000740 DJK6 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25699603" PMDBI20035191 n.a. PMDBM2021752 29387 Staphylococcus epidermis Not Specified PMDBD2000741 D-Leucine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25001104" PMDBI20035192 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD2000742 D-LL-37 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21605457" PMDBI20035193 n.a. PMDBM2021755 271848 Burkholderia thailandensis E264 PMDBD2000742 D-LL-37 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26196513" PMDBI20035194 n.a. PMDBM2021752 29387 Staphylococcus epidermis Not Specified PMDBD2000743 D-Methionine Therapeutic Substance Phase 3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25001104" PMDBI20035195 n.a. "PMID: 30581775; PMID: 24944053" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000744 Dodecyl beta-maltoside Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035196 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD2000745 Dolutegravir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Integrase n.a. PMID "PMID: 30581775; PMID: 21719464" PMDBI20035202 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000746 Doripenem Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 2528587" PMDBI20035203 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000746 Doripenem Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 19243706" PMDBI20035206 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000746 Doripenem Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Cell division protein n.a. PMID "PMID: 30581775; PMID: 19243706" PMDBI20035207 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD2000746 Doripenem Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 4 n.a. PMID "PMID: 30581775; PMID: 19485791" PMDBI20035208 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD1170 Doxycycline Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 16S rRNA n.a. PMID "PMID: 30581775; PMID: 9661007" PMDBI20035211 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD1170 Doxycycline Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S4 n.a. PMID "PMID: 30581775; PMID: 20592239" PMDBI20035213 n.a. "PMID: 30581775; PMID: 23299903" 208964 Pseudomonas aeruginosa PAO1 PMDBD1170 Doxycycline Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035214 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAF-79 PMDBD1170 Doxycycline Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23299903" PMDBI20035215 n.a. PMDBM2021752 29387 Staphylococcus epidermis Not Specified PMDBD2000747 D-Phenylalanine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25001104" PMDBI20035216 n.a. PMDBM2021756 53249 Pseudoalteromonas sp. SC2014 PMDBD2000747 D-Phenylalanine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27664053" PMDBI20035217 n.a. PMDBM2021752 29387 Staphylococcus epidermis Not Specified PMDBD2000748 D-Proline Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25001104" PMDBI20035218 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000749 D-tert-Leucine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035219 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000749 D-tert-Leucine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035220 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000750 D-Tryptophan Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035221 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000750 D-Tryptophan Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035222 n.a. PMDBM2021752 29387 Staphylococcus epidermis Not Specified PMDBD2000751 D-Tyrosine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25001104" PMDBI20035223 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATTC 12228 PMDBD2000751 D-Tyrosine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035224 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000751 D-Tyrosine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035225 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000751 D-Tyrosine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035226 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000751 D-Tyrosine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035227 n.a. PMDBM2020183 1309 Streptococcus mutans Not Specified PMDBD2000752 Econazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27764679" PMDBI20035228 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20035229 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Reverse transcriptase/RNaseH n.a. PMID "PMID: 30581775; PMID: 9878993" PMDBI20035233 n.a. PMDBM2020177 n.a. Staphylococcus aureus RN1HG PMDBD2000753 Elemental silver Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20035234 n.a. PMDBM2020177 n.a. Staphylococcus aureus UAMS-1 PMDBD299 Ellagic Acid "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22242149" PMDBI20035235 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD299 Ellagic Acid "Therapeutic Substance; Herbal Substance" compound n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20035236 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2000754 Elliptophenone A Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20035237 n.a. PMDBM2020177 n.a. Staphylococcus aureus L32 (MRSA) PMDBD2000754 Elliptophenone A Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20035238 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000754 Elliptophenone A Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20035239 n.a. PMDBM2020183 n.a. Streptococcus mutans LMG 14558 PMDBD2000755 Emodin Therapeutic Substance Terminated n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17220400" PMDBI20035240 n.a. "PMID: 30581775; PMID: 21852522" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000755 Emodin Therapeutic Substance Terminated n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035241 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia GIMT1.118 PMDBD2000755 Emodin Therapeutic Substance Terminated n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21852522" PMDBI20035242 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD1172 Emtricitabine Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Reverse transcriptase/RNaseH n.a. PMID "PMID: 30581775; PMID: 14609348" PMDBI20035252 n.a. PMDBM2020080 n.a. Bacillus subtilis ATCC 39087 PMDBD1174 Enalapril Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25038633" PMDBI20035253 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD2000756 Enfuvirtide Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Envelope glycoprotein n.a. PMID "PMID: 30581775; PMID: 16160172" PMDBI20035258 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 2834313" PMDBI20035259 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 2834313" PMDBI20035260 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 2834313" PMDBI20035261 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 2834313" PMDBI20035302 n.a. "PMID: 30581775; PMID: 18330563" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000757 Ephedrine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035303 n.a. PMDBM2021137 539 Eikenella corrodens 1073 PMDBD308 Epicatechin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21150103" PMDBI20035304 n.a. PMDBM2021137 539 Eikenella corrodens 1073 PMDBD2000758 Epicatechin gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21150103" PMDBI20035305 n.a. PMDBM2021248 5476 Candida albicans Not Specified PMDBD2000759 Epicatechin-3-gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19898545" PMDBI20035306 n.a. PMDBM2021248 5476 Candida albicans Not Specified PMDBD2000760 Epigallocatechin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19898545" PMDBI20035307 n.a. PMDBM2021137 539 Eikenella corrodens 1073 PMDBD2000760 Epigallocatechin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21150103" PMDBI20035308 n.a. PMDBM2020177 n.a. Staphylococcus aureus 815 CT PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035309 n.a. PMDBM2020177 n.a. Staphylococcus aureus 810 CT PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035310 n.a. PMDBM2020177 n.a. Staphylococcus aureus 5ME PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035311 n.a. PMDBM2020177 n.a. Staphylococcus aureus CZ 11 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035312 n.a. PMDBM2020177 n.a. Staphylococcus aureus 74CCH PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035313 n.a. PMDBM2020177 n.a. Staphylococcus aureus 6ME PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035314 n.a. PMDBM2020177 n.a. Staphylococcus aureus 808CT PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035315 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035316 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 813 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035317 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 14ME PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035318 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 807CT PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035319 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 23S PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035320 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 10NC PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035321 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 809 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035322 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 20ME PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035323 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 15NC PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035324 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 21ME PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035325 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 26ME PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035326 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 9NC PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035327 n.a. "PMID: 30581775; PMID: 16189116" 176280 Staphylococcus epidermidis ATCC 12228 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020178 PMDBI20035328 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 7753 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035329 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 7777 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16189116" PMDBI20035330 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035331 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035332 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035333 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035334 n.a. PMDBM2021248 5476 Candida albicans Not Specified PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19898545" PMDBI20035335 n.a. PMDBM2021137 539 Eikenella corrodens 1073 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21150103" PMDBI20035336 n.a. PMDBM2021137 n.a. Eikenella corrodens 1073 é“»æ”uxS PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21150103" PMDBI20035337 n.a. "PMID: 30581775; PMID: 22169220" 210007 Streptococcus mutans UA159 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20035338 n.a. PMDBM2020261 n.a. Aeromonas hydrophila NA1 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20035339 n.a. PMDBM2020261 n.a. Aeromonas hydrophila LBA2 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20035340 n.a. PMDBM2020520 n.a. Citrobacter freundii R2A5 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20035341 n.a. PMDBM2020214 n.a. Enterobacter cancerogenus LBA4 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20035342 n.a. PMDBM2010380 n.a. Enterobacter ludwigi SWA1 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20035343 n.a. PMDBM2020791 n.a. Klebsiella variicola SWA2 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20035344 n.a. PMDBM2020153 n.a. Pseudomonas japonica TSA3 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20035345 n.a. PMDBM2021050 n.a. Raoultella ornithinolytica TSA7 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20035346 n.a. PMDBM2020219 n.a. Serratia marcescens SWA6 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26139614" PMDBI20035347 n.a. "PMID: 30581775; PMID: 28402019" 373153 Streptococcus pneumoniae D39 PMDBD2000761 Epigallocatechin Gallate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2021153 PMDBI20035348 n.a. PMDBM2020035 n.a. Escherichia coli K-12 MG 1655 PMDBD2000762 epsilon-Polylysine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20089325" PMDBI20035349 n.a. PMDBM2020177 n.a. Staphylococcus aureus A7510 PMDBD2000762 epsilon-Polylysine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20089325" PMDBI20035350 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2000763 epsilon-viniferin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23819562" PMDBI20035351 n.a. "PMID: 30581775; PMID: 23819562" 652611 Pseudomonas aeruginosa PA14 PMDBD2000763 epsilon-viniferin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035352 n.a. "PMID: 30581775; PMID: 23819562" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000763 epsilon-viniferin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035353 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD1179 Ertapenem Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 10223931" PMDBI20035359 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD1179 Ertapenem Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2 n.a. PMID "PMID: 30581775; PMID: 10223931" PMDBI20035361 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD1179 Ertapenem Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2 n.a. PMID "PMID: 30581775; PMID: 10223931" PMDBI20035363 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD1179 Ertapenem Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2 n.a. PMID "PMID: 30581775; PMID: 10223931" PMDBI20035365 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD1179 Ertapenem Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2 n.a. PMID "PMID: 30581775; PMID: 10223931" PMDBI20035387 n.a. "PMID: 30581775; PMID: 26363499" 210007 Streptococcus mutans UA159 PMDBD2000764 Erythritol Therapeutic Substance Phase 2/3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20035388 n.a. PMDBM2010245 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 23S rRNA n.a. PMID "PMID: 30581775; PMID: 3122849" PMDBI20035392 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 50S ribosomal protein L22 n.a. PMID "PMID: 30581775; PMID: 12225755" PMDBI20035403 n.a. PMDBM2020620 1747 Propionibacterium acnes LMG 16711 PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24251377" PMDBI20035404 n.a. PMDBM2020620 n.a. Propionibacterium acnes LMG 16712 PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24251377" PMDBI20035405 n.a. PMDBM2020620 n.a. Propionibacterium acnes LMG 16715 PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24251377" PMDBI20035406 n.a. "PMID: 30581775; PMID: 23503622" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000765 Esculentin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035407 n.a. "PMID: 30581775; PMID: 18330563" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000766 Esculetin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035408 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD2000766 Esculetin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035409 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2000766 Esculetin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035410 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD2000766 Esculetin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035411 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD2000766 Esculetin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035412 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000766 Esculetin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20035413 n.a. "PMID: 30581775; PMID: 18330563" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000767 Esculin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035414 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD2000768 Esculin hydrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035415 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2000768 Esculin hydrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035416 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD2000768 Esculin hydrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035417 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD2000768 Esculin hydrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035418 n.a. PMDBM2020080 n.a. Bacillus subtilis ATCC 39087 PMDBD2000769 Esomeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25038633" PMDBI20035419 n.a. PMDBM2020889 1773 Mycobacterium tuberculosis Not Specified PMDBD2000770 Ethambutol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Probable arabinosyltransferase B n.a. PMID "PMID: 30581775; PMID: 11854934" PMDBI20035437 n.a. PMDBM2020219 n.a. Serratia marcescens ATCC 27117 PMDBD2000771 Ethane-1,2-diamine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28350449" PMDBI20035438 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD2000772 Ethyl acetate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26004723" PMDBI20035439 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000773 Ethyl gallate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 2401679" PMDBI20035440 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000773 Ethyl gallate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20035441 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000773 Ethyl gallate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20035442 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000773 Ethyl gallate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20035443 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000773 Ethyl gallate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20035444 n.a. PMDBM2020177 n.a. Staphylococcus aureus 007/FV (MRSA) PMDBD2000774 Ethylene glycol tetraacetic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23712617" PMDBI20035445 n.a. PMDBM2020177 n.a. Staphylococcus aureus 011/LP (MRSA) PMDBD2000774 Ethylene glycol tetraacetic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23712617" PMDBI20035446 n.a. PMDBM2020177 n.a. Staphylococcus aureus 028/FV (MRSA) PMDBD2000774 Ethylene glycol tetraacetic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23712617" PMDBI20035447 n.a. PMDBM2020177 n.a. Staphylococcus aureus 5668/B PMDBD2000774 Ethylene glycol tetraacetic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23712617" PMDBI20035448 n.a. PMDBM2020177 n.a. Staphylococcus aureus 5741/B PMDBD2000774 Ethylene glycol tetraacetic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23712617" PMDBI20035449 n.a. PMDBM2020177 n.a. Staphylococcus aureus 1532/SW PMDBD2000774 Ethylene glycol tetraacetic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23712617" PMDBI20035450 n.a. PMDBM2020177 n.a. Staphylococcus aureus 1620/SW PMDBD2000774 Ethylene glycol tetraacetic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23712617" PMDBI20035451 n.a. PMDBM2020080 1423 Bacillus subtilis Not Specified PMDBD2000775 Ethylenediametetraacetic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18787817" PMDBI20035452 n.a. PMDBM2020848 n.a. Listeria monocytogenes LM13 PMDBD2000775 Ethylenediametetraacetic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22029913" PMDBI20035453 n.a. PMDBM2020848 n.a. Listeria monocytogenes LM14 PMDBD2000775 Ethylenediametetraacetic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22029913" PMDBI20035454 n.a. PMDBM2020848 n.a. Listeria monocytogenes LM15 PMDBD2000775 Ethylenediametetraacetic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22029913" PMDBI20035455 n.a. PMDBM2020848 n.a. Listeria monocytogenes LM19 PMDBD2000775 Ethylenediametetraacetic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22029913" PMDBI20035456 n.a. PMDBM2020848 n.a. Listeria monocytogenes LM21 PMDBD2000775 Ethylenediametetraacetic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22029913" PMDBI20035457 n.a. PMDBM2020848 n.a. Listeria monocytogenes LM22 PMDBD2000775 Ethylenediametetraacetic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22029913" PMDBI20035458 n.a. PMDBM2020848 n.a. Listeria monocytogenes LM31 PMDBD2000775 Ethylenediametetraacetic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22029913" PMDBI20035459 n.a. PMDBM2020848 n.a. Listeria monocytogenes LM32 PMDBD2000775 Ethylenediametetraacetic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22029913" PMDBI20035460 n.a. PMDBM2021757 n.a. Halomonas pacifica ATCC 27122 PMDBD2000775 Ethylenediametetraacetic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24166155" PMDBI20035461 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000776 Eucarobustol E Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28584159" PMDBI20035462 n.a. "PMID: 30581775; PMID: 23264268" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000777 Eugenol Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035463 n.a. PMDBM2020177 n.a. Staphylococcus aureus MSSA ATCCb 29213 PMDBD2000777 Eugenol Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25781975" PMDBI20035464 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA CCARMa3969 PMDBD2000777 Eugenol Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25781975" PMDBI20035465 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA CCARM 3912 PMDBD2000777 Eugenol Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25781975" PMDBI20035466 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA CCARM 3903 PMDBD2000777 Eugenol Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25781975" PMDBI20035467 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA CCARM 3807 PMDBD2000777 Eugenol Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25781975" PMDBI20035468 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA CCARM 3108 PMDBD2000777 Eugenol Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25781975" PMDBI20035469 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (Wound) PMDBD2000777 Eugenol Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25781975" PMDBI20035470 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (Nasal cavity) PMDBD2000777 Eugenol Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25781975" PMDBI20035471 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (catheter) PMDBD2000777 Eugenol Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25781975" PMDBI20035472 n.a. PMDBM2020177 n.a. Staphylococcus aureus MSSA (Blood) PMDBD2000777 Eugenol Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25781975" PMDBI20035473 n.a. PMDBM2020177 n.a. Staphylococcus aureus MSSA (Pus) PMDBD2000777 Eugenol Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25781975" PMDBI20035474 n.a. PMDBM2020177 n.a. Staphylococcus aureus MSSA (Ear discharge) PMDBD2000777 Eugenol Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25781975" PMDBI20035475 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA (Urine) PMDBD2000777 Eugenol Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25781975" PMDBI20035476 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000777 Eugenol Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27808174" PMDBI20035477 n.a. "PMID: 30581775; PMID: 27808174" 679895 Escherichia coli BW25113 PMDBD2000777 Eugenol Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020035 PMDBI20035478 n.a. PMDBM2020035 511145 Escherichia coli MG1655 PMDBD2000777 Eugenol Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27808174" PMDBI20035479 n.a. PMDBM2020482 197 Campylobacter jejuni NCTC 11168 PMDBD2000778 Evodiamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27230628" PMDBI20035480 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis BM185 PMDBD2000779 F2,5,12W Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21376541" PMDBI20035481 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis BM492 PMDBD2000779 F2,5,12W Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21376541" PMDBI20035482 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 12406738" PMDBI20035483 n.a. PMDBM2021248 n.a. Candida albicans CAF2-1 PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15302838" PMDBI20035484 n.a. PMDBM2021248 n.a. Candida albicans CHK23 PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15302838" PMDBI20035485 n.a. PMDBM2021758 n.a. Candida parapsilosis 74/046 PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15817776" PMDBI20035486 n.a. PMDBM2020177 n.a. Staphylococcus aureus MSSA PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16569866" PMDBI20035487 n.a. PMDBM2021248 n.a. Candida albicans GDH 2346 PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16980403" PMDBI20035488 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035489 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035490 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035491 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035492 n.a. PMDBM2021248 n.a. Candida albicans ATCC 76615 PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20641010" PMDBI20035493 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20641010" PMDBI20035495 n.a. PMDBM2021759 n.a. Candida dubliniensis CBS8500 PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20641010" PMDBI20035496 n.a. PMDBM2021758 n.a. Candida parapsilosis Y0501 PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20641010" PMDBI20035497 n.a. PMDBM2021739 n.a. Candida tropicalis ATCC 750 PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20641010" PMDBI20035498 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 55133 PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21857375" PMDBI20035499 n.a. PMDBM2020178 1282 Staphylococcus epidermidis 1457 PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21857375" PMDBI20035500 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 1457 铻朼gr PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21857375" PMDBI20035501 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis 1457 é“»æ”uxS PMDBD2000780 Farnesol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21857375" PMDBI20035502 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000781 faropenem medoxomil Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Peptidoglycan synthase FtsI n.a. PMID "PMID: 30581775; PMID: 12886052" PMDBI20035503 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae serotype 4 ATCC BAA-334 PMDBD2000781 faropenem medoxomil Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 12886052" PMDBI20035505 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae serotype 4 TIGR4 PMDBD2000781 faropenem medoxomil Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 12886052" PMDBI20035507 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000782 Fenclonine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035508 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000782 Fenclonine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20035509 n.a. PMDBM2020100 n.a. Klebsiella pneumoniae B5055 PMDBD2000783 Ferric chloride Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23889975" PMDBI20035510 n.a. "PMID: 30581775; PMID: 24958247" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000784 Ferrous Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035511 n.a. "PMID: 30581775; PMID: 18330563" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000785 Ferulic Acid Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035512 n.a. PMDBM2020177 n.a. Staphylococcus aureus UAMS-1 PMDBD2000785 Ferulic Acid Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22242149" PMDBI20035513 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2000785 Ferulic Acid Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24067082" PMDBI20035514 n.a. PMDBM2021248 n.a. Candida albicans BWP17 PMDBD2000786 FK506 Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20035515 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2000787 Flavone Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21930760" PMDBI20035516 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD2000788 Flavonoids 3 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26070141" PMDBI20035517 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD2000789 Flavonoids 7 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26070141" PMDBI20035518 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 8861529" PMDBI20035519 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 8861529" PMDBI20035520 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 8861529" PMDBI20035521 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 8861529" PMDBI20035542 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD2000790 Floxacillin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 318800" PMDBI20035543 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD2000790 Floxacillin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 318800" PMDBI20035548 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD1197 Flucloxacillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 318800" PMDBI20035549 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD1197 Flucloxacillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 318800" PMDBI20035558 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Lanosterol 14-alpha demethylase n.a. PMID "PMID: 30581775; PMID: 15314102" PMDBI20035559 n.a. PMDBM2021248 n.a. Candida albicans ATCC MYA-2876 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Lanosterol 14-alpha demethylase n.a. PMID "PMID: 30581775; PMID: 15314102" PMDBI20035564 n.a. PMDBM2021248 n.a. Candida albicans CAI4 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17261564" PMDBI20035565 n.a. PMDBM2021248 n.a. Candida albicans CAPR306A PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17261564" PMDBI20035566 n.a. PMDBM2021248 n.a. Candida albicans CAPR518 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17261564" PMDBI20035567 n.a. PMDBM2021248 n.a. Candida albicans CAPR514 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17261564" PMDBI20035568 n.a. PMDBM2021248 n.a. Candida albicans CAPR518A PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17261564" PMDBI20035569 n.a. PMDBM2021248 n.a. Candida albicans CAPR514A PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17261564" PMDBI20035570 n.a. PMDBM2021248 n.a. Candida albicans CAPR507 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17261564" PMDBI20035571 n.a. PMDBM2021248 n.a. Candida albicans CAPR510 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17261564" PMDBI20035572 n.a. PMDBM2021248 n.a. Candida albicans CI 158 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17261564" PMDBI20035573 n.a. PMDBM2021248 n.a. Candida albicans CI 168 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17261564" PMDBI20035574 n.a. PMDBM2021248 n.a. Candida albicans CI 113 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17261564" PMDBI20035575 n.a. PMDBM2021248 n.a. Candida albicans CI 127 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17261564" PMDBI20035576 n.a. PMDBM2021248 n.a. Candida albicans CI 166 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17261564" PMDBI20035577 n.a. PMDBM2021248 n.a. Candida albicans CI 190 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17261564" PMDBI20035578 n.a. PMDBM2021248 n.a. Candida albicans SH 855 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17261564" PMDBI20035579 n.a. PMDBM2021248 n.a. Candida albicans CHK21 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17261564" PMDBI20035580 n.a. PMDBM2021248 n.a. Candida albicans 14053 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21924600" PMDBI20035582 n.a. PMDBM2021248 5476 Candida albicans DAY185 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28155334" PMDBI20035583 n.a. PMDBM2021248 n.a. Candida albicans BWP17 PMDBD2000791 Fluperlapine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20035584 n.a. PMDBM2021248 n.a. Candida albicans BWP17 PMDBD2000792 Fluspiriline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20035585 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD2000793 Fosamprenavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Pol polyprotein n.a. PMID "PMID: 30581775; PMID: 11752352" PMDBI20035591 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2000794 Fosaphenytoin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26241210" PMDBI20035592 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2000794 Fosaphenytoin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26241210" PMDBI20035593 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD1206 Fosfomycin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: UDP-N-acetylglucosamine 1-carboxyvinyltransferase n.a. PMID "PMID: 30581775; PMID: 7608103" PMDBI20035600 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000795 Framycetin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S12 n.a. PMID "PMID: 30581775; PMID: 8605174" PMDBI20035601 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD2000795 Framycetin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 16S rRNA n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20035606 n.a. "PMID: 30581775; PMID: 21852522" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000796 Fraxin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035607 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia GIMT1.118 PMDBD2000796 Fraxin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21852522" PMDBI20035608 n.a. PMDBM2020177 n.a. Staphylococcus aureus Smith diffuse (SD) PMDBD2000797 FS8 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23965956" PMDBI20035609 n.a. "PMID: 30581775; PMID: 22884365" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000798 Furanone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035610 n.a. "PMID: 30581775; PMID: 11782502" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000799 Furanone 56 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035611 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000799 Furanone 56 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18791004" PMDBI20035612 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000799 Furanone 56 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19098295" PMDBI20035613 n.a. "PMID: 30581775; PMID: 22578766" 210007 Streptococcus mutans UA159 PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20035614 n.a. PMDBM2020183 n.a. Streptococcus mutans luxSmutant PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22578766" PMDBI20035615 n.a. "PMID: 30581775; PMID: 28261183" 652611 Pseudomonas aeruginosa PA14 PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035616 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (A11) PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20035617 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (B3) PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20035618 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (B8) PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20035619 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (B11) PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20035620 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (C5) PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20035621 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (D7) PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20035622 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (F5) PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20035623 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (F7) PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20035624 n.a. "PMID: 30581775; PMID: 28261183" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035625 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (A5) PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20035626 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (B2) PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20035627 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (B10) PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20035628 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (D10) PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20035629 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (E9) PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20035630 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Clinical isolate (F3) PMDBD2000800 Furanone C-30 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28261183" PMDBI20035631 n.a. PMDBM2020035 n.a. Escherichia coli O103:H2 (1153) PMDBD2000801 Furanone F202 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24391047" PMDBI20035632 n.a. PMDBM2020035 n.a. Escherichia coli O103:H2 (1242) PMDBD2000801 Furanone F202 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24391047" PMDBI20035633 n.a. PMDBM2020035 n.a. Escherichia coli O103:H2 (10705) PMDBD2000801 Furanone F202 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24391047" PMDBI20035634 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000802 Furanone-2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18791004" PMDBI20035635 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000803 Furanone-3 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18791004" PMDBI20035636 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000804 Furanone-5 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18791004" PMDBI20035637 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000805 Furanone-6 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18791004" PMDBI20035638 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium ATCC14028 PMDBD2000806 Furanone-8 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18791004" PMDBI20035639 n.a. "PMID: 30581775; PMID: 28140677" 652611 Pseudomonas aeruginosa PA14 PMDBD2000807 Furvina Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035640 n.a. PMDBM2020035 562 Escherichia coli Not Specified PMDBD2000808 Fusidic Acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Chloramphenicol acetyltransferase 3 n.a. PMID "PMID: 30581775; PMID: 6354181" PMDBI20035641 n.a. PMDBM2021760 599 Salmonella Typhi Not Specified PMDBD2000808 Fusidic Acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Chloramphenicol acetyltransferase n.a. PMID "PMID: 30581775; PMID: 6354181" PMDBI20035649 n.a. PMDBM2010320 n.a. Streptomyces sp. R61 PMDBD2000808 Fusidic Acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Elongation factor G n.a. PMID "PMID: 30581775; PMID: 19289529" PMDBI20035650 n.a. PMDBM2021761 274 Thermus thermophilus Not Specified PMDBD2000808 Fusidic Acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Elongation factor G n.a. PMID "PMID: 30581775; PMID: 19833919" PMDBI20035652 n.a. PMDBM2020177 n.a. Staphylococcus aureus RN1HG PMDBD2000808 Fusidic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20035653 n.a. PMDBM2020177 n.a. Staphylococcus aureus Mu50 PMDBD2000808 Fusidic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20035654 n.a. PMDBM2020177 n.a. Staphylococcus aureus ET013 (MRSA) PMDBD2000808 Fusidic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20035655 n.a. PMDBM2020177 n.a. Staphylococcus aureus ET041 (MRSA) PMDBD2000808 Fusidic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20035657 n.a. PMDBM2020035 1322345 Escherichia coli ATCC 25922 PMDBD2000809 FV7 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24945359" PMDBI20035658 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000809 FV7 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24945359" PMDBI20035659 n.a. PMDBM2021143 n.a. Streptococcus gordonii DL1 PMDBD2000810 G H12 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26859135" PMDBI20035660 n.a. "PMID: 30581775; PMID: 26859135" 864567 Streptococcus mitis ATCC 6249 PMDBD2000810 G H12 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2021148 PMDBI20035661 n.a. "PMID: 30581775; PMID: 26859135" 210007 Streptococcus mutans UA159 PMDBD2000810 G H12 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20035662 n.a. PMDBM2020254 n.a. Streptococcus salivarius ATCC 13419 PMDBD2000810 G H12 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26859135" PMDBI20035663 n.a. PMDBM2020184 888807 Streptococcus sanguinis ATCC 10556 PMDBD2000810 G H12 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26859135" PMDBI20035664 n.a. PMDBM2021156 246202 Streptococcus sobrinus 6715 PMDBD2000810 G H12 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26859135" PMDBI20035665 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000811 G10KHc Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16940063" PMDBI20035666 n.a. PMDBM2021143 n.a. Streptococcus gordonii Challis (DL1) PMDBD2000812 G2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17060534" PMDBI20035667 n.a. "PMID: 30581775; PMID: 17060534" 210007 Streptococcus mutans UA159 PMDBD2000812 G2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20035668 n.a. PMDBM2020184 n.a. Streptococcus sanguinis NY101 PMDBD2000812 G2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17060534" PMDBI20035669 n.a. PMDBM2020183 n.a. Streptococcus mutans UA140 PMDBD2000812 G2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21860239" PMDBI20035670 n.a. PMDBM2021137 539 Eikenella corrodens 1073 PMDBD378 Gallic Acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21150103" PMDBI20035671 n.a. PMDBM2020177 n.a. Staphylococcus aureus UAMS-1 PMDBD378 Gallic Acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22242149" PMDBI20035672 n.a. PMDBM2020035 562 Escherichia coli Not Specified PMDBD378 Gallic Acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25974286" PMDBI20035673 n.a. PMDBM2020183 1309 Streptococcus mutans Not Specified PMDBD378 Gallic Acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25974286" PMDBI20035674 n.a. "PMID: 30581775; PMID: 24958247" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000813 Gallium cation Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035675 n.a. PMDBM2020035 562 Escherichia coli Not Specified PMDBD2000814 Gallium Nitrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26369125" PMDBI20035676 n.a. PMDBM2021137 539 Eikenella corrodens 1073 PMDBD2000815 Gallocatechin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21150103" PMDBI20035677 n.a. PMDBM2021137 539 Eikenella corrodens 1073 PMDBD2000816 Gallocatechin gallate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21150103" PMDBI20035678 n.a. PMDBM2010183 n.a. Human herpesvirus 1 17 PMDBD2000817 Ganciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Thymidine kinase n.a. PMID "PMID: 30581775; PMID: 9715911" PMDBI20035682 n.a. "PMID: 30581775; PMID: 15716452" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000818 Garlic extract Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035683 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae serotype 4 ATCC BAA-334 PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit B n.a. PMID "PMID: 30581775; PMID: 11131958" PMDBI20035687 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae serotype 4 TIGR4 PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit B n.a. PMID "PMID: 30581775; PMID: 11131958" PMDBI20035727 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD1213 Gemifloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 11796351" PMDBI20035729 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD1213 Gemifloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 11796351" PMDBI20035731 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD1213 Gemifloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 11796351" PMDBI20035733 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD1213 Gemifloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 11796351" PMDBI20035767 n.a. PMDBM2020222 39490 Eubacterium ramulus Not Specified PMDBD386 Genistein "Therapeutic Substance; Herbal Substance" antineoplastic and antitumor n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 11959436" PMDBI20035768 n.a. PMDBM2020267 820 Bacteroides uniformis Not Specified PMDBD386 Genistein "Therapeutic Substance; Herbal Substance" antineoplastic and antitumor n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21525249" PMDBI20035769 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD2000819 Gentamicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 16S rRNA n.a. PMID "PMID: 30581775; PMID: 10619838" PMDBI20035770 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000819 Gentamicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S12 n.a. PMID "PMID: 30581775; PMID: 10619838" PMDBI20035772 n.a. PMDBM2020080 1423 Bacillus subtilis 168 PMDBD2000819 Gentamicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: NH(3)-dependent NAD(+) synthetase n.a. PMID "PMID: 30581775; PMID: 12852767" PMDBI20035778 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000819 Gentamicin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S12 n.a. PMID "PMID: 30581775; PMID: 10619838" PMDBI20035781 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2000820 Ginger oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20035782 n.a. "PMID: 30581775; PMID: 23917321" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000821 GL13K Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035783 n.a. PMDBM2021143 n.a. Streptococcus gordonii ML-5 PMDBD2000821 GL13K Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25372402" PMDBI20035784 n.a. PMDBM2020080 n.a. Bacillus subtilis ATCC 39087 PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25038633" PMDBI20035785 n.a. PMDBM2020482 n.a. Campylobacter jejuni M129 PMDBD2000822 Glucose Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17259368" PMDBI20035786 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000823 Glycinamide hydrochloride Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20035787 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000823 Glycinamide hydrochloride Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20035788 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000823 Glycinamide hydrochloride Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20035789 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa NCIM 5029 PMDBD2000824 Glycomonoterpenes (G-citral) Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27854038" PMDBI20035790 n.a. PMDBM2020258 n.a. Vibrio cholerae MTCC 0139 PMDBD2000824 Glycomonoterpenes (G-citral) Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27854038" PMDBI20035791 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa NCIM 5029 PMDBD2000825 Glycomonoterpenes (G-citron) Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27854038" PMDBI20035792 n.a. PMDBM2020258 n.a. Vibrio cholerae MTCC 0139 PMDBD2000825 Glycomonoterpenes (G-citron) Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27854038" PMDBI20035793 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD2000826 Gossypetin hexamethyl ether Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26140409" PMDBI20035794 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia SM33 PMDBD2000827 Grepafloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 14693533" PMDBI20035795 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000828 Guaiacol Therapeutic Substance Phase 3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27808174" PMDBI20035796 n.a. PMDBM2021248 n.a. Candida albicans BWP17 PMDBD2000829 GW 5074 Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20035797 n.a. PMDBM2021248 n.a. Candida albicans BWP17 PMDBD2000830 GW-9662 Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20035798 n.a. PMDBM2021248 n.a. Candida albicans BWP17 PMDBD2000831 HA14-1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20035799 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2000832 Hamamelitannin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20035800 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA02 PMDBD2000832 Hamamelitannin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20035801 n.a. PMDBM2020177 n.a. Staphylococcus aureus Mu50 PMDBD2000832 Hamamelitannin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20035802 n.a. PMDBM2020177 n.a. Staphylococcus aureus NRS384 PMDBD2000832 Hamamelitannin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20035803 n.a. PMDBM2020177 n.a. Staphylococcus aureus New bould 305 PMDBD2000832 Hamamelitannin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20035804 n.a. PMDBM2020177 n.a. Staphylococcus aureus NRS149 PMDBD2000832 Hamamelitannin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20035805 n.a. PMDBM2020177 n.a. Staphylococcus aureus NRS123 PMDBD2000832 Hamamelitannin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20035806 n.a. PMDBM2020177 n.a. Staphylococcus aureus NRS112 PMDBD2000832 Hamamelitannin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20035807 n.a. PMDBM2020177 n.a. Staphylococcus aureus NRS153 PMDBD2000832 Hamamelitannin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20035808 n.a. PMDBM2021113 n.a. Staphylococcus capitis ET005 PMDBD2000832 Hamamelitannin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20035809 n.a. PMDBM2021114 n.a. Staphylococcus caprae NW003 PMDBD2000832 Hamamelitannin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20035810 n.a. PMDBM2021762 n.a. Staphylococcus chromogenes NW110 PMDBD2000832 Hamamelitannin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20035811 n.a. PMDBM2021115 n.a. Staphylococcus cohnii ET027 PMDBD2000832 Hamamelitannin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20035812 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ET013 PMDBD2000832 Hamamelitannin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20035813 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD2000833 HE10 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26221537" PMDBI20035814 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD2000834 HE12 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26221537" PMDBI20035815 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD2000835 HE4 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26221537" PMDBI20035816 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis SeBER PMDBD2000836 Hepcidin 20 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24645694" PMDBI20035817 n.a. "PMID: 30581775; PMID: 22045628" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000837 Heptadecanoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035818 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2000838 Heptamethoxyflavone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23891936" PMDBI20035819 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD2000838 Heptamethoxyflavone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26140409" PMDBI20035820 n.a. PMDBM2020177 561307 Staphylococcus aureus RN4220 PMDBD2000839 Hesperetin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28365326" PMDBI20035821 n.a. PMDBM2020177 n.a. Staphylococcus aureus SA1199B PMDBD2000839 Hesperetin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28365326" PMDBI20035822 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD420 Hesperidin "Therapeutic Substance; Herbal Substance" anti-allergy n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20035823 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD420 Hesperidin "Therapeutic Substance; Herbal Substance" anti-allergy n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20035824 n.a. PMDBM2020192 n.a. Yersinia enterocolitica CECT 4315 PMDBD420 Hesperidin "Therapeutic Substance; Herbal Substance" anti-allergy n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22533445" PMDBI20035825 n.a. PMDBM2020177 561307 Staphylococcus aureus RN4220 PMDBD420 Hesperidin "Therapeutic Substance; Herbal Substance" anti-allergy n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28365326" PMDBI20035826 n.a. PMDBM2020177 n.a. Staphylococcus aureus SA1199B PMDBD420 Hesperidin "Therapeutic Substance; Herbal Substance" anti-allergy n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28365326" PMDBI20035827 n.a. PMDBM2021153 1313 Streptococcus pneumoniae Not Specified PMDBD2000840 Hetacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 1095502" PMDBI20035828 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD2000840 Hetacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 1095502" PMDBI20035832 n.a. "PMID: 30581775; PMID: 1095502" 171101 Streptococcus pneumoniae R6 PMDBD2000840 Hetacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID PMDBM2021153 PMDBI20035845 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20035846 n.a. PMDBM2020035 562 Escherichia coli RP437 PMDBD2000841 Hexameric peptide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20097816" PMDBI20035847 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000842 Hexyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20035848 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000842 Hexyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20035849 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000842 Hexyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20035850 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000842 Hexyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20035851 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000842 Hexyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20035852 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2000843 Hinokitiol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28152096" PMDBI20035853 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90029 PMDBD2000843 Hinokitiol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28152096" PMDBI20035854 n.a. PMDBM2021248 n.a. Candida albicans KCMF 20017 PMDBD2000843 Hinokitiol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28152096" PMDBI20035855 n.a. PMDBM2021747 n.a. Candida glabrata ATCC 90030 PMDBD2000843 Hinokitiol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28152096" PMDBI20035856 n.a. PMDBM2021747 n.a. Candida glabrata KCMF 20161 PMDBD2000843 Hinokitiol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28152096" PMDBI20035857 n.a. PMDBM2010530 n.a. Candida guiliermondi KCMF 20104 PMDBD2000843 Hinokitiol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28152096" PMDBI20035858 n.a. PMDBM2021758 n.a. Candida parapsilosis ATCC 90018 PMDBD2000843 Hinokitiol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28152096" PMDBI20035859 n.a. PMDBM2021758 n.a. Candida parapsilosis KCMF 20154 PMDBD2000843 Hinokitiol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28152096" PMDBI20035860 n.a. PMDBM2021739 n.a. Candida tropicalis KCMF 20197 PMDBD2000843 Hinokitiol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28152096" PMDBI20035861 n.a. PMDBM2021248 5476 Candida albicans Not Specified PMDBD2000844 Histatin 5 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19249746" PMDBI20035862 n.a. PMDBM2021248 n.a. Candida albicans CAF4-2 PMDBD2000844 Histatin 5 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24247141" PMDBI20035863 n.a. PMDBM2021747 n.a. Candida glabrata 931010 PMDBD2000844 Histatin 5 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24247141" PMDBI20035864 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000845 hLF1-11 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27902776" PMDBI20035865 n.a. PMDBM2021248 n.a. Candida albicans CA688 PMDBD2000845 hLF1-11 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27902776" PMDBI20035866 n.a. PMDBM2021248 n.a. Candida albicans CA22 PMDBD2000845 hLF1-11 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27902776" PMDBI20035867 n.a. PMDBM2021248 n.a. Candida albicans CA37 PMDBD2000845 hLF1-11 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27902776" PMDBI20035868 n.a. PMDBM2020151 1424337 Pseudomonas aeruginosa ATCC 15442 PMDBD2000846 Holothuroidin 1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23800329" PMDBI20035869 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000846 Holothuroidin 1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23800329" PMDBI20035870 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000846 Holothuroidin 1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23800329" PMDBI20035871 n.a. PMDBM2020151 1424337 Pseudomonas aeruginosa ATCC 15442 PMDBD2000847 Holothuroidin 2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23800329" PMDBI20035872 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000847 Holothuroidin 2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23800329" PMDBI20035873 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000847 Holothuroidin 2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23800329" PMDBI20035874 n.a. PMDBM2020183 n.a. Streptococcus mutans ATCC 10449 PMDBD2000848 Hsn5 12-mer Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16595638" PMDBI20035875 n.a. PMDBM2021248 5476 Candida albicans Not Specified PMDBD2000849 Human beta-defensin 3 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19249746" PMDBI20035876 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis MRSE287 PMDBD2000849 Human beta-defensin 3 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23273885" PMDBI20035877 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 43300 PMDBD2000849 Human beta-defensin 3 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23273885" PMDBI20035878 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 PMDBD2000849 Human beta-defensin 3 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26119274" PMDBI20035879 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000849 Human beta-defensin 3 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26119274" PMDBI20035880 n.a. PMDBM2020177 n.a. Staphylococcus aureus 2346775 PMDBD2000850 Hydnocarpin D Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26273725" PMDBI20035881 n.a. "PMID: 30581775; PMID: 24645272" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000851 Hydrogen peroxide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035882 n.a. PMDBM2020183 n.a. Streptococcus mutans LMG 14558 PMDBD2000852 Hypericin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17220400" PMDBI20035883 n.a. "PMID: 30581775; PMID: 28810631" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000853 Hyperoside Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035884 n.a. PMDBM2021763 412900 Sphingomonas sp. Ibu-2 Not Specified PMDBD1231 Ibuprofen Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23329679" PMDBI20035885 n.a. PMDBM2010544 n.a. Human herpesvirus 1 Not Specified PMDBD438 Idoxuridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Thymidine kinase n.a. PMID "PMID: 30581775; PMID: 9336833" PMDBI20035886 n.a. PMDBM2020075 n.a. Acinetobacter baumannii SENTRY C8 PMDBD2000854 IDR-1018 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24852171" PMDBI20035887 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia IIIa 4813 PMDBD2000854 IDR-1018 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24852171" PMDBI20035888 n.a. PMDBM2020035 1045010 Escherichia coli O157 PMDBD2000854 IDR-1018 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24852171" PMDBI20035889 n.a. PMDBM2020100 n.a. Klebsiella pneumoniae ATTC 13883 PMDBD2000854 IDR-1018 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24852171" PMDBI20035890 n.a. "PMID: 30581775; PMID: 24852171" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000854 IDR-1018 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035891 n.a. "PMID: 30581775; PMID: 24852171" 652611 Pseudomonas aeruginosa PA14 PMDBD2000854 IDR-1018 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035892 n.a. PMDBM2020168 n.a. Salmonella enterica Serovar Typhimurium 14028S PMDBD2000854 IDR-1018 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24852171" PMDBI20035893 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD2000854 IDR-1018 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24852171" PMDBI20035894 n.a. PMDBM2021245 884204 Burkholderia pseudomallei 1026b PMDBD2000855 IG-13 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22005071" PMDBI20035895 n.a. PMDBM2021245 884204 Burkholderia pseudomallei 1026b PMDBD2000856 IG-19 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22005071" PMDBI20035896 n.a. PMDBM2021245 884204 Burkholderia pseudomallei 1026b PMDBD2000857 IG-25 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22005071" PMDBI20035897 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000858 Imazalil Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20035898 n.a. "PMID: 30581775; PMID: 21844316" 210007 Streptococcus mutans UA159 PMDBD2000859 IMB-2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20035899 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2 n.a. PMID "PMID: 30581775; PMID: 3873871" PMDBI20035900 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Beta-lactamase n.a. PMID "PMID: 30581775; PMID: 3873871" PMDBI20035907 n.a. PMDBM2020080 1423 Bacillus subtilis 168 PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 17488146" PMDBI20035915 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2000860 Imperatorin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23891936" PMDBI20035916 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD1238 Indinavir Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Pol polyprotein n.a. PMID "PMID: 30581775; PMID: 8724039" PMDBI20035918 n.a. PMDBM2010236 n.a. Human immunodeficiency virus Not Specified PMDBD1238 Indinavir Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: HIV-1 protease n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20035924 n.a. "PMID: 30581775; PMID: 18330563" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000861 Indirubin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035925 n.a. "PMID: 30581775; PMID: 16159245" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000862 Indol AHL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035926 n.a. "PMID: 30581775; PMID: 18528414" 679895 Escherichia coli BW25113 PMDBD445 Indole "Therapeutic Substance; Herbal Substance" Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020035 PMDBI20035927 n.a. PMDBM2020035 n.a. Escherichia coli BW25113 tnaA PMDBD445 Indole "Therapeutic Substance; Herbal Substance" Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18528414" PMDBI20035928 n.a. PMDBM2020035 n.a. Escherichia coli BW25113 sdiA PMDBD445 Indole "Therapeutic Substance; Herbal Substance" Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18528414" PMDBI20035929 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD445 Indole "Therapeutic Substance; Herbal Substance" Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035930 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD445 Indole "Therapeutic Substance; Herbal Substance" Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035931 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD445 Indole "Therapeutic Substance; Herbal Substance" Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035932 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD445 Indole "Therapeutic Substance; Herbal Substance" Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20035933 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD445 Indole "Therapeutic Substance; Herbal Substance" Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035934 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD445 Indole "Therapeutic Substance; Herbal Substance" Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25287229" PMDBI20035935 n.a. PMDBM2020945 n.a. Pantoea agglomerans YS19 PMDBD445 Indole "Therapeutic Substance; Herbal Substance" Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26923129" PMDBI20035936 n.a. PMDBM2010551 n.a. Acinetobacter oleiovorans DR1 PMDBD445 Indole "Therapeutic Substance; Herbal Substance" Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28251783" PMDBI20035937 n.a. PMDBM2020035 83333 Escherichia coli K-12 PMDBD445 Indole "Therapeutic Substance; Herbal Substance" Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28251783" PMDBI20035938 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD445 Indole "Therapeutic Substance; Herbal Substance" Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28251783" PMDBI20035939 n.a. PMDBM2021266 55601 Vibrio anguillarum NB10 PMDBD445 Indole "Therapeutic Substance; Herbal Substance" Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28251783" PMDBI20035940 n.a. PMDBM2021216 2902295 Vibrio campbellii ATCC BAA-1116 PMDBD445 Indole "Therapeutic Substance; Herbal Substance" Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28251783" PMDBI20035941 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000863 Indole-3-acetaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035942 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000864 Indole-3-acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035943 n.a. PMDBM2021216 2902295 Vibrio campbellii ATCC BAA-1116 PMDBD2000864 Indole-3-acetamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28251783" PMDBI20035944 n.a. PMDBM2021216 2902295 Vibrio campbellii ATCC BAA-1116 PMDBD2000865 Indole-3-acetic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28251783" PMDBI20035945 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000866 Indole-3-carboxyaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035946 n.a. PMDBM2020258 n.a. Vibrio cholerae VCO1 PMDBD2000866 Indole-3-carboxyaldehyde Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26939983" PMDBI20035947 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000867 Indole-7-carboxylic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035948 n.a. "PMID: 30581775; PMID: 18591225" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000868 Indolicidin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035949 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 PMDBD2000868 Indolicidin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23070152" PMDBI20035950 n.a. PMDBM2020177 n.a. Staphylococcus aureus RN1HG PMDBD2000869 Ionic silver Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20035951 n.a. PMDBM2020035 562 Escherichia coli Not Specified PMDBD455 Irinotecan Therapeutic Substance antineoplastic enzyme inhibitor n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 8706020" PMDBI20035952 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000870 Isatin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035953 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2000871 Isobutanol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24688528" PMDBI20035954 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20035955 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000872 Isoeugenol Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27808174" PMDBI20035956 n.a. PMDBM2020177 n.a. Staphylococcus aureus 2346775 PMDBD2000873 Isohydnocarpin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26273725" PMDBI20035957 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU7 PMDBD2000874 Isoliquiritigenin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20035958 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU38 PMDBD2000874 Isoliquiritigenin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20035959 n.a. PMDBM2020753 n.a. Haemophilus influenzae NU48 PMDBD2000874 Isoliquiritigenin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25154700" PMDBI20035960 n.a. PMDBM2020889 1773 Mycobacterium tuberculosis Not Specified PMDBD2000875 Isoniazid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Enoyl-[acyl-carrier-protein] reductase [NADH] n.a. PMID "PMID: 30581775; PMID: 7623658" PMDBI20035973 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2000876 Isopropanol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24688528" PMDBI20035974 n.a. PMDBM2021248 n.a. Candida albicans BWP17-DPP3-GFP PMDBD2000877 Isoriccardin C Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22174935" PMDBI20035975 n.a. PMDBM2020177 n.a. Staphylococcus aureus 2346775 PMDBD2000878 Isosilybin A Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26273725" PMDBI20035976 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD2000879 Isosinensetin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26140409" PMDBI20035977 n.a. "PMID: 30581775; PMID: 19585989" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000880 Isothiocyanate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20035978 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20035979 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000881 Ivalin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26394911" PMDBI20035980 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 50S ribosomal protein L4 n.a. PMID "PMID: 30581775; PMID: 10898684" PMDBI20035981 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 50S ribosomal protein L4 n.a. PMID "PMID: 30581775; PMID: 10898684" PMDBI20035982 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 50S ribosomal protein L4 n.a. PMID "PMID: 30581775; PMID: 10898684" PMDBI20035983 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 50S ribosomal protein L4 n.a. PMID "PMID: 30581775; PMID: 10898684" PMDBI20035984 n.a. PMDBM2020183 n.a. Streptococcus mutans ATCC 27351 PMDBD2000882 K4-S4 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16687459" PMDBI20035985 n.a. PMDBM2010556 n.a. Candida tropicalis Clinical isolate PMDBD2000883 KABT-AMP Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23649308" PMDBI20035986 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000884 Kaempherol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20035987 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD2000884 Kaempherol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20035988 n.a. PMDBM2020177 n.a. Staphylococcus aureus UAMS-1 PMDBD2000884 Kaempherol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22242149" PMDBI20035989 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD466 Kanamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S12 n.a. PMID "PMID: 30581775; PMID: 8657204" PMDBI20035992 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD466 Kanamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 16S rRNA n.a. PMID "PMID: 30581775; PMID: 16957099" PMDBI20035999 n.a. PMDBM2020035 n.a. Escherichia coli K-12 MG 1655 PMDBD2000885 kappa-Pyrosulfite Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20089325" PMDBI20036000 n.a. PMDBM2020183 1309 Streptococcus mutans Not Specified PMDBD2000886 Kaurenoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23662113" PMDBI20036001 n.a. PMDBM2021245 884204 Burkholderia pseudomallei 1026b PMDBD2000887 KD-13 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22005071" PMDBI20036002 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" fungal infections n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Lanosterol 14-alpha demethylase n.a. PMID "PMID: 30581775; PMID: 1627190" PMDBI20036003 n.a. PMDBM2021248 n.a. Candida albicans ATCC MYA-2876 PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" fungal infections n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Lanosterol 14-alpha demethylase n.a. PMID "PMID: 30581775; PMID: 1627190" PMDBI20036011 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000888 knightine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20036012 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000888 knightine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20036013 n.a. PMDBM2021218 n.a. Vibrio harveyi PHY-2A PMDBD2000888 knightine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22905751" PMDBI20036014 n.a. "PMID: 30581775; PMID: 26557964" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000889 Kojic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036015 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAK01 PMDBD2000889 Kojic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26557964" PMDBI20036016 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAK02 PMDBD2000889 Kojic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26557964" PMDBI20036017 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAK03 PMDBD2000889 Kojic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26557964" PMDBI20036018 n.a. "PMID: 30581775; PMID: 20956070" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000890 KSL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036019 n.a. PMDBM2021248 n.a. Candida albicans ATCC SC5314 PMDBD2000891 KSL-W Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24195531" PMDBI20036020 n.a. PMDBM2020035 1045010 Escherichia coli O157 PMDBD2000892 KT2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25767037" PMDBI20036021 n.a. "PMID: 30581775; PMID: 25761937" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000893 L- K6L9 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036022 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000894 L-2-Bromophenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20036023 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000895 L-4-Carbamoylphenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20036024 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000895 L-4-Carbamoylphenylalanine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20036025 n.a. PMDBM2021248 n.a. Candida albicans BWP17 PMDBD2000896 L-744,832 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20036026 n.a. PMDBM2021750 n.a. Aspergillus fumigatus JM3 PMDBD2000897 Lactoferricin B Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22410856" PMDBI20036027 n.a. PMDBM2021248 n.a. Candida albicans SJ11 PMDBD2000897 Lactoferricin B Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22410856" PMDBI20036028 n.a. PMDBM2021764 n.a. Fusarium solani JW21 PMDBD2000897 Lactoferricin B Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22410856" PMDBI20036029 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD1246 Lamivudine Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Reverse transcriptase/RNaseH n.a. PMID "PMID: 30581775; PMID: 1283519" PMDBI20036030 n.a. PMDBM2010560 n.a. Hepatitis B virus F Not Specified PMDBD1246 Lamivudine Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Protein P n.a. PMID "PMID: 30581775; PMID: 11230757" PMDBI20036033 n.a. PMDBM2020069 n.a. Pseudomonas fluorescens H2S PMDBD2000898 Lanthanum chloride Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 2624463" PMDBI20036034 n.a. PMDBM2020177 n.a. Staphylococcus aureus N315 (MRSA) PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036035 n.a. PMDBM2020177 n.a. Staphylococcus aureus T25 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036036 n.a. PMDBM2020177 n.a. Staphylococcus aureus T22 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036037 n.a. PMDBM2020177 n.a. Staphylococcus aureus T24 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036038 n.a. PMDBM2020177 n.a. Staphylococcus aureus LQ6 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036039 n.a. PMDBM2020177 n.a. Staphylococcus aureus BP7 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036040 n.a. PMDBM2020177 n.a. Staphylococcus aureus B530 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036041 n.a. PMDBM2020177 n.a. Staphylococcus aureus B51 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036042 n.a. PMDBM2020177 n.a. Staphylococcus aureus BP1 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036043 n.a. PMDBM2020177 n.a. Staphylococcus aureus B31 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036044 n.a. PMDBM2020177 n.a. Staphylococcus aureus CS9 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036045 n.a. PMDBM2021762 n.a. Staphylococcus chromogenes S42 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036046 n.a. PMDBM2021762 n.a. Staphylococcus chromogenes S72 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036047 n.a. PMDBM2021116 n.a. Staphylococcus equorum LQ12 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036048 n.a. PMDBM2021116 n.a. Staphylococcus equorum T71 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036049 n.a. PMDBM2021117 n.a. Staphylococcus haemolyticus S62 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036050 n.a. PMDBM2021117 n.a. Staphylococcus haemolyticus S64 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036051 n.a. PMDBM2021125 n.a. Staphylococcus saprophyticus LQ11 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036052 n.a. PMDBM2021125 n.a. Staphylococcus saprophyticus T56 PMDBD2000899 L-Aspartate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25687923" PMDBI20036053 n.a. PMDBM2020080 1423 Bacillus subtilis 168 PMDBD2000900 Latamoxef Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 3918982" PMDBI20036054 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2000900 Latamoxef Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 3918982" PMDBI20036058 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD2000901 L-Canavanine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20036059 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2000901 L-Canavanine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20036060 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD2000901 L-Canavanine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20036061 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD2000901 L-Canavanine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20036062 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000902 L-carnosine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036063 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000902 L-carnosine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20036064 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2000903 L-cysteic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20036065 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2000903 L-cysteic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036066 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2000903 L-cysteic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20036067 n.a. PMDBM2020005 n.a. Bacillus cereus var. mycoides 0042 PMDBD2000904 Lemon Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20036068 n.a. PMDBM2020035 n.a. Escherichia coli 582 PMDBD2000904 Lemon Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20036069 n.a. PMDBM2021742 n.a. Pichia anomala 8061Mo PMDBD2000904 Lemon Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20036070 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2000905 Lemon oil Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20036071 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD1257 Levofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 9598779" PMDBI20036072 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD1257 Levofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 9598779" PMDBI20036073 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD1257 Levofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 9598779" PMDBI20036074 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD1257 Levofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 9598779" PMDBI20036087 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia SM33 PMDBD1257 Levofloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 14693533" PMDBI20036112 n.a. "PMID: 30581775; PMID: 26149536" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000906 LF11-215 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036113 n.a. "PMID: 30581775; PMID: 26149536" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000907 LF11-227 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036114 n.a. "PMID: 30581775; PMID: 26149536" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000908 LF11-322 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036115 n.a. "PMID: 30581775; PMID: 26149536" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000909 LF11-324 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036116 n.a. "PMID: 30581775; PMID: 20477900" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000910 LFampin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036117 n.a. "PMID: 30581775; PMID: 20477900" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000911 Lfcin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036118 n.a. "PMID: 30581775; PMID: 25246957" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000912 L-fucose cluster Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036119 n.a. PMDBM2020005 n.a. Bacillus cereus var. mycoides 0042 PMDBD2000913 Limonene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20036120 n.a. PMDBM2020035 n.a. Escherichia coli 582 PMDBD2000913 Limonene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20036121 n.a. PMDBM2021742 n.a. Pichia anomala 8061Mo PMDBD2000913 Limonene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20036122 n.a. "PMID: 30581775; PMID: 26294065" 864567 Streptococcus mitis ATCC 6249 PMDBD2000913 Limonene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2021148 PMDBI20036123 n.a. "PMID: 30581775; PMID: 26294065" 210007 Streptococcus mutans UA159 PMDBD2000913 Limonene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036124 n.a. PMDBM2020253 160490 Streptococcus pyogenes SF370 PMDBD2000913 Limonene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26294065" PMDBI20036125 n.a. PMDBM2020253 n.a. Streptococcus pyogenes M56 PMDBD2000913 Limonene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26294065" PMDBI20036126 n.a. PMDBM2020253 n.a. Streptococcus pyogenes M65 PMDBD2000913 Limonene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26294065" PMDBI20036127 n.a. PMDBM2020253 n.a. Streptococcus pyogenes M74 PMDBD2000913 Limonene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26294065" PMDBI20036128 n.a. PMDBM2020253 n.a. Streptococcus pyogenes M100 PMDBD2000913 Limonene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26294065" PMDBI20036129 n.a. PMDBM2020253 n.a. Streptococcus pyogenes St38 PMDBD2000913 Limonene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26294065" PMDBI20036130 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2000913 Limonene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27702795" PMDBI20036131 n.a. PMDBM2021248 5476 Candida albicans DAY185 PMDBD2000913 Limonene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28155334" PMDBI20036132 n.a. PMDBM2020005 n.a. Bacillus cereus var. mycoides 0042 PMDBD2000914 Linalool Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20036133 n.a. PMDBM2020035 n.a. Escherichia coli 582 PMDBD2000914 Linalool Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20036134 n.a. PMDBM2021742 n.a. Pichia anomala 8061Mo PMDBD2000914 Linalool Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20036135 n.a. PMDBM2020075 n.a. Acinetobacter baumannii LMG 1025 PMDBD2000914 Linalool Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26901586" PMDBI20036136 n.a. PMDBM2020075 n.a. Acinetobacter baumannii LMG 1041 PMDBD2000914 Linalool Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26901586" PMDBI20036137 n.a. PMDBM2020075 n.a. Acinetobacter baumannii AcB 10/10 PMDBD2000914 Linalool Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26901586" PMDBI20036138 n.a. PMDBM2020075 n.a. Acinetobacter baumannii AcB 23/10 PMDBD2000914 Linalool Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26901586" PMDBI20036139 n.a. PMDBM2020075 n.a. Acinetobacter baumannii AcB 24/10 PMDBD2000914 Linalool Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26901586" PMDBI20036140 n.a. PMDBM2021248 5476 Candida albicans DAY185 PMDBD2000914 Linalool Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28155334" PMDBI20036141 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 23S rRNA n.a. PMID "PMID: 30581775; PMID: 12690106" PMDBI20036144 n.a. PMDBM2020177 n.a. Staphylococcus aureus Smith diffuse (SD) PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16621147" PMDBI20036149 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23070152" PMDBI20036150 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000915 lin-SB056 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26614437" PMDBI20036151 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000915 lin-SB056 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26614437" PMDBI20036152 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000916 lin-SB056-1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26614437" PMDBI20036153 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000916 lin-SB056-1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26614437" PMDBI20036154 n.a. "PMID: 30581775; PMID: 26557964" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000917 Lipoic acid Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036155 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAK01 PMDBD2000917 Lipoic acid Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26557964" PMDBI20036156 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAK02 PMDBD2000917 Lipoic acid Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26557964" PMDBI20036157 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAK03 PMDBD2000917 Lipoic acid Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26557964" PMDBI20036158 n.a. "PMID: 30581775; PMID: 20211885" 210007 Streptococcus mutans UA159 PMDBD2000918 Listerine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036159 n.a. PMDBM2020183 n.a. Streptococcus mutans CGMCC1.2500 PMDBD2000919 L-K6 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25056289" PMDBI20036160 n.a. PMDBM2021245 884204 Burkholderia pseudomallei 1026b PMDBD2000920 LL-13 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22005071" PMDBI20036161 n.a. "PMID: 30581775; PMID: 22908164" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000921 LL13-37 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036162 n.a. PMDBM2021245 884204 Burkholderia pseudomallei 1026b PMDBD2000922 LL-19 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22005071" PMDBI20036163 n.a. PMDBM2021245 884204 Burkholderia pseudomallei 1026b PMDBD2000923 LL-25 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22005071" PMDBI20036164 n.a. PMDBM2021245 884204 Burkholderia pseudomallei 1026b PMDBD2000924 LL-31 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22005071" PMDBI20036165 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2000925 LL-37 Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20002576" PMDBI20036166 n.a. PMDBM2021765 2047875 Francisella novicida Not Specified PMDBD2000925 LL-37 Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20399752" PMDBI20036167 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD2000925 LL-37 Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21605457" PMDBI20036168 n.a. PMDBM2021245 884204 Burkholderia pseudomallei 1026b PMDBD2000925 LL-37 Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22005071" PMDBI20036169 n.a. "PMID: 30581775; PMID: 22908164" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000925 LL-37 Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036170 n.a. PMDBM2021242 n.a. Aggregatibacter actinomycetemcomitans ATCC 29523 PMDBD2000925 LL-37 Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23836819" PMDBI20036171 n.a. PMDBM2021242 714 Aggregatibacter actinomycetemcomitans JP2 PMDBD2000925 LL-37 Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23836819" PMDBI20036172 n.a. PMDBM2021242 1035194 Aggregatibacter actinomycetemcomitans Y4 PMDBD2000925 LL-37 Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23836819" PMDBI20036173 n.a. PMDBM2021242 n.a. Aggregatibacter actinomycetemcomitans ATCC 33384 PMDBD2000925 LL-37 Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23836819" PMDBI20036174 n.a. "PMID: 30581775; PMID: 24071034" 1116236 Acinetobacter baumannii AB5711 PMDBD2000925 LL-37 Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020075 PMDBI20036175 n.a. PMDBM2020075 n.a. Acinetobacter baumannii AB 5075 PMDBD2000925 LL-37 Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24071034" PMDBI20036176 n.a. PMDBM2020177 n.a. Staphylococcus aureus LUH14616 PMDBD2000925 LL-37 Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24841266" PMDBI20036177 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000925 LL-37 Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25285879" PMDBI20036179 n.a. PMDBM2021755 271848 Burkholderia thailandensis E264 PMDBD2000925 LL-37 Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26196513" PMDBI20036180 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2000925 LL-37 Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26238597" PMDBI20036181 n.a. "PMID: 30581775; PMID: 22908164" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000926 LL7-37 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036182 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD2000927 Lomefloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 7492077" PMDBI20036183 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD2000927 Lomefloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 7492077" PMDBI20036184 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD2000927 Lomefloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 7492077" PMDBI20036185 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD2000927 Lomefloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 7492077" PMDBI20036214 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD1259 Lopinavir Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Pol polyprotein n.a. PMID "PMID: 30581775; PMID: 11151088" PMDBI20036215 n.a. PMDBM2010236 n.a. Human immunodeficiency virus Not Specified PMDBD1259 Lopinavir Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: HIV-1 protease n.a. PMID "PMID: 30581775; PMID: 11752352" PMDBI20036221 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD1260 Lorazepam Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26241210" PMDBI20036222 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD1260 Lorazepam Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26241210" PMDBI20036223 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000928 L-ornithine hydrochloride Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20036224 n.a. PMDBM2020080 n.a. Bacillus subtilis ATCC 39087 PMDBD2000929 Losartran Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25038633" PMDBI20036225 n.a. PMDBM2021756 53249 Pseudoalteromonas sp. SC2014 PMDBD2000930 L-Phenylalanine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27664053" PMDBI20036226 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD2000931 L-Phenylalanine-D-Lysine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27161246" PMDBI20036227 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD2000932 L-Phenylalanine-L-Lysine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27161246" PMDBI20036228 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2000933 L-pipecolic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20036229 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000933 L-pipecolic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20036230 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2000933 L-pipecolic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20036231 n.a. PMDBM2020080 n.a. Bacillus subtilis ATCC 6051 PMDBD2000030 L-tryptophan Therapeutic Substance amino acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28819217" PMDBI20036232 n.a. "PMID: 30581775; PMID: 28819217" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000030 L-tryptophan Therapeutic Substance amino acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036233 n.a. PMDBM2021261 90371 Salmonella enterica serovar Typhimurium SL1344 PMDBD2000030 L-tryptophan Therapeutic Substance amino acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28819217" PMDBI20036234 n.a. PMDBM2020177 n.a. Staphylococcus aureus AH1121 PMDBD2000030 L-tryptophan Therapeutic Substance amino acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28819217" PMDBI20036235 n.a. PMDBM2021267 914127 Vibrio vulnificus M06-24/O PMDBD2000030 L-tryptophan Therapeutic Substance amino acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28819217" PMDBI20036236 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD1263 L-Tyrosine Dietary Substances amino acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20036237 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD1263 L-Tyrosine Dietary Substances amino acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20036238 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD1263 L-Tyrosine Dietary Substances amino acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20036239 n.a. PMDBM2020035 n.a. Escherichia coli J96 (UPEC) PMDBD2000934 Luteolin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25051393" PMDBI20036240 n.a. PMDBM2020035 n.a. Escherichia coli CFT073 (UPEC) PMDBD2000934 Luteolin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25051393" PMDBI20036241 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S4 n.a. PMID "PMID: 30581775; PMID: 5087060" PMDBI20036247 n.a. "PMID: 30581775; PMID: 23340019" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000935 Lys-a1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036248 n.a. PMDBM2021149 1303 Streptococcus oralis ATCC 10557 PMDBD2000935 Lys-a1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23340019" PMDBI20036249 n.a. "PMID: 30581775; PMID: 23340019" 888048 Streptococcus parasanguinis ATCC 903 PMDBD2000935 Lys-a1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020252 PMDBI20036250 n.a. PMDBM2020254 n.a. Streptococcus salivarius ATCC 7073 PMDBD2000935 Lys-a1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23340019" PMDBI20036251 n.a. PMDBM2020184 888807 Streptococcus sanguinis ATCC 10556 PMDBD2000935 Lys-a1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23340019" PMDBI20036252 n.a. PMDBM2021156 n.a. Streptococcus sobrinus ATCC 6715 PMDBD2000935 Lys-a1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23340019" PMDBI20036253 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000936 Lysozyme Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28397768" PMDBI20036254 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD2000936 Lysozyme Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28397768" PMDBI20036255 n.a. "PMID: 30581775; PMID: 17060534" 210007 Streptococcus mutans UA159 PMDBD2000937 M8-33 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036256 n.a. PMDBM2020184 n.a. Streptococcus sanguinis NY101 PMDBD2000937 M8-33 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17060534" PMDBI20036257 n.a. "PMID: 30581775; PMID: 17060534" 210007 Streptococcus mutans UA159 PMDBD2000938 M8G2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036258 n.a. PMDBM2020184 n.a. Streptococcus sanguinis NY101 PMDBD2000938 M8G2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17060534" PMDBI20036259 n.a. PMDBM2020258 n.a. Vibrio cholerae FY Vc 6226 PMDBD2000939 Macromomycin B Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24106077" PMDBI20036260 n.a. PMDBM2021741 n.a. Cryptococcus neoformans B3501 PMDBD2000940 Magainin-I Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17057089" PMDBI20036261 n.a. PMDBM2020032 n.a. Enterococcus faecalis III PMDBD2000940 Magainin-I Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19345992" PMDBI20036262 n.a. PMDBM2021766 n.a. Listeria ivanovii Li4pVS2 PMDBD2000940 Magainin-I Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19345992" PMDBI20036263 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 29213 PMDBD2000940 Magainin-I Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19345992" PMDBI20036264 n.a. PMDBM2020183 n.a. Streptococcus mutans ATCC 10449 PMDBD2000941 Magainin-II Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16595638" PMDBI20036265 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000941 Magainin-II Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25285879" PMDBI20036266 n.a. "PMID: 30581775; PMID: 21910441" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000942 Malabaricone C Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036267 n.a. PMDBM2021744 5833 Plasmodium falciparum Not Specified PMDBD517 Mefloquine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Fe(II)-protoporphyrin IX n.a. PMID "PMID: 30581775; PMID: 14967191" PMDBI20036268 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa 1162 PMDBD2000943 Melittin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23760014" PMDBI20036269 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa 3547 PMDBD2000943 Melittin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23760014" PMDBI20036270 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa 4007 PMDBD2000943 Melittin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23760014" PMDBI20036271 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa 3399 PMDBD2000943 Melittin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23760014" PMDBI20036272 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa 1034 PMDBD2000943 Melittin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23760014" PMDBI20036273 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000943 Melittin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25285879" PMDBI20036274 n.a. PMDBM2020183 n.a. Streptococcus mutans UA140 PMDBD2000944 Melittin B Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21860239" PMDBI20036275 n.a. PMDBM2020261 n.a. Aeromonas hydrophila WAF-38 PMDBD2000945 Menthol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26029178" PMDBI20036276 n.a. "PMID: 30581775; PMID: 26029178" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000945 Menthol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036277 n.a. PMDBM2020253 1314 Streptococcus pyogenes Not Specified PMDBD2000946 Merimepodib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Inosine-5'-monophosphate dehydrogenase n.a. PMID "PMID: 30581775; PMID: 11288107" PMDBI20036279 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Beta-lactamase OXA-10 n.a. PMID "PMID: 30581775; PMID: 7803882" PMDBI20036280 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: D-alanyl-D-alanine carboxypeptidase DacB n.a. PMID "PMID: 30581775; PMID: 9099227" PMDBI20036285 n.a. PMDBM2010322 n.a. Candida spp. Not Specified PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25631674" PMDBI20036286 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000947 Meta-bromo-thiolactone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24143808" PMDBI20036287 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2000948 meta-toluidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25537269" PMDBI20036288 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD2000949 Methacycline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 16S rRNA n.a. PMID "PMID: 30581775; PMID: 15156014" PMDBI20036292 n.a. "PMID: 30581775; PMID: 19855933" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000950 methanesulfonylbenzene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036293 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD2000951 Methanol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26004723" PMDBI20036294 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20036295 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2000952 Methyl eugenol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27808174" PMDBI20036296 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000953 Methyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20036297 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000953 Methyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036298 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000953 Methyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036299 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000953 Methyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036300 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000953 Methyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036301 n.a. "PMID: 30581775; PMID: 22251040" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000954 Methyl indole-7-carboxylate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036302 n.a. PMDBM2021245 28450 Burkholderia pseudomallei KHW PMDBD2000955 Methylthiopropylamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 2003500" PMDBI20036303 n.a. PMDBM2021153 1313 Streptococcus pneumoniae Not Specified PMDBD2000956 Meticillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20036304 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD2000956 Meticillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20036308 n.a. "PMID: 30581775; PMID: 7447421" 171101 Streptococcus pneumoniae R6 PMDBD2000956 Meticillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID PMDBM2021153 PMDBI20036312 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD2000956 Meticillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: MecA PBP2' (penicillin binding protein 2') n.a. PMID "PMID: 30581775; PMID: 16946250" PMDBI20036313 n.a. PMDBM2020099 1502 Clostridium perfringens Not Specified PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 231450" PMDBI20036314 n.a. PMDBM2020226 85962 Helicobacter pylori ATCC 700392 PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Oxygen-insensitive NADPH nitroreductase n.a. PMID "PMID: 30581775; PMID: 10543743" PMDBI20036315 n.a. PMDBM2020226 85962 Helicobacter pylori 26695 PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Oxygen-insensitive NADPH nitroreductase n.a. PMID "PMID: 30581775; PMID: 10543743" PMDBI20036322 n.a. PMDBM2020552 1501 Clostridium pasteurianum Not Specified PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Iron hydrogenase 1 n.a. PMID "PMID: 30581775; PMID: 16550436" PMDBI20036327 n.a. "PMID: 30581775; PMID: 20038616" 431947 Porphyromonas gingivalis ATCC 33277 PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" antibiotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020236 PMDBI20036328 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD1294 Mezlocillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 2683579" PMDBI20036329 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD1294 Mezlocillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 2683579" PMDBI20036330 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD1294 Mezlocillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2 n.a. PMID "PMID: 30581775; PMID: 2683579" PMDBI20036331 n.a. PMDBM2021153 1313 Streptococcus pneumoniae Not Specified PMDBD1294 Mezlocillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 2683579" PMDBI20036338 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAN 74 PMDBD2000957 Micafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23879871" PMDBI20036339 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAN 102 PMDBD2000957 Micafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23879871" PMDBI20036340 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAN 28 PMDBD2000957 Micafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23879871" PMDBI20036341 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAN 32 PMDBD2000957 Micafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23879871" PMDBI20036342 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAN 41 PMDBD2000957 Micafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23879871" PMDBI20036343 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAN 42 PMDBD2000957 Micafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23879871" PMDBI20036344 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAN 12 PMDBD2000957 Micafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23879871" PMDBI20036345 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAN 11 PMDBD2000957 Micafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23879871" PMDBI20036346 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAN 48 PMDBD2000957 Micafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23879871" PMDBI20036347 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAN 62 PMDBD2000957 Micafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23879871" PMDBI20036348 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAN 80 PMDBD2000957 Micafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23879871" PMDBI20036349 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAN 87 PMDBD2000957 Micafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23879871" PMDBI20036350 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAN 97 PMDBD2000957 Micafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23879871" PMDBI20036351 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAN 50 PMDBD2000957 Micafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23879871" PMDBI20036352 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAN 39 PMDBD2000957 Micafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23879871" PMDBI20036353 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAN 14 PMDBD2000957 Micafungin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23879871" PMDBI20036354 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Lanosterol 14-alpha demethylase n.a. PMID "PMID: 30581775; PMID: 8834867" PMDBI20036355 n.a. PMDBM2021248 n.a. Candida albicans ATCC MYA-2876 PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Lanosterol 14-alpha demethylase n.a. PMID "PMID: 30581775; PMID: 8834867" PMDBI20036363 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2000958 Midazolam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26241210" PMDBI20036364 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2000958 Midazolam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26241210" PMDBI20036365 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD1296 Minocycline Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S4 n.a. PMID "PMID: 30581775; PMID: 14723559" PMDBI20036367 n.a. PMDBM2020177 n.a. Staphylococcus aureus Smith diffuse (SD) PMDBD1296 Minocycline Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16289474" PMDBI20036368 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD1296 Minocycline Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 16S rRNA n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20036370 n.a. PMDBM2020620 1747 Propionibacterium acnes LMG 16711 PMDBD1296 Minocycline Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24251377" PMDBI20036371 n.a. PMDBM2020620 n.a. Propionibacterium acnes LMG 16712 PMDBD1296 Minocycline Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24251377" PMDBI20036372 n.a. PMDBM2020620 n.a. Propionibacterium acnes LMG 16715 PMDBD1296 Minocycline Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24251377" PMDBI20036373 n.a. PMDBM2020075 470 Acinetobacter baumannii Not Specified PMDBD1299 Mitomycin C Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27939675" PMDBI20036374 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20036375 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 9598779" PMDBI20036376 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 9598779" PMDBI20036377 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 9598779" PMDBI20036378 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 9598779" PMDBI20036387 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia SM33 PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 14693533" PMDBI20036392 n.a. PMDBM2020888 1235988 Mycobacterium avium 101 PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15561879" PMDBI20036393 n.a. "PMID: 30581775; PMID: 15561879" 243243 Mycobacterium avium 104 PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020888 PMDBI20036394 n.a. PMDBM2020888 n.a. Mycobacterium avium 109 PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15561879" PMDBI20036395 n.a. PMDBM2020888 n.a. Mycobacterium avium A5 PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15561879" PMDBI20036420 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28409362" PMDBI20036421 n.a. PMDBM2020888 1764 Mycobacterium avium Not Specified PMDBD2000959 Moxifloxacin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 15004073" PMDBI20036422 n.a. PMDBM2020183 n.a. Streptococcus mutans ATCC 10449 PMDBD2000960 MUC7 12-mer-D Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16595638" PMDBI20036423 n.a. PMDBM2020183 n.a. Streptococcus mutans ATCC 10449 PMDBD2000961 MUC7 12-mer-L Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16595638" PMDBI20036424 n.a. PMDBM2020183 n.a. Streptococcus mutans ATCC 10449 PMDBD2000962 MUC7 12-mer-L4 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16595638" PMDBI20036425 n.a. PMDBM2020183 n.a. Streptococcus mutans ATCC 10449 PMDBD2000963 MUC7 20-mer Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16595638" PMDBI20036426 n.a. PMDBM2020080 1423 Bacillus subtilis 168 PMDBD2000964 Mucobromic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25335695" PMDBI20036427 n.a. PMDBM2020080 1423 Bacillus subtilis 168 PMDBD2000965 Mucochloric acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25335695" PMDBI20036428 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2000966 Mustard oil Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20036429 n.a. PMDBM2020177 561307 Staphylococcus aureus RN4220 PMDBD2000967 Myricetin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28365326" PMDBI20036430 n.a. PMDBM2020177 n.a. Staphylococcus aureus SA1199B PMDBD2000967 Myricetin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28365326" PMDBI20036431 n.a. PMDBM2020177 561307 Staphylococcus aureus RN4220 PMDBD2000968 Myricitrin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28365326" PMDBI20036432 n.a. "PMID: 30581775; PMID: 22045628" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000969 Myristic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036433 n.a. PMDBM2020035 n.a. Escherichia coli ATCC 10536 PMDBD2000969 Myristic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25656290" PMDBI20036434 n.a. PMDBM2020100 n.a. Klebsiella pneumoniae ATCC 10031 PMDBD2000969 Myristic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25656290" PMDBI20036435 n.a. PMDBM2021025 n.a. Proteus mirabilis ATCC 7002 PMDBD2000969 Myristic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25656290" PMDBI20036436 n.a. PMDBM2021026 n.a. Proteus vulgaris ATCC 49132 PMDBD2000969 Myristic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25656290" PMDBI20036437 n.a. PMDBM2020219 n.a. Serratia marcescens a clinical isolate having GenBank Acc no. FJ584421 PMDBD2000969 Myristic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25656290" PMDBI20036438 n.a. PMDBM2020258 n.a. Vibrio cholerae VCO1 PMDBD2000969 Myristic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26939983" PMDBI20036439 n.a. "PMID: 30581775; PMID: 22045628" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000970 Myristoyl-DL-carnitine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036440 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2000971 Myrrh oil Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20036441 n.a. PMDBM2020848 n.a. Listeria monocytogenes KCTC 3710 PMDBD2000972 Myxinidin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26450121" PMDBI20036442 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000972 Myxinidin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26450121" PMDBI20036443 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000972 Myxinidin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26450121" PMDBI20036444 n.a. PMDBM2020848 n.a. Listeria monocytogenes KCTC 3710 PMDBD2000973 Myxinidin1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26450121" PMDBI20036445 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000973 Myxinidin1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26450121" PMDBI20036446 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000973 Myxinidin1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26450121" PMDBI20036447 n.a. PMDBM2020848 n.a. Listeria monocytogenes KCTC 3710 PMDBD2000974 Myxinidin2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26450121" PMDBI20036448 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000974 Myxinidin2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26450121" PMDBI20036449 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000974 Myxinidin2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26450121" PMDBI20036450 n.a. PMDBM2020848 n.a. Listeria monocytogenes KCTC 3710 PMDBD2000975 Myxinidin3 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26450121" PMDBI20036451 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2000975 Myxinidin3 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26450121" PMDBI20036452 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000975 Myxinidin3 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26450121" PMDBI20036453 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000976 N -(3-nitro-4-hydroxy-benzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20036454 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000976 N -(3-nitro-4-hydroxy-benzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036455 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000976 N -(3-nitro-4-hydroxy-benzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036456 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000976 N -(3-nitro-4-hydroxy-benzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036457 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000976 N -(3-nitro-4-hydroxy-benzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036458 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000977 N -(4-trifluoromethyl-benzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20036459 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000977 N -(4-trifluoromethyl-benzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036460 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000977 N -(4-trifluoromethyl-benzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036461 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000977 N -(4-trifluoromethyl-benzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036462 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000977 N -(4-trifluoromethyl-benzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036463 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000978 N -(5-bromo-2-hydroxy-benzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20036464 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000978 N -(5-bromo-2-hydroxy-benzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036465 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000978 N -(5-bromo-2-hydroxy-benzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036466 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000978 N -(5-bromo-2-hydroxy-benzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036467 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000978 N -(5-bromo-2-hydroxy-benzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036468 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000979 N -(pyridin-3-yl-methylene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20036469 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000979 N -(pyridin-3-yl-methylene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036470 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000979 N -(pyridin-3-yl-methylene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036471 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000979 N -(pyridin-3-yl-methylene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036472 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000979 N -(pyridin-3-yl-methylene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036473 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000980 N -[(3-chloro-isoquinolin-4-yl)methylene] benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036474 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD2000981 N 3-(2-thienylcarbonyl)-4-bromo-1,5-dimethyl-1H-pyrazole-3-carbohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20036475 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2000981 N 3-(2-thienylcarbonyl)-4-bromo-1,5-dimethyl-1H-pyrazole-3-carbohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20036476 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD2000981 N 3-(2-thienylcarbonyl)-4-bromo-1,5-dimethyl-1H-pyrazole-3-carbohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20036477 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD2000981 N 3-(2-thienylcarbonyl)-4-bromo-1,5-dimethyl-1H-pyrazole-3-carbohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20036478 n.a. PMDBM2020075 470 Acinetobacter baumannii Not Specified PMDBD2000982 N-((1E)-{4-ethoxy-3-[(8-oxo-1,5,6,8-tetrahydro-2H-1,5-methanopyrido[1,2-a][1,5]diazocin-3(4H)-yl)methyl]phenyl}methylene)-3,4,5-trihydroxybenzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24117391" PMDBI20036479 n.a. "PMID: 30581775; PMID: 24117391" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000982 N-((1E)-{4-ethoxy-3-[(8-oxo-1,5,6,8-tetrahydro-2H-1,5-methanopyrido[1,2-a][1,5]diazocin-3(4H)-yl)methyl]phenyl}methylene)-3,4,5-trihydroxybenzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036480 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000983 N-((2R,3R,4S,5S,6R)-2,4,5-Trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)butyramide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036481 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000984 N-((2R,3R,4S,5S,6R)-2,4,5-Trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)dodecanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036482 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000985 N-((2R,3R,4S,5S,6R)-2,4,5-Trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)hexanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036483 n.a. "PMID: 30581775; PMID: 28049617" 652611 Pseudomonas aeruginosa PA14 PMDBD2000986 N-((2R,3R,4S,5S,6R)-2,4,5-Trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)octanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036484 n.a. "PMID: 30581775; PMID: 20453898" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000987 N-(1,3-benzothiazol-2-yl)butanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036485 n.a. "PMID: 30581775; PMID: 20453898" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000988 N-(1,3-Thiazol-2-yl)butanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036486 n.a. "PMID: 30581775; PMID: 20453898" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000989 N-(2-oxothiolan-3-yl)butanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036487 n.a. "PMID: 30581775; PMID: 20453898" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000990 N-(2-Pyridinyl)butanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036488 n.a. "PMID: 30581775; PMID: 20453898" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000991 N-(2-Pyrimidinyl)butanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036489 n.a. "PMID: 30581775; PMID: 20453898" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000992 N-(4,5-Dihydro-1,3-thiazol-2-yl)butanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036490 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2000993 N-(4-Bromobenzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20036491 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2000993 N-(4-Bromobenzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036492 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2000993 N-(4-Bromobenzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036493 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2000993 N-(4-Bromobenzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036494 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2000993 N-(4-Bromobenzylidene)benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036495 n.a. PMDBM2020236 1403335 Porphyromonas gingivalis 381 PMDBD2000994 N-(4-hydroxy-2-methylphenyl)-3-oxododecanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19778324" PMDBI20036496 n.a. "PMID: 30581775; PMID: 20453898" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000995 N-(4-Hydroxyphenyl)butanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036497 n.a. "PMID: 30581775; PMID: 20453898" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000996 N-(4-Morpholinyl)butanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036498 n.a. "PMID: 30581775; PMID: 20453898" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000997 N-(4-Pyridinyl)butanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036499 n.a. "PMID: 30581775; PMID: 20453898" 208964 Pseudomonas aeruginosa PAO1 PMDBD2000998 N-(5-Methyl-1,2-oxazol-3-yl)butanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036500 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD2000999 N-(6-tert-butyl-2,3-dihydro- 2-methylpyridazin-4-yl)-5-chlorothiophene-2-carbohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20036501 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2000999 N-(6-tert-butyl-2,3-dihydro- 2-methylpyridazin-4-yl)-5-chlorothiophene-2-carbohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20036502 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD2000999 N-(6-tert-butyl-2,3-dihydro- 2-methylpyridazin-4-yl)-5-chlorothiophene-2-carbohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20036503 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD2000999 N-(6-tert-butyl-2,3-dihydro- 2-methylpyridazin-4-yl)-5-chlorothiophene-2-carbohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20036504 n.a. PMDBM2020236 1403335 Porphyromonas gingivalis 381 PMDBD2001000 N-(pyrrolidin-3-yl)dodecanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19778324" PMDBI20036505 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2001001 N-[(3-chloro-isoquinolin-4-yl)methylene]benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20036506 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2001001 N-[(3-chloro-isoquinolin-4-yl)methylene]benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036507 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2001001 N-[(3-chloro-isoquinolin-4-yl)methylene]benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036508 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2001001 N-[(3-chloro-isoquinolin-4-yl)methylene]benzohydrazide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036509 n.a. PMDBM2021266 n.a. Vibrio anguillarum LMG4411 PMDBD2001002 N-[5-(6-amino-9H-purin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19778962" PMDBI20036510 n.a. PMDBM2021216 n.a. Vibrio campbellii LMG21363 PMDBD2001002 N-[5-(6-amino-9H-purin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19778962" PMDBI20036511 n.a. PMDBM2021267 n.a. Vibrio vulnificus LMG 16867 PMDBD2001002 N-[5-(6-amino-9H-purin-9-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19778962" PMDBI20036512 n.a. "PMID: 30581775; PMID: 28350449" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001003 N1-(7-chloroquinolin-4-yl)dodecane-1,12-diamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036513 n.a. PMDBM2020219 n.a. Serratia marcescens ATCC 27117 PMDBD2001003 N1-(7-chloroquinolin-4-yl)dodecane-1,12-diamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28350449" PMDBI20036514 n.a. PMDBM2020219 n.a. Serratia marcescens ATCC 27117 PMDBD2001004 N1-(7-chloroquinolin-4-yl)ethane-1,2-diamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28350449" PMDBI20036515 n.a. "PMID: 30581775; PMID: 28350449" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001005 N1-(7-chloroquinolin-4-yl)octane-1,8-diamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036516 n.a. PMDBM2020219 n.a. Serratia marcescens ATCC 27117 PMDBD2001005 N1-(7-chloroquinolin-4-yl)octane-1,8-diamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28350449" PMDBI20036517 n.a. "PMID: 30581775; PMID: 28350449" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001006 N1-[7-(trifluoromethyl)quinolin-4-yl]dodecane-1,12-diamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036518 n.a. PMDBM2020219 n.a. Serratia marcescens ATCC 27117 PMDBD2001006 N1-[7-(trifluoromethyl)quinolin-4-yl]dodecane-1,12-diamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28350449" PMDBI20036519 n.a. PMDBM2020219 n.a. Serratia marcescens ATCC 27117 PMDBD2001007 N1-[7-(trifluoromethyl)quinolin-4-yl]ethane-1,2-diamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28350449" PMDBI20036520 n.a. PMDBM2020219 n.a. Serratia marcescens ATCC 27117 PMDBD2001008 N1-[7-(trifluoromethyl)quinolin-4-yl]octane-1,8-diamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28350449" PMDBI20036521 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2001009 NA10 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24078467" PMDBI20036522 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2001010 NA12 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24078467" PMDBI20036523 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2001011 NA8 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24078467" PMDBI20036524 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2001012 NA8H Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24078467" PMDBI20036525 n.a. PMDBM2020177 n.a. Staphylococcus aureus A7510 PMDBD2001013 Na-Benzoate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20089325" PMDBI20036526 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD2001014 NA-CATH Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21605457" PMDBI20036527 n.a. PMDBM2021755 271848 Burkholderia thailandensis E264 PMDBD2001014 NA-CATH Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26196513" PMDBI20036528 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD2001015 NA-CATH-ATRA1-ATRA1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21605457" PMDBI20036529 n.a. PMDBM2010633 n.a. Coagulase- negative staphylococci CNS 5 PMDBD2001016 N-Acetylcysteine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28237766" PMDBI20036530 n.a. PMDBM2010634 n.a. Coagulase- negative staphylococci CNS 6 PMDBD2001016 N-Acetylcysteine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28237766" PMDBI20036531 n.a. PMDBM2010635 n.a. Coagulase- negative staphylococci CNS 19 PMDBD2001016 N-Acetylcysteine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28237766" PMDBI20036532 n.a. PMDBM2010636 n.a. Coagulase- negative staphylococci CNS 26 PMDBD2001016 N-Acetylcysteine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28237766" PMDBI20036533 n.a. PMDBM2010637 n.a. Coagulase- negative staphylococci CNS 27 PMDBD2001016 N-Acetylcysteine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28237766" PMDBI20036534 n.a. PMDBM2010638 n.a. Coagulase- negative staphylococci CNS 42 PMDBD2001016 N-Acetylcysteine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28237766" PMDBI20036535 n.a. PMDBM2010639 n.a. Coagulase- negative staphylococci CNS 192 PMDBD2001016 N-Acetylcysteine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28237766" PMDBI20036536 n.a. PMDBM2010640 n.a. Coagulase- negative staphylococci CNS 33 PMDBD2001016 N-Acetylcysteine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28237766" PMDBI20036537 n.a. PMDBM2021018 n.a. Corynebacterium ammoniagenes IEGM 1862 PMDBD2001016 N-Acetylcysteine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28237766" PMDBI20036538 n.a. PMDBM2021767 n.a. Mycobacterium smegmatis mc2155 PMDBD2001016 N-Acetylcysteine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28237766" PMDBI20036539 n.a. PMDBM2020620 n.a. Propionibacterium acnes VKM Ac 1450 PMDBD2001016 N-Acetylcysteine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28237766" PMDBI20036540 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2001016 N-Acetylcysteine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28237766" PMDBI20036541 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 33591 PMDBD2001016 N-Acetylcysteine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28237766" PMDBI20036542 n.a. PMDBM2020253 n.a. Streptococcus pyogenes ATCC 8668 PMDBD2001016 N-Acetylcysteine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28237766" PMDBI20036543 n.a. PMDBM2020482 n.a. Campylobacter jejuni M129 PMDBD2001017 NaCl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17259368" PMDBI20036544 n.a. PMDBM2021153 1313 Streptococcus pneumoniae Not Specified PMDBD2001018 Nafcillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20036545 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD2001018 Nafcillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20036549 n.a. "PMID: 30581775; PMID: 7447421" 171101 Streptococcus pneumoniae R6 PMDBD2001018 Nafcillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID PMDBM2021153 PMDBI20036553 n.a. PMDBM2020177 n.a. Staphylococcus aureus A7510 PMDBD2001019 Na-Propionate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20089325" PMDBI20036554 n.a. PMDBM2020035 n.a. Escherichia coli K-12 MG 1655 PMDBD2001020 Na-Pyrosulfite Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20089325" PMDBI20036555 n.a. PMDBM2020183 n.a. Streptococcus mutans MT 8148 PMDBD2001020 Na-Pyrosulfite Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20089325" PMDBI20036556 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD574 Naringenin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20036557 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD574 Naringenin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20036558 n.a. "PMID: 30581775; PMID: 23449917" 208964 Pseudomonas aeruginosa PAO1 PMDBD574 Naringenin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036559 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20036560 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20036561 n.a. PMDBM2020192 n.a. Yersinia enterocolitica CECT 4315 PMDBD575 Naringin Herbal Substance Anti-oxidant, anti-cancer and blood cholesterol lowering effect n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22533445" PMDBI20036562 n.a. "PMID: 30581775; PMID: 17369333" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001021 N-Decanoyl cyclopentylamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036563 n.a. "PMID: 30581775; PMID: 24327212" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001022 N-decanoyl-L- homoserine benzyl ester Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036564 n.a. PMDBM2010236 n.a. Human immunodeficiency virus Not Specified PMDBD2001023 Nelfinavir Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: HIV-1 protease n.a. PMID "PMID: 30581775; PMID: 11396919" PMDBI20036572 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2001024 Neoeriocitrin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20036573 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD2001024 Neoeriocitrin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20036574 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2001025 Neohesperidin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20036575 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD2001025 Neohesperidin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20036576 n.a. PMDBM2020192 n.a. Yersinia enterocolitica CECT 4315 PMDBD2001025 Neohesperidin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22533445" PMDBI20036577 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD579 Neomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S12 n.a. PMID "PMID: 30581775; PMID: 6103875" PMDBI20036579 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD579 Neomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 16S rRNA n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20036586 n.a. PMDBM2021248 5476 Candida albicans DAY185 PMDBD2001026 Nerolidol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28155334" PMDBI20036587 n.a. "PMID: 30581775; PMID: 20453898" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001027 N-Ethylacetanilide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036588 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD2001028 Netilmicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 16S rRNA n.a. PMID "PMID: 30581775; PMID: 16891542" PMDBI20036590 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001028 Netilmicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S12 n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20036593 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD582 Nevirapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Reverse transcriptase n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20036601 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD2001029 n-Hexane Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26004723" PMDBI20036602 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 15692 PMDBD2001030 Niacinamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Exotoxin A n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20036603 n.a. "PMID: 30581775; PMID: 17016423" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001030 Niacinamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Exotoxin A n.a. PMID PMDBM2020151 PMDBI20036604 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa 1C PMDBD2001030 Niacinamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Exotoxin A n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20036605 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PRS 101 PMDBD2001030 Niacinamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Exotoxin A n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20036606 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa LMG 12228 PMDBD2001030 Niacinamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Exotoxin A n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20036612 n.a. "PMID: 30581775; PMID: 23254430" 652611 Pseudomonas aeruginosa PA14 PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036613 n.a. PMDBM2021741 5207 Cryptococcus neoformans Not Specified PMDBD592 nimesulide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27866353" PMDBI20036614 n.a. PMDBM2021768 523103 Trichophyton mentagrophytes Not Specified PMDBD592 nimesulide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27866353" PMDBI20036615 n.a. PMDBM2020848 n.a. Listeria monocytogenes ATCC 7644 PMDBD2001031 Nisin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20414650" PMDBI20036616 n.a. PMDBM2020177 n.a. Staphylococcus aureus 815 PMDBD2001031 Nisin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20414650" PMDBI20036617 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2001031 Nisin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20414650" PMDBI20036618 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 9027 PMDBD2001031 Nisin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21431164" PMDBI20036619 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 PMDBD2001031 Nisin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23070152" PMDBI20036620 n.a. PMDBM2020177 n.a. Staphylococcus aureus Xen 31 (MRSA) PMDBD2001031 Nisin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25319566" PMDBI20036621 n.a. PMDBM2021769 873 Desulfovibrio africanus Not Specified PMDBD2001032 Nitazoxanide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Pyruvate-flavodoxin oxidoreductase n.a. PMID "PMID: 30581775; PMID: 17158936" PMDBI20036623 n.a. PMDBM2020201 1535 Clostridium leptum Not Specified PMDBD595 nitrazepam Therapeutic Substance anticonvulsant and hypnotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 9310649" PMDBI20036624 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Glutathione reductase n.a. PMID "PMID: 30581775; PMID: 16275032" PMDBI20036633 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Probable pyruvate-flavodoxin oxidoreductase n.a. PMID "PMID: 30581775; PMID: 6363380" PMDBI20036641 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001033 Nitrofurantoin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S10 n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20036643 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2001034 n-Methyl-D-valine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20036644 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2001034 n-Methyl-D-valine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20036645 n.a. PMDBM2020219 n.a. Serratia marcescens AS-1S PMDBD2001035 N-Nonanoyl-cyclopentylamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17675425" PMDBI20036646 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2001036 Nobiletin Therapeutic Substance Preclinical n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23891936" PMDBI20036647 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD2001036 Nobiletin Therapeutic Substance Preclinical n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26140409" PMDBI20036648 n.a. "PMID: 30581775; PMID: 21852522" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001037 Nodakenetin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036649 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia GIMT1.118 PMDBD2001037 Nodakenetin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21852522" PMDBI20036650 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2001038 Norbgugaine 12 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23489623" PMDBI20036651 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia SM33 PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 14693533" PMDBI20036652 n.a. PMDBM2020177 n.a. Staphylococcus aureus MR23 (MRSA) PMDBD608 Norgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20036653 n.a. PMDBM2020177 n.a. Staphylococcus aureus MS3 (MSSA) PMDBD608 Norgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20036654 n.a. PMDBM2020177 n.a. Staphylococcus aureus MS4-5 (MSSA) PMDBD608 Norgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20036655 n.a. PMDBM2020177 n.a. Staphylococcus aureus MS18 (MSSA) PMDBD608 Norgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20036656 n.a. PMDBM2020177 n.a. Staphylococcus aureus SH1000 (MSSA) PMDBD608 Norgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20036657 n.a. PMDBM2020177 n.a. Staphylococcus aureus MR2 (MRSA) PMDBD608 Norgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20036658 n.a. PMDBM2020177 n.a. Staphylococcus aureus (MRSA) MR4 PMDBD608 Norgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20036659 n.a. PMDBM2020177 n.a. Staphylococcus aureus MR11 (MRSA) PMDBD608 Norgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20036660 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis SE4 PMDBD608 Norgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20036661 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis SE21 PMDBD608 Norgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28758016" PMDBI20036662 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2001039 Norpinguisone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21384863" PMDBI20036663 n.a. PMDBM2020080 n.a. Bacillus subtilis ATCC 19385 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26350146" PMDBI20036664 n.a. PMDBM2020035 n.a. Escherichia coli ATCC PTA 1798 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26350146" PMDBI20036665 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25330 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26350146" PMDBI20036666 n.a. "PMID: 30581775; PMID: 26817804" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036667 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA02 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036668 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA04 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036669 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA08 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036670 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA10 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036671 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA16 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036672 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA29 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036673 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA30 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036674 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA32 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036675 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA38 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036676 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA40 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036677 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA41 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036678 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA47 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036679 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA49 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036680 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA52 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036681 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA58 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036682 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA60 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036683 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA62 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036684 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA68 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036685 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA71 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26817804" PMDBI20036686 n.a. PMDBM2020075 n.a. Acinetobacter baumannii AB 1 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27864804" PMDBI20036687 n.a. PMDBM2020100 n.a. Klebsiella pneumoniae KP 1 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27864804" PMDBI20036688 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA 1 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27864804" PMDBI20036689 n.a. PMDBM2020177 n.a. Staphylococcus aureus SA 1 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27864804" PMDBI20036690 n.a. "PMID: 30581775; PMID: 27922663" 210007 Streptococcus mutans UA159 PMDBD2001040 Norspermidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036691 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD2001041 Novobiocin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 1 n.a. PMID "PMID: 30581775; PMID: 2830840" PMDBI20036694 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa 1162 PMDBD2001042 NRC-16 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23760014" PMDBI20036695 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa 3547 PMDBD2001042 NRC-16 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23760014" PMDBI20036696 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa 4007 PMDBD2001042 NRC-16 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23760014" PMDBI20036697 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa 3399 PMDBD2001042 NRC-16 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23760014" PMDBI20036698 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa 1034 PMDBD2001042 NRC-16 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23760014" PMDBI20036699 n.a. PMDBM2021248 5476 Candida albicans Not Specified PMDBD1325 Nystatin Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Ergosterol n.a. PMID "PMID: 30581775; PMID: 16500971" PMDBI20036700 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD1325 Nystatin Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20036701 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2001043 O-(2,6-Dichlorobenzyl)-D-tyrosine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20036702 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2001043 O-(2,6-Dichlorobenzyl)-D-tyrosine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20036703 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2001044 Octadecyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20036704 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2001044 Octadecyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036705 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2001044 Octadecyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036706 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2001044 Octadecyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036707 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2001044 Octadecyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036708 n.a. PMDBM2020035 562 Escherichia coli RP437 PMDBD2001045 Octameric peptide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20097816" PMDBI20036709 n.a. PMDBM2020219 n.a. Serratia marcescens ATCC 27117 PMDBD2001046 octane-1,8-diamine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28350449" PMDBI20036710 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2001047 Octyl gallate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20036711 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2001047 Octyl gallate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036712 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2001047 Octyl gallate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036713 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2001047 Octyl gallate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20036714 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2001047 Octyl gallate Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036715 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 7963747" PMDBI20036716 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 7963747" PMDBI20036717 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 7963747" PMDBI20036718 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 7963747" PMDBI20036727 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia SM33 PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 14693533" PMDBI20036760 n.a. PMDBM2021245 n.a. Burkholderia pseudomallei bpsl3 null mutant of KHW PMDBD2001048 OHC10HL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21252275" PMDBI20036761 n.a. PMDBM2021245 28450 Burkholderia pseudomallei KHW PMDBD2001048 OHC10HL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21252275" PMDBI20036762 n.a. PMDBM2021245 n.a. Burkholderia pseudomallei bpsl3 null mutant of KHW PMDBD2001049 OHC8HL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21252275" PMDBI20036763 n.a. PMDBM2021245 28450 Burkholderia pseudomallei KHW PMDBD2001049 OHC8HL Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21252275" PMDBI20036764 n.a. PMDBM2020177 n.a. Staphylococcus aureus UAMS-1 PMDBD2001050 Oleanolic Acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22242149" PMDBI20036765 n.a. PMDBM2021767 1772 Mycobacterium smegmatis Not Specified PMDBD2001050 Oleanolic Acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28103726" PMDBI20036766 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 9027 PMDBD1327 Oleic Acid Dietary Substances a naturally occurring fatty acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23844805" PMDBI20036767 n.a. "PMID: 30581775; PMID: 26149536" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001051 O-LF11-215 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036768 n.a. "PMID: 30581775; PMID: 26149536" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001052 O-LF11-227 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036769 n.a. PMDBM2020177 n.a. Staphylococcus aureus RN1HG PMDBD2001053 Olive oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20036770 n.a. PMDBM2020080 n.a. Bacillus subtilis ATCC 39087 PMDBD2001054 Olmesartran Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25038633" PMDBI20036771 n.a. PMDBM2020177 n.a. Staphylococcus aureus SC01 PMDBD2001055 O-Methyl-D-tyrosine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20036772 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2001055 O-Methyl-D-tyrosine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20036773 n.a. PMDBM2020192 n.a. Yersinia enterocolitica CECT 4315 PMDBD2001056 Orange extract Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22533445" PMDBI20036774 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001057 Oregano oil Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20036775 n.a. PMDBM2010204 n.a. Influenza A virus A PMDBD2001058 Oseltamivir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Neuraminidase n.a. PMID "PMID: 30581775; PMID: 12435681" PMDBI20036776 n.a. PMDBM2010681 n.a. Influenza A virus Chile PMDBD2001058 Oseltamivir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Neuraminidase n.a. PMID "PMID: 30581775; PMID: 12435681" PMDBI20036777 n.a. PMDBM2010682 n.a. Influenza A virus 1 PMDBD2001058 Oseltamivir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Neuraminidase n.a. PMID "PMID: 30581775; PMID: 12435681" PMDBI20036778 n.a. PMDBM2010683 n.a. Influenza A virus 1983 H1N1 PMDBD2001058 Oseltamivir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Neuraminidase n.a. PMID "PMID: 30581775; PMID: 12435681" PMDBI20036795 n.a. PMDBM2021248 n.a. Candida albicans CAI4 PMDBD2001059 OSIP108 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24566179" PMDBI20036796 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2001059 OSIP108 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24566179" PMDBI20036797 n.a. PMDBM2021248 n.a. Candida albicans DAY286 PMDBD2001059 OSIP108 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24566179" PMDBI20036798 n.a. PMDBM2021248 n.a. Candida albicans CAF2 PMDBD2001059 OSIP108 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24566179" PMDBI20036799 n.a. PMDBM2021248 n.a. Candida albicans B2630 PMDBD2001059 OSIP108 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24566179" PMDBI20036800 n.a. PMDBM2021248 n.a. Candida albicans B63195 PMDBD2001059 OSIP108 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24566179" PMDBI20036801 n.a. PMDBM2021248 5476 Candida albicans Not Specified PMDBD2001059 OSIP108 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24566179" PMDBI20036802 n.a. PMDBM2021759 n.a. Candida dubliniensis NCPF 3949 PMDBD2001059 OSIP108 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24566179" PMDBI20036803 n.a. PMDBM2021747 n.a. Candida glabrata BG2 PMDBD2001059 OSIP108 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24566179" PMDBI20036804 n.a. PMDBM2021748 n.a. Candida krusei IHEM 6104 PMDBD2001059 OSIP108 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24566179" PMDBI20036805 n.a. PMDBM2021153 1313 Streptococcus pneumoniae Not Specified PMDBD2001060 Oxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: enicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20036806 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD2001060 Oxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20036810 n.a. "PMID: 30581775; PMID: 7447421" 171101 Streptococcus pneumoniae R6 PMDBD2001060 Oxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID PMDBM2021153 PMDBI20036814 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD2001060 Oxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20036815 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD2001060 Oxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20036818 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD2001060 Oxacillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2 n.a. PMID "PMID: 30581775; PMID: 18505853" PMDBI20036819 n.a. "PMID: 30581775; PMID: 20038616" 431947 Porphyromonas gingivalis ATCC 33277 PMDBD2001061 Oxantel Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020236 PMDBI20036820 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD632 Oxiconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20036821 n.a. "PMID: 30581775; PMID: 23819562" 652611 Pseudomonas aeruginosa PA14 PMDBD2001062 Oxyresveratrol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036822 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001062 Oxyresveratrol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25007234" PMDBI20036823 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD1339 Oxytetracycline Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S4 n.a. PMID "PMID: 30581775; PMID: 6163479" PMDBI20036827 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD1339 Oxytetracycline Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 16S rRNA n.a. PMID "PMID: 30581775; PMID: 16978353" PMDBI20036835 n.a. PMDBM2020620 1747 Propionibacterium acnes LMG 16711 PMDBD1339 Oxytetracycline Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24251377" PMDBI20036836 n.a. PMDBM2020620 n.a. Propionibacterium acnes LMG 16712 PMDBD1339 Oxytetracycline Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24251377" PMDBI20036837 n.a. PMDBM2020620 n.a. Propionibacterium acnes LMG 16715 PMDBD1339 Oxytetracycline Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24251377" PMDBI20036838 n.a. PMDBM2020177 n.a. Staphylococcus aureus LUH14616 PMDBD2001063 P10 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24841266" PMDBI20036839 n.a. "PMID: 30581775; PMID: 26097095" 210007 Streptococcus mutans UA159 PMDBD2001064 P15-CSP Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20036840 n.a. PMDBM2020177 n.a. Staphylococcus aureus LUH14616 PMDBD2001065 P60.4Ac Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24841266" PMDBI20036841 n.a. PMDBM2010691 n.a. Human respiratory syncytial virus B 18537 PMDBD2001066 Palivizumab Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Fusion glycoprotein F0 n.a. PMID "PMID: 30581775; PMID: 17990791" PMDBI20036844 n.a. PMDBM2020035 316407 Escherichia coli W3110 PMDBD2001067 Palmitic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22045628" PMDBI20036845 n.a. "PMID: 30581775; PMID: 22045628" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001067 Palmitic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036846 n.a. PMDBM2020035 316407 Escherichia coli W3110 PMDBD2001068 Palmitoyl-DL-carnitine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22045628" PMDBI20036847 n.a. "PMID: 30581775; PMID: 22045628" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001068 Palmitoyl-DL-carnitine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036848 n.a. PMDBM2020035 n.a. Escherichia coli ATCC O157 PMDBD2001069 Pa-MAP Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26916401" PMDBI20036849 n.a. PMDBM2020100 n.a. Klebsiella pneumoniae KPC 001825971 PMDBD2001069 Pa-MAP Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26916401" PMDBI20036850 n.a. PMDBM2020080 n.a. Bacillus subtilis ATCC 39087 PMDBD2001070 Pantaprazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25038633" PMDBI20036851 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2001071 para-anisidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25537269" PMDBI20036852 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD2001072 para-Benzoquinone Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20036853 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD2001072 para-Benzoquinone Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20036854 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD2001072 para-Benzoquinone Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20036855 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD2001072 para-Benzoquinone Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20036856 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2001073 para-ethoxyaniline Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25537269" PMDBI20036857 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2001074 para-ethylaniline Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25537269" PMDBI20036858 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2001075 para-toluidine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25537269" PMDBI20036859 n.a. PMDBM2021761 300852 Thermus thermophilus HB8 PMDBD2001076 Paromomycin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S10 n.a. PMID "PMID: 30581775; PMID: 19438282" PMDBI20036860 n.a. PMDBM2021761 300852 Thermus thermophilus ATCC 27634 PMDBD2001076 Paromomycin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S10 n.a. PMID "PMID: 30581775; PMID: 19438282" PMDBI20036861 n.a. PMDBM2021761 n.a. Thermus thermophilus DSM 579 PMDBD2001076 Paromomycin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S10 n.a. PMID "PMID: 30581775; PMID: 19438282" PMDBI20036862 n.a. PMDBM2020282 85698 Achromobacter xylosoxidans Not Specified PMDBD2001077 Patulin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20111864" PMDBI20036863 n.a. PMDBM2021757 n.a. Halomonas pacifica ATCC 27122 PMDBD2001077 Patulin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24166155" PMDBI20036864 n.a. PMDBM2021770 n.a. Marinobacter hydrocarbonoclasticus ATCC 27132 PMDBD2001077 Patulin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24166155" PMDBI20036865 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2001078 p-Coumaric acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24067082" PMDBI20036866 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 9027 PMDBD2001078 p-Coumaric acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26370951" PMDBI20036867 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD1349 Pefloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 1 n.a. PMID "PMID: 30581775; PMID: 2830840" PMDBI20036868 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD1349 Pefloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 7689456" PMDBI20036869 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD1349 Pefloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 7689456" PMDBI20036870 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD1349 Pefloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 7689456" PMDBI20036871 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD1349 Pefloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 7689456" PMDBI20036928 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD646 Pefloxacin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 15673722" PMDBI20036929 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD646 Pefloxacin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 15673722" PMDBI20036930 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD646 Pefloxacin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 15673722" PMDBI20036931 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD646 Pefloxacin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA topoisomerase 4 subunit A n.a. PMID "PMID: 30581775; PMID: 15673722" PMDBI20036952 n.a. "PMID: 30581775; PMID: 27539815" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001079 Pelargonidin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036953 n.a. PMDBM2010544 n.a. Human herpesvirus 1 Not Specified PMDBD2001080 Penciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA polymerase catalytic subunit n.a. PMID "PMID: 30581775; PMID: 11752352" PMDBI20036962 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2001081 Penicillenol A1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28377634" PMDBI20036963 n.a. "PMID: 30581775; PMID: 28377634" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001081 Penicillenol A1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036964 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001081 Penicillenol A1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28377634" PMDBI20036965 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2001082 Penicillenol A2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28377634" PMDBI20036966 n.a. "PMID: 30581775; PMID: 28377634" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001082 Penicillenol A2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036967 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001082 Penicillenol A2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28377634" PMDBI20036968 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2001083 Penicillenol B1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28377634" PMDBI20036969 n.a. "PMID: 30581775; PMID: 28377634" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001083 Penicillenol B1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036970 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001083 Penicillenol B1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28377634" PMDBI20036971 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2001084 Penicillenol B2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28377634" PMDBI20036972 n.a. "PMID: 30581775; PMID: 28377634" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001084 Penicillenol B2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036973 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001084 Penicillenol B2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28377634" PMDBI20036974 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2001085 Penicillenol C1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28377634" PMDBI20036975 n.a. "PMID: 30581775; PMID: 28377634" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001085 Penicillenol C1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036976 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001085 Penicillenol C1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28377634" PMDBI20036977 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2001086 Penicillenol C2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28377634" PMDBI20036978 n.a. "PMID: 30581775; PMID: 28377634" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001086 Penicillenol C2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036979 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001086 Penicillenol C2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28377634" PMDBI20036980 n.a. PMDBM2020005 1396 Bacillus cereus Not Specified PMDBD2001087 Penicillic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18787817" PMDBI20036981 n.a. PMDBM2020080 1423 Bacillus subtilis Not Specified PMDBD2001087 Penicillic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18787817" PMDBI20036982 n.a. PMDBM2021771 134375 Achromobacter sp. Not Specified PMDBD2001087 Penicillic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20111864" PMDBI20036983 n.a. PMDBM2020282 85698 Achromobacter xylosoxidans Not Specified PMDBD2001087 Penicillic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20111864" PMDBI20036984 n.a. "PMID: 30581775; PMID: 20111864" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001087 Penicillic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036985 n.a. PMDBM2020848 n.a. Listeria monocytogenes 568 PMDBD2001088 Penicillin G Therapeutic Substance Phase 3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20036986 n.a. PMDBM2020848 169963 Listeria monocytogenes EGD-e PMDBD2001088 Penicillin G Therapeutic Substance Phase 3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20036987 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2a PMDBD2001088 Penicillin G Therapeutic Substance Phase 3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20036988 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2b PMDBD2001088 Penicillin G Therapeutic Substance Phase 3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20036989 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 9027 PMDBD2001089 Pentagalloylglucose Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26529040" PMDBI20036990 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001089 Pentagalloylglucose Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26529040" PMDBI20036991 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2001089 Pentagalloylglucose Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26529040" PMDBI20036992 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD2001090 Pentamethoxyflavone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26140409" PMDBI20036993 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2001091 Pentanol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 2468852" PMDBI20036994 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001092 Peppermint oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20036995 n.a. PMDBM2020261 n.a. Aeromonas hydrophila WAF-38 PMDBD2001092 Peppermint oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26029178" PMDBI20036996 n.a. "PMID: 30581775; PMID: 26029178" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001092 Peppermint oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20036997 n.a. PMDBM2021248 5476 Candida albicans Not Specified PMDBD2001093 Peptide 1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25591960" PMDBI20036998 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia 4813 PMDBD2001094 Peptide 1037 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22354291" PMDBI20036999 n.a. PMDBM2020848 n.a. Listeria monocytogenes LM568 PMDBD2001094 Peptide 1037 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22354291" PMDBI20037000 n.a. "PMID: 30581775; PMID: 22354291" 652611 Pseudomonas aeruginosa PA14 PMDBD2001094 Peptide 1037 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037001 n.a. "PMID: 30581775; PMID: 22354291" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001094 Peptide 1037 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037002 n.a. PMDBM2021741 n.a. Cryptococcus neoformans B3501 PMDBD2001095 PG-1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17057089" PMDBI20037003 n.a. PMDBM2020035 n.a. Escherichia coli ATCC 10536 PMDBD2001096 Phenanthrene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25656290" PMDBI20037004 n.a. PMDBM2020100 n.a. Klebsiella pneumoniae ATCC 10031 PMDBD2001096 Phenanthrene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25656290" PMDBI20037005 n.a. PMDBM2021025 n.a. Proteus mirabilis ATCC 7002 PMDBD2001096 Phenanthrene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25656290" PMDBI20037006 n.a. PMDBM2021026 n.a. Proteus vulgaris ATCC 49132 PMDBD2001096 Phenanthrene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25656290" PMDBI20037007 n.a. PMDBM2020219 n.a. Serratia marcescens a clinical isolate having GenBank Acc no. FJ584421 PMDBD2001096 Phenanthrene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25656290" PMDBI20037008 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2001097 Phenobarbitone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26241210" PMDBI20037009 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2001097 Phenobarbitone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26241210" PMDBI20037010 n.a. PMDBM2020219 n.a. Serratia marcescens FJ584421 PMDBD2001098 Phenol,2,4-bis(1,1-dimethylethyl) Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25377484" PMDBI20037011 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001099 Phenoxymethylpenicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: D-alanyl-D-alanine carboxypeptidase DacB n.a. PMID "PMID: 30581775; PMID: 10592235" PMDBI20037012 n.a. PMDBM2020852 1421 Lysinibacillus sphaericus Not Specified PMDBD2001099 Phenoxymethylpenicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin acylase n.a. PMID "PMID: 30581775; PMID: 10592235" PMDBI20037013 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD2001099 Phenoxymethylpenicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037015 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD2001099 Phenoxymethylpenicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037021 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD2001099 Phenoxymethylpenicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: MecA PBP2' (penicillin binding protein 2') n.a. PMID "PMID: 30581775; PMID: 19289525" PMDBI20037023 n.a. PMDBM2020035 511145 Escherichia coli MG1655 PMDBD2001100 Phenyl-arginine-b-naphthylamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24176982" PMDBI20037024 n.a. "PMID: 30581775; PMID: 24176982" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001100 Phenyl-arginine-b-naphthylamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037025 n.a. PMDBM2020177 n.a. Staphylococcus aureus NCTC strain 8532 PMDBD2001100 Phenyl-arginine-b-naphthylamide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24176982" PMDBI20037026 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD1363 Phenytoin Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26241210" PMDBI20037027 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD1363 Phenytoin Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26241210" PMDBI20037028 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2001101 Phloretin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21930760" PMDBI20037029 n.a. PMDBM2020177 561307 Staphylococcus aureus RN4220 PMDBD2001101 Phloretin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28365326" PMDBI20037030 n.a. PMDBM2020177 n.a. Staphylococcus aureus SA1199B PMDBD2001101 Phloretin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28365326" PMDBI20037031 n.a. PMDBM2020177 561307 Staphylococcus aureus RN4220 PMDBD2001102 Phloridzin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28365326" PMDBI20037032 n.a. PMDBM2020035 n.a. Escherichia coli MC4100 PMDBD2001103 Phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23226268" PMDBI20037033 n.a. "PMID: 30581775; PMID: 23226268" 679895 Escherichia coli BW25113 PMDBD2001103 Phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020035 PMDBI20037034 n.a. PMDBM2020035 511145 Escherichia coli MG1655 PMDBD2001103 Phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23226268" PMDBI20037035 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2001104 Phosphorylserine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20037036 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 12228 PMDBD2001104 Phosphorylserine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25658642" PMDBI20037037 n.a. PMDBM2020177 n.a. Staphylococcus aureus NCTC 10788 PMDBD2001105 Phylloseptin-1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20451254" PMDBI20037038 n.a. "PMID: 30581775; PMID: 23791670" 431947 Porphyromonas gingivalis ATCC 33277 PMDBD2001106 phys-GL13K Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020236 PMDBI20037039 n.a. "PMID: 30581775; PMID: 26557964" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001107 Picolinic acid Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037040 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAK01 PMDBD2001107 Picolinic acid Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26557964" PMDBI20037041 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAK02 PMDBD2001107 Picolinic acid Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26557964" PMDBI20037042 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAK03 PMDBD2001107 Picolinic acid Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26557964" PMDBI20037043 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001108 Pine needle oil Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20037044 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2001109 Pinguisenol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21384863" PMDBI20037045 n.a. PMDBM2021153 1313 Streptococcus pneumoniae Not Specified PMDBD1365 Piperacillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 3 n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20037046 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC BAA-255 PMDBD1365 Piperacillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID "PMID: 30581775; PMID: 7447421" PMDBI20037049 n.a. "PMID: 30581775; PMID: 7447421" 171101 Streptococcus pneumoniae R6 PMDBD1365 Piperacillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 2B n.a. PMID PMDBM2021153 PMDBI20037052 n.a. PMDBM2020848 n.a. Listeria monocytogenes 568 PMDBD1365 Piperacillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20037053 n.a. PMDBM2020848 169963 Listeria monocytogenes EGD-e PMDBD1365 Piperacillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20037054 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2a PMDBD1365 Piperacillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20037055 n.a. PMDBM2020848 n.a. Listeria monocytogenes 1/2b PMDBD1365 Piperacillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25136010" PMDBI20037056 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD1365 Piperacillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25285879" PMDBI20037057 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2001110 Piperacillin-Tazobactam Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18022289" PMDBI20037058 n.a. PMDBM2010322 n.a. Candida spp. Not Specified PMDBD2001110 Piperacillin-Tazobactam Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25631674" PMDBI20037059 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 12461003" PMDBI20037060 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 12461003" PMDBI20037065 n.a. PMDBM2020099 1502 Clostridium perfringens 13 PMDBD1368 Pivmecillinam Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 14527775" PMDBI20037066 n.a. PMDBM2020099 37763 Clostridium perfringens Type A PMDBD1368 Pivmecillinam Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin-binding protein 1A n.a. PMID "PMID: 30581775; PMID: 14527775" PMDBI20037071 n.a. "PMID: 30581775; PMID: 27220074" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001111 Platyphylloside Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037072 n.a. "PMID: 30581775; PMID: 21703317" 210007 Streptococcus mutans UA159 PMDBD2001112 Pleurocidin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037073 n.a. PMDBM2020033 n.a. Enterococcus faecium ATCC 19434 PMDBD2001112 Pleurocidin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22921812" PMDBI20037074 n.a. PMDBM2020035 1322345 Escherichia coli ATCC 25922 PMDBD2001112 Pleurocidin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22921812" PMDBI20037075 n.a. PMDBM2020035 n.a. Escherichia coli O-157 ATCC 43895 PMDBD2001112 Pleurocidin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22921812" PMDBI20037076 n.a. PMDBM2020620 n.a. Propionibacterium acnes ATCC 6919 PMDBD2001112 Pleurocidin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22921812" PMDBI20037077 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2001112 Pleurocidin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22921812" PMDBI20037078 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2001112 Pleurocidin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22921812" PMDBI20037079 n.a. PMDBM2021248 n.a. Candida albicans BWP17-DPP3-GFP PMDBD2001113 PLF Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22174935" PMDBI20037080 n.a. PMDBM2021025 n.a. Proteus mirabilis PM-SJ415 PMDBD2001114 p-nitrophenyl glycerol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19619987" PMDBI20037081 n.a. PMDBM2020075 n.a. Acinetobacter baumannii Ab1 PMDBD2001115 Polyethyleneimine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24913563" PMDBI20037082 n.a. PMDBM2020075 n.a. Acinetobacter baumannii ATCC 1960 PMDBD2001115 Polyethyleneimine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24913563" PMDBI20037083 n.a. PMDBM2021248 n.a. Candida albicans Ca1 PMDBD2001115 Polyethyleneimine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24913563" PMDBI20037084 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2001115 Polyethyleneimine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24913563" PMDBI20037085 n.a. PMDBM2020177 n.a. Staphylococcus aureus Sa1 PMDBD2001115 Polyethyleneimine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24913563" PMDBI20037086 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 29213 PMDBD2001115 Polyethyleneimine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24913563" PMDBI20037087 n.a. PMDBM2020178 n.a. Staphylococcus epidermis Se1 PMDBD2001115 Polyethyleneimine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24913563" PMDBI20037088 n.a. PMDBM2020178 n.a. Staphylococcus epidermis ATCC 155 PMDBD2001115 Polyethyleneimine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24913563" PMDBI20037089 n.a. "PMID: 30581775; PMID: 27923523" 522373 Stenotrophomonas maltophilia K279a PMDBD2001116 Polymyxin B Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2021132 PMDBI20037090 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia H43306 PMDBD2001116 Polymyxin B Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27923523" PMDBI20037091 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia S18202 PMDBD2001116 Polymyxin B Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27923523" PMDBI20037092 n.a. "PMID: 30581775; PMID: 27923523" 522373 Stenotrophomonas maltophilia K279a PMDBD690 Polysorbate 80 Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2021132 PMDBI20037093 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia H43306 PMDBD690 Polysorbate 80 Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27923523" PMDBI20037094 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia S18202 PMDBD690 Polysorbate 80 Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27923523" PMDBI20037095 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD1372 Posaconazole Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Lanosterol 14-alpha demethylase n.a. PMID "PMID: 30581775; PMID: 14657086" PMDBI20037096 n.a. PMDBM2021248 n.a. Candida albicans ATCC MYA-2876 PMDBD1372 Posaconazole Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Lanosterol 14-alpha demethylase n.a. PMID "PMID: 30581775; PMID: 14657086" PMDBI20037113 n.a. PMDBM2020177 n.a. Staphylococcus aureus RN1HG PMDBD2001117 Povidone Iodine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20037114 n.a. PMDBM2020177 n.a. Staphylococcus aureus Mu50 PMDBD2001117 Povidone Iodine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20037115 n.a. PMDBM2020177 n.a. Staphylococcus aureus ET013 (MRSA) PMDBD2001117 Povidone Iodine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20037116 n.a. PMDBM2010719 n.a. Schistosoma Not Specified PMDBD1376 Praziquantel Therapeutic substance Anti-infection n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Schistosome calcium ion (Ca2+) channels n.a. PMID "PMID: 30581775; PMID: 18978535" PMDBI20037117 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2001118 Pro-Gly Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23210926" PMDBI20037118 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 35556 PMDBD2001119 Prolificin A Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20037119 n.a. PMDBM2020177 n.a. Staphylococcus aureus L32 (MRSA) PMDBD2001119 Prolificin A Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20037120 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2001119 Prolificin A Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22170780" PMDBI20037121 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2001120 prop-2-ene-1-SO-thioperoxol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037122 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2001121 Propanol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24688528" PMDBI20037123 n.a. "PMID: 30581775; PMID: 24016798" 1169286 Enterococcus faecalis ATCC 19433 PMDBD2001122 Propyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20037124 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 25923 PMDBD2001122 Propyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20037125 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2001122 Propyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20037126 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 35547 PMDBD2001122 Propyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24016798" PMDBI20037127 n.a. "PMID: 30581775; PMID: 24016798" 1257041 Streptococcus mutans ATCC 25175 PMDBD2001122 Propyl gallate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037128 n.a. PMDBM2020177 1280 Staphylococcus aureus ATCC 25923 PMDBD2001123 Protamine sulphate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23508481" PMDBI20037129 n.a. "PMID: 30581775; PMID: 18330563" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001124 Protocatechuic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037130 n.a. PMDBM2020183 n.a. Streptococcus mutans NCIMB 702062 PMDBD2001125 Pseudomonas Quinolone Signal Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25854411" PMDBI20037131 n.a. "PMID: 30581775; PMID: 18330563" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001126 Psoralen Therapeutic Substance Phase 3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037132 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 29213 PMDBD2001127 PTP-7 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21887652" PMDBI20037133 n.a. PMDBM2020889 1773 Mycobacterium tuberculosis Not Specified PMDBD1392 Pyrazinamide Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: PROBABLE FATTY ACID SYNTHASE FAS (FATTY ACID SYNTHETASE) n.a. PMID "PMID: 30581775; PMID: 10973326" PMDBI20037137 n.a. PMDBM2021744 n.a. Plasmodium falciparum isolate K1 PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Bifunctional dihydrofolate reductase-thymidylate synthase n.a. PMID "PMID: 30581775; PMID: 2677719" PMDBI20037138 n.a. PMDBM2021744 n.a. Plasmodium falciparum Thailand PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Bifunctional dihydrofolate reductase-thymidylate synthase n.a. PMID "PMID: 30581775; PMID: 2677719" PMDBI20037149 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 29213 PMDBD2001128 Pyrimidinedione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26431532" PMDBI20037150 n.a. PMDBM2020177 n.a. Staphylococcus aureus CCARM 3903 (MRSA) PMDBD2001128 Pyrimidinedione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26431532" PMDBI20037151 n.a. PMDBM2020177 n.a. Staphylococcus aureus CCARM 3912 (MRSA) PMDBD2001128 Pyrimidinedione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26431532" PMDBI20037152 n.a. PMDBM2020177 n.a. Staphylococcus aureus CCARM 3108 (MRSA) PMDBD2001128 Pyrimidinedione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26431532" PMDBI20037153 n.a. PMDBM2020177 n.a. Staphylococcus aureus CCARM 3969 (MRSA) PMDBD2001128 Pyrimidinedione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26431532" PMDBI20037154 n.a. PMDBM2020177 n.a. Staphylococcus aureus CCARM 3807 (MRSA) PMDBD2001128 Pyrimidinedione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26431532" PMDBI20037155 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2001128 Pyrimidinedione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26431532" PMDBI20037156 n.a. "PMID: 30581775; PMID: 26431532" 373153 Streptococcus pneumoniae D39 PMDBD2001128 Pyrimidinedione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2021153 PMDBI20037157 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC 6303 PMDBD2001128 Pyrimidinedione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26431532" PMDBI20037158 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae ATCC 49619 PMDBD2001128 Pyrimidinedione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26431532" PMDBI20037159 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae 7101975 PMDBD2001128 Pyrimidinedione Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26431532" PMDBI20037160 n.a. PMDBM2021266 n.a. Vibrio anguillarum LMG4411 PMDBD2001129 Pyrogallol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19778962" PMDBI20037161 n.a. PMDBM2021216 n.a. Vibrio campbellii LMG21363 PMDBD2001129 Pyrogallol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19778962" PMDBI20037162 n.a. PMDBM2020258 n.a. Vibrio cholerae NCTC8457 PMDBD2001129 Pyrogallol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19778962" PMDBI20037163 n.a. PMDBM2021267 n.a. Vibrio vulnificus LMG 16867 PMDBD2001129 Pyrogallol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19778962" PMDBI20037164 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20037165 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD717 Quercetin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20037166 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD717 Quercetin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20037167 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 9027 PMDBD717 Quercetin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26370951" PMDBI20037168 n.a. "PMID: 30581775; PMID: 26808465" 208964 Pseudomonas aeruginosa PAO1 PMDBD717 Quercetin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037169 n.a. PMDBM2020177 n.a. Staphylococcus aureus UAMS-1 PMDBD2001130 Quercetin Dihydrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22242149" PMDBI20037170 n.a. PMDBM2020177 n.a. Staphylococcus aureus UAMS-1 PMDBD2001131 Quercetin-3-O-glucuronide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22242149" PMDBI20037171 n.a. PMDBM2021744 5833 Plasmodium falciparum Not Specified PMDBD1395 Quinine Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Fe(II)-protoporphyrin IX n.a. PMID "PMID: 30581775; PMID: 14967191" PMDBI20037173 n.a. PMDBM2020183 n.a. Streptococcus mutans LMG 14558 PMDBD2001132 Quinizarin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17220400" PMDBI20037174 n.a. PMDBM2020219 n.a. Serratia marcescens ATCC 27117 PMDBD2001133 Quinolin-8-ol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28350449" PMDBI20037175 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2001134 Quinupristin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 50S ribosomal protein L22 n.a. PMID "PMID: 30581775; PMID: 12000992" PMDBI20037177 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD2001134 Quinupristin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 23S rRNA n.a. PMID "PMID: 30581775; PMID: 15059283" PMDBI20037179 n.a. PMDBM2020250 623 Shigella flexneri Not Specified PMDBD2001134 Quinupristin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 50S ribosomal protein L10 n.a. PMID "PMID: 30581775; PMID: 15059283" PMDBI20037190 n.a. PMDBM2020177 n.a. Staphylococcus aureus Smith diffuse (SD) PMDBD1396 Quinupristin/dalfopristin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16621147" PMDBI20037191 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD1399 Raltegravir Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Integrase n.a. PMID "PMID: 30581775; PMID: 18095922" PMDBI20037193 n.a. PMDBM2020379 n.a. Bacillus amyloliquefaciens VTT E-052804 PMDBD2001135 Raspberry KAS 434 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24944110" PMDBI20037194 n.a. PMDBM2020759 n.a. Hafnia paralvei VTT E-113185 PMDBD2001135 Raspberry KAS 434 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24944110" PMDBI20037195 n.a. PMDBM2020906 n.a. Obesumbacterium proteus VTT E-113187 PMDBD2001135 Raspberry KAS 434 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24944110" PMDBI20037196 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa VTT E-082794 PMDBD2001135 Raspberry KAS 434 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24944110" PMDBI20037197 n.a. PMDBM2021746 n.a. Pseudomonas libaniensis VTT E-052840 PMDBD2001135 Raspberry KAS 434 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24944110" PMDBI20037198 n.a. "PMID: 30581775; PMID: 28175292" 210007 Streptococcus mutans UA159 PMDBD739 Reserpine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037199 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001136 Resorcinol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25007234" PMDBI20037200 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 18828 PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20037201 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20037202 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20037203 n.a. PMDBM2021244 n.a. Burkholderia multivorans LMG 17588 PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20037204 n.a. "PMID: 30581775; PMID: 23819562" 652611 Pseudomonas aeruginosa PA14 PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037205 n.a. "PMID: 30581775; PMID: 23819562" 208964 Pseudomonas aeruginosa PAO1 PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037206 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24067082" PMDBI20037207 n.a. PMDBM2020177 n.a. Staphylococcus aureus subsp.aureusCOL (MRSA) PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24970710" PMDBI20037208 n.a. PMDBM2020035 1322345 Escherichia coli ATCC 25922 PMDBD2001137 R-FV-I16 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24945359" PMDBI20037209 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2001137 R-FV-I16 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24945359" PMDBI20037210 n.a. PMDBM2020183 n.a. Streptococcus mutans LMG 14558 PMDBD2001138 Rhein Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17220400" PMDBI20037211 n.a. "PMID: 30581775; PMID: 21852522" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001138 Rhein Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037212 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia GIMT1.118 PMDBD2001138 Rhein Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21852522" PMDBI20037213 n.a. PMDBM2020620 n.a. Propionibacterium acnes NRPC 034 PMDBD2001139 Rhodomyrtone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27923605" PMDBI20037214 n.a. PMDBM2020620 n.a. Propionibacterium acnes NRPC 035 PMDBD2001139 Rhodomyrtone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27923605" PMDBI20037215 n.a. PMDBM2020620 n.a. Propionibacterium acnes NRPC 036 PMDBD2001139 Rhodomyrtone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27923605" PMDBI20037216 n.a. PMDBM2020620 n.a. Propionibacterium acnes NRPC 039 PMDBD2001139 Rhodomyrtone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27923605" PMDBI20037217 n.a. PMDBM2020620 n.a. Propionibacterium acnes NRPC 040 PMDBD2001139 Rhodomyrtone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27923605" PMDBI20037218 n.a. PMDBM2020620 n.a. Propionibacterium acnes DMST 14916 PMDBD2001139 Rhodomyrtone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27923605" PMDBI20037219 n.a. PMDBM2021245 884204 Burkholderia pseudomallei 1026b PMDBD2001140 RI-19 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22005071" PMDBI20037220 n.a. PMDBM2010204 n.a. Influenza A virus A PMDBD742 Ribavirin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: NA-directed RNA polymerase catalytic subunit n.a. PMID "PMID: 30581775; PMID: 14563844" PMDBI20037221 n.a. PMDBM2010738 n.a. Influenza A virus Beijing PMDBD742 Ribavirin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: NA-directed RNA polymerase catalytic subunit n.a. PMID "PMID: 30581775; PMID: 14563844" PMDBI20037222 n.a. PMDBM2010739 n.a. Influenza A virus 11 PMDBD742 Ribavirin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: NA-directed RNA polymerase catalytic subunit n.a. PMID "PMID: 30581775; PMID: 14563844" PMDBI20037223 n.a. PMDBM2010740 n.a. Influenza A virus 1956 H1N1 PMDBD742 Ribavirin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: NA-directed RNA polymerase catalytic subunit n.a. PMID "PMID: 30581775; PMID: 14563844" PMDBI20037224 n.a. PMDBM2010741 n.a. DengueVirusType 2 Not Specified PMDBD742 Ribavirin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Genome polyprotein n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037225 n.a. PMDBM2010742 n.a. Human parainfluenza virus type 2 Not Specified PMDBD742 Ribavirin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: RNA-directed RNA polymerase L n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037236 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA-directed RNA polymerase subunit alpha n.a. PMID "PMID: 30581775; PMID: 7849340" PMDBI20037241 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001141 Rifalazil Therapeutic Substance Phase 3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA-directed RNA polymerase subunit beta n.a. PMID "PMID: 30581775; PMID: 7492091" PMDBI20037242 n.a. PMDBM2020178 1282 Staphylococcus epidermidis Not Specified PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 3196598" PMDBI20037243 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA-directed RNA polymerase subunit beta n.a. PMID "PMID: 30581775; PMID: 4942761" PMDBI20037246 n.a. PMDBM2020177 n.a. Staphylococcus aureus Smith diffuse (SD) PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16289474" PMDBI20037249 n.a. PMDBM2020889 1773 Mycobacterium tuberculosis Not Specified PMDBD2001142 Rifapentine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA-directed RNA polymerase subunit beta' n.a. PMID "PMID: 30581775; PMID: 9661035" PMDBI20037253 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD2001143 Rilpivirine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Reverse transcriptase n.a. PMID "PMID: 30581775; PMID: 19548857" PMDBI20037255 n.a. PMDBM2010204 n.a. Influenza A virus A PMDBD1403 Rimantadine Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Matrix protein 2 n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037256 n.a. PMDBM2010205 n.a. Influenza A virus Ann Arbor PMDBD1403 Rimantadine Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Matrix protein 2 n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037257 n.a. PMDBM2010206 n.a. Influenza A virus 6 PMDBD1403 Rimantadine Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Matrix protein 2 n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037258 n.a. PMDBM2010207 n.a. Influenza A virus 1960 H2N2 PMDBD1403 Rimantadine Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Matrix protein 2 n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037275 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Pol polyprotein n.a. PMID "PMID: 30581775; PMID: 7477168" PMDBI20037277 n.a. PMDBM2010236 n.a. Human immunodeficiency virus Not Specified PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: HIV-1 protease n.a. PMID "PMID: 30581775; PMID: 17627597" PMDBI20037282 n.a. PMDBM2021245 884204 Burkholderia pseudomallei 1026b PMDBD2001144 RK-19 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22005071" PMDBI20037283 n.a. PMDBM2021245 884204 Burkholderia pseudomallei 1026b PMDBD2001145 RK-25 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22005071" PMDBI20037284 n.a. PMDBM2021245 884204 Burkholderia pseudomallei 1026b PMDBD2001146 RK-31 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22005071" PMDBI20037285 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA PMDBD2001147 RNAIII-inhibiting Peptide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 15215107" PMDBI20037286 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 29213 PMDBD2001147 RNAIII-inhibiting Peptide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26571297" PMDBI20037288 n.a. PMDBM2020177 n.a. Staphylococcus aureus XJ75302 (MRSA) PMDBD2001147 RNAIII-inhibiting Peptide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26571297" PMDBI20037289 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ATCC 14990 PMDBD2001147 RNAIII-inhibiting Peptide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26571297" PMDBI20037290 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis XJ75284 (MRSE) PMDBD2001147 RNAIII-inhibiting Peptide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26571297" PMDBI20037291 n.a. "PMID: 30581775; PMID: 14701912" 652611 Pseudomonas aeruginosa PA14 PMDBD2001148 Rosmarinic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037292 n.a. PMDBM2020261 n.a. Aeromonas hydrophila AH 1 PMDBD2001148 Rosmarinic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27739324" PMDBI20037293 n.a. PMDBM2020261 n.a. Aeromonas hydrophila AH 12 PMDBD2001148 Rosmarinic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27739324" PMDBI20037294 n.a. PMDBM2020261 n.a. Aeromonas hydrophila MTCC 1739 PMDBD2001148 Rosmarinic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27739324" PMDBI20037295 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001149 Rosoxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit B n.a. PMID "PMID: 30581775; PMID: 3010848" PMDBI20037303 n.a. PMDBM2020035 1045010 Escherichia coli O157 PMDBD2001150 RT2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25767037" PMDBI20037304 n.a. PMDBM2021245 n.a. Burkholderia pseudomallei H777 PMDBD2001151 RTA3 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23785532" PMDBI20037305 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis MRSE PMDBD2001152 R-Thanatin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23917310" PMDBI20037306 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia SM33 PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 14693533" PMDBI20037307 n.a. PMDBM2020482 197 Campylobacter jejuni NCTC 11168 PMDBD2001153 Rutaecarpine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27230628" PMDBI20037308 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20037309 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20037310 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 9027 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" decrease capillary fragility n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26370951" PMDBI20037311 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2001154 S-(2-Aminoethyl)-L-cysteine hydrochloride Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037312 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2001154 S-(2-Aminoethyl)-L-cysteine hydrochloride Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20037313 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2001155 S-(2-thiazoyl)-L-cysteine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037314 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2001156 S-(2-thienyl)-L-cysteine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20037315 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2001156 S-(2-thienyl)-L-cysteine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037316 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2001157 S-(4-tolyl)-L-cysteine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20037317 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2001157 S-(4-tolyl)-L-cysteine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037318 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2001157 S-(4-tolyl)-L-cysteine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20037319 n.a. "PMID: 30581775; PMID: 17060534" 210007 Streptococcus mutans UA159 PMDBD2001158 S6L3-33 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037320 n.a. PMDBM2020184 n.a. Streptococcus sanguinis NY101 PMDBD2001158 S6L3-33 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17060534" PMDBI20037321 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001159 Sage oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20037322 n.a. PMDBM2021248 n.a. Candida albicans 1 PMDBD2001160 Salicylic Acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 8390997" PMDBI20037323 n.a. PMDBM2020785 n.a. Enterobacter aerogenes ATCC 29212 PMDBD2001160 Salicylic Acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 8390997" PMDBI20037324 n.a. PMDBM2020032 n.a. Enterococcus faecalis ATCC 25912 PMDBD2001160 Salicylic Acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 8390997" PMDBI20037325 n.a. PMDBM2020100 n.a. Klebsiella pneumoniae 1 PMDBD2001160 Salicylic Acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 8390997" PMDBI20037326 n.a. "PMID: 30581775; PMID: 16777217" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001160 Salicylic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037327 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2001160 Salicylic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23489623" PMDBI20037328 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538P PMDBD2001161 Sanguinarine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22182580" PMDBI20037329 n.a. PMDBM2020178 176279 Staphylococcus epidermidis ATCC 35984 PMDBD2001161 Sanguinarine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22182580" PMDBI20037330 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD2001162 Saquinavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Pol polyprotein n.a. PMID "PMID: 30581775; PMID: 9297727" PMDBI20037334 n.a. PMDBM2010236 n.a. Human immunodeficiency virus Not Specified PMDBD2001162 Saquinavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: HIV-1 protease n.a. PMID "PMID: 30581775; PMID: 19040279" PMDBI20037340 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2001163 S-carboxylmethyl-L-cysteine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20037341 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2001163 S-carboxylmethyl-L-cysteine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037342 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2001164 Scopoletin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20037343 n.a. PMDBM2021242 714 Aggregatibacter actinomycetemcomitans JP2 PMDBD2001165 Scrambled LL-37 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23836819" PMDBI20037344 n.a. PMDBM2021242 1035194 Aggregatibacter actinomycetemcomitans Y4 PMDBD2001165 Scrambled LL-37 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23836819" PMDBI20037345 n.a. PMDBM2021242 n.a. Aggregatibacter actinomycetemcomitans VT726S PMDBD2001165 Scrambled LL-37 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23836819" PMDBI20037346 n.a. PMDBM2021242 n.a. Aggregatibacter actinomycetemcomitans ATCC 29532 PMDBD2001165 Scrambled LL-37 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23836819" PMDBI20037347 n.a. PMDBM2021242 n.a. Aggregatibacter actinomycetemcomitans ATCC 33384 PMDBD2001165 Scrambled LL-37 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23836819" PMDBI20037348 n.a. PMDBM2021242 n.a. Aggregatibacter actinomycetemcomitans VT726Sltx- PMDBD2001165 Scrambled LL-37 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23836819" PMDBI20037349 n.a. "PMID: 30581775; PMID: 25761937" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001166 Seg6D Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037350 n.a. "PMID: 30581775; PMID: 25761937" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001167 Seg6L Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037351 n.a. PMDBM2020183 n.a. Streptococcus mutans LMG 14558 PMDBD2001168 Sennidin A Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17220400" PMDBI20037352 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20037353 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2001169 S-ethyl-L-cysteine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037354 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2001169 S-ethyl-L-cysteine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20037355 n.a. "PMID: 30581775; PMID: 21852522" 208964 Pseudomonas aeruginosa PAO1 PMDBD780 Shikonin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037356 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia GIMT1.118 PMDBD780 Shikonin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21852522" PMDBI20037357 n.a. PMDBM2020032 1351 Enterococcus faecalis OG1RF PMDBD2001170 Siamycin I Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17071762" PMDBI20037358 n.a. PMDBM2020177 n.a. Staphylococcus aureus RN1HG PMDBD2001171 Silver dihydrogen citrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20037359 n.a. PMDBM2020177 n.a. Staphylococcus aureus Mu50 PMDBD2001171 Silver dihydrogen citrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20037360 n.a. PMDBM2020177 n.a. Staphylococcus aureus ET013 (MRSA) PMDBD2001171 Silver dihydrogen citrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20037361 n.a. PMDBM2020177 n.a. Staphylococcus aureus ET041 (MRSA) PMDBD2001171 Silver dihydrogen citrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20037362 n.a. "PMID: 30581775; PMID: 24958247" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001172 Silver Ion Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037363 n.a. PMDBM2021248 n.a. Candida albicans MTCC 7315 PMDBD1416 Silver nanoparticles Environmental Chemicals Nanoparticles n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25056565" PMDBI20037364 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MTCC 4673 PMDBD1416 Silver nanoparticles Environmental Chemicals Nanoparticles n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25056565" PMDBI20037365 n.a. PMDBM2020177 n.a. Staphylococcus aureus MTCC 9542 PMDBD1416 Silver nanoparticles Environmental Chemicals Nanoparticles n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25056565" PMDBI20037366 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis CSF 41498 PMDBD1416 Silver nanoparticles Environmental Chemicals Nanoparticles n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25596861" PMDBI20037367 n.a. "PMID: 30581775; PMID: 26595817" 208964 Pseudomonas aeruginosa PAO1 PMDBD1416 Silver nanoparticles Environmental Chemicals Nanoparticles n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037368 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 2592 PMDBD1416 Silver nanoparticles Environmental Chemicals Nanoparticles n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26595817" PMDBI20037369 n.a. PMDBM2020035 562 Escherichia coli Not Specified PMDBD1416 Silver nanoparticles Environmental Chemicals Nanoparticles n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27585261" PMDBI20037370 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD1416 Silver nanoparticles Environmental Chemicals Nanoparticles n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27585261" PMDBI20037372 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa NCIM 2948 PMDBD2001173 Silver nanowires Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23224498" PMDBI20037373 n.a. PMDBM2020472 n.a. Burkholderia cepacia ATCC 17759 PMDBD2001174 Silver nitrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20037374 n.a. PMDBM2020035 n.a. Escherichia coli ATCC 25312 PMDBD2001174 Silver nitrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20037375 n.a. PMDBM2020797 378753 Kocuria rhizophila ATCC 9341 PMDBD2001174 Silver nitrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20037376 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 9027 PMDBD2001174 Silver nitrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20037377 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001174 Silver nitrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20037378 n.a. "PMID: 30581775; PMID: 28756196" 176280 Staphylococcus epidermidis ATCC 12228 PMDBD2001174 Silver nitrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020178 PMDBI20037379 n.a. PMDBM2020177 n.a. Staphylococcus aureus RN1HG PMDBD2001175 Silver sulfadiazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20037380 n.a. PMDBM2020177 n.a. Staphylococcus aureus Mu50 PMDBD2001175 Silver sulfadiazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20037381 n.a. PMDBM2020177 n.a. Staphylococcus aureus ET013 (MRSA) PMDBD2001175 Silver sulfadiazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20037382 n.a. PMDBM2020177 n.a. Staphylococcus aureus ET041 (MRSA) PMDBD2001175 Silver sulfadiazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20037383 n.a. PMDBM2020177 n.a. Staphylococcus aureus RN1HG PMDBD2001176 Silver sulphate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23490006" PMDBI20037384 n.a. PMDBM2020177 n.a. Staphylococcus aureus 2346775 PMDBD2001177 Silybin Therapeutic Substance Phase 2/3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26273725" PMDBI20037385 n.a. PMDBM2010758 n.a. Hepatitis C virus Not Specified PMDBD2001178 Simeprevir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: NS3 protease n.a. PMID "PMID: 30581775; PMID: 18678486" PMDBI20037386 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2001179 Sinapic acid Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24067082" PMDBI20037387 n.a. PMDBM2021153 n.a. Streptococcus pneumoniae D-39 (NCTC 7466) PMDBD2001180 Sinefungin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25050323" PMDBI20037388 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2001181 Sinensetin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20037389 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD2001181 Sinensetin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20163489" PMDBI20037390 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2001181 Sinensetin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23891936" PMDBI20037391 n.a. "PMID: 30581775; PMID: 20211885" 210007 Streptococcus mutans UA159 PMDBD2001182 Sm6(L1)2C Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037392 n.a. "PMID: 30581775; PMID: 20211885" 210007 Streptococcus mutans UA159 PMDBD2001183 Sm6(L2)B33 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037393 n.a. "PMID: 30581775; PMID: 20211885" 210007 Streptococcus mutans UA159 PMDBD2001184 Sm6(L3)2C Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037394 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Pa5 PMDBD2001185 SMAP-29 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20037395 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Pa9 PMDBD2001185 SMAP-29 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20037396 n.a. PMDBM2020177 n.a. Staphylococcus aureus Sa4 PMDBD2001185 SMAP-29 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20037397 n.a. PMDBM2020177 n.a. Staphylococcus aureus Sa7 PMDBD2001185 SMAP-29 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20037398 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia Sm109 PMDBD2001185 SMAP-29 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20037399 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia Sm143 PMDBD2001185 SMAP-29 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20037400 n.a. PMDBM2021755 271848 Burkholderia thailandensis E264 PMDBD2001185 SMAP-29 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26196513" PMDBI20037401 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2001186 S-methyl- L-cysteine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037402 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2001186 S-methyl- L-cysteine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20037403 n.a. "PMID: 30581775; PMID: 25175797" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001187 Sodium ascorbate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037404 n.a. PMDBM2020069 n.a. Pseudomonas fluorescens H2S PMDBD2001188 Sodium Chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 2624463" PMDBI20037405 n.a. PMDBM2020482 n.a. Campylobacter jejuni M129 PMDBD2001188 Sodium Chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17259368" PMDBI20037406 n.a. PMDBM2020069 n.a. Pseudomonas fluorescens H2S PMDBD2001189 Sodium sulfate Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 2624463" PMDBI20037407 n.a. PMDBM2021772 n.a. Actinoplanes missouriensis ATCC 14538 PMDBD2001190 Sorbitol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Xylose isomerase n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037408 n.a. PMDBM2021772 n.a. Actinoplanes missouriensis DSM 43046 PMDBD2001190 Sorbitol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Xylose isomerase n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037409 n.a. PMDBM2021772 n.a. Actinoplanes missouriensis CBS 188.64 PMDBD2001190 Sorbitol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Xylose isomerase n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037410 n.a. PMDBM2021772 n.a. Actinoplanes missouriensis JCM 3121 PMDBD2001190 Sorbitol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Xylose isomerase n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037411 n.a. PMDBM2021772 n.a. Actinoplanes missouriensis NCIMB 12654 PMDBD2001190 Sorbitol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Xylose isomerase n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037412 n.a. PMDBM2021772 n.a. Actinoplanes missouriensis NBRC 102363 PMDBD2001190 Sorbitol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Xylose isomerase n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037413 n.a. PMDBM2021772 512565 Actinoplanes missouriensis 431 PMDBD2001190 Sorbitol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Xylose isomerase n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037414 n.a. PMDBM2021773 1669 Arthrobacter sp. NRRL B3728 PMDBD2001190 Sorbitol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Xylose isomerase n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037415 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001190 Sorbitol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Malate synthase G n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037416 n.a. PMDBM2021774 1929 Streptomyces rubiginosus Not Specified PMDBD2001190 Sorbitol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Xylose isomerase n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037427 n.a. PMDBM2010769 n.a. Bacteroides Not Specified PMDBD788 sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 9110360" PMDBI20037428 n.a. PMDBM2020007 28111 Bacteroides eggerthii Not Specified PMDBD788 sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 9110360" PMDBI20037429 n.a. PMDBM2020420 29523 Bacteroides vulgatus Not Specified PMDBD788 sorivudine Therapeutic Substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 9110360" PMDBI20037430 n.a. PMDBM2021248 5476 Candida albicans Not Specified PMDBD2001191 S-OSIP108 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24566179" PMDBI20037431 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa 15442 PMDBD2001192 SP1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25401078" PMDBI20037432 n.a. PMDBM2020177 n.a. Staphylococcus aureus 25923 PMDBD2001192 SP1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25401078" PMDBI20037433 n.a. PMDBM2020177 n.a. Staphylococcus aureus 29213 PMDBD2001192 SP1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25401078" PMDBI20037434 n.a. PMDBM2020177 n.a. Staphylococcus aureus 6538 PMDBD2001192 SP1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25401078" PMDBI20037435 n.a. PMDBM2020177 n.a. Staphylococcus aureus RP62A PMDBD2001192 SP1 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25401078" PMDBI20037436 n.a. PMDBM2020258 666 Vibrio cholerae Not Specified PMDBD2001193 Spermine Therapeutic Substance Terminated n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28827313" PMDBI20037437 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2001194 S-phenyl-L-cysteine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20037438 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2001194 S-phenyl-L-cysteine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037439 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2001194 S-phenyl-L-cysteine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20037440 n.a. "PMID: 30581775; PMID: 22715388" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001195 S-phenyl-L-cysteine sulfoxide Therapeutic Substance Preclinical n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037441 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2001196 S-propyl-L-cysteine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037442 n.a. PMDBM2020889 1773 Mycobacterium tuberculosis Not Specified PMDBD2001197 SQ109 Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28162983" PMDBI20037443 n.a. PMDBM2020183 n.a. Streptococcus mutans MT 8148 PMDBD2001198 Ssp (A4K-A11K) Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28394940" PMDBI20037444 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD2001199 Stavudine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Reverse transcriptase/RNaseH n.a. PMID "PMID: 30581775; PMID: 8861550" PMDBI20037446 n.a. PMDBM2020258 n.a. Vibrio cholerae VCO1 PMDBD2001200 Stearic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26939983" PMDBI20037447 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2001201 Stilbene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24067082" PMDBI20037448 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD804 Streptomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S12 n.a. PMID "PMID: 30581775; PMID: 7928982" PMDBI20037451 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 29213 PMDBD804 Streptomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21887652" PMDBI20037452 n.a. "PMID: 30581775; PMID: 24705563" 208964 Pseudomonas aeruginosa PAO1 PMDBD804 Streptomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037453 n.a. PMDBM2020177 n.a. Staphylococcus aureus N315 (MRSA) PMDBD2001202 Streptorubin B Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26027829" PMDBI20037454 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2001203 Subtilosin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27914001" PMDBI20037455 n.a. PMDBM2020732 585528 Gardnerella vaginalis ATCC 14018 PMDBD2001203 Subtilosin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27914001" PMDBI20037456 n.a. PMDBM2020848 n.a. Listeria monocytogenes ScottA PMDBD2001203 Subtilosin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27914001" PMDBI20037457 n.a. PMDBM2020482 n.a. Campylobacter jejuni M129 PMDBD2001204 Sucrose Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17259368" PMDBI20037458 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD806 Sulbactam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Beta-lactamase n.a. PMID "PMID: 30581775; PMID: 14621983" PMDBI20037460 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20037461 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001205 Sulfacetamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydropteroate synthase n.a. PMID "PMID: 30581775; PMID: 13873645" PMDBI20037462 n.a. PMDBM2010780 n.a. Baker's yeast Not Specified PMDBD2001205 Sulfacetamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Folic acid synthesis protein FOL1 n.a. PMID "PMID: 30581775; PMID: 14700578" PMDBI20037463 n.a. PMDBM2010781 n.a. Dihydropteroate synthase type-1 Not Specified PMDBD2001205 Sulfacetamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydropteroate synthase type-1 n.a. PMID "PMID: 30581775; PMID: 14700578" PMDBI20037466 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001206 Sulfacytine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydropteroate synthase n.a. PMID "PMID: 30581775; PMID: 1195474" PMDBI20037469 n.a. PMDBM2021744 5833 Plasmodium falciparum Not Specified PMDBD808 Sulfadiazine Therapeutic Substance antibiotic n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydropteroate synthetase n.a. PMID "PMID: 30581775; PMID: 9127492" PMDBI20037472 n.a. PMDBM2021744 5833 Plasmodium falciparum Not Specified PMDBD2001207 Sulfadiazine Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydropteroate synthetase n.a. PMID "PMID: 30581775; PMID: 9127492" PMDBI20037475 n.a. PMDBM2021744 n.a. Plasmodium falciparum isolate K1 PMDBD2001208 Sulfadoxine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Bifunctional dihydrofolate reductase-thymidylate synthase n.a. PMID "PMID: 30581775; PMID: 15099990" PMDBI20037476 n.a. PMDBM2021744 n.a. Plasmodium falciparum Thailand PMDBD2001208 Sulfadoxine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Bifunctional dihydrofolate reductase-thymidylate synthase n.a. PMID "PMID: 30581775; PMID: 15099990" PMDBI20037481 n.a. PMDBM2021744 5833 Plasmodium falciparum Not Specified PMDBD2001208 Sulfadoxine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydropteroate synthetase n.a. PMID "PMID: 30581775; PMID: 19220141" PMDBI20037484 n.a. PMDBM2021744 5833 Plasmodium falciparum Not Specified PMDBD2001209 Sulfalene Therapeutic Substance Withdrawn from market n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydropteroate synthetase n.a. PMID "PMID: 30581775; PMID: 8195839" PMDBI20037487 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001210 Sulfamerazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydropteroate synthase n.a. PMID "PMID: 30581775; PMID: 4577373" PMDBI20037490 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001211 Sulfamethazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydropteroate synthase n.a. PMID "PMID: 30581775; PMID: 4577373" PMDBI20037493 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001212 Sulfamethizole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydropteroate synthase n.a. PMID "PMID: 30581775; PMID: 2372557" PMDBI20037496 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD1427 Sulfamethoxazole Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydropteroate synthase n.a. PMID "PMID: 30581775; PMID: 7486915" PMDBI20037500 n.a. PMDBM2021744 5833 Plasmodium falciparum Not Specified PMDBD2001213 Sulfamoxole Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydropteroate synthetase n.a. PMID "PMID: 30581775; PMID: 9127492" PMDBI20037501 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD810 Sulfanilamide "Therapeutic Substance; Herbal Substance" anti-infective n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydropteroate synthase n.a. PMID "PMID: 30581775; PMID: 9127492" PMDBI20037504 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001214 Sulfaphenazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydropteroate synthase n.a. PMID "PMID: 30581775; PMID: 7486915" PMDBI20037505 n.a. PMDBM2021744 5833 Plasmodium falciparum Not Specified PMDBD2001215 Sulfathiazole Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydropteroate synthetase n.a. PMID "PMID: 30581775; PMID: 2694948" PMDBI20037506 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001216 Sulfisoxazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydropteroate synthase n.a. PMID "PMID: 30581775; PMID: 7016423" PMDBI20037510 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001216 Sulfisoxazole Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Dihydropteroate synthase n.a. PMID "PMID: 30581775; PMID: 7486915" PMDBI20037514 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2001217 Syringic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24067082" PMDBI20037515 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2001218 Tachyplesin III Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18022289" PMDBI20037516 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD2001219 Tangeretin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26140409" PMDBI20037517 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001220 Tangerine oil Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20037518 n.a. PMDBM2021025 n.a. Proteus mirabilis PM-SJ415 PMDBD2001221 Tannic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19619987" PMDBI20037519 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 10145 PMDBD2001221 Tannic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21291979" PMDBI20037520 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2001221 Tannic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24067082" PMDBI20037521 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa N6P6 PMDBD2001221 Tannic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26245683" PMDBI20037522 n.a. PMDBM2020314 n.a. Actinomyces oris MG1 PMDBD2001222 Taurine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20037523 n.a. "PMID: 30581775; PMID: 25081571" 210007 Streptococcus mutans UA159 PMDBD2001222 Taurine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037524 n.a. PMDBM2020184 n.a. Streptococcus sanguis 10556 PMDBD2001222 Taurine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25081571" PMDBI20037525 n.a. PMDBM2021760 599 Salmonella Typhi Not Specified PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Beta-lactamase TEM n.a. PMID "PMID: 30581775; PMID: 10511459" PMDBI20037526 n.a. PMDBM2020035 562 Escherichia coli Not Specified PMDBD826 Tazobactam Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Beta-lactamase SHV-1 n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037528 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001224 Tea tree oil Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20037529 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 PMDBD2001225 Teichoplanin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23070152" PMDBI20037530 n.a. PMDBM2010758 n.a. Hepatitis C virus Not Specified PMDBD2001226 Telaprevir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Genome polyprotein n.a. PMID "PMID: 30581775; PMID: 18479202" PMDBI20037531 n.a. PMDBM2010758 n.a. Hepatitis C virus Not Specified PMDBD2001226 Telaprevir Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Hepatitis C virus NS3-4A serine protease n.a. PMID "PMID: 30581775; PMID: 18479202" PMDBI20037532 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2001228 Telekin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26394911" PMDBI20037533 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD1440 Telithromycin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 23S rRNA n.a. PMID "PMID: 30581775; PMID: 15386111" PMDBI20037539 n.a. "PMID: 30581775; PMID: 24958247" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001229 Tellurite Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037540 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD832 Tenofovir Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Reverse transcriptase/RNaseH n.a. PMID "PMID: 30581775; PMID: 12462284" PMDBI20037542 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2001230 Terconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20037543 n.a. PMDBM2020005 n.a. Bacillus cereus var. mycoides 0042 PMDBD2001231 Terpinene-4-ol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20037544 n.a. PMDBM2020035 n.a. Escherichia coli 582 PMDBD2001231 Terpinene-4-ol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20037545 n.a. PMDBM2021742 n.a. Pichia anomala 8061Mo PMDBD2001231 Terpinene-4-ol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20037546 n.a. PMDBM2020155 n.a. Pseudomonas putida 291T PMDBD2001231 Terpinene-4-ol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23789847" PMDBI20037547 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2001232 Tert-butanol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24688528" PMDBI20037548 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2001233 Tet-20 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21377727" PMDBI20037549 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2001234 Tet-213 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21377727" PMDBI20037550 n.a. PMDBM2020177 n.a. Staphylococcus aureus Isolate 1 PMDBD2001234 Tet-213 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25785171" PMDBI20037551 n.a. PMDBM2020177 n.a. Staphylococcus aureus Isolate 2 PMDBD2001234 Tet-213 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25785171" PMDBI20037552 n.a. PMDBM2020177 n.a. Staphylococcus aureus Isolate 3 PMDBD2001234 Tet-213 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25785171" PMDBI20037553 n.a. PMDBM2020177 n.a. Staphylococcus aureus Isolate 4 PMDBD2001234 Tet-213 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25785171" PMDBI20037554 n.a. PMDBM2020177 n.a. Staphylococcus aureus Isolate 5 PMDBD2001234 Tet-213 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25785171" PMDBI20037555 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2001235 Tet-26 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21377727" PMDBI20037556 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD2001236 Tetracycline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 16S rRNA n.a. PMID "PMID: 30581775; PMID: 1725100" PMDBI20037557 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001236 Tetracycline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S7 n.a. PMID "PMID: 30581775; PMID: 2200507" PMDBI20037562 n.a. PMDBM2020035 562 Escherichia coli Not Specified PMDBD2001236 Tetracycline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Multidrug translocase MdfA n.a. PMID "PMID: 30581775; PMID: 8426364" PMDBI20037566 n.a. PMDBM2020035 562 Escherichia coli RP437 PMDBD2001237 Tetrameric peptide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 20097816" PMDBI20037567 n.a. "PMID: 30581775; PMID: 27731921" 652611 Pseudomonas aeruginosa PA14 PMDBD2001238 Tetrazol-1-yl Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037568 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2001239 Thiazolidinedione-8 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24796422" PMDBI20037569 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2001239 Thiazolidinedione-8 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25645835" PMDBI20037571 n.a. PMDBM2020183 1309 Streptococcus mutans Not Specified PMDBD2001239 Thiazolidinedione-8 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26904013" PMDBI20037572 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20037573 n.a. PMDBM2020035 n.a. Escherichia coli O103:H2 (1153) PMDBD2001240 Thiophenone TF101 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24391047" PMDBI20037574 n.a. PMDBM2020035 n.a. Escherichia coli O103:H2 (1242) PMDBD2001240 Thiophenone TF101 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24391047" PMDBI20037575 n.a. PMDBM2020035 n.a. Escherichia coli O103:H2 (10705) PMDBD2001240 Thiophenone TF101 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24391047" PMDBI20037576 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20037577 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2001241 Thymol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27808174" PMDBI20037578 n.a. "PMID: 30581775; PMID: 28233286" 1257041 Streptococcus mutans ATCC 25175 PMDBD2001241 Thymol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037579 n.a. PMDBM2020177 1280 Staphylococcus aureus Not Specified PMDBD1454 Ticarcillin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Penicillin binding protein 2a n.a. PMID "PMID: 30581775; PMID: 2387996" PMDBI20037580 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001242 Tigecycline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S9 n.a. PMID "PMID: 30581775; PMID: 6723578" PMDBI20037581 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD2001242 Tigecycline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 16S rRNA n.a. PMID "PMID: 30581775; PMID: 16723578" PMDBI20037592 n.a. PMDBM2020177 n.a. Staphylococcus aureus Smith diffuse (SD) PMDBD2001242 Tigecycline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23965956" PMDBI20037593 n.a. PMDBM2020177 n.a. Staphylococcus aureus UAMS-1 PMDBD2001243 Tiliroside Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22242149" PMDBI20037594 n.a. PMDBM2010790 n.a. Enterobacteria phage T4 Not Specified PMDBD2001244 Timolol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Lysozyme n.a. PMID "PMID: 30581775; PMID: 10592235" PMDBI20037595 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20037596 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD2001245 Tipranavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Pol polyprotein n.a. PMID "PMID: 30581775; PMID: 11752352" PMDBI20037604 n.a. PMDBM2010236 n.a. Human immunodeficiency virus Not Specified PMDBD2001226 Tipranavir Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: HIV-1 protease n.a. PMID "PMID: 30581775; PMID: 16060700" PMDBI20037612 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001246 Titanium dioxide Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27690228" PMDBI20037613 n.a. PMDBM2021248 n.a. Candida albicans BWP17 PMDBD2001247 TMB-8 Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20037614 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2001248 TMC-151s C Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25302529" PMDBI20037615 n.a. PMDBM2020889 1773 Mycobacterium tuberculosis Not Specified PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: minoglycoside 2'-N-acetyltransferase n.a. PMID "PMID: 30581775; PMID: 12161746" PMDBI20037616 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 30S ribosomal protein S12 n.a. PMID "PMID: 30581775; PMID: 15332709" PMDBI20037617 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16940063" PMDBI20037619 n.a. PMDBM2010214 n.a. Enteric bacteria and other eubacteria Not Specified PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 16S rRNA n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037625 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG 16656 PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20037626 n.a. PMDBM2021244 87883 Burkholderia multivorans LMG 13010 PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 19146953" PMDBI20037628 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Pa5 PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20037629 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa Pa9 PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20037630 n.a. PMDBM2020177 n.a. Staphylococcus aureus Sa4 PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20037631 n.a. PMDBM2020177 n.a. Staphylococcus aureus Sa7 PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20037632 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia Sm143 PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21849157" PMDBI20037633 n.a. "PMID: 30581775; PMID: 22314537" 208964 Pseudomonas aeruginosa PAO1 PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037634 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa CF438 PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22314537" PMDBI20037635 n.a. PMDBM2020471 n.a. Burkholderia cenocepacia LMG16656 PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20037636 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA02 PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20037637 n.a. PMDBM2020177 n.a. Staphylococcus aureus Mu50 PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20037638 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28323149" PMDBI20037639 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 27853 PMDBD2001249 Tobramycin-bismuth-ethanedithiol Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28323149" PMDBI20037640 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2001250 Tomentosin Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26394911" PMDBI20037641 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25288093" PMDBI20037642 n.a. PMDBM2021248 n.a. Candida albicans CA2 PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25288093" PMDBI20037643 n.a. PMDBM2021248 n.a. Candida albicans CA10 PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25288093" PMDBI20037644 n.a. PMDBM2021248 n.a. Candida albicans CA15 PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25288093" PMDBI20037645 n.a. PMDBM2021759 n.a. Candida dubliniensis NCPF 3949 PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25288093" PMDBI20037646 n.a. PMDBM2021747 n.a. Candida glabrata BG2 PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25288093" PMDBI20037647 n.a. PMDBM2021748 n.a. Candida krusei IHEM 6104 PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25288093" PMDBI20037648 n.a. PMDBM2020151 208963 Pseudomonas aeruginosa UCBPP-PA14 PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25288093" PMDBI20037649 n.a. PMDBM2020177 n.a. Staphylococcus aureus SH1000 PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25288093" PMDBI20037650 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis CH PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25288093" PMDBI20037651 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2001251 trans-2-dodecenoic acid Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21778264" PMDBI20037652 n.a. PMDBM2020258 n.a. Vibrio cholerae CIP 106860 PMDBD2001252 trans-2-Nonenal Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21249192" PMDBI20037653 n.a. PMDBM2021218 n.a. Vibrio harveyi BB127 PMDBD2001252 trans-2-Nonenal Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21249192" PMDBI20037654 n.a. PMDBM2020258 n.a. Vibrio cholerae CIP 106860 PMDBD2001253 trans-2-Pentenal Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21249192" PMDBI20037655 n.a. PMDBM2021218 n.a. Vibrio harveyi BB126 PMDBD2001253 trans-2-Pentenal Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21249192" PMDBI20037656 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD1470 trans-Resveratrol Therapeutic substance Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25007234" PMDBI20037657 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001254 trans-Stillbene Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25007234" PMDBI20037658 n.a. PMDBM2020151 287 Pseudomonas aeruginosa Not Specified PMDBD2001255 Tricaine Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25537269" PMDBI20037659 n.a. PMDBM2020183 n.a. Streptococcus mutans LMG 14558 PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 17220400" PMDBI20037660 n.a. "PMID: 30581775; PMID: 24094824" 210007 Streptococcus mutans UA159 PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037661 n.a. PMDBM2021243 486619 Bacillus anthracis A0193 PMDBD2001256 Triclosan Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Enoyl-[acyl-carrier-protein] reductase [NADH] n.a. PMID "PMID: 30581775; PMID: 10592235" PMDBI20037662 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001256 Triclosan Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI n.a. PMID "PMID: 30581775; PMID: 10592235" PMDBI20037663 n.a. PMDBM2020226 85962 Helicobacter pylori ATCC 700392 PMDBD2001256 Triclosan Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI n.a. PMID "PMID: 30581775; PMID: 10592235" PMDBI20037664 n.a. PMDBM2020226 85962 Helicobacter pylori 26695 PMDBD2001256 Triclosan Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI n.a. PMID "PMID: 30581775; PMID: 10592235" PMDBI20037665 n.a. PMDBM2020889 1773 Mycobacterium tuberculosis Not Specified PMDBD2001256 Triclosan Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Enoyl-[acyl-carrier-protein] reductase [NADH] n.a. PMID "PMID: 30581775; PMID: 10592235" PMDBI20037666 n.a. PMDBM2020177 n.a. Staphylococcus aureus MRSA252 PMDBD2001256 Triclosan Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI n.a. PMID "PMID: 30581775; PMID: 10592235" PMDBI20037667 n.a. "PMID: 30581775; PMID: 27503150" 1201292 Enterococcus faecalis ATCC 29212 PMDBD2001257 Triethyl[2-({10,15,20,24,26,29,31,33,34-nonakis[3-(triethylphosphaniumyl)propoxy]hexacyclo[21.2.2.2,.2,.2,.2]pentatriaconta-1(25),3(35),4,6(34),8,10,13,15,18,20,23,26,28,30,32-pentadecaen-4-yl}oxy)ethyl]phosphanium decabromide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20037668 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 33592 PMDBD2001257 Triethyl[2-({10,15,20,24,26,29,31,33,34-nonakis[3-(triethylphosphaniumyl)propoxy]hexacyclo[21.2.2.2,.2,.2,.2]pentatriaconta-1(25),3(35),4,6(34),8,10,13,15,18,20,23,26,28,30,32-pentadecaen-4-yl}oxy)ethyl]phosphanium decabromide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27503150" PMDBI20037669 n.a. "PMID: 30581775; PMID: 27503150" 1201292 Enterococcus faecalis ATCC 29212 PMDBD2001258 Triethyl[3-({33-[2-(triethylazaniumyl)ethoxy]-10,15,20,25,27,29,31,34-octakis[3-(triethylazaniumyl)propoxy]hexacyclo[21.2.2.2.2.2.2]pentatriaconta-1(25),3,5,8,10,13,15,18,20,23,26,28,30,32,34-pentadecaen-4-yl}oxy)propyl]azanium decabromide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20037670 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 33592 PMDBD2001258 Triethyl[3-({33-[2-(triethylazaniumyl)ethoxy]-10,15,20,25,27,29,31,34-octakis[3-(triethylazaniumyl)propoxy]hexacyclo[21.2.2.2.2.2.2]pentatriaconta-1(25),3,5,8,10,13,15,18,20,23,26,28,30,32,34-pentadecaen-4-yl}oxy)propyl]azanium decabromide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27503150" PMDBI20037671 n.a. PMDBM2021132 n.a. Stenotrophomonas maltophilia SM33 PMDBD2001259 Trimethoprim-sulfamethoxazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 14693533" PMDBI20037672 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD2001260 Trimethoxyflavone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26140409" PMDBI20037673 n.a. "PMID: 30581775; PMID: 27503150" 1201292 Enterococcus faecalis ATCC 29212 PMDBD2001261 Trimethyl(3-{4-[3-(trimethylazaniumyl)propoxy]phenoxy}propyl)azanium dibromide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20037674 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 33592 PMDBD2001261 Trimethyl(3-{4-[3-(trimethylazaniumyl)propoxy]phenoxy}propyl)azanium dibromide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27503150" PMDBI20037675 n.a. "PMID: 30581775; PMID: 27503150" 1201292 Enterococcus faecalis ATCC 29212 PMDBD2001262 Trimethyl(3-{4-[3-(trimethylphosphaniumyl)propoxy]phenoxy}propyl)phosphanium dibromide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20037676 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 33592 PMDBD2001262 Trimethyl(3-{4-[3-(trimethylphosphaniumyl)propoxy]phenoxy}propyl)phosphanium dibromide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27503150" PMDBI20037677 n.a. "PMID: 30581775; PMID: 27503150" 1201292 Enterococcus faecalis ATCC 29212 PMDBD2001263 Trimethyl[2-({10,15,20,24,26,29,31,33,34-nonakis[3-(trimethylphosphaniumyl)propoxy]hexacyclo[21.2.2.2,.2,.2,.2]pentatriaconta-1(25),3(35),4,6(34),8,10,13,15,18,20,23,26,28,30,32-pentadecaen-4-yl}oxy)ethyl]phosphanium decabromide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20037678 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 33592 PMDBD2001263 Trimethyl[2-({10,15,20,24,26,29,31,33,34-nonakis[3-(trimethylphosphaniumyl)propoxy]hexacyclo[21.2.2.2,.2,.2,.2]pentatriaconta-1(25),3(35),4,6(34),8,10,13,15,18,20,23,26,28,30,32-pentadecaen-4-yl}oxy)ethyl]phosphanium decabromide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27503150" PMDBI20037679 n.a. "PMID: 30581775; PMID: 27503150" 1201292 Enterococcus faecalis ATCC 29212 PMDBD2001264 Trimethyl[3-({33-[2-(trimethylazaniumyl)ethoxy]-10,15,20,25,27,29,31,34-octakis[3-(trimethylazaniumyl)propoxy]hexacyclo[21.2.2.2,.2,.2,.2]pentatriaconta-1(25),3,5,8,10,13,15,18,20,23,26,28,30,32,34-pentadecaen-4-yl}oxy)propyl]azanium decabromide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20037680 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 33592 PMDBD2001264 Trimethyl[3-({33-[2-(trimethylazaniumyl)ethoxy]-10,15,20,25,27,29,31,34-octakis[3-(trimethylazaniumyl)propoxy]hexacyclo[21.2.2.2,.2,.2,.2]pentatriaconta-1(25),3,5,8,10,13,15,18,20,23,26,28,30,32,34-pentadecaen-4-yl}oxy)propyl]azanium decabromide Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27503150" PMDBI20037681 n.a. PMDBM2020753 n.a. Haemophilus influenzae ATCC 51907 PMDBD1483 Trovafloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 10428901" PMDBI20037682 n.a. PMDBM2020753 n.a. Haemophilus influenzae DSM 11121 PMDBD1483 Trovafloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 10428901" PMDBI20037683 n.a. PMDBM2020753 n.a. Haemophilus influenzae KW20 PMDBD1483 Trovafloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 10428901" PMDBI20037684 n.a. PMDBM2020753 71421 Haemophilus influenzae Rd PMDBD1483 Trovafloxacin Therapeutic substance Antibiotics n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA gyrase subunit A n.a. PMID "PMID: 30581775; PMID: 10428901" PMDBI20037721 n.a. PMDBM2021248 n.a. Candida albicans ATCC 10231 PMDBD2001265 Tyrosol Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26801208" PMDBI20037722 n.a. PMDBM2021747 n.a. Candida glabrata ATCC 90030 PMDBD2001265 Tyrosol Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26801208" PMDBI20037723 n.a. "PMID: 30581775; PMID: 26801208" 1257041 Streptococcus mutans ATCC 25175 PMDBD2001265 Tyrosol Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020183 PMDBI20037724 n.a. PMDBM2021248 n.a. Candida albicans BWP17 PMDBD2001266 Tyrphostin 9 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20037725 n.a. PMDBM2021248 n.a. Candida albicans BWP17 PMDBD2001267 Tyrphostin AG1478 Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20037726 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PAO1 (pMRP9-1) PMDBD2001268 TZD-C8 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26593271" PMDBI20037727 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2001269 Umbelliferone Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25027570" PMDBI20037728 n.a. PMDBM2020035 n.a. Escherichia coli ATCC 10536 PMDBD2001270 Undecanoic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25656290" PMDBI20037729 n.a. PMDBM2020100 n.a. Klebsiella pneumoniae ATCC 10031 PMDBD2001270 Undecanoic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25656290" PMDBI20037730 n.a. PMDBM2021025 n.a. Proteus mirabilis ATCC 7002 PMDBD2001270 Undecanoic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25656290" PMDBI20037731 n.a. PMDBM2021026 n.a. Proteus vulgaris ATCC 49132 PMDBD2001270 Undecanoic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25656290" PMDBI20037732 n.a. PMDBM2020219 n.a. Serratia marcescens a clinical isolate having GenBank Acc no. FJ584421 PMDBD2001270 Undecanoic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25656290" PMDBI20037733 n.a. "PMID: 30581775; PMID: 24944053" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001271 Undecyl beta-maltoside Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037734 n.a. PMDBM2020035 83333 Escherichia coli K12 PMDBD2001272 Uracil Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Ribosomal small subunit pseudouridine synthase A n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037735 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2001272 Uracil Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Uracil-DNA glycosylase n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037736 n.a. PMDBM2010183 n.a. Human herpesvirus 1 17 PMDBD2001272 Uracil Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Uracil-DNA glycosylase n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037740 n.a. PMDBM2020035 562 Escherichia coli ATCC 25404 PMDBD2001273 Ursolic acid Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16000817" PMDBI20037741 n.a. PMDBM2020035 n.a. Escherichia coli JM109 PMDBD2001273 Ursolic acid Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16000817" PMDBI20037742 n.a. "PMID: 30581775; PMID: 16000817" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001273 Ursolic acid Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037743 n.a. PMDBM2021218 2902295 Vibrio harveyi BB120 PMDBD2001273 Ursolic acid Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16000817" PMDBI20037744 n.a. PMDBM2020177 n.a. Staphylococcus aureus UAMS-1 PMDBD2001273 Ursolic Acid Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 22242149" PMDBI20037745 n.a. PMDBM2020177 n.a. Staphylococcus aureus subsp.aureusCOL (MRSA) PMDBD2001273 Ursolic Acid Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24970710" PMDBI20037746 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 9027 PMDBD2001273 Ursolic Acid Therapeutic Substance Phase 2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26370951" PMDBI20037747 n.a. PMDBM2021248 n.a. Candida albicans ATCC 90028 PMDBD2001274 Usnic acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26411891" PMDBI20037748 n.a. PMDBM2021775 31958 Amycolatopsis orientalis Not Specified PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: dTDP-epi-vancosaminyltransferase n.a. PMID "PMID: 30581775; PMID: 15122882" PMDBI20037749 n.a. PMDBM2020177 n.a. Staphylococcus aureus Smith diffuse (SD) PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 16621147" PMDBI20037750 n.a. "PMID: 30581775; PMID: 18430491" 1201292 Enterococcus faecalis ATCC 29212 PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020032 PMDBI20037751 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 43300 PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 18430491" PMDBI20037752 n.a. PMDBM2020033 1352 Enterococcus faecium Not Specified PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: D-alanyl-D-alanine dipeptidase n.a. PMID "PMID: 30581775; PMID: 20404117" PMDBI20037753 n.a. PMDBM2020177 n.a. Staphylococcus aureus subsp.aureusCOL (MRSA) PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24970710" PMDBI20037754 n.a. PMDBM2010322 n.a. Candida spp. Not Specified PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 25631674" PMDBI20037755 n.a. PMDBM2020177 n.a. Staphylococcus aureus Mu50 PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20037756 n.a. PMDBM2020177 n.a. Staphylococcus aureus NRS384 PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20037757 n.a. PMDBM2020177 n.a. Staphylococcus aureus New bould 305 PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20037758 n.a. PMDBM2020177 n.a. Staphylococcus aureus NRS149 PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20037759 n.a. PMDBM2020177 n.a. Staphylococcus aureus NRS123 PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20037760 n.a. PMDBM2020177 n.a. Staphylococcus aureus NRS112 PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20037761 n.a. PMDBM2020177 n.a. Staphylococcus aureus NRS153 PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20037762 n.a. PMDBM2021113 n.a. Staphylococcus capitis ET005 PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20037763 n.a. PMDBM2021114 n.a. Staphylococcus caprae NW003 PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20037764 n.a. PMDBM2021762 n.a. Staphylococcus chromogenes NW110 PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20037765 n.a. PMDBM2021115 n.a. Staphylococcus cohnii ET027 PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20037766 n.a. PMDBM2020178 n.a. Staphylococcus epidermidis ET013 PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26828772" PMDBI20037767 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2001275 Vanillic acid Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24067082" PMDBI20037768 n.a. PMDBM2020261 644 Aeromonas hydrophila Not Specified PMDBD2001276 Vanillin Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23539151" PMDBI20037769 n.a. PMDBM2020035 83334 Escherichia coli O157:H7 PMDBD2001276 Vanillin Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27808174" PMDBI20037770 n.a. "PMID: 30581775; PMID: 23831483" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001277 Vanillylacetone Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037771 n.a. PMDBM2020889 1773 Mycobacterium tuberculosis Not Specified PMDBD893 Verapamil "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28162983" PMDBI20037772 n.a. PMDBM2010808 n.a. Human herpesvirus 3 Not Specified PMDBD1489 Vidarabine Therapeutic substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Thymidine kinase n.a. PMID "PMID: 30581775; PMID: 10592235" PMDBI20037773 n.a. PMDBM2010544 n.a. Human herpesvirus 1 Not Specified PMDBD1489 Vidarabine Therapeutic substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Thymidine kinase n.a. PMID "PMID: 30581775; PMID: 12122323" PMDBI20037777 n.a. PMDBM2010809 n.a. Human herpesvirus 4 Not Specified PMDBD1489 Vidarabine Therapeutic substance antiviral n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: DNA polymerase catalytic subunit n.a. PMID "PMID: 30581775; PMID: 16797734" PMDBI20037784 n.a. PMDBM2020889 1773 Mycobacterium tuberculosis Not Specified PMDBD2001278 Viomycin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: 70S ribosome n.a. PMID "PMID: 30581775; PMID: 20154709" PMDBI20037785 n.a. PMDBM2020033 1352 Enterococcus faecium Not Specified PMDBD2001279 Virginiamycin M1 Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Streptogramin A acetyltransferase n.a. PMID "PMID: 30581775; PMID: 17016423" PMDBI20037787 n.a. PMDBM2020297 n.a. Acinetobacter nosocomialis ATCC 17903 PMDBD2001280 Virstatin Therapeutic Substance Preclinical n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 2597561" PMDBI20037788 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2001281 Vitamin C Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21930760" PMDBI20037789 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2001282 Vitamin E Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21930760" PMDBI20037790 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa MTCC 2488 PMDBD2001283 Vitexin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 27000525" PMDBI20037791 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20037792 n.a. PMDBM2020032 1351 Enterococcus faecalis Not Specified PMDBD2001284 VS2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24966779" PMDBI20037793 n.a. PMDBM2020032 1351 Enterococcus faecalis Not Specified PMDBD2001285 VSL2 Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24966779" PMDBI20037794 n.a. PMDBM2021248 n.a. Candida albicans BWP17 PMDBD2001286 W-7 Hydrochloride Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20037795 n.a. PMDBM2020177 n.a. Staphylococcus aureus BMA/FR/0.32/0074 PMDBD2001287 Wheat bran Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24588934" PMDBI20037796 n.a. PMDBM2021248 n.a. Candida albicans BWP17 PMDBD2001288 YC-1 compound Therapeutic Substance Patented Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 21903824" PMDBI20037797 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD2001289 Yohimbine hydrochloride Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20037798 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD2001290 Zalcitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Reverse transcriptase/RNaseH n.a. PMID "PMID: 30581775; PMID: 7614775" PMDBI20037800 n.a. PMDBM2010204 n.a. Influenza A virus A PMDBD2001291 Zanamivir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Neuraminidase n.a. PMID "PMID: 30581775; PMID: 11413297" PMDBI20037801 n.a. PMDBM2010813 n.a. Influenza A virus Bangkok PMDBD2001291 Zanamivir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Neuraminidase n.a. PMID "PMID: 30581775; PMID: 11413297" PMDBI20037802 n.a. PMDBM2010682 n.a. Influenza A virus 1 PMDBD2001291 Zanamivir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Neuraminidase n.a. PMID "PMID: 30581775; PMID: 11413297" PMDBI20037803 n.a. PMDBM2010814 n.a. Influenza A virus 1979 H3N2 PMDBD2001291 Zanamivir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Neuraminidase n.a. PMID "PMID: 30581775; PMID: 11413297" PMDBI20037816 n.a. PMDBM2010815 n.a. Influenza B virus B PMDBD2001291 Zanamivir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Neuraminidase n.a. PMID "PMID: 30581775; PMID: 18488077" PMDBI20037817 n.a. PMDBM2010816 n.a. Influenza B virus Beijing PMDBD2001291 Zanamivir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Neuraminidase n.a. PMID "PMID: 30581775; PMID: 18488077" PMDBI20037818 n.a. PMDBM2010817 n.a. Influenza B virus 1 PMDBD2001291 Zanamivir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Neuraminidase n.a. PMID "PMID: 30581775; PMID: 18488077" PMDBI20037819 n.a. PMDBM2010818 n.a. Influenza B virus 1987 PMDBD2001291 Zanamivir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Neuraminidase n.a. PMID "PMID: 30581775; PMID: 18488077" PMDBI20037824 n.a. "PMID: 30581775; PMID: 28255686" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001292 Zeaxanthin Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037825 n.a. PMDBM2010180 n.a. Human immunodeficiency virus 1 Not Specified PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. target: Reverse transcriptase n.a. PMID "PMID: 30581775; PMID: 9084959" PMDBI20037830 n.a. PMDBM2020035 n.a. Escherichia coli 042 (EAEC) PMDBD2001293 Zinc Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23958904" PMDBI20037831 n.a. "PMID: 30581775; PMID: 2495824" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001294 Zinc Dichloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037832 n.a. "PMID: 30581775; PMID: 24958247" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001295 Zinc Nitrate Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037833 n.a. PMDBM2020035 n.a. Escherichia coli O157:H7 (ATCC 43895) PMDBD2001296 Zinc oxide Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24958247" PMDBI20037834 n.a. "PMID: 30581775; PMID: 24958247" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001296 Zinc oxide Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037835 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001296 Zinc oxide Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24958247" PMDBI20037836 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC BAA-1707 (MRSA) PMDBD2001296 Zinc oxide Therapeutic Substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 24958247" PMDBI20037837 n.a. PMDBM2020472 n.a. Burkholderia cepacia ATCC 17759 PMDBD2001297 Zinc sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20037838 n.a. PMDBM2020035 n.a. Escherichia coli ATCC 25312 PMDBD2001297 Zinc sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20037839 n.a. PMDBM2020797 378753 Kocuria rhizophila ATCC 9341 PMDBD2001297 Zinc sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20037840 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa ATCC 9027 PMDBD2001297 Zinc sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20037841 n.a. PMDBM2020177 n.a. Staphylococcus aureus ATCC 6538 PMDBD2001297 Zinc sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 28756196" PMDBI20037842 n.a. "PMID: 30581775; PMID: 28756196" 176280 Staphylococcus epidermidis ATCC 12228 PMDBD2001297 Zinc sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020178 PMDBI20037843 n.a. "PMID: 30581775; PMID: 26084709" 208964 Pseudomonas aeruginosa PAO1 PMDBD2001298 ZnO nanoparticles Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037844 n.a. "PMID: 30581775; PMID: 26084709" 652611 Pseudomonas aeruginosa PA14 PMDBD2001298 ZnO nanoparticles Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMDBM2020151 PMDBI20037845 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA14lasR rhlR PMDBD2001298 ZnO nanoparticles Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26084709" PMDBI20037846 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa INP-42 PMDBD2001298 ZnO nanoparticles Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26084709" PMDBI20037847 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa INP-42R PMDBD2001298 ZnO nanoparticles Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26084709" PMDBI20037848 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa INP-37 PMDBD2001298 ZnO nanoparticles Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26084709" PMDBI20037849 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa INP-58M PMDBD2001298 ZnO nanoparticles Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26084709" PMDBI20037850 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa INP-58R PMDBD2001298 ZnO nanoparticles Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26084709" PMDBI20037851 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa 5U (C5) PMDBD2001298 ZnO nanoparticles Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26084709" PMDBI20037852 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA14 TC5 PMDBD2001298 ZnO nanoparticles Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26084709" PMDBI20037853 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA14 E12 PMDBD2001298 ZnO nanoparticles Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26084709" PMDBI20037854 n.a. PMDBM2020151 n.a. Pseudomonas aeruginosa PA14mexR PMDBD2001298 ZnO nanoparticles Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26084709" PMDBI20037855 n.a. PMDBM2020151 1339266 Pseudomonas aeruginosa M10 PMDBD2001298 ZnO nanoparticles Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26084709" PMDBI20037856 n.a. PMDBM2020151 1339264 Pseudomonas aeruginosa ID4365 PMDBD2001298 ZnO nanoparticles Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26084709" PMDBI20037857 n.a. PMDBM2020151 1339265 Pseudomonas aeruginosa IGB83 PMDBD2001298 ZnO nanoparticles Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26084709" PMDBI20037858 n.a. PMDBM2020151 1339263 Pseudomonas aeruginosa 148 PMDBD2001298 ZnO nanoparticles Therapeutic substance n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 26084709" PMDBI20037859 n.a. PMDBM2021248 5476 Candida albicans SC5314 PMDBD916 Zotepine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 30581775; PMID: 23689719" PMDBI20037860 n.a. PMDBM2020268 821 Bacteroides vulgatus PMDBD314 erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Erythromycin causes cell shape defects (blebbing, cytoplasmic shrinkage, cell lysis) PMID PMID: 34646011 PMDBI20037861 n.a. PMDBM2020267 820 Bacteroides uniformis PMDBD314 erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Erythromycin causes cell shape defects (blebbing, cytoplasmic shrinkage, cell lysis) PMID PMID: 34646011 PMDBI20037862 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD2001299 Alternariaspp. toxins Environmental Chemicals n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Mycotoxins may be metabolized and used as carbon source by specific bacteriaa PMID PMID: 33847775 PMDBI20037864 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD147 carboxymethylcellulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. nduction of virulence factors such as flagella, type 1 pili and long polar fimbriae PMID PMID: 33027647 PMDBI20037865 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD2001300 polysorbate-80 Environmental Chemicals n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. nduction of virulence factors such as flagella, type 1 pili and long polar fimbriae PMID PMID: 33027647 PMDBI20037866 Microbes metabolize substances PMDBM2021776 1263054 B. thetaiotaomicron PMDBD281 diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Deacetylation of both diltiazem and diltiazem metabolites in the gut isbt4096dependent PMID PMID: 31158845 PMDBI20037868 n.a. n.a. n.a. Reduction of digoxin to dihydrodigoxin throughcgroperon PMDBD294 duloxetine Therapeutic Substance Major Depressive Disorder. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "After uptake duloxetine binds to proteins in bacteria; differences in bioaccumulation between strains may depend on different uptake and efflux systems" PMID PMID: 33847775 PMDBI20037869 n.a. PMDBM2010836 n.a. L. caseiDSM20011 PMDBD2001301 As toxicity Environmental Chemicals n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Species have amino groups which were favorable for As binding sites PMID PMID: 18028332 PMDBI20037870 n.a. PMDBM2010837 n.a. L. acidophilusandL. crispatusDSM20584 PMDBD2001301 As toxicity Environmental Chemicals n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Produce S-layered proteins PMID PMID: 14645095 PMDBI20037871 n.a. PMDBM2021777 1263034 A. muciniphila PMDBD2001302 Cd detoxification Environmental Chemicals n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ameliorated the gut barrier role and increase the secretion of mucins in intestine DOI https://doi.org/10.3389%2Ffimmu.2018.01824 PMDBI20037872 n.a. PMDBM2021326 n.a. L. rhamnosusGR-1 PMDBD2001303 Pb and Cd toxicity Environmental Chemicals n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Block translocation of Pb and Cd via intestinal epithelium PMID PMID: 30426826 PMDBI20037873 n.a. PMDBM2010840 n.a. L. brevis23,017 PMDBD2001304 treat Hg toxicity Environmental Chemicals n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Hg absorbed by the bacteria and forms gut barrier PMID PMID: 30369917 PMDBI20037874 n.a. PMDBM2021778 n.a. L. plantarumCCFM8610 and CCFM8661 PMDBD2001305 Pb toxicity Environmental Chemicals n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Chelation therapy via bacterial binding metal capacity PMID PMID: 32066008 PMDBI20037875 n.a. PMDBM2010842 n.a. F. prausnitziiandO. ruminantium PMDBD2001305 Pb toxicity Environmental Chemicals n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Up-regulate the tight junction protein expression in gut and increases fecal excretion DOI https://doi.org/10.1038%2Fs41467-018-07803-9 PMDBI20037876 Microbes metabolize substances PMDBM2020088 853 F. prausnitzii PMDBD2001301 As toxicity Environmental Chemicals n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. These bacteria can biotransform arsenical compounds and build up this toxin for excretion via feces and urine DOI https://link.springer.com/doi/10.1186/2050-6511-14-62 PMDBI20037877 n.a. PMDBM2010844 n.a. L. plantarumCCFM8610 andBacillus cereus PMDBD2001306 Cd toxicity Environmental Chemicals n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. DOI https://doi.org/10.3389%2Ffimmu.2018.01824 PMDBI20037878 n.a. PMDBM2021327 n.a. L. reuteriP16 PMDBD2001305 Pb toxicity Environmental Chemicals n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Supplementation reduces the heat shock protein caused by Pb-exposure DOI https://doi.org/10.3389%2Ffimmu.2018.01824 PMDBI20037879 n.a. PMDBM2010846 n.a. L. plantarumTW1-1 PMDBD2001307 t Cr toxicity Environmental Chemicals n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. impeding uptake via the gut barrier DOI https://doi.org/10.3389%2Ffimmu.2018.01824 PMDBI10001 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD95 Baicalin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Baicalein; oroxylin A" "Hydrolysis; deglycosylation" n.a. Increase Efficacy n.a. n.a. "Inflammation; diabetes mellitus; tumor" n.a. Increased activity PMID "PMID: 26569070; PMID: 22516259; PMID: 24947972; PMID: 24033282" PMDBI10002 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD618 Olsalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylclic acid Azo reduction n.a. "Increase Efficacy; Increase Toxicity" In vivo Dog "Inflammatory diseases(ulcerative colitis; Crohn閳ユç?disease; rheumatoid arthritis)" n.a. Increased activity or causing side effects(anorexia and nausea) PMID "PMID: 26569070; PMID: 11230497" PMDBI10003 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. N-oxide bond cleavage n.a. Decrease Efficacy In vivo Dog Peptic ulcer disease n.a. Decreased intestinal absorption and systemic bioavailability PMID "PMID: 26569070; PMID: 13481854" PMDBI10004 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD731 Ranitidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. N-oxide bond cleavage n.a. Decrease Efficacy n.a. n.a. Peptic ulcer disease n.a. Decreased intestinal absorption and systemic bioavailability PMID "PMID: 26569070; PMID: 13481854" PMDBI10005 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD358 Flucytosine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-fluorouracil Deamination n.a. "Increase Efficacy; Increase Toxicity" In vivo BDIX strain rat n.a. n.a. Increased activity or toxicity PMID "PMID: 26569070; PMID: 14768038" PMDBI10007 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. "sulindac sulfide; sulinpyrzone sulfide" Reduction n.a. Increase Efficacy In vivo Rat Irinotecan-induced diarrhea model n.a. Increased activity PMID "PMID: 26569070; PMID: 18927500" PMDBI10008 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD816 Sulindac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. "sulindac sulfide; sulinpyrzone sulfide" Reduction n.a. Increase Efficacy In vivo Rat Irinotecan-induced diarrhea model n.a. Increased activity PMID "PMID: 26569070; PMID: 18927500" PMDBI10009 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD447 Insulin human Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Peptides Proteolysis n.a. Decrease Efficacy In vivo BALB/c mouse Health n.a. Decreased activity PMID "PMID: 26569070; PMID: 21051639" PMDBI10010 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD492 Loperamide oxide Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. Loperamide Reduction n.a. Increase Efficacy n.a. n.a. n.a. n.a. Increased activity PMID "PMID: 26569070; PMID: 21148486" PMDBI10011 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-aminonitrazepam Nitroreduction n.a. Increase Toxicity In vivo Mouse Moderate to severe insomnia n.a. Inducing teratogenicity PMID "PMID: 26569070; PMID: 21156650" PMDBI10012 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD600 Nitroglycerin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. "Glyceryl-1,3-dinitrate; glyceryl-1,2-dinitrate; glyceryl-1-mononitrate; glyceryl-2-mononitrate" Denitration n.a. Decrease Efficacy n.a. n.a. Angina pectoris n.a. Decreased activity PMID "PMID: 26569070; PMID: 22902524" PMDBI10013 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD279 Dihydroxyphenylalanine (DOPA) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. "m-tyramine; m-hydroxylphenylacetic acid" Dehydroxylation n.a. Increase Efficacy n.a. n.a. Parkinson閳ユç?disease (PD) n.a. Increased activity PMID "PMID: 26569070; PMID: 24264989" PMDBI10014 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Deconjugation n.a. "Decrease Efficacy; Increase Toxicity" n.a. n.a. n.a. n.a. "Decreased activity; increased side effects(diarrhea; anorexia; weight loss)" PMID "PMID: 26569070; PMID: 24264990" PMDBI10015 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "Lactic acid; 3-hydroxybutanoic acid; cyclohexanecarboxylic acid; 2-hydroxyvaleric acid" "Hydrolysis; demethylation; hydroxylation/dehydroxylation; ç?oxidation" n.a. n.a. n.a. Cardiovascular disease n.a. Altering its lipid-lowering activity PMID "PMID: 26569070; PMID: 5913083" PMDBI10016 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. "Benzisoxazole ring scission; Benzisoxazole ring hydroxylation" "Ring cleavage; hydroxylation" Increase Toxicity In vitro Human n.a. n.a. Inducting symptoms of Parkinson閳ユç?disease PMID "PMID: 26569070; PMID: 6836275" PMDBI10017 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. p-aminphenyl-2-amino-1é–?3-propanediol "Amine formation; hydrolysis" Increase Toxicity n.a. n.a. n.a. n.a. Inducing bone marrow aplasia PMID "PMID: 26569070; PMID: 8706020" PMDBI10019 Microbes metabolize substances PMDBM159 n.a. Clostridium sp. PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "Dihydrodaidzein; equol; O-desmethylanolensin(ODMAé–?Reduction; phenolic ring opening" n.a. Increase Efficacy n.a. n.a. "Osteoporosis; menopausal symptoms; cardiovascular diseases; obesity" n.a. Increased activity PMID PMID: 26569070 PMDBM2020051 PMDBI10020 Microbes metabolize substances PMDBM15 78352 anaerobic bacterium 'strain 7' PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "Dihydrodaidzein; equol; O-desmethylanolensin(ODMAé–?Reduction; phenolic ring opening" n.a. Increase Efficacy n.a. n.a. "Osteoporosis; menopausal symptoms; cardiovascular diseases; obesity" n.a. Increased activity PMID PMID: 26569070 PMDBM2020049 PMDBI10021 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD386 Genistein "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. Production of 5-hydroxyequol Hydrogenation n.a. n.a. n.a. n.a. "Obesity; Type 2 diabetes" n.a. n.a. PMID PMID: 26569070 PMDBI10022 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. Compound K Hydrolysis n.a. Increase Efficacy n.a. n.a. "Inflammation; tumor" n.a. Increased activity PMID PMID: 26569070 PMDBI10023 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. Compound K Hydrolysis n.a. Increase Efficacy n.a. n.a. "Inflammation; tumor" n.a. Increased activity PMID PMID: 26569070 PMDBI10024 Microbes metabolize substances PMDBM2020057 n.a. Eubacterium sp. GLH PMDBD408 Glycyrrhizin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 18-ç?glycyrrhetinic acid Hydrolysis n.a. Increase Efficacy n.a. n.a. Inflammation n.a. Increased activity PMID PMID: 26569070 PMDBI10025 Microbes metabolize substances PMDBM344 n.a. Pseudocera PMDBD420 Hesperidin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. Hesperetin Deglycosylation n.a. Increase Efficacy n.a. n.a. n.a. n.a. Increased activity PMID PMID: 26569070 PMDBI10026 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. "Monosaccharides; lactate, acetate; butyrate" Hydrolysis n.a. n.a. n.a. n.a. n.a. n.a. "Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli)" PMID PMID: 26569070 PMDBI10027 Microbes metabolize substances PMDBM2020032 n.a. Enterococcus faecalis PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. "Monosaccharides; lactate, acetate; butyrate" Hydrolysis n.a. n.a. n.a. n.a. n.a. n.a. "Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli)" PMID PMID: 26569070 PMDBI10028 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. "Monosaccharides; lactate, acetate; butyrate" Hydrolysis n.a. n.a. n.a. n.a. n.a. n.a. "Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli)" PMID PMID: 26569070 PMDBI10029 Microbes metabolize substances PMDBM2020031 37734 Enterococcus casseliflavus PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. "Monosaccharides; lactate, acetate; butyrate" Hydrolysis n.a. n.a. n.a. n.a. n.a. n.a. "Stimulating the growth of beneficial bacteria(Bifidobacteria; Lactobacilli)" PMID PMID: 26569070 PMDBI10030 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "levametabol-I; levametabol-II; levametabol-III" Thiazole ring opening n.a. Increase Efficacy n.a. n.a. Colon cancer n.a. Increased activity PMID PMID: 26569070 PMDBI10031 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "levametabol-I; levametabol-II; levametabol-III" Thiazole ring opening n.a. Increase Efficacy n.a. n.a. Colon cancer n.a. Increased activity PMID PMID: 26569070 PMDBI10032 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD527 Metamfetamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. "Amphetamine; norephedrine; an unknown metabolite" Demethylation n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Decreased activity PMID PMID: 26569070 PMDBI10033 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD527 Metamfetamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. "Amphetamine; norephedrine; an unknown metabolite" Demethylation n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Decreased activity PMID PMID: 26569070 PMDBI10034 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD527 Metamfetamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. "Amphetamine; norephedrine; an unknown metabolite" Demethylation n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Decreased activity PMID PMID: 26569070 PMDBI10035 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. corresponding sulfide metabolites Reduction n.a. Decrease Efficacy n.a. n.a. Gastric ulcer n.a. Decreased activity PMID PMID: 26569070 PMDBI10036 Microbes metabolize substances PMDBM2020031 37734 Enterococcus casseliflavus PMDBD718 Quercetin-3-glucoside "Herbal Substance; Dietary Substance" "Medicinal Herbal Compounds; Dietary Compounds" n.a. n.a. n.a. n.a. "Butyrate; acetate; 3,4-dihydroxyphenylacetic acid" Deglycosylation n.a. n.a. n.a. n.a. "Cardiovascular disease; tumors" n.a. n.a. PMID PMID: 26569070 PMDBI10037 Microbes metabolize substances PMDBM2020222 39490 Eubacterium ramulus PMDBD718 Quercetin-3-glucoside "Herbal Substance; Dietary Substance" "Medicinal Herbal Compounds; Dietary Compounds" n.a. n.a. n.a. n.a. "Butyrate; acetate; 3,4-dihydroxyphenylacetic acid" Deglycosylation n.a. n.a. n.a. n.a. "Cardiovascular disease; tumors" n.a. n.a. PMID PMID: 26569070 PMDBI10038 Microbes metabolize substances PMDBM2020046 n.a. Clostridioides difficile PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "acetaminophen sulfate; glucuronide" "O-Sulfation; C-S cleavage of acetaminophen-3-cysteine" "Increase Efficacy; Decrease Toxicity" n.a. n.a. n.a. Microbial product(p-cresol) could alter the ratio of metabolites Altered activity or toxicity PMID PMID: 26569070 PMDBI10039 Microbes metabolize substances PMDBM2020213 n.a. Eggerthella lenta PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "Dihydrodigoxin; dihydrodigoxigenin" Reduction n.a. Decrease Efficacy In vivo Human Heart disease n.a. Decreased cardiac activity PMID PMID: 26569070 PMDBI10040 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "m-tyrosine; m-tyramine; m-hydroxyphenylacetic acid" Dehydroxylation n.a. Decrease Efficacy n.a. n.a. Parkinson閳ユç?disease (PD) n.a. Decreased activity PMID PMID: 26569070 PMDBI10041 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "N-(2-hydroxyethyl)-oxamic acid; acetamide" Reduction n.a. Increase Toxicity n.a. n.a. n.a. n.a. Probably increase its liver toxicity PMID PMID: 26569070 PMDBI10042 Microbes metabolize substances PMDBM2020008 n.a. Bacteroides fragilis PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil Hydrolysis n.a. Increase Toxicity n.a. n.a. n.a. Metabolites can inactivate a key liver enzyme Lead to lethal toxicity when co-administered with 5-fluorouracil PMID "PMID: 26569070; PMID: 27591027" PMDBI10043 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil Hydrolysis n.a. Increase Toxicity n.a. n.a. n.a. Metabolites can inactivate a key liver enzyme Lead to lethal toxicity when co-administered with 5-fluorouracil PMID "PMID: 26569070; PMID: 27591027" PMDBI10044 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil Hydrolysis n.a. Increase Toxicity n.a. n.a. n.a. Metabolites can inactivate a key liver enzyme Lead to lethal toxicity when co-administered with 5-fluorouracil PMID "PMID: 26569070; PMID: 27591027" PMDBI10045 Microbes metabolize substances PMDBM2020268 821 Bacteroides vulgatus PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil Hydrolysis n.a. Increase Toxicity n.a. n.a. n.a. Metabolites can inactivate a key liver enzyme Lead to lethal toxicity when co-administered with 5-fluorouracil PMID "PMID: 26569070; PMID: 27591027" PMDBI10046 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil Hydrolysis n.a. Increase Toxicity n.a. n.a. n.a. Metabolites can inactivate a key liver enzyme Lead to lethal toxicity when co-administered with 5-fluorouracil PMID "PMID: 26569070; PMID: 27591027" PMDBI10047 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. Microbial arylamine N-acetyltransferases Differences in gut microbial metabolism contribute to variations in drug efficacy PMID "PMID: 11344150; PMID: 26972811" PMDBI10048 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD90 Azo dyes Environmental Substance "Industrial Chemicals; Pollutants" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduce azo bond n.a. PMID "PMID: 26972811; PMID: 14489780" PMDBI10049 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD305 Enrofloxacin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Enrofloxacin-or vancomycin-treated Microbial fermentation of carbohydrates is disrupted "Decrease concentrations of amino acids and SCFAs;increase oligosaccharide levels" PMID "PMID: 18698804; PMID: 26972811" PMDBI10050 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Enrofloxacin-or vancomycin-treated Microbial fermentation of carbohydrates is disrupted "Decrease concentrations of amino acids and SCFAs;increase oligosaccharide levels" PMID "PMID: 18698804; PMID: 26972811" PMDBI10053 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD650 Pentobarbital Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Animal model Germ-free,colonized n.a. Germ-free animals are more efficient at metabolizing drug PMID "PMID: 19742318; PMID: 26972811" PMDBI10054 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. Treatment is positively associated with the production by the microbiota(lithocholic acid, taurolithocholic acid and glycolithocholic acid) PMID "PMID: 22022402; PMID: 26972811" PMDBI10055 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD627 Oxaliplatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Production of reactive oxygen species Induces apoptosis PMID "PMID: 24264989; PMID: 26972811" PMDBI10056 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Promote the translocation of bacteria into secondary lymphoid organs Limit tumour growth PMID "PMID: 24264990; PMID: 26972811" PMDBI10057 Microbes metabolize substances PMDBM2020213 n.a. Eggerthella lenta PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. dihydrodigoxin n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Cgr operon n.a. PMID "PMID: 6836275; PMID: 26972811" PMDBI10058 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD422 Heterocyclic amines Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. é“?glucuronidases Microbiota contribute to associations between the risk of CRC and the intake of heterocyclic amines PMID "PMID: 8055651; PMID: 26972811" PMDBI10059 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial ç?glucuronidase,liberate the sugar moiety from SN-38G "Re-activate the drug causing increased toxicity(towards intestinal epithelial cells);exacerbate the diarrhoea" PMID "PMID: 8891470; PMID: 26972811" PMDBI10060 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD9 7-ethyl-10-hydroxycamptothecin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. "SN-38G; ;cyanuric acid" n.a. n.a. Increase Toxicity In vivo Animal model Germ-free,colonized n.a. Metabolites are harmful to the host PMID PMID: 26972811 PMDBI10061 Microbes metabolize substances PMDBM242 32066 Fusobacteria PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial metabolite p-cresol competes with drug Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite?NAPQI PMID PMID: 26972811 PMDBI10062 Microbes metabolize substances PMDBM2020046 n.a. Clostridioides difficile PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial metabolite p-cresol competes with drug Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite?NAPQI PMID PMID: 26972811 PMDBI10063 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial metabolite p-cresol competes with drug Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite?NAPQI PMID PMID: 26972811 PMDBI10064 Microbes metabolize substances PMDBM3 n.a. Actinobacteria PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial metabolite p-cresol competes with drug Impede the ability to detoxify acetaminophen,accumulate the toxic metabolite?NAPQI PMID PMID: 26972811 PMDBI10065 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD50 Anti-PD-L1 therapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase the efficacy of PD-1 PMID PMID: 26972811 PMDBI10066 Microbes metabolize substances PMDBM381 1279 Staphylococcus PMDBD51 Anti-TNF antibobies Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Therapy is accompanied by a substantial increase in the abundance of bacteria PMID PMID: 26972811 PMDBI10067 Microbes metabolize substances PMDBM22 162425 Aspergillus nidulans PMDBD119 Black tea Dietary Substance Drinks n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase the abundance of A.?muciniphila PMID PMID: 26972811 PMDBI10069 Microbes metabolize substances PMDBM337 1224 Proteobacteria PMDBD190 Choline-containing compounds Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbial glycyl radical enzymes Associate with the risk of cardiovascular disease PMID PMID: 26972811 PMDBI10070 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD190 Choline-containing compounds Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbial glycyl radical enzymes Associate with the risk of cardiovascular disease PMID PMID: 26972811 PMDBI10071 Microbes metabolize substances PMDBM2020008 n.a. Bacteroides fragilis PMDBD231 CTLA-4 blockade Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Blockade immunotherapy PMID PMID: 26972811 PMDBI10072 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD231 CTLA-4 blockade Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Blockade immunotherapy PMID PMID: 26972811 PMDBI10073 Microbes metabolize substances PMDBM2020033 n.a. Enterococcus faecium PMDBD245 Daidzin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. equol n.a. n.a. n.a. n.a. n.a. n.a. Glycosidic cleavage and reduction n.a. PMID PMID: 26972811 PMDBI10074 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp. PMDBD245 Daidzin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. equol n.a. n.a. n.a. n.a. n.a. n.a. Glycosidic cleavage and reduction n.a. PMID PMID: 26972811 PMDBI10075 Microbes metabolize substances PMDBM276 97478 Lactobacillus mucosae PMDBD245 Daidzin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. equol n.a. n.a. n.a. n.a. n.a. n.a. Glycosidic cleavage and reduction n.a. PMID PMID: 26972811 PMDBI10076 Microbes metabolize substances PMDBM2020053 1929886 Eggerthella sp. PMDBD245 Daidzin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. equol n.a. n.a. n.a. n.a. n.a. n.a. Glycosidic cleavage and reduction n.a. PMID PMID: 26972811 PMDBI10077 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD272 Dietary phosphatidylcholine Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacteria provide a link for drugs PMID PMID: 26972811 PMDBI10078 Microbes metabolize substances PMDBM249 644652 Gordonibacter PMDBD299 Ellagic acid "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolize ellagitannins PMID PMID: 26972811 PMDBI10079 Microbes metabolize substances PMDBM22 162425 Aspergillus nidulans PMDBD411 Grape-derived polyphenols Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase the abundance of A.?muciniphila PMID PMID: 26972811 PMDBI10080 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD421 Heterocyclic amine 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reactivate the compound PMID PMID: 26972811 PMDBI10081 Microbes metabolize substances PMDBM127 194 Campylobacter PMDBD457 Isoaminile Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. cyclohexylamine n.a. n.a. n.a. In vivo Animal model n.a. n.a. Exhibit toxicity PMID PMID: 26972811 PMDBI10082 Microbes metabolize substances PMDBM208 561 Escherichia PMDBD457 Isoaminile Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. cyclohexylamine n.a. n.a. n.a. In vivo Animal model n.a. n.a. Exhibit toxicity PMID PMID: 26972811 PMDBI10083 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD457 Isoaminile Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. cyclohexylamine n.a. n.a. n.a. In vivo Animal model n.a. n.a. Exhibit toxicity PMID PMID: 26972811 PMDBI10084 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD457 Isoaminile Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. cyclohexylamine n.a. n.a. n.a. In vivo Animal model n.a. n.a. Exhibit toxicity PMID PMID: 26972811 PMDBI10085 Microbes metabolize substances PMDBM175 1716 Corynebacterium PMDBD457 Isoaminile Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. cyclohexylamine n.a. n.a. n.a. In vivo Animal model n.a. n.a. Exhibit toxicity PMID PMID: 26972811 PMDBI10086 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD460 Isoflavones Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolites bind to oestrogen receptors May elicit protective effects against breast cancer PMID PMID: 26972811 PMDBI10087 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD460 Isoflavones Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolites bind to oestrogen receptors May elicit protective effects against breast cancer PMID PMID: 26972811 PMDBI10088 Microbes metabolize substances PMDBM3 n.a. Actinobacteria PMDBD460 Isoflavones Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolites bind to oestrogen receptors May elicit protective effects against breast cancer PMID PMID: 26972811 PMDBI10089 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD480 Lignans "Herbal Substance; Dietary Substance" "Medicinal Herbal Compounds; Dietary Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolites bind to oestrogen receptors May elicit protective effects against breast cancer PMID PMID: 26972811 PMDBI10090 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD480 Lignans "Herbal Substance; Dietary Substance" "Medicinal Herbal Compounds; Dietary Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolites bind to oestrogen receptors May elicit protective effects against breast cancer PMID PMID: 26972811 PMDBI10091 Microbes metabolize substances PMDBM3 n.a. Actinobacteria PMDBD480 Lignans "Herbal Substance; Dietary Substance" "Medicinal Herbal Compounds; Dietary Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolites bind to oestrogen receptors May elicit protective effects against breast cancer PMID PMID: 26972811 PMDBI10093 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy In vivo Animal model Germ-free,colonized Conversion into a downstream metabolite with reduced bioactivity n.a. PMID PMID: 26972811 PMDBI10094 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD610 NSAIDs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. "SN-38G; ;cyanuric acid" n.a. n.a. Increase Toxicity In vivo Animal model Germ-free,colonized n.a. Metabolites are harmful to the host PMID PMID: 26972811 PMDBI10095 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD662 Phenoxyethanol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. "SN-38G; ;cyanuric acid" n.a. n.a. Increase Toxicity In vivo Animal model Germ-free,colonized n.a. Metabolites are harmful to the host PMID PMID: 26972811 PMDBI10096 Microbes metabolize substances PMDBM2020062 577 Raoultella terrigena PMDBD662 Phenoxyethanol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. cyanuric acid n.a. n.a. n.a. In vivo Animal model n.a. n.a. Lead to increased kidney damage PMID PMID: 26972811 PMDBI10097 Microbes metabolize substances PMDBM2020062 577 Raoultella terrigena PMDBD662 Phenoxyethanol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolism by the bacteria Lead to kidney stones PMID PMID: 26972811 PMDBI10098 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila PMDBD684 Polyphenols "Herbal Substance; Dietary Substance" "Medicinal Herbal Compounds; Dietary Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Fed high-fat diets Couple with substantial sevenfold-to-tenfold blooms of drug Limit the risk of systemic inflammation PMID PMID: 26972811 PMDBI10099 Microbes metabolize substances PMDBM138 1898207 Clostridiales bacterium PMDBD761 Saccharin "Therapeutic Substance; Dietary Substance; Herbal Substance" "Investigational Drug; Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro Mouse Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms n.a. Increase the abundance of bacteria PMID PMID: 26972811 PMDBI10100 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD772 Secoisolariciresinol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. enterodiol,enterolactone n.a. n.a. n.a. n.a. n.a. n.a. n.a. Product the cancer-protective compounds PMID PMID: 26972811 PMDBI10101 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Bioavailability n.a. n.a. n.a. Modulate the expression of host transporters,or directly compete with host transporters Contribute to?the absorption of simvastatin PMID PMID: 26972811 PMDBI10102 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD810 Sulfanilamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy In vivo Animal model Germ-free,colonized Conversion to bioactive form Contribute to therapeutic concentrations PMID PMID: 26972811 PMDBI10103 Microbes metabolize substances PMDBM2020032 n.a. Enterococcus faecalis PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat "Antibiotic-treated or germ-free;convention" n.a. Result in drug cleavage PMID PMID: 26972811 PMDBI10104 Microbes metabolize substances PMDBM2020065 1591 Lactobacillus sp. PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat "Antibiotic-treated or germ-free;convention" n.a. Result in drug cleavage PMID PMID: 26972811 PMDBI10105 Microbes metabolize substances PMDBM60 29523 Bacteroides sp. PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat "Antibiotic-treated or germ-free;convention" n.a. Result in drug cleavage PMID PMID: 26972811 PMDBI10106 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy In vivo Animal model Germ-free,colonized Conversion to bioactive form Contribute to therapeutic concentrations PMID PMID: 26972811 PMDBI10107 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human Kidney transplant recipient n.a. The abundance of the gut bacterium has a positive correlation with an increase in tacrolimus dosing PMID PMID: 26972811 PMDBI10108 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD852 TMAO Environmental Substance Human Metabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacteria provide a link for drugs PMID PMID: 26972811 PMDBI10109 Microbes metabolize substances PMDBM138 1898207 Clostridiales bacterium PMDBD906 Xylitol "Therapeutic Substance; Herbal Substance; Dietary Substance" "Approved Drug; Medicinal Herbal Compounds; Dietary Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro Mouse Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms n.a. Increase the abundance of bacteria PMID PMID: 26972811 PMDBI10110 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD147 Carboxymethylcellulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. "Decrease the abundance of Bacteroidales;increase the abundance of mucolytic bacteria" The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome PMID PMID: 26972811 PMDBI10111 Microbes metabolize substances PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD147 Carboxymethylcellulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. "Decrease the abundance of Bacteroidales;increase the abundance of mucolytic bacteria" The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome PMID PMID: 26972811 PMDBI10112 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD690 Polysorbate 80 Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. "Decrease the abundance of Bacteroidales;increase the abundance of mucolytic bacteria" The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome PMID PMID: 26972811 PMDBI10113 Microbes metabolize substances PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD691 Polysorbate 81 Environmental Substance "Industrial Chemicals; Pollutants" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. "Decrease the abundance of Bacteroidales;increase the abundance of mucolytic bacteria" The shifts in microbiota are accompanied by low-grade inflammation,increased gut permeability, increased weight and adiposity, and the development of metabolic syndrome PMID PMID: 26972811 PMDBI10114 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD402 Glucuronidated compound Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Convention, germ-free é“?glucuronidases Reactivate the toxic compound and augment genotoxicity PMID PMID: 26972811 PMDBI10115 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD810 Sulfanilamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. triamino benzene,sulfanilamide n.a. n.a. Increase Efficacy n.a. n.a. n.a. Reduce azo bond Activate drug PMID PMID: 26972811 PMDBI10122 Microbes metabolize substances PMDBM2020032 n.a. Enterococcus faecalis PMDBD772 Secoisolariciresinol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. n.a. Increase Efficacy In vivo Rat Germ-free,or germ-free colonized with a bacterial consortium Metabolism by bacteria Protective effects against breast cancer PMID PMID: 26972811 PMDBI10123 Microbes metabolize substances PMDBM2020084 1736 Eubacterium limosum PMDBD772 Secoisolariciresinol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. n.a. Increase Efficacy In vivo Rat Germ-free,or germ-free colonized with a bacterial consortium Metabolism by bacteria Protective effects against breast cancer PMID PMID: 26972811 PMDBI10124 Microbes metabolize substances PMDBM2020202 29347 [Clostridium] scindens PMDBD772 Secoisolariciresinol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. n.a. Increase Efficacy In vivo Rat Germ-free,or germ-free colonized with a bacterial consortium Metabolism by bacteria Protective effects against breast cancer PMID PMID: 26972811 PMDBI10125 Microbes metabolize substances PMDBM2020197 n.a. Blautia producta PMDBD772 Secoisolariciresinol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. n.a. Increase Efficacy In vivo Rat Germ-free,or germ-free colonized with a bacterial consortium Metabolism by bacteria Protective effects against breast cancer PMID PMID: 26972811 PMDBI10126 Microbes metabolize substances PMDBM2020213 n.a. Eggerthella lenta PMDBD772 Secoisolariciresinol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. n.a. Increase Efficacy In vivo Rat Germ-free,or germ-free colonized with a bacterial consortium Metabolism by bacteria Protective effects against breast cancer PMID PMID: 26972811 PMDBI10127 Microbes metabolize substances PMDBM2020065 341220 Lactonifactor longoviformis PMDBD772 Secoisolariciresinol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. enterodiol and entero lactone n.a. n.a. Increase Efficacy In vivo Rat Germ-free,or germ-free colonized with a bacterial consortium Metabolism by bacteria Protective effects against breast cancer PMID PMID: 26972811 PMDBI10128 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD263 Diclofenac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial ç?glucuronidase Cause mitochondrial and endo plasmic reticulum stress, compromise mucosal integrity and promote?inflammation PMID PMID: 26972811 PMDBI10129 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial ç?glucuronidase Cause mitochondrial and endo plasmic reticulum stress, compromise mucosal integrity and promote?inflammation PMID PMID: 26972811 PMDBI10130 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial ç?glucuronidase Cause mitochondrial and endo plasmic reticulum stress, compromise mucosal integrity and promote?inflammation PMID PMID: 26972811 PMDBI10131 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD761 Saccharin "Therapeutic Substance; Dietary Substance; Herbal Substance" "Investigational Drug; Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro Mouse Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms n.a. Increase the abundance of bacteria PMID PMID: 26972811 PMDBI10132 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD830 Tempol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. "Increase the abundance of Bacteroidetes;decrease the abundance of Firmicutes" PMID PMID: 26972811 PMDBI10133 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD830 Tempol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduce members of the genus Lactobacillus PMID PMID: 26972811 PMDBI10134 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD906 Xylitol "Therapeutic Substance; Herbal Substance; Dietary Substance" "Approved Drug; Medicinal Herbal Compounds; Dietary Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro Mouse Colonized with gut micro organisms from NAS-treated mice,or with faecal microorganisms n.a. Increase the abundance of bacteria PMID PMID: 26972811 PMDBI10135 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease expression of genes involved in antimicrobial defence Nearly eradicated the lactobacilli PMID PMID: 26972811 PMDBI10136 Microbes metabolize substances PMDBM2020046 n.a. Clostridioides difficile PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Piglet n.a. n.a. Promote colonization by opportunistic pathogens PMID PMID: 26972811 PMDBI10137 Microbes metabolize substances PMDBM128 5476 Candida albicans PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Piglet n.a. n.a. Promote colonization by opportunistic pathogens PMID PMID: 26972811 PMDBI10138 Microbes metabolize substances PMDBM2020046 n.a. Clostridioides difficile PMDBD52 Antibiotic Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. "Cause antibiotic-associated diarrhoea(AAD);pseudomembranous colitis(can cause death)" PMID PMID: 26972811 PMDBI10139 Microbes metabolize substances PMDBM128 5476 Candida albicans PMDBD160 Cefoperazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Total number of bacteria is reduced;overgrowth of C.albicans" Allergic-airways diease develops after challenge with mould spores PMID PMID: 26972811 PMDBI10140 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD173 Cephalosporins Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Suppression of lactocilli and bifidobacterial;overgrowth of C.albicans" Increase susceptibility to asthma PMID PMID: 26972811 PMDBI10141 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD173 Cephalosporins Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Suppression of lactocilli and bifidobacterial;overgrowth of C.albicans" Increase susceptibility to asthma PMID PMID: 26972811 PMDBI10142 Microbes metabolize substances PMDBM128 5476 Candida albicans PMDBD173 Cephalosporins Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Suppression of lactocilli and bifidobacterial;overgrowth of C.albicans" Increase susceptibility to asthma PMID PMID: 26972811 PMDBI10143 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD466 Kanamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Total number of anaerobes is reduced Clinical scores for atopic dermatitis are higher PMID PMID: 26972811 PMDBI10144 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp. PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. More bifidobacterium spp. PMID PMID: 26972811 PMDBI10145 Microbes metabolize substances PMDBM2020059 n.a. Gram-negative bacterium B1G-1A PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Reduce expression of the gene encoding REG3ç»?n.a. Reduce expression of the gene encoding REG3ç»?n.a. PMID PMID: 26972811 PMDBI10146 Microbes metabolize substances PMDBM2020059 n.a. Gram-negative bacterium B1G-1A PMDBD579 Neomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Reduce expression of the gene encoding REG3ç»?n.a. Reduce expression of the gene encoding REG3ç»?n.a. PMID PMID: 26972811 PMDBI10147 Microbes metabolize substances PMDBM371 n.a. Salmonella enterica subsp. enterica serovar Typhimurium PMDBD804 Streptomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Streptomycin treated Butyrate contribute to the increased infiltration of neutrophils Result in an increased inflammatory state PMID PMID: 26972811 PMDBI10148 Microbes metabolize substances PMDBM404 n.a. Unidentified vaginal microbes PMDBD884 Unspecified antibiotic Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Loss of vaginal lactobacilli;and overgrowth of C.albicans" n.a. PMID PMID: 26972811 PMDBI10149 Microbes metabolize substances PMDBM128 5476 Candida albicans PMDBD884 Unspecified antibiotic Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Loss of vaginal lactobacilli;and overgrowth of C.albicans" n.a. PMID PMID: 26972811 PMDBI10150 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Gram-negatinve populations are depleted(not being restricted by vancomycin) PMID PMID: 26972811 PMDBI10151 Microbes metabolize substances PMDBM2020059 n.a. Gram-negative bacterium B1G-1A PMDBD888 Vancomycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Reduce expression of the gene encoding REG3ç»?n.a. Reduce expression of the gene encoding REG3ç»?n.a. PMID PMID: 26972811 PMDBI10152 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. hydroxyiminonizatidine n.a. n.a. n.a. In vitro Human n.a. Cleavage on an N-oxide bond n.a. PMID "PMID: 27485182; PMID: 11955801" PMDBI10155 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD565 Nabumetone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 4-(6-methoxy-2-naphthyl)-butan-2-ol (reduced nabumetone) n.a. n.a. Decrease Efficacy "In vivo (Rat); In vitro (Human)" "Rat; Human" n.a. n.a. "Cause lower absorbtion of nabumetone and lower its bioavailability;[drug interaction:erythromycin and tetracycline suppresses the reduction of digoxin]" PMID "PMID: 23584048; PMID: 27485182" PMDBI10156 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. a phosphorylated derivative and active 2-hydroxy lovastatic acid n.a. n.a. n.a. In vivo Rat n.a. Hydrolyzed [drug interaction]:antibiotics decreases the bioavailability of the active metabolite PMID "PMID: 27485182; PMID: 24947972" PMDBI10157 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD497 Lovastatin related compounds Therapeutic Substance n.a. n.a. n.a. n.a. n.a. a phosphorylated derivative and active 2-hydroxy lovastatic acid n.a. n.a. n.a. In vivo Rat n.a. Hydrolyzed [drug interaction]:antibiotics decreases the bioavailability of the active metabolite PMID "PMID: 27485182; PMID: 24947972" PMDBI10158 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "In vivo; In vitro" "Human; Rabbit" Ileostomy patients Microbiota seems to be only site of sulfinpyrazone reduction(in man) n.a. PMID "PMID: 3630204; PMID: 27485182" PMDBI10159 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD816 Sulindac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulindac sulfide n.a. n.a. n.a. "In vivo; In vitro" "Human; Rabbit" n.a. n.a. n.a. PMID "PMID: 3630204; PMID: 27485182" PMDBI10160 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid (mesalazine)and sulfapyridine n.a. n.a. Decrease Toxicity In vivo Human Ulcerative colitis Bacterial azoreductases Lead to side effect PMID "PMID: 27485182; PMID: 4147555" PMDBI10161 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. p-aminophenyl-2-amin-1,3-propanediol n.a. n.a. Increase Toxicity In vitro human n.a. n.a. Produce toxic metabolite related to risk of marrow aplasia PMID "PMID: 27485182; PMID: 4165044" PMDBI10162 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. N-(2-hydroxyethyl)-oxamic acid and acetamide n.a. n.a. n.a. In vivo Rat Conventional(CV), germ-free(GF) Reductive modification,disrupt the imidazole ring n.a. PMID "PMID: 27485182; PMID: 430360" PMDBI10163 Microbes metabolize substances PMDBM2020099 n.a. Clostridium perfringens PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. N-(2-hydroxyethyl)-oxamic acid and acetamide n.a. n.a. n.a. In vivo Rat Conventional(CV), germ-free(GF) Reductive modification,disrupt the imidazole ring n.a. PMID "PMID: 27485182; PMID: 430360" PMDBI10164 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. m-tyramine and m-hydroxyphenylacetic acid n.a. n.a. n.a. In vivo Rat Conventional, in pathogen free Dehydroxylation of the catechol ring Form the metabolites PMID "PMID: 4723308; PMID: 27485182" PMDBI10165 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD553 Misonidazole Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. amino derivative n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 6260109; PMID: 27485182" PMDBI10166 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD96 Balsalazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. n.a. In vivo "Mouse; Rat; Ferret" n.a. n.a. n.a. PMID "PMID: 27485182; PMID: 6345112" PMDBI10167 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat Germ-free and ex-germ-free Nitro reduction n.a. PMID "PMID: 27485182; PMID: 6506755" PMDBI10168 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. dihydroxy-risperidone and hydroxyl-ke-to-risperidone n.a. n.a. n.a. In vivo Rat n.a. n.a. [drug interaction]:(in the liver)antibiotics decrease the bioavailability of risperidone. PMID "PMID: 27485182; PMID: 7512019" PMDBI10169 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulfide metabolites n.a. n.a. n.a. In vivo Rat n.a. Reductive metabolism n.a. PMID "PMID: 27485182; PMID: 7629748" PMDBI10170 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 2-sulfamoylacetylphenol n.a. n.a. n.a. In vivo "Mouse; Rat; Hamster; Rabbit; Guinea pig" n.a. Reductive metabolism [drug interaction]:antibiotics inhibit the urinary and faecal excretion of metabolites PMID "PMID: 9231340; PMID: 27485182" PMDBI10171 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. dihydrodigoxin and dihydrodigoxigenin n.a. n.a. Decrease Efficacy In vivo human Health Formation of inactive metabolites Have lower cardiac activity PMID "PMID: 27485182; PMID: 7266632" PMDBI10172 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid n.a. n.a. n.a. n.a. "Human; Rat; Guinea pig; Dog" n.a. Acetylated by the gut microbiota n.a. PMID PMID: 27485182 PMDBI10173 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD811 Sulfapyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid n.a. n.a. n.a. n.a. "Human; Rat; Guinea pig; Dog" n.a. Acetylated by the gut microbiota n.a. PMID PMID: 27485182 PMDBI10174 Microbes metabolize substances PMDBM2020046 n.a. Clostridioides difficile PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. p-cresol sulfate and phenylacetylglutamine n.a. n.a. Increase Toxicity n.a. n.a. n.a. "O-sulfation; C-S cleavage of acetaminophen-3-cysteine" Increased toxicity PMID PMID: 27485182 PMDBI10175 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. fructose and galactose n.a. n.a. Increase Efficacy n.a. n.a. n.a. Hydrolysis of enzymes of the intestinal bacteria Lead to laxative effect of lactulose PMID PMID: 27485182 PMDBI10176 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. fructose and galactose n.a. n.a. Increase Efficacy n.a. n.a. n.a. Hydrolysis of enzymes of the intestinal bacteria Lead to laxative effect of lactulose PMID PMID: 27485182 PMDBI10177 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. fructose and galactose n.a. n.a. Increase Efficacy n.a. n.a. n.a. Hydrolysis of enzymes of the intestinal bacteria Lead to laxative effect of lactulose PMID PMID: 27485182 PMDBI10178 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. levametabol-I,levametabol-II,and levametabol-III n.a. n.a. Increase Efficacy n.a. human n.a. Open thiazole ring "Increased activity;[drug interaction]:antibiotics increase a stronger clinical effect of levamisole" PMID PMID: 27485182 PMDBI10179 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. levametabol-I,levametabol-II,and levametabol-III n.a. n.a. Increase Efficacy n.a. human n.a. Open thiazole ring "Increased activity;[drug interaction]:antibiotics increase a stronger clinical effect of levamisole" PMID PMID: 27485182 PMDBI10180 Microbes metabolize substances PMDBM2020035 1322345 Escherichia coli ATCC 25922 PMDBD565 Nabumetone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. a reduced pharmacologically inactive metabolite n.a. n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Cause lower absorbtion and lower bioavailability of the drug PMID PMID: 27485182 PMDBI10181 Microbes metabolize substances PMDBM2020201 1535 [Clostridium] leptum PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-aminonitrazepam n.a. n.a. n.a. In vivo "Mouse; Rat" n.a. Nitro reduction Produce products with teratogenic effects PMID PMID: 27485182 PMDBI10182 Microbes metabolize substances PMDBM60 29523 Bacteroides sp. PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil n.a. n.a. n.a. n.a. n.a. n.a. n.a. [drug interaction]:metabolites cause toxic level of anticancer drug 5-fluorouracil PMID PMID: 27485182 PMDBI10183 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD580 Neoprontosil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulfanilamide n.a. n.a. Increase Efficacy n.a. n.a. n.a. Reduction of the azo bond by azoreductases of the large intestinal microbiota "Activate prodrug,have antibacterial effect;[drug interaction]:antbiotics suppress the conversion of prontosil" PMID PMID: 27485182 PMDBI10184 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD810 Sulfanilamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. sulfanilamide n.a. n.a. Increase Efficacy n.a. n.a. n.a. Reduction of the azo bond by azoreductases of the large intestinal microbiota "Activate prodrug,have antibacterial effect;[drug interaction]:antbiotics suppress the conversion of prontosil" PMID PMID: 27485182 PMDBI10185 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. Increase Toxicity In vivo Mouse n.a. é“?glucuronidases "Cause diarrhoea;[drug interaction]:(rat)ciprofloxacin and amoxapine can suppress diarrhoea" PMID "PMID: 21051639; PMID: 28270698" PMDBI10186 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD229 CpG oligodeoxynucleotides Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Bacteria regulate the immune response to chemotherapy(primes tumour-associated innate myeloid cells for inflammatory cytokine production) [drug interaction]:antibiotic or germ-free (sterile) status attenuates this response PMID "PMID: 24264989; PMID: 28270698" PMDBI10187 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. "Cause commensal bacteria translocation into secondary lymphoid organs;reduce the abundance of lactobacilli and enterococci;[drug interaction]:long-term antibiotics reduce the capacity of cyclophosphamide" PMID "PMID: 24264990; PMID: 28270698" PMDBI10188 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD290 Doxorubicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. "Cause commensal bacteria translocation into secondary lymphoid organs;reduce the abundance of lactobacilli and enterococci;[drug interaction]:long-term antibiotics reduce the capacity of cyclophosphamide" PMID "PMID: 24264990; PMID: 28270698" PMDBI10189 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Toxicity In vivo C57BL/6J mouse TLR2 knockout vs wildtype mice TLR2 signalling and drug transporter p-gp Bacteria regulate against chemotherapy-induced small bowel injury PMID "PMID: 25589072; PMID: 28270698" PMDBI10190 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD397 Ginsenosides Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolized via microbiota from compound?K79 "Metabolites have anti-proliferative effects in human colon cancer cells;[drug interaction]:co-treatment with 5-FU and its pro-drug intermediate 5é–?deoxy-5-fluorouridine,potentiate the anticancer effects" PMID "PMID: 25625815; PMID: 28270698" PMDBI10191 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD231 CTLA-4 blockade Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Specific pathogen-free,germ-free(GF) n.a. "MCA205 sarcoma progression is not controlled(in germ-free mice;or those treated with broad-spectrum antibiotics)" PMID "PMID: 26541610; PMID: 28270698" PMDBI10192 Microbes metabolize substances PMDBM300 2100 Mycoplasma hyorhinis PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterium encode a thymidine phosphorylase Restrict the cytostatic activity of pyrimidine nucleoside analogue compounds PMID PMID: 28270698 PMDBI10193 Microbes metabolize substances PMDBM300 2100 Mycoplasma hyorhinis PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterium encode a thymidine phosphorylase Restrict the cytostatic activity of pyrimidine nucleoside analogue compounds PMID PMID: 28270698 PMDBI10194 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp. PMDBD50 Anti-PD-L1 therapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Exhibit the association with antitumour T-cell responses(through dendritic cell activation) Combination of microbiota and anti-PD-L1 improve tumour control,inducte tumour-specific T?cells,increase T?cells in the tumour microenvironment PMID PMID: 28270698 PMDBI10195 Microbes metabolize substances PMDBM337 1224 Proteobacteria PMDBD149 Carmustine, Etoposide, Cytarabine and melphalan combination Therapeutic Substance Drug Combination n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reducte bacteria that?limit inflammation,increase bacteria associated with colitis PMID PMID: 28270698 PMDBI10196 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD149 Carmustine, Etoposide, Cytarabine and melphalan combination Therapeutic Substance Drug Combination n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reducte bacteria that?limit inflammation,increase bacteria associated with colitis PMID PMID: 28270698 PMDBI10197 Microbes metabolize substances PMDBM3 n.a. Actinobacteria PMDBD149 Carmustine, Etoposide, Cytarabine and melphalan combination Therapeutic Substance Drug Combination n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reducte bacteria that?limit inflammation,increase bacteria associated with colitis PMID PMID: 28270698 PMDBI10198 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD229 CpG oligodeoxynucleotides Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 28270698 PMDBI10199 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD229 CpG oligodeoxynucleotides Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 28270698 PMDBI10200 Microbes metabolize substances PMDBM120 80840 Burkholderiales PMDBD231 CTLA-4 blockade Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. A cocktail of bacteria ameliorate CTLA-4-blockade-induced subclinical colitis and colon inflammatory scores in antibiotic-treated?mice PMID PMID: 28270698 PMDBI10201 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD231 CTLA-4 blockade Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. A cocktail of bacteria ameliorate CTLA-4-blockade-induced subclinical colitis and colon inflammatory scores in antibiotic-treated?mice PMID PMID: 28270698 PMDBI10202 Microbes metabolize substances PMDBM376 n.a. Segmented filamentous bacteria PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Gram-positive commensals mediate accumulation of TH17 and TH1-cell response PMID PMID: 28270698 PMDBI10203 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Gram-positive commensals mediate accumulation of TH17 and TH1-cell response PMID PMID: 28270698 PMDBI10204 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Fed a diet(high in protein, l-leucine, fish oil and specific oligosaccharides) n.a. Reduce incidence and severity of Pseudomonas aeruginosa translocation PMID PMID: 28270698 PMDBI10205 Microbes metabolize substances PMDBM2020217 1354 Enterococcus hirae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse "Inoculated with MCA205 tumours;microbiota-depleted" As an orchestrator of cyclophosphamide effects n.a. PMID PMID: 28270698 PMDBI10206 Microbes metabolize substances PMDBM2020270 487174 Barnesiella intestinihominis PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse "Inoculated with MCA205 tumours;microbiota-depleted" As an orchestrator of cyclophosphamide effects n.a. PMID PMID: 28270698 PMDBI10207 Microbes metabolize substances PMDBM2020217 1354 Enterococcus hirae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10208 Microbes metabolize substances PMDBM277 1622 Lactobacillus murinus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10209 Microbes metabolize substances PMDBM2020130 33959 Lactobacillus johnsonii PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10212 Microbes metabolize substances PMDBM2020217 1354 Enterococcus hirae PMDBD290 Doxorubicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10213 Microbes metabolize substances PMDBM277 1622 Lactobacillus murinus PMDBD290 Doxorubicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10214 Microbes metabolize substances PMDBM2020130 33959 Lactobacillus johnsonii PMDBD290 Doxorubicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10216 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD299 Ellagic acid "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. urolithins n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 28270698 PMDBI10218 Microbes metabolize substances PMDBM299 2093 Mycoplasma PMDBD384 Gemcitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Pyrimidine nucleoside phosphorylase and cytidine deaminase enzyme Have deleterious effects on its therapeutic efficacy PMID PMID: 28270698 PMDBI10219 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD452 Ipilimumab Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterially mediated B vitamin production and polyamine transport deficiencies Bacteria is associated with increased risk of CTLA?4 blockade?induced colitis PMID PMID: 28270698 PMDBI10220 Microbes metabolize substances PMDBM194 543 Enterobacteriaceae PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. Increase abundance of bacteria "Cause diarrhoea;" PMID PMID: 28270698 PMDBI10221 Microbes metabolize substances PMDBM2020255 1308 Streptococcus thermophilus PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis PMID PMID: 28270698 PMDBI10222 Microbes metabolize substances PMDBM2020046 n.a. Clostridioides difficile PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. Increase abundance of bacteria "Cause diarrhoea;" PMID PMID: 28270698 PMDBI10223 Microbes metabolize substances PMDBM2020119 1579 Lactobacillus acidophilus PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis PMID PMID: 28270698 PMDBI10224 Microbes metabolize substances PMDBM279 1590 Lactobacillus plantarum PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis PMID PMID: 28270698 PMDBI10225 Microbes metabolize substances PMDBM278 1597 Lactobacillus paracasei PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis PMID PMID: 28270698 PMDBI10226 Microbes metabolize substances PMDBM2020013 1685 Bifidobacterium breve PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis PMID PMID: 28270698 PMDBI10227 Microbes metabolize substances PMDBM2020193 216816 Bifidobacterium longum PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis PMID PMID: 28270698 PMDBI10228 Microbes metabolize substances PMDBM271 1585 Lactobacillus delbrueckii subsp. bulgaricus PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis PMID PMID: 28270698 PMDBI10229 Microbes metabolize substances PMDBM103 1682 Bifidobacterium longum subsp. infantis PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Reduce diarrhoea and weight loss,increase intestinal crypt proliferation,inhibit apoptosis PMID PMID: 28270698 PMDBI10231 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduce diversity and shift in relative abundance associated with chemotherapy-induced diarrhoea PMID PMID: 28270698 PMDBI10232 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. "Reduce microbial abundance(decrease anaerobes and streptococci,relative increase of Bacteroides);change in microbiota is associated with diarrhoea" PMID PMID: 28270698 PMDBI10233 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduce diversity and shift in relative abundance associated with chemotherapy-induced diarrhoea PMID PMID: 28270698 PMDBI10234 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. "Reduce microbial abundance(decrease anaerobes and streptococci,relative increase of Bacteroides);change in microbiota is associated with diarrhoea" PMID PMID: 28270698 PMDBI10235 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduce diversity and shift in relative abundance associated with chemotherapy-induced diarrhoea PMID PMID: 28270698 PMDBI10236 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. "Reduce microbial abundance(decrease anaerobes and streptococci,relative increase of Bacteroides);change in microbiota is associated with diarrhoea" PMID PMID: 28270698 PMDBI10237 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD689 Polysaccharides (after cyclophosphamide administration) Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. "Resulte in the enrichment of bifidobacteria and a reduction in the levels of Bacteroidetes;might protect against the adverse effects of chemotherapy" PMID PMID: 28270698 PMDBI10238 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD689 Polysaccharides (after cyclophosphamide administration) Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. "Resulte in the enrichment of bifidobacteria and a reduction in the levels of Bacteroidetes;might protect against the adverse effects of chemotherapy" PMID PMID: 28270698 PMDBI10239 Microbes metabolize substances PMDBM2020008 n.a. Bacteroides fragilis PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil (BVU) n.a. n.a. n.a. n.a. n.a. n.a. Gut bacterial phosphorolytic enzyme [drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients PMID PMID: 28270698 PMDBI10240 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil (BVU) n.a. n.a. n.a. n.a. n.a. n.a. Gut bacterial phosphorolytic enzyme [drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients PMID PMID: 28270698 PMDBI10241 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil (BVU) n.a. n.a. n.a. n.a. n.a. n.a. Gut bacterial phosphorolytic enzyme [drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients PMID PMID: 28270698 PMDBI10242 Microbes metabolize substances PMDBM2020268 821 Bacteroides vulgatus PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil (BVU) n.a. n.a. n.a. n.a. n.a. n.a. Gut bacterial phosphorolytic enzyme [drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients PMID PMID: 28270698 PMDBI10243 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil (BVU) n.a. n.a. n.a. n.a. n.a. n.a. Gut bacterial phosphorolytic enzyme [drug interaction]:combination with 5-FU can increase in systemic concentrations of 5-FU and is associated with the death of patients PMID PMID: 28270698 PMDBI10245 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD580 Neoprontosil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbiota-driven drug metabolism Affect drug disposition and toxicity PMID PMID: 28270698 PMDBI10246 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD810 Sulfanilamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbiota-driven drug metabolism Affect drug disposition and toxicity PMID PMID: 28270698 PMDBI10247 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD123 Brivudine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. bromovinyluracil (BVU) n.a. n.a. Increase Toxicity In vivo Mouse Conventional(CV),germ-free(GF) Microbial enzymes "Conversion to hepatotoxic BVU;(GF)reduce systemic BVU exposure" PMID PMID: 30733391 PMDBI10248 Microbes metabolize substances PMDBM2020263 n.a. Bacteroides ovatus PMDBD123 Brivudine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. bromovinyluracil (BVU) n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. "Conversion to hepatotoxic BVU;(GF)reduce systemic BVU exposure" PMID PMID: 30733391 PMDBI10249 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. aminoclonazepam (NH2-CLZ),aminohydroxyclonazepam (NH2OH-CLZ) n.a. n.a. Increase Toxicity In vivo Mouse Conventional(CV),germ-free(GF) Contribute to the reductive metabolism of CLZ Lead to toxicity PMID PMID: 30733391 PMDBI10250 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. bromovinyluracil (BVU) n.a. n.a. Increase Toxicity In vivo Mouse Conventional(CV), germ-free(GF) Microbial enzymes Metabolized by members of this genus PMID PMID: 30733391 PMDBI10251 Microbes metabolize substances PMDBM2020263 n.a. Bacteroides ovatus PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. bromovinyluracil (BVU) n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. Metabolized by members of this genus PMID PMID: 30733391 PMDBI10252 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. 2-hydroxy lovastatic acid,2-hydroxy simvastatin acid n.a. n.a. Increase Efficacy In vivo Rat n.a. n.a. "Product an active form;drug interaction:antibiotics suppresses the pharmacologic effects" PMID "PMID: 9728898; PMID: 24947972; PMID: 25926432; PMID: 25571290" PMDBI10253 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. 2-hydroxy lovastatic acid,2-hydroxy simvastatin acid n.a. n.a. Increase Efficacy In vivo Rat n.a. n.a. "Product an active form;drug interaction:antibiotics suppresses the pharmacologic effects" PMID "PMID: 9728898; PMID: 24947972; PMID: 25926432; PMID: 25571290" PMDBI10254 Microbes metabolize substances PMDBM2020099 n.a. Clostridium perfringens PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. N-(2-hydroxyethyl)-oxamic acid and acetamide n.a. n.a. n.a. In vivo Rat n.a. Reduced metabolites n.a. PMID "PMID: 231450; PMID: 430360; PMID: 25926432" PMDBI10255 Microbes metabolize substances PMDBM2020253 1314 Streptococcus pyogenes PMDBD810 Sulfanilamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. sulfanilamide n.a. n.a. Increase Efficacy In vivo Mouse Streptococcus pyogenes systemic infection The gut microbiota transformed drug by azoreductases "Exhibit potent antibacterial activity;drug interaction:antibiotics suppresses the conversion" PMID "PMID: 4405598; Peppercorn and Goldman,1976; PMID: 25926432" PMDBI10256 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. calycosin n.a. n.a. n.a. n.a. n.a. n.a. Aromatic hydroxylase and O-methyltransferase Drug interaction:antibiotics suppresses the transformation PMID "PMID: 9657051; PMID: 25926432; PMID: 9781846" PMDBI10257 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. Increase Toxicity In vivo Human Cancer The b-glucuronidases of the gut microbiota "Causes diarrhea;drug interaction:coadministration of the poorly absorbed aminoglycoside antibiotic neomycin could be advantageous for diarrhea" PMID "PMID: 25926432; PMID: 11350876" PMDBI10258 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD817 Sulindac sulfide "Therapeutic Substance; Environmental Substance" Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro Human or rabbit faeces n.a. Drug interaction:metronidazole decreases the formation of sulfides of sulindac ex vivo PMID "PMID: 3630204; PMID: 25926432" PMDBI10259 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD580 Neoprontosil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulfanilamide n.a. n.a. Increase Efficacy In vivo Rat n.a. n.a. "Product the pharmacologically active metabolite;drug interaction:antibiotics reduced the amount of sulfanilamide excreted in the urine after oral administration" PMID "PMID: 5173017; PMID: 25926432" PMDBI10260 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD553 Misonidazole Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. 1-(2-aminoimidazol-1-yl)-3-methoxypropan-2-ol n.a. n.a. Increase Toxicity In vivo Rat Convention,germ-free n.a. Drug interaction:antibiotic inhibits misonidazole transformation and toxicity PMID "PMID: 6260109; PMID: 25926432" PMDBI10261 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-aminoclonazepam n.a. n.a. n.a. In vivo Rat Germ-free and ex閳ユå¾erm-free The reductive metabolism Drug interaction:antibiotic suppresses the reduction PMID "PMID: 6506755; PMID: 25926432" PMDBI10262 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD492 Loperamide oxide Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. loperamide n.a. n.a. n.a. In vivo "Rat; Dog" n.a. Microbiota is involved in reduction Drug interaction:absorption of orally delivered loperamide oxide is lower when administered with cotrimoxazole PMID "PMID: 25926432; PMID: 8838438" PMDBI10263 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD245 Daidzin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. daidzein,calycosin n.a. n.a. Increase Efficacy n.a. n.a. n.a. C-glucosidases and O-glucosidases Drug interaction:Antibiotic inhibits the metabolism of isoflavone glycosides PMID "PMID: 9657051; PMID: 25926432" PMDBI10264 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD714 Puerarin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. daidzein,calycosin n.a. n.a. Increase Efficacy n.a. n.a. n.a. C-glucosidases and O-glucosidases Drug interaction:Antibiotic inhibits the metabolism of isoflavone glycosides PMID "PMID: 9657051; PMID: 25926432" PMDBI10265 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD339 Fenfluramine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. "Human; Mouse" n.a. Deglycosylating enzymes of bacteria "Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats" PMID "PMID: 25926432; PMID: 9875509" PMDBI10266 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD420 Hesperidin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. "Human; Mouse" n.a. Deglycosylating enzymes of bacteria "Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats" PMID "PMID: 25926432; PMID: 9875509" PMDBI10267 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD574 Naringenin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. "Human; Mouse" n.a. Deglycosylating enzymes of bacteria "Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats" PMID "PMID: 25926432; PMID: 9875509" PMDBI10268 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. "Human; Mouse" n.a. Deglycosylating enzymes of bacteria "Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats" PMID "PMID: 25926432; PMID: 9875509" PMDBI10269 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD770 Scutellaria baicalensis root Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. "Human; Mouse" n.a. Deglycosylating enzymes of bacteria "Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats" PMID "PMID: 25926432; PMID: 9875509" PMDBI10270 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD904 Wognoside Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. "Human; Mouse" n.a. Deglycosylating enzymes of bacteria "Metabolites might exhibit aspirin-like pharmacologic effects;drug interaction:antibiotics reduces metabolites excreted into the urine of rats" PMID "PMID: 25926432; PMID: 9875509" PMDBI10271 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. dihydrodigoxin,dihydrodigoxigenin n.a. n.a. Decrease Efficacy In vivo Human Health n.a. "Convert to the inactive metabolites;attenuates the drug閳ユç?effects;drug interaction:antibiotics閿涘潒rythromycin and tetracycline閿涘〃locks the reduction of digoxin" PMID "PMID: 25926432; PMID:7266632" PMDBI10272 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD816 Sulindac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulindac sulfide n.a. n.a. n.a. In vivo Rabbit n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10273 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Transform drugs and phytochemicals into bioinactive metabolites Affect the pharmacokinetics PMID PMID: 25926432 PMDBI10274 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. 5-hydroxy-equol n.a. n.a. n.a. n.a. "Human; Animal models" n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10275 Microbes metabolize substances PMDBM2020002 446660 Adlercreutzia equolifaciens PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. 5-hydroxy-equol n.a. n.a. n.a. n.a. "Human; Animal models" n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10276 Microbes metabolize substances PMDBM2020070 n.a. Slackia equolifaciens PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. 5-hydroxy-equol n.a. n.a. n.a. n.a. "Human; Animal models" n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10277 Microbes metabolize substances PMDBM2020071 n.a. Slackia isoflavoniconvertens PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. 5-hydroxy-equol n.a. n.a. n.a. n.a. "Human; Animal models" n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10278 Microbes metabolize substances PMDBM2020134 1363 Lactococcus garvieae PMDBD386 Genistein "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. 5-hydroxy-equol n.a. n.a. n.a. n.a. "Human; Animal models" n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10279 Microbes metabolize substances PMDBM2020002 446660 Adlercreutzia equolifaciens PMDBD386 Genistein "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. 5-hydroxy-equol n.a. n.a. n.a. n.a. "Human; Animal models" n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10280 Microbes metabolize substances PMDBM2020070 n.a. Slackia equolifaciens PMDBD386 Genistein "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. 5-hydroxy-equol n.a. n.a. n.a. n.a. "Human; Animal models" n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10281 Microbes metabolize substances PMDBM2020071 n.a. Slackia isoflavoniconvertens PMDBD386 Genistein "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. 5-hydroxy-equol n.a. n.a. n.a. n.a. "Human; Animal models" n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10282 Microbes metabolize substances PMDBM367 41978 Ruminococcus sp. PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. 20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K) n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Drug interaction:antibiotics inhibits the metabolism PMID PMID: 25926432 PMDBI10283 Microbes metabolize substances PMDBM2020067 1945593 Oscillibacter sp. PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. 20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K) n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Drug interaction:antibiotics inhibits the metabolism PMID PMID: 25926432 PMDBI10284 Microbes metabolize substances PMDBM398 1981025 Sutterella sp. PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. 20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K) n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Drug interaction:antibiotics inhibits the metabolism PMID PMID: 25926432 PMDBI10285 Microbes metabolize substances PMDBM2020060 2049029 Holdemania sp. PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. 20-O-20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (compound K) n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Drug interaction:antibiotics inhibits the metabolism PMID PMID: 25926432 PMDBI10286 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. Transform drugs and phytochemicals into bioactive metabolites Affect the pharmacokinetics PMID PMID: 25926432 PMDBI10287 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. fructose,galactose n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:combination treatment with neomycin and lactulose reduces the blood ammonia concentration in pigs PMID PMID: 25926432 PMDBI10288 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. fructose,galactose n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:combination treatment with neomycin and lactulose reduces the blood ammonia concentration in pigs PMID PMID: 25926432 PMDBI10289 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. fructose,galactose n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:combination treatment with neomycin and lactulose reduces the blood ammonia concentration in pigs PMID PMID: 25926432 PMDBI10290 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. levametabol-I, levametabol-II, and levametabol-III n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction: Combined therapy with tetracycline and levamisole has a stronger biologic effect PMID PMID: 25926432 PMDBI10291 Microbes metabolize substances PMDBM63 n.a. Bacteroides spp. PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. levametabol-I, levametabol-II, and levametabol-III n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction: Combined therapy with tetracycline and levamisole has a stronger biologic effect PMID PMID: 25926432 PMDBI10292 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. Transform drugs and phytochemicals into bioactive metabolites Affect the pharmacokinetics PMID PMID: 25926432 PMDBI10293 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Transform drugs and phytochemicals into bioinactive metabolites Affect the pharmacokinetics PMID PMID: 25926432 PMDBI10294 Microbes metabolize substances PMDBM2020223 39491 [Eubacterium] rectale PMDBD668 Picosulfuric acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. free diphenol[4,49-(pyridin-2-ylmethanediyl)diphenol] n.a. n.a. Increase Efficacy n.a. n.a. n.a. Arylsulfate sulfotransferase of bacteria "Have a laxative effect;drug interaction:antibiotics inhibits the transformation" PMID PMID: 25926432 PMDBI10295 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD731 Ranitidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Transform drugs and phytochemicals into bioinactive metabolites Affect the pharmacokinetics PMID PMID: 25926432 PMDBI10296 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. Increase Efficacy n.a. n.a. n.a. Azoreductases produced by metabolize Induces anti-inflammatory effects PMID PMID: 25926432 PMDBI10297 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD308 Epicatechin Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10298 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD48 Anthocyanidins Herbal Substance Herbal Compounds n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10299 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD96 Balsalazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. n.a. In vivo Human n.a. Drug interaction:antibiotic suppresses the metabolism,limit its effectiveness PMID PMID: 25926432 PMDBI10300 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD191 Cianidanol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. phenolic acids n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10301 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD358 Flucytosine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-fluorouracil n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antimicrobial agents may reduce the antifungal effect of flucytosine PMID PMID: 25926432 PMDBI10302 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD407 Glycyrrhizic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 18b-glycyrrhetic acid n.a. n.a. n.a. In vivo Rat Germ-free n.a. Drug interaction:antibiotics(amoxicillin and metronidazole)suppresses the conversion PMID PMID: 25926432 PMDBI10303 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD420 Hesperidin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. hesperetin n.a. n.a. n.a. In vivo Rat n.a. n.a. "Suppress gut bacterial glycosidase activities;drug interaction:Antibiotic inhibits the metabolism " PMID PMID: 25926432 PMDBI10304 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. tyramine,m-hydroxyphenylacetic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics(vancomycin)inhibits the dehydroxylation of bile acid by the gut microbiota PMID PMID: 25926432 PMDBI10305 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-amino-nitrazepam n.a. n.a. Increase Toxicity In vivo Rat n.a. Transform drugs and phytochemicals into toxic metabolites "Affect the pharmacokinetics,product an active teratogenic substance;drug interaction: antibiotic reduced nitrazepam-induced teratogenicity" PMID PMID: 25926432 PMDBI10306 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. hydroxyiminonizatidine n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 25926432 PMDBI10307 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD731 Ranitidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. hydroxyiminoranitidine n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics(rifampicin)decreases the absorption of ranitidine PMID PMID: 25926432 PMDBI10308 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. dihydroxy-risperidone,hydroxy-keto-risperidone n.a. n.a. n.a. In vivo Rat n.a. Scission of isoxazole Drug interaction:Antibiotics(rifampin)inhibit the bioavailability of risperidone in the liver PMID PMID: 25926432 PMDBI10309 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD770 Scutellaria baicalensis root Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. oroxylin A n.a. n.a. n.a. n.a. n.a. n.a. Aromatic hydroxylase and O-methyltransferase n.a. PMID PMID: 25926432 PMDBI10310 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD776 Sennosides Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. rheinanthrone n.a. n.a. Increase Efficacy n.a. n.a. n.a. Reductase(s) and 3- b-D-glucosidase(s) "Product a purgative compound;drug interaction:antibiotics閿涘æ½hloramphenicol, streptomycin, and rifampicin閿涘â€nhibits the biotransformation" PMID PMID: 25926432 PMDBI10311 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulfinpyrazone sulfide n.a. n.a. n.a. In vivo Rabbit n.a. n.a. Drug interaction:Metronidazole decreases the extent of sulfinpyrazone reduction in rabbits in vivo PMID PMID: 25926432 PMDBI10312 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 2-sulfamoyacetylphenol n.a. n.a. n.a. n.a. n.a. n.a. Through the reduction n.a. PMID PMID: 25926432 PMDBI10314 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD432 Hydrazine Environmental Substance "Industrial Chemicals; Medicinal chemicals" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Toxicity In vivo Rat n.a. DszA/NtaA-like oxygenase n.a. PMID "PMID: 19396371; PMID: 26261284" PMDBI10315 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD372 Fostamatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Human Health O-demethylation and dihydroxylation by bacteria n.a. PMID "PMID: 26261284; PMID: 20371637" PMDBI10316 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity In vivo Mouse n.a. Reactivated by bacterially expressed b-glucuronidase Result in diarrhea PMID "PMID: 26261284; PMID: 21051639" PMDBI10317 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD114 BILR355 Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterially mediated N-oxide reduction Drug interaction:(with ritonavir)bacterial mediated reactions predominate PMID "PMID: 26261284; PMID: 22393121" PMDBI10318 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD5 2-chloro-5-nitro-N-phenylbenzamide Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterial nitroreductases Alter its mutagenicity PMID "PMID: 26261284; PMID: 22450444" PMDBI10319 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD56 Antiobiotics Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics effect the functional activity of bacteria PMID "PMID: 26261284; PMID: 23332745" PMDBI10320 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics effect the functional activity of bacteria PMID "PMID: 26261284; PMID: 23332745" PMDBI10321 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD657 Phenacetin Therapeutic Substance Approved Drug (Withdrawn) n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics effect the functional activity of bacteria PMID "PMID: 26261284; PMID: 23332745" PMDBI10322 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics effect the functional activity of bacteria PMID "PMID: 26261284; PMID: 23332745" PMDBI10323 Microbes metabolize substances PMDBM396 n.a. Sulfite-reducing bacterium LF11mE1 PMDBD768 Saturated fats Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Excess consumption of fat leads to an increase in the growth of bacteria Increase the formation of proinflammatory and genotoxic secondary bile acids(deoxycholate) PMID "PMID: 26261284; PMID: 24355793" PMDBI10324 Microbes metabolize substances PMDBM2020046 n.a. Clostridioides difficile PMDBD768 Saturated fats Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Excess consumption of fat leads to an increase in the growth of bacteria Increase the formation of proinflammatory and genotoxic secondary bile acids(deoxycholate) PMID "PMID: 26261284; PMID: 24355793" PMDBI10325 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Alter the gut microbiota PMID "PMID: 26261284; PMID: 24413286" PMDBI10327 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD662 Phenoxyethanol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. cyanuric acid n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial formation of its metabolite Lead to toxicity PMID "PMID: 26261284; PMID: 25105361" PMDBI10328 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Alter the pharmacokinetics of tacrolimus PMID "PMID: 26261284; PMID: 25815766" PMDBI10329 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD77 Astragali radix Herbal Substance Medicinal Herb n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. Calycosin-7-O-b-D-glucoside may alter the composition of the gut microbiome Promot the growth of beneficial organisms(Lactobacillus and Bifidobacterium) PMID "PMID: 26261284; PMID: 26101224" PMDBI10330 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD138 Calycosin-7-O-b-D-glucoside Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. Calycosin-7-O-b-D-glucoside may alter the composition of the gut microbiome Promot the growth of beneficial organisms(Lactobacillus and Bifidobacterium) PMID "PMID: 26261284; PMID: 26101224" PMDBI10331 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD309 Epimedium grandiflorum top (flavonoids) Herbal Substance Medicinal Herb n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolized by the colonic microflora to circulate in the plasma [disease]osteoporosis may modulate the metabolism of Epimedii and may affect its bioavailability and efficacy PMID "PMID: 26135008; PMID: 26261284" PMDBI10332 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbial (p-cresol) may compete for a host enzyme (SULT1A1) PMID PMID: 26261284 PMDBI10333 Microbes metabolize substances PMDBM2020210 876 Desulfovibrio desulfuricans PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Sulfate-reducing bacteria Product a more toxic form of arsenic PMID PMID: 26261284 PMDBI10335 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD135 Butyric Acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Produce relatively high levels of butyrate in the gastrointestinal tract Limit the growth of pathogenic microorganisms PMID PMID: 26261284 PMDBI10336 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD135 Butyric Acid Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Produce relatively high levels of butyrate in the gastrointestinal tract Limit the growth of pathogenic microorganisms PMID PMID: 26261284 PMDBI10337 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. tetrahydrocurcumin n.a. n.a. Increase Efficacy n.a. n.a. n.a. Enzyme(identified as CurA) n.a. PMID PMID: 26261284 PMDBI10338 Microbes metabolize substances PMDBM2020213 n.a. Eggerthella lenta PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Cardiac glycoside expressed by bacteria Drug is inactivated PMID PMID: 26261284 PMDBI10339 Microbes metabolize substances PMDBM2020226 210 Helicobacter pylori PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Sequestration of bacteria Reactivated by microbially expressed enzymes PMID PMID: 26261284 PMDBI10340 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD597 Nitrobenzodiazepine Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Bacterial nitroreductase(NfsB) n.a. PMID PMID: 26261284 PMDBI10341 Microbes metabolize substances PMDBM2020228 1270 Micrococcus luteus PMDBD683 Polyaromatic compounds Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. hydroxyl metabolites n.a. n.a. n.a. n.a. n.a. n.a. n.a. Exhibit estrogenic activities PMID PMID: 26261284 PMDBI10342 Microbes metabolize substances PMDBM2020046 n.a. Clostridioides difficile PMDBD697 PPIs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug is associated with Clostridium difficule infections PMID PMID: 26261284 PMDBI10344 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Enzyme(identified as CurA) n.a. PMID PMID: 26261284 PMDBI10345 Microbes metabolize substances PMDBM191 547 Enterobacter PMDBD866 Tretazicar Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA)) n.a. PMID PMID: 26261284 PMDBI10346 Microbes metabolize substances PMDBM381 1279 Staphylococcus PMDBD866 Tretazicar Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA)) n.a. PMID PMID: 26261284 PMDBI10347 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD866 Tretazicar Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA)) n.a. PMID PMID: 26261284 PMDBI10348 Microbes metabolize substances PMDBM298 1763 Mycobacterium PMDBD866 Tretazicar Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA)) n.a. PMID PMID: 26261284 PMDBI10349 Microbes metabolize substances PMDBM26 55087 Bacillus PMDBD866 Tretazicar Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Additional enzymes expressed by bacteria(capable of azo and nitro reduction)((AzoR and NfsA)) n.a. PMID PMID: 26261284 PMDBI10350 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Be extensively metabolized by microbiota(demethylation, carbon-carbon bond cleavage, a or b oxidation,dihydroxylation, and cyclization of simvastatin) n.a. PMID PMID: 26261284 PMDBI10351 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD808 Sulfadiazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-amino 5-salicylic acid n.a. n.a. Increase Efficacy n.a. n.a. n.a. Convert drug to its pharmacologically active form by microbial enzymes n.a. PMID PMID: 26261284 PMDBI10352 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. Increase Toxicity In vivo Mouse n.a. Convertion to SN-38 "Lead to the severe intestinal side effect of diarrhea;[drug interaction:Antibiotic/a potent inhibitor of ç?glucuronidase can reduce intestinal side effect]" PMID "PMID: 26569070; PMID: 18927500" PMDBI10353 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. High level of a microbial metabolite(p-cresol) "Show low postdose acetaminophen sulfate to acetaminophen glucuronide;alter the bioavailability;lead to hepatotoxicity;[drug interaction]:(rat)antibiotic lead to higher level of acetaminophen glutathione conjugates" PMID "PMID: 26569070; PMID: 19667173" PMDBI10354 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Several gut microbial-derived secondary bile acids Secondary bile acids can predict effect of simvastatin PMID "PMID: 26569070; PMID: 24947972" PMDBI10355 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Alter the composition of gut microbiota;induce the translocation(Gram positive bacteria)into secondary lymphoid organs" PMID PMID: 26569070 PMDBI10356 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulfide metabolites n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Reduction Decreased activity PMID PMID: 26569070 PMDBI10357 Microbes metabolize substances PMDBM2020046 n.a. Clostridioides difficile PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. Acetaminophen sulfate and glucuronide n.a. n.a. "Decrease Efficacy; Increase Toxicity" n.a. n.a. n.a. "O-Sulfation; C-S cleavage of acetaminophen-3-cysteine" Decrease activity,or increase cellular toxicity PMID PMID: 26569070 PMDBI10358 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD230 CpG-oligonucleotide immunotherapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Germ free,orantibiotic-treated Disruption of gut microbiota Microbiota impairs the therapeutic responses of tumors PMID PMID: 26569070 PMDBI10359 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. Dihydrodaidzein, equol, or O-desmethylanolensin(ODMA) n.a. n.a. Increase Efficacy n.a. n.a. n.a. Reduction, phenolic ring opening Increased activity PMID PMID: 26569070 PMDBI10361 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. HGH 136 PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. Dihydrodaidzein, equol, or O-desmethylanolensin(ODMA) n.a. n.a. Increase Efficacy n.a. n.a. n.a. Reduction, phenolic ring opening Increased activity PMID PMID: 26569070 PMDBI10362 Microbes metabolize substances PMDBM2020213 n.a. Eggerthella lenta PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. dihydrodigoxin n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Key enzyme: A cytochrome-encoding operon (termed the cardiac glycoside reductase) Produce inactive metabolite PMID PMID: 26569070 PMDBI10363 Microbes metabolize substances PMDBM2020267 820 Bacteroides uniformis PMDBD386 Genistein "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. 5-hydroxyequol n.a. n.a. n.a. n.a. n.a. n.a. Hydrogenation n.a. PMID PMID: 26569070 PMDBI10364 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. Compound K n.a. n.a. Increase Efficacy n.a. n.a. n.a. Hydrolysis Increased activity PMID PMID: 26569070 PMDBI10365 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. Compound K n.a. n.a. Increase Efficacy n.a. n.a. n.a. Hydrolysis Increased activity PMID PMID: 26569070 PMDBI10366 Microbes metabolize substances PMDBM2020057 n.a. Eubacterium sp. GLH PMDBD407 Glycyrrhizic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 18-ç?glycyrrhetinic acid n.a. n.a. Increase Efficacy n.a. n.a. n.a. Hydrolysis Increased activity PMID PMID: 26569070 PMDBI10367 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Monosaccharides n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli) PMID PMID: 26569070 PMDBI10368 Microbes metabolize substances PMDBM2020032 n.a. Enterococcus faecalis PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Monosaccharides n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli) PMID PMID: 26569070 PMDBI10369 Microbes metabolize substances PMDBM2020027 28141 Cronobacter sakazakii PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Monosaccharides n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli) PMID PMID: 26569070 PMDBI10370 Microbes metabolize substances PMDBM2020031 37734 Enterococcus casseliflavus PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Monosaccharides n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis Stimulating the growth of beneficial bacteria (Bifidobacteria,Lactobacilli) PMID PMID: 26569070 PMDBI10371 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. levametabol-I, II and III n.a. n.a. Increase Efficacy n.a. n.a. n.a. Thiazole ring opening Increased activity PMID PMID: 26569070 PMDBI10372 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. levametabol-I, II and III n.a. n.a. Increase Efficacy n.a. n.a. n.a. Thiazole ring opening Increased activity PMID PMID: 26569070 PMDBI10373 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD527 Metamfetamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Amphetamine, norephedrine and an unknown metabolite n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Demethylation Decreased activity PMID PMID: 26569070 PMDBI10374 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD527 Metamfetamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Amphetamine, norephedrine and an unknown metabolite n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Demethylation Decreased activity PMID PMID: 26569070 PMDBI10375 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD527 Metamfetamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Amphetamine, norephedrine and an unknown metabolite n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Demethylation Decreased activity PMID PMID: 26569070 PMDBI10376 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD682 Platinum chemotherapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Germ free,orantibiotic-treated Disruption of gut microbiota Microbiota impairs the therapeutic responses of tumors PMID PMID: 26569070 PMDBI10377 Microbes metabolize substances PMDBM2020031 37734 Enterococcus casseliflavus PMDBD718 Quercetin-3-glucoside "Herbal Substance; Dietary Substance" "Medicinal Herbal Compounds; Dietary Compounds" n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. n.a. n.a. n.a. n.a. n.a. Deglycosylation n.a. PMID PMID: 26569070 PMDBI10378 Microbes metabolize substances PMDBM2020222 39490 Eubacterium ramulus PMDBD718 Quercetin-3-glucoside "Herbal Substance; Dietary Substance" "Medicinal Herbal Compounds; Dietary Compounds" n.a. n.a. n.a. n.a. Butyrate, acetate, 3,4-dihydroxyphenylacetic acid n.a. n.a. n.a. n.a. n.a. n.a. Deglycosylation n.a. PMID PMID: 26569070 PMDBI10381 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD263 Diclofenac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Diclofenac glucuronide Hydrolysis to diclofenac n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 27591027; PMID: 24780296; PMID: 22328575" PMDBI10382 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD358 Flucytosine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-fluorouracil Deamination n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 27591027; PMID: 12714804; PMID: 3729334" PMDBI10387 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. Double bond reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 6836275; PMID: 24637603; PMID: 27591027; PMID: 1500644; PMID: 2759492" PMDBI10388 Microbes metabolize substances PMDBM2020046 n.a. Clostridioides difficile PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. Double bond reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 6836275; PMID: 24637603; PMID: 27591027; PMID: 1500644; PMID: 2759492" PMDBI10389 Microbes metabolize substances PMDBM2020213 n.a. Eggerthella lenta PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. Double bond reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 6836275; PMID: 24637603; PMID: 27591027; PMID: 1500644; PMID: 2759492" PMDBI10390 Microbes metabolize substances PMDBM2020213 n.a. Eggerthella lenta PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. Double bond reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 6836275; PMID: 24637603; PMID: 27591027; PMID: 1500644; PMID: 2759492" PMDBI10392 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356" PMDBI10393 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356" PMDBI10394 Microbes metabolize substances PMDBM134 546 Citrobacter freundii PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356" PMDBI10395 Microbes metabolize substances PMDBM2020097 571 Klebsiella oxytoca PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356" PMDBI10396 Microbes metabolize substances PMDBM257 574 Klebsiella pneumoniae subsp. ozaenae PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356" PMDBI10397 Microbes metabolize substances PMDBM2020229 582 Morganella morganii PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356" PMDBI10398 Microbes metabolize substances PMDBM2020219 615 Serratia marcescens PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356" PMDBI10399 Microbes metabolize substances PMDBM2020250 623 Shigella flexneri PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356" PMDBI10400 Microbes metabolize substances PMDBM2020258 666 Vibrio cholerae PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356" PMDBI10401 Microbes metabolize substances PMDBM2020235 703 Plesiomonas shigelloides PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356" PMDBI10402 Microbes metabolize substances PMDBM2020044 35703 Citrobacter amalonaticus PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356" PMDBI10403 Microbes metabolize substances PMDBM259 39831 Klebsiella pneumoniae subsp. rhinoscleromatis PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356" PMDBI10404 Microbes metabolize substances PMDBM2020045 67824 Citrobacter farmeri PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl-5-aminosalicylic acid Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 1425876; PMID: 27591027; PMID: 8353847; PMID: 7520936; PMID: 2890356" PMDBI10405 Microbes metabolize substances PMDBM2020204 1509 Clostridium sporogenes PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Benzisoxazole ring reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 27591027; PMID: 9231340; PMID: 1615700" PMDBI10408 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD731 Ranitidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. N-oxide reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 27591027; PMID: 11564550" PMDBI10409 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. N-oxide reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 27591027; PMID: 11955801" PMDBI10412 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. Thiazole ring opening n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 27591027; PMID: 1949905" PMDBI10413 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. Thiazole ring opening n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 27591027; PMID: 1949905" PMDBI10414 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD372 Fostamatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. metabolite R529 O-Demethylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 27591027; PMID: 20371637" PMDBI10420 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD811 Sulfapyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl sulfapyridine Acetylation n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 27591027; PMID: 2890356" PMDBI10422 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Sulfoxide reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 27591027; PMID: 3630204" PMDBI10423 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD816 Sulindac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Sulfoxide reduction n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 27591027; PMID: 3630204" PMDBI10439 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 glucuronide Glucuronide hydrolysis n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027" PMDBI10440 Microbes metabolize substances PMDBM2020008 n.a. Bacteroides fragilis PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 glucuronide Glucuronide hydrolysis n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027" PMDBI10441 Microbes metabolize substances PMDBM2020251 1311 Streptococcus agalactiae PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 glucuronide Glucuronide hydrolysis n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027" PMDBI10442 Microbes metabolize substances PMDBM2020099 n.a. Clostridium perfringens PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 glucuronide Glucuronide hydrolysis n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "PMID: 16437251; PMID: 26364932; PMID: 9744772; PMID: 11344150; PMID: 27591027" PMDBI10443 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD7 3,4-Dihydro-5-Methyl-Isoquinolinone Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Convention and germ-free n.a. DHQ production was dependent on bacteria PMID "PMID: 27782392; PMID: 19234110" PMDBI10444 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug modulate or interact with the microbiota PMID "PMID: 21060933; PMID: 27782392" PMDBI10445 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD430 Hippuric acid Environmental Substance "Industrial Chemicals; Pollutants; Toxic Agents" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy In vivo Mouse Germ-free,or with antibiotics n.a. Drug concentration in urine is reduced in either germ-free mice or in mice treated with antibiotics PMID "PMID: 27782392; PMID: 23342949" PMDBI10446 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Increase hat fatty acid metabolism Contribute to metformin therapy PMID "PMID: 25038099; PMID: 27782392" PMDBI10447 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug modulate or interact with the microbiota PMID "PMID: 25038099; PMID: 27782392" PMDBI10448 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD475 Levocarnitine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. TMA, TMAO n.a. n.a. n.a. n.a. n.a. n.a. L-carnitine is metabolized to TMA by microbiota Decrease AGE levels PMID "PMID: 25636076; PMID: 27782392" PMDBI10449 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. é“?glucuronidase enzyme of bacteria "Cause gut inflammation and irritation;drug interaction:irinotecan with a ç?glucuronidase inhibitor decreases harmful metabolites and alleviates the gastrointestinal inflammation" PMID "PMID: 27782392; PMID: 26364932" PMDBI10452 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. m-tyramine n.a. n.a. n.a. In vivo Mouse Germ-free n.a. (GF mice)reduce metabolism of L-DOPA,prolong L-DOPA half-life and hence activity PMID "PMID: 4974346; PMID: 27782392" PMDBI10453 Microbes metabolize substances PMDBM2020055 n.a. Escherichia sp. PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Cause an increase of Escherichia spp Result in an increase of gas metabolism pathways(side effect of metformin) PMID PMID: 27782392 PMDBI10454 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD3 2,8-DHQ (including 2,4-DHQ) Environmental Substance Human Metabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. Drug is involved in the pathogenicity of bacteria PMID PMID: 27782392 PMDBI10455 Microbes metabolize substances PMDBM194 543 Enterobacteriaceae PMDBD75 Aspartame "Therapeutic Substance; Dietary Substance; Herbal Substance" "Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. SCFA(propionate) n.a. n.a. n.a. In vivo Rat n.a. n.a. Aspartame increased total bacteria PMID PMID: 27782392 PMDBI10456 Microbes metabolize substances PMDBM2020201 1535 [Clostridium] leptum PMDBD75 Aspartame "Therapeutic Substance; Dietary Substance; Herbal Substance" "Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. SCFA(propionate) n.a. n.a. n.a. In vivo Rat n.a. n.a. Aspartame increased total bacteria PMID PMID: 27782392 PMDBI10457 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD92 B-GOSr (prebiotic oligosaccharide) Therapeutic Substance n.a. n.a. n.a. n.a. n.a. SCFA(acetate) n.a. n.a. n.a. n.a. Human n.a. n.a. Bacteria populations increases acetate PMID PMID: 27782392 PMDBI10458 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD189 Choline "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. trimethylamine (TMA) n.a. n.a. n.a. n.a. n.a. n.a. n.a. Have a direct relationship to cardiovascular disease and atherosclerosis PMID PMID: 27782392 PMDBI10459 Microbes metabolize substances PMDBM2020213 n.a. Eggerthella lenta PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. dihydrodigoxin n.a. n.a. Decrease Efficacy n.a. n.a. n.a. The cgr operon within strains of E. lenta reduce fumarate in E. lenta to reduce digoxin Lack cardiac activity PMID PMID: 27782392 PMDBI10460 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. lactic acid,acetic acid n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Produce its therapeutic metabolites PMID PMID: 27782392 PMDBI10461 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. lactic acid,acetic acid n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Produce its therapeutic metabolites PMID PMID: 27782392 PMDBI10462 Microbes metabolize substances PMDBM136 186801 Clostridia PMDBD787 Sodium cyclamate Dietary Substance "Dietary Compounds; Artificial Sweeteners" n.a. n.a. n.a. n.a. cyclohexylamine n.a. n.a. n.a. n.a. "Human; Mouse" n.a. n.a. Drug interaction:antibiotic treatment reduce cyclohexylamine production PMID PMID: 27782392 PMDBI10463 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD787 Sodium cyclamate Dietary Substance "Dietary Compounds; Artificial Sweeteners" n.a. n.a. n.a. n.a. cyclohexylamine n.a. n.a. n.a. n.a. "Human; Mouse" n.a. n.a. Drug interaction:antibiotic treatment reduce cyclohexylamine production PMID PMID: 27782392 PMDBI10464 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD6 3,3-dimethyl-1-butanol Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. TMA, TMAO n.a. n.a. n.a. In vivo Mouse n.a. n.a. Drug interaction:inhibition of TMA lyase inhibits microbial production of TMA, reducing TMAO levels PMID PMID: 27782392 PMDBI10465 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD68 Arabinoxylan-oligosaccharides Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. "SCFA; phenol, pcresol" n.a. n.a. n.a. n.a. Human n.a. n.a. AXOS supplementation has a long-term effect on colonic microbe community PMID PMID: 27782392 PMDBI10466 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD73 Aryl hydrocarbon receptor activator Environmental Substance "Industrial Chemicals; Pollutants; Toxic Agents" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Alter the gut microbiota community its metabolic function PMID PMID: 27782392 PMDBI10467 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD299 Ellagic acid "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Alter the gut microbiota community its metabolic function PMID PMID: 27782392 PMDBI10468 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Alter the gut microbiota community its metabolic function PMID PMID: 27782392 PMDBI10469 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD610 NSAIDs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Cleave the glucuronide by bacteria "Yield harmful metabolites,cause the formation of ulcers in the gut;" PMID PMID: 27782392 PMDBI10470 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD656 Persistent organic pollutant Environmental Substance "Industrial Chemicals; Pollutants" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Alter the gut microbiota community its metabolic function PMID PMID: 27782392 PMDBI10471 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. Hippuric acid n.a. n.a. n.a. In vivo Mouse n.a. n.a. Drug interaction:antibiotic(rifaximin)decreases microbial metabolites(hippuric acid) PMID PMID: 27782392 PMDBI10472 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD830 Tempol Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. Tç綧CA n.a. n.a. n.a. In vivo Mouse n.a. n.a. Tempol reduces BSH activity of bacteria and produces antiobesity effects PMID PMID: 27782392 PMDBI10473 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD627 Oxaliplatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Immunomodulation Mediated by TLR4 and reactive oxygen species production by myeloid cells PMID "PMID: 18555978; PMID: 28270698" PMDBI10475 Microbes metabolize substances PMDBM299 2093 Mycoplasma PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases Decrease Efficacy n.a. n.a. n.a. Enzymatic degradation Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity PMID PMID: 28270698 PMDBI10476 Microbes metabolize substances PMDBM299 2093 Mycoplasma PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases Decrease Efficacy n.a. n.a. n.a. Enzymatic degradation Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity PMID PMID: 28270698 PMDBI10477 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD50 Anti-PD-L1 therapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Immunomodulation "Tumour?specific T?cell induction;increase T?cells in?tumour microenvironment" PMID PMID: 28270698 PMDBI10478 Microbes metabolize substances PMDBM337 1224 Proteobacteria PMDBD149 Carmustine, Etoposide, Cytarabine and melphalan combination Therapeutic Substance Drug Combination n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Reduced diversity; ecological network function" Chemotherapy associated with reduction in bacteria that?limit inflammation and increase in bacteria associated with colitis PMID PMID: 28270698 PMDBI10479 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD149 Carmustine, Etoposide, Cytarabine and melphalan combination Therapeutic Substance Drug Combination n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Reduced diversity; ecological network function" Chemotherapy associated with reduction in bacteria that?limit inflammation and increase in bacteria associated with colitis PMID PMID: 28270698 PMDBI10480 Microbes metabolize substances PMDBM3 n.a. Actinobacteria PMDBD149 Carmustine, Etoposide, Cytarabine and melphalan combination Therapeutic Substance Drug Combination n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Reduced diversity; ecological network function" Chemotherapy associated with reduction in bacteria that?limit inflammation and increase in bacteria associated with colitis PMID PMID: 28270698 PMDBI10481 Microbes metabolize substances PMDBM359 1263 Ruminococcus PMDBD229 CpG oligodeoxynucleotides Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Immunomodulation Priming of tumour?associated myeloid inflammatory responses PMID PMID: 28270698 PMDBI10482 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD229 CpG oligodeoxynucleotides Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Immunomodulation Priming of tumour?associated myeloid inflammatory responses PMID PMID: 28270698 PMDBI10483 Microbes metabolize substances PMDBM29 171549 Bacteroidales PMDBD231 CTLA-4 blockade Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Immunomodulation Decreased activation of splenic effector CD4 + T?cells and?tumour?infiltrating lymphocytes PMID PMID: 28270698 PMDBI10484 Microbes metabolize substances PMDBM376 n.a. Segmented filamentous bacteria PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Immunomodulation Gram?positive commensals mediate accumulation of TH 17 and TH 1?cell response PMID PMID: 28270698 PMDBI10485 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Immunomodulation Gram?positive commensals mediate accumulation of TH 17 and TH 1?cell response PMID PMID: 28270698 PMDBI10486 Microbes metabolize substances PMDBM2020217 1354 Enterococcus hirae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Translocation Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10487 Microbes metabolize substances PMDBM277 1622 Lactobacillus murinus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Translocation Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10488 Microbes metabolize substances PMDBM2020130 33959 Lactobacillus johnsonii PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Translocation Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10489 Microbes metabolize substances PMDBM2020217 1354 Enterococcus hirae PMDBD290 Doxorubicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Translocation Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10490 Microbes metabolize substances PMDBM277 1622 Lactobacillus murinus PMDBD290 Doxorubicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Translocation Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10491 Microbes metabolize substances PMDBM2020130 33959 Lactobacillus johnsonii PMDBD290 Doxorubicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Translocation Commensal bacteria cross the intestinal barrier to enter secondary lymphoid organs PMID PMID: 28270698 PMDBI10492 Microbes metabolize substances PMDBM299 2093 Mycoplasma PMDBD384 Gemcitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. Mycoplasma encoded nucleoside phosphorylases Decrease Efficacy n.a. n.a. n.a. Enzymatic degradation Mycoplasma encoded nucleoside phosphorylases restrict cytostatic activity PMID PMID: 28270698 PMDBI10493 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD452 Ipilimumab Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. Bacterially mediated B vitamin production and polyamine transport deficiencies associated with increased risk of?CTLA?4 blockade?induced colitis PMID PMID: 28270698 PMDBI10494 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. Bacterial ç?glucuronidase "Increase Efficacy; Increase Toxicity" n.a. n.a. n.a. Enzymatic degradation Bacterial ç?glucuronidase cleaves glucuronide from inactive metabolite, releasing active metabolite (SN?38) in the gut PMID PMID: 28270698 PMDBI10497 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Reduced diversity; ecological network function" Reduced diversity and shifts in relative abundance associated with chemotherapy?induced diarrhoea PMID PMID: 28270698 PMDBI10498 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Reduced diversity; ecological network function" Reduced diversity and shifts in relative abundance associated with chemotherapy?induced diarrhoea PMID PMID: 28270698 PMDBI10499 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. N-acetylation by microbial N-acetyltransferases Yield a inactive metabolite PMID "PMID: 11344150; PMID: 28642381" PMDBI10500 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. "sulfapyridine;5-ASA;N-acetyl 5-ASA" n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Reduce Lack anti-inflammatory PMID "PMID: 1425876; PMID: 28642381" PMDBI10501 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD397 Ginsenosides Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Inhibit cytochrome P-450s;affect host xenobiotic metabolism" PMID "PMID: 16547074; PMID: 28642381" PMDBI10502 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "antioxidant indole-3-propionic acid;the neurotransmitter tryptamine;indole" n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. Generate the uremic toxin indoxyl sulfate PMID "PMID: 17146590; PMID: 28642381" PMDBI10503 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD241 Cysteine-S-conjugates of xenobiotics Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. thiol metabolites n.a. n.a. n.a. n.a. n.a. n.a. Cleave cysteine-S-conjugates of polychlorinated biphenyls by C-S ç?lyases Serve as a sole nitrogen,a potential role in nutrient acquisition PMID "PMID: 20306345; PMID: 28642381" PMDBI10504 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. "é“?glucuronidase enzymes hydrolyze SN-38G;regenerate active agent" "Cause intestinal damage and severe diarrhea;drug interaction:inhibitors" PMID "PMID: 21051639; PMID: 28642381" PMDBI10505 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD107 Berberine Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Bioavailability n.a. n.a. n.a. n.a. Allow intestinal absorption PMID "PMID: 26174047; PMID: 28642381" PMDBI10506 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD815 Sulfoxide Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduce the sulfoxide n.a. PMID "PMID: 3630204; PMID: 28642381" PMDBI10507 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD90 Azo dyes Environmental Substance "Industrial Chemicals; Pollutants" n.a. n.a. n.a. n.a. mutagenic bis-aniline benzidine n.a. n.a. Increase Toxicity In vivo Mouse n.a. n.a. Increase carcinogen exposure PMID "PMID: 3726894; PMID: 28642381" PMDBI10508 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD540 Methylmercury Environmental Substance "Industrial Chemicals; Pollutants; Toxic Agents" n.a. n.a. n.a. n.a. inorganic mercury n.a. n.a. Decrease Toxicity In vivo Rat n.a. n.a. Lead to less toxicity,facilitate mercury excretion PMID "PMID: 626001; PMID: 28642381" PMDBI10509 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD44 Amygdalin "Herbal Substance; Dietary Substance" "Medicinal Herbal Compounds; Dietary Compounds" n.a. n.a. n.a. n.a. mandelonitrile n.a. n.a. Increase Toxicity n.a. n.a. n.a. Hydrolyze the glycosidic linkage Produce benzaldehydy and toxic cyanide PMID "PMID: 7362642; PMID: 28642381" PMDBI10510 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduce the N-oxide n.a. PMID "PMID: 7628301; PMID: 28642381" PMDBI10511 Microbes metabolize substances PMDBM2020213 n.a. Eggerthella lenta PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. dihydrodigoxin n.a. n.a. n.a. n.a. "Human; GF mice" n.a. Flavin-dependent reductase(Cgr2) n.a. PMID PMID: 28642381 PMDBI10512 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD54 Anticancer drugs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase or decrease the efficacy of drug PMID PMID: 28642381 PMDBI10513 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD54 Anticancer drugs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase or decrease the efficacy of drug PMID PMID: 28642381 PMDBI10514 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD152 CB954 Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Direct chemical modification n.a. PMID PMID: 28642381 PMDBI10515 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD359 Fludarabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Direct chemical modification n.a. PMID PMID: 28642381 PMDBI10516 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD384 Gemcitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Direct chemical modification n.a. PMID PMID: 28642381 PMDBI10517 Microbes metabolize substances PMDBM270 1580 Lactobacillus brevis PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. mtyramine n.a. n.a. n.a. n.a. n.a. n.a. Microbial decarboxylation and p-dehydroxylation(a tyrosine decarboxylase accepts L-dopa in vitro) Contribute to the substantial variation PMID PMID: 28642381 PMDBI10518 Microbes metabolize substances PMDBM255 570 Klebsiella PMDBD662 Phenoxyethanol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. cyanuric acid n.a. n.a. Increase Toxicity In vivo Mouse n.a. Deaminate Lead to renal toxicity PMID PMID: 28642381 PMDBI10519 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD404 Gluten Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Elicit an enhanced gluten-specific immune response(compare with peptieds produced by Lactobacillus spp.from healthy individuals) PMID PMID: 28642381 PMDBI10520 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD839 Thiazolidinediones Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat Diet-induced obesity n.a. Indirectlyaffect gut bacteria(HFD leads to an increase in the relative abundance of Proteobacteria) PMID "PMID: 27751827; PMID: 28973971" PMDBI10521 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD12 Acarbose "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Human Hyperlipidemia or T2D "Prevent starch processing and absorption;" "Enhance starch-fermenting and butyrate-producing bacteria;inhibit starch use by propionate-producing bacteria;increase Lactobacillus,Bifidobacterium and other SCFA-producing bacteria;associated with a diminution of Enterobacteriaceae,Bacteroidaceae and lecithinase positive Clostridum in human feces" PMID PMID: 28973971 PMDBI10522 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD12 Acarbose "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Affect nutrient sources of bacteria Block the growth of E.coli PMID PMID: 28973971 PMDBI10523 Microbes metabolize substances PMDBM375 n.a. SCFA-producing bacteria PMDBD55 Antidiabetic drugs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Positively influence the bacteria PMID PMID: 28973971 PMDBI10524 Microbes metabolize substances PMDBM375 n.a. SCFA-producing bacteria PMDBD428 High-fiber diets Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Positively influence the bacteria PMID PMID: 28973971 PMDBI10525 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD442 Incretin Environmental Substance Human Metabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro Primary murine colonic culture n.a. Microbiota fermentation products Influence incretin secretion PMID PMID: 28973971 PMDBI10526 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD487 Liraglutide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse High-fat diet(HFD),HF-fed,diabetes-induced n.a. "Enrich Firmicutes;deplete Bacteroidetes,Proteobacteria and Actinobacteria phyla;enrich 13 phylotypes(Allobaculum,Turicibacter,Anaerostipes,Blautia,Lactobacillus,Butyricimonas,Desulfovibrio);decrease 20 phylotypes in the orders Clostridiales and Bacteroidales" PMID PMID: 28973971 PMDBI10527 Microbes metabolize substances PMDBM208 561 Escherichia PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. Inhibit the dihydrofolate reductase activity of bacteria Influence the side-effects of drug PMID PMID: 28973971 PMDBI10528 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. SCFA-producing bacteria Enric the bacteria PMID PMID: 28973971 PMDBI10529 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Positive effects PMID PMID: 28973971 PMDBI10530 Microbes metabolize substances PMDBM322 33024 Phascolarctobacterium PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. SCFA-producing bacteria Enric the bacteria PMID PMID: 28973971 PMDBI10531 Microbes metabolize substances PMDBM112 572511 Blautia PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. SCFA-producing bacteria Enric the bacteria PMID PMID: 28973971 PMDBI10532 Microbes metabolize substances PMDBM121 580596 Butyricicoccus PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. SCFA-producing bacteria Enric the bacteria PMID PMID: 28973971 PMDBI10533 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse High-fat diet (HFD) n.a. Decrease bacterial diversity PMID PMID: 28973971 PMDBI10534 Microbes metabolize substances PMDBM337 1224 Proteobacteria PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Positive effects PMID PMID: 28973971 PMDBI10535 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse High-fat diet (HFD) n.a. Decrease bacterial diversity PMID PMID: 28973971 PMDBI10536 Microbes metabolize substances PMDBM407 74201 Verrucomicrobia PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse High-fat diet (HFD) Genus Akkermansia Increase the relative abundance of bacteria PMID PMID: 28973971 PMDBI10537 Microbes metabolize substances PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Promote bacteria growth Contribute to the glucose-lowering effect PMID PMID: 28973971 PMDBI10538 Microbes metabolize substances PMDBM12 174708 Allobaculum PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Positive effects PMID PMID: 28973971 PMDBI10539 Microbes metabolize substances PMDBM173 84107 Coriobacteriaceae PMDBD550 Miglitol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse A high fat and high glucose diet Suppression of intestinal inflammation Reverse the increase of bacteria PMID PMID: 28973971 PMDBI10540 Microbes metabolize substances PMDBM204 128827 Erysipelotrichaceae PMDBD550 Miglitol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse A high fat and high glucose diet Suppression of intestinal inflammation Reverse the increase of bacteria PMID PMID: 28973971 PMDBI10541 Microbes metabolize substances PMDBM375 n.a. SCFA-producing bacteria PMDBD667 Physical activity Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Positively influence the bacteria PMID PMID: 28973971 PMDBI10542 Microbes metabolize substances PMDBM337 1224 Proteobacteria PMDBD674 Pioglitazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat High-fat diet (HFD) Correlate with the decrease of plasma endotoxin, TNF-æµ?, IL-6 and MCP-1 levels Reduce the abundance of bacteria PMID PMID: 28973971 PMDBI10543 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD769 Saxagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse HF-fed,diabetic-induced n.a. "Enrich Firmicutes,mainly the genera Lactobacillus,Allobaculum and Turicibacter;contain less Bacteroides and Prevotella;decrease the phylum Bacteroidetes" PMID PMID: 28973971 PMDBI10544 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD785 Sitagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat Diabetes n.a. "Increase in the relative abundance of Bacteroidetes and Proteobacteria;decrease Firmicute;influence SCFA-producing bacteria;Lactobacillus and Bifidobacterium are depleted in feces" PMID PMID: 28973971 PMDBI10545 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD898 Voglibose Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease the Firmicutes to Bacteroidetes ratio and higher the abundance in Verrucomicrobia PMID PMID: 28973971 PMDBI10546 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. acetylated 5-aminosalicylic acid n.a. n.a. Increase Efficacy n.a. n.a. n.a. N-acetyltransferases from bacteria Exert physiopathological effects,increase activity PMID "PMID: 11344150; PMID: 30227749" PMDBI10547 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD731 Ranitidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Lead to poor bioavailability of ranitidine PMID "PMID: 11564550; PMID: 30227749" PMDBI10548 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD560 Morphine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Hydrolysis of glucuronide Increase drug toxicity PMID "PMID: 1185599; PMID: 30227749" PMDBI10549 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. N-oxide bond cleavage Decrease activity PMID "PMID: 30227749; PMID: 11955801" PMDBI10550 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. M1 (demethylbutyryl metabolite), M4 (hydroxylated metabolite), M8 (the active hydroxy acid metabolite), and M9 (hydroxylated M8) n.a. n.a. n.a. In vitro "Human; Rat" n.a. n.a. Produce four metabolites PMID "PMID: 30227749; PMID: 24947972" PMDBI10551 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD253 Deleobuvir Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. CD 6168 n.a. n.a. n.a. n.a. n.a. n.a. An alkene reduction by the gut microbiota n.a. PMID "PMID: 30227749; PMID: 26068924" PMDBI10552 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD39 Amlodipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Increase activity PMID "PMID: 30227749; PMID: 26630218" PMDBI10553 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD307 Epacadostat Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. Amidine metabolite n.a. n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Decrease activity PMID "PMID: 30227749; PMID: 27457784" PMDBI10554 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Amine formation n.a. PMID "PMID: 30227749; PMID: 4165044" PMDBI10555 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD810 Sulfanilamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Azoreductase enzymes,Activation of azo-bond containing prodrug to sulfanilamid Increase toxicity PMID "PMID: 5173017; PMID: 30227749" PMDBI10556 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD814 Sulfonamide antibiotics Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbial transformation n.a. PMID "PMID: 5173017; PMID: 30227749" PMDBI10557 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-aminoclonazepam n.a. n.a. Increase Toxicity n.a. n.a. n.a. Nitro reduction n.a. PMID "PMID: 6506755; PMID: 30227749" PMDBI10558 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Isoxazole scission or hydroxylation Decrease activity PMID "PMID: 7512019; PMID: 30227749" PMDBI10559 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD492 Loperamide oxide Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. active drug loperamide n.a. n.a. Increase Efficacy n.a. "Human; Dog; Rat " n.a. n.a. Make the metabolism and increase activity of loperamide oxide PMID "PMID: 7628301; PMID: 30227749" PMDBI10560 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. No alteration of pharmacokinetics PMID "PMID: 7629748; PMID: 30227749" PMDBI10561 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD137 Calcitonin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Susceptible to proteolysis,Protease Increase large-intestinal absorption,decrease activity PMID "PMID: 30227749; PMID: 9055189" PMDBI10562 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD447 Insulin human Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Susceptible to proteolysis,Protease Increase large-intestinal absorption,decrease activity PMID "PMID: 30227749; PMID: 9055189" PMDBI10563 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD194 Cimetidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Influence drug delivery and absorption PMID PMID: 30227749 PMDBI10564 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD332 Famotidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Influence drug delivery and absorption PMID PMID: 30227749 PMDBI10565 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Influence drug delivery and absorption PMID PMID: 30227749 PMDBI10566 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl)uracil n.a. n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Reduce activity PMID PMID: 30227749 PMDBI10567 Microbes metabolize substances PMDBM2020046 n.a. Clostridioides difficile PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Decrease Efficacy; Increase Toxicity" n.a. n.a. n.a. P-cresol(microbial metabolite) reduces metabolic clearance "Reduce activity;delay the metabolism of drug in the human body and increase risk of hepatotoxicity" PMID PMID: 30227749 PMDBI10568 Microbes metabolize substances PMDBM195 n.a. Enterobacteriales PMDBD18 Acetylsalicylic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. "Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency" PMID PMID: 30227749 PMDBI10569 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD18 Acetylsalicylic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. "Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency" PMID PMID: 30227749 PMDBI10570 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD18 Acetylsalicylic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. "Modulate the metabolism and pharmacokinetics;Potentiate the therapeutic potency" PMID PMID: 30227749 PMDBI10571 Microbes metabolize substances PMDBM2020035 316435 Escherichia coli Nissle 1917 PMDBD36 Amiodarone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. DEA n.a. n.a. "Increase Efficacy; Increase Bioavailability" In vivo Animal model n.a. n.a. Increase bioavailability of AMI,increase plasma levels of desethylamiodarone(DEA),promote the absorption of AMI and increase the activity of CYP2C PMID PMID: 30227749 PMDBI10572 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD96 Balsalazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. Increase Toxicity n.a. n.a. n.a. "Reduction and Release of 5-aminosalicylic acid;Azoreductases" Increase toxicity PMID PMID: 30227749 PMDBI10573 Microbes metabolize substances PMDBM2020213 n.a. Eggerthella lenta PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. digoxigenin,or dihydrodigoxin n.a. n.a. Decrease Efficacy In vitro human n.a. Reduction "Produce inactive metabolites;[interaction]:(gnotobiotic mice)dietary protein reduces microbial metabolism of digoxin(vivo) and changes drug concentration(in the serum and urine);[drug interaction]:antibiotics(tetracycline or erythromycin) increase plasma concentration of digoxin" PMID PMID: 30227749 PMDBI10574 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD403 Glucuronides Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. diclofenac,ketoprofen,indomethacin n.a. n.a. Increase Toxicity n.a. n.a. n.a. Hydrolysis of the glycosidicbon Increase toxicity PMID PMID: 30227749 PMDBI10575 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD403 Glucuronides Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. diclofenac,ketoprofen,indomethacin n.a. n.a. Increase Toxicity n.a. n.a. n.a. Hydrolysis of the glycosidicbon Increase toxicity PMID PMID: 30227749 PMDBI10576 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp. PMDBD403 Glucuronides Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. diclofenac,ketoprofen,indomethacin n.a. n.a. Increase Toxicity n.a. n.a. n.a. Hydrolysis of the glycosidicbon Increase toxicity PMID PMID: 30227749 PMDBI10577 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. Increase Toxicity n.a. n.a. n.a. Hydrolysis of the glycosidicbon,bacterial b-glucuronidases Increase toxicity PMID PMID: 30227749 PMDBI10578 Microbes metabolize substances PMDBM2020268 821 Bacteroides vulgatus PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. Increase Toxicity n.a. n.a. n.a. Hydrolysis of the glycosidicbon,bacterial b-glucuronidases Increase toxicity PMID PMID: 30227749 PMDBI10579 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. Increase Toxicity n.a. n.a. n.a. Hydrolysis of the glycosidicbon,bacterial b-glucuronidases Increase toxicity PMID PMID: 30227749 PMDBI10580 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. lactic and acetic acidsactive metabolite n.a. n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Reduce activity PMID PMID: 30227749 PMDBI10581 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. lactic and acetic acidsactive metabolite n.a. n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Reduce activity PMID PMID: 30227749 PMDBI10582 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. lactic and acetic acidsactive metabolite n.a. n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Reduce activity PMID PMID: 30227749 PMDBI10583 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. Thiazole ring opening Increase activity PMID PMID: 30227749 PMDBI10584 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. Thiazole ring opening Increase activity PMID PMID: 30227749 PMDBI10585 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Catalyze p-dehydroxylation of L-dopa to mhydroxyphenylacetic acid n.a. PMID PMID: 30227749 PMDBI10586 Microbes metabolize substances PMDBM2020226 210 Helicobacter pylori PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Bioavailability In vivo Human Parkinson閳ユç?disease (PD) Dehydroxylation "Reduce acute L-dopa absorption;reduce L-dopa onset time, ON duration, motor severity, and quality of life parameters" PMID PMID: 30227749 PMDBI10587 Microbes metabolize substances PMDBM2020099 n.a. Clostridium perfringens PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. N-(2-hydroxyethyl)-oxamic acid and acetamide n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Reduction Reduce activity PMID PMID: 30227749 PMDBI10588 Microbes metabolize substances PMDBM2020201 1535 [Clostridium] leptum PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-acetylaminonitrazepam n.a. n.a. Decrease Toxicity n.a. n.a. n.a. Nitroreductase Produce teratogenic activity metabolites,Induce teratogenicity PMID PMID: 30227749 PMDBI10589 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD618 Olsalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. Increase Toxicity n.a. n.a. n.a. "Reduction and Release of 5-aminosalicylic acid;Azoreductases" Increase toxicity PMID PMID: 30227749 PMDBI10590 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Affect the pharmacokinetics and pharmacodynamics;increase the risk of myopathy" PMID PMID: 30227749 PMDBI10591 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. Increase Toxicity n.a. n.a. n.a. "Reduction and Release of 5-aminosalicylic acid;Azoreductases" Increase toxicity PMID PMID: 30227749 PMDBI10592 Microbes metabolize substances PMDBM2020204 1509 Clostridium sporogenes PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 2-sulphamoylacetylphenol n.a. n.a. Increase Efficacy n.a. n.a. n.a. Zonisamide reductase Increase activity PMID PMID: 30227749 PMDBI10593 Microbes metabolize substances PMDBM2020069 294 Pseudomonas fluorescens PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reductive metabolism n.a. PMID PMID: 30227749 PMDBI10594 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reductive metabolism n.a. PMID PMID: 30227749 PMDBI10595 Microbes metabolize substances PMDBM2020268 821 Bacteroides vulgatus PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reductive metabolism n.a. PMID PMID: 30227749 PMDBI10596 Microbes metabolize substances PMDBM2020032 n.a. Enterococcus faecalis PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reductive metabolism n.a. PMID PMID: 30227749 PMDBI10597 Microbes metabolize substances PMDBM2020204 1509 Clostridium sporogenes PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reductive metabolism n.a. PMID PMID: 30227749 PMDBI10598 Microbes metabolize substances PMDBM2020012 1681 Bifidobacterium bifidum PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reductive metabolism n.a. PMID PMID: 30227749 PMDBI10599 Microbes metabolize substances PMDBM282 47715 Lactobacillus rhamnosus PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reductive metabolism n.a. PMID PMID: 30227749 PMDBI10600 Microbes metabolize substances PMDBM371 n.a. Salmonella enterica subsp. enterica serovar Typhimurium PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reductive metabolism n.a. PMID PMID: 30227749 PMDBI10601 Microbes metabolize substances PMDBM2020057 n.a. Eubacterium sp. PMDBD96 Balsalazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. Increase Toxicity n.a. n.a. n.a. "Reduction and Release of 5-aminosalicylic acid;Azoreductases" Increase toxicity PMID PMID: 30227749 PMDBI10602 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD263 Diclofenac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterial b-glucuronidases Reduce intestinal tract toxicity PMID PMID: 30227749 PMDBI10603 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterial b-glucuronidases Reduce intestinal tract toxicity PMID PMID: 30227749 PMDBI10604 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Bacterial b-glucuronidases Reduce intestinal tract toxicity PMID PMID: 30227749 PMDBI10605 Microbes metabolize substances PMDBM2020057 n.a. Eubacterium sp. PMDBD618 Olsalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. Increase Toxicity n.a. n.a. n.a. "Reduction and Release of 5-aminosalicylic acid;Azoreductases" Increase toxicity PMID PMID: 30227749 PMDBI10606 Microbes metabolize substances PMDBM2020057 n.a. Eubacterium sp. PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-aminosalicylic acid n.a. n.a. Increase Toxicity n.a. n.a. n.a. "Reduction and Release of 5-aminosalicylic acid;Azoreductases" Increase toxicity PMID PMID: 30227749 PMDBI10607 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. N-acetyltransferase Acetylating to acid PMID "PMID: 11344150; PMID: 30338735" PMDBI10608 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Metabolized by bacteria n.a. PMID "PMID: 30338735; PMID: 11955801" PMDBI10609 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD814 Sulfonamide antibiotics Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Azoreductase enzymes Activation of prodrug to 5-aminosalicylic acid PMID "PMID: 30338735; PMID: 1711964" PMDBI10610 Microbes metabolize substances PMDBM2020099 n.a. Clostridium perfringens PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduction to acetamide PMID "PMID: 30338735; PMID: 231450" PMDBI10611 Microbes metabolize substances PMDBM2020064 n.a. Bacterium DZY-HS11 PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. Reduce the abundance of bacteria n.a. PMID "PMID: 30338735; PMID: 24413286" PMDBI10612 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. é“?D-glucosidase, æµ?L-rhamnosidase,æµ?D-glucosidase enzyme Drug interaction:antibiotics can reduce the biotransformation PMID "PMID: 30338735; PMID: 24947972" PMDBI10613 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. é“?glucuronidase Hydrolysis of glucuronide PMID "PMID: 28922; PMID: 30338735" PMDBI10614 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD588 Nifedipine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID "PMID: 30338735; PMID: 29790376" PMDBI10615 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD588 Nifedipine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Hypoxic conditions at high altitudes Changes of intestinal microflora caused by high plateau hypoxia Increase the bioavailability of drug PMID "PMID: 30338735; PMID: 29790376" PMDBI10616 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. Result in increased toxicity PMID "PMID: 30338735; PMID: 430360" PMDBI10617 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulfapyridine and 5-ASA n.a. n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Lose activity PMID "PMID: 30338735; PMID: 4402374" PMDBI10618 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Active 5-aminosalicyclic acid by intestinal azoreductase enzymes Increase the drug PMID "PMID: 30338735; PMID: 4402374" PMDBI10619 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD279 Dihydroxyphenylalanine (DOPA) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Direct dopa to alternative metabolic pathways PMID "PMID: 4723308; PMID: 30338735" PMDBI10620 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD72 Artificial sweetener cyclamate Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis n.a. PMID "PMID: 7362642; PMID: 30338735" PMDBI10621 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD680 Plant-derived glycosides(amygdalin) Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis n.a. PMID "PMID: 7362642; PMID: 30338735" PMDBI10622 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD492 Loperamide oxide Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. loperamide n.a. n.a. n.a. n.a. "Human; Dog; Rat " n.a. Bacteria affect activation of prodrugs and drug inactivation n.a. PMID "PMID: 30338735; PMID: 7628301" PMDBI10623 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-acetylaminonitrazepam n.a. n.a. n.a. n.a. n.a. n.a. Nitroreductase n.a. PMID "PMID: 30338735; PMID: 9310649" PMDBI10624 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. p-cresol n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30338735 PMDBI10625 Microbes metabolize substances PMDBM195 n.a. Enterobacteriales PMDBD18 Acetylsalicylic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics can potentiate the therapeutic potency PMID PMID: 30338735 PMDBI10626 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD18 Acetylsalicylic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics can potentiate the therapeutic potency PMID PMID: 30338735 PMDBI10627 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD18 Acetylsalicylic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:antibiotics can potentiate the therapeutic potency PMID PMID: 30338735 PMDBI10628 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. calycosin n.a. n.a. n.a. n.a. n.a. n.a. Bacteria produces O-methyltransferase and aromatic hydroxylase n.a. PMID PMID: 30338735 PMDBI10629 Microbes metabolize substances PMDBM2020213 n.a. Eggerthella lenta PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. dihydrodigoxigenin,dihydrodigoxin n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Reduction to inactive metabolites n.a. PMID PMID: 30338735 PMDBI10630 Microbes metabolize substances PMDBM208 561 Escherichia PMDBD284 Diosmin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by diosmetin n.a. PMID PMID: 30338735 PMDBI10631 Microbes metabolize substances PMDBM196 1350 Enterococcus PMDBD284 Diosmin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by diosmetin n.a. PMID PMID: 30338735 PMDBI10632 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD284 Diosmin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by diosmetin n.a. PMID PMID: 30338735 PMDBI10633 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD284 Diosmin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by diosmetin n.a. PMID PMID: 30338735 PMDBI10634 Microbes metabolize substances PMDBM87 1678 Bifidobacterium PMDBD284 Diosmin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by diosmetin n.a. PMID PMID: 30338735 PMDBI10635 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis and release of SN-38 Leads to GI toxicity PMID PMID: 30338735 PMDBI10636 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis and release of SN-38 Leads to GI toxicity PMID PMID: 30338735 PMDBI10637 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. é“?glucuronidases Enhance the irinotecan toxicity PMID PMID: 30338735 PMDBI10638 Microbes metabolize substances PMDBM2020268 821 Bacteroides vulgatus PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. é“?glucuronidases Enhance the irinotecan toxicity PMID PMID: 30338735 PMDBI10639 Microbes metabolize substances PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. é“?glucuronidases Enhance the irinotecan toxicity PMID PMID: 30338735 PMDBI10640 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp. PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. n.a. n.a. n.a. n.a. Hydrolysis and release of SN-38 Leads to GI toxicity PMID PMID: 30338735 PMDBI10641 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. acetic lactic,acids active n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30338735 PMDBI10642 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. acetic lactic,acids active n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30338735 PMDBI10643 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. acetic lactic,acids active n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30338735 PMDBI10644 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. levametabol-I,levametabol-III n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Generate active metabolites PMID PMID: 30338735 PMDBI10645 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. levametabol-I,levametabol-III n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Generate active metabolites PMID PMID: 30338735 PMDBI10647 Microbes metabolize substances PMDBM2020223 39491 [Eubacterium] rectale PMDBD714 Puerarin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. daidzein n.a. n.a. n.a. n.a. n.a. n.a. Convert by bacteria n.a. PMID PMID: 30338735 PMDBI10648 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by quercetin n.a. PMID PMID: 30338735 PMDBI10649 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by quercetin n.a. PMID PMID: 30338735 PMDBI10650 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by quercetin n.a. PMID PMID: 30338735 PMDBI10651 Microbes metabolize substances PMDBM216 1730 Eubacterium PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by quercetin n.a. PMID PMID: 30338735 PMDBI10652 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp. PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond, followed by quercetin n.a. PMID PMID: 30338735 PMDBI10653 Microbes metabolize substances PMDBM208 561 Escherichia PMDBD770 Scutellaria baicalensis root Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond,followed by baicalein. n.a. PMID PMID: 30338735 PMDBI10654 Microbes metabolize substances PMDBM385 1301 Streptococcus PMDBD770 Scutellaria baicalensis root Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond,followed by baicalein. n.a. PMID PMID: 30338735 PMDBI10655 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD770 Scutellaria baicalensis root Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond,followed by baicalein. n.a. PMID PMID: 30338735 PMDBI10656 Microbes metabolize substances PMDBM216 1730 Eubacterium PMDBD770 Scutellaria baicalensis root Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond,followed by baicalein. n.a. PMID PMID: 30338735 PMDBI10657 Microbes metabolize substances PMDBM2020037 41200 Bifidobacterium sp. PMDBD770 Scutellaria baicalensis root Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Generated to glycosidic bond,followed by baicalein. n.a. PMID PMID: 30338735 PMDBI10658 Microbes metabolize substances PMDBM268 n.a. Lactobacillus PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. Increase the risk of myopathy PMID PMID: 30338735 PMDBI10659 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. (E)-5-(2-bromovinyl) uracil n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30338735 PMDBI10660 Microbes metabolize substances PMDBM247 2701 Gardnerella PMDBD832 Tenofovir Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Catabolized tenofovir into an inactive compound n.a. PMID PMID: 30338735 PMDBI10661 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD915 Zonisamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 2-sulphamoylacetylphenol n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30338735 PMDBI10662 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD244 Daidzein "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. Calycosin n.a. n.a. n.a. n.a. n.a. n.a. Aromatic hydroxylase,O-methyltransferase n.a. PMID PMID: 30338735 PMDBI10663 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD57 Anti?PD?1 therapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human Metastatic melanoma n.a. "Higher relative abundance of bacteria in responding (R) patients;therapy is defined by eight species driven by Bifidobacterium longum" PMID PMID: 30530851 PMDBI10664 Microbes metabolize substances PMDBM2020193 216816 Bifidobacterium longum PMDBD57 Anti?PD?1 therapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human Metastatic melanoma n.a. "Higher relative abundance of bacteria in responding (R) patients;therapy is defined by eight species driven by Bifidobacterium longum" PMID PMID: 30530851 PMDBI10665 Microbes metabolize substances PMDBM2020266 239935 Akkermansia muciniphila PMDBD57 Anti?PD?1 therapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human Non-small cell lung cancer n.a. Increased relative abundance of bacteria in PD-1 R PMID PMID: 30530851 PMDBI10666 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. SLCO1B1 Increase Efficacy In vivo Human n.a. n.a. 221% increase in simvastatin AUC for homozygotes PMID "PMID: 19833260; PMID: 18650507; PMID: 24918167; PMID: 22380001; PMID: 31171383" PMDBI10668 Microbes metabolize substances PMDBM2020213 n.a. Eggerthella lenta PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. Lactone ring reduction ABCB1 Increase Toxicity In vivo Human n.a. n.a. "Decreased AUC; narrow therapeutic window" PMID "PMID: 24637603; PMID: 18334914; PMID: 31171383" PMDBI10669 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD900 Warfarin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. CYP2C9 n.a. n.a. Human n.a. Vitamin K production Altered activity of drug PMID "PMID: 22380001; PMID: 17042764; PMID: 26962786; PMID: 31171383" PMDBI10670 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD124 Bromazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Nitroreduction n.a. Increase Toxicity n.a. Human n.a. n.a. Amino-metabolite generation, Inactivation PMID "PMID: 27591027; PMID: 30227749; PMID: 31171383" PMDBI10671 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD124 Bromazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Nitroreduction n.a. Decrease Efficacy n.a. Human n.a. n.a. Change to inactive metabolite PMID "PMID: 27591027; PMID: 30227749; PMID: 31171383" PMDBI10672 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Nitroreduction n.a. Increase Toxicity n.a. Human n.a. n.a. Amino-metabolite generation, Inactivation PMID "PMID: 27591027; PMID: 30227749; PMID: 31171383" PMDBI10673 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Nitroreduction n.a. Decrease Efficacy n.a. Human n.a. n.a. Change to inactive metabolite PMID "PMID: 27591027; PMID: 30227749; PMID: 31171383" PMDBI10674 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD263 Diclofenac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Deglucuronidation n.a. Increase Toxicity n.a. Human n.a. n.a. "Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions" PMID "PMID: 27591027; PMID: 30227749; PMID: 31171383" PMDBI10675 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Deglucuronidation n.a. Increase Toxicity n.a. Human n.a. n.a. "Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions" PMID "PMID: 27591027; PMID: 30227749; PMID: 31171383" PMDBI10676 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Deglucuronidation n.a. Increase Toxicity n.a. Human n.a. n.a. "Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions" PMID "PMID: 27591027; PMID: 30227749; PMID: 31171383" PMDBI10677 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD468 Ketoprofen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. Deglucuronidation n.a. Increase Toxicity n.a. Human n.a. n.a. "Reformation of cytotoxic drug;Diarrhea, bowel distress, GI lesions" PMID "PMID: 27591027; PMID: 30227749; PMID: 31171383" PMDBI10678 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Nitroreduction n.a. Increase Toxicity n.a. Human n.a. n.a. Amino-metabolite generation, Inactivation PMID "PMID: 27591027; PMID: 30227749; PMID: 31171383" PMDBI10679 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Nitroreduction n.a. Decrease Efficacy n.a. Human n.a. n.a. Change to inactive metabolite PMID "PMID: 27591027; PMID: 30227749; PMID: 31171383" PMDBI10680 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38G metabolite Deglucuronidation UGT1A1*28閳ユオilbert's syndromeé–?Increase Toxicity In vitro Human Health n.a. "Defect in glucuronidation; increased toxicity" PMID "PMID: 29104759; PMID: 18349289; PMID: 31171383" PMDBI10681 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. Sulfonation "UGT1A; SULT1A3" Decrease Toxicity In vitro Human n.a. n.a. "Increased rate of glucuronidation; decreased risk of liver failure" PMID "PMID: 23408116; PMID: 19667173; PMID: 29705271; PMID: 31171383" PMDBI10682 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD123 Brivudine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. additional bromovinyluracil n.a. DYPD Increase Toxicity In vitro Human n.a. n.a. "Hepatotoxicity; bromovinyluracil prevents clearance of 5-FU" PMID "PMID: 9690942; PMID: 30733391; PMID: 31171383" PMDBI10683 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. additional bromovinyluracil n.a. DYPD Increase Toxicity n.a. Human n.a. n.a. "Hepatotoxicity; bromovinyluracil prevents clearance of 5-FU" PMID "PMID: 9690942; PMID: 30733391; PMID: 31171383" PMDBI10684 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD96 Balsalazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. local 5-ASA Azoreduction n.a. Increase Efficacy In vivo Human Ulcerative colitis n.a. Prodrug activation: local 5-ASA release PMID "PMID: 27591027; PMID: 31171383" PMDBI10685 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD137 Calcitonin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Proteolysis n.a. Decrease Efficacy In vitro Human n.a. n.a. Breakdown of therapeutic protein PMID "PMID: 27591027; PMID: 31171383" PMDBI10686 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. p-aminophenyl-2-amino-1,3-propanediol Nitroreduction n.a. Increase Toxicity n.a. Human n.a. n.a. Bone marrow toxicity PMID "PMID: 27591027; PMID: 31171383" PMDBI10687 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD447 Insulin human Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Proteolysis n.a. Decrease Efficacy In vitro Human n.a. n.a. Breakdown of therapeutic protein PMID "PMID: 27591027; PMID: 31171383" PMDBI10688 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD453 Ipsalazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. local 5-ASA Azoreduction n.a. Increase Efficacy In vivo Human Ulcerative colitis n.a. Prodrug activation: local 5-ASA release PMID "PMID: 27591027; PMID: 31171383" PMDBI10689 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD580 Neoprontosil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Azoreduction n.a. Increase Efficacy In vitro Rat n.a. n.a. Antibiotic activation PMID "PMID: 27591027; PMID: 31171383" PMDBI10690 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD618 Olsalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. local 5-ASA Azoreduction n.a. Increase Efficacy In vivo Human Ulcerative colitis n.a. Prodrug activation: local 5-ASA release PMID "PMID: 27591027; PMID: 31171383" PMDBI10691 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD668 Picosulfuric acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Desulfation n.a. Increase Efficacy n.a. Human n.a. n.a. Solubility increase PMID "PMID: 27591027; PMID: 31171383" PMDBI10692 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD711 Prontosil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Azoreduction n.a. Increase Efficacy In vivo "Mouse (I.C.I. Albino strain); Rat (Wistar albino); Hamster" n.a. n.a. Antibiotic activation PMID "PMID: 27591027; PMID: 31171383" PMDBI10693 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD808 Sulfadiazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. local 5-ASA Azoreduction n.a. Increase Efficacy n.a. Human n.a. n.a. Prodrug activation: local 5-ASA release PMID "PMID: 27591027; PMID: 31171383" PMDBI10694 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD525 Mesalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. N-Acetylation n.a. Decrease Efficacy n.a. Human n.a. n.a. "Less efficacy; possible pancreatic toxicity" PMID "PMID: 30227749; PMID: 31171383" PMDBI10695 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD36 Amiodarone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. N-dealkylation n.a. Increase Efficacy In vivo Rat EcN-treated rats n.a. Increased bioavailability of active metabolite PMID "PMID: 30227749; PMID: 31171383" PMDBI10696 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD221 Codeine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. Deglucuronidation n.a. Increase Efficacy n.a. Human n.a. n.a. Reformation of active metabolite PMID "PMID: 30227749; PMID: 31171383" PMDBI10697 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. Lactone ring reduction n.a. Decrease Efficacy n.a. Human n.a. n.a. Change to inactive metabolite PMID "PMID: 30227749; PMID: 31171383" PMDBI10698 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD527 Metamfetamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. N-Demethylation n.a. Decrease Efficacy n.a. Human n.a. n.a. Change to inactive metabolite PMID "PMID: 30227749; PMID: 31171383" PMDBI10699 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD560 Morphine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. Deglucuronidation n.a. Increase Efficacy n.a. Human n.a. n.a. Reformation of active metabolite PMID "PMID: 30227749; PMID: 31171383" PMDBI10700 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD123 Brivudine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. N-Dealkylation n.a. Increase Toxicity In vitro Human n.a. n.a. "Bacteroides-mediated hepatotoxicity; potentially fatal 5-FU accumulation" PMID "PMID: 30733391; PMID: 31171383" PMDBI10701 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD788 Sorivudine Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. N-Dealkylation n.a. Increase Toxicity n.a. Human n.a. n.a. "Bacteroides-mediated hepatotoxicity; potentially fatal 5-FU accumulation" PMID "PMID: 30733391; PMID: 31171383" PMDBI10702 Microbes metabolize substances PMDBM2020226 210 Helicobacter pylori PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. P-Dehydroxylation n.a. Decrease Efficacy n.a. Human n.a. n.a. Decrease in L-dopa absorption PMID PMID: 31171383 PMDBI10703 Microbes metabolize substances PMDBM2020151 287 Pseudomonas aeruginosa PMDBD560 Morphine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. morphine-glucuronide metabolite Deglucuronidation "SLC22A1; OCT1" n.a. n.a. Human n.a. n.a. "Decreased clearance of morphine; Induces virulence in some strains of Pseudomonas aeruginosa" PMID PMID: 31171383 PMDBI10704 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD315 Estradiol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Bioavailability In vitro human n.a. é“?glucuronidase mediate deconjugation and enterohepatic circulation of estrogen "Greater absroption of estrogens;develop estrogen-driven cancer" PMID "PMID: 27107051; PMID: 31184303; PMID: 24187630" PMDBI10705 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity In vivo BALB/c mouse Health "Microbial ç?glucuronidases mediate the reactivation of metabolite閿涘æ½econjugation and reactivation of SN-38é–?Cause toxicity(epithelial damage;severe diarrhea);analog:plant-based compound scutellarin(inadvertently modulating the effect of cancer therapy)" PMID "PMID: 29104759; PMID: 21051639; PMID: 31184303" PMDBI10706 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD825 Taurine conjugated bile acid Environmental Substance Human Metabolite n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. "Meidate de-conjugation of taurineconjugates;generate hydrogen sulfid" Contribute to the etiology of cancer PMID "PMID: 27003186; PMID: 31184303" PMDBI10707 Microbes metabolize substances PMDBM2020213 n.a. Eggerthella lenta PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. human n.a. "Be linked to cgr operon expression levels;human microbiome reductase inactivates the drug" "Lead to inactivation and decreased bioavailability;drug substructure similarity:cardenolides(great),progesterone閵嗕æ­ortisone(bad);" PMID PMID: 31184303 PMDBI10708 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD30 Altretamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. Human n.a. Alter the drug structure "Cause diarrhea and kidney damage;interaction:tamoxifen閵嗕龚iphenhydramine閵嗕辜heobromine" PMID PMID: 31184303 PMDBI10709 Microbes metabolize substances PMDBM2020155 303 Pseudomonas putida PMDBD30 Altretamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbial N-demethylase enzymes "Lead to similar toxic effects as seen with melamine;Substrate similar(no evidence)" PMID PMID: 31184303 PMDBI10710 Microbes metabolize substances PMDBM393 211046 Styrax aureus PMDBD434 Hypochlorite Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Human cutaneous T cell lymphoma n.a. Reduce the amount of bacteria PMID "PMID: 18835065; PMID: 31186074" PMDBI10711 Microbes metabolize substances PMDBM403 n.a. Unidentified probiotic PMDBD226 Common azole treatment Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reduce the amount of azoleresistant fungal strains PMID "PMID: 25362524; PMID: 31186074" PMDBI10712 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Reactivate drug by the ç?glucuronidase enzyme Result in side effects( stage 4 diarrhea and gastrointestinal damage) PMID "PMID: 31186074; PMID: 26364932" PMDBI10713 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. m-tyramine, m-hydroxyphenylacetic acid (m-HPAA) n.a. n.a. Decrease Efficacy In vivo Rat n.a. n.a. Decrease L-DOPA half-life and efficacy PMID "PMID: 4723308; PMID: 31186074" PMDBI10714 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD471 Lactulose Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. acetic,lactic acid n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Product therapeutic metabolites PMID "PMID: 6804597; PMID: 31186074" PMDBI10715 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD53 Antibiotic (extensive treatment) Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Eliminate the majority of the intestinal microbiome and improve harmful bacteria(Clostridium difficile) "Lead to intestinal complications(antibiotic-associated diarrhea and colitis);drug interaction: C. difficile can be treated with vancomycin and metronidazole" PMID PMID: 31186074 PMDBI10716 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD124 Bromazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-aminoclonazepam,2-(2-amino-5-bromobenzoyl) pyridine n.a. n.a. n.a. n.a. n.a. n.a. Gut microbial nitroreductase activity n.a. PMID "PMID: 2893665; PMID: 6506755" PMDBI10717 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-aminoclonazepam,2-(2-amino-5-bromobenzoyl) pyridine n.a. n.a. n.a. n.a. n.a. n.a. Gut microbial nitroreductase activity n.a. PMID "PMID: 2893665; PMID: 6506755" PMDBI10718 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD695 Potassium oxonate Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. cyanuric acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 10997934 PMDBI10719 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. N-acetyl sulfapyridine,N-acetyl-5-aminosalicylic acid n.a. n.a. n.a. In vitro "Human; Rat; Guinea pig; Dog" n.a. Bacterial N-acetylation n.a. PMID PMID: 1425876 PMDBI10720 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD668 Picosulfuric acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 4,40-dihydroxydiphenyl-(2 pyridyl)-methane n.a. n.a. n.a. n.a. n.a. n.a. Conversion by gut bacteria n.a. PMID PMID: 1507649 PMDBI10721 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD666 Phosphate or sulfate ester prodrugs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. The drug act on hydrolytic enzymes of bacteria n.a. PMID PMID: 1507649 PMDBI10722 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-amino 5-salicylic acid n.a. n.a. Increase Efficacy n.a. n.a. n.a. Microbial azoreductases "Convert to its pharmacologically active form;enhance drug distribution閿涙lsalazine閵嗕攻alsalazide閿涘潟nflammatory bowel disease閿涘鈧î„柡鈧î„æ”°ntroduction of azo bonds" PMID PMID: 18305431 PMDBI10723 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD52 Antibiotic Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Eliminate vitamin K-producing bacteria Lead to alteration in coagulation status PMID PMID: 18841274 PMDBI10724 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-aminonitrazepam,7-acetylaminonitrazepam n.a. n.a. Increase Toxicity In vivo Rat Pregnant Gut microbial nitroreductase activity "Lead to nitrazepam-related teratogenicity;drug interaction:antibiotic reduced metabolites" PMID PMID: 1925980 PMDBI10725 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. N-acetyl p-benzoquuinone imine n.a. n.a. Increase Toxicity In vivo Human Health A microbial-derived metabolite p-cresol compete with acetaminophen Impede the ability for the liver to detoxify PMID "PMID: 19667173; PMID: 31462078" PMDBI10726 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD372 Fostamatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbial O-dealkylation n.a. PMID PMID: 20371637 PMDBI10727 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD755 Rosuvastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Toxicity n.a. n.a. n.a. Compete with TMA for metabolism by FMO3 Cause side effect on fish odor syndrom PMID PMID: 21422137 PMDBI10728 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Alterations in bacteria(expansion of proinflammatory bacteria) PMID PMID: 22328575 PMDBI10729 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. 1-(2-aminoimidazol-1-yl)-3 methoxypropanol-2-ol and acetamide n.a. n.a. n.a. In vivo Rat n.a. Gut microbiome閳ユ徆erived nitroreduction Lead to rat carcinogen PMID PMID: 231450 PMDBI10730 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. n.a. Microbial inactivation PMID PMID: 23869020 PMDBI10731 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD230 CpG-oligonucleotide immunotherapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Prime murine immune cells to secrete tumor necrosis factor(TNF) Stimulate the immune system to attack cancer cells PMID PMID: 24264989 PMDBI10733 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug interaction:long-term antibiotic treatment might lead to a failure to control serum cholesterol levels PMID PMID: 24947972 PMDBI10734 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Lead to activation of drug PMID PMID: 25091594 PMDBI10735 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD300 Eltrombopag Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Human; Dog" n.a. Reductive cleavag n.a. PMID PMID: 25581726 PMDBI10736 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD478 Levosimendan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Human; Dog" n.a. Reductive cleavag n.a. PMID PMID: 25581726 PMDBI10737 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD445 Indole "Therapeutic Substance; Herbal Substance" Investigational Drug n.a. n.a. n.a. n.a. indole-3-propionic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. Provide ligands for the aryl hydrocarbon receptor PMID PMID: 26041783 PMDBI10738 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD880 Tryptophan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. indole-3-propionic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. Provide ligands for the aryl hydrocarbon receptor PMID PMID: 26041783 PMDBI10739 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. B-glucuronidase activity "Lead to severe diarrhea;drug interaction:antibiotic mixtures(streptomycin,penicillin or neomycin and bacitracin)eliminated fecal b-glucuronidase activity; TJ-14 administration moderate weight loss and delay the drug-associated diarrhea; the P-glycoprotein and (cMOA T/MRP2) inhibitor of cyclosporin A or (UDP)-glucuronosyltransferase inhibitor valproic acid increased intestinal toxicity" PMID PMID: 26518357 PMDBI10740 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase Efficacy In vivo Mouse n.a. é“?glucuronidases Enhance pharmacological effect PMID PMID: 26701907 PMDBI10741 Microbes metabolize substances PMDBM402 n.a. Unidentified oral microbes PMDBD697 PPIs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Associated with changes toward a less healthy gut microbiome and in line with changes predisposing users to infection with C. difficile Species of bacteria were seen to be over-represented in the fecal microbiome PMID PMID: 26719299 PMDBI10742 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD697 PPIs Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Changes in bacterial populations(decrease Bacteroidetes and increase Firmicutes) "Predispose PPI-treated subjects to C. difficile infection;[drug interaction]:frequent use of PPIs can exacerbate NSAID-induced small intestinal injury;[probiotics]prevent NSAID-induced damage in patients receiving PPI and NSAIDs" PMID PMID: 26923470 PMDBI10743 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD755 Rosuvastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse With rosuvastatin Reduce hepatic expression of the CYP27a1,alter the concentrations of bile acids Contribute to the composition of gut microbiota PMID PMID: 28209601 PMDBI10744 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Toxicity n.a. n.a. n.a. n.a. Causes toxic side effects PMID PMID: 29104759 PMDBI10745 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. dopamine n.a. n.a. n.a. n.a. n.a. n.a. Tyrosine decarboxylase n.a. PMID PMID: 30659181 PMDBI10746 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD358 Flucytosine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-FU n.a. n.a. n.a. n.a. n.a. n.a. Deamination by bacteria n.a. PMID PMID: 3729334 PMDBI10747 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD4 2-amino-3,6-dihydro-3H-imidazo[4,5-f]quinoline Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. 7-hydroxy metabolite n.a. n.a. n.a. n.a. n.a. n.a. Gut microbiotal oxidation/dehydrogenation n.a. PMID PMID: 3821779 PMDBI10748 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD16 Acetaminophen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug is deacetylated n.a. PMID PMID: 4418213 PMDBI10749 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD657 Phenacetin Therapeutic Substance Approved Drug (Withdrawn) n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug is deacetylated n.a. PMID PMID: 4418213 PMDBI10750 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD476 Levodopa "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. m-hydroxyphenylacetic acid n.a. n.a. n.a. In vivo Rat n.a. Some microbial dehydroxylation Reduce the exposure of the drug in the brain PMID PMID: 5343357 PMDBI10751 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Normal n.a. n.a. PMID PMID: 5345205 PMDBI10752 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD727 Radiation sensitizer misonidazole Therapeutic Substance n.a. n.a. n.a. n.a. n.a. l-(2-l-(2-aminoimidazol-l-yl)-3-methoxypropan-2-ol n.a. n.a. n.a. In vivo Rat Normal,germ-free(GF) Nitroreduction Drug interaction:penicillin increased drug exposure and decreased neurotoxicity PMID PMID: 6260109 PMDBI10753 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo "Rat; Dog" n.a. Reductive metabolism n.a. PMID PMID: 7512019 PMDBI10754 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD137 Calcitonin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. "Drug is rapidly degraded;more prone to proteolysis;drug interaction:protease inhibitors(camostat/aprotinin) improve the stability and bioavailability of these peptides" PMID PMID: 7550138 PMDBI10755 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD492 Loperamide oxide Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. loperamide,the ranitidine,nitazidine n.a. n.a. n.a. In vivo Dog n.a. n.a. n.a. PMID PMID: 7628301 PMDBI10756 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. sulfide metabolite n.a. n.a. n.a. n.a. n.a. n.a. Reduction n.a. PMID PMID: 7629748 PMDBI10757 Microbes metabolize substances PMDBM400 n.a. Unidentified anaerobic bacterium PMDBD87 Azetirelin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. Drug interaction:concentrations of the drug were maintained after the administration of antibiotic PMID PMID: 9279880 PMDBI10758 Microbes metabolize substances PMDBM31 816 Bacteroides PMDBD2 1-b-D-arabinofuranosyl-5-(E)-(2-bromovinyl)uracil Environmental Substance Unclassified Environmental Substances n.a. n.a. n.a. n.a. BVU n.a. n.a. n.a. In vivo Rat n.a. The result of hydrolysis by anaerobic bacteria Drug interaction: the drug with the anticancer drug 5-FU or prodrugs tegafur,5-FU accumulate(increase toxicity, including death) PMID PMID: 9808711 PMDBI10759 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD810 Sulfanilamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. molecule sulfanilamide n.a. n.a. Increase Efficacy n.a. n.a. n.a. n.a. Generate the active form of the drug PMID PMID: 31235939 PMDBI10760 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Mouse Germ-free(GF) Bt4096 encodes an enzyme that metabolizes diltiazem n.a. PMID PMID: 31235939 PMDBI10761 Microbes metabolize substances PMDBM232 216851 Faecalibacterium PMDBD57 Anti?PD?1 therapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Human melanoma n.a. Prolong progession-free survival PMID PMID: 31462078 PMDBI10762 Microbes metabolize substances PMDBM80 976 Bacteroidetes PMDBD176 Checkpoint inhibitor therapy Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Toxicity n.a. n.a. n.a. Overabundance of the bacteroidetes phylum Decrease occrrence of side effect PMID PMID: 31462078 PMDBI10763 Microbes metabolize substances PMDBM2020213 n.a. Eggerthella lenta PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. dihydrodigoxin n.a. n.a. Decrease Bioavailability n.a. Human n.a. A cytochrome-encoding operon (termed the cardiac glycoside reductase) "Convert to the inactive microbial metabolite;limit absorbtion;drug interaction:antibiotics,arginine-rich diet(impair this reaction)" PMID PMID: 31462078 PMDBI10764 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD755 Rosuvastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Human Hyperlipidemia Activity of bacteria containing bile salt hydrolases Phyla Firmicutes閵嗕笚usobacteria閿涘潱egatively associated with LDL-C levelsé–?Cyanobacteria閵嗕俯entisphaerae(positively) PMID PMID: 31462078 PMDBI10765 Microbes metabolize substances PMDBM239 1239 Firmicutes PMDBD755 Rosuvastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Human Hyperlipidemia Bile salt hydrolase activity Reduce LDL-C levels PMID PMID: 31462078 PMDBI10766 Microbes metabolize substances PMDBM280 1598 Lactobacillus reuteri PMDBD755 Rosuvastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Human Hyperlipidemia Bile salt hydrolase activity Reduce LDL-C levels PMID PMID: 31462078 PMDBI10767 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD455 Irinotecan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. SN-38 n.a. n.a. Increase Toxicity n.a. n.a. n.a. "é“?glucuronidases remove the glucuronide group;reactive the drug" "Sever diarrhea;drug interaction(mice:oral administration of a specific inhibitor of the ç?glucuronidase enzyme,reduce irinotecan-induced toxicity)" PMID PMID: 31462078 PMDBI10768 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD270 Dietary choline Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. trimethylamine-N-oxide(TMAO) n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbiome-derived metabolites Interfer with drug pharmacokinetics and pharmacodynamics PMID PMID: 31462078 PMDBI10769 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD475 Levocarnitine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. trimethylamine-N-oxide(TMAO) n.a. n.a. Increase Toxicity n.a. n.a. n.a. Microbiome-derived metabolites Interfer with drug pharmacokinetics and pharmacodynamics PMID PMID: 31462078 PMDBI10770 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD18 Acetylsalicylic acid Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Damage the mucosa of the upper GI tract;be able to distinguish aspirin users:(Prevotella species, Bacteroides species, a member of the Ruminococaceae family, and Barnesiella species" PMID PMID: 31462078 PMDBI10771 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD39 Amlodipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Human; Rat" n.a. Presystemic metabolism by dehydrogenation "Decreased amount of active drug reaching target tissues;its major metabolite increased;drug interaction:rat(pretreated with ampicillin),enhance amlodipine's absorption;" PMID PMID: 31462078 PMDBI10772 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD78 Atorvastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Human; Rat" "High-fat diet (Rat); Hypercholesterolemia (Human)" Decreased amount of secondary bile acids Increase abundance of putative anti-inflammatory species PMID PMID: 31462078 PMDBI10773 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD143 Captopril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat Hypertensive "Decreased intestinal permeability and fibrosis; and improved villi length" Reverse the dysbiotic state PMID PMID: 31462078 PMDBI10774 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-aminoclonazapam n.a. n.a. n.a. n.a. n.a. n.a. Reduction reactions Drug interaction:antibiotics(inhibit) PMID PMID: 31462078 PMDBI10777 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease Efficacy n.a. n.a. n.a. Microbial-derived bile acids competing for host uptake transporters Decreased amount of drug reaching target tissues PMID PMID: 31462078 PMDBI10778 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Human n.a. Bacterial-derived bile acids(lithocholic acid,taurolithocholic acid,glycolithocholic acid) Predict the magnitude of LDL-C lowering PMID PMID: 31462078 PMDBI10780 Microbes metabolize substances PMDBM401 n.a. Unidentified gut microbes PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 7-amino-nitrazepam n.a. n.a. Increase Toxicity n.a. n.a. n.a. Nitro reduction by microbiota "Produce a teratogenic metabolite;drug interaction:antibiotics(inhibit)" PMID PMID: 31462078 PMDBI10842 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD26 Alfuzosin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI10843 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD29 Alprenolol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI10844 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.828 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI10845 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD140 Camylofine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI10846 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD141 Capecitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.688 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI10847 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD204 Clemizole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI10848 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD285 Diphenylpyraline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI10849 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD323 Ethoxzolamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI10850 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD456 Irsogladine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI10851 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD488 Lofexidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI10852 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD543 Metitepine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI10853 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD625 Orphenadrine citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI10854 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD629 Oxcarbazepine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI10855 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD640 Papaverine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI10856 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD642 Paroxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.378 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI10857 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD752 Rizatriptan benzoate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI10858 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD819 Sulpiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.399 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI10859 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD876 Trimetazidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI10860 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD893 Verapamil "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI10861 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.952 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI10862 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD13 Acecainide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI10863 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD13 Acecainide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.345 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI10864 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD46 Anastrozole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI10865 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD46 Anastrozole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI10866 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD103 Benzthiazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI10867 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD103 Benzthiazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI10868 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD112 Bicalutamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.612 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI10869 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD112 Bicalutamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI10870 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD130 Bupropion Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI10871 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD130 Bupropion Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.682 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI10872 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD170 Celecoxib "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI10873 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD170 Celecoxib "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.898 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI10874 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD234 Cyclobenzaprine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI10875 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD234 Cyclobenzaprine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.449 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI10876 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD439 Imatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI10877 Microbes metabolize substances PMDBM2020052 n.a. Anaerostipes sp. PMDBD439 Imatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI10878 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD521 Memantine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI10879 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD521 Memantine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI10880 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD538 Methsuximide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.51 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI10881 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD538 Methsuximide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI10882 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD542 Methysergide maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI10883 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD542 Methysergide maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI10884 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD545 Metoprolol tartrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.347 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI10885 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD545 Metoprolol tartrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.328 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI10886 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD569 Naftopidil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI10887 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD569 Naftopidil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.006 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI10888 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD582 Nevirapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI10889 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD582 Nevirapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI10890 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD845 Thiothixene Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.577 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI10891 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD845 Thiothixene Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI10892 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD864 Tranilast Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI10893 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD864 Tranilast Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI10894 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD897 Vinpocetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI10895 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD897 Vinpocetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI10896 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD286 Dipyridamole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI10897 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD286 Dipyridamole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI10898 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD286 Dipyridamole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.805 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI10899 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD289 Doxazosin mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI10900 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD289 Doxazosin mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI10901 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD289 Doxazosin mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI10902 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD302 Enalapril maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.439 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI10903 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD302 Enalapril maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI10904 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD302 Enalapril maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI10905 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD370 Fluvoxamine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI10906 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD370 Fluvoxamine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI10907 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD370 Fluvoxamine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI10908 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD781 Sildenafil citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.494 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI10909 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD781 Sildenafil citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.524 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI10910 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD781 Sildenafil citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.424 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI10911 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD820 Sumatriptan succinate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI10912 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD820 Sumatriptan succinate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI10913 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD820 Sumatriptan succinate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI10914 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD900 Warfarin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI10915 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD900 Warfarin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI10916 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD900 Warfarin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI10917 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD913 Ziprasidone mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI10918 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD913 Ziprasidone mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI10919 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD913 Ziprasidone mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI10920 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD32 Amantadine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.378 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI10921 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD32 Amantadine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.422 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI10922 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD32 Amantadine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.347 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI10923 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD32 Amantadine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI10924 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI10925 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.327 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI10926 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI10927 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI10928 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD312 Ergotamine tartrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.956 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI10929 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD312 Ergotamine tartrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI10930 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD312 Ergotamine tartrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.23 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI10931 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD312 Ergotamine tartrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.969 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI10932 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD517 Mefloquine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.977 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI10933 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD517 Mefloquine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI10934 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD517 Mefloquine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI10935 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD517 Mefloquine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.995 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI10936 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD648 Penbutolol sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.44 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI10937 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD648 Penbutolol sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI10938 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD648 Penbutolol sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI10939 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD648 Penbutolol sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI10940 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI10941 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.725 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI10942 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI10943 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.128 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI10944 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD822 Tadalafil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI10945 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD822 Tadalafil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.547 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI10946 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD822 Tadalafil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.523 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI10947 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD822 Tadalafil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.434 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI10948 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD115 Biperiden Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.385 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI10949 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD115 Biperiden Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.361 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI10950 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD115 Biperiden Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.488 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI10951 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD115 Biperiden Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.583 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI10952 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD541 Methylphenidate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI10953 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD541 Methylphenidate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.538 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI10954 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD541 Methylphenidate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI10955 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD541 Methylphenidate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI10956 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD321 Ethopropazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI10957 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD321 Ethopropazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI10958 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD321 Ethopropazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI10959 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD321 Ethopropazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI10960 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD321 Ethopropazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI10961 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD663 Phenytoin sodium Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI10962 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD663 Phenytoin sodium Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI10963 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD663 Phenytoin sodium Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI10964 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD663 Phenytoin sodium Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.326 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI10965 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD663 Phenytoin sodium Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI10966 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD873 Trihexyphenidyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI10967 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD873 Trihexyphenidyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.526 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI10968 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD873 Trihexyphenidyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.386 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI10969 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD873 Trihexyphenidyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.331 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI10970 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD873 Trihexyphenidyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI10971 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD194 Cimetidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI10972 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD194 Cimetidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI10973 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD194 Cimetidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI10974 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD194 Cimetidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI10975 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD194 Cimetidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI10976 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD194 Cimetidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI10977 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.38 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI10978 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI10979 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.327 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI10980 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.961 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI10981 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI10982 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI10983 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD568 Nafronyl oxalate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI10984 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD568 Nafronyl oxalate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.581 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI10985 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD568 Nafronyl oxalate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI10986 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD568 Nafronyl oxalate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI10987 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD568 Nafronyl oxalate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI10988 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD568 Nafronyl oxalate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI10989 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD614 Olanzapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.708 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI10990 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD614 Olanzapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.538 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI10991 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD614 Olanzapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.057 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI10992 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD614 Olanzapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI10993 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD614 Olanzapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI10994 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD614 Olanzapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI10995 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD45 Anagrelide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.398 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI10996 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD45 Anagrelide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI10997 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD45 Anagrelide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI10998 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD45 Anagrelide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI10999 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD45 Anagrelide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.431 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11000 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD45 Anagrelide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11001 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD45 Anagrelide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.346 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11002 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD111 Bezafibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.382 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11003 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD111 Bezafibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.486 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11004 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD111 Bezafibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.554 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11005 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD111 Bezafibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.437 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11006 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD111 Bezafibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11007 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD111 Bezafibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11008 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD111 Bezafibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.709 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11009 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD146 Carbetapentane citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11010 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD146 Carbetapentane citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11011 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD146 Carbetapentane citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.344 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11012 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD146 Carbetapentane citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11013 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD146 Carbetapentane citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11014 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD146 Carbetapentane citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11015 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD146 Carbetapentane citrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.649 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11016 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD181 Chlormezanone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11017 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD181 Chlormezanone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11018 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD181 Chlormezanone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI11019 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD181 Chlormezanone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.331 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11020 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD181 Chlormezanone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11021 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD181 Chlormezanone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11022 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD181 Chlormezanone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.412 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11023 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD266 Dicyclomine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.817 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11024 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD266 Dicyclomine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.585 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11025 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD266 Dicyclomine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11026 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD266 Dicyclomine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11027 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD266 Dicyclomine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.695 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11028 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD266 Dicyclomine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11029 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD266 Dicyclomine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11030 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD340 Fenofibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.545 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11031 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD340 Fenofibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.417 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11032 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD340 Fenofibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.516 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11033 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD340 Fenofibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.559 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11034 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD340 Fenofibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.05 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11035 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD340 Fenofibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.308 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11036 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD340 Fenofibrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.855 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11037 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.527 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11038 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.649 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI11039 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.82 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI11040 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.067 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11041 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.827 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11042 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.136 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11043 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.204 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11044 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD585 Nicergoline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.477 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11045 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD585 Nicergoline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11046 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD585 Nicergoline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11047 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD585 Nicergoline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11048 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD585 Nicergoline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.698 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11049 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD585 Nicergoline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.744 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11050 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD585 Nicergoline Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.567 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11051 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD730 Ramipril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.41 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI11052 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD730 Ramipril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.65 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11053 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD730 Ramipril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11054 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD730 Ramipril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11055 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD730 Ramipril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.377 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11056 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD730 Ramipril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11057 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD730 Ramipril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.692 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11058 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD622 Ooscapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11059 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD622 Ooscapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11060 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD622 Ooscapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.343 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11061 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD622 Ooscapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11062 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD622 Ooscapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11063 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD622 Ooscapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.378 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11064 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD622 Ooscapine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11065 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD621 Oorgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.713 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11066 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD621 Oorgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.162 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11067 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD621 Oorgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.328 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11068 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD621 Oorgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.324 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11069 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD621 Oorgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.486 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11070 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD621 Oorgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.704 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI11071 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD621 Oorgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.47 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11072 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD621 Oorgestimate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.287 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11073 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD731 Ranitidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11074 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD731 Ranitidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11075 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD731 Ranitidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.878 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11076 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD731 Ranitidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11077 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD731 Ranitidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11078 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD731 Ranitidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11079 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD731 Ranitidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11080 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD731 Ranitidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11081 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11082 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11083 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11084 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11085 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.343 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI11086 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.345 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11087 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11088 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.843 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11089 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11090 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.605 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11091 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11092 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11093 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.336 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11094 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.363 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11095 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11096 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11097 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11098 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11099 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.751 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11100 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11101 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11102 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11103 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.62 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11104 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.693 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11105 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.77 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11106 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.801 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11107 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.492 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11108 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.476 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11109 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11110 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.713 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11111 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11112 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11113 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.355 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11114 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.554 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11115 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11116 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.937 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11117 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.453 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11118 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.656 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11119 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.701 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11120 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11121 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.857 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11122 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11123 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11124 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD653 Pericyazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11125 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11126 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.531 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11127 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.817 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11128 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11129 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.549 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11130 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.808 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI11131 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.673 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11132 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI11133 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD704 Primaquine phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11134 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11135 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11136 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.521 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11137 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.561 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11138 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.355 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11139 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.521 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11140 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11141 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.868 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11142 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.68 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11143 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11144 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.19 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11145 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11146 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11147 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.324 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11148 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11149 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.736 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11150 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.44 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11151 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11152 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11153 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11154 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.081 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11155 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.555 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11156 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.188 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11157 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.906 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11158 Microbes metabolize substances PMDBM2020052 n.a. Anaerostipes sp. PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.751 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11159 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.029 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11160 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.37 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11161 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11162 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.767 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11163 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.81 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11164 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11165 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11166 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11167 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.651 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11168 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11169 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.798 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI11170 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11171 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.737 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11172 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.74 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11173 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD469 Ketorolac tromethamine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.764 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11174 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.539 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11175 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11176 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.518 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11177 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11178 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11179 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.545 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11180 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.377 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11181 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11182 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.336 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11183 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD634 Oxybutynin chloride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11184 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD636 Paclitaxel "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11185 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD636 Paclitaxel "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11186 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD636 Paclitaxel "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.572 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11187 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD636 Paclitaxel "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.661 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11188 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD636 Paclitaxel "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.509 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11189 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD636 Paclitaxel "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.411 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI11190 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD636 Paclitaxel "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11191 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD636 Paclitaxel "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.36 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11192 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD636 Paclitaxel "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11193 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD636 Paclitaxel "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11194 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11195 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11196 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11197 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.748 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11198 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.38 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11199 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11200 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11201 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.508 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11202 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.508 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11203 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI11204 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.371 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11205 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.529 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11206 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.629 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11207 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.545 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11208 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.681 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11209 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.701 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11210 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.629 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11211 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.896 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11212 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11213 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.907 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11214 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11215 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11216 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.807 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11217 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11218 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11219 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11220 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11221 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11222 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11223 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.568 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11224 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11225 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11226 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.865 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11227 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11228 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.644 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11229 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.872 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11230 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.417 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11231 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11232 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11233 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.531 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI11234 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11235 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.491 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11236 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11237 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11238 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.411 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11239 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11240 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.441 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11241 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.473 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11242 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.423 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11243 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11244 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11245 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD399 Gliclazide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11246 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.852 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11247 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11248 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.737 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11249 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.069 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11250 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11251 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.52 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11252 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI11253 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11254 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.529 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11255 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.759 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11256 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD732 Rebamipide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.767 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11257 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11258 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11259 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11260 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11261 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.638 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11262 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11263 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.912 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI11264 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.546 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11265 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.681 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11266 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11267 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.724 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11268 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.406 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11269 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11270 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.791 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11271 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.51 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11272 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.473 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11273 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11274 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11275 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11276 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.596 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11277 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11278 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.783 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11279 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.814 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11280 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.723 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11281 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.735 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11282 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11283 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.592 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11284 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11285 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.589 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11286 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.039 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11287 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.496 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11288 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11289 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11290 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.564 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11291 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11292 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD377 Galantamine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.495 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11293 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD377 Galantamine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.494 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11294 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD377 Galantamine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11295 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD377 Galantamine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.627 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11296 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD377 Galantamine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11297 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD377 Galantamine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.589 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11298 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD377 Galantamine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11299 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD377 Galantamine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11300 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD377 Galantamine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.563 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11301 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD377 Galantamine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.67 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11302 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD377 Galantamine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11303 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD377 Galantamine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11304 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD415 Griseofulvin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11305 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD415 Griseofulvin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.782 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11306 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD415 Griseofulvin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11307 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD415 Griseofulvin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.721 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11308 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD415 Griseofulvin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11309 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD415 Griseofulvin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11310 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD415 Griseofulvin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11311 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD415 Griseofulvin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11312 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD415 Griseofulvin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11313 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD415 Griseofulvin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11314 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD415 Griseofulvin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.585 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11315 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD415 Griseofulvin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11316 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11317 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11318 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.828 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11319 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.764 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11320 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11321 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.525 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11322 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI11323 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11324 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11325 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11326 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11327 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11328 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD572 Naloxone "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI11329 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD572 Naloxone "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11330 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD572 Naloxone "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.722 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11331 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD572 Naloxone "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.98 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11332 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD572 Naloxone "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11333 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD572 Naloxone "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.548 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11334 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD572 Naloxone "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.723 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11335 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD572 Naloxone "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.924 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11336 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD572 Naloxone "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.839 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11337 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD572 Naloxone "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.898 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11338 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD572 Naloxone "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.708 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11339 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD572 Naloxone "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.155 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11340 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11341 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11342 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11343 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.454 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11344 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11345 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11346 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11347 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11348 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11349 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11350 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.569 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11351 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD573 Naproxen(+) Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11352 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11353 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11354 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.568 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11355 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.62 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11356 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11357 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11358 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11359 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.352 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11360 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11361 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.693 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11362 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11363 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD581 Neostigmine bromide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11364 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.999 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11365 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.567 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11366 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.856 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11367 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.73 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11368 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.886 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11369 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.784 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11370 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.005 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11371 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI11372 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11373 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11374 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.619 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11375 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.615 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11376 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD223 Colchicine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.371 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11377 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD223 Colchicine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11378 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD223 Colchicine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.647 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11379 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD223 Colchicine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11380 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD223 Colchicine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11381 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD223 Colchicine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11382 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD223 Colchicine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11383 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD223 Colchicine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.359 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11384 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD223 Colchicine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11385 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD223 Colchicine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.495 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11386 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD223 Colchicine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11387 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD223 Colchicine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11388 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD223 Colchicine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.574 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11389 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI11390 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11391 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11392 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11393 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.828 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11394 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.781 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11395 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11396 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.207 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11397 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.401 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11398 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.677 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11399 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.654 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11400 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.964 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11401 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD281 Diltiazem Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.453 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11402 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11403 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11404 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11405 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI11406 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11407 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI11408 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.785 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11409 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11410 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11411 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.601 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11412 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11413 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11414 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD311 Ergonovine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.655 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11415 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.533 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11416 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11417 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11418 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.405 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11419 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11420 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11421 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11422 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11423 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11424 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11425 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.63 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11426 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.602 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11427 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD495 Losartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.753 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11428 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11429 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11430 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI11431 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.477 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11432 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11433 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11434 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI11435 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.523 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11436 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.526 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11437 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11438 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.635 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11439 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11440 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.727 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11441 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11442 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11443 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.952 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11444 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11445 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.422 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11446 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.505 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11447 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.514 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI11448 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11449 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.451 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11450 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11451 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.574 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11452 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11453 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11454 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11455 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.476 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11456 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11457 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11458 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.352 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11459 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.427 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11460 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11461 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.422 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11462 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.358 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11463 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11464 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11465 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11466 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.501 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11467 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11468 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.385 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11469 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11470 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11471 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11472 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11473 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.672 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11474 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.432 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11475 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11476 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11477 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.484 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11478 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11479 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11480 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11481 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.685 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11482 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.688 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11483 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11484 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.446 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11485 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11486 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11487 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11488 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11489 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11490 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.569 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11491 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11492 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11493 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.645 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11494 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11495 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.78 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11496 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.423 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11497 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.369 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11498 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11499 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11500 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.333 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11501 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11502 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11503 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.325 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11504 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11505 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11506 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11507 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11508 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI11509 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.821 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI11510 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD108 Betamethasone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.012 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11511 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11512 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11513 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11514 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11515 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11516 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11517 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.334 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11518 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11519 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11520 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.997 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11521 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11522 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11523 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11524 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.606 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11525 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.669 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11526 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.922 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11527 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.225 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11528 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.632 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11529 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.426 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11530 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.691 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11531 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.975 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11532 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.243 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11533 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.653 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11534 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.566 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11535 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.604 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI11536 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.683 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11537 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.092 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11538 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.46 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11539 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.656 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11540 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.322 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11541 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11542 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.724 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11543 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.494 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11544 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.428 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11545 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11546 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.599 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11547 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11548 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11549 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.391 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11550 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11551 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11552 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11553 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11554 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.606 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11555 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11556 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.043 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11557 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.6 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11558 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.968 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11559 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.215 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11560 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11561 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.342 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11562 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.623 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11563 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.764 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11564 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.722 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11565 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.787 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11566 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.253 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11567 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.544 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11568 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.018 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11569 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.902 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11570 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD482 Linagliptin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.569 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI11571 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.482 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11572 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.627 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11573 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11574 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.518 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11575 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.719 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11576 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11577 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11578 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.768 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11579 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.603 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11580 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.641 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11581 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.592 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11582 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11583 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.398 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11584 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11585 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11586 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.013 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11587 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.989 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11588 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.126 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11589 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.787 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11590 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.806 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11591 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11592 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.545 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11593 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.516 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11594 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.052 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11595 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.534 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11596 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.684 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11597 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.833 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11598 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.934 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11599 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.596 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11600 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD547 Mevastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11601 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11602 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11603 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11604 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.747 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11605 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11606 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.064 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11607 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.816 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11608 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.812 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11609 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11610 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.847 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11611 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.909 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11612 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.738 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11613 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.022 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11614 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.932 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11615 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.922 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11616 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD341 Fenspiride Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.153 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11617 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11618 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.577 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11619 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11620 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11621 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.497 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11622 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11623 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11624 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.542 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11625 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.356 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11626 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11627 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11628 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11629 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11630 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.829 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11631 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.761 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11632 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD707 Procarbazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.969 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11633 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11634 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.908 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11635 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11636 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.867 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11637 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.66 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11638 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11639 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.619 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11640 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.678 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11641 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.065 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11642 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11643 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11644 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.676 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11645 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11646 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.637 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11647 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.628 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11648 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.825 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11649 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11650 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11651 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI11652 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11653 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.449 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11654 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11655 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.651 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11656 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11657 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11658 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.532 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11659 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11660 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11661 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.625 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11662 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.737 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11663 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.547 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11664 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD887 Valsartan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11665 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.502 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11666 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.701 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11667 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.748 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11668 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.795 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11669 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.734 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11670 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11671 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11672 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.83 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11673 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11674 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11675 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.329 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11676 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.491 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11677 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.709 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11678 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11679 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.548 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11680 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.629 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11681 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD109 Betamethasone valerate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11682 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11683 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11684 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11685 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.659 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11686 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.685 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11687 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11688 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.708 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11689 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11690 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.628 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11691 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11692 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.344 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI11693 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.439 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11694 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11695 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11696 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11697 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.516 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11698 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD240 Cyproterone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11699 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD537 Methoxsalen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11700 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD537 Methoxsalen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.146 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11701 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD537 Methoxsalen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11702 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD537 Methoxsalen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11703 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD537 Methoxsalen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.011 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11704 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD537 Methoxsalen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.089 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11705 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD537 Methoxsalen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.492 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11706 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD537 Methoxsalen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11707 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD537 Methoxsalen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.711 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11708 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD537 Methoxsalen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.709 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11709 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD537 Methoxsalen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.918 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11710 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD537 Methoxsalen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11711 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD537 Methoxsalen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11712 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD537 Methoxsalen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11713 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD537 Methoxsalen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11714 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD537 Methoxsalen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11715 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD537 Methoxsalen "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.93 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11716 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.385 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11717 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11718 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11719 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.656 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11720 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.487 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11721 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11722 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11723 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11724 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.406 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11725 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.434 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11726 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11727 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.543 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11728 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11729 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11730 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.756 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11731 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI11732 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.776 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11733 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.371 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11734 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11735 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11736 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11737 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.128 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11738 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.417 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11739 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.412 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11740 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.488 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11741 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.703 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11742 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.35 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11743 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.723 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11744 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11745 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11746 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11747 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.678 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11748 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.75 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11749 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11750 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.856 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11751 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.481 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11752 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11753 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.604 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11754 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.57 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11755 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.577 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11756 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11757 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11758 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11759 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.769 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11760 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11761 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI11762 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.51 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11763 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.383 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11764 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.472 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11765 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11766 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.72 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11767 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11768 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11769 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11770 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI11771 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11772 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.807 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11773 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.415 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11774 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.837 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11775 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.674 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11776 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11777 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11778 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11779 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.864 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11780 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11781 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.498 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11782 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11783 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11784 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11785 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.752 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11786 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.802 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11787 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11788 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11789 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.405 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11790 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.757 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11791 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.104 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI11792 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.732 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11793 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11794 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11795 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.963 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11796 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.656 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11797 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.777 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11798 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.94 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11799 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11800 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.545 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11801 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.231 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11802 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.171 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11803 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.133 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11804 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.821 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11805 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.837 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11806 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.653 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11807 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.3 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11808 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.178 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11809 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11810 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.432 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11811 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11812 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11813 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.564 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11814 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.872 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11815 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.591 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11816 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.896 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11817 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.84 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11818 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.812 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11819 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.828 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11820 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.965 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11821 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.757 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11822 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.05 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11823 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11824 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.01 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11825 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD669 Pidotimod Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.072 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11826 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11827 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.838 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11828 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11829 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.411 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11830 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.771 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11831 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.549 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11832 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11833 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11834 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11835 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.425 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11836 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI11837 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.415 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11838 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.625 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11839 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11840 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11841 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11842 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11843 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11844 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11845 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.648 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11846 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11847 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11848 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.501 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11849 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.971 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11850 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11851 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.977 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11852 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11853 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.437 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11854 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11855 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.719 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11856 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11857 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.857 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11858 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI11859 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11860 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI11861 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI11862 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI11863 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11864 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.785 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI11865 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11866 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.58 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI11867 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD148 Carisoprodol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.86 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11868 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11869 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.383 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11870 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11871 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11872 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11873 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.488 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11874 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.468 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11875 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.607 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11876 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.369 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11877 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.472 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11878 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.339 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11879 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11880 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.333 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11881 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11882 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.393 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11883 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11884 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11885 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.631 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11886 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.783 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11887 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.68 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11888 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.907 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11889 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.538 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11890 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.715 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11891 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11892 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.724 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11893 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.608 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11894 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11895 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.585 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11896 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI11897 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.501 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11898 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11899 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11900 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.44 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11901 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.359 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11902 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11903 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.445 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11904 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.367 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11905 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.563 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11906 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI11907 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.562 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11908 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.725 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11909 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI11910 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.563 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11911 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.708 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI11912 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.96 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11913 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.906 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI11914 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.399 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11915 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11916 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.876 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11917 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.782 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11918 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.839 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11919 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.089 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11920 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI11921 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11922 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11923 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.7 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11924 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11925 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11926 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11927 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI11928 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.706 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI11929 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.988 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11930 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11931 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.179 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11932 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI11933 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11934 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.096 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11935 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.183 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11936 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11937 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.764 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11938 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.351 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11939 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11940 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.819 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11941 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI11942 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.402 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11943 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.624 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11944 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11945 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11946 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI11947 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.544 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11948 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11949 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11950 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.522 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11951 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD474 Levamisole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.697 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11952 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11953 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11954 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.761 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11955 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11956 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.761 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI11957 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.76 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11958 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11959 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.551 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI11960 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11961 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.777 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11962 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.439 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11963 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.399 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11964 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.492 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11965 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.651 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11966 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.467 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11967 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI11968 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.373 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI11969 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI11970 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI11971 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11972 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD490 Loperamide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI11973 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.332 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI11974 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11975 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11976 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.712 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI11977 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.756 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI11978 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.024 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI11979 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11980 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11981 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI11982 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI11983 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI11984 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11985 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.401 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI11986 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.386 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11987 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI11988 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI11989 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11990 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.616 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI11991 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI11992 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI11993 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD519 Megestrol acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI11994 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI11995 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI11996 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.579 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI11997 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.565 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI11998 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.571 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI11999 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.148 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12000 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.847 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI12001 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.952 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12002 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.823 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12003 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI12004 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12005 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.814 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI12006 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.477 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12007 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.605 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12008 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.684 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12009 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.648 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12010 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.674 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12011 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.682 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12012 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.645 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12013 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.846 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12014 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.658 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI12015 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.769 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12016 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12017 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12018 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.616 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12019 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI12020 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.323 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI12021 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.432 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI12022 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12023 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.496 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI12024 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.686 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12025 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.794 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12026 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.386 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12027 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12028 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.6 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12029 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.395 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12030 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI12031 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12032 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.565 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12033 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.594 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12034 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI12035 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.694 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12036 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.663 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12037 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.759 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12038 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.613 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI12039 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12040 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.644 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI12041 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.638 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12042 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.819 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12043 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI12044 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12045 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.77 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12046 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12047 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.575 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12048 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.711 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12049 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.449 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12050 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.963 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12051 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.506 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI12052 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI12053 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12054 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12055 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.661 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI12056 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI12057 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.391 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI12058 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.489 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI12059 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.664 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12060 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD203 Clemastine fumarate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.526 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12061 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.55 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12062 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI12063 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.44 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12064 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI12065 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.837 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12066 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.987 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12067 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.839 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12068 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.55 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12069 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.252 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12070 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.86 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12071 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12072 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.05 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12073 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.676 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12074 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12075 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.045 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI12076 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12077 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.149 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12078 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12079 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.351 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12080 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI12081 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12082 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12083 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD274 Diflorasone diacetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12084 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.421 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12085 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12086 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.382 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12087 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12088 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.557 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12089 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.659 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12090 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.35 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12091 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12092 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.611 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12093 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.423 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12094 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.524 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12095 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12096 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.396 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12097 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.355 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12098 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.342 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12099 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI12100 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.338 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12101 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12102 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12103 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.672 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12104 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12105 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.74 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12106 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD275 Digitoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.903 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12107 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.678 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12108 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.787 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12109 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI12110 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI12111 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12112 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12113 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.414 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12114 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI12115 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.337 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12116 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.691 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12117 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.496 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12118 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.581 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12119 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12120 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.466 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI12121 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.354 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12122 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.691 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12123 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.624 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI12124 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.726 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12125 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.537 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12126 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.712 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12127 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12128 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.979 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI12129 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD874 Trimebutine maleate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.808 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12130 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12131 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12132 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12133 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.638 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12134 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.624 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12135 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.561 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12136 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.341 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12137 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.368 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12138 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12139 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.597 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12140 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.433 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12141 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.522 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12142 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12143 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.361 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12144 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.324 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12145 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.327 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12146 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12147 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.416 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12148 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.605 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12149 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12150 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.69 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12151 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.818 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12152 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.791 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12153 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD216 Clopidogrel sulfate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.972 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12154 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.971 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12155 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.822 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12156 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.841 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12157 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.928 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12158 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.801 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12159 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI12160 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.372 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12161 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.82 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI12162 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.463 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12163 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.765 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12164 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.672 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12165 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.051 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12166 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI12167 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.211 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12168 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.774 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12169 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.357 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI12170 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.451 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12171 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.808 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12172 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.964 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI12173 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.901 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12174 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.398 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12175 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.827 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI12176 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.019 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12177 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD821 Tacrolimus "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.753 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI12178 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.11 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12179 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.856 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12180 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.076 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12181 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.041 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12182 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.244 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12183 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.931 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12184 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12185 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12186 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.365 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI12187 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12188 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.685 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12189 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.884 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12190 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.5 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12191 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.94 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12192 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.782 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12193 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI12194 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.486 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI12195 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.61 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12196 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.419 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12197 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12198 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.666 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12199 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12200 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.462 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI12201 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12202 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12203 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD496 Lovastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.789 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12204 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.592 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12205 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12206 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.456 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12207 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12208 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12209 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12210 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.472 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12211 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.42 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12212 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.778 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12213 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.648 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12214 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.898 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12215 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI12216 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.376 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI12217 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12218 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.445 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12219 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.478 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12220 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.39 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12221 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.426 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI12222 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12223 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.618 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12224 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.529 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI12225 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.62 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12226 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12227 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12228 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.704 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12229 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI12230 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.597 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12231 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD699 Pranoprofen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.934 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12232 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI12233 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.497 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12234 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.513 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12235 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.834 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12236 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.375 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12237 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.809 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12238 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.459 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI12239 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.582 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12240 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.322 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI12241 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.485 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12242 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.627 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12243 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12244 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.909 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12245 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.608 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12246 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.344 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12247 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.596 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12248 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.54 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12249 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.558 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12250 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.457 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12251 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.628 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12252 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.469 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12253 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12254 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12255 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.749 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12256 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.77 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12257 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.734 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12258 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.766 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12259 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.905 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12260 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.539 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12261 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.504 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12262 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.957 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12263 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.57 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12264 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.895 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12265 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.404 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI12266 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.349 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI12267 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.811 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12268 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.434 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI12269 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12270 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12271 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.57 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12272 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.823 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12273 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.641 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12274 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.415 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12275 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.431 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12276 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.333 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI12277 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.387 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12278 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.474 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12279 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.704 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12280 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12281 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.688 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12282 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.716 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12283 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.34 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12284 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.687 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI12285 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.759 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12286 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.773 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12287 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.633 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12288 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.877 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12289 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.737 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12290 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.699 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12291 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.23 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12292 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.9 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12293 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.742 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12294 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.675 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12295 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.287 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12296 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.602 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12297 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12298 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.304 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12299 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.4 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12300 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.075 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12301 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.163 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12302 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.091 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12303 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.049 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12304 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.485 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12305 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.018 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12306 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.449 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12307 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.025 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12308 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.377 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12309 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.714 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12310 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12311 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.525 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12312 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.985 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12313 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.379 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12314 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.232 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12315 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.198 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12316 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.726 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12317 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD895 Vilazodone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.194 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12318 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.863 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12319 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.667 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI12320 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI12321 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.458 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12322 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.773 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12323 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.084 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12324 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.485 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12325 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.916 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12326 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.495 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI12327 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.475 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12328 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.073 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12329 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.272 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12330 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.27 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12331 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.392 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12332 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.776 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12333 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.231 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12334 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12335 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.913 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12336 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.389 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12337 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.878 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI12338 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.315 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12339 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.262 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12340 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.321 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12341 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.516 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12342 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.852 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12343 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.786 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12344 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.815 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12345 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.797 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12346 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.785 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12347 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD252 Deflazacort Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.926 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12348 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.603 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12349 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.022 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12350 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.84 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12351 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.405 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12352 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.199 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12353 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.744 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12354 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.635 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12355 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.919 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12356 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.957 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12357 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.857 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI12358 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.998 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12359 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.783 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12360 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.331 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12361 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.225 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12362 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.153 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12363 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.791 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12364 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.893 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12365 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.383 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12366 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.409 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12367 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.95 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12368 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.474 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12369 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.096 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12370 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.639 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12371 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.397 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12372 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.783 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12373 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.554 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12374 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.872 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12375 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.353 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12376 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.818 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12377 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.942 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12378 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.097 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12379 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI12380 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.608 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12381 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.541 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12382 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12383 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.061 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12384 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.639 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI12385 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.924 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12386 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.487 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12387 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.841 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12388 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.447 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI12389 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.717 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12390 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.384 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12391 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12392 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.8 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12393 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.062 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12394 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.698 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12395 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12396 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.588 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12397 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI12398 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI12399 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI12400 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12401 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.669 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12402 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.514 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12403 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.642 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12404 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.746 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12405 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.391 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12406 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.817 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12407 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.859 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12408 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.753 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12409 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.948 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12410 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.476 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI12411 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.464 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12412 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.621 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12413 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.632 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12414 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.616 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12415 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.661 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12416 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.532 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12417 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.561 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12418 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12419 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.335 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12420 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.751 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12421 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.394 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12422 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.002 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12423 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.636 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12424 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.581 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12425 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.461 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI12426 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.35 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12427 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.511 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12428 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.326 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI12429 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.362 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI12430 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.45 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI12431 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12432 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.543 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12433 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.418 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12434 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.552 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI12435 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.452 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12436 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.677 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12437 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.849 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12438 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.71 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12439 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI12440 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.682 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12441 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.03 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12442 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.342 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12443 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.806 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12444 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12445 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12446 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.949 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12447 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.962 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12448 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.505 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12449 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12450 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.892 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12451 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.838 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12452 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.598 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI12453 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.178 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12454 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.073 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12455 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.515 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12456 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.735 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12457 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.381 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12458 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.801 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12459 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.054 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12460 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.949 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12461 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.897 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12462 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.898 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12463 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.549 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12464 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.476 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12465 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.901 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12466 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.863 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12467 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.134 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12468 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12469 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.19 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI12470 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.756 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12471 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.091 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12472 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.015 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12473 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.674 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12474 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.202 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12475 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.358 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI12476 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.39 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12477 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12478 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.573 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12479 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.132 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12480 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.995 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12481 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.233 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12482 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.173 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12483 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.672 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12484 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.38 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12485 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.826 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12486 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.316 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12487 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12488 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.901 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12489 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.305 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12490 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.537 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12491 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.273 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12492 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.14 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12493 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.74 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12494 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.875 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI12495 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.369 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12496 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.404 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12497 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.04 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12498 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.159 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12499 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.066 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12500 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.859 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12501 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.981 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12502 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.76 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12503 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.89 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12504 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.799 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12505 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.489 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12506 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.161 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12507 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.91 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12508 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD620 Oorethindrone acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.97 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12509 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.794 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12510 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI12511 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.298 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12512 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.488 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12513 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.93 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12514 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.33 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12515 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.418 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12516 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.144 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12517 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.766 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12518 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.133 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12519 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.491 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12520 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.834 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12521 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.607 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12522 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.56 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12523 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.379 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12524 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.133 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12525 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.876 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12526 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI12527 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.379 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12528 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.033 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12529 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.37 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12530 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.251 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12531 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.435 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12532 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.493 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12533 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.444 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI12534 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.025 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12535 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.586 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12536 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.811 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12537 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.766 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12538 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.382 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12539 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.362 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12540 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.313 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12541 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.428 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12542 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.922 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12543 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.831 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12544 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.629 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12545 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD757 Roxatidine acetate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.419 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12546 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.071 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12547 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.164 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12548 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.959 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI12549 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.427 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12550 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.801 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12551 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.567 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12552 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.715 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12553 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.715 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12554 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.804 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12555 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.483 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12556 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.837 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI12557 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.556 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12558 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.672 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12559 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.664 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12560 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.684 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12561 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.679 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI12562 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.066 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12563 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.333 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12564 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.515 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12565 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.066 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12566 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.664 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12567 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.527 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12568 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.443 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12569 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.612 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12570 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.289 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12571 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.55 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12572 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.027 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI12573 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.566 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12574 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.885 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI12575 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.815 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12576 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.039 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12577 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.853 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI12578 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.933 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12579 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.728 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12580 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.386 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI12581 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.23 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12582 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.706 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12583 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.426 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12584 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.312 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12585 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD725 Racecadotril Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.694 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12586 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.254 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12587 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.717 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12588 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.057 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12589 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.932 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12590 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.366 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12591 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.244 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12592 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.772 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12593 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.939 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12594 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.431 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12595 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.026 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12596 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.799 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI12597 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.139 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12598 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.106 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI12599 Microbes metabolize substances PMDBM2020052 n.a. Anaerostipes sp. PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.652 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI12600 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.671 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12601 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.798 [FDR-adjusted p-Value=0.049] PMID PMID: 31158845 PMDBI12602 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.556 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI12603 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.522 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI12604 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12605 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.923 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12606 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.75 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12607 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.818 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12608 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.556 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12609 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.06 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI12610 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.205 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12611 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.869 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI12612 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.016 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12613 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.877 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12614 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI12615 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.613 [FDR-adjusted p-Value=0.047] PMID PMID: 31158845 PMDBI12616 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.21 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12617 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.515 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI12618 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.262 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12619 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.105 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI12620 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.674 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12621 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.003 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI12622 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.905 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12623 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.878 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI12624 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.903 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12625 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.253 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12626 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.293 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12627 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.344 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12628 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.166 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12629 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.92 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI12630 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.968 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12631 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.756 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12632 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.657 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12633 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.917 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12634 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD617 Olmesartan medoxomil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.731 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12635 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.875 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12636 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.65 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12637 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12638 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.535 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12639 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.821 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12640 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.695 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12641 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.789 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12642 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.348 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI12643 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.559 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12644 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.566 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI12645 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.445 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12646 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.567 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12647 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12648 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.46 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12649 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.514 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12650 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.539 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12651 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.43 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12652 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI12653 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.479 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12654 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.689 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12655 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.726 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12656 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12657 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.795 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12658 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.634 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI12659 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.587 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12660 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.47 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12661 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.536 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12662 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.984 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12663 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.602 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12664 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.635 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12665 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.155 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12666 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.662 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12667 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.442 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12668 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.429 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12669 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.003 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12670 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.932 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI12671 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.669 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12672 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12673 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.614 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12674 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.718 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12675 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.824 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12676 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.383 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12677 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12678 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.448 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12679 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12680 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.123 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12681 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.932 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12682 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.017 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12683 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.064 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12684 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.606 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12685 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.215 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12686 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.37 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12687 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.479 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12688 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.38 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12689 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD366 Fluoxetine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.666 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12690 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.764 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12691 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.178 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12692 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.136 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12693 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.872 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12694 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.888 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI12695 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.961 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12696 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.886 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12697 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.983 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12698 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.213 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12699 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.094 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12700 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.006 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12701 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.715 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12702 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.719 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12703 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.59 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12704 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.471 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12705 Microbes metabolize substances PMDBM2020052 n.a. Anaerostipes sp. PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.21 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12706 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.719 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12707 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.711 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12708 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.4 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI12709 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.977 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12710 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.813 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12711 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.98 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12712 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.047 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12713 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.105 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12714 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.241 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12715 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.52 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12716 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.531 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12717 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.243 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12718 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.089 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12719 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.536 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12720 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.164 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12721 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.581 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12722 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.589 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12723 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.825 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12724 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.806 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12725 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.878 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12726 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.017 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12727 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.08 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12728 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.877 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12729 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.086 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12730 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.323 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12731 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.613 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12732 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.071 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12733 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.578 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12734 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.856 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12735 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.69 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12736 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.729 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12737 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.323 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12738 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.792 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12739 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.153 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12740 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.479 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12741 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.225 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12742 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.878 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12743 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.966 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12744 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.11 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12745 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.19 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12746 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.103 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12747 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.037 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12748 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD658 Phenazopyridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.173 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12749 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.479 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12750 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.222 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12751 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.514 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12752 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.516 [FDR-adjusted p-Value=0.044] PMID PMID: 31158845 PMDBI12753 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.868 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12754 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.937 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12755 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.569 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12756 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.556 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12757 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.907 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12758 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.631 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12759 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.588 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI12760 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.073 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12761 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.508 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12762 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.095 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12763 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.385 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12764 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.858 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12765 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.938 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12766 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.443 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12767 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.168 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12768 Microbes metabolize substances PMDBM2020052 n.a. Anaerostipes sp. PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.237 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12769 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.484 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12770 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.786 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12771 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.982 [FDR-adjusted p-Value=0.033] PMID PMID: 31158845 PMDBI12772 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.999 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12773 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.666 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12774 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.08 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12775 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.639 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12776 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.384 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI12777 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.432 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12778 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.272 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12779 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.037 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12780 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.551 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12781 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.975 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12782 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.045 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12783 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.736 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12784 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.463 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12785 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.258 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12786 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.846 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12787 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.876 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12788 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.669 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12789 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.286 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12790 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.928 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12791 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.836 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12792 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.663 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12793 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.509 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12794 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.279 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12795 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.725 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12796 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.586 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12797 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.322 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12798 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.234 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12799 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.631 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12800 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.224 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12801 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.648 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12802 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.056 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12803 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.351 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12804 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.911 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12805 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.167 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12806 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.405 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12807 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.389 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12808 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD596 Nitrendipine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.722 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12809 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.247 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12810 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.714 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI12811 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.046 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12812 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.7 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12813 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.59 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12814 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.234 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12815 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.08 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12816 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.639 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12817 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.631 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12818 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.502 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12819 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.242 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12820 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.629 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI12821 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.679 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12822 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.826 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12823 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.064 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12824 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.088 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12825 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.113 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12826 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.256 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12827 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI12828 Microbes metabolize substances PMDBM2020052 n.a. Anaerostipes sp. PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.337 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12829 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.522 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12830 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.657 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12831 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.071 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12832 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.478 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12833 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.296 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12834 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.007 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12835 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.693 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12836 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.184 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12837 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.241 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12838 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.182 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12839 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.031 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI12840 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.585 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12841 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.384 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12842 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.184 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12843 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.663 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12844 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.888 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12845 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.605 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12846 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.08 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12847 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.916 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12848 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.857 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12849 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.876 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12850 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.892 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12851 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.749 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12852 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.751 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12853 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.002 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI12854 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.854 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12855 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.072 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12856 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.61 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12857 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.01 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12858 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.927 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12859 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.039 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12860 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.252 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12861 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.303 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12862 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.032 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12863 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.974 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12864 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.435 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI12865 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.844 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12866 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.252 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12867 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.327 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12868 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.522 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12869 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.398 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12870 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.576 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12871 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.641 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12872 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.756 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12873 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.211 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12874 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.21 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI12875 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.326 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12876 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.625 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12877 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.355 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12878 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.221 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12879 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.879 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12880 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.405 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12881 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.161 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI12882 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.51 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12883 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.402 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12884 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.773 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI12885 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.078 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12886 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.639 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12887 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.163 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12888 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.325 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12889 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.75 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12890 Microbes metabolize substances PMDBM2020052 n.a. Anaerostipes sp. PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.885 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12891 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.333 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12892 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.636 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12893 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.896 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI12894 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.977 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12895 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.401 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12896 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.688 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12897 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.251 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12898 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.946 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12899 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.152 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12900 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.03 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12901 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.863 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12902 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.098 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12903 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.082 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12904 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.527 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12905 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.682 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12906 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.753 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12907 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.781 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12908 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.021 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12909 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.284 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12910 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.676 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12911 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.668 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12912 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.134 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12913 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.536 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12914 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.592 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12915 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.624 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12916 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.053 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12917 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.387 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12918 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.609 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12919 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.995 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12920 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.603 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12921 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.448 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12922 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.943 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12923 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.845 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12924 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.338 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI12925 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.026 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12926 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.933 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12927 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.026 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12928 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.31 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12929 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.418 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12930 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.685 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12931 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.839 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12932 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.07 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI12933 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.71 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12934 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.543 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12935 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.994 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12936 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.593 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12937 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.098 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12938 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.438 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12939 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.525 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI12940 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.89 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12941 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.897 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12942 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.917 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12943 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.806 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI12944 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.455 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12945 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.668 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12946 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.736 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12947 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.436 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12948 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.657 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12949 Microbes metabolize substances PMDBM2020052 n.a. Anaerostipes sp. PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.553 [FDR-adjusted p-Value=0.043] PMID PMID: 31158845 PMDBI12950 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.366 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12951 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.364 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12952 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.382 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI12953 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.528 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12954 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.408 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12955 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.623 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12956 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.413 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI12957 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.462 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12958 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.353 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI12959 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.799 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12960 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.044 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI12961 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.3 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI12962 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.446 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12963 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.374 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12964 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.503 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12965 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.456 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12966 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.48 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI12967 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI12968 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.534 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12969 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.877 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12970 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.507 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12971 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.781 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12972 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.517 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12973 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.493 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI12974 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.49 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12975 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.454 [FDR-adjusted p-Value=0.034] PMID PMID: 31158845 PMDBI12976 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.223 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12977 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.579 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12978 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.917 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12979 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.462 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12980 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12981 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.643 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI12982 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.079 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI12983 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI12984 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.675 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI12985 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.289 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12986 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI12987 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.065 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI12988 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.818 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI12989 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.175 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12990 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.693 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI12991 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.665 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12992 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.712 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI12993 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12994 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.584 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12995 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.831 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI12996 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.742 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI12997 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.79 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI12998 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.578 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI12999 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.758 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13000 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.654 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13001 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD563 Mycophenolate mofetil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.662 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13002 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.242 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13003 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.889 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13004 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.012 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI13005 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.164 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13006 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.789 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13007 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.977 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13008 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.865 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI13009 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.348 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13010 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.02 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13011 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.211 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13012 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.826 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI13013 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.958 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13014 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.617 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI13015 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.327 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13016 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.321 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13017 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.717 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13018 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.993 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13019 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.841 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13020 Microbes metabolize substances PMDBM2020052 n.a. Anaerostipes sp. PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.574 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI13021 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.64 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI13022 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.73 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13023 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.714 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI13024 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI13025 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.641 [FDR-adjusted p-Value=0.046] PMID PMID: 31158845 PMDBI13026 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.963 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13027 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.784 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13028 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.699 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI13029 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.016 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13030 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.364 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13031 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.13 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13032 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.272 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI13033 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.081 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI13034 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.023 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13035 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.773 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13036 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.897 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13037 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.911 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI13038 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.097 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13039 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.343 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13040 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.933 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13041 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.361 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13042 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.887 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13043 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.127 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13044 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.731 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI13045 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.789 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13046 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.647 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13047 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.022 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI13048 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.976 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI13049 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.519 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI13050 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.569 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13051 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.921 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13052 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.925 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI13053 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.718 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13054 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.102 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13055 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.548 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13056 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.563 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13057 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.576 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI13058 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.512 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13059 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.707 [FDR-adjusted p-Value=0.05] PMID PMID: 31158845 PMDBI13060 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.699 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13061 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.622 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13062 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.157 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13063 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.198 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13064 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.895 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13065 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.066 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13066 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.099 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13067 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD125 Bromocriptine mesylate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.795 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13068 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.539 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13069 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.594 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13070 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.053 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13071 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.579 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI13072 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.15 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13073 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.246 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13074 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.121 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13075 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.363 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13076 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.878 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13077 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.194 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13078 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.106 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI13079 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.731 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13080 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.636 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI13081 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.508 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI13082 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.532 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13083 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.365 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13084 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.445 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13085 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.004 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13086 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.445 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI13087 Microbes metabolize substances PMDBM2020052 n.a. Anaerostipes sp. PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.862 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13088 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.171 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13089 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.7 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13090 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.543 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI13091 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.38 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13092 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.008 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13093 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.066 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13094 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.342 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13095 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.631 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13096 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.282 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13097 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.099 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13098 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.865 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13099 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.995 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13100 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.119 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13101 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.964 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13102 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.665 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13103 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.65 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13104 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.393 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13105 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.315 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13106 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.548 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13107 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.281 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13108 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.8 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI13109 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.034 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13110 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.254 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13111 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.375 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13112 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.213 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13113 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.255 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13114 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.258 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13115 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.892 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13116 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.842 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13117 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.076 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13118 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.066 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13119 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.762 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13120 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.481 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13121 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.063 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13122 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.104 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13123 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.135 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13124 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.006 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13125 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.42 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13126 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.588 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13127 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.58 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13128 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.77 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13129 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.83 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13130 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.775 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13131 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.56 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13132 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.334 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13133 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.788 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13134 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.839 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13135 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.877 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13136 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.094 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13137 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.667 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13138 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.29 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13139 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.686 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13140 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.012 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13141 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.172 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13142 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.539 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI13143 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.805 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13144 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.544 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13145 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.099 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13146 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.901 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13147 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.527 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13148 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.834 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13149 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.318 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI13150 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.742 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13151 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.254 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI13152 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.623 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13153 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.624 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13154 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.772 [FDR-adjusted p-Value=0.028] PMID PMID: 31158845 PMDBI13155 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.139 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13156 Microbes metabolize substances PMDBM2020052 n.a. Anaerostipes sp. PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.848 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13157 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.913 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13158 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.237 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13159 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.912 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13160 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.35 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13161 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.388 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13162 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.995 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13163 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.165 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13164 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.416 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13165 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.826 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13166 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.035 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13167 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.009 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13168 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.493 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13169 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.68 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI13170 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.212 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13171 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.48 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13172 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.371 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13173 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.315 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13174 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.112 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13175 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.335 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13176 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.81 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI13177 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.617 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13178 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.506 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13179 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.442 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13180 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.285 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13181 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.181 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13182 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.454 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13183 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.857 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13184 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.594 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13185 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.994 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI13186 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.247 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13187 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.019 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13188 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.43 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13189 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.818 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13190 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.465 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13191 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.732 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13192 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.232 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13193 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.789 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13194 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.758 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI13195 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.135 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13196 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.834 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13197 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.187 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13198 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.772 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13199 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.917 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13200 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.995 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13201 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.67 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13202 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.352 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13203 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.019 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13204 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.655 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13205 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD246 Danazol Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.937 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13206 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.126 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13207 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.763 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13208 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.59 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13209 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.097 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13210 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.675 [FDR-adjusted p-Value=0.037] PMID PMID: 31158845 PMDBI13211 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.823 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI13212 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.724 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI13213 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.867 [FDR-adjusted p-Value=0.022] PMID PMID: 31158845 PMDBI13214 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.32 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13215 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.068 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13216 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.1 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13217 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.523 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13218 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.841 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13219 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.955 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI13220 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.708 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI13221 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.407 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13222 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.364 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13223 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.848 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13224 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.248 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13225 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.84 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13226 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.892 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13227 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.048 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13228 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.744 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13229 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.042 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13230 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.687 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13231 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.783 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13232 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.833 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI13233 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.968 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13234 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.611 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI13235 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.32 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13236 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.227 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13237 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.44 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13238 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.429 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13239 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.804 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13240 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.024 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13241 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.912 [FDR-adjusted p-Value=0.026] PMID PMID: 31158845 PMDBI13242 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.086 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI13243 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.877 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI13244 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.491 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13245 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.817 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13246 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.831 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13247 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.717 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13248 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.158 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13249 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.367 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13250 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.126 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13251 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.638 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13252 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.433 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13253 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.12 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13254 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.345 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13255 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.595 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13256 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.46 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13257 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.636 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13258 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.291 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13259 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.178 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13260 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.41 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13261 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.888 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13262 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.138 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13263 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.314 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13264 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.67 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13265 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.406 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13266 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.404 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13267 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.57 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13268 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.716 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI13269 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.131 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13270 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.916 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13271 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.244 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13272 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.117 [FDR-adjusted p-Value=0.048] PMID PMID: 31158845 PMDBI13273 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.334 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13274 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.709 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13275 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.928 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13276 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.363 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13277 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.109 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13278 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.531 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13279 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.103 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13280 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.76 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13281 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.572 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13282 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.686 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13283 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.301 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13284 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.649 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13285 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.671 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13286 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.8 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI13287 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.733 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13288 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.947 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI13289 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.983 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13290 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.5 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13291 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.028 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13292 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.156 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13293 Microbes metabolize substances PMDBM2020052 n.a. Anaerostipes sp. PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.414 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13294 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.609 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13295 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.062 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13296 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.408 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13297 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.032 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13298 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.373 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13299 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.668 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13300 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.97 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13301 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.147 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13302 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.801 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13303 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.683 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13304 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.671 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13305 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.378 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13306 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.635 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13307 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.59 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13308 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.38 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13309 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.096 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13310 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.521 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13311 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.22 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13312 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.556 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13313 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.53 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13314 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.423 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13315 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.089 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13316 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.893 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13317 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.92 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13318 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.898 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13319 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.645 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13320 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.407 [FDR-adjusted p-Value=0.042] PMID PMID: 31158845 PMDBI13321 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.183 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13322 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.762 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13323 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.166 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13324 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.863 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13325 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.529 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13326 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.676 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13327 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.927 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13328 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.609 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI13329 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.216 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13330 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.259 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13331 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.117 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13332 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.366 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13333 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.709 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13334 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.738 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13335 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.065 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13336 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.642 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13337 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.583 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13338 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.576 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13339 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.617 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13340 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.831 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13341 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.52 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI13342 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.595 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13343 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.215 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13344 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.392 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13345 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.268 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13346 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.246 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13347 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD261 Diacetamate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.28 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13348 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.156 [FDR-adjusted p-Value=0.038] PMID PMID: 31158845 PMDBI13349 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.966 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13350 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.873 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13351 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.453 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13352 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.013 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13353 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.812 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI13354 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.563 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13355 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.397 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13356 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.517 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13357 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.289 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13358 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.345 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13359 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.876 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13360 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.183 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI13361 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.458 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13362 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.355 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13363 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.371 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13364 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.558 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13365 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.065 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13366 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.334 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13367 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.464 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13368 Microbes metabolize substances PMDBM2020052 n.a. Anaerostipes sp. PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.374 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13369 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.584 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13370 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.429 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13371 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.412 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13372 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.3 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13373 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.363 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13374 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.442 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13375 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.385 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13376 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.391 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13377 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.379 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13378 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.379 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13379 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.844 [FDR-adjusted p-Value=0.02] PMID PMID: 31158845 PMDBI13380 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.526 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13381 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.546 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13382 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.901 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13383 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.173 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13384 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.316 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13385 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.874 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13386 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.784 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13387 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.195 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13388 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.467 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13389 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.27 [FDR-adjusted p-Value=0.018] PMID PMID: 31158845 PMDBI13390 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.311 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13391 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.146 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI13392 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.006 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13393 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.571 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13394 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.505 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13395 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.849 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13396 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.314 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13397 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.645 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13398 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.733 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13399 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.445 [FDR-adjusted p-Value=0.025] PMID PMID: 31158845 PMDBI13400 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.543 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13401 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.405 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13402 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.966 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13403 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.581 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13404 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.699 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13405 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.776 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13406 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.296 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13407 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.344 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13408 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.443 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13409 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.416 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13410 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.173 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13411 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.615 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13412 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.786 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13413 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.363 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13414 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.249 [FDR-adjusted p-Value=0.029] PMID PMID: 31158845 PMDBI13415 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.861 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13416 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.686 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13417 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.893 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13418 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.546 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13419 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.601 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13420 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.731 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13421 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.281 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13422 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.742 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13423 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.148 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13424 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.706 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13425 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.802 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13426 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.855 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13427 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.448 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13428 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.162 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13429 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.005 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13430 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.718 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13431 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.153 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13432 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.851 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13433 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.201 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13434 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.659 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13435 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.61 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13436 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.892 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13437 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.492 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13438 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.986 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13439 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.578 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13440 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.773 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13441 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.513 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13442 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.681 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13443 Microbes metabolize substances PMDBM2020052 n.a. Anaerostipes sp. PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.667 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13444 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.467 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13445 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.362 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13446 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.316 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13447 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.65 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13448 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.463 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13449 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.2 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13450 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.427 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13451 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.436 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13452 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.415 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13453 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.481 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13454 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.097 [FDR-adjusted p-Value=0.039] PMID PMID: 31158845 PMDBI13455 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.775 [FDR-adjusted p-Value=0.036] PMID PMID: 31158845 PMDBI13456 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.071 [FDR-adjusted p-Value=0.023] PMID PMID: 31158845 PMDBI13457 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.503 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13458 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.67 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13459 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.396 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13460 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.764 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13461 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.628 [FDR-adjusted p-Value=0.035] PMID PMID: 31158845 PMDBI13462 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.499 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13463 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.014 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13464 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.563 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13465 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.246 [FDR-adjusted p-Value=0.041] PMID PMID: 31158845 PMDBI13466 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.067 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13467 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.917 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI13468 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.804 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13469 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.496 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13470 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.786 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13471 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.449 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13472 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.045 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13473 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.212 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13474 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.419 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13475 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.364 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13476 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.679 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13477 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.287 [FDR-adjusted p-Value=0.045] PMID PMID: 31158845 PMDBI13478 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.319 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13479 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.391 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13480 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.987 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13481 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.875 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13482 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.814 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13483 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.65 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13484 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.944 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13485 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.527 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13486 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.421 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13487 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.418 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13488 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.794 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13489 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.716 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13490 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.222 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13491 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.207 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13492 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.66 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13493 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.531 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13494 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.252 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13495 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.654 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13496 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.87 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13497 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.612 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13498 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.102 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13499 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.027 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13500 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.233 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13501 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.813 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13502 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.878 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13503 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.22 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13504 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.378 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13505 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.752 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13506 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.091 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13507 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.989 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13508 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-12.105 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13509 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.313 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13510 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.466 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13511 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.173 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13512 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.918 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13513 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.431 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13514 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.122 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13515 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.718 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13516 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.5 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13517 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.186 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13518 Microbes metabolize substances PMDBM2020052 n.a. Anaerostipes sp. PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.204 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13519 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.255 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13520 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.885 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13521 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.918 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13522 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.422 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13523 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.311 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13524 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.728 [FDR-adjusted p-Value=0.031] PMID PMID: 31158845 PMDBI13525 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.452 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13526 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.686 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13527 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.712 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13528 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.324 [FDR-adjusted p-Value=0.032] PMID PMID: 31158845 PMDBI13529 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.654 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13530 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.456 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13531 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.716 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13532 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.49 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13533 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.584 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13534 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.081 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13535 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.328 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13536 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.122 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13537 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.549 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13538 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.863 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13539 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.547 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13540 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.23 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13541 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.41 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13542 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.369 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13543 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.192 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13544 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.472 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13545 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.201 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13546 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.266 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13547 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.587 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13548 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.506 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13549 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.678 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13550 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.639 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13551 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.854 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13552 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.863 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13553 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.33 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13554 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.0 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13555 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.708 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13556 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.324 [FDR-adjusted p-Value=0.027] PMID PMID: 31158845 PMDBI13557 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.482 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13558 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.339 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13559 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.438 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13560 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.176 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13561 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.146 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13562 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.462 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13563 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.412 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13564 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.394 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13565 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.531 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13566 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.5 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13567 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.735 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13568 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.213 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13569 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.349 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13570 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.329 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13571 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.467 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13572 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.69 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13573 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-11.127 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13574 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.295 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13575 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.788 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13576 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.796 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13577 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.658 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13578 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.571 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13579 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.068 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13580 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.955 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13581 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.441 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13582 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.52 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13583 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.869 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13584 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.412 [FDR-adjusted p-Value=0.015] PMID PMID: 31158845 PMDBI13585 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.969 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13586 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.142 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13587 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.785 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13588 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.529 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13589 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.376 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13590 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.657 [FDR-adjusted p-Value=0.019] PMID PMID: 31158845 PMDBI13591 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.488 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13592 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.949 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13593 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.2 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13594 Microbes metabolize substances PMDBM2020052 n.a. Anaerostipes sp. PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.127 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13595 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.673 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13596 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.432 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13597 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.41 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13598 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.326 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13599 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.147 [FDR-adjusted p-Value=0.011] PMID PMID: 31158845 PMDBI13600 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.965 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13601 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.968 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13602 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.823 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13603 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.304 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13604 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.47 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13605 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.907 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13606 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.297 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13607 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.973 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13608 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.704 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13609 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.711 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13610 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.726 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13611 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.622 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13612 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.618 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13613 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.254 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13614 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.301 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13615 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.758 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13616 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.454 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13617 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.289 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13618 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.754 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13619 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.645 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13620 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.417 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13621 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.376 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13622 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.877 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13623 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.918 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13624 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.905 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13625 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.588 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13626 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.235 [FDR-adjusted p-Value=0.014] PMID PMID: 31158845 PMDBI13627 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.155 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13628 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.954 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13629 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.768 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13630 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.734 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13631 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.71 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13632 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.074 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13633 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.528 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13634 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.385 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13635 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.445 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13636 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.393 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13637 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.216 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13638 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.383 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13639 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.233 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13640 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.234 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13641 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.345 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13642 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.025 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13643 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.014 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13644 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.95 [FDR-adjusted p-Value=0.009] PMID PMID: 31158845 PMDBI13645 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.492 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13646 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.196 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13647 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.862 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13648 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.808 [FDR-adjusted p-Value=0.013] PMID PMID: 31158845 PMDBI13649 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.753 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13650 Microbes metabolize substances PMDBM34 n.a. Bacteroides caccae ATCC43185 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.773 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13651 Microbes metabolize substances PMDBM211 n.a. Escherichia coli BW25113 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.945 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13652 Microbes metabolize substances PMDBM154 n.a. Clostridium ramosum DSM1402 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.55 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13653 Microbes metabolize substances PMDBM89 n.a. Bifidobacterium adolescentis ATCC 15703 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.373 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13654 Microbes metabolize substances PMDBM40 n.a. Bacteroides eggerthii DSM20697 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.959 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13655 Microbes metabolize substances PMDBM114 n.a. Blautia hansenii DSM20583 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.119 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13656 Microbes metabolize substances PMDBM2020051 n.a. Clostridium sp. PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.079 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13657 Microbes metabolize substances PMDBM364 n.a. Ruminococcus gnavus ATCC29149 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.484 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13658 Microbes metabolize substances PMDBM38 n.a. Bacteroides dorei DSM17855 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.711 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13659 Microbes metabolize substances PMDBM35 n.a. Bacteroides cellulosilyticus DSM14838 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.503 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13660 Microbes metabolize substances PMDBM76 n.a. Bacteroides vulgatus ATCC8482 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-10.705 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13661 Microbes metabolize substances PMDBM168 n.a. Collinsella aerofaciens ATCC25986 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.12 [FDR-adjusted p-Value=0.016] PMID PMID: 31158845 PMDBI13662 Microbes metabolize substances PMDBM150 n.a. Clostridium hathewayi DSM13479 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.579 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13663 Microbes metabolize substances PMDBM16 n.a. Anaerococcus hydrogenalis DSM7454 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.747 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13664 Microbes metabolize substances PMDBM158 n.a. Clostridium scindens ATCC35704 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.42 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13665 Microbes metabolize substances PMDBM21 n.a. Anaerotruncus colihominis DSM17241 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.17 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13666 Microbes metabolize substances PMDBM144 n.a. Clostridium bolteae ATCCBAA-613 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.643 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13667 Microbes metabolize substances PMDBM164 n.a. Clostridium symbiosum ATCC14940 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.399 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13668 Microbes metabolize substances PMDBM41 n.a. Bacteroides finegoldii DSM17565 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.707 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13669 Microbes metabolize substances PMDBM312 n.a. Parabacteroides johnsonii DSM18315 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.462 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13670 Microbes metabolize substances PMDBM2020052 n.a. Anaerostipes sp. PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.543 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13671 Microbes metabolize substances PMDBM230 n.a. Eubacterium ventriosum ATCC27560 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-6.097 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13672 Microbes metabolize substances PMDBM366 n.a. Ruminococcus lactaris ATCC29176 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.181 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13673 Microbes metabolize substances PMDBM339 n.a. Proteus penneri ATCC35198 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-5.443 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13674 Microbes metabolize substances PMDBM185 n.a. Edwardsiella tarda ATCC23685 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.542 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13675 Microbes metabolize substances PMDBM184 n.a. Dorea formicigenerans ATCC27755 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.027 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13676 Microbes metabolize substances PMDBM192 n.a. Enterobacter cancerogenus ATCC35316 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-7.617 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13677 Microbes metabolize substances PMDBM342 n.a. Providencia stuartii ATCC25827 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-8.09 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13678 Microbes metabolize substances PMDBM161 n.a. Clostridium spiroforme DSM1552 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-9.853 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13679 Microbes metabolize substances PMDBM54 n.a. Bacteroides intestinalis DSM17393 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-3.116 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13680 Microbes metabolize substances PMDBM310 n.a. Parabacteroides distasonis ATCC8503 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.99 [FDR-adjusted p-Value=0.012] PMID PMID: 31158845 PMDBI13681 Microbes metabolize substances PMDBM59 n.a. Bacteroides pectinophilus ATCC43243 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.76 [FDR-adjusted p-Value=0.03] PMID PMID: 31158845 PMDBI13682 Microbes metabolize substances PMDBM327 n.a. Pretovella copri DSM18205 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.312 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13683 Microbes metabolize substances PMDBM142 n.a. Clostridium asparagiforme DSM15981 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.948 [FDR-adjusted p-Value=0.017] PMID PMID: 31158845 PMDBI13684 Microbes metabolize substances PMDBM96 n.a. Bifidobacterium breve DSM20213 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-4.484 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13685 Microbes metabolize substances PMDBM172 n.a. Coprococcus comes ATCC27758 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.892 [FDR-adjusted p-Value=0.021] PMID PMID: 31158845 PMDBI13686 Microbes metabolize substances PMDBM220 n.a. Eubacterium hallii DSM3353 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.732 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13687 Microbes metabolize substances PMDBM104 n.a. Bifidobacterium longum subsp. Infantis CCUG52486 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.468 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13688 Microbes metabolize substances PMDBM370 n.a. Ruminococcus torques ATCC27756 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.958 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13689 Microbes metabolize substances PMDBM49 n.a. Bacteroides fragilis NCTC 9343 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.307 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13690 Microbes metabolize substances PMDBM79 n.a. Bacteroides xylanisolvens DSM18836 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.779 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13691 Microbes metabolize substances PMDBM281 n.a. Lactobacillus reuteri CF48-3A BEI HM-102 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.879 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13692 Microbes metabolize substances PMDBM74 n.a. Bacteroides uniformis ATCC8492 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.232 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13693 Microbes metabolize substances PMDBM66 n.a. Bacteroides stercoris ATCC43183 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.417 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13694 Microbes metabolize substances PMDBM2020036 n.a. Bifidobacterium ruminatum PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.706 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13695 Microbes metabolize substances PMDBM8 n.a. Akkermansia muciniphila ATCC BAA-835 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.859 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13696 Microbes metabolize substances PMDBM340 n.a. Providencia alcalifaciens DSM30120 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.112 [FDR-adjusted p-Value=0.04] PMID PMID: 31158845 PMDBI13697 Microbes metabolize substances PMDBM341 n.a. Providencia rettgeri DSM1131 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.788 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13698 Microbes metabolize substances PMDBM169 n.a. Collinsella intestinalis DSM13280 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.406 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13699 Microbes metabolize substances PMDBM115 n.a. Blautia luti DSM14534 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.642 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13700 Microbes metabolize substances PMDBM356 n.a. Roseburia intestinalis L1-82 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.147 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13701 Microbes metabolize substances PMDBM304 n.a. Odoribacter splanchnius PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.449 [FDR-adjusted p-Value=0.002] PMID PMID: 31158845 PMDBI13702 Microbes metabolize substances PMDBM58 n.a. Bacteroides ovatus ATCC8483 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.952 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13703 Microbes metabolize substances PMDBM314 n.a. Parabacteroides merdae ATCC43184 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.709 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13704 Microbes metabolize substances PMDBM36 n.a. Bacteroides coprophilus DSM18228 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.73 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13705 Microbes metabolize substances PMDBM77 n.a. Bacteroides WH2 WH2 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.928 [FDR-adjusted p-Value=0.006] PMID PMID: 31158845 PMDBI13706 Microbes metabolize substances PMDBM225 n.a. Eubacterium rectale ATCC33656 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.421 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13707 Microbes metabolize substances PMDBM395 n.a. Subdoligranulum variabile DSM15176 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.337 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13708 Microbes metabolize substances PMDBM163 n.a. Clostridium sporogenes ATCC15579 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.252 [FDR-adjusted p-Value=0.01] PMID PMID: 31158845 PMDBI13709 Microbes metabolize substances PMDBM200 n.a. Enterococcus faecalis V583 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.065 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13710 Microbes metabolize substances PMDBM119 n.a. Bryantia formatexigens DSM 14469 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.043 [FDR-adjusted p-Value=0.008] PMID PMID: 31158845 PMDBI13711 Microbes metabolize substances PMDBM10 n.a. Alistipes indistinctus DSM 22520 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.689 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13712 Microbes metabolize substances PMDBM218 n.a. Eubacterium biforme DSM3989 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.387 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13713 Microbes metabolize substances PMDBM149 n.a. Clostridium difficile 120 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.87 [FDR-adjusted p-Value=0.007] PMID PMID: 31158845 PMDBI13714 Microbes metabolize substances PMDBM71 n.a. Bacteroides thetaiotaomicron VPI-5482 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.729 [FDR-adjusted p-Value=0.005] PMID PMID: 31158845 PMDBI13715 Microbes metabolize substances PMDBM69 n.a. Bacteroides thetaiotaomicron 3731 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.835 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13716 Microbes metabolize substances PMDBM70 n.a. Bacteroides thetaiotaomicron 7330 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.624 [FDR-adjusted p-Value=0.004] PMID PMID: 31158845 PMDBI13717 Microbes metabolize substances PMDBM43 n.a. Bacteroides fragilis 3397 T10 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.695 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13718 Microbes metabolize substances PMDBM374 n.a. Salmonella typhimurium LT2 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.086 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13719 Microbes metabolize substances PMDBM187 n.a. Eggerthella lenta ATCC25559 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.188 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13720 Microbes metabolize substances PMDBM410 n.a. Victivallis vadensis ATCC BAA-548 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-0.887 [FDR-adjusted p-Value=0.024] PMID PMID: 31158845 PMDBI13721 Microbes metabolize substances PMDBM52 n.a. Bacteroides fragilis T(B)9 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.069 [FDR-adjusted p-Value=0.001] PMID PMID: 31158845 PMDBI13722 Microbes metabolize substances PMDBM45 n.a. Bacteroides fragilis DS-208 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.966 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13723 Microbes metabolize substances PMDBM47 n.a. Bacteroides fragilis HMW610 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.267 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13724 Microbes metabolize substances PMDBM48 n.a. Bacteroides fragilis HMW615 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-1.621 [FDR-adjusted p-Value=0.003] PMID PMID: 31158845 PMDBI13725 Microbes metabolize substances PMDBM44 n.a. Bacteroides fragilis ATCC43859 PMDBD639 Pantoprazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Metabolism significantly decreased the drug concentration by: log2(fold change)=-2.158 [FDR-adjusted p-Value=0.0] PMID PMID: 31158845 PMDBI13726 Microbes metabolize substances PMDBM2020058 n.a. Gordonibacter urolithinfaciens sp. nov PMDBD645 Pedunculagin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Ellagic acid; urolithin A, B, C and D" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.foodres.2011.04.027; PMID: 24744017" PMDBI13727 Microbes metabolize substances PMDBM130 n.a. Chaetomium spp. PMDBD95 Baicalin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "4é–?5,6,7-tetrahydroxyflavone; 5,7-dihydroxy-6-methoxxyflavone" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. DOI "; DOI: 10.1016/j.molcatb.2007.08.009" PMDBI13729 Microbes metabolize substances PMDBM51 n.a. Bacteroides fragilis subspp. Thetaotus PMDBD780 Shikonin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Anhydroalkannin; deoxyshikonin; cycloshikonin; metaboshikonin I; metaboshikonin II; shikometabolins A; B, C, D and E" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. DOI "; DOI: 10.1016/S0040-4020(01)81108-X" PMDBI13735 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD644 Pectin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Nogalacturonic acid; SCFAs" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 10742206 PMDBI13736 Microbes metabolize substances PMDBM229 n.a. Eubacterium spp. SDG-2 PMDBD773 Secoisolariciresinol diglucoside Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "(-)-secoisolariciresinol; 3-demethyl-(-)-secoisolariciresinol; 2-(3-hydroxybenzyl)-3-(4-hydroxy-3-methoxybenzyl)butane-1; 4-diol; didemethylsecoisolariciresinol" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11086885 PMDBI13737 Microbes metabolize substances PMDBM320 n.a. Peptostreptococcus spp. SDG-1 PMDBD773 Secoisolariciresinol diglucoside Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "(-)-secoisolariciresinol; 3-demethyl-(-)-secoisolariciresinol; 2-(3-hydroxybenzyl)-3-(4-hydroxy-3-methoxybenzyl)butane-1; 4-diol; didemethylsecoisolariciresinol" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11086885 PMDBI13738 Microbes metabolize substances PMDBM229 n.a. Eubacterium spp. SDG-2 PMDBD136 Caffeic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Dihydrocaffeic acid; m-hydroxyphenylpropionic acid" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11767089 PMDBI13739 Microbes metabolize substances PMDBM63 n.a. Bacteroides spp. PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "20(S)-ginsenoside Rh2; 20(S)-protopanaxadiol; 20(R)-ginsenoside Rh2; 20(R)-protopanaxadiol" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11824558 PMDBI13740 Microbes metabolize substances PMDBM109 n.a. Bifidobacterium spp. PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "20(S)-ginsenoside Rh2; 20(S)-protopanaxadiol; 20(R)-ginsenoside Rh2; 20(R)-protopanaxadiol" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11824558 PMDBI13741 Microbes metabolize substances PMDBM228 n.a. Eubacterium spp. PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "20(S)-ginsenoside Rh2; 20(S)-protopanaxadiol; 20(R)-ginsenoside Rh2; 20(R)-protopanaxadiol" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11824558 PMDBI13742 Microbes metabolize substances PMDBM2020021 1492 Clostridium butyricum PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Isophorbol; deoxyphorbol; 4ç?9æµ?20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4ç?9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4ç?9a,20-trihydroxy-14(13é–?2)-abeo12aH-1,6-tigliadiene-3,13-dione" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13743 Microbes metabolize substances PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Isophorbol; deoxyphorbol; 4ç?9æµ?20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4ç?9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4ç?9a,20-trihydroxy-14(13é–?2)-abeo12aH-1,6-tigliadiene-3,13-dione" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13744 Microbes metabolize substances PMDBM51 n.a. Bacteroides fragilis subspp. Thetaotus PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Isophorbol; deoxyphorbol; 4ç?9æµ?20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4ç?9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4ç?9a,20-trihydroxy-14(13é–?2)-abeo12aH-1,6-tigliadiene-3,13-dione" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13745 Microbes metabolize substances PMDBM2020200 n.a. Clostridium innocuum ES 24-06 PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Isophorbol; deoxyphorbol; 4ç?9æµ?20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4ç?9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4ç?9a,20-trihydroxy-14(13é–?2)-abeo12aH-1,6-tigliadiene-3,13-dione" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13746 Microbes metabolize substances PMDBM2020225 n.a. Fusobacterium nucleatum G-470 PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Isophorbol; deoxyphorbol; 4ç?9æµ?20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4ç?9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4ç?9a,20-trihydroxy-14(13é–?2)-abeo12aH-1,6-tigliadiene-3,13-dione" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13747 Microbes metabolize substances PMDBM2020234 n.a. Peptostreptococcus anaerobius 0240 PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Isophorbol; deoxyphorbol; 4ç?9æµ?20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4ç?9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4ç?9a,20-trihydroxy-14(13é–?2)-abeo12aH-1,6-tigliadiene-3,13-dione" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13748 Microbes metabolize substances PMDBM319 n.a. Peptostreptococcus intermedius EBF 77/25 PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Isophorbol; deoxyphorbol; 4ç?9æµ?20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4ç?9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4ç?9a,20-trihydroxy-14(13é–?2)-abeo12aH-1,6-tigliadiene-3,13-dione" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13749 Microbes metabolize substances PMDBM338 n.a. Proteus mirabillis S2 PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Isophorbol; deoxyphorbol; 4ç?9æµ?20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4ç?9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4ç?9a,20-trihydroxy-14(13é–?2)-abeo12aH-1,6-tigliadiene-3,13-dione" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13750 Microbes metabolize substances PMDBM368 n.a. Ruminococcus spp. P01-3 PMDBD665 Phorbol Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Isophorbol; deoxyphorbol; 4ç?9æµ?20-trihydroxy-13,15-seco-1,6,15-tigliatriene-3,13-dione; 4ç?9a,20-trihydroxy-15,16,17-trinor-1,6-tigliadiene-3,13-dione; 4ç?9a,20-trihydroxy-14(13é–?2)-abeo12aH-1,6-tigliadiene-3,13-dione" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 11848202 PMDBI13751 Microbes metabolize substances PMDBM2020041 831 Butyrivibrio fibrisolvens PMDBD485 Linoleic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Rumenic acid (RA; cis-9, trans-11-18:2), trans-9, trans-11-18:2, and trans-10, cis-12-18:2" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 17644775 PMDBI13752 Microbes metabolize substances PMDBM2020042 43305 Butyrivibrio proteoclasticus PMDBD485 Linoleic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Rumenic acid (RA; cis-9, trans-11-18:2), trans-9, trans-11-18:2, and trans-10, cis-12-18:2" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 17644775 PMDBI13755 Microbes metabolize substances PMDBM2020262 n.a. Bacteroides intestinalis AM-1 PMDBD177 Chenodeoxycholic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 7-oxo-lithocholic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 19243441 PMDBI13756 Microbes metabolize substances PMDBM2020262 n.a. Bacteroides intestinalis AM-1 PMDBD188 Cholic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. 7-oxo-deoxycholic acid n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 19243441 PMDBI13757 Microbes metabolize substances PMDBM2020053 n.a. Eggerthella sp. Julong732 PMDBD277 Dihydrodaidzein Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. (3S)-equol n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 19304836 PMDBI13759 Microbes metabolize substances PMDBM2020008 n.a. Bacteroides fragilis PMDBD385 Geniposide Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Genipin n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. n.a. PMID PMID: 22553067 PMDBI13760 Microbes metabolize substances PMDBM2020193 n.a. Bifidobacterium longum HY8001 PMDBD385 Geniposide Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Genipin n.a. n.a. Increase Toxicity n.a. n.a. n.a. n.a. n.a. PMID PMID: 22553067 PMDBI13761 Microbes metabolize substances PMDBM193 550 Enterobacter cloacae PMDBD107 Berberine Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Dihydroberberine n.a. n.a. Increase Bioavailability n.a. n.a. n.a. n.a. n.a. PMID PMID: 26174047 PMDBI13762 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD107 Berberine Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Dihydroberberine n.a. n.a. Increase Bioavailability n.a. n.a. n.a. n.a. n.a. PMID PMID: 26174047 PMDBI13763 Microbes metabolize substances PMDBM2020177 1280 Staphylococcus aureus PMDBD107 Berberine Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Dihydroberberine n.a. n.a. Increase Bioavailability n.a. n.a. n.a. n.a. n.a. PMID PMID: 26174047 PMDBI13764 Microbes metabolize substances PMDBM2020032 n.a. Enterococcus faecalis PMDBD107 Berberine Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Dihydroberberine n.a. n.a. Increase Bioavailability n.a. n.a. n.a. n.a. n.a. PMID PMID: 26174047 PMDBI13765 Microbes metabolize substances PMDBM2020033 n.a. Enterococcus faecium PMDBD107 Berberine Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. Dihydroberberine n.a. n.a. Increase Bioavailability n.a. n.a. n.a. n.a. n.a. PMID PMID: 26174047 PMDBI13766 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13767 Microbes metabolize substances PMDBM2020193 n.a. Bifidobacterium longum H-1 PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13768 Microbes metabolize substances PMDBM2020013 n.a. Bifidobacterium breve K-110 PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13769 Microbes metabolize substances PMDBM99 n.a. Bifidobacterium K-506 PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13770 Microbes metabolize substances PMDBM2020056 n.a. Eubacterium A-44 PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13771 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13772 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD389 Ginsenoside Rb1 "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13773 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD390 Ginsenoside Rb2 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13774 Microbes metabolize substances PMDBM2020193 n.a. Bifidobacterium longum H-1 PMDBD390 Ginsenoside Rb2 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13775 Microbes metabolize substances PMDBM2020013 n.a. Bifidobacterium breve K-110 PMDBD390 Ginsenoside Rb2 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13776 Microbes metabolize substances PMDBM99 n.a. Bifidobacterium K-506 PMDBD390 Ginsenoside Rb2 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13777 Microbes metabolize substances PMDBM2020056 n.a. Eubacterium A-44 PMDBD390 Ginsenoside Rb2 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13778 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD390 Ginsenoside Rb2 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13779 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD390 Ginsenoside Rb2 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13780 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD391 Ginsenoside Rc Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13781 Microbes metabolize substances PMDBM2020193 n.a. Bifidobacterium longum H-1 PMDBD391 Ginsenoside Rc Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13782 Microbes metabolize substances PMDBM2020013 n.a. Bifidobacterium breve K-110 PMDBD391 Ginsenoside Rc Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13783 Microbes metabolize substances PMDBM99 n.a. Bifidobacterium K-506 PMDBD391 Ginsenoside Rc Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13784 Microbes metabolize substances PMDBM2020056 n.a. Eubacterium A-44 PMDBD391 Ginsenoside Rc Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13785 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD391 Ginsenoside Rc Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13786 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD391 Ginsenoside Rc Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside compound K n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13787 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD392 Ginsenoside Re Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "protopanaxatriol; ginsenoside F1; ginsenoside Rh1" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13788 Microbes metabolize substances PMDBM2020083 n.a. Bacteroides stercoris HJ-15 PMDBD392 Ginsenoside Re Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "protopanaxatriol; ginsenoside F1; ginsenoside Rh1" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13789 Microbes metabolize substances PMDBM2020056 n.a. Eubacterium A-44 PMDBD392 Ginsenoside Re Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "protopanaxatriol; ginsenoside F1; ginsenoside Rh1" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13790 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD392 Ginsenoside Re Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "protopanaxatriol; ginsenoside F1; ginsenoside Rh1" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13791 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD393 Ginsenoside Rf Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "protopanaxatriol; ginsenoside F1; ginsenoside Rh1" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13792 Microbes metabolize substances PMDBM2020083 n.a. Bacteroides stercoris HJ-15 PMDBD393 Ginsenoside Rf Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "protopanaxatriol; ginsenoside F1; ginsenoside Rh1" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13793 Microbes metabolize substances PMDBM2020056 n.a. Eubacterium A-44 PMDBD393 Ginsenoside Rf Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "protopanaxatriol; ginsenoside F1; ginsenoside Rh1" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13794 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD393 Ginsenoside Rf Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "protopanaxatriol; ginsenoside F1; ginsenoside Rh1" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13795 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD394 Ginsenoside Rg1 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "protopanaxatriol; ginsenoside F1; ginsenoside Rh1" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13796 Microbes metabolize substances PMDBM2020083 n.a. Bacteroides stercoris HJ-15 PMDBD394 Ginsenoside Rg1 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "protopanaxatriol; ginsenoside F1; ginsenoside Rh1" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13797 Microbes metabolize substances PMDBM2020056 n.a. Eubacterium A-44 PMDBD394 Ginsenoside Rg1 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "protopanaxatriol; ginsenoside F1; ginsenoside Rh1" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13798 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD394 Ginsenoside Rg1 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "protopanaxatriol; ginsenoside F1; ginsenoside Rh1" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13799 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13800 Microbes metabolize substances PMDBM2020193 n.a. Bifidobacterium longum H-1 PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13801 Microbes metabolize substances PMDBM2020013 n.a. Bifidobacterium breve K-110 PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13802 Microbes metabolize substances PMDBM99 n.a. Bifidobacterium K-506 PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13803 Microbes metabolize substances PMDBM2020056 n.a. Eubacterium A-44 PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13804 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13805 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD395 Ginsenoside Rg3 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh2 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13806 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD396 Ginsenoside Rg5 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13807 Microbes metabolize substances PMDBM2020193 n.a. Bifidobacterium longum H-1 PMDBD396 Ginsenoside Rg5 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13808 Microbes metabolize substances PMDBM2020013 n.a. Bifidobacterium breve K-110 PMDBD396 Ginsenoside Rg5 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13809 Microbes metabolize substances PMDBM99 n.a. Bifidobacterium K-506 PMDBD396 Ginsenoside Rg5 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13810 Microbes metabolize substances PMDBM2020056 n.a. Eubacterium A-44 PMDBD396 Ginsenoside Rg5 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13811 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD396 Ginsenoside Rg5 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13812 Microbes metabolize substances PMDBM2020167 28135 Prevotella oris PMDBD396 Ginsenoside Rg5 Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. ginsenoside Rh3 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13813 Microbes metabolize substances PMDBM63 n.a. Bacteroides spp. PMDBD397 Ginsenosides Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13814 Microbes metabolize substances PMDBM284 n.a. Lactobacillus spp. PMDBD397 Ginsenosides Therapeutic Substance Investigational Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29983606 PMDBI13819 Microbes metabolize substances PMDBM2020063 29370 Lacrimispora sphenoides PMDBD775 Sennoside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "8-glucosylrheinanthrone; rheinanthrone; sennidin" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 3368516 PMDBI13820 Microbes metabolize substances PMDBM2020223 39491 [Eubacterium] rectale PMDBD775 Sennoside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "8-glucosylrheinanthrone; rheinanthrone; sennidin" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 3368516 PMDBI13821 Microbes metabolize substances PMDBM228 n.a. Eubacterium spp. PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. Dihydrodigoxin n.a. n.a. Decrease Toxicity n.a. n.a. n.a. n.a. n.a. PMID PMID: 7266632 PMDBI13822 Microbes metabolize substances PMDBM390 n.a. Streptococcus S-2 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid" n.a. n.a. Increase Bioavailability n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13823 Microbes metabolize substances PMDBM55 n.a. Bacteroides J-37 PMDBD245 Daidzin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "Daidzein; 2,4-dihydroxyacetophenone; 4-hydroxybenzoic acid; resorcinol; 4-hydroxyphenylacetic acid; 2,4-dihydroxybenzoic acid" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13824 Microbes metabolize substances PMDBM2020056 n.a. Eubacterium A-44 PMDBD245 Daidzin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "Daidzein; 2,4-dihydroxyacetophenone; 4-hydroxybenzoic acid; resorcinol; 4-hydroxyphenylacetic acid; 2,4-dihydroxybenzoic acid" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13825 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD245 Daidzin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "Daidzein; 2,4-dihydroxyacetophenone; 4-hydroxybenzoic acid; resorcinol; 4-hydroxyphenylacetic acid; 2,4-dihydroxybenzoic acid" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13826 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD575 Naringin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13827 Microbes metabolize substances PMDBM231 n.a. Eubacterium YK-4 PMDBD575 Naringin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13828 Microbes metabolize substances PMDBM235 n.a. Feptostreptoccous YK-10 PMDBD575 Naringin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13829 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD575 Naringin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13830 Microbes metabolize substances PMDBM275 n.a. Lactobacillus L-2 PMDBD575 Naringin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13831 Microbes metabolize substances PMDBM390 n.a. Streptococcus S-2 PMDBD575 Naringin Herbal Substance Medicinal Herbal Compounds n.a. n.a. n.a. n.a. "Naringenin; 4-hydroxybenzoic acid; phloroglucinol; 2,4,6-trihydroxybenzoic acid; 4-hydroxyphenylacetic acid" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13832 Microbes metabolize substances PMDBM56 n.a. Bacteroides JY-6 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13833 Microbes metabolize substances PMDBM92 n.a. Bifidobacterium B-9 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13834 Microbes metabolize substances PMDBM231 n.a. Eubacterium YK-4 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13835 Microbes metabolize substances PMDBM243 n.a. Fusobacterium K-60 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI13836 Microbes metabolize substances PMDBM275 n.a. Lactobacillus L-2 PMDBD760 Rutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. n.a. n.a. "Quercetin; 4-hydroxybenzoic acid; 3,4-dDihydroxybenzoic acid; 3,4-dihydroxyphenylacetic acid" n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 9875509 PMDBI20001 Substances alter microbe abundance PMDBM2020035 562 Escherichia coli PMDBD11 Acacia catechu Herbal Substance Medicinal Herb epicatechin- and catechins-rich extract n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 28422543 PMDBI20002 Substances alter microbe abundance PMDBM372 n.a. Salmonella spp. PMDBD11 Acacia catechu Herbal Substance Medicinal Herb epicatechin- and catechins-rich extract n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 28422543 PMDBI20003 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD27 Aloe vera Herbal Substance Medicinal Herb Aloe vera mucilage n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 25504136 PMDBI20004 Substances alter microbe abundance PMDBM24 n.a. Atopobium spp. PMDBD27 Aloe vera Herbal Substance Medicinal Herb Aloe vera mucilage n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 25504136 PMDBI20005 Substances alter microbe abundance PMDBM118 n.a. Blautia spp. PMDBD994 AMC formula Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro Human Type 2 diabetes with hyperlipidemia n.a. n.a. PMID PMID: 29789365 PMDBI20006 Substances alter microbe abundance PMDBM234 n.a. Faecalibacterium spp. PMDBD994 AMC formula Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro Human Type 2 diabetes with hyperlipidemia n.a. n.a. PMID PMID: 29789365 PMDBI20007 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD58 Antrodia cinnamomea Herbal Substance Medicinal Herb water extract n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Obesity n.a. n.a. PMID PMID: 28630461 PMDBI20009 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD97 Bawei Xileisan Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20010 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD97 Bawei Xileisan Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20011 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD139 Camellia sinensis Herbal Substance Medicinal Herb catechin-rich extract n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 30856467 PMDBI20012 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD139 Camellia sinensis Herbal Substance Medicinal Herb catechin-rich extract n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 30856467 PMDBI20013 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD139 Camellia sinensis Herbal Substance Medicinal Herb catechin-rich extract n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 30856467 PMDBI20014 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD139 Camellia sinensis Herbal Substance Medicinal Herb catechin-rich extract n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 30856467 PMDBI20015 Substances alter microbe abundance PMDBM307 119852 Oscillospira PMDBD139 Camellia sinensis Herbal Substance Medicinal Herb catechin-rich extract n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 30856467 PMDBI20016 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20017 Substances alter microbe abundance PMDBM13 1283313 Alloprevotella PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20018 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20019 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20020 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20021 Substances alter microbe abundance PMDBM305 459786 Oscillibacter PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20022 Substances alter microbe abundance PMDBM30 n.a. Bacteroidales unclassified PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20023 Substances alter microbe abundance PMDBM139 n.a. Clostridiales unclassified PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20024 Substances alter microbe abundance PMDBM265 n.a. Lachnospiraceae unclassified PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20025 Substances alter microbe abundance PMDBM358 n.a. Ruminococcaceae unclassified PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20026 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD192 Cichorium intybus Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20033 Substances alter microbe abundance PMDBM2020194 28117 Alistipes putredinis PMDBD232 Curcuma longa Herbal Substance Medicinal Herb Roots n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20034 Substances alter microbe abundance PMDBM2020054 1432052 Eisenbergiella tayi PMDBD232 Curcuma longa Herbal Substance Medicinal Herb Roots n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20036 Substances alter microbe abundance PMDBM2020215 169435 Anaerotruncus colihominis PMDBD379 Ganoderma lucidum Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20037 Substances alter microbe abundance PMDBM63 n.a. Bacteroides spp. PMDBD379 Ganoderma lucidum Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20038 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD379 Ganoderma lucidum Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20039 Substances alter microbe abundance PMDBM2020232 328812 Parabacteroides goldsteinii PMDBD379 Ganoderma lucidum Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20040 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD379 Ganoderma lucidum Herbal Substance Medicinal Herb n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20041 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD379 Ganoderma lucidum Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20044 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Pig Diarrhea n.a. n.a. PMID PMID: 31057525 PMDBI20045 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20046 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20047 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Pig Diarrhea n.a. n.a. PMID PMID: 31057525 PMDBI20048 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20049 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Pig Diarrhea n.a. n.a. PMID PMID: 31057525 PMDBI20050 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20051 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20052 Substances alter microbe abundance PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20053 Substances alter microbe abundance PMDBM248 204475 Gemmiger PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20054 Substances alter microbe abundance PMDBM302 283168 Odoribacter PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20055 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20056 Substances alter microbe abundance PMDBM322 33024 Phascolarctobacterium PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Pig Diarrhea n.a. n.a. PMID PMID: 31057525 PMDBI20057 Substances alter microbe abundance PMDBM343 46205 Pseudobutyrivibrio PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20058 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Pig Diarrhea n.a. n.a. PMID PMID: 31057525 PMDBI20059 Substances alter microbe abundance PMDBM264 n.a. Lachnospiraceae incertae sedis PMDBD383 Gegen Qilian decoction Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. n.a. PMID PMID: 25279787 PMDBI20060 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase 10-85 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20061 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase 10-85 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20062 Substances alter microbe abundance PMDBM135 508459 Cloacibacillus PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase 10-85 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20063 Substances alter microbe abundance PMDBM179 872 Desulfovibrio PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase 10-85 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20064 Substances alter microbe abundance PMDBM2020032 n.a. Enterococcus faecalis PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20065 Substances alter microbe abundance PMDBM248 204475 Gemmiger PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase 10-85 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20066 Substances alter microbe abundance PMDBM2020100 573 Klebsiella pneumoniae PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20067 Substances alter microbe abundance PMDBM315 577310 Parasutterella PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase 10-85 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20068 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase 10-85 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20069 Substances alter microbe abundance PMDBM397 40544 Sutterella PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase > 150 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20070 Substances alter microbe abundance PMDBM228 n.a. Eubacterium spp. PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20071 Substances alter microbe abundance PMDBM321 n.a. Phascolarctobacter PMDBD405 Glycyrrhiza glabra Herbal Substance Medicinal Herb Roots n.a. Increase > 150 fold n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20072 Substances alter microbe abundance PMDBM297 248038 Mucispirillum PMDBD406 Glycyrrhiza uralensis Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20073 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD406 Glycyrrhiza uralensis Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20075 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20076 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20077 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20078 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20079 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20080 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20081 Substances alter microbe abundance PMDBM317 186804 Peptostreptococcaceae PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20082 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20083 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20084 Substances alter microbe abundance PMDBM351 171550 Rikenellaceae PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20085 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20086 Substances alter microbe abundance PMDBM2020248 46228 [Ruminococcus] lactaris PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20087 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20088 Substances alter microbe abundance PMDBM397 40544 Sutterella PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20089 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20092 Substances alter microbe abundance PMDBM262 n.a. Lachnospiracae PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20093 Substances alter microbe abundance PMDBM352 n.a. Rosburia ssp, S24-7 PMDBD486 Linum usitatissimum Herbal Substance Medicinal Herb Seeds n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20098 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20099 Substances alter microbe abundance PMDBM2020068 85831 Bacteroides acidifaciens PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20100 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20101 Substances alter microbe abundance PMDBM2020197 n.a. Blautia producta PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20102 Substances alter microbe abundance PMDBM2020198 501571 Butyricicoccus pullicaecorum PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20103 Substances alter microbe abundance PMDBM2020048 358743 Enterocloster citroniae PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20104 Substances alter microbe abundance PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20105 Substances alter microbe abundance PMDBM280 1598 Lactobacillus reuteri PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20106 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20107 Substances alter microbe abundance PMDBM2020165 1265 Ruminococcus flavefaciens PMDBD605 Nopal Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20108 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD612 Oil tea Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. PMID PMID: 30122197 PMDBI20109 Substances alter microbe abundance PMDBM60 29523 Bacteroides sp. PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb Seeds n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24341731 PMDBI20110 Substances alter microbe abundance PMDBM2020012 1681 Bifidobacterium bifidum PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb Seeds n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24341731 PMDBI20111 Substances alter microbe abundance PMDBM2020043 28121 Butyrivibrio sp. PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb Seeds n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24341731 PMDBI20112 Substances alter microbe abundance PMDBM2020057 n.a. Eubacterium sp. PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb Seeds n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24341731 PMDBI20113 Substances alter microbe abundance PMDBM272 1613 Lactobacillus fermentum PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb Seeds n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24341731 PMDBI20114 Substances alter microbe abundance PMDBM272 1613 Lactobacillus fermentum PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.foodhyd.2017.12.026 PMDBI20115 Substances alter microbe abundance PMDBM280 1598 Lactobacillus reuteri PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb Seeds n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24341731 PMDBI20116 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.foodhyd.2017.12.026 PMDBI20117 Substances alter microbe abundance PMDBM332 n.a. Prevotella pneumophila PMDBD681 Plantago asiatica L. Herbal Substance Medicinal Herb n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. In vivo Rat Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.foodhyd.2017.12.026 PMDBI20118 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD693 Pomegranate extract "Herbal Substance; Dietary Substance" "Herbal Substance; Dietary Substance" n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20119 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD693 Pomegranate extract "Herbal Substance; Dietary Substance" "Herbal Substance; Dietary Substance" n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20120 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD696 Potentilla discolor Bunge Herbal Substance Medicinal Herb n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. PMID PMID: 30897784 PMDBI20122 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD722 Qushi Huayu Fang Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Chronic liver disease n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20123 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD722 Qushi Huayu Fang Herbal Substance TCM Formula n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Non-alcoholic fatty liver disease (NAFLD) n.a. n.a. PMID PMID: 23453736 PMDBI20129 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD733 Red Ginseng Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20130 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD733 Red Ginseng Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20131 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD754 Rosmarinus officinals Herbal Substance Medicinal Herb Leaves n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20132 Substances alter microbe abundance PMDBM2020201 1535 [Clostridium] leptum PMDBD754 Rosmarinus officinals Herbal Substance Medicinal Herb Leaves n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20133 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD754 Rosmarinus officinals Herbal Substance Medicinal Herb Leaves n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20134 Substances alter microbe abundance PMDBM288 1243 Leuconostoc PMDBD754 Rosmarinus officinals Herbal Substance Medicinal Herb Leaves n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20135 Substances alter microbe abundance PMDBM316 1253 Pediococcus PMDBD754 Rosmarinus officinals Herbal Substance Medicinal Herb Leaves n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20137 Substances alter microbe abundance PMDBM2020038 1532 Blautia coccoides PMDBD754 Rosmarinus officinals Herbal Substance Medicinal Herb Leaves n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20138 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD763 Salvia officinalis Herbal Substance Medicinal Herb Leaves n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20139 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD763 Salvia officinalis Herbal Substance Medicinal Herb Leaves n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20140 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD774 Semen Coicis Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20141 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD774 Semen Coicis Herbal Substance Medicinal Herb n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20142 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD782 Silybum marianum Herbal Substance Medicinal Herb Fruits n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20143 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD782 Silybum marianum Herbal Substance Medicinal Herb Fruits n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20144 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD782 Silybum marianum Herbal Substance Medicinal Herb Fruits n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20145 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD835 Terminalia arjuna Herbal Substance Medicinal Herb hydro-ethanolic extract n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30367989 PMDBI20149 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD885 Urolithin-A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20150 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD885 Urolithin-A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20151 Substances alter microbe abundance PMDBM23 5062 Aspergillus oryzae PMDBD886 Vaccinium myrtillus Herbal Substance Medicinal Herb Fruits n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20152 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD886 Vaccinium myrtillus Herbal Substance Medicinal Herb Fruits n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20153 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD886 Vaccinium myrtillus Herbal Substance Medicinal Herb Fruits n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20154 Substances alter microbe abundance PMDBM290 2172 Methanobrevibacter PMDBD886 Vaccinium myrtillus Herbal Substance Medicinal Herb Fruits n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20155 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD886 Vaccinium myrtillus Herbal Substance Medicinal Herb Fruits n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20156 Substances alter microbe abundance PMDBM2020260 1583 Weissella confusa PMDBD886 Vaccinium myrtillus Herbal Substance Medicinal Herb Fruits n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20158 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD905 Xiao-Qing-Long Tang Herbal Substance TCM Formula n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 31396536 PMDBI20159 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD905 Xiao-Qing-Long Tang Herbal Substance TCM Formula n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 31396536 PMDBI20160 Substances alter microbe abundance PMDBM3 n.a. Actinobacteria PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20161 Substances alter microbe abundance PMDBM3 n.a. Actinobacteria PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20162 Substances alter microbe abundance PMDBM12 174708 Allobaculum PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20163 Substances alter microbe abundance PMDBM85 31953 Bifidobacteriaceae PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20164 Substances alter microbe abundance PMDBM86 85004 Bifidobacteriales PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20165 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20166 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20167 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Decrease Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20168 Substances alter microbe abundance PMDBM206 526525 Erysipelotrichales PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20169 Substances alter microbe abundance PMDBM207 526524 Erysipelotrichia PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20170 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20171 Substances alter microbe abundance PMDBM205 n.a. Erysipelotrichacesae PMDBD911 Zingiber officinale Herbal Substance Medicinal Herb Roots n.a. Increase Significantly n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 31408679 PMDBI20172 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD507 Magnoloside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Functional dyspepsia (FD) n.a. n.a. PMID PMID: 31412264 PMDBI20173 Substances alter microbe abundance PMDBM2020035 562 Escherichia coli PMDBD378 Gallic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 31344423 PMDBI20174 Substances alter microbe abundance PMDBM2020035 562 Escherichia coli PMDBD717 Quercetin Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 31344423 PMDBI20175 Substances alter microbe abundance PMDBM2020035 562 Escherichia coli PMDBD195 Cinnamon essential oil Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 17551716 PMDBI20176 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20177 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD688 Polysaccharide Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20179 Substances alter microbe abundance PMDBM330 840 Prevotella loescheii PMDBD688 Polysaccharide Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20180 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD914 Zn(ii)-curcumin Environmental Substance Nutrient Supplement n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Doxorubicin-induced cardiotoxicity n.a. n.a. PMID PMID: 31432062 PMDBI20181 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD507 Magnoloside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Functional dyspepsia (FD) n.a. n.a. PMID PMID: 31412264 PMDBI20182 Substances alter microbe abundance PMDBM246 1236 Gammaproteobacteria PMDBD507 Magnoloside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Functional dyspepsia (FD) n.a. n.a. PMID PMID: 31412264 PMDBI20183 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD688 Polysaccharide Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Over-fatigue and acute cold stress (OACS) n.a. n.a. PMID PMID: 26932472 PMDBI20184 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD615 Oligofructose Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Over-fatigue and acute cold stress (OACS) n.a. n.a. PMID PMID: 26932472 PMDBI20185 Substances alter microbe abundance PMDBM2020177 1280 Staphylococcus aureus PMDBD195 Cinnamon essential oil Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 17551716 PMDBI20188 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD378 Gallic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 31344423 PMDBI20189 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD717 Quercetin Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 31344423 PMDBI20190 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD786 Sodium butyrate Environmental Substance Microbiota metabolite n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Non-alcoholic fatty liver disease (NAFLD) n.a. n.a. PMID PMID: 28104981 PMDBI20191 Substances alter microbe abundance PMDBM272 1613 Lactobacillus fermentum PMDBD688 Polysaccharide Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20195 Substances alter microbe abundance PMDBM63 n.a. Bacteroides spp. PMDBD688 Polysaccharide Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Over-fatigue and acute cold stress (OACS) n.a. n.a. PMID PMID: 26932472 PMDBI20196 Substances alter microbe abundance PMDBM63 n.a. Bacteroides spp. PMDBD615 Oligofructose Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Over-fatigue and acute cold stress (OACS) n.a. n.a. PMID PMID: 26932472 PMDBI20199 Substances alter microbe abundance PMDBM322 33024 Phascolarctobacterium PMDBD802 Stachyose Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20201 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD28 Aloin Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Fisher 344 rat n.a. n.a. PMID PMID: 28525602 PMDBI20202 Substances alter microbe abundance PMDBM174 84999 Coriobacteriales PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Colon cancer n.a. n.a. PMID PMID: 26218141 PMDBI20203 Substances alter microbe abundance PMDBM174 84999 Coriobacteriales PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Wild type n.a. n.a. PMID PMID: 26218141 PMDBI20204 Substances alter microbe abundance PMDBM86 85004 Bifidobacteriales PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Colon cancer n.a. n.a. PMID PMID: 26218141 PMDBI20205 Substances alter microbe abundance PMDBM86 85004 Bifidobacteriales PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Wild type n.a. n.a. PMID PMID: 26218141 PMDBI20207 Substances alter microbe abundance PMDBM14 135622 Alteromonadales PMDBD507 Magnoloside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Functional dyspepsia (FD) n.a. n.a. PMID PMID: 31412264 PMDBI20209 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Colon cancer n.a. n.a. PMID PMID: 26218141 PMDBI20210 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20211 Substances alter microbe abundance PMDBM267 186826 Lactobacillales PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Colon cancer n.a. n.a. PMID PMID: 26218141 PMDBI20212 Substances alter microbe abundance PMDBM267 186826 Lactobacillales PMDBD233 Curcumin "Therapeutic Substance; Herbal Substance" "Investigational Drug; Medicinal Herbal Compounds" n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Wild type n.a. n.a. PMID PMID: 26218141 PMDBI20216 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD688 Polysaccharide Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Over-fatigue and acute cold stress (OACS) n.a. n.a. PMID PMID: 26932472 PMDBI20217 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD615 Oligofructose Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Over-fatigue and acute cold stress (OACS) n.a. n.a. PMID PMID: 26932472 PMDBI20218 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD28 Aloin Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Fisher 344 rat n.a. n.a. PMID PMID: 28525602 PMDBI20219 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20220 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD136 Caffeic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20221 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD914 Zn(ii)-curcumin Environmental Substance Nutrient Supplement n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Doxorubicin-induced cardiotoxicity n.a. n.a. PMID PMID: 31432062 PMDBI20222 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD507 Magnoloside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Functional dyspepsia (FD) n.a. n.a. PMID PMID: 31412264 PMDBI20223 Substances alter microbe abundance PMDBM394 292632 Subdoligranulum PMDBD507 Magnoloside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Functional dyspepsia (FD) n.a. n.a. PMID PMID: 31412264 PMDBI20224 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20225 Substances alter microbe abundance PMDBM296 437755 Moryella PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20227 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD786 Sodium butyrate Environmental Substance Microbiota metabolite n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Non-alcoholic fatty liver disease (NAFLD) n.a. n.a. PMID PMID: 28104981 PMDBI20229 Substances alter microbe abundance PMDBM121 580596 Butyricicoccus PMDBD914 Zn(ii)-curcumin Environmental Substance Nutrient Supplement n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Doxorubicin-induced cardiotoxicity n.a. n.a. PMID PMID: 31432062 PMDBI20230 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD786 Sodium butyrate Environmental Substance Microbiota metabolite n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Non-alcoholic fatty liver disease (NAFLD) n.a. n.a. PMID PMID: 28104981 PMDBI20234 Substances alter microbe abundance PMDBM118 n.a. Blautia spp. PMDBD530 Metformin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes with hyperlipidemia n.a. n.a. PMID PMID: 29789365 PMDBI20240 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD136 Caffeic acid Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Ulcerative colitis n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI20241 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD914 Zn(ii)-curcumin Environmental Substance Nutrient Supplement n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Doxorubicin-induced cardiotoxicity n.a. n.a. PMID PMID: 31432062 PMDBI20243 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD688 Polysaccharide Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Over-fatigue and acute cold stress (OACS) n.a. n.a. PMID PMID: 26932472 PMDBI20244 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD615 Oligofructose Herbal Substance Medicinal Herbal Compounds n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Over-fatigue and acute cold stress (OACS) n.a. n.a. PMID PMID: 26932472 PMDBI20245 Substances alter microbe abundance PMDBM335 n.a. Prevotellaceae_NK3B31_group PMDBD507 Magnoloside A Herbal Substance Medicinal Herbal Compounds n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Functional dyspepsia (FD) n.a. n.a. PMID PMID: 31412264 PMDBI30001 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD20 Activated soy pod fiber Dietary Substance Dietary Compounds (47.9% carbohydrates, 30% protein, 13.4% fat, with 175 娓璯/g glyceollin), 15% w/w, 16 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6NTac mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30002 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD20 Activated soy pod fiber Dietary Substance Dietary Compounds (47.9% carbohydrates, 30% protein, 13.4% fat, with 175 娓璯/g glyceollin), 15% w/w, 16 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6NTac mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30003 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD20 Activated soy pod fiber Dietary Substance Dietary Compounds (47.9% carbohydrates, 30% protein, 13.4% fat, with 175 娓璯/g glyceollin), 15% w/w, 16 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6NTac mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30004 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD20 Activated soy pod fiber Dietary Substance Dietary Compounds (47.9% carbohydrates, 30% protein, 13.4% fat, with 175 娓璯/g glyceollin), 15% w/w, 16 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6NTac mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30005 Substances alter microbe abundance PMDBM285 1357 Lactococcus PMDBD20 Activated soy pod fiber Dietary Substance Dietary Compounds (47.9% carbohydrates, 30% protein, 13.4% fat, with 175 娓璯/g glyceollin), 15% w/w, 16 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6NTac mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30006 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD20 Activated soy pod fiber Dietary Substance Dietary Compounds (47.9% carbohydrates, 30% protein, 13.4% fat, with 175 娓璯/g glyceollin), 15% w/w, 16 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6NTac mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30007 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD20 Activated soy pod fiber Dietary Substance Dietary Compounds (47.9% carbohydrates, 30% protein, 13.4% fat, with 175 娓璯/g glyceollin), 15% w/w, 16 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6NTac mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30008 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD21 Agaricus bisporus Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Pig Normal n.a. n.a. PMID PMID: 30424006 PMDBI30010 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD60 Apple juice Dietary Substance Drinks free access, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30011 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD60 Apple juice Dietary Substance Drinks free access, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30012 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD61 Apple juice colloid Dietary Substance Drinks free access, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30013 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD64 Aqueous soy extract Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30014 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD64 Aqueous soy extract Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30015 Substances alter microbe abundance PMDBM526 n.a. Enterobacteria PMDBD64 Aqueous soy extract Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30016 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD64 Aqueous soy extract Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30017 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD64 Aqueous soy extract Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30018 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD65 Aqueous soy extract (fermented soy product) Dietary Substance Dietary Compounds 2.8 mL/kg bw/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30019 Substances alter microbe abundance PMDBM504 n.a. Enterococcus spp. PMDBD65 Aqueous soy extract (fermented soy product) Dietary Substance Dietary Compounds 2.8 mL/kg bw/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30020 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD65 Aqueous soy extract (fermented soy product) Dietary Substance Dietary Compounds 2.8 mL/kg bw/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30021 Substances alter microbe abundance PMDBM504 n.a. Enterococcus spp. PMDBD66 Aqueous soy extract (hypecholesterolemic plus unfermented soy product) Dietary Substance Dietary Compounds 2.8 mL/kg bw/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30022 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD67 Aqueous soy extract (hypercholesterolemic plus isoflavone-supplemented fermented soy product) Dietary Substance Dietary Compounds 2.8 mL/kg bw?2.1 mg of total isoflavone/kg bw/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30023 Substances alter microbe abundance PMDBM504 n.a. Enterococcus spp. PMDBD67 Aqueous soy extract (hypercholesterolemic plus isoflavone-supplemented fermented soy product) Dietary Substance Dietary Compounds 2.8 mL/kg bw?2.1 mg of total isoflavone/kg bw/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30024 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD67 Aqueous soy extract (hypercholesterolemic plus isoflavone-supplemented fermented soy product) Dietary Substance Dietary Compounds 2.8 mL/kg bw?2.1 mg of total isoflavone/kg bw/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30028 Substances alter microbe abundance PMDBM2020061 576 Klebsiella sp. PMDBD120 Black tea extract Dietary Substance Dietary Compounds 1000 mg/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30028 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD120 Black tea extract Dietary Substance Dietary Compounds 1000 mg/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30033 Substances alter microbe abundance PMDBM2020226 210 Helicobacter pylori PMDBD142 Capsaicin Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 28405001 PMDBI30034 Substances alter microbe abundance PMDBM2020236 837 Porphyromonas gingivalis PMDBD142 Capsaicin Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 28405001 PMDBI30035 Substances alter microbe abundance PMDBM2020177 1280 Staphylococcus aureus PMDBD142 Capsaicin Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 28405001 PMDBI30036 Substances alter microbe abundance PMDBM2020013 n.a. Bifidobacterium breve NZRM3932 PMDBD171 Centurion cultivar blueberry extract Dietary Substance Dietary Compounds 10?25% v/v Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30037 Substances alter microbe abundance PMDBM511 n.a. Lactobacillus rhamnosus NZRM 299 PMDBD171 Centurion cultivar blueberry extract Dietary Substance Dietary Compounds 10?25% v/v Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30038 Substances alter microbe abundance PMDBM524 n.a. Clostridium histolyticum group PMDBD220 Cocoa drink Dietary Substance Drinks 29 mg cocoa flavanols, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30039 Substances alter microbe abundance PMDBM504 n.a. Enterococcus spp. PMDBD220 Cocoa drink Dietary Substance Drinks 29 mg cocoa flavanols, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30040 Substances alter microbe abundance PMDBM505 n.a. Eubacterium rectale?C. coccoides group PMDBD220 Cocoa drink Dietary Substance Drinks 29 mg cocoa flavanols, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30041 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD220 Cocoa drink Dietary Substance Drinks 29 mg cocoa flavanols, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30042 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD220 Cocoa drink Dietary Substance Drinks 494 mg cocoa flavanols, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30043 Substances alter microbe abundance PMDBM504 n.a. Enterococcus spp. PMDBD220 Cocoa drink Dietary Substance Drinks 494 mg cocoa flavanols, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30044 Substances alter microbe abundance PMDBM505 n.a. Eubacterium rectale?C. coccoides group PMDBD220 Cocoa drink Dietary Substance Drinks 494 mg cocoa flavanols, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30045 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD220 Cocoa drink Dietary Substance Drinks 494 mg cocoa flavanols, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30046 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD228 Conventional soy milk (26.5% ç?conglycinin/38.7% glycinin) Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30047 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD228 Conventional soy milk (26.5% ç?conglycinin/38.7% glycinin) Dietary Substance Drinks 500 mL/day, 3 months Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30048 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD228 Conventional soy milk (26.5% ç?conglycinin/38.7% glycinin) Dietary Substance Drinks 500 mL/day, 3 months Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30049 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD228 Conventional soy milk (26.5% ç?conglycinin/38.7% glycinin) Dietary Substance Drinks 500 mL/day, 3 months Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30050 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD228 Conventional soy milk (26.5% ç?conglycinin/38.7% glycinin) Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30051 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD227 Conventional soy milk Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30052 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD227 Conventional soy milk Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30053 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD251 Dealcoholized red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30054 Substances alter microbe abundance PMDBM523 n.a. Blautia coccoides?Eubacterium rectale PMDBD251 Dealcoholized red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30055 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD251 Dealcoholized red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30056 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD251 Dealcoholized red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30057 Substances alter microbe abundance PMDBM242 32066 Fusobacteria PMDBD251 Dealcoholized red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30058 Substances alter microbe abundance PMDBM25 91061 Bacilli PMDBD258 Deshipu stachyose granules Dietary Substance Dietary Compounds 0.42, 0.83, 2.49 g/kg BW/day, 14 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30061 Substances alter microbe abundance PMDBM516 n.a. Bacteroidaceae/Bifidobacteriaceae ratio PMDBD269 Diet rich in fiber Dietary Substance Foods n.a. Gut Increase Significantly n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24390308 PMDBI30062 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD269 Diet rich in fiber Dietary Substance Foods n.a. Gut Decrease Significantly n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24390308 PMDBI30063 Substances alter microbe abundance PMDBM12 174708 Allobaculum PMDBD271 Dietary fiber Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI30064 Substances alter microbe abundance PMDBM17 2086 Anaeroplasma PMDBD271 Dietary fiber Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI30065 Substances alter microbe abundance PMDBM19 244127 Anaerotruncus PMDBD271 Dietary fiber Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI30066 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD271 Dietary fiber Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI30067 Substances alter microbe abundance PMDBM285 1357 Lactococcus PMDBD271 Dietary fiber Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI30068 Substances alter microbe abundance PMDBM301 182709 Oceanobacillus PMDBD271 Dietary fiber Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI30069 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD271 Dietary fiber Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Obesity n.a. n.a. DOI DOI: 10.1016/j.eng.2018.11.013 PMDBI30070 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD301 Emulsifiers (P80 and CMC) Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30071 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD301 Emulsifiers (P80 and CMC) Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30072 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD343 Fermentable fibre (inulin) Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30073 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD343 Fermentable fibre (inulin) Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30074 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD344 Fermented aqueous soy extract (by Enterococcus faecium and Lactobacillus helveticus) Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30075 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD344 Fermented aqueous soy extract (by Enterococcus faecium and Lactobacillus helveticus) Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30076 Substances alter microbe abundance PMDBM526 n.a. Enterobacteria PMDBD344 Fermented aqueous soy extract (by Enterococcus faecium and Lactobacillus helveticus) Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30077 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD344 Fermented aqueous soy extract (by Enterococcus faecium and Lactobacillus helveticus) Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo New Zealand white rabbit n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30078 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD344 Fermented aqueous soy extract (by Enterococcus faecium and Lactobacillus helveticus) Dietary Substance Dietary Compounds 2.8 mL/kg BW/day, 60 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Golden Syrian hamsters n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30079 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD345 Fermented soy milk Dietary Substance Drinks 500 mL/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30080 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD345 Fermented soy milk Dietary Substance Drinks 500 mL/day, 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30081 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD345 Fermented soy milk Dietary Substance Drinks 500 mL/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30082 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD346 Fermented soy milk (by Enterococcus faecium) Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30083 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD346 Fermented soy milk (by Enterococcus faecium) Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30084 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD346 Fermented soy milk (by Enterococcus faecium) Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30085 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD346 Fermented soy milk (by Enterococcus faecium) Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30086 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD346 Fermented soy milk (by Enterococcus faecium) Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30087 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD347 Fermented soy milk (by Lactobacillus plantarum) Dietary Substance Drinks 2 mL/animal, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30088 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD347 Fermented soy milk (by Lactobacillus plantarum) Dietary Substance Drinks 2 mL/animal, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30089 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD347 Fermented soy milk (by Lactobacillus plantarum) Dietary Substance Drinks 2 mL/animal, 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30090 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD347 Fermented soy milk (by Lactobacillus plantarum) Dietary Substance Drinks 2 mL/animal, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30091 Substances alter microbe abundance PMDBM63 n.a. Bacteroides spp. PMDBD348 Fermented soy product Dietary Substance Drinks 3 mL/kg bw/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30093 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD348 Fermented soy product Dietary Substance Drinks 3 mL/kg bw/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30095 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD349 Fermented soybean milk Dietary Substance Drinks 100 g/day, 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30097 Substances alter microbe abundance PMDBM3 n.a. Actinobacteria PMDBD351 Fibre Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30098 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD351 Fibre Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30099 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD373 Freeze-dried doenjang Dietary Substance Foods 5% w/w, 7 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30101 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD373 Freeze-dried doenjang Dietary Substance Foods 5% w/w, 7 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30102 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD373 Freeze-dried doenjang Dietary Substance Foods 5% w/w, 7 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30103 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD373 Freeze-dried doenjang Dietary Substance Foods 5% w/w, 7 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30104 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD373 Freeze-dried doenjang Dietary Substance Foods 5% w/w, 7 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30105 Substances alter microbe abundance PMDBM302 283168 Odoribacter PMDBD373 Freeze-dried doenjang Dietary Substance Foods 5% w/w, 7 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30106 Substances alter microbe abundance PMDBM528 n.a. Pseudof lavonifractor PMDBD373 Freeze-dried doenjang Dietary Substance Foods 5% w/w, 7 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30107 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD373 Freeze-dried doenjang Dietary Substance Foods 5% w/w, 7 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30108 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD409 Grape antioxidant dietary fiber Dietary Substance Dietary Compounds 50 g/kg diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30109 Substances alter microbe abundance PMDBM2020119 n.a. Lactobacillus acidophilus ATCC 4356 PMDBD409 Grape antioxidant dietary fiber Dietary Substance Dietary Compounds nonextractable polyphenols 2.4 mg/mL Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30110 Substances alter microbe abundance PMDBM510 n.a. Lactobacillus reuteri ATCC 23272 PMDBD409 Grape antioxidant dietary fiber Dietary Substance Dietary Compounds nonextractable polyphenols 2.4 mg/mL Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30111 Substances alter microbe abundance PMDBM513 n.a. Paenibacillus spp. PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 60 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30111 Substances alter microbe abundance PMDBM515 n.a. Bacillus spp. PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 60 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30112 Substances alter microbe abundance PMDBM2020209 49338 Desulfitobacterium hafniense PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 60 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30113 Substances alter microbe abundance PMDBM513 n.a. Paenibacillus spp. PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 7.2 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30113 Substances alter microbe abundance PMDBM515 n.a. Bacillus spp. PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 7.2 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30114 Substances alter microbe abundance PMDBM2020209 49338 Desulfitobacterium hafniense PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 7.2 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30115 Substances alter microbe abundance PMDBM512 n.a. Nocardioides spp. PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 7.2 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30116 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 7.2 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30116 Substances alter microbe abundance PMDBM514 n.a. Acinobacter spp. PMDBD410 Grape pomace cocentrate and grape seed extract Dietary Substance Dietary Compounds 7.2 g/kg, 21 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30117 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD412 Green tea Dietary Substance Drinks 1000 mL/day, 10 days Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30118 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD413 Green tea extracts Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30119 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD413 Green tea extracts Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30120 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD414 Green tea leaves powder Dietary Substance Dietary Compounds 4% w/w of GTf + Lactobacillus plantarum DSM 15313 Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30121 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD426 High-fat (saturated and unsaturated) Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30122 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD426 High-fat (saturated and unsaturated) Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30123 Substances alter microbe abundance PMDBM399 191303 Turicibacter PMDBD426 High-fat (saturated and unsaturated) Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30124 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD427 High-fat and high-sugar diet Dietary Substance Foods n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30125 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD427 High-fat and high-sugar diet Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30126 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD427 High-fat and high-sugar diet Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30127 Substances alter microbe abundance PMDBM293 31969 Mollicutes PMDBD427 High-fat and high-sugar diet Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30128 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD429 High-flavanol cocoa powder extract Dietary Substance Dietary Compounds "1 mg/mL; 0.4 mg/mL flavanols" Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30129 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD448 Intact soy protein isolate Dietary Substance Dietary Compounds 24% w/w, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Golden Syrian hamsters n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30130 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD501 Low-fibre diet Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30131 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD501 Low-fibre diet Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30132 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD499 Low glycinin soy milk (49.5% ç?conglycinin/6% glycinin) Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30133 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD499 Low glycinin soy milk (49.5% ç?conglycinin/6% glycinin) Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30134 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD499 Low glycinin soy milk (49.5% ç?conglycinin/6% glycinin) Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30135 Substances alter microbe abundance PMDBM518 n.a. Bacteroides?Prevotella PMDBD498 Low glycinin soy milk Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30136 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD498 Low glycinin soy milk Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30137 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD498 Low glycinin soy milk Dietary Substance Drinks 500 mL/day, 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30138 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD500 Low-fiber diet Dietary Substance Foods n.a. Gut Increase Significantly n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24390308 PMDBI30139 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD500 Low-fiber diet Dietary Substance Foods n.a. Gut Increase Significantly n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 24390308 PMDBI30140 Substances alter microbe abundance PMDBM129 2747 Carnobacterium PMDBD509 Marine oil Dietary Substance Nutrient Supplement 18% Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Arctic charr n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30141 Substances alter microbe abundance PMDBM525 n.a. Cytophaga-Flexibacter PMDBD509 Marine oil Dietary Substance Nutrient Supplement 18% Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Arctic charr n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30142 Substances alter microbe abundance PMDBM291 1269 Micrococcus PMDBD509 Marine oil Dietary Substance Nutrient Supplement 18% Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Arctic charr n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30143 Substances alter microbe abundance PMDBM294 46225 Moraxella PMDBD509 Marine oil Dietary Substance Nutrient Supplement 18% Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Arctic charr n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30144 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD509 Marine oil Dietary Substance Nutrient Supplement 18% Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Arctic charr n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30145 Substances alter microbe abundance PMDBM2020013 n.a. Bifidobacterium breve NZRM3932 PMDBD510 Maru cultivar blueberry extract Dietary Substance Dietary Compounds 10?25% v/v Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30146 Substances alter microbe abundance PMDBM2020012 n.a. Bifidobacterium bifidum HDD541 PMDBD557 Monomeric-rich fraction grape seed extract Dietary Substance Dietary Compounds 414 mg/g total phenolics Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30147 Substances alter microbe abundance PMDBM2020013 1036735 Bifidobacterium breve CECT 7263 PMDBD557 Monomeric-rich fraction grape seed extract Dietary Substance Dietary Compounds 414 mg/g total phenolics Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30148 Substances alter microbe abundance PMDBM509 n.a. Lactobacillus plantarum IFPL93 PMDBD557 Monomeric-rich fraction grape seed extract Dietary Substance Dietary Compounds 414 mg/g total phenolics Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30149 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD15 Acesulfame-potassium Dietary Substance "Dietary Compounds; Artificial Sweeteners" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30150 Substances alter microbe abundance PMDBM2020201 1535 [Clostridium] leptum PMDBD75 Aspartame "Therapeutic Substance; Dietary Substance; Herbal Substance" "Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30151 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD761 Saccharin "Therapeutic Substance; Dietary Substance; Herbal Substance" "Investigational Drug; Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30152 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD761 Saccharin "Therapeutic Substance; Dietary Substance; Herbal Substance" "Investigational Drug; Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30153 Substances alter microbe abundance PMDBM399 191303 Turicibacter PMDBD761 Saccharin "Therapeutic Substance; Dietary Substance; Herbal Substance" "Investigational Drug; Dietary Compounds; Artificial Sweetener; Medicinal Herbal Compounds" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30155 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD604 Nonfermented soybean milk Dietary Substance Drinks 100 g/day, 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30157 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD613 Okara (soy pulp/soy fiber) Dietary Substance Dietary Compounds 0.3 g/kg BW/day, 28 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30158 Substances alter microbe abundance PMDBM2020035 562 Escherichia coli PMDBD613 Okara (soy pulp/soy fiber) Dietary Substance Dietary Compounds 0.3 g/kg BW/day, 28 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30160 Substances alter microbe abundance PMDBM507 n.a. Lactobacillus bulgaricus LBY-27 PMDBD616 Oligomeric-rich fraction grape seed extract Dietary Substance Dietary Compounds 279 mg/g total phenolics Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30161 Substances alter microbe abundance PMDBM508 n.a. Lactobacillus casei IFPL7190 PMDBD616 Oligomeric-rich fraction grape seed extract Dietary Substance Dietary Compounds 279 mg/g total phenolics Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30162 Substances alter microbe abundance PMDBM177 191394 Deferribacteraceae PMDBD643 Partially hydrolyzed soy protein isolate Dietary Substance Dietary Compounds 24% w/w, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Golden Syrian hamsters n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30163 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD643 Partially hydrolyzed soy protein isolate Dietary Substance Dietary Compounds 24% w/w, 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Golden Syrian hamsters n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30164 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD685 Polyphenols (caffeic acid) Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30165 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD686 Polyphenols (grape and/or cranberry extract) Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30166 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD687 Polyphenols (resveratrol) Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30167 Substances alter microbe abundance PMDBM2020013 n.a. Bifidobacterium breve NRRL B-41408 PMDBD692 Pomegranate byproduct Dietary Substance Dietary Compounds 0.01% (v/v) of PPE Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30168 Substances alter microbe abundance PMDBM502 n.a. Bifidobacterium infantis NRRL B-41661 PMDBD692 Pomegranate byproduct Dietary Substance Dietary Compounds 0.01% (v/v) of PPE Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30170 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD693 Pomegranate extract "Herbal Substance; Dietary Substance" "Herbal Substance; Dietary Substance" 250 mg/kg, 25 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30172 Substances alter microbe abundance PMDBM519 n.a. Bacteroides?Prevotella spp. PMDBD694 Pomegranate peel extract Dietary Substance Dietary Compounds 0.2% (6 mg/day), 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30173 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD694 Pomegranate peel extract Dietary Substance Dietary Compounds 0.2% (6 mg/day), 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30174 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD706 Proanthocyanidin-rich grape seed extract Dietary Substance Dietary Compounds 0.5 g/day/subject extract (0.19 g/day/subject as proanthocyanidins), 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30175 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD734 Red meat (haem) Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30176 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD734 Red meat (haem) Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30177 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD734 Red meat (haem) Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30178 Substances alter microbe abundance PMDBM530 n.a. Sulfate-reducing bacteria PMDBD734 Red meat (haem) Dietary Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30179 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30180 Substances alter microbe abundance PMDBM517 n.a. Bacteroides uniformis sp. PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30181 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30182 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30183 Substances alter microbe abundance PMDBM523 n.a. Blautia coccoides?Eubacterium rectale PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30184 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30185 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30186 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30187 Substances alter microbe abundance PMDBM242 32066 Fusobacteria PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30188 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30189 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD735 Red wine Dietary Substance Drinks 272 mL/day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30190 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD736 Red wine grape extract Dietary Substance Dietary Compounds 1000 mg polyphenols/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30191 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD736 Red wine grape extract Dietary Substance Dietary Compounds 1000 mg polyphenols/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30192 Substances alter microbe abundance PMDBM135 508459 Cloacibacillus PMDBD736 Red wine grape extract Dietary Substance Dietary Compounds 1000 mg polyphenols/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30193 Substances alter microbe abundance PMDBM2020061 576 Klebsiella sp. PMDBD736 Red wine grape extract Dietary Substance Dietary Compounds 1000 mg polyphenols/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30194 Substances alter microbe abundance PMDBM409 172900 Victivallis PMDBD736 Red wine grape extract Dietary Substance Dietary Compounds 1000 mg polyphenols/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30195 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD737 Regular soy milk Dietary Substance Drinks 500 mL/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30196 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD737 Regular soy milk Dietary Substance Drinks 500 mL/day, 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30197 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD737 Regular soy milk Dietary Substance Drinks 500 mL/day, 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30198 Substances alter microbe abundance PMDBM81 n.a. Bacteroidetes/Firmicutes ratio PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse High-fat diet (HFD) n.a. n.a. PMID PMID: 24722352 PMDBI30199 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse High-fat diet (HFD) n.a. n.a. PMID PMID: 24722352 PMDBI30200 Substances alter microbe abundance PMDBM2020032 n.a. Enterococcus faecalis PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse High-fat diet (HFD) n.a. n.a. PMID PMID: 24722352 PMDBI30201 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD740 Resveratrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse High-fat diet (HFD) n.a. n.a. PMID PMID: 24722352 PMDBI30202 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD766 Saturated fat Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30203 Substances alter microbe abundance PMDBM110 35832 Bilophila PMDBD766 Saturated fat Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30204 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD766 Saturated fat Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30205 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD766 Saturated fat Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30206 Substances alter microbe abundance PMDBM293 31969 Mollicutes PMDBD766 Saturated fat Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30207 Substances alter microbe abundance PMDBM529 n.a. S24-7 (Bacteroidetes) PMDBD766 Saturated fat Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30208 Substances alter microbe abundance PMDBM399 191303 Turicibacter PMDBD766 Saturated fat Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30209 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD767 Saturated fat (palmitate) Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30210 Substances alter microbe abundance PMDBM529 n.a. S24-7 (Bacteroidetes) PMDBD767 Saturated fat (palmitate) Dietary Substance Dietary Compounds n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30211 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD790 Soy isoflavones Dietary Substance Dietary Compounds 100 mg, 2 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30212 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD790 Soy isoflavones Dietary Substance Dietary Compounds 100 mg, 2 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30213 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD790 Soy isoflavones Dietary Substance Dietary Compounds 100 mg, 2 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30214 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD790 Soy isoflavones Dietary Substance Dietary Compounds 100 mg, 2 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30216 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD790 Soy isoflavones Dietary Substance Dietary Compounds 100 mg, 2 months Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30217 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD791 Soy isoflavones (daidzein, genistein, glycitein) Dietary Substance Dietary Compounds 12.5 g of 40% isoflavone extract, 14 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Czech Fleckvieh é‘?Holstein cows n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30218 Substances alter microbe abundance PMDBM85 31953 Bifidobacteriaceae PMDBD791 Soy isoflavones (daidzein, genistein, glycitein) Dietary Substance Dietary Compounds 12.5 g of 40% isoflavone extract, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Czech Fleckvieh é‘?Holstein cows n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30219 Substances alter microbe abundance PMDBM237 204430 Fibrobacteria PMDBD791 Soy isoflavones (daidzein, genistein, glycitein) Dietary Substance Dietary Compounds 12.5 g of 40% isoflavone extract, 14 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Czech Fleckvieh é‘?Holstein cows n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30220 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD791 Soy isoflavones (daidzein, genistein, glycitein) Dietary Substance Dietary Compounds 12.5 g of 40% isoflavone extract, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Czech Fleckvieh é‘?Holstein cows n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30221 Substances alter microbe abundance PMDBM267 186826 Lactobacillales PMDBD791 Soy isoflavones (daidzein, genistein, glycitein) Dietary Substance Dietary Compounds 12.5 g of 40% isoflavone extract, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Czech Fleckvieh é‘?Holstein cows n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30222 Substances alter microbe abundance PMDBM323 203683 Planctomycetia PMDBD791 Soy isoflavones (daidzein, genistein, glycitein) Dietary Substance Dietary Compounds 12.5 g of 40% isoflavone extract, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Czech Fleckvieh é‘?Holstein cows n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30223 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD791 Soy isoflavones (daidzein, genistein, glycitein) Dietary Substance Dietary Compounds 12.5 g of 40% isoflavone extract, 14 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Czech Fleckvieh é‘?Holstein cows n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30224 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD791 Soy isoflavones (daidzein, genistein, glycitein) Dietary Substance Dietary Compounds 12.5 g of 40% isoflavone extract, 14 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Czech Fleckvieh é‘?Holstein cows n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30225 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD792 Soy milk Dietary Substance Drinks 1 month Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30226 Substances alter microbe abundance PMDBM2020013 1685 Bifidobacterium breve PMDBD792 Soy milk Dietary Substance Drinks 1 month Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30227 Substances alter microbe abundance PMDBM103 1682 Bifidobacterium longum subsp. infantis PMDBD792 Soy milk Dietary Substance Drinks 1 month Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30228 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD792 Soy milk Dietary Substance Drinks 1 month Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30229 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD792 Soy milk Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30230 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD792 Soy milk Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30231 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD792 Soy milk Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30232 Substances alter microbe abundance PMDBM526 n.a. Enterobacteria PMDBD792 Soy milk Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30233 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD792 Soy milk Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30234 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD792 Soy milk Dietary Substance Drinks 3 mL/kg of BW/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30235 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30236 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30237 Substances alter microbe abundance PMDBM12 174708 Allobaculum PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30238 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30239 Substances alter microbe abundance PMDBM123 574697 Butyricimonas PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30240 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30241 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30242 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30243 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30244 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD793 Soy milk (powder) Dietary Substance Drinks 12% w/w, 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30245 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD794 Soy protein Dietary Substance Dietary Compounds 20% w/w, 16 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30247 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD794 Soy protein Dietary Substance Dietary Compounds 20% w/w, 16 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30248 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD795 Soy protein concentrate (SPC) Dietary Substance Dietary Compounds 27% w/w, 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Golden Syrian hamsters n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30249 Substances alter microbe abundance PMDBM85 31953 Bifidobacteriaceae PMDBD795 Soy protein concentrate (SPC) Dietary Substance Dietary Compounds 27% w/w, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Golden Syrian hamsters n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30250 Substances alter microbe abundance PMDBM503 n.a. Clostridiales spp. PMDBD795 Soy protein concentrate (SPC) Dietary Substance Dietary Compounds 27% w/w, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Golden Syrian hamsters n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30251 Substances alter microbe abundance PMDBM2 469 Acinetobacter PMDBD796 Soybean oil Dietary Substance Foods 18% Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Arctic charr n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30252 Substances alter microbe abundance PMDBM2020261 644 Aeromonas hydrophila PMDBD796 Soybean oil Dietary Substance Foods 18% Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Arctic charr n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30253 Substances alter microbe abundance PMDBM2020224 833 Fibrobacter succinogenes PMDBD796 Soybean oil Dietary Substance Foods 4% w/w, 21 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Holstein cows Primiparous n.a. n.a. PMID PMID: 27798832 PMDBI30254 Substances alter microbe abundance PMDBM2020245 1264 Ruminococcus albus PMDBD796 Soybean oil Dietary Substance Foods 4% w/w, 21 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Holstein cows Primiparous n.a. n.a. PMID PMID: 27798832 PMDBI30255 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD797 Soygerm powder Dietary Substance Dietary Compounds 2.5 g/day, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30257 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD827 Tea polyphenols Dietary Substance Dietary Compounds Suphenon, 0.4 g/3 times per day, 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30258 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD854 Tofu diet Dietary Substance Foods 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Hannover rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30259 Substances alter microbe abundance PMDBM527 n.a. Lactic acid producing bacteria PMDBD854 Tofu diet Dietary Substance Foods 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Hannover rat n.a. n.a. n.a. PMID PMID: 27798832 PMDBI30260 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD882 Unfermented soy product Dietary Substance Foods 3 mL/kg bw/day, 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30261 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD883 Unsaturated fat Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30262 Substances alter microbe abundance PMDBM268 n.a. Lactobacillus PMDBD883 Unsaturated fat Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30263 Substances alter microbe abundance PMDBM293 31969 Mollicutes PMDBD883 Unsaturated fat Dietary Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 30262901 PMDBI30264 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD901 Western high-fat diets Dietary Substance Foods n.a. Gut Increase Significantly n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 18407065 PMDBI30265 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD902 Wild blueberry Dietary Substance Foods 25 g/day, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30266 Substances alter microbe abundance PMDBM2020119 1579 Lactobacillus acidophilus PMDBD902 Wild blueberry Dietary Substance Foods 25 g/day, 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30267 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD903 Wine polyphenols Dietary Substance Dietary Compounds 50 mg/kg bw, 15 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30268 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD903 Wine polyphenols Dietary Substance Dietary Compounds 50 mg/kg bw, 15 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI30269 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD903 Wine polyphenols Dietary Substance Dietary Compounds 50 mg/kg bw, 15 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 24033291 PMDBI40001 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 24 娓璯/kg per day in the diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25768209" PMDBI40001 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.58E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Wild-type and Ahr-/- mice n.a. n.a. PMID PMID: 29555994 PMDBI40002 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 24 娓璯/kg per day in the diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25768209" PMDBI40002 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Wild-type and Ahr-/- mice n.a. n.a. PMID PMID: 29555994 PMDBI40003 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.32E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40003 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 24 娓璯/kg per day in the diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Wild-type and Ahr-/- mice n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25768209" PMDBI40004 Substances alter microbe abundance PMDBM666 830 Butyrivibrio PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 24 娓璯/kg per day in the diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25768209" PMDBI40004 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.28E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Wild-type and Ahr-/- mice n.a. n.a. PMID PMID: 29555994 PMDBI40005 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000682966] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40005 Substances alter microbe abundance PMDBM777 117743 Flavobacteria PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 24 娓璯/kg per day in the diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Wild-type and Ahr-/- mice n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25768209" PMDBI40006 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 娓璯/kg bodyweight biweekly by gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631" PMDBI40006 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.99E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40007 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 娓璯/kg bodyweight biweekly by gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631" PMDBI40007 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40008 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 娓璯/kg bodyweight biweekly by gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631" PMDBI40008 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.72E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40009 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 娓璯/kg bodyweight biweekly by gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631" PMDBI40009 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40010 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 娓璯/kg bodyweight biweekly by gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631" PMDBI40010 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.84E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40011 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40011 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 娓璯/kg bodyweight biweekly by gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631" PMDBI40012 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40012 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 娓璯/kg bodyweight biweekly by gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631" PMDBI40013 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.03E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40013 Substances alter microbe abundance PMDBM738 194924 Desulfovibrionaceae PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 娓璯/kg bodyweight biweekly by gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631" PMDBI40014 Substances alter microbe abundance PMDBM632 207244 Anaerostipes PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 6 娓璯/kg bodyweight biweekly by gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27221631" PMDBI40014 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40015 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1011 Acesulfame potassium Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28594855" PMDBI40015 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.04E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40016 Substances alter microbe abundance PMDBM397 40544 Sutterella PMDBD1011 Acesulfame potassium Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28594855" PMDBI40016 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40017 Substances alter microbe abundance PMDBM632 207244 Anaerostipes PMDBD1011 Acesulfame potassium Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28594855" PMDBI40017 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.32E-07] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40018 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.84E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40018 Substances alter microbe abundance PMDBM815 n.a. lactic acid bacteria PMDBD1019 Aflatoxin B1 Environmental Substance Biological Contaminants n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26612839" PMDBI40019 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1416 Silver nanoparticles Environmental Substance Nanoparticles (NPs) 9, 18, and 36 mg/kg body weight for 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 24877679" PMDBI40019 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.08E-06] n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40020 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD1020 Aldicarb Environmental Substance Pesticides 2 ppm (approximately 0.3 mg/kg bw/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30406643" PMDBI40020 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40021 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1020 Aldicarb Environmental Substance Pesticides 2 ppm (approximately 0.3 mg/kg bw/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30406643" PMDBI40021 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40022 Substances alter microbe abundance PMDBM173 84107 Coriobacteriaceae PMDBD1020 Aldicarb Environmental Substance Pesticides 2 ppm (approximately 0.3 mg/kg bw/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30406643" PMDBI40022 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.62E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40023 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD1020 Aldicarb Environmental Substance Pesticides 2 ppm (approximately 0.3 mg/kg bw/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30406643" PMDBI40023 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.49E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40024 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1020 Aldicarb Environmental Substance Pesticides 2 ppm (approximately 0.3 mg/kg bw/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30406643" PMDBI40024 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.59E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40025 Substances alter microbe abundance PMDBM637 1385 Bacillales PMDBD1020 Aldicarb Environmental Substance Pesticides 2 ppm (approximately 0.3 mg/kg bw/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30406643" PMDBI40025 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.41E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40026 Substances alter microbe abundance PMDBM632 207244 Anaerostipes PMDBD1020 Aldicarb Environmental Substance Pesticides 2 ppm (approximately 0.3 mg/kg bw/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30406643" PMDBI40026 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40027 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27268458" PMDBI40027 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000289729] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40028 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 100 ppb for 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28973555" PMDBI40028 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.20E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40029 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0 or 10 ppm for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 24413286" PMDBI40029 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.37E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40030 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0 or 10 ppm for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 24413286" PMDBI40030 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.45E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40031 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0 or 10 ppm in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 24490651" PMDBI40031 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40032 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 100 ppb for 13 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28973555" PMDBI40032 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00597968] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40033 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27268458" PMDBI40033 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40034 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40034 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0 or 10 ppm in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 24490651" PMDBI40035 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40035 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0.05 mg/kg bw Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30108172" PMDBI40036 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.77E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40036 Substances alter microbe abundance PMDBM727 1117 Cyanobacteria PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0 or 10 ppm for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 24413286" PMDBI40037 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40037 Substances alter microbe abundance PMDBM2020121 97253 Eubacterium plexicaudatum PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0.05 mg/kg bw Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30108172" PMDBI40038 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40038 Substances alter microbe abundance PMDBM731 200930 Deferribacteres PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0.05 mg/kg bw Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30108172" PMDBI40039 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40039 Substances alter microbe abundance PMDBM2020139 248039 Mucispirillum schaedleri PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0.05 mg/kg bw Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30108172" PMDBI40040 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002343758] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40040 Substances alter microbe abundance PMDBM965 544448 Tenericutes PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0 or 10 ppm for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 24413286" PMDBI40041 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000176808] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40041 Substances alter microbe abundance PMDBM809 1506553 Lachnoclostridium PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0.05 mg/kg bw Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30108172" PMDBI40042 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.76E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40042 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1041 Arsenic and zinc Environmental Substance "Heavy Metals; Toxic Agents" Zinc restriction and 0, 50, 500 ppb inorganic arsenic in drinking water for 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30518676" PMDBI40043 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.84E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40043 Substances alter microbe abundance PMDBM934 22 Shewanella PMDBD1041 Arsenic and zinc Environmental Substance "Heavy Metals; Toxic Agents" Zinc restriction and 0, 50, 500 ppb inorganic arsenic in drinking water for 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30518676" PMDBI40044 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.80E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40044 Substances alter microbe abundance PMDBM907 67575 Rheinheimera PMDBD1041 Arsenic and zinc Environmental Substance "Heavy Metals; Toxic Agents" Zinc restriction and 0, 50, 500 ppb inorganic arsenic in drinking water for 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30518676" PMDBI40045 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40045 Substances alter microbe abundance PMDBM795 189772 Herpetosiphonales PMDBD1041 Arsenic and zinc Environmental Substance "Heavy Metals; Toxic Agents" Zinc restriction and 0, 50, 500 ppb inorganic arsenic in drinking water for 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30518676" PMDBI40046 Substances alter microbe abundance PMDBM2020201 1535 Clostridium leptum PMDBD75 Aspartame Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 25313461" PMDBI40046 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.29E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40047 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD75 Aspartame Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 25313461" PMDBI40047 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0002712] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40048 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD75 Aspartame Environmental Substance Artificial Sweeteners n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 25313461" PMDBI40048 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.28E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40049 Substances alter microbe abundance PMDBM2 469 Acinetobacter PMDBD1047 Atrazine Environmental Substance Pesticides 1.0 娓璯/l atrazine dose (0.42 娓璯/l measured) in water environment starting at 4.5 months of age for 7 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29356515" PMDBI40049 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40050 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1047 Atrazine Environmental Substance Pesticides 1.0 娓璯/l atrazine dose (0.42 娓璯/l measured) in water environment starting at 4.5 months of age for 7 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29356515" PMDBI40050 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000313055] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40051 Substances alter microbe abundance PMDBM673 1016 Capnocytophaga PMDBD1047 Atrazine Environmental Substance Pesticides 1.0 娓璯/l atrazine dose (0.42 娓璯/l measured) in water environment starting at 4.5 months of age for 7 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29356515" PMDBI40051 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000651143] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40052 Substances alter microbe abundance PMDBM613 642 Aeromonas PMDBD1048 "Atrazine; estradiol; PCB126; PCB153" Environmental Substance Persistent Organic Pollutants DMSO or 1.0 娓璯/l of environmental pollutant mixture Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29356515" PMDBI40052 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000569297] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40053 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1050 Azoxystrobin Environmental Substance Pesticides 5 mg/kg azoxystrobin in dry soil environment for 28 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31284112" PMDBI40053 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001780397] n.a. n.a. n.a. n.a. In vivo Enchytraeus crypticus Health n.a. n.a. PMID PMID: 29555994 PMDBI40054 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1050 Azoxystrobin Environmental Substance Pesticides 0.1 mg/kg azoxystrobin in dry soil environment for 28 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31284112" PMDBI40054 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.84E-05] n.a. n.a. n.a. n.a. In vivo Enchytraeus crypticus Health n.a. n.a. PMID PMID: 29555994 PMDBI40055 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29523931" PMDBI40055 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000507548] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40056 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29523931" PMDBI40056 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.59E-06] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40057 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29523931" PMDBI40057 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002065724] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40058 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29523931" PMDBI40058 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.06E-05] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40059 Substances alter microbe abundance PMDBM315 577310 Parasutterella PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29523931" PMDBI40059 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006585507] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40060 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29523931" PMDBI40060 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00010915] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40061 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29523931" PMDBI40061 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.44E-05] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40062 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.08E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40062 Substances alter microbe abundance PMDBM784 1378 Gemella PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29523931" PMDBI40063 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40063 Substances alter microbe abundance PMDBM784 1378 Gemella PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29523931" PMDBI40064 Substances alter microbe abundance PMDBM636 292480 Atopostipes PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29523931" PMDBI40064 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.76E-06] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40065 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000121136] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40065 Substances alter microbe abundance PMDBM863 1100891 Paenalcaligenes PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week. compared with normal diet+vehicle group Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29523931" PMDBI40066 Substances alter microbe abundance PMDBM672 1331051 Candidatus Saccharimonas PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29523931" PMDBI40066 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.70E-05] n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID PMID: 29555994 PMDBI40067 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40067 Substances alter microbe abundance PMDBM997 n.a. æµ?Diversity PMDBD1001 2,2',4,4'-Tetrabromodiphenyl ether Environmental Substance Persistent Organic Pollutants 0, 0.002, and 0.2 mg/kg BDE-47 from GD 6 to PND 21. Male mice selected to be either on normal diet or HFD for 14 week Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Primigravida ICR mice n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29523931" PMDBI40068 Substances alter microbe abundance PMDBM12 174708 Allobaculum PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127" PMDBI40068 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40069 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127" PMDBI40069 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.36E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40070 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127" PMDBI40070 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.60E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40071 Substances alter microbe abundance PMDBM297 248038 Mucispirillum PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127" PMDBI40071 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000864218] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40072 Substances alter microbe abundance PMDBM307 119852 Oscillospira PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127" PMDBI40072 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00358652] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40073 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127" PMDBI40073 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.57E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40074 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127" PMDBI40074 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000539056] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40075 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127" PMDBI40075 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD186 Chlorprothixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.02E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40076 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127" PMDBI40076 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD916 Zotepine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0056596] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40077 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127" PMDBI40077 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD917 Zuclopenthixol dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000933639] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40078 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD185 Chlorpromazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000323877] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40078 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127" PMDBI40079 Substances alter microbe abundance PMDBM618 506 Alcaligenaceae PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127" PMDBI40079 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD710 Promethazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003400942] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40080 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD86 Azelastine HCl Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40080 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127" PMDBI40081 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD655 Perphenazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002509681] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40081 Substances alter microbe abundance PMDBM988 203557 Verrucomicrobiaceae PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127" PMDBI40082 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD235 Cyclobenzaprine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001347342] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40082 Substances alter microbe abundance PMDBM870 577309 Paraprevotella PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127" PMDBI40083 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD74 Asenapine maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003502773] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40083 Substances alter microbe abundance PMDBM871 n.a. Paraprevotellaceae PMDBD1052 Benzo[a]pyrene Environmental Substance Persistent Organic Pollutants 50 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27503127" PMDBI40084 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD418 Haloperidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006623603] n.a. n.a. n.a. n.a. n.a. Rodent Health n.a. n.a. PMID PMID: 29555994 PMDBI40084 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD1054 "Berry fruits(cranberries; raspberries)" Environmental Substance Foods n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 25080446" PMDBI40085 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1061 "bisphenol A; ethinyl estradiol" Environmental Substance "Industrial Compounds; Bisphenols" incorporation into the diet from periconception through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.1124/pr.118.015768; PMID: 27624382" PMDBI40085 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD513 Mebhydroline 1,5-naphtalenedisulfonate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.22E-05] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40086 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD1061 "bisphenol A; ethinyl estradiol" Environmental Substance "Industrial Compounds; Bisphenols" incorporation into the diet from periconception through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.1124/pr.118.015768; PMID: 27624382" PMDBI40086 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD871 Triflupromazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000685478] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40087 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1061 "bisphenol A; ethinyl estradiol" Environmental Substance "Industrial Compounds; Bisphenols" incorporation into the diet from periconception through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.1124/pr.118.015768; PMID: 27624382" PMDBI40087 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD184 Chlorpheniramine maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003216147] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40088 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27624382" PMDBI40088 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD820 Sumatriptan succinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008307524] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40089 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 12é–?8 娓璯/kg feed weight in dog food contaminated with BPA can lining, 14 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27932218" PMDBI40089 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD865 Trazodone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000277264] n.a. n.a. n.a. n.a. In vivo Dog Gonadectomized n.a. n.a. PMID PMID: 29555994 PMDBI40090 Substances alter microbe abundance PMDBM290 2172 Methanobrevibacter PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27624382" PMDBI40090 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD104 Benzydamine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000584515] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40091 Substances alter microbe abundance PMDBM293 31969 Mollicutes PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27624382" PMDBI40091 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD99 Benfluorex hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007068035] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40092 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 2 娓璯/L BPA + 100娓璯/l nano-TiO2 in water environment for 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29356515" PMDBI40092 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD126 Bromperidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009428028] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40093 Substances alter microbe abundance PMDBM307 119852 Oscillospira PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 200 娓璯/kg bw dams dosed orally from GD 15 to PND 7 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29034330" PMDBI40093 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD179 Chlorcyclizine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000594816] n.a. n.a. n.a. n.a. In vivo Rabbit Health n.a. n.a. PMID PMID: 29555994 PMDBI40094 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.21E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40094 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27624382" PMDBI40095 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40095 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 200 娓璯/kg bw dams dosed orally from GD 15 to PND 7 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rabbit Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29034330" PMDBI40096 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40096 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 30 娓璯/kg BW gavaged from PND 28 to 56 Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Nonobese diabetic n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30600366" PMDBI40097 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40097 Substances alter microbe abundance PMDBM2020263 28116 Bacteroides ovatus PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 12é–?8 娓璯/kg feed weight in dog food contaminated with BPA can lining, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Dog Gonadectomized n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27932218" PMDBI40098 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.82E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40098 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27624382" PMDBI40099 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40099 Substances alter microbe abundance PMDBM63 29523 Bacteroides spp. PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 12é–?8 娓璯/kg feed weight in dog food contaminated with BPA can lining, 14 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Dog Gonadectomized n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27932218" PMDBI40100 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40100 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 50 娓璯/kg bw dams dosed orally from GD 15 to weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29101397" PMDBI40101 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40101 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 200 娓璯/kg bw dams dosed orally from GD 15 to PND 7 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rabbit Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29034330" PMDBI40102 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40102 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27624382" PMDBI40103 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40103 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 50 娓璯/kg bw dams dosed orally from GD 15 to weaning Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29101397" PMDBI40104 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40104 Substances alter microbe abundance PMDBM799 81 Hyphomicrobium PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 0, 2, and 20 娓璯/L and 2 or 20 娓璯/L BPA + 100娓璯/l nano-TiO2 in water environment for 3 months Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29356515" PMDBI40105 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40105 Substances alter microbe abundance PMDBM850 481 Neisseriaceae PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 0, 0.2, 0.6, 1.7, 2.9, 5.7, 11.5, 23.0, or 45.0 å¨“ç’ in water environment Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish embryo Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30321396" PMDBI40106 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.39E-05] n.a. n.a. n.a. n.a. In vitro n.a. Health n.a. n.a. PMID PMID: 29555994 PMDBI40106 Substances alter microbe abundance PMDBM619 507 Alcaligenes PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 25, 250, and 2500 娓璯/L in nutritional medium for 10 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29778027" PMDBI40107 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40107 Substances alter microbe abundance PMDBM682 1046 Chromatiaceae PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 0, 0.2, 0.6, 1.7, 2.9, 5.7, 11.5, 23.0, or 45.0 mM in water environment Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish embryo Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30321396" PMDBI40108 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro n.a. Health n.a. n.a. PMID PMID: 29555994 PMDBI40108 Substances alter microbe abundance PMDBM839 33882 Microbacterium PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 25, 250, and 2500 娓璯/L in nutritional medium for 10 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29778027" PMDBI40109 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.55E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40109 Substances alter microbe abundance PMDBM2020092 188913 Cetobacterium somerae PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 12é–?8 娓璯/kg feed weight in dog food contaminated with BPA can lining, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Dog Gonadectomized n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27932218" PMDBI40110 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40110 Substances alter microbe abundance PMDBM851 203693 Nitrospira PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 30 娓璯/kg BW gavaged from PND 28 to 56 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Nonobese diabetic n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30600366" PMDBI40111 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40111 Substances alter microbe abundance PMDBM786 219685 Gemmatimonadetes PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 30 娓璯/kg BW gavaged from PND 28 to 56 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Nonobese diabetic n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30600366" PMDBI40112 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.27E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40112 Substances alter microbe abundance PMDBM832 1091138 Lawsonia PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 0, 2, and 20 娓璯/L and 2 or 20 娓璯/L BPA + 100娓璯/l nano-TiO2 in water environment for 3 months Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29356515" PMDBI40113 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40113 Substances alter microbe abundance PMDBM778 n.a. Flexispira spp PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 12é–?8 娓璯/kg feed weight in dog food contaminated with BPA can lining, 14 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Dog Gonadectomized n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27932218" PMDBI40114 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.83E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40114 Substances alter microbe abundance PMDBM843 n.a. Mogibacteriaceae PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27624382" PMDBI40115 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.14E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40115 Substances alter microbe abundance PMDBM843 n.a. Mogibacteriaceae PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27624382" PMDBI40116 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40116 Substances alter microbe abundance PMDBM888 n.a. Prevotella spp. PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 12é–?8 娓璯/kg feed weight in dog food contaminated with BPA can lining, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Dog Gonadectomized n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27932218" PMDBI40117 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40117 Substances alter microbe abundance PMDBM920 n.a. Ruminococcus spp. PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 12é–?8 娓璯/kg feed weight in dog food contaminated with BPA can lining, 14 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Dog Gonadectomized n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27932218" PMDBI40118 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40118 Substances alter microbe abundance PMDBM962 n.a. Sutterella spp. PMDBD1060 Bisphenol A Environmental Substance "Industrial Compounds; Bisphenols" 50 mg/kg feed weight (approximately 10 mg/kg bw) F0 dams exposed through chow 2 weeks before mating through PND 30 (weaning), F0 males exposed breeding through weaning Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27624382" PMDBI40119 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 0, 5, 100, and 200 娓璯/ l from Gosner stage 26 to 38 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31121551" PMDBI40119 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.79E-05] n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. n.a. PMID PMID: 29555994 PMDBI40120 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm in drinking water for 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 26352046" PMDBI40120 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.23E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40121 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 0, 50, and 500 娓璯 Cd/l in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30597321" PMDBI40121 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.16E-06] n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID PMID: 29555994 PMDBI40122 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 26352046" PMDBI40122 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40123 Substances alter microbe abundance PMDBM242 203490 Fusobacteria PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 0, 50, and 500 娓璯 Cd/l in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30597321" PMDBI40123 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID PMID: 29555994 PMDBI40124 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40124 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 0, 5, 100, and 200 娓璯/ l from Gosner stage 26 to 38 Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31121551" PMDBI40125 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40125 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 0, 50, and 500 娓璯 Cd/l in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30597321" PMDBI40126 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40126 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 0, 5, 100, and 200 娓璯/ l from Gosner stage 26 to 38 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31121551" PMDBI40127 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40127 Substances alter microbe abundance PMDBM679 180162 Cetobacterium PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 0, 50, and 500 娓璯 Cd/l in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30597321" PMDBI40128 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40128 Substances alter microbe abundance PMDBM998 n.a. ç»?Proteobacteria PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 26352046" PMDBI40129 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000119893] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40129 Substances alter microbe abundance PMDBM998 n.a. ç»?Proteobacteria PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm in drinking water for 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 26352046" PMDBI40130 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1074 Carbamate aldicarb Environmental Substance Pesticides n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 30406643" PMDBI40130 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.29E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40131 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.43E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40131 Substances alter microbe abundance PMDBM632 207244 Anaerostipes PMDBD1074 Carbamate aldicarb Environmental Substance Pesticides n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 30406643" PMDBI40132 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1076 Carbendazim Environmental Substance Pesticides 100 and 500 mg/kg/bw in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26071454" PMDBI40132 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40133 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1076 Carbendazim Environmental Substance Pesticides 100 and 500 mg/kg/bw in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26071454" PMDBI40133 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40134 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40134 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1076 Carbendazim Environmental Substance Pesticides 100 and 500 mg/kg/bw in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26071454" PMDBI40135 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40135 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1076 Carbendazim Environmental Substance Pesticides 100 and 500 mg/kg/bw in food Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26071454" PMDBI40136 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1076 Carbendazim Environmental Substance Pesticides 0.2é–? mg/kg orally via drinking water for 14 weeks starting at 6 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30496565" PMDBI40136 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.92E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40137 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40137 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD1076 Carbendazim Environmental Substance Pesticides 0.2é–? mg/kg orally via drinking water for 14 weeks starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30496565" PMDBI40138 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.40E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40138 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1076 Carbendazim Environmental Substance Pesticides 0.2é–? mg/kg orally via drinking water for 14 weeks starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30496565" PMDBI40139 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40139 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1076 Carbendazim Environmental Substance Pesticides 0.2é–? mg/kg orally via drinking water for 14 weeks starting at 6 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30496565" PMDBI40140 Substances alter microbe abundance PMDBM29 171549 Bacteroidales PMDBD1079 carboxymethylcellulose or polysorbate-80 Environmental Substance Food Additives Feeding mice for 12 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25731162" PMDBI40140 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40141 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000275861] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40141 Substances alter microbe abundance PMDBM2020247 33038 Ruminococcus gnavus PMDBD1079 carboxymethylcellulose or polysorbate-80 Environmental Substance Food Additives Feeding mice for 12 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25731162" PMDBI40142 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40142 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.37E-05] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40143 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40143 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40144 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40144 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.94E-05] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40145 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 100nM Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27634282" PMDBI40145 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.40E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40146 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40146 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.51E-05] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40147 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 100nM Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27634282" PMDBI40147 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40148 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40148 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40149 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40149 Substances alter microbe abundance PMDBM399 191303 Turicibacter PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40150 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40150 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 500 ug/L Cd in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321" PMDBI40151 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40151 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 500 ug/L Cd in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321" PMDBI40152 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.17E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40152 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 100nM Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27634282" PMDBI40153 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40153 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40154 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000172932] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40154 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 100nM Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27634282" PMDBI40155 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.63E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40155 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40156 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.52E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40156 Substances alter microbe abundance PMDBM613 642 Aeromonas PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 500 ug/L Cd in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321" PMDBI40157 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40157 Substances alter microbe abundance PMDBM603 12916 Acidovorax PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 500 ug/L Cd in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321" PMDBI40158 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.91E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40158 Substances alter microbe abundance PMDBM944 13687 Sphingomonas PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 100nM Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27634282" PMDBI40159 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.67E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40159 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 20 or 100 ppm-mg/L in drinking water for 8weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40160 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40160 Substances alter microbe abundance PMDBM2020152 43263 Pseudomonas alcaligenes PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 500 ug/L Cd in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321" PMDBI40161 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.08E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40161 Substances alter microbe abundance PMDBM671 84646 Candidatus Odyssella PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 500 ug/L Cd in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321" PMDBI40162 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40162 Substances alter microbe abundance PMDBM679 180162 Cetobacterium PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 500 ug/L Cd in drinking water for 4 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321" PMDBI40163 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40163 Substances alter microbe abundance PMDBM623 n.a. Alpha and beta diversity PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 100nM Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27634282" PMDBI40164 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.11E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40164 Substances alter microbe abundance PMDBM853 n.a. norank_c_Cyanobacteria PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 500 ug/L Cd in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321" PMDBI40165 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40165 Substances alter microbe abundance PMDBM854 n.a. norank_f_Erysipelotrichaceae PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 500 ug/L Cd in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321" PMDBI40166 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.98E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40166 Substances alter microbe abundance PMDBM981 n.a. Unclassified_f_Comamonadaceae PMDBD1068 Cadmium Environmental Substance "Heavy Metals; Toxic Agents" 500 ug/L Cd in drinking water for 4 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Cyprinus carpio Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30597321" PMDBI40167 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.97E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40167 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1107 Chlorothalonil Environmental Substance Pesticides Chlorothalonil : 10 娓璯/l in 30% sucrose solution for 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27579024" PMDBI40168 Substances alter microbe abundance PMDBM109 n.a. Bifidobacterium spp. PMDBD1111 Chlorpyrifos Environmental Substance Pesticides Chronic exposure to low doses Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.1124/pr.118.015768; PMID: 23135753" PMDBI40168 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. "In vitro; In vivo(Rat)" "Human; Rats" n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40169 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD1111 Chlorpyrifos Environmental Substance Pesticides Chronic exposure to low doses Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.1124/pr.118.015768; PMID: 23135753" PMDBI40169 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. "In vitro; In vivo(Rat)" "Human; Rats" n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40170 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40170 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg body weight per day by oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27018521" PMDBI40171 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003263891] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40171 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg body weight per day by oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27018521" PMDBI40172 Substances alter microbe abundance PMDBM2020038 1532 Clostridium coccoides PMDBD1111 Chlorpyrifos Environmental Substance Pesticides "1 or 3.5 mg/kg gavage to dams from GD 1 until PND 21, gavage to pups from PND 21 to 60; inulin cotreatment" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27827942" PMDBI40172 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.51E-05] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40173 Substances alter microbe abundance PMDBM13 1283313 Alloprevotella PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 0.3 or 3 mg/kg by gavage daily for 9 weeks starting at 9 weeks of age with high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29109040" PMDBI40173 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.94E-05] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40174 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/day in oil to SHIME for 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27827942" PMDBI40174 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40175 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 or 5 mg/kg bw/day by oral gavage from GD 0 to PND 21 (dams) and PND 21é–?0 (pups) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 25643018" PMDBI40175 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009959859] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40176 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 0.3 or 3 mg/kg by gavage daily for 9 weeks starting at 9 weeks of age with normal-or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29109040" PMDBI40176 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.45E-05] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40177 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/day in oil to SHIME for 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27827942" PMDBI40177 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40178 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg per day for 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23135753" PMDBI40178 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003138697] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40179 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg by gavage daily for 30 days beginning at 12 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27018521" PMDBI40179 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001045178] n.a. n.a. n.a. n.a. In vivo Kunming mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40180 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1111 Chlorpyrifos Environmental Substance Pesticides "1 or 3.5 mg/kg gavage to dams from GD 1 until PND 21, gavage to pups from PND 21 to 60; inulin cotreatment" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27827942" PMDBI40180 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.19E-05] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40181 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg bw/day by oral gavage from GD 0 to PND 21 (dams) and PND 21é–?0 (pups) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23135753" PMDBI40181 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.51E-06] n.a. n.a. n.a. n.a. In vivo Wistar Hannover rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40182 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg per day for 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23135753" PMDBI40182 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40183 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides "3.5 mg/day injection in media into SHIME reactor for 30 days; cells treated with SHIME supernatant for 6 or 24 h; inulin cotreatment" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro "SHIME intestinal environment mimic model; Caco-2/TC7 human intestinal cells" Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29808406" PMDBI40183 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.53E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40184 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 or 5 mg/kg bw/day by oral gavage from GD 0 to PND 21 (dams) and PND 21é–?0 (pups) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 25643018" PMDBI40184 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.25E-05] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40185 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg by gavage daily for 30 days beginning at 12 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27018521" PMDBI40185 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001902308] n.a. n.a. n.a. n.a. In vivo Kunming mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40186 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg bw/day by oral gavage from GD 0 to PND 21 (dams) and PND 21é–?0 (pups) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23135753" PMDBI40186 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001339048] n.a. n.a. n.a. n.a. In vivo Wistar Hannover rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40187 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg per day for 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23135753" PMDBI40187 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001689365] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40188 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/day in oil to SHIME for 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27827942" PMDBI40188 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40189 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002157434] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40189 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 5 mg/kg by gavage daily at 4 weeks of age for 12 weeks with normal-or high-fat diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo "C57BL/6 mouse; CD1 (ICR) mouse" Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30744700" PMDBI40190 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.73E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40190 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 30é–?00 娓璯/l in water environment for 21 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31400786" PMDBI40191 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.02E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40191 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 or 5 mg/kg bw/day by oral gavage from GD 0 to PND 21 (dams) and PND 21é–?0 (pups) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 25643018" PMDBI40192 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.89E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40192 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 5 mg/kg by gavage daily at 4 weeks of age for 12 weeks with normal-or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo "C57BL/6 mouse; CD1 (ICR) mouse" Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30744700" PMDBI40193 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000559075] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40193 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg by gavage daily for 30 days beginning at 12 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Kunming mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27018521" PMDBI40194 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40194 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg bw/day by oral gavage from GD 0 to PND 21 (dams) and PND 21é–?0 (pups) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Hannover rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23135753" PMDBI40195 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.26E-05] n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model Health n.a. n.a. PMID PMID: 29555994 PMDBI40195 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg per day for 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23135753" PMDBI40196 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001078837] n.a. n.a. n.a. n.a. In vitro "SHIME intestinal environment mimic model; Caco-2/TC7 human intestinal cells" Health n.a. n.a. PMID PMID: 29555994 PMDBI40196 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1111 Chlorpyrifos Environmental Substance Pesticides "3.5 mg/day injection in media into SHIME reactor for 30 days; cells treated with SHIME supernatant for 6 or 24 h; inulin cotreatment" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29808406" PMDBI40197 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000244787] n.a. n.a. n.a. n.a. In vitro SHIME intestinal environment mimic model Health n.a. n.a. PMID PMID: 29555994 PMDBI40197 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/day in oil to SHIME for 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27827942" PMDBI40198 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40198 Substances alter microbe abundance PMDBM612 1375 Aerococcus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 0.3 or 3 mg/kg by gavage daily for 9 weeks starting at 9 weeks of age with normal-or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29109040" PMDBI40199 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.64E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40199 Substances alter microbe abundance PMDBM625 29331 Amphibacillus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 0.3 or 3 mg/kg by gavage daily for 9 weeks starting at 9 weeks of age with normal-or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29109040" PMDBI40200 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.86E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40200 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 1 mg/kg by gavage daily for 30 days beginning at 12 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Kunming mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27018521" PMDBI40201 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000422533] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40201 Substances alter microbe abundance PMDBM663 41275 Brevundimonas PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 0.3 or 3 mg/kg by gavage daily for 9 weeks starting at 9 weeks of age with normal-or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29109040" PMDBI40202 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000756371] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40202 Substances alter microbe abundance PMDBM973 82802 Trichococcus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 0.3 or 3 mg/kg by gavage daily for 9 weeks starting at 9 weeks of age with norma diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29109040" PMDBI40203 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000129582] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40203 Substances alter microbe abundance PMDBM859 133925 Olsenella PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 0.3 or 3 mg/kg by gavage daily for 9 weeks starting at 9 weeks of age with normal-or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29109040" PMDBI40204 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001220011] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40204 Substances alter microbe abundance PMDBM760 580024 Enterorhabdus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 0.3 or 3 mg/kg by gavage daily for 9 weeks starting at 9 weeks of age with normal-or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29109040" PMDBI40205 Substances alter microbe abundance PMDBM120 80840 Burkholderiales PMDBD1111 Chlorpyrifos Environmental Substance Pesticides Treated strips following manufacturer's instructions for 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27579024" PMDBI40205 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000112711] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40206 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 650 娓璯/kg in sugar syrup for 24é–?4 h of interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31378758" PMDBI40206 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000301738] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40207 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003741022] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40207 Substances alter microbe abundance PMDBM86 85004 Bi?dobacteriales PMDBD1111 Chlorpyrifos Environmental Substance Pesticides Treated strips following manufacturer's instructions for 6 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27579024" PMDBI40208 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000249869] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40208 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1111 Chlorpyrifos Environmental Substance Pesticides 650 娓璯/kg in sugar syrup for 24é–?4 h of interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31378758" PMDBI40209 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1115 Chromium (VI) Environmental Substance "Heavy Metals; Toxic Agents" 2 mM for 7 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.3390/nu11010022; PMID: 29118411" PMDBI40209 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005590073] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40210 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1115 Chromium (VI) Environmental Substance "Heavy Metals; Toxic Agents" 2 mM for 7 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.3390/nu11010022; PMID: 29118411" PMDBI40210 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.74E-05] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40211 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000223955] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40211 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1115 Chromium (VI) Environmental Substance "Heavy Metals; Toxic Agents" 2 mM for 7 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.3390/nu11010022; PMID: 29118411" PMDBI40212 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00431781] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40212 Substances alter microbe abundance PMDBM965 544448 Tenericutes PMDBD1115 Chromium (VI) Environmental Substance "Heavy Metals; Toxic Agents" 2 mM for 7 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.3390/nu11010022; PMID: 29118411" PMDBI40213 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000488322] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40213 Substances alter microbe abundance PMDBM871 n.a. Paraprevotellaceae PMDBD1115 Chromium (VI) Environmental Substance "Heavy Metals; Toxic Agents" 2 mM for 7 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.3390/nu11010022; PMID: 29118411" PMDBI40214 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40214 Substances alter microbe abundance PMDBM921 n.a. S24-7 PMDBD1115 Chromium (VI) Environmental Substance "Heavy Metals; Toxic Agents" 2 mM for 7 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.3390/nu11010022; PMID: 29118411" PMDBI40215 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003977197] n.a. n.a. n.a. n.a. n.a. Medaka fishes Health n.a. n.a. PMID PMID: 29555994 PMDBI40215 Substances alter microbe abundance PMDBM943 204457 Sphingomonadales PMDBD1132 Crude extracts of metabolites from Microcystis aeruginosa Environmental Substance Biological Contaminants n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4 PMDBI40216 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005043812] n.a. n.a. n.a. n.a. n.a. Medaka fishes Health n.a. n.a. PMID PMID: 29555994 PMDBI40216 Substances alter microbe abundance PMDBM927 1936988 Saprospirales PMDBD1132 Crude extracts of metabolites from Microcystis aeruginosa Environmental Substance Biological Contaminants n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4 PMDBI40217 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005682417] n.a. n.a. n.a. n.a. n.a. Medaka fishes Health n.a. n.a. PMID PMID: 29555994 PMDBI40217 Substances alter microbe abundance PMDBM846 n.a. Mycobacterium spp. PMDBD1132 Crude extracts of metabolites from Microcystis aeruginosa Environmental Substance Biological Contaminants n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4 PMDBI40218 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD713 Protriptyline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005259467] n.a. n.a. n.a. n.a. n.a. Medaka fishes Health n.a. n.a. PMID PMID: 29555994 PMDBI40218 Substances alter microbe abundance PMDBM852 n.a. Nocardia spp. PMDBD1132 Crude extracts of metabolites from Microcystis aeruginosa Environmental Substance Biological Contaminants n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1007/978-981-15-4759-1_4 PMDBI40219 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1133 Cyclamate Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:10.1038/npjbiofilms.2016.3; PMID: 4655823" PMDBI40219 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD431 Hycanthone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004412596] n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40220 Substances alter microbe abundance PMDBM2020193 216816 Bi?dobacterium longum PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates Newborns who did not receive intravenous infusion (control) vs newborns with respiratory distress who were given intravenous infusions Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human Health Newborn infants n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31356917" PMDBI40220 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD433 Hydrocortisone base Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008623045] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40221 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates 0, 1, or 10 mg/kg/day (oral gavage every other day)0, 10, or 100 å¨“ç’ DEHP in cecal contents(in vitro) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31822602" PMDBI40221 Substances alter microbe abundance PMDBM2020238 47678 Bacteroides caccae PMDBD296 Eburnamonine (-) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002903472] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40222 Substances alter microbe abundance PMDBM302 283168 Odoribacter PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates 0, 1, or 10 mg/kg/day (oral gavage every other day)0, 10, or 100 å¨“ç’ DEHP in cecal contents(in vitro) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31822602" PMDBI40222 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.05E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40223 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40223 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates 0, 1, or 10 mg/kg/day (oral gavage every other day)0, 10, or 100 å¨“ç’ DEHP in cecal contents(in vitro) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31822602" PMDBI40224 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.14E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40224 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates 0, 1, or 10 mg/kg/day (oral gavage every other day)0, 10, or 100 å¨“ç’ DEHP in cecal contents(in vitro) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31822602" PMDBI40225 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40225 Substances alter microbe abundance PMDBM865 44249 Paenibacillus PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates 0, 1, or 10 mg/kg/day (oral gavage every other day)0, 10, or 100 å¨“ç’ DEHP in cecal contents(in vitro) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31822602" PMDBI40226 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40226 Substances alter microbe abundance PMDBM809 1506553 Lachnoclostridium PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates 0, 10, or 100 å¨“ç’ DEHP in cecal contents (in vitro) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31822602" PMDBI40227 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.37E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40227 Substances alter microbe abundance PMDBM809 1506553 Lachnoclostridium PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates 0, 1, or 10 mg/kg/day (oral gavage every other day) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31822602" PMDBI40228 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. n.a. Human Health Newborn infants n.a. n.a. PMID PMID: 29555994 PMDBI40228 Substances alter microbe abundance PMDBM915 n.a. Rothia spp. PMDBD1153 Di(2-ethylhexyl) phthlate Environmental Substance Phthalates Newborns who did not receive intravenous infusion (control) vs newborns with respiratory distress who were given intravenous infusions Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31356917" PMDBI40229 Substances alter microbe abundance PMDBM2020035 562 Escherichia coli PMDBD1146 Deoxynivalenol Environmental Substance Biological Contaminants 100 娓璯/kg DON Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24260424" PMDBI40229 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40230 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40230 Substances alter microbe abundance PMDBM890 n.a. Prevotella/Bacteroides PMDBD1146 Deoxynivalenol Environmental Substance Biological Contaminants 100 娓璯/kg DON Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24260424" PMDBI40231 Substances alter microbe abundance PMDBM25 91061 Bacilli PMDBD1147 "DEP; methylparaben; triclosan" Environmental Substance Phthalates 0.1735, 0.105, and 0.05 mg/kg/day Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27301250" PMDBI40231 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000104068] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40232 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1147 "DEP; methylparaben; triclosan" Environmental Substance Phthalates 0.1735, 0.105, and 0.05 mg/kg/day Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27301250" PMDBI40232 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.45E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40233 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003986644] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40233 Substances alter microbe abundance PMDBM749 641853 Elusimicrobia PMDBD1147 "DEP; methylparaben; triclosan" Environmental Substance Phthalates 0.1735, 0.105, and 0.05 mg/kg/day Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27301250" PMDBI40234 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40234 Substances alter microbe abundance PMDBM805 43994 Johnsonella PMDBD1155 Diazinon Environmental Substance Pesticides 13 weeks of diazinon exposure (4 ppm) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Specific pathogen-free n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 27203275" PMDBI40235 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40235 Substances alter microbe abundance PMDBM805 43994 Johnsonella PMDBD1155 Diazinon Environmental Substance Pesticides 13 weeks of diazinon exposure (4 ppm) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 27203275" PMDBI40236 Substances alter microbe abundance PMDBM120 80840 Burkholderiales PMDBD1155 Diazinon Environmental Substance Pesticides 4 mg/l in drinking water for 13 weeks starting at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27203275" PMDBI40236 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.23E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40237 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD1155 Diazinon Environmental Substance Pesticides 4 mg/l in drinking water for 13 weeks starting at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27203275" PMDBI40237 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40238 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1155 Diazinon Environmental Substance Pesticides 4 mg/l in drinking water for 13 weeks starting at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27203275" PMDBI40238 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40239 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1155 Diazinon Environmental Substance Pesticides 4 mg/l in drinking water for 13 weeks starting at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27203275" PMDBI40239 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.12E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40240 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD1155 Diazinon Environmental Substance Pesticides 4 mg/l in drinking water for 13 weeks starting at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27203275" PMDBI40240 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40241 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40241 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1155 Diazinon Environmental Substance Pesticides 4 mg/l in drinking water for 13 weeks starting at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27203275" PMDBI40242 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40242 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD1155 Diazinon Environmental Substance Pesticides 4 mg/l in drinking water for 13 weeks starting at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27203275" PMDBI40243 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1157 Dichlorodiphenyl-dichloroethylene Environmental Substance Pesticides 1 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 28392238" PMDBI40243 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.39E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40244 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1157 Dichlorodiphenyl-dichloroethylene Environmental Substance Pesticides 1 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 28392238" PMDBI40244 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40245 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1157 Dichlorodiphenyl-dichloroethylene Environmental Substance Pesticides 1 mg/kg body weight per day via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 28392238" PMDBI40245 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40246 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD1157 Dichlorodiphenyl-dichloroethylene Environmental Substance Pesticides 1 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 28392238" PMDBI40246 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40247 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.38E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40247 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1157 Dichlorodiphenyl-dichloroethylene Environmental Substance Pesticides 1 mg/kg body weight per day via oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 28392238" PMDBI40248 Substances alter microbe abundance PMDBM13 1283313 Alloprevotella PMDBD1159 Diethyl phosphate (metabolite of CPF+ others)(I) Environmental Substance Pesticides 0.08 or 0.13 mg/kg by gavage daily for 20 weeks starting at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31137755" PMDBI40248 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000489548] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40249 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1159 Diethyl phosphate (metabolite of CPF+ others)(I) Environmental Substance Pesticides 0.08 or 0.13 mg/kg by gavage daily for 20 weeks starting at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31137755" PMDBI40249 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.10E-06] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40250 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40250 Substances alter microbe abundance PMDBM792 209 Helicobacter PMDBD1159 Diethyl phosphate (metabolite of CPF+ others)(I) Environmental Substance Pesticides 0.08 or 0.13 mg/kg by gavage daily for 20 weeks starting at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31137755" PMDBI40251 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.06E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40251 Substances alter microbe abundance PMDBM870 577309 Paraprevotella PMDBD1159 Diethyl phosphate (metabolite of CPF+ others)(I) Environmental Substance Pesticides 0.08 or 0.13 mg/kg by gavage daily for 20 weeks starting at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31137755" PMDBI40252 Substances alter microbe abundance PMDBM2020155 303 Pseudomonas putida PMDBD1164 DMP, DEP, and DBP combined Environmental Substance Phthalates 500 mg/l Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31467957" PMDBI40252 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vivo "Hypophthalmichthys molitrix; Hypophthalmichthys Nobilis" Health n.a. n.a. PMID PMID: 29555994 PMDBI40253 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40253 Substances alter microbe abundance PMDBM2020080 1423 Bacillus subtilis PMDBD1164 DMP, DEP, and DBP combined Environmental Substance Phthalates 500 mg/l Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo "Hypophthalmichthys molitrix; Hypophthalmichthys Nobilis" Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31467957" PMDBI40254 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40254 Substances alter microbe abundance PMDBM2020153 256466 Pseudomonas japonica PMDBD1164 DMP, DEP, and DBP combined Environmental Substance Phthalates 500 mg/l Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo "Hypophthalmichthys molitrix; Hypophthalmichthys Nobilis" Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31467957" PMDBI40255 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40255 Substances alter microbe abundance PMDBM2020074 1287736 Achromobacter aegrifaciens PMDBD1164 DMP, DEP, and DBP combined Environmental Substance Phthalates 500 mg/l Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo "Hypophthalmichthys molitrix; Hypophthalmichthys Nobilis" Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31467957" PMDBI40256 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1173 Emulsi?ers (P80 and CMC) Environmental Substance Unclassified Environmental Substances n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 25731162" PMDBI40256 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.99E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40257 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.57E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40257 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1173 Emulsi?ers (P80 and CMC) Environmental Substance Unclassified Environmental Substances n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 25731162" PMDBI40258 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 and100 mg/kg/day in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25766299" PMDBI40258 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.16E-06] n.a. n.a. n.a. n.a. In vivo Sprague-Dawley Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40259 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 and100 mg/kg/day in food Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25766299" PMDBI40259 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.96E-06] n.a. n.a. n.a. n.a. In vivo Sprague-Dawley Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40260 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 and100 mg/kg/day in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25766299" PMDBI40260 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000427754] n.a. n.a. n.a. n.a. In vivo Sprague-Dawley Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40261 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 and100 mg/kg/day in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25766299" PMDBI40261 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.05E-06] n.a. n.a. n.a. n.a. In vivo Sprague-Dawley Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40262 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40262 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 and100 mg/kg/day in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague-Dawley Rat Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25766299" PMDBI40263 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40263 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 and100 mg/kg/day in food Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague-Dawley Rat Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25766299" PMDBI40264 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 or 100 mg/kg via diet for 90 days starting at 9 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 25766299" PMDBI40264 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40265 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 or 100 mg/kg via diet for 90 days starting at 9 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 25766299" PMDBI40265 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000109768] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40266 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000281647] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40266 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1176 Epoxiconazole Environmental Substance Pesticides 4 or 100 mg/kg via diet for 90 days starting at 9 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 25766299" PMDBI40267 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1194 Fipronil Environmental Substance Pesticides 0.25 or 1.0 娓璯/kg in sugar syrup for 24é–?4 h of interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31378758" PMDBI40267 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002053979] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40268 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40268 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1194 Fipronil Environmental Substance Pesticides 0.25 or 1.0 娓璯/kg in sugar syrup for 24é–?4 h of interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31378758" PMDBI40269 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.09E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40269 Substances alter microbe abundance PMDBM2020176 1196083 Snodgrassella alvi PMDBD1194 Fipronil Environmental Substance Pesticides 0.25 or 1.0 娓璯/kg in sugar syrup for 24é–?4 h of interior worker bees Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31378758" PMDBI40270 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40270 Substances alter microbe abundance PMDBM2020124 1196095 Gilliamella apicola PMDBD1194 Fipronil Environmental Substance Pesticides 0.25 or 1.0 娓璯/kg in sugar syrup for 24é–?4 h of interior worker bees Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31378758" PMDBI40271 Substances alter microbe abundance PMDBM2020202 29347 Clostridium scindens PMDBD1208 Fox River mixture (PCBs mixture) Environmental Substance Persistent Organic Pollutants 6 or 30 mg/kg once daily via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30496569" PMDBI40271 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40272 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1208 Fox River mixture (PCBs mixture) Environmental Substance Persistent Organic Pollutants 6 or 30 mg/kg once daily via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30496569" PMDBI40272 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40273 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1208 Fox River mixture (PCBs mixture) Environmental Substance Persistent Organic Pollutants 6 or 30 mg/kg once daily via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30496569" PMDBI40273 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000288831] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40274 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001529607] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40274 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD1208 Fox River mixture (PCBs mixture) Environmental Substance Persistent Organic Pollutants 6 or 30 mg/kg once daily via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30496569" PMDBI40275 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40275 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1208 Fox River mixture (PCBs mixture) Environmental Substance Persistent Organic Pollutants 6 or 30 mg/kg once daily via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30496569" PMDBI40276 Substances alter microbe abundance PMDBM2020032 1351 Enterococcus faecalis PMDBD1218 Glyphosate Environmental Substance Pesticides n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:10.1038/npjbiofilms.2016.3; PMID: 23396248" PMDBI40276 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000124525] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40277 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1218 Glyphosate Environmental Substance Pesticides 50 ng/L, 0.1 g/L and 2.25 g/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29854581" PMDBI40277 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40278 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40278 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1218 Glyphosate Environmental Substance Pesticides 50 ng/L, 0.1 g/L and 2.25 g/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29854581" PMDBI40279 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.22E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40279 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1218 Glyphosate Environmental Substance Pesticides 50 ng/L, 0.1 g/L and 2.25 g/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29854581" PMDBI40280 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.43E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40280 Substances alter microbe abundance PMDBM921 n.a. S24-7 PMDBD1218 Glyphosate Environmental Substance Pesticides 50 ng/L, 0.1 g/L and 2.25 g/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29854581" PMDBI40281 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1218 Glyphosate Environmental Substance Pesticides "1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks" Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29843725" PMDBI40281 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.59E-05] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40282 Substances alter microbe abundance PMDBM121 580596 Butyricicoccus PMDBD1218 Glyphosate Environmental Substance Pesticides 5 mg/kg/day oral dose via biscuits daily from GD 10 to PND 22 (weaning) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31066122" PMDBI40282 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.91E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40283 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD1218 Glyphosate Environmental Substance Pesticides 0.8, 4, and 20 mg/l in diet from days 2 to 5 after grafting (larval stage) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29992812" PMDBI40283 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.38E-06] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40284 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD1218 Glyphosate Environmental Substance Pesticides 0.8, 4, and 20 mg/l in diet from days 2 to 5 after grafting (larval stage) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29992812" PMDBI40284 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40285 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1218 Glyphosate Environmental Substance Pesticides 0.8, 4, and 20 mg/l in diet from days 2 to 5 after grafting (larval stage) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29992812" PMDBI40285 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40286 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1218 Glyphosate Environmental Substance Pesticides 5 mg/kg/day oral dose via biscuits daily from GD 10 to PND 22 (weaning) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31066122" PMDBI40286 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00209371] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40287 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1218 Glyphosate Environmental Substance Pesticides 0.8, 4, and 20 mg/l in diet from days 2 to 5 after grafting (larval stage) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29992812" PMDBI40287 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000812744] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40288 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1218 Glyphosate Environmental Substance Pesticides "1.5 or 7.5 mM in sugar syrup for 15 days; infection with parasite" Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30990837" PMDBI40288 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.24E-06] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40289 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1218 Glyphosate Environmental Substance Pesticides 5 mg/l for 5 days of adult workers Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30249635" PMDBI40289 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.07E-06] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40290 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1218 Glyphosate Environmental Substance Pesticides "1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29843725" PMDBI40290 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.45E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40291 Substances alter microbe abundance PMDBM297 248038 Mucispirillum PMDBD1218 Glyphosate Environmental Substance Pesticides "1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks" Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29843725" PMDBI40291 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40292 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1218 Glyphosate Environmental Substance Pesticides "1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks" Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29843725" PMDBI40292 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40293 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD1218 Glyphosate Environmental Substance Pesticides 0.8, 4, and 20 mg/l in diet from days 2 to 5 after grafting (larval stage) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29992812" PMDBI40293 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.65E-06] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40294 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD1218 Glyphosate Environmental Substance Pesticides 0.8, 4, and 20 mg/l in diet from days 2 to 5 after grafting (larval stage) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29992812" PMDBI40294 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.38E-06] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40295 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1218 Glyphosate Environmental Substance Pesticides "1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29843725" PMDBI40295 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000105033] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40296 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002594892] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40296 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1218 Glyphosate Environmental Substance Pesticides 5 mg/kg/day oral dose via biscuits daily from GD 10 to PND 22 (weaning) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31066122" PMDBI40297 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.58E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40297 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1218 Glyphosate Environmental Substance Pesticides "5 or 10 mg/l for 5 days of adult workers; 1 mM for 2 days or 0.1 mM for 5 days of newly hatched workers" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30249635" PMDBI40298 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.18E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40298 Substances alter microbe abundance PMDBM615 416916 Aggregatibacter PMDBD1218 Glyphosate Environmental Substance Pesticides "1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29843725" PMDBI40299 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000269368] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40299 Substances alter microbe abundance PMDBM2020176 1196083 Snodgrassella alvi PMDBD1218 Glyphosate Environmental Substance Pesticides "5 or 10 mg/l for 5 days of adult workers; 1 mM for 2 days or 0.1 mM for 5 days of newly hatched workers" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30249635" PMDBI40300 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40300 Substances alter microbe abundance PMDBM2020176 1196083 Snodgrassella alvi PMDBD1218 Glyphosate Environmental Substance Pesticides "1.5 or 7.5 mM in sugar syrup for 15 days; infection with parasite" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30990837" PMDBI40301 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40301 Substances alter microbe abundance PMDBM2020124 1196095 Gilliamella apicola PMDBD1218 Glyphosate Environmental Substance Pesticides "1.5 or 7.5 mM in sugar syrup for 15 days; infection with parasite" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30990837" PMDBI40302 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40302 Substances alter microbe abundance PMDBM2020124 1196095 Gilliamella apicola PMDBD1218 Glyphosate Environmental Substance Pesticides 5 mg/l for 5 days of adult workers Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30249635" PMDBI40303 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40303 Substances alter microbe abundance PMDBM729 n.a. Dasytricha spp. PMDBD1218 Glyphosate Environmental Substance Pesticides 1, 10, 100 娓璯/ml in rumen ?uid cultured in DAISY incubators for 48 h Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Nonlactating Holstein-Friesian cow rumen ?uid n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 25407376" PMDBI40304 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000209667] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40304 Substances alter microbe abundance PMDBM745 n.a. Diplodinium spp. PMDBD1218 Glyphosate Environmental Substance Pesticides 1, 10, 100 娓璯/ml in rumen ?uid cultured in DAISY incubators for 48 h Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Nonlactating Holstein-Friesian cow rumen ?uid n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 25407376" PMDBI40305 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005817323] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40305 Substances alter microbe abundance PMDBM761 n.a. Entodinium spp. PMDBD1218 Glyphosate Environmental Substance Pesticides 1, 10, 100 娓璯/ml in rumen ?uid cultured in DAISY incubators for 48 h Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Nonlactating Holstein-Friesian cow rumen ?uid n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 25407376" PMDBI40306 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40306 Substances alter microbe abundance PMDBM762 n.a. Epidinium spp. PMDBD1218 Glyphosate Environmental Substance Pesticides 1, 10, 100 娓璯/ml in rumen ?uid cultured in DAISY incubators for 48 h Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Nonlactating Holstein-Friesian cow rumen ?uid n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 25407376" PMDBI40307 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.21E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40307 Substances alter microbe abundance PMDBM861 n.a. Ophryoscolex spp. PMDBD1218 Glyphosate Environmental Substance Pesticides 1, 10, 100 娓璯/ml in rumen ?uid cultured in DAISY incubators for 48 h Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Nonlactating Holstein-Friesian cow rumen ?uid n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 25407376" PMDBI40308 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.47E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40308 Substances alter microbe abundance PMDBM998 n.a. ç»?Proteobacteria PMDBD1218 Glyphosate Environmental Substance Pesticides 0.8, 4, and 20 mg/l in diet from days 2 to 5 after grafting (larval stage) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29992812" PMDBI40309 Substances alter microbe abundance PMDBM127 194 Campylobacter PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.075é–? mg/ml in media for up to 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Bacterial strains from poultry n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23224412" PMDBI40309 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00055263] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40310 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides Bacterial strains from rat feces were treated with 0.1 ppb, 400 ppm, or 5000 ppm in media for 24 h Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29854581" PMDBI40310 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000699998] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40311 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 250 or 500 mg/kg bw/day dose by gavage beginning at 1 month of age for 1 day, 6 weeks, or 12 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29635013" PMDBI40311 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000160752] n.a. n.a. n.a. n.a. In vivo Swiss mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40312 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.075é–? mg/ml in media for up to 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Bacterial strains from poultry n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23224412" PMDBI40312 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001030079] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40313 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides Bacterial strains from rat feces were treated with 400 ppm or 5000 ppm in media for 24 h Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29854581" PMDBI40313 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001585698] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40314 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 5 mg/kg/day oral dose via biscuits daily from GD 10 to PND 22 (weaning) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31066122" PMDBI40314 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006143524] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40315 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 250 or 500 mg/kg bw/day dose by gavage beginning at 1 month of age for 1 day, 6 weeks, or 12 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29635013" PMDBI40315 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000970824] n.a. n.a. n.a. n.a. In vivo Swiss mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40316 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.075é–? mg/ml in media for up to 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Bacterial strains from poultry n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23224412" PMDBI40316 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000518619] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40317 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.075é–? mg/ml in media for up to 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro Bacterial strains from poultry n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23224412" PMDBI40317 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.96E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40318 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides "1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29843725" PMDBI40318 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00065096] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40319 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 250 or 500 mg/kg bw/day dose by gavage beginning at 1 month of age for 1 day, 6 weeks, or 12 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29635013" PMDBI40319 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000617244] n.a. n.a. n.a. n.a. In vivo Swiss mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40320 Substances alter microbe abundance PMDBM297 248038 Mucispirillum PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides "1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks" Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29843725" PMDBI40320 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.89E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40321 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides "1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks" Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29843725" PMDBI40321 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000159762] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40322 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides "1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks" Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29843725" PMDBI40322 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40323 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.00022 to 3.6 g/l in cultured bacteria from caecum of wild turtles Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29475651" PMDBI40323 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000560041] n.a. n.a. n.a. n.a. In vivo Hawaiian green turtles Health n.a. n.a. PMID PMID: 29555994 PMDBI40324 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.54E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40324 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 5 mg/kg/day oral dose via biscuits daily from GD 10 to PND 22 (weaning) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31066122" PMDBI40325 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.99E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40325 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.1 ppb, 400 ppm, or 5000 ppm in tap water for 673 days (50 ng/l, 0.1 g/l, and 2.25 g/l of glyphosate, respectively) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29854581" PMDBI40326 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000324943] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40326 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 250 or 500 mg/kg bw/day dose by gavage beginning at 1 month of age for 1 day, 6 weeks, or 12 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Swiss mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29635013" PMDBI40327 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00165225] n.a. n.a. n.a. n.a. In vitro Bacterial strains from poultry n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40327 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.075é–? mg/ml in media for up to 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23224412" PMDBI40328 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD494 Loratadine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002103888] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40328 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides Bacterial strains from rat feces were treated with 0.1 ppb, 400 ppm, or 5000 ppm in media for 24 h Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29854581" PMDBI40329 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000539738] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40329 Substances alter microbe abundance PMDBM938 620 Shigella PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.00022 to 3.6 g/l in cultured bacteria from caecum of wild turtles Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Hawaiian green turtles Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29475651" PMDBI40330 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.01E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40330 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides "1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks" Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29843725" PMDBI40331 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.94E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40331 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.1 ppb, 400 ppm, or 5000 ppm in tap water for 673 days (50 ng/l, 0.1 g/l, and 2.25 g/l of glyphosate, respectively) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29854581" PMDBI40332 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000278128] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40332 Substances alter microbe abundance PMDBM866 53335 Pantoea PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.00022 to 3.6 g/l in cultured bacteria from caecum of wild turtles Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Hawaiian green turtles Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29475651" PMDBI40333 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005331174] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40333 Substances alter microbe abundance PMDBM892 210425 Proteus PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides 0.00022 to 3.6 g/l in cultured bacteria from caecum of wild turtles Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Hawaiian green turtles Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29475651" PMDBI40334 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00888111] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40334 Substances alter microbe abundance PMDBM615 416916 Aggregatibacter PMDBD1219 Glyphosate-based herbicide Environmental Substance Pesticides "1.75 mg/kg bw/day in drinking water to dams from GD 6 through weaning (PND 28); pups dosed in drinking water following weaning for 6 or 13 weeks" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29843725" PMDBI40335 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000160215] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI40335 Substances alter microbe abundance PMDBM840 n.a. microbial diversity PMDBD1223 Hexachlorocyclohexane Environmental Substance Persistent Organic Pollutants n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31394347" PMDBI40336 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1223 Hexachlorocyclohexane Environmental Substance Pesticides Colostrum samples collected from eastern China Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31394347" PMDBI40336 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006648497] n.a. n.a. n.a. n.a. In vitro Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40337 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD1223 Hexachlorocyclohexane Environmental Substance Pesticides Colostrum samples collected from eastern China Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31394347" PMDBI40337 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000208434] n.a. n.a. n.a. n.a. In vitro Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40338 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.49E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40338 Substances alter microbe abundance PMDBM892 210425 Proteus PMDBD1223 Hexachlorocyclohexane Environmental Substance Pesticides Colostrum samples collected from eastern China Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro Human n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31394347" PMDBI40339 Substances alter microbe abundance PMDBM110 35832 Bilophila PMDBD1279 Mercury Environmental Substance "Heavy Metals; Toxic Agents" Hg (2 mg/kg body weight) through dietary for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432" PMDBI40339 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003048825] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40340 Substances alter microbe abundance PMDBM123 574697 Butyricimonas PMDBD1279 Mercury Environmental Substance "Heavy Metals; Toxic Agents" Hg (2 mg/kg body weight) through dietary for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432" PMDBI40340 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000241869] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40341 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1279 Mercury Environmental Substance "Heavy Metals; Toxic Agents" Hg (2 mg/kg body weight) through dietary for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432" PMDBI40341 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000680623] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40342 Substances alter microbe abundance PMDBM2 469 Acinetobacter PMDBD1279 Mercury Environmental Substance "Heavy Metals; Toxic Agents" Hg (2 mg/kg body weight) through dietary for 90 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432" PMDBI40342 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD172 Cephalosporanic acid, 7-amino Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000250272] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40343 Substances alter microbe abundance PMDBM307 119852 Oscillospira PMDBD1279 Mercury Environmental Substance "Heavy Metals; Toxic Agents" Hg (2 mg/kg body weight) through dietary for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432" PMDBI40343 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00665058] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40344 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1279 Mercury Environmental Substance "Heavy Metals; Toxic Agents" Hg (2 mg/kg body weight) through dietary for 90 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432" PMDBI40344 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD713 Protriptyline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00893217] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40345 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD858 Toltrazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001700046] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40345 Substances alter microbe abundance PMDBM946 1569 Sporosarcina PMDBD1279 Mercury Environmental Substance "Heavy Metals; Toxic Agents" Hg (2 mg/kg body weight) through dietary for 90 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432" PMDBI40346 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD12 Acarbose "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000422533] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40346 Substances alter microbe abundance PMDBM733 51514 Dehalobacterium PMDBD1279 Mercury Environmental Substance "Heavy Metals; Toxic Agents" Hg (2 mg/kg body weight) through dietary for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432" PMDBI40347 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD319 Ethacrynic acid "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000869818] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40347 Substances alter microbe abundance PMDBM804 227979 Jeotgalicoccus PMDBD1279 Mercury Environmental Substance "Heavy Metals; Toxic Agents" Hg (2 mg/kg body weight) through dietary for 90 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432" PMDBI40348 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD857 Tolnaftate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009316771] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40348 Substances alter microbe abundance PMDBM965 544448 Tenericutes PMDBD1279 Mercury Environmental Substance "Heavy Metals; Toxic Agents" Hg (2 mg/kg body weight) through dietary for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432" PMDBI40349 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD193 Cilnidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009528998] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40349 Substances alter microbe abundance PMDBM628 n.a. anaerobic bacteria PMDBD1279 Mercury Environmental Substance "Heavy Metals; Toxic Agents" Hg (2 mg/kg body weight) through dietary for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30105432" PMDBI40350 Substances alter microbe abundance PMDBM179 872 Desulfovibrio PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50 and 100mg/kg body weight in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27393971" PMDBI40350 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD515 Meclofenamic acid sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000537636] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40351 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50 and 100mg/kg body weight in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27393971" PMDBI40351 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis enterotoxigenic PMDBD701 Prenylamine lactate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001316391] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40352 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50 and 100mg/kg body weight in food Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27393971" PMDBI40352 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.82E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40353 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50 and 100mg/kg body weight in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27393971" PMDBI40353 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.75E-05] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40354 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50 and 100mg/kg body weight in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27393971" PMDBI40354 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40355 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.71E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40355 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50 and 100mg/kg body weight in food Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27393971" PMDBI40356 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.99E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40356 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50 and 100mg/kg body weight in food Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27393971" PMDBI40357 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.76E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40357 Substances alter microbe abundance PMDBM734 28221 Deltaproteobacteria PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50 and 100mg/kg body weight in food Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 27393971" PMDBI40358 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD303 Enilconazole Environmental Substance Pesticides n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 27393971" PMDBI40358 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.79E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40359 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD303 Enilconazole Environmental Substance Pesticides n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 27393971" PMDBI40359 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.61E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40360 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50, or 100 mg/kg bw/day orally via diet for 4 weeks beginning at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27393971" PMDBI40360 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40361 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD303 Enilconazole Environmental Substance Pesticides 100 or 1000 娓璯/l for 1,7, or 21 days in aquatic environment at 6 months of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28888875" PMDBI40361 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.99E-06] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40362 Substances alter microbe abundance PMDBM242 203490 Fusobacteria PMDBD303 Enilconazole Environmental Substance Pesticides 100 or 1000 娓璯/l for 1,7, or 21 days in aquatic environment at 6 months of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28888875" PMDBI40362 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.15E-06] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40363 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50, or 100 mg/kg bw/day orally via diet for 4 weeks beginning at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27393971" PMDBI40363 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40364 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD303 Enilconazole Environmental Substance Pesticides 100 or 1000 娓璯/l for 1,7, or 21 days in aquatic environment at 6 months of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28888875" PMDBI40364 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.71E-06] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40365 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40365 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD303 Enilconazole Environmental Substance Pesticides 100 or 1000 娓璯/l for 1,7, or 21 days in aquatic environment at 6 months of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28888875" PMDBI40366 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40366 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD303 Enilconazole Environmental Substance Pesticides 0.1, 0.5, or 2.5 mg/kg bw/day orally via diet for 2, 5, or 15 weeks beginning at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30496565" PMDBI40367 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.75E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40367 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD303 Enilconazole Environmental Substance Pesticides 25, 50, or 100 mg/kg bw/day orally via diet for 4 weeks beginning at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27393971" PMDBI40368 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40368 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD303 Enilconazole Environmental Substance Pesticides 100 or 1000 娓璯/l for 1,7, or 21 days in aquatic environment at 6 months of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28888875" PMDBI40369 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40369 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD303 Enilconazole Environmental Substance Pesticides 100 or 1000 娓璯/l for 1,7, or 21 days in aquatic environment at 6 months of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28888875" PMDBI40370 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1234 Imidacloprid Environmental Substance Pesticides 10é–?00 å¨“ç’ in food (length of treatment not given) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28578396" PMDBI40370 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.69E-06] n.a. n.a. n.a. n.a. In vivo Drosophila melanogaster Health n.a. n.a. PMID PMID: 29555994 PMDBI40371 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1234 Imidacloprid Environmental Substance Pesticides 3.5 娓璯/kg in sugar syrup for 24é–?4 h to interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31378758" PMDBI40371 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000267555] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40372 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.79E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40372 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1234 Imidacloprid Environmental Substance Pesticides 3.5 娓璯/kg in sugar syrup for 24é–?4 h to interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31378758" PMDBI40373 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.76E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40373 Substances alter microbe abundance PMDBM600 434 Acetobacter PMDBD1234 Imidacloprid Environmental Substance Pesticides 10é–?00 å¨“ç’ in food (length of treatment not given) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Drosophila melanogaster Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28578396" PMDBI40374 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 100 and 500 ppm for 8 weeks in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 24325943" PMDBI40374 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.79E-05] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40375 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm for 13 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28234468" PMDBI40375 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.73E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40376 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 100 and 500 ppm for 8 weeks in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 24325943" PMDBI40376 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.71E-06] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40377 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 100 and 500 ppm for 8 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 24325943" PMDBI40377 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.95E-06] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40378 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm for 13 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28234468" PMDBI40378 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.32E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40379 Substances alter microbe abundance PMDBM307 119852 Oscillospira PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28234468" PMDBI40379 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.03E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40380 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm for 13 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28234468" PMDBI40380 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.78E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40381 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28234468" PMDBI40381 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.76E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40382 Substances alter microbe abundance PMDBM399 191303 Turicibacter PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 100 and 500 ppm for 8 weeks in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 24325943" PMDBI40382 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.64E-05] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40383 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40383 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 100 and 500 ppm for 8 weeks in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 24325943" PMDBI40384 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40384 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 100 and 500 ppm for 8 weeks in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 24325943" PMDBI40385 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.02E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40385 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 100 and 500 ppm for 8 weeks in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 24325943" PMDBI40386 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40386 Substances alter microbe abundance PMDBM843 n.a. Mogibacteriaceae PMDBD1264 Malathion Environmental Substance Pesticides n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 29097220" PMDBI40387 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1264 Malathion Environmental Substance Pesticides 2 mg/l (approximately 0.6 mg/kg BW/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29097220" PMDBI40387 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.76E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40388 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD1264 Malathion Environmental Substance Pesticides 2 mg/l (approximately 0.6 mg/kg BW/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29097220" PMDBI40388 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.90E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40389 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1264 Malathion Environmental Substance Pesticides 2 mg/l (approximately 0.6 mg/kg BW/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29097220" PMDBI40389 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.59E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40390 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD1264 Malathion Environmental Substance Pesticides 2 mg/l (approximately 0.6 mg/kg BW/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29097220" PMDBI40390 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.82E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40391 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1264 Malathion Environmental Substance Pesticides 2 mg/l (approximately 0.6 mg/kg BW/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29097220" PMDBI40391 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.84E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40392 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40392 Substances alter microbe abundance PMDBM884 186818 Planococcaceae PMDBD1264 Malathion Environmental Substance Pesticides 2 mg/l (approximately 0.6 mg/kg BW/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29097220" PMDBI40393 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.63E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40393 Substances alter microbe abundance PMDBM632 207244 Anaerostipes PMDBD1264 Malathion Environmental Substance Pesticides 2 mg/l (approximately 0.6 mg/kg BW/day) in drinking water for 13 weeks beginning at 8 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29097220" PMDBI40394 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1265 Manganese Environmental Substance "Heavy Metals; Toxic Agents" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28610994" PMDBI40394 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40395 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1265 Manganese Environmental Substance "Heavy Metals; Toxic Agents" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28610994" PMDBI40395 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001677974] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40396 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40396 Substances alter microbe abundance PMDBM80 976 Bacteroidetes PMDBD1265 Manganese Environmental Substance "Heavy Metals; Toxic Agents" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28610994" PMDBI40397 Substances alter microbe abundance PMDBM13 1283313 Alloprevotella PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30384071" PMDBI40397 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.81E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40398 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30384071" PMDBI40398 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.67E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40399 Substances alter microbe abundance PMDBM315 577310 Parasutterella PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30384071" PMDBI40399 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40400 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30384071" PMDBI40400 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40401 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40401 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30384071" PMDBI40402 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.09E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40402 Substances alter microbe abundance PMDBM964 195950 Tannerella PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30384071" PMDBI40403 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000906821] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40403 Substances alter microbe abundance PMDBM715 1348911 Coprobacter PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30384071" PMDBI40404 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002477444] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40404 Substances alter microbe abundance PMDBM803 1392389 Intestinimonas PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30384071" PMDBI40405 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001321505] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40405 Substances alter microbe abundance PMDBM797 1573535 Holdemanella PMDBD1304 Monoethylhexyl phthalate Environmental Substance Phthalates 0 or 0.05 mg/kg MEHP with normal diet or high-fat diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30384071" PMDBI40406 Substances alter microbe abundance PMDBM110 35832 Bilophila PMDBD1278 Mercuric chloride Environmental Substance "Heavy Metals; Toxic Agents" 0 or 2 mg/kg bw HgCl2 for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30105432" PMDBI40406 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000170551] n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID PMID: 29555994 PMDBI40407 Substances alter microbe abundance PMDBM123 574697 Butyricimonas PMDBD1278 Mercuric chloride Environmental Substance "Heavy Metals; Toxic Agents" 0 or 2 mg/kg bw HgCl2 for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30105432" PMDBI40407 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00457977] n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID PMID: 29555994 PMDBI40408 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1278 Mercuric chloride Environmental Substance "Heavy Metals; Toxic Agents" 0 or 2 mg/kg bw HgCl2 for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30105432" PMDBI40408 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.95E-06] n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID PMID: 29555994 PMDBI40409 Substances alter microbe abundance PMDBM2 469 Acinetobacter PMDBD1278 Mercuric chloride Environmental Substance "Heavy Metals; Toxic Agents" 0 or 2 mg/kg bw HgCl2 for 90 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30105432" PMDBI40409 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001126779] n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID PMID: 29555994 PMDBI40410 Substances alter microbe abundance PMDBM307 119852 Oscillospira PMDBD1278 Mercuric chloride Environmental Substance "Heavy Metals; Toxic Agents" 0 or 2 mg/kg bw HgCl2 for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30105432" PMDBI40410 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.27E-06] n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID PMID: 29555994 PMDBI40411 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1278 Mercuric chloride Environmental Substance "Heavy Metals; Toxic Agents" 0 or 2 mg/kg bw HgCl2 for 90 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30105432" PMDBI40411 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID PMID: 29555994 PMDBI40412 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.03E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40412 Substances alter microbe abundance PMDBM946 1569 Sporosarcina PMDBD1278 Mercuric chloride Environmental Substance "Heavy Metals; Toxic Agents" 0 or 2 mg/kg bw HgCl2 for 90 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30105432" PMDBI40413 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40413 Substances alter microbe abundance PMDBM733 51514 Dehalobacterium PMDBD1278 Mercuric chloride Environmental Substance "Heavy Metals; Toxic Agents" 0 or 2 mg/kg bw HgCl2 for 90 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30105432" PMDBI40414 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001022261] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40414 Substances alter microbe abundance PMDBM804 227979 Jeotgalicoccus PMDBD1278 Mercuric chloride Environmental Substance "Heavy Metals; Toxic Agents" 0 or 2 mg/kg bw HgCl2 for 90 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Kunming mice Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30105432" PMDBI40415 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1278 Mercuric chloride Environmental Substance "Heavy Metals; Toxic Agents" 0 or 150 ppm in drinking water for 30 day Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31733937" PMDBI40415 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.61E-05] n.a. n.a. n.a. n.a. In vivo Hyline chicken Health n.a. n.a. PMID PMID: 29555994 PMDBI40416 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008610966] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40416 Substances alter microbe abundance PMDBM945 203692 Spirochaetes PMDBD1278 Mercuric chloride Environmental Substance "Heavy Metals; Toxic Agents" 0 or 150 ppm in drinking water for 90 day Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Hyline chicken Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31733937" PMDBI40417 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40417 Substances alter microbe abundance PMDBM965 544448 Tenericutes PMDBD1278 Mercuric chloride Environmental Substance "Heavy Metals; Toxic Agents" 0 or 150 ppm in drinking water for 30 day Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Hyline chicken Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31733937" PMDBI40418 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40418 Substances alter microbe abundance PMDBM965 544448 Tenericutes PMDBD1278 Mercuric chloride Environmental Substance "Heavy Metals; Toxic Agents" 0 or 150 ppm in drinking water for 60 day Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Hyline chicken Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31733937" PMDBI40419 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.91E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40419 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD530 Metformin Environmental Substance Approved Drug n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 27999002; PMID: 28530702" PMDBI40420 Substances alter microbe abundance PMDBM2 469 Acinetobacter PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" Fathead minnow (FHM): control (0.02 娓璯/g), 0.72 娓璯/g, 5.50 娓璯/g Hg dry weight for twice a day for 30 days Mice: control (0.02 娓璯/g), 0.43 娓璯/g, 4.39 娓璯/g Hg dry weight in diet for twice a day for 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29943971" PMDBI40420 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000646302] n.a. n.a. n.a. n.a. In vivo "FHM; CD-1 mice" Health n.a. n.a. PMID PMID: 29555994 PMDBI40421 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" 0 or 4 mg/kg bw MeHg by intragastric gavage for 4 weeks every other day. Some of the MeHg-poisoned rats were given 2.74 mg/kg bw sodium selenite. MeHg + sodium selenite compared with MeHg group Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31585392" PMDBI40421 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.57E-05] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40422 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" 0 or 4 mg/kg bw MeHg by intragastric gavage for 4 weeks every other day. Some of the MeHg-poisoned rats were given 2.74 mg/kg bw sodium selenite. MeHg treatment groups compared with control Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31585392" PMDBI40422 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000125508] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40423 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.22E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40423 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" 0 or 4 mg/kg bw MeHg by intragastric gavage for 4 weeks every other day. MeHg treatment groups compared with control Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31585392" PMDBI40424 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.07E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40424 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" 4 mg/kg bw MeHg by intragastric gavage for 4 weeks every other day. MeHg-poisoned rats were given 2.74 mg/kg bw sodium selenite. MeHg+sodium selenite compared with MeHg Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31585392" PMDBI40425 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40425 Substances alter microbe abundance PMDBM613 642 Aeromonas PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" Fathead minnow (FHM): control (0.02 娓璯/g), 0.72 娓璯/g, 5.50 娓璯/g Hg dry weight for twice a day for 30 days Mice: control (0.02 娓璯/g), 0.43 娓璯/g, 4.39 娓璯/g Hg dry weight in diet for twice a day for 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo "FHM; CD-1 mice" Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29943971" PMDBI40426 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.69E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40426 Substances alter microbe abundance PMDBM727 1117 Cyanobacteria PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" 0 or 4 mg/kg bw MeHg by intragastric gavage for 4 weeks every other day. Some of the MeHg-poisoned rats were given 2.74 mg/kg bw sodium selenite Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31585392" PMDBI40427 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.52E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40427 Substances alter microbe abundance PMDBM679 180162 Cetobacterium PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" Fathead minnow (FHM): control (0.02 娓璯/g), 0.72 娓璯/g, 5.50 娓璯/g Hg dry weight for twice a day for 30 days Mice: control (0.02 娓璯/g), 0.43 娓璯/g, 4.39 娓璯/g Hg dry weight in diet for twice a day for 30 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo "FHM; CD-1 mice" Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29943971" PMDBI40428 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.62E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40428 Substances alter microbe abundance PMDBM626 n.a. an unclassi?ed member of the Neisseriaceae family PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" Fathead minnow (FHM): control (0.02 娓璯/g), 0.72 娓璯/g, 5.50 娓璯/g Hg dry weight for twice a day for 30 days Mice: control (0.02 娓璯/g), 0.43 娓璯/g, 4.39 娓璯/g Hg dry weight in diet for twice a day for 30 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo "FHM; CD-1 mice" Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29943971" PMDBI40429 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" 0 or 10 娓璯/kg bw (oral dosing) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31918252" PMDBI40429 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.76E-05] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40430 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" 0 or 10 娓璯/kg bw (oral dosing) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31918252" PMDBI40430 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000187809] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40431 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" 0 or 10 娓璯/kg bw (oral dosing) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31918252" PMDBI40431 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00759669] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40432 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" 0 or 10 娓璯/kg bw (oral dosing) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31918252" PMDBI40432 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.27E-05] n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40433 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000857592] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40433 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" 0 or 10 娓璯/kg bw (oral dosing) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31918252" PMDBI40434 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003534694] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40434 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" 0 or 10 娓璯/kg bw (oral dosing) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31918252" PMDBI40435 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001829832] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40435 Substances alter microbe abundance PMDBM909 41295 Rhodospirillaceae PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" 0 or 10 娓璯/kg bw (oral dosing) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31918252" PMDBI40436 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000416203] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40436 Substances alter microbe abundance PMDBM794 72293 Helicobacteraceae PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" 0 or 10 娓璯/kg bw (oral dosing) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31918252" PMDBI40437 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001836614] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40437 Substances alter microbe abundance PMDBM876 186807 Peptococcaceae PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" 0 or 10 娓璯/kg bw (oral dosing) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31918252" PMDBI40438 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.79E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40438 Substances alter microbe abundance PMDBM738 194924 Desulfovibrionaceae PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" 0 or 10 娓璯/kg bw (oral dosing) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31918252" PMDBI40439 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003903545] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40439 Substances alter microbe abundance PMDBM963 995019 Sutterellaceae PMDBD540 Methylmercury Environmental Substance "Heavy Metals; Toxic Agents" 0 or 10 娓璯/kg bw (oral dosing) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Sprague Dawley rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31918252" PMDBI40440 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD546 Metronidazole Environmental Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 21321077" PMDBI40440 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003217095] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40441 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.49E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40441 Substances alter microbe abundance PMDBM629 n.a. anaerobic Bacteroidales PMDBD546 Metronidazole "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 21321077" PMDBI40442 Substances alter microbe abundance PMDBM2020202 29347 Clostridium scindens PMDBD1301 Mixture "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" "clindamycin; ampicillin" Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25337874" PMDBI40442 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.98E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40443 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1301 Mixture Environmental Substance "Approved Drug; Antibiotics" "metronidazole; metronidazole; gentamicin" Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29524228" PMDBI40443 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.07E-06] n.a. n.a. n.a. n.a. In vivo Piglet Health n.a. n.a. PMID PMID: 29555994 PMDBI40444 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1301 Mixture "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" "metronidazole; metronidazole; gentamicin" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29524228" PMDBI40444 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vivo Piglet Health n.a. n.a. PMID PMID: 29555994 PMDBI40445 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000385531] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40445 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1301 Mixture "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" "ampicillin; streptomycin; clindamycin" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26963277" PMDBI40446 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000187916] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40446 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1301 Mixture "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" "metronidazole; metronidazole; gentamicin" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Piglet Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29524228" PMDBI40447 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.97E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40447 Substances alter microbe abundance PMDBM992 338 Xanthomonas PMDBD1301 Mixture Environmental Substance "Approved Drug; Antibiotics" "ampicillin; streptomycin; clindamycin" Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26963277" PMDBI40448 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004975989] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40448 Substances alter microbe abundance PMDBM952 40323 Stenotrophomonas PMDBD1301 Mixture Environmental Substance "Approved Drug; Antibiotics" "ampicillin; streptomycin; clindamycin" Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26963277" PMDBI40449 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.96E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40449 Substances alter microbe abundance PMDBM628 n.a. anaerobic bacteria PMDBD1301 Mixture "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" nor?oxacin and ampicillin (1g/Leach) for 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 18326786" PMDBI40450 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00262628] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40450 Substances alter microbe abundance PMDBM933 n.a. Shannon index PMDBD1301 Mixture "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" Neomycin sulfate (1g/L), vancomycin (500mg/L) and ampicillin (1g/L), and metronidazole (1g/L) each day by gavage for 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 31434991" PMDBI40451 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000504227] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40451 Substances alter microbe abundance PMDBM678 n.a. Cecal aerobic bacteria PMDBD1301 Mixture "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" nor?oxacin and ampicillin (1g/Leach) for 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 18326786" PMDBI40452 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD1317 Neotame Environmental Substance Artificial Sweeteners n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 29425148" PMDBI40452 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40453 Substances alter microbe abundance PMDBM2020035 562 Escherichia coli PMDBD1319 Nickel Environmental Substance "Heavy Metals; Toxic Agents" 0é–?00 mg/kg NiCl2 for 42 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25164205" PMDBI40453 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003029048] n.a. n.a. n.a. n.a. In vivo Broilers Health n.a. n.a. PMID PMID: 29555994 PMDBI40454 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1319 Nickel Environmental Substance "Heavy Metals; Toxic Agents" 0é–?00 mg/kg NiCl2 for 42 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25164205" PMDBI40454 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001704304] n.a. n.a. n.a. n.a. In vivo Broilers Health n.a. n.a. PMID PMID: 29555994 PMDBI40455 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002511467] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40455 Substances alter microbe abundance PMDBM504 n.a. Enterococcus spp. PMDBD1319 Nickel Environmental Substance "Heavy Metals; Toxic Agents" 0é–?00 mg/kg NiCl2 for 42 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Broilers Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25164205" PMDBI40456 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40456 Substances alter microbe abundance PMDBM967 n.a. The bacterial diversity PMDBD1319 Nickel Environmental Substance "Heavy Metals; Toxic Agents" 0é–?00 mg/kg NiCl2 for 42 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Broilers Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25164205" PMDBI40457 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.24E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40457 Substances alter microbe abundance PMDBM661 n.a. Bi?dobacterium spp. PMDBD1319 Nickel Environmental Substance "Heavy Metals; Toxic Agents" 0é–?00 mg/kg NiCl2 for 42 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Broilers Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25164205" PMDBI40458 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.59E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40458 Substances alter microbe abundance PMDBM775 n.a. F16 PMDBD1320 Nicotine Environmental Substance Unclassified Environmental Substances n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 29035044" PMDBI40459 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40459 Substances alter microbe abundance PMDBM775 n.a. F16 PMDBD1320 Nicotine Environmental Substance Unclassified Environmental Substances n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 29035044" PMDBI40460 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1326 Ochratoxin A Environmental Substance Biological Contaminants 0, 70, and 210 娓璯/kg body weight via oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24973096" PMDBI40460 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017055] n.a. n.a. n.a. n.a. In vivo Fisher 344 rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40461 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1330 Omega-3 PUFA supplementation Environmental Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.1124/pr.118.015768; PMID: 28951525" PMDBI40461 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000135733] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40462 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1330 Omega-3 PUFA supplementation Environmental Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.1124/pr.118.015768; PMID: 28951525" PMDBI40462 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005294977] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40463 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.82E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40463 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1330 Omega-3 PUFA supplementation Environmental Substance Dietary Compounds n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.1124/pr.118.015768; PMID: 28951525" PMDBI40464 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40464 Substances alter microbe abundance PMDBM850 481 Neisseriaceae PMDBD1335 Other bisphenols Environmental Substance "Industrial Compounds; Bisphenols" BPF (0, 0.2, 0.6, 1.8, 5.2, 15.3, 45.0 娓ç’) in water environment for 10 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish embryo Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30321396" PMDBI40465 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40465 Substances alter microbe abundance PMDBM850 481 Neisseriaceae PMDBD1335 Other bisphenols Environmental Substance "Industrial Compounds; Bisphenols" BPS (0, 0.2, 0.6, 1.8, 5.2, 15.3, 45.0 娓ç’) in water environment for 10 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish embryo Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30321396" PMDBI40466 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.06E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40466 Substances alter microbe abundance PMDBM682 1046 Chromatiaceae PMDBD1335 Other bisphenols Environmental Substance "Industrial Compounds; Bisphenols" BPF(0, 0.2, 0.6, 1.8, 5.2, 15.3, 45.0 娓ç’) in water environment for 10 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish embryo Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30321396" PMDBI40467 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000612559] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40467 Substances alter microbe abundance PMDBM726 246874 Cryomorphaceae PMDBD1335 Other bisphenols Environmental Substance "Industrial Compounds; Bisphenols" BPS(0, 0.2, 0.6, 1.8, 5.2, 15.3, 45.0 娓ç’) in water environment for 10 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish embryo Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30321396" PMDBI40468 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides 1 mg/kg bw/day daily by gavage for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28392238" PMDBI40468 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.62E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40469 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides 1 mg/kg bw/day daily by gavage for 8 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28392238" PMDBI40469 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0018713] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40470 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides 1 mg/kg bw/day daily by gavage for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28392238" PMDBI40470 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40471 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides "2 mg/kg bw/day by gavage for 8 weeks beginning at 4 weeks of age; cotreatment and recovery with pectin" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31195221" PMDBI40471 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000859086] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40472 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides 1 mg/kg bw/day daily by gavage for 8 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28392238" PMDBI40472 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000671946] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40473 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40473 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides 1 mg/kg bw/day daily by gavage for 8 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28392238" PMDBI40474 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008623045] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40474 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides "2 mg/kg bw/day by gavage for 8 weeks beginning at 4 weeks of age; cotreatment and recovery with pectin" Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31195221" PMDBI40475 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00406747] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40475 Substances alter microbe abundance PMDBM727 1117 Cyanobacteria PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides "2 mg/kg bw/day by gavage for 8 weeks beginning at 4 weeks of age; cotreatment and recovery with pectin" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31195221" PMDBI40476 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001913202] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40476 Substances alter microbe abundance PMDBM731 200930 Deferribacteres PMDBD1340 p,p'-Dichlorodiphenyldichloroethylene Environmental Substance Pesticides "2 mg/kg bw/day by gavage for 8 weeks beginning at 4 weeks of age; cotreatment and recovery with pectin" Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31195221" PMDBI40477 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1370 Polycyclic aromatic hydrocarbon Environmental Substance Persistent Organic Pollutants No exposure to oil (northern Norway area)or 0.01 ppm exposure to oil (southern Norway area) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31336609" PMDBI40477 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000343393] n.a. n.a. n.a. n.a. In vivo Gadus Morhua Health n.a. n.a. PMID PMID: 29555994 PMDBI40478 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40478 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001921381] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40479 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40479 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002112696] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40480 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40480 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.97E-05] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40481 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40481 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003286927] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40482 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40482 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000437689] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40483 Substances alter microbe abundance PMDBM399 191303 Turicibacter PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40483 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.38E-06] n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40484 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.27E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40484 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40485 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000276431] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40485 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40486 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003731208] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40486 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 100 or 500 ppm-mg/L in drinking water for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24325943" PMDBI40487 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 32 ppm for 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.3390/nu11010022; PMID: 26962054" PMDBI40487 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD265 Dicumarol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00203836] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40488 Substances alter microbe abundance PMDBM285 1357 Lactococcus PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 32 ppm for 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.3390/nu11010022; PMID: 26962054" PMDBI40488 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD172 Cephalosporanic acid, 7-amino Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.03E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40489 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003573495] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40489 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 32 ppm for 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.3390/nu11010022; PMID: 26962054" PMDBI40490 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000762503] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40490 Substances alter microbe abundance PMDBM738 194924 Desulfovibrionaceae PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 32 ppm for 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.3390/nu11010022; PMID: 26962054" PMDBI40491 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00184996] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40491 Substances alter microbe abundance PMDBM677 204458 Caulobacterales PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 32 ppm for 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.3390/nu11010022; PMID: 26962054" PMDBI40492 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD713 Protriptyline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003451354] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40492 Substances alter microbe abundance PMDBM760 580024 Enterorhabdus PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 32 ppm for 2 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.3390/nu11010022; PMID: 26962054" PMDBI40493 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD319 Ethacrynic acid "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000683269] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40493 Substances alter microbe abundance PMDBM711 n.a. Clostridium XIVb PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 32 ppm for 2 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.3390/nu11010022; PMID: 26962054" PMDBI40494 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1345 PCB congeners Environmental Substance Persistent Organic Pollutants 5 mg/kg (P77 and P153) and 50 mg/kg (P126) per week via oral gavage then with HF diet Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29674211" PMDBI40494 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD670 Pimethixene maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003050721] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40495 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD710 Promethazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00641235] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40495 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1345 PCB congeners Environmental Substance Persistent Organic Pollutants 5 mg/kg (P77 and P153) and 50 mg/kg (P126) per week via oral gavage then with HF diet Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29674211" PMDBI40496 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23632211" PMDBI40496 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD438 Idoxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007141128] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40497 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD515 Meclofenamic acid sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008962491] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40497 Substances alter microbe abundance PMDBM2020178 1282 Staphylococcus epidermidis PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23632211" PMDBI40498 Substances alter microbe abundance PMDBM2020008 n.a. Bacteroides fragilis nontoxigenic PMDBD675 Pipemidic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001002675] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40498 Substances alter microbe abundance PMDBM719 1653 Corynebacteriaceae PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23632211" PMDBI40499 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40499 Substances alter microbe abundance PMDBM2020185 2039 Tropheryma whipplei PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Increase Fold change = 1.5 n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23632211" PMDBI40500 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40500 Substances alter microbe abundance PMDBM2020182 68892 Streptococcus infantis PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23632211" PMDBI40501 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40501 Substances alter microbe abundance PMDBM988 203557 Verrucomicrobiaceae PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23632211" PMDBI40502 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40502 Substances alter microbe abundance PMDBM2020090 526863 Candidatus Aquirestis calciphila PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23632211" PMDBI40503 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40503 Substances alter microbe abundance PMDBM898 n.a. Pseudomonas plecoglossicida strain CGMCC 2093 PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23632211" PMDBI40504 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40504 Substances alter microbe abundance PMDBM899 n.a. Pseudomonas plecoglossicida strain R18 PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23632211" PMDBI40505 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40505 Substances alter microbe abundance PMDBM900 n.a. Pseudomonas putida strain SRI156 PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23632211" PMDBI40506 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40506 Substances alter microbe abundance PMDBM649 n.a. Bacteroides thetaiotaomicron strain 8669 PMDBD1346 PCB congeners (PCB153, PCB138, PCB180) Environmental Substance Persistent Organic Pollutants Exercise for 5 days followed by 2 days of oral exposure to PCB mixture (150 mmol/kg) Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 23632211" PMDBI40507 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1347 PCB mixture Environmental Substance Persistent Organic Pollutants 0, 0.1, 1, or 6 mg/kg/day starting 2 weeks before gestation and continuing through PND 21 Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31336350" PMDBI40507 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Congenic wildtype (WT) (75% C57BL/6 and 25% Sv129) DM mice (mutations in FMR1 and RyR) Health n.a. n.a. PMID PMID: 29555994 PMDBI40508 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1347 PCB mixture Environmental Substance Persistent Organic Pollutants 0, 0.1, 1, or 6 mg/kg/day starting 2 weeks before gestation and continuing through PND 21 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31336350" PMDBI40508 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Congenic wildtype (WT) (75% C57BL/6 and 25% Sv129) DM mice (mutations in FMR1 and RyR) Health n.a. n.a. PMID PMID: 29555994 PMDBI40509 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40509 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1347 PCB mixture Environmental Substance Persistent Organic Pollutants 0, 0.1, 1, or 6 mg/kg/day starting 2 weeks before gestation and continuing through PND 21 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Congenic wildtype (WT) (75% C57BL/6 and 25% Sv129) DM mice (mutations in FMR1 and RyR) Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31336350" PMDBI40510 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40510 Substances alter microbe abundance PMDBM654 28216 Betaproteobacteria PMDBD1347 PCB mixture Environmental Substance Persistent Organic Pollutants 0, 0.1, 1, or 6 mg/kg/day starting 2 weeks before gestation and continuing through PND 21 Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Congenic wildtype (WT) (75% C57BL/6 and 25% Sv129) DM mice (mutations in FMR1 and RyR) Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31336350" PMDBI40511 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40511 Substances alter microbe abundance PMDBM734 28221 Deltaproteobacteria PMDBD1347 PCB mixture Environmental Substance Persistent Organic Pollutants 0, 0.1, 1, or 6 mg/kg/day starting 2 weeks before gestation and continuing through PND 21 Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Congenic wildtype (WT) (75% C57BL/6 and 25% Sv129) DM mice (mutations in FMR1 and RyR) Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31336350" PMDBI40512 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40512 Substances alter microbe abundance PMDBM731 200930 Deferribacteres PMDBD1347 PCB mixture Environmental Substance Persistent Organic Pollutants DM mice compared with WT mice following exposure to 1 mg/kg/day PCB dose Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Mouse with FMR1 and RyR double mutations n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31336350" PMDBI40513 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40513 Substances alter microbe abundance PMDBM644 n.a. Bacteroidales family S7-25 PMDBD1347 PCB mixture Environmental Substance Persistent Organic Pollutants 0, 0.1, 1, or 6 mg/kg/day starting 2 weeks before gestation and continuing through PND 21 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Congenic wildtype (WT) (75% C57BL/6 and 25% Sv129) DM mice (mutations in FMR1 and RyR) Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31336350" PMDBI40514 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD1348 PCB-126 Environmental Substance Persistent Organic Pollutants 0 or1 娓璵ol/kg/day at weeks 2 and 4 Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30373033" PMDBI40514 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse Ldlr-/- mice n.a. n.a. PMID PMID: 29555994 PMDBI40515 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40515 Substances alter microbe abundance PMDBM997 n.a. æµ?Diversity PMDBD1348 PCB-126 Environmental Substance Persistent Organic Pollutants 0 or1 娓璵ol/kg/day at weeks 2 and 4 Cecum Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Ldlr-/- mice n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30373033" PMDBI40516 Substances alter microbe abundance PMDBM12 174708 Allobaculum PMDBD1351 Penicillin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" low doses to mice early in life Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25126780" PMDBI40516 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40517 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1351 Penicillin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" low doses to mice early in life Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25126780" PMDBI40517 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40518 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40518 Substances alter microbe abundance PMDBM634 49082 Arthromitus PMDBD1351 Penicillin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" low doses to mice early in life Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25126780" PMDBI40519 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40519 Substances alter microbe abundance PMDBM81 n.a. Bacteroidetes/Firmicutes ratio PMDBD1352 "Penicillin G; erythromycin, or both" "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" 60/10 mg/mL in drinking water for 6/14 weeks, total concentration Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 27503388" PMDBI40520 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1353 Pentachlorophenol Environmental Substance Pesticides 0é–?00 娓璯/L in water Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26378342" PMDBI40520 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Carassius auratus Health n.a. n.a. PMID PMID: 29555994 PMDBI40521 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40521 Substances alter microbe abundance PMDBM833 445 Legionella PMDBD1353 Pentachlorophenol Environmental Substance Pesticides 0é–?00 娓璯/L in water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Carassius auratus Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26378342" PMDBI40522 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40522 Substances alter microbe abundance PMDBM633 1663 Arthrobacter PMDBD1353 Pentachlorophenol Environmental Substance Pesticides 0é–?00 娓璯/L in water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Carassius auratus Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26378342" PMDBI40523 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40523 Substances alter microbe abundance PMDBM839 33882 Microbacterium PMDBD1353 Pentachlorophenol Environmental Substance Pesticides 0é–?00 娓璯/L in water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Carassius auratus Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26378342" PMDBI40524 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40524 Substances alter microbe abundance PMDBM683 59732 Chryseobacterium PMDBD1353 Pentachlorophenol Environmental Substance Pesticides 0é–?00 娓璯/L in water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Carassius auratus Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26378342" PMDBI40525 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1353 Pentachlorophenol Environmental Substance Pesticides 1, 50, or 100 娓璯/l in water environment for 28 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 26378342" PMDBI40525 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.30E-05] n.a. n.a. n.a. n.a. In vivo Carassius auratus Health n.a. n.a. PMID PMID: 29555994 PMDBI40526 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40526 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1353 Pentachlorophenol Environmental Substance Pesticides 1, 50, or 100 娓璯/l in water environment for 28 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Carassius auratus Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 26378342" PMDBI40527 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/4 mL/kg body weight per day by oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26898931" PMDBI40527 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40528 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/4 mL/kg body weight per day by oral gavage Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26898931" PMDBI40528 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40529 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/4 mL/kg body weight per day by oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26898931" PMDBI40529 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40530 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/4 mL/kg body weight per day by oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26898931" PMDBI40530 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40531 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40531 Substances alter microbe abundance PMDBM886 836 Porphyromonas PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/4 mL/kg body weight per day by oral gavage Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26898931" PMDBI40532 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/kg body weight gavage from PND 6 to 21,4-month follow-up period Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 26898931" PMDBI40532 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40533 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/kg body weight gavage from PND 6 to 21,4-month follow-up period Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 26898931" PMDBI40533 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40534 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/kg body weight gavage from PND 6 to 21,4-month follow-up period Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 26898931" PMDBI40534 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID PMID: 29555994 PMDBI40535 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40535 Substances alter microbe abundance PMDBM886 836 Porphyromonas PMDBD1358 Permethrin Environmental Substance Pesticides 34 mg/kg body weight gavage from PND 6 to 21, 4-month follow-up period Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Wistar Rat Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 26898931" PMDBI40536 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1359 PFAS: F-53B Environmental Substance Persistent Organic Pollutants 0, 1, 3, or 10 娓璯/l for 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31319243" PMDBI40536 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000923016] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40537 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1359 PFAS: F-53B Environmental Substance Persistent Organic Pollutants 0, 1, 3, or 10 娓璯/l for 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31319243" PMDBI40537 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40538 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD1359 PFAS: F-53B Environmental Substance Persistent Organic Pollutants 0, 1, 3, or 10 娓璯/l for 10 weeks, after subchronic exposure Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31319243" PMDBI40538 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40539 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40539 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1359 PFAS: F-53B Environmental Substance Persistent Organic Pollutants 0, 1, 3, or 10 娓璯/l for 10 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31319243" PMDBI40540 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Marine medaka Health n.a. n.a. PMID PMID: 29555994 PMDBI40540 Substances alter microbe abundance PMDBM883 118 Planctomyces PMDBD1356 Perfluorobutanesulfonic acid Environmental Substance Persistent Organic Pollutants 0, 1.0, 2.9, 9.5 娓璯/l for the entire lifecycle Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065 PMDBI40541 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Marine medaka Health n.a. n.a. PMID PMID: 29555994 PMDBI40541 Substances alter microbe abundance PMDBM989 662 Vibrio PMDBD1356 Perfluorobutanesulfonic acid Environmental Substance Persistent Organic Pollutants 0, 1.0, 2.9, 9.5 娓璯/l for the entire lifecycle, in F1 females after exposure of F0 parents to 9.5 娓璯/ l PDBS Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065 PMDBI40542 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Marine medaka Health n.a. n.a. PMID PMID: 29555994 PMDBI40542 Substances alter microbe abundance PMDBM679 180162 Cetobacterium PMDBD1356 Perfluorobutanesulfonic acid Environmental Substance Persistent Organic Pollutants 2.9 娓璯/l for the entire lifecycle Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID DOI: 10.1093/toxsci/kfaa065 PMDBI40543 Substances alter microbe abundance PMDBM123 574697 Butyricimonas PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725" PMDBI40543 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.63E-05] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40544 Substances alter microbe abundance PMDBM179 872 Desulfovibrio PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725" PMDBI40544 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40545 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725" PMDBI40545 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40546 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725" PMDBI40546 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40547 Substances alter microbe abundance PMDBM307 119852 Oscillospira PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725" PMDBI40547 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40548 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725" PMDBI40548 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40549 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725" PMDBI40549 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40550 Substances alter microbe abundance PMDBM323 203683 Planctomycetes PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725" PMDBI40550 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001659558] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40551 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725" PMDBI40551 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004276717] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40552 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725" PMDBI40552 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001403982] n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40553 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00013257] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40553 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725" PMDBI40554 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00921525] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40554 Substances alter microbe abundance PMDBM733 51514 Dehalobacterium PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725" PMDBI40555 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40555 Substances alter microbe abundance PMDBM681 200795 Chloro?exi PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725" PMDBI40556 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40556 Substances alter microbe abundance PMDBM602 204432 Acidobacteria PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725" PMDBI40557 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40557 Substances alter microbe abundance PMDBM965 544448 Tenericutes PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725" PMDBI40558 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40558 Substances alter microbe abundance PMDBM971 n.a. TM7 PMDBD1387 Propamocarb Environmental Substance Pesticides 300 mg/L in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 29137890; PMID: 29906725" PMDBI40559 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1387 Propamocarb Environmental Substance Pesticides 1é–?0 mg/l in drinking water for 10 weeks beginning at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29906725" PMDBI40559 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40560 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1387 Propamocarb Environmental Substance Pesticides 3é–?00 mg/l in drinking water (0.5é–?0 mg/kg bw/day)for 28 days starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29137890" PMDBI40560 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00615579] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40561 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1387 Propamocarb Environmental Substance Pesticides 1000 娓璯/l in water environment for 7 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30544157" PMDBI40561 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40562 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1387 Propamocarb Environmental Substance Pesticides 3é–?00 mg/l in drinking water (0.5é–?0 mg/kg bw/day)for 28 days starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29137890" PMDBI40562 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40563 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1387 Propamocarb Environmental Substance Pesticides 3é–?00 mg/l in drinking water (0.5é–?0 mg/kg bw/day)for 28 days starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29137890" PMDBI40563 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.91E-06] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40564 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1387 Propamocarb Environmental Substance Pesticides 3é–?00 mg/l in drinking water (0.5é–?0 mg/kg bw/day)for 28 days starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29137890" PMDBI40564 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40565 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1387 Propamocarb Environmental Substance Pesticides 100 and 1000 娓璯/l in water environment for 7 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30544157" PMDBI40565 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID PMID: 29555994 PMDBI40566 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40566 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1387 Propamocarb Environmental Substance Pesticides 1é–?0 mg/l in drinking water for 10 weeks beginning at 6 weeks of age Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29906725" PMDBI40567 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00811522] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40567 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1387 Propamocarb Environmental Substance Pesticides 3é–?00 mg/l in drinking water (0.5é–?0 mg/kg bw/day)for 28 days starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29137890" PMDBI40568 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40568 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1387 Propamocarb Environmental Substance Pesticides 100 and 1000 娓璯/l in water environment for 7 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Zebrafish Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 30544157" PMDBI40569 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.89E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40569 Substances alter microbe abundance PMDBM965 544448 Tenericutes PMDBD1387 Propamocarb Environmental Substance Pesticides 3é–?00 mg/l in drinking water (0.5é–?0 mg/kg bw/day)for 28 days starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29137890" PMDBI40570 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40570 Substances alter microbe abundance PMDBM971 n.a. TM7 PMDBD1387 Propamocarb Environmental Substance Pesticides 3é–?00 mg/l in drinking water (0.5é–?0 mg/kg bw/day)for 28 days starting at 6 weeks of age Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 29137890" PMDBI40571 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human Cirrhosis n.a. n.a. PMID PMID: 29555994 PMDBI40571 Substances alter microbe abundance PMDBM987 31977 Veillonellaceae PMDBD747 Rifaximin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 24374295" PMDBI40572 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.42E-05] n.a. n.a. n.a. n.a. In vitro Human Cirrhosis n.a. n.a. PMID PMID: 29555994 PMDBI40572 Substances alter microbe abundance PMDBM770 186806 Eubacteriaceae PMDBD747 Rifaximin Environmental Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 24374295" PMDBI40573 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD761 Saccharin Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 25231862" PMDBI40573 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40574 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD761 Saccharin Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28472674" PMDBI40574 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002632027] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40575 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD761 Saccharin Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 25231862" PMDBI40575 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40576 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD761 Saccharin Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28472674" PMDBI40576 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0001943] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40577 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD761 Saccharin Environmental Substance Artificial Sweeteners n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28472674" PMDBI40577 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40578 Substances alter microbe abundance PMDBM399 191303 Turicibacter PMDBD761 Saccharin Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28472674" PMDBI40578 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004295111] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40579 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD1411 "saccharin; sucralose; aspartame" Environmental Substance Noncaloric Artificial Sweeteners (NAS) n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25231862" PMDBI40579 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000650497] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40580 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1411 "saccharin; sucralose; aspartame" Environmental Substance Noncaloric Artificial Sweeteners (NAS) n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25231862" PMDBI40580 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003295689] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40581 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD1422 Splenda Environmental Substance Artificial Sweeteners The commercial formulation of sucralose, containing 1.1% w/w sucralose plus maltodextrin and glucose Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:10.1038/npjbiofilms.2016.3; PMID: 18800291" PMDBI40581 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000945301] n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40582 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1422 Splenda Environmental Substance Artificial Sweeteners The commercial formulation of sucralose, containing 1.1% w/w sucralose plus maltodextrin and glucose Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:10.1038/npjbiofilms.2016.3; PMID: 18800291" PMDBI40582 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40583 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1422 Splenda Environmental Substance Artificial Sweeteners The commercial formulation of sucralose, containing 1.1% w/w sucralose plus maltodextrin and glucose Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:10.1038/npjbiofilms.2016.3; PMID: 18800291" PMDBI40583 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40584 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40584 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1422 Splenda Environmental Substance Artificial Sweeteners The commercial formulation of sucralose, containing 1.1% w/w sucralose plus maltodextrin and glucose Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID "DOI:10.1038/npjbiofilms.2016.3; PMID: 18800291" PMDBI40585 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006747737] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40585 Substances alter microbe abundance PMDBM627 n.a. anaerobes PMDBD1422 Splenda Environmental Substance Artificial Sweeteners The commercial formulation of sucralose, containing 1.1% w/w sucralose plus maltodextrin and glucose Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID "DOI:10.1038/npjbiofilms.2016.3; PMID: 18800291" PMDBI40586 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.50E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40586 Substances alter microbe abundance PMDBM972 n.a. total aerobic bacteria PMDBD1422 Splenda Environmental Substance Artificial Sweeteners The commercial formulation of sucralose, containing 1.1% w/w sucralose plus maltodextrin and glucose Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID "DOI:10.1038/npjbiofilms.2016.3; PMID: 18800291" PMDBI40587 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD804 Streptomycin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" 200 mg/L in drinking water for 9 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 26754178" PMDBI40587 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007729025] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40588 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD804 Streptomycin Environmental Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25145536; PMID: 21633507" PMDBI40588 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40589 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD804 Streptomycin Environmental Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25145536; PMID: 21633507" PMDBI40589 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003459073] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40590 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD804 Streptomycin Environmental Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25145536; PMID: 21633507" PMDBI40590 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40591 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD804 Streptomycin Environmental Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25145536; PMID: 21633507" PMDBI40591 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001233291] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40592 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD1426 Sucralose Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28790923" PMDBI40592 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001691631] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40593 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD1426 Sucralose Environmental Substance Artificial Sweeteners n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28790923" PMDBI40593 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40594 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002099054] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40594 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD1426 Sucralose Environmental Substance Artificial Sweeteners n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28790923" PMDBI40595 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1435 Tau-?uvalinate Environmental Substance Pesticides Treated strips following manufacturer's instructions for 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27579024" PMDBI40595 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.23E-06] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40596 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40596 Substances alter microbe abundance PMDBM676 76892 Caulobacteraceae PMDBD1435 Tau-?uvalinate Environmental Substance Pesticides Treated strips following manufacturer's instructions for 6 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27579024" PMDBI40597 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1446 Tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0é–?0 娓璯/kg/day for 28 and 92 days with the latter having a 30-day recovery period Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28475713" PMDBI40597 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40598 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1446 Tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0 or 6 娓璯/kg biweekly for 26 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27221631" PMDBI40598 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007347466] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Prediabetic hyperglycemic state n.a. n.a. PMID PMID: 29555994 PMDBI40599 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD1446 Tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0 or 6 娓璯/kg biweekly for 26 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27221631" PMDBI40599 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Prediabetic hyperglycemic state n.a. n.a. PMID PMID: 29555994 PMDBI40600 Substances alter microbe abundance PMDBM2020008 817 Bacteroides fragilis PMDBD1446 Tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0 or30 娓璯/kg/day every 4 days for 28 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28936204" PMDBI40600 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001083172] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40601 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40601 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1446 Tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0 or 6 娓璯/kg biweekly for 26 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Prediabetic hyperglycemic state n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27221631" PMDBI40602 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40602 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1446 Tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0 or 6 娓璯/kg biweekly for 26 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Prediabetic hyperglycemic state n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27221631" PMDBI40603 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40603 Substances alter microbe abundance PMDBM738 194924 Desulfovibrionaceae PMDBD1446 Tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0 or 6 娓璯/kg biweekly for 26 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Prediabetic hyperglycemic state n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27221631" PMDBI40604 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000991397] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40604 Substances alter microbe abundance PMDBM928 n.a. Segmented ?lamentous bacteria (SFB) PMDBD1446 Tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0 or30 娓璯/kg/day every 4 days for 28 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28936204" PMDBI40605 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.28E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40605 Substances alter microbe abundance PMDBM606 n.a. Actinobacteria cluster ACK M1 PMDBD1003 2,3,7,8-tetrachlorodibenzo-p-dioxin Environmental Substance Persistent Organic Pollutants 0 or 6 娓璯/kg biweekly for 26 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Prediabetic hyperglycemic state n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27221631" PMDBI40606 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 0 or 24 娓璯/kg/day for 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 25768209" PMDBI40606 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40607 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 0 or 24 娓璯/kg/day for 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 25768209" PMDBI40607 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40608 Substances alter microbe abundance PMDBM305 459786 Oscillibacter PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 24 娓璯/kg per day in the diet for 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 25768209" PMDBI40608 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD494 Loratadine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000507497] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40609 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40609 Substances alter microbe abundance PMDBM777 117743 Flavobacteria PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 0 or 24 娓璯/kg/day for 5 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 25768209" PMDBI40610 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000324146] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40610 Substances alter microbe abundance PMDBM928 n.a. Segmented ?lamentous bacteria (SFB) PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 0 or 24 娓璯/kg/day for 5 days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 25768209" PMDBI40611 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002723341] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40611 Substances alter microbe abundance PMDBM667 n.a. Butyrivibrio spp. PMDBD1002 2,3,7,8-tetrachlorodibenzofuran Environmental Substance Persistent Organic Pollutants 0 or 24 娓璯/kg/day for 5 days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 25768209" PMDBI40612 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1449 Thiamethoxam Environmental Substance Pesticides 1.7 娓璯/kg in sugar syrup for 24é–?4 h of interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31378758" PMDBI40612 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.49E-05] n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID PMID: 29555994 PMDBI40613 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40613 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1449 Thiamethoxam Environmental Substance Pesticides 1.7 娓璯/kg in sugar syrup for 24é–?4 h of interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31378758" PMDBI40614 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40614 Substances alter microbe abundance PMDBM624 28211 Alphaproteobacteria PMDBD1449 Thiamethoxam Environmental Substance Pesticides 1.7 娓璯/kg in sugar syrup for 24é–?4 h of interior worker bees Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31378758" PMDBI40615 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40615 Substances alter microbe abundance PMDBM2020124 1196095 Gilliamella apicola PMDBD1449 Thiamethoxam Environmental Substance Pesticides 1.7 娓璯/kg in sugar syrup for 24é–?4 h of interior worker bees Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Honeybees Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 31378758" PMDBI40616 Substances alter microbe abundance PMDBM173 84107 Coriobacteriaceae PMDBD1468 Traffic-related air Environmental Substance Environmental Chemicals n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.1124/pr.118.015768; PMID: 29220800" PMDBI40616 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40617 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD1468 Traffic-related air Environmental Substance Environmental Chemicals n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.1124/pr.118.015768; PMID: 29220800" PMDBI40617 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.13E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40618 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1476 Trichlorfon Environmental Substance Pesticides 12 娓璯/g bw single dose by oral gavage at 8 weeks of age, collected 24 h after dosing Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27168998" PMDBI40618 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD265 Dicumarol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002320022] n.a. n.a. n.a. n.a. In vivo Japanese quail Health n.a. n.a. PMID PMID: 29555994 PMDBI40619 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1476 Trichlorfon Environmental Substance Pesticides 12 娓璯/g bw single dose by oral gavage at 8 weeks of age, collected 24 h after dosing Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 27168998" PMDBI40619 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000109489] n.a. n.a. n.a. n.a. In vivo Japanese quail Health n.a. n.a. PMID PMID: 29555994 PMDBI40620 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD869 Triclosan Environmental Substance Unclassified Environmental Substances n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28606169" PMDBI40620 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009510718] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40621 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD869 Triclosan Environmental Substance Unclassified Environmental Substances n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28606169" PMDBI40621 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD186 Chlorprothixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001963588] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40622 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD713 Protriptyline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000469925] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40622 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD869 Triclosan Environmental Substance Unclassified Environmental Substances n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28606169" PMDBI40623 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD559 Moricizine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.08E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40623 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD869 Triclosan Environmental Substance Unclassified Environmental Substances n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28606169" PMDBI40624 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD502 Loxapine succinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003157443] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40624 Substances alter microbe abundance PMDBM975 n.a. Turicibacteraceae PMDBD869 Triclosan Environmental Substance Unclassified Environmental Substances n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI:?10.3390/toxics8010019; PMID: 28606169" PMDBI40625 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD888 Vancomycin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25970503" PMDBI40625 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD875 Trimeprazine tartrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003354848] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40626 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD888 Vancomycin Environmental Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25970503" PMDBI40626 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD431 Hycanthone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006642697] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40627 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD888 Vancomycin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 24316517" PMDBI40627 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD438 Idoxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000352557] n.a. n.a. n.a. n.a. In vivo Human Obese n.a. n.a. PMID PMID: 29555994 PMDBI40628 Substances alter microbe abundance PMDBM239 1239 Gram-positive bacteria PMDBD888 Vancomycin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 24316517" PMDBI40628 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD515 Meclofenamic acid sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006173365] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40629 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD888 Vancomycin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25970503" PMDBI40629 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD360 Flufenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000601342] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40630 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD888 Vancomycin Environmental Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25970503" PMDBI40630 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD742 Ribavirin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001080494] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40631 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD888 Vancomycin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25970503" PMDBI40631 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD674 Pioglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000755608] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40632 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD888 Vancomycin Environmental Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 24316517" PMDBI40632 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD325 Etofenamate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000304871] n.a. n.a. n.a. n.a. In vivo Human Obese n.a. n.a. PMID PMID: 29555994 PMDBI40633 Substances alter microbe abundance PMDBM351 171550 Rikenellaceae PMDBD888 Vancomycin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25970503" PMDBI40633 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD363 Flunixin meglumine Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001747188] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40634 Substances alter microbe abundance PMDBM397 40544 Sutterella PMDBD888 Vancomycin Environmental Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 25970503" PMDBI40634 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD337 Fenbufen Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006136783] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40635 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD739 Reserpine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001439963] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40635 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD888 Vancomycin Environmental Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 22422004" PMDBI40636 Substances alter microbe abundance PMDBM2020263 n.a. Bacteroides ovatus PMDBD809 Sulfamonomethoxine Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000129611] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40636 Substances alter microbe abundance PMDBM988 203557 Verrucomicrobiaceae PMDBD888 Vancomycin Environmental Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 22422004" PMDBI40637 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.34E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40637 Substances alter microbe abundance PMDBM788 n.a. Gram-negative bacteria PMDBD888 Vancomycin Environmental Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.envpol.2016.11.045; PMID: 24316517" PMDBI40638 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1496 ç?Hexachlorocyclo hexane Environmental Substance Pesticides 10 mg/kg daily by gavage for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28392238" PMDBI40638 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.55E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40639 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1496 ç?Hexachlorocyclo hexane Environmental Substance Pesticides 10 mg/kg daily by gavage for 8 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28392238" PMDBI40639 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40640 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1496 ç?Hexachlorocyclo hexane Environmental Substance Pesticides 10 mg/kg daily by gavage for 8 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28392238" PMDBI40640 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.10E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40641 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD1496 ç?Hexachlorocyclo hexane Environmental Substance Pesticides 10 mg/kg daily by gavage for 8 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28392238" PMDBI40641 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.66E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40642 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.55E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40642 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1496 ç?Hexachlorocyclo hexane Environmental Substance Pesticides 10 mg/kg daily by gavage for 8 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1093/toxsci/kfaa065; PMID: 28392238" PMDBI40643 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40643 Substances alter microbe abundance PMDBM968 n.a. The diversity of microbiota in colon PMDBD1301 Mixture Environmental Substance "Approved Drug; Antibiotics" Bacitracin (108.0mg), ampicillin (43.2mg), neomycin (108mg), vancomycin and meropenem (21.6 mg)(6.48mg) dissolved in 4.5 mL for 11 days by oral gavage (10mL/kg) Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "Acetate(Decrease); n-butyrate (Decrease); propionate (Decrease);" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26923630" PMDBI40644 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1301 Mixture Environmental Substance "Approved Drug; Antibiotics" penicillin VK, vancomycin for 7 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Acetate(Increase); propionate(Increase); butyrate(Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 22914093" PMDBI40644 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.48E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40645 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1114 Chromium Environmental Substance "Heavy Metals; Toxic Agents" 416 娓璯 Cr6+ L-1 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "carbohydrate metabolism (Increase); energy metabolism (Increase); metabolism of cofactors and vitamins(Increase); amino acid metabolism (Increase); nucleotide metabolism(Increase); metabolic diseases, (Increase); xenobiotics lipid metabolism(Increase); biodegradation metabolism (Increase); immune system diseases (Increase); infectious diseases (Increase); neurodegenerative diseases (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30384300" PMDBI40645 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.51E-06] n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. n.a. PMID PMID: 29555994 PMDBI40646 Substances alter microbe abundance PMDBM613 642 Aeromonas PMDBD1114 Chromium Environmental Substance "Heavy Metals; Toxic Agents" 416 娓璯 Cr6+ L-1 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "carbohydrate metabolism (Increase); energy metabolism (Increase); metabolism of cofactors and vitamins(Increase); amino acid metabolism (Increase); nucleotide metabolism(Increase); metabolic diseases, (Increase); xenobiotics lipid metabolism(Increase); biodegradation metabolism (Increase); immune system diseases (Increase); infectious diseases (Increase); neurodegenerative diseases (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30384300" PMDBI40646 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.95E-06] n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. n.a. PMID PMID: 29555994 PMDBI40647 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.51E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40647 Substances alter microbe abundance PMDBM922 95818 Saccharibacteria PMDBD1114 Chromium Environmental Substance "Heavy Metals; Toxic Agents" 416 娓璯 Cr6+ L-1 Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. "carbohydrate metabolism (Increase); energy metabolism (Increase); metabolism of cofactors and vitamins(Increase); amino acid metabolism (Increase); nucleotide metabolism(Increase); metabolic diseases, (Increase); xenobiotics lipid metabolism(Increase); biodegradation metabolism (Increase); immune system diseases (Increase); infectious diseases (Increase); neurodegenerative diseases (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30384300" PMDBI40648 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40648 Substances alter microbe abundance PMDBM855 n.a. Norank_f_Hados. Sed. Eubac.3 PMDBD1114 Chromium Environmental Substance "Heavy Metals; Toxic Agents" 416 娓璯 Cr6+ L-1 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. "carbohydrate metabolism (Increase); energy metabolism (Increase); metabolism of cofactors and vitamins(Increase); amino acid metabolism (Increase); nucleotide metabolism(Increase); metabolic diseases, (Increase); xenobiotics lipid metabolism(Increase); biodegradation metabolism (Increase); immune system diseases (Increase); infectious diseases (Increase); neurodegenerative diseases (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30384300" PMDBI40649 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.09E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40649 Substances alter microbe abundance PMDBM856 n.a. Norank_f_Peptostreptococcaceae PMDBD1114 Chromium Environmental Substance "Heavy Metals; Toxic Agents" 416 娓璯 Cr6+ L-1 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. "carbohydrate metabolism (Increase); energy metabolism (Increase); metabolism of cofactors and vitamins(Increase); amino acid metabolism (Increase); nucleotide metabolism(Increase); metabolic diseases, (Increase); xenobiotics lipid metabolism(Increase); biodegradation metabolism (Increase); immune system diseases (Increase); infectious diseases (Increase); neurodegenerative diseases (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30384300" PMDBI40650 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.47E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40650 Substances alter microbe abundance PMDBM966 n.a. The bacterial community diversity PMDBD1114 Chromium Environmental Substance "Heavy Metals; Toxic Agents" 416 娓璯 Cr6+ L-1 Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. "carbohydrate metabolism (Increase); energy metabolism (Increase); metabolism of cofactors and vitamins(Increase); amino acid metabolism (Increase); nucleotide metabolism(Increase); metabolic diseases, (Increase); xenobiotics lipid metabolism(Increase); biodegradation metabolism (Increase); immune system diseases (Increase); infectious diseases (Increase); neurodegenerative diseases (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30384300" PMDBI40651 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.99E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40651 Substances alter microbe abundance PMDBM970 n.a. TM6_Dependentiae PMDBD1114 Chromium Environmental Substance "Heavy Metals; Toxic Agents" 416 娓璯 Cr6+ L-1 Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo Bufo gargarizans Health n.a. "carbohydrate metabolism (Increase); energy metabolism (Increase); metabolism of cofactors and vitamins(Increase); amino acid metabolism (Increase); nucleotide metabolism(Increase); metabolic diseases, (Increase); xenobiotics lipid metabolism(Increase); biodegradation metabolism (Increase); immune system diseases (Increase); infectious diseases (Increase); neurodegenerative diseases (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 30384300" PMDBI40652 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 3 mg/L drinking water for 90days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881" PMDBI40652 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.57E-05] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40653 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 3 mg/L drinking water for 90days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881" PMDBI40653 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.05E-05] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40654 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 3 mg/L drinking water for 90days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881" PMDBI40654 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.68E-06] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40655 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 3 mg/L drinking water for 90days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881" PMDBI40655 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.10E-05] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40656 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.10E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40656 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 3 mg/L drinking water for 90days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. "Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881" PMDBI40657 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40657 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 3 mg/L drinking water for 90days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. "Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881" PMDBI40658 Substances alter microbe abundance PMDBM602 204432 Acidobacteria PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 3 mg/L drinking water for 90days Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881" PMDBI40658 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.56E-05] n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40659 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.43E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40659 Substances alter microbe abundance PMDBM965 544448 Tenericutes PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 3 mg/L drinking water for 90days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. "Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881" PMDBI40660 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40660 Substances alter microbe abundance PMDBM728 n.a. Cyanobacteria/Chloroplast PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 3 mg/L drinking water for 90days Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. "Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881" PMDBI40661 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.09E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40661 Substances alter microbe abundance PMDBM971 n.a. TM7 PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 3 mg/L drinking water for 90days Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo CD1 (ICR) mouse Health n.a. "Carbohydrate transport and metabolism(Increase); secondary metabolites biosynthesis(Decrease); inorganic ion transport and metabolism(Decrease); tetracycline resistance genes (Increase);transport and catabolism (Decrease)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 25048881" PMDBI40662 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1497 ç?lactam Environmental Substance "Approved Drug; Antibiotics" Intravenous cefazolin alone for 14 days. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Five putative glycerophospholipids and fatty acid carnitines (Increase); GTPases(Decrease); aerobic CobN cobaltochelatases (Decrease); antimicrobial peptide transporters (Increase);multidrug ef?ux pumps (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 23236009" PMDBI40662 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.41E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40663 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1497 ç?lactam Environmental Substance "Approved Drug; Antibiotics" Intravenous cefazolin alone for 14 days. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Five putative glycerophospholipids and fatty acid carnitines (Increase); GTPases(Decrease); aerobic CobN cobaltochelatases (Decrease); antimicrobial peptide transporters (Increase);multidrug ef?ux pumps (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 23236009" PMDBI40663 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.60E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40664 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.10E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40664 Substances alter microbe abundance PMDBM969 n.a. The diversity of total bacteria PMDBD1497 ç?lactam "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" Intravenous cefazolin alone for 14 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "Five putative glycerophospholipids and fatty acid carnitines (Increase); GTPases(Decrease); aerobic CobN cobaltochelatases (Decrease); antimicrobial peptide transporters (Increase);multidrug ef?ux pumps (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 23236009" PMDBI40665 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD881 Tylosin Environmental Substance "Approved Drug; Antibiotics" 0.333 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entneré–?Doudoroff pathway (Increase); the classic Embden閳ユ彈eyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40665 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.52E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40666 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD881 Tylosin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" 0.333 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entneré–?Doudoroff pathway (Increase); the classic Embden閳ユ彈eyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40666 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.08E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40667 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD881 Tylosin Environmental Substance "Approved Drug; Antibiotics" 0.333 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entneré–?Doudoroff pathway (Increase); the classic Embden閳ユ彈eyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40667 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.42E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40668 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD881 Tylosin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" 0.333 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entneré–?Doudoroff pathway (Increase); the classic Embden閳ユ彈eyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40668 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.42E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40669 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD881 Tylosin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" 0.333 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entneré–?Doudoroff pathway (Increase); the classic Embden閳ユ彈eyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40669 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.80E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40670 Substances alter microbe abundance PMDBM351 171550 Rikenellaceae PMDBD881 Tylosin Environmental Substance "Approved Drug; Antibiotics" 0.333 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entneré–?Doudoroff pathway (Increase); the classic Embden閳ユ彈eyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40670 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.94E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40671 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD881 Tylosin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" 0.333 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entneré–?Doudoroff pathway (Increase); the classic Embden閳ユ彈eyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40671 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40672 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD881 Tylosin Environmental Substance "Approved Drug; Antibiotics" 0.333 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entneré–?Doudoroff pathway (Increase); the classic Embden閳ユ彈eyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40672 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.43E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40673 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.48E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40673 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD881 Tylosin Environmental Substance "Approved Drug; Antibiotics" 0.333 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entneré–?Doudoroff pathway (Increase); the classic Embden閳ユ彈eyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40674 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.44E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40674 Substances alter microbe abundance PMDBM841 n.a. microbiota PMDBD881 Tylosin Environmental Substance "Approved Drug; Antibiotics" 0.333 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut delay microbiota maturation n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entneré–?Doudoroff pathway (Increase); the classic Embden閳ユ彈eyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40675 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.38E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40675 Substances alter microbe abundance PMDBM976 n.a. unclassi?ed Clostridiales PMDBD881 Tylosin Environmental Substance "Approved Drug; Antibiotics" 0.333 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entneré–?Doudoroff pathway (Increase); the classic Embden閳ユ彈eyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40676 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.66E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40676 Substances alter microbe abundance PMDBM911 n.a. Richness and Shannon evenness PMDBD881 Tylosin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" 0.333 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entneré–?Doudoroff pathway (Increase); the classic Embden閳ユ彈eyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40677 Substances alter microbe abundance PMDBM645 n.a. Bacteroidales other PMDBD881 Tylosin Environmental Substance "Approved Drug; Antibiotics" 0.333 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Glycolysis (Decrease); gluconeogenesis (Decrease); tRNA biosynthesis (Decrease); nucleoside (inosine) and amino acid (leucine)biosynthesis (Increase); the citric acid cycle (Increase); the alternate Entneré–?Doudoroff pathway (Increase); the classic Embden閳ユ彈eyerhoff pathway (Decrease); isoprenoid biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40677 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.39E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40678 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD42 Amoxicillin Environmental Substance "Approved Drug; Antibiotics" 0.167 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40678 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40679 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD42 Amoxicillin Environmental Substance "Approved Drug; Antibiotics" 0.167 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40679 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.64E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40680 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD42 Amoxicillin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" 0.167 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40680 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40681 Substances alter microbe abundance PMDBM351 171550 Rikenellaceae PMDBD42 Amoxicillin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" 0.167 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40681 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40682 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD42 Amoxicillin Environmental Substance "Approved Drug; Antibiotics" 0.167 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40682 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.09E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40683 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD42 Amoxicillin Environmental Substance "Approved Drug; Antibiotics" 0.167 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40683 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000393088] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40684 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.43E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40684 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD42 Amoxicillin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" 0.167 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40685 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000750494] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40685 Substances alter microbe abundance PMDBM841 n.a. microbiota PMDBD42 Amoxicillin Environmental Substance "Approved Drug; Antibiotics" 0.167 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut delay microbiota maturation n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40686 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.91E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40686 Substances alter microbe abundance PMDBM932 n.a. Shannon evenness PMDBD42 Amoxicillin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" 0.167 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40687 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002379728] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40687 Substances alter microbe abundance PMDBM976 n.a. unclassi?ed Clostridiales PMDBD42 Amoxicillin Environmental Substance "Approved Drug; Antibiotics" 0.167 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40688 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.43E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40688 Substances alter microbe abundance PMDBM910 n.a. Richness PMDBD42 Amoxicillin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" 0.167 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. "Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40689 Substances alter microbe abundance PMDBM645 n.a. Bacteroidales other PMDBD42 Amoxicillin "Therapeutic Substance; Environmental Substance" "Approved Drug; Antibiotics" 0.167 mg mL-1 at days 10é–?5, 28é–?1 and 37é–?0 of life Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. "Glycolysis (Decrease); isoprenoid biosynthesis (Decrease); tRNA biosynthesis (Decrease); ribosomes (Decrease); proline and vitamin biosynthesis (Increase); LPS synthesis, (Increase); oxalate-degrading capacity (Decrease); pyruvate oxidation and molecular transport (Increase)" PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26123276" PMDBI40689 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.43E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40690 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm As for 4 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Indolelacticacid Decrease PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24413286" PMDBI40690 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.08E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40691 Substances alter microbe abundance PMDBM204 128827 Erysipelotrichaceae PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm As for 4 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Indolelacticacid Decrease PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24413286" PMDBI40691 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40692 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40692 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm As for 4 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. Indolelacticacid Decrease PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24413286" PMDBI40693 Substances alter microbe abundance PMDBM675 424536 Catabacteriaceae PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm As for 4 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Indolelacticacid Decrease PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24413286" PMDBI40693 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000174956] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40694 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40694 Substances alter microbe abundance PMDBM690 538999 Clostridiales incertae sedis PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm As for 4 weeks in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. Indolelacticacid Decrease PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24413286" PMDBI40695 Substances alter microbe abundance PMDBM638 n.a. Bacillales_Other PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm As for 4 weeks in drinking water Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Indolelacticacid Decrease PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24413286" PMDBI40695 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40696 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.55E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40696 Substances alter microbe abundance PMDBM691 n.a. Clostridiales_unassigned PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm As for 4 weeks in drinking water Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. Indolelacticacid Decrease PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 24413286" PMDBI40697 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000390662] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40697 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD530 Metformin Therapeutic Substance Approved Drug 6-week-old mice were fed an HFD for 28 weeks. Metformin (300 mg/kg of body weight) was administered every day during the HFD for 10 weeks. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. metformin promotes in vivo the growth of the bacterial species PMID PMID: 25038099 PMDBI40698 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40698 Substances alter microbe abundance PMDBM703 69824 Clostridium cocleatum PMDBD530 Metformin Therapeutic Substance Approved Drug 6-week-old mice were fed an HFD for 28 weeks. Metformin (300 mg/kg of body weight) was administered every day during the HFD for 10 weeks. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. metformin promotes in vivo the growth of the bacterial species PMID PMID: 25038099 PMDBI40699 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD1032 Anti PD-1 therapy Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Melanoma n.a. Reduced diversity PMID PMID: 31675176 PMDBI40699 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.97E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40700 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD1032 Anti PD-1 therapy Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. Melanoma n.a. Reduced diversity PMID PMID: 31675176 PMDBI40700 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40701 Substances alter microbe abundance PMDBM2020033 1352 Enterococcus faecium PMDBD1032 Anti PD-1 therapy Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Melanoma n.a. Reduced diversity PMID PMID: 31675176 PMDBI40701 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.63E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40702 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1032 Anti PD-1 therapy Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Melanoma n.a. Reduced diversity PMID PMID: 31675176 PMDBI40702 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40703 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001858081] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40703 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD1032 Anti PD-1 therapy Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40704 Substances alter microbe abundance PMDBM2020202 29347 Clostridium scindens PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40704 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001596639] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40705 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40705 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00323688] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40706 Substances alter microbe abundance PMDBM345 135621 Pseudomonadaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40706 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.06E-05] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40707 Substances alter microbe abundance PMDBM632 207244 Anaerostipes PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40707 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.96E-05] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40708 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000478376] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40708 Substances alter microbe abundance PMDBM2020162 301302 Roseburia faecis PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40709 Substances alter microbe abundance PMDBM345 135621 Pseudomonadaceae PMDBD1200 Fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40709 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.71E-05] n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40710 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001275288] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40710 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD1200 Fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40711 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000758779] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40711 Substances alter microbe abundance PMDBM988 203557 Verrucomicrobiaceae PMDBD1200 Fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Reduced diversity PMID PMID: 31675176 PMDBI40712 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD535 Methotrexate Therapeutic Substance Approved Drug Rats were injected once intravenously in the tail vein with Methotrexate (90 mg/kg). n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Methotrexate results in reduced microbiota diversity and compositional shifts in the abundance of Bacteroides associated with the induction of diarrhea in rats. PMID PMID: 25376667 PMDBI40712 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.17E-05] n.a. n.a. n.a. n.a. In vivo Wistar Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40713 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0,10,or 250 ppb As(III) for 2,5, or 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26529668" PMDBI40713 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002546255] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40714 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0,10,or 250 ppb As(III) for 2,5, or 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26529668" PMDBI40714 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000322832] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40715 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0,10,or 250 ppb As(III) for 2,5, or 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26529668" PMDBI40715 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.60E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40716 Substances alter microbe abundance PMDBM28 815 Bacteroidaceae PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0,10,or 250 ppb As(III) for 2,5, or 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26529668" PMDBI40716 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000958761] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40717 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0,10,or 250 ppb As(III) for 2,5, or 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26529668" PMDBI40717 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001797486] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40718 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0,10,or 250 ppb As(III) for 2,5, or 10 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26529668" PMDBI40718 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.31E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40719 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00040782] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40719 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD70 Arsenic Environmental Substance "Heavy Metals; Toxic Agents" 0,10,or 250 ppb As(III) for 2,5, or 10 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 26529668" PMDBI40720 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm Pb for 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 28234468" PMDBI40720 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.23E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40721 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm Pb for 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 28234468" PMDBI40721 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.02E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40722 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm Pb for 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 28234468" PMDBI40722 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006561372] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40723 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm Pb for 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 28234468" PMDBI40723 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.09E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40724 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.74E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40724 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm Pb for 13 weeks Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 28234468" PMDBI40725 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.87E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40725 Substances alter microbe abundance PMDBM916 n.a. Ruminococcaceae_other PMDBD1251 Lead Environmental Substance "Heavy Metals; Toxic Agents" 10 ppm Pb for 13 weeks Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6J mouse Health n.a. n.a. PMID "DOI: 10.1007/978-981-15-4759-1_4; PMID: 28234468" PMDBI40726 Substances alter microbe abundance PMDBM2020035 562 Escherichia coli PMDBD1004 5-aminosalicylic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40726 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40727 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1004 5-aminosalicylic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40727 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000244742] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40728 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1004 5-aminosalicylic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40728 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002834728] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40729 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1004 5-aminosalicylic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40729 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008429051] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40730 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.08E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40730 Substances alter microbe abundance PMDBM938 620 Shigella PMDBD1004 5-aminosalicylic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40731 Substances alter microbe abundance PMDBM2020035 562 Escherichia coli PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug Female DA rats were given a single 150 mg/ kg i.p. dose of 5-FU. n.a. Increase P < 0.05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. 5-FU treatment causes significant changes in intestinal flora and mucin secretion in rats. These changes may contribute to the development of chemotherapy-induced mucositis. PMID PMID: 19176868 PMDBI40731 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40732 Substances alter microbe abundance PMDBM284 n.a. Lactobacillus spp. PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug Female DA rats were given a single 150 mg/ kg i.p. dose of 5-FU. n.a. Decrease P < 0.05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. 5-FU treatment causes significant changes in intestinal flora and mucin secretion in rats. These changes may contribute to the development of chemotherapy-induced mucositis. PMID PMID: 19176868 PMDBI40732 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007469016] n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40733 Substances alter microbe abundance PMDBM63 29523 Bacteroides spp. PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug Female DA rats were given a single 150 mg/ kg i.p. dose of 5-FU. n.a. Decrease P < 0.05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. 5-FU treatment causes significant changes in intestinal flora and mucin secretion in rats. These changes may contribute to the development of chemotherapy-induced mucositis. PMID PMID: 19176868 PMDBI40733 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007503786] n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40734 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40734 Substances alter microbe abundance PMDBM951 n.a. Staphylococcus spp. PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug Female DA rats were given a single 150 mg/ kg i.p. dose of 5-FU. n.a. Increase P < 0.05 n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. 5-FU treatment causes significant changes in intestinal flora and mucin secretion in rats. These changes may contribute to the development of chemotherapy-induced mucositis. PMID PMID: 19176868 PMDBI40735 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000321751] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40735 Substances alter microbe abundance PMDBM709 n.a. Clostridium spp. PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug Female DA rats were given a single 150 mg/ kg i.p. dose of 5-FU. n.a. Increase P < 0.05 n.a. n.a. n.a. n.a. In vivo Rat n.a. n.a. 5-FU treatment causes significant changes in intestinal flora and mucin secretion in rats. These changes may contribute to the development of chemotherapy-induced mucositis. PMID PMID: 19176868 PMDBI40736 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1009 ACE inhibitors Therapeutic Substance Drug Class n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40736 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.64E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40737 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008333416] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40737 Substances alter microbe abundance PMDBM2020113 88431 Dorea longicatena PMDBD1009 ACE inhibitors Therapeutic Substance Drug Class n.a. Gut Decrease Bacterial taxa negatively associated with drug use. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40738 Substances alter microbe abundance PMDBM120 80840 Burkholderiales PMDBD1017 Adalimumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Juvenile Idiopathic Arthritis (JIA) n.a. Microbiota as JIA therapy response biomarker PMID PMID: 31675176 PMDBI40738 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.80E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40739 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD1017 Adalimumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40739 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000835296] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40740 Substances alter microbe abundance PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD1017 Adalimumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40740 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.27E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40741 Substances alter microbe abundance PMDBM322 33024 Phascolarctobacterium PMDBD1017 Adalimumab Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40741 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003263891] n.a. n.a. n.a. n.a. In vivo Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI40742 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.78E-05] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI40742 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1017 Adalimumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40743 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD186 Chlorprothixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000462902] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI40743 Substances alter microbe abundance PMDBM810 28050 Lachnospira PMDBD1017 Adalimumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40744 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD713 Protriptyline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001072952] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI40744 Substances alter microbe abundance PMDBM748 84111 Eggerthella PMDBD1017 Adalimumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40745 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD559 Moricizine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00019571] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI40745 Substances alter microbe abundance PMDBM2020162 301302 Roseburia faecis PMDBD1017 Adalimumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI40746 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1023 Alpha blockers Therapeutic Substance Drug Class n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40746 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD502 Loxapine succinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000612907] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40747 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD875 Trimeprazine tartrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000324701] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40747 Substances alter microbe abundance PMDBM987 31977 Veillonellaceae PMDBD1023 Alpha blockers Therapeutic Substance Drug Class n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40748 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD670 Pimethixene maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005767488] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40748 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1023 Alpha blockers Therapeutic Substance Drug Class n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40749 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD764 Saquinavir mesylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009785517] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40749 Substances alter microbe abundance PMDBM740 39948 Dialister PMDBD1023 Alpha blockers Therapeutic Substance Drug Class n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40750 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI40750 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD526 Mesoridazine besylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001895632] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40751 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40751 Substances alter microbe abundance PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD606 Norcyclobenzaprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007567399] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40752 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8036475; PMID: 8243490; PMID: 7961199" PMDBI40752 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.64E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40753 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490" PMDBI40753 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.82E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40754 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 16272491; PMID: 9023640" PMDBI40754 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40755 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1906634; Infection 1991:208é–?5; PMID: 7961199" PMDBI40755 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40756 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI40756 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.03E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40757 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI40757 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40758 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1906634" PMDBI40758 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40759 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI40759 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40760 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640; PMID: 8243490; PMID: 1906634" PMDBI40760 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.50E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40761 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640; PMID: 8243490; Infection 1991:208é–?5" PMDBI40761 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40762 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640; PMID: 1906634; Infection 1991:208é–?5" PMDBI40762 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40763 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8036475; PMID: 8243490; PMID: 7961199" PMDBI40763 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.53E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40764 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25006989" PMDBI40764 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40765 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640; PMID: 8036475; PMID: 8243490; PMID: 1906634" PMDBI40765 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40766 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1906634" PMDBI40766 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40767 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; Infection 1991:208é–?5" PMDBI40767 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.90E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40768 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25006989" PMDBI40768 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40769 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640; PMID: 8036475; PMID: 8243490; PMID: 1906634; PMID: 7961199" PMDBI40769 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.83E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40770 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1906634" PMDBI40770 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40771 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40771 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40772 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640; PMID: 8243490; PMID: 1906634" PMDBI40772 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.90E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40773 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI40773 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40774 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25006989; Infection 1991:208é–?5" PMDBI40774 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40775 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640; PMID: 8243490; PMID: 7961199" PMDBI40775 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.44E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40776 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40776 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40777 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25006989" PMDBI40777 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.46E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40778 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 16272491" PMDBI40778 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40779 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490" PMDBI40779 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.72E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40780 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1906634; Infection 1991:208é–?5" PMDBI40780 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40781 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1906634" PMDBI40781 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40782 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40782 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40783 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 1906634" PMDBI40783 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40784 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI40784 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40785 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40785 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640; PMID: 8243490; PMID: 7961199" PMDBI40786 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40786 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1906634; Infection 1991:208é–?5" PMDBI40787 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40787 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI40788 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640" PMDBI40788 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40789 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.33E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40789 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 9023640" PMDBI40790 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.32E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40790 Substances alter microbe abundance PMDBM740 39948 Dialister PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25006989" PMDBI40791 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40791 Substances alter microbe abundance PMDBM844 90690 Morganella PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9023640" PMDBI40792 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.32E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40792 Substances alter microbe abundance PMDBM814 n.a. Lachnospirum spp. PMDBD42 Amoxicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI40793 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979" PMDBI40793 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40794 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979" PMDBI40794 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.89E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40795 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979" PMDBI40795 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40796 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979" PMDBI40796 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40797 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979" PMDBI40797 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.76E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40798 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979" PMDBI40798 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40799 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979" PMDBI40799 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.92E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40800 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979" PMDBI40800 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.98E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40801 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.55E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40801 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979" PMDBI40802 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979" PMDBI40802 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40803 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.50E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40803 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979" PMDBI40804 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.10E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40804 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1029 Amoxicillin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979" PMDBI40805 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 15004076; PMID: 11868762" PMDBI40805 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.63E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40806 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 27973989" PMDBI40806 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.71E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40807 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020; PMID: 23209691; PMID: 15004076" PMDBI40807 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005211253] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40808 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762" PMDBI40808 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40809 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020; PMID: 27973989; PMID: 23209691; PMID: 11868762" PMDBI40809 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008278923] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40810 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020" PMDBI40810 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.14E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40811 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762" PMDBI40811 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40812 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762" PMDBI40812 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.28E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40813 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 27973989" PMDBI40813 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.85E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40814 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 15004076" PMDBI40814 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40815 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762" PMDBI40815 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.94E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40816 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 27973989" PMDBI40816 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40817 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23209691" PMDBI40817 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40818 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.82E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40818 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23209691; PMID: 15004076; PMID: 11868762" PMDBI40819 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1030 Amoxicillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020" PMDBI40819 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.23E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40820 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1031 Ampicillin Therapeutic Substance "Approved Drug; Antibiotics" Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ampicillin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI40820 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.92E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40821 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1031 Ampicillin Therapeutic Substance "Approved Drug; Antibiotics" Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ampicillin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI40821 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.14E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40822 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1031 Ampicillin Therapeutic Substance "Approved Drug; Antibiotics" Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ampicillin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI40822 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40823 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD1031 Ampicillin Therapeutic Substance "Approved Drug; Antibiotics" Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ampicillin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI40823 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.33E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40824 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD1031 Ampicillin Therapeutic Substance "Approved Drug; Antibiotics" Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ampicillin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI40824 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40825 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1031 Ampicillin Therapeutic Substance "Approved Drug; Antibiotics" Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ampicillin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI40825 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40826 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.41E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40826 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD1031 Ampicillin Therapeutic Substance "Approved Drug; Antibiotics" Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Ampicillin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI40827 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.03E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40827 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1031 Ampicillin Therapeutic Substance "Approved Drug; Antibiotics" Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Ampicillin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI40828 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000191748] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40828 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1031 Ampicillin Therapeutic Substance "Approved Drug; Antibiotics" Ampicillin (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Ampicillin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI40829 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1031 Ampicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40829 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40830 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1031 Ampicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40830 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000507497] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40831 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1031 Ampicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40831 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.60E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40832 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1031 Ampicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40832 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40833 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1031 Ampicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40833 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003325765] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40834 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40834 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000681488] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40835 Substances alter microbe abundance PMDBM305 459786 Oscillibacter PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40835 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.44E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40836 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40836 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.60E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40837 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40837 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000180117] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40838 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007728184] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40838 Substances alter microbe abundance PMDBM85 31953 Bifidobacteriaceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40839 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40839 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40840 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40840 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40841 Substances alter microbe abundance PMDBM618 506 Alcaligenaceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40841 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004873795] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40842 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40842 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40843 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001295533] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40843 Substances alter microbe abundance PMDBM758 81852 Enterococcaceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40844 Substances alter microbe abundance PMDBM631 186333 Anaeroplasmataceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40844 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000358235] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40845 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.20E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40845 Substances alter microbe abundance PMDBM876 186807 Peptococcaceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40846 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40846 Substances alter microbe abundance PMDBM978 186928 unclassified Lachnospiraceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40847 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.16E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40847 Substances alter microbe abundance PMDBM980 552397 unclassified Ruminococcaceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40848 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000108547] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40848 Substances alter microbe abundance PMDBM858 1853231 Odoribacteraceae PMDBD1033 Antibiotics (previous month antibiotics) Therapeutic Substance Drug Class n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40849 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.55E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40849 Substances alter microbe abundance PMDBM732 n.a. Dehalobacteriaceae PMDBD1034 Antihistamines (H1 inhibitor) Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40850 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD1035 Antihistamines (H2 inhibitor) Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40850 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40851 Substances alter microbe abundance PMDBM2020047 208479 Clostridium bolteae PMDBD1036 Antihistamines (H3 inhibitor) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40851 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001729015] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40852 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1040 aracytine Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI40852 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000103719] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40853 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1040 aracytine Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI40853 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40854 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1040 aracytine Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI40854 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000146112] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40855 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40855 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.26E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40856 Substances alter microbe abundance PMDBM2020047 208479 Clostridium bolteae PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40856 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005367666] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40857 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40857 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007823119] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40858 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40858 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004605859] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40859 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40859 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002015009] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40860 Substances alter microbe abundance PMDBM2020263 28116 Bacteroides ovatus PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40860 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005268297] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40861 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40861 Substances alter microbe abundance PMDBM85 31953 Bifidobacteriaceae PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40862 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.94E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40862 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40863 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000806109] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40863 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40864 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40864 Substances alter microbe abundance PMDBM2020184 1305 Streptococcus sanguinis PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40865 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007399353] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40865 Substances alter microbe abundance PMDBM2020183 1309 Streptococcus mutans PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40866 Substances alter microbe abundance PMDBM2020014 1689 Bifidobacterium dentium PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40866 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003190057] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40867 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.32E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40867 Substances alter microbe abundance PMDBM770 186806 Eubacteriaceae PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40868 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.53E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40868 Substances alter microbe abundance PMDBM812 n.a. Lachnospiraceae bacterium 3 1 57FAA CT1 PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40869 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004551067] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40869 Substances alter microbe abundance PMDBM813 n.a. Lachnospiraceae bacterium 7 1 58FAA PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40870 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD88 Azithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 12111597" PMDBI40870 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000251723] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40871 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD88 Azithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 12111597" PMDBI40871 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001757589] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40872 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD88 Azithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 12111597" PMDBI40872 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.14E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40873 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1049 Azlocillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564" PMDBI40873 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00032003] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40874 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1049 Azlocillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564" PMDBI40874 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000532567] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40875 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1049 Azlocillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564" PMDBI40875 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001694919] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40876 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1049 Azlocillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564" PMDBI40876 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002181305] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40877 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1049 Azlocillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564" PMDBI40877 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000201749] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40878 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1049 Azlocillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564" PMDBI40878 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0035891] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40879 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1049 Azlocillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564" PMDBI40879 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40880 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1049 Azlocillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564" PMDBI40880 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00016844] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40881 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1049 Azlocillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3704564" PMDBI40881 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008277451] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40882 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1051 Bacampicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356" PMDBI40882 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003377072] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40883 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1051 Bacampicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356" PMDBI40883 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000131961] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40884 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1051 Bacampicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356" PMDBI40884 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001986996] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40885 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1051 Bacampicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356" PMDBI40885 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007710688] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40886 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1051 Bacampicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356" PMDBI40886 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40887 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1051 Bacampicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356" PMDBI40887 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.64E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40888 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1051 Bacampicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356" PMDBI40888 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004546858] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40889 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.24E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40889 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1051 Bacampicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356" PMDBI40890 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.92E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40890 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1051 Bacampicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356" PMDBI40891 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40891 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD1051 Bacampicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356" PMDBI40892 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005217961] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40892 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1051 Bacampicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 511356" PMDBI40893 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD1055 Beta blockers Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40893 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002422736] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40894 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1055 Beta blockers Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40894 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD265 Dicumarol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001765715] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40895 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD172 Cephalosporanic acid, 7-amino Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40895 Substances alter microbe abundance PMDBM2020183 1309 Streptococcus mutans PMDBD1055 Beta blockers Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40896 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004974898] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40896 Substances alter microbe abundance PMDBM785 n.a. Gemellaceae PMDBD1071 Calcium Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI40897 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1080 carmustine Therapeutic Substance Approved Drug n.a. n.a. Decrease P = 0.0002 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI40897 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002066042] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40898 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD1080 carmustine Therapeutic Substance Approved Drug n.a. n.a. Decrease P = 0.0002 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI40898 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40899 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD1080 carmustine Therapeutic Substance Approved Drug n.a. n.a. Increase P = 0.0002 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI40899 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD338 Fendiline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.81E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40900 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262" PMDBI40900 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD713 Protriptyline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.59E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40901 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262" PMDBI40901 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD559 Moricizine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000100831] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40902 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3441750" PMDBI40902 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD502 Loxapine succinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.92E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40903 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262" PMDBI40903 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD916 Zotepine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.84E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40904 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40904 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002355867] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40905 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3441750" PMDBI40905 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD875 Trimeprazine tartrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000653747] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40906 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40906 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD12 Acarbose "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001158548] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40907 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3441750" PMDBI40907 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD319 Ethacrynic acid "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.40E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40908 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3441750" PMDBI40908 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD670 Pimethixene maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.26E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40909 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262" PMDBI40909 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD708 Prochlorperazine dimaleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00869897] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40910 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3441750" PMDBI40910 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD185 Chlorpromazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003157656] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40911 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40911 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD710 Promethazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40912 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3441750" PMDBI40912 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD419 Haloprogin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000426281] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40913 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40913 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD235 Cyclobenzaprine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004347253] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40914 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262" PMDBI40914 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD705 Proadifen hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008016364] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40915 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID DOI: 10.1016/j.jinf.2019.10.008 PMDBI40915 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD40 Amodiaquin dihydrochloride dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003290192] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40916 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3441750" PMDBI40916 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002824993] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40917 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD526 Mesoridazine besylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000861551] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40917 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262" PMDBI40918 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD491 Loperamide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007377276] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40918 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3441750" PMDBI40919 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1083 Cefaclor Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262" PMDBI40919 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD17 Acetopromazine maleate salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003467683] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40920 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD154 Cefadroxil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382" PMDBI40920 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD702 Pridinol methanesulfonate salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000103469] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40921 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD154 Cefadroxil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382" PMDBI40921 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD71 Artemisinin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000890931] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40922 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD154 Cefadroxil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382" PMDBI40922 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD239 Cyproheptadine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001175749] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40923 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD154 Cefadroxil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382" PMDBI40923 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD728 Raloxifene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003432585] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40924 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD154 Cefadroxil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382" PMDBI40924 Substances alter microbe abundance PMDBM2020267 820 Bacteroides uniformis PMDBD679 Pizotifen malate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000111644] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40925 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD154 Cefadroxil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382" PMDBI40925 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.58E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40926 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD154 Cefadroxil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382" PMDBI40926 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.98E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40927 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1085 Cefepime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502" PMDBI40927 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40928 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1085 Cefepime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502" PMDBI40928 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40929 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD1085 Cefepime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502" PMDBI40929 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40930 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1085 Cefepime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502" PMDBI40930 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.63E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40931 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1085 Cefepime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502" PMDBI40931 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.96E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40932 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1085 Cefepime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502" PMDBI40932 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.29E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40933 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1085 Cefepime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502" PMDBI40933 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000104443] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40934 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1085 Cefepime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502" PMDBI40934 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40935 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1085 Cefepime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502" PMDBI40935 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.94E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40936 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1085 Cefepime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502" PMDBI40936 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00052783] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40937 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1085 Cefepime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502" PMDBI40937 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40938 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1085 Cefepime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502" PMDBI40938 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40939 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.99E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40939 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1085 Cefepime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502" PMDBI40940 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.86E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40940 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1085 Cefepime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1452502" PMDBI40941 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1086 Cefetamet-pivoxil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110" PMDBI40941 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.12E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40942 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD158 Cefixime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3222669; PMID: 8618110" PMDBI40942 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.01E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40943 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD158 Cefixime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3222669; PMID: 8618110" PMDBI40943 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.94E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40944 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD158 Cefixime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262; PMID: 8618110" PMDBI40944 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.94E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40945 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD158 Cefixime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3222669; PMID: 8618110" PMDBI40945 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40946 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD158 Cefixime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3579262; PMID: 3222669" PMDBI40946 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.64E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40947 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD158 Cefixime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110" PMDBI40947 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40948 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD158 Cefixime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3222669" PMDBI40948 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40949 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD158 Cefixime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110" PMDBI40949 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40950 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD158 Cefixime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110" PMDBI40950 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.19E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40951 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD158 Cefixime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110" PMDBI40951 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.65E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40952 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD158 Cefixime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3222669" PMDBI40952 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.65E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40953 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40953 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD158 Cefixime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110" PMDBI40954 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.66E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40954 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD158 Cefixime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3222669; PMID: 8618110" PMDBI40955 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.30E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40955 Substances alter microbe abundance PMDBM923 590 Salmonella PMDBD158 Cefixime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110" PMDBI40956 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.29E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40956 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD158 Cefixime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110" PMDBI40957 Substances alter microbe abundance PMDBM137 186802 Clostridiales PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" C57BL/6 J mice(five to six mice per group) were supplemented with sterile water with cefoperazone (0.5 mg/mL) for 7 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Cefoperazone-treated mice promote the growthand morphogenesis of Candida Albicans PMID PMID: 31769789 PMDBI40957 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40958 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054" PMDBI40958 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40959 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6927284" PMDBI40959 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40960 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054" PMDBI40960 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.64E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40961 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054" PMDBI40961 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40962 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6927284" PMDBI40962 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40963 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6927284" PMDBI40963 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40964 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054" PMDBI40964 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40965 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" Cefoperazone (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animalsé–?gut. PMID PMID: 26173701 PMDBI40965 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.28E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40966 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054" PMDBI40966 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.26E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40967 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054" PMDBI40967 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.94E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40968 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054" PMDBI40968 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40969 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054" PMDBI40969 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.68E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40970 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054" PMDBI40970 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40971 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" Cefoperazone (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animalsé–?gut. PMID PMID: 26173701 PMDBI40971 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.30E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40972 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" Cefoperazone (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animalsé–?gut. PMID PMID: 26173701 PMDBI40972 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40973 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6927284" PMDBI40973 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40974 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" Cefoperazone (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animalsé–?gut. PMID PMID: 26173701 PMDBI40974 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.10E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40975 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054" PMDBI40975 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40976 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6927284" PMDBI40976 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.01E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40977 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054" PMDBI40977 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40978 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" Cefoperazone (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animalsé–?gut. PMID PMID: 26173701 PMDBI40978 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.98E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40979 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.73E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40979 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" Cefoperazone (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animalsé–?gut. PMID PMID: 26173701 PMDBI40980 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.84E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40980 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054" PMDBI40981 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.58E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40981 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" Cefoperazone (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animalsé–?gut. PMID PMID: 26173701 PMDBI40982 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000141464] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40982 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6619054" PMDBI40983 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" C57BL/6 J mice(five to six mice per group) were supplemented with sterile water with cefoperazone (0.5 mg/mL) for 7 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Cefoperazone-treated mice promote the growthand morphogenesis of Candida Albicans PMID PMID: 31769789 PMDBI40983 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.61E-05] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI40984 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.22E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40984 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" C57BL/6 J mice(five to six mice per group) were supplemented with sterile water with cefoperazone (0.5 mg/mL) for 7 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Cefoperazone-treated mice promote the growthand morphogenesis of Candida Albicans PMID PMID: 31769789 PMDBI40985 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.02E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40985 Substances alter microbe abundance PMDBM864 186822 Paenibacillaceae PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" C57BL/6 J mice(five to six mice per group) were supplemented with sterile water with cefoperazone (0.5 mg/mL) for 7 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Cefoperazone-treated mice promote the growthand morphogenesis of Candida Albicans PMID PMID: 31769789 PMDBI40986 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40986 Substances alter microbe abundance PMDBM975 n.a. Turicibacteraceae PMDBD160 Cefoperazone Therapeutic Substance "Approved Drug; Antibiotics" C57BL/6 J mice(five to six mice per group) were supplemented with sterile water with cefoperazone (0.5 mg/mL) for 7 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Cefoperazone-treated mice promote the growthand morphogenesis of Candida Albicans PMID PMID: 31769789 PMDBI40987 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1087 Cefotaxime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40987 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.21E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40988 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1087 Cefotaxime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40988 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40989 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1087 Cefotaxime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40989 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.33E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40990 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1087 Cefotaxime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40990 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.00E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40991 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1087 Cefotaxime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40991 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40992 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1087 Cefotaxime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40992 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.94E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40993 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD164 Cefotetan Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40993 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40994 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD164 Cefotetan Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40994 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40995 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD164 Cefotetan Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40995 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.78E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40996 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD164 Cefotetan Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40996 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40997 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD164 Cefotetan Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40997 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.00E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40998 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD164 Cefotetan Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40998 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI40999 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI40999 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41000 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848" PMDBI41000 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41001 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41001 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.02E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41002 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6508264" PMDBI41002 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.39E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41003 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848" PMDBI41003 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.07E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41004 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848" PMDBI41004 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.21E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41005 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848" PMDBI41005 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.43E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41006 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848" PMDBI41006 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000321397] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41007 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848" PMDBI41007 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000288543] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41008 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41008 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41009 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41009 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.80E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41010 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848; PMID: 6508264" PMDBI41010 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.28E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41011 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41011 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41012 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6508264" PMDBI41012 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.99E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41013 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41013 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41014 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848; PMID: 6508264" PMDBI41014 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41015 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848" PMDBI41015 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.25E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41016 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6508264" PMDBI41016 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41017 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6508264" PMDBI41017 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003081374] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41018 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.03E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41018 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848; PMID: 6508264" PMDBI41019 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6508264" PMDBI41019 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.01E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41020 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.00E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41020 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6807848" PMDBI41021 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.30E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41021 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6508264" PMDBI41022 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001280508] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41022 Substances alter microbe abundance PMDBM892 210425 Proteus PMDBD1088 Cefoxitin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6508264" PMDBI41023 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1089 Cefpirome Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1601763" PMDBI41023 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000585698] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41024 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 7961199" PMDBI41024 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.58E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41025 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110" PMDBI41025 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.22E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41026 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 7961199" PMDBI41026 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.39E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41027 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110; PMID: 7961199" PMDBI41027 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.61E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41028 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110" PMDBI41028 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000134609] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41029 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 7961199" PMDBI41029 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.26E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41030 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 7961199" PMDBI41030 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41031 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490" PMDBI41031 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000197672] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41032 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490" PMDBI41032 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.39E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41033 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110" PMDBI41033 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00226359] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41034 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 7961199" PMDBI41034 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000266312] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41035 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7961199" PMDBI41035 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006634684] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41036 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 8618110" PMDBI41036 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41037 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110" PMDBI41037 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41038 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 7961199" PMDBI41038 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000182756] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41039 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490" PMDBI41039 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.21E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41040 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.41E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41040 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110" PMDBI41041 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41041 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490; PMID: 7961199" PMDBI41042 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.86E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41042 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8243490" PMDBI41043 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1091 Cefprozil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1590680" PMDBI41043 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.38E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41044 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1091 Cefprozil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1590680" PMDBI41044 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41045 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1091 Cefprozil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1590680" PMDBI41045 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017654] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41046 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1091 Cefprozil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1590680" PMDBI41046 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009344181] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41047 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1092 Ceftaroline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399" PMDBI41047 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000117632] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41048 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1092 Ceftaroline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399" PMDBI41048 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000159192] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41049 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1092 Ceftaroline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399" PMDBI41049 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000280716] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41050 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1092 Ceftaroline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399" PMDBI41050 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001127486] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41051 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1092 Ceftaroline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399" PMDBI41051 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001563951] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41052 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1092 Ceftaroline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399" PMDBI41052 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002638689] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41053 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1092 Ceftaroline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399" PMDBI41053 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000514387] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41054 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000178054] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41054 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1092 Ceftaroline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399" PMDBI41055 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1092 Ceftaroline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20231399" PMDBI41055 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.01E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41056 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1093 Ceftaroline/avibactam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638" PMDBI41056 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41057 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1093 Ceftaroline/avibactam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638" PMDBI41057 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.87E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41058 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1093 Ceftaroline/avibactam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638" PMDBI41058 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004419106] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41059 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1093 Ceftaroline/avibactam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638" PMDBI41059 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00029395] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41060 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1093 Ceftaroline/avibactam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638" PMDBI41060 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002426018] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41061 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1093 Ceftaroline/avibactam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638" PMDBI41061 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000325495] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41062 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1093 Ceftaroline/avibactam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638" PMDBI41062 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00811522] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41063 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1093 Ceftaroline/avibactam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638" PMDBI41063 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005806766] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41064 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000761829] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41064 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1093 Ceftaroline/avibactam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987638" PMDBI41065 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1094 Ceftazidime/avibactam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25979639" PMDBI41065 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41066 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1094 Ceftazidime/avibactam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25979639" PMDBI41066 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.82E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41067 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1094 Ceftazidime/avibactam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25979639" PMDBI41067 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000394597] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41068 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1094 Ceftazidime/avibactam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25979639" PMDBI41068 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41069 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1094 Ceftazidime/avibactam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25979639" PMDBI41069 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005675801] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41070 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1094 Ceftazidime/avibactam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25979639" PMDBI41070 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41071 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1094 Ceftazidime/avibactam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25979639" PMDBI41071 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.33E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41072 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.37E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41072 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1094 Ceftazidime/avibactam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25979639" PMDBI41073 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1095 Ceftibuten Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8132366; PMID: 7961199" PMDBI41073 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001913202] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41074 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1095 Ceftibuten Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7961199" PMDBI41074 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009732678] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41075 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1095 Ceftibuten Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8132366" PMDBI41075 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006752846] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41076 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1095 Ceftibuten Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7961199" PMDBI41076 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.61E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41077 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1095 Ceftibuten Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8132366; PMID: 7961199" PMDBI41077 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.57E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41078 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1095 Ceftibuten Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8132366; PMID: 7961199" PMDBI41078 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00289599] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41079 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1095 Ceftibuten Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8132366" PMDBI41079 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD172 Cephalosporanic acid, 7-amino Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41080 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1095 Ceftibuten Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7961199" PMDBI41080 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003326216] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41081 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1095 Ceftibuten Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7961199" PMDBI41081 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.28E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41082 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1095 Ceftibuten Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8132366" PMDBI41082 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD338 Fendiline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41083 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD186 Chlorprothixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000380382] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41083 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1095 Ceftibuten Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7961199" PMDBI41084 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1096 Ceftobiprole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20926263" PMDBI41084 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD516 Meclozine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001419173] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41085 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1096 Ceftobiprole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20926263" PMDBI41085 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD713 Protriptyline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.15E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41086 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1096 Ceftobiprole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20926263" PMDBI41086 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD559 Moricizine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41087 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1096 Ceftobiprole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20926263" PMDBI41087 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD502 Loxapine succinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.36E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41088 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1096 Ceftobiprole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20926263" PMDBI41088 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD916 Zotepine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.34E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41089 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1096 Ceftobiprole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20926263" PMDBI41089 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001704304] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41090 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD875 Trimeprazine tartrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41090 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1096 Ceftobiprole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20926263" PMDBI41091 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592; PMID: 1800369; PMID: 3992209; PMID: 11020259" PMDBI41091 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD917 Zuclopenthixol dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003428916] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41092 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11531985; PMID: 15388432" PMDBI41092 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD12 Acarbose "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000656515] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41093 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592; PMID: 11020259" PMDBI41093 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD319 Ethacrynic acid "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000372795] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41094 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3992209; PMID: 11020259" PMDBI41094 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD670 Pimethixene maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41095 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592; PMID: 1767260; PMID: 3138129; PMID: 3992209; PMID: 11531985; PMID: 11020259; PMID: 15388432" PMDBI41095 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD708 Prochlorperazine dimaleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007973156] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41096 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592; PMID: 3138129; PMID: 11531985; PMID: 11020259; PMID: 15388432" PMDBI41096 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD185 Chlorpromazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.26E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41097 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3992209" PMDBI41097 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD710 Promethazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41098 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3138129" PMDBI41098 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD701 Prenylamine lactate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000287651] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41099 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11531985" PMDBI41099 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD419 Haloprogin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002177626] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41100 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41100 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD235 Cyclobenzaprine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00597968] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41101 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3138129" PMDBI41101 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD705 Proadifen hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003489677] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41102 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11531985; PMID: 11020259; PMID: 15388432" PMDBI41102 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD196 Cinnarizine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004182486] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41103 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592; PMID: 11531985; PMID: 11020259" PMDBI41103 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD526 Mesoridazine besylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000191026] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41104 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1800369; PMID: 2396083; PMID: 3138129; PMID: 3992209; PMID: 15388432" PMDBI41104 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD41 Amoxapine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.46E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41105 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3138129" PMDBI41105 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD17 Acetopromazine maleate salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003784869] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41106 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3992209; PMID: 11020259" PMDBI41106 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD702 Pridinol methanesulfonate salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41107 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3992209; PMID: 11020259" PMDBI41107 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD441 Imiquimod Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005790619] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41108 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD719 Quetiapine hemifumarate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000472811] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41108 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1800369; PMID: 2396083; PMID: 3138129; PMID: 3992209; PMID: 11531985; PMID: 11020259; PMID: 15388432" PMDBI41109 Substances alter microbe abundance PMDBM2020268 821 Bacteroides vulgatus PMDBD536 Methotrimeprazine maleat salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006991298] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41109 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1097 Ceftriaxone Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3992209" PMDBI41110 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1098 Cefuroxime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41110 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41111 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1098 Cefuroxime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41111 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41112 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1098 Cefuroxime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41112 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.66E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41113 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1098 Cefuroxime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41113 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41114 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1098 Cefuroxime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41114 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41115 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1098 Cefuroxime Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41115 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41116 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9; PMID: 8618110; PMID: 7961199" PMDBI41116 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41117 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9; PMID: 9314469; PMID: 7961199" PMDBI41117 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41118 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469" PMDBI41118 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.29E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41119 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9" PMDBI41119 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002247276] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41120 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469" PMDBI41120 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.79E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41121 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9; PMID: 8618110; PMID: 7961199" PMDBI41121 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41122 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469" PMDBI41122 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41123 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7961199" PMDBI41123 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41124 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9" PMDBI41124 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41125 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469" PMDBI41125 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41126 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9" PMDBI41126 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41127 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469" PMDBI41127 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41128 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110; PMID: 7961199" PMDBI41128 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41129 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9" PMDBI41129 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41130 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7961199" PMDBI41130 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41131 Substances alter microbe abundance PMDBM316 1253 Pedicoccus PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469" PMDBI41131 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41132 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9" PMDBI41132 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41133 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469" PMDBI41133 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41134 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110" PMDBI41134 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41135 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9" PMDBI41135 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41136 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000349651] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41136 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110; PMID: 7961199" PMDBI41137 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41137 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1993:185-9; PMID: 9314469" PMDBI41138 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469" PMDBI41138 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41139 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41139 Substances alter microbe abundance PMDBM923 590 Salmonella PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110" PMDBI41140 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41140 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1099 Cefuroxime axetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8618110" PMDBI41141 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1100 Cefuroxime axetil followed vancomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469" PMDBI41141 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41142 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1100 Cefuroxime axetil followed vancomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469" PMDBI41142 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.06E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41143 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1100 Cefuroxime axetil followed vancomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469" PMDBI41143 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41144 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1100 Cefuroxime axetil followed vancomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469" PMDBI41144 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41145 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1101 Cefuroxime axetil than vancomycIn Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469" PMDBI41145 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41146 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1101 Cefuroxime axetil than vancomycIn Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469" PMDBI41146 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.18E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41147 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1101 Cefuroxime axetil than vancomycIn Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469" PMDBI41147 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001081854] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41148 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.22E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41148 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1101 Cefuroxime axetil than vancomycIn Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469" PMDBI41149 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41149 Substances alter microbe abundance PMDBM875 n.a. Pedicoccus PMDBD1101 Cefuroxime axetil than vancomycIn Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9314469" PMDBI41150 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1102 Cephaloridine Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41150 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41151 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1102 Cephaloridine Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41151 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.97E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41152 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1103 Cephazolin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41152 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41153 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1103 Cephazolin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41153 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.42E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41154 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1103 Cephazolin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41154 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000495356] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41155 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1103 Cephazolin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41155 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41156 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41156 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41157 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41157 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41158 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41158 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008452406] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41159 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41159 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.38E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41160 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41160 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41161 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Increase Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41161 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41162 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Increase Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41162 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000146181] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41163 Substances alter microbe abundance PMDBM307 119852 Oscillospira PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41163 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41164 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Increase Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41164 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41165 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41165 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41166 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41166 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41167 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41167 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.55E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41168 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41168 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41169 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Increase Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41169 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.08E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41170 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.72E-06] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41170 Substances alter microbe abundance PMDBM836 906 Megasphaera PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Increase Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41171 Substances alter microbe abundance PMDBM635 1380 Atopobium PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Increase Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41171 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41172 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000133401] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41172 Substances alter microbe abundance PMDBM810 28050 Lachnospira PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41173 Substances alter microbe abundance PMDBM630 165779 Anaerococcus PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41173 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41174 Substances alter microbe abundance PMDBM611 447020 Adlercreutzia PMDBD1104 Chemotherapy Therapeutic Substance Drug Class n.a. n.a. Decrease Mann-Whitney U test, FDR-corrected P<0.05 n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41174 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41175 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522" PMDBI41175 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41176 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2941281; PMID: 2940965; PMID: 2934338" PMDBI41176 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009577361] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41177 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522; PMID: 9646219" PMDBI41177 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41178 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2356443; PMID: 2941281; PMID: 2940965" PMDBI41178 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.56E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41179 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI41179 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.26E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41180 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405" PMDBI41180 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000677598] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41181 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405" PMDBI41181 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000376726] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41182 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9646219" PMDBI41182 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009237436] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41183 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6517559" PMDBI41183 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000135542] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41184 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2938072; PMID: 3438150; PMID: 9257749; PMID: 2356443; PMID: 3182454; PMID: 3428128; PMID: 2941281" PMDBI41184 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003770771] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41185 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9255893" PMDBI41185 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.60E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41186 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 28333351; PMID: 2356443; PMID: 3182454; PMID: 2940965" PMDBI41186 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.35E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41187 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405; PMID: 2938072; PMID: 9257749; PMID: 9646219" PMDBI41187 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41188 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405; PMID: 9257749; PMID: 9646219; PMID: 3182454; PMID: 2934338" PMDBI41188 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41189 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522" PMDBI41189 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.60E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41190 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2940965" PMDBI41190 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001467225] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41191 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522" PMDBI41191 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.42E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41192 Substances alter microbe abundance PMDBM247 2701 Gardnerella PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI41192 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41193 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9646219" PMDBI41193 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41194 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9257749; PMID: 9646219" PMDBI41194 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41195 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2356443; PMID: 2940965" PMDBI41195 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000878667] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41196 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25658522" PMDBI41196 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000631183] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41197 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9646219; PMID: 2934338" PMDBI41197 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41198 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2356443; PMID: 2941281; PMID: 2940965" PMDBI41198 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001974927] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41199 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" Ciprofloxacin (10 mg/kg of body weight) was administered via oral gavage for one time. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animalsé–?gut. PMID PMID: 26173701 PMDBI41199 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001467284] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI41200 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI41200 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000165512] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41201 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987611" PMDBI41201 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41202 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9646219" PMDBI41202 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41203 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2941281" PMDBI41203 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.14E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41204 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405" PMDBI41204 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000524332] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41205 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522" PMDBI41205 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD12 Acarbose "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000404149] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41206 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405" PMDBI41206 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD571 Nalidixic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002768125] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41207 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25658522" PMDBI41207 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD633 Oxolinic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003090159] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41208 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9257749" PMDBI41208 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD742 Ribavirin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007617779] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41209 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9257749; PMID: 9646219; PMID: 2356443; PMID: 2941281; PMID: 2940965; PMID: 6517559" PMDBI41209 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD674 Pioglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007046361] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41210 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2356443; PMID: 2940965; PMID: 6517559" PMDBI41210 Substances alter microbe abundance PMDBM2020010 371601 Bacteroides xylanisolvens PMDBD236 Cyclopenthiazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002922821] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41211 Substances alter microbe abundance PMDBM397 40544 Sutterella PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20847294" PMDBI41211 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41212 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI41212 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41213 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405" PMDBI41213 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41214 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522; PMID: 2356443; PMID: 2940965; PMID: 2934338" PMDBI41214 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41215 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41215 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25922405; PMID: 25658522; PMID: 20847294" PMDBI41216 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41216 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" Ciprofloxacin (10 mg/kg of body weight) was administered via oral gavage for one time. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Ciprofloxacin prevented the colonization by Clostridium difficile in animalsé–?gut. PMID PMID: 26173701 PMDBI41217 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9646219; PMID: 2934338; PMID: 6517559" PMDBI41217 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41218 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987611" PMDBI41218 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41219 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2940965" PMDBI41219 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41220 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41220 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987611" PMDBI41221 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41221 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2356443" PMDBI41222 Substances alter microbe abundance PMDBM740 39948 Dialister PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522" PMDBI41222 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41223 Substances alter microbe abundance PMDBM798 61170 Holdemania PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI41223 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41224 Substances alter microbe abundance PMDBM814 n.a. Lachnospirum spp. PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405" PMDBI41224 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41225 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1119 Ciprofloxacin plus clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9255893" PMDBI41225 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41226 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1119 Ciprofloxacin plus clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9255893" PMDBI41226 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41227 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 12111597; PMID: 10716083" PMDBI41227 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41228 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385" PMDBI41228 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41229 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385; PMID: 10716083" PMDBI41229 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41230 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385" PMDBI41230 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41231 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 1837385; PMID: 10716083" PMDBI41231 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41232 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI41232 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41233 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385; PMID: 10716083" PMDBI41233 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41234 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 1837385; PMID: 10716083" PMDBI41234 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41235 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI41235 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41236 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.06E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41236 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI41237 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41237 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI41238 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41238 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 1837385; PMID: 10716083" PMDBI41239 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385" PMDBI41239 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41240 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 10716083" PMDBI41240 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41241 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385; PMID: 10716083" PMDBI41241 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41242 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI41242 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41243 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 1837385; PMID: 12111597" PMDBI41243 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41244 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385" PMDBI41244 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41245 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 12111597; PMID: 10716083" PMDBI41245 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41246 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 10716083" PMDBI41246 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41247 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385; PMID: 10716083" PMDBI41247 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41248 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI41248 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41249 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI41249 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41250 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385" PMDBI41250 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41251 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI41251 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41252 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI41252 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.61E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41253 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385" PMDBI41253 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41254 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI41254 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41255 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193; PMID: 10716083" PMDBI41255 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41256 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI41256 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41257 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385" PMDBI41257 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41258 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD201 Clarithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI41258 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41259 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979" PMDBI41259 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41260 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11552917" PMDBI41260 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41261 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979; PMID: 11552917" PMDBI41261 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41262 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20352091" PMDBI41262 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41263 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979; PMID: 11552917" PMDBI41263 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41264 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979; PMID: 20352091; PMID: 11552917" PMDBI41264 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41265 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979" PMDBI41265 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41266 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11552917" PMDBI41266 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41267 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979; PMID: 11552917" PMDBI41267 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41268 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979; PMID: 11552917" PMDBI41268 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000691798] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41269 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 20352091" PMDBI41269 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41270 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979; PMID: 20352091; PMID: 11552917" PMDBI41270 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41271 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.71E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41271 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979" PMDBI41272 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41272 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1121 Clarithromycin plus metronidazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10552979" PMDBI41273 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD206 Clinafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132" PMDBI41273 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41274 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD206 Clinafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132" PMDBI41274 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41275 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD206 Clinafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132" PMDBI41275 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41276 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD206 Clinafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132" PMDBI41276 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41277 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD206 Clinafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132" PMDBI41277 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41278 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD206 Clinafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132" PMDBI41278 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41279 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD206 Clinafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132" PMDBI41279 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41280 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD206 Clinafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132" PMDBI41280 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41281 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD206 Clinafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132" PMDBI41281 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41282 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD206 Clinafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132" PMDBI41282 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.58E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41283 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD206 Clinafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132" PMDBI41283 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41284 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD206 Clinafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132" PMDBI41284 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000201053] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41285 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD206 Clinafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132" PMDBI41285 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.19E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41286 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD206 Clinafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11073132" PMDBI41286 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41287 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; PMID: 25445201; PMID: 15640226; Microbial Ecology in Health and Disease 1994:17é–?5" PMDBI41287 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41288 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 15640226; Microbial Ecology in Health and Disease 1994:17é–?5" PMDBI41288 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41289 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25922405" PMDBI41289 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41290 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25922405" PMDBI41290 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41291 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 17577812; PMID: 15640226; Microbial Ecology in Health and Disease 1994:17é–?5" PMDBI41291 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41292 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 17577812" PMDBI41292 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41293 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; Microbial Ecology in Health and Disease 1994:17é–?5" PMDBI41293 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41294 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; Microbial Ecology in Health and Disease 1994:17é–?5" PMDBI41294 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41295 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 19107676; PMID: 15640226" PMDBI41295 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41296 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 17577812" PMDBI41296 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41297 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1994:17é–?5" PMDBI41297 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41298 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" Clindamycin (10 mg/kg) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Clindamycin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI41298 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000458844] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI41299 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; PMID: 15640226" PMDBI41299 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41300 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI41300 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41301 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405" PMDBI41301 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41302 Substances alter microbe abundance PMDBM247 2701 Gardnerella PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526" PMDBI41302 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004838051] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41303 Substances alter microbe abundance PMDBM247 2701 Gardnerella PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987611" PMDBI41303 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.15E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41304 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 17577812; PMID: 15640226; Microbial Ecology in Health and Disease 1994:17é–?5" PMDBI41304 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41305 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; PMID: 25445201; PMID: 15640226; Microbial Ecology in Health and Disease 1994:17é–?5" PMDBI41305 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41306 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" Clindamycin (10 mg/kg) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Clindamycin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI41306 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI41307 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; PMID: 25445201; PMID: 17046967; PMID: 15640226; Microbial Ecology in Health and Disease 1994:17é–?5" PMDBI41307 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41308 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" Clindamycin (10 mg/kg) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Clindamycin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI41308 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI41309 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" Clindamycin (10 mg/kg) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Clindamycin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI41309 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004146819] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI41310 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987611" PMDBI41310 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41311 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25922405" PMDBI41311 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41312 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25922405" PMDBI41312 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41313 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1994:17é–?5" PMDBI41313 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41314 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526" PMDBI41314 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41315 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; Microbial Ecology in Health and Disease 1994:17é–?5" PMDBI41315 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.50E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41316 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI41316 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41317 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" Clindamycin (10 mg/kg) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Clindamycin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI41317 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI41318 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" Clindamycin (10 mg/kg) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Clindamycin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI41318 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI41319 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; PMID: 25445201;PMID: 15640226; Microbial Ecology in Health and Disease 1994:17é–?5" PMDBI41319 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41320 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" Clindamycin (10 mg/kg) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Clindamycin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI41320 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 29555994 PMDBI41321 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007296817] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41321 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI41322 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41322 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25922405" PMDBI41323 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006721124] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41323 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" Clindamycin (10 mg/kg) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Clindamycin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI41324 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 17577812; PMID: 15640226; Microbial Ecology in Health and Disease 1994:17é–?5" PMDBI41324 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000347105] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41325 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526" PMDBI41325 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD494 Loratadine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001480541] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41326 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987611" PMDBI41326 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41327 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.23E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41327 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526" PMDBI41328 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005860626] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41328 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25987611" PMDBI41329 Substances alter microbe abundance PMDBM740 39948 Dialister PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI41329 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD470 Lacidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001704978] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41330 Substances alter microbe abundance PMDBM814 n.a. Lachnospirum spp. PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275; PMID: 25922405" PMDBI41330 Substances alter microbe abundance PMDBM2020011 1680 Bifidobacterium adolescentis PMDBD712 Propidium iodide Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.55E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41331 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41331 Substances alter microbe abundance PMDBM136 186801 Clostridia PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41332 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41332 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram+ bacteria showed a reduction in pTh17 responses and their tumors were resistant to cyclophosphamide. PMID "PMID: 24264990; PMID: 29789015" PMDBI41333 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41333 Substances alter microbe abundance PMDBM173 84107 Coriobacteriaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41334 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41334 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Male Balb/c mice were administered intraperitoneally with CTX at 100 mg/kg for 5 days. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse n.a. n.a. Disruption of mucosal barrier and colonization resistance may be partly responsible for the bacterial translocation during chemotherapy. PMID "PMID: 23791611; PMID: 29789015" PMDBI41335 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41335 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram+ bacteria showed a reduction in pTh17 responses and their tumors were resistant to cyclophosphamide. PMID "PMID: 24264990; PMID: 29789015" PMDBI41336 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41336 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Male Balb/c mice were administered intraperitoneally with CTX at 100 mg/kg for 5 days. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse n.a. n.a. Disruption of mucosal barrier and colonization resistance may be partly responsible for the bacterial translocation during chemotherapy. PMID "PMID: 23791611; PMID: 29789015" PMDBI41337 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41337 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Male Balb/c mice were administered intraperitoneally with CTX at 100 mg/kg for 5 days. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse n.a. n.a. Disruption of mucosal barrier and colonization resistance may be partly responsible for the bacterial translocation during chemotherapy. PMID "PMID: 23791611; PMID: 29789015" PMDBI41338 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41338 Substances alter microbe abundance PMDBM25 91061 Bacilli PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41339 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.71E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41339 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram+ bacteria showed a reduction in pTh17 responses and their tumors were resistant to cyclophosphamide. PMID "PMID: 24264990; PMID: 29789015" PMDBI41340 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41340 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41341 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41341 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram+ bacteria showed a reduction in pTh17 responses and their tumors were resistant to cyclophosphamide. PMID "PMID: 24264990; PMID: 29789015" PMDBI41342 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41342 Substances alter microbe abundance PMDBM293 31969 Mollicutes PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41343 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41343 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41344 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41344 Substances alter microbe abundance PMDBM334 171552 Prevotellaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41345 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41345 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Male Balb/c mice were administered intraperitoneally with CTX at 100 mg/kg for 5 days. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo BALB/c mouse n.a. n.a. Disruption of mucosal barrier and colonization resistance may be partly responsible for the bacterial translocation during chemotherapy. PMID "PMID: 23791611; PMID: 29789015" PMDBI41346 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41346 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram+ bacteria showed a reduction in pTh17 responses and their tumors were resistant to cyclophosphamide. PMID "PMID: 24264990; PMID: 29789015" PMDBI41347 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.07E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41347 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41348 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41348 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41349 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41349 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41350 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41350 Substances alter microbe abundance PMDBM618 506 Alcaligenaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41351 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41351 Substances alter microbe abundance PMDBM624 28211 Alphaproteobacteria PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41352 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41352 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41353 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41353 Substances alter microbe abundance PMDBM909 41295 Rhodospirillaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41354 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41354 Substances alter microbe abundance PMDBM717 84998 Coriobacteriia PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41355 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41355 Substances alter microbe abundance PMDBM947 90964 Staphylococcaceae PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41356 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41356 Substances alter microbe abundance PMDBM651 200643 Bacteroidia PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41357 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41357 Substances alter microbe abundance PMDBM921 n.a. S24-7 PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug Intra-peritoneal (ip) injections once a week for 28 consecutive days of cyclophosphamide treatment at 150 mg/kg body weight. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID "PMID: 25553830; PMID: 29789015" PMDBI41358 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41358 Substances alter microbe abundance PMDBM702 n.a. Clostridium cluster XIVa PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Health n.a. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram+ bacteria showed a reduction in pTh17 responses and their tumors were resistant to cyclophosphamide. PMID "PMID: 24264990; PMID: 29789015" PMDBI41359 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41359 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1137 Dalbavancin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 16840427" PMDBI41360 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.96E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41360 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1137 Dalbavancin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 16840427" PMDBI41361 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41361 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1137 Dalbavancin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 16840427" PMDBI41362 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41362 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1137 Dalbavancin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 16840427" PMDBI41363 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000153485] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41363 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1137 Dalbavancin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 16840427" PMDBI41364 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41364 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD287 Dirithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127" PMDBI41365 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41365 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD287 Dirithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127" PMDBI41366 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41366 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD287 Dirithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127" PMDBI41367 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41367 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD287 Dirithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127" PMDBI41368 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41368 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD287 Dirithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127" PMDBI41369 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41369 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD287 Dirithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127" PMDBI41370 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41370 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD287 Dirithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127" PMDBI41371 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41371 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD287 Dirithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127" PMDBI41372 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41372 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD287 Dirithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1748127" PMDBI41373 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41373 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1170 Doxycycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23332619" PMDBI41374 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41374 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1170 Doxycycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23332619; PMID: 6648373" PMDBI41375 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41375 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1170 Doxycycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6648373" PMDBI41376 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41376 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1170 Doxycycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23332619" PMDBI41377 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41377 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1170 Doxycycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6648373" PMDBI41378 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41378 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1170 Doxycycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23332619; PMID: 6648373" PMDBI41379 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41379 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1170 Doxycycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23332619" PMDBI41380 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.40E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41380 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1170 Doxycycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6648373" PMDBI41381 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41381 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1170 Doxycycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6648373" PMDBI41382 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41382 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1170 Doxycycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23332619; PMID: 6648373" PMDBI41383 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41383 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1170 Doxycycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23332619; PMID: 6648373" PMDBI41384 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41384 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1170 Doxycycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6648373" PMDBI41385 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41385 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1170 Doxycycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23332619; PMID: 6648373" PMDBI41386 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41386 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1170 Doxycycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6648373" PMDBI41387 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41387 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1170 Doxycycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6648373" PMDBI41388 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41388 Substances alter microbe abundance PMDBM892 210425 Proteus PMDBD1170 Doxycycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 6648373" PMDBI41389 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41389 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD304 Enoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305" PMDBI41390 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.78E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41390 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD304 Enoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305" PMDBI41391 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41391 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD304 Enoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305" PMDBI41392 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41392 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD304 Enoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305" PMDBI41393 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41393 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD304 Enoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305" PMDBI41394 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41394 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD304 Enoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305" PMDBI41395 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41395 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD304 Enoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305" PMDBI41396 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41396 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD304 Enoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305" PMDBI41397 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41397 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD304 Enoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305" PMDBI41398 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.21E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41398 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD304 Enoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305" PMDBI41399 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41399 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD304 Enoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305" PMDBI41400 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41400 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD304 Enoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3476305" PMDBI41401 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41401 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1179 Ertapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 15388432" PMDBI41402 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.92E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41402 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1179 Ertapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 15388432" PMDBI41403 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41403 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1179 Ertapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 15388432" PMDBI41404 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41404 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1179 Ertapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 15388432" PMDBI41405 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41405 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1179 Ertapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 15388432" PMDBI41406 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41406 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1179 Ertapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 15388432" PMDBI41407 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41407 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD314 Erythromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385" PMDBI41408 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41408 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD314 Erythromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385" PMDBI41409 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41409 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD314 Erythromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7071527" PMDBI41410 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41410 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD314 Erythromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385" PMDBI41411 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41411 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD314 Erythromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7071527" PMDBI41412 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41412 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD314 Erythromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385; PMID: 7071527" PMDBI41413 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41413 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD314 Erythromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385" PMDBI41414 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.41E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41414 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD314 Erythromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7071527" PMDBI41415 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41415 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD314 Erythromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7071527" PMDBI41416 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0065524] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41416 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD314 Erythromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385; PMID: 7071527" PMDBI41417 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001890094] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41417 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD314 Erythromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385" PMDBI41418 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.45E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41418 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD314 Erythromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385" PMDBI41419 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41419 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD314 Erythromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7071527" PMDBI41420 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41420 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD314 Erythromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385; PMID: 7071527" PMDBI41421 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41421 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD314 Erythromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385" PMDBI41422 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002922229] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41422 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD314 Erythromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385" PMDBI41423 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.34E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41423 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD314 Erythromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1837385; PMID: 7071527" PMDBI41424 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Juvenile Idiopathic Arthritis (JIA) n.a. n.a. PMID PMID: 29555994 PMDBI41424 Substances alter microbe abundance PMDBM120 80840 Burkholderiales PMDBD1184 Etanercept Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as JIA therapy response biomarker PMID PMID: 31675176 PMDBI41425 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. Rheumatoid arthritis n.a. n.a. PMID PMID: 29555994 PMDBI41425 Substances alter microbe abundance PMDBM857 1161 Nostocales PMDBD1184 Etanercept Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 31675176 PMDBI41426 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000779058] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41426 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD327 Etoposide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41427 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41427 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD327 Etoposide Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41428 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.13E-05] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41428 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD327 Etoposide Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41429 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41429 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD353 Fleroxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3144539" PMDBI41430 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41430 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD353 Fleroxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3144539" PMDBI41431 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.21E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41431 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD353 Fleroxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3144539" PMDBI41432 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD494 Loratadine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00109898] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41432 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD353 Fleroxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3144539" PMDBI41433 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007685758] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41433 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD353 Fleroxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3144539" PMDBI41434 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009131895] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41434 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1197 Flucloxacillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020" PMDBI41435 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008270317] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41435 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1197 Flucloxacillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020" PMDBI41436 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008178731] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41436 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1197 Flucloxacillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020" PMDBI41437 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000977939] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41437 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1197 Flucloxacillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020" PMDBI41438 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000413539] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41438 Substances alter microbe abundance PMDBM892 210425 Proteus PMDBD1197 Flucloxacillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3312020" PMDBI41439 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD25 Alfacalcidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007674264] n.a. n.a. n.a. n.a. n.a. n.a. Acute lymphocytic leukemia (ALL) n.a. n.a. PMID PMID: 29555994 PMDBI41439 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD1200 Fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as ALL chemotherapy response biomarker PMID PMID: 31675176 PMDBI41440 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD182 Chlorotrianisene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003982696] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41440 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1206 Fosfomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2013503" PMDBI41441 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD712 Propidium iodide Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.48E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41441 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1206 Fosfomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2013503; PMID: 318971" PMDBI41442 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD799 Spectinomycin dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41442 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1206 Fosfomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2013503" PMDBI41443 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD238 Cyclosporin A Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003650878] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41443 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1206 Fosfomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 318971" PMDBI41444 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD278 Dihydrostreptomycin sulfate "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41444 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1206 Fosfomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2013503; PMID: 318971" PMDBI41445 Substances alter microbe abundance PMDBM2020193 216816 Bifidobacterium longum PMDBD570 Naftopidil dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.67E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41445 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1206 Fosfomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2013503" PMDBI41446 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1206 Fosfomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2013503" PMDBI41447 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD1206 Fosfomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2013503" PMDBI41448 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1206 Fosfomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 318971" PMDBI41449 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1206 Fosfomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2013503" PMDBI41450 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1211 Garenoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415" PMDBI41451 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD1211 Garenoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415" PMDBI41452 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1211 Garenoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415" PMDBI41453 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1211 Garenoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415" PMDBI41454 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1211 Garenoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415" PMDBI41455 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1211 Garenoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415" PMDBI41456 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1211 Garenoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415" PMDBI41457 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1211 Garenoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415" PMDBI41458 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1211 Garenoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415" PMDBI41459 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1211 Garenoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 12047415" PMDBI41460 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD380 Gatifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10078781" PMDBI41461 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD380 Gatifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10078781" PMDBI41462 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD380 Gatifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10078781" PMDBI41463 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD380 Gatifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10078781" PMDBI41464 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD380 Gatifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10078781" PMDBI41465 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD380 Gatifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10078781" PMDBI41466 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD380 Gatifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10078781" PMDBI41467 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD380 Gatifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10078781" PMDBI41468 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD380 Gatifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI41469 Substances alter microbe abundance PMDBM2020046 1496 Peptoclostridium difficile PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID "PMID: 29473096; PMID: 29789015" PMDBI41470 Substances alter microbe abundance PMDBM2020035 562 Escherichia coli PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID "PMID: 29473096; PMID: 29789015" PMDBI41471 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID "PMID: 29473096; PMID: 29789015" PMDBI41472 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID "PMID: 29473096; PMID: 29789015" PMDBI41473 Substances alter microbe abundance PMDBM29 171549 Bacteroidales PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID "PMID: 29473096; PMID: 29789015" PMDBI41474 Substances alter microbe abundance PMDBM2020068 85831 Bacteroides acidifaciens PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID "PMID: 29473096; PMID: 29789015" PMDBI41475 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID "PMID: 29473096; PMID: 29789015" PMDBI41476 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID "PMID: 29473096; PMID: 29789015" PMDBI41477 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID "PMID: 29473096; PMID: 29789015" PMDBI41478 Substances alter microbe abundance PMDBM2020266 239935 Akkermansia muciniphila PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID "PMID: 29473096; PMID: 29789015" PMDBI41479 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID "PMID: 29473096; PMID: 29789015" PMDBI41480 Substances alter microbe abundance PMDBM819 1605 Lactobacillus animalis PMDBD384 Gemcitabine Therapeutic Substance Approved Drug gemcitabine injection once per week for 3 weeks n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse Pancreatic ductal adenocarcinoma xenografted n.a. n.a. PMID "PMID: 29473096; PMID: 29789015" PMDBI41481 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1213 Gemifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800" PMDBI41482 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1213 Gemifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764" PMDBI41483 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1213 Gemifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800; PMID: 11158764" PMDBI41484 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1213 Gemifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800; PMID: 11158764" PMDBI41485 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1213 Gemifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800" PMDBI41486 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1213 Gemifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800" PMDBI41487 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1213 Gemifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764" PMDBI41488 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1213 Gemifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800" PMDBI41489 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1213 Gemifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764" PMDBI41490 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1213 Gemifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800; PMID: 11158764" PMDBI41491 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1213 Gemifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800" PMDBI41492 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1213 Gemifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800" PMDBI41493 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1213 Gemifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11233800" PMDBI41494 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41495 Substances alter microbe abundance PMDBM19 244127 Anaerotruncus PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41496 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed a normal-chow diet for a period of 6 weeks. Gut Increase p<0.001 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41497 Substances alter microbe abundance PMDBM285 1357 Lactococcus PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41498 Substances alter microbe abundance PMDBM302 283168 Odoribacter PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41499 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41500 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41501 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed a normal-chow diet for a period of 6 weeks. Gut Decrease p<0.001 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41502 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41503 Substances alter microbe abundance PMDBM831 420345 Lactonifactor PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41504 Substances alter microbe abundance PMDBM832 1091138 Lawsonia PMDBD1224 High-fat diet (HFD) Dietary Substance Diet C57BL/6 mice fed aahigh-fat diet (HFD) for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41505 Substances alter microbe abundance PMDBM120 80840 Burkholderiales PMDBD1239 Infliximab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Juvenile Idiopathic Arthritis (JIA) n.a. Microbiota as JIA therapy response biomarker PMID PMID: 31675176 PMDBI41506 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD1239 Infliximab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI41507 Substances alter microbe abundance PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD1239 Infliximab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI41508 Substances alter microbe abundance PMDBM322 33024 Phascolarctobacterium PMDBD1239 Infliximab Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI41509 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1239 Infliximab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI41510 Substances alter microbe abundance PMDBM810 28050 Lachnospira PMDBD1239 Infliximab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI41511 Substances alter microbe abundance PMDBM748 84111 Eggerthella PMDBD1239 Infliximab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI41512 Substances alter microbe abundance PMDBM2020162 301302 Roseburia faecis PMDBD1239 Infliximab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI41513 Substances alter microbe abundance PMDBM2020046 1496 Peptoclostridium difficile PMDBD455 Irinotecan Therapeutic Substance Approved Drug Irinotecan (125 mg/kgé‘? days) n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Fisher 344 rat Colon cancer n.a. n.a. PMID "PMID: 22844397; PMID: 29789015" PMDBI41514 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD455 Irinotecan Therapeutic Substance Approved Drug Irinotecan (125 mg/kgé‘? days) n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Fisher 344 rat Colon cancer n.a. n.a. PMID "PMID: 22844397; PMID: 29789015" PMDBI41515 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.50E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41515 Substances alter microbe abundance PMDBM317 186804 Clostridium cluster XI PMDBD455 Irinotecan Therapeutic Substance Approved Drug Irinotecan (125 mg/kgé‘? days) n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Fisher 344 rat Colon cancer n.a. n.a. PMID "PMID: 22844397; PMID: 29789015" PMDBI41516 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41516 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1249 Latamoxef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41517 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41517 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1249 Latamoxef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41518 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41518 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1249 Latamoxef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41519 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.02E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41519 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1249 Latamoxef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41520 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.56E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41520 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1249 Latamoxef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41521 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.14E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41521 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1249 Latamoxef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41522 Substances alter microbe abundance PMDBM2020085 28026 Bifidobacterium pseudocatenulatum PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41522 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41523 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41523 Substances alter microbe abundance PMDBM2020040 40520 Ruminococcus obeum PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41524 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41524 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41525 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41525 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41526 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.35E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41526 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41527 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.72E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41527 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41528 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41528 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41529 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41529 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41530 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41530 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41531 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.72E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41531 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41532 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41532 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41533 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.71E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41533 Substances alter microbe abundance PMDBM305 459786 Oscillibacter PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41534 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.12E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41534 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41535 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.41E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41535 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41536 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.50E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41536 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41537 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41537 Substances alter microbe abundance PMDBM979 41296 unclassified Rhodospirillaceae PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41538 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41538 Substances alter microbe abundance PMDBM2020083 46506 Bacteroides stercoris PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41539 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41539 Substances alter microbe abundance PMDBM2020101 116085 Coprococcus catus PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41540 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.53E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41540 Substances alter microbe abundance PMDBM643 1118061 Bacteroidales bacterium ph8 PMDBD1250 Laxatives Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41541 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.53E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41541 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1252 Lemofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064" PMDBI41542 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000310041] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41542 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD1252 Lemofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064" PMDBI41543 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41543 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1252 Lemofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064; PMID: 1885423" PMDBI41544 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.97E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41544 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1252 Lemofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064" PMDBI41545 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.28E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41545 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1252 Lemofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064" PMDBI41546 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41546 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1252 Lemofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064" PMDBI41547 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.53E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41547 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1252 Lemofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064" PMDBI41548 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41548 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1252 Lemofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064" PMDBI41549 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41549 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1252 Lemofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064" PMDBI41550 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.53E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41550 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1252 Lemofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1885423" PMDBI41551 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41551 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1252 Lemofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064" PMDBI41552 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.14E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41552 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1252 Lemofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064" PMDBI41553 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41553 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1252 Lemofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2303064" PMDBI41554 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41554 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1254 Lenapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072" PMDBI41555 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41555 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1254 Lenapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072" PMDBI41556 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41556 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1254 Lenapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072" PMDBI41557 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41557 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1254 Lenapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072" PMDBI41558 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41558 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1254 Lenapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072" PMDBI41559 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.56E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41559 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1254 Lenapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072" PMDBI41560 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41560 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1254 Lenapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072" PMDBI41561 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41561 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1254 Lenapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072" PMDBI41562 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.05E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41562 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1254 Lenapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072" PMDBI41563 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.88E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41563 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD1254 Lenapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072" PMDBI41564 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41564 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1254 Lenapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072" PMDBI41565 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.72E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41565 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1254 Lenapenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8089072" PMDBI41566 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41566 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1257 Levofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1512920" PMDBI41567 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41567 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1257 Levofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254; PMID: 1512920" PMDBI41568 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41568 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1257 Levofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254; PMID: 1512920" PMDBI41569 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.60E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41569 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1257 Levofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254; PMID: 1512920" PMDBI41570 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.60E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41570 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1257 Levofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254" PMDBI41571 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.77E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41571 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1257 Levofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1512920" PMDBI41572 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41572 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1257 Levofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254; PMID: 1512920" PMDBI41573 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41573 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1257 Levofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254" PMDBI41574 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41574 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1257 Levofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1512920" PMDBI41575 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.47E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41575 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1257 Levofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254; PMID: 1512920" PMDBI41576 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41576 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1257 Levofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254; PMID: 1512920" PMDBI41577 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.71E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41577 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD1257 Levofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1512920" PMDBI41578 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41578 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1257 Levofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1512920" PMDBI41579 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.13E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41579 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD484 Linezolid Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762" PMDBI41580 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41580 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD484 Linezolid Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762" PMDBI41581 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000338291] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41581 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD484 Linezolid Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762" PMDBI41582 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.41E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41582 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD484 Linezolid Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762" PMDBI41583 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.24E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41583 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD484 Linezolid Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762" PMDBI41584 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41584 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD484 Linezolid Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762" PMDBI41585 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41585 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD484 Linezolid Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762" PMDBI41586 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41586 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD484 Linezolid Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11868762" PMDBI41587 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41587 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD493 Loracarbef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8036475" PMDBI41588 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.77E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41588 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD493 Loracarbef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174" PMDBI41589 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41589 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD493 Loracarbef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174" PMDBI41590 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41590 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD493 Loracarbef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174" PMDBI41591 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41591 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD493 Loracarbef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174" PMDBI41592 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41592 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD493 Loracarbef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8036475; PMID: 1853174" PMDBI41593 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.52E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41593 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD493 Loracarbef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174" PMDBI41594 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.10E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41594 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD493 Loracarbef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8036475" PMDBI41595 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41595 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD493 Loracarbef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174" PMDBI41596 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.59E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41596 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD493 Loracarbef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174" PMDBI41597 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.52E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41597 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD493 Loracarbef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174" PMDBI41598 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.12E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41598 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD493 Loracarbef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174" PMDBI41599 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41599 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD493 Loracarbef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174" PMDBI41600 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41600 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD493 Loracarbef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174" PMDBI41601 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.50E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41601 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD493 Loracarbef Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1853174" PMDBI41602 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.79E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41602 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1268 MCB3837 Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 24931053" PMDBI41603 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.78E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41603 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1268 MCB3837 Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 24931053" PMDBI41604 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41604 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1268 MCB3837 Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 24931053" PMDBI41605 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41605 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1268 MCB3837 Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 24931053" PMDBI41606 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41606 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1268 MCB3837 Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 24931053" PMDBI41607 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.64E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41607 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1268 MCB3837 Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 24931053" PMDBI41608 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41608 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1268 MCB3837 Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 24931053" PMDBI41609 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41609 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41610 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.62E-07] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41610 Substances alter microbe abundance PMDBM3 201174 Actinobacteria PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41611 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.55E-06] n.a. n.a. n.a. n.a. n.a. Human non-Hodgkin's lymphoma n.a. n.a. PMID PMID: 29555994 PMDBI41611 Substances alter microbe abundance PMDBM337 1224 Proteobacteria PMDBD520 Melphalan Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 26147207; PMID: 29789015" PMDBI41612 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.64E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41612 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD524 Meropenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390" PMDBI41613 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41613 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD524 Meropenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390" PMDBI41614 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41614 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD524 Meropenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390" PMDBI41615 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.56E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41615 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD524 Meropenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390" PMDBI41616 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.28E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41616 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD524 Meropenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390" PMDBI41617 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.88E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41617 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD524 Meropenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390" PMDBI41618 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41618 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD524 Meropenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390" PMDBI41619 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.03E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41619 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD524 Meropenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390" PMDBI41620 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41620 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD524 Meropenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390" PMDBI41621 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.04E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41621 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD524 Meropenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390" PMDBI41622 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007130854] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41622 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD524 Meropenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390" PMDBI41623 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.15E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41623 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD524 Meropenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390" PMDBI41624 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.14E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41624 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD524 Meropenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390" PMDBI41625 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.62E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41625 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD524 Meropenem Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1915390" PMDBI41626 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 23804561 PMDBI41626 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.53E-07] n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41627 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.07E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41627 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41628 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.52E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41628 Substances alter microbe abundance PMDBM168 411903 Collinsella aerofaciens ATCC 25986 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41629 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41629 Substances alter microbe abundance PMDBM168 411903 Collinsella aerofaciens ATCC 25986 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41630 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000181568] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41630 Substances alter microbe abundance PMDBM169 521003 Collinsella intestinalis DSM 13280 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41631 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.67E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41631 Substances alter microbe abundance PMDBM169 521003 Collinsella intestinalis DSM 13280 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41632 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.81E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41632 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41633 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.14E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41633 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41634 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.43E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41634 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41635 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41635 Substances alter microbe abundance PMDBM19 244127 Anaerotruncus PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41636 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000106944] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41636 Substances alter microbe abundance PMDBM192 500639 Enterobacter cancerogenus ATCC 35316 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=3.455607077, FDR-p value=8.24019E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41637 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.35E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41637 Substances alter microbe abundance PMDBM192 500639 Enterobacter cancerogenus ATCC 35316 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.530215106, FDR-p value=2.92612E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41638 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41638 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41639 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41639 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. Microbial shifts under metformin treatment contribute to improved glucose control and to adverse effects. PMID PMID: 26633628 PMDBI41640 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.75E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41640 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41641 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.23E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41641 Substances alter microbe abundance PMDBM2020035 562 Escherichia coli PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41642 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00016296] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41642 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a normal-chow diet were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 23804561 PMDBI41643 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.43E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41643 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Increase p<0.001 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41644 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD494 Loratadine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.02E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41644 Substances alter microbe abundance PMDBM285 1357 Lactococcus PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41645 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.46E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41645 Substances alter microbe abundance PMDBM302 283168 Odoribacter PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41646 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000470942] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41646 Substances alter microbe abundance PMDBM308 375288 Parabacteroides PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41647 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41647 Substances alter microbe abundance PMDBM342 471874 Providencia stuartii ATCC 25827 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.37429031, FDR-p value=0.006587299 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41648 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.49E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41648 Substances alter microbe abundance PMDBM342 471874 Providencia stuartii ATCC 25827 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41649 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.81E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41649 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41650 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.84E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41650 Substances alter microbe abundance PMDBM38 547042 Bacteroides coprophilus DSM 18228 = JCM 13818 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41651 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.43E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41651 Substances alter microbe abundance PMDBM38 547042 Bacteroides coprophilus DSM 18228 = JCM 13818 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41652 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41652 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41653 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000345879] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41653 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41654 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003454674] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41654 Substances alter microbe abundance PMDBM395 411471 Subdoligranulum variabile DSM 15176 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-0.555370186, FDR-p value=0.003267857 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41655 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00063536] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41655 Substances alter microbe abundance PMDBM395 411471 Subdoligranulum variabile DSM 15176 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41656 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41656 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a normal-chow diet were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut No significant change p<0.001 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 23804561 PMDBI41657 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41657 Substances alter microbe abundance PMDBM407 74201 Verrucomicrobia PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice, fed a ahigh-fat diet (HFD), were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Increase p<0.001 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41658 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.39E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41658 Substances alter microbe abundance PMDBM2020008 817 Bacteroides fragilis PMDBD530 Metformin Therapeutic Substance Approved Drug newly diagnosed individuals with T2D who received oral metformin hydrochloride treatment (1000 mg b.i.d, Merck Serono) for 3 d. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. metformin acts in part through a B. fragilis-GUDCA-intestinal FXR axis to improve metabolic dysfunction, including hyperglycemia. PMID PMID: 30397356 PMDBI41659 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.71E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41659 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41660 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001204364] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41660 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a normal-chow diet were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. n.a. PMID PMID: 23804561 PMDBI41661 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41661 Substances alter microbe abundance PMDBM80 200643 Bacteroidetes PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Decrease p<0.001 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41662 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001470956] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41662 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Increase p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41663 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00025014] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41663 Substances alter microbe abundance PMDBM710 1511 Clostridium sticklandii PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-1.632748187, FDR-p value=1.04667E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41664 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.58E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41664 Substances alter microbe abundance PMDBM710 1511 Clostridium sticklandii PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-1.53115063, FDR-p value=6.68753E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41665 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD172 Cephalosporanic acid, 7-amino Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.96E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41665 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41666 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.95E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41666 Substances alter microbe abundance PMDBM2020113 88431 Dorea longicatena PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41667 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD382 Gefitinib "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.45E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41667 Substances alter microbe abundance PMDBM736 177439 Desulfotalea psychrophila LSv54 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41668 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD818 Suloctidil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008448038] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41668 Substances alter microbe abundance PMDBM736 177439 Desulfotalea psychrophila LSv54 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41669 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD516 Meclozine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00037081] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41669 Substances alter microbe abundance PMDBM735 188626 Dermacoccus sp. Ellin185 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.408391853, FDR-p value=0.002834337 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41670 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD472 Lansoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41670 Substances alter microbe abundance PMDBM735 188626 Dermacoccus sp. Ellin185 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.505327642, FDR-p value=0.002245307 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41671 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.90E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41671 Substances alter microbe abundance PMDBM741 198628 Dickeya dadantii 3937 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.80251936, FDR-p value=0.047280665 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41672 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD85 Azathioprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.94E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41672 Substances alter microbe abundance PMDBM741 198628 Dickeya dadantii 3937 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.267692359, FDR-p value=0.005809229 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41673 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD425 Hexetidine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.86E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41673 Substances alter microbe abundance PMDBM737 207559 Desulfovibrio alaskensis G20 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.700365998, FDR-p value=0.023893497 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41674 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD47 Anethole-trithione Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.26E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41674 Substances alter microbe abundance PMDBM737 207559 Desulfovibrio alaskensis G20 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41675 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD724 Rabeprazole Sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.53E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41675 Substances alter microbe abundance PMDBM873 218491 Pectobacterium atrosepticum SCRI1043 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.305509866, FDR-p value=0.024240865 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41676 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD182 Chlorotrianisene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004929581] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41676 Substances alter microbe abundance PMDBM873 218491 Pectobacterium atrosepticum SCRI1043 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41677 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD712 Propidium iodide Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000452093] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41677 Substances alter microbe abundance PMDBM924 218493 Salmonella bongori NCTC 12419 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.265290612, FDR-p value=0.002107056 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41678 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD238 Cyclosporin A Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004008817] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41678 Substances alter microbe abundance PMDBM924 218493 Salmonella bongori NCTC 12419 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.380107218, FDR-p value=0.000710559 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41679 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD320 Ethaverine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.86E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41679 Substances alter microbe abundance PMDBM664 243160 Burkholderia mallei ATCC 23344 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41680 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD641 Parbendazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.40E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41680 Substances alter microbe abundance PMDBM664 243160 Burkholderia mallei ATCC 23344 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41681 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD326 Etomidate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009471157] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41681 Substances alter microbe abundance PMDBM882 243265 Photorhabdus luminescens subsp. laumondii TTO1 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.025852269, FDR-p value=0.013302006 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41682 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD890 Vardenafil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001064221] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41682 Substances alter microbe abundance PMDBM882 243265 Photorhabdus luminescens subsp. laumondii TTO1 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41683 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD891 Vecuronium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000140478] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41683 Substances alter microbe abundance PMDBM825 257314 Lactobacillus johnsonii NCC 533 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.869448838, FDR-p value=0.011460102 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41684 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.49E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41684 Substances alter microbe abundance PMDBM825 257314 Lactobacillus johnsonii NCC 533 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41685 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD196 Cinnarizine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001296087] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41685 Substances alter microbe abundance PMDBM665 269482 Burkholderia vietnamiensis G4 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41686 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD310 Epirizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41686 Substances alter microbe abundance PMDBM665 269482 Burkholderia vietnamiensis G4 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41687 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD154 Cefadroxil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000723187] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41687 Substances alter microbe abundance PMDBM685 290338 Citrobacter koseri ATCC BAA-895 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.322795865, FDR-p value=0.001184309 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41688 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD336 Fenbendazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002022672] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41688 Substances alter microbe abundance PMDBM685 290338 Citrobacter koseri ATCC BAA-895 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.550284088, FDR-p value=0.000191515 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41689 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD79 Atovaquone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005811135] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41689 Substances alter microbe abundance PMDBM693 290402 Clostridium beijerinckii NCIMB 8052 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-3.935456291, FDR-p value=1.68244E-09 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41690 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD14 Acenocoumarol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.21E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41690 Substances alter microbe abundance PMDBM693 290402 Clostridium beijerinckii NCIMB 8052 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-3.180967822, FDR-p value=1.63819E-06 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41691 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD122 Bosentan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.36E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41691 Substances alter microbe abundance PMDBM621 293826 Alkaliphilus metalliredigens QYMF PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-1.396739312, FDR-p value=0.008992925 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41692 Substances alter microbe abundance PMDBM2020040 40520 Blautia obeum PMDBD631 Oxibendazol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00615387] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41692 Substances alter microbe abundance PMDBM621 293826 Alkaliphilus metalliredigens QYMF PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41693 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41693 Substances alter microbe abundance PMDBM827 314315 Lactobacillus sakei subsp. sakei 23K PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41694 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41694 Substances alter microbe abundance PMDBM827 314315 Lactobacillus sakei subsp. sakei 23K PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41695 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.21E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41695 Substances alter microbe abundance PMDBM993 316273 Xanthomonas campestris pv. vesicatoria str. 85-10 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.785442807, FDR-p value=0.001647526 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41696 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.41E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41696 Substances alter microbe abundance PMDBM993 316273 Xanthomonas campestris pv. vesicatoria str. 85-10 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41697 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.03E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41697 Substances alter microbe abundance PMDBM935 318167 Shewanella frigidimarina NCIMB 400 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41698 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41698 Substances alter microbe abundance PMDBM935 318167 Shewanella frigidimarina NCIMB 400 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41699 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.57E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41699 Substances alter microbe abundance PMDBM622 350688 Alkaliphilus oremlandii OhILAs PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-1.404113177, FDR-p value=0.012985681 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41700 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41700 Substances alter microbe abundance PMDBM622 350688 Alkaliphilus oremlandii OhILAs PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-1.268766679, FDR-p value=0.029253235 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41701 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41701 Substances alter microbe abundance PMDBM2020082 357276 Bacteroides dorei PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41702 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.09E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41702 Substances alter microbe abundance PMDBM669 360107 Campylobacter hominis ATCC BAA-381 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41703 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41703 Substances alter microbe abundance PMDBM669 360107 Campylobacter hominis ATCC BAA-381 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41704 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.54E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41704 Substances alter microbe abundance PMDBM2020098 386415 Clostridium novyi NT PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-2.399368333, FDR-p value=0.022167527 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41705 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.46E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41705 Substances alter microbe abundance PMDBM2020098 386415 Clostridium novyi NT PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-2.284918994, FDR-p value=0.029253235 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41706 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.63E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41706 Substances alter microbe abundance PMDBM996 393305 Yersinia enterocolitica subsp. enterocolitica 8081 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.120033541, FDR-p value=0.006748256 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41707 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.27E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41707 Substances alter microbe abundance PMDBM996 393305 Yersinia enterocolitica subsp. enterocolitica 8081 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.401555425, FDR-p value=0.001114606 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41708 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41708 Substances alter microbe abundance PMDBM782 393480 Fusobacterium nucleatum subsp. polymorphum ATCC 10953 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41709 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41709 Substances alter microbe abundance PMDBM782 393480 Fusobacterium nucleatum subsp. polymorphum ATCC 10953 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41710 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.19E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41710 Substances alter microbe abundance PMDBM656 398513 Bifidobacterium bifidum NCIMB 41171 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41711 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.54E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41711 Substances alter microbe abundance PMDBM656 398513 Bifidobacterium bifidum NCIMB 41171 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41712 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.56E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41712 Substances alter microbe abundance PMDBM930 399741 Serratia proteamaculans 568 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.055616701, FDR-p value=0.044674306 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41713 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.02E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41713 Substances alter microbe abundance PMDBM930 399741 Serratia proteamaculans 568 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41714 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41714 Substances alter microbe abundance PMDBM756 399742 Enterobacter sp. 638 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.73204629, FDR-p value=0.003071288 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41715 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41715 Substances alter microbe abundance PMDBM756 399742 Enterobacter sp. 638 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.869186914, FDR-p value=0.001278267 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41716 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41716 Substances alter microbe abundance PMDBM936 399804 Shewanella putrefaciens 200 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.430097656, FDR-p value=0.000474933 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41717 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.45E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41717 Substances alter microbe abundance PMDBM936 399804 Shewanella putrefaciens 200 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41718 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41718 Substances alter microbe abundance PMDBM995 406817 Xenorhabdus nematophila ATCC 19061 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.359407385, FDR-p value=0.013649734 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41719 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41719 Substances alter microbe abundance PMDBM995 406817 Xenorhabdus nematophila ATCC 19061 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41720 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.76E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41720 Substances alter microbe abundance PMDBM994 406818 Xenorhabdus bovienii SS-2004 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.228183644, FDR-p value=0.044674306 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41721 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41721 Substances alter microbe abundance PMDBM994 406818 Xenorhabdus bovienii SS-2004 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41722 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41722 Substances alter microbe abundance PMDBM893 411467 Pseudoflavonifractor capillosus ATCC 29799 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-0.438854387, FDR-p value=0.029026142 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41723 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41723 Substances alter microbe abundance PMDBM893 411467 Pseudoflavonifractor capillosus ATCC 29799 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41724 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.79E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41724 Substances alter microbe abundance PMDBM655 411481 Bifidobacterium adolescentis L2-32 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-1.742138652, FDR-p value=0.010221867 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41725 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.46E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41725 Substances alter microbe abundance PMDBM655 411481 Bifidobacterium adolescentis L2-32 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41726 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.14E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41726 Substances alter microbe abundance PMDBM831 420345 Lactonifactor PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41727 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41727 Substances alter microbe abundance PMDBM830 420890 Lactococcus garvieae Lg2 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41728 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.57E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41728 Substances alter microbe abundance PMDBM830 420890 Lactococcus garvieae Lg2 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41729 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.26E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41729 Substances alter microbe abundance PMDBM824 440497 Lactobacillus jensenii 1153 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.215894228, FDR-p value=0.047280665 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41730 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41730 Substances alter microbe abundance PMDBM824 440497 Lactobacillus jensenii 1153 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41731 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41731 Substances alter microbe abundance PMDBM641 441769 Bacillus coahuilensis m4-4 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.031673872, FDR-p value=0.009194719 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41732 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41732 Substances alter microbe abundance PMDBM641 441769 Bacillus coahuilensis m4-4 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.078729007, FDR-p value=0.005809229 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41733 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.39E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41733 Substances alter microbe abundance PMDBM696 445337 Clostridium botulinum C str. Eklund PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-3.695314834, FDR-p value=0.000183528 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41734 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41734 Substances alter microbe abundance PMDBM696 445337 Clostridium botulinum C str. Eklund PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-2.299844607, FDR-p value=0.022714196 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41735 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00243064] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41735 Substances alter microbe abundance PMDBM692 445973 Clostridium bartlettii DSM 16795 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-2.643594699, FDR-p value=1.25224E-09 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41736 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41736 Substances alter microbe abundance PMDBM692 445973 Clostridium bartlettii DSM 16795 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-2.230344191, FDR-p value=3.86591E-07 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41737 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41737 Substances alter microbe abundance PMDBM712 445975 Collinsella stercoris DSM 13279 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41738 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.64E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41738 Substances alter microbe abundance PMDBM712 445975 Collinsella stercoris DSM 13279 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41739 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000524699] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41739 Substances alter microbe abundance PMDBM984 450749 Veillonella sp. 6_1_27 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41740 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.28E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41740 Substances alter microbe abundance PMDBM984 450749 Veillonella sp. 6_1_27 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41741 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004980222] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41741 Substances alter microbe abundance PMDBM707 451755 Clostridium perfringens E str. JGS1987 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-2.683428005, FDR-p value=0.000160155 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41742 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41742 Substances alter microbe abundance PMDBM707 451755 Clostridium perfringens E str. JGS1987 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-1.689121212, FDR-p value=0.029059088 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41743 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41743 Substances alter microbe abundance PMDBM706 451756 Clostridium perfringens CPE str. F4969 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-3.47198195, FDR-p value=3.86591E-07 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41744 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001738587] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41744 Substances alter microbe abundance PMDBM706 451756 Clostridium perfringens CPE str. F4969 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-2.15525023, FDR-p value=0.003081898 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41745 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001096791] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41745 Substances alter microbe abundance PMDBM2020023 457396 Clostridium sp. 7_2_43FAA PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-3.595495199, FDR-p value=1.74946E-07 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41746 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.54E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41746 Substances alter microbe abundance PMDBM2020023 457396 Clostridium sp. 7_2_43FAA PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-2.755719438, FDR-p value=0.000178937 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41747 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.23E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41747 Substances alter microbe abundance PMDBM918 457412 Ruminococcus sp. 5_1_39BFAA PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=0.601222601, FDR-p value=0.035744039 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41748 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.67E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41748 Substances alter microbe abundance PMDBM918 457412 Ruminococcus sp. 5_1_39BFAA PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=0.644897181, FDR-p value=0.019241663 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41749 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41749 Substances alter microbe abundance PMDBM765 465817 Erwinia tasmaniensis Et1/99 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.599688661, FDR-p value=0.001225249 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41750 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.17E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41750 Substances alter microbe abundance PMDBM765 465817 Erwinia tasmaniensis Et1/99 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.449901175, FDR-p value=3.63324E-06 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41751 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00012308] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41751 Substances alter microbe abundance PMDBM2020094 469595 Citrobacter sp. 30_2 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.656980457, FDR-p value=0.000288855 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41752 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.15E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41752 Substances alter microbe abundance PMDBM2020094 469595 Citrobacter sp. 30_2 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.952388911, FDR-p value=2.92612E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41753 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.32E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41753 Substances alter microbe abundance PMDBM783 469606 Fusobacterium nucleatum subsp. vincentii 4_1_13 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41754 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41754 Substances alter microbe abundance PMDBM783 469606 Fusobacterium nucleatum subsp. vincentii 4_1_13 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41755 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41755 Substances alter microbe abundance PMDBM940 471855 Slackia heliotrinireducens DSM 20476 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41756 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000196949] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41756 Substances alter microbe abundance PMDBM940 471855 Slackia heliotrinireducens DSM 20476 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41757 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41757 Substances alter microbe abundance PMDBM694 498214 Clostridium botulinum A3 str. Loch Maree PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-2.075608857, FDR-p value=0.000211621 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41758 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41758 Substances alter microbe abundance PMDBM694 498214 Clostridium botulinum A3 str. Loch Maree PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-1.749316365, FDR-p value=0.002715502 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41759 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.70E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41759 Substances alter microbe abundance PMDBM704 500633 Clostridium hiranonis DSM 13275 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41760 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.43E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41760 Substances alter microbe abundance PMDBM704 500633 Clostridium hiranonis DSM 13275 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41761 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41761 Substances alter microbe abundance PMDBM688 500640 Citrobacter youngae ATCC 29220 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.852298241, FDR-p value=0.000320929 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41762 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41762 Substances alter microbe abundance PMDBM688 500640 Citrobacter youngae ATCC 29220 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.955117605, FDR-p value=0.00026017 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41763 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004717236] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41763 Substances alter microbe abundance PMDBM767 502347 Escherichia albertii TW07627 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.559216276, FDR-p value=0.000171663 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41764 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.48E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41764 Substances alter microbe abundance PMDBM767 502347 Escherichia albertii TW07627 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.644468481, FDR-p value=0.000155853 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41765 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.26E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41765 Substances alter microbe abundance PMDBM908 506534 Rheinheimera sp. A13L PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.163610081, FDR-p value=0.010593629 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41766 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.60E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41766 Substances alter microbe abundance PMDBM908 506534 Rheinheimera sp. A13L PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.282398293, FDR-p value=0.005103239 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41767 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41767 Substances alter microbe abundance PMDBM808 507522 Klebsiella pneumoniae 342 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=3.02111568, FDR-p value=0.00034365 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41768 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41768 Substances alter microbe abundance PMDBM808 507522 Klebsiella pneumoniae 342 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=4.522142971, FDR-p value=5.02008E-09 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41769 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.71E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41769 Substances alter microbe abundance PMDBM608 525245 Actinomyces coleocanis DSM 15436 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.462058179, FDR-p value=0.037370083 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41770 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.44E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41770 Substances alter microbe abundance PMDBM608 525245 Actinomyces coleocanis DSM 15436 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41771 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.36E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41771 Substances alter microbe abundance PMDBM720 525262 Corynebacterium jeikeium ATCC 43734 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41772 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00282779] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41772 Substances alter microbe abundance PMDBM720 525262 Corynebacterium jeikeium ATCC 43734 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41773 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.47E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41773 Substances alter microbe abundance PMDBM721 525263 Corynebacterium lipophiloflavum DSM 44291 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.887722054, FDR-p value=0.01941076 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41774 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.10E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41774 Substances alter microbe abundance PMDBM721 525263 Corynebacterium lipophiloflavum DSM 44291 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.213645212, FDR-p value=0.003944251 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41775 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.45E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41775 Substances alter microbe abundance PMDBM722 525264 Corynebacterium pseudogenitalium ATCC 33035 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41776 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.83E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41776 Substances alter microbe abundance PMDBM722 525264 Corynebacterium pseudogenitalium ATCC 33035 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41777 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.08E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41777 Substances alter microbe abundance PMDBM724 525268 Corynebacterium striatum ATCC 6940 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.937531565, FDR-p value=0.01941076 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41778 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0001362] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41778 Substances alter microbe abundance PMDBM724 525268 Corynebacterium striatum ATCC 6940 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.332867835, FDR-p value=0.003071288 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41779 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.40E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41779 Substances alter microbe abundance PMDBM817 525306 Lactobacillus acidophilus ATCC 4796 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.692905134, FDR-p value=0.033240142 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41780 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001159592] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41780 Substances alter microbe abundance PMDBM817 525306 Lactobacillus acidophilus ATCC 4796 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.913457198, FDR-p value=0.013709185 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41781 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000661825] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41781 Substances alter microbe abundance PMDBM820 525310 Lactobacillus brevis subsp. gravesensis ATCC 27305 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.293771827, FDR-p value=0.029253235 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41782 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.20E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41782 Substances alter microbe abundance PMDBM820 525310 Lactobacillus brevis subsp. gravesensis ATCC 27305 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41783 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001031773] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41783 Substances alter microbe abundance PMDBM823 525326 Lactobacillus gasseri JV-V03 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.189352734, FDR-p value=0.004093915 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41784 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00027409] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41784 Substances alter microbe abundance PMDBM823 525326 Lactobacillus gasseri JV-V03 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41785 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.75E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41785 Substances alter microbe abundance PMDBM828 525365 Lactobacillus ultunensis DSM 16047 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.772985275, FDR-p value=0.009779385 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41786 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.33E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41786 Substances alter microbe abundance PMDBM828 525365 Lactobacillus ultunensis DSM 16047 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41787 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41787 Substances alter microbe abundance PMDBM834 525367 Listeria grayi DSM 20601 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41788 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.58E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41788 Substances alter microbe abundance PMDBM834 525367 Listeria grayi DSM 20601 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41789 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41789 Substances alter microbe abundance PMDBM950 525376 Staphylococcus epidermidis W23144 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.374785171, FDR-p value=0.044870479 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41790 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003531295] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41790 Substances alter microbe abundance PMDBM950 525376 Staphylococcus epidermidis W23144 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41791 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000530647] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41791 Substances alter microbe abundance PMDBM906 533247 Raphidiopsis brookii D9 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.588467041, FDR-p value=0.010704071 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41792 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002100295] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41792 Substances alter microbe abundance PMDBM906 533247 Raphidiopsis brookii D9 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41793 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004374242] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41793 Substances alter microbe abundance PMDBM700 536227 Clostridium carboxidivorans P7 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-2.320074187, FDR-p value=0.00392092 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41794 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.15E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41794 Substances alter microbe abundance PMDBM700 536227 Clostridium carboxidivorans P7 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41795 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001863675] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41795 Substances alter microbe abundance PMDBM698 536233 Clostridium botulinum E1 str. 'BoNT E Beluga' PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-3.802220104, FDR-p value=5.02008E-09 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41796 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009606166] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41796 Substances alter microbe abundance PMDBM698 536233 Clostridium botulinum E1 str. 'BoNT E Beluga' PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-3.356574993, FDR-p value=3.86591E-07 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41797 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000926063] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41797 Substances alter microbe abundance PMDBM848 546263 Neisseria elongata subsp. glycolytica ATCC 29315 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.561060703, FDR-p value=0.00252331 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41798 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.30E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41798 Substances alter microbe abundance PMDBM848 546263 Neisseria elongata subsp. glycolytica ATCC 29315 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41799 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000327625] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41799 Substances alter microbe abundance PMDBM849 546266 Neisseria mucosa ATCC 25996 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.939340536, FDR-p value=0.001544492 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41800 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00575307] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41800 Substances alter microbe abundance PMDBM849 546266 Neisseria mucosa ATCC 25996 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.063888827, FDR-p value=0.000843551 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41801 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00132593] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41801 Substances alter microbe abundance PMDBM983 546273 Veillonella dispar ATCC 17748 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41802 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000516951] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41802 Substances alter microbe abundance PMDBM983 546273 Veillonella dispar ATCC 17748 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41803 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000117098] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41803 Substances alter microbe abundance PMDBM659 547043 Bifidobacterium pseudocatenulatum DSM 20438 = JCM 1200 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41804 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.99E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41804 Substances alter microbe abundance PMDBM659 547043 Bifidobacterium pseudocatenulatum DSM 20438 = JCM 1200 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41805 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006857437] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41805 Substances alter microbe abundance PMDBM674 553178 Capnocytophaga gingivalis ATCC 33624 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.510785896, FDR-p value=0.032299347 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41806 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.10E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41806 Substances alter microbe abundance PMDBM674 553178 Capnocytophaga gingivalis ATCC 33624 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.521956757, FDR-p value=0.035377676 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41807 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD431 Hycanthone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000289776] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41807 Substances alter microbe abundance PMDBM668 553220 Campylobacter gracilis RM3268 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41808 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD319 Ethacrynic acid "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005559527] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41808 Substances alter microbe abundance PMDBM668 553220 Campylobacter gracilis RM3268 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41809 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD720 Quinacrine dihydrochloride dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008674811] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41809 Substances alter microbe abundance PMDBM781 556263 Fusobacterium necrophorum D12 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.627931551, FDR-p value=0.019241663 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41810 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD419 Haloprogin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005736582] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41810 Substances alter microbe abundance PMDBM781 556263 Fusobacterium necrophorum D12 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41811 Substances alter microbe abundance PMDBM2020047 208479 Enterocloster bolteae PMDBD69 Aripiprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002537439] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41811 Substances alter microbe abundance PMDBM744 561229 Dickeya zeae Ech1591 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.910451267, FDR-p value=0.043895048 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41812 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.61E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41812 Substances alter microbe abundance PMDBM744 561229 Dickeya zeae Ech1591 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.971726928, FDR-p value=0.031075441 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41813 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.17E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41813 Substances alter microbe abundance PMDBM874 561231 Pectobacterium wasabiae WPP163 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.3812479, FDR-p value=0.01941076 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41814 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.77E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41814 Substances alter microbe abundance PMDBM874 561231 Pectobacterium wasabiae WPP163 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41815 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.07E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41815 Substances alter microbe abundance PMDBM889 563008 Prevotella oris C735 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41816 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.06E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41816 Substances alter microbe abundance PMDBM889 563008 Prevotella oris C735 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41817 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41817 Substances alter microbe abundance PMDBM759 565654 Enterococcus casseliflavus EC10 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.183354227, FDR-p value=0.043895048 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41818 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.19E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41818 Substances alter microbe abundance PMDBM759 565654 Enterococcus casseliflavus EC10 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41819 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00021134] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41819 Substances alter microbe abundance PMDBM743 579405 Dickeya dadantii Ech703 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.114542755, FDR-p value=0.039417774 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41820 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.86E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41820 Substances alter microbe abundance PMDBM743 579405 Dickeya dadantii Ech703 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.501949726, FDR-p value=0.008015127 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41821 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.18E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41821 Substances alter microbe abundance PMDBM818 585524 Lactobacillus amylolyticus DSM 11664 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.773792802, FDR-p value=0.013709185 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41822 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41822 Substances alter microbe abundance PMDBM818 585524 Lactobacillus amylolyticus DSM 11664 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41823 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41823 Substances alter microbe abundance PMDBM742 590409 Dickeya dadantii Ech586 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.467930302, FDR-p value=0.025565282 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41824 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41824 Substances alter microbe abundance PMDBM742 590409 Dickeya dadantii Ech586 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41825 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000619008] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41825 Substances alter microbe abundance PMDBM697 592027 Clostridium botulinum D str. 1873 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-3.809632604, FDR-p value=2.33067E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41826 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.06E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41826 Substances alter microbe abundance PMDBM697 592027 Clostridium botulinum D str. 1873 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-2.863663383, FDR-p value=0.00138343 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41827 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001313179] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41827 Substances alter microbe abundance PMDBM868 592316 Pantoea sp. At-9b PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.765848702, FDR-p value=0.048292655 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41828 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41828 Substances alter microbe abundance PMDBM868 592316 Pantoea sp. At-9b PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.382110424, FDR-p value=0.002681787 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41829 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41829 Substances alter microbe abundance PMDBM881 596315 Peptostreptococcus stomatis DSM 17678 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-0.977184181, FDR-p value=0.027617344 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41830 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41830 Substances alter microbe abundance PMDBM881 596315 Peptostreptococcus stomatis DSM 17678 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41831 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00061907] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41831 Substances alter microbe abundance PMDBM887 596327 Porphyromonas uenonis 60-3 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41832 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.06E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41832 Substances alter microbe abundance PMDBM887 596327 Porphyromonas uenonis 60-3 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41833 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41833 Substances alter microbe abundance PMDBM789 626369 Granulicatella elegans ATCC 700633 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41834 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41834 Substances alter microbe abundance PMDBM789 626369 Granulicatella elegans ATCC 700633 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41835 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.84E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41835 Substances alter microbe abundance PMDBM902 629259 Pseudomonas syringae pv. morsprunorum str. M302280 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.934384014, FDR-p value=0.029620989 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41836 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41836 Substances alter microbe abundance PMDBM902 629259 Pseudomonas syringae pv. morsprunorum str. M302280 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41837 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.76E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41837 Substances alter microbe abundance PMDBM699 632245 Clostridium butyricum E4 str. BoNT E BL5262 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-3.617949905, FDR-p value=1.85148E-08 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41838 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41838 Substances alter microbe abundance PMDBM699 632245 Clostridium butyricum E4 str. BoNT E BL5262 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-3.356166923, FDR-p value=3.86591E-07 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41839 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.15E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41839 Substances alter microbe abundance PMDBM860 633147 Olsenella uli DSM 7084 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41840 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001835278] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41840 Substances alter microbe abundance PMDBM860 633147 Olsenella uli DSM 7084 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41841 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004692789] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41841 Substances alter microbe abundance PMDBM764 634500 Erwinia billingiae Eb661 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.691049642, FDR-p value=0.00252331 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41842 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41842 Substances alter microbe abundance PMDBM764 634500 Erwinia billingiae Eb661 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.888477517, FDR-p value=0.000683858 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41843 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001117861] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41843 Substances alter microbe abundance PMDBM747 634503 Edwardsiella ictaluri 93-146 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.087120925, FDR-p value=0.021796713 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41844 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.32E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41844 Substances alter microbe abundance PMDBM747 634503 Edwardsiella ictaluri 93-146 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41845 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00079853] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41845 Substances alter microbe abundance PMDBM686 637910 Citrobacter rodentium ICC168 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.660488871, FDR-p value=4.16674E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41846 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.25E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41846 Substances alter microbe abundance PMDBM686 637910 Citrobacter rodentium ICC168 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.677704858, FDR-p value=2.02091E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41847 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.28E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41847 Substances alter microbe abundance PMDBM730 639282 Deferribacter desulfuricans SSM1 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-2.315385139, FDR-p value=0.022255128 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41848 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41848 Substances alter microbe abundance PMDBM730 639282 Deferribacter desulfuricans SSM1 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41849 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.08E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41849 Substances alter microbe abundance PMDBM751 640513 Enterobacter asburiae LF7a PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.32807204, FDR-p value=0.011456502 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41850 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000234995] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41850 Substances alter microbe abundance PMDBM751 640513 Enterobacter asburiae LF7a PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.797095531, FDR-p value=0.001075253 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41851 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.39E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41851 Substances alter microbe abundance PMDBM917 641112 Ruminococcus flavefaciens FD-1 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-0.97431946, FDR-p value=0.009565832 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41852 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41852 Substances alter microbe abundance PMDBM917 641112 Ruminococcus flavefaciens FD-1 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41853 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.16E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41853 Substances alter microbe abundance PMDBM939 649764 Slackia exigua ATCC 700122 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41854 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.46E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41854 Substances alter microbe abundance PMDBM939 649764 Slackia exigua ATCC 700122 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41855 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41855 Substances alter microbe abundance PMDBM739 653733 Desulfurispirillum indicum S5 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.115968801, FDR-p value=0.024240865 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41856 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.64E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41856 Substances alter microbe abundance PMDBM739 653733 Desulfurispirillum indicum S5 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41857 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000103471] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41857 Substances alter microbe abundance PMDBM769 656449 Escherichia coli TW10509 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.567658358, FDR-p value=0.000191515 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41858 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000171892] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41858 Substances alter microbe abundance PMDBM769 656449 Escherichia coli TW10509 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.721061424, FDR-p value=0.000129651 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41859 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41859 Substances alter microbe abundance PMDBM2020216 657323 Ruminococcus sp. SR1/5 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41860 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.13E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41860 Substances alter microbe abundance PMDBM2020216 657323 Ruminococcus sp. SR1/5 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41861 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.71E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41861 Substances alter microbe abundance PMDBM723 662755 Corynebacterium resistens DSM 45100 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41862 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000638361] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41862 Substances alter microbe abundance PMDBM723 662755 Corynebacterium resistens DSM 45100 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41863 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.06E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41863 Substances alter microbe abundance PMDBM954 663952 Streptococcus dysgalactiae subsp. dysgalactiae ATCC 27957 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41864 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000100702] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41864 Substances alter microbe abundance PMDBM954 663952 Streptococcus dysgalactiae subsp. dysgalactiae ATCC 27957 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41865 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.10E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41865 Substances alter microbe abundance PMDBM929 667129 Serratia odorifera DSM 4582 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.211691931, FDR-p value=0.017934627 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41866 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.34E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41866 Substances alter microbe abundance PMDBM929 667129 Serratia odorifera DSM 4582 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.329116737, FDR-p value=0.011449719 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41867 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.30E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41867 Substances alter microbe abundance PMDBM990 675811 Vibrio furnissii CIP 102972 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.248372349, FDR-p value=0.024240865 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41868 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.20E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41868 Substances alter microbe abundance PMDBM990 675811 Vibrio furnissii CIP 102972 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41869 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.07E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41869 Substances alter microbe abundance PMDBM793 679897 Helicobacter mustelae 12198 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=4.130588109, FDR-p value=0.0007715 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41870 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.29E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41870 Substances alter microbe abundance PMDBM793 679897 Helicobacter mustelae 12198 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=4.569821736, FDR-p value=0.000106099 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41871 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000185668] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41871 Substances alter microbe abundance PMDBM914 680646 Rothia mucilaginosa DY-18 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.199480889, FDR-p value=0.035377676 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41872 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.37E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41872 Substances alter microbe abundance PMDBM914 680646 Rothia mucilaginosa DY-18 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41873 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.37E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41873 Substances alter microbe abundance PMDBM725 693216 Cronobacter turicensis z3032 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.45720173, FDR-p value=0.00252331 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41874 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41874 Substances alter microbe abundance PMDBM725 693216 Cronobacter turicensis z3032 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.963526975, FDR-p value=0.000106099 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41875 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.55E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41875 Substances alter microbe abundance PMDBM640 699184 Bacillus cereus SJ1 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.178117422, FDR-p value=0.004656101 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41876 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.66E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41876 Substances alter microbe abundance PMDBM640 699184 Bacillus cereus SJ1 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.750279107, FDR-p value=0.000246599 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41877 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.05E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41877 Substances alter microbe abundance PMDBM718 700015 Coriobacterium glomerans PW2 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41878 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001584198] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41878 Substances alter microbe abundance PMDBM718 700015 Coriobacterium glomerans PW2 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41879 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000254074] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41879 Substances alter microbe abundance PMDBM755 701347 Enterobacter lignolyticus SCF1 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.050390527, FDR-p value=0.00639885 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41880 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001440752] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41880 Substances alter microbe abundance PMDBM755 701347 Enterobacter lignolyticus SCF1 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.443474267, FDR-p value=0.000474933 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41881 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000247101] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41881 Substances alter microbe abundance PMDBM835 702453 Listeria seeligeri FSL N1-067 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41882 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000562878] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41882 Substances alter microbe abundance PMDBM835 702453 Listeria seeligeri FSL N1-067 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41883 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003421461] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41883 Substances alter microbe abundance PMDBM605 707232 Acinetobacter haemolyticus ATCC 19194 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.320471234, FDR-p value=0.000595034 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41884 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004646157] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41884 Substances alter microbe abundance PMDBM605 707232 Acinetobacter haemolyticus ATCC 19194 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41885 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001423006] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41885 Substances alter microbe abundance PMDBM822 712938 Lactobacillus fermentum CECT 5716 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.348898935, FDR-p value=0.037504396 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41886 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003996211] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41886 Substances alter microbe abundance PMDBM822 712938 Lactobacillus fermentum CECT 5716 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41887 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.71E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41887 Substances alter microbe abundance PMDBM763 716540 Erwinia amylovora ATCC 49946 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.249706167, FDR-p value=0.037264707 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41888 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.08E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41888 Substances alter microbe abundance PMDBM763 716540 Erwinia amylovora ATCC 49946 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.872804342, FDR-p value=0.002834337 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41889 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000380382] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41889 Substances alter microbe abundance PMDBM753 716541 Enterobacter cloacae subsp. cloacae ATCC 13047 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.407318727, FDR-p value=0.000352065 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41890 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.19E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41890 Substances alter microbe abundance PMDBM753 716541 Enterobacter cloacae subsp. cloacae ATCC 13047 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.432745788, FDR-p value=0.000211621 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41891 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00469744] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41891 Substances alter microbe abundance PMDBM754 718254 Enterobacter cloacae subsp. cloacae NCTC 9394 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.659961714, FDR-p value=4.8626E-06 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41892 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000328272] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41892 Substances alter microbe abundance PMDBM754 718254 Enterobacter cloacae subsp. cloacae NCTC 9394 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=4.038769728, FDR-p value=3.86591E-07 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41893 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002546255] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41893 Substances alter microbe abundance PMDBM701 720554 Clostridium clariflavum DSM 19732 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41894 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00739182] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41894 Substances alter microbe abundance PMDBM701 720554 Clostridium clariflavum DSM 19732 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41895 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001734051] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41895 Substances alter microbe abundance PMDBM904 741091 Rahnella sp. Y9602 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.724851882, FDR-p value=0.000257223 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41896 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.21E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41896 Substances alter microbe abundance PMDBM904 741091 Rahnella sp. Y9602 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41897 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000202694] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41897 Substances alter microbe abundance PMDBM903 745277 Rahnella aquatilis CIP 78.65 = ATCC 33071 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.132822941, FDR-p value=0.012098214 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41898 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000126633] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41898 Substances alter microbe abundance PMDBM903 745277 Rahnella aquatilis CIP 78.65 = ATCC 33071 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41899 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004646898] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41899 Substances alter microbe abundance PMDBM776 748224 Faecalibacterium cf. prausnitzii KLE1255 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-0.728616189, FDR-p value=0.023392474 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41900 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.47E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41900 Substances alter microbe abundance PMDBM776 748224 Faecalibacterium cf. prausnitzii KLE1255 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41901 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005306086] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41901 Substances alter microbe abundance PMDBM894 748280 Pseudogulbenkiania sp. NH8B PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-1.427383556, FDR-p value=0.044870479 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41902 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005212897] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41902 Substances alter microbe abundance PMDBM894 748280 Pseudogulbenkiania sp. NH8B PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41903 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009795205] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41903 Substances alter microbe abundance PMDBM948 754026 Staphylococcus aureus subsp. aureus MRSA177 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.325157575, FDR-p value=0.013709185 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41904 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009586015] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41904 Substances alter microbe abundance PMDBM948 754026 Staphylococcus aureus subsp. aureus MRSA177 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41905 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD265 Dicumarol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006726948] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41905 Substances alter microbe abundance PMDBM662 759914 Brachyspira pilosicoli 95/1000 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41906 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007631742] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41906 Substances alter microbe abundance PMDBM662 759914 Brachyspira pilosicoli 95/1000 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41907 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000869382] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41907 Substances alter microbe abundance PMDBM796 760142 Hippea maritima DSM 10411 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-1.415675601, FDR-p value=0.047280665 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41908 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD338 Fendiline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006460559] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41908 Substances alter microbe abundance PMDBM796 760142 Hippea maritima DSM 10411 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41909 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD516 Meclozine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001293302] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41909 Substances alter microbe abundance PMDBM958 760570 Streptococcus parasanguinis ATCC 15912 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.134677832, FDR-p value=0.044674306 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41910 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD85 Azathioprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.13E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41910 Substances alter microbe abundance PMDBM958 760570 Streptococcus parasanguinis ATCC 15912 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41911 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD470 Lacidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001391325] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41911 Substances alter microbe abundance PMDBM609 762963 Actinomyces sp. oral taxon 170 str. F0386 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41912 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD193 Cilnidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001096233] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41912 Substances alter microbe abundance PMDBM609 762963 Actinomyces sp. oral taxon 170 str. F0386 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41913 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.63E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41913 Substances alter microbe abundance PMDBM646 762984 Bacteroides clarus YIT 12056 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.168360159, FDR-p value=0.029253235 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41914 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD523 Mercaptopurine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.08E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41914 Substances alter microbe abundance PMDBM646 762984 Bacteroides clarus YIT 12056 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41915 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000404149] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41915 Substances alter microbe abundance PMDBM931 768490 Serratia sp. AS12 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.970477841, FDR-p value=0.029253235 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41916 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD39 Amlodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008944477] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41916 Substances alter microbe abundance PMDBM931 768490 Serratia sp. AS12 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41917 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD145 Carbenoxolone disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002796885] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41917 Substances alter microbe abundance PMDBM658 871562 Bifidobacterium dentium ATCC 27679 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41918 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD867 Tribenoside Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004733857] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41918 Substances alter microbe abundance PMDBM658 871562 Bifidobacterium dentium ATCC 27679 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41919 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD342 Fentiazac Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000634437] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41919 Substances alter microbe abundance PMDBM614 878320 Aeromonas caviae Ae398 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.440430469, FDR-p value=0.024240865 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41920 Substances alter microbe abundance PMDBM2020046 n.a. Clostridioides difficile PMDBD401 Gliquidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006069732] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41920 Substances alter microbe abundance PMDBM614 878320 Aeromonas caviae Ae398 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41921 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.96E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41921 Substances alter microbe abundance PMDBM877 879308 Peptoniphilus sp. oral taxon 375 str. F0436 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=0.421746652, FDR-p value=0.049124707 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41922 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.11E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41922 Substances alter microbe abundance PMDBM877 879308 Peptoniphilus sp. oral taxon 375 str. F0436 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41923 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41923 Substances alter microbe abundance PMDBM985 879309 Veillonella sp. oral taxon 158 str. F0412 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41924 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41924 Substances alter microbe abundance PMDBM985 879309 Veillonella sp. oral taxon 158 str. F0412 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41925 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.57E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41925 Substances alter microbe abundance PMDBM925 882884 Salmonella enterica subsp. arizonae serovar 62:z4,z23:- str. RSK2980 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.529077443, FDR-p value=0.00037212 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41926 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41926 Substances alter microbe abundance PMDBM925 882884 Salmonella enterica subsp. arizonae serovar 62:z4,z23:- str. RSK2980 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.626655863, FDR-p value=0.000171663 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41927 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41927 Substances alter microbe abundance PMDBM821 888027 Lactobacillus delbrueckii subsp. lactis DSM 20072 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.868633697, FDR-p value=0.028170194 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41928 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41928 Substances alter microbe abundance PMDBM821 888027 Lactobacillus delbrueckii subsp. lactis DSM 20072 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41929 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41929 Substances alter microbe abundance PMDBM847 888742 Neisseria bacilliformis ATCC BAA-1200 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41930 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41930 Substances alter microbe abundance PMDBM847 888742 Neisseria bacilliformis ATCC BAA-1200 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41931 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41931 Substances alter microbe abundance PMDBM885 891974 Plautia stali symbiont PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=3.192733917, FDR-p value=0.029253235 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41932 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41932 Substances alter microbe abundance PMDBM885 891974 Plautia stali symbiont PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41933 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41933 Substances alter microbe abundance PMDBM772 903814 Eubacterium limosum KIST612 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41934 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.40E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41934 Substances alter microbe abundance PMDBM772 903814 Eubacterium limosum KIST612 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41935 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41935 Substances alter microbe abundance PMDBM926 909945 Salmonella enterica subsp. enterica serovar Dublin str. SD3246 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.61522486, FDR-p value=0.00026017 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41936 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41936 Substances alter microbe abundance PMDBM926 909945 Salmonella enterica subsp. enterica serovar Dublin str. SD3246 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.788588462, FDR-p value=5.97097E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41937 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.28E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41937 Substances alter microbe abundance PMDBM991 911104 Weissella cibaria KACC 11862 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.964812413, FDR-p value=0.043895048 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41938 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41938 Substances alter microbe abundance PMDBM991 911104 Weissella cibaria KACC 11862 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41939 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41939 Substances alter microbe abundance PMDBM695 929506 Clostridium botulinum BKT015925 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Decrease log2FC=-3.819744919, FDR-p value=5.29255E-05 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41940 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41940 Substances alter microbe abundance PMDBM695 929506 Clostridium botulinum BKT015925 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Decrease log2FC=-2.755940694, FDR-p value=0.003267857 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41941 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.57E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41941 Substances alter microbe abundance PMDBM604 980514 Acinetobacter baumannii TCDC-AB0715 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=1.547944979, FDR-p value=0.024240865 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41942 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41942 Substances alter microbe abundance PMDBM604 980514 Acinetobacter baumannii TCDC-AB0715 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41943 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.33E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41943 Substances alter microbe abundance PMDBM901 996285 Pseudomonas stutzeri DSM 4166 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.546250033, FDR-p value=0.008015127 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41944 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.33E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41944 Substances alter microbe abundance PMDBM901 996285 Pseudomonas stutzeri DSM 4166 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41945 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41945 Substances alter microbe abundance PMDBM806 1006551 Klebsiella oxytoca KCTC 1686 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.795582236, FDR-p value=0.00026017 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41946 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.64E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41946 Substances alter microbe abundance PMDBM806 1006551 Klebsiella oxytoca KCTC 1686 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.672789777, FDR-p value=2.2381E-07 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41947 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41947 Substances alter microbe abundance PMDBM750 1028307 Enterobacter aerogenes KCTC 2190 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.354538187, FDR-p value=0.003574388 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41948 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41948 Substances alter microbe abundance PMDBM750 1028307 Enterobacter aerogenes KCTC 2190 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.842625114, FDR-p value=0.000191515 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41949 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.53E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41949 Substances alter microbe abundance PMDBM826 1040964 Lactobacillus ruminis SPM0211 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41950 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41950 Substances alter microbe abundance PMDBM826 1040964 Lactobacillus ruminis SPM0211 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41951 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41951 Substances alter microbe abundance PMDBM752 1045856 Enterobacter cloacae EcWSU1 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.12259286, FDR-p value=0.024051055 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41952 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.10E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41952 Substances alter microbe abundance PMDBM752 1045856 Enterobacter cloacae EcWSU1 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.169148203, FDR-p value=0.018165801 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41953 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41953 Substances alter microbe abundance PMDBM616 1050720 Agrobacterium tumefaciens F2 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41954 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41954 Substances alter microbe abundance PMDBM616 1050720 Agrobacterium tumefaciens F2 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41955 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41955 Substances alter microbe abundance PMDBM891 1051006 Propionibacterium acnes SK182B-JCVI PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41956 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41956 Substances alter microbe abundance PMDBM891 1051006 Propionibacterium acnes SK182B-JCVI PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41957 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.46E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41957 Substances alter microbe abundance PMDBM960 1051074 Streptococcus thermophilus JIM 8232 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41958 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41958 Substances alter microbe abundance PMDBM960 1051074 Streptococcus thermophilus JIM 8232 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41959 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41959 Substances alter microbe abundance PMDBM837 1064535 Megasphaera elsdenii DSM 20460 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41960 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.27E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41960 Substances alter microbe abundance PMDBM837 1064535 Megasphaera elsdenii DSM 20460 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41961 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41961 Substances alter microbe abundance PMDBM955 1069533 Streptococcus infantarius subsp. infantarius CJ18 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41962 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41962 Substances alter microbe abundance PMDBM955 1069533 Streptococcus infantarius subsp. infantarius CJ18 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41963 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41963 Substances alter microbe abundance PMDBM895 1089456 Pseudomonas aeruginosa NCGM2.S1 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=1.761073416, FDR-p value=0.047280665 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41964 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.56E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41964 Substances alter microbe abundance PMDBM895 1089456 Pseudomonas aeruginosa NCGM2.S1 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.594793617, FDR-p value=7.95032E-07 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41965 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41965 Substances alter microbe abundance PMDBM832 1091138 Lawsonia PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice fed a ahigh-fat diet (HFD) were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Decrease p<0.05 n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. n.a. PMID PMID: 23804561 PMDBI41966 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.33E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41966 Substances alter microbe abundance PMDBM867 1123863 Pantoea ananatis LMG 5342 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=2.708788524, FDR-p value=0.000596366 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41967 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41967 Substances alter microbe abundance PMDBM867 1123863 Pantoea ananatis LMG 5342 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. Increase log2FC=2.823475384, FDR-p value=0.00037212 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41968 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-06] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41968 Substances alter microbe abundance PMDBM829 1423814 Lactobacillus vaginalis ATCC 49540 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41969 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.08E-05] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41969 Substances alter microbe abundance PMDBM829 1423814 Lactobacillus vaginalis ATCC 49540 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41970 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.33E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41970 Substances alter microbe abundance PMDBM802 1505657 Intestinibacter PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human Type 2 diabetes n.a. Microbial shifts under metformin treatment contribute to improved glucose control and to adverse effects. PMID PMID: 26633628 PMDBI41971 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41971 Substances alter microbe abundance PMDBM2020173 n.a. Shewanella sp. Ana-3 PMDBD530 Metformin Therapeutic Substance Approved Drug 4 months of metformin treatment vs control n.a. Increase log2FC=3.121166792, FDR-p value=0.00416827 n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Altered gut microbiota mediates some of metformin閳ユç?antidiabetic effects. PMID PMID: 28530702 PMDBI41972 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI41972 Substances alter microbe abundance PMDBM2020173 n.a. Shewanella sp. Ana-3 PMDBD530 Metformin Therapeutic Substance Approved Drug 2 months of metformin treatment vs control n.a. No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 28530702 PMDBI41973 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41973 Substances alter microbe abundance PMDBM617 n.a. Akkermansia spp. PMDBD530 Metformin Therapeutic Substance Approved Drug C57BL/6 mice, fed either a normal-chow diet or ahigh-fat diet (HFD), were treated with 300 mg/kg/day of metformin by oral gavage for a period of 6 weeks. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Type 2 diabetes n.a. The Akkermansia spp. Population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. The increase in the Akkermansia spp. population may contribute to the antidiabetic effects of metformin. PMID PMID: 23804561 PMDBI41974 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41974 Substances alter microbe abundance PMDBM652 n.a. Barnesiellaceae PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI41975 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41975 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Acute lymphocytic leukemia (ALL) n.a. Microbiota as ALL chemotherapy response biomarker PMID PMID: 31675176 PMDBI41976 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41976 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Microbiota as ALL chemotherapy response biomarker PMID PMID: 31675176 PMDBI41977 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41977 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Microbiota as ALL chemotherapy response biomarker PMID PMID: 31675176 PMDBI41978 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.90E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41978 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Microbiota as ALL chemotherapy response biomarker PMID PMID: 31675176 PMDBI41979 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41979 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD546 Metronidazole Therapeutic Substance "Approved Drug; Antibiotics" Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI41980 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.36E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41980 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD546 Metronidazole Therapeutic Substance "Approved Drug; Antibiotics" Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI41981 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41981 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD546 Metronidazole Therapeutic Substance "Approved Drug; Antibiotics" Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI41982 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41982 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD546 Metronidazole Therapeutic Substance "Approved Drug; Antibiotics" Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI41983 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.77E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41983 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD546 Metronidazole Therapeutic Substance "Approved Drug; Antibiotics" Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI41984 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41984 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD546 Metronidazole Therapeutic Substance "Approved Drug; Antibiotics" Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI41985 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41985 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD546 Metronidazole Therapeutic Substance "Approved Drug; Antibiotics" Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI41986 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.78E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41986 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD546 Metronidazole Therapeutic Substance "Approved Drug; Antibiotics" Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI41987 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.07E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41987 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD546 Metronidazole Therapeutic Substance "Approved Drug; Antibiotics" Metronidazole (0.5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Metronidazole increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI41988 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1294 Mezlocillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41988 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41989 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.33E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41989 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1294 Mezlocillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41990 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41990 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1294 Mezlocillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41991 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.36E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41991 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1294 Mezlocillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41992 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41992 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1294 Mezlocillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI41993 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41993 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1294 Mezlocillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889" PMDBI41994 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.28E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41994 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD1296 Minocycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI41995 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41995 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1296 Minocycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI41996 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41996 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD1296 Minocycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI41997 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.12E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41997 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD1296 Minocycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI41998 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41998 Substances alter microbe abundance PMDBM247 2701 Gardnerella PMDBD1296 Minocycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI41999 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI41999 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1296 Minocycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI42000 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42000 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1296 Minocycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI42001 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.37E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42001 Substances alter microbe abundance PMDBM397 40544 Sutterella PMDBD1296 Minocycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI42002 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005474974] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42002 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD1296 Minocycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI42003 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.87E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42003 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1296 Minocycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI42004 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42004 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD1296 Minocycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI42005 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.33E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42005 Substances alter microbe abundance PMDBM740 39948 Dialister PMDBD1296 Minocycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26556275" PMDBI42006 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD562 Moxifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI42006 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42007 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD562 Moxifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI42007 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42008 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42008 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD562 Moxifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI42009 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42009 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD562 Moxifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI42010 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.36E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42010 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD562 Moxifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI42011 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.28E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42011 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD562 Moxifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI42012 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42012 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD562 Moxifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI42013 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000283455] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42013 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD562 Moxifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI42014 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.35E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42014 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD562 Moxifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI42015 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42015 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD562 Moxifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI42016 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42016 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD562 Moxifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI42017 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.10E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42017 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD562 Moxifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 10716083" PMDBI42018 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42018 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1308 Nalidixic acid Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2938072" PMDBI42019 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.59E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42019 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1308 Nalidixic acid Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2938072" PMDBI42020 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.05E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42020 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1308 Nalidixic acid Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2938072" PMDBI42021 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD599 Nitrofurantoin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522" PMDBI42021 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.77E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42022 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.58E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42022 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD599 Nitrofurantoin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522" PMDBI42023 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42023 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD599 Nitrofurantoin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522" PMDBI42024 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.77E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42024 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD599 Nitrofurantoin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9210003" PMDBI42025 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42025 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD599 Nitrofurantoin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9210003" PMDBI42026 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.41E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42026 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD599 Nitrofurantoin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522" PMDBI42027 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.29E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42027 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD599 Nitrofurantoin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522" PMDBI42028 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.43E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42028 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD599 Nitrofurantoin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522" PMDBI42029 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000100844] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42029 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD599 Nitrofurantoin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522" PMDBI42030 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42030 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD599 Nitrofurantoin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522" PMDBI42031 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42031 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD599 Nitrofurantoin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522" PMDBI42032 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42032 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD599 Nitrofurantoin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25766736" PMDBI42033 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42033 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD599 Nitrofurantoin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25658522" PMDBI42034 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD607 Norfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419" PMDBI42034 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42035 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD607 Norfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419" PMDBI42035 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42036 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.98E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42036 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD607 Norfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419" PMDBI42037 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.47E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42037 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD607 Norfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419; PMID: 3438150; PMID: 3729360; PMID: 9210003" PMDBI42038 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.23E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42038 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD607 Norfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419; PMID: 7559202; PMID: 9210003" PMDBI42039 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001820012] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42039 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD607 Norfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7559202" PMDBI42040 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42040 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD607 Norfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419" PMDBI42041 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.21E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42041 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD607 Norfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419" PMDBI42042 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42042 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD607 Norfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419; PMID: 7559202" PMDBI42043 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42043 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD607 Norfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419" PMDBI42044 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004419677] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42044 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD607 Norfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7559202" PMDBI42045 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.70E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42045 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD607 Norfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419" PMDBI42046 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.73E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42046 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD607 Norfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419; PMID: 7559202" PMDBI42047 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.43E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42047 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD607 Norfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419; PMID: 7559202" PMDBI42048 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.80E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42048 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD607 Norfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3563419; PMID: 7559202" PMDBI42049 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.35E-05] n.a. n.a. n.a. n.a. n.a. Human Juvenile Idiopathic Arthritis (JIA) n.a. n.a. PMID PMID: 29555994 PMDBI42049 Substances alter microbe abundance PMDBM166 102106 Collinsella PMDBD1324 NSAIDs and sulfasalazine therapy Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as JIA therapy response biomarker PMID PMID: 31675176 PMDBI42050 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD611 Ofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25445201" PMDBI42050 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008990004] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42051 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD611 Ofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200" PMDBI42051 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00294464] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42052 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD611 Ofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9360254" PMDBI42052 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001729015] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42053 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42053 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD611 Ofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200; PMID: 9360254" PMDBI42054 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.40E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42054 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD611 Ofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200; PMID: 3471178; PMID: 3182454" PMDBI42055 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.59E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42055 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD611 Ofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200; PMID: 3182454; PMID: 9360254" PMDBI42056 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.77E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42056 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD611 Ofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3182454; PMID: 9360254" PMDBI42057 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.46E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42057 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD611 Ofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200" PMDBI42058 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000185636] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42058 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD611 Ofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200" PMDBI42059 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.73E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42059 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD611 Ofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25445201; PMID: 3134200" PMDBI42060 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000981233] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42060 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD611 Ofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25445201" PMDBI42061 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD494 Loratadine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000221323] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42061 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD611 Ofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200; PMID: 9360254" PMDBI42062 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42062 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD611 Ofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200" PMDBI42063 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006417648] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42063 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD611 Ofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3471178" PMDBI42064 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.08E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42064 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD611 Ofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3471178" PMDBI42065 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.06E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42065 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD611 Ofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 25445201; PMID: 3134200; PMID: 9360254" PMDBI42066 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004788164] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42066 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD611 Ofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3134200" PMDBI42067 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.87E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42067 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD1332 Opiates (opioid) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42068 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.83E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42068 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD1332 Opiates (opioid) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42069 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000451654] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42069 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1332 Opiates (opioid) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42070 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000568494] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42070 Substances alter microbe abundance PMDBM770 186806 Eubacteriaceae PMDBD1332 Opiates (opioid) Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42071 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000253827] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42071 Substances alter microbe abundance PMDBM732 n.a. Dehalobacteriaceae PMDBD1332 Opiates (opioid) Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42072 Substances alter microbe abundance PMDBM131 990719 Christensenellaceae PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42072 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42073 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000468584] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42073 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42074 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000893552] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42074 Substances alter microbe abundance PMDBM263 186803 Lachnospiraceae PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42075 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00147683] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42075 Substances alter microbe abundance PMDBM317 186804 Peptostreptococcaceae PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42076 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.88E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42076 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42077 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004209638] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42077 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42078 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD265 Dicumarol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009617755] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42078 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42079 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005776539] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42079 Substances alter microbe abundance PMDBM2020014 1689 Bifidobacterium dentium PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42080 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.55E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42080 Substances alter microbe abundance PMDBM862 75682 Oxalobacteraceae PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42081 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD25 Alfacalcidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.63E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42081 Substances alter microbe abundance PMDBM770 186806 Eubacteriaceae PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42082 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD858 Toltrazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007164988] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42082 Substances alter microbe abundance PMDBM732 n.a. Dehalobacteriaceae PMDBD1342 Paracetamol Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42083 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD12 Acarbose "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000436959] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42083 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1343 Paromomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26178862" PMDBI42084 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1343 Paromomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26178862" PMDBI42084 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD470 Lacidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00390871] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42085 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1343 Paromomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26178862" PMDBI42085 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD319 Ethacrynic acid "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001641042] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42086 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD185 Chlorpromazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000926722] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42086 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1343 Paromomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26178862" PMDBI42087 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD857 Tolnaftate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007289477] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42087 Substances alter microbe abundance PMDBM232 216851 Faecalibacterium PMDBD1343 Paromomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26178862" PMDBI42088 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD238 Cyclosporin A Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.26E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42088 Substances alter microbe abundance PMDBM798 61170 Holdemania PMDBD1343 Paromomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 26178862" PMDBI42089 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD571 Nalidixic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008240679] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42089 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1349 Pefloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2938072" PMDBI42090 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD633 Oxolinic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.67E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42090 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1349 Pefloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2938072" PMDBI42091 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD197 Cinoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42091 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1349 Pefloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 1597205" PMDBI42092 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1351 Penicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; PMID: 3846592" PMDBI42092 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007239027] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42093 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1351 Penicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382" PMDBI42093 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004608193] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42094 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD842 Thioguanosine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00037355] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42094 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1351 Penicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526" PMDBI42095 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD444 Indatraline hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00684289] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42095 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1351 Penicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI42096 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD384 Gemcitabine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.50E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42096 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1351 Penicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382; PMID: 118526" PMDBI42097 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD145 Carbenoxolone disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.87E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42097 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1351 Penicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382" PMDBI42098 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD328 Etretinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000341198] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42098 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1351 Penicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI42099 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD636 Paclitaxel "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.59E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42099 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1351 Penicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526" PMDBI42100 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD661 Phenindione Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00940513] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42100 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1351 Penicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382" PMDBI42101 Substances alter microbe abundance PMDBM2020099 n.a. Clostridium perfringens PMDBD82 Azacytidine-5 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.19E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42101 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1351 Penicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382" PMDBI42102 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42102 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1351 Penicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526; PMID: 3846592" PMDBI42103 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42103 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1351 Penicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382; PMID: 118526; PMID: 3846592" PMDBI42104 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.80E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42104 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1351 Penicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9181382; PMID: 118526" PMDBI42105 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.56E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42105 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1351 Penicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526" PMDBI42106 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42106 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD1351 Penicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526" PMDBI42107 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42107 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1351 Penicillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 118526" PMDBI42108 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42108 Substances alter microbe abundance PMDBM703 69824 Clostridium cocleatum PMDBD1360 Phenformin Therapeutic Substance Approved Drug 6-week-old mice were fed an HFD for 28 weeks. Metformin (300 mg/kg of body weight) was administered every day during the HFD for 10 weeks. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. PMID PMID: 25038099 PMDBI42109 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1365 Piperacillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI42109 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.84E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42110 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1365 Piperacillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI42110 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.26E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42111 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.61E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42111 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1365 Piperacillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI42112 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.87E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42112 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1365 Piperacillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI42113 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.42E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42113 Substances alter microbe abundance PMDBM814 n.a. Lachnospirum spp. PMDBD1365 Piperacillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI42114 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1368 Pivmecillinam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889" PMDBI42114 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42115 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1368 Pivmecillinam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889" PMDBI42115 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.88E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42116 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42116 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1368 Pivmecillinam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889" PMDBI42117 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42117 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1368 Pivmecillinam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889" PMDBI42118 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.05E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42118 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1368 Pivmecillinam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889" PMDBI42119 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1368 Pivmecillinam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889" PMDBI42119 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.10E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42120 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.28E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42120 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1368 Pivmecillinam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889" PMDBI42121 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000176723] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42121 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1368 Pivmecillinam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889" PMDBI42122 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42122 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1368 Pivmecillinam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889" PMDBI42123 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42123 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1368 Pivmecillinam Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11450889" PMDBI42124 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1371 Polymyxin E Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3378584" PMDBI42124 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.22E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42125 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1371 Polymyxin E Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3378584" PMDBI42125 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42126 Substances alter microbe abundance PMDBM2020047 208479 Clostridium bolteae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42126 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42127 Substances alter microbe abundance PMDBM173 84107 Coriobacteriaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42127 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42128 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42128 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.73E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42129 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42129 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42130 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42130 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42131 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42131 Substances alter microbe abundance PMDBM357 541000 Ruminococcaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42132 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.03E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42132 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42133 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42133 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42134 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42134 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42135 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.06E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42135 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42136 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42136 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42137 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.94E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42137 Substances alter microbe abundance PMDBM618 506 Alcaligenaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42138 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.87E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42138 Substances alter microbe abundance PMDBM872 712 Pasteurellaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42139 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.86E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42139 Substances alter microbe abundance PMDBM790 724 Haemophilus PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42140 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42140 Substances alter microbe abundance PMDBM2020126 729 Haemophilus parainfluenzae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42141 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.57E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42141 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42142 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.43E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42142 Substances alter microbe abundance PMDBM2020184 1305 Streptococcus sanguinis PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42143 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000158672] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42143 Substances alter microbe abundance PMDBM2020183 1309 Streptococcus mutans PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42144 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.90E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42144 Substances alter microbe abundance PMDBM2020179 1328 Streptococcus anginosus PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42145 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42145 Substances alter microbe abundance PMDBM607 1654 Actinomyces PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42146 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.13E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42146 Substances alter microbe abundance PMDBM2020014 1689 Bifidobacterium dentium PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42147 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.91E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42147 Substances alter microbe abundance PMDBM610 2049 Actinomycetaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42148 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.91E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42148 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42149 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.53E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42149 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42150 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.36E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42150 Substances alter microbe abundance PMDBM2020120 39488 Eubacterium hallii PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42151 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.25E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42151 Substances alter microbe abundance PMDBM2020122 39496 Eubacterium ventriosum PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42152 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42152 Substances alter microbe abundance PMDBM758 81852 Enterococcaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42153 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42153 Substances alter microbe abundance PMDBM2020113 88431 Dorea longicatena PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42154 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42154 Substances alter microbe abundance PMDBM2020101 116085 Coprococcus catus PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42155 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42155 Substances alter microbe abundance PMDBM876 186807 Peptococcaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42156 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000215531] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42156 Substances alter microbe abundance PMDBM779 203492 Fusobacteriaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42157 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42157 Substances alter microbe abundance PMDBM732 n.a. Dehalobacteriaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42158 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.63E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42158 Substances alter microbe abundance PMDBM766 n.a. Erysipelotrichaceae noname PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42159 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.53E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42159 Substances alter microbe abundance PMDBM785 n.a. Gemellaceae PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42160 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000217474] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42160 Substances alter microbe abundance PMDBM986 n.a. Veillonella unclassified PMDBD1390 Proton pump inhibitors Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42161 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1396 Quinupristin/dalfopristin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11751777" PMDBI42161 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.01E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42162 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1396 Quinupristin/dalfopristin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11751777" PMDBI42162 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.89E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42163 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1396 Quinupristin/dalfopristin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11751777" PMDBI42163 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003441605] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42164 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.47E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42164 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD1396 Quinupristin/dalfopristin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11751777" PMDBI42165 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD740 Resveratrol Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 31906281 PMDBI42165 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.15E-06] n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI42166 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD740 Resveratrol Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 31906281 PMDBI42166 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002743209] n.a. n.a. n.a. n.a. In vivo Mouse Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI42167 Substances alter microbe abundance PMDBM2020032 1351 Enterococcus faecalis PMDBD740 Resveratrol Therapeutic Substance Approved Drug resveratrol with 200 mg per kg per day n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 24722352; PMID: 31906281" PMDBI42167 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000469876] n.a. n.a. n.a. n.a. In vivo Kunming mice Type 2 diabetes n.a. n.a. PMID PMID: 29555994 PMDBI42168 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42168 Substances alter microbe abundance PMDBM240 n.a. Firmicutes/Bacteroidetes ratio PMDBD740 Resveratrol Therapeutic Substance Approved Drug resveratrol with 200 mg per kg per day n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Kunming mice Type 2 diabetes n.a. n.a. PMID "PMID: 24722352; PMID: 31906281" PMDBI42169 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.82E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42169 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD740 Resveratrol Therapeutic Substance Approved Drug resveratrol with 200 mg per kg per day n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Kunming mice Type 2 diabetes n.a. n.a. PMID "PMID: 24722352; PMID: 31906281" PMDBI42170 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.25E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42170 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD740 Resveratrol Therapeutic Substance Approved Drug resveratrol with 200 mg per kg per day n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Kunming mice Type 2 diabetes n.a. n.a. PMID "PMID: 24722352; PMID: 31906281" PMDBI42171 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.30E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42171 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD740 Resveratrol Therapeutic Substance Approved Drug resveratrol with 200 mg per kg per day n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Kunming mice Type 2 diabetes n.a. n.a. PMID "PMID: 24722352; PMID: 31906281" PMDBI42172 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD747 Rifaximin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181" PMDBI42172 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.84E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42173 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD747 Rifaximin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181" PMDBI42173 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42174 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD747 Rifaximin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181" PMDBI42174 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.61E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42175 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42175 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD747 Rifaximin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181" PMDBI42176 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42176 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD747 Rifaximin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 29307995; PMID: 23565181" PMDBI42177 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42177 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD747 Rifaximin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181" PMDBI42178 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.83E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42178 Substances alter microbe abundance PMDBM328 838 Prevotella PMDBD747 Rifaximin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 29307995; PMID: 23565181" PMDBI42179 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42179 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD747 Rifaximin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181" PMDBI42180 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009455871] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42180 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD747 Rifaximin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 29307995" PMDBI42181 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42181 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD747 Rifaximin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181" PMDBI42182 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42182 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD747 Rifaximin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181" PMDBI42183 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42183 Substances alter microbe abundance PMDBM780 848 Fusobacterium PMDBD747 Rifaximin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 29307995" PMDBI42184 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42184 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD747 Rifaximin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181" PMDBI42185 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000213422] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42185 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD747 Rifaximin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 29307995; PMID: 23565181" PMDBI42186 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001307245] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42186 Substances alter microbe abundance PMDBM814 n.a. Lachnospirum spp. PMDBD747 Rifaximin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 23565181" PMDBI42187 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1404 Ritipenem acoxil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8300248" PMDBI42187 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005301499] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42188 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000964707] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42188 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1404 Ritipenem acoxil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8300248" PMDBI42189 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.53E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42189 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1404 Ritipenem acoxil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8300248" PMDBI42190 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD758 Roxithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2039207" PMDBI42190 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.21E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42191 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD758 Roxithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2039207" PMDBI42191 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42192 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007815455] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42192 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD758 Roxithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2039207" PMDBI42193 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.98E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42193 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD758 Roxithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2039207" PMDBI42194 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1410 Rulfoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7559202; PMID: 8961053" PMDBI42194 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000491757] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42195 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1410 Rulfoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7559202; PMID: 8961053" PMDBI42195 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42196 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0078121] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42196 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1410 Rulfoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7559202" PMDBI42197 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002583972] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42197 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1410 Rulfoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7559202; PMID: 8961053" PMDBI42198 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.58E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42198 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1410 Rulfoxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7559202" PMDBI42199 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1417 Sitafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450" PMDBI42199 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.62E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42200 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1417 Sitafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450" PMDBI42200 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42201 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1417 Sitafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450" PMDBI42201 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42202 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.34E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42202 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1417 Sitafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450" PMDBI42203 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001779948] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42203 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1417 Sitafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450" PMDBI42204 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.86E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42204 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1417 Sitafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450" PMDBI42205 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.66E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42205 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1417 Sitafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450" PMDBI42206 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.34E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42206 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1417 Sitafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450" PMDBI42207 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.90E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42207 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD1417 Sitafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450" PMDBI42208 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.74E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42208 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1417 Sitafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7752450" PMDBI42209 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1419 Solithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 27139483" PMDBI42209 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001023755] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42210 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1419 Solithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 27139483" PMDBI42210 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000102773] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42211 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.87E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42211 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1419 Solithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 27139483" PMDBI42212 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.70E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42212 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1419 Solithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 27139483" PMDBI42213 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.75E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42213 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1419 Solithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 27139483" PMDBI42214 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1419 Solithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 27139483" PMDBI42214 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42215 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1419 Solithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 27139483" PMDBI42215 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000770567] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42216 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00034551] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42216 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1419 Solithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 27139483" PMDBI42217 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD798 Sparfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837" PMDBI42217 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00080865] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42218 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD798 Sparfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837" PMDBI42218 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000533178] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42219 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD798 Sparfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837" PMDBI42219 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000283823] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42220 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001027896] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42220 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD798 Sparfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837" PMDBI42221 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.34E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42221 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD798 Sparfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837" PMDBI42222 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.37E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42222 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD798 Sparfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837" PMDBI42223 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.41E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42223 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD798 Sparfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837" PMDBI42224 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000661483] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42224 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD798 Sparfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837" PMDBI42225 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD371 Folic acid "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017316] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42225 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD798 Sparfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837" PMDBI42226 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD288 Disulfiram Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001296427] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42226 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD798 Sparfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837" PMDBI42227 Substances alter microbe abundance PMDBM203 1547 Erysipelatoclostridium ramosum PMDBD243 Dacarbazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000695859] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42227 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD798 Sparfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837" PMDBI42228 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42228 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD798 Sparfloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8203837" PMDBI42229 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.76E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42229 Substances alter microbe abundance PMDBM173 84107 Coriobacteriaceae PMDBD1423 SSRI antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42230 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.47E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42230 Substances alter microbe abundance PMDBM317 186804 Peptostreptococcaceae PMDBD1423 SSRI antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42231 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42231 Substances alter microbe abundance PMDBM85 31953 Bifidobacteriaceae PMDBD1423 SSRI antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42232 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.02E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42232 Substances alter microbe abundance PMDBM689 31979 Clostridiaceae PMDBD1423 SSRI antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42233 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42233 Substances alter microbe abundance PMDBM871 n.a. Paraprevotellaceae PMDBD1423 SSRI antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42234 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42234 Substances alter microbe abundance PMDBM975 n.a. Turicibacteraceae PMDBD1423 SSRI antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42235 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42235 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.22E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42236 Substances alter microbe abundance PMDBM2020047 208479 Clostridium bolteae PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42236 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42237 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42237 Substances alter microbe abundance PMDBM170 33042 Coprococcus PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42238 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.51E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42238 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42239 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00030367] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42239 Substances alter microbe abundance PMDBM182 189330 Dorea PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42240 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.33E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42240 Substances alter microbe abundance PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42241 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42241 Substances alter microbe abundance PMDBM317 186804 Peptostreptococcaceae PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42242 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.73E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42242 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42243 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.02E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42243 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42244 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.64E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42244 Substances alter microbe abundance PMDBM2020113 88431 Dorea longicatena PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42245 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.82E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42245 Substances alter microbe abundance PMDBM838 n.a. Methanobrevibacter unclassified PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42246 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42246 Substances alter microbe abundance PMDBM878 n.a. Peptostreptococcaceae noname PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42247 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.13E-05] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42247 Substances alter microbe abundance PMDBM879 n.a. Peptostreptococcaceae noname unclassified PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42248 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.32E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42248 Substances alter microbe abundance PMDBM714 n.a. Coprobacillus unclassified PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42249 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42249 Substances alter microbe abundance PMDBM811 n.a. Lachnospiraceae bacterium 2 1 58FAA PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42250 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42250 Substances alter microbe abundance PMDBM812 n.a. Lachnospiraceae bacterium 3 1 57FAA CT1 PMDBD1424 Statins Therapeutic Substance Drug Class n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42251 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42251 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD804 Streptomycin Therapeutic Substance "Approved Drug; Antibiotics" Streptomycin (5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Streptomycin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI42252 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.39E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42252 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD804 Streptomycin Therapeutic Substance "Approved Drug; Antibiotics" Streptomycin (5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Streptomycin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI42253 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42253 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD804 Streptomycin Therapeutic Substance "Approved Drug; Antibiotics" Streptomycin (5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Streptomycin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI42254 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42254 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD804 Streptomycin Therapeutic Substance "Approved Drug; Antibiotics" Streptomycin (5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Streptomycin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI42255 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42255 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD804 Streptomycin Therapeutic Substance "Approved Drug; Antibiotics" Streptomycin (5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Streptomycin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI42256 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42256 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD804 Streptomycin Therapeutic Substance "Approved Drug; Antibiotics" Streptomycin (5 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Streptomycin increased the level of colonization by Clostridium difficile in animalsé–?gut PMID PMID: 26173701 PMDBI42257 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. n.a. Human Juvenile Idiopathic Arthritis (JIA) n.a. Microbiota and JIA susceptibility PMID PMID: 31675176 PMDBI42257 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.35E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42258 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.60E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42258 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1428 Sulphalene Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 333556" PMDBI42259 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.52E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42259 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1429 Sulphasomidine Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 333556" PMDBI42260 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1437 Teicoplanin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064" PMDBI42260 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.53E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42261 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.47E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42261 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1437 Teicoplanin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064" PMDBI42262 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.77E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42262 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1437 Teicoplanin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064" PMDBI42263 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42263 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1437 Teicoplanin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064" PMDBI42264 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1438 Telavancin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 21982049" PMDBI42264 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42265 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1438 Telavancin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 21982049" PMDBI42265 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42266 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.22E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42266 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1438 Telavancin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 21982049" PMDBI42267 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42267 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1438 Telavancin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 21982049" PMDBI42268 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42268 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1438 Telavancin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 21982049" PMDBI42269 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.40E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42269 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1438 Telavancin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 21982049" PMDBI42270 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.77E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42270 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1438 Telavancin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 21982049" PMDBI42271 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005906099] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42271 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1438 Telavancin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 21982049" PMDBI42272 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1440 Telithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI42272 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.49E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42273 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1440 Telithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI42273 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000601093] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42274 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.25E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42274 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1440 Telithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI42275 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00181158] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42275 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1440 Telithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI42276 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.31E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42276 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1440 Telithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI42277 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.17E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42277 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1440 Telithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI42278 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.14E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42278 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1440 Telithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI42279 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42279 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1440 Telithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI42280 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.14E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42280 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1440 Telithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI42281 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42281 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1440 Telithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI42282 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42282 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1440 Telithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI42283 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42283 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1440 Telithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI42284 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42284 Substances alter microbe abundance PMDBM880 1257 Peptostreptococcus PMDBD1440 Telithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI42285 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.06E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42285 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD1440 Telithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI42286 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42286 Substances alter microbe abundance PMDBM982 29465 Veillonella PMDBD1440 Telithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11062193" PMDBI42287 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42287 Substances alter microbe abundance PMDBM239 1239 Firmicutes PMDBD1451 Thiopurines Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vivo Mouse n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42288 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1454 Ticarcillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI42288 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42289 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42289 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1454 Ticarcillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI42290 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.02E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42290 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1454 Ticarcillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI42291 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42291 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1454 Ticarcillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI42292 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42292 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1454 Ticarcillin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 3846592" PMDBI42293 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816" PMDBI42293 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000138652] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42294 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42294 Substances alter microbe abundance PMDBM175 1716 Corynebacterium PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816" PMDBI42295 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42295 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816" PMDBI42296 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003205469] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42296 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816" PMDBI42297 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42297 Substances alter microbe abundance PMDBM216 1730 Eubacterium PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816" PMDBI42298 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.77E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42298 Substances alter microbe abundance PMDBM26 55087 Bacillus PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816" PMDBI42299 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.06E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42299 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816" PMDBI42300 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42300 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816" PMDBI42301 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.79E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42301 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816" PMDBI42302 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.11E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42302 Substances alter microbe abundance PMDBM385 1301 Streptococcus PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816" PMDBI42303 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.78E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42303 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816" PMDBI42304 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42304 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816" PMDBI42305 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.94E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42305 Substances alter microbe abundance PMDBM842 1268 Micrococcaceae PMDBD1455 Ticarcillin/clavulanate Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 2606816" PMDBI42306 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD1457 Tigecycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 24243316; PMID: 17005820" PMDBI42306 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.53E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42307 Substances alter microbe abundance PMDBM141 1485 Clostridium PMDBD1457 Tigecycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 17005820" PMDBI42307 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.42E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42308 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.87E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42308 Substances alter microbe abundance PMDBM191 547 Enterobacter PMDBD1457 Tigecycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 17005820" PMDBI42309 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.15E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42309 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1457 Tigecycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 24243316" PMDBI42310 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00013664] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42310 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1457 Tigecycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 24243316; PMID: 17005820" PMDBI42311 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42311 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1457 Tigecycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 17005820" PMDBI42312 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42312 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1457 Tigecycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 24243316; PMID: 17005820" PMDBI42313 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.79E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42313 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1457 Tigecycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 17005820" PMDBI42314 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42314 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1457 Tigecycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 17005820" PMDBI42315 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42315 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1457 Tigecycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 17005820" PMDBI42316 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.80E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42316 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD1457 Tigecycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 17005820" PMDBI42317 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002397008] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42317 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1457 Tigecycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 24243316; PMID: 17005820" PMDBI42318 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42318 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1457 Tigecycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 17005820" PMDBI42319 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42319 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1477 Tricyclic antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42320 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007296105] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42320 Substances alter microbe abundance PMDBM384 1300 Streptococcaceae PMDBD1477 Tricyclic antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42321 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000117411] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42321 Substances alter microbe abundance PMDBM85 31953 Bifidobacteriaceae PMDBD1477 Tricyclic antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42322 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.78E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42322 Substances alter microbe abundance PMDBM87 1678 Bifidobacterium PMDBD1477 Tricyclic antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42323 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.02E-06] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42323 Substances alter microbe abundance PMDBM816 33958 Lactobacillaceae PMDBD1477 Tricyclic antidepressants Therapeutic Substance Drug Class n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42324 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000100937] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42324 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD877 Trimethoprim Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7247360" PMDBI42325 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42325 Substances alter microbe abundance PMDBM2 469 Acinetobacter PMDBD877 Trimethoprim Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7247360" PMDBI42326 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.02E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42326 Substances alter microbe abundance PMDBM346 286 Pseudomonas PMDBD877 Trimethoprim Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 7247360" PMDBI42327 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.79E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42327 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1480 Trimethoprim/sulfamethoxazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9210003" PMDBI42328 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42328 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1480 Trimethoprim/sulfamethoxazole Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 9210003" PMDBI42329 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000263951] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42329 Substances alter microbe abundance PMDBM194 543 Enterobacteriaceae PMDBD1483 Trovafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764" PMDBI42330 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42330 Substances alter microbe abundance PMDBM196 1350 Enterococcus PMDBD1483 Trovafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764" PMDBI42331 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007412673] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42331 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD1483 Trovafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764" PMDBI42332 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.58E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42332 Substances alter microbe abundance PMDBM255 570 Klebsiella PMDBD1483 Trovafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764" PMDBI42333 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.66E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42333 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD1483 Trovafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764" PMDBI42334 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.46E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42334 Substances alter microbe abundance PMDBM684 544 Citrobacter PMDBD1483 Trovafloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 11158764" PMDBI42335 Substances alter microbe abundance PMDBM112 572511 Blautia PMDBD1485 Ustekinumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42335 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42336 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.98E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42336 Substances alter microbe abundance PMDBM2020035 562 Escherichia coli PMDBD1485 Ustekinumab Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42337 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI42337 Substances alter microbe abundance PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD1485 Ustekinumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42338 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI42338 Substances alter microbe abundance PMDBM353 841 Roseburia PMDBD1485 Ustekinumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42339 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.14E-06] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI42339 Substances alter microbe abundance PMDBM359 1263 Ruminococcus PMDBD1485 Ustekinumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42340 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.84E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42340 Substances alter microbe abundance PMDBM938 620 Shigella PMDBD1485 Ustekinumab Therapeutic Substance Approved Drug n.a. n.a. Decrease n.a. n.a. n.a. n.a. n.a. In vivo Human n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42341 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002742893] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI42341 Substances alter microbe abundance PMDBM2020162 301302 Roseburia faecis PMDBD1485 Ustekinumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42342 Substances alter microbe abundance PMDBM2020046 1496 Clostridium difficile PMDBD888 Vancomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064" PMDBI42342 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000130388] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42343 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003535641] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42343 Substances alter microbe abundance PMDBM208 561 Escherichia PMDBD888 Vancomycin Therapeutic Substance "Approved Drug; Antibiotics" Vancomycin (0.625 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Vancomycin prevented the colonization by Clostridium difficile in animalsé–?gut. PMID PMID: 26173701 PMDBI42344 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001497309] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42344 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD888 Vancomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut No significant change n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064" PMDBI42345 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000631234] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42345 Substances alter microbe abundance PMDBM268 1578 Lactobacillus PMDBD888 Vancomycin Therapeutic Substance "Approved Drug; Antibiotics" Vancomycin (0.625 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Vancomycin prevented the colonization by Clostridium difficile in animalsé–?gut. PMID PMID: 26173701 PMDBI42346 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.41E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42346 Substances alter microbe abundance PMDBM31 816 Bacteroides PMDBD888 Vancomycin Therapeutic Substance "Approved Drug; Antibiotics" Vancomycin (0.625 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Vancomycin prevented the colonization by Clostridium difficile in animalsé–?gut. PMID PMID: 26173701 PMDBI42347 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000110855] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42347 Substances alter microbe abundance PMDBM325 171551 Porphyromonadaceae PMDBD888 Vancomycin Therapeutic Substance "Approved Drug; Antibiotics" Vancomycin (0.625 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Vancomycin prevented the colonization by Clostridium difficile in animalsé–?gut. PMID PMID: 26173701 PMDBI42348 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008553647] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42348 Substances alter microbe abundance PMDBM381 1279 Staphylococcus PMDBD888 Vancomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064" PMDBI42349 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000314737] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42349 Substances alter microbe abundance PMDBM6 239934 Akkermansia PMDBD888 Vancomycin Therapeutic Substance "Approved Drug; Antibiotics" Vancomycin (0.625 mg/ml) was administered in the mouse drinking water for 5 days. Gut Increase n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Vancomycin prevented the colonization by Clostridium difficile in animalsé–?gut. PMID PMID: 26173701 PMDBI42350 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42350 Substances alter microbe abundance PMDBM82 397864 Barnesiella PMDBD888 Vancomycin Therapeutic Substance "Approved Drug; Antibiotics" Vancomycin (0.625 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Vancomycin prevented the colonization by Clostridium difficile in animalsé–?gut. PMID PMID: 26173701 PMDBI42351 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000202747] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42351 Substances alter microbe abundance PMDBM9 239759 Alistipes PMDBD888 Vancomycin Therapeutic Substance "Approved Drug; Antibiotics" Vancomycin (0.625 mg/ml) was administered in the mouse drinking water for 5 days. Gut Decrease n.a. n.a. n.a. n.a. n.a. In vivo C57BL/6 mouse Health n.a. Vancomycin prevented the colonization by Clostridium difficile in animalsé–?gut. PMID PMID: 26173701 PMDBI42352 Substances alter microbe abundance PMDBM2020050 84030 Lacrimispora saccharolytica PMDBD847 Thyroxine (L) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001274877] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42352 Substances alter microbe abundance PMDBM875 n.a. Pedicoccus PMDBD888 Vancomycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "DOI: 10.1016/j.jinf.2019.10.008; PMID: 8627064" PMDBI42353 Substances alter microbe abundance PMDBM120 80840 Burkholderiales PMDBD1487 Vedolizumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42353 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42354 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.79E-07] n.a. n.a. n.a. n.a. n.a. Human Inflammatory bowel disease (IBD) n.a. n.a. PMID PMID: 29555994 PMDBI42354 Substances alter microbe abundance PMDBM2020163 360807 Roseburia inulinivorans PMDBD1487 Vedolizumab Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42355 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. Human n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42355 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD1492 Vitamin D Therapeutic Substance Approved Drug n.a. n.a. Increase n.a. n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32409589 PMDBI42356 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42356 Microbes metabolize substances PMDBM801 n.a. Intestinal microflora PMDBD490 Loperamide Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. loperamide n.a. n.a. Activation of prodrug In vivo "rat; dog" n.a. n.a. n.a. PMID PMID: 7628301 PMDBI42357 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42357 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD618 Olsalazine Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. n.a. n.a. n.a. Activation of prodrug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 32652007; PMID: 25091594; PMID: 32466672" PMDBI42358 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD812 Sulfasalazine Therapeutic Substance "Approved Drug; Prodrug" Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. "sulfapyridine; 5-aminosalicylate" Azo bond reduction azoreductase and nitroreductase Activation of prodrug In vitro Human Health n.a. n.a. PMID "PMID: 30158249; PMID: 8565901; PMID: 25091594" PMDBI42358 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.92E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42359 Microbes metabolize substances PMDBM141 1485 Clostridium PMDBD812 Sulfasalazine Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. "sulfapyridine; 5-aminosalicylate" Azo bond reduction azoreductase Activation of prodrug n.a. Human Inflammatory bowel disease (IBD) n.a. Sulfasalazine is prodrug converted to the active agent 2-ASA by gut microbes PMID PMID: 31675176 PMDBI42359 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42360 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42360 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD812 Sulfasalazine Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. "sulfapyridine; 5-aminosalicylate" Azo bond reduction azoreductase Activation of prodrug In vitro n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes PMID PMID: 31675176 PMDBI42361 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.25E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42361 Microbes metabolize substances PMDBM216 1730 Eubacterium PMDBD812 Sulfasalazine Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. "sulfapyridine; 5-aminosalicylate" Azo bond reduction azoreductase Activation of prodrug In vitro n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 4-ASA by gut microbes PMID PMID: 31675176 PMDBI42362 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42362 Microbes metabolize substances PMDBM328 838 Prevotella PMDBD812 Sulfasalazine Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. "sulfapyridine; 5-aminosalicylate" Azo bond reduction azoreductase Activation of prodrug In vitro n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes PMID PMID: 31675176 PMDBI42363 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42363 Microbes metabolize substances PMDBM2020247 33038 Ruminococcus gnavus PMDBD812 Sulfasalazine Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. "sulfapyridine; 5-aminosalicylate" Azo bond reduction azoreductase Activation of prodrug In vitro n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 3-ASA by gut microbes PMID PMID: 31675176 PMDBI42364 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42364 Microbes metabolize substances PMDBM371 90371 Salmonella typhimurium PMDBD812 Sulfasalazine Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. "sulfapyridine; 5-aminosalicylate" Azo bond reduction azoreductase Activation of prodrug In vitro n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes PMID PMID: 31675176 PMDBI42365 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42365 Microbes metabolize substances PMDBM9 239759 Alistipes PMDBD812 Sulfasalazine Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. "sulfapyridine; 5-aminosalicylate" Azo bond reduction azoreductase Activation of prodrug In vitro n.a. n.a. n.a. Sulfasalazine is prodrug converted to the active agent 5-ASA by gut microbes PMID PMID: 31675176 PMDBI42366 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42366 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD96 Balsalazide Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. n.a. n.a. n.a. Activation of prodrug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 32652007; PMID: 25091594; PMID: 32466672" PMDBI42367 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42367 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD636 Paclitaxel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vivo Caenorhabditis elegans n.a. n.a. developmental delay PMID "PMID: 30890566; PMID: 28431244" PMDBI42368 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42368 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD636 Paclitaxel Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vivo Caenorhabditis elegans n.a. n.a. developmental delay PMID "PMID: 30890566; PMID: 28431244" PMDBI42369 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42369 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-fluorouridine monophospate Phosphorylation Uracil phosphoribosyltransferase Increase activity In vivo Caenorhabditis elegans n.a. n.a. Lead to sterility PMID "PMID: 30890566; PMID: 28431244" PMDBI42370 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42370 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. 5-fluorouridine monophospate Phosphorylation Uracil phosphoribosyltransferase Increase activity In vivo Caenorhabditis elegans n.a. n.a. Lead to sterility PMID "PMID: 30890566; PMID: 28431244" PMDBI42371 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42371 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1005 5-fluoro-2'-deoxyuridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vivo Caenorhabditis elegans n.a. n.a. completely sterile PMID "PMID: 30890566; PMID: 28431244" PMDBI42372 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42372 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1072 Camptothecin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vivo Caenorhabditis elegans n.a. n.a. production of few dead embryos PMID "PMID: 30890566; PMID: 28431244" PMDBI42373 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42373 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD1072 Camptothecin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vivo Caenorhabditis elegans n.a. n.a. production of few dead embryos PMID "PMID: 30890566; PMID: 28431244" PMDBI42374 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.79E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42374 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD141 Capecitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42375 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.80E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42375 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD141 Capecitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42376 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42376 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD200 Cladribine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42377 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42377 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD200 Cladribine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42378 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42378 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42379 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.85E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42379 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD327 Etoposide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42380 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42380 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD327 Etoposide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42381 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42381 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD384 Gemcitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42382 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.80E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42382 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD384 Gemcitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42383 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42383 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD455 Irinotecan Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42384 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42384 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD455 Irinotecan Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42385 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42385 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42386 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42386 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42387 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42387 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1006 5-fluorocytosine Therapeutic Substance "Approved Drug; Prodrug" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vitro n.a. n.a. n.a. Increase chemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42388 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.78E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42388 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD1006 5-fluorocytosine Therapeutic Substance "Approved Drug; Prodrug" n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42389 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.63E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42389 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1008 6-Mercaptopurine-2é–?deoxyriboside Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vitro n.a. n.a. n.a. Increase hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42390 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42390 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1015 Actinomycin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42391 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42391 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1038 AQ4N Therapeutic Substance "Approved Drug; Prodrug" n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vitro n.a. n.a. n.a. Increase cemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42392 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42392 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1039 Ara G hydrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42393 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42393 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD1039 Ara G hydrate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42394 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42394 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1082 CB1954 Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vitro n.a. n.a. n.a. Increase hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42395 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42395 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD1082 CB1954 Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vitro n.a. n.a. n.a. Increase hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42396 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42396 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1124 Clofarabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42397 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.71E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42397 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD1124 Clofarabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42398 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.82E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42398 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1136 Cytarabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42399 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42399 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD1136 Cytarabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42400 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42400 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1142 Daunorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42401 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42401 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD1142 Daunorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42402 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42402 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1182 Estramustine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42403 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42403 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1198 Fludarabine de phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vitro n.a. n.a. n.a. Increase hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42404 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.25E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42404 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD1198 Fludarabine de phosphate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vitro n.a. n.a. n.a. Increase hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42405 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42405 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1232 Idarubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42406 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42406 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1275 Menadione Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42407 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42407 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1299 Mitomycin C Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42408 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42408 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1300 Mitoxantrone Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42409 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42409 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1314 Nelarabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42410 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.80E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42410 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD1314 Nelarabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42411 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42411 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1354 Pentostatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42412 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.80E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42412 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD1354 Pentostatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42413 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42413 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1425 Streptonegrin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42414 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.37E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42414 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1436 Tegafur Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Increase activity In vitro n.a. n.a. n.a. Increase hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42415 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42415 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD1436 Tegafur Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42416 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.86E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42416 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1486 Valacyclovir Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42417 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42417 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1489 Vidarabine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42418 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.81E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42418 Microbes metabolize substances PMDBM2020066 1643 Listeria welshimeri PMDBD1489 Vidarabine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42419 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00692846] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42419 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1490 Vinblastine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. No change of activity In vitro n.a. n.a. n.a. n.a. PMID "PMID: 26416623; PMID: 30890566" PMDBI42420 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42420 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1498 é“?Lapachone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Decrease hemotherapeutic drug cytotoxicity in vitro. PMID "PMID: 26416623; PMID: 30890566" PMDBI42421 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42421 Microbes metabolize substances PMDBM2020213 84112 Eggerthella lenta PMDBD276 Digoxin Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. dihydrodigoxin Reduction Cardiac glycoside reductase "Reduce bioavailability; Decrease activity" In vivo Mouse n.a. n.a. Digoxin is converted to the inactive metabolite dihydrodigoxin by Eggerthella lenta, limiting the amount of active drug that is absorbed into the systemic circulation. PMID PMID: 23869020 PMDBI42422 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42422 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug inactivation In vivo Mouse n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42423 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42423 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD124 Bromazepam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. Nitro reduction Nitroreductase Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566 PMDBI42424 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42424 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD136 Caffeic acid Therapeutic Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. Reduction and dehydoxylation n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566 PMDBI42425 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42425 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD189 Choline Therapeutic Substance Dietary Compounds n.a. n.a. n.a. n.a. Trimethylamine C-N bond cleavage elimination/oxidation Glycyl radical enzymes Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO PMID PMID: 30890566 PMDBI42426 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42426 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. 7-aminoclonazapam Nitro reduction Nitroreductase Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566 PMDBI42427 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42427 Microbes metabolize substances PMDBM2020076 626932 Alistipes indistinctus PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42428 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42428 Microbes metabolize substances PMDBM2020002 446660 Adlercreutzia equolifaciens PMDBD245 Daidzin Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. "daidzein; equol" n.a. Bacterial ç?glucosidases Metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 30890566; PMID: 12468591" PMDBI42429 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.37E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42429 Microbes metabolize substances PMDBM941 n.a. Slackia spp. PMDBD245 Daidzin Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. "daidzein; equol" n.a. Bacterial ç?glucosidases Metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 30890566; PMID: 12468591" PMDBI42430 Microbes metabolize substances PMDBM2020047 208479 Clostridium bolteae PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Microbiota species involved in ALL chemotherapeutics metabolism PMID PMID: 31675176 PMDBI42430 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42431 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42431 Microbes metabolize substances PMDBM2020008 817 Bacteroides fragilis PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42432 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000164863] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42432 Microbes metabolize substances PMDBM2020036 78346 Bifidobacterium ruminantium PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42433 Microbes metabolize substances PMDBM2020202 29347 Clostridium scindens PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. Dexamethasone side chain cleavage n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Microbiota species involved in ALL chemotherapeutics metabolism PMID PMID: 31675176 PMDBI42433 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000138066] n.a. n.a. n.a. n.a. In vitro n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42434 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.79E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42434 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD263 Diclofenac Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Glucuronide hydrolysis Bacterial ç?glucuronidases Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566 PMDBI42435 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42435 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug inactivation In vivo Mouse n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42436 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42436 Microbes metabolize substances PMDBM211 679895 Escherichia coli BW25113 PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. "7-deoxydoxorubicinol; 7-deoxydoxorubicinolone" n.a. n.a. Reduced toxicity In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 30890566; PMID: 29160065" PMDBI42437 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42437 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumoniae PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 30890566; PMID: 29160065" PMDBI42438 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42438 Microbes metabolize substances PMDBM2020186 575 Raoultella planticola PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug inactivation In vivo Mouse n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42439 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.72E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42439 Microbes metabolize substances PMDBM2020186 575 Raoultella planticola PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. "7-deoxydoxorubicinol; 7-deoxydoxorubicinolone" reductive deglycosylation n.a. reduced toxicity In vitro High-throughput incubation assays n.a. n.a. For cancer patients, inactivation of doxorubicin by gut microbes could result in a decrease in active doxorubicin levels, potentially altering the efficacy of chemotherapeutic treatment and the severity of side effects. PMID "PMID: 30890566; PMID: 29160065" PMDBI42440 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42440 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD384 Gemcitabine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug inactivation In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42441 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000977135] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42441 Microbes metabolize substances PMDBM2020007 28111 Bacteroides eggerthii PMDBD439 Imatinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42442 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42442 Microbes metabolize substances PMDBM2020268 821 Bacteroides vulgatus PMDBD439 Imatinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42443 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42443 Microbes metabolize substances PMDBM2020083 46506 Bacteroides stercoris PMDBD439 Imatinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42444 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42444 Microbes metabolize substances PMDBM2020144 387661 Parabacteroides johnsonii PMDBD439 Imatinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug activation In vitro n.a. n.a. n.a. Microbiota as ALL chemotherapy response biomarker PMID PMID: 31675176 PMDBI42445 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42445 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Glucuronide hydrolysis Bacterial ç?glucuronidases Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566 PMDBI42446 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.78E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42446 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD453 Ipsalazide Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32466672 PMDBI42447 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42447 Microbes metabolize substances PMDBM2020213 84112 Eggerthella lenta PMDBD476 Levodopa Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. m-tyramine n.a. molybdenum-dependent dehydroxylase "Decreases bioavailability; Increase toxicity" In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 31196984; PMID: 32409589" PMDBI42448 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.05E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42448 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD476 Levodopa Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. dopamine decarboxylation Gut bacterial tyrosine decarboxylases Decreases bioavailability In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 31196984; PMID: 30659181; PMID: 32409589" PMDBI42449 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.44E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42449 Microbes metabolize substances PMDBM2020033 1352 Enterococcus faecium PMDBD476 Levodopa Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. dopamine decarboxylation Gut bacterial tyrosine decarboxylases Decreases bioavailability In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 31196984; PMID: 30659181; PMID: 32409589" PMDBI42450 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000426771] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42450 Microbes metabolize substances PMDBM284 n.a. Lactobacillus spp. PMDBD476 Levodopa Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. dopamine decarboxylation Gut bacterial tyrosine decarboxylases Decreases bioavailability In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 32409589; PMID: 30659181; PMID: 32409589" PMDBI42451 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42451 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD496 Lovastatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Hydroxylation n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 30890566; PMID: 24947972" PMDBI42452 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42452 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32652007 PMDBI42453 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42453 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD595 Nitrazepam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. 7-amino-nitrazepam Nitro reduction Nitroreductase Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Nitrazepam is metabolized into 7-aminonitrazepam, which undergoes host hepatic metabolism into a teratogen PMID PMID: 30890566 PMDBI42454 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42454 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD602 Nizatidine Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. nitroso-deoxygenated metabolite n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42455 Microbes metabolize substances PMDBM103 1682 Bifidobacterium longum subsp. Infantis PMDBD740 Resveratrol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. piceid n.a. n.a. Does not change activity n.a. n.a. n.a. n.a. n.a. PMID "PMID: 9784180; PMID: 27497981; PMID: 31906281" PMDBI42455 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42456 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0001689] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42456 Microbes metabolize substances PMDBM2020119 1579 Lactobacillus acidophilus PMDBD740 Resveratrol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. piceid n.a. n.a. Does not change activity In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 9784180; PMID: 27497981; PMID: 31906281" PMDBI42457 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42457 Microbes metabolize substances PMDBM639 1396 Bacillus cereus PMDBD740 Resveratrol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. piceid n.a. n.a. Does not change activity In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 9784180; PMID: 27497981; PMID: 31906281" PMDBI42458 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42458 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD750 Risperidone Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. ketone n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42459 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004132065] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42459 Microbes metabolize substances PMDBM757 543 Enterobacteriaceae PMDBD788 Sorivudine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. (e)-5-(2-bromovinyl) uracil n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 31885474 PMDBI42460 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42460 Microbes metabolize substances PMDBM650 n.a. Bacteroidetes sp. PMDBD788 Sorivudine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. (e)-5-(2-bromovinyl) uracil n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 31885474 PMDBI42461 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.32E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42461 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD788 Sorivudine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. Hydrolysis Phosphorylysases Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Reduction and dehydoxylation Bromovinyluracil produced is metablized by the host to an inhibitor of host dihydropyrimidine dehydrogenase, leading to increased concentrations of 5-FU (anticancer drug) PMID PMID: 30890566 PMDBI42462 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42462 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD813 Sulfinpyrazone Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. n.a. sulfoxide reduction n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42463 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42463 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD816 Sulindac Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. deoxysulindac sulfoxide reduction n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42464 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42464 Microbes metabolize substances PMDBM2020088 853 Faecalibacterium prausnitzii PMDBD821 Tacrolimus Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. M1 n.a. n.a. Decrease activity In vitro n.a. n.a. n.a. Faecalibacterium prausnitzii metabolizes tacrolimus into less potent metabolites M1, which is 15-fold less potent than tacrolimus as an immunosuppressant. PMID PMID: 30598508 PMDBI42465 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.14E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42465 Microbes metabolize substances PMDBM800 n.a. Indole-producing bacteria PMDBD880 Tryptophan Dietary Substance Dietary Compounds n.a. Gut n.a. n.a. indole Deamination Tryptophanase Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Production of indole, which may have a role as an interspecies and interkingdom signaling molecule PMID "PMID: 30890566; PMID: 26439294" PMDBI42466 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42466 Microbes metabolize substances PMDBM801 n.a. Intestinal microflora PMDBD1006 5-fluorocytosine Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. 5-fluorouracil deamination n.a. Increase toxicity In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 3729334 PMDBI42467 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42467 Microbes metabolize substances PMDBM299 2093 Mycoplasma PMDBD1007 5-fluorodeoxyuridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug inactivation In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42468 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42468 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1026 Amino acids Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. Peptide bond formation Peptide synthetase Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Dipeiptide aldehyde produced can inhibit human cathepsins L PMID "PMID: 30890566; PMID: 28111075" PMDBI42469 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.49E-06] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42469 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1058 Bile acids Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. Deconjugation Bile salt hydrolyase Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 30890566; PMID: 25483337" PMDBI42470 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42470 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1081 Carnitine Therapeutic Substance Dietary Compounds n.a. n.a. n.a. n.a. Trimethylamine Oxidation/Reduction Carnitine oxygenase Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Production of TMA, associated with atherosclerosis and cardiovascular disease following host production of TMAO PMID PMID: 30890566 PMDBI42471 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42471 Microbes metabolize substances PMDBM2020082 357276 Bacteroides dorei PMDBD1129 Corticosteroids Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42472 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42472 Microbes metabolize substances PMDBM2020002 446660 Adlercreutzia equolifaciens PMDBD1214 Genistin Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. genistein n.a. Bacterial ç?glucosidases Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 30890566; PMID: 12468591" PMDBI42473 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42473 Microbes metabolize substances PMDBM941 n.a. Slackia spp. PMDBD1214 Genistin Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. genistein n.a. Bacterial ç?glucosidases Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 30890566; PMID: 12468591" PMDBI42474 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.27E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42474 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1216 Glucocorticoids Therapeutic Substance Drug Class n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32652007 PMDBI42475 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42475 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1237 Indigestible polysaccharides Therapeutic Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. Fermentation "Saccharolytic pathways; butyryl-CoA:acetate CoA transferase" Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30890566 PMDBI42476 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001404915] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42476 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1263 L-tyrosine Therapeutic Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. Removal of carboxyl group Decarboxylase Drug metabolism In vitro High-throughput incubation assays n.a. n.a. Bacterial production of p-cresol, which is sulfated by the host. P-cresol competes with acetaminophen for sulfation. PMID PMID: 30890566 PMDBI42477 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42477 Microbes metabolize substances PMDBM2020100 573 Klebsiella pneumonia PMDBD1273 Melamine Dietary Substance "Dietary Compounds; Industrial Compounds" Melamine was administered orally to rats at a daily dose of 600 mg/kg for 15 days. n.a. n.a. n.a. cyanuric acid Hydrolysis n.a. Increase toxicity In vivo Rat Health n.a. Conversion to cyanuric acid, which cocrystallizes with melamine in kidneys and leads to renal toxicity. PMID "PMID: 30890566; PMID: 23408055" PMDBI42478 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42478 Microbes metabolize substances PMDBM2020062 577 Klebsiella terrigena PMDBD1273 Melamine Dietary Substance "Dietary Compounds; Industrial Compounds" Melamine was administered orally to rats at a daily dose of 600 mg/kg for 15 days. n.a. n.a. n.a. cyanuric acid Hydrolysis n.a. Increase toxicity In vivo Rat Health n.a. Conversion to cyanuric acid, which cocrystallizes with melamine in kidneys and leads to renal toxicity. PMID "PMID: 30890566; PMID: 23408055" PMDBI42479 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.80E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42479 Microbes metabolize substances PMDBM2020129 575 Klebsiella planticola PMDBD1273 Melamine Dietary Substance "Dietary Compounds; Industrial Compounds" Melamine was administered orally to rats at a daily dose of 600 mg/kg for 15 days. n.a. n.a. n.a. cyanuric acid Hydrolysis n.a. Increase toxicity In vivo Rat Health n.a. Conversion to cyanuric acid, which cocrystallizes with melamine in kidneys and leads to renal toxicity. PMID "PMID: 30890566; PMID: 23408055" PMDBI42480 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42480 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1280 Mesalazines Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32652007 PMDBI42481 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003379116] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42481 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1327 Oleic acid Dietary Substance Dietary Compounds n.a. n.a. n.a. n.a. n.a. Acylation N-acyl synthase Metabolism In vitro High-throughput incubation assays n.a. n.a. Products are able to modulate GPCRs PMID "PMID: 30890566; PMID: 25483337" PMDBI42482 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. n.a. n.a. Acute lymphocytic leukemia (ALL) n.a. n.a. PMID PMID: 29555994 PMDBI42482 Microbes metabolize substances PMDBM337 1224 Proteobacteria PMDBD1369 Polychemotherapy Therapeutic Substance Drug Class n.a. Gut n.a. n.a. n.a. n.a. n.a. Increased chemotherapy induced HEM toxicity In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42483 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42483 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1450 Thioguanine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32652007 PMDBI42484 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000275271] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42484 Microbes metabolize substances PMDBM2020032 1351 Enterococcus faecalis PMDBD1451 Thiopurines Therapeutic Substance Drug Class n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug activation In vitro n.a. n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42485 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD494 Loratadine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000295286] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42485 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1451 Thiopurines Therapeutic Substance Drug Class n.a. n.a. n.a. n.a. n.a. n.a. n.a. Drug activation In vitro n.a. n.a. n.a. n.a. PMID PMID: 31675176 PMDBI42486 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42486 Microbes metabolize substances PMDBM2020009 818 Bacteroides thetaiotaomicron PMDBD1451 Thiopurines Therapeutic Substance Drug Class n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug activation In vitro n.a. n.a. n.a. Microbiota as IBD therapy response biomarker PMID PMID: 31675176 PMDBI42487 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42487 Microbes metabolize substances PMDBM2020070 498718 Slackia equolifaciens PMDBD1470 Trans-resveratrol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. dihydroresveratrol n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 23283496; PMID: 31906281" PMDBI42488 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001027457] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42488 Microbes metabolize substances PMDBM2020002 446660 Adlercreutzia equolifaciens PMDBD1470 Trans-resveratrol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. dihydroresveratrol n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 23283496; PMID: 31906281" PMDBI42489 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.98E-05] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42489 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1470 Trans-resveratrol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. 3,4'-dihydroxy-trans-stilbene n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 23283496; PMID: 31906281" PMDBI42490 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001915979] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42490 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1470 Trans-resveratrol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. 3,4'-dihydroxybibenzyl n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 23283496; PMID: 31906281" PMDBI42491 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002315632] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42491 Microbes metabolize substances PMDBM203 1547 Clostridium ramosum PMDBD455 Irinotecan Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. SN-38 Glucuronide hydrolysis Bacterial ç?glucuronidases "Metabolize prodrug to active form; Increase toxicity" In vitro High-throughput incubation assays n.a. n.a. Irinotecan is converted to SN-38-G by the host and converted back into cytotoxic SN-38 in intestine by bacterial ç?glucuronidases, thereby provoking epithelial cell damage, increasing diarrhea and impairing treatment efficacy. PMID "PMID: 21789126; PMID: 21051639" PMDBI42492 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002376626] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42492 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD455 Irinotecan Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. SN-38 Glucuronide hydrolysis Bacterial ç?glucuronidases "Metabolize prodrug to active form; Increase toxicity" In vitro High-throughput incubation assays n.a. n.a. Irinotecan is converted to SN-38-G by the host and converted back into cytotoxic SN-38 in intestine by bacterial ç?glucuronidases, thereby provoking epithelial cell damage, increasing diarrhea and impairing treatment efficacy. PMID "PMID: 21789126; PMID: 21051639" PMDBI42493 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42493 Microbes metabolize substances PMDBM2020268 821 Bacteroides vulgatus PMDBD455 Irinotecan Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. SN-38 Glucuronide hydrolysis Bacterial ç?glucuronidases "Metabolize prodrug to active form; Increase toxicity" In vitro High-throughput incubation assays n.a. n.a. Irinotecan is converted to SN-38-G by the host and converted back into cytotoxic SN-38 in intestine by bacterial ç?glucuronidases, thereby provoking epithelial cell damage, increasing diarrhea and impairing treatment efficacy. PMID "PMID: 21789126; PMID: 21051639" PMDBI42494 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42494 Microbes metabolize substances PMDBM653 n.a. Beta-glucuronidase encoding species PMDBD455 Irinotecan Therapeutic Substance "Approved Drug; Prodrug" n.a. Gut n.a. n.a. SN-38 Glucuronide hydrolysis Bacterial ç?glucuronidases "Metabolize prodrug to active form; Increase toxicity" In vitro High-throughput incubation assays n.a. n.a. Irinotecan is converted to SN-38-G by the host and converted back into cytotoxic SN-38 in intestine by bacterial ç?glucuronidases, thereby provoking epithelial cell damage, increasing diarrhea and impairing treatment efficacy. PMID "PMID: 21789126; PMID: 21051639" PMDBI42495 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002306283] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42495 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD10 Abacavir Sulfate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42496 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009152734] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42496 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD112 Bicalutamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42497 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003241472] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42497 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD115 Biperiden Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42498 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001134983] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42498 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD122 Bosentan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42499 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD172 Cephalosporanic acid, 7-amino Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.43E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42499 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD128 Budesonide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42500 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008783433] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42500 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD130 Bupropion Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42501 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD186 Chlorprothixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006089512] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42501 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42502 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD516 Meclozine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.51E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42502 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD16 Acetaminophen Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42503 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD85 Azathioprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00322275] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42503 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD175 Cetirizine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42504 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD917 Zuclopenthixol dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004949573] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42504 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD194 Cimetidine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42505 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD62 Apramycin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.84E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42505 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42506 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD132 Butenafine Hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.15E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42506 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD215 Clonidine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42507 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD182 Chlorotrianisene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000149994] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42507 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD22 Albendazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42508 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD712 Propidium iodide Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001348701] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42508 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD223 Colchicine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42509 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD523 Mercaptopurine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002094487] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42509 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD234 Cyclobenzaprine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42510 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD705 Proadifen hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004225595] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42510 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD237 Cyclophosphamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42511 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD74 Asenapine maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006518934] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42511 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD249 Dasatinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42512 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD200 Cladribine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.80E-07] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42512 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD26 Alfuzosin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42513 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD196 Cinnarizine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001760582] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42513 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD263 Diclofenac Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42514 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD591 Nilutamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001197623] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42514 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD266 Dicyclomine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42515 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD743 Ribostamycin sulfate salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002052349] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42515 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD276 Digoxin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42516 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD436 Ibutilide fumarate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005740186] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42516 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD286 Dipyridamole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42517 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD703 Prilocaine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000109489] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42517 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD293 Drospirenone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42518 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD276 Digoxin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006949505] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42518 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42519 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD317 Estropipate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009514871] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42519 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD30 Altretamine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42520 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD416 Guanadrel sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008720694] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42520 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD313 Erlotinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42521 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD593 Nimodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009606651] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42521 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD317 Estropipate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42522 Substances alter microbe abundance PMDBM2020206 74426 Collinsella aerofaciens PMDBD38 Amiprilose hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004929581] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42522 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD318 Eszopiclone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42523 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42523 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD32 Amantadine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42524 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.11E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42524 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD324 Etodolac Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42525 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.80E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42525 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD327 Etoposide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42526 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42526 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD329 Ezetimibe Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42527 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42527 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD332 Famotidine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42528 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42528 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD334 Febuxostat Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42529 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.69E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42529 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42530 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42530 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD352 Finasteride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42531 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42531 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD357 Fluconazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42532 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.88E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42532 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD367 Fluphenazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42533 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42533 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD377 Galantamine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42534 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.04E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42534 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42535 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42535 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD382 Gefitinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42536 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.11E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42536 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD39 Amlodipine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42537 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.78E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42537 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD400 Glipizide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42538 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42538 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD41 Amoxapine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42539 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42539 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD415 Griseofulvin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42540 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.76E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42540 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD418 Haloperidol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42541 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42541 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD439 Imatinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42542 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42542 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD446 Indomethacin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42543 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42543 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD45 Anagrelide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42544 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42544 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD454 Irbesartan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42545 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42545 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD46 Anastrozole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42546 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42546 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD463 Itraconazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42547 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42547 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD467 Ketoconazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42548 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42548 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD468 Ketoprofen Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42549 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42549 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD472 Lansoprazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42550 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42550 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD473 Leflunomide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42551 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.16E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42551 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD477 Levonorgestrel Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42552 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.28E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42552 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42553 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42553 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD490 Loperamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42554 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42554 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD494 Loratadine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42555 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42555 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD496 Lovastatin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42556 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42556 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD511 Mebendazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42557 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.77E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42557 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD517 Mefloquine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42558 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42558 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD521 Memantine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42559 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.11E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42559 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD528 Metaxalone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42560 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.76E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42560 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD530 Metformin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42561 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42561 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD537 Methoxsalen Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42562 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42562 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42563 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42563 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42564 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42564 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD554 Mitotane Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42565 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42565 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42566 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.13E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42566 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42567 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42567 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD576 Nateglinide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42568 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.13E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42568 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD582 Nevirapine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42569 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42569 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD602 Nizatidine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42570 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.18E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42570 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD611 Ofloxacin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42571 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.56E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42571 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD614 Olanzapine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42572 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42572 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42573 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42573 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42574 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42574 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD629 Oxcarbazepine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42575 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.88E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42575 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42576 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.95E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42576 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD642 Paroxetine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42577 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42577 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD655 Perphenazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42578 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42578 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42579 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42579 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD674 Pioglitazone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42580 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.10E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42580 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD69 Aripiprazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42581 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42581 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42582 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42582 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD721 Quinapril Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42583 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42583 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD729 Ramelteon Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42584 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.84E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42584 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD730 Ramipril Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42585 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42585 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD738 Repaglinide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42586 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.66E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42586 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD739 Reserpine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42587 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42587 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42588 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.66E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42588 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42589 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42589 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD748 Riluzole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42590 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42590 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD751 Ritonavir Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42591 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42591 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD779 Sertraline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42592 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42592 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD783 Simvastatin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42593 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42593 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD789 Sotalol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42594 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.67E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42594 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD79 Atovaquone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42595 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42595 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD808 Sulfadiazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42596 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42596 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD822 Tadalafil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42597 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42597 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42598 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42598 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD855 Tolazamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42599 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42599 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD863 Trandolapril Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42600 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42600 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD873 Trihexyphenidyl Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42601 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.73E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42601 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42602 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.13E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42602 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42603 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42603 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD890 Vardenafil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42604 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42604 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD893 Verapamil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42605 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42605 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD899 Voriconazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42606 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42606 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD900 Warfarin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42607 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42607 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42608 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42608 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD908 Zaleplon Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42609 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42609 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD910 Zileuton Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42610 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42610 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD98 Benazepril Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42611 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42611 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1000 4-Aminosalicylic Acid Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42612 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42612 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1010 Acebutolol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42613 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42613 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1012 Acetohexamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42614 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.10E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42614 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1013 Acitretin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42615 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42615 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1014 Acrivastine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42616 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42616 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1016 Acyclovir Zovirax Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42617 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42617 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1018 Adefovir Dipivoxil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42618 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004056104] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42618 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1022 Alosetron Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42619 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000849895] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42619 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1024 Ambrisentan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42620 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42620 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1025 Amiloride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42621 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.56E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42621 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1027 Aminophylline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42622 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42622 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1028 Amitriptyline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42623 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.76E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42623 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1037 Apomorphine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42624 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42624 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1042 Artemether Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42625 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42625 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD74 Asenapine Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42626 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005069808] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42626 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1044 Aspirin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42627 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42627 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1045 Atazanavir Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42628 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42628 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1046 Atorvastatin Calcium Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42629 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42629 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1053 Benztropine Mesylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42630 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007454688] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42630 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1057 Bexarotene Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42631 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000759868] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42631 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1059 Bisoprolol Fumarate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42632 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42632 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD125 Bromocriptine Mesylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42633 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002866397] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42633 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1063 Brompheniramine Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42634 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42634 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1064 Bumetanide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42635 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.77E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42635 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1065 Buspirone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42636 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42636 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1066 Butorphanol-(+)-Tartrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42637 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42637 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1067 Cabergoline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42638 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42638 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1069 Caffeine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42639 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.74E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42639 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1070 Calcitriol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42640 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000417653] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42640 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1073 Candesartan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42641 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00343082] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42641 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1075 Carbamazepine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42642 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42642 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1077 Carbidopa Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42643 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.66E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42643 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1078 Carbinoxamine Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42644 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42644 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1084 Cefditoren Pivoxil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42645 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42645 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1090 Cefpodoxime Proxetil Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42646 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00052388] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42646 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1106 Chloroquine Diphosphate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42647 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000769478] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42647 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1108 Chlorothiazide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42648 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002624633] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42648 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD184 Chlorpheniramine Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42649 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.19E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42649 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1110 Chlorpropamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42650 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42650 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1112 Chlorthalidone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42651 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004828422] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42651 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1113 Chlorzoxazone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42652 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42652 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1116 Cilostazol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42653 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000165081] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42653 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1117 Cinacalcet Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42654 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001136075] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42654 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1118 Ciprofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42655 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000283328] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42655 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1120 Citalopram Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42656 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.25E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42656 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42657 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42657 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1122 Clindamycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42658 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD494 Loratadine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000241584] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42658 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1123 Clobazam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42659 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42659 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1125 Clomiphene Citrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42660 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42660 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1126 Clomipramine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42661 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008944881] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42661 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1127 Clopidogrel Hydrogen Sulfate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42662 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000296205] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42662 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1128 Clozapine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42663 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42663 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1131 Cromolyn Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42664 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003892562] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42664 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1134 Cyclosporine A Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42665 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42665 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1135 Cyproheptadine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42666 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00112447] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42666 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1139 Dapsone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42667 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003489629] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42667 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1140 Darifenacin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42668 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000110866] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42668 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1141 Darunavir Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42669 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006347589] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42669 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1143 Deferasirox Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42670 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000493545] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42670 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1144 Delavirdine Mesylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42671 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000199681] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42671 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1145 Demeclocycline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42672 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004739732] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42672 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1148 Desipramine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42673 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005017795] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42673 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1149 Desloratadine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42674 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000207101] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42674 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1150 Desvenlafaxine Succinate Hydrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42675 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.04E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42675 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1151 Dexchlorpheniramine Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42676 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.70E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42676 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1152 Dextromethorphan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42677 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009519216] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42677 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1154 Diazepam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42678 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000234948] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42678 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1156 Diazoxide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42679 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD382 Gefitinib "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000233009] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42679 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1158 Dienogest Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42680 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD338 Fendiline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003648773] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42680 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1160 Diflunisal Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42681 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD818 Suloctidil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000432177] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42681 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1161 Dimenhydrinate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42682 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD472 Lansoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.66E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42682 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1162 Diphenhydramine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42683 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD25 Alfacalcidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000508931] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42683 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1163 Disopyramide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42684 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD85 Azathioprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000735586] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42684 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1165 Dofetilide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42685 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD431 Hycanthone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005921662] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42685 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1167 Donepezil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42686 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD47 Anethole-trithione Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003428591] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42686 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD289 Doxazosin Mesylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42687 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD470 Lacidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009136971] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42687 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1169 Doxepin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42688 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD799 Spectinomycin dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.96E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42688 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1170 Doxycycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42689 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD720 Quinacrine dihydrochloride dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002051243] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42689 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1171 Dutasteride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42690 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD840 Thiethylperazine dimalate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004408996] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42690 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1172 Emtricitabine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42691 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD890 Vardenafil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006625292] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42691 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1174 Enalapril Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42692 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD523 Mercaptopurine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000355458] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42692 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1175 Enalaprilat Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42693 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD450 Iohexol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.15E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42693 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1177 Eprosartan Mesylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42694 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD444 Indatraline hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008151822] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42694 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD312 Ergotamine Tartrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42695 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD332 Famotidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.96E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42695 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1180 Escitalopram Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42696 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD628 Oxaprozin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005356222] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42696 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1181 Esomeprazole Potassium Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42697 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD532 Methantheline bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008706801] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42697 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1183 Estrone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42698 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD912 Ziprasidone Hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003648773] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42698 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1186 Ethinyl Estradiol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42699 Substances alter microbe abundance PMDBM2020208 410072 Coprococcus comes PMDBD31 Alverine citrate salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006749194] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42699 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1187 Ethionamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42700 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42700 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1188 Everolimus Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42701 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42701 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1190 Felbamate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42702 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.03E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42702 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1191 Fenoprofen Calcium Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42703 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.08E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42703 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1192 Fexofenadine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42704 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.96E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42704 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1193 Fingolimod Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42705 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42705 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1195 Flavoxate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42706 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.40E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42706 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1196 Flecainide Acetate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42707 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42707 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1201 Flurbiprofen Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42708 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42708 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1203 Fluvastatin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42709 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.15E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42709 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD370 Fluvoxamine Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42710 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42710 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1205 Formoterol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42711 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.31E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42711 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1207 Fosinopril Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42712 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42712 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1209 Furosemide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42713 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42713 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1210 Gabapentin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42714 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42714 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1212 Gemfibrozil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42715 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42715 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1213 Gemifloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42716 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42716 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1215 Glimepiride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42717 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42717 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1217 Glyburide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42718 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42718 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1220 Granisetron Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42719 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000150075] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42719 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1221 Guanabenz Acetate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42720 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.96E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42720 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1222 Guanfacine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42721 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42721 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1225 Hydralazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42722 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.13E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42722 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1226 Hydrochlorothiazide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42723 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42723 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1228 Hydroflumethiazide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42724 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42724 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1229 Hydroxychloroquine Sulfate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42725 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.97E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42725 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1230 Hydroxyzine Dihydrochloride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42726 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42726 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1231 Ibuprofen Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42727 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000227146] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42727 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1235 Imipramine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42728 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.68E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42728 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1236 Indapamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42729 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42729 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1238 Indinavir Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42730 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42730 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1240 Isocarboxazid Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42731 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42731 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1241 Isradipine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42732 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42732 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD469 Ketorolac Tromethamine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42733 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42733 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1243 Ketotifen Fumarate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42734 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42734 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1244 Labetalol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42735 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.42E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42735 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1245 Lacosamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42736 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.43E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42736 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1246 Lamivudine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42737 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42737 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1247 Lamotrigine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42738 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42738 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1248 Lapatinib Ditosylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42739 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42739 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1253 Lenalidomide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42740 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42740 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1255 Letrozole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42741 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42741 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1256 Levocetirizine Dihydrochloride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42742 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.05E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42742 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1257 Levofloxacin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42743 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42743 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1258 Lincomycin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42744 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42744 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1259 Lopinavir Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42745 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42745 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1261 Losartan Potassium Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42746 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00821249] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42746 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD502 Loxapine Succinate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42747 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.63E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42747 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1266 Maprotiline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42748 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42748 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1267 Maraviroc Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42749 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42749 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1269 Meclizine Dihydrochloride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42750 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42750 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1270 Meclofenamate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42751 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00023782] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42751 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1271 Mefenamic Acid Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42752 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.35E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42752 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1274 Meloxicam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42753 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42753 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1276 Mepenzolate Bromide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42754 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42754 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1277 Meprobamate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42755 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42755 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1281 Mestranol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42756 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42756 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1282 Metaproterenol Hemisulfate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42757 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42757 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1283 Methazolamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42758 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42758 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1284 Methenamine Hippurate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42759 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42759 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1285 Methimazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42760 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42760 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1286 Methocarbamol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42761 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42761 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1287 Methylergonovine Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42762 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.27E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42762 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1289 Metoclopramide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42763 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.07E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42763 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1290 Metolazone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42764 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002419759] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42764 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD545 Metoprolol Tartrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42765 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42765 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1292 Metyrapone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42766 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.11E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42766 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1293 Mexiletine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42767 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42767 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1295 Milnacipran Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42768 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.07E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42768 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1296 Minocycline Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42769 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42769 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1297 Mirtazapine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42770 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42770 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1302 Modafinil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42771 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42771 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1303 Moexipril Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42772 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42772 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1306 Mycophenolic Acid Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42773 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42773 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1307 Nadolol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42774 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42774 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1309 Naltrexone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42775 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42775 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1310 Naproxen Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42776 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42776 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1311 Naratriptan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42777 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.30E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42777 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1312 Nebivolol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42778 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.32E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42778 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1313 Nefazodone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42779 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42779 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1315 Nelfinavir Mesylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42780 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.43E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42780 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1321 Nisoldipine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42781 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42781 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1323 Nortriptyline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42782 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42782 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1325 Nystatin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42783 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.61E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42783 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1328 Olmesartan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42784 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42784 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1329 Olopatadine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42785 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42785 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1331 Ondansetron Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42786 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42786 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1334 Oseltamivir Phosphate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42787 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.09E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42787 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1337 Oxtriphylline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42788 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42788 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD634 Oxybutynin Chloride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42789 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42789 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1339 Oxytetracycline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42790 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.92E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42790 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1341 Palonosetron Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42791 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42791 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1344 Pazopanib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42792 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42792 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD647 Pemirolast Potassium Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42793 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42793 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1355 Pentoxifylline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42794 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42794 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1357 Perindopril Erbumine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42795 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006943422] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42795 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1361 Phenoxybenzamine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42796 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.71E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42796 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1362 Phenylephrine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42797 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42797 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1363 Phenytoin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42798 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42798 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1364 Pilocarpine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42799 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.46E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42799 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1366 Piroxicam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42800 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42800 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1367 Pitavastatin Calcium Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42801 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42801 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1372 Posaconazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42802 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.06E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42802 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1373 Pramipexole Dihydrochloride Monohydrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42803 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42803 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1375 Pravastatin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42804 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.46E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42804 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1376 Praziquantel Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42805 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.38E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42805 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1377 Prazosin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42806 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42806 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD704 Primaquine Phosphate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42807 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.17E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42807 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1381 Primidone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42808 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.98E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42808 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1383 Procainamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42809 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42809 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1385 Promethazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42810 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42810 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1386 Propafenone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42811 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004285355] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42811 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1388 Propranolol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42812 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42812 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1389 Propylthiouracil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42813 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.71E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42813 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1391 Protriptyline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42814 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42814 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1392 Pyrazinamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42815 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42815 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1393 Quetiapine Fumarate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42816 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004498] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42816 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1394 Quinidine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42817 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003450843] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42817 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1395 Quinine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42818 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0084923] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42818 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1397 Rabeprazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42819 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000842546] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42819 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1398 Raloxifene Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42820 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000121143] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42820 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1399 Raltegravir Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42821 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42821 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1400 Ranolazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42822 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000387379] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42822 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1401 Rasagiline Mesylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42823 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42823 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1403 Rimantadine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42824 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD494 Loratadine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42824 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1405 Rivastigmine Tartrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42825 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42825 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1406 Ropinirole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42826 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42826 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1407 Rosiglitazone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42827 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009131912] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42827 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1408 Rosuvastatin Calcium Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42828 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000361304] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42828 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1409 Rufinamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42829 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00112447] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42829 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD764 Saquinavir Mesylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42830 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42830 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1413 Scopolamine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42831 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001634087] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42831 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1414 Selegiline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42832 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42832 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD781 Sildenafil Citrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42833 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0003577] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42833 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1418 Sitagliptin Phosphate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42834 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.06E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42834 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1420 Sorafenib Tosylate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42835 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005395687] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42835 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD820 Sumatriptan Succinate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42836 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.27E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42836 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1431 Sunitinib Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42837 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD382 Gefitinib "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42837 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1432 Tacrine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42838 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD91 Aztreonam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42838 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1433 Tamoxifen Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42839 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD472 Lansoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.31E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42839 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1434 Tamsulosin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42840 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.32E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42840 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1439 Telbivudine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42841 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD425 Hexetidine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003042737] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42841 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1440 Telithromycin Therapeutic Substance "Approved Drug; Antibiotics" n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42842 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD47 Anethole-trithione Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.39E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42842 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1441 Temazepam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42843 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD724 Rabeprazole Sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.06E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42843 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1442 Terazosin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42844 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD182 Chlorotrianisene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008706801] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42844 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1443 Terbinafine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42845 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD320 Ethaverine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.84E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42845 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1444 Terbutaline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42846 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD641 Parbendazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003381699] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42846 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1445 Tetrabenazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42847 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD891 Vecuronium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000745054] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42847 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1447 Thalidomide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42848 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000758779] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42848 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1448 Theophylline Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42849 Substances alter microbe abundance PMDBM2020211 39486 Dorea formicigenerans PMDBD473 Leflunomide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002219157] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42849 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1450 Thioguanine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42850 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.87E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42850 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1452 Thioridazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42851 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.76E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42851 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1453 Tiagabine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42852 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.24E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42852 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1456 Ticlopidine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42853 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.91E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42853 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1458 Tizanidine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42854 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.56E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42854 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1459 Tolbutamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42855 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42855 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1461 Tolmetin sodium dihydrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42856 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.51E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42856 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1462 Tolterodine Tartrate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42857 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.27E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42857 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1463 Tolvaptan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42858 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.26E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42858 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1464 Topiramate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42859 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.16E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42859 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1465 Topotecan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42860 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.21E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42860 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1466 Toremifene Base Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42861 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.69E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42861 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1467 Torsemide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42862 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.67E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42862 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1469 Tramadol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42863 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.76E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42863 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1471 Tranylcypromine Hemisulfate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42864 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.22E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42864 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1472 Trazodone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42865 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.24E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42865 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1473 Triamcinolone Acetonide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42866 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.58E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42866 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1474 Triamterene Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42867 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.26E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42867 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1475 Triazolam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42868 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.52E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42868 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1478 Trifluoperazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42869 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.24E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42869 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1479 Trimethobenzamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42870 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.58E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42870 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1481 Trimipramine Maleate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42871 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42871 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1482 Trospium Chloride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42872 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.77E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42872 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1488 Venlafaxine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42873 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.37E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42873 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1491 Vinorelbine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42874 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.87E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42874 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1494 Ziprasidone hydrochloride Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42875 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.22E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42875 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1495 Zolmitriptan Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42876 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.05E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42876 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD116 Bisacodyl Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42877 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.76E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42877 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD141 Capecitabine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42878 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.18E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42878 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD142 Capsaicin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42879 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42879 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD210 Clofazimine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42880 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.28E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42880 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD214 Clonazepam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42881 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.80E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42881 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD259 Dexamethasone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42882 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.39E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42882 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD294 Duloxetine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42883 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.50E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42883 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42884 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.28E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42884 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD315 Estradiol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42885 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42885 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD331 Famciclovir Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42886 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001029457] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42886 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD366 Fluoxetine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42887 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003422085] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42887 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD546 Metronidazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42888 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42888 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD565 Nabumetone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42889 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.74E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42889 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD591 Nilutamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42890 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.48E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42890 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD593 Nimodipine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42891 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.37E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42891 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42892 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.07E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42892 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD638 Paliperidone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42893 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.91E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42893 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD639 Pantoprazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42894 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.01E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42894 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD744 Rifabutin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42895 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.70E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42895 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD750 Risperidone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42896 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.16E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42896 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD812 Sulfasalazine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42897 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.67E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42897 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD816 Sulindac Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42898 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42898 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42899 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.07E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42899 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD85 Azathioprine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42900 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42900 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42901 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.30E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42901 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1021 Allopurinol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42902 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001552307] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42902 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1056 Betamethasone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42903 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000290109] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42903 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1105 Chenodiol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42904 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.10E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42904 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1130 Cortisone Acetate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42905 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.58E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42905 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1138 Dantrolene Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42906 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.39E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42906 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1166 Dolasetron Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42907 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.17E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42907 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD319 Ethacrynic Acid Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42908 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.19E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42908 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1189 Exemestane Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42909 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001088287] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42909 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1199 Fludrocortisone Acetate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42910 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.36E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42910 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1202 Flutamide Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42911 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.51E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42911 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1227 Hydrocortisone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42912 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006144696] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42912 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1227 Hydrocortisone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42913 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.10E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42913 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1233 Iloperidone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42914 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.07E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42914 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1260 Lorazepam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42915 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000779058] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42915 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD519 Megestrol Acetate Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42916 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42916 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1288 Methylprednisolone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42917 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002482895] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42917 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1298 Misoprostol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42918 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001496762] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42918 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD563 Mycophenolate Mofetil Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42919 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.64E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42919 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1318 Nicardipine Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42920 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.55E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42920 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1322 Nitisinone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42921 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.77E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42921 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1336 Oxazepam Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42922 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.14E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42922 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1374 Prasugrel Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42923 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.89E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42923 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1378 Prednisolone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42924 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.70E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42924 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1379 Prednisone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42925 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42925 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1382 Probenecid Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42926 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.72E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42926 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1384 Progesterone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42927 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00019363] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42927 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1402 Rifampin Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42928 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009392496] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42928 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1421 Spironolactone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42929 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000110867] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42929 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1427 Sulfamethoxazole Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42930 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.56E-06] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42930 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1460 Tolcapone Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42931 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000166937] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42931 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1484 Ursodiol Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42932 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000963399] n.a. n.a. n.a. n.a. In vitro Human gut microbiota ex vivo mixed culturing system Health n.a. n.a. PMID PMID: 29555994 PMDBI42932 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1493 Vorinostat Therapeutic Substance Approved Drug n.a. Gut n.a. n.a. n.a. n.a. n.a. Drug metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 32526207 PMDBI42933 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001088834] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42933 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD16 Acetaminophen Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42934 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.02E-05] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42934 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD476 Levodopa Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42935 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.87E-06] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42935 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD546 Metronidazole Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42936 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000281578] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42936 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD619 Omeprazole Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42937 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.30E-05] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42937 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD783 Simvastatin Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42938 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006630414] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42938 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD915 Zonisamide Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42939 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.64E-05] n.a. n.a. n.a. n.a. In vitro Human Health n.a. n.a. PMID PMID: 29555994 PMDBI42939 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD1139 Dapsone Therapeutic Substance Approved Drug Drug was incubated with human colon microbiota for 24 hours under strict anaerobic culture conditions. Gut n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 30158249 PMDBI42940 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006477672] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42940 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID "PMID: 30890566; PMID: 28431244" PMDBI42941 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.62E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42941 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID "PMID: 30890566; PMID: 28431244" PMDBI42942 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.03E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42942 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD327 Etoposide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID "PMID: 30890566; PMID: 28431244" PMDBI42943 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000136718] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42943 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD327 Etoposide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID "PMID: 30890566; PMID: 28431244" PMDBI42944 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.32E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42944 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID "PMID: 30890566; PMID: 28431244" PMDBI42945 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.96E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42945 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID "PMID: 30890566; PMID: 28431244" PMDBI42946 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000206272] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42946 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD829 Temozolomide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID "PMID: 30890566; PMID: 28431244" PMDBI42947 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.27E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42947 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD829 Temozolomide Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID "PMID: 30890566; PMID: 28431244" PMDBI42948 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.32E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42948 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD1005 5-fluoro-2'-deoxyuridine Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID "PMID: 30890566; PMID: 28431244" PMDBI42949 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001003844] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42949 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1316 Neocarzinostatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID "PMID: 30890566; PMID: 28431244" PMDBI42950 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002535612] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42950 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD1316 Neocarzinostatin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID "PMID: 30890566; PMID: 28431244" PMDBI42951 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42951 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1431 Sunitinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID "PMID: 30890566; PMID: 28431244" PMDBI42952 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000207238] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42952 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD1431 Sunitinib Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID "PMID: 30890566; PMID: 28431244" PMDBI42953 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.73E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42953 Microbes metabolize substances PMDBM2020035 562 Escherichia coli PMDBD1433 Tamoxifen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID "PMID: 30890566; PMID: 28431244" PMDBI42954 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000445674] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42954 Microbes metabolize substances PMDBM713 283 Comamonas PMDBD1433 Tamoxifen Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vivo Caenorhabditis elegans n.a. n.a. No effect on Caenorhabditis elegans PMID "PMID: 30890566; PMID: 28431244" PMDBI42955 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001653916] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42955 Microbes metabolize substances PMDBM768 469008 Escherichia coli BL21(DE3) PMDBD290 Doxorubicin Therapeutic Substance Approved Drug n.a. n.a. n.a. n.a. n.a. n.a. n.a. Microbe does not metabolize drug In vitro High-throughput incubation assays n.a. n.a. n.a. PMID "PMID: 30890566; PMID: 29160065" PMDBI42956 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000320991] n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42956 Microbes metabolize substances PMDBM977 n.a. Unclassified gut microbiota PMDBD445 Indole Environmental Substance Metabolite n.a. n.a. n.a. n.a. "indoxyl sulfate; indole-3-propionic acid; isatin; 5-hydroxyindole" n.a. n.a. Metabolism In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 26439294 PMDBI42957 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42958 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42959 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.25E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42960 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000105176] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42961 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000483527] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42962 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001923619] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42963 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002615896] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42964 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004328366] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42965 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42966 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.32E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42967 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.19E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42968 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.47E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42969 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006216034] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42970 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42971 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000150815] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42972 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42973 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD85 Azathioprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007574365] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42974 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD418 Haloperidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00721154] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42975 Substances alter microbe abundance PMDBM2020213 n.a. Eggerthella lenta PMDBD129 Bufexamac Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00773707] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42976 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.18E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42977 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42978 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42979 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42980 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.88E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42981 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.15E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42982 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.18E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42983 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42984 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.15E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42985 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.15E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42986 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42987 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42988 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.57E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42989 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.00E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42990 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.94E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42991 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42992 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.15E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42993 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42994 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002697598] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42995 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.15E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42996 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.24E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42997 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.15E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42998 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.24E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI42999 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43000 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00405416] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43001 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.24E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43002 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.18E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43003 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.19E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43004 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.88E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43005 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.39E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43006 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43007 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43008 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43009 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43010 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006329494] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43011 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43012 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.02E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43013 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000154779] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43014 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.27E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43015 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.19E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43016 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.22E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43017 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.58E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43018 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.28E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43019 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000384468] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43020 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.22E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43021 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.53E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43022 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.24E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43023 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.34E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43024 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.39E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43025 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.40E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43026 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.02E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43027 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.75E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43028 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.39E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43029 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43030 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.24E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43031 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43032 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.31E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43033 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43034 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.26E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43035 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.53E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43036 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.88E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43037 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.26E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43038 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.41E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43039 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43040 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.27E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43041 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.88E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43042 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.26E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43043 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43044 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43045 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.15E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43046 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.38E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43047 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.20E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43048 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.54E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43049 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43050 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD91 Aztreonam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.99E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43051 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD438 Idoxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000843474] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43052 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD571 Nalidixic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001295934] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43053 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD633 Oxolinic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43054 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD197 Cinoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43055 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD675 Pipemidic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.77E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43056 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD842 Thioguanosine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43057 Substances alter microbe abundance PMDBM2020035 585397 Escherichia coli ED1a PMDBD678 Pivmecillinam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43058 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.22E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43059 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.72E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43060 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43061 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43062 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43063 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43064 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43065 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43066 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43067 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43068 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43069 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43070 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43071 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43072 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000619485] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43073 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.19E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43074 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43075 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43076 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007723953] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43077 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43078 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43079 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43080 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.62E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43081 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43082 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43083 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43084 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00126153] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43085 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43086 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43087 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43088 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000751721] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43089 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43090 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43091 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.90E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43092 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43093 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43094 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005361641] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43095 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.67E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43096 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43097 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43098 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43099 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43100 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43101 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43102 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43103 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43104 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43105 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.00E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43106 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43107 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43108 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43109 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43110 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.78E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43111 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43112 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43113 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43114 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43115 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43116 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43117 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43118 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43119 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43120 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43121 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.03E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43122 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002511467] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43123 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43124 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43125 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43126 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43127 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43128 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43129 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43130 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43131 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43132 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43133 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD91 Aztreonam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43134 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD571 Nalidixic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000480935] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43135 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD633 Oxolinic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43136 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD197 Cinoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43137 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD675 Pipemidic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43138 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD200 Cladribine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.73E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43139 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD842 Thioguanosine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.33E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43140 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD678 Pivmecillinam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43141 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD350 Fexofenadine HCl Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008281463] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43142 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD359 Fludarabine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00022021] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43143 Substances alter microbe abundance PMDBM2020035 585034 Escherichia coli IAI1 PMDBD364 Fluorometholone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005527231] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43144 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43145 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.58E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43146 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.02E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43147 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43148 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43149 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43150 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43151 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.99E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43152 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.48E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43153 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43154 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.41E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43155 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.53E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43156 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43157 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.58E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43158 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43159 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.43E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43160 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.06E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43161 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43162 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.75E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43163 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.91E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43164 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.79E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43165 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43166 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43167 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.00E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43168 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43169 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.47E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43170 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.19E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43171 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.04E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43172 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43173 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000407513] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43174 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.03E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43175 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.49E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43176 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43177 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43178 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43179 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43180 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000166937] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43181 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43182 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.11E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43183 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43184 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43185 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43186 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.46E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43187 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.78E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43188 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.26E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43189 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000200215] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43190 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.96E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43191 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.28E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43192 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43193 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43194 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43195 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.44E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43196 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43197 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43198 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43199 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.50E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43200 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.54E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43201 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.64E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43202 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.25E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43203 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43204 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43205 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.68E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43206 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43207 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.05E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43208 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43209 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002160053] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43210 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43211 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43212 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000949381] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43213 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43214 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.70E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43215 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.14E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43216 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000273365] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43217 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.58E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43218 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.49E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43219 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.91E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43220 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.08E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43221 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.84E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43222 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.08E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43223 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43224 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.82E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43225 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003050721] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43226 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.55E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43227 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43228 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.37E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43229 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.50E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43230 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43231 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000180873] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43232 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43233 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.44E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43234 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.48E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43235 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005040288] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43236 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43237 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.61E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43238 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43239 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009240568] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43240 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.81E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43241 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009959859] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43242 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.15E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43243 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43244 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43245 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43246 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.61E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43247 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.19E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43248 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.63E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43249 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008468237] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43250 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43251 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.12E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43252 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003586475] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43253 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.03E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43254 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.60E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43255 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43256 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.61E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43257 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43258 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43259 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003395309] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43260 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.58E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43261 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43262 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43263 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.79E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43264 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000575937] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43265 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43266 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006847773] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43267 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.14E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43268 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD494 Loratadine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.80E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43269 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43270 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003762061] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43271 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.82E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43272 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000213422] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43273 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000354051] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43274 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.87E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43275 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43276 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000409922] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43277 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001196707] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43278 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00171391] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43279 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002062169] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43280 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003959654] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43281 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000919651] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43282 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000587621] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43283 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000147452] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43284 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005291612] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43285 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003077566] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43286 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD382 Gefitinib "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001858081] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43287 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD338 Fendiline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009434026] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43288 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD818 Suloctidil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.94E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43289 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD516 Meclozine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001303223] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43290 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD916 Zotepine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001711794] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43291 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004276717] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43292 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD917 Zuclopenthixol dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005211733] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43293 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD132 Butenafine Hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002639895] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43294 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD425 Hexetidine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000285174] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43295 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD870 Trifluoperazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000767287] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43296 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD417 Halofantrine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001229724] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43297 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD701 Prenylamine lactate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001383791] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43298 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD86 Azelastine HCl Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007897794] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43299 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD655 Perphenazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003200122] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43300 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD211 Clofilium tosylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00386463] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43301 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD705 Proadifen hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003952581] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43302 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD779 Sertraline "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008314918] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43303 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD381 GBR 12909 dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004498] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43304 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD847 Thyroxine (L) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001698405] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43305 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD606 Norcyclobenzaprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000421185] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43306 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD256 Deptropine citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002434065] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43307 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD267 Dicyclomine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002806708] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43308 Substances alter microbe abundance PMDBM2020221 39485 [Eubacterium] eligens PMDBD282 Dimethisoquin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004750396] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43309 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000378371] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43310 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000409003] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43311 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000361878] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43312 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000306383] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43313 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000170551] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43314 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000214078] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43315 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000974908] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43316 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017063] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43317 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001033647] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43318 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000338955] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43319 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000172554] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43320 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000898138] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43321 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000262719] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43322 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00040424] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43323 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000355776] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43324 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000166057] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43325 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000935714] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43326 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000361878] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43327 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000273851] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43328 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001400586] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43329 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000169166] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43330 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000214299] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43331 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000399994] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43332 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000162753] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43333 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000265494] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43334 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000221545] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43335 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000209646] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43336 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001837541] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43337 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000691821] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43338 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000165922] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43339 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000166057] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43340 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000170551] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43341 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000353513] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43342 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000355771] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43343 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000213422] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43344 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000399703] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43345 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000988593] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43346 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000170551] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43347 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000168726] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43348 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000165512] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43349 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000164611] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43350 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000165993] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43351 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000166937] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43352 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00021134] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43353 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0004071] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43354 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000169084] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43355 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001492278] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43356 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002294069] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43357 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000163771] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43358 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000271581] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43359 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001038111] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43360 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000361878] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43361 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000362657] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43362 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000384931] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43363 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000387318] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43364 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000382397] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43365 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000402648] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43366 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000166057] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43367 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008421756] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43368 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000167597] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43369 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001040151] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43370 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001923597] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43371 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000168984] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43372 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000967328] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43373 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000401702] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43374 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001080112] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43375 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000167548] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43376 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000976862] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43377 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000271267] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43378 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000412089] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43379 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000170885] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43380 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000346097] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43381 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000169502] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43382 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001055051] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43383 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000165993] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43384 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000164898] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43385 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000170513] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43386 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000165512] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43387 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00034623] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43388 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000407731] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43389 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000168628] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43390 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000168706] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43391 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000168435] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43392 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000168822] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43393 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000165] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43394 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000216184] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43395 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000271872] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43396 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000271267] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43397 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000403341] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43398 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00016811] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43399 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017063] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43400 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001199846] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43401 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000405409] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43402 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0001689] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43403 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000163962] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43404 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000453083] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43405 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000372795] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43406 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001039356] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43407 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001718902] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43408 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000230873] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43409 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000350754] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43410 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000202747] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43411 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000982525] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43412 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000407345] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43413 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000171186] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43414 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000165993] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43415 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005029022] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43416 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003862578] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43417 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000169084] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43418 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003261408] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43419 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000991355] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43420 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000279971] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43421 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000347934] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43422 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000166653] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43423 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000207066] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43424 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000169425] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43425 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001026634] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43426 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000449161] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43427 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002922821] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43428 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000168449] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43429 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000957735] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43430 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001224807] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43431 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000165081] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43432 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002168721] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43433 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001593325] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43434 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00079504] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43435 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00028298] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43436 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00811522] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43437 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003193652] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43438 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001445676] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43439 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000170773] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43440 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD494 Loratadine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000905297] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43441 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000166388] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43442 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000162663] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43443 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00166258] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43444 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002765864] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43445 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD83 Azaguanine-8 Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000195813] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43446 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003048825] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43447 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003451354] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43448 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001010013] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43449 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001928589] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43450 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001468787] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43451 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001557165] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43452 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001929889] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43453 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000556732] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43454 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003665325] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43455 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000569178] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43456 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002436407] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43457 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000755219] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43458 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005069808] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43459 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000965664] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43460 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00029395] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43461 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001925619] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43462 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00126153] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43463 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000439773] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43464 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002310188] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43465 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000282724] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43466 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007492184] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43467 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD382 Gefitinib "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000198323] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43468 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD338 Fendiline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004664749] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43469 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD818 Suloctidil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003364809] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43470 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD516 Meclozine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009134219] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43471 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD472 Lansoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00073008] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43472 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD25 Alfacalcidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00282026] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43473 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD916 Zotepine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001843987] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43474 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000219214] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43475 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006471855] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43476 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD62 Apramycin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005453684] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43477 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD425 Hexetidine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000769692] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43478 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD12 Acarbose "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000460108] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43479 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD724 Rabeprazole Sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00183633] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43480 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD870 Trifluoperazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003095836] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43481 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD708 Prochlorperazine dimaleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006409321] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43482 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD799 Spectinomycin dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008337197] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43483 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD464 Ivermectin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00339554] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43484 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD417 Halofantrine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002281473] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43485 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD368 Fluphenazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003104732] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43486 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD701 Prenylamine lactate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006182585] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43487 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD320 Ethaverine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004729501] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43488 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD641 Parbendazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005696752] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43489 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD764 Saquinavir mesylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003173408] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43490 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD840 Thiethylperazine dimalate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001757155] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43491 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD86 Azelastine HCl Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0041032] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43492 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD891 Vecuronium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000301514] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43493 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD211 Clofilium tosylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000200168] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43494 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD479 Lidoflazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001454241] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43495 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD779 Sertraline "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001553159] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43496 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD74 Asenapine maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003655819] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43497 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD444 Indatraline hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005829803] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43498 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD491 Loperamide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002894824] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43499 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD513 Mebhydroline 1,5-naphtalenedisulfonate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002495343] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43500 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD871 Triflupromazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008014017] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43501 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD371 Folic acid "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001145843] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43502 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD369 Fluspirilen Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009483084] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43503 Substances alter microbe abundance PMDBM2020223 39491 [Eubacterium] rectale PMDBD248 Darifenacin hydrobromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001015196] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43608 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43609 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43610 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.19E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43611 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43612 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43613 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43614 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43615 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.43E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43616 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.81E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43617 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43618 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.09E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43619 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43620 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43621 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43622 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43623 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.47E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43624 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43625 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.04E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43626 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43627 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43628 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.72E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43629 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43630 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43631 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.80E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43632 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.56E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43633 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43634 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.06E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43635 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.07E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43636 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43637 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.38E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43638 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.57E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43639 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000473102] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43640 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004079502] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43641 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43642 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.60E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43643 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.52E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43644 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.28E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43645 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.46E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43646 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43647 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.56E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43648 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43649 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.46E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43650 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43651 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.46E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43652 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.16E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43653 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43654 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.89E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43655 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.12E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43656 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000312424] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43657 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.43E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43658 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.83E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43659 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.48E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43660 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43661 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000181202] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43662 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.50E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43663 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000686529] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43664 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43665 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43666 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.23E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43667 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.19E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43668 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.81E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43669 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000686521] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43670 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001427007] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43671 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43672 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43673 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000711793] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43674 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43675 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.02E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43676 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.54E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43677 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43678 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43679 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008164124] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43680 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.19E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43681 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000949493] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43682 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.91E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43683 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000198677] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43684 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.55E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43685 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003529462] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43686 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.03E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43687 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007174905] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43688 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.05E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43689 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001721254] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43690 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005573957] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43691 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43692 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002834728] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43693 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001049058] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43694 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000149183] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43695 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003173959] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43696 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43697 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004700317] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43698 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000686935] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43699 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.55E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43700 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43701 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004579591] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43702 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD494 Loratadine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008854011] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43703 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001957133] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43704 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43705 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43706 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43707 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003224539] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43708 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001227586] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43709 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD857 Tolnaftate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003395954] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43710 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD464 Ivermectin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006102465] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43711 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD847 Thyroxine (L) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009357149] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43712 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD358 Flucytosine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007454192] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43713 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD150 Carvedilol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004253894] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43714 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD330 Fadrozole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007672282] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43715 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD110 Betaxolol hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006477728] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43716 Substances alter microbe abundance PMDBM278 1597 Lactobacillus paracasei PMDBD449 Iocetamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.86E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43717 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43718 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43719 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43720 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43721 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43722 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43723 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.57E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43724 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43725 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43726 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43727 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43728 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43729 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43730 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43731 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43732 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43733 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43734 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43735 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43736 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43737 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43738 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43739 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43740 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43741 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43742 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43743 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43744 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43745 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43746 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43747 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43748 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43749 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.33E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43750 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43751 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43752 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43753 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.57E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43754 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43755 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43756 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43757 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43758 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43759 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43760 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43761 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43762 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43763 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43764 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001166423] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43765 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43766 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43767 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43768 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43769 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43770 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43771 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43772 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43773 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43774 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000270398] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43775 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43776 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43777 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43778 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43779 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43780 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.57E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43781 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43782 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43783 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43784 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.57E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43785 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43786 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43787 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43788 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43789 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43790 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43791 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43792 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43793 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43794 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43795 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43796 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43797 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43798 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00021442] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43799 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43800 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43801 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002400165] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43802 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.55E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43803 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43804 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43805 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43806 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43807 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43808 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43809 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43810 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43811 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001063906] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43812 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43813 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43814 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43815 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43816 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.88E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43817 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43818 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43819 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43820 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43821 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43822 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004208369] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43823 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001074754] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43824 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.65E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43825 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43826 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000298156] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43827 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43828 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43829 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43830 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.53E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43831 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43832 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43833 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.28E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43834 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43835 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002107446] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43836 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43837 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43838 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.38E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43839 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.29E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43840 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43841 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43842 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00021713] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43843 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.48E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43844 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43845 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002177626] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43846 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000732883] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43847 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43848 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.96E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43849 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43850 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006814855] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43851 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43852 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006094828] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43853 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001265417] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43854 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004225506] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43855 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD265 Dicumarol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000511457] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43856 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000994849] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43857 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD91 Aztreonam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.19E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43858 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD559 Moricizine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002627508] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43859 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD502 Loxapine succinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.54E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43860 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD875 Trimeprazine tartrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006969853] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43861 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD858 Toltrazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003783935] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43862 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD431 Hycanthone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001979002] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43863 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD720 Quinacrine dihydrochloride dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000154227] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43864 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD438 Idoxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001120241] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43865 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD806 Sulbactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43866 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD764 Saquinavir mesylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003155935] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43867 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD360 Flufenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004838187] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43868 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD202 Clavulanate potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000334219] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43869 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD529 Metergoline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002160053] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43870 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD363 Flunixin meglumine Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000691593] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43871 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD829 Temozolomide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008274591] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43872 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD247 Dantrolene sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002634804] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43873 Substances alter microbe abundance PMDBM2020230 28118 Odoribacter splanchnicus PMDBD289 Doxazosin mesylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008264925] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43874 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43875 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43876 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43877 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43878 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43879 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.80E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43880 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.59E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43881 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43882 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.25E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43883 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43884 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43885 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43886 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43887 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43888 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43889 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.62E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43890 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43891 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.44E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43892 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43893 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43894 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.78E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43895 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43896 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43897 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.82E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43898 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43899 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43900 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43901 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43902 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43903 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.53E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43904 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43905 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43906 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.76E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43907 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43908 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43909 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43910 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.33E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43911 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43912 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43913 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.09E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43914 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43915 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.47E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43916 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43917 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43918 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43919 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43920 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.47E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43921 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43922 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43923 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43924 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43925 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43926 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.28E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43927 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43928 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.79E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43929 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.54E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43930 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43931 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000453712] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43932 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43933 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.74E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43934 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.62E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43935 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.76E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43936 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43937 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43938 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43939 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.16E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43940 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.70E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43941 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43942 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43943 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.71E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43944 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43945 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.12E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43946 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.36E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43947 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.44E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43948 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43949 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.72E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43950 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.94E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43951 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43952 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43953 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000646374] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43954 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000112269] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43955 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43956 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43957 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000199681] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43958 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43959 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43960 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43961 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.35E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43962 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.22E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43963 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43964 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.78E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43965 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43966 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003167824] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43967 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43968 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.54E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43969 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001800915] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43970 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000153415] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43971 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43972 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007636386] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43973 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.85E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43974 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.82E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43975 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43976 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.94E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43977 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.03E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43978 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000192316] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43979 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.59E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43980 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.66E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43981 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.62E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43982 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.53E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43983 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43984 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000485641] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43985 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000213793] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43986 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.94E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43987 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000407345] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43988 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43989 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.47E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43990 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.70E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43991 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.30E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43992 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43993 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000970824] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43994 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0023746] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43995 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.02E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43996 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.73E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43997 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008757232] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43998 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000112711] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI43999 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.55E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44000 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.03E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44001 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001985399] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44002 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.05E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44003 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004049483] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44004 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD265 Dicumarol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000114306] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44005 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000479833] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44006 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44007 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44008 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000137683] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44009 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44010 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD186 Chlorprothixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000776517] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44011 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD559 Moricizine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000165707] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44012 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD502 Loxapine succinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44013 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD916 Zotepine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003256341] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44014 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009098165] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44015 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD875 Trimeprazine tartrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.92E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44016 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD917 Zuclopenthixol dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000575241] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44017 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD858 Toltrazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.75E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44018 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD132 Butenafine Hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000999474] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44019 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD670 Pimethixene maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007677224] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44020 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD870 Trifluoperazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001621938] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44021 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD708 Prochlorperazine dimaleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008917598] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44022 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD185 Chlorpromazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003429568] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44023 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD710 Promethazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44024 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD720 Quinacrine dihydrochloride dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000100254] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44025 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD193 Cilnidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002695836] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44026 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD515 Meclofenamic acid sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003019082] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44027 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD368 Fluphenazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005572399] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44028 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD655 Perphenazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001361982] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44029 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004467722] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44030 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD360 Flufenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001149242] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44031 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD40 Amodiaquin dihydrochloride dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.09E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44032 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD69 Aripiprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00018774] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44033 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD437 Idebenone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003822923] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44034 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000762378] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44035 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD325 Etofenamate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000338854] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44036 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD554 Mitotane Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003007578] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44037 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD726 Racepinephrine HCl Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000111392] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44038 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD647 Pemirolast potassium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006799706] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44039 Substances alter microbe abundance PMDBM2020231 823 Parabacteroides distasonis PMDBD723 R(-) Apomorphine hydrochloride hemihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00016442] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44040 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44041 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44042 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44043 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44044 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44045 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44046 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44047 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44048 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44049 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44050 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44051 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44052 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44053 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44054 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44055 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44056 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44057 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44058 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44059 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44060 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44061 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44062 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44063 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44064 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44065 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44066 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44067 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44068 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44069 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44070 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44071 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.49E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44072 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44073 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44074 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44075 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44076 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.24E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44077 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44078 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44079 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44080 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44081 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44082 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44083 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44084 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44085 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44086 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44087 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44088 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44089 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44090 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44091 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44092 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44093 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44094 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44095 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44096 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.30E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44097 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44098 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44099 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44100 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44101 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44102 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.97E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44103 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44104 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44105 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.90E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44106 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44107 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44108 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.67E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44109 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44110 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44111 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44112 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.65E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44113 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44114 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.37E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44115 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44116 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.21E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44117 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.41E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44118 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.47E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44119 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00034437] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44120 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44121 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.61E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44122 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44123 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.58E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44124 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44125 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000181202] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44126 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.76E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44127 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44128 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.81E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44129 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44130 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.08E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44131 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.59E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44132 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.73E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44133 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005381005] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44134 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44135 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.73E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44136 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.64E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44137 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003097339] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44138 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.30E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44139 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44140 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000170427] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44141 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002584087] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44142 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.90E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44143 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44144 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44145 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.63E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44146 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001809617] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44147 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44148 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44149 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44150 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003093329] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44151 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002866397] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44152 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000970824] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44153 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44154 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.23E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44155 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007133259] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44156 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.97E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44157 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000403341] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44158 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44159 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000151975] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44160 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001688439] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44161 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003190057] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44162 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007296817] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44163 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000126222] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44164 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.01E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44165 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000997738] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44166 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD709 Promazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44167 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD322 Ethopropazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44168 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44169 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD856 Tolfenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000141002] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44170 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD265 Dicumarol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006860033] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44171 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002065448] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44172 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD544 Metixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44173 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44174 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD186 Chlorprothixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00216403] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44175 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD713 Protriptyline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006955194] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44176 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD559 Moricizine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.37E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44177 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD502 Loxapine succinate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44178 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD875 Trimeprazine tartrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.55E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44179 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD858 Toltrazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.03E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44180 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD132 Butenafine Hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0018713] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44181 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD670 Pimethixene maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000120861] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44182 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD185 Chlorpromazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003605615] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44183 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD710 Promethazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.93E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44184 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD193 Cilnidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009525141] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44185 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD515 Meclofenamic acid sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000845062] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44186 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD197 Cinoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.79E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44187 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD360 Flufenamic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008821497] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44188 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD479 Lidoflazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44189 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD40 Amodiaquin dihydrochloride dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.40E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44190 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD742 Ribavirin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003021836] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44191 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD549 Mifepristone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.97E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44192 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD461 Isosorbide dinitrate "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001898209] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44193 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD41 Amoxapine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008486101] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44194 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD726 Racepinephrine HCl Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005817496] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44195 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD647 Pemirolast potassium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003849058] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44196 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD584 Nicardipine hydrochloride "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005823836] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44197 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD333 Famprofazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004960818] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44198 Substances alter microbe abundance PMDBM2020233 46503 Parabacteroides merdae PMDBD564 N6-methyladenosine Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004484062] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44199 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000105362] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44200 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000337554] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44201 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000204718] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44202 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.40E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44203 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.29E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44204 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.42E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44205 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44206 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000937349] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44207 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002795386] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44208 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44209 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44210 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006006895] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44211 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.50E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44212 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000333615] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44213 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44214 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44215 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44216 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.55E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44217 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44218 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000335395] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44219 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.33E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44220 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.29E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44221 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44222 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.84E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44223 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000101163] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44224 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.80E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44225 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002363748] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44226 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001576716] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44227 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44228 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.46E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44229 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44230 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.32E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44231 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.03E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44232 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005302486] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44233 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44234 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44235 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.46E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44236 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.32E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44237 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44238 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44239 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.53E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44240 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.73E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44241 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44242 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44243 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000862574] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44244 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.24E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44245 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44246 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44247 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.54E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44248 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44249 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000119098] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44250 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000102179] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44251 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000103492] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44252 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000355466] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44253 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44254 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000338971] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44255 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.87E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44256 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.58E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44257 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.67E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44258 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.52E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44259 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44260 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000312742] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44261 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000877737] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44262 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.61E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44263 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.40E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44264 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.35E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44265 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000333376] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44266 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.32E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44267 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.58E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44268 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.38E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44269 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44270 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44271 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44272 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.04E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44273 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00193131] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44274 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.13E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44275 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00216796] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44276 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.49E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44277 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.33E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44278 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.53E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44279 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44280 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.14E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44281 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.63E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44282 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.27E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44283 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44284 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002799645] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44285 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44286 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.35E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44287 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00773707] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44288 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000322932] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44289 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.74E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44290 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.63E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44291 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.14E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44292 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000129378] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44293 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000348442] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44294 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44295 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00048278] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44296 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005092649] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44297 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.09E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44298 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000334037] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44299 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000251723] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44300 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008944356] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44301 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002185392] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44302 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.89E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44303 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007296817] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44304 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.67E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44305 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.46E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44306 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000660736] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44307 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.79E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44308 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003414426] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44309 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.73E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44310 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002523703] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44311 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.60E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44312 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000187809] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44313 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003915281] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44314 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.10E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44315 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0028704] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44316 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000188147] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44317 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000548876] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44318 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00027388] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44319 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003241269] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44320 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002796885] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44321 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005071009] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44322 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44323 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.35E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44324 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00615387] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44325 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000180705] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44326 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000172153] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44327 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000600373] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44328 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007431509] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44329 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001747188] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44330 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007611659] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44331 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000263044] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44332 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008678266] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44333 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003764233] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44334 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000955606] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44335 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.20E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44336 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD338 Fendiline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008811167] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44337 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD186 Chlorprothixene hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003321156] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44338 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD91 Aztreonam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000688403] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44339 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD916 Zotepine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004271679] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44340 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004270959] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44341 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD85 Azathioprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000171237] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44342 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD917 Zuclopenthixol dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002177626] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44343 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD858 Toltrazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001053227] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44344 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD870 Trifluoperazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000746972] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44345 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD708 Prochlorperazine dimaleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003039172] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44346 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD438 Idoxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006327976] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44347 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD368 Fluphenazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001603792] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44348 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD806 Sulbactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000796508] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44349 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD419 Haloprogin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003972536] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44350 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD840 Thiethylperazine dimalate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000454427] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44351 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD523 Mercaptopurine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000214679] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44352 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD779 Sertraline "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002797396] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44353 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD69 Aripiprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008493167] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44354 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD200 Cladribine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004324909] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44355 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD461 Isosorbide dinitrate "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000673767] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44356 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD384 Gemcitabine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000437895] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44357 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD451 Iopanoic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000901834] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44358 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD578 Nefazodone HCl Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006634379] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44359 Substances alter microbe abundance PMDBM2020237 165179 Prevotella copri PMDBD213 Clomipramine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000642265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44360 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.12E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44361 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44362 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.88E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44363 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44364 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44365 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000183397] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44366 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44367 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.94E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44368 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.90E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44369 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.84E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44370 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44371 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002785984] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44372 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.45E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44373 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44374 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.97E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44375 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44376 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44377 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.93E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44378 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44379 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00010614] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44380 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44381 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000258893] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44382 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44383 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44384 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.21E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44385 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.79E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44386 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00023389] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44387 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000114592] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44388 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.18E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44389 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.88E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44390 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.96E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44391 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.84E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44392 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.89E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44393 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.88E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44394 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000232154] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44395 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44396 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44397 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.96E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44398 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44399 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44400 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44401 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44402 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000232311] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44403 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44404 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44405 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002579406] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44406 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000626908] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44407 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.57E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44408 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.74E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44409 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.74E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44410 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.81E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44411 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.71E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44412 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44413 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.92E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44414 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44415 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.97E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44416 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.79E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44417 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001497261] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44418 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.82E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44419 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44420 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.43E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44421 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44422 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004555788] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44423 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.89E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44424 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.29E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44425 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.21E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44426 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44427 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44428 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.81E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44429 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44430 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.85E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44431 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44432 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44433 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44434 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.93E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44435 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000142897] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44436 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44437 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44438 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44439 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.75E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44440 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44441 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002297368] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44442 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000253591] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44443 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.29E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44444 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.03E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44445 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44446 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.68E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44447 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44448 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.55E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44449 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44450 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44451 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000964707] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44452 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.60E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44453 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.82E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44454 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44455 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44456 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002911093] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44457 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44458 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.64E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44459 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44460 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44461 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.27E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44462 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44463 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009830868] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44464 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44465 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.48E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44466 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.29E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44467 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.90E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44468 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.00E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44469 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000183536] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44470 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44471 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.88E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44472 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000142269] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44473 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44474 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.42E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44475 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.83E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44476 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44477 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000165427] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44478 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.74E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44479 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.32E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44480 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.59E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44481 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44482 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000341198] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44483 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44484 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44485 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005257452] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44486 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.80E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44487 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.39E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44488 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000103252] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44489 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000342803] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44490 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD909 Zidovudine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44491 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006374774] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44492 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001652559] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44493 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009074269] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44494 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000281831] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44495 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD872 Trifluridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.39E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44496 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001005864] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44497 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.08E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44498 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000271321] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44499 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000130393] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44500 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD172 Cephalosporanic acid, 7-amino Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44501 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003428481] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44502 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44503 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD818 Suloctidil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000251723] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44504 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000404048] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44505 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD917 Zuclopenthixol dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000835203] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44506 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD431 Hycanthone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000688404] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44507 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD870 Trifluoperazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000360067] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44508 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD708 Prochlorperazine dimaleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005482844] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44509 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD712 Propidium iodide Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44510 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD417 Halofantrine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007614793] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44511 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD720 Quinacrine dihydrochloride dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000822814] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44512 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD368 Fluphenazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00250842] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44513 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD238 Cyclosporin A Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.40E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44514 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD806 Sulbactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000472372] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44515 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD764 Saquinavir mesylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00602832] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44516 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD655 Perphenazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44517 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD211 Clofilium tosylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000254099] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44518 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD479 Lidoflazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.05E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44519 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD154 Cefadroxil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002679627] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44520 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD39 Amlodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00126153] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44521 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD529 Metergoline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002585901] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44522 Substances alter microbe abundance PMDBM2020244 301301 Roseburia hominis PMDBD254 Demecarium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000207856] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44523 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000225141] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44524 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000406033] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44525 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000135092] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44526 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000164879] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44527 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000183586] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44528 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000681488] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44529 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000477981] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44530 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000183647] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44531 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001195925] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44532 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000133856] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44533 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000151221] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44534 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000416305] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44535 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000160919] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44536 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000342522] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44537 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000131781] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44538 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000141125] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44539 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000468263] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44540 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000133224] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44541 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000169425] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44542 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000241328] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44543 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00018783] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44544 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000646073] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44545 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000325894] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44546 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000239345] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44547 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000179511] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44548 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000132494] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44549 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00066158] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44550 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000345801] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44551 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000536192] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44552 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001243714] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44553 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00018963] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44554 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000166377] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44555 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000133365] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44556 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000138652] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44557 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000133484] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44558 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000691798] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44559 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000309554] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44560 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000686521] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44561 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000185636] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44562 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000209985] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44563 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000159446] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44564 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000171847] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44565 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000133498] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44566 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00021134] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44567 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000658811] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44568 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000323156] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44569 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000172121] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44570 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000190957] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44571 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000750365] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44572 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000243363] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44573 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000179188] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44574 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000606965] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44575 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000138933] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44576 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000131781] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44577 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000300773] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44578 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000253591] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44579 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000233624] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44580 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000315934] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44581 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000128455] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44582 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000346874] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44583 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000126331] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44584 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00095505] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44585 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000602138] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44586 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000135328] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44587 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000604897] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44588 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000320023] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44589 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001211448] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44590 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000166057] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44591 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000925813] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44592 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000172471] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44593 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00033814] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44594 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017552] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44595 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000144555] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44596 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000233624] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44597 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000687091] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44598 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000133324] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44599 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000131961] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44600 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000202857] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44601 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00015911] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44602 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44603 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000324492] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44604 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00018563] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44605 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000148521] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44606 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000132382] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44607 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000245651] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44608 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000166421] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44609 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000681488] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44610 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000175753] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44611 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000155772] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44612 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000362476] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44613 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000216779] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44614 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000185438] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44615 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000422533] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44616 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000372124] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44617 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000140634] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44618 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000178834] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44619 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000250692] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44620 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000424954] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44621 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000833633] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44622 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004538411] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44623 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00015842] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44624 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000133224] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44625 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000635361] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44626 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000508555] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44627 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000333791] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44628 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000216356] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44629 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0001943] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44630 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001979002] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44631 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0064412] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44632 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000152121] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44633 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007277845] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44634 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005828529] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44635 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000563638] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44636 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000177543] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44637 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000133859] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44638 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00019455] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44639 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000665366] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44640 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000166653] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44641 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000175664] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44642 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001187417] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44643 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00022602] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44644 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000543699] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44645 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000899543] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44646 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000160194] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44647 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000132871] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44648 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004838187] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44649 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003185447] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44650 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003522489] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44651 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004038344] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44652 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000751703] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44653 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000215102] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44654 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000925335] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44655 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002287279] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44656 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000484892] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44657 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000800613] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44658 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000156512] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44659 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD494 Loratadine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000426132] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44660 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000142009] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44661 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000246537] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44662 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008092593] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44663 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002131008] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44664 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00061337] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44665 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001020538] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44666 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD843 Thioridazine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00089262] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44667 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001194454] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44668 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000559087] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44669 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000236766] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44670 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000241562] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44671 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000336385] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44672 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000364452] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44673 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000750365] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44674 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000930375] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44675 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000454054] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44676 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000151975] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44677 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD534 Methiothepin maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000672828] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44678 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD37 Amiodarone hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0002565] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44679 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000269858] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44680 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000158052] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44681 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD778 Sertindole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000223961] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44682 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000673509] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44683 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD382 Gefitinib "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000630469] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44684 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD338 Fendiline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003134602] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44685 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD818 Suloctidil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00082887] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44686 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD516 Meclozine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001403155] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44687 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD472 Lansoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000428798] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44688 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD25 Alfacalcidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001149386] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44689 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD671 Pimozide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001273328] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44690 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000750365] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44691 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD858 Toltrazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006747685] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44692 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD62 Apramycin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000841542] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44693 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD132 Butenafine Hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005890941] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44694 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD425 Hexetidine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000580982] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44695 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD47 Anethole-trithione Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000981846] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44696 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD470 Lacidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006991061] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44697 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD724 Rabeprazole Sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000854305] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44698 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD870 Trifluoperazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002532969] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44699 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD799 Spectinomycin dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000311386] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44700 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD857 Tolnaftate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007521944] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44701 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD464 Ivermectin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00087023] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44702 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD417 Halofantrine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000894084] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44703 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD368 Fluphenazine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005479453] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44704 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD701 Prenylamine lactate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004760197] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44705 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD320 Ethaverine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001686706] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44706 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD641 Parbendazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00080764] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44707 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD278 Dihydrostreptomycin sulfate "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000428843] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44708 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD326 Etomidate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008448038] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44709 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD840 Thiethylperazine dimalate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004535848] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44710 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD86 Azelastine HCl Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006525874] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44711 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD890 Vardenafil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000586538] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44712 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD211 Clofilium tosylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004885272] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44713 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD479 Lidoflazine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008916378] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44714 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001487911] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44715 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD388 Gentamicine sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008614335] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44716 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD310 Epirizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003382732] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44717 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD381 GBR 12909 dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007394277] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44718 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD450 Iohexol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004750711] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44719 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002620571] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44720 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD784 Sisomicin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005840765] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44721 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD554 Mitotane Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003977147] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44722 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD749 Riluzole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00913864] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44723 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD369 Fluspirilen Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000392987] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44724 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD608 Norgestimate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005430066] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44725 Substances alter microbe abundance PMDBM2020189 166486 Roseburia intestinalis PMDBD362 Flunarizine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004676065] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44726 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.06E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44727 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44728 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.08E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44729 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44730 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44731 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44732 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44733 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44734 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.49E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44735 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44736 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44737 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000283578] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44738 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44739 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44740 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44741 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44742 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.96E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44743 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44744 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44745 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.37E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44746 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44747 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44748 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44749 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44750 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44751 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.96E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44752 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44753 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44754 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.45E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44755 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000132773] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44756 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44757 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44758 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44759 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44760 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.03E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44761 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44762 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00122221] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44763 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44764 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44765 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.79E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44766 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44767 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.85E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44768 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44769 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44770 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44771 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44772 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44773 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44774 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44775 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.30E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44776 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.50E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44777 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.10E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44778 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.10E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44779 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.00E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44780 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44781 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.99E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44782 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44783 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000651391] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44784 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44785 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44786 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.52E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44787 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44788 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44789 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44790 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44791 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44792 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.30E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44793 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44794 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44795 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44796 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44797 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.53E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44798 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44799 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000271654] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44800 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44801 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.06E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44802 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.09E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44803 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44804 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44805 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000217512] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44806 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44807 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.79E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44808 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44809 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44810 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44811 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.30E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44812 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.14E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44813 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44814 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44815 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.53E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44816 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.12E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44817 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44818 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44819 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000159192] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44820 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.49E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44821 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44822 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.08E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44823 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44824 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44825 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44826 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001070784] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44827 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44828 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.42E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44829 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44830 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.64E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44831 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.63E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44832 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44833 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.21E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44834 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.03E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44835 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44836 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.10E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44837 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44838 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.62E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44839 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.50E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44840 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44841 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44842 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.31E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44843 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004078377] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44844 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44845 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD494 Loratadine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.23E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44846 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44847 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD826 Tazobactam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.83E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44848 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.78E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44849 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001808803] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44850 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.50E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44851 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.00E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44852 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.71E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44853 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44854 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.64E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44855 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD298 Efavirenz Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0002032] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44856 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.87E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44857 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.52E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44858 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD382 Gefitinib "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001950525] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44859 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD472 Lansoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000152827] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44860 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000196508] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44861 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD62 Apramycin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000238177] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44862 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD47 Anethole-trithione Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.26E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44863 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD724 Rabeprazole Sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001688439] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44864 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD182 Chlorotrianisene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002425866] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44865 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD326 Etomidate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002512885] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44866 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD461 Isosorbide dinitrate "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.26E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44867 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD202 Clavulanate potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008071607] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44868 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD14 Acenocoumarol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006136303] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44869 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD313 Erlotinib Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005683558] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44870 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD505 Lynestrenol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000228354] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44871 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD280 Diloxanide furoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009077749] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44872 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD587 Nicorandil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002266077] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44873 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD698 Pranlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007658516] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44874 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD398 Glafenine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.35E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44875 Substances alter microbe abundance PMDBM2020246 40518 Ruminococcus bromii PMDBD836 Testosterone propionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000556732] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44876 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44877 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44878 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44879 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.86E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44880 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44881 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.10E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44882 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44883 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44884 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44885 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44886 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44887 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000314817] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44888 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44889 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44890 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44891 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44892 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44893 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.71E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44894 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44895 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.50E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44896 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44897 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44898 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44899 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44900 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44901 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.06E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44902 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44903 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44904 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000172471] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44905 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.57E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44906 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44907 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.17E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44908 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.71E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44909 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.69E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44910 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.67E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44911 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44912 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.11E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44913 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44914 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44915 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44916 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44917 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44918 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44919 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44920 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44921 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44922 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44923 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000164947] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44924 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44925 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44926 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44927 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44928 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.75E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44929 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.79E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44930 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44931 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44932 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44933 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44934 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.24E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44935 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44936 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.72E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44937 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44938 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.81E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44939 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44940 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44941 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44942 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001636301] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44943 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44944 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000477981] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44945 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44946 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000798186] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44947 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44948 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44949 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44950 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44951 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44952 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.11E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44953 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.24E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44954 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44955 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.40E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44956 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44957 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000151975] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44958 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001363477] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44959 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44960 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44961 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.73E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44962 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44963 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44964 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44965 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44966 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44967 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000895076] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44968 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000133971] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44969 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.15E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44970 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.50E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44971 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.61E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44972 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44973 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002313221] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44974 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44975 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.74E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44976 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.82E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44977 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44978 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44979 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44980 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.26E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44981 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44982 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003813771] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44983 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44984 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44985 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.17E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44986 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44987 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.56E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44988 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44989 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009392496] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44990 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003780078] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44991 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD877 Trimethoprim Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44992 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44993 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.65E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44994 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44995 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44996 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44997 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000740599] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44998 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009586657] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI44999 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009222294] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45000 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45001 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009425311] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45002 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45003 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.75E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45004 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.71E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45005 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45006 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.71E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45007 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007923075] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45008 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45009 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45010 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005475023] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45011 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD518 Mefloquine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000473573] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45012 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00446964] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45013 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.81E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45014 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005149904] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45015 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD652 Perhexiline maleate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001596797] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45016 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000214389] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45017 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000133859] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45018 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001543463] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45019 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000919651] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45020 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD859 Toremifene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001890094] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45021 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000958761] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45022 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD417 Halofantrine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006930773] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45023 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD891 Vecuronium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000543623] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45024 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD381 GBR 12909 dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000891288] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45025 Substances alter microbe abundance PMDBM2020247 33038 [Ruminococcus] gnavus PMDBD450 Iohexol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002666464] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45026 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.33E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45027 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45028 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45029 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.84E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45030 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.77E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45031 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45032 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45033 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.72E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45034 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.82E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45035 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45036 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45037 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45038 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.40E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45039 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45040 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45041 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.14E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45042 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000150969] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45043 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45044 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45045 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006468553] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45046 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45047 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45048 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.51E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45049 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.74E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45050 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.39E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45051 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45052 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45053 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.73E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45054 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000778131] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45055 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.48E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45056 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.28E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45057 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000141893] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45058 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.68E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45059 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45060 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45061 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45062 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.47E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45063 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.96E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45064 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45065 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45066 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.64E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45067 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.22E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45068 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.19E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45069 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.93E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45070 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45071 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45072 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.75E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45073 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000404096] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45074 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000646322] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45075 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.77E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45076 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.19E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45077 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.05E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45078 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.57E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45079 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.57E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45080 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.77E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45081 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.63E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45082 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45083 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.69E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45084 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45085 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45086 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.63E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45087 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.25E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45088 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.33E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45089 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.97E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45090 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45091 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008930242] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45092 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45093 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45094 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.58E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45095 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.46E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45096 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45097 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45098 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45099 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004828422] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45100 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.78E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45101 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.19E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45102 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.81E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45103 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.47E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45104 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.61E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45105 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.65E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45106 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.24E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45107 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.18E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45108 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45109 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.87E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45110 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45111 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45112 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000787021] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45113 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45114 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45115 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.01E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45116 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.67E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45117 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45118 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.98E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45119 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.98E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45120 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007772802] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45121 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.83E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45122 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001391235] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45123 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000207669] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45124 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.11E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45125 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.25E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45126 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45127 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45128 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.77E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45129 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.17E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45130 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.61E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45131 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.16E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45132 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45133 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45134 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.07E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45135 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.40E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45136 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000331598] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45137 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD805 Streptozotocin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.46E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45138 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45139 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00358652] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45140 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000244933] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45141 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.52E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45142 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.11E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45143 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD113 Bifonazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.45E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45144 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000118131] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45145 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000240309] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45146 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD268 Dienestrol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.34E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45147 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD133 Butoconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.53E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45148 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009028298] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45149 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000360321] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45150 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.79E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45151 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD777 Sertaconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000100649] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45152 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD494 Loratadine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000561844] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45153 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD205 Clemizole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000273281] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45154 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD807 Sulconazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45155 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001354778] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45156 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000110537] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45157 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.28E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45158 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.34E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45159 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.01E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45160 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD316 Estradiol Valerate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000575241] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45161 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD467 Ketoconazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45162 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD76 Astemizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000536906] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45163 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD306 Entacapone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45164 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002561027] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45165 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD803 Stanozolol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.55E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45166 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD382 Gefitinib "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003385786] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45167 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD818 Suloctidil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001171004] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45168 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD472 Lansoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.12E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45169 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD619 Omeprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.29E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45170 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD62 Apramycin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.57E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45171 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD132 Butenafine Hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007511804] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45172 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD425 Hexetidine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000160806] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45173 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD47 Anethole-trithione Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.20E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45174 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD724 Rabeprazole Sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.36E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45175 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD182 Chlorotrianisene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001283709] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45176 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD857 Tolnaftate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000374146] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45177 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD464 Ivermectin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.51E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45178 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD320 Ethaverine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.16E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45179 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD641 Parbendazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.60E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45180 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD278 Dihydrostreptomycin sulfate "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000776173] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45181 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD326 Etomidate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.42E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45182 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD890 Vardenafil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000390662] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45183 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD831 Tenatoprazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.91E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45184 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD388 Gentamicine sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001548607] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45185 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD310 Epirizole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45186 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD783 Simvastatin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004017029] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45187 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD784 Sisomicin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0001018] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45188 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD336 Fenbendazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0001339] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45189 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD22 Albendazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001083172] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45190 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD79 Atovaquone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002191168] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45191 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD313 Erlotinib Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002028454] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45192 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD749 Riluzole hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000384151] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45193 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD584 Nicardipine hydrochloride "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003157294] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45194 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD473 Leflunomide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.77E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45195 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD591 Nilutamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000442687] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45196 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD505 Lynestrenol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003709083] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45197 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD10 Abacavir Sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000584373] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45198 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD533 Methiazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000164286] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45199 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD592 Nimesulide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001019344] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45200 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD131 Butamben Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001622822] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45201 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD762 Salmeterol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002505954] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45202 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD134 Butylparaben Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000285497] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45203 Substances alter microbe abundance PMDBM2020249 33039 [Ruminococcus] torques PMDBD861 Tracazolate hydrochloride Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000232154] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45204 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45205 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.84E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45206 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45207 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45208 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.55E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45209 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45210 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45211 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45212 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.96E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45213 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45214 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45215 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45216 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45217 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.92E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45218 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45219 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45220 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.71E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45221 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45222 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45223 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45224 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.46E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45225 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45226 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.89E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45227 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.45E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45228 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45229 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45230 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45231 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.83E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45232 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.00E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45233 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.18E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45234 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45235 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45236 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45237 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45238 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45239 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45240 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.08E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45241 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45242 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.53E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45243 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45244 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45245 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.45E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45246 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45247 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45248 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45249 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.90E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45250 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45251 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.85E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45252 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.84E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45253 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.14E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45254 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45255 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.08E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45256 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45257 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45258 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45259 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45260 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45261 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00127379] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45262 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.91E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45263 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.11E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45264 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.84E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45265 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45266 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.92E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45267 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001734051] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45268 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45269 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45270 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.88E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45271 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45272 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45273 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001708248] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45274 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.82E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45275 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45276 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45277 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD522 Merbromin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.0005815] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45278 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.66E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45279 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45280 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45281 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.75E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45282 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45283 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45284 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45285 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.92E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45286 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45287 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45288 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.79E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45289 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.89E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45290 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45291 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00406747] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45292 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000750268] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45293 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.08E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45294 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45295 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45296 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006240123] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45297 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.03E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45298 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45299 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001963582] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45300 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000100118] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45301 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45302 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45303 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.53E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45304 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.54E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45305 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.40E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45306 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001859804] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45307 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00012336] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45308 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.20E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45309 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.73E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45310 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.21E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45311 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000596883] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45312 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45313 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.52E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45314 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000240274] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45315 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008363427] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45316 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.10E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45317 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD303 Enilconazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009673022] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45318 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45319 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45320 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000160215] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45321 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=4.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45322 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD265 Dicumarol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.54E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45323 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD262 Diclazuril Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008913545] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45324 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD25 Alfacalcidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.005574865] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45325 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD62 Apramycin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008830102] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45326 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD799 Spectinomycin dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000358033] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45327 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD193 Cilnidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009376224] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45328 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD278 Dihydrostreptomycin sulfate "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000349122] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45329 Substances alter microbe abundance PMDBM2020252 1318 Streptococcus parasanguinis PMDBD388 Gentamicine sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009968201] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45330 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.82E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45331 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45332 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.71E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45333 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45334 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45335 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45336 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45337 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.83E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45338 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45339 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.72E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45340 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45341 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.69E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45342 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45343 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45344 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.77E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45345 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45346 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45347 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.67E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45348 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45349 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.71E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45350 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45351 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45352 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45353 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.95E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45354 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.00E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45355 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001009145] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45356 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45357 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.65E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45358 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.25E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45359 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45360 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.56E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45361 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00357394] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45362 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45363 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.67E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45364 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.71E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45365 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45366 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.64E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45367 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45368 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.62E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45369 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45370 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.55E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45371 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.47E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45372 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45373 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD609 Novobiocin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45374 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45375 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.00E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45376 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.60E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45377 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45378 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45379 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.98E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45380 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45381 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45382 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.72E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45383 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.72E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45384 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45385 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.54E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45386 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.89E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45387 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=9.44E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45388 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45389 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45390 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45391 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.59E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45392 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45393 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD879 Troleandomycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45394 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45395 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.09E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45396 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.56E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45397 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45398 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.07E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45399 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.72E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45400 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD556 Monensin sodium salt Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.55E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45401 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.39E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45402 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45403 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45404 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD295 Ebselen Therapeutic Substance Investigational Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000623909] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45405 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45406 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD264 Dicloxacillin sodium salt hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45407 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.67E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45408 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD889 Vancomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45409 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45410 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD94 Bacitracin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45411 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD250 Daunorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45412 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45413 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.52E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45414 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD869 Triclosan "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.62E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45415 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.76E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45416 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD356 Flucloxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45417 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001329469] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45418 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45419 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD459 Isoconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003205469] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45420 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD218 Clotrimazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006108494] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45421 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD219 Cloxacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45422 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000279971] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45423 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45424 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD567 Nafcillin sodium salt monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45425 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD548 Miconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006471536] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45426 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD101 Benzbromarone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45427 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD626 Oxacillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45428 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD210 Clofazimine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004620385] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45429 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45430 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.66E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45431 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD850 Tioconazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001995732] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45432 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD630 Oxethazaine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.29E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45433 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD297 Econazole nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004177971] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45434 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=2.25E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45435 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45436 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.84E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45437 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45438 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD632 Oxiconazole Nitrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003427444] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45439 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD355 Floxuridine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45440 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45441 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD291 Doxorubicin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.72E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45442 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD424 Hexestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001027956] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45443 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.51E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45444 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD907 Zafirlukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=7.48E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45445 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD335 Felodipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004629765] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45446 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD824 Tamoxifen citrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001510749] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45447 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD327 Etoposide "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45448 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD273 Diethylstilbestrol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.004139029] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45449 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD851 Tiratricol, 3,3',5-triiodothyroacetic acid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45450 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD106 Bepridil hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008500296] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45451 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD878 Troglitazone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.61E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45452 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.77E-07] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45453 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.64E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45454 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD212 Clomiphene citrate (Z,E) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.009110665] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45455 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD34 Amikacin hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.70E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45456 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD853 Tobramycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.44E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45457 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD81 Avermectin B1a Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007766915] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45458 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD265 Dicumarol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000465018] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45459 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD558 Montelukast Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.92E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45460 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD516 Meclozine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002196121] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45461 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD25 Alfacalcidol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.93E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45462 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD62 Apramycin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00394427] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45463 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD470 Lacidipine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.007635661] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45464 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD712 Propidium iodide Environmental Substance Unclassified Environmental Substances n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.34E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45465 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD464 Ivermectin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00248147] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45466 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD828 Telmisartan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006928984] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45467 Substances alter microbe abundance PMDBM2020254 1304 Streptococcus salivarius PMDBD22 Albendazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.003156937] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45468 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD744 Rifabutin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45469 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD292 Doxycycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45470 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD187 Chlortetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45471 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD860 Tosufloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45472 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD178 Chloramphenicol "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45473 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD552 Minocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45474 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD514 Meclocycline sulfosalicylate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.13E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45475 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD255 Demeclocycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45476 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD531 Methacycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45477 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD180 Chlorhexidine "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45478 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD354 Florfenicol Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45479 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD199 Ciprofloxacin hydrochloride monohydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45480 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD746 Rifapentine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45481 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD88 Azithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.76E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45482 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD208 Clindamycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45483 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD201 Clarithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45484 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD206 Clinafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45485 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD837 Tetracycline hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45486 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD484 Linezolid Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45487 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD562 Moxifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45488 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD838 Thiamphenicol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45489 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD635 Oxytetracycline dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45490 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD745 Rifampicin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.87E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45491 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD375 Furazolidone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45492 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD594 Niridazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45493 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD144 Carbadox Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45494 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD105 Benzylpenicillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45495 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD566 Nadifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45496 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD380 Gatifloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45497 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD765 Sarafloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45498 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD747 Rifaximin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45499 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD374 Furaltadone hydrochloride Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45500 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD524 Meropenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45501 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD314 Erythromycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45502 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD465 Josamycin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45503 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD483 Lincomycin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45504 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD589 Nifuroxazide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.93E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45505 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD155 Cefazolin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45506 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD676 Piperacillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45507 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD758 Roxithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45508 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD423 Hexachlorophene Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45509 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD24 Alexidine dihydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45510 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD881 Tylosin "Therapeutic Substance; Herbal Substance" "Approved Drug (veterinary medicine); Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45511 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD848 Ticarcillin sodium Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45512 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD287 Dirithromycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.36E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45513 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD801 Spiramycin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45514 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD586 Niclosamide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45515 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD841 Thimerosal Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.91E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45516 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD80 Auranofin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45517 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD217 Closantel Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45518 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD100 Benzathine benzylpenicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45519 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD43 Ampicillin trihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45520 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD163 Cefotaxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45521 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD161 Cefoperazone dihydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45522 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD42 Amoxicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45523 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD376 Fusidic acid sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=3.16E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45524 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD598 Nitrofural Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.80E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45525 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD102 Benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45526 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD844 Thiostrepton Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.29E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45527 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD753 Ronidazole Therapeutic Substance Approved Drug (veterinary medicine) n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45528 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD823 Talampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45529 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD798 Sparfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45530 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD174 Cephalothin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45531 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD849 Tinidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.93E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45532 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD156 Cefdinir Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45533 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD759 Rufloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45534 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD624 Ornidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45535 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD162 Ceforanide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45536 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD440 Imipenem Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45537 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD660 Phenethicillin potassium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45538 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD546 Metronidazole "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45539 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD166 Cefoxitin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45540 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD590 Nifurtimox Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45541 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD771 Secnidazole Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45542 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD539 Methyl benzethonium chloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45543 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD260 Diacerein Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45544 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD183 Chloroxine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45545 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD649 Pentamidine isethionate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.27E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45546 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD599 Nitrofurantoin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45547 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD169 Cefuroxime sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45548 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD561 Moxalactam disodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45549 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD157 Cefepime hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45550 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD164 Cefotetan Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45551 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD89 Azlocillin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45552 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD165 Cefotiam hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.72E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45553 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD159 Cefmetazole sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00017265] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45554 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD209 Clioquinol Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45555 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD257 Dequalinium dichloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45556 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD304 Enoxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45557 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD493 Loracarbef Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45558 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD489 Lomefloxacin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45559 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD168 Ceftazidime pentahydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.16E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45560 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD8 5-fluorouracil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45561 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD361 Flumequine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45562 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD93 Bacampicillin hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.86E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45563 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD158 Cefixime Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45564 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD846 Thonzonium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45565 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD611 Ofloxacin "Therapeutic Substance; Herbal Substance" "Approved Drug; Medicinal Herbal Compounds" n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45566 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD504 Lymecycline Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=8.76E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45567 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD607 Norfloxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45568 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD224 Colistin sulfate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=6.19E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45569 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD167 Cefsulodin sodium salt Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.006092327] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45570 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD677 Pivampicillin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45571 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD715 Pyrimethamine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45572 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD834 Terfenadine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002974409] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45573 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD646 Pefloxacine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45574 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD506 Mafenide hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000124422] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45575 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD153 Cefaclor hydrate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.85E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45576 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD716 Pyrvinium pamoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.15E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45577 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD535 Methotrexate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45578 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD33 Amethopterin (R,S) Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45579 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD49 Anthralin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45580 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD353 Fleroxacin Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45581 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD63 Aprepitant Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008757071] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45582 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD672 Pinaverium bromide Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45583 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD172 Cephalosporanic acid, 7-amino Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.001967198] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45584 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD818 Suloctidil Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000149165] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45585 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD91 Aztreonam Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=5.04E-06] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45586 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD85 Azathioprine Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.002817096] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45587 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD238 Cyclosporin A Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.00310105] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45588 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD235 Cyclobenzaprine hydrochloride Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008100327] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45589 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD433 Hydrocortisone base Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.008929837] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45590 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD910 Zileuton Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000426281] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45591 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD800 Spiperone Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=0.000133269] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994 PMDBI45592 Substances alter microbe abundance PMDBM2020257 29466 Veillonella parvula PMDBD555 Mometasone furoate Therapeutic Substance Approved Drug n.a. n.a. Decrease Drug significantly inhibits microbe growth at 20 å¨“ç’ [FDR-adjusted p-Value=1.46E-05] n.a. n.a. n.a. n.a. In vitro High-throughput incubation assays n.a. n.a. n.a. PMID PMID: 29555994